PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Smith-Sorensen, B; Lind, GE; Skotheim, RI; Fossa, SD; Fodstad, O; Stenwig, AE; Jakobsen, KS; Lothe, RA				Smith-Sorensen, B; Lind, GE; Skotheim, RI; Fossa, SD; Fodstad, O; Stenwig, AE; Jakobsen, KS; Lothe, RA			Frequent promoter hypermethylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene in testicular cancer	ONCOGENE			English	Article						CpG methylation; MGMT; CDKN2A; testicular cancer; germ cell tumour; allelic imbalance	GERM-CELL TUMORS; CPG-ISLAND METHYLATION; DNA-REPAIR GENES; INACTIVATION; EXPRESSION; INHIBITION; NEOPLASIA; PROGNOSIS; AGENTS; REGION	Testicular germ cell tumours are classified into two major histological subgroups, seminomas and nonseminomas. All tumours display several recurrent chromosomal aberrations, but few target genes have been identified. Previous studies have shown that genome-wide hypermethylation of CpG islands is significantly more prevalent in nonseminomas than in seminomas. We have studied two potential target genes in testicular cancer. A series of 70 tumours were analysed for methylation of CpG sites in the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter, and in exon la of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A). In addition, eight microsatellite markers within and flanking these genes at chromosome arms 10q and 9p, respectively, were analysed for allelic imbalances. Allele alterations were frequently seen at 9p loci (47 out of 70, 67%), but none of the tumours (none out of 55) showed methylation of CDKN2A. On the other hand, a high frequency of MGMT promoter methylation (32 out of 69, 46%) was found, as well as allelic imbalances at 10q markers (50 out of 70, 71%). A significantly higher methylation frequency was found in nonseminomas (24 out of 35, 69%) compared to seminomas (eight out of 33, 24%) (P = 0.0003, Fisher's exact test). Immunohistochemical analysis of the MGMT protein in a subgroup (n = 20) of the testicular tumours supported the hypothesis of gene silencing being the functional consequence of the promoter methylation. In summary, our data suggest that inactivation of MGMT contributes to development of nonseminomatous testicular cancer.	Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway; Univ Oslo, Inst Biol, Div Mol Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Radiotherapy & Oncol, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo	Lothe, RA (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.		Skotheim, Rolf I./H-6192-2017	Skotheim, Rolf I./0000-0002-5609-4048; Lothe, Ragnhild A./0000-0002-1693-1032				ATKIN NB, 1982, LANCET, V2, P1349; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bearzatto A, 2000, CANCER RES, V60, P3262; CASTEDO SMMJ, 1989, CANCER RES, V49, P5696; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; Chaubert P, 1997, AM J PATHOL, V151, P859; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; HARRIS LC, 1994, NUCLEIC ACIDS RES, V22, P4614, DOI 10.1093/nar/22.22.4614; Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101; Heidenreich A, 2000, EUR UROL, V37, P121, DOI 10.1159/000020128; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hui R, 2000, CLIN CANCER RES, V6, P2777; JOSEFSEN D, 1993, BRIT J CANCER, V67, P568, DOI 10.1038/bjc.1993.104; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058; Looijenga LHJ, 1999, INT J CANCER, V83, P809, DOI 10.1002/(SICI)1097-0215(19991210)83:6<809::AID-IJC20>3.0.CO;2-0; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; MOSTOFI FK, 1976, WORLD HLTH ORG, V16, P1; MURTY VVVS, 1994, ONCOGENE, V9, P2245; Murty VVVS, 1998, SEMIN ONCOL, V25, P133; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Preuss I, 1996, INT J CANCER, V65, P506, DOI 10.1002/(SICI)1097-0215(19960208)65:4<506::AID-IJC19>3.0.CO;2-7; QIAN XL, 1995, CARCINOGENESIS, V16, P1385, DOI 10.1093/carcin/16.6.1385; Qian XLC, 1997, CANCER RES, V57, P3672; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Skotheim RI, 2002, CANCER RES, V62, P2359; Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840	45	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8878	8884		10.1038/sj.onc.1205978	http://dx.doi.org/10.1038/sj.onc.1205978			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483540				2022-12-17	WOS:000179734400021
J	Zhu, GH; Lenzi, M; Schwartz, EL				Zhu, GH; Lenzi, M; Schwartz, EL			The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells	ONCOGENE			English	Article						thymidine phosphorylase; angiogenic factor; transcription regulation; colorectal cancer	ENDOTHELIAL GROWTH-FACTOR; MURINE URIDINE PHOSPHORYLASE; HUMAN COLORECTAL-CARCINOMA; NF-KAPPA-B; FACTOR-ALPHA; FACTOR GENE; DEPENDENT INDUCTION; GASTRIC-CARCINOMA; INTERFERON-GAMMA; LUNG-CANCER	Thymidine phosphorylase (TP; also known as platelet-derived endothelial cell growth factor, PD-ECGF) is an angiogenic factor that is chemotactic for endothelial cells and has been found to induce neovascularization in vivo. TP is frequently overexpressed in human solid tumors, where its expression has been correlated with increased tumor microvessel density, invasion, and metastasis, and shorter patient survival. In this report, TP activity in the WiDr colon carcinoma cell line was found to be induced 100-fold by tumor necrosis factor (TNFalpha), a secretory product of activated macrophages that has indirect angiogenic activities. Increased TP activity was accompanied by increased TP mRNA levels and without an increase in mRNA stability. TNFalpha-induced TP mRNA levels were reduced by mithramycin, a DNA-binding transcription inhibitor specific for GC-rich sequences. Transcriptional regulation by TNFa was confirmed by transient transfection of WiDr with upstream TP sequences in a luciferase reporter construct. Deletion analysis of the reporter pinpointed two regions of the TP promoter with regulatory elements for both TNFalpha-inducible and basal expression, and they contained, respectively, three and one consensus binding sites for the Sp1-family of transcription factors. One additional region contributed only to basal TP expression, and it contained three Sp1 sites. TNFalpha-induced TP expression decreased when point mutations were made in three of the four Sp1 sites postulated to contribute to both basal and TNFalpha-inducible expression. Electrophoretic mobility shift assays further demonstrated binding of nuclear Sp1 to these three sites. Sp1-binding activity was also increased in cells treated with TNFalpha. These studies establish a role for Sp1 in the regulation of expression of the angiogenic factor TP in colon cancer WiDr cells.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Schwartz, EL (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL CANCER INSTITUTE [R01CA054422, R01CA089352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89352, P01-CA13330, R01-CA54422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cakouros D, 2001, J IMMUNOL, V167, P302, DOI 10.4049/jimmunol.167.1.302; Cao DL, 1999, CANCER RES, V59, P4997; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; EDA H, 1993, JPN J CANCER RES, V84, P341, DOI 10.1111/j.1349-7006.1993.tb02876.x; EDA H, 1993, CANCER CHEMOTH PHARM, V32, P333, DOI 10.1007/BF00735915; Engels K, 1997, J PATHOL, V182, P414, DOI 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Goto H, 2001, CANCER RES, V61, P469; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Griffiths L, 1997, CANCER RES, V57, P570; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Koukourakis MI, 1998, BRIT J CANCER, V77, P1696, DOI 10.1038/bjc.1998.280; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Lee AHS, 1999, J PATHOL, V187, P285; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Maeda K, 1996, BRIT J CANCER, V73, P884, DOI 10.1038/bjc.1996.177; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POLVERINI PJ, 1984, LAB INVEST, V51, P635; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSENBAUM JT, 1988, AM J PATHOL, V133, P47; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SATO N, 1987, J NATL CANCER I, V79, P1383; Sawada N, 1998, CLIN CANCER RES, V4, P1013; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz EL, 1998, CANCER RES, V58, P1551; SCHWARTZ EL, 1995, J BIOL CHEM, V270, P19073, DOI 10.1074/jbc.270.32.19073; Seki N, 2000, EUR J CANCER, V36, P68, DOI 10.1016/S0959-8049(99)00201-4; Shimaoka S, 2000, CANCER, V88, P2220, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2220::AID-CNCR4>3.3.CO;2-3; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SUMIZAWA T, 1993, J BIOCHEM-TOKYO, V114, P9, DOI 10.1093/oxfordjournals.jbchem.a124146; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi Y, 1998, CLIN CANCER RES, V4, P429; Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146; TAKEBAYASHI Y, 1995, CANCER LETT, V95, P57, DOI 10.1016/0304-3835(95)03865-T; Takebayashi Y, 1996, JNCI-J NATL CANCER I, V88, P1110, DOI 10.1093/jnci/88.16.1110; TEVAEARAI HT, 1992, EUR J CANCER, V28A, P368, DOI 10.1016/S0959-8049(05)80055-3; van Triest B, 2000, CLIN CANCER RES, V6, P1063; WATANABE SI, 1995, J BIOL CHEM, V270, P12191, DOI 10.1074/jbc.270.20.12191; WATANABE SI, 1995, BIOCHEM BIOPH RES CO, V216, P265, DOI 10.1006/bbrc.1995.2619; Zhang DK, 2001, CANCER RES, V61, P6899; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2618	58	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8477	8485		10.1038/sj.onc.1206030	http://dx.doi.org/10.1038/sj.onc.1206030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466967				2022-12-17	WOS:000179480100010
J	Sugimoto, M; Martin, N; Wilks, DP; Tamai, K; Huot, TJG; Pantoja, C; Okumura, K; Serrano, M; Hara, E				Sugimoto, M; Martin, N; Wilks, DP; Tamai, K; Huot, TJG; Pantoja, C; Okumura, K; Serrano, M; Hara, E			Activation of cyclin DI-kinase in murine fibroblasts lacking both p21(Cip1) and P27(Kip1)	ONCOGENE			English	Article						cyclin D1; CDK4; p21(Cip1); p27(Kip1); cell cycle	D-DEPENDENT KINASES; POTENTIAL MEDIATOR; DIRECT INHIBITION; CDK4; PROTEIN; P21; PHOSPHORYLATION; EXPRESSION; P16(INK4A); CELLS	Deregulation of D-type cyclin-dependent kinases (CDK4 and 6) is widely observed in various human cancers, illustrating their importance in cell cycle control. Like other cyclin-dependent kinases (CDKs), assembly with cyclins is the most critical step for activation of CDK4/6. As previously reported elsewhere, we observed that the level of cyclinD1-CDK4 complex and its associated kinase activity were significantly low in asynchronously proliferating mouse embryo fibroblasts lacking both p21(Cip1) and p27(Kip1) (p21/p27-null MEFs). These evidences imply, that p21(Cip1) and p27(Kip1) CDK inhibitors are 'essential activators' of cyclin D-kinases. We, however, discovered here that both the assembly and activation of cyclin D1-CDK4 complex occur when quiescent p21/p27-null MEFs were stimulated to re-enter the cell cycle. This mitogen-induced cyclin D1-kinase activity was blocked by overexpression of p16(INK4a) and resulted in the inhibition of S phase entry in p21/p27-null MEFs. Furthermore, ectopic expression of p34(SEI-1), a mitogen-induced CDK4 binding protein, increased the levels of active cyclinD1-CDK4 complex in asynchronously proliferating p21/p27-null MEFs. Together, our results suggest that there are several independent ways to stimulate the assembly of cyclin D1-CDK4 kinases. Although p21(Cip1) and p27(Kip1) play a role in this process, our results demonstrate that additional mechanisms must occur in G0 to S phase transition.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England; Med & Biol Labs Co Ltd, Nagano 3960002, Japan; London Res Inst, Canc Res UK, London WC2A 3PX, England; Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; Cancer Research UK; Juntendo University; University of Manchester	Hara, E (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England.	Ehara@pier.man.ac.uk	Tamai, Katsuyuki/F-4743-2013; Serrano, Manuel/H-2634-2015	Tamai, Katsuyuki/0000-0003-4094-3911; Serrano, Manuel/0000-0001-7177-9312; Sugimoto, Masataka/0000-0001-8737-8097; Pantoja, Cristina/0000-0003-0180-5823				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Parry D, 1999, MOL CELL BIOL, V19, P1775; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	45	62	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8067	8074		10.1038/sj.onc.1206019	http://dx.doi.org/10.1038/sj.onc.1206019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444543				2022-12-17	WOS:000179231400001
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction	ONCOGENE			English	Article						NQO1; ARE; t-BHQ; c-Maf	ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; SUBUNIT GENE; NRF2; PROTEIN; BINDING; FAMILY	Anti-oxidant response element (ARE) and nuclear factors including Nrf2 and small Maf (MafG and MafK) proteins are known to regulate expression and induction of detoxifying enzyme genes including quinone oxidoreductase1 (NQO1). Nrf2 upregulates and small Maf proteins lacking the transcriptional activation domain down regulates ARE-mediated expression and induction. In this report, we have investigated the role of c-Maf (large Mal) containing the transcriptional activation domain in the regulation of ARE-mediated genes expression. The overexpression of c-Maf in human hepatoblastoma (Hep-G2) cells led to the repression of ARE-mediated NQO1 and GST Ya genes expression and induction in response to tert-butyl hydroquinone (t-BHQ). This was in contrast to the role of c-Maf in the activation of Maf recognition element (MARE) mediated p53 gene expression. Deletion of transcriptional activation domain of c-Maf (<^>c-Maf) led to significant loss of MARE-mediated p53 gene expression but had no effect on the repression of ARE-mediated NQO1 gene expression. The overexpression of MafG in Hep-G2 cells repressed both ARE and MARE-mediated genes expression. The co-expression of c-Maf with MafG rescued the MafG repression of MARE but not ARE-mediated gene expression. Band and super shift assays showed the presence of c-Maf in the ARE-nuclear protein complex. Similar assays with in vitro translated proteins revealed that both c-Maf and <^>c-Maf bound to NQO1 gene ARE as homodimers and heterodimers with small Maf but not as heterodimers with Nrf2. Mutational analysis of the NQO1 gene ARE indicated that core ARE sequence is essential for binding of c-Maf leading to repression of NQO1 gene expression. Northern analysis revealed that c-Maf expression increases 2 h after t-BHQ treatment. It reached a plateau at 4 h after t-BHQ treatment. The results together led to the conclusion that c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and induction in response to anti-oxidants.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Matsushima-Hibiya Y, 1998, BIOCHEM BIOPH RES CO, V245, P412, DOI 10.1006/bbrc.1998.8447; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	36	62	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5301	5312		10.1038/sj.onc.1205642	http://dx.doi.org/10.1038/sj.onc.1205642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149651				2022-12-17	WOS:000177193900011
J	MacKenzie, KL; Franco, S; Naiyer, AJ; May, C; Sadelain, M; Rafii, S; Moore, MAS				MacKenzie, KL; Franco, S; Naiyer, AJ; May, C; Sadelain, M; Rafii, S; Moore, MAS			Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras	ONCOGENE			English	Article						telomerase; oncogenes; transformation; immortalization; endothelial cells	MAMMARY EPITHELIAL-CELLS; LIFE-SPAN; HUMAN FIBROBLASTS; IMMORTAL CELLS; EARLY REGION; H-RAS; GROWTH; ANGIOGENESIS; CANCER; HTERT	We have modelled multiple stages of malignant transformation of human endothelial cells (ECs) by overexpressing the catalytic subunit of human telomerase (hTERT), together with SV40 T antigen (SV40T) and oncogenic N-ras. Transfection with hTERT alone, led to the immortalization of two out of three cultures of bone marrow-derived ECs (BMECs). One hTERT transduced BMEC culture underwent a long proliferative lag before resuming proliferation. BMECs transfected with hTERT alone were functionally and phenotypically normal. BMECs transfected with SV40T (BMSVTs) had an extended lifespan, but eventually succumbed to crisis. BMSVTs exhibited a partially transformed phenotype, demonstrating growth factor independence, altered antigen expression and forming tiny, infrequent colonies in vitro. Transduction of BMSVTs with hTERT resulted in immortalization of 4 out of 4 cultures. BMSVTs immortalized with hTERT formed large colonies in vitro and small transient tumours in viro. BMECs coexpressing SV40T, hTERT and N-ras exhibited an overtly transformed phenotype; forming very large colonies with an altered morphology and generating rapidly growing tumours in vivo. These investigations demonstrate transformation of human ECs to an overtly malignant phenotype. This model will be useful for understanding mechanisms underlying vascular and angiogenic neoplasias, as well as for testing drugs designed to curtail aberrant EC growth.	Sloan Kettering Canc Inst, James Ewing Lab Dev Haematopoiesis, New York, NY USA; Sloan Kettering Canc Inst, Dept Human Genet, New York, NY USA; Cornell Univ, Med Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	MacKenzie, KL (corresponding author), Childrens Canc Inst Australia Med Res, High St,POB 81, Randwick, NSW 2031, Australia.		Mackenzie, Karen/F-1310-2011; MacKenzie, Karen/N-5849-2019	MacKenzie, Karen/0000-0003-2996-1617	NCI NIH HHS [CA59350] Funding Source: Medline; NHLBI NIH HHS [HL 61401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA059350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1989, CANCER RES, V49, P4682; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; Couch V, 2000, MAYO CLIN PROC, V75, P265; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelhardt M, 1997, BLOOD, V90, P182; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FICKLING SA, 1992, EXP CELL RES, V201, P517, DOI 10.1016/0014-4827(92)90303-P; FOX PL, 1994, ONCOGENE, V9, P3519; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; FROMENT O, 1994, CANCER RES, V54, P5340; GIMBRONE MA, 1976, CELL, V9, P685, DOI 10.1016/0092-8674(76)90132-X; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOHENWARTER O, 1992, J BIOTECHNOL, V25, P349, DOI 10.1016/0168-1656(92)90167-8; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LAND H, 1983, SCIENCE, V222, P769; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; MAHER J, 1995, ONCOGENE, V11, P1639; Mark RJ, 1996, CANCER, V77, P2400, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RAFII S, 1994, BLOOD, V84, P10; RAK J, 1995, CANCER RES, V55, P4575; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Scott-Taylor TH, 1998, GENE THER, V5, P621, DOI 10.1038/sj.gt.3300633; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	55	62	65	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4200	4211		10.1038/sj.onc.1205425	http://dx.doi.org/10.1038/sj.onc.1205425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082607				2022-12-17	WOS:000176174200002
J	Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY				Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY			Inhibition of HOS expression and activities by Wnt pathway	ONCOGENE			English	Article						beta TrCP; HOS; ubiquitin ligase; F-box protein; beta-catenin; NF-kappa B	I-KAPPA-B; F-BOX PROTEIN; BETA-CATENIN; UBIQUITIN LIGASE; ALPHA UBIQUITINATION; SIGNALING PATHWAYS; COMPLEX; TRCP; ACTIVATION; SCF	betaTrCP and HOS are closely related F-box proteins, which play key roles in ubiquitination and degradation of beta-catenin and IkappaB through associating with those phosphorylated substrates and recruiting SCF E3 ubiquitin ligase. Here we report that activation of Wnt/beta-catenin signal transduction pathway elevates betaTrCP levels but inhibits expression of HOS in 293T cells. Similar disparity is likely to exist in human colorectal tumors. In the NIH3T3 cells, which express HOS, but not betaTrCP, Wnt/beta-catenin signaling leads to inhibition of HOS promoter activity and NF-kappaB-driven transcription as well as to stabilization of P-catenin. These results indicate that expression and activities of HOS are negatively regulated by Wnt/beta-catenin pathway.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan	University of Pennsylvania; AMC Cancer Research Center; National Cancer Center - Japan	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E,VET, Philadelphia, PA 19104 USA.			Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Saitoh T, 2001, INT J ONCOL, V18, P959; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; SPIEGELMAN VS, 2001, J BIOL CHEM, V24, P24; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					856	860		10.1038/sj.onc.1205132	http://dx.doi.org/10.1038/sj.onc.1205132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850814				2022-12-17	WOS:000173427000017
J	Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA				Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA			The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver	ONCOGENE			English	Article						HBV; apoptosis; liver; mitochondria; cytochrome c; caspase	CYTOCHROME-C RELEASE; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; IN-VIVO; CELL-LINES; BCL-2; GENE; HBX; MITOCHONDRIA; DEATH	The role of the hepatitis B virus protein HBx in liver cell proliferation and apoptosis remains controversial. Using a transgenic mouse model, we have recently shown that HBx stimulates the apoptotic turnover of hepatocytes, independently of p53. In this paper, we tested whether the proapoptotic function of HBx can interfere with Bcl-2 during hepatic apoptosis in vivo. HBx transgenic mice were crossed with PK-hBcl-2 mice that are protected against Fas killing by constitutive overexpression of Bcl-2 in hepatocytes. In a lethal challenge with Fas antibodies, HBx expressed at low levels restored sensitivity to Fas-mediated apoptosis and fulminant hepatic failure in mice overexpressing Bcl-2. Furthermore, cytochrome c release from mitochondria and caspase 3 activation were restored to normal levels in HBx/Bcl-2 mice during transduction of the Fas signal. Thus, the proapoptotic activity of HBx overcomes or bypasses the inhibitory effect of Bcl-2 against Fas cytotoxicity. This effect was not apparently mediated through downregulation of the PK-hBcl-2 transgene or via delocalization of the Bcl-2 protein, and a direct interaction of HBx with Bcl-2, Bcl-X-L or Bax could not be evidenced in yeast two-hybrid assays. We further show that apoptosis induced by ectopic expression of HBx is associated with mitochondrial membrane alterations and caspase 3 activation. Our data indicate that the dominant function of HBx upon Bcl-2-regulated control of apoptosis might play an important role in the pathogenesis of chronic hepatitis B.	Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, F-75724 Paris, France; Univ Geneva Sci III, Dept Biol Cellulaire, Geneva, Switzerland; Univ Paris 05, Inserm U129, Paris, France; Inst Pasteur, Inserm U163, Unite Recombinaison & Express Genet, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buendia, MA (corresponding author), Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, 28 Rue Dr Roux, F-75724 Paris, France.	mbuendia@pasteur.fr	Pollicino, Teresa/HDN-3708-2022; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035; Neuveut, Christine/0000-0001-6520-271X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; GraslKraupp B, 1997, HEPATOLOGY, V25, P906, DOI 10.1002/hep.510250420; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spengler U, 1996, CYTOKINE, V8, P864, DOI 10.1006/cyto.1996.0115; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WANG XW, 1995, CANCER RES, V55, P6012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	69	62	69	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					377	386		10.1038/sj.onc.1205110	http://dx.doi.org/10.1038/sj.onc.1205110			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821950				2022-12-17	WOS:000173311200006
J	Pardo, OE; Arcaro, A; Salerno, G; Tetley, TD; Valovka, T; Gout, I; Seckl, MJ				Pardo, OE; Arcaro, A; Salerno, G; Tetley, TD; Valovka, T; Gout, I; Seckl, MJ			Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells	ONCOGENE			English	Article						S6K2; FGF-2; SCLC; signal transduction	FIBROBLAST-GROWTH-FACTOR; LUNG-CANCER CELLS; ACTIVATED PROTEIN-KINASE; STEM-CELL; SIGNAL-TRANSDUCTION; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; LIGAND-BINDING; FACTOR FAMILY; IN-VIVO	Here, we show that fibroblast growth factor-2 (FGF-2) induces proliferation of H-510 and H-69 small cell lung cancer (SCLC) cells. However, the optimal response to FGF-2 was obtained at 10-fold lower concentrations in H-510 cells. This correlated with the selective activation of the mitogen-activated protein kinase kinase (MEK) pathway in H-510, but not H-69 cells. Moreover, inhibition of MEK with PD098059 blocked FGF-2-induced proliferation in H-510 cells only. Similarly, ribosomal protein S6 kinase 2 (S6K2), a recently identified homologue of S6K1 was activated by FGF-2 in H-510, but not H-69 cells. This activation was independent of phosphatidylinositol-3 kinase, but was sensitive to inhibition of the MEK pathway. These data suggest that S6K2 is a novel downstream target of MEK. The potency of FGF-2 in H-510 cells might reflect this additional MEK/S6K2 signalling. In contrast to S6K2, S6K1 was activated in both SCLC cell lines. Inhibition of the mammalian target of rapamycin with 10 ng/ml rapamycin blocked S6K1 activation and proliferation of both lines. However, even at 100 ng/ml, rapamycin only partially inhibited S6K2. Strikingly, this correlated with inhibition of MEK signalling. Our data indicate that S6K1, and possibly S6K2, are involved in FGF-2-induced SCLC cell growth, a notion supported by the overexpression and higher baseline activity of both isoforms in SCLC lines, as compared to normal human type-II pneumocytes.	Imperial Coll Sch Med, Div Med, Lung Canc Biol Grp, London W12 ONN, England; Imperial Coll Sch Med, Natl Heart & Lung Inst, London W6 8RF, England; UCL Royal Free & Univ Coll Med Sch, Ludwig Inst Canc Res, Cell Regulat Lab, London W1W 7BS, England; Inst Mol Biol & Genet, Kiev, Ukraine	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU	Seckl, MJ (corresponding author), Imperial Coll Sch Med, Div Med, Lung Canc Biol Grp, Hammersmith Campus, London W12 ONN, England.	m.seckl@ic.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; BELINSKY SA, 1992, CANCER RES, V52, P3164; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BUNN PA, 1990, P NATL ACAD SCI USA, V87, P2162, DOI 10.1073/pnas.87.6.2162; CARNEY DN, 1980, CANCER RES, V40, P1820; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORDONCARDO C, 1990, LAB INVEST, V63, P832; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P386, DOI 10.1016/S0006-291X(05)81305-1; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gazdar AF, 1981, SMALL CELL LUNG CANC, P145; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HIBI K, 1991, ONCOGENE, V6, P2291; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krystal GW, 1996, CANCER RES, V56, P370; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Linder C, 1998, ANTICANCER RES, V18, P2063; MACAULAY VM, 1990, CANCER RES, V50, P2511; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; RON D, 1993, J BIOL CHEM, V268, P5388; Seckl MJ, 1998, RESP PHARM & PHARMAC, P129; SECKL MJ, 1994, CANCER RES, V54, P6143; SETHI T, 1991, CANCER RES, V51, P3621; Seufferlein T, 1996, CANCER RES, V56, P3895; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SMYTH JF, 1986, Q J MED, V61, P969; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALOVKA T, 1999, BIOPOLYMERS CELL, V15, P1; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yiangou C, 1997, BRIT J CANCER, V76, P1419, DOI 10.1038/bjc.1997.573; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231; [No title captured]	53	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7658	7667		10.1038/sj.onc.1204994	http://dx.doi.org/10.1038/sj.onc.1204994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753643				2022-12-17	WOS:000172124100008
J	Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST				Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST			Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes	ONCOGENE			English	Article						early-onset colorectal cancer; chromosomal instability; DNA ploidy; microsatellite instability	COMPARATIVE GENOMIC HYBRIDIZATION; YOUNG-PATIENTS; GENETIC INSTABILITY; COLON-CANCER; TUMORS; P53; MUTATIONS; CARCINOGENESIS; CHECKPOINT; CARCINOMAS	Colorectal cancer has been described in terms of genetic instability selectively affecting either microsatellite sequences (MIN) or chromosome number and structure (CIN). A subgroup with apparently stable, near-diploid chromosomes and stable microsatellites (MACS) also exists. These distinctions are important, partly because of their value in highlighting different pathways of carcinogenesis, and partly because of their direct relevance to prognosis. Study of early-onset cancer has often proved a fruitful resource for the identification of the nature and function of cancer susceptibility genes. In a study of colorectal cancer with stable microsatellite DNA, we describe 22 early-onset tumours (mean age = 33), compared with 16 late-onset tumours (mean age = 68). Both groups contained carcinomas with the MACS phenotype, characterized by near diploid DNA content, as defined by flow cytometry, and minimal chromosome arm deletion or amplification (six or less events per genome), determined by comparative genomic hybridization (CGH). Minimal chromosome imbalance correlated strongly with diploid DNA content (P<0.001). The proportion of MACS cancers was significantly greater in early-onset as compared to late-onset tumours (64 vs 13%, P=0.005). Of the chromosome arm imbalances commonly observed in late-onset tumours, only 18q- was observed more than twice amongst the 14 early-onset MACS tumours. Seventy-nine per cent of these MACS tumours were located in the distal colon, and 69% were at advanced clinico-pathological stages (with lymph node or distant metastasis). A positive family history of colorectal or other cancers was elicited in seven patients in the MACS early-onset group, and one additional patient in this group had a metachronous ovarian cancer. The results suggest that MACS cancer may have a genetic basis different from either MIN or CIN, and further studies of these cancers may lead to discovery of new mechanisms of colorectal carcinogenesis and cancer susceptibility.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Oncol, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China	University of Cambridge; University of Hong Kong; University of Hong Kong; University of Edinburgh; University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		Yuen, Siu/K-6311-2014; Leung, Suet Yi/C-4340-2009; Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/Q-2710-2019; Farrington, Susan M/C-7319-2013; Leung, Suet Yi/T-9620-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389; Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; CLARKE AR, 1994, ONCOGENE, V9, P1767; Cottu PH, 1996, ONCOGENE, V13, P2727; Curtis LJ, 2000, J PATHOL, V192, P440; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAWN MT, 1995, CANCER RES, V55, P3721; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung SY, 2000, ONCOGENE, V19, P4079, DOI 10.1038/sj.onc.1203740; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTHE RA, 1993, CANCER RES, V53, P5849; MERRITT AJ, 1994, CANCER RES, V54, P614; Miyazaki M, 1999, CANCER RES, V59, P5283; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; SCHLEGEL J, 1995, CANCER RES, V55, P6002; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	35	62	65	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4871	4876		10.1038/sj.onc.1204653	http://dx.doi.org/10.1038/sj.onc.1204653			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521198				2022-12-17	WOS:000170271800011
J	Hemenway, CS; de Erkenez, AC; Gould, GCD				Hemenway, CS; de Erkenez, AC; Gould, GCD			The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias	ONCOGENE			English	Article						polycomb group proteinsMLL fusion genes; fluorescent protein tagging	TRANSCRIPTIONAL REPRESSOR; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; GROUP-COMPLEXES; TRITHORAX-GROUP; GAGA-FACTOR; MOUSE; CHROMATIN; IDENTIFICATION; BINDING	Polycomb group (PcG) proteins assemble to form large multiprotein complexes involved in gene silencing, Evidence suggests that PcG complexes are heterogeneous with respect to both protein composition and specific function, MPc3 is a recently described mouse Polycomb (Pc) protein that shares structural homology with at least two other Pc proteins, M33 and MPc2, All three Pc proteins bind another PcG protein, RING1, through a conserved carboxy-terminal C-box motif, Here, data are presented demonstrating that MPc3 also interacts with AF9, a transcriptional activator implicated in the development of acute leukemias. The carboxy-terminus of AF9 is fused to the MLL protein in leukemias characterized by t(9;11)(p22;q23) chromosomal translocations, importantly, it is the carboxy-terminus of AF9 to which MPc,7 binds, The AF9 binding site of MPc3 maps to a central, non-conserved, region of the polypeptide sequence. In contrast to MPc3, data indicate that the Pc protein M33 does not interact with AF9, This finding suggests a potentially unique role for MPc3 in linking a PcG silencing complex to a transcriptional activator protein.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [1K01 CA78318-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bel S, 1998, DEVELOPMENT, V125, P3543; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; Hemenway CS, 2000, GENE, V242, P31, DOI 10.1016/S0378-1119(99)00540-5; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; IIDA S, 1993, ONCOGENE, V8, P3085; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Morgan H, 2000, FASEB J, V14, P1109, DOI 10.1096/fasebj.14.9.1109; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Takihara Y, 1997, DEVELOPMENT, V124, P3673; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	38	62	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3798	3805		10.1038/sj.onc.1204478	http://dx.doi.org/10.1038/sj.onc.1204478			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439343				2022-12-17	WOS:000169494700005
J	Sheng, W; Decaussin, G; Sumner, S; Ooka, T				Sheng, W; Decaussin, G; Sumner, S; Ooka, T			N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2	ONCOGENE			English	Article						EBV; malignant transforming activity; Bcl-2; c-myc; rodent fibroblast	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE-PROTEIN; OPEN READING FRAME; KAPPA-B; NASOPHARYNGEAL CARCINOMA; CELL-DEATH; C-MYC; EMBRYO FIBROBLASTS; EXPRESSION; EBV	The BARF1 gene encoded by the Epstein-Barr virus induces morphological changes, loss of contact inhibition and anchorage independence in established rodent Balb/c3T3 fibroblast, BARF1 gene was also capable of inducing malignant transformation in a human Louckes B cell line. Our recent study showed that BARF1 gene had an ability to immortalize primary epithelial cells. However we do not know which region(s) of BARF1 protein is(are) responsible for inducing malignant transformation in established rodent cells. Using the deletion mutants, we now localized malignant transforming region in N-terminal of BARF1 protein. The mutants lacking this region were unable to transform the cells in malignant state, Furthermore, we demonstrated that only the mutants containing this region rendered the cells resistant to apoptosis induced by serum deprivation. Surprisingly, the BARF1 gene was capable of:activating anti-apoptotic Bcl-2 expression and this activation was due to the N-terminal transforming region. These data suggest that the cooperation of BARF1 with Bcl-2 is essential for the induction of malignant transformation.	Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, F-69372 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, Rue Guillaume Paradin, F-69372 Lyon 08, France.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; de Turenne-Tessier M, 1997, VIRUS RES, V52, P73, DOI 10.1016/S0168-1702(97)00101-9; Decaussin G, 2000, CANCER RES, V60, P5584; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; DETHE G, 1982, HERPESVIRUSES, V1, P25; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY; KLEIN G, 1973, HERPESVIRUSES, P521; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OOKA T, 1991, SPRINGER SEMIN IMMUN, V13, P233, DOI 10.1007/BF00201471; OOKA T, 1983, J VIROL, V46, P187, DOI 10.1128/JVI.46.1.187-195.1983; OOKA T, 1980, VIROLOGY, V104, P219, DOI 10.1016/0042-6822(80)90379-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; RICKINSON AB, 1996, FIELDS VIROLOGY, V2, P2396; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SbihLammali F, 1996, VIROLOGY, V222, P64, DOI 10.1006/viro.1996.0398; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; STOCKBINE LD, 1998, J VIROL, V72, P4015; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TAO Q, 1994, J CLIN PATHOL, V47, P589, DOI 10.1136/jcp.47.7.589; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; zur Hausen A, 2000, CANCER RES, V60, P2745	54	62	70	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1176	1185		10.1038/sj.onc.1204217	http://dx.doi.org/10.1038/sj.onc.1204217			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313861				2022-12-17	WOS:000167570100004
J	Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H				Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H			Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis	ONCOGENE			English	Article						Smad; mutation; acute myelogeneous leukemia; leukemogenesis; transforming growth factor-beta	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; DPC4 GENE; CELLS; PROTEINS; PROMOTER; RECEPTOR; BINDING; TRANSACTIVATION	The Smad family proteins are critical components of the transforming growth factor (TGF)-beta signaling pathway, TGF-beta is a multipotent cytokine that elicits many biological functions. In particular, TGF-beta exhibits effects on the cell cycle manifested by G1-phase arrest, differentiation, or apoptosis of several target cells, suggesting that disruption of TGF-beta signaling pathway could be involved in cancer formation, Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (Delta (483-552)) in acute myelogeneous leukemia, Both of the mutated Smad4 proteins lack transcriptional activities, Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The Delta (483-552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-beta signaling. This is the first report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-beta signaling pathway could lead to acute myelogeneous leukemia.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Drexler H G, 1986, Tumour Biol, V6, P503; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	38	62	71	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					88	96		10.1038/sj.onc.1204057	http://dx.doi.org/10.1038/sj.onc.1204057			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244507				2022-12-17	WOS:000166361400010
J	Bearss, DJ; Hurley, LH; Von Hoff, DD				Bearss, DJ; Hurley, LH; Von Hoff, DD			Telomere maintenance mechanisms as a target for drug development	ONCOGENE			English	Review						telomere; telomerase; G-quadruplex; drug targets	CATALYTIC SUBUNIT GENE; TERMINAL TRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE; REVERSE-TRANSCRIPTASE; CATIONIC PORPHYRINS; HUMAN-CHROMOSOMES; QUADRUPLEX DNA; IMMORTAL CELLS; TUMOR-CELLS; ACTIVE-SITE	The shortening of the telomeric DNA sequences at the ends of chromosomes is thought to play a critical role in regulating the lifespan of human cells. Since all dividing cells are subject to the loss of telomeric sequences, cells with long proliferative lifespans need mechanisms to maintain telomere integrity. It appears that the activation of the enzyme telomerase is the major mechanism by which these cells maintain their telomeres, The proposal that a critical step in the process of the malignant transformation of cells is the upregulation of expression of telomerase has made this enzyme a potentially useful prognostic and diagnostic marker for cancer, as well as a new target for therapeutic intervention for the treatment of patients with cancer, It is now clear that simply inhibiting telomerase may not result in the anticancer effects that were originally hypothesized. While telomerase may not be the universal target for cancer therapy, we certainly believe that targeting the telomere maintenance mechanisms will be important in future research aimed toward a successful strategy for curing cancer.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Pharm, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Von Hoff, DD (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.		Bearss, David/Q-9141-2019	Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NATIONAL CANCER INSTITUTE [U19CA067760] Funding Source: NIH RePORTER; NCI NIH HHS [CA67760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; AGBANDJE M, 1992, J MED CHEM, V35, P1418, DOI 10.1021/jm00086a010; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anantha NV, 1998, BIOCHEMISTRY-US, V37, P2709, DOI 10.1021/bi973009v; Bare LA, 1998, DRUG DEVELOP RES, V43, P109, DOI 10.1002/(SICI)1098-2299(199802)43:2<109::AID-DDR4>3.0.CO;2-O; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Briem H, 1996, J MED CHEM, V39, P3401, DOI 10.1021/jm950800y; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamilton SE, 1999, CHEM BIOL, V6, P343, DOI 10.1016/S1074-5521(99)80046-5; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; Han FXG, 1999, J AM CHEM SOC, V121, P3561, DOI 10.1021/ja984153m; HAN H, 2000, BIOCHEMISTRY-US, V39, P5295; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922; Haq I, 1999, J AM CHEM SOC, V121, P1768, DOI 10.1021/ja981554t; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1995, TELOMERES, P11; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; Izbicka E, 1999, CANCER RES, V59, P639; IZBICKA E, 1999, P AM SOC CANC ONCOL, V18, pA631; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; Kyo S, 1997, CANCER RES, V57, P610; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marco-Haviv Y, 1999, J MOL BIOL, V286, P45, DOI 10.1006/jmbi.1998.2461; MEHLE C, 1994, CANCER RES, V54, P236; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Multani AS, 1998, INT J ONCOL, V13, P923; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; ODAGIRI E, 1994, CANCER, V73, P2975; Ohashi K, 1996, CANCER, V77, P1747, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1747::AID-CNCR50>3.0.CO;2-W; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pandit B, 1998, BIOCHEM BIOPH RES CO, V251, P620, DOI 10.1006/bbrc.1998.9509; Park KH, 1998, INT J ONCOL, V13, P489; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; RAYMOND E, 1996, P 6 ANN S CANC RES S, V23; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schuitmaker JJ, 1996, J PHOTOCH PHOTOBIO B, V34, P3, DOI 10.1016/1011-1344(96)07342-3; SCIADINI MF, 1994, P AN M AM SOC CLIN, V13, P129; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sommerfeld HJ, 1996, CANCER RES, V56, P218; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; SUN D, 1997, J MED CHEM, V8, P1063; TANIOUS FA, 1992, BIOCHEMISTRY-US, V31, P11632, DOI 10.1021/bi00161a050; Tsao JI, 1997, CLIN CANCER RES, V3, P627; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wheelhouse R. T., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P430; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yashima K, 1997, CANCER RES, V57, P2373; Yasumoto S, 1996, ONCOGENE, V13, P433	121	62	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6632	6641		10.1038/sj.onc.1204092	http://dx.doi.org/10.1038/sj.onc.1204092			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426649				2022-12-17	WOS:000167704000010
J	Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R				Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R			Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice	ONCOGENE			English	Article						maspin; WAP-TAg transgenic mice; mammary tumor progression	BREAST-CANCER; T-ANTIGEN; SERPIN; CELLS; EXPRESSION; SUPPRESSOR; SV40; GENE; TRANSACTIVATION; INVASION	Maspin is a unique serpin involved in the suppression of tumor growth and metastasis. To investigate whether increased levels of maspin protect against tumor progression in vivo, we established a transgenic model in which maspin is targeted to mammary epithelial cells by the Whey Acidic Protein (WAP) promoter for overexpression. We crossed these WAP-maspin transgenic mice with the WAP-TAg mouse model of tumor progression. Maspin overexpression increased the rate of apoptosis of both preneoplastic and carcinomatous mammary epithelial cells. Maspin reduced tumor growth through a combination of reduced angiogenesis and increased apoptosis, The number of pulmonary metastases was reduced in the presence of maspin overexpression, These data demonstrate that targeted overexpression of maspin can inhibit tumor progression in vivo, likely through a combination of increased apoptosis, decreased angiogenesis, and inhibition of tumor cell migration.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Maryland, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Baylor College of Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER; NCI NIH HHS [CA79736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Hendrix MJC, 2000, NAT MED, V6, P374, DOI 10.1038/74624; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Obermair A, 1997, J NATL CANCER I, V89, P1212, DOI 10.1093/jnci/89.16.1212; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	27	62	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6053	6058		10.1038/sj.onc.1204006	http://dx.doi.org/10.1038/sj.onc.1204006			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146557				2022-12-17	WOS:000165827900012
J	Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT				Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT			Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas	ONCOGENE			English	Article						acyl-CoA synthetase; fatty acid; glioma; growth stimulation	PROTEIN; HETEROZYGOSITY; EXPRESSION; REPLICATION; THIOESTERS; TRANSPORT; COENZYME; CLONING; GENOME; ACS2	Acyl-CoA synthetase (ACS) ligates fatty acid and CoA to produce acyl-CoA, an essential molecule in fatty acid metabolism and cell proliferation. ACS5 is a recently characterized ACS isozyme highly expressed in proliferating 3T3-L1 cells. Molecular characterization of the human ACS5 gene revealed that the gene is located on chromosome 10q25.1-q25.2, spans approximately 46 kb, comprises 21 exons and 22 introns, and encodes a 683 amino acid protein, Two major ACS5 transcripts of 2,5-and 3,7-kb are distributed in a wide range of tissues with the highest expression in uterus and spleen. Markedly increased levels of ACS5 transcripts were detected in a glioma line, A172 cells, and primary gliomas of grade IV malignancy,,while ACS5 expression was found to be low in normal brain. Immunohistochemical analysis also revealed strong immunostaining with an anti-ACS5 antibody in glioblastomas. U87MG glioma cells infected with an adenovirus encoding ACS5 displayed induced cell growth on exposure to palmitate, Consistent with the induction of cell growth, the virus infected cells displayed induced uptake of palmitate, These results demonstrate a novel fatty acid-induced glioma cell growth mediated by ACS5.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.			Cho, Yong-Yeon/0000-0003-1107-2651				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERBST RA, 1994, CANCER RES, V54, P3111; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; KARLBOM AE, 1993, HUM GENET, V92, P169; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pizer ES, 1998, CANCER RES, V58, P4611; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E	27	62	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5919	5925		10.1038/sj.onc.1203981	http://dx.doi.org/10.1038/sj.onc.1203981			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127823				2022-12-17	WOS:000165563100011
J	Tolkacheva, T; Chan, AML				Tolkacheva, T; Chan, AML			Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene	ONCOGENE			English	Article						Ras; PTEN; endometrium; transformation	PHOSPHATIDYLINOSITOL 3-KINASE; ENDOMETRIAL CANCERS; GLIOBLASTOMA CELLS; SIGNALING PATHWAY; PTEN; MUTATIONS; PROTOONCOGENE; ACTIVATION; CARCINOMA; PROTEINS	The human PTEN/MMAC1/TEP1 (PTEN) tumor suppressor gene encodes a phosphatase with specificity towards the D3 phosphate of phosphatidylinositides. PTEN mutations hale been reported in the endometrioid type of uterine tumors which are associated with frequent activations of the Ras oncogenes. In this study, we report the ability of PTEN to potently inhibit H-Ras induced morphological transformation and anchorage-independent growth in NIH3T3 cells. This novel activity of PTEN was correlated more with its ability to suppress the phosphatidylinositol 3-kinase (PI3-K)-dependent signaling cascade, but not the mitogen-activated protein kinase (MAPK) pathway. To define the minimal region in PTEN protein that is responsible for this anti-oncogenic activity, a panel of carboxyl-terminal truncation mutants was generated. While deletions of 4 and 33 amino acids do not have marked effects, removal of up to 68 amino acids drastically reduced the ability of PTEN to inhibit Ras transformation. The propensity of these mutants to suppress Ras transformation is correlated with their relative ability to dephosphorylate inositol (1,3,4,5)-tetrakisphosphate in vitro, and to suppress Akt kinase activity in cultured cells. In addition, we have evidence to suggest that the C-terminal region of PTEN contributes to the stability of the encoded gene product.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AML (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R29CA078509, R01CA066654] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA66654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheney IW, 1998, CANCER RES, V58, P2331; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maxwell GL, 1998, CANCER RES, V58, P2500; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Obata K, 1998, CANCER RES, V58, P2095; Osada M, 1999, MOL CELL BIOL, V19, P6333; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tashiro H, 1997, AM J PATHOL, V150, P177; Tashiro H, 1997, CANCER RES, V57, P3935; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	43	62	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					680	689		10.1038/sj.onc.1203331	http://dx.doi.org/10.1038/sj.onc.1203331			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698513				2022-12-17	WOS:000085192000010
J	Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH				Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH			Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1)	ONCOGENE			English	Article						HPK1; JNK; caspase; apoptosis; adaptor	GERMINAL CENTER KINASE; RADIATION-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CELL-DEATH; PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; GAMMA-RADIATION; JNK ACTIVATION	Activation of c-Jun N-terminal kinase (JNK) by Fas ligation is caspase-dependent, suggesting that caspases may regulate activators of the JNK pathway. Here, we report that an upstream activator of JNK, hematopoietic progenitor kinase I (HPK1), was cleaved during apoptosis, Cleavage of HPK1 was blocked by peptide inhibitors for caspases. HPK1 was efficiently processed by recombinant caspase 3 in vitro. A conserved caspase recognition site, DDVD (amino acids 382-385), was found in the HPK1 protein sequence. By testing HPK1 proteins with in vivo and in vitro cleavage assays, we showed that aspartic acid residue 385 is the target for caspases. HPK1 cleavage separated the amino N-terminal kinase domain from the carboxyl C-terminal regulatory domain, and enhanced HPK1 kinase activity. Unlike the full-length HPK1, the N-terminal cleaved product failed to bind adaptor molecules Grb2 (growth factor receptor-bound protein 2) and Crk (CT10 regulator of kinase). The C-terminal fragment, although having three proline-rich domains, bound to Grb2 and Crk less efficiently than the full-length HPK1 protein. Taken together, the cleavage of HPK1 by caspase profoundly changed its biochemical properties.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Hoechst Marion Roussel, CNS Dept, Bridgewater, NJ 08807 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002	NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Ling P, 1999, MOL CELL BIOL, V19, P1359; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shiah SG, 1999, CANCER RES, V59, P391; SONG O, 1996, EMBO J, V15, P3238; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO Z, 1997, J BIOL CHEM, V272, P2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	48	62	64	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7370	7377		10.1038/sj.onc.1203116	http://dx.doi.org/10.1038/sj.onc.1203116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602493				2022-12-17	WOS:000084119400023
J	Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R				Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R			Serine phosphorylation of paxillin by heregulin-beta 1: role of p38 mitogen activated protein kinase	ONCOGENE			English	Article						heregulin; signaling; spreading; paxillin; motility	FOCAL ADHESION KINASE; NEU DIFFERENTIATION FACTOR; HEPATOCYTE GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; RECEPTOR INTERACTIONS; CARCINOMA-CELLS; GENE-PRODUCT; HUMAN-BREAST; CANCER	The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown, Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/filopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase). Since the process of cell migration must involve changes in adhesion, we explored the potential HRG regulation of paxillin, a major cytoskeletal phosphoprotein of focal adhesion. We report that HRG stimulation of noninvasive breast cancer cells resulted in stimulation of p38 mitogen-activated protein kinase (p38(MAPK)), extracellular signal-regulated kinases (ERK) and PI-3K, and a concurrent unexpected increase in the level of paxillin phosphorylation on serine residue which was sensitive to protein-phosphatase 2b but not to protein tyrosine phosphatase 1, In addition, HRG triggered a rapid redistribution of paxillin to the perinuclear regions from the tyrosine-phosphorylated focal adhesions, and increased cell scattering. There was no effect of HRG on the state of phosphorylation and localization of focal adhesion kinase, The HRG-induced increase in serine phosphorylation of paxillin and cell scattering were selectively inhibited by a specific inhibitor of p38(MAPK) or a dominant-negative p38(MAPK) mutant, but not by inhibitors of p42/44(MAPK) or PI-3 kinase pathways. For the first time our results have shown that HRG, a potent migratory growth factor stimulates serine phosphorylation of paxillin. These findings suggest a role of p38(MAPK) dependent signal transduction pathway(s) in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape alterations and motility.	Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65746, CA80066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KIM HH, 1994, J BIOL CHEM, V269, P24747; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LO L, 1999, IN PRESS MOL CARCINO; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARTE BM, 1995, ONCOGENE, V10, P167; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHLAEPFER DD, 1994, NATURE, V372, P786; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vadlamudi R, 1999, CANCER RES, V59, P2843; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	47	62	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7253	7264		10.1038/sj.onc.1203163	http://dx.doi.org/10.1038/sj.onc.1203163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602479				2022-12-17	WOS:000084119400009
J	Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS				Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS			The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells	ONCOGENE			English	Article						BRCA-1; breast cancer; transcriptional control; Brn-3b; POU family transcription factors	NEURONAL CELLS; GENE BRCA1; DOMAIN; PROTEIN; DIFFERENTIATION; PROMOTER; GROWTH; MUTATIONS; DISTINCT; OPPOSITE	The BRCA-1 tumour supressor gene was identified on the basis of mutations which occur in familial breast cancer indicating that its inactivation can cause this disease. Although BRCA-1 does not appear to be mutated in sporadic breast cancer, its expression has been shown to be reduced in tumour material from such cases. We show here that mammary tumours which have reduced levels of BRCA-1 expression show enhanced expression of the Brn-3b POU family transcription factor at both the mRNA and protein levels. This elevated expression of Brn-3b is not found in normal mammary cells, benign tumours or in malignant tumour samples which do not exhibit reduced levels of BRCA-1. In contrast, no correlation was noted between BRCA-1 and expression of the related factor Brn-3a. Moreover, Brn-3b but not Brn-3a can strongly repress the BRCA-1 promoter approximately 20-fold in mammary tumour cells. To our knowledge, this is the first report of a transcription factor which regulates BRCA-1 expression. Thus, Brn-3b may play an important role in regulating expression of BRCA-1 in mammary tumours with enhanced expression of Brn-3b resulting in reduced BRCA-1 expression and thereby being potentially important in tumour development.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of London; University College London; University of Pennsylvania; University of Pennsylvania	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.							ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Latchman DS, 1997, INT J ONCOL, V10, P1133; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Rao VN, 1996, ONCOGENE, V12, P523; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VAHAUA O, 1995, NAT GENET, V9, P444; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	37	62	64	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6684	6691		10.1038/sj.onc.1203072	http://dx.doi.org/10.1038/sj.onc.1203072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597274				2022-12-17	WOS:000083792000008
J	Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB				Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB			VEGI, a new member of the TNF family activates Nuclear Factor-kappa B and c-Jun N-terminal kinase and modulates cell growth	ONCOGENE			English	Article						VEGI; NF-kappa B; apoptosis; JNK	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR FAMILY; LIGAND; APOPTOSIS; SUPERFAMILY; DEATH; ANGIOGENESIS; LYMPHOTOXIN; INHIBITOR; CYTOKINE	Recently a new member of the human tumor necrosis factor (TNF) family named as VEGI was reported. However, very little is known about the biological activities displayed by this cytokine. In this report, we show that in myeloid cells VEGI activated the transcription factor kappa B (NF-kappa B) as determined by the electrophoretic mobility shift assay, induced degradation of I kappa B alpha, and nuclear translocation of p65 subunit of NF-kappa B. VEGI also activated NF-kappa B-dependent reporter gene expression. In addition, VEGI activated c-Jun N-terminal kinase. When examined for growth modulatory effects, VEGI inhibited the proliferation of breast carcinoma (MCF-7), epithelial (HeLa), and myeloid (U-937 and ML-1a) tumor cells; and activated caspase-3 leading to PARP cleavage. VEGI-induced cytotoxicity was potentiated by inhibitors of protein synthesis. VEGI also induced proliferation of normal human foreskin fibroblast cells. The activity of VEGI could neither be neutralized by antibodies against TNF, nor could it compete with TNF binding, indicating that the activity of VEGI is not due to TNF and it binds to a distinct receptor. These results suggest that VEGI, a new member of the TNF family, has a signaling pathway similar to TNF and is most likely a multifunctional cytokine.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AGGARWAL BB, 1985, METHOD ENZYMOL, V116, P441; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Haridas V, 1998, J IMMUNOL, V161, P1; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; Kumar A, 1998, J IMMUNOL, V161, P776; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	35	62	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6496	6504		10.1038/sj.onc.1203059	http://dx.doi.org/10.1038/sj.onc.1203059			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597252				2022-12-17	WOS:000083709200012
J	Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD				Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD			Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; MYCN oncogene; MRP gene; antisense; transfection; cytotoxicity	RESISTANCE-ASSOCIATED PROTEIN; NEURO-BLASTOMA CELLS; MULTIDRUG-RESISTANCE; N-MYC; P-GLYCOPROTEIN; TUMOR-CELLS; OVEREXPRESSION; SENSITIVITY	We have recently shown a close correlation between expression of the Multidrug Resistance-associated Protein (MRP) gene and the MYCN oncogene and provided evidence that high MRP expression is a powerful independent predictor of poor outcome in neuroblastoma (Norris ct al., New Engl. J, Med., 334, 231-238, 1996), The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. Concomitant with,MYCN down-regulation, the level of MRP expression was decreased in the NBAS-4 and NBAS-5 antisense transfectants. These cells demonstrated significantly increased sensitivity to the high affinity MRP substrates vincristine, doxorubicin, sodium arsenate and potassium antimony tartrate, but not to the poor MRP substrates, taxol or cisplatin, Similarly, transfection of full-length MYCN cDNA into SH-EP neuroblastoma cells resulted in increased MRP expression and significantly increased resistance specifically to MRP substrates. The results provide evidence for the MYCN oncogene influencing cytotoxic drug response via regulation of MRP gene expression, Our data also provide a link between the malignant and chemoresistant phenotypes of this childhood malignancy.	Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia; Oncotech Inc, Irvine, CA USA; Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Univ Illinois, Dept Pediat, Chicago, IL USA	Children's Cancer Institute; University of Sydney; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Norris, MD (corresponding author), Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia.		Cohn, Susan/AAB-6010-2021; Kavallaris, Maria/J-5240-2014	Gilbert, Jayne/0000-0001-5034-386X; Norris, Murray/0000-0002-0632-4589; Cohn, Susan/0000-0001-5749-7650; Haber, Michelle/0000-0003-2036-8817				BORDOW SB, 1994, CANCER RES, V54, P5036; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; FLENS MJ, 1994, CANCER RES, V54, P4557; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRANT CE, 1994, CANCER RES, V54, P357; HABER M, 1989, CANCER RES, V49, P5281; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; NORRIS MD, 1998, IN PRESS EUR J CANC; RASCHELLA G, 1994, CANCER RES, V54, P2251; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHNEIDER E, 1994, CANCER RES, V54, P152; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SPENGLER BA, 1986, CANCER TREAT REP, V70, P959; Stram DO, 1996, J CLIN ONCOL, V14, P2417, DOI 10.1200/JCO.1996.14.9.2417; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1995, EUR J CANCER, V31A, P516, DOI 10.1016/0959-8049(95)00060-V; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	22	62	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2777	2782		10.1038/sj.onc.1202859	http://dx.doi.org/10.1038/sj.onc.1202859			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348353				2022-12-17	WOS:000080124900014
J	Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL				Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL			Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins	ONCOGENE			English	Article						p21; E2F; HBP1; Sp1	CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; INHIBITOR P21(WAF1/CIP1); GENE-EXPRESSION; WAF1/CIP1 GENE; S-PHASE; INDUCTION; P21; E2F	The Cdk inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, although its expression is induced by a number of mitogens that promote cell proliferation. We have found that E2F1 and E2F3, transcription factors that activate genes required for cell cycle progression, are strong activators of the p21 promoter. In contrast, HBP1 (HMG-box protein-1), a novel retinoblastoma protein-binding protein, can repress the p21 promoter and inhibit induction of p21 expression by E2F, Both E2Fs and HBP1 regulate p21 transcription through cis-acting elements located between nucleotides -119 to + 16 of the p21 promoter and the DNA binding domains of each of these proteins are required for activity. Sequences between -119 and -60 basepairs containing four Spl consensus elements and two noncanonical E2F binding sites are of major importance for E2F activation, although E2F1 and E2F3 differ in the extent of their ability to activate expression when this segment is deleted. The opposing effects of E2Fs and HBP1 on p21 promoter activity suggest that interplay between these factors may determine the level of p21 transcription in vivo.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tufts University	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048836, R01DK056283, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044634] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48836, R01 DK056283-05, R01 DK056283, P30 DK-34928] Funding Source: Medline; NIGMS NIH HHS [GM44634] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GARTEL AL, 1996, P SOC EXP BIOL MED, V213, P137; GARTEL AL, 1998, IN PRESS PROGR MOL S, V22; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MICHIELI P, 1994, CANCER RES, V54, P3391; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	52	62	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3463	3469		10.1038/sj.onc.1202240	http://dx.doi.org/10.1038/sj.onc.1202240			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030670				2022-12-17	WOS:000078086200007
J	Kominsky, S; Johnson, HM; Bryan, G; Tanabe, T; Hobeika, AC; Subramaniam, PS; Torres, B				Kominsky, S; Johnson, HM; Bryan, G; Tanabe, T; Hobeika, AC; Subramaniam, PS; Torres, B			IFN gamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21(WAF1/CIP1)	ONCOGENE			English	Article						interferon gamma; glioblastoma; cyclin dependent kinase 2; p21(WAF1)/(CIP1)	TUMOR-SUPPRESSOR GENE; P21; P53; EXPRESSION; INDUCTION; MUTATIONS; ARREST	Glioblastoma is a highly aggressive form of brain cancer characterized by uncontrolled cell growth resulting from a loss of cell cycle regulation. In this study we determined the antiproliferative effects of interferon gamma (IFN gamma) on the glioblastoma cell lines T98G, SNB-19 and U-373, focusing on the ability of IFN gamma, to increase levels of p21(WAF1/CIP1), important negative regulator of cell cycle events. IFN gamma, was found to inhibit the growth of all cell lines, with inhibition ranging from 82.2% to 45.%.Flow cytometry analysis showed that IFN gamma treatment caused a cell cycle delay in the G(1) or S phases. The strength of this delay varied, correlating with the degree by which IFNgamma inhibited proliferation of each cell line. IFN gamma, treatment increased the production of the cyclin dependent kinase inhibitor (CKI) p21(WAF1/CIP1) in all cell lines, the level and kinetics of production of which correlated with the degree and stage of inhibition of cellular proliferation. Further, immunoprecipitation of p21(WAF1/CIP1) in complexes of p21(WAF1/CIP1)/cyclin-dependent kinase 2 (cdk2)/cyclin showed that the amount of p21(WAF1/CIP1) in the complexes and the inhibition of cdk2-cyclin kinase activity correlated with the level of p21(WAF1/CIP1) produced in the cells by IFN gamma. These results show that IFN gamma has significant antiproliferative effects on the glioblastoma cell lines and suggest that p21(WAF1/CIF1) plays a role in mediating these effects.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Kominsky, S (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.				NCI NIH HHS [CA38587] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	13	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2973	2979		10.1038/sj.onc.1202217	http://dx.doi.org/10.1038/sj.onc.1202217			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881699				2022-12-17	WOS:000077427800004
J	Deng, J; Xia, WY; Hung, MC				Deng, J; Xia, WY; Hung, MC			Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo	ONCOGENE			English	Article						tumor suppression; apoptosis; adenovirus 5 E1A; murine melanoma	PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; E1A GENE-PRODUCTS; TRANSCRIPTIONAL REPRESSION; ULTRAVIOLET-RADIATION; MURINE MELANOMA; BREAST-CANCER; SOLID TUMORS; RAT-CELLS; EXPRESSION	Disruption of apoptotic pathways is a major factor in the multistep process of tumorigenesis, whereas induction of apoptosis can be important for tumor suppression and cancer therapy. The adenovirus type 5 E1A gene provides a useful tool to study the function of tumor suppression and apoptosis. E1A has been shown to induce apoptosis in different systems in vitro . However, this activity has not been well characterized in vivo. Therefore, the effect of this activity and the link to the in vivo biological function are not clear. To answer these questions, we introduced E1A into murine melanoma cells and characterized the biological features both in vitro and in vivo. Expression of the EIA gene does not affect the proliferation rate of tumor cells in vitro, but inhibits tumor growth in vivo. The in vitro analysis indicated that the E1A-expressing tumor cells are sensitive to serum depletion-induced apoptosis. Importantly, E1A-mediated apoptosis was also identified in vivo, suggesting this activity contributed to the tumor suppressive function. The in vivo apoptotic pattern was unique: most of the apoptotic cells were around the periphery of the tumors, implicating the interaction of these cells with stress stimuli irt vivo. In addition, E1A also rendered the tumor cells susceptible to the cytotoxicity of other anticancer agents, a feature useful for improving the efficacy of cancer therapy. The results provide a functional link between in vitro activity and in vivo effects.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Boulakia CA, 1996, ONCOGENE, V12, P529; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHEN PW, 1993, J IMMUNOL, V151, P244; CHU G, 1994, J BIOL CHEM, V269, P787; COOK JL, 1989, J IMMUNOL, V142, P4527; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Donawho CK, 1996, J IMMUNOL, V157, P781; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN M, 1995, CANCER RES, V55, P2470; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Jansen B, 1997, CANCER RES, V57, P362; KERBEL RS, 1994, INVAS METAST, V14, P50; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; PIERCEALL WE, 1992, CANCER RES, V52, P3946; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SHIH IM, 1993, J INVEST DERMATOL, V100, P196; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRENT JC, 1996, EMBO J, V15, P4459; TSUJI Y, 1993, J IMMUNOL, V150, P1897; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wu JX, 1996, ANTICANCER RES, V16, P2233; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG YJ, 1995, ONCOGENE, V10, P1947	58	62	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2167	2175		10.1038/sj.onc.1202148	http://dx.doi.org/10.1038/sj.onc.1202148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811448				2022-12-17	WOS:000076698200003
J	Wang, RX; Brunner, T; Zhang, LY; Shi, YF				Wang, RX; Brunner, T; Zhang, LY; Shi, YF			Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression	ONCOGENE			English	Article						fungal metabolite; c-myc; FasL; apoptosis; T cell hybridoma	T-CELL HYBRIDOMAS; ACTIVATION-INDUCED APOPTOSIS; CHROMOBACTERIUM-VIOLACEUM NO-968; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; LYMPHOCYTES; ANTIGEN; CD95; SENSITIVITY	Activation of T lymphocytes often leads to cellular activation, production of cytokines, entry into cell cycle, and expression of Fas (CD95) and Fas ligand (FasL), Although it is well established that the interaction of Fas and Fast results in apoptosis, mechanisms for regulated expression of Fas and Fast are unclear. Our previous work with antisense oligodeoxynucleotides suggested that the protooncogene c-myc is obligatory for activation-induced apoptosis, To study the relationship between myc and the Fas/FasL expression, we employed the antisense method and a newly identified fungal metabolite, FR901228, which has been shown to specifically inhibit expression of c-myc in fibroblasts, We found that FR901228 could effectively block activation-induced apoptosis in T cell hybridomas and this was correlated with its specific inhibition of c-myc expression, Both FR901228 and antisense oligodeoxynucleotide to c-myc had similar effect in inhibiting Fast expression. These treatments did not affect activation-induced production of IL-2, nor the expression of Fas, In addition, FR901228 inhibited the expression of Fast in 3T3 fibroblasts, but not these transfected with c-myc, supporting a specific role of c-myc in this process. Thus, c-Myc plays a fundamental role in the regulation of the expression of Fast, but not Fas and IL-2, Our data further defined the requirement of c-Myc in activation-induced apoptosis in T cells.	Amer Red Cross, Jerome H Holland Lab, Dept Immunol, Rockville, MD 20855 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	American Red Cross; La Jolla Institute for Immunology	Shi, YF (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Immunol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MERCEP M, 1989, J IMMUNOL, V142, P4085; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1995, CANCER RES, V55, P1982; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUDA T, 1995, J IMMUNOL, V154, P3806; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579; Williams MS, 1996, J IMMUNOL, V157, P2395; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	37	62	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1503	1508		10.1038/sj.onc.1202059	http://dx.doi.org/10.1038/sj.onc.1202059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794227	Green Submitted			2022-12-17	WOS:000076089900002
J	Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ				Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ			Concordant methylation of the ER and N33 genes in glioblastoma multiforme	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; aging; estrogen receptor; N33	TUMOR-SUPPRESSOR GENE; RECEPTOR CPG ISLAND; ESTROGEN-RECEPTOR; DNA METHYLATION; EPITHELIAL-CELLS; HYPERMETHYLATION; EXPRESSION; INACTIVATION; GLIOMAS; CANCER	Methylation of promoter-associated CpG islands appears to be a potential way by which tumor suppressor genes are inactivated in cancer. Using Southern blot analysis, we have studied the methylation of several genes in glioblastoma multiforme (GBM), trying to determine their contribution to tumorigenesis. Genes studied included the estrogen receptor (ER), N33, the candidate tumor-suppressors P15, P16 and HIC1 and a control gene, c-abl, Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GEM respectively. HIC1 methylation was detected in normal brain as well, but appeared to be more extensive in tumors. ER and N33 methylation were significantly more frequent in tumors from individuals over the age of 40 (70% and 88% vs 36% and 14%). In addition, there was a strong association between EX and N33 methylation, which were concordant in 81% of the cases (P< 0.01). ER and N33 methylation in GEM may therefore appear as a result of shared etiologic factors, which may relate in part to aging cell populations in the brain.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesia & Crit Care, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [P30CA06973, 5UO1CA64928, 5RO1CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318, U01CA064928, P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bondy ML, 1996, CANCER RES, V56, P1484; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Fueyo J, 1996, ONCOGENE, V13, P1615; Furnari FB, 1995, CANCER SURV, V25, P233; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Issa JPJ, 1996, CANCER RES, V56, P3655; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; Jones PA, 1996, CANCER RES, V56, P2463; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTAGATI S, 1994, J NEUROCHEM, V63, P2058; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VERTINO PM, 1993, CANCER RES, V53, P1684; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	37	62	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3197	3202		10.1038/sj.onc.1201831	http://dx.doi.org/10.1038/sj.onc.1201831			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671399				2022-12-17	WOS:000074261300013
J	Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW				Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW			Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice	ONCOGENE			English	Article						BCL3; NF-kappa B; transgenic mice	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; ONCOPROTEIN BCL-3; DNA-BINDING; CELL; ENCODES; EXPRESSION; HOMODIMERS	The candidate proto-oncogene BCL3 was isolated through its involvement in the t(14;19) found in chronic lymphocytic leukemia and other B-cell neoplasms. As a member of the I kappa B family, BCL3 plays a role in the immune response by interactions with the NF-kappa B family of transcription factors. In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated five lines of E mu-BCL3 transgenic mice. Transgenic animals develop normally but show splenomegaly and an accumulation of mature B cells in lymph nodes, bone marrow and peritoneal cavity. A hyperresponsive immune system is suggested by the follicular hyperplasia and plasmacytosis in lymph nodes of unimmunized animals, increased incidence of antibodies to self-antigens, and a heightened response to crosslinking of surface ISM. Statistically significant decreases in serum IgM and IgG3, but an increase in IgG1 and IgA were also observed. No lymphoid neoplasms have been identified in transgenic animals. The expansion of B cells in vivo is consistent with the overexpression of BCL3 as being one step in the multi-step process of leukemogenesis. The phenotype also suggests that BCL3 plays a part in B cell proliferation and isotype switching.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	McKeithan, TW (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			McKeithan, Timothy/0000-0003-2242-3074; Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [P30CA14599, CA55356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055356, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASOU H, 1993, BRIT J HAEMATOL, V85, P492; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BHATIA K, 1991, ONCOGENE, V6, P1569; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; Datta SK, 1997, J CLIN IMMUNOL, V17, P11, DOI 10.1023/A:1027328226918; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FULLER KA, 1993, J IMMUNOL, V151, P4505; GERONDAKIS S, 1991, IMMUNOGENETICS, V34, P392, DOI 10.1007/BF01787490; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; KENTER AL, 1993, J IMMUNOL, V151, P4718; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Lin SC, 1996, MOL CELL BIOL, V16, P4591; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MADAIO MP, 1984, J IMMUNOL, V132, P872; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Michaux L, 1997, CANCER GENET CYTOGEN, V94, P36, DOI 10.1016/S0165-4608(96)00247-6; NAKAJIMA A, 1995, EUR J IMMUNOL, V25, P3060, DOI 10.1002/eji.1830251112; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SCHRIEVER F, 1992, ADV IMMUNOL, V51, P243, DOI 10.1016/S0065-2776(08)60489-7; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Snapper CM, 1996, J IMMUNOL, V156, P183; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	39	62	64	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2333	2343		10.1038/sj.onc.1201771	http://dx.doi.org/10.1038/sj.onc.1201771			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620550				2022-12-17	WOS:000073428000005
J	Umikawa, M; Tanaka, K; Kamei, T; Shimizu, K; Imamura, H; Sasaki, T; Takai, Y				Umikawa, M; Tanaka, K; Kamei, T; Shimizu, K; Imamura, H; Sasaki, T; Takai, Y			Interaction of Rho1p target Bni1p with F-actin-binding elongation factor 1 alpha: implication in Rho1p-regulated reorganization of the actin cytoskeleton in Saccharomyces cerevisiae	ONCOGENE			English	Article						Rho; actin cytoskeleton; EF1 alpha	PROTEIN-KINASE-C; YEAST PROTEIN; BUDDING YEAST; IDENTIFICATION; DICTYOSTELIUM; GENE; FACTOR-1-ALPHA; TRANSFORMATION; MORPHOGENESIS; DROSOPHILA	The RHO1 gene encodes a homolog of mammalian RhoA small G protein in the yeast Saccharomyces cerevisiae. We have shown that Bni1p is one of the downstream targets of Rho1p and regulates reorganization of the actin cytoskeleton through the interaction with profilin, an actin monomer-binding protein. A Bni1p-binding protein was affinity purified from the yeast cytosol fraction and was identified to be Tef1p/Tef2p, translation elongation factor 1 alpha (EF1 alpha). EF1 alpha is an essential component of the protein synthetic machinery and also possesses the actin filament (F-actin)binding and -bundling activities. EF1 alpha bound to the 186 amino acids region of Bni1p, located between the FH1 domain, the proline-rich profilin-binding domain, and the FH2 domain, of which function is not known. The binding of Bni1p to EF1 alpha inhibited its F-actin-binding and -bundling activities. The BNI1 gene deleted in the EF1 alpha-binding region did not suppress the bni1 bnr1 mutation in which the actin organization was impaired. These results suggest that the Rho1p-Bni1p system regulates reorganization of the actin cytoskeleton through the interaction with both EF1 alpha and profilin.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DEMMA M, 1990, J BIOL CHEM, V265, P2286; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Edmonds BT, 1996, J CELL SCI, V109, P2705; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN C, 1987, GENE, V67, P21; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Higuchi R., 1989, PCR TECHNOLOGY, P61; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MARHOUL JF, 1995, GENETICS, V139, P537; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Sambrook J, 1989, MOL CLONING LAB MANU; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; Sherman F., 1986, METHODS YEAST GENETI; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	43	62	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2011	2016		10.1038/sj.onc.1201724	http://dx.doi.org/10.1038/sj.onc.1201724			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591785				2022-12-17	WOS:000073079400013
J	Comer, KA; Dennis, PA; Armstrong, L; Catino, JJ; Kastan, MB; Kumar, CC				Comer, KA; Dennis, PA; Armstrong, L; Catino, JJ; Kastan, MB; Kumar, CC			Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein	ONCOGENE			English	Article						alpha-actin; p53; transactivation; cytoskeleton	RAS-TRANSFORMED CELLS; WILD-TYPE P53; DNA-DAMAGE; CELLULAR-RESPONSE; BINDING PROTEIN; PROMOTER; EXPRESSION; GROWTH; CHECKPOINT; SEQUENCE	Smooth muscle (sm) alpha-actin is expressed in vascular smooth muscle cells and fibroblast cells. Its expression is regulated by cell proliferation and repressed during oncogenic transformation, In this study, we demonstrate that p53 activation is associated with a dramatic increase in organized microfilament bundles and an increase in sm alpha-actin mRNA level. Wild-type p53, but not mutant p53, strongly stimulated human sm alpha-actin promoter activity in p53 null cell lines. The sequences homologous to the p53 consensus sequence and to the p53 binding sequence from the muscle creatine kinase, were found within a specific region of the sm alpha-actin promoter. This sequence was sufficient to confer p53-dependent activation to a heterologous promoter and p53 was capable of binding to this sequence as assessed by gel shift analysis. Ionizing irradiation of colorectal tumor cells caused an increase in alpha-actin mRNA level in a p53-dependent manner. Taken together, these results demonstrate that human sm alpha-actin gene is a transcriptional target for p53 tumor suppressor protein and represents the first example of a cytoskeletal gene with a functionally defined p53 response element.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Merck & Company; Schering-Plough Research Institute; Johns Hopkins University; Johns Hopkins Medicine	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.				NIEHS NIH HHS [R01ES05777] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUSHEL P, 1995, ONCOGENE, V10, P1361; CHEN JY, 1993, ONCOGENE, V8, P2159; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; KAJSTURA J, 1993, CELL BIOL INT, V17, P1023, DOI 10.1006/cbir.1993.1032; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR CC, 1995, J BIOCHEM-TOKYO, V118, P1285, DOI 10.1093/oxfordjournals.jbchem.a125020; KUMAR CC, 1992, CANCER RES, V52, P6877; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCHUGH KM, 1988, NUCLEIC ACIDS RES, V16, P4167, DOI 10.1093/nar/16.9.4167; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OWENS GK, 1986, J BIOL CHEM, V261, P3373; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; REDDY S, 1990, J BIOL CHEM, V265, P1683; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMALL JV, 1993, P SOC EXP BIOL MED, P57; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	45	62	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1299	1308		10.1038/sj.onc.1201645	http://dx.doi.org/10.1038/sj.onc.1201645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546431				2022-12-17	WOS:000072422000008
J	Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG				Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG			Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube	ONCOGENE			English	Article						Eph; ephrin; receptor; kinase; development; neural	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; FLOOR PLATE; KIT-LIGAND; TRANSMEMBRANE LIGANDS; MOLECULAR-CLONING; COMMISSURAL AXONS; MESSENGER-RNAS; NERVOUS-SYSTEM; IN-VITRO	The ephrins are a family of ligands that bind to Eph family receptor tyrosine kinases, and have been implicated in axon guidance and other patterning processes during vertebrate development. We describe here the identification and characterization of murine ephrin-B3. The cDNA encodes a 340 amino acid transmembrane molecule, most closely related to the two other known transmembrane ligands, ephrin-B1 and ephrin-B2. In addition to homology in their extracellular receptor binding domains, these transmembrane ligands share striking homology between their cytoplasmic domains, with 31 of the last 34 amino acids of ephrin-B3 being identical to ephrin-B2, suggesting functional interactions of the cytoplasmic tail. While most Eph family ligands are promiscuous in their interactions with Eph receptors, binding studies with the five receptors known to bind other transmembrane ligands only revealed a high affinity interaction of ephrin-B3 with EphB3, with a dissociation constant of approximately 1 nM. In situ hybridization of mouse embryos showed ephrin-B3 is expressed prominently at the dorsal and ventral midline of the neural tube, particularly in the floor plate, a structure with key functions in patterning the nervous system. The isolation of this ligand may help to elucidate the molecular basis of patterning activities at the neural tube midline.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL)	Flanagan, JG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.		Klein, Ruediger/C-6147-2008; Flanagan, John/AAM-2995-2020; Brambilla, Riccardo/A-6082-2010	Klein, Ruediger/0000-0002-3109-0163; Brambilla, Riccardo/0000-0003-3569-5706; Bergemann, Andrew/0000-0002-0027-7662	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; BRAMBILLA R, 1996, MOL CELL NEUROSCI, V6, P487; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; CIOSSEK T, 1995, ONCOGENE, V11, P2085; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Donoghue MJ, 1996, MOL CELL NEUROSCI, V8, P185, DOI 10.1006/mcne.1996.0056; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Flanagan JG, 1997, CELL, V90, P403; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLANAGAN JG, IN PRESS ANN REV NEU, V21; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; Kilpatrick TJ, 1996, MOL CELL NEUROSCI, V7, P62, DOI 10.1006/mcne.1996.0005; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Ohta K, 1996, MECH DEVELOP, V54, P59, DOI 10.1016/0925-4773(95)00461-0; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Sakano S, 1996, ONCOGENE, V13, P813; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SMITH A, 1997, CURRENT BIOL; SOANS C, 1994, ONCOGENE, V9, P3353; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WU Q, 1995, DEVELOPMENT, V121, P4005; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Zhang JH, 1996, J NEUROSCI, V16, P7182; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	69	62	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					471	480		10.1038/sj.onc.1201557	http://dx.doi.org/10.1038/sj.onc.1201557			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484836				2022-12-17	WOS:000071739400005
J	Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL				Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL			Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1	ONCOGENE			English	Article						MEK kinase 1; apoptosis; UVC; cisplatin	PROTEIN-KINASE; C-JUN; BINDING PROTEINS; TYROSINE KINASE; CERAMIDE; PATHWAY; GROWTH; ERK; MYC	MEK kinases (MEKKs) are serine-threonine kinases that regulate sequential protein phosphorylation pathways involving mitogen-activated protein kinases (MAPKs), including members of the Jun kinase (JNK) family. MEKK1 is a 196 kDa protein that when cleaved by caspase-3-like proteases generates an active COOH-terminal kinase domain. Expression of the MEKK1 kinase domain is sufficient to induce apoptosis. Mutation of MEKK1 to prevent its proteolytic cleavage protects cells from MEKK1-mediated cell death even though the JNK pathway is still activated, indicating that JNK activation is not sufficient to induce cell death. The inducible acute expression at modest levels of the activated MEKK1 kinase domain can be used to potentiate the apoptotic response to low dose ultraviolet irradiation and cisplatin. Similarly, in L929 fibrosarcoma cells inducible acute expression of the kinase domain of MEKK1 markedly increased the cell death response to tumor necrosis factor alpha(TNF alpha). The findings demonstrate that acute expression of an active farm of MEKK1 can potentiate the cell death response to external stress stimuli. Manipulation of MEKK1 proteolysis and its regulation of signal pathways involved in apoptosis has significant potential for anticancer therapies when used in combination with therapeutic agents at doses that alone have little or modest effects on cell viability.	NATL JEWISH CTR IMMUNOL & RESP MED,PROGRAM MOL SIGNAL TRANSDUCT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 37871, DK 48845] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHU G, 1994, J BIOL CHEM, V269, P787; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANGER GR, 1997, IN PRESS EMBO J; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FESHEL K, 1991, AM J PATHOL, V139, P251; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEIBI M, 1993, GENE DEV, V7, P2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; JNO P, 1997, MOL CELL BIOL, V17, P24; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KRYPRIANOU N, 1991, J NATL CANCER I, V83, P346; KRYRIAKIS JM, 1994, NATURE, V369, P156; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; ROITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P151; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	62	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2439	2447		10.1038/sj.onc.1201421	http://dx.doi.org/10.1038/sj.onc.1201421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395240				2022-12-17	WOS:A1997YE96300006
J	Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL				Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL			SEN6, a locus for SV40-mediated immortalization of human cells, maps to 6q26-27	ONCOGENE			English	Article						immortalization; growth suppressor; SV40, SEN6; senescence	DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN-DIPLOID FIBROBLASTS; NON-HODGKINS-LYMPHOMA; LARGE T-ANTIGEN; INDEFINITE DIVISION; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; DISTINCT REGIONS; GENETIC-ANALYSIS; SIMIAN VIRUS-40	Normal cells show a Limited lifespan in culture and the phenotype of cellular senescence, Tumors and tumor cell lines have typically overcome this form of growth suppression and grow continuously as immortal cell lines in culture, We have exploited the DNA virus SV40 to study the mechanism by which human fibroblasts overcome senescence and become immortal, Multiple steps have now been identified, including inactivation of cellular growth suppressors through direct interaction with SV40 large T antigen and through mutation of a gene on chromosome 6 (designated SEN6), In this study, we sublocalize the site of SEN6 to 6q26-27 based on molecular genetic analysis, Twelve SV40-immortalized fibroblast cell lines share a deletion in this area based on assessment for loss of heterozygostiy (LOH) for seven informative markers on 6q, Two immortal cell lines (AR5 and HALneo) appeared to have retained separate single copies of chromosome 6 despite the fact that they are both derived from the same preimmortal SV40-transformant and should share the same mutated allele of SEN6 (Hubbard-Smith et al., 1992), Detailed analysis by polymerase chain reaction, restriction fragment length polymorphism and fluorescence in situ hybridization shows, however, that although they differ for 17 markers from the centromere to 6q26, they share AR5 derived sequences (eight markers) distal to 6q26 including the minimal deletion region, further supporting the assignment of SEN6 to this region, Since human tumors including non-Hodgkins lymphoma, mammary carcinoma and ovarian carcinoma show LOH in 6q26-27, inactivation of SEN6 may be responsible for immortalization of these tumors as well.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; CYPRUS INST NEUROL & GENET,DEPT CYTOGENET,NICOSIA,CYPRUS; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; LOS ALAMOS NATL LAB,CELLULAR & MOL BIOL GRP,LOS ALAMOS,NM	Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; United States Department of Energy (DOE); Los Alamos National Laboratory			Kim, Soo Hyun/ABG-8773-2020; Gamberi, Barbara/AAA-7508-2019	Kim, Soo Hyun/0000-0002-9394-1437; Gamberi, Barbara/0000-0003-3616-5838	NIA NIH HHS [AG04821, AG00378] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004821, P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banga SS, 1996, CYTOGENET CELL GENET, V73, P295, DOI 10.1159/000134359; BANGA SS, 1996, AM J HUM GENET; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BRAVARD A, 1992, INT J CANCER, V52, P797, DOI 10.1002/ijc.2910520521; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CASSON AG, 1991, CANCER RES, V51, P4495; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUJII M, 1995, ONCOGENE, V11, P627; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOFFSCHIR F, 1992, INT J CANCER, V52, P130, DOI 10.1002/ijc.2910520123; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI S, 1994, MOL CELL BIOL, V14, P7182, DOI 10.1128/MCB.14.11.7182; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MITELMAN F, 1991, CATALOG CHROMOSOME A, V1, P393; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OFFIT K, 1993, BLOOD, V82, P2157; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; Patsalis PC, 1995, CLIN GENET, V48, P275; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PURRELLO M, 1994, GENOMICS, V22, P94, DOI 10.1006/geno.1994.1349; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROSEN DR, 1995, CYTOGENET CELL GENET, V69, P279, DOI 10.1159/000133979; SAGAWARA O, 1990, SCIENCE, V247, P707; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Small MB, 1996, J CELL PHYSIOL, V168, P727, DOI 10.1002/(SICI)1097-4652(199609)168:3<727::AID-JCP26>3.0.CO;2-U; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRASK BJ, 1992, METHOD CELL BIOL, V35, P3; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; Wiesmuller L, 1996, J VIROL, V70, P737; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	68	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					313	321		10.1038/sj.onc.1200842	http://dx.doi.org/10.1038/sj.onc.1200842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018117				2022-12-17	WOS:A1997WD51600007
J	Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R				Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R			Cell-cycle regulation of B-Myb protein expression: Specific phosphorylation during the S phase of the cell cycle	ONCOGENE			English	Article						B-Myb; cell cycle; phosphorylation; cyclin dependent kinase	C-MYB; HEMATOPOIETIC-CELLS; A-MYB; PROLIFERATION; TRANSCRIPTION; ACTIVATION; CDC2	Previous studies revealed that transcription of B-Myb, which encodes a transcription factor related to the c-Myb proto-oncoprotein, is cell-cycle regulated by an E2F transcription factor-mediated repression mechanism operating in G(0)/G(1). To begin to determine the consequences of transcriptional regulation on B-Myb function, we report here further studies of B-Myb protein expression in the cell cycle. We found that G(0)-arrest of serum-deprived mouse fibroblasts was achieved without significant reduction in B-Myb levels, moreover, overexpression of B-Myb in stably transfected cells did not prevent their entry into G(0). Following serum-induction of arrested fibroblasts, B-Myb abundance increased as cells entered S phase to levels significantly greater than found in cycling cells. This was accompanied by the appearance of a novel phosphorylated form of B-Myb (112 kDa) of distinctly lower electrophoretic mobility than B-Myb present in G(1) (110 kDa). The 112 kDa species was S phase-specific even in transfected cells overexpressing B-Myb. Consistent with modification in the S phase of the cell cycle, preliminary evidence suggested that a cyclin A/cdk2, but not cyclin E/cdk2 or cyclin D1/cdk4, complex could induce a similar electrophoretic mobility change in baculovirus-specified B-Myb. These findings show that B-Myb expression may be subject to two levels of control during the cell cycle, transcription and protein phosphorylation.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HARPER JW, 1993, CELL, V75, P805; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	32	62	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649845				2022-12-17	WOS:A1996UK49800003
J	Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y				Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y			Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation	ONCOGENE			English	Article						p53 mutations; colon carcinoma; cell cycle arrest; transfection	WILD-TYPE P53; COLORECTAL TUMORIGENESIS; TUMOR SUPPRESSION; BREAST-CANCER; GROWTH ARREST; MUTANT P53; PROTEIN; DNA; GENE; INSTABILITY	The LoVo colon carcinoma cell line that presents two wild type p53 alleles was used as the recipient for a series of transfections with p53 expression vectors coding for wild-type or three different mutants (143ala, 175his or 273his). The parental cell line as well as all clones that had rearranged the plasmid with consequent loss of p53 c-DNA were readily blocked at the G1/S boundary following 10 Gy of irradiation. For each mutation two clones with different levels of mutant protein expression were selected. Confirmation of the integration of the exogenous sequence was obtained by the expression of the mutant m-RNA, established by reverse transcription and DGGE or Southern blot. Flow cytometric measurements of 5-bromodeoxyuridine incorporation revealed a total G(1)/S block of the 143ala transfectants, similarly to the parental and control transfectant cells, but little or no cell cycle block for the 175his and 273his clones. Although it has been shown in vitro that all three mutations interfere with transcriptional activation by the wild-type protein, not only did we observe p53 protein induction and nuclear accumulation following irradiation, but WAF-1/CIP-1 m-RNA was increased in some of the clones for which the G1/S block was abolished. Our results show that mutant p53 proteins are to some extent submitted to the control of the cellular environment in cancer cells with wild type p53 alleles, but with an efficacy that depends on the mutation.	INST CURIE,UMR CYTOGENET MOLEC & ONCOL 147,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Chevillard, Sylvie/0000-0001-5889-4041				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALL PA, 1993, ONCOGENE, V8, P203; HANN, 1995, NAT GENET, V9, P221; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLSTEIN M, 1991, SCIENCE, V253, P49; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VSOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1995, ONCOGENE, V11, P141; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	62	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					875	882						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632910				2022-12-17	WOS:A1996TW68600019
J	Zhan, SL; Shapiro, DN; Helman, LJ				Zhan, SL; Shapiro, DN; Helman, LJ			Loss of imprinting of IGF2 in Ewing's sarcoma	ONCOGENE			English	Article						IGF2; Ewing's sarcoma; genomic imprinting; pediatric sarcoma	FACTOR-II GENE; GROWTH-FACTOR; WILMS-TUMOR; METHYLATION; EXPRESSION; RELAXATION; TRANSLOCATION; FUSION	yInsulin-like Growth Factor 2 (IGF2) has recently been demonstrated to be maternally imprinted in both mice and humans, We previously reported loss of imprinting (LOI) of IGF2 in rhabdomyosarcoma (RMS) where IGF2 has been shown to act as an autocrine growth factor and play an important role in pathogenesis, Since IGF2 does not appear to play a role in the pathogenesis of Ewing's sarcoma, we sought to determine whether normal IGF2 imprinting was maintained in these tumors, Of 32 Ewing's tumors examined for imprinting of IGF2, 10 were informative heterozygotes and three of these expressed IGF2 biallelically. Furthermore, all three tumors with LOI and five of seven tumors with normal imprinting transcribed IGF2 mRNA at lower levels while relatively higher levels of IGFS expression was observed in the remaining two tumors with normal imprinting, These data demonstrate altered imprinting of IGF2 occurs some Ewing's sarcomas, However, LOI of IGF2 Ewing's sarcoma was not associated with increased expression of IGF2 mRNA, suggesting that LOI may not be involved in the regulation of IGF2 expression and may be related to genetic or epigenetic abnormalities in tumors independent of IGF2 expression.	NCI, PEDIAT BRANCH, MOLEC ONCOL SECT, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EKSBERG R, 1993, NAT GENET, V5, P143; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GLOUDEMANS T, 1992, CANCER RES, V52, P6516; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; KONDO M, 1995, ONCOGENE, V10, P1193; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STEENMAN MJC, 1994, NAT GENET, V7, P432; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YUNIS EJ, 1986, AM J SURG PATHOL, V10, P54; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	31	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2503	2507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545106				2022-12-17	WOS:A1995TP18800005
J	vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL				vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL			Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells	ONCOGENE			English	Article						Ret; Pas; Raf; signal transduction; MAP kinase; cAMP	PHOSPHORYLATION; PROTOONCOGENE; INHIBITION; MUTATIONS; COMPLEX; PROTEIN; CAMP; SHC	Ret is a receptor tyrosine kinase predominantly expressed in tissue derived from the neuroectoderm and is involved in multiple endocrine neoplasia type 2A and 2B, familiar medullary thyroid carcinoma, and Hirschsprung's disease, The ligand for the receptor is still unknown, Previously, using a human epidermal growth factor receptor - Ret chimaeric receptor (HERRet) stably transfected into fibroblasts, it was shown that Pet activation induces the activation of p21ras, but, surprisingly, activation of extracellular signal-regulated kinase 2 (ERK2) was not observed (Santoro et al, (1994), Mol. Cell, Biol., 14, 663), In this report we describe early signaling events induced by the activated HERRet fusion receptor in a cell line derived from neuroectodermal tissue, SK-N-MC, In these cells, activated HERRet induces tyrosine phosphorylation of She, complex formation of She with Grb2 and Sos and activation of p21ras, Importantly, also ERK2 is activated, This activation was strong and sustained for at least 2 h, Activation was abolished by the dominant negative p21ras(asn17) mutant, showing that activation of ERK2 is mediated by p21ras, These results suggest that Pet can induce ERK2 activation in a p21ras dependent manner in cells derived from tissue where Pet is endogenously expressed.	UNIV UTRECHT,PHYSIOL CHEM LAB,GRAD SCH DEV BIOL,3508 TA UTRECHT,NETHERLANDS; HUBRECHT LAB,GRAD SCH DEV BIOL,3584 CT UTRECHT,NETHERLANDS	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)				Medema, Jan Paul/0000-0003-3045-2924				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1994, HUM MOL GENET, V3, P1439; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BASU T, 1994, ONCOGENE, V9, P3483; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	40	62	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2207	2214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570170				2022-12-17	WOS:A1995TK70200003
J	DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J				DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J			DIFFERENTIAL REGULATION OF MAX AND ROLE OF C-MYC DURING ERYTHROID AND MYELOMONOCYTIC DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Note						C-MYC; MAX; K562 CELLS; DIFFERENTIATION	MURINE ERYTHROLEUKEMIA-CELLS; MYELOID-LEUKEMIA CELLS; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE AUTOREGULATION; GROWTH-INHIBITION; PHORBOL ESTER; LINE K562; ONCOGENE; PROTEIN	The protein Max binds to c-Myc and the heterodimer c-Myc/Max seems to be the active form in vivo. While the expression of c-myc is extensively regulated, no major changes in max expression have been reported so far with respect to differentiation, We have studied the expression of c-Myc and Max during in vitro differentiation of the bipotent human myeloid leukemia K562 cell line, This cell model system allowed us to compare c-Myc and Max expression during differentiation along erythroid (induced by 1-beta-D-arabinofuranosyl-cytosine) and myelomonocytic lineages (induced by 12-0-tetradecanoylphorbol-13-acetate). We found that c-myc expression decreased as a result of both differentiating treatments, The expression level of max remained unchanged during myelomonocytic differentiation, In contrast, max mRNA and protein were dramatically down-regulated during erythroid differentiation of K562 cells, thus demonstrating that max gene is subjected to regulation during differentiation, We also studied the expression of the other two described members of the c-Myc network: mxi1 and mad. mxi1 expression increased during erythroid differentiation but was strongly downregulated during myelomonocytic differentiation of K562, mad was constitutively expressed during K562 erythroid differentiation and slightly increased during induction of the myelomonocytic pathway, We have obtained K562 sublines stably transfected with a zinc-inducible c-myc gene, In these clones the overexpression of c-Myc did not interfere with TPA-induced myelomonocytic differentiation. In contrast, erythroid differentiation was significantly inhibited upon c-myc induction despite the downregulation of endogeneous max expression, These results suggest a differential role for c-Myc in the human myeloid cell differentiation depending on the cell lineage.	UNIV CANTABRIA,FAC MED,DEPT BIOL MOLEC,E-39011 SANTANDER,SPAIN	Universidad de Cantabria			Canelles, Matilde/AAB-1011-2019; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Leon, Javier/0000-0001-5803-0112; Canelles, Matilde/0000-0003-2973-609X; Delgado, M. Dolores/0000-0003-4682-4040				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cleveland J L, 1988, Oncogene Res, V3, P357; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOFFMANLIEBERMA.B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, BLOOD REV, V2, P121, DOI 10.1016/0268-960X(88)90034-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAMBROOK F, 1989, MOL CLONING LABORATO; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; TONINI GP, 1987, CANCER RES, V47, P4544; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	42	62	64	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731722				2022-12-17	WOS:A1995QU68100024
J	WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF				WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF			WT1, THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, REPRESSES TRANSCRIPTION THROUGH AN INTERACTIVE NUCLEAR-PROTEIN	ONCOGENE			English	Note						WT1; TUMOR SUPPRESSOR; TRANSCRIPTION; INTERACTIVE PROTEIN	FACTOR-A-CHAIN; KIDNEY DEVELOPMENT; UROGENITAL SYSTEM; EXPRESSION; GROWTH; CELLS; KRUPPEL; DOMAINS; LOCUS; DNA	The Wilms' tumor suppressor gene, wt1, encodes a transcription factor of the zinc finger family, Mutations in WT1 have been detected in subsets of Wilm's tumor and in patients,vith the Denys-Drash Syndrome, In order to determine how WT1 regulates transcription and perhaps the consequences that mutations in WT1 may have, we established that residues 85-124 and 181-250 of WT1 constitute domains that function independently with DNA binding domain to repress or activate transcription, respectively, and function equally effectively with heterologous promoters, suggesting the activator and repressor domains interact with nuclear components of general importance, To seek evidence for such components, increasing concentrations of WT1 repressor domain without a zinc finger DNA binding domain were co-transfected with fixed concentrations of wild-type (wt) WT1 and PDGF A-chain promoter/reporter gene constructs, As levels of the repressor domain were increased, a progressive loss of wt WT1 repressor activity and a progressive increase in its activation were observed, suggesting that the repressor domain of WT1 competes with wt WT1 for an interactive protein that is an essential component of the repressor activity of wt WT1, Because the most common mutation associated with Denys-Drash Syndrome disrupts the zinc finger domains of WT1, the results also suggest that the mutant WT1 may have aberrant DNA binding activity and perhaps function as a dominant negative effector	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital			Huang, Jeffrey/J-5248-2017; Huang, Jeffrey K./AAH-2418-2021	Huang, Jeffrey/0000-0003-0996-9451; Huang, Jeffrey K./0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, P5828; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	29	62	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1243	1247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700651				2022-12-17	WOS:A1995QN35300028
J	UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K				UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K			MICROSATELLITE INSTABILITY IN PROSTATE-CANCER	ONCOGENE			English	Note						MICROSATELLITE INSTABILITY; PROSTATE CANCER	GENETIC INSTABILITY; ALLELIC LOSS; MUTATIONS; GROWTH; COLON	Assessment of the genetic instability of a microsatellite has indicated a new mechanism in human carcinogenesis. Examination was made to determine whether microsatellite instability is associated with the onset of prostate cancer. Twenty-nine DNA samples from 24 primary prostate cancer, two metastatic lymph-node and three benign prostatic hypertrophy patients were used. Differences in unrelated microsatellites for tumor and normal DNA were detected in nine of 24 (37.5%) cases. Seven of 11 (63.6%) with poorly differentiated adenocarcinomas and seven of 15 (46.7%) stage D metastatic patients showed somatic instability in a number of microsatellites. Statistically significant differences in well to moderately differentiated tumors and poorly differentiated cancer (P=0.015, Chi-square test), were detected but not for stages A-C and D (P=0.2311). Genetic alterations would thus appear to be rare in low grade and/or early prostate cancers but more common in high grade and/or advanced prostate cancers.	KITASATO UNIV,SCH MED,DEPT CLIN PATHOL,KANAGAWA 228,JAPAN	Kitasato University	UCHIDA, T (corresponding author), KITASATO UNIV,SCH MED,DEPT UROL,KANAGAWA 228,JAPAN.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVA GS, 1993, CANCER RES, V53, P3869; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1990, CELL, V56, P917; UCHIDA T, 1994, CANCER RES, V54, P3682; UCHIDA T, 1993, BRIT J CANCER, V68, P751, DOI 10.1038/bjc.1993.423; WEBER JL, 1989, AM J HUM GENET, V144, P388; 1991, HTLH WELFARE STATIST, P417; 1992, GENERAL RULE CLIN PA	26	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1019	1022						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898920				2022-12-17	WOS:A1995QL03800025
J	LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF				LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF			C-MYC INHIBITS MYOGENIC DIFFERENTIATION AND MYOD EXPRESSION BY A MECHANISM WHICH CAN BE DISSOCIATED FROM CELL-TRANSFORMATION	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TERMINAL DIFFERENTIATION; MUSCLE-CELLS; PROTEIN; GENE; MAX; PROLIFERATION; ONCOGENE; JUN	The c-Myc oncoprotein is a basic-helix-loop-helix-leucine zipper (b-HLH-LZ) transcription factor involved in regulating cell proliferation and differentiation. We have used retrovirus-mediated gene transfer to investigate the effect of ectopic c-Myc expression on the spontaneous differentiation of primary quail myoblasts in vitro. Unlike normal myoblasts, c-Myc-expressing myoblasts are unable to form myotubes or express muscle-specific genes, such as myosin, and show severely reduced expression of the myogenic regulatory factors myoD, myogenin, and myf5. The c-Myc leucine zipper (LZ) motif is essential for the differentiation block since myoblasts expressing a mutant with a partial deletion of this region, c-Myc Delta 7, differentiate and express myoD family regulators and muscle-specific genes normally. Remarkably, c-Myc Delta 7, like wild-type c-Myc, retains the capacity to transform the growth phenotype of myoblasts, and associates with the b-HLH-LZ Myc partner protein Max in transformed cells. We conclude that the block to myogenic differentiation induced by c-Myc can be dissociated from cell transformation per se, and that this attribute correlates more closely with down-regulation of myoD family gene expression. These findings are discussed in the light of current models of Myc function.	BEATSON INST CANC RES,WOLFSON LAB MOLEC PATHOL,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			la rocca, severina anna/D-8028-2011; Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CATLING AD, 1993, ONCOGENE, V8, P1875; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GROSSI M, 1991, ONCOGENE, V6, P1767; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PATCHINSKY T, 1986, J VIROL, V59, P341; Penn L J, 1990, Semin Cancer Biol, V1, P69; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SU HY, 1991, ONCOGENE, V6, P1759; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	50	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3499	3508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970710				2022-12-17	WOS:A1994PT39200012
J	SOLER, C; ALVAREZ, CV; BEGUINOT, L; CARPENTER, G				SOLER, C; ALVAREZ, CV; BEGUINOT, L; CARPENTER, G			POTENT SHC TYROSINE PHOSPHORYLATION BY EPIDERMAL GROWTH-FACTOR AT LOW RECEPTOR DENSITY OR IN THE ABSENCE OF RECEPTOR AUTOPHOSPHORYLATION SITES	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; MAP KINASE; ADAPTER PROTEIN; RAS; GRB2; SOS; INTERNALIZATION	The importance of epidermal growth factor (EGF) receptor expression level and autophosphorylation sites in src homology and collagen protein (SHC) tyrosine phosphorylation has been studied. In contrast to EGF-induced tyrosine phosphorylation of the GTPase-activating protein for ras (rasGAP) and phospholipase C-gamma 1 (PLC-gamma 1), SHC tyrosine phosphorylation occurs at a very low receptor density in parental NIH3T3 mouse fibroblasts expressing less than 1 x 10(4) EGF receptors per cell. In transfected NlH3T3 cells expressing human EGF receptors (similar to 4 x 10(5) receptors per cell), maximal levels of SHC and PLC-gamma 1 tyrosine phosphorylation occur when approximately 4 x 10(4) receptors or more are occupied by ligand. At lower levels of receptor occupancy only SHC posphorylation was significant. Also, EGF treatment of mouse keratinocytes, which represent a physiological target of EGF, express a low number of EGF receptors (similar to 2 x 10(4) receptors per cell), and stringently require EGF to grow, results in intense SHC tyrosine phosphorylation, compared to rasGAP or PLC-gamma 1. SHC is also efficiently tyrosine phosphorylated by an EGF receptor deletion mutant (Dc214) that is devoid of autophosphorylation sites, but which remains mitogenically responsive to EGF. The EGF receptor mutant Dc214 is able to activate the ras guanine nucleotide exchanger and phosphorylate mitogen-activated protein kinase (MAPK), presumable as a result of complex formation between tyrosine phosphorylated SHC and GRB2. These results indicate that potent EGF-induced SHC tyrosine phosphorylation can be triggered in cells having relatively few receptors. Also, our data show that EGF receptors are able to phosphorylate SHC, activate the exchange of guanine nucleotide on ras and phosphorylate MAPK by a mechanism that does not require receptor autophosphorylation sites and, therefore, the src homology 2 (SH2):phosphotyrosine-dependent interaction of SHC or GRB2 with the EGF receptor.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; CNR, DIBIT, MOLEC ONCOL LAB, I-20133 MILAN, ITALY; CNR, INST NEUROSCI & BIOIMMOGINI, I-20133 MILAN, ITALY	Vanderbilt University; Vanderbilt University; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			Soler, Concepció/L-1185-2014; Alvarez, Clara V/AAN-4173-2020	Soler, Concepció/0000-0001-6502-5012; Alvarez, Clara V/0000-0003-1500-4058	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1993, FORUM TRENDS EXPT CL, V3, P35; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN S, 1962, J BIOL CHEM, V237, P1555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HACK N, 1993, J BIOL CHEM, V268, P26441; HELIN K, 1991, ONCOGENE, V6, P825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASUI H, 1991, CANCER RES, V51, P6170; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZENDEGUI J G, 1988, Journal of Cellular Physiology, V136, P257, DOI 10.1002/jcp.1041360207	42	62	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2207	2215						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036006				2022-12-17	WOS:A1994NX62900012
J	TAKESHIMA, H; IZAWA, I; LEE, PSY; SAFDAR, N; LEVIN, VA; SAYA, H				TAKESHIMA, H; IZAWA, I; LEE, PSY; SAFDAR, N; LEVIN, VA; SAYA, H			DETECTION OF CELLULAR PROTEINS THAT INTERACT WITH THE NF2 TUMOR-SUPPRESSOR GENE-PRODUCT	ONCOGENE			English	Article							ASSOCIATION; KINASE; NEUROFIBROMATOSIS-2; IDENTIFICATION; GROWTH; EZRIN; PHOSPHORYLATION; RECEPTOR; RADIXIN; FAMILY	The neurofibromatosis type 2 (Nn) gene was recently cloned, and the protein it encodes (merlin) was revealed to belong to a family of proteins that link cytoskeletal components with proteins in the cell membrane. To elucidate the biological function of merlin, we produced a bacterial fusion protein consisting of glutathione S-transferase and merlin and used it to detect five merlin-binding cellular proteins, designated p165, p145, p125, p85 and p70, by a protein-binding assay. p165 and merlin were phosphorylated on serine/threonine residues, and immunoprecipitation showed that p85 bound the native form of merlin. Although the entire merlin-ezrin-radixin-moesin (MERM) homology domain of merlin was found to be essential for binding to all five proteins, the MERM homology domains of ezrin and moesin did not bind to any of the five proteins. Since most reported NF2 mutations are in the region we determined was necessary for binding, the mutations probably impair binding. Therefore, the formation of the protein complex is probably crucial for tumor suppression.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Saya, Hideyuki/J-4325-2013		NATIONAL CANCER INSTITUTE [P30CA016672, P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CHICCHETTI P, 1992, SCIENCE, V257, P803; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; HARLOW E, 1988, ANTIBODIES LABORATOR; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; NISHI T, 1991, ONCOGENE, V6, P1555; PRIES PN, 1988, CANCER RES, V48, P4633; PRIES PN, 1988, CANCER RES, V48, P6530; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SATO N, 1992, J CELL SCI, V103, P131; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOS M, 1984, J LARYNGOL OTOL, V98, P685, DOI 10.1017/S0022215100147292; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215	31	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2135	2144						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8035998				2022-12-17	WOS:A1994NX62900003
J	SPANDAU, DF				SPANDAU, DF			DISTINCT CONFORMATIONS OF P53 ARE OBSERVED AT DIFFERENT STAGES OF KERATINOCYTE DIFFERENTIATION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; GROWTH ARREST; E6 PROTEINS; ANTIGEN; MUTATIONS; BINDING	p53 is a multifunctional protein that has been shown to inhibit the growth of transformed cells, arrest the cell cycle of normal cells, regulate gene transcription and influence cellular differentiation, apoptosis and senescence. This study was undertaken to determine if the expression of p53 in keratinocytes varied during epidermal differentiation. Fresh frozen-sections of normal human epidermis were subjected to immunofluorescence using a panel of anti-p53 monoclonal antibodies. The monoclonal antibody 122 specifically stained the basal layer of the epidermis. No staining was observed in other cell layers of the epidermis using the 122 antibody. When the 240 antibody was used, p53 was only detected in granular layer cells. No other anti-p53 monoclonal antibody stained normal epidermis. Immunofluorescent analyses of cultured keratinocytes revealed staining patterns that correlated with the staining pattern seen in vivo. Immunoprecipitation assays of the cultured keratinocytes indicated that each monoclonal antibody, with the exception of DO-1, could only detect a fraction of the total p53 present in the cultures. This diversity of reactivity was presumed to be due to the masking and exposing of the various epitopes on p53 through the binding of other proteins. Finally, in cultured human keratinocytes, p53 was found to be a relatively stable protein with a half-life of 5 h.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	SPANDAU, DF (corresponding author), INDIANA UNIV,SCH MED,DEPT DERMATOL,MED LIB BLDG,RM 349,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA.							AGOFF SN, 1993, SCIENCE, V259, P854; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MOLES JP, 1993, ONCOGENE, V8, P583; MONTENARH M, 1992, ONCOGENE, V7, P1673; RADY P, 1992, CANCER RES, V52, P3804; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	39	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1861	1868						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516060				2022-12-17	WOS:A1994NR68500008
J	ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B				ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B			ONGOING MUTATIONS IN THE N-TERMINAL DOMAIN OF C-MYC AFFECT TRANSACTIVATION IN BURKITTS-LYMPHOMA CELL-LINES	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SWITCH REGION; EXPRESSION; GENE; PHOSPHORYLATION; TRANSFORMATION; FIBROBLASTS; APOPTOSIS; ONCOGENE	A panel of 18 Burkitt's lymphoma (BL) and nine other cell Lines was examined for mutations in the N-terminal transactivation domain of c-Myc. Mutations leading to exchange of amino acids were detected in 13 BL but in none of the control cell lines. Mutations in c-Mye clustered between amino acid positions 57 and 62. Thr-58 and Ser-62 are known phosphorylation sites of c-Myc in vivo. BL cell lines derived from the same tumour revealed different mutations. Mutant cDNAs of the BL cell line Raji differed at 14 positions indicating ongoing mutation of the translocated c-myc during long-term propagation in cell culture. The effect of mutations on transactivation by c-Mye was tested by expression of GAL4/c-Myc fusion proteins in the BL cell line Raji. Mutants with an amino acid exchange at positions 58 or 60 transactivated a reporter gene two- to fivefold weaker than wildtype c-Myc, Thr-58 and Ser-62 were replaced by aspartic acid to mimic constitutively phosphorylated forms of c-Myc. These mutants transactivated two- to three-fold weaker than wildtype c-Mye indicating that a negative charge at positions 58 and/or 62 per se does not enhance transactivation. We propose that mutations in the N-terminal domain of c-Mye correlate with reduced transactivation and provide a growth advantage for BL cells.	GSF MUNICH,UMWELT & GESUNDHEIT FORSCHUNGSZENTRUM,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Albert, Thomas Karl/0000-0002-2488-0706				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APEL TW, 1992, ONCOGENE, V7, P1267; ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1990, ONCOGENE, V5, P1397; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALK MH, 1993, INT J CANCER, V55, P1; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSONM, 1993, ONCOGENE, V8, P3199; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LILLIE JW, 1989, NATURE, V341, P179; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SETH A, 1992, J BIOL CHEM, V267, P24796; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; YANO T, 1993, ONCOGENE, V8, P2741; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	36	62	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					759	763						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108117				2022-12-17	WOS:A1994MW55100010
J	DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ				DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ			MOLECULAR-CLONING OF A NOVEL RECEPTOR TYROSINE KINASE, TIF, HIGHLY EXPRESSED IN HUMAN OVARY AND TESTIS	ONCOGENE			English	Note							HUMAN INTERFERON-GAMMA; LEUKEMIA-CELLS; GENE	Using a combination of polymerase chain reaction and conventional cDNA library screening approaches, we have cloned and characterized a putative receptor tyrosine kinase termed tif. The extracellular domain of tif has an immunoglobulin-like loop and a fibronectin type III structure. The intracellular domain contains a tyrosine kinase domain. Compared with ryk, a ubiquitously expressed receptor tyrosine kinase, tif expression is tissue-specific with human ovary and testis containing the highest amount of tif mRNA. Many other tested human tissues such as heart, liver, pancreas and thymus do not contain detectable levels of tif mRNA. The molecular cloning and characterization of tif cDNA will facilitate the identification of a potential ligand(s) for the putative receptor and the study of its biological role.	HIPPLE CANC RES CTR,BIOL RESPONSE MODIFIERS LAB,DAYTON,OH 45439; HIPPLE CANC RES CTR,BLOOD CELL GROWTH FACTOR LAB,DAYTON,OH 45439		DAI, W (corresponding author), HIPPLE CANC RES CTR,MOLEC BIOL LAB,4100 S KETTERING BLVD,DAYTON,OH 45439, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI32483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DAI W, 1993, BLOOD, V5, P1214; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; Sambrook J., 1989, MOL CLONING LAB MANU; SIMONEAUX DK, 1992, J CELL BIOCHEM, V16, P101; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TSIFTSOGLOU AS, 1991, EXP HEMATOL, V19, P928; TUY FPD, 1983, NATURE, V305, P435; ULLRICH A, 1990, CELL, V61, P201; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	20	62	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					975	979						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108143				2022-12-17	WOS:A1994MW55100037
J	SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T				SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T			A NOVEL YES-RELATED KINASE, YRK, IS EXPRESSED AT ELEVATED LEVELS IN NEURAL AND HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; AVIAN-SARCOMA VIRUS; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; FIBRONECTIN GENE; SRC FAMILY; TRANSFORMATION; FYN; ASSOCIATION	While screening a chicken kidney cDNA library for the normal homolog of the yes oncogene, we isolated a clone that encodes a novel non-receptor type protein tyrosine kinase of the Src family. We named this gene product Yrk (York), as an acronym for Yes-related kinase. As predicted from the cDNA sequence, the Yrk protein consists of 536 amino acids and has all the canonical features of a Src kinase. At the amino terminus it contains a myristylation signal, followed by a unique domain, SH3 and SH2 motifs, an ATP binding site, a kinase region and a carboxy-terminal sequence with a potential regulatory tyrosine at position 530. The sequence of the Yrk protein showed 79% identity with human Fyn and 72% identity with chicken Yes. To eliminate the possibility that the Yrk protein is an avian homolog of mammalian Fyn, we isolated and sequenced the chicken fyn cDNA. The sequence data together with Southern and Northern blot analyses showed that the chicken yrk gene is distinct from the chicken fyn gene. Antibodies generated against the unique domain of the yrk protein expressed in bacteria precipitated a 60-kDa protein that was active in an immune complex kinase assay and was phosphorylated on tyrosine. Expression of the Yrk protein in adult chicken tissues was elevated in cerebellum and spleen. Relatively high levels of Yrk were also found in lung and skin.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Rockefeller University; University of Tokyo	SUDOL, M (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BRADFORD M, 1988, ANAL BIOCHEM, V58, P705; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FAGAN JB, 1981, J BIOL CHEM, V256, P520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, IN PRESS MOL BASIS H; SUDOL M, 1992, IN PRESS NEUROCHEM I; TOYOSHIMA K, 1990, ADV SEC MESS PHOSPH, V24, P284; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; Veillette A, 1991, Semin Immunol, V3, P143; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOSHIDA M, 1980, NATURE, V287, P653, DOI 10.1038/287653a0; ZHAO YH, 1990, ONCOGENE, V5, P1629	39	62	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455940				2022-12-17	WOS:A1993KT22000002
J	REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP				REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP			MUTATIONAL ANALYSIS OF MAX - ROLE OF BASIC, HELIX LOOP HELIX LEUCINE ZIPPER DOMAINS IN DNA-BINDING, DIMERIZATION AND REGULATION OF MYC-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							ESCHERICHIA-COLI; PROTO-ONCOGENE; GROWTH-FACTOR; PROTEINS; EXPRESSION; CELLS; OLIGOMERIZATION; PURIFICATION; SPECIFICITY; ENHANCER	The Max protein forms a heterodimeric complex with the Myc family of proteins and binds to DNA in a sequence-specific manner. We investigated the role of the helix-loop-helix (HLH), leucine zipper (LZ) and basic domains of Max in protein complex formation, DNA-binding activity and transcriptional regulation. We mutagenized the basic, HLH and LZ domains of Max and studied the ability of the normal and mutant proteins to bind to DNA as both homo- and heterodimers and their ability to heterodimerize with Myc. Helix-1 and helix-2 regions of Max were found to be critical for homodimer formation and subsequent DNA binding, while the LZ was essential for heterodimer formation. In transient transfection assays the Myc protein functioned as a transcriptional activator while Max protein repressed the trans-activation observed with Myc.	FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST,PHILADELPHIA,PA 19140; WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA10817, CA52009, CA21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNEROT CD, 1987, P NATL ACAD SCI USA, V84, P6796; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BEREBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WIEGLER M, 1978, CELL, V14, P725; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	37	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2085	2092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408152				2022-12-17	WOS:A1992JP42400027
J	KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE				KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE			SURFACE EXPRESSION OF ERBB-2 PROTEIN IS POSTTRANSCRIPTIONALLY REGULATED IN MAMMARY EPITHELIAL-CELLS BY EPIDERMAL GROWTH-FACTOR AND BY THE CULTURE DENSITY	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; BETA-CASEIN GENE; FACTOR-RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; POLYACRYLAMIDE GELS; C-ERBB-2 PROTEIN; KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS	The control of expression of the erbB-2 protein was examined in two mammary epithelial cells lines, HC11 and 31E. The erbB-2 protein content varied dramatically depending upon cell density and upon the presence of epidermal growth factor (EGF) in the culture medium. The changes in protein content were not due to variation in the erbB-2 mRNA level. Analysis of the metabolic turnover of the erbB-2 protein showed that its rate of degradation was two- to threefold higher in cells growing at low density than in cells confluent for 2 days. The addition of EGF to the culture medium caused an increase in the phosphoamino acid content and an increase in the turnover of the erbB-2 protein. Cell fractionation experiments were performed, and a shift in the cellular localization of the erbB-2 protein towards the lysosomal compartment in EGF-treated HC11 cells was found. This is reflected by an increase in the degradation rate of the erbB-2 protein. These findings suggest that in mammary epithelial cells the stability of the erbB-2 protein is an important regulatory control point in determining the level of the protein. The degradation rate is sensitive to cell confluency and is controlled by EGF receptor activity.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND; ACAD SCI USSR,INST CYTOL,LENINGRAD,USSR	Friedrich Miescher Institute for Biomedical Research; Russian Academy of Sciences			taverna, daniela/J-8358-2016; Kornilova, Elena Sergeevna/AAB-5559-2021	taverna, daniela/0000-0002-6365-527X; Kornilova, Elena/0000-0002-2951-6292; Hoeck, Wolfgang/0000-0001-9142-7103				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DATI C, 1990, ONCOGENE, V5, P1001; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GAMOU S, 1987, J BIOL CHEM, V262, P6708; GORMAN RM, 1987, J CELL PHYSIOL, V131, P158, DOI 10.1002/jcp.1041310204; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1987, TSITOLOGIYA+, V29, P904; LACROIX H, 1989, ONCOGENE, V4, P145; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MUNSON PJ, 1990, CANCER RES, V50, P3947; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RICHARDS J, 1982, EXP CELL RES, V141, P433, DOI 10.1016/0014-4827(82)90231-2; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; RIZZINO A, 1988, CANCER RES, V48, P4266; SAINSBURY JRC, 1987, LANCET, V1, P1398; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	46	62	64	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					511	519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347917				2022-12-17	WOS:A1992HK00500017
J	FISHER, F; JAYARAMAN, PS; GODING, CR				FISHER, F; JAYARAMAN, PS; GODING, CR			C-MYC AND THE YEAST TRANSCRIPTION FACTOR PHO4 SHARE A COMMON CACGTG-BINDING MOTIF	ONCOGENE			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; LEUCINE ZIPPER; REGULATORY PROTEINS; PHOSPHATASE REGULON; EXPRESSION; DIFFERENTIATION; GENE; ONCOGENE	The basic-helix-loop-helix (b-HLH) motif is common to a number of proteins involved in transcriptional regulation and cell-type determination. The b-HLH motif is also present in the S. cerevisiae transcription factor PHO4 which positively regulates the acid phosphatase gene PHO5. In this report we show that the b-HLH region of PHO4 is sufficient to confer specific DNA-binding to the sequence CACGTG and, by comparison of the basic regions of PHO4 with those of other recently isolated CACGTG-binding proteins, we identify a specific subset of conserved amino acids in the basic region likely to confer DNA-binding specificity. On the basis of these observations we predict successfully the effect of substituting the PHO4 basic region with that from c-myc and show that the chimaeric protein activates transcription from the CACGTG elements present in the PHO5 UAS. From these data it is clear that the myc basic region confers specific binding to the sequence CACGTG.	MARIE SKLODOWSKA CURIE MEM INST,CHART,OXTED RH8 0TL,SURREY,ENGLAND		GODING, CR (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Goding, Colin/0000-0002-1614-3909; /0000-0002-6500-9095				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; ARIMA K, 1983, NUCLEIC ACIDS RES, V11, P1657, DOI 10.1093/nar/11.6.1657; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEGRAIN M, 1986, NUCLEIC ACIDS RES, V14, P3059, DOI 10.1093/nar/14.7.3059; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	36	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1099	1104						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861859				2022-12-17	WOS:A1991GV26000001
J	HOFFMANLIEBERMANN, B; LIEBERMANN, DA				HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SUPPRESSION OF C-MYC AND C-MYB IS TIGHTLY LINKED TO TERMINAL DIFFERENTIATION INDUCED BY IL6 OR LIF AND NOT GROWTH-INHIBITION IN MYELOID-LEUKEMIA CELLS	ONCOGENE			English	Article							MESSENGER-RNA; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION; GENE-EXPRESSION; PROTO-ONCOGENE; PROTEINS; ARREST; MOUSE; PROLIFERATION; TRANSCRIPTION	Cell proliferation and differentiation are intimately related processes where the proto-oncogenes c-myc and c-myb have been implicated to play a role. Previously, we have shown that both c-myc and c-myb were induced in normal myeloid precursors when the cells were stimulated for growth, were expressed in the autonomously proliferating myeloid leukemic M1 cell line and were rapidly suppressed in both normal and M1 cells following induction of terminal differentiation associated with growth arrest. In order to distinguish molecular events associated with terminal differentiation versus those due to growth inhibition, as well as to increase our understanding of the role of the proto-oncogenes c-myc and c-myb in both of these cellular processes, in this work we have studied the expression of c-myc and c-myb in M1 cells induced for growth inhibition associated with terminal differentiation (via treatment with the physiological inducers IL6 or leukemia inhibitory factor <LIF>), partial differentiation (using IL1 or LPS) or no detectable differentiation properties (using IFN-beta or IFN-gamma). We show that, for all the treatments used in this study, down regulation of the proto-oncogenes c-myc and c-myb occurred only when M1 cells were stimulated to undergo terminal differentiation. In addition, we transfected the M1 cell line with a vector containing the c-myc gene under control of the beta-actin promoter, so that c-myc was no longer down regulated by IL6 or LIF. Previously, we have shown that in the presence of the myeloid differentiation inducers IL6 or LIF, these M1myc cells were blocked at an intermediate stage of myeloid differentiation and continued to proliferate. In sharp contrast to their altered response to IL6 or LIF, M1myc cells were as responsive as the parental M1 cells to growth suppression by the different antiproliferative compounds which do not induce terminal differentiation. Thus, continued expression of c-myc had no effect on growth suppression induced by IL1, IFN-beta, IFN-gamma and LPS. Taken together, these results indicate that c-myc and c-myb down regulation is not necessary for growth suppression, but down regulation of c-myc is, and c-myb may be, essential for terminal differentiation.			HOFFMANLIEBERMANN, B (corresponding author), UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOFFMANLIEBERMA.B, 1991, IN PRESS MOL CELL; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; IKEGAKI N, 1990, ONCOGENE, V5, P397; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMANN D, 1978, CELL, V15, P823, DOI 10.1016/0092-8674(78)90267-2; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LODMICO P, 1984, NATURE, V312, P458; LORD KA, 1990, ONCOGENE, V5, P387; LOTEM J, 1978, INT J CANCER, V22, P214, DOI 10.1002/ijc.2910220216; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; ONOZAKI K, 1987, CANCER RES, V47, P2397; ONOZAKI K, 1989, CANCER RES, V49, P3602; ONOZAKI K, 1988, J IMMUNOL, V140, P112; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; SHABO Y, 1988, BLOOD, V72, P2070; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIESE B, 1978, P NATL ACAD SCI USA, V75, P1374	45	62	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					903	909						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906157				2022-12-17	WOS:A1991GU62200003
J	MELLERICK, DM; OSBORN, M; WEBER, K				MELLERICK, DM; OSBORN, M; WEBER, K			ON THE NATURE OF SEROLOGICAL TISSUE POLYPEPTIDE ANTIGEN (TPA) - MONOCLONAL KERATIN-8, KERATIN-18, AND KERATIN-19 ANTIBODIES REACT DIFFERENTLY WITH TPA PREPARED FROM HUMAN CULTURED CARCINOMA-CELLS AND TPA IN HUMAN SERUM	ONCOGENE			English	Article									MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY	Max Planck Society								BAKER WC, 1988, J UROLOGY, V140, P436, DOI 10.1016/S0022-5347(17)41652-1; BEHAM A, 1986, VIRCHOWS ARCH A, V409, P641, DOI 10.1007/BF00713430; BJORKLUND B, 1957, INT ARCH ALLER A IMM, V10, P153, DOI 10.1159/000228374; BJORKLUND B, 1980, TUMORDIAGNOSTIK, P9; BJORKLUND B, 1980, TUMORDIAGNOSTIK, P78; BJORKLUND B, 1983, CANCER DETECT PREV, V6, P41; BJORKLUND B, 1973, IMMUNOLOGICAL TECHNI, P133; BJORKLUND V, 1982, ACTA PATH MICRO IM A, V90, P471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASELITZ J, 1983, Applied Pathology, V1, P115; CHAN R, 1986, CANCER RES, V46, P6353; CLAUDI S, 1983, PROTIDES BIOL FLUIDS, V31, P457; DEBUS E, 1982, EMBO J, V1, P1641, DOI 10.1002/j.1460-2075.1982.tb01367.x; DEBUS E, 1984, AM J PATHOL, V114, P121; DOMAGALA W, 1986, ACTA CYTOL, V30, P225; DRAHOVSKY D, 1984, PROTIDES BIOL FLUIDS, V32, P719; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; FRANKE WW, 1981, COLD SPRING HARB SYM, V46, P431, DOI 10.1101/SQB.1982.046.01.041; FRANKE WW, 1979, EXP CELL RES, V118, P95, DOI 10.1016/0014-4827(79)90587-1; FUCHS E, 1985, ANN NY ACAD SCI, V455, P436, DOI 10.1111/j.1749-6632.1985.tb50427.x; GEISLER N, 1986, J ULTRA MOL STRUCT R, V94, P239, DOI 10.1016/0889-1605(86)90070-4; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1982, NATURE, V296, P448, DOI 10.1038/296448a0; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; Geisler N., 1986, P41; GEISLER N, 1983, EMBO J, V2, P2059, DOI 10.1002/j.1460-2075.1983.tb01700.x; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HATZFELD M, 1987, J MOL BIOL, V197, P237, DOI 10.1016/0022-2836(87)90122-7; HATZFELD M, 1987, THESIS U HEIDELBERG; HOLLMANN M, 1985, BIOCHEM BIOPH RES CO, V128, P34, DOI 10.1016/0006-291X(85)91640-7; INOUE M, 1985, CANCER, V55, P2618, DOI 10.1002/1097-0142(19850601)55:11<2618::AID-CNCR2820551114>3.0.CO;2-S; KIRSCH J, 1983, TUMORDIAGN THER, V4, P222; KREIENBERG R, 1985, ONKOLOGIE, V8, P253, DOI 10.1159/000215669; KUMAR S, 1981, BRIT J UROL, V53, P578, DOI 10.1111/j.1464-410X.1981.tb03264.x; KURKI P, 1983, J RHEUMATOL, V10, P558; KURKI P, 1984, ALCOHOL CLIN EXP RES, V8, P212, DOI 10.1111/j.1530-0277.1984.tb05841.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LONING T, 1983, INT J GYNECOL PATHOL, V2, P105; LUNING B, 1980, BIOCHIM BIOPHYS ACTA, V624, P90, DOI 10.1016/0005-2795(80)90228-7; LUNING B, 1983, ACTA CHEM SCAND B, V37, P731, DOI 10.3891/acta.chem.scand.37b-0731; LUNING B, 1985, PROTIDES BIOL FLUIDS, V32, P717; LUTHGENS M, 1983, CANCER DETECT PREV, V6, P51; LUTHGENS M, 1985, TUMORDIAGN THER, V6, P1; LUTHGENS M, 1980, TUMOR DIAGNOSTIK, V2, P63; MADRI JA, 1983, LAB INVEST, V48, P98; MAGIN TM, 1986, DIFFERENTIATION, V30, P254, DOI 10.1111/j.1432-0436.1986.tb00788.x; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MENENDEZBOTET CJ, 1978, CLIN CHEM, V24, P868; MERRILL WW, 1984, AM REV RESPIR DIS, V130, P905; Moll R, 1987, Curr Top Pathol, V77, P71; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MROSS KB, 1985, ONCOLOGY, V42, P288, DOI 10.1159/000226048; NATHRATH WBJ, 1985, J HISTOCHEM CYTOCHEM, V33, P99, DOI 10.1177/33.2.3968422; NELSON WJ, 1981, EUR J BIOCHEM, V116, P51, DOI 10.1111/j.1432-1033.1981.tb05299.x; OCHI Y, 1985, CLIN CHIM ACTA, V151, P157, DOI 10.1016/0009-8981(85)90319-5; OEHR P, 1982, TUMORDIAGN THER, V3, P195; OEHR P, 1984, NUC COMPACT, V15, P152; OEHR P, 1981, TUMORDIAGNOSTIK, V2, P283; OSBORN M, 1986, LAB INVEST, V55, P497; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; OSBORN M, 1982, PATHOL RES PRACT, V175, P128; PANUCCI A, 1986, J CLIN PATHOL, V39, P75, DOI 10.1136/jcp.39.1.75; PANUCCI A, 1985, BRIT J CANCER, V52, P801, DOI 10.1038/bjc.1985.262; PAULICK R, 1985, CANCER DETECT PREV, V8, P115; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RASMUSON T, 1983, RECENT RES CANCER, V84, P331; REDELIUS P, 1980, ACTA CHEM SCAND B, V34, P265, DOI 10.3891/acta.chem.scand.34b-0265; ROSSITTO PV, 1988, J UROLOGY, V140, P431, DOI 10.1016/S0022-5347(17)41651-X; SALVATI F, 1985, CANCER DETECT PREV, V8, P111; SCHILLER DL, 1983, CELL BIOL INT REP, V7, P3, DOI 10.1016/0309-1651(83)90098-X; SCHLEGEL G, 1981, TUMORDIAGNOSTIK, V2, P6; SKRYTEN A, 1981, TUMORDIAGNOSTIK, V2, P117; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1980, P NATL ACAD SCI-BIOL, V77, P4534, DOI 10.1073/pnas.77.8.4534; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; SUN TT, 1985, ANN NY ACAD SCI, V455, P307, DOI 10.1111/j.1749-6632.1985.tb50419.x; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76; TOLLE HG, 1985, EUR J CELL BIOL, V38, P234; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG SCG, 1982, CELL, V30, P361, DOI 10.1016/0092-8674(82)90234-3; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x; WEBER K, 1982, EMBO J, V1, P1155, DOI 10.1002/j.1460-2075.1982.tb00006.x; WEBER K, 1984, CANCER CELL, V1, P153; WIKLUND B, 1981, ACTA CHEM SCAND B, V35, P325, DOI 10.3891/acta.chem.scand.35b-0325	93	62	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					1007	1017						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695723				2022-12-17	WOS:A1990DP41500008
J	ISHIZAKA, Y; OCHIAI, M; TAHIRA, T; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; OCHIAI, M; TAHIRA, T; SUGIMURA, T; NAGAO, M			ACTIVATION OF THE RET-II ONCOGENE WITHOUT A SEQUENCE ENCODING A TRANSMEMBRANE DOMAIN AND TRANSFORMING ACTIVITY OF 2 RET-II ONCOGENE PRODUCTS DIFFERING IN CARBOXY-TERMINI DUE TO ALTERNATIVE SPLICING	ONCOGENE			English	Article											ISHIZAKA, Y (corresponding author), NATL CANC CTR RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI,5 CHOME,CHUO KU,TOKYO 104,JAPAN.							BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIZAKA Y, 1987, CARCINOGENESIS, V8, P1575, DOI 10.1093/carcin/8.11.1575; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENONG GLC, 1987, EMBO J, V6, P4035; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	62	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					789	794						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2734021				2022-12-17	WOS:A1989AA66000015
J	ZAJDEL, MEB; BLAIR, GE				ZAJDEL, MEB; BLAIR, GE			THE INTRACELLULAR-DISTRIBUTION OF THE TRANSFORMATION-ASSOCIATED PROTEIN P53 IN ADENOVIRUS-TRANSFORMED RODENT CELLS	ONCOGENE			English	Article									UNIV LEEDS,DEPT BIOCHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FUNG BP, 1985, CELL TISSUE RES, V239, P43, DOI 10.1007/BF00214901; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARWOOD LMJ, 1975, INT J CANCER, V16, P498, DOI 10.1002/ijc.2910160317; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RODRIGUEZ J, 1960, VIROLOGY, V12, P316, DOI 10.1016/0042-6822(60)90205-1; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SOMPAYRAC LM, 1983, MOL CELL BIOL, V3, P290, DOI 10.1128/MCB.3.2.290; TUCKER RW, 1979, CELL, V17, P527, DOI 10.1016/0092-8674(79)90261-7; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; ZAJDEL MEB, 1985, BIOCHEM J, V225, P649, DOI 10.1042/bj2250649; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	37	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					579	584						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290806				2022-12-17	WOS:A1988N841500008
J	Liu, F; Zhang, H; Xie, F; Tao, D; Xiao, XY; Huang, C; Wang, M; Gu, CH; Zhang, XP; Jiang, GS				Liu, Feng; Zhang, Hui; Xie, Fei; Tao, Dan; Xiao, Xingyuan; Huang, Chao; Wang, Miao; Gu, Chaohui; Zhang, Xiaoping; Jiang, Guosong			Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis	ONCOGENE			English	Article							MATRIX-METALLOPROTEINASE POLYMORPHISMS; CIRCULAR RNAS; TUMOR-SUPPRESSOR; EXPRESSION; ABUNDANT	Circular RNAs (circRNAs) have been increasingly indicated to be important participants in the development and progression of various malignant tumors. Our previous studies found that hundreds of circRNAs were aberrantly expressed in bladder cancer (BC) by high-throughput sequencing and we have confirmed that the downregulated circRNAs circHIPK3, circRNA BCRC-3, and circNR3C1 played inhibitory roles in BC progression. In this study, we focused on the upregulated circRNAs and identified a novel circular RNA, hsa_circ_0001361 (circ0001361), was expressed at high levels in BC tissues and cell lines based on RNA-Seq data and qRT-PCR analysis, and it was positively corelated with pathologic grade and muscle invasion. Moreover, Kaplan-Meier survival analysis implied that BC patients with high circ0001361 expression level had a poor overall survival. Functionally, circ0001361 promoted BC cell invasion and metastasis both in vitro and in vivo, but had no effect on cell cycle and proliferation. Mechanistically, RNA sequencing analysis indicated that MMP9 was upregulated in circ0001361-overexpressed BC cells, and MMP9 was verified to mediate circ0001361-induced cell migration and invasion. Furthermore, we demonstrated that circ0001361 could directly interact with miR-491-5p to upregulate MMP9 expression. Collectively, our findings indicate that circ0001361 plays oncogenic role in BC invasion and metastasis through targeting the miR-491-5p/MMP9 axis, and it might be a potential novel target for BC therapy.	[Liu, Feng; Zhang, Hui; Xie, Fei; Xiao, Xingyuan; Huang, Chao; Wang, Miao; Zhang, Xiaoping; Jiang, Guosong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China; [Xie, Fei] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266013, Peoples R China; [Tao, Dan] Fifth Hosp Wuhan, Dept Oncol, Wuhan 430050, Peoples R China; [Gu, Chaohui] Zhengzhou Univ, Affiliated Hosp 1, Dept Urol, Zhengzhou 450052, Henan, Peoples R China	Huazhong University of Science & Technology; Qingdao University; Zhengzhou University	Zhang, XP; Jiang, GS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China.	xzhang@hust.edu.cn; jiangguosongdoc@hotmail.com			National Natural Science Foundation of China [81672529, 81772724, 81874091, 81602234, 81702524]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Nos. 81672529, 81772724, 81874091, 81602234, 81702524).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Arnaiz E, 2019, SEMIN CANCER BIOL, V58, P90, DOI 10.1016/j.semcancer.2018.12.002; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Bray F, 2018, CA-CANCER J CLIN, V68, P5; Brockschmidt A, 2012, BRAIN, V135, P1027, DOI 10.1093/brain/aws045; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Chen X, 2018, CLIN CANCER RES, V24, P6319, DOI 10.1158/1078-0432.CCR-18-1270; Chen ZL, 2019, ONCOGENE, V38, P6017, DOI 10.1038/s41388-019-0857-8; Cheng ZX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11129-5; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Gu CH, 2018, MOL THER-NUCL ACIDS, V13, P633, DOI 10.1016/j.omtn.2018.10.008; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; HSU MT, 1979, NATURE, V280, P339, DOI 10.1038/280339a0; Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297; Hui Zeng, 2015, FEBS Lett, V589, P812, DOI 10.1016/j.febslet.2015.02.014; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kader AK, 2007, CLIN CANCER RES, V13, P2614, DOI 10.1158/1078-0432.CCR-06-1187; Kader AK, 2006, CANCER RES, V66, P11644, DOI 10.1158/0008-5472.CAN-06-1212; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu HW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0908-8; Liu HW, 2018, AGING-US, V10, P2606, DOI 10.18632/aging.101573; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Pirooz HJ, 2018, J CELL BIOCHEM, V119, P5126, DOI 10.1002/jcb.26471; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Sun RF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.134; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713; Weren RDA, 2015, J PATHOL, V236, P155, DOI 10.1002/path.4520; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Wu J, 2018, CANCER LETT, V430, P179, DOI 10.1016/j.canlet.2018.05.033; Xie F, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0892-z; Xu YJ, 2017, AM J CANCER RES, V7, P2545; Yang CD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0771-7; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Zheng FX, 2019, CANCER LETT, V460, P139, DOI 10.1016/j.canlet.2019.06.018; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhong ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37840	56	61	62	6	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1696	1709		10.1038/s41388-019-1092-z	http://dx.doi.org/10.1038/s41388-019-1092-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31705065				2022-12-17	WOS:000514923000006
J	Zeng, FR; Wang, QY; Wang, SY; Liang, SM; Huang, WM; Guo, Y; Peng, J; Li, M; Zhu, WL; Guo, LL				Zeng, Fanrui; Wang, Qiongyao; Wang, Shuyu; Liang, Shumei; Huang, Weimei; Guo, Ying; Peng, Juan; Li, Man; Zhu, Weiliang; Guo, Linlang			Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	ONCOGENE			English	Article							NONCODING RNA; DOWN-REGULATION; MICRORNA; CATENIN; GENE; INCREASE	The functional effects of long noncoding RNAs (lncRNAs) in cancer have been widely recognized. However, there is little research on SCLC-related lncRNAs. Here, long intergenic nonprotein coding RNA 173 (Linc00173) was first shown to be involved in chemoresistance and progression of small-cell lung cancer (SCLC). We found that Linc00173 was highly expressed in SCLC chemoresistant cell lines, and promoted SCLC cells chemoresistance, proliferation, and migration-invasion. Animal studies validated that Linc00173 induced tumor chemoresistance and growth of SCLC in vivo. Moreover, Linc00173 upregulated Etk through functioning as a competitive endogenous RNA (ceRNA) by "sponging" miRNA-218 and led to the upregulation of GSKIP and NDRG1, resulting in the translocation of beta-catenin. Importantly, expression analysis revealed that both Linc00173 and Etk were upregulated in SCLC patient samples and exhibiting positive Linc00173/Etk correlation. High expression of Linc00173 closely correlated with chemoresistance, extensive stage, and shorter survival in SCLC patients. Collectively, our study illustrated a Linc00173-mediated process that facilitated chemoresistance and progression in SCLC, which might provide treatment strategy against SCLC.	[Zeng, Fanrui; Wang, Shuyu; Liang, Shumei; Huang, Weimei; Li, Man; Guo, Linlang] Southern Med Univ, Zhujiang Hosp, Dept Pathol, 253 Gongye Rd, Guangzhou 510282, Peoples R China; [Zeng, Fanrui] Guangzhou Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou 510080, Peoples R China; [Wang, Qiongyao; Zhu, Weiliang] Southern Med Univ, Zhujiang Hosp, Dept Oncol, 253 Gongye Rd, Guangzhou 510282, Peoples R China; [Guo, Ying] Southern Med Univ, Zhujiang Hosp, Dept Organ Transplantat, Guangzhou 510282, Guangdong, Peoples R China; [Peng, Juan] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510150, Peoples R China	Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University	Guo, LL (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Pathol, 253 Gongye Rd, Guangzhou 510282, Peoples R China.; Zhu, WL (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Oncol, 253 Gongye Rd, Guangzhou 510282, Peoples R China.	zhuwl2017@163.com; linlangg@yahoo.com	Wang, shuyu/GZM-3462-2022	Guo, Linlang/0000-0002-1859-7592	National Natural Science Foundation of China [81572244, 81602631, 81772458]; Natural Science Foundation of Guangdong Province [2015A030311028]; Clinical Research Initiative Project of Southern Medical University [LC2016ZD029]; Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province [2017KZDXM015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Clinical Research Initiative Project of Southern Medical University; Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81572244, 81602631, and 81772458); Natural Science Foundation of Guangdong Province (key) (2015A030311028); The Clinical Research Initiative Project of Southern Medical University (LC2016ZD029); Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province (2017KZDXM015).	Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cazalla D, 2010, SCIENCE, V328, P1563, DOI 10.1126/science.1187197; Chen X, 2012, TRENDS BIOCHEM SCI, V37, P457, DOI 10.1016/j.tibs.2012.08.005; Dema A, 2016, J BIOL CHEM, V291, P19618, DOI 10.1074/jbc.M116.738047; Guo LL, 2010, EUR J CANCER, V46, P1692, DOI 10.1016/j.ejca.2010.02.043; Guo LL, 2010, EXP MOL PATHOL, V88, P401, DOI 10.1016/j.yexmp.2010.02.003; Guo LL, 2010, EUR J CANCER, V46, P636, DOI 10.1016/j.ejca.2009.11.009; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Kim SS, 2018, NUCLEIC ACIDS RES, V46, P1424, DOI 10.1093/nar/gkx1221; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Leung AKL, 2015, TRENDS CELL BIOL, V25, P601, DOI 10.1016/j.tcb.2015.07.005; Lin CC, 2009, J CELL BIOCHEM, V108, P1325, DOI 10.1002/jcb.22362; Lu WJ, 2015, ONCOTARGET, V6, P29847, DOI 10.18632/oncotarget.4913; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Makarova JA, 2016, PROG HISTOCHEM CYTO, V51, P33, DOI 10.1016/j.proghi.2016.06.001; Mao Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27307-2; Niu YC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0575-6; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Sabari JK, 2017, NAT REV CLIN ONCOL, V14, P549, DOI 10.1038/nrclinonc.2017.71; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schwarzer A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00212-4; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun YQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0113-5; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713; Wang Q, 2017, CLIN CANCER RES, V24, P1475; Wang YF, 2017, CANCER LETT, V401, P53, DOI 10.1016/j.canlet.2017.04.031; Wei T, 2011, CANCER LETT, V309, P151, DOI 10.1016/j.canlet.2011.05.029; Xiao J, 2017, CELL PHYSIOL BIOCHEM, V43, P1926, DOI 10.1159/000484116; Xiao L, 2018, GASTROENTEROLOGY, V154, P599, DOI 10.1053/j.gastro.2017.10.009	36	61	64	1	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					293	307		10.1038/s41388-019-0984-2	http://dx.doi.org/10.1038/s41388-019-0984-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477834				2022-12-17	WOS:000507766400004
J	Yang, TT; Ren, C; Qiao, PY; Han, X; Wang, L; Lv, SJ; Sun, YH; Liu, ZJ; Du, Y; Yu, ZH				Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Lv, Shijun; Sun, Yonghong; Liu, Zhijun; Du, Yu; Yu, Zhenhai			PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer	ONCOGENE			English	Article							GLYCOLYSIS; AUTOPHAGY; INCREASES; KINASES; PKM2; PIM2	Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer.	[Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Yu, Zhenhai] Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China; [Lv, Shijun; Sun, Yonghong] Weifang Med Univ, Affiliated Hosp, Dept Pathol, Weifang, Shandong, Peoples R China; [Liu, Zhijun; Du, Yu] Weifang Med Univ, Dept Med Microbiol, Weifang, Shandong, Peoples R China	Weifang Medical University; Weifang Medical University; Weifang Medical University	Yu, ZH (corresponding author), Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China.	tomsyu@163.com	Liu, Zhijun/AAV-9805-2021		Innovation Fund of National Natural Science Foundation of China [81602440, 81602301, 81471048]; Shandong Province College Science and Technology Plan Project [J16LL08, J17KA254]; Projects of Medical and Health Technology Development Program in Shandong province [2016WS0688, 2017WS398]; National Natural Science Foundation of Shangdong Province [ZR2014HM086]	Innovation Fund of National Natural Science Foundation of China; Shandong Province College Science and Technology Plan Project; Projects of Medical and Health Technology Development Program in Shandong province; National Natural Science Foundation of Shangdong Province	The study was supported by research grants from Innovation Fund of National Natural Science Foundation of China (Grant no. 81602440, 81602301, and 81471048), Shandong Province College Science and Technology Plan Project (Grant no. J16LL08 and J17KA254), Projects of Medical and Health Technology Development Program in Shandong province (Grant no. 2016WS0688 and 2017WS398), National Natural Science Foundation of Shangdong Province (Grant no. ZR2014HM086).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Blanco-Aparicio C, 2013, BIOCHEM PHARMACOL, V85, P629, DOI 10.1016/j.bcp.2012.09.018; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Deng GP, 2015, J BIOL CHEM, V290, P20211, DOI 10.1074/jbc.M115.638221; Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Lee JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00906-9; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; McDonald JE, 2017, CLIN CANCER RES, V23, P1981, DOI 10.1158/1078-0432.CCR-16-0235; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Ren CN, 2018, MOL ONCOL, V12, P690, DOI 10.1002/1878-0261.12192; Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019; Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026; Tan VP, 2015, AUTOPHAGY, V11, P963, DOI 10.1080/15548627.2015.1042195; Uddin N, 2015, CANCER SCI, V106, P718, DOI 10.1111/cas.12668; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Xia HG, 2015, J CELL BIOL, V210, P705, DOI 10.1083/jcb.201503044; Xiong XP, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.103; Yu ZH, 2016, BIOCHEM BIOPH RES CO, V473, P953, DOI 10.1016/j.bbrc.2016.03.160; Yu ZH, 2014, CELL SIGNAL, V26, P1560, DOI 10.1016/j.cellsig.2014.03.016; Yu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088301; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Zhang XH, 2015, INT J MED SCI, V12, P487, DOI 10.7150/ijms.10982; Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33	29	61	63	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5997	6009		10.1038/s41388-018-0386-x	http://dx.doi.org/10.1038/s41388-018-0386-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29985480	Green Published, hybrid			2022-12-17	WOS:000449562500007
J	Labgaa, I; Villacorta-Martin, C; D'Avola, D; Craig, AJ; von Felden, J; Martins, SN; Sia, D; Stueck, A; Ward, SC; Fiel, MI; Mahajan, M; Tabrizian, P; Thung, SN; Ang, C; Friedman, SL; Llovet, JM; Schwartz, M; Villanueva, A				Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia; Craig, Amanda J.; von Felden, Johann; Martins-Filho, Sebastiao N.; Sia, Daniela; Stueck, Ashley; Ward, Stephen C.; Fiel, M. Isabel; Mahajan, Milind; Tabrizian, Parissa; Thung, Swan N.; Ang, Celina; Friedman, Scott L.; Llovet, Josep M.; Schwartz, Myron; Villanueva, Augusto			A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULATING TUMOR DNA; CELL-FREE DNA; DROPLET DIGITAL PCR; CLONAL EVOLUTION; LIQUID BIOPSY; LUNG-CANCER; HETEROGENEITY; PROGRESSION; RESISTANCE; LANDSCAPE	Cellular components of solid tumors including DNA are released into the bloodstream, but data on circulating-free DNA (cfDNA) in hepatocellular carcinoma (HCC) are still scarce. This study aimed at analyzing mutations in cfDNA and their correlation with tissue mutations in patients with HCC. We included 8 HCC patients treated with surgical resection for whom we collected paired tissue and plasma/serum samples. We analyzed 45 specimens, including multiregional tumor tissue sampling (n = 24), peripheral blood mononuclear cells (PMBC, n = 8), plasma (n = 8) and serum (n = 5). Ultra-deep sequencing (5500x coverage) of all exons was performed in a targeted panel of 58 genes, including frequent HCC driver genes and druggable mutations. Mutations detected in plasma included known HCC oncogenes and tumor suppressors (e.g., TERT promoter, TP53, and NTRK3) as well as a candidate druggable mutation (JAK1). This approach increased the detection rates previously reported for mutations in plasma of HCC patients. A thorough characterization of cis mutations found in plasma confirmed their tumoral origin, which provides definitive evidence of the release of HCC-derived DNA fragments into the bloodstream. This study demonstrates that ultra-deep sequencing of cfDNA is feasible and can confidently detect somatic mutations found in tissue; these data reinforce the role of plasma DNA as a promising minimally invasive tool to interrogate HCC genetics.	[Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia; Craig, Amanda J.; von Felden, Johann; Martins-Filho, Sebastiao N.; Sia, Daniela; Tabrizian, Parissa; Friedman, Scott L.; Llovet, Josep M.; Schwartz, Myron; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Dept Med, Liver Canc Program, Tisch Canc Inst,Grad Sch Biomed Sci,Div Liver Dis, New York, NY 10029 USA; [Labgaa, Ismail] Lausanne Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland; [D'Avola, Delia] Clin Univ Navarra, Liver Unit, Pamplona, Spain; [D'Avola, Delia] Clin Univ Navarra, CIBEREHD, Pamplona, Spain; [von Felden, Johann] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Martins-Filho, Sebastiao N.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; [Martins-Filho, Sebastiao N.] Univ Toronto, Univ Hlth Network, Dept Pathol & Lab Med, Toronto, ON, Canada; [Stueck, Ashley; Ward, Stephen C.; Fiel, M. Isabel; Mahajan, Milind; Thung, Swan N.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Stueck, Ashley] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Mahajan, Milind] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Tabrizian, Parissa; Schwartz, Myron] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA; [Ang, Celina; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY 10029 USA; [Llovet, Josep M.] Univ Barcelona, Hosp Clin, Liver Canc Translat Res Lab, BCLC Grp,IDIBAPS,CIBEREHD, Catalonia, Spain; [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Icahn School of Medicine at Mount Sinai; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra; University of Hamburg; University Medical Center Hamburg-Eppendorf; Universidade de Sao Paulo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Icahn School of Medicine at Mount Sinai; Dalhousie University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Liver Canc Program, Tisch Canc Inst,Grad Sch Biomed Sci,Div Liver Dis, New York, NY 10029 USA.; Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY 10029 USA.	augusto.villanueva@mssm.edu	D'Avola, Delia/AAD-4289-2020; Llovet, Josep M/ABB-6264-2021; Llovet, Josep M/D-4340-2014	D'Avola, Delia/0000-0002-0907-6648; Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Labgaa, Ismail/0000-0003-4286-2170; Stueck, Ashley/0000-0002-0328-6687; Craig, Amanda/0000-0001-8987-019X; Villanueva, Augusto/0000-0003-3585-3727; Martins Filho, Sebastiao/0000-0002-6123-2601; Sia, Daniela/0000-0002-9000-611X; von Felden, Johann/0000-0003-2839-5174	Swiss National Science Foundation; Foundation Roberto Gianna Gonella; Foundation SICPA; Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Cancer Research Grant from Nuovo Soldati Foundation; Ruth L. Kirschstein NRSA Institutional Research Training Grant [T32 CA078207]; German Research Foundation [FE 1746/1-1]; Brazilian National Council for Scientific and Technological Development; Associacao Piauiense de Combate ao Cancer; European Commission [259744, 667273-2]; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute [SAF-2016-76390]; Asociacion Espanola para el Estudio del Cancer [CA150272P1]; U.S. Department of Defense [CA150272P1, CA150272P3, W81XWH-16-1-0455]; Tisch Cancer Institute (Cancer Center Grant) [P30 CA196521]; NIH [DK56621]; American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award; NATIONAL CANCER INSTITUTE [P30CA196521, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056621] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Foundation Roberto Gianna Gonella; Foundation SICPA; Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Cancer Research Grant from Nuovo Soldati Foundation; Ruth L. Kirschstein NRSA Institutional Research Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); Brazilian National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Associacao Piauiense de Combate ao Cancer; European Commission(European CommissionEuropean Commission Joint Research Centre); Samuel Waxman Cancer Research Foundation; Spanish National Health Institute(Spanish Government); Asociacion Espanola para el Estudio del Cancer; U.S. Department of Defense(United States Department of Defense); Tisch Cancer Institute (Cancer Center Grant); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	IL is supported by a grant from the Swiss National Science Foundation, from Foundation Roberto & Gianna Gonella and Foundation SICPA. DD is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH) and the Cancer Research Grant from Nuovo Soldati Foundation. AJC is supported by a Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32 CA078207). JvF is supported by a grant from the German Research Foundation (FE 1746/1-1). SNM is supported by grants from the Brazilian National Council for Scientific and Technological Development, and "Associacao Piauiense de Combate ao Cancer". JML is supported by grants from the European Commission (Heptromic, proposal number 259744; HEPCAR, proposal number 667273-2), the Samuel Waxman Cancer Research Foundation, the Spanish National Health Institute (J.M.L: SAF-2016-76390), the Asociacion Espanola para el Estudio del Cancer and the U.S. Department of Defense (CA150272P1). AV is supported by the U.S. Department of Defense (CA150272P3) and the Tisch Cancer Institute (Cancer Center Grant P30 CA196521). SLF is supported by NIH grant DK56621 and the U.S. Department of Defense (Contract No. W81XWH-16-1-0455). This study was funded by the American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award to AV.	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; BURKI E, 1948, OPHTHALMOLOGICA, V115, P241; Cai ZX, 2017, INT J CANCER, V141, P977, DOI 10.1002/ijc.30798; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Huang A, 2017, J HEPATOL, V67, P293, DOI 10.1016/j.jhep.2017.03.005; Huang A, 2016, J CANCER, V7, P1907, DOI 10.7150/jca.15823; Izumchenko E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9258; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Labgaa I, 2015, DISCOV MED, V19, P263; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liao WJ, 2016, ONCOTARGET, V7, P40481, DOI 10.18632/oncotarget.9629; Lin XJ, 2015, LANCET ONCOL, V16, P804, DOI 10.1016/S1470-2045(15)00048-0; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349; Ono A, 2015, CELL MOL GASTROENTER, V1, P516, DOI 10.1016/j.jcmgh.2015.06.009; Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; US Food and Drug Administration, FDA APPR 1 BLOOD TES; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhai WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14565; Zill OA, 2015, CANCER DISCOV, V5, P1040, DOI 10.1158/2159-8290.CD-15-0274	40	61	61	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3740	3752		10.1038/s41388-018-0206-3	http://dx.doi.org/10.1038/s41388-018-0206-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628508	Green Accepted			2022-12-17	WOS:000437975200010
J	Sunshine, JC; Jahchan, NS; Sage, J; Choi, J				Sunshine, J. C.; Jahchan, N. S.; Sage, J.; Choi, J.			Are there multiple cells of origin of Merkel cell carcinoma?	ONCOGENE			English	Review							SMALL T-ANTIGEN; TRANSGENIC MOUSE MODEL; MUTATIONAL LANDSCAPE; PROSTATE-CANCER; LUNG-CANCER; ANTIANDROGEN RESISTANCE; LINEAGE PLASTICITY; TUMOR-DEVELOPMENT; STEM-CELLS; POLYOMAVIRUS	Merkel cell carcinoma (MCC) is a rare but lethal cancer with the highest case-by-case fatality rate among all skin cancers. Eighty percent of cancers are associated with the Merkel cell polyomavirus (MCPyV). Twenty percent of MCCs are virus negative. Recent epidemiological data suggest that there are important, clinically relevant differences between these two subtypes of MCC. Recent studies in cancer genomics, mouse genetics, and virology experiments have transformed our understanding of MCC pathophysiology. Importantly, dramatic differences in the genetics of these two MCC subtypes suggest fundamental differences in their pathophysiology. We review these recent works and find that they provocatively suggest that MCPyV-positive and MCPyV-negative MCCs arise from two different cells of origin: the MCPyV-negative MCC from epidermal keratinocytes and the MCPyV-positive MCC from dermal fibroblasts. If true, this would represent the first cancer that we are aware of that evolves from cells of origin from two distinct germ layers: MCPyV-negative MCCs from ectodermal keratinocytes and MCPyV-positive MCCs from mesodermal fibroblasts. Future epigenetic experiments may prove valuable in confirming these distinct lineages for these MCC subtypes, especially for the clinical importance the cell of origin has on MCC treatment and prevention.	[Sunshine, J. C.; Choi, J.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Jahchan, N. S.; Sage, J.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Jahchan, N. S.; Sage, J.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Choi, J.] Northwestern Univ, Feinberg Sch Med, Dept Biochem Mol Genet, Chicago, IL 60611 USA; [Choi, J.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Stanford University; Stanford University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA.; Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem Mol Genet, Chicago, IL 60611 USA.; Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA.	jaehyuk.choi@northwestern.edu	Choi, Jaehyuk/N-6532-2019	Choi, Jaehyuk/0000-0003-2379-2226; Sunshine, Joel/0000-0001-9987-6712	NCI [K08 CA 191019, R21 CA167104-01]; NATIONAL CANCER INSTITUTE [R01CA201513, R21CA167104] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	S.J.C. is the Ruth K. Freinkel Assistant Professor of Dermatology. S.J.C. is supported by the NCI (K08 CA 191019). S. J.S. is the Harriet and Mary Zelencik Scientist in Children's Cancer and Blood Diseases. The mouse work was supported by the NCI (R21 CA167104-01). The mice were maintained according to practices prescribed by the NIH at Stanford's Research Animal Facility accredited by the AAPLAC (protocol 13565). We thank Dr. David MacPherson for the Pten mutant mice and Dr. Anton Berns for the Trp53 mutant mice. We would like to thank everyone in the Sage laboratory who helped in the generation and characterization of all the mutant mouse cohorts, specifically Margaret Zhu, Kim Tran, Garrett Seitz, and Anuradha Tathireddy, as well as Dr. Jinah Kim for help with the histopathology.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Chitsazzadeh V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12601; Choi J, 2015, NAT GENET, V47, P1011, DOI 10.1038/ng.3356; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Cui M, 2014, MOL CANCER RES, V12, P654, DOI 10.1158/1541-7786.MCR-13-0554; Gonzalez-Vela MDC, 2017, J INVEST DERMATOL, V137, P197, DOI 10.1016/j.jid.2016.08.015; Elston D, 2013, DERMATOPATHOLOGY; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Furney SJ, 2014, PIGM CELL MELANOMA R, V27, P835, DOI 10.1111/pcmr.12279; Garneski KM, 2009, J INVEST DERMATOL, V129, P246, DOI 10.1038/jid.2008.229; Goh G, 2016, ONCOTARGET, V7, P3393, DOI 10.18632/oncotarget.6494; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Heath M, 2008, J AM ACAD DERMATOL, V58, P375, DOI 10.1016/j.jaad.2007.11.020; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Houben R, 2012, INT J CANCER, V130, P847, DOI 10.1002/ijc.26076; Houben R, 2010, J VIROL, V84, P7064, DOI 10.1128/JVI.02400-09; Jayaraman SS, 2014, J INVEST DERMATOL, V134, P213, DOI 10.1038/jid.2013.276; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lemasson G, 2012, J EUR ACAD DERMATOL, V26, DOI 10.1111/j.1468-3083.2011.04132.x; Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Maricich SM, 2009, SCIENCE, V324, P1580, DOI 10.1126/science.1172890; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; McGirt LY, 2015, BLOOD, V126, P508, DOI 10.1182/blood-2014-11-611194; Milholland B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15183; Moll I, 2005, EUR J CELL BIOL, V84, P259, DOI 10.1016/j.ejcb.2004.12.023; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Puram RV, 2016, CELL, V165, P303, DOI 10.1016/j.cell.2016.03.015; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Sauer CM, 2017, CRIT REV ONCOL HEMAT, V116, P99, DOI 10.1016/j.critrevonc.2017.05.009; Schadendorf D, 2017, EUR J CANCER, V71, P53, DOI 10.1016/j.ejca.2016.10.022; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Semenova EA, 2015, GENE DEV, V29, P1447, DOI 10.1101/gad.263145.115; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shuda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142329; Shuda M, 2014, J INVEST DERMATOL, V134, P1479, DOI 10.1038/jid.2013.483; SIBLEY RK, 1985, AM J SURG PATHOL, V9, P95, DOI 10.1097/00000478-198502000-00004; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; Spurgeon ME, 2015, CANCER RES, V75, P1068, DOI 10.1158/0008-5472.CAN-14-2425; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Tilling T, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/680410; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Van Keymeulen A, 2009, J CELL BIOL, V187, P91, DOI 10.1083/jcb.200907080; Verhaegen ME, 2017, CANCER RES, V77, P3151, DOI 10.1158/0008-5472.CAN-17-0035; Verhaegen ME, 2015, J INVEST DERMATOL, V135, P1415, DOI 10.1038/jid.2014.446; Viatour P, 2008, CELL STEM CELL, V3, P416, DOI 10.1016/j.stem.2008.07.009; Vieites B, 2009, ACTA DERM-VENEREOL, V89, P184, DOI 10.2340/00015555-0563; VISSCHER D, 1989, MODERN PATHOL, V2, P331; Wendzicki JA, 2015, CURR OPIN VIROL, V11, P38, DOI 10.1016/j.coviro.2015.01.009; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Woo SH, 2010, DEVELOPMENT, V137, P3965, DOI 10.1242/dev.055970; zur Hausen A, 2013, CANCER RES, V73, P4982, DOI 10.1158/0008-5472.CAN-13-0616	68	61	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1409	1416		10.1038/s41388-017-0073-3	http://dx.doi.org/10.1038/s41388-017-0073-3			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321666	Green Accepted			2022-12-17	WOS:000427459500001
J	Ferrer, CM; Lu, TY; Bacigalupa, ZA; Katsetos, CD; Sinclair, DA; Reginato, MJ				Ferrer, C. M.; Lu, T. Y.; Bacigalupa, Z. A.; Katsetos, C. D.; Sinclair, D. A.; Reginato, M. J.			O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway	ONCOGENE			English	Article							BETA-N-ACETYLGLUCOSAMINE; PROTEIN-KINASE AMPK; GLCNAC TRANSFERASE; TRANSCRIPTION FACTOR; CYTOSOLIC PROTEINS; CROSS-TALK; METABOLISM; TUMORIGENESIS; SIRTUINS; CELLS	Tumors utilize aerobic glycolysis to support growth and invasion. However, the molecular mechanisms that link metabolism with invasion are not well understood. The nutrient sensor O-linked-beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) modifies intracellular proteins with N-acetylglucosamine. Cancers display elevated O-GlcNAcylation and suppression of O-GlcNAcylation inhibits cancer invasion and metastasis. Here, we show that the regulation of cancer invasion by OGT is dependent on the NAD+-dependent deacetylase SIRT1. Reducing O-GlcNAcylation elevates SIRT1 levels and activity in an AMPK (AMP-activated protein kinase a)-dependent manner. Reduced O-GlcNAcylation in cancer cells leads to SIRT1-mediated proteasomal degradation of oncogenic transcription factor FOXM1 in an MEK/ERK-dependent manner. SIRT1 is critical for OGT-mediated regulation of FOXM1 ubiquitination and reducing SIRT1 activity reverses OGT-mediated regulation of FOXM1. Moreover, we show that SIRT1 levels are required for OGT-mediated regulation of invasion and metastasis in breast cancer cells. Thus, O-GlcNAcylation is a central component linking metabolism to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.	[Katsetos, C. D.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Katsetos, C. D.] Drexel Univ, Coll Med, St Christophers Hosp Children, Dept Pediat, Philadelphia, PA 19104 USA; [Sinclair, D. A.] Harvard Med Sch, Dept Genet, Paul F Glenn Labs Biol Mech Aging, Boston, MA USA	Drexel University; Drexel University; Harvard University; Harvard Medical School	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245N 15th St,NCB Room 11117, Philadelphia, PA 19102 USA.	Mauricio.Reginato@drexelmed.edu		Sinclair, David/0000-0002-9936-436X	NCI [CA183574, CA155413]; NIH/NIA [AG028730]; NATIONAL CANCER INSTITUTE [R01CA155413, F31CA183574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028730, R37AG028730] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Valerie Sodi for critical reading of this manuscript. This work is supported by NCI grants CA183574 (to CMF), CA155413 (to MJR) and NIH/NIA grant AG028730 (to DAS).	Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588; Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101; Bullen JW, 2014, J BIOL CHEM, V289, P10592, DOI 10.1074/jbc.M113.523068; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chang HC, 2014, TRENDS ENDOCRIN MET, V25, P138, DOI 10.1016/j.tem.2013.12.001; Choi JE, 2014, CURR OPIN GENET DEV, V26, P24, DOI 10.1016/j.gde.2014.05.005; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Ferrer CM, 2014, METHODS MOL BIOL, V1176, P73, DOI 10.1007/978-1-4939-0992-6_7; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Fulop N, 2008, BIOGERONTOLOGY, V9, P139, DOI 10.1007/s10522-007-9123-5; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI [10.1038/nchembio.520, 10.1038/NCHEMBIO.520]; Gu YC, 2010, CANCER RES, V70, P6344, DOI 10.1158/0008-5472.CAN-09-1887; Guarente L, 2011, COLD SH Q B, V76, P81, DOI 10.1101/sqb.2011.76.010629; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lau AW, 2014, AM J CANCER RES, V4, P245; Lewis BA, 2014, J BIOL CHEM, V289, P34440, DOI 10.1074/jbc.R114.595439; Lok GTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023790; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Lynch TP, 2011, CELL CYCLE, V10, P1712, DOI 10.4161/cc.10.11.15561; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Roth M, 2014, ONCOGENE, V33, P1609, DOI 10.1038/onc.2013.120; Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Yang YR, 2015, ONCOTARGET, V6, P12529, DOI 10.18632/oncotarget.3725; Yang YR, 2012, AGING CELL, V11, P439, DOI 10.1111/j.1474-9726.2012.00801.x; Yeung F, 2015, ONCOGENE, V34, P798, DOI 10.1038/onc.2014.39; Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1	52	61	63	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					559	569		10.1038/onc.2016.228	http://dx.doi.org/10.1038/onc.2016.228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345396	Green Accepted, Green Submitted			2022-12-17	WOS:000394166700012
J	Kumar, R; Li, DQ; Muller, S; Knapp, S				Kumar, R.; Li, D-Q; Mueller, S.; Knapp, S.			Epigenomic regulation of oncogenesis by chromatin remodeling	ONCOGENE			English	Review							METASTASIS-ASSOCIATED PROTEIN-1; I HISTONE DEACETYLASES; TUMOR-SUPPRESSOR GENE; SMALL-CELL CARCINOMA; FREQUENT INACTIVATING MUTATIONS; RECURRENT SOMATIC MUTATIONS; MALIGNANT RHABDOID TUMORS; HUMAN PROSTATE-CANCER; DNA-DAMAGE RESPONSE; MTA1 MESSENGER-RNA	Disruption of the intricate gene expression program represents one of major driving factors for the development, progression and maintenance of human cancer, and is often associated with acquired therapeutic resistance. At the molecular level, cancerous phenotypes are the outcome of cellular functions of critical genes, regulatory interactions of histones and chromatin remodeling complexes in response to dynamic and persistent upstream signals. A large body of genetic and biochemical evidence suggests that the chromatin remodelers integrate the extracellular and cytoplasmic signals to control gene activity. Consequently, widespread dysregulation of chromatin remodelers and the resulting inappropriate expression of regulatory genes, together, lead to oncogenesis. We summarize the recent developments and current state of the dysregulation of the chromatin remodeling components as the driving mechanism underlying the growth and progression of human tumors. Because chromatin remodelers, modifying enzymes and protein-protein interactions participate in interpreting the epigenetic code, selective chromatin remodelers and bromodomains have emerged as new frontiers for pharmacological intervention to develop future anti-cancer strategies to be used either as single-agent or in combination therapies with chemotherapeutics or radiotherapy.	[Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Kumar, R.] Rajiv Gandhi Ctr Biotechnol, Canc Biol Program, Thiruvananthapuram, Kerala, India; [Li, D-Q] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Shanghai Med Coll, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Shanghai Med Coll, Key Lab Epigenet Shanghai, Shanghai, Peoples R China; [Mueller, S.; Knapp, S.] Univ Oxford, Nuffield Dept Clin Med, Old Rd Campus, Oxford OX3 7LD, England; [Mueller, S.; Knapp, S.] Dept Pharmaceut Chem, Riedberg Campus, Frankfurt, Germany; [Mueller, S.; Knapp, S.] Buchmann Inst Life Sci, Riedberg Campus, Frankfurt, Germany	George Washington University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Fudan University; Fudan University; Fudan University; Fudan University; University of Oxford	Kumar, R (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA.; Knapp, S (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Old Rd Campus, Oxford OX3 7LD, England.	bcmrxk@gwu.edu; knapp@pharmchem.uni-frankfurt.de	Kumar, Rakesh/ABD-1065-2020; Knapp, Stefan/AAG-2347-2019	Kumar, Rakesh/0000-0001-7664-0803; Knapp, Stefan/0000-0001-5995-6494; Muller-Knapp, Susanne/0000-0003-2402-4157	National Institutes of Health grants [CA98823, CA090970]; National Natural Science Foundation of China [81372847, 81572584]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [2013-06]; Innovation Program of Shanghai Municipal Education Commission [2015ZZ007]; Structural Genomic Consortium [1097737]; AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA); Janssen; Merck Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Welcome Trust	National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Structural Genomic Consortium; AbbVie(AbbVie); Bayer Pharma AG; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada(Genome Canada); Innovative Medicines Initiative (EU/EFPIA); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck Co.(Merck & Company); Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Welcome Trust(Wellcome Trust)	We are in debt to our colleagues in this field whose original work may have not been cited here due to space limitations. The chromatin remodeling and signaling work in Kumar laboratory is being supported by grants from the National Institutes of Health grants CA98823 and CA090970. The Li laboratory is funded by the National Natural Science Foundation of China (Number 81372847 and 81572584), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (Number 2013-06) and the Innovation Program of Shanghai Municipal Education Commission (Number 2015ZZ007). The Knapp laboratory is supported by the Structural Genomic Consortium, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute for Innovation, the Genome Canada, the Innovative Medicines Initiative (EU/EFPIA), Janssen, Merck & Co., Novartis Pharma AG, the Ontario Ministry of Economic Development and Innovation, Pfizer, the Sao Paulo Research Foundation-FAPESP, Takeda, and the Welcome Trust.	Adams H, 2010, EXPERT OPIN THER TAR, V14, P577, DOI 10.1517/14728221003796609; Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alqarni SSM, 2014, J BIOL CHEM, V289, P21844, DOI 10.1074/jbc.M114.558940; Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884; Aydin OZ, 2014, CELL CYCLE, V13, P3016, DOI 10.4161/15384101.2014.956551; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Balasubramaniam S, 2013, CLIN CANCER RES, V19, P2657, DOI 10.1158/1078-0432.CCR-12-3049; Bamborough P, 2015, J MED CHEM, V58, P6151, DOI 10.1021/acs.jmedchem.5b00773; Bao Yunhe, 2007, Cell, V129, P632, DOI 10.1016/j.cell.2007.04.018; Bao YH, 2011, CELL, V144, P158, DOI 10.1016/j.cell.2010.12.024; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Basheer F, 2015, EXP HEMATOL, V43, P718, DOI 10.1016/j.exphem.2015.06.004; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Biegel JA, 1999, CANCER RES, V59, P74; Bisson N, 2012, CELL CYCLE, V11, P1316, DOI 10.4161/cc.19685; Brown PJ, 2015, FUTURE MED CHEM, V7, P1901, DOI 10.4155/fmc.15.127; Burrows AE, 2010, P NATL ACAD SCI USA, V107, P14280, DOI 10.1073/pnas.1009559107; Buurman R, 2012, GASTROENTEROLOGY, V143, P811, DOI 10.1053/j.gastro.2012.05.033; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Campos B, 2011, CANCER SCI, V102, P387, DOI 10.1111/j.1349-7006.2010.01792.x; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Caramel J, 2008, CANCER RES, V68, P6154, DOI 10.1158/0008-5472.CAN-08-0115; Caron C, 2010, ONCOGENE, V29, P5171, DOI 10.1038/onc.2010.259; Chen P., 2015, J MED CHEM; Chen TJ, 2011, APMIS, V119, P808, DOI 10.1111/j.1600-0463.2011.02808.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Choi J, 2009, NUCLEIC ACIDS RES, V37, P5993, DOI 10.1093/nar/gkp660; Choi JH, 2009, CANCER RES, V69, P1407, DOI 10.1158/0008-5472.CAN-08-3602; Chu HY, 2014, TUMOR BIOL, V35, P3487, DOI 10.1007/s13277-013-1460-1; Ciro M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131; Clapier CR, 2012, NATURE, V492, P280, DOI 10.1038/nature11625; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Clark PGK, 2015, ANGEW CHEM INT EDIT, V54, P6217, DOI 10.1002/anie.201501394; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Dar AA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv034; Darr J, 2014, ONCOGENE, V33, P3024, DOI 10.1038/onc.2013.261; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Drouin L, 2015, J MED CHEM, V58, P2553, DOI 10.1021/jm501963e; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Euskirchen G, 2012, J BIOL CHEM, V287, P30897, DOI 10.1074/jbc.R111.309302; Fang FM, 2011, AM J PATHOL, V178, P2407, DOI 10.1016/j.ajpath.2011.01.043; Fedorov O, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500723; Feng XH, 2014, MOL CELLS, V37, P699, DOI 10.14348/molcells.2014.0029; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2012, FEBS LETT, V586, P2692, DOI 10.1016/j.febslet.2012.04.045; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flynn EM, 2015, STRUCTURE, V23, P1801, DOI 10.1016/j.str.2015.08.004; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Giaginis C, 2014, TUMOR BIOL, V35, P61, DOI 10.1007/s13277-013-1007-5; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Grand F, 1999, CANCER RES, V59, P3870; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/NCHEMBIO.1859, 10.1038/nchembio.1859]; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114; Gunduz E, 2005, INT J ONCOL, V26, P201; Hah N, 2010, CANCER RES, V70, P4402, DOI 10.1158/0008-5472.CAN-09-2767; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Heeboll S, 2008, HISTOL HISTOPATHOL, V23, P1069, DOI 10.14670/HH-23.1069; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Higashijima J, 2011, ONCOL REP, V26, P343, DOI 10.3892/or.2011.1312; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hofer MD, 2004, CANCER RES, V64, P825, DOI 10.1158/0008-5472.CAN-03-2755; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Hwang WL, 2014, NATURE, V512, P213, DOI 10.1038/nature13380; Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442; Iguchi H, 2000, INT J ONCOL, V16, P1211; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Iwagami Y, 2013, BRIT J CANCER, V109, P502, DOI 10.1038/bjc.2013.320; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; James LI, 2013, J MED CHEM, V56, P7358, DOI 10.1021/jm400919p; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Jin QX, 2015, TUMOR BIOL, V36, P1895, DOI 10.1007/s13277-014-2791-2; Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Jordan NV, 2013, MOL CELL BIOL, V33, P3011, DOI 10.1128/MCB.01443-12; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; Kahali B, 2014, ONCOTARGET, V5, P3316, DOI 10.18632/oncotarget.1945; Kapoor P, 2015, GENE DEV, V29, P591, DOI 10.1101/gad.257626.114; Kapur P, 2013, LANCET ONCOL, V14, P159, DOI 10.1016/S1470-2045(12)70584-3; Kasten MM, 2011, CELL, V144, DOI 10.1016/j.cell.2011.01.007; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kim MS, 2011, HISTOPATHOLOGY, V58, P660, DOI 10.1111/j.1365-2559.2011.03819.x; Knapp S, 2013, CHEMMEDCHEM, V8, P1885, DOI 10.1002/cmdc.201300344; Kothandapani A, 2012, EXP CELL RES, V318, P1973, DOI 10.1016/j.yexcr.2012.06.011; Kuwahara Y, 2013, MOL CANCER RES, V11, P251, DOI 10.1158/1541-7786.MCR-12-0390; Kwon SJ, 2015, MOL CANCER THER, V14, P597, DOI 10.1158/1535-7163.MCT-14-0372; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Lee H, 2009, J GASTROEN HEPATOL, V24, P1445, DOI 10.1111/j.1440-1746.2009.05965.x; Lee SH, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.116; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Li DQ, 2014, CANCER METAST REV, V33, P993, DOI 10.1007/s10555-014-9524-2; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066679; Li H, 2014, TUMOR BIOL, V35, P5771, DOI 10.1007/s13277-014-1766-7; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li WF, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-78; Liang PI, 2012, J CLIN PATHOL, V65, P802, DOI 10.1136/jclinpath-2012-200897; Lichner Z, 2013, AM J PATHOL, V182, P1163, DOI 10.1016/j.ajpath.2013.01.007; Lin CY, 2012, J CLIN PATHOL, V65, P687, DOI 10.1136/jclinpath-2012-200786; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Lin H, 2009, CLIN CANCER RES, V15, P6404, DOI 10.1158/1078-0432.CCR-09-1135; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Link KA, 2008, CANCER RES, V68, P4551, DOI 10.1158/0008-5472.CAN-07-6392; Liu J, 2015, MOL ONCOL, V9, P218, DOI 10.1016/j.molonc.2014.08.007; Liu SL, 2012, TUMOR BIOL, V33, P1485, DOI 10.1007/s13277-012-0399-y; Liu TB, 2013, HUM PATHOL, V44, P2275, DOI 10.1016/j.humpath.2013.05.009; Liu Xi-bo, 2010, Chinese Journal of Pathology, V39, P591, DOI 10.3760/cma.j.issn.0529-5807.2010.09.004; Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Loyola A, 2003, MOL CELL BIOL, V23, P6759, DOI 10.1128/MCB.23.19.6759-6768.2003; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Lu P, 2013, NUCLEUS-AUSTIN, V4, P374, DOI 10.4161/nucl.26654; Ludwigsen J, 2013, EMBO REP, V14, P1092, DOI 10.1038/embor.2013.160; Luk E, 2010, CELL, V143, P725, DOI 10.1016/j.cell.2010.10.019; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maitra A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3873; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marquard L, 2008, HISTOPATHOLOGY, V53, P267, DOI [10.1111/j.1365-2559.2008.03109.x, 10.1111/j.0309-0167.2008.03109.x]; Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x; Marquez SB, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00372; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Mayer C, 2008, EMBO REP, V9, P774, DOI 10.1038/embor.2008.109; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Modena P, 2005, CANCER RES, V65, P4012, DOI 10.1158/0008-5472.CAN-04-3050; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Mora-Blanco EL, 2014, ONCOGENE, V33, P933, DOI 10.1038/onc.2013.37; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992; Murzina NV, 2008, STRUCTURE, V16, P1077, DOI 10.1016/j.str.2008.05.006; Musselman CA, 2012, P NATL ACAD SCI USA, V109, P787, DOI 10.1073/pnas.1113655109; Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008-5472.CAN-12-4593; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Orvis T, 2014, CANCER RES, V74, P6486, DOI 10.1158/0008-5472.CAN-14-0061; Pan MR, 2012, J BIOL CHEM, V287, P6764, DOI 10.1074/jbc.M111.287037; Papadakis AI, 2015, CELL RES, V25, P445, DOI 10.1038/cr.2015.16; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Park JO, 2011, EUR ARCH OTO-RHINO-L, V268, P1329, DOI 10.1007/s00405-010-1478-6; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Petty E, 2013, TRENDS GENET, V29, P621, DOI 10.1016/j.tig.2013.06.006; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Reddy SDN, 2012, J BIOL CHEM, V287, P27843, DOI 10.1074/jbc.M112.348474; Revenko AS, 2010, MOL CELL BIOL, V30, P5260, DOI 10.1128/MCB.00484-10; Reynolds N, 2012, EMBO J, V31, P593, DOI 10.1038/emboj.2011.431; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053; Ryme J, 2009, J CELL BIOCHEM, V108, P565, DOI 10.1002/jcb.22288; Sakamaki A, 2015, CARCINOGENESIS, V36, P622, DOI 10.1093/carcin/bgv044; Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280; Santiago C, 2011, J COMPUT AID MOL DES, V25, P1171, DOI 10.1007/s10822-011-9505-2; Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4; Sausen M, 2013, NAT GENET, V45, P12, DOI 10.1038/ng.2493; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shen JJC, 2008, CANCER RES, V68, P4050, DOI 10.1158/0008-5472.CAN-07-3240; Shen J, 2015, CANCER RES, V75, P754, DOI 10.1158/0008-5472.CAN-14-1301; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sheu JJC, 2013, J PATHOL, V229, P559, DOI 10.1002/path.4147; Sheu JJC, 2010, J BIOL CHEM, V285, P38260, DOI 10.1074/jbc.M110.138735; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Smith-Roe SL, 2015, ONCOTARGET, V6, P732, DOI 10.18632/oncotarget.2715; Song SJ, 2014, MOL CANCER RES, V12, P560, DOI 10.1158/1541-7786.MCR-13-0427; Sperlazza J, 2015, BLOOD, V126, P1462, DOI 10.1182/blood-2015-03-631606; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Sullivan LM, 2013, MODERN PATHOL, V26, P385, DOI 10.1038/modpathol.2012.175; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tae S, 2011, NUCLEIC ACIDS RES, V39, P5424, DOI 10.1093/nar/gkr170; Tai HC, 2012, J CLIN PATHOL, V65, P248, DOI 10.1136/jclinpath-2011-200413; Taulli R, 2014, ONCOGENE, V33, P2354, DOI 10.1038/onc.2013.188; Theodoulou N. H., 2015, J MED CHEM; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.0.CO;2-4; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torchy MP, 2015, CELL MOL LIFE SCI, V72, P2491, DOI 10.1007/s00018-015-1880-8; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van de Wijngaart DJ, 2009, MOL ENDOCRINOL, V23, P1776, DOI 10.1210/me.2008-0280; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vidi PA, 2014, NUCLEIC ACIDS RES, V42, P6365, DOI 10.1093/nar/gku296; Vidler LR, 2012, J MED CHEM, V55, P7346, DOI 10.1021/jm300346w; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang DH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039920, 10.1371/journal.pone.0040364]; Wang G, 2016, CANCER DISCOV, V1, P1; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang L, 2014, CELL STEM CELL, V14, P575, DOI 10.1016/j.stem.2014.02.013; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Watanabe R, 2014, CANCER RES, V74, P2465, DOI 10.1158/0008-5472.CAN-13-3608; Watanabe S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8108; Wei Wang, 2014, Advances in Materials Science and Engineering, DOI 10.1155/2014/494851; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wijdeven RH, 2015, CANCER RES, V75, P4176, DOI 10.1158/0008-5472.CAN-15-0380; Wilson BG, 2014, MOL CELL BIOL, V34, P1136, DOI 10.1128/MCB.01372-13; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Wong AKC, 2000, CANCER RES, V60, P6171; Wu M, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-1; Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991; Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Xie CY, 2014, TUMOR BIOL, V35, P7595, DOI 10.1007/s13277-014-2008-8; Xu Y, 2010, ONCOGENE, V29, P4090, DOI 10.1038/onc.2010.159; Xu YC, 2012, EXP CELL RES, V318, P177, DOI 10.1016/j.yexcr.2011.11.010; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yadon AN, 2011, CELL, V144, P454, DOI 10.1016/j.cell.2011.01.019; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Yang YI, 2014, CANCER RES, V74, P2258, DOI 10.1158/0008-5472.CAN-13-2459; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Ye JQ, 2014, HUM PATHOL, V45, P2430, DOI 10.1016/j.humpath.2014.08.007; Ye Y, 2009, MOL CANCER RES, V7, P1984, DOI 10.1158/1541-7786.MCR-09-0119; Yu L, 2013, FEBS LETT, V587, P2542, DOI 10.1016/j.febslet.2013.06.029; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao H, 2011, ONCOTARGET, V2, P886; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057; Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104	298	61	62	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4423	4436		10.1038/onc.2015.513	http://dx.doi.org/10.1038/onc.2015.513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804164				2022-12-17	WOS:000382153100001
J	He, K; Zheng, X; Li, M; Zhang, L; Yu, J				He, K.; Zheng, X.; Li, M.; Zhang, L.; Yu, J.			mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation	ONCOGENE			English	Article							NF-KAPPA-B; TRANSLATION INITIATION; COLORECTAL-CANCER; MAMMALIAN TARGET; MULTIPLE-MYELOMA; KINASE INHIBITOR; PHASE-II; PUMA; PATHWAY; STRESS	The mammalian target of rapamycin (mTOR) is commonly activated in colon cancer. mTOR complex 1 (mTORC1) is a major downstream target of the PI3K/ATK pathway and activates protein synthesis by phosphorylating key regulators of messenger RNA translation and ribosome synthesis. Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors, and suppress proliferation and tumor angiogenesis and invasion. We now show that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenografts through the DR5, FADD and caspase-8 axis, and is strongly enhanced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 5-fluorouracil. The induction of DR5 by rapalogs is mediated by the ER stress regulator and transcription factor CHOP, but not the tumor suppressor p53, on rapid and sustained inhibition of 4E-BP1 phosphorylation, and attenuated by eIF4E expression. ATP-competitive mTOR/PI3K inhibitors also promote DR5 induction and FADD-dependent apoptosis in colon cancer cells. These results establish activation of ER stress and the death receptor pathway as a novel anticancer mechanism of mTOR inhibitors.	[He, K.; Zheng, X.; Li, M.; Yu, J.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; [He, K.; Zheng, X.; Li, M.; Zhang, L.; Yu, J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhang, L.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Hillman Canc Ctr Res Pavil,Suite 2-26h,5117 Ctr A, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000	NIH [CA129829, CA106348, CA172136]; American Cancer Society [RGS-10-124-01-CCE];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA129829, R01CA106348, R01CA121105, P30CA047904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bert Vogelstein (Howard Hughes Medical Institute, Johns Hopkins University) for p53-KO HCT116, Richard J. Youle (NIH) for BAX/BAK-DKO HCT116 cells, Shi-Yong Sun (Emory University) for FADD-DN construct and Nahum Sonenberg (McGill University) for eIF4E construct. This work is supported by NIH grant CA129829, American Cancer Society grant RGS-10-124-01-CCE (YJ) and NIH grants CA106348, CA172136 (ZL). This project used the UPCI shared facilities including flow cytometry, animal and histopathology and were supported in part by award P30CA047904.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Descamps G, 2012, BRIT J CANCER, V106, P1660, DOI 10.1038/bjc.2012.139; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635; Fan SQ, 2010, NEOPLASIA, V12, P346, DOI 10.1593/neo.10144; Fournier MJ, 2013, MOL CELL BIOL, V33, P2285, DOI 10.1128/MCB.01517-12; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; HALL PA, 1994, J CELL SCI, V107, P3569; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasty P, 2014, CANCER PREV RES, V7, P169, DOI 10.1158/1940-6207.CAPR-13-0299; He K, 2013, MOL CANCER THER, V12, P2559, DOI 10.1158/1535-7163.MCT-13-0284; Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353; Kuhn JG, 2007, CLIN CANCER RES, V13, P7401, DOI 10.1158/1078-0432.CCR-07-0781; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043158; Sun Q, 2007, MOL CANCER THER, V6, P3180, DOI 10.1158/1535-7163.MCT-07-0265; Sun QH, 2011, CLIN CANCER RES, V17, P2361, DOI 10.1158/1078-0432.CCR-10-2262; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yellen P, 2013, CANCER LETT, V333, P239, DOI 10.1016/j.canlet.2013.01.041; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang L, 2013, CURR COLORECT CANC R, V9, P331, DOI 10.1007/s11888-013-0188-z; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096; Zheng XN, 2013, MOL CANCER THER, V12, P777, DOI 10.1158/1535-7163.MCT-12-1146	53	61	67	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					148	157		10.1038/onc.2015.79	http://dx.doi.org/10.1038/onc.2015.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25867072	Green Accepted			2022-12-17	WOS:000368193900002
J	Lozupone, F; Borghi, M; Marzoli, F; Azzarito, T; Matarrese, P; Iessi, E; Venturi, G; Meschini, S; Canitano, A; Bona, R; Cara, A; Fais, S				Lozupone, F.; Borghi, M.; Marzoli, F.; Azzarito, T.; Matarrese, P.; Iessi, E.; Venturi, G.; Meschini, S.; Canitano, A.; Bona, R.; Cara, A.; Fais, S.			TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells	ONCOGENE			English	Article							PROTON PUMP INHIBITORS; VACUOLAR H+-ATPASE; MULTIDRUG-RESISTANCE; INTRACELLULAR PH; MELANOMA-CELLS; ENERGY-METABOLISM; SUBUNIT ISOFORMS; IN-VITRO; INVASION; METASTASIS	An inverted pH gradient across the cell membranes is a typical feature of malignant cancer cells that are characterized by extracellular acidosis and cytosol alkalization. These dysregulations are able to create a unique milieu that favors tumor progression, metastasis and chemo/immune-resistance traits of solid tumors. A key event mediating tumor cell pH alterations is an aberrant activation of ion channels and proton pumps such as (H+)-vacuolar-ATPase (V-ATPase). TM9SF4 is a poorly characterized transmembrane protein that we have recently shown to be related to cannibal behavior of metastatic melanoma cells. Here, we demonstrate that TM9SF4 represents a novel V-ATPase-associated protein involved in V-ATPase activation. We have observed in HCT116 and SW480 colon cancer cell lines that TM9SF4 interacts with the ATP6V1H subunit of the V-ATPase V1 sector. Suppression of TM9SF4 with small interfering RNAs strongly reduces assembly of V-ATPase V0/V1 sectors, thus reversing tumor pH gradient with a decrease of cytosolic pH, alkalization of intracellular vesicles and a reduction of extracellular acidity. Such effects are associated with a significant inhibition of the invasive behavior of colon cancer cells and with an increased sensitivity to the cytotoxic effects of 5-fluorouracil. Our study shows for the first time the important role of TM9SF4 in the aberrant constitutive activation of the V-ATPase, and the development of a malignant phenotype, supporting the potential use of TM9SF4 as a target for future anticancer therapies.	[Lozupone, F.; Marzoli, F.; Azzarito, T.; Matarrese, P.; Iessi, E.; Venturi, G.; Canitano, A.; Bona, R.; Cara, A.; Fais, S.] Ist Super Sanita, Therapeut Res & Med Evaluat Dept, I-00161 Rome, Italy; [Borghi, M.] Ist Super Sanita, Infect Parasit & Immune Mediated Dis Dept, I-00161 Rome, Italy; [Meschini, S.] Ist Super Sanita, Technol & Hlth Dept, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Lozupone, F (corresponding author), Ist Super Sanita, Dept Drug Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	francesco.lozupone@iss.it	Lozupone, Francesco/H-2998-2016; Cara, Andrea/M-4865-2015; CANITANO, ANDREA/O-1907-2017; Matarrese, Paola/A-4369-2014; VENTURI, GIULIETTA/O-8123-2015; Cara, Andrea/AAA-4238-2021; BORGHI, MARTINA/M-4355-2015; Iessi, Elisabetta/O-2460-2017; Fais, Stefano/J-8638-2016; Bona, Roberta/O-1730-2017; MESCHINI, STEFANIA/E-9091-2015	Lozupone, Francesco/0000-0002-4959-9400; Cara, Andrea/0000-0003-4967-1895; CANITANO, ANDREA/0000-0002-1494-1237; VENTURI, GIULIETTA/0000-0002-9078-8350; Cara, Andrea/0000-0003-4967-1895; BORGHI, MARTINA/0000-0001-6313-0273; Iessi, Elisabetta/0000-0001-7221-9173; Fais, Stefano/0000-0001-9060-2766; Bona, Roberta/0000-0002-9226-3734; MESCHINI, STEFANIA/0000-0001-9079-1181; matarrese, paola/0000-0001-5477-3752; marzoli, francesca/0000-0002-1353-527X	AIRC Associazione Italiana per la Ricerca sul Cancro; Airc Grant [10602, IG 11505n]	AIRC Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Airc Grant(Fondazione AIRC per la ricerca sul cancro)	We thank Dr Angelo De Milito for helpful discussion, Pasqualina Leone for her contribution in plasmid cloning and Dr Tonino Sofia for his suggestions. This study was supported by AIRC Associazione Italiana per la Ricerca sul Cancro. Airc Grant '10602' and 'IG 11505n'. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Avnet S, 2013, BBA-MOL BASIS DIS, V1832, P1105, DOI 10.1016/j.bbadis.2013.04.003; Capecci J, 2013, J BIOL CHEM, V288, P32731, DOI 10.1074/jbc.M113.503771; Chang H, 2011, BREAST CANCER RES TR, V125, P55, DOI 10.1007/s10549-010-0825-z; Chen M, 2012, J CELL BIOCHEM, V113, P2474, DOI 10.1002/jcb.24122; Chung CH, 2011, LAB INVEST, V91, P732, DOI 10.1038/labinvest.2011.8; Daniel C, 2013, BBA-MOL BASIS DIS, V1832, P606, DOI 10.1016/j.bbadis.2013.01.020; De Milito Angelo, 2005, Future Oncol, V1, P779, DOI 10.2217/14796694.1.6.779; De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; De Milito A, 2010, INT J CANCER, V127, P207, DOI 10.1002/ijc.25009; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805; Fogarty FM, 2014, ONCOGENE, V33, P4653, DOI 10.1038/onc.2013.403; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Graham RM, 2014, ONCOTARGET, V5, P1162, DOI 10.18632/oncotarget.1699; He PF, 2009, AUTOPHAGY, V5, P52, DOI 10.4161/auto.5.1.7247; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Lozupone F, 2009, EMBO REP, V10, P1348, DOI 10.1038/embor.2009.236; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MacKinnon RN, 2010, GENE CHROMOSOME CANC, V49, P998, DOI 10.1002/gcc.20806; Marshansky V, 2014, BBA-BIOENERGETICS, V1837, P857, DOI 10.1016/j.bbabio.2014.01.018; Michel V, 2013, INT J CANCER, V132, pE1, DOI 10.1002/ijc.27811; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Niikura K, 2006, DRUG NEWS PERSPECT, V19, P139, DOI 10.1358/dnp.2006.19.3.977442; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Oo HZ, 2014, PATHOBIOLOGY, V81, P138, DOI 10.1159/000357821; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Parks SK, 2011, J CELL PHYSIOL, V226, P299, DOI 10.1002/jcp.22400; Perez-Sayans M, 2010, CANCER LETT, V295, P135, DOI 10.1016/j.canlet.2010.03.019; Perrin J, 2015, J INNATE IMMUN, V7, P37, DOI 10.1159/000365112; Qi J, 2007, J BIOENERG BIOMEMBR, V39, P423, DOI 10.1007/s10863-007-9116-8; Raghunand N, 2000, DRUG RESIST UPDATE, V3, P39, DOI 10.1054/drup.2000.0119; Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; de Souza ACS, 2011, CELL PHYSIOL BIOCHEM, V28, P771, DOI 10.1159/000335792; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; SEO JT, 1994, PFLUG ARCH EUR J PHY, V426, P75, DOI 10.1007/BF00374673; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; Spugnini EP, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-221; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sun-Wada GH, 2013, HISTOL HISTOPATHOL, V28, P805, DOI 10.14670/HH-28.805; Supino R, 2009, ANN NY ACAD SCI, V1171, P606, DOI 10.1111/j.1749-6632.2009.04705.x; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wiedmann RM, 2012, CANCER RES, V72, P5976, DOI 10.1158/0008-5472.CAN-12-1772; Xu JY, 2012, CARCINOGENESIS, V33, P2432, DOI 10.1093/carcin/bgs277; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023; Zaravinos A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018135; Zhang Y, 2013, CANCER BIOL THER, V14, P81, DOI 10.4161/cbt.22958	52	61	67	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5163	5174		10.1038/onc.2014.437	http://dx.doi.org/10.1038/onc.2014.437			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659576				2022-12-17	WOS:000362233400006
J	Orfanelli, U; Jachetti, E; Chiacchiera, F; Grioni, M; Brambilla, P; Briganti, A; Freschi, M; Martinelli-Boneschi, F; Doglioni, C; Montorsi, F; Bellone, M; Casari, G; Pasini, D; Lavorgna, G				Orfanelli, U.; Jachetti, E.; Chiacchiera, F.; Grioni, M.; Brambilla, P.; Briganti, A.; Freschi, M.; Martinelli-Boneschi, F.; Doglioni, C.; Montorsi, F.; Bellone, M.; Casari, G.; Pasini, D.; Lavorgna, G.			Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer	ONCOGENE			English	Article							CELL-DEATH; EXPRESSION SIGNATURE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; PROGRESSION; CHANNEL; DIFFERENTIATION; ACTIVATION; BIOMARKERS; DISEASE	Overwhelming evidence indicates that cancer is a genetic disease caused by the accumulation of mutations in oncogenes and tumor suppressor genes. It is also increasingly apparent, however, that cancer depends not only on mutations in these coding genes but also on alterations in the large class of non-coding RNAs. Here, we report that one such long non-coding RNA, TRPM2-AS, an antisense transcript of TRPM2, which encodes an oxidative stress-activated ion channel, is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. Moreover, targets of existing drugs and treatments were found to be consistently associated with high TRPM2-AS levels in both targeted cells and patients, ultimately suggesting that the measurement of the expression levels of TRPM2-AS allows not only for the early identification of aggressive PCa tumors, but also identifies a subset of at-risk patients who would benefit from currently available, but mostly differently purposed, therapeutic agents.	[Orfanelli, U.; Briganti, A.; Montorsi, F.; Casari, G.; Lavorgna, G.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy; [Orfanelli, U.; Casari, G.; Lavorgna, G.] Ctr Translat Genom & Bioinformat, Milan, Italy; [Jachetti, E.; Grioni, M.; Bellone, M.] Ist Sci San Raffaele, Cellular Immunol Unit, I-20132 Milan, Italy; [Chiacchiera, F.; Pasini, D.] European Inst Oncol IEO, Dept Expt Oncol, Milan, Italy; [Brambilla, P.; Martinelli-Boneschi, F.] Ist Sci San Raffaele, Inst Expt Neurol INSPE, Div Neurosci, Lab Genet Neurol Complex Disorders, I-20132 Milan, Italy; [Briganti, A.; Montorsi, F.] Dept Urol, Milan, Italy; [Freschi, M.; Doglioni, C.] Univ Vita Salute San Raffaele, Dept Pathol, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS European Institute of Oncology (IEO); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Lavorgna, G (corresponding author), Ist Sci San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.	matteo.bellone@hsr.it; giovanni.lavorgna@hsr.it	Briganti, Alberto/AAN-1965-2020; Montorsi, Francesco/AAN-2473-2020; Matteo, Grioni/AAN-5912-2020; Chiacchiera, Fulvio/ABD-6137-2020; Jachetti, Elena/C-2145-2017; Lavorgna, Giovanni/AAN-2575-2020; Chiacchiera, Fulvio/K-6740-2016; Bellone, Matteo/B-6922-2013; Casari, Giorgio/J-3070-2018; Orfanelli, Ugo/AAN-4787-2020; Pasini, Diego/J-9674-2012	Matteo, Grioni/0000-0002-9930-042X; Jachetti, Elena/0000-0001-6483-7350; Chiacchiera, Fulvio/0000-0003-3830-2090; Bellone, Matteo/0000-0002-2586-2569; Casari, Giorgio/0000-0002-0115-8980; DOGLIONI, Claudio/0000-0002-4969-5216; Pasini, Diego/0000-0002-9879-6486; martinelli boneschi, filippo/0000-0002-9955-1368; Orfanelli, Ugo/0000-0003-3792-9174	Alleanza Contro il Cancro (AACR); Italian Ministry of Health; Associazione Italiana per la Ricerca sul Cancro (AIRC)	Alleanza Contro il Cancro (AACR); Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Alleanza Contro il Cancro (AACR) to GL, the Italian Ministry of Health to MB and the Associazione Italiana per la Ricerca sul Cancro (AIRC) to MB.	Agell L, 2012, AM J PATHOL, V181, P1585, DOI 10.1016/j.ajpath.2012.08.005; Bai JZ, 2010, NEUROTOXICOLOGY, V31, P204, DOI 10.1016/j.neuro.2010.01.001; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-507; Chen SJ, 2013, AM J PHYSIOL-CELL PH, V304, pC548, DOI 10.1152/ajpcell.00069.2012; Cheville JC, 2008, J CLIN ONCOL, V26, P3930, DOI 10.1200/JCO.2007.15.6752; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Di AK, 2012, NAT IMMUNOL, V13, P29, DOI 10.1038/ni.2171; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hessels D, 2009, NAT REV UROL, V6, P255, DOI 10.1038/nrurol.2009.40; Irshad S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006408; Ishii M, 2007, ANTICANCER RES, V27, P3987; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; Markert EK, 2011, P NATL ACAD SCI USA, V108, P21276, DOI 10.1073/pnas.1117029108; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Miller BA, 2006, J MEMBRANE BIOL, V209, P31, DOI 10.1007/s00232-005-0839-3; Miller EW, 2007, NAT CHEM BIOL, V3, P263, DOI 10.1038/nchembio871; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Orfanelli U, 2008, CELL RES, V18, P1128, DOI 10.1038/cr.2008.296; Penney KL, 2011, J CLIN ONCOL, V29, P2391, DOI 10.1200/JCO.2010.32.6421; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ribeiro FR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022317; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Schroder FH, 2012, BJU INT, V110, P3, DOI 10.1111/j.1464-410X.2012.011428.x; Simon RM, 2009, J NATL CANCER I, V101, P1446, DOI 10.1093/jnci/djp335; Stark JR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3601; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tandefelt DG, 2013, EUR UROL, V64, P941, DOI 10.1016/j.eururo.2013.02.039; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; US Department of Health and Human Services FDA, 2007, CTR DRUG EV RES CTR; Verma S, 2012, NEUROSCI LETT, V530, P41, DOI 10.1016/j.neulet.2012.09.044; Wang GH, 2010, AM J TRANSL RES, V2, P65; Xia J, 2013, JNCI-J NATL CANCER I, V105, P546, DOI 10.1093/jnci/djt017; Xing Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000088; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Zeng X, 2010, PROSTATE CANCER P D, V13, P195, DOI 10.1038/pcan.2009.55; Zhang WY, 2006, AM J PHYSIOL-CELL PH, V290, pC1146, DOI 10.1152/ajpcell.00205.2005	55	61	63	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2094	2102		10.1038/onc.2014.144	http://dx.doi.org/10.1038/onc.2014.144			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24931166				2022-12-17	WOS:000353173400009
J	Itahana, Y; Han, R; Barbier, S; Lei, Z; Rozen, S; Itahana, K				Itahana, Y.; Han, R.; Barbier, S.; Lei, Z.; Rozen, S.; Itahana, K.			The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense	ONCOGENE			English	Article							URATE OXIDASE; IDENTIFICATION; GLUT9; INACTIVATION; REGULATOR; ARREST; FAMILY; CANCER; DAMAGE; RISK	Only humans and higher primates have high uric acid blood levels. Although high uric acid causes gout, it has been linked with human longevity because of its hypothetical antioxidant function. Recent studies reveal that p53 has significant roles in cellular metabolism. One example of this is an antioxidant function that potentially contributes to tumor suppression. Here, we reported a first beneficial link between p53 and uric acid. We identified the uric acid transporter SLC2A9 (also known as GLUT9) as a direct p53 target gene and a key downstream effector in the reduction of reactive oxygen species (ROS) through transporting uric acid as a source of antioxidant. Oxidative stress induced SLC2A9 expression in a p53-dependent manner, and inhibition of SLC2A9 by small interfering RNA (siRNA) or anti-gout drugs such as probenecid significantly increased ROS levels in an uric acid-dependent manner and greatly sensitized cancer cells to chemotherapeutic drugs. Conversely, expression of SLC2A9 reduced ROS and protected against DNA damage and cell death, suggesting its antioxidant function. The increased production of ROS because of p53 loss was rescued by SLC2A9 expression. Furthermore, decreased SLC2A9 expression was observed in several cancer types and was associated with a poorer prognosis. Our findings suggest that the p53-SLC2A9 pathway is a novel antioxidant mechanism that uses uric acid to maintain ROS homeostasis and prevent accumulation of ROS-associated damage that potentially contributes to cancer development.	[Itahana, Y.; Han, R.; Lei, Z.; Rozen, S.; Itahana, K.] Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Barbier, S.] Duke NUS Grad Med Sch Singapore, Ctr Quantitat Med, Off Clin Sci, Singapore 169857, Singapore; [Lei, Z.; Rozen, S.] Duke NUS Grad Med Sch Singapore, Ctr Computat Biol, Singapore 169857, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Itahana, K (corresponding author), Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Room 07-18,Level 7,8 Coll Rd, Singapore 169857, Singapore.	koji.itahana@duke-nus.edu.sg	Rozen, Steven G./J-5939-2013; Itahana, Koji/J-5505-2013	Rozen, Steven G./0000-0002-4288-0056; Itahana, Koji/0000-0002-7241-2894	Singapore Ministry of Education AcRF Tier 2 fund [MOE2013-T2-1-123]; Duke-NUS core grant	Singapore Ministry of Education AcRF Tier 2 fund(Ministry of Education, Singapore); Duke-NUS core grant	We acknowledge funding from the Singapore Ministry of Education AcRF Tier 2 fund (MOE2013-T2-1-123) and the Duke-NUS core grant. We thank Dr Gerald Evan for providing Mdm2<SUP>+/+</SUP>; p53<SUP>ER/-</SUP> and Mdm2<SUP>-/-</SUP>; p53<SUP>ER/-</SUP> MEFs, Dr. Bert Vogelstein for HCT116 (p53<SUP>+/+</SUP>) and HCT116 (p53<SUP>-/-</SUP>) cell lines, Dr Yanping Zhang for p53 and green-fluorescent protein adenoviruses. We also thank Drs David Virshup, Patrick Casey, Kanaga Sabapathy and Paul Yen for critical reading of the manuscript. We thank Lee Guan Hwee Bernard for technical assistance.	AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Anzai N, 2008, J BIOL CHEM, V283, P26834, DOI 10.1074/jbc.C800156200; Augustin R, 2004, J BIOL CHEM, V279, P16229, DOI 10.1074/jbc.M312226200; Augustin R, 2010, IUBMB LIFE, V62, P315, DOI 10.1002/iub.315; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bibert S, 2009, AM J PHYSIOL-RENAL, V297, pF612, DOI 10.1152/ajprenal.00139.2009; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campos-Arroyo D, 2012, CANCER CHEMOTH PHARM, V69, P495, DOI 10.1007/s00280-011-1725-6; Caulfield MJ, 2008, PLOS MED, V5, P1509, DOI 10.1371/journal.pmed.0050197; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Clegg HV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038212; CUTLER RG, 1991, AM J CLIN NUTR, V53, pS373, DOI 10.1093/ajcn/53.1.373S; de Lau LML, 2005, ANN NEUROL, V58, P797, DOI 10.1002/ana.20663; Dehghan A, 2008, LANCET, V372, P1953, DOI 10.1016/S0140-6736(08)61343-4; Doring A, 2008, NAT GENET, V40, P430, DOI 10.1038/ng.107; Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Itahana Y, 2012, CURR DRUG TARGETS, V13, P1633, DOI 10.2174/138945012803529992; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; Kim TS, 2006, INT J GERIATR PSYCH, V21, P344, DOI 10.1002/gps.1469; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Li S, 2007, PLOS GENET, V3, P2156, DOI 10.1371/journal.pgen.0030194; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Matsuo H, 2008, AM J HUM GENET, V83, P744, DOI 10.1016/j.ajhg.2008.11.001; Oda M, 2002, MOL BIOL EVOL, V19, P640, DOI 10.1093/oxfordjournals.molbev.a004123; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; Pietraforte D, 2006, FREE RADICAL BIO MED, V41, P1753, DOI 10.1016/j.freeradbiomed.2006.08.014; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preitner F, 2009, P NATL ACAD SCI USA, V106, P15501, DOI 10.1073/pnas.0904411106; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; So A, 2010, J CLIN INVEST, V120, P1791, DOI 10.1172/JCI42344; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3	50	61	67	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1799	1810		10.1038/onc.2014.119	http://dx.doi.org/10.1038/onc.2014.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858040				2022-12-17	WOS:000352158000007
J	Wen, Z; Liu, H; Li, M; Li, B; Gao, W; Shao, Q; Fan, B; Zhao, F; Wang, Q; Xie, Q; Yang, Y; Yu, J; Qu, X				Wen, Z.; Liu, H.; Li, M.; Li, B.; Gao, W.; Shao, Q.; Fan, B.; Zhao, F.; Wang, Q.; Xie, Q.; Yang, Y.; Yu, J.; Qu, X.			Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; ISCHEMIC TISSUES; GENE-EXPRESSION; GROWTH-FACTOR; MOUSE MODEL; PROGRESSION; CARCINOMA; PATHWAYS; LIPOXYGENASE; MATRILYSIN	5-lipoxygenase (5-LOX), a member of the lipoxygenase gene family, is a key enzyme assisting in the conversion of arachidonic acid to 5-HETE and leukotrienes. Tumor-associated macrophages (TAMs) have a critical role in the progression and metastasis of many tumors, including ovarian tumors. Moreover, TAMs are often found in a high density in the hypoxic areas of tumors. However, the relevant mechanisms have not been studied explicitly until now. In this study, we found that the expression of 5-LOX strongly correlated with the density of TAMs in hypoxic areas of human ovarian tumor tissues. In cultured ovarian cancer cells, 5-LOX metabolites were increased under hypoxic conditons. Increased 5-LOX metabolites from hypoxic ovarian cancer cells promoted migration and invasion of macrophages, which was further demonstrated to be mediated by the upregulation of matrix metalloproteinase (MMP)-7 expression through the p38 pathway. Besides, we also showed that 5-LOX metabolites enhanced the release of tumor necrosis factor (TNF-alpha) and heparin-binding epidermal growth factor-like growth factor through upregulation of MMP-7. Furthermore, in animal models, Zileuton (a selective and specific 5-LOX inhibitor) reduced the MMP-7 expression and the number of macrophages infiltrating in the xenograft. Our findings suggest for the first time that increased metabolites of 5-LOX from hypoxic ovarian cancer cells promote TAM infiltration. These results of this study have immediate translational implications for the therapeutic exploitation of TAMs.	[Wen, Z.; Liu, H.; Gao, W.; Shao, Q.; Wang, Q.; Xie, Q.; Yang, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Jinan 250100, Peoples R China; [Wen, Z.; Liu, H.; Gao, W.; Shao, Q.; Wang, Q.; Xie, Q.; Yang, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Prote Shandong Prov, Jinan 250100, Peoples R China; [Li, M.; Li, B.; Fan, B.; Zhao, F.; Yu, J.] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Yu, J (corresponding author), Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.	jinmingyusd@126.com; xunqusd@126.com		Qu, Xun/0000-0002-2521-3761	National Natural Science Foundation of China [31270971, 81072406]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Colin D Funk, Department of Physiology and Biochemistry, Queen's University for providing us with essential material and a technical guide. This study was supported by National Natural Science Foundation of China (Nos. 31270971, 81072406).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bingham BA, 2013, CLIN NUCL MED, V38, pE140, DOI 10.1097/RLU.0b013e318263869d; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Brigatte P, 2011, AMINO ACIDS, V40, P101, DOI 10.1007/s00726-010-0512-8; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Chang MC, 2012, BIOCHEM J, V442, P293, DOI 10.1042/BJ20110282; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Chu J, 2011, AM J PATHOL, V178, P1762, DOI 10.1016/j.ajpath.2010.12.032; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Freedman RS, 2007, CLIN CANCER RES, V13, P5736, DOI 10.1158/1078-0432.CCR-07-0583; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594; Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Horiuchi A, 2012, INT J CANCER, V131, P1755, DOI 10.1002/ijc.27448; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kioi M, 2003, ONCOGENE, V22, P8662, DOI 10.1038/sj.onc.1207181; Kummer NT, 2012, J CELL BIOCHEM, V113, P1998, DOI 10.1002/jcb.24069; Lee SK, 2012, INT J CANCER, V131, pE190, DOI 10.1002/ijc.27381; Lewis JS, 2000, J PATHOL, V192, P150, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Maniecki MB, 2012, INT J CANCER, V131, P2320, DOI 10.1002/ijc.27506; Megias J, 2007, BRIT J PHARMACOL, V150, P977, DOI 10.1038/sj.bjp.0707184; Meng YR, 2010, CANCER RES, V70, P1534, DOI 10.1158/0008-5472.CAN-09-2995; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; Phuangsab A, 2001, CANCER LETT, V172, P27, DOI 10.1016/S0304-3835(01)00617-6; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reinartz S, 2014, INT J CANCER, V134, P32, DOI 10.1002/ijc.28335; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ruhrberg C, 2010, NAT MED, V16, P861, DOI 10.1038/nm0810-861; Schroder A, 2013, J UROLOGY, V189, P2377, DOI 10.1016/j.juro.2012.12.110; Sitia G, 2004, J CLIN INVEST, V113, P1158, DOI 10.1172/JCI200421087; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47; Yamaguchi Tatsuyuki, 1995, Life Sciences, V56, P379; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	54	61	63	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1241	1252		10.1038/onc.2014.85	http://dx.doi.org/10.1038/onc.2014.85			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662827				2022-12-17	WOS:000350687100004
J	Beristain, AG; Molyneux, SD; Joshi, PA; Pomroy, NC; Di Grappa, MA; Chang, MC; Kirschner, LS; Prive, GG; Pujana, MA; Khokha, R				Beristain, A. G.; Molyneux, S. D.; Joshi, P. A.; Pomroy, N. C.; Di Grappa, M. A.; Chang, M. C.; Kirschner, L. S.; Prive, G. G.; Pujana, M. A.; Khokha, R.			PKA signaling drives mammary tumorigenesis through Src	ONCOGENE			English	Article							PROTEIN-KINASE-A; ELEVATED AROMATASE EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; SUBUNIT TYPE 1A; BREAST-CANCER; CARNEY COMPLEX; REGULATORY SUBUNITS; CELL-CYCLE; C-SRC; PRKAR1A	Protein kinase A (PKA) hyperactivation causes hereditary endocrine neoplasias; however, its role in sporadic epithelial cancers is unknown. Here, we show that heightened PKA activity in the mammary epithelium generates tumors. Mammary-restricted biallelic ablation of Prkar1a, which encodes for the critical type-I PKA regulatory subunit, induced spontaneous breast tumors characterized by enhanced type-II PKA activity. Downstream of this, Src phosphorylation occurs at residues serine-17 and tyrosine-416 and mammary cell transformation is driven through a mechanism involving Src signaling. The phenotypic consequences of these alterations consisted of increased cell proliferation and, accordingly, expansion of both luminal and basal epithelial cell populations. In human breast cancer, low PRKAR1A/high SRC expression defines basal-like and HER2 breast tumors associated with poor clinical outcome. Together, the results of this study define a novel molecular mechanism altered in breast carcinogenesis and highlight the potential strategy of inhibiting SRC signaling in treating this cancer subtype in humans.	[Beristain, A. G.; Molyneux, S. D.; Joshi, P. A.; Pomroy, N. C.; Di Grappa, M. A.; Khokha, R.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [Molyneux, S. D.; Joshi, P. A.; Prive, G. G.; Khokha, R.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [Chang, M. C.; Khokha, R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; [Kirschner, L. S.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; [Pujana, M. A.] Hosp Llobregat, IDIBELL, Catalan Inst Oncol, Breast Canc & Syst Biol Unit,Translat Res Lab, Barcelona, Spain	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University System of Ohio; Ohio State University; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Pujana, Miquel Angel/N-3127-2014; Chang, Martin/J-2329-2016	Pujana, Miquel Angel/0000-0003-3222-4044; Khokha, Rama/0000-0002-6028-1524; Prive, Gilbert/0000-0002-0712-4319; Beristain, Alexander/0000-0002-1117-6242; Joshi, Purna/0000-0002-1628-9940	Canadian Breast Cancer Foundation (CBCF); Spanish Ministry of Health grant [FIS-PI12/01528, RD12/0036/0008]; CBCF fellowship; NATIONAL CANCER INSTITUTE [P01CA124570] Funding Source: NIH RePORTER	Canadian Breast Cancer Foundation (CBCF); Spanish Ministry of Health grant; CBCF fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Megan K Barker and Paul Waterhouse for critical reading of the manuscript. We would also like to acknowledge Shareen Ezzat for sharing the small molecule Dasatinib, Vuk Stambolic for offering insight into biochemistry experiments and the IDIBELL's Biostatistics Unit for help in analyzing breast cancer data sets. This work was supported by a Canadian Breast Cancer Foundation (CBCF) grant to RK and the Spanish Ministry of Health grant FIS-PI12/01528 and RD12/0036/0008 to MAP. AGB holds a CBCF fellowship.	Almeida MQ, 2011, MOL CELL ENDOCRINOL, V336, P162, DOI 10.1016/j.mce.2010.11.018; Almeida MQ, 2010, HUM MOL GENET, V19, P1387, DOI 10.1093/hmg/ddq014; Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Baker MA, 2006, J CELL SCI, V119, P3182, DOI 10.1242/jcs.03055; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bossis I, 2004, ENDOCRINOLOGY, V145, P5452, DOI 10.1210/en.2004-0900; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARNEY JA, 1991, AM J SURG PATHOL, V15, P722, DOI 10.1097/00000478-199108000-00002; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Elsberger B, 2009, AM J PATHOL, V175, P1389, DOI 10.2353/ajpath.2009.090273; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gold MG, 2013, J BIOL CHEM, V288, P17111, DOI 10.1074/jbc.M112.447326; Griffin KJ, 2004, CANCER RES, V64, P8811, DOI 10.1158/0008-5472.CAN-04-3620; Griffin KJ, 2004, J MED GENET, V41, P923, DOI 10.1136/jmg.2004.028043; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Lim CJ, 2007, NAT CELL BIOL, V9, P415, DOI 10.1038/ncb1561; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Moujalled D, 2011, EMBO REP, V12, P77, DOI 10.1038/embor.2010.190; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nadella KS, 2008, CANCER RES, V68, P2671, DOI 10.1158/0008-5472.CAN-07-6002; Neary CL, 2004, ONCOGENE, V23, P8847, DOI 10.1038/sj.onc.1208165; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pavel E, 2008, MOL ENDOCRINOL, V22, P430, DOI 10.1210/me.2007-0369; Prat A, 2012, BREAST CANCER RES TR, V135, P301, DOI 10.1007/s10549-012-2143-0; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; Soulard A, 2010, MOL BIOL CELL, V21, P3475, DOI 10.1091/mbc.E10-03-0182; Subbaramaiah K, 2008, J BIOL CHEM, V283, P3433, DOI 10.1074/jbc.M705409200; Subbaramaiah K, 2012, CANCER DISCOV, V2, P356, DOI 10.1158/2159-8290.CD-11-0241; Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wilson GR, 2006, BRIT J CANCER, V95, P1410, DOI 10.1038/sj.bjc.6603444; Yin ZR, 2008, CIRCULATION, V117, P1414, DOI 10.1161/CIRCULATIONAHA.107.759233	48	61	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1160	1173		10.1038/onc.2014.41	http://dx.doi.org/10.1038/onc.2014.41			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662820				2022-12-17	WOS:000350122100009
J	Poortinga, G; Quinn, LM; Hannan, RD				Poortinga, G.; Quinn, L. M.; Hannan, R. D.			Targeting RNA polymerase I to treat MYC-driven cancer	ONCOGENE			English	Review							RIBOSOMAL-PROTEIN L11; C-MYC; DROSOPHILA-MYC; GENE-EXPRESSION; DNA-BINDING; ORNITHINE-DECARBOXYLASE; THERAPEUTIC STRATEGY; MYC/MAX DIMERIZATION; CELLULAR GROWTH; EMERGING TARGET	The MYC oncoprotein and transcription factor is dysregulated in a majority of human cancers and is considered a major driver of the malignant phenotype. As such, developing drugs for effective inhibition of MYC in a manner selective to malignancies is a 'holy grail' of transcription factor-based cancer therapy. Recent advances in elucidating MYC biology in both normal cells and pathological settings were anticipated to bring inhibition of tumorigenic MYC function closer to the clinic. However, while the extensive array of cellular pathways that MYC impacts present numerous fulcrum points on which to leverage MYC's therapeutic potential, identifying the critical target(s) for MYC-specific cancer therapy has been difficult to achieve. Somewhat unexpectedly, MYC's fundamental role in regulating the 'housekeeping' process of ribosome biogenesis, one of the most ubiquitously required and conserved cell functions, may provide the Achilles' heel for therapeutically targeting MYC-driven tumors.	[Poortinga, G.; Hannan, R. D.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 8006, Australia; [Poortinga, G.; Hannan, R. D.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Poortinga, G.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Quinn, L. M.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Hannan, R. D.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Hannan, R. D.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Hannan, R. D.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; University of Queensland	Hannan, RD (corresponding author), Peter MacCallum Canc Ctr, Div Res, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	ross.hannan@petermac.org		Quinn, Leonie/0000-0002-3911-6508; Hannan, Ross/0000-0002-2166-4493				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boi M, 2012, ASH ANN M, V120, P4872; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bonham AJ, 2013, NUCLEIC ACIDS RES, V41, P754, DOI 10.1093/nar/gks1085; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks Tracy A, 2010, Genes Cancer, V1, P641; Brown RV, 2011, J BIOL CHEM, V286, P41018, DOI 10.1074/jbc.M111.274720; Brown SJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-442; Bui Thi V, 2010, Genes Cancer, V1, P568; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Bywater MJ, 2013, NAT REV CANCER, V13, P299, DOI 10.1038/nrc3496; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961; Dai JX, 2011, J AM CHEM SOC, V133, P17673, DOI 10.1021/ja205646q; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Daneshvar K, 2013, BIOL OPEN, V2, P1, DOI 10.1242/bio.20122725; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang Chi V, 2010, Genes Cancer, V1, P526; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Drygin D, 2013, DRUG DISCOV TODAY, pS1359; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Frenzel Anna, 2010, Genes Cancer, V1, P660, DOI 10.1177/1947601910377488; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gamble LD, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00162; Gomez-Curet I, 2006, J PEDIATR SURG, V41, P207, DOI 10.1016/j.jpedsurg.2005.10.025; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hammoudeh DI, 2009, J AM CHEM SOC, V131, P7390, DOI 10.1021/ja900616b; Hamperl S, 2013, BBA-GENE REGUL MECH, V1829, P405, DOI 10.1016/j.bbagrm.2012.12.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannan RD, 2013, EXPERT OPIN THER TAR, V17, P873, DOI 10.1517/14728222.2013.818658; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Hurley LH, 2006, SEMIN ONCOL, V33, P498, DOI 10.1053/j.seminoncol.2006.04.012; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jamerson MH, 2004, J MAMMARY GLAND BIOL, V9, P27, DOI 10.1023/B:JOMG.0000023586.69263.0b; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kiessling A, 2006, CHEM BIOL, V13, P745, DOI 10.1016/j.chembiol.2006.05.011; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koh JT, 2007, ACS CHEM BIOL, V2, P599, DOI 10.1021/cb700183s; Kong J, 2012, NAT REV GENET, V13, P383, DOI 10.1038/nrg3184; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar N, 2008, BIOCHEMISTRY-US, V47, P13179, DOI 10.1021/bi801064j; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Laurenti E, 2009, CURR OPIN CELL BIOL, V21, P844, DOI 10.1016/j.ceb.2009.09.006; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111; Lee LA, 2006, CURR TOP MICROBIOL, V302, P145; Leung JY, 2012, ONCOGENE, V31, P2545, DOI 10.1038/onc.2011.433; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Levens David, 2010, Genes Cancer, V1, P547; Li MY, 2011, MOL CELL, V43, P1023, DOI 10.1016/j.molcel.2011.08.020; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Littlewood TD, 2012, CELL, V151, P11, DOI 10.1016/j.cell.2012.09.006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Loven J, 2010, P NATL ACAD SCI USA, V107, P1553, DOI 10.1073/pnas.0913517107; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Marinkovic D, 2004, NUCLEIC ACIDS RES, V32, P5368, DOI 10.1093/nar/gkh877; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Moberg KHK, 2004, CURR BIOL, V14, P10; Mustata G, 2009, J MED CHEM, V52, P1247, DOI 10.1021/jm801278g; Nemeth A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Orian A, 2005, COLD SH Q B, V70, P299, DOI 10.1101/sqb.2005.70.019; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Prochownik Edward V, 2010, Genes Cancer, V1, P650; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rounbehler RJ, 2009, CANCER RES, V69, P547, DOI 10.1158/0008-5472.CAN-08-2968; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Russell J, 2006, BIOCHEM SOC SYMP, V73, P203; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanij E, 2009, EPIGENETICS-US, V4, P274, DOI 10.4161/epi.4.6.9449; Sanij E, 2008, J CELL BIOL, V183, P1259, DOI 10.1083/jcb.200805146; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Sedoris KC, 2012, MOL CANCER THER, V11, P66, DOI 10.1158/1535-7163.MCT-11-0515; Seitz V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026837; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Sun D, 2009, J MED CHEM, V52, P2863, DOI 10.1021/jm900055s; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Suzuki A, 2012, CANCER SCI, V103, P632, DOI 10.1111/j.1349-7006.2012.02219.x; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Varlakhanova NV, 2009, CANCER RES, V69, P7487, DOI 10.1158/0008-5472.CAN-08-4832; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wall M, 2013, CANCER DISCOV, V3, P82, DOI 10.1158/2159-8290.CD-12-0404; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker MM, 2004, CURR BIOL, V14, P6; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wu CH, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000090; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yang JP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2469; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	182	61	61	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					403	412		10.1038/onc.2014.13	http://dx.doi.org/10.1038/onc.2014.13			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24608428				2022-12-17	WOS:000348451300001
J	Parrish, JK; Sechler, M; Winn, RA; Jedlicka, P				Parrish, J. K.; Sechler, M.; Winn, R. A.; Jedlicka, P.			The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma	ONCOGENE			English	Article						Ewing sarcoma; microRNA; epigenetics; histone demethylase	ONCOGENIC TRANSCRIPTION; CELL-LINES; EXPRESSION; CHROMATIN; DIFFERENTIATION; SENSITIVITY; MICRORNAS; EPIGENOME; THERAPY; HYPOXIA	Ewing Sarcoma is a biologically aggressive bone and soft tissue malignancy affecting children and young adults. Ewing Sarcoma pathogenesis is driven by EWS/Ets fusion oncoproteins, of which EWS/Fli1 is the most common. We have previously shown that microRNAs (miRs) regulated by EWS/Fli1 contribute to the pro-oncogenic program in Ewing Sarcoma. Here we show that miR-22, an EWS/Fli1-repressed miR, is inhibitory to Ewing Sarcoma clonogenic and anchorage-independent cell growth, even at modest overexpression levels. Our studies further identify the H3K9me1/2 histone demethylase KDM3A (JMJD1A/JHDM2A) as a new miR-22-regulated gene. We show that KDM3A is overexpressed in Ewing Sarcoma, and that its depletion inhibits clonogenic and anchorage-independent growth in multiple patient-derived cell lines, and tumorigenesis in a xenograft model. KDM3A depletion further results in augmentation of the levels of the repressive H3K9me2 histone mark, and downregulation of pro-oncogenic factors in Ewing Sarcoma. Together, our studies identify the histone demethylase KDM3A as a new, miR-regulated, tumor promoter in Ewing Sarcoma.	[Parrish, J. K.; Jedlicka, P.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Sechler, M.; Jedlicka, P.] Univ Colorado Denver, Canc Biol Grad Program, Aurora, CO 80045 USA; [Winn, R. A.] Univ Illinois, Dept Med, Chicago, IL USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jedlicka, P (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu			Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award [W81XWH-12-1-0296]; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Colorado School of Medicine and Cancer Center; US Department of Veterans' Affairs;  [R01CA138528-2522717]; NATIONAL CANCER INSTITUTE [R01CA138528, P30CA046934] Funding Source: NIH RePORTER	Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Colorado School of Medicine and Cancer Center; US Department of Veterans' Affairs(US Department of Veterans Affairs); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathrin Bernt and Tobias Neff for advice on histone mark analysis, Steve Lessnick for retroviral packaging constructs, Heide Ford for critical reading of the manuscript, and the University of Colorado Cancer Center DNA Sequencing, Flow Cytometry, and Functional Genomics core facilities. This work was supported by the Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award (W81XWH-12-1-0296), Alex's Lemonade Stand Foundation for Childhood Cancer, and funds from the University of Colorado School of Medicine and Cancer Center (to PJ); and Merit Award from the US Department of Veterans' Affairs and R01CA138528-2522717 (to RAW).	Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chen HB, 2010, CARCINOGENESIS, V31, P2136, DOI 10.1093/carcin/bgq197; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8; Li J, 2010, GYNECOL ONCOL, V119, P543, DOI 10.1016/j.ygyno.2010.08.034; Ludwig JA, 2008, CURR OPIN ONCOL, V20, P412, DOI 10.1097/CCO.0b013e328303ba1d; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Ryan RJH, 2012, SCIENCE, V336, P1513, DOI 10.1126/science.1223730; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shirato H, 2009, J BIOL CHEM, V284, P733, DOI 10.1074/jbc.M804994200; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Ting Y, 2010, BIOCHEM BIOPH RES CO, V394, P606, DOI 10.1016/j.bbrc.2010.03.030; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Wai DH, 2002, INT J ONCOL, V20, P441; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733	45	61	63	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					257	262		10.1038/onc.2013.541	http://dx.doi.org/10.1038/onc.2013.541			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362521	Green Accepted			2022-12-17	WOS:000347790500013
J	Yang, Y; Liu, R; Qiu, R; Zheng, Y; Huang, W; Hu, H; Ji, Q; He, H; Shang, Y; Gong, Y; Wang, Y				Yang, Y.; Liu, R.; Qiu, R.; Zheng, Y.; Huang, W.; Hu, H.; Ji, Q.; He, H.; Shang, Y.; Gong, Y.; Wang, Y.			CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3 A in DNA methylation-based epigenetic silencing	ONCOGENE			English	Article						CRL4B; SUV39H1; DNMT3A; HP1; transcriptional repression	FACTOR-BINDING PROTEIN-3; HISTONE H2A UBIQUITINATION; METHYLTRANSFERASES DNMT3A; CHROMATIN MODIFICATIONS; HUMAN HOMOLOG; LYSINE 9; GENE; LIGASE; GROWTH; H3	Cullin 4B (CUL4B) is a component of the Cullin4B-Ring E3 ligase complex (CRL4B) that functions in proteolysis and is implicated in tumorigenesis. Here, we report that CRL4B is associated with histone methyltransferase SUV39H1, heterochromatin protein 1 (HP1) and DNA methyltransferases 3A (DNMT3A). We showed that CRL4B, through catalyzing H2AK119 nnonoubiquitination, facilitates H3K9 tri-methylation and DNA methylation, two key epigenetic modifications involved in DNA methylation-based gene silencing. Depletion of CUL4B resulted in loss of not only H2AK119 monoubiquitination but also H3K9 trimethylation and DNA methylation, leading to derepression of a collection of genes, including the tumor suppressor IGFBP3. We demonstrated that CUL4B promotes cell proliferation and invasion, which are consistent with a tumorigenic phenotype, at least partially by repressing IGFBP3. We found that the expression of CUL4B is markedly upregulated in samples of human cervical carcinoma and is negatively correlated with the expression of IGFBP3. Our experiments unveiled a coordinated action between histone ubiquitination/methylation and DNA methylation in transcription repression, providing a mechanism for CUL4B in tunnorigenesis.	[Yang, Y.; Liu, R.; Hu, H.; Ji, Q.; Gong, Y.; Wang, Y.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Key Lab Expt Teratol,Minist Educ, Jinan 250100, Shandong, Peoples R China; [Qiu, R.; Zheng, Y.; Huang, W.; Shang, Y.; Wang, Y.] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China; [He, H.] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada	Shandong University; Tianjin Medical University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Wang, Y (corresponding author), Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China.	yanwang@tmu.edu.cn			National Natural Science Foundation of China [81322032, 31171240, 90919053]; Ministry of Education of China [NECT-12-1067]; National Basic Research Program of China [2013CB910900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by grants (81322032,31171240 and 90919053 to YW) from the National Natural Science Foundation of China, grant (NECT-12-1067 to YW) from the Ministry of Education of China, and grant (2013CB910900 to YG) from the National Basic Research Program of China.	Aucott R, 2008, J CELL BIOL, V183, P597, DOI 10.1083/jcb.200804041; Baarends WM, 2005, MOL CELL BIOL, V25, P1041, DOI 10.1128/MCB.25.3.1041-1053.2005; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhattacharyya N, 2006, J BIOL CHEM, V281, P24588, DOI 10.1074/jbc.M509463200; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chen CY, 2012, HUM MOL GENET, V21, P4270, DOI 10.1093/hmg/dds261; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dumbliauskas E, 2011, EMBO J, V30, P731, DOI 10.1038/emboj.2010.359; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Guerrero-Santoro J, 2008, CANCER RES, V68, P5014, DOI 10.1158/0008-5472.CAN-07-6162; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9; He YZJ, 2006, GENE DEV, V20, P2949, DOI 10.1101/gad.1483206; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Hong Eun-Jin Erica, 2005, RNA Biol, V2, P106, DOI 10.4161/rna.2.3.2131; Horn PJ, 2005, GENE DEV, V19, P1705, DOI 10.1101/gad.1328005; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Kapetanaki MG, 2006, P NATL ACAD SCI USA, V103, P2588, DOI 10.1073/pnas.0511160103; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kopanja D, 2011, DEV BIOL, V352, P278, DOI 10.1016/j.ydbio.2011.01.028; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li F, 2008, CELL, V135, P272, DOI 10.1016/j.cell.2008.08.036; Liu HC, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-112; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; McGinty RK, 2008, NATURE, V453, P812, DOI 10.1038/nature06906; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nakagawa T, 2011, MOL CELL, V43, P381, DOI 10.1016/j.molcel.2011.05.033; Nakagawa T, 2008, GENE DEV, V22, P37, DOI 10.1101/gad.1609708; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nguyen' S, 2007, DEV DYNAM, V236, P1663, DOI 10.1002/dvdy.21176; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Qiao Q, 2011, J BIOL CHEM, V286, P8361, DOI 10.1074/jbc.M110.204115; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Schindl M, 2007, ANTICANCER RES, V27, P949; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Siegmund KD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000895; Singhal S, 2003, CANCER BIOL THER, V2, P291, DOI 10.4161/cbt.2.3.399; Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tarpey PS, 2007, AM J HUM GENET, V80, P345, DOI 10.1086/511134; Thon G, 2000, GENETICS, V155, P551; Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Watanabe D, 2006, NEUROSCIENCE, V142, P727, DOI 10.1016/j.neuroscience.2006.07.053; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Williams AC, 2000, CANCER RES, V60, P22; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Yin Y, 2011, DEV BIOL, V356, P51, DOI 10.1016/j.ydbio.2011.05.661; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568; Zhao YB, 2010, J BIOL CHEM, V285, P4355, DOI 10.1074/jbc.M109.034710; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zou YX, 2007, AM J HUM GENET, V80, P561, DOI 10.1086/512489; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	86	61	63	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					104	118		10.1038/onc.2013.522	http://dx.doi.org/10.1038/onc.2013.522			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292684				2022-12-17	WOS:000349740100010
J	Driemel, C; Kremling, H; Schumacher, S; Will, D; Wolters, J; Lindenlauf, N; Mack, B; Baldus, SA; Hoya, V; Pietsch, JM; Panagiotidou, P; Raba, K; Vay, C; Vallbohmer, D; Harreus, U; Knoefel, WT; Stoecklein, NH; Gires, O				Driemel, C.; Kremling, H.; Schumacher, S.; Will, D.; Wolters, J.; Lindenlauf, N.; Mack, B.; Baldus, S. A.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Raba, K.; Vay, C.; Vallboehmer, D.; Harreus, U.; Knoefel, W. T.; Stoecklein, N. H.; Gires, O.			Context-dependent adaption of EpCAM expression in early systemic esophageal cancer	ONCOGENE			English	Article						EpCAM; esophageal cancers; disseminated tumor cells	CELL ADHESION MOLECULE; DISSEMINATED TUMOR-CELLS; EP-CAM; CARCINOMA; MAINTENANCE; PHENOTYPE; HALLMARKS; TARGET; CD326	The role of the epithelial cell adhesion molecule EpCAM in cancer progression remains largely unclear. High expression of EpCAM in primary tumors is often associated with more aggressive phenotypes and EpCAM is the prime epithelial antigen in use to isolate circulating tumor cells (CTCs) and characterize disseminated tumor cells (DTCs). However, reduced expression of EpCAM was associated with epithelial-to-mesenchymal transition (EMT) and reports on a lack of EpCAM on CTCs emerged. These contradictory observations might reflect a context-dependent adaption of EpCAM expression during metastatic progression. To test this, EpCAM expression was monitored in esophageal cancer at different sites of early systemic disease. Although most of the primary esophageal tumors expressed high levels of EpCAM, the majority of DTCs in bone marrow lacked EpCAM. In vitro, downregulation of EpCAM expression at the plasma membrane was observed in migrating and invading cells, and was associated with a partial loss of the epithelial phenotype and with significantly decreased proliferation. Accordingly, induction of EMT through the action of TGF beta resulted in substantial loss of EpCAM cell surface expression on esophageal cancer cells. Knock-down or natural loss of EpCAM recapitulated these effects as it reduced proliferation while enhancing migration and invasion of cancer cells. Importantly, expression of EpCAM on DTCs was significantly associated with the occurrence of lymph node metastases and with significantly decreased overall survival of esophageal cancer patients. We validated this observation by showing that high expression of EpCAM promoted tumor outgrowth after xenotransplantation of esophageal carcinoma cells. The present data disclose a dynamic expression of EpCAM throughout tumor progression, where EpCAM(high) phenotypes correlate with proliferative stages, whereas EpCAM(low/negative) phenotypes associated with migration, invasion and dissemination. Thus, differing expression levels of EpCAM must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells.	[Driemel, C.; Schumacher, S.; Wolters, J.; Lindenlauf, N.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Vay, C.; Vallboehmer, D.; Knoefel, W. T.; Stoecklein, N. H.] Univ Hosp, Dept Gen Visceral & Pediat Surg, Dusseldorf, Germany; [Driemel, C.; Schumacher, S.; Wolters, J.; Lindenlauf, N.; Baldus, S. A.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Raba, K.; Vay, C.; Vallboehmer, D.; Knoefel, W. T.; Stoecklein, N. H.] Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Kremling, H.; Will, D.; Mack, B.; Harreus, U.; Gires, O.] Univ Munich, Grosshadern Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, D-81377 Munich, Bavaria, Germany; [Baldus, S. A.] Univ Hosp, Inst Pathol, Dusseldorf, Germany; [Raba, K.] Univ Hosp, Inst Transplantat Diagnost & Cellular Therapy, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; University of Munich	Gires, O (corresponding author), Univ Munich, Grosshadern Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Marchioninistr 15, D-81377 Munich, Bavaria, Germany.	Olivier.gires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017; Raba, Katharina/B-8697-2017	Gires, Olivier/0000-0002-2292-7064; Raba, Katharina/0000-0001-8818-4219; Driemel, Christiane/0000-0001-9595-3768	Wilhelm-Sander-Stiftung [2009.083.1]; Deutsche Forschungsgemeinschaft (DFG) [STO464/2-2]; Rudolf-Bartling Stiftung [II/89]	Wilhelm-Sander-Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Rudolf-Bartling Stiftung	This project was funded by The Wilhelm-Sander-Stiftung (2009.083.1), in part by the Deutsche Forschungsgemeinschaft (DFG STO464/2-2), the Rudolf-Bartling Stiftung (II/89). We thank Christof Seifarth for excellent technical support.	Alix-Panabieres C, 2008, CLIN CANCER RES, V14, P5013, DOI 10.1158/1078-0432.CCR-07-5125; Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Chaves-Perez A, 2013, ONCOGENE, V32, P641, DOI 10.1038/onc.2012.75; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Imrich S, 2012, CELL ADHES MIGR, V6, P30, DOI 10.4161/cam.18953; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kimura H, 2007, INT J ONCOL, V30, P171; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Klein CA, 2009, CANCER RES, V69, P5285, DOI 10.1158/0008-5472.CAN-08-4586; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Ng VY, 2010, STEM CELLS, V28, P29, DOI 10.1002/stem.221; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002; Raffel A, 2010, EUR J ENDOCRINOL, V162, P391, DOI 10.1530/EJE-08-0916; Rao CG, 2005, INT J ONCOL, V27, P49; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Stoecklein NH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-165; Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916; van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187; Vannier C, 2013, J BIOL CHEM, V288, P18643, DOI 10.1074/jbc.M113.467787; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Winter MJ, 2007, MOL CELL BIOCHEM, V302, P19, DOI 10.1007/s11010-007-9420-y	36	61	65	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4904	4915		10.1038/onc.2013.441	http://dx.doi.org/10.1038/onc.2013.441			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141784				2022-12-17	WOS:000343767900003
J	Ueda, J; Matsuda, Y; Yamahatsu, K; Uchida, E; Naito, Z; Korc, M; Ishiwata, T				Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Uchida, E.; Naito, Z.; Korc, M.; Ishiwata, T.			Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases	ONCOGENE			English	Article						ESRP1; pancreatic cancer; FGFR-2 IIIb; FGFR-2 IIIc; EMT	KERATINOCYTE GROWTH-FACTOR; IMMOBILIZED PH GRADIENTS; MESENCHYMAL TRANSITION; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; ENHANCED EXPRESSION; COLORECTAL-CANCER; RECEPTOR; CELLS; CARCINOMA	Epithelial splicing regulatory protein 1 (ESRP1) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb expression. Here we assessed the role of ESRP1 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis was performed using anti-ESRP1, FGFR-2 IIIb and FGFR-2 IIIc antibodies in 123 PDAC cases. ESRP1 expression vector and small interference RNA (siRNA) targeting ESRP1 were transfected into human PDAC cells, and cell growth, migration and invasion were analyzed. In vivo heterotopic and orthotopic implantations using ESRP1 overexpression clones were performed and effects on pancreatic tumor volumes and hepatic and pulmonary metastases determined. ESRP1 immunoreactivity was strong in the nuclei of cancer cells in well-to-moderately differentiated PDACs but weak in poorly differentiated cancers. Well-to-moderately differentiated cancers also exhibited high FGFR-2 IIIb and low FGFR-2 IIIc expression, whereas this ratio was reversed in the poorly differentiated cancers. Increased ESRP1 expression was associated with longer survival in comparison with low ESRP1 expression, and PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro, whereas ESRP1 siRNA-transfected KLM-1 cells exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. In vivo, ESRP1-overexpressing clones formed significantly fewer liver metastases as compared with control clones. ESRP1 regulates the expression pattern of FGFR-2 isoforms, attenuates cell growth, migration, invasion and metastasis, and is a favorable prognostic factor in PDAC. Therefore, devising mechanisms to upregulate ESRP1 may exert a beneficial therapeutic effect in PDAC.	[Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Naito, Z.; Ishiwata, T.] Nippon Med Sch, Dept Pathol, Tokyo 1138602, Japan; [Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Naito, Z.; Ishiwata, T.] Nippon Med Sch, Dept Integrat Oncol Pathol, Tokyo 1138602, Japan; [Ueda, J.; Yamahatsu, K.; Uchida, E.] Nippon Med Sch, Grad Sch Med, Dept Surg Organ & Biol Regulat, Tokyo 1138602, Japan; [Korc, M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Korc, M.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Korc, M.] Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA	Nippon Medical School; Nippon Medical School; Nippon Medical School; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Ishiwata, T (corresponding author), Nippon Med Sch, Dept Pathol, 1-1-5 Sendagi, Tokyo 1138602, Japan.	ishiwata@nms.ac.jp	Ishiwata, Toshiyuki/H-1151-2014	Ishiwata, Toshiyuki/0000-0002-4180-0069	Japan Society for the Promotion of Science [22591531, 22689038, 23650604]; NIH [R37-CA-075059]; NATIONAL CANCER INSTITUTE [R01CA075059, R37CA075059] Funding Source: NIH RePORTER	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We express our appreciation to Dr Masahito Hagio for helpful discussion and Dr Tetsushi Yamamoto, Mr Yuji Yanagisawa, Ms Taeko Suzuki, Ms Yoko Kawamoto and Ms Kiyoko Kawahara (Department of Pathology, Nippon Medical School) for their excellent technical assistance. We also thank Dr Shin-ichi Tsuchiya (Division of Surgical Pathology, Nippon Medical School Hospital) for preparing tissue blocks. This work was supported by Grants-in-Aid for Scientific Research (C, No.22591531 for TI), a Grant-in-Aid for Young Scientists (A, No. 22689038 for YM) a Grant-in-Aid for Challenging Exploratory Research (No. 23650604 for YM) from the Japan Society for the Promotion of Science, and in part by NIH grant R37-CA-075059 to MK.	Bailey KM, 2008, J BIOL CHEM, V283, P13714, DOI 10.1074/jbc.M709329200; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cho K, 2007, AM J PATHOL, V170, P1964, DOI 10.2353/ajpath.2007.060935; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gorg A, 1997, ELECTROPHORESIS, V18, P328, DOI 10.1002/elps.1150180306; Gorg A, 1999, ELECTROPHORESIS, V20, P712; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hovhannisyan RH, 2007, J BIOL CHEM, V282, P36265, DOI 10.1074/jbc.M704188200; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Ishiwata T, 2012, AM J PATHOL, V180, P1928, DOI 10.1016/j.ajpath.2012.01.020; Johnson M, 2009, CELL SIGNAL, V21, P1471, DOI 10.1016/j.cellsig.2009.02.023; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Katoh M, 2009, J INVEST DERMATOL, V129, P1861, DOI 10.1038/jid.2009.97; Kawase R, 2010, INT J ONCOL, V36, P331, DOI 10.3892/ijo_00000504; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006; Leontieva OV, 2009, CELL CYCLE, V8, P490, DOI 10.4161/cc.8.3.7679; Matsuda Y, 2011, CANCER BIOL THER, V11, P512, DOI 10.4161/cbt.11.5.14673; Matsuda Y, 2008, INT J ONCOL, V33, P1177, DOI 10.3892/ijo_00000107; Mauger DM, 2008, MOL CELL BIOL, V28, P5403, DOI 10.1128/MCB.00739-08; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Seiden-Long I, 2008, CARCINOGENESIS, V29, P647, DOI 10.1093/carcin/bgn009; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Suemizu H, 2007, INT J ONCOL, V31, P741; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tuveson DA, 2012, CELL, V148, P21, DOI 10.1016/j.cell.2011.12.021; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wickstrom SA, 2010, DEV CELL, V19, P574, DOI 10.1016/j.devcel.2010.09.007; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yan L, 2013, DIGEST DIS SCI, V58, P389, DOI 10.1007/s10620-012-2341-y	48	61	63	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4485	4495		10.1038/onc.2013.392	http://dx.doi.org/10.1038/onc.2013.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24077287	Green Accepted, Green Submitted			2022-12-17	WOS:000341158800004
J	Cante-Barrett, K; Pieters, R; Meijerink, JPP				Cante-Barrett, K.; Pieters, R.; Meijerink, J. P. P.			Myocyte enhancer factor 2C in hematopoiesis and leukemia	ONCOGENE			English	Review						MEF2C; hematopoiesis; leukemia	TRANSCRIPTION FACTOR MEF2C; ACUTE LYMPHOBLASTIC-LEUKEMIA; HELIX-LOOP-HELIX; MADS-BOX; CELL PROLIFERATION; MENTAL-RETARDATION; MUSCLE DEVELOPMENT; GENE-EXPRESSION; DNA-BINDING; T-CELLS	MEF2C is a selectively expressed transcription factor involved in different transcriptional complexes. Originally identified as an essential regulator of muscle development, ectopic expression of MEF2C as a result of chromosomal rearrangements is now linked to leukemia. Specifically, high MEF2C expression has been linked to mixed lineage leukemia-rearranged acute myeloid leukemia as well as to the immature subgroup of T-cell acute lymphoblastic leukemia. This review focuses on the role of MEF2C in the hematopoietic system and on aberrant MEF2C expression in human leukemia.	[Cante-Barrett, K.; Pieters, R.; Meijerink, J. P. P.] ErasmusMC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Meijerink, JPP (corresponding author), ErasmusMC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.meijerink@erasmusmc.nl	Meijerink, Jules P/D-4393-2017	Meijerink, Jules P/0000-0002-6860-798X; Cante-Barrett, Kirsten/0000-0003-0418-8445	Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA) [2008-029]	Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA)	This work is supported by the Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA), 2008-029 (KCB)).	Ab Hakim NH, 2010, GENES CELLS, V15, P255, DOI 10.1111/j.1365-2443.2009.01378.x; Agarwal P, 2011, DEVELOPMENT, V138, P2555, DOI 10.1242/dev.056804; Agatheeswaran S, 2013, LEUKEMIA, V27, P1578, DOI 10.1038/leu.2012.339; Akhtar MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034863; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; Andrews SF, 2012, EUR J IMMUNOL, V42, P1327, DOI 10.1002/eji.201142226; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Barbosa AC, 2008, P NATL ACAD SCI USA, V105, P9391, DOI 10.1073/pnas.0802679105; Bienvenu T, 2013, NEUROGENETICS, V14, P71, DOI 10.1007/s10048-012-0344-7; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Chen SL, 2000, GENE DEV, V14, P1209; Cho EG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024027; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Debnath I, 2013, INT IMMUNOL, V25, P99, DOI 10.1093/intimm/dxs088; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gagan J, 2012, J BIOL CHEM, V287, P40360, DOI 10.1074/jbc.M112.378414; Gekas C, 2009, BLOOD, V113, P3461, DOI 10.1182/blood-2008-07-167577; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Ji ZX, 2009, MOL GENET GENOMICS, V281, P1, DOI 10.1007/s00438-008-0393-7; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kang Jungseog, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-5; Khiem D, 2008, P NATL ACAD SCI USA, V105, P17067, DOI 10.1073/pnas.0804868105; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Le Meur N, 2010, J MED GENET, V47, P22, DOI 10.1136/jmg.2009.069732; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Li Z, 2008, J NEUROSCI, V28, P6557, DOI 10.1523/JNEUROSCI.0134-08.2008; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meijerink JPP, 2010, BEST PRACT RES CL HA, V23, P307, DOI 10.1016/j.beha.2010.08.002; Micheli L, 2005, MOL CELL BIOL, V25, P2242, DOI 10.1128/MCB.25.6.2242-2259.2005; Micheli L, 2011, J BIOL CHEM, V286, P5691, DOI 10.1074/jbc.M110.162842; Mikhail FM, 2011, AM J MED GENET A, V155A, P2386, DOI 10.1002/ajmg.a.34177; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nagel S, 2008, LEUKEMIA, V22, P600, DOI 10.1038/sj.leu.2405067; Nagel S, 2003, CANCER RES, V63, P5329; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Pallavi SK, 2012, EMBO J, V31, P2895, DOI 10.1038/emboj.2012.129; Prima V, 2007, LEUKEMIA, V21, P2470, DOI 10.1038/sj.leu.2404962; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Przybylski GK, 2006, HAEMATOLOGICA, V91, P317; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Ribeiro MSJ, 2009, CURR PROTEIN PEPT SC, V10, P570; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rothenberg EV, 2008, SEMIN IMMUNOL, V20, P236, DOI 10.1016/j.smim.2008.07.006; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schuler A, 2008, BLOOD, V111, P4532, DOI 10.1182/blood-2007-10-116343; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Sekiyama Y, 2012, CELL MOL NEUROBIOL, V32, P129, DOI 10.1007/s10571-011-9743-9; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Stehling-Sun S, 2009, NAT IMMUNOL, V10, P289, DOI 10.1038/ni.1694; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; Van Vlierberghe P, 2011, J EXP MED, V208, P2571, DOI 10.1084/jem.20112239; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verzi MP, 2007, DEV CELL, V12, P645, DOI 10.1016/j.devcel.2007.03.007; Vincentz JW, 2008, DEV DYNAM, V237, P3809, DOI 10.1002/dvdy.21803; Vong LH, 2005, GENESIS, V43, P43, DOI 10.1002/gene.20152; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wilker PR, 2008, NAT IMMUNOL, V9, P603, DOI 10.1038/ni.1609; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Winslow MM, 2006, IMMUNITY, V24, P141, DOI 10.1016/j.immuni.2005.12.013; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhu BM, 2005, J BIOL CHEM, V280, P28749, DOI 10.1074/jbc.M502491200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004; Zweier M, 2011, MOL SYNDROMOL, V2, P164, DOI 10.1159/000337496	86	61	63	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					403	410		10.1038/onc.2013.56	http://dx.doi.org/10.1038/onc.2013.56			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23435431				2022-12-17	WOS:000330214600001
J	Yang, Q; Jie, Z; Ye, S; Li, Z; Han, Z; Wu, J; Yang, C; Jiang, Y				Yang, Q.; Jie, Z.; Ye, S.; Li, Z.; Han, Z.; Wu, J.; Yang, C.; Jiang, Y.			Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility	ONCOGENE			English	Article						gastric tumorigenesis; microRNA; miR-27a; single-nucleotide polymorphisms	HOX GENES; DROSHA-DGCR8 COMPLEX; MICRORNA NETWORKS; EXPRESSION; RISK; TARGET; CELLS; MIRNA; TRANSFORMATION; TUMORIGENESIS	MicroRNAs (miRNAs) are noncoding RNAs that function as post-transcriptional regulators of tumor oncogenes and suppressors. Single-nucleotide polymorphisms (SNPs) in miRNA genes are a novel class of genetic variations in the human genome that are currently being identified and investigated in human cancers. In this study, we aimed to investigate whether SNPs in the miR-27a gene affect miR-27a expression and alter susceptibility to gastric cancer. Therefore, we conducted a case-control population study and the allele and genotype frequencies for polymorphism rs11671784 in miR-27a gene were examined in the study population. As a result, we found that the G/A polymorphism in the miR-27a gene exhibited a significant effect on gastric cancer risk. Compared with GG homozygotes, subjects who were GA heterozygotes or AA homozygotes exhibited a decreased risk of gastric cancer. The G/A polymorphism impaired the processing of pre-miR-27a to mature miR-27a, resulting in significantly reduced expression of mature miR-27a and an increased level of its target HOXA10. Furthermore, we confirmed these findings in in vitro studies by overexpressing pre-miR-27a carrying G or A allele. It provided further evidence demonstrating that allelic difference of rs11671784 is linked to gastric tumorigenesis. In summary, our results indicate that the G/A polymorphism in miR-27a gene (rs11671784) decreases miR-27a expression, reduces gastric cancer risk and plays a role in gastric tumorigenesis. This is the first study to address the role and function of miR-27a polymorphism rs11671784 in gastric cancer. These results could be useful to assess individual susceptibility of gastric cancer and will improve our understanding of the potential contribution of miRNA SNPs to cancer pathogenesis.	[Yang, Q.; Han, Z.; Wu, J.; Jiang, Y.] Guangzhou Med Univ, Inst Chem Carcinogenesis, State Key Lab Resp Dis, Guangzhou 510182, Guangdong, Peoples R China; [Jie, Z.; Li, Z.] Nanchang Univ, Dept Gen Surg, Affiliated Hosp 1, Nanchang, Peoples R China; [Ye, S.] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Yang, C.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Yang, C.] Michigan State Univ, Ctr Integrat Toxicol, E Lansing, MI 48824 USA	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Nanchang University; Sun Yat Sen University; Michigan State University; Michigan State University	Jiang, Y (corresponding author), Guangzhou Med Univ, Inst Chem Carcinogenesis, 195 Dongfeng Rd West, Guangzhou 510182, Guangdong, Peoples R China.	jiangyiguo@yahoo.com		Jiang, Yiguo/0000-0002-9499-2594	National Natural Science Foundation of China [30771780, 30972443, 81102099]; Natural Science Foundation of Guangdong Province [9251018201000004]; University Talent Program of Guangdong [2010-79]; University Talent Program of Guangzhou [10A003D]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); University Talent Program of Guangdong; University Talent Program of Guangzhou	We thank Xin Zhou and Wei Li (Department of General Surgery, First Affiliated Hospital of Nanchang University) for collecting the clinicopathologic information utilized in this study. We thank Chengjie Liang (Laboratory Animal Center, Guangzhou Medical University) for assistance with the nude mice assays. This work was supported by the National Natural Science Foundation of China (30771780, 30972443 to YJ and 81102099 to QY), the Natural Science Foundation of Guangdong Province (9251018201000004 to YJ), the University Talent Program of Guangdong (2010-79 to YJ) and the University Talent Program of Guangzhou (10A003D to YJ).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bornschein J, 2011, HELICOBACTER, V16, P45, DOI 10.1111/j.1523-5378.2011.00880.x; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Cantile M, 2011, CURR MED CHEM, V18, P4872, DOI 10.2174/092986711797535182; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Catucci I, 2012, BREAST CANCER RES TR, V133, P805, DOI 10.1007/s10549-012-2011-y; Chintharlapalli S, 2009, INT J CANCER, V125, P1965, DOI 10.1002/ijc.24530; Cillo C, 2011, INT J CANCER, V129, P2577, DOI 10.1002/ijc.25941; Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gonzalez CA, 2012, INT J CANCER, V130, P745, DOI 10.1002/ijc.26430; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hu Y, 2011, RNA BIOL, V8, P861, DOI 10.4161/rna.8.5.16034; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kelley JR, 2003, J CLIN EPIDEMIOL, V56, P1, DOI 10.1016/S0895-4356(02)00534-6; Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lerner M, 2011, CELL CYCLE, V10, P2172, DOI 10.4161/cc.10.13.16248; Leung WK, 2008, LANCET ONCOL, V9, P279, DOI 10.1016/S1470-2045(08)70072-X; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nunes Fabio Daumas, 2003, Pesqui Odontol Bras, V17, P94; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sun GH, 2009, RNA, V15, P1640, DOI 10.1261/rna.1560209; Sun QM, 2010, CANCER SCI, V101, P2241, DOI 10.1111/j.1349-7006.2010.01667.x; Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103; Yang L, 2005, CANCER EPIDEM BIOMAR, V14, P243; Yang QY, 2011, CARCINOGENESIS, V32, P713, DOI 10.1093/carcin/bgr035; Zhang M, 2012, EUR J CANCER CARE, V21, P274, DOI 10.1111/j.1365-2354.2011.01308.x; Zhou Y, 2012, J CANCER RES CLIN, V138, P939, DOI 10.1007/s00432-012-1164-8	44	61	63	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					193	202		10.1038/onc.2012.569	http://dx.doi.org/10.1038/onc.2012.569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246964				2022-12-17	WOS:000329440700007
J	Cagnol, S; Rivard, N				Cagnol, S.; Rivard, N.			Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition	ONCOGENE			English	Article						ERK; KRAS; BRAF; DUSP; intestinal epithelial cells; colorectal cancer	INTESTINAL EPITHELIAL-CELLS; PROTEIN-TYROSINE PHOSPHATASES; COLON-CARCINOMA CELLS; MAP KINASE-ACTIVITY; COLORECTAL-CANCER; SPATIOTEMPORAL REGULATION; REGULATED KINASE; CELLULAR-TRANSFORMATION; PROTEASOMAL DEGRADATION; MESENCHYMAL TRANSITION	Gain-of-function mutations in KRAS and BRAF genes are found in up to 50% of colorectal cancers. These mutations result in the activation of the BRAF/MEK signaling pathway culminating in the stimulation of ERK1/2 mitogen-activated protein kinases. Upon activation, ERK1/2 translocate from the cytoplasm to the nucleus. This process has been shown to be required for the induction of many cellular responses, although the molecular mechanisms regulating ERK nuclear function, especially under oncogenic stimulation, remain to be explored. Herein, we examined the spatiotemporal regulation of ERK1/2 activity upon oncogenic activation of KRAS(G12V) and BRAF(V600E) in normal intestinal epithelial crypt cells (IECs). Results demonstrate that expression of these oncogenes markedly stimulated ERK1/2 activities and morphologically transformed IECs. Importantly however, ERK phosphorylation was not observed in the nucleus, but restricted to the cytoplasm of KRAS(G12V)- and BRAF(V600E)-transformed IECs. The absence of nuclear ERK phosphorylation was due to a vanadate-sensitive phosphatase activity. Nuclear ERK dephosphorylation was found to be tightly correlated with the rapid expression of DUSP4 phosphatase induced in an MEK-dependent manner. In addition, MEK-dependent phosphorylation of T361, T363, S390 and S395 residues highly stabilized DUSP4 protein. Finally, in human colorectal cancer cells, ERK1/2 activities were also confined to the cytoplasm and treatment with pervanadate reactivated ERK1/2 in the nucleus. Accordingly, DUSP4 mRNAs were found to be highly expressed, in an MEK-dependent manner, in all colorectal cancer cells analyzed. These findings indicate that DUSP4 functions as part of a negative feedback mechanism in the control of the duration and magnitude of nuclear ERK activation during intestinal tumorigenesis. Oncogene (2013) 32, 564-576; doi:10.1038/onc.2012.88; published online 19 March 2012	[Cagnol, S.; Rivard, N.] Univ Sherbrooke, Fac Med & Sci Sante, CIHR Team Digest Epithelium, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med & Sci Sante, CIHR Team Digest Epithelium, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca			Canadian Institutes of Health and Research [MT-14405]; Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling	Canadian Institutes of Health and Research(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling	We thank Pierre Pothier for critical reading of the manuscript, and Anne Vezina and Etienne Lemieux for their technical assistance. This research was supported by a grant from the Canadian Institutes of Health and Research to NR (MT-14405). NR is a recipient of a Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling.	Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Armstrong SP, 2009, MOL ENDOCRINOL, V23, P510, DOI 10.1210/me.2008-0333; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Cagnol S, 2006, APOPTOSIS, V11, P337, DOI 10.1007/s10495-006-4065-y; Caunt CJ, 2008, J BIOL CHEM, V283, P26612, DOI 10.1074/jbc.M801500200; Caunt CJ, 2008, J BIOL CHEM, V283, P6241, DOI 10.1074/jbc.M706624200; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Katagiri C, 2005, J BIOL CHEM, V280, P14716, DOI 10.1074/jbc.M500200200; Komatsu K, 2005, GASTROENTEROLOGY, V129, P577, DOI 10.1053/j.gastro.2005.06.003; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kucharska A, 2009, CELL SIGNAL, V21, P1794, DOI 10.1016/j.cellsig.2009.07.015; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattison CP, 2000, GENE DEV, V14, P1229; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nishimura T, 2008, TUMOR BIOL, V29, P343, DOI 10.1159/000176044; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Peng DJ, 2010, CELL CYCLE, V9, P4650, DOI 10.4161/cc.9.23.13957; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Simoneau M, 2011, CELL SIGNAL, V23, P269, DOI 10.1016/j.cellsig.2010.09.011; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; Vakiani E, 2011, J PATHOL, V223, P219, DOI 10.1002/path.2796; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Voisin L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-337; Volmat V, 2001, J CELL SCI, V114, P3433; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Yuen ST, 2002, CANCER RES, V62, P6451	53	61	64	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					564	576		10.1038/onc.2012.88	http://dx.doi.org/10.1038/onc.2012.88			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430215				2022-12-17	WOS:000316164700004
J	Bangert, A; Cristofanon, S; Eckhardt, I; Abhari, BA; Kolodziej, S; Hacker, S; Vellanki, SHK; Lausen, J; Debatin, KM; Fulda, S				Bangert, A.; Cristofanon, S.; Eckhardt, I.; Abhari, B. A.; Kolodziej, S.; Haecker, S.; Vellanki, S. H. K.; Lausen, J.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP	ONCOGENE			English	Article						apoptosis; TRAIL; glioblastoma; HDACI; cFLIP	NF-KAPPA-B; LYMPHOCYTIC-LEUKEMIA CELLS; DRUG-INDUCED APOPTOSIS; HDAC INHIBITORS; MALIGNANT GLIOMA; CANCER-CELLS; DEATH; FLIP; ACTIVATION; EXPRESSION	Glioblastoma is the most common primary brain tumor with a very poor prognosis, calling for novel treatment strategies. Here, we provide first evidence that histone deacetylase inhibitors (HDACI) prime glioblastoma cells for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) -induced apoptosis at least in part by c-myc-mediated downregulation of cellular FLICE-inhibitory protein (cFLIP). Pretreatment with distinct HDACI (MS275, suberoylanilide hydroxamic acid, valproic acid) significantly enhances TRAIL-induced apoptosis in several glioblastoma cell lines. Monitoring a panel of apoptosis-regulatory proteins revealed that MS275 reduces the expression of cFLIP(L) and cFLIP(S). This leads to decreased recruitment of cFLIP(L) and cFLIP(S) and increased activation of caspase-8 to the TRAIL death-inducing signaling complex, resulting in enhanced cleavage of caspase-8, -9 and -3 and caspase-dependent apoptosis. Also, MS275 promotes TRAIL-triggered processing of Bid, activation of Bax, loss of mitochondrial membrane potential and release of cytochrome c. MS275-mediated downregulation of cFLIP occurs at the mRNA level independent of proteasome-or caspase-mediated degradation, and is preceded by upregulation of nuclear levels of c-myc, a transcriptional repressor of cFLIP. Notably, MS275 causes increased binding of c-myc to the cFLIP promoter and reduces cFLIP promoter activity. Indeed, knockdown of c-myc partially rescues cFLIP(L) from MS275-inferred downregulation and significantly decreases TRAIL-and MS275-induced apoptosis. Also, overexpression of cFLIP(L) or cFLIP(S) significantly reduces MS275- and TRAIL-induced apoptosis. Importantly, MS275 sensitizes primary cultured glioblastoma cells towards TRAIL and cooperates with TRAIL to reduce long-term clonogenic survival of glioblastoma cells and to suppress glioblastoma growth in vivo underscoring the clinical relevance of this approach. Thus, these findings demonstrate that HDACI represent a promising strategy to prime glioblastoma for TRAIL-induced apoptosis by targeting cFLIP.	[Cristofanon, S.; Eckhardt, I.; Abhari, B. A.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Bangert, A.; Haecker, S.; Vellanki, S. H. K.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, Ulm, Germany; [Kolodziej, S.; Lausen, J.] Inst Biomed Res, Frankfurt, Germany	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Else Kroner-Fresenius-Stiftung; European Community (ApopTrain, APO-SYS);  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else Kroner-Fresenius-Stiftung; European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); 	We thank O Micheau (Dijon, France) and M Leverkus (Mannheim, Germany) for providing cFLIP vectors. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Else Kroner-Fresenius-Stiftung, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carlisi D, 2009, EUR J CANCER, V45, P2425, DOI 10.1016/j.ejca.2009.06.024; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Eyupoglu LY, 2006, MOL CANCER THER, V5, P1248, DOI 10.1158/1535-7163.MCT-05-0533; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2008, CURR CANCER DRUG TAR, V8, P132, DOI 10.2174/156800908783769355; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897; Inoue S, 2009, MOL CANCER THER, V8, P3088, DOI 10.1158/1535-7163.MCT-09-0451; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim EH, 2005, ONCOGENE, V24, P6877, DOI 10.1038/sj.onc.1208851; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuijlen JMA, 2010, NEUROPATH APPL NEURO, V36, P168, DOI 10.1111/j.1365-2990.2010.01069.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MICHEAU O, 2006, APOPTOSIS CANC THERA, P120; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitchell KO, 2000, CANCER RES, V60, P6318; Nieminen AI, 2007, EMBO J, V26, P1055, DOI 10.1038/sj.emboj.7601551; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Sanchez-Perez T, 2010, CELL DEATH DIFFER, V17, P883, DOI 10.1038/cdd.2009.176; Simonini MV, 2006, P NATL ACAD SCI USA, V103, P1587, DOI 10.1073/pnas.0510341103; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153	48	61	63	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4677	4688		10.1038/onc.2011.614	http://dx.doi.org/10.1038/onc.2011.614			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266862				2022-12-17	WOS:000310724400003
J	Datta, J; Smith, A; Lang, JC; Islam, M; Dutt, D; Teknos, TN; Pan, Q				Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.			microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C epsilon	ONCOGENE			English	Article						head and neck cancer; protein kinase C; microRNA; miR-107	EXPRESSION; APOPTOSIS; INVASION	Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600 000 new cases diagnosed each year. Understanding the molecular pathways that lead to HNSCC is crucial to identify new targets for anti-cancer drug development. Protein kinase C epsilon (PKC epsilon) is elevated in HNSCC and regulates the activation of Akt, Stat3 and Rho GTPases. To date, the molecular mechanism of PKC epsilon dysregulation in HNSCC remains to be elucidated. In silico analysis identified three putative microRNA-107 (miR-107) binding sites in the 3'-untranslated region (UTR) of PKC epsilon. An inverse relationship was revealed between miR-107 and PKCe in HNSCC cell lines. Delivery of miR-107 reduced PKCe levels in SCC15, SCC25 and CAL27, three HNSCC cell lines with high PKC epsilon and low miR-107. The activity of a luciferase reporter construct containing the 3'-UTR of PKCe was downregulated by miR-107 and mutations in the three cognate miR-107 binding sites completely ablated the regulation by miR-107. Treatment with miR-107 significantly blocked cell proliferation, DNA replication, colony formation and invasion in SCC25 and CAL27 cells. Ectopic expression of miR-resistant PKCe was sufficient to partially rescue the loss-of-function phenotype in miR-107-overexpressing SCC25 cells. Tumor growth in nude mice was retarded by 93 +/- 7% in CAL27/miR-107 cells compared with CAL27/miR-control cells. Last, human primary HNSCC tumors with elevated PKCe had reduced miR-107 expression. Our results demonstrate that PKCe is directly regulated by miR-107 and, moreover, suggest that miR-107 may be a potential anti-cancer therapeutic for HNSCC. Oncogene (2012) 31, 4045-4053; doi:10.1038/onc.2011.565; published online 12 December 2011	[Datta, J.; Lang, J. C.; Islam, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Dutt, D.] VIT Univ, Sch Biosci & Technol, Dept Biomed Genet, Vellore, Tamil Nadu, India	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Vellore Institute of Technology	Pan, Q (corresponding author), Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 W 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	Reever, Larson/H-9685-2019; Pan, Quintin/E-3808-2011	Reever, Larson/0000-0002-5692-4793; 	National Cancer Institute at the National Institutes of Health [R01CA135096]; American Cancer Society [RSG0821901]; Michelle Theado Memorial Grant; John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA135096] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Michelle Theado Memorial Grant; John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Cancer Institute at the National Institutes of Health (R01CA135096); American Cancer Society (RSG0821901); the Michelle Theado Memorial Grant and the John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center.	Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Aziz MH, 2010, ONCOGENE, V29, P3100, DOI 10.1038/onc.2010.63; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cohen EEW, 2009, CANCER RES, V69, P65, DOI 10.1158/0008-5472.CAN-08-0377; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de la Pena FA, 2011, J BIOL CHEM, V286, P20778, DOI 10.1074/jbc.M110.198069; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Feng L, 2012, MED ONCOL, V29, P856, DOI 10.1007/s12032-011-9823-1; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li XH, 2011, J CELL MOL MED, V15, P1887, DOI 10.1111/j.1582-4934.2010.01194.x; Liu XQ, 2009, CANCER LETT, V286, P217, DOI 10.1016/j.canlet.2009.05.030; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; MARTINEZGIMENO C, 1995, HEAD NECK-J SCI SPEC, V17, P516, DOI 10.1002/hed.2880170609; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107	29	61	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4045	4053		10.1038/onc.2011.565	http://dx.doi.org/10.1038/onc.2011.565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158047	Green Accepted			2022-12-17	WOS:000308688800005
J	Ou, WB; Corson, JM; Flynn, DL; Lu, WP; Wise, SC; Bueno, R; Sugarbaker, DJ; Fletcher, JA				Ou, W-B; Corson, J. M.; Flynn, D. L.; Lu, W-P; Wise, S. C.; Bueno, R.; Sugarbaker, D. J.; Fletcher, J. A.			AXL regulates mesothelioma proliferation and invasiveness	ONCOGENE			English	Article						AXL; receptor tyrosine kinases; proliferation; invasiveness; mesothelioma	RECEPTOR TYROSINE KINASE; MALIGNANT PLEURAL MESOTHELIOMA; GASTROINTESTINAL STROMAL TUMORS; ENDOTHELIAL GROWTH-FACTOR; FACTOR SCATTER FACTOR; MET RECEPTOR; CELL-LINE; FACTOR-I; C-MET; EXPRESSION	Mesothelioma is an asbestos-associated and notoriously chemotherapy-resistant neoplasm. Activation of the receptor tyrosine kinases (RTKs), epidermal growth factor receptor and MET, has been described in subsets of mesothelioma, suggesting that TKs might represent therapeutic targets in this highly lethal disease. We employed proteomic screening by phosphotyrosine immunoaffinity purification and tandem mass spectrometry to characterize RTK activation in mesothelioma cell lines. These assays demonstrated expression and activation of the AXL protein, which is an RTK with known oncogenic properties in non-mesothelial cancer types. AXL was expressed and activated strongly in 8 of 9 mesothelioma cell lines and 6 of 12 mesothelioma biopsies, including each of 12 mesotheliomas with spindle-cell histology. Somatic AXL mutations were not found, but all mesotheliomas expressed an alternatively spliced AXL transcript with in-frame deletion of exon 10, and six of seven mesothelioma cell lines expressed the AXL ligand, growth arrest-specific 6 (GAS6). GAS6 expression appeared to be functionally relevant, as indicated by modulation of AXL tyrosine phosphorylation by knockdown of endogeneous GAS6, and by administration of exogenous GAS6. AXL silencing by lentivirus-mediated short hairpin RNA suppressed mesothelioma migration and cellular proliferation due to G1 arrest. The AXL inhibitor DP-3975 inhibited cell migration and proliferation in mesotheliomas with strong AXL activation. DP-3975 response in these tumors was characterized by inhibition of PI3-K/AKT/mTOR and RAF/MAPK signaling. AXL inhibition suppressed mesothelioma anchorage-independent growth, with reduction in colony numbers and size. These studies suggest that AXL inhibitors warrant clinical evaluation in mesothelioma. Oncogene (2011) 30, 1643-1652; doi:10.1038/onc.2010.555; published online 6 December 2010	[Ou, W-B; Corson, J. M.; Fletcher, J. A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ou, W-B; Corson, J. M.; Fletcher, J. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Lu, W-P; Wise, S. C.] Deciphera Pharmaceut LLC, Dept Res Discovery, Lawrence, KS USA; [Bueno, R.; Sugarbaker, D. J.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ou, WB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	wou@rics.bwh.harvard.edu; jfletcher@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442	Brigham and Women's Hospital	Brigham and Women's Hospital	This research was supported by funding from the International Mesothelioma Program at Brigham and Women's Hospital.	Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; CARBONE M, 1994, ONCOGENE, V9, P1781; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DEMETRI GD, 1989, BLOOD, V74, P940; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Janne PA, 2002, CANCER RES, V62, P5242; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; LEE TC, 1993, CANCER RES, V53, P2858; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Meric F, 2002, CLIN CANCER RES, V8, P361; Mukohara T, 2005, CLIN CANCER RES, V11, P8122, DOI 10.1158/1078-0432.CCR-05-1191; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Pache JC, 1998, AM J PATHOL, V152, P333; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pass HI, 1996, CANCER RES, V56, P4044; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; Rubin BP, 2001, CANCER RES, V61, P8118; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Tsao AS, 2007, MOL CANCER THER, V6, P1962, DOI 10.1158/1535-7163.MCT-07-0052; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Xia GB, 2005, CLIN CANCER RES, V11, P4305, DOI 10.1158/1078-0432.CCR-04-2109; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929	43	61	63	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1643	1652		10.1038/onc.2010.555	http://dx.doi.org/10.1038/onc.2010.555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132014				2022-12-17	WOS:000289239400003
J	Dangi-Garimella, S; Strouch, MJ; Grippo, PJ; Bentrem, DJ; Munshi, HG				Dangi-Garimella, S.; Strouch, M. J.; Grippo, P. J.; Bentrem, D. J.; Munshi, H. G.			Collagen regulation of let-7 in pancreatic cancer involves TGF-beta 1-mediated membrane type 1-matrix metalloproteinase expression	ONCOGENE			English	Article						TGF-beta 1; collagen; ERK1/2; MT1-MMP; let-7; fibrosis	EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; DUCTAL ADENOCARCINOMA; MICRORNA EXPRESSION; CELL-PROLIFERATION; TUMOR-DEVELOPMENT; INVASION; MT1-MMP; FAMILY; RAS	Pancreatic ductal adenocarcinoma (PDAC) is associated with a pronounced collagen-rich fibrosis known as desmoplastic reaction; however, the role of fibrosis in PDAC is poorly understood. In this report we show that collagen can regulate the tumor suppressive let-7 family of microRNAs in pancreatic cancer cells. PDAC cells growing in 3D collagen gels repress mature let-7 without affecting the precursor form of let-7 in part through increased expression of membrane type 1-matrix metallo-proteinase (MT1-MMP, MMP-14) and ERK1/2 activation. PDAC cells in collagen also demonstrate increased TGF-beta 1 signaling, and blocking TGF-beta 1 signaling attenuated collagen-induced MT1-MMP expression, ERK1/2 activation and repression of let-7 levels. Although MT1-MMP overexpression was not sufficient to inhibit let-7 on 2D tissue culture plastic, overexpression of MT1-MMP in PDAC cells embedded in 3D collagen gels or grown in vivo repressed let-7 levels. Importantly, MT1-MMP expression significantly correlated with decreased levels of let-7 in human PDAC tumor specimens. Overall, our study emphasizes the interplay between the key proteinase MT1-MMP and its substrate type I collagen in modulating microRNA expression, and identifies an additional mechanism by which fibrosis may contribute to PDAC progression. Oncogene (2011) 30, 1002-1008; doi:10.1038/onc.2010.485; published online 8 November 2010	[Dangi-Garimella, S.; Munshi, H. G.] Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Strouch, M. J.; Grippo, P. J.; Bentrem, D. J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Surg Oncol, Chicago, IL 60611 USA; [Grippo, P. J.; Bentrem, D. J.; Munshi, H. G.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Bentrem, D. J.; Munshi, H. G.] Jesse Brown VA Med Ctr, Chicago, IL USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Dangi-Garimella, S (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, 303 E Super Ave,Lurie 3-117, Chicago, IL 60611 USA.	s-dangi-garimella@northwestern.edu; h-munshi@northwestern.edu			NCI [R01CA126888]; Elsa U Pardee Foundation; National Pancreas Foundation; NATIONAL CANCER INSTITUTE [R01CA126888] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Elsa U Pardee Foundation; National Pancreas Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was supported by Grant R01CA126888 (HGM) from the NCI, and funding from the Elsa U Pardee Foundation (HGM) and the National Pancreas Foundation (HGM).	Aoyagi Y, 2004, BRIT J CANCER, V91, P1316, DOI 10.1038/sj.bjc.6602141; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Dangi-Garimella S, 2010, J BIOL CHEM, V285, P28363, DOI 10.1074/jbc.M110.146019; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dillhoff M, 2008, J GASTROINTEST SURG, V12, P2171, DOI 10.1007/s11605-008-0584-x; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; IMAMURA T, 1995, PANCREAS, V11, P357, DOI 10.1097/00006676-199511000-00007; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lohr M, 2001, CANCER RES, V61, P550; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; MORRIS JP, 2005, SCI STKE, pPE41; Oh JS, 2010, INT J RADIAT ONCOL, V76, P5, DOI 10.1016/j.ijrobp.2009.08.028; Ottaviano AJ, 2006, CANCER RES, V66, P7032, DOI 10.1158/0008-5472.CAN-05-4421; Park JK, 2009, PANCREAS, V38, pE190, DOI 10.1097/MPA.0b013e3181ba82e1; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Roy S, 2009, CARDIOVASC RES, V82, P21, DOI 10.1093/cvr/cvp015; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sounnil NE, 2010, INT J CANCER, V126, P1067, DOI 10.1002/ijc.24690; Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	33	61	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	8					1002	1008		10.1038/onc.2010.485	http://dx.doi.org/10.1038/onc.2010.485			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21057545	Green Accepted			2022-12-17	WOS:000287695900011
J	Koslowski, M; Luxemburger, U; Tureci, O; Sahin, U				Koslowski, M.; Luxemburger, U.; Tuereci, Oe; Sahin, U.			Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1 alpha	ONCOGENE			English	Article						cancer; hypoxia-inducible factor; methylation	INDUCIBLE FACTOR-I; DNA METHYLATION; ERYTHROPOIETIN GENE; HIF-ALPHA; EXPRESSION; BINDING; CANCER; INDUCTION; FACTOR-1; CELLS	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) is frequently over-expressed in human cancers and controls the expression of several genes that have been implicated in tumor growth and progression. Activity of HIF-1 alpha in cancer cells is regulated at the transcriptional, translational and post-translational level by multiple inter-and coacting molecular pathways. In this report, we reveal for the first time that tumor-associated CpG demethylation facilitates positive autoregulation of HIF-1 alpha, resulting in amplification of hypoxia-induced transactivation of HIF-1 alpha target genes. The HIF-1 alpha promoter harbors a hypoxia response element that is normally repressed by methylation of a CpG dinucleotide located in the core element. In colon cancer cell lines and in primary colon cancer specimens, however, we found frequent aberrant demethylation of this element, enabling binding of HIF-1 alpha to its own promoter resulting in autotransactivation of HIF-1 alpha expression. Our results provide novel and highly unexpected insights into the complexity of HIF-1 alpha regulation in cancer cells and implicate that tumor-associated CpG demethylation augments HIF-1 alpha-mediated effects on malignant cell growth. Oncogene (2011) 30, 876-882; doi:10.1038/onc.2010.481; published online 1 November 2010	[Koslowski, M.; Luxemburger, U.; Sahin, U.] TRON Ctr Translat Oncol & Immunol GmbH, D-55131 Mainz, Germany; [Tuereci, Oe] Ganymed Pharmaceut AG, Mainz, Germany		Sahin, U (corresponding author), TRON Ctr Translat Oncol & Immunol GmbH, Langenbeckstr 1, D-55131 Mainz, Germany.	sahin@uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg A P, 1988, Prog Clin Biol Res, V279, P309; FEINBERG AP, 1988, CANCER RES, V48, P1159; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Koslowski M, 2004, CANCER RES, V64, P5988, DOI 10.1158/0008-5472.CAN-04-1187; Koslowski M, 2006, HUM MOL GENET, V15, P2392, DOI 10.1093/hmg/ddl163; Koslowski M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-77; Koslowski M, 2009, J BIOL CHEM, V284, P28607, DOI 10.1074/jbc.M109.031120; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Sahin U, 2008, CLIN CANCER RES, V14, P7624, DOI 10.1158/1078-0432.CCR-08-1547; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Serfling E, 2006, TRENDS IMMUNOL, V27, P461, DOI 10.1016/j.it.2006.08.005; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WAINFAN E, 1992, CANCER RES, V52, pS2071; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Yin H, 2000, BLOOD, V95, P111, DOI 10.1182/blood.V95.1.111.001k20_111_119; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zundel W, 2000, GENE DEV, V14, P391	44	61	65	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					876	882		10.1038/onc.2010.481	http://dx.doi.org/10.1038/onc.2010.481			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	21042279				2022-12-17	WOS:000287444600011
J	Desch, P; Asslaber, D; Kern, D; Schnidar, H; Mangelberger, D; Alinger, B; Stoecher, M; Hofbauer, SW; Neureiter, D; Tinhofer, I; Aberger, F; Hartmann, TN; Greil, R				Desch, P.; Asslaber, D.; Kern, D.; Schnidar, H.; Mangelberger, D.; Alinger, B.; Stoecher, M.; Hofbauer, S. W.; Neureiter, D.; Tinhofer, I.; Aberger, F.; Hartmann, T. N.; Greil, R.			Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells	ONCOGENE			English	Article						chronic lymphocytic leukemia; apoptosis; hedgehog; stromal cells; GLI transcription factors	HEDGEHOG SIGNALING PATHWAY; MARROW STROMAL CELLS; SONIC HEDGEHOG; B-CELLS; ZAP-70 EXPRESSION; CD38 EXPRESSION; NEURAL-TUBE; STEM-CELLS; IN-VITRO; CANCER	The Hedgehog (Hh) pathway regulates cell proliferation and survival and contributes to tumorigenesis. We investigated the expression and function of this pathway in B-cell chronic lymphocytic leukemia (CLL) cells and in healthy B lymphocytes. Profiling of cognate Hh pathway members revealed reduced expression of two key Hh signaling effectors, Smoothened (SMOH) and GLI, in CLL cells, whereas transcription levels of other investigated members resembled normal B-lymphocyte levels. Examining the functional role of SMOH and GLI in cell survival, we found that CLL cells were hardly sensitive toward specific SMOH inhibition, but showed an unspecific decline in cell viability in response to high concentrations of the SMOH antagonist cyclopamine. In contrast, treatment with the novel GLI antagonist GANT61 reduced expression of the target gene Patched and preferentially decreased the viability of malignant cells. Specific RNA interference knockdown experiments in a CLL-derived cell line confirmed the autonomous role of GLI in malignant cell survival. GANT61-induced apoptosis in primary leukemic cells was partly attenuated by protective stromal cells, but not soluble sonic hedgehog ligand. In summary, our data show a downregulation of the classical Hh pathway in CLL and suggest an intrinsic SMOH-independent role of GLI in the ex vivo survival of CLL cells. Oncogene (2010) 29, 4885-4895; doi: 10.1038/onc.2010.243; published online 5 July 2010	[Desch, P.; Asslaber, D.; Stoecher, M.; Hofbauer, S. W.; Tinhofer, I.; Hartmann, T. N.; Greil, R.] Paracelsus Med Univ, Lab Immunol & Mol Canc Res, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, A-5020 Salzburg, Austria; [Kern, D.; Schnidar, H.; Mangelberger, D.; Aberger, F.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Alinger, B.; Neureiter, D.] Paracelsus Med Univ, Inst Pathol, A-5020 Salzburg, Austria; [Tinhofer, I.] Charite, Translat Radiobiol & Radiooncol Res Lab, Clin Dept Radiotherapy CCM CVK, Berlin, Germany	Paracelsus Private Medical University; Salzburg University; Paracelsus Private Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hartmann, TN (corresponding author), Paracelsus Med Univ, Lab Immunol & Mol Canc Res, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, A-5020 Salzburg, Austria.	t.hartmann@salk.at; r.greil@salk.at	Hartmann, Tanja Nicole/C-9345-2017; Greil, Richard F/C-7673-2017; Aberger, Fritz/B-6357-2012; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Greil, Richard F/0000-0002-4462-3694; Aberger, Fritz/0000-0003-2009-6305; Hartmann, Tanja Nicole/0000-0002-0377-7179; Asslaber, Daniela/0000-0002-8711-016X; Tinhofer, Ingeborg/0000-0002-0512-549X; Hartmann, Tanja Nicole/0000-0002-2633-7301	Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH [P021]; ONB [13420]; PFIZER corporation Austria; Province of Salzburg; Austrian Science Fund (FWF) [W1213, P20652]; Austrian Genome programme Gen-AU	Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH; ONB; PFIZER corporation Austria; Province of Salzburg; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Genome programme Gen-AU	This work was supported by the Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH, SFB program P021 to RG, ONB research Grant 13420 to TNH., an unrestricted grant from PFIZER corporation Austria Ges.m.b.H, Vienna, and grants from the province of Salzburg. We thank Dr Reinhard Vlasak for help with the production of recombinant Shh protein. FA was supported by Austrian Science Fund (FWF) Grants W1213, P20652 and by the Austrian Genome programme Gen-AU.	Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1999, J MOL MED-JMM, V77, P266, DOI 10.1007/s001090050350; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Ecke I, 2008, MOL CARCINOGEN, V47, P361, DOI 10.1002/mc.20394; Ferretti E, 2008, EMBO J, V27, P2616, DOI 10.1038/emboj.2008.172; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007-0167; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper Maria, 2007, V397, P67; KNUUTILA S, 1986, NEW ENGL J MED, V314, P865, DOI 10.1056/NEJM198604033141401; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee J, 1997, DEVELOPMENT, V124, P2537; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsenko NU, 2008, B EXP BIOL MED+, V145, P240, DOI 10.1007/s10517-008-0060-3; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI23409; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; Patten PEM, 2008, BLOOD, V111, P5173, DOI 10.1182/blood-2007-08-108605; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Seiffert M, 2007, LEUKEMIA, V21, P1977, DOI 10.1038/sj.leu.2404863; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zanotti R, 2007, LEUKEMIA, V21, P102, DOI 10.1038/sj.leu.2404458; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	60	61	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4885	4895		10.1038/onc.2010.243	http://dx.doi.org/10.1038/onc.2010.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20603613				2022-12-17	WOS:000281578700003
J	Lovric, MM; Hawkins, CJ				Lovric, M. M.; Hawkins, C. J.			TRAIL treatment provokes mutations in surviving cells	ONCOGENE			English	Article						late effects; second malignancies; Apo-2L; DNA damage; mutagenesis; HPRT	APOPTOSIS-INDUCING LIGAND; CASPASE-ACTIVATED DNASE; DOUBLE-STRAND BREAKS; IN-VIVO; CONVERTING-ENZYME; HUMAN HEPATOCYTES; MAMMALIAN-CELLS; TUMOR-GROWTH; CANCER; DEATH	Chemotherapy and radiotherapy commonly damage DNA and trigger p53-dependent apoptosis through intrinsic apoptotic pathways. Two unfortunate consequences of this mechanism are resistance due to blockade of p53 or intrinsic apoptosis pathways, and mutagenesis of nonmalignant surviving cells which can impair cellular function or provoke second malignancies. Death ligand-based drugs, such as tumor necrosis factor-related apoptosis inducing ligand (TRAIL), stimulate extrinsic apoptotic signaling, and may overcome resistance to treatments that induce intrinsic apoptosis. As death receptor ligation does not damage DNA as a primary mechanism of pro-apoptotic action, we hypothesized that surviving cells would remain genetically unscathed, suggesting that death ligand-based therapies may avoid some of the adverse effects associated with traditional cancer treatments. Surprisingly, however, treatment with sub-lethal concentrations of TRAIL or FasL was mutagenic. Mutations arose in viable cells that contained active caspases, and overexpression of the caspase-8 inhibitor crmA or silencing of caspase-8 abolished TRAIL-mediated mutagenesis. Downregulation of the apoptotic nuclease caspase-activated DNAse (CAD)/DNA fragmentation factor 40 (DFF40) prevented the DNA damage associated with TRAIL treatment. Although death ligands do not need to damage DNA in order to induce apoptosis, surviving cells nevertheless incur DNA damage after treatment with these agents. Oncogene (2010) 29, 5048-5060; doi:10.1038/onc.2010.242; published online 19 July 2010	[Lovric, M. M.; Hawkins, C. J.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Bundoora, Vic 3083, Australia; [Hawkins, C. J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Childrens Canc Ctr, Parkville, Vic 3052, Australia	La Trobe University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Hawkins, CJ (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Kingsbury Dr, Bundoora, Vic 3083, Australia.	c.hawkins@latrobe.edu.au	Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071; Green, Maja/0000-0002-7982-2503	Cancer Council Victoria [384400]; La Trobe University; National Health and Medical Research Council [541930]; Australian Research Council [FT0991464]	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); La Trobe University; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	This study was funded by a Cancer Council Victoria Grant-in-Aid (#384400), a La Trobe University Postgraduate scholarship to MML, a National Health and Medical Research Council Career Development Award (#541930) and Australian Research Council Future Fellowship (#FT0991464) to CJH. We are grateful to Anissa Jabbour for the MEF cells and advice, to Rebecca Bilardi for assistance in establishing the gamma H2AX assay and to Lahiru Gangoda for help with fluorescence microscopy. We thank Tanja Kitevska for proofreading, Delara Pantaki, Sarah Roberts, Sunil Kumar and Livleen Kaur for technical assistance and members of the Hawkins laboratory and Children's Cancer Centre for advice and suggestions.	Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Ashley DM, 2008, BRIT J CANCER, V99, P294, DOI 10.1038/sj.bjc.6604459; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; DEMARS R, 1971, FED PROC, V30, P944; Dickerman JD, 2007, PEDIATRICS, V119, P554, DOI 10.1542/peds.2006-2826; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evens AM, 2008, NAT CLIN PRACT ONCOL, V5, P543, DOI 10.1038/ncponc1186; Frankenberg-Schwager M, 2005, TOXICOLOGY, V212, P175, DOI 10.1016/j.tox.2005.04.015; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Gocke E, 2009, TOXICOL LETT, V190, P254, DOI 10.1016/j.toxlet.2009.03.016; Hao CH, 2004, CANCER RES, V64, P8502, DOI 10.1158/0008-5472.CAN-04-2599; Hartlerode AJ, 2009, BIOCHEM J, V423, P157, DOI 10.1042/BJ20090942; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Jabbour AM, 2009, CELL DEATH DIFFER, V16, P555, DOI 10.1038/cdd.2008.179; Jeha S, 2009, SEMIN HEMATOL, V46, P76, DOI 10.1053/j.seminhematol.2008.09.009; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Knight MJ, 2004, MOL CARCINOGEN, V39, P173, DOI 10.1002/mc.20011; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuo LJ, 2008, IN VIVO, V22, P305; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leverkus M, 2000, CANCER RES, V60, P553; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Meadows AT, 2009, J CLIN ONCOL, V27, P2356, DOI 10.1200/JCO.2008.21.1920; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Olive PL, 2009, CYTOM PART B-CLIN CY, V76B, P79, DOI 10.1002/cyto.b.20450; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rice SC, 2004, CANCER RES, V64, P4464, DOI 10.1158/0008-5472.CAN-03-3940; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; Veld CWOH, 1997, MUTAGENESIS, V12, P417, DOI 10.1093/mutage/12.6.417; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Watters GP, 2009, MUTAT RES-GEN TOX EN, V679, P50, DOI 10.1016/j.mrgentox.2009.07.007; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2000, ACTA BIOCHIM POL, V47, P1037; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Winer E, 2009, J CLIN ONCOL, V27, P812, DOI 10.1200/JCO.2008.21.2134; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45	53	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	36					5048	5060		10.1038/onc.2010.242	http://dx.doi.org/10.1038/onc.2010.242			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20639907	hybrid, Green Published			2022-12-17	WOS:000281620100005
J	Tromp, JM; Tonino, SH; Elias, JA; Jaspers, A; Luijks, DM; Kater, AP; van Lier, RAW; van Oers, MHJ; Eldering, E				Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Jaspers, A.; Luijks, D. M.; Kater, A. P.; van Lier, R. A. W.; van Oers, M. H. J.; Eldering, E.			Dichotomy in NF-kappa B signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering	ONCOGENE			English	Article						CLL; CD40; TLR9; NF-kappa B; Bcl-X-L; IgVH mutation status	CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES; CD40 STIMULATION; SURVIVAL; EXPRESSION; PHENOTYPE; APOPTOSIS; RECEPTOR; GENE; PROLIFERATION	Chronic lymphocytic leukemia (CLL) cells circulating in peripheral blood (PB) differ from the leukemic fraction in lymph nodes (LNs) with respect to cell division and drug sensitivity. CD40 stimulation of PB CLL cells in vitro results in chemoresistance and provides a partial model for the LN microenvironment. The TLR9 ligand CpG induces proliferation in immunoglobulin variable heavy-chain- unmutated CLL, but apoptosis in immunoglobulin variable heavy-chain-mutated CLL. To juxtapose proliferative with antiapoptotic signals, we investigated the effects of CpG in the context of CD40 ligation in mutated versus unmutated CLL cells in this study. Prolonged CD40 ligation induced classical, followed by alternative nuclear factor-kappa B (NF-kappa B), activity in both subgroups, correlating with enhanced Bfl-1 and Bcl-X-L levels, respectively. A dichotomy in NF-kappa B signaling occurred on combined CD40/TLR9 triggering. This induced declining p52 and Bcl-X-L levels, and reversed chemoresistance only in mutated cells, whereas unmutated cells proliferated, maintained p52 and Bcl-X-L and remained chemoresistant. The pivotal contribution of Bcl-X-L to chemoresistance was shown by the BH3 mimetic ABT-737 and RNA interference. Finally, in ex vivo LN samples, p52, p65 and Bcl-X-L levels were highly expressed, corroborating the in vitro findings. Thus, a distinction in NF-kappa B activation and drug susceptibility in mutated versus unmutated (LN-like) CLL cells was uncovered, which was causally linked to Bcl-X-L levels. Oncogene (2010) 29, 5071-5082; doi:10.1038/onc.2010.248; published online 28 June 2010	[Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Jaspers, A.; van Lier, R. A. W.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Noord Holland, Netherlands; [Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Luijks, D. M.; Kater, A. P.; van Oers, M. H. J.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Noord Holland, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Tromp, JM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands.	j.m.tromp@amc.uva.nl		van Lier, Rene/0000-0002-3201-7144	Dutch Cancer Society (KWF) [UvA 2007-3856]	Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We thank professor Carel JM van Noessel and Dr Richard Bende (department of pathology, AMC) for obtaining lymph node material of CLL patients. We are very grateful to the patients for donating blood samples. ABT-737, a BH3 mimetic, was obtained under MTA from Abbott (Abbott Park, courtesy Dr S Rosenberg). This work was supported by the Dutch Cancer Society (KWF), Grant no. UvA 2007-3856.	Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Caligaris-Cappio F, 2008, J CLIN ONCOL, V26, P4497, DOI 10.1200/JCO.2007.15.4393; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Chiorazzi N, 2007, BEST PRACT RES CL HA, V20, P399, DOI 10.1016/j.beha.2007.03.007; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Damle RN, 2002, BLOOD, V99, P4087, DOI 10.1182/blood.V99.11.4087; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Decker T, 2000, BLOOD, V95, P999, DOI 10.1182/blood.V95.3.999.003k10_999_1006; Decker T, 2001, LEUKEMIA LYMPHOMA, V42, P301, DOI 10.3109/10428190109064586; Endo T, 2007, BLOOD, V109, P703, DOI 10.1182/blood-2006-06-027755; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Fakler M, 2008, BLOOD, V112, P317; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghia P, 2005, CURR TOP MICROBIOL, V294, P135, DOI 10.1007/3-540-29933-5_8; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hewamana S, 2008, BLOOD, V111, P4681, DOI 10.1182/blood-2007-11-125278; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Kater AP, 2004, BRIT J HAEMATOL, V127, P404, DOI 10.1111/j.1365-2141.2004.05225.x; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; KEATING MJ, 2003, HEMATOL-AM SOC HEMAT, V5, P153; Kipps TJ, 2007, BEST PRACT RES CL HA, V20, P415, DOI 10.1016/j.beha.2007.04.001; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; LANKESTER AC, 1995, BLOOD, V86, P1090; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Lopez-Guerra M, 2009, CLIN CANCER RES, V15, P2767, DOI 10.1158/1078-0432.CCR-08-2382; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI23409; Nedellec S, 2005, J IMMUNOL, V174, P3749, DOI 10.4049/jimmunol.174.6.3749; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Rodriguez A, 2004, CLIN CANCER RES, V10, P6796, DOI 10.1158/1078-0432.CCR-04-0753; Romano MF, 1998, BLOOD, V92, P990; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Silke J, 2010, CELL DEATH DIFFER, V17, P35, DOI 10.1038/cdd.2009.114; Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003; Tas SW, 2007, BLOOD, V110, P1540, DOI 10.1182/blood-2006-11-056010; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Gent R, 2008, CANCER RES, V68, P10137, DOI 10.1158/0008-5472.CAN-08-2325; Wierda WG, 2003, BRIT J HAEMATOL, V120, P452, DOI 10.1046/j.1365-2141.2003.04118.x; Willimott S, 2007, BRIT J HAEMATOL, V138, P721, DOI 10.1111/j.1365-2141.2007.06717.x; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676	54	61	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5071	5082		10.1038/onc.2010.248	http://dx.doi.org/10.1038/onc.2010.248			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581863				2022-12-17	WOS:000281620100007
J	Valli, A; Rosner, M; Fuchs, C; Siegel, N; Bishop, CE; Dolznig, H; Madel, U; Feichtinger, W; Atala, A; Hengstschlager, M				Valli, A.; Rosner, M.; Fuchs, C.; Siegel, N.; Bishop, C. E.; Dolznig, H.; Maedel, U.; Feichtinger, W.; Atala, A.; Hengstschlaeger, M.			Embryoid body formation of human amniotic fluid stem cells depends on mTOR	ONCOGENE			English	Article						amniotic fluid; stem cell; EB; mTOR	DIFFERENTIATION; MOUSE; BODIES; ACTIVATION; PLURIPOTENCY; DISRUPTION; GROWTH; RICTOR; OCT-4; GENE	Human amniotic fluid stem cells (hAFSCs) harbor high proliferative capacity and high differentiation potential and do not raise the ethical concerns associated with human embryonic stem cells. The formation of three-dimensional aggregates known as embryoid bodies (EBs) is the principal step in the differentiation of pluripotent embryonic stem cells. Using c-Kit-positive hAFSC lines, we show here that these stem cells harbor the potential to form EBs. As part of the two kinase complexes, mTORC1 and mTORC2, mammalian target of rapamycin (mTOR) is the key component of an important signaling pathway, which is involved in the regulation of cell proliferation, growth, tumor development and differentiation. Blocking intracellular mTOR activity through the inhibitor rapamycin or through specific small interfering RNA approaches revealed hAFSC EB formation to depend on mTORC1 and mTORC2. These findings demonstrate hAFSCs to be a new and powerful biological system to recapitulate the three-dimensional and tissue level contexts of in vivo development and identify the mTOR pathway to be essential for this process. Oncogene (2010) 29, 966-977; doi:10.1038/onc.2009.405; published online 23 November 2009	[Valli, A.; Rosner, M.; Fuchs, C.; Siegel, N.; Dolznig, H.; Hengstschlaeger, M.] Med Univ Vienna, Dept Med Genet, A-1090 Vienna, Austria; [Bishop, C. E.; Atala, A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA; [Bishop, C. E.; Atala, A.] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27103 USA; [Maedel, U.; Feichtinger, W.] Wunschbabyzentrum, Vienna, Austria	Medical University of Vienna; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Hengstschlager, M (corresponding author), Med Univ Vienna, Dept Med Genet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585; Atala, Anthony/0000-0001-8186-2160; Fuchs, Christiane/0000-0002-5052-3198	FWF Austrian Science Fund [P18894-B12]; Herzfelder'sche Familienstiftung; European Community [FP6 036097-2]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD060097] Funding Source: NIH RePORTER	FWF Austrian Science Fund(Austrian Science Fund (FWF)); Herzfelder'sche Familienstiftung; European Community(European Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Research in our laboratory is supported by the FWF Austrian Science Fund (P18894-B12), by the Herzfelder'sche Familienstiftung and by the Research Training Network 'Developing a stem cell based therapy to replace nephrons lost through reflux nephropathy' (http://www.kidstem.org) funded by the European Community as part of the Framework program 6 (FP6 036097-2).	Aboushwareb T, 2008, NAT CLIN PRACT UROL, V5, P621, DOI 10.1038/ncpuro1228; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Blazquez C, 2006, CELL RES, V16, P93, DOI 10.1038/sj.cr.7310012; Bossolasco P, 2006, CELL RES, V16, P329, DOI 10.1038/sj.cr.7310043; Cananzi M, 2009, REPROD BIOMED ONLINE, V18, P17, DOI 10.1016/S1472-6483(10)60111-3; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Ditadi A, 2009, BLOOD, V113, P3953, DOI 10.1182/blood-2008-10-182105; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; GUALANDRIS A, 2008, FASEB J, V23, P1; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hengstschlager M, 2005, AM J MED GENET A, V133A, P48, DOI 10.1002/ajmg.a.30520; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Karlmark KR, 2005, INT J MOL MED, V16, P987; Kim GD, 2008, TOXICOL LETT, V180, P166, DOI 10.1016/j.toxlet.2008.05.023; Kim J, 2007, CELL PROLIFERAT, V40, P75; Koike M, 2007, J BIOSCI BIOENG, V104, P294, DOI 10.1263/jbb.104.294; Kolambkar YM, 2007, J MOL HISTOL, V38, P405, DOI 10.1007/s10735-007-9118-1; Kurosawa H, 2007, J BIOSCI BIOENG, V103, P389, DOI 10.1263/jbb.103.389; Lim SM, 2009, STEM CELLS, V27, P363, DOI 10.1634/stemcells.2008-1008; Maherali N, 2008, COLD SH Q B, V73, P157, DOI 10.1101/sqb.2008.73.017; Narita N, 1997, DEVELOPMENT, V124, P3755; Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Pennings G, 2007, REPROD BIOMED ONLINE, V14, P92, DOI 10.1016/S1472-6483(10)60737-7; Perin L, 2007, CELL PROLIFERAT, V40, P936, DOI 10.1111/j.1365-2184.2007.00478.x; Perin L, 2008, METHOD CELL BIOL, V86, P85, DOI 10.1016/S0091-679X(08)00005-8; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Prusa AR, 2004, AM J OBSTET GYNECOL, V191, P309, DOI 10.1016/j.ajog.2003.12.014; Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Rosner M, 2008, MUTAT RES-REV MUTAT, V659, P284, DOI 10.1016/j.mrrev.2008.06.001; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Sampath P, 2008, CELL STEM CELL, V2, P448, DOI 10.1016/j.stem.2008.03.013; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Siegel N, 2007, STEM CELL REV, V3, P256, DOI 10.1007/s12015-007-9003-z; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Trounson A, 2007, NAT BIOTECHNOL, V25, P62, DOI 10.1038/nbt0107-62; Tsai MS, 2006, BIOL REPROD, V74, P545, DOI 10.1095/biolreprod.105.046029; Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279; Ungrin MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001565; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	50	61	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					966	977		10.1038/onc.2009.405	http://dx.doi.org/10.1038/onc.2009.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935716	Green Accepted			2022-12-17	WOS:000274604400004
J	Westhoff, MA; Kandenwein, JA; Karl, S; Vellanki, SHK; Braun, V; Eramo, A; Antoniadis, G; Debatin, KM; Fulda, S				Westhoff, M-A; Kandenwein, J. A.; Karl, S.; Vellanki, S. H. K.; Braun, V.; Eramo, A.; Antoniadis, G.; Debatin, K-M; Fulda, S.			The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair	ONCOGENE			English	Article						apoptosis; PI3 kinase; GBM	PEGYLATED LIPOSOMAL DOXORUBICIN; DEPENDENT PROTEIN-KINASE; DRUG-INDUCED APOPTOSIS; GROWTH-FACTOR RECEPTOR; HUMAN TUMOR-CELLS; MALIGNANT GLIOMA; STEM-CELLS; CANCER; ACTIVATION; STRAND	The failure of conventional therapies in glioblastoma (GBM) is largely due to an aberrant activity of survival cascades, such as PI3 kinase (PI3K)/Akt-mediated signaling. This study is the first to show that the class I PI3K inhibitor, PI-103, enhances chemotherapy-induced cell death of GBM cells. Concurrent treatment with PI-103 and DNA-damaging drugs, in particular doxorubicin, significantly increases apoptosis and reduces colony formation compared with chemotherapy treatment alone. The underlying molecular mechanism for this chemosensitization was shown by two independent approaches, that is, pharmacological and genetic inhibition of PI3K, DNA-PK and mTOR, to involve inhibition of DNA-PK-mediated DNA repair. Accordingly, blockage of PI3K or DNA-PK, but not of mTOR, significantly delays the resolution of doxorubicin-induced DNA damage and concomitantly increases apoptosis. Importantly, not only are several GBM cell lines chemosensitized by PI-103 but also GBM stem cells. Clinical relevance was further confirmed by the use of primary cultured GBM cells, which also exhibit increased cell death and reduced colony formation on combined treatment with PI-103 and doxorubicin. By identifying class I PI3K inhibitors as powerful agents in enhancing the lethality of DNA-damaging drugs, to which GBMs are usually considered unresponsive, our findings have important implications for the design of rational combination regimens in overcoming the frequent chemoresistance of GBM. Oncogene (2009) 28, 3586-3596; doi: 10.1038/onc.2009.215; published online 27 July 2009	[Westhoff, M-A; Kandenwein, J. A.; Karl, S.; Vellanki, S. H. K.; Antoniadis, G.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Kandenwein, J. A.] Univ Ulm, Dept Neurosurg, Bezirkskrankenhaus Guenzburg, D-89069 Ulm, Germany; [Braun, V.] Evangel Jung Stilling Krankenhaus, Dept Neurosurg, Siegen, Germany; [Eramo, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; Istituto Superiore di Sanita (ISS)	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Westhoff, Mike-Andrew/ABA-9272-2021; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Eramo, Adriana/K-6694-2016	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Eramo, Adriana/0000-0002-0814-6683; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; European Community; Novartis Stiftung fur therapeutische Forschung; University of Ulm junior research grant;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); European Community(European Commission); Novartis Stiftung fur therapeutische Forschung; University of Ulm junior research grant; 	We thank H Lane (Novartis Institute for BioMedical Research, Oncology Basel, Novartis Pharma AG, Basel, Switzerland) for providing everolimus, R Pallini and R De Maria for glioblastoma-initiating cells and S Piater for expert technical assistance. This work was supported by grants from Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, European Community (ApopTrain, APO-SYS), Novartis Stiftung fur therapeutische Forschung and IAP6/18 (to SF), and the University of Ulm junior research grant (to JAK).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brendler-Schwaab S, 2005, MUTAGENESIS, V20, P245, DOI 10.1093/mutage/gei033; Cavaliere R, 2007, NEUROL CLIN, V25, P1141, DOI 10.1016/j.ncl.2007.07.012; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Chen JS, 2008, MOL CANCER THER, V7, P841, DOI 10.1158/1535-7163.MCT-07-0393; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Colman H, 2008, ARCH NEUROL-CHICAGO, V65, P877, DOI 10.1001/archneur.65.7.877; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fulda S, 1997, CANCER RES, V57, P3823; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Glas M, 2007, ONCOLOGY-BASEL, V72, P302, DOI 10.1159/000113052; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hau P, 2004, CANCER, V100, P1199, DOI 10.1002/cncr.20073; Ihle NT, 2009, MOL CANCER THER, V8, P1, DOI 10.1158/1535-7163.MCT-08-0801; Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Koehn H, 2007, ANTI-CANCER DRUG, V18, P419, DOI 10.1097/CAD.0b013e328012a9a0; Kreisl TN, 2009, J NEURO-ONCOL, V92, P99, DOI 10.1007/s11060-008-9741-z; Lees-Miller SP, 2008, CANCER CELL, V13, P379, DOI 10.1016/j.ccr.2008.04.010; Maira SM, 2008, EXPERT OPIN THER TAR, V12, P223, DOI 10.1517/14728222.12.2.223 ; Maira SM, 2009, BIOCHEM SOC T, V37, P265, DOI 10.1042/BST0370265; Newton HB, 2008, CURR TREAT OPTION NE, V10, P285, DOI 10.1007/s11940-008-0031-z; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pawelczak KS, 2008, NUCLEIC ACIDS RES, V36, P4022, DOI 10.1093/nar/gkn344; Prevo R, 2008, CANCER RES, V68, P5915, DOI 10.1158/0008-5472.CAN-08-0757; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; TISDALE MJ, 1985, BRIT J CANCER, V52, P789, DOI 10.1038/bjc.1985.259; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Veuger SJ, 2003, CANCER RES, V63, P6008; Yaneva M, 2005, NUCLEIC ACIDS RES, V33, P5320, DOI 10.1093/nar/gki821; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	53	61	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3586	3596		10.1038/onc.2009.215	http://dx.doi.org/10.1038/onc.2009.215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633683				2022-12-17	WOS:000270851700007
J	Endo, K; Kondo, S; Shackleford, J; Horikawa, T; Kitagawa, N; Yoshizaki, T; Furukawa, M; Zen, Y; Pagano, JS				Endo, K.; Kondo, S.; Shackleford, J.; Horikawa, T.; Kitagawa, N.; Yoshizaki, T.; Furukawa, M.; Zen, Y.; Pagano, J. S.			Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration	ONCOGENE			English	Article						latent membrane protein 1; ezrin; nasopharyngeal carcinoma; cell migration	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; EPITHELIAL-CELLS; ERM PROTEINS; KINASE-C; MEMBRANE-PROTEIN-1; GROWTH; EXPRESSION; INDUCTION; CYTOSKELETON; MOTILITY	Tumor metastasis is a complex phenomenon that is the culmination of effects of numerous cellular factors. We have shown that the Epstein-Barr virus (EBV) oncoprotein, latent membrane protein 1(LMP1), is capable of inducing a wide range of such factors in cell culture, expression of which is also elevated in the LMP1-expressing tumor, nasopharyngeal carcinoma (NPC), a highly invasive neoplasm. Recently, the membrane crosslinker protein, ezrin, has been implicated in tumor cell metastasis and malignant progression. In this study, we evaluated the possible role of LMP1 and ezrin in the pathophysiology of NPC. We show that C-terminal phosphorylation of ezrin is increased by the expression of LMP1 in nasopharyngeal (NP) cells through a protein kinase C (PKC) pathway. LMP1 enhances the organization of a ternary complex of CD44, ezrin and F-actin, which is a prerequisite for ezrin phosphorylation. In NPC tissues, the expression of phosphoezrin and LMP1 is directly correlated. Silencing of endogenously expressed ezrin suppresses LMP1-induced cell motility and invasiveness. Moreover, the inhibition of ezrin phosphorylation by PKC inhibitor suppresses migration and invasion of NP cells. These data show that the phosphorylation of ezrin and its recruitment to the cell membrane linked to F-actin and CD44 is a process required for LMP1-stimulated cell motility and invasion of NP cells.	[Pagano, J. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Pagano, J. S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Endo, K.; Kondo, S.; Horikawa, T.; Kitagawa, N.; Yoshizaki, T.; Furukawa, M.] Kanazawa Univ, Grad Sch Med, Div Otolaryngol, Kanazawa, Ishikawa, Japan; [Zen, Y.] Kanazawa Univ Hosp, Div Pathol, Kanazawa, Ishikawa, Japan	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kanazawa University; Kanazawa University	Pagano, JS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, West Dr, Chapel Hill, NC 27599 USA.	joseph_pagano@med.unc.edu			NCI [CA 19014]; Nakayama Foundation for Human Science (Tokyo, Japan); NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042371] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nakayama Foundation for Human Science (Tokyo, Japan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Sai Wah Tsao and Erik K Flemington for the NP69SV40T cell line and the Ad-AH cell line, respectively. We thank Drs Yojiro Kotake and Yuki Okada for helpful advice. This work was supported by NCI (CA 19014) (JSP) and the Nakayama Foundation for Human Science (Tokyo, Japan) (KE).	Auvinen E, 2007, EXP CELL RES, V313, P824, DOI 10.1016/j.yexcr.2006.12.002; Baumgartner M, 2006, P NATL ACAD SCI USA, V103, P13391, DOI 10.1073/pnas.0605950103; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; CONTRERASBRODIN BA, 1991, J GEN VIROL, V72, P3025, DOI 10.1099/0022-1317-72-12-3025; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Fais S, 2004, TRENDS MOL MED, V10, P249, DOI 10.1016/j.molmed.2004.04.005; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Hiscox S, 1999, J CELL SCI, V112, P3081; Hopkins AM, 2007, AM J PHYSIOL-GASTR L, V292, pG806, DOI 10.1152/ajpgi.00333.2006; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kondo S, 2005, INT J CANCER, V115, P368, DOI 10.1002/ijc.20849; Kondo S, 2007, J VIROL, V81, P1554, DOI 10.1128/JVI.02222-06; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park JH, 2002, VIROLOGY, V303, P345, DOI 10.1006/viro.2002.1638; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; RAAB-TRAUB N, 1987, Journal of Experimental Pathology (New York), V3, P449; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; TAKIMOTO T, 1988, LARYNGOSCOPE, V98, P1334; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wakisaka N, 2002, CANCER RES, V62, P6337; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; WALTER J, 1995, INT J CANCER, V61, P363, DOI 10.1002/ijc.2910610315; Yan GR, 2007, CELL SIGNAL, V19, P341, DOI 10.1016/j.cellsig.2006.07.019; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Yoshizaki T, 2005, EPSTEIN-BARR VIRUS, P171; Zhang Y, 2006, J CANCER RES CLIN, V132, P685, DOI 10.1007/s00432-006-0117-5	43	61	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1725	1735		10.1038/onc.2009.20	http://dx.doi.org/10.1038/onc.2009.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234486	Green Accepted, Green Submitted			2022-12-17	WOS:000265022000007
J	Bhattacharyya, S; Ishida, W; Wu, M; Wilkes, M; Mori, Y; Hinchcliff, M; Leof, E; Varga, J				Bhattacharyya, S.; Ishida, W.; Wu, M.; Wilkes, M.; Mori, Y.; Hinchcliff, M.; Leof, E.; Varga, J.			A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate	ONCOGENE			English	Article						c-Abl; imatinib mesylate; TGF-beta; Egr-1; fibrosis; fibroblast	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; TGF-BETA; SYSTEMIC-SCLEROSIS; TRANSCRIPTION FACTORS; SKIN FIBROBLASTS; CELLULAR-RESPONSE; POSITIVE CELLS; COLLAGEN GENE; DNA-DAMAGE	The nonreceptor protein tyrosine kinase c-Abl regulates cell proliferation and survival. Recent studies provide evidence that implicate c-Abl as a mediator for. brotic responses induced by transforming growth factor-beta (TGF-beta), but the precise mechanisms underlying this novel oncogene function are unknown. Here, we report that when expressed in normal fibroblasts, a constitutively active mutant of Abl that causes chronic myelogenous leukemia (CML) stimulated the expression and transcriptional activity of the early growth response factor 1 (Egr1). Mouse embryonic fibroblasts (MEFs), lacking c-Abl, were resistant to TGF-beta stimulation. Responsiveness of these MEFs to TGF-beta could be rescued by wild-type c-Abl, but not by a kinase-deficient mutant form of c-Abl. Furthermore, Abl kinase activity was necessary for the induction of Egr-1 by TGF-beta in normal fibroblasts, and Egr-1 was required for stimulation of collagen by Bcr-Abl. Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1. Collectively, these results position Egr-1 downstream of c-Abl in the. brotic response, delineate a novel Egr-1-dependent intracellular signaling mechanism that underlies the involvement of c-Abl in certain TGF-beta responses, and identify Egr-1 as a target of inhibition by imatinib. Furthermore, the findings show in situ activation of c-Abl paralleling the upregulated tissue expression of Egr-1 that accompanies fibrosis. Pharmacological targeting of c-Abl and its downstream effector pathways may, therefore, represent a novel therapeutic approach to blocking TGF-beta-dependent fibrotic processes.	[Bhattacharyya, S.; Ishida, W.; Wu, M.; Mori, Y.; Hinchcliff, M.; Varga, J.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA; [Wilkes, M.; Leof, E.] Mayo Clin, Div Pulm Med, Rochester, MN USA	Northwestern University; Feinberg School of Medicine; Mayo Clinic	Varga, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, 240 E Huron St, Chicago, IL 60611 USA.	j-varga@northwestern.edu	Varga, John/AAK-6472-2021; Bhattacharyya, Swati/W-8145-2019	Wilkes, Mark/0000-0002-9600-6831; Hinchcliff, Monique/0000-0002-8652-9890	National Institutes of Health [AR-42309]; Department of Defence [W81-XWH-06-01-0278]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055816] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defence; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Anthony Koleske (Yale University, New Haven, CT, USA) and Pamela Woodring (The Salk Institute, La Jolla, CA) for Abl- null/Arg-null and Abl reconstituted mouse embryonic. broblasts, and Leonidas Platanias (North-western University Feinberg School of Medicine) for Bcr-Abl plasmids and helpful discussions. This study was supported by grants from the National Institutes of Health (AR-42309) and the Department of Defence (W81-XWH-06-01-0278).	Bhattacharyya S, 2008, AM J PATHOL, V173, P1085, DOI 10.2353/ajpath.2008.080382; Bonn D, 2004, LANCET INFECT DIS, V4, P255, DOI 10.1016/S1473-3099(04)01014-X; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Ceni E, 2006, GASTROENTEROLOGY, V131, P1235, DOI 10.1053/j.gastro.2006.08.009; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P311, DOI 10.1002/art.22314; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; He X, 2006, CELL, V127, P40, DOI 10.1016/j.cell.2006.09.016; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ishida W, 2006, ARTHRITIS RHEUM, V54, pS776; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; Khachigian LM, 2006, CIRC RES, V98, P186, DOI 10.1161/01.RES.0000200177.53882.c3; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; La Rosee P, 2002, EXP HEMATOL, V30, P729, DOI 10.1016/S0301-472X(02)00836-6; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Leask A, 2008, CELL SIGNAL, V20, P1409, DOI 10.1016/j.cellsig.2008.01.006; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lobo VJSA, 2005, BIOCHEM J, V387, P231, DOI 10.1042/BJ20040927; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mori Y, 2004, ARTHRITIS RHEUM-US, V50, P4008, DOI 10.1002/art.20658; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; MOUSTAKAS A, 2005, ONCOGENE, V24, P5742; Pannu J, 2004, CURR OPIN RHEUMATOL, V16, P739, DOI 10.1097/01.bor.0000137894.63091.1a; Pannu J, 2008, ARTHRITIS RHEUM-US, V58, P2528, DOI 10.1002/art.23698; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rajkumar VS, 2006, AM J PATHOL, V169, P2254, DOI 10.2353/ajpath.2006.060196; Renshaw MW, 2000, ONCOGENE, V19, P3216, DOI 10.1038/sj.onc.1203667; Rosenbloom J, 2008, ARTHRITIS RHEUM, V58, P2219, DOI 10.1002/art.23634; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stuart JR, 2005, ONCOGENE, V24, P8085, DOI 10.1038/sj.onc.1208953; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Takagawa S, 2003, J INVEST DERMATOL, V121, P41, DOI 10.1046/j.1523-1747.2003.12308.x; Takahashi T, 2005, J BIOL CHEM, V280, P7100, DOI 10.1074/jbc.M411064200; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Varga JA, 2008, RHEUM DIS CLIN N AM, V34, P115, DOI 10.1016/j.rdc.2007.11.002; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wenner CE, 2003, J CELL PHYSIOL, V196, P42, DOI 10.1002/jcp.10243; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000	63	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1285	1297		10.1038/onc.2008.479	http://dx.doi.org/10.1038/onc.2008.479			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151753	Green Accepted			2022-12-17	WOS:000264116000001
J	Goicoechea, SM; Bednarski, B; Garcia-Mata, R; Prentice-Dunn, H; Kim, HJ; Otey, CA				Goicoechea, S. M.; Bednarski, B.; Garcia-Mata, R.; Prentice-Dunn, H.; Kim, H. J.; Otey, C. A.			Palladin contributes to invasive motility in human breast cancer cells	ONCOGENE			English	Article						podosomes; migration; actin; metastasis	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; INFLUENCES ZYXIN LOCALIZATION; PROTEIN PALLADIN; BINDING PARTNER; ACTIN CYTOSKELETON; DORSAL RUFFLES; ALPHA-ACTININ; PODOSOMES; INVADOPODIA	Cancer metastasis involves multiple steps including detachment of the metastatic cells from neighboring cells, the acquisition of motility and invasion to other tissue. All of these steps require the reorganization of the actin cytoskeleton. In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in tumors compared with benign breast tissue, and also expressed significantly higher in four invasive breast cancer cell lines when compared with four non-invasive cell lines. In addition, we found that palladin plays a key role in the formation of podosomes. Podosomes are actin-rich structures that function in adhesion and matrix degradation, and have been found in many invasive cell types. Our results show that phorbol ester treatment stimulated the formation of palladin-containing podosomes in invasive, but not in non-invasive cell lines. More importantly, palladin knockdown resulted in decreased podosome formation and a significant reduction in transwell migration and invasive motility. Palladin overexpression induced podosome formation in the non-invasive MCF7 cells, which are otherwise unable to form podosomes, suggesting that palladin plays a critical role in the assembly of podosomes. Overall, these results indicate that palladin overexpression contributes to the invasive behavior of metastatic cells.	[Goicoechea, S. M.; Prentice-Dunn, H.; Otey, C. A.] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; [Bednarski, B.; Kim, H. J.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; [Garcia-Mata, R.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Goicoechea, SM (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, 103 Mason Farm Rd,5320 MBRB, Chapel Hill, NC 27599 USA.	sgoico@med.unc.edu		Goicoechea, Silvia/0000-0003-1107-389X; Garcia-Mata, Rafael/0000-0002-7116-4411	NIH [GM61743, CA09688]; NIH K08 [CA098240]; NATIONAL CANCER INSTITUTE [K08CA098240, T32CA009688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH K08(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to the following former lab members for their assistance in the early stages of this project: Dr Mana Parast, Amir Aghajanian and Xinshuo Wang. We thank Xiaoya Ding and Dave Cowan for help with immunohistochemistry. We also thank Dr Cercina Onesto for kindly sharing the breast cancer cell lines. This work was supported by NIH Grant GM61743 (to CO). HJK was supported by NIH K08 Grant CA098240 and BB was supported by NIH training Grant CA09688.	Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2003, MOL CELL NEUROSCI, V23, P661, DOI 10.1016/S1044-7431(03)00127-1; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Calle Y, 2006, EUR J CELL BIOL, V85, P151, DOI 10.1016/j.ejcb.2005.09.003; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Dixon RDS, 2008, J BIOL CHEM, V283, P6222, DOI 10.1074/jbc.M707694200; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Gimona M, 2003, MOL BIOL CELL, V14, P2482, DOI 10.1091/mbc.E02-11-0743; Gimona M, 2006, INT J BIOCHEM CELL B, V38, P1875, DOI 10.1016/j.biocel.2006.05.003; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; Gringel A, 2006, J CELL PHYSIOL, V209, P568, DOI 10.1002/jcp.20777; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Hai CM, 2002, EXP CELL RES, V280, P64, DOI 10.1006/excr.2002.5592; Hatakeyama H, 2006, PROTEOMICS, V6, P6300, DOI 10.1002/pmic.200600488; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Jin L, 2007, CIRC RES, V100, P817, DOI 10.1161/01.RES.0000261351.54147.de; Kelly T, 1998, CLIN EXP METASTAS, V16, P501, DOI 10.1023/A:1006538200886; Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008-5472.CAN-04-1408; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; MONSKY WL, 1994, CANCER RES, V54, P5702; Mykkanen OM, 2001, MOL BIOL CELL, V12, P3060, DOI 10.1091/mbc.12.10.3060; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pogue-Geile KL, 2006, PLOS MED, V3, P2216, DOI 10.1371/journal.pmed.0030516; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Ronty M, 2005, EXP CELL RES, V310, P88, DOI 10.1016/j.yexcr.2005.06.026; Ronty M, 2004, FEBS LETT, V566, P30, DOI 10.1061/j.febslet.2004.04.006; Ronty M, 2007, EXP CELL RES, V313, P2575, DOI 10.1016/j.yexcr.2007.04.030; Ronty MJ, 2006, J INVEST DERMATOL, V126, P2387, DOI 10.1038/sj.jid.5700427; Roy P, 2004, CELL MOTIL CYTOSKEL, V57, P84, DOI 10.1002/cm.10160; Ryu B, 2001, CANCER RES, V61, P1833; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Suehara Y, 2006, PROTEOMICS, V6, P4402, DOI 10.1002/pmic.200600196; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Wittenmayer N, 2004, MOL BIOL CELL, V15, P1600, DOI 10.1091/mbc.E03-12-0873; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	50	61	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					587	598		10.1038/onc.2008.408	http://dx.doi.org/10.1038/onc.2008.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978809	Green Accepted, Green Submitted			2022-12-17	WOS:000262866500012
J	van Gorp, AGM; Vos, KED; Brenkman, AB; Bremer, A; van den Broek, N; Zwartkruis, F; Hershey, JW; Burgering, BMT; Calkhoven, CF; Coffer, PJ				van Gorp, A. G. M.; van der Vos, K. E.; Brenkman, A. B.; Bremer, A.; van den Broek, N.; Zwartkruis, F.; Hershey, J. W.; Burgering, B. M. T.; Calkhoven, C. F.; Coffer, P. J.			AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B	ONCOGENE			English	Article						eIF4B; mTOR; MEK; PKB; translation	MESSENGER-RNA TRANSLATION; HELICASE ACTIVITY; MTOR; CANCER; EIF4B; AKT; RECRUITMENT; DEFICIENCY; RAPAMYCIN; PEPTIDE	Eukaryotic translation initiation factor 4B (eIF4B) plays a critical role during the initiation of protein synthesis and its activity can be regulated by multiple phosphorylation events. In a search for novel protein kinase B (PKB/c-akt) substrates, we identified eIF4B as a potential target. Using an in vitro kinase assay, we found that PKB can directly phosphorylate eIF4B on serine 422 (ser422). Activation of a conditional PKB mutant, interleukin-3 (IL-3) or insulin stimulation resulted in PKB-dependent phosphorylation of this residue in vivo. This was prevented by pretreatment of cells with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or pharmacological inhibition of PKB. Pretreatment of cells with rapamycin, inhibiting mTOR or U0126 to inhibit MEK, had little effect on eIF4B ser422 phosphorylation. In contrast, following amino-acid refeeding, eIF4B ser422 phosphorylation was found to be mammalian target of rapamycin (mTOR)-dependent. We further identified eIF4B ser406 as a novel mitogen-regulated phosphorylation site. Insulin-induced phosphorylation of eIF4B ser406 was dependent on both MEK and mTOR activity. Utilizing a novel translational control luciferase assay, we could further demonstrate that phosphorylation of ser406 or ser422 is essential for optimal translational activity of eIF4B. These data provide novel insights into complex multikinase regulation of eIF4B phosphorylation and reveal an important mechanism by which PKB can regulate translation, potentially critical for the transforming capacity of this AGC kinase family member.	[van Gorp, A. G. M.; van der Vos, K. E.; Coffer, P. J.] Univ Med Ctr Utrecht, Mol Immunol Lab, Dept Immunol, Utrecht, Netherlands; [Brenkman, A. B.; van den Broek, N.] Univ Med Ctr Utrecht, Dept Endocrinol & Metab Dis, Utrecht, Netherlands; [Bremer, A.; Calkhoven, C. F.] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany; [Zwartkruis, F.; Burgering, B. M. T.] Univ Med Ctr Utrecht, Dept Physiol Chem, Ctr Biomed Genet, Utrecht, Netherlands; [Hershey, J. W.] Univ Calif Davis, Dept Biol Chem, Sch Med, Davis, CA 95616 USA; [Coffer, P. J.] Univ Med Ctr Utrecht, Dept Pediat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Utrecht University; Utrecht University Medical Center; University of California System; University of California Davis; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr, Mol Immunol Lab, Dept Immunol KC 020852, Lundlaan 6, NL-3584 CA Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Calkhoven, Cornelis/0000-0001-6318-7210	Dutch Scientific Organization [917.36.316]	Dutch Scientific Organization(Netherlands Organization for Scientific Research (NWO))	AGM van Gorp and KE van der Vos were supported by a grant from the Dutch Scientific Organization (NWO; ZonMw 917.36.316).	BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Calkhoven CF, 2000, GENE DEV, V14, P1920; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; GANI R, 1976, EXP CELL RES, V97, P249, DOI 10.1016/0014-4827(76)90614-5; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; NARANDA T, 1994, J BIOL CHEM, V269, P14465; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Parker PJ, 2001, BIOCHEM SOC T, V29, P860, DOI 10.1042/0300-5127:0290860; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; van Gorp AGM, 2006, CANCER RES, V66, P10760, DOI 10.1158/0008-5472.CAN-06-1111; Wiesenthal V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj029; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	42	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					95	106		10.1038/onc.2008.367	http://dx.doi.org/10.1038/onc.2008.367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836482				2022-12-17	WOS:000262294100010
J	Ou, WB; Zhu, MJ; Demetri, GD; Fletcher, CDM; Fletcher, JA				Ou, W-b; Zhu, M-j; Demetri, G. D.; Fletcher, C. D. M.; Fletcher, J. A.			Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors	ONCOGENE			English	Article						PRKCQ; KIT; shRNA; gastrointestinal neoplasm; sarcoma; imatinib	RECEPTOR TYROSINE KINASES; KAPPA-B ACTIVATION; RETINOID-X-RECEPTOR; T-CELL-ACTIVATION; PKC-THETA; INTESTINAL EPITHELIUM; ANTICANCER THERAPY; IMATINIB MESYLATE; MOLECULAR-CLONING; GENE-EXPRESSION	Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumors (GISTs), and the KIT/PDGFRA kinase inhibitor, imatinib, is standard of care for patients with metastatic GIST. However, most of these patients eventually develop clinical resistance to imatinib and other KIT/PDGFRA kinase inhibitors and there is an urgent need to identify novel therapeutic strategies. We reported previously that protein kinase C-theta (PKC theta) is activated in GIST, irrespective of KIT or PDGFRA mutational status, and is expressed at levels unprecedented in other mesenchymal tumors, therefore serving as a diagnostic marker of GIST. Herein, we characterize biological functions of PKC theta in imatinib-sensitive and imatinib-resistant GISTs, showing that lentivirus-mediated PKC theta knockdown is accompanied by inhibition of KIT expression in three KIT+/PKC theta+ GIST cell lines, but not in a comparator KIT+/PKCh theta-Ewing's sarcoma cell line. PKC theta knockdown in the KIT+ GISTs was associated with inhibition of the phosphatidylinositol-3-kinase/AKT signaling pathway, upregulation of the cyclin-dependent kinase inhibitors p21 and p27, antiproliferative effects due to G(1) arrest and induction of apoptosis, comparable to the effects seen after direct knockdown of KIT expression by KIT short-hairpin RNA. These novel findings highlight that PKC theta warrants clinical evaluation as a potential therapeutic target in GISTs, including those cases containing mutations that confer resistance to KIT/PDGFRA kinase inhibitors.	[Ou, W-b; Zhu, M-j; Fletcher, C. D. M.; Fletcher, J. A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Demetri, G. D.] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA; [Demetri, G. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Ou, WB (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	wou@rics.bwh.harvard.edu; jfletcher@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442	GI SPORE [1P50CA127003-01]; Life Raft Group; Cesarini Team for the Pan-Massachusetts Challenge; Virginia and Daniel K Ludwig Trust for Cancer Research; Ronald O Perelman Fund; Stutman GIST Cancer Research Fund; Rubenstein Foundation; NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	GI SPORE; Life Raft Group; Cesarini Team for the Pan-Massachusetts Challenge; Virginia and Daniel K Ludwig Trust for Cancer Research; Ronald O Perelman Fund; Stutman GIST Cancer Research Fund; Rubenstein Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from an anonymous donor, GI SPORE 1P50CA127003-01, the Life Raft Group, Cesarini Team for the Pan-Massachusetts Challenge, the Virginia and Daniel K Ludwig Trust for Cancer Research, the Ronald O Perelman Fund for Cancer Research, the Stutman GIST Cancer Research Fund, the Rubenstein Foundation and Leslie's Links. We thank Sarah E Bulmer and William Hahn for providing shRNA constructs.	Allander SV, 2001, CANCER RES, V61, P8624; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; BAIER G, 1993, J BIOL CHEM, V268, P4997; Banan A, 2005, J PHARMACOL EXP THER, V313, P962, DOI 10.1124/jpet.104.083428; Banan A, 2004, AM J PHYSIOL-CELL PH, V287, pC218, DOI 10.1152/ajpcell.00575.2003; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Blay JY, 2005, ANN ONCOL, V16, P566, DOI 10.1093/annonc/mdi127; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Cerda SR, 2006, ONCOGENE, V25, P3123, DOI 10.1038/sj.onc.1209360; CHANG JD, 1993, J BIOL CHEM, V268, P14208; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Deeds L, 2003, J BIOL CHEM, V278, P39782, DOI 10.1074/jbc.M306854200; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Drevs J, 2003, CURR DRUG TARGETS, V4, P113, DOI 10.2174/1389450033346885; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Janeway KA, 2007, CANCER RES, V67, P9084, DOI 10.1158/0008-5472.CAN-07-1938; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Medinger M, 2005, CURR PHARM DESIGN, V11, P1139, DOI 10.2174/1381612053507611; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2001, CANCER RES, V61, P8118; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Southwell BR, 2003, NEUROGASTROENT MOTIL, V15, P139, DOI 10.1046/j.1365-2982.2003.00394.x; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tarn C, 2006, CANCER RES, V66, P5477, DOI 10.1158/0008-5472.CAN-05-3906; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Villalba M, 1999, J IMMUNOL, V163, P5813; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	54	61	63	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5624	5634		10.1038/onc.2008.177	http://dx.doi.org/10.1038/onc.2008.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18521081	Green Accepted			2022-12-17	WOS:000259280800008
J	Stutz, MA; Shattuck, DL; Laederich, MB; Carraway, KL; Sweeney, C				Stutz, M. A.; Shattuck, D. L.; Laederich, M. B.; Carraway, K. L., III; Sweeney, C.			LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII	ONCOGENE			English	Article						EGFRvIII; LRIG1; negative regulator; glioblastoma	GROWTH-FACTOR RECEPTOR; KINASE INHIBITORS; DOWN-REGULATION; CELL CARCINOMA; ACTIVATION; RESISTANCE; GENE; UBIQUITYLATION; EXPRESSION; CANCER	Epidermal growth factor receptor (EGFR) mutation is frequently observed in human cancer and contributes to the growth, survival and therapeutic resistance of tumors. EGFRvIII is an oncogenic EGFR mutant resulting from the deletion of exons 2-7 and is the most common EGFR mutant observed in glioblastoma multiforme, an aggressive brain tumor. EGFRvIII is constitutively active but poorly ubiquitinated, leading to inefficient receptor trafficking to lysosomes and unattenuated oncogenic signaling. The mechanism by which EGFRvIII evades downregulation is not fully understood although recent studies suggest that its interaction with the ubiquitin ligase Cbl may be compromised. In this study, we examine the regulation of EGFRvIII by the recently identified negative regulator, LRIG1, which targets EGFR through recognition of its extracellular domain. Here, we determine whether the extracellular domain deletion in EGFRvIII renders it refractory to LRIG1 regulation. We find that EGFRvIII retains interaction with LRIG1 and is in fact more sensitive to LRIG1 action than wild-type receptor. We demonstrate that LRIG1 regulation of EGFRvIII is distinct from the only other known mechanism of EGFR regulation, Cbl-mediated degradation. Ectopic expression of LRIG1 in EGFRvIII(+) glioblastoma cells opposes EGFRvIII-driven tumor cell proliferation, survival, motility and invasion. Finally, RNAi-mediated silencing of LRIG1 alters EGFRvIII intracellular trafficking and leads to enhanced EGFRvIII expression, suggesting that loss of LRIG1 in tumors may contribute to a permissive environment for EGFRvIII overexpression, contributing to EGFRvIII oncogenesis.	[Stutz, M. A.; Shattuck, D. L.; Laederich, M. B.; Carraway, K. L., III; Sweeney, C.] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis	Sweeney, C (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Room 1000,4645 2nd Ave, Sacramento, CA 95817 USA.	casweeney@ucdavis.edu			NIH [CA118384, GM068994]; DOD BCRP [W81XWH-06-1-0772]; NATIONAL CANCER INSTITUTE [R01CA118384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068994] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Webster Cavenee from the Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, California for the U87MG parental and EGFRvIII expressing glioblastoma cells. We thank Dr Laurel Beckett, Chief of the Division of Biostatistics at UC Davis School of Medicine, for statistical consultation. We thank Carol Oxford, Manager of the UC Davis Optical Biology Core, for her assistance in the flow cytometry experiments. This work was supported by NIH grants CA118384 (CS) and GM068994 (KLC). DLS is a recipient of a DOD BCRP predoctoral fellowship Award no. W81XWH-06-1-0772.	Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Aoki T, 2007, EXPERT OPIN PHARMACO, V8, P3133, DOI 10.1517/14656566.8.18.3133; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Davies GC, 2006, ONCOGENE, V25, P6497, DOI 10.1038/sj.onc.1209662; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Han W, 2006, CANCER BIOL THER, V5, P1361, DOI 10.4161/cbt.5.10.3226; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Kirisits A, 2007, INT J BIOCHEM CELL B, V39, P2173, DOI 10.1016/j.biocel.2007.07.012; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; Lindstrom AK, 2008, INT J GYNECOL CANCER, V18, P312, DOI 10.1111/j.1525-1438.2007.01021.x; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Peschard P, 2007, MOL CELL, V27, P474, DOI 10.1016/j.molcel.2007.06.023; Raizer RJ, 2005, J NEURO-ONCOL, V74, P77, DOI 10.1007/s11060-005-0603-7; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Sweeney C, 2006, J MAMMARY GLAND BIOL, V11, P89, DOI 10.1007/s10911-006-9015-3; Tanemura A, 2005, DERMATOL SURG, V31, P423, DOI 10.1097/00042728-200504000-00008; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	34	61	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5741	5752		10.1038/onc.2008.185	http://dx.doi.org/10.1038/onc.2008.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542056	Green Accepted			2022-12-17	WOS:000259487100009
J	Baird, SK; Aerts, JL; Eddaoudi, A; Lockley, M; Lemoine, NR; McNeish, IA				Baird, S. K.; Aerts, J. L.; Eddaoudi, A.; Lockley, M.; Lemoine, N. R.; McNeish, I. A.			Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer	ONCOGENE			English	Article						adenovirus; ovarian cancer; apoptosis; autophagy; necrosis	INDUCED APOPTOSIS; AUTOPHAGY; PROTEIN; INHIBITION; RB; 3-METHYLADENINE; BIOLUMINESCENCE; PATHWAYS; GENES; ADP	Oncolytic adenoviral mutants have considerable activity in ovarian cancer. However, the mechanisms by which they induce cell death remain uncertain. dl922-947, which contains a 24 bp deletion in E1A CR2, is more potent than both E1A wild-type adenoviruses and the E1B-55K deletion mutant dl1520 (Onyx-015). We investigated the mode of death induced by three E1A CR2-deleted replicating adenoviruses in models of ovarian cancer and also the importance of E3 11.6 (adenovirus death protein) in determining this mode of death. Ovarian cancer cells were infected with dl922-947 (E3 11.6(+)) and dlCR2 (E3 11.6(-)). We also generated dlCR2 tSmac, which also encodes the gene for processed Smac/DIABLO. Classical apoptosis does not occur in adenoviral cell death and there is no role for mitochondria. Expression of Smac/DIABLO does not enhance cytotoxicity nor increase apoptotic features. A role for cathepsins and lysosomal membrane permeability was excluded. Autophagy is induced, but is not the mode of death and may act as a cell survival mechanism. There is no evidence of pure necrosis, while the presence of E3 11.6 does not modulate the mode or extent of cell death. Thus, E1A CR2-deleted oncolytic adenoviral cytotoxicity in ovarian cancer may de. ne a novel mode of programmed cell death.	[Baird, S. K.; Aerts, J. L.; Lockley, M.; Lemoine, N. R.; McNeish, I. A.] John Vane Sci Ctr, Barts & London Queen Marys Sch Med, Inst Canc, Canc Res UK Clin Ctr,Ctr Mol Oncol, London EC1M 6BQ, England; [Eddaoudi, A.] Canc Res UK London Res Inst, FACS Lab, London, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK	McNeish, IA (corresponding author), John Vane Sci Ctr, Barts & London Queen Marys Sch Med, Inst Canc, Canc Res UK Clin Ctr,Ctr Mol Oncol, Charterhouse Sq, London EC1M 6BQ, England.	iain.mcneish@cancer.org.uk	Aerts, Joeri/J-6957-2014	Aerts, Joeri/0000-0002-9902-3696; McNeish, Iain/0000-0002-9387-7586; lockley, michelle/0000-0002-9281-5789; Eddaoudi, Ayad/0000-0001-5272-6426	MRC [G0601891, G84/6553] Funding Source: UKRI; Cancer Research UK [A4119, C9423/A4119] Funding Source: Medline; Medical Research Council [G84/6553, G0601891, G0601891(82080)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abou El Hassan MAI, 2004, J VIROL, V78, P12243, DOI 10.1128/JVI.78.22.12243-12251.2004; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Leyton J, 2006, CANCER RES, V66, P9178, DOI 10.1158/0008-5472.CAN-06-1539; Lockley M, 2006, CANCER RES, V66, P989, DOI 10.1158/0008-5472.CAN-05-2691; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; McNeish IA, 2001, CANCER GENE THER, V8, P308, DOI 10.1038/sj.cgt.7700305; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433; Subramanian T, 2006, J VIROL, V80, P2000, DOI 10.1128/JVI.80.4.2000-2012.2006; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Yaginuma Y, 1997, EXP CELL RES, V233, P233, DOI 10.1006/excr.1997.3560; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	37	61	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3081	3090		10.1038/sj.onc.1210977	http://dx.doi.org/10.1038/sj.onc.1210977			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071311	Green Accepted			2022-12-17	WOS:000255897600001
J	Tan, M; Gu, Q; He, H; Pamarthy, D; Semenza, GL; Sun, Y				Tan, M.; Gu, Q.; He, H.; Pamarthy, D.; Semenza, G. L.; Sun, Y.			SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1 alpha ubiquitination and degradation	ONCOGENE			English	Article						E3 ligase; HIF-1; hypoxia; SAG; transcription; ubiquitination	HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-SUPPRESSOR COMPLEX; PROTEIN; LIGASE; SAG; HYDROXYLATION; GROWTH; ACTIVATION; EXPRESSION; COMPONENT	SAG (sensitive to apoptosis gene) or ROC2/RBX2 is the second family member of ROC1/RBX1, a component of SCF (Skp1, Cullin, F-box protein) and VCB (von Hippel-Lindau (VHL), Cullin and Elongin B/C) E3 ubiquitin ligases. SAG protected cells from hypoxia-induced apoptosis when overexpressed. We report here that SAG was subjected to hypoxia induction at the levels of mRNA and protein. Hypoxia induction of SAG was largely HIF-1 alpha dependent. A consensus HIF-1-binding site, GCGTG was identified in the first intron of the SAG gene. In response to hypoxia, HIF-1 bound to this site and transactivated SAG expression. SAG transactivation required both the intact binding site in cis and HIF-1 alpha in trans. On the other hand, like its family member, ROC1, SAG promoted VHL-mediated HIF-1 alpha ubiquitination and degradation, which was significantly inhibited upon small interfering RNA silencing of SAG or ROC1. Furthermore, the endogenous HIF-1 alpha at both basal and hypoxia-induced levels was significantly increased upon SAG silencing. Finally, SAG forms in vivo complex with Cul-5 and VHL under hypoxia condition. These results suggest an HIF-1-SAG feedback loop in response to hypoxia, as follows: hypoxia induces HIF-1 to transactivate SAG. Induced SAG then promotes HIF-1 alpha ubiquitination and degradation. This feedback loop may serve as a cellular defensive mechanism to reduce potential cytotoxic effects of prolonged HIF-1 activation under hypoxia.	[Tan, M.; Gu, Q.; He, H.; Pamarthy, D.; Sun, Y.] Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Pediat, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Med, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Oncol, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Radiat Oncol, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287; Pamarthy, Deepika/0000-0003-2486-7437	NATIONAL CANCER INSTITUTE [R01CA111554, R21CA116982, R01CA118762] Funding Source: NIH RePORTER; NCI NIH HHS [CA111554, CA118762, CA116982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chanalaris A, 2003, J MOL CELL CARDIOL, V35, P257, DOI 10.1016/S0022-2828(03)00003-8; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Felder CB, 1999, AAPS PHARMSCI, V1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kim SY, 2003, BIOCHEM BIOPH RES CO, V301, P671, DOI 10.1016/S0006-291X(03)00018-4; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang GY, 2001, J CEREBR BLOOD F MET, V21, P722, DOI 10.1097/00004647-200106000-00010; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231	25	61	63	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1404	1411		10.1038/sj.onc.1210780	http://dx.doi.org/10.1038/sj.onc.1210780			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828303				2022-12-17	WOS:000253548200007
J	Akbari, MR; Malekzadeh, R; Nasrollahzadeh, D; Amanian, D; Islami, F; Li, S; Zandvakili, I; Shakeri, R; Sotoudeh, M; Aghceli, K; Salahi, R; Pourshams, A; Semnani, S; Boffetta, P; Dawsey, SM; Ghadirian, P; Narod, SA				Akbari, M. R.; Malekzadeh, R.; Nasrollahzadeh, D.; Amanian, D.; Islami, F.; Li, S.; Zandvakili, I.; Shakeri, R.; Sotoudeh, M.; Aghceli, K.; Salahi, R.; Pourshams, A.; Semnani, S.; Boffetta, P.; Dawsey, S. M.; Ghadirian, P.; Narod, S. A.			Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma	ONCOGENE			English	Article						esophageal squamous cell carcinoma; Turkmen population; BRCA2; K3326X; Fanconi anemia pathway	POLYMORPHIC STOP CODON; FANCONI-ANEMIA; CANCER SUSCEPTIBILITY; BREAST-CANCER; GENETIC SUSCEPTIBILITY; PANCREATIC-CANCER; ALLELIC LOSS; CROSS-LINKS; DNA-BINDING; IRAN	The incidence of esophageal squamous cell carcinoma (ESCC) is very high among the Turkmen population of Iran. Family studies suggest a genetic component to the disease. Turkmen are ethnically homogenous and are well suited for genetic studies. A previous study from China suggested that BRCA2 might play a role in the etiology of ESCC. We screened for mutations in the coding region of the BRCA2 gene in the germline DNA of 197 Turkmen patients with ESCC. A nonsense variant, K3326X, was identified in 9 of 197 cases (4.6%) vs 2 of 254 controls (0.8%) (OR = 6.0, 95% CI = 1.3-28; P = 0.01). This mutation leads to the loss of the C-terminal domain of the BRCA2 protein, a part of the region of interaction with the FANCD2 protein. We observed nine other BRCA2 variants in single cases only, including two deletions, and seven missense mutations. Six of these were judged to be pathogenic. In total, a suspicious deleterious BRCA2 variant was identified in 15 of 197 ESCC cases (7.6%).	[Akbari, M. R.; Malekzadeh, R.; Nasrollahzadeh, D.; Amanian, D.; Islami, F.; Shakeri, R.; Sotoudeh, M.; Aghceli, K.; Pourshams, A.] Univ Tehran, Shariati Hosp, Digest Dis Res Ctr, Tehran 14114, Iran; [Akbari, M. R.; Li, S.; Zandvakili, I.; Narod, S. A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada; [Akbari, M. R.] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada; [Semnani, S.] Golestan Univ Med Sci, Res Ctr Gastroentrol, Gorgan, Iran; [Boffetta, P.] Int Agcy Res Canc, F-69372 Lyon, France; [Dawsey, S. M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Ghadirian, P.] Univ Montreal, CHUM Hotel Dieu, Epidemiol Res Unit Res Ctr, Montreal, PQ, Canada	Tehran University of Medical Sciences; University of Tehran; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Golestan University of Medical Sciences; World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universite de Montreal	Narod, SA (corresponding author), Univ Tehran, Shariati Hosp, Digest Dis Res Ctr, Tehran 14114, Iran.	malek@ams.ac.ir	Boffetta, Paolo/AAI-7767-2021; Semnani, Shahryar/N-2270-2016; Malekzadeh, Reza/U-1382-2017; Zandvakili, Inuk/P-7241-2019; Narod, Steven A/AAA-6112-2022; Zandvakili, Inuk/C-8496-2011	Boffetta, Paolo/0000-0002-3811-2791; Semnani, Shahryar/0000-0002-8768-6142; Malekzadeh, Reza/0000-0002-9820-6335; Zandvakili, Inuk/0000-0003-3409-0019; Islami, Farhad/0000-0002-7357-5994; Malekzadeh, Reza/0000-0003-1043-3814; , Ramin/0000-0003-0487-3629; Pourshams, Akram/0000-0002-7950-3983	NATIONAL CANCER INSTITUTE [Z01CP000185] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbari MR, 2006, INT J CANCER, V119, P1047, DOI 10.1002/ijc.21906; Alter BP, 2005, ARCH OTOLARYNGOL, V131, P635, DOI 10.1001/archotol.131.7.635; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Atanassov BS, 2005, GENE CHROMOSOME CANC, V44, P429, DOI 10.1002/gcc.20255; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; GHADIRIAN P, 1985, CANCER-AM CANCER SOC, V56, P2112, DOI 10.1002/1097-0142(19851015)56:8<2112::AID-CNCR2820560838>3.0.CO;2-3; Houghtaling S, 2005, HUM MOL GENET, V14, P3027, DOI 10.1093/hmg/ddi334; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hu N, 2004, ONCOGENE, V23, P852, DOI 10.1038/sj.onc.1207150; Hu N, 2003, CANCER DETECT PREV, V27, P132, DOI 10.1016/S0361-090X(03)00031-X; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; HUSSAR DA, 2003, DRUG ADVISOR, V2, P1; Islami F, 2004, BRIT J CANCER, V90, P1402, DOI 10.1038/sj.bjc.6601737; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; Lowenfels AB, 2005, J CELL BIOCHEM, V95, P649, DOI 10.1002/jcb.20461; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Martin ST, 2005, ONCOGENE, V24, P3652, DOI 10.1038/sj.onc.1208411; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; McAllister KA, 2002, CANCER RES, V62, P990; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morimatsu M, 1998, CANCER RES, V58, P3441; Narod SA, 2002, NAT REV CANCER, V2, P113, DOI 10.1038/nrc726; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; POUR P, 1974, CANCER-AM CANCER SOC, V33, P1649, DOI 10.1002/1097-0142(197406)33:6<1649::AID-CNCR2820330627>3.0.CO;2-0; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498; Saidi F, 2000, BRIT J CANCER, V83, P1249, DOI 10.1054/bjoc.2000.1414; SCHOTTENFELD D, 1984, SEMIN ONCOL, V11, P92; Simard J, 2003, ENDOCR-RELAT CANCER, V10, P225, DOI 10.1677/erc.0.0100225; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tian XX, 2005, CANCER RES, V65, P4747, DOI 10.1158/0008-5472.CAN-05-0018; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	46	61	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1290	1296		10.1038/sj.onc.1210739	http://dx.doi.org/10.1038/sj.onc.1210739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724471				2022-12-17	WOS:000253407000011
J	Charette, ST; McCance, DJ				Charette, S. T.; McCance, D. J.			The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner	ONCOGENE			English	Article						Akt; cervical cancer; HPV-16; migration; p27; RhoA	CELL-MIGRATION; EXPRESSION; P27(KIP1); P27; PROGRESSION; ARREST	Cyclin-dependent kinase inhibitor p27(kip1) (p27) has recently been implicated as a positive regulator of cellular motility and is a marker of poor prognosis in several forms of cancer when localized to the cytoplasm. Cytoplasmic p27 exerts its effect on migration by binding to and inhibiting the activation of the small GTPase and cytoskeletal organizer RhoA, consequentially loosening cell substrate grip and enhancing movement. Using DNA damage as a p27 nuclear import signal, we found that the E7 oncoprotein from human papillomavirus type 16 (HPV-16), the etiological agent of cervical cancer, enhanced both the cytoplasmic retention of p27 and the migration of human foreskin keratinocytes (HFKs) in a phosphoinositide-3 kinase (PI3K)/Akt-dependent manner using a standard wound assay. Increased migration in E7-expressing HFKs correlated with an Akt-regulated downregulation of RhoA activity through p27 binding under conditions where a p27 nuclear import signal is given (that is, DNA damage). Under these conditions, inhibition of the downstream RhoA effector ROCK enhanced control cell migration, whereas relatively unaffecting E7-expressing cells, further implicating that the inhibitory effect of E7 on RhoA positively regulates migration. We believe that the E7 protein from HPV-16 can modulate the cytoplasmic localization of p27 and may in turn regulate tumor metastasis/aggressiveness through the PI3K/Akt pathway.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester	McCance, DJ (corresponding author), Queens Univ, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BTQ 7BL, Antrim, North Ireland.	d.mccance@qub.ac.uk			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM068411] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI030798, AI030798] Funding Source: Medline; NIGMS NIH HHS [T32 GM068411, GM068411] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Dellas A, 1998, ANTICANCER RES, V18, P3991; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Fiedler M, 2004, FASEB J, V18, P1120, DOI 10.1096/fj.03-1332fje; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016/j.ygyno.2003.11.035; Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Menges CW, 2006, CANCER RES, V66, P5555, DOI 10.1158/0008-5472.CAN-06-0499; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watanabe J, 2002, BRIT J CANCER, V87, P81, DOI 10.1038/sj.bjc.6600434; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; WU S, 1960, CLIN CANCER RES, V12, P2032	20	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7386	7390		10.1038/sj.onc.1210541	http://dx.doi.org/10.1038/sj.onc.1210541			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533372	Green Accepted			2022-12-17	WOS:000250955700011
J	Salon, C; Merdzhanova, G; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Salon, C.; Merdzhanova, G.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.			E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors	ONCOGENE			English	Article						cyclin E; E2F-1; Skp2; lung tumors	BOX PROTEIN SKP2; CELL; DEGRADATION; OVEREXPRESSION; EXPRESSION; TARGET; CARCINOMA; BINDS; GENE; SCF	The transcription factor E2F-1 plays a crucial role in the control of cellular growth. We previously reported its differential pattern of expression in human lung tumors. In this study, we have investigated the relationships linking the status of E2F-1 and a mediator of its proteasomal degradation, the S-phase kinase-associated protein 2 (Skp2) F-box protein. Using immunohistochemistry in a series of 129 lung tumors of all histological types, we demonstrate that Skp2 accumulates preferentially in high-grade neuroendocrine (HGNE) lung carcinomas (86%, P<0.0001), and show that Skp2 overexpression is associated with advanced stages (P<0.0001) and nodal metastasis (P<0.0001) in neuroendocrine (NE) lung tumors. Unexpectedly, we observe that Skp2 and E2F-1 expression directly correlates in NE lung tumors (P<0.0001). Moreover, using cellular models, we identify Skp2 as a new E2F-1 transcriptional target. Furthermore, we also provide evidence that Skp2 interacts physiologically with E2F-1 and stimulates its transcriptional activity toward the cyclin E promoter. Consistently, we demonstrate that cyclin E expression directly correlates with Skp2 (P<0.0001) and E2F-1 (P = 0.0001) status in NE lung tumors. Overall, our data provide the first evidence of a direct and functional interconnection between the E2F-1, Skp2 and cyclin E oncoproteins in HGNE lung carcinomas.	Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, F-38042 Grenoble 09, France; Univ Grenoble 1, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Eymin, B (corresponding author), Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, BP170, F-38042 Grenoble 09, France.	Beatrice.Eymin@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019; gazzeri, sylvie/M-1961-2013	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Osoegawa A, 2004, J CLIN ONCOL, V22, P4165, DOI 10.1200/JCO.2004.01.035; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Takanami I, 2005, ONCOL REP, V13, P727; TRAVIS WD, 1999, WHO INT HIST CLASSIF; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	31	61	64	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6927	6936		10.1038/sj.onc.1210499	http://dx.doi.org/10.1038/sj.onc.1210499			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17471231	Green Submitted			2022-12-17	WOS:000250188400008
J	Akdemir, F; Christich, A; Sogame, N; Chapo, J; Abrams, JM				Akdemir, F.; Christich, A.; Sogame, N.; Chapo, J.; Abrams, J. M.			p53 directs focused genomic responses in Drosophila	ONCOGENE			English	Article						apoptosis; p53; radiation; Drosophila; cell death	RIBONUCLEOTIDE REDUCTASE GENE; CELL-DEATH; DNA-DAMAGE; CASPASE DRONC; APOPTOSIS; MELANOGASTER; PROTEINS; SMAC/DIABLO; ACTIVATION; PATHWAYS	p53 is a fundamental determinant of cancer susceptibility and other age-related pathologies. Similar to mammalian counterparts, Drosophila p53 integrates stress signals and elicits apoptotic responses that maintain genomic stability. To illuminate core-adaptive functions controlled by this gene family, we examined the Drosophila p53 regulatory network at a genomic scale. In development, the absence of p53 impacted constitutive expression for a surprisingly broad scope of genes. By contrast, stimulus-dependent responses governed by Drosophila p53 were limited in scope. The vast majority of stress responders were induced and p53 dependent (RIPD) genes. The signature set of 29 'high stringency' RIPD genes identified here were enriched for intronless loci, with a non-uniform distribution that includes a recently evolved cluster unique to Drosophila melanogaster. Two RIPD genes, with known and unknown biochemical activities, were functionally examined. One RIPD gene, designated XRP1, maintains genome stability after genotoxic challenge and prevents cell proliferation upon induced expression. A second gene, RnrL, is an apoptogenic effector required for caspase activation in a model of p53-dependent killing. Together, these studies identify ancient and convergent features of the p53 regulatory network.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	John.Abrams@utsouthwestern.edu	akdemir, fatih/AAR-5764-2021	AKDEMIR, FATIH/0000-0003-3023-9453	PHS HHS [R01G-M072124] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Blanchette M, 2004, MOL CELL, V14, P775, DOI 10.1016/j.molcel.2004.06.012; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen P, 2004, CELL DEATH DIFFER, V11, P704, DOI 10.1038/sj.cdd.4401406; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Colombani J, 2006, CURR BIOL, V16, P1453, DOI 10.1016/j.cub.2006.05.059; COURGEON AM, 1972, NATURE-NEW BIOL, V238, P250, DOI 10.1038/newbio238250a0; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordstrom W, 2000, CELL DEATH DIFFER, V7, P1035, DOI 10.1038/sj.cdd.4400766; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Sakharkar MK, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-67; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	30	61	62	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5184	5193		10.1038/sj.onc.1210328	http://dx.doi.org/10.1038/sj.onc.1210328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310982				2022-12-17	WOS:000248674200002
J	Feng, FY; Varambally, S; Tomlins, SA; Chun, PY; Lopez, CA; Li, X; Davis, MA; Chinnaiyan, AM; Lawrence, TS; Nyati, MK				Feng, F. Y.; Varambally, S.; Tomlins, S. A.; Chun, P. Y.; Lopez, C. A.; Li, X.; Davis, M. A.; Chinnaiyan, A. M.; Lawrence, T. S.; Nyati, M. K.			Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity	ONCOGENE			English	Article						gemcitabine; EGFR; head and neck neoplasm	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; PHASE-II; EGF RECEPTOR; RADIATION CONCURRENT; SIGNALING NETWORK; DOWN-REGULATION; KINASE-ACTIVITY; ADVANCED HEAD; TGF-ALPHA	We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. In two human head and neck cancer cell lines, UMSCC-1 and UMSCC-6, we demonstrated an approximately 80% decrease in total EGFR levels at 72 h after a 2-h treatment with 1 mu m gemcitabine. Neither cisplatin nor 5-fluorouracil, which are used to treat head and neck cancer, caused EGFR degradation. EGFR downregulation did not occur at the level of transcription, as assessed by reverse transcription-polymerase chain reaction (RT-PCR), but instead occurred via phosphorylation and ubiquitination of the receptor along a proteosome/lysosome-mediated pathway. Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. These results suggest that EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death. These findings also indicate that caution should be exercised when combining gemcitabine with agents that may prevent EGFR degradation, such as EGFR tyrosine kinase inhibitors administered in a suboptimal sequence or proteosome inhibitors.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nyati, MK (corresponding author), Univ Michigan, Dept Radiat Oncol, Room 3011,1331 E Ann St, Ann Arbor, MI 48109 USA.	nyati@umich.edu		Varambally, Sooryanarayana/0000-0002-2277-1127	NATIONAL CANCER INSTITUTE [P30CA046592, P50CA097248] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA46592, 1 P50 CA97248, P50 CA097248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Ang KK, 2002, CANCER RES, V62, P7350; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Eisbruch A, 2001, J CLIN ONCOL, V19, P792, DOI 10.1200/JCO.2001.19.3.792; Eisbruch A, 2002, INT J RADIAT ONCOL, V53, P23, DOI 10.1016/S0360-3016(02)02712-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; LAWRENCE TS, 1992, CANCER RES, V52, P3698; Lawrence TS, 2001, CLIN CANCER RES, V7, P314; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Macabeo-Ong M, 2002, MODERN PATHOL, V15, P979, DOI 10.1097/01.MP.0000026054.62220.FC; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; MIZUNO H, 2005, MOL CARCINOG; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Nyati MK, 2004, CLIN CANCER RES, V10, P691, DOI 10.1158/1078-0432.CCR-1041-03; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pomerantz RG, 2004, SEMIN ONCOL, V31, P734, DOI 10.1053/j.seminoncol.2004.09.015; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	40	61	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3431	3439		10.1038/sj.onc.1210129	http://dx.doi.org/10.1038/sj.onc.1210129			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146438				2022-12-17	WOS:000246579600013
J	Uht, RM; Amos, S; Martin, PM; Riggan, AE; Hussaini, IM				Uht, R. M.; Amos, S.; Martin, P. M.; Riggan, A. E.; Hussaini, I. M.			The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway	ONCOGENE			English	Article						PKC-eta; AP-1; ERK; Elk-1; glioblastoma; proliferation	SIGNAL-TRANSDUCTION; HUMAN GLIOMA; TRANSCRIPTION FACTORS; IN-VITRO; RECEPTOR TRANSACTIVATION; MALIGNANT GLIOMAS; GROWTH; AP-1; INHIBITION; EXPRESSION	Glioblastoma multiforme (GBM) is the highest grade of astrocytoma. GBM pathogenesis has been linked to receptor tyrosine kinases and kinases further down signal-transduction pathways - in particular, members of the protein kinase C (PKC) family. The expression and activity of various PKC isoforms are increased in malignant astrocytomas, but not in non-neoplastic astrocytes. This suggests that PKC activity contributes to tumor progression. The level of PKC-eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferation of two glioblastoma cell lines, U-1242 MG and U-251 MG. Normally, U-1242 cells do not express PKC-eta, and PMA inhibits their proliferation. Conversely, PMA increases proliferation of U-1242 cells that are stably transfected with PKC-eta (U-1242-PKC-eta). PMA treatment also stimulates proliferation of U-251 cells, which express PKC-eta. Here, we determined that extracellular signal-regulated kinase (ERK) and Elk-1 are downstream targets of PKC-eta. Elk-1-mediated transcriptional activity correlates with the PKC-eta-mediated mitogenic response. Pretreatment of U-1242-PKC-eta cells with inhibitors of PKC or MAPK/ERK kinase (MEK) (bisindolyl maleimide (BIM) or U0126, respectively) blocked both PMA-induced Elk-1 transcriptional activity and PMA-stimulated proliferation. An overexpressed dominant-negative PKC-eta reduced the mitogenic response in U-251 cells, as did reduction of Elk-1 by small interfering RNA. Taken together, these results strongly suggest that PKC-eta-mediated glioblastoma proliferation involves MEK/mitogen-activated protein (MAP) kinase phosphorylation, activation of ERK and subsequently of Elk-1. Elk-1 target genes involved in GBM proliferative responses have yet to be identified.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Uht, RM (corresponding author), Univ Virginia, Sch Med, Dept Pathol, MR 5,Rm 3123,415 Lane Rd, Charlottesville, VA 22908 USA.	ruht@virginia.edu		Amos, Samson/0000-0003-2780-2276	NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035122] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NINDS NIH HHS [R01 NS35122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; BALTUCH GH, 1995, CAN J NEUROL SCI, V22, P264, DOI 10.1017/S0317167100039457; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; Dooley NP, 1998, NEUROREPORT, V9, P1727, DOI 10.1097/00001756-199806010-00011; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eller JL, 2005, NEUROSURGERY, V56, P155, DOI 10.1227/01.NEU.0000145865.25689.55; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Houillier C, 2006, CANCER-AM CANCER SOC, V106, P2218, DOI 10.1002/cncr.21819; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Hussaini IM, 1999, GLIA, V25, P71, DOI 10.1002/(SICI)1098-1136(19990101)25:1<71::AID-GLIA7>3.0.CO;2-0; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KLEIHEUS P, 1997, PATHOLOGY GENETICS T; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mischel PS, 2003, BRAIN PATHOL, V13, P52; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sharif TR, 1999, INT J ONCOL, V14, P327; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; *US CANC STAT WORK, 2005, US DEP HHS, P50; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zellner A, 1998, CLIN CANCER RES, V4, P1797	40	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2885	2893		10.1038/sj.onc.1210090	http://dx.doi.org/10.1038/sj.onc.1210090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146445				2022-12-17	WOS:000246210800008
J	Choi, YL; Tsukasaki, K; O'Neill, MC; Yamada, Y; Onimaru, Y; Matsumoto, K; Ohashi, J; Yamashita, Y; Tsutsumi, S; Kaneda, R; Takada, S; Aburatani, H; Kamihira, S; Nakamura, T; Tomonaga, M; Mano, H				Choi, Y. L.; Tsukasaki, K.; O'Neill, M. C.; Yamada, Y.; Onimaru, Y.; Matsumoto, K.; Ohashi, J.; Yamashita, Y.; Tsutsumi, S.; Kaneda, R.; Takada, S.; Aburatani, H.; Kamihira, S.; Nakamura, T.; Tomonaga, M.; Mano, H.			A genomic analysis of adult T-cell leukemia	ONCOGENE			English	Article						adult T-cell leukemia; DNA microarray; MET; artificial neural network	HEPATOCYTE GROWTH-FACTOR; VIRUS TYPE-I; C-MET PROTOONCOGENE; GENE-EXPRESSION; HOMOZYGOUS DELETIONS; HTLV-I; LYMPHOMA; IDENTIFICATION; LEUKEMIA/LYMPHOMA; FEATURES	Adult T-cell leukemia (ATL) is an intractable malignancy of CD4(+) T cells that is etiologically associated with infection by human T-cell leukemia virus-type I. Most individuals in the chronic stage of ATL eventually undergo progression to a highly aggressive acute stage. To clarify the mechanism responsible for this stage progression, we isolated CD4(+) cells from individuals in the chronic ( n =19) or acute ( n = 22) stages of ATL and subjected them to pro. ling of gene expression with DNA micro-arrays containing > 44 000 probe sets. Changes in chromosome copy number were also examined for 24 cell specimens with the use of microarrays harboring similar to 50 000 probe sets. Stage-dependent changes in gene expression pro. le and chromosome copy number were apparent. Furthermore, expression of the gene for MET, a receptor tyrosine kinase for hepatocyte growth factor (HGF), was shown to be specific to the acute stage of ATL, and the plasma concentration of HGF was increased in individuals in either the acute or chronic stage. HGF induced proliferation of a MET-positive ATL cell line, and this effect was blocked by antibodies to HGF. The HGF-MET signaling pathway is thus a potential therapeutic target for ATL.	Jichi Med Univ, Div Funct Genom, Shimotsukeshi, Tochigi 3290498, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Nagasaki 852, Japan; Univ Maryland, Dept Biol Sci, Baltimore, MD 21201 USA; Nagasaki Univ, Dept Lab Med, Grad Sch Biomed Sci, Nagasaki 852, Japan; Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Osaka, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo, Japan; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan	Jichi Medical University; Nagasaki University; University System of Maryland; University of Maryland Baltimore; Nagasaki University; Osaka University; University of Tokyo; University of Tokyo	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Matsumoto, Kunio/D-8441-2015; OHASHI, JUN/G-5907-2015	Matsumoto, Kunio/0000-0002-6532-4482; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; CESARMAN E, 1992, BLOOD, V80, P3205; Choi YL, 2004, LEUKEMIA, V18, P556, DOI 10.1038/sj.leu.2403261; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lockett A, 2005, J MANAGE INQUIRY, V14, P139, DOI 10.1177/1056492605276645; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOTOKURA T, 1988, BIOCHEM BIOPH RES CO, V154, P1182, DOI 10.1016/0006-291X(88)90265-3; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nosaka K, 2000, CANCER RES, V60, P1043; O'Neill MC, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-13; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Tamiya S, 1998, BLOOD, V91, P3935; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Tsukasaki K, 2004, INT J CANCER, V109, P875, DOI 10.1002/ijc.20028; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	38	61	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1245	1255		10.1038/sj.onc.1209898	http://dx.doi.org/10.1038/sj.onc.1209898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909099				2022-12-17	WOS:000244406400015
J	Camilleri-Broet, S; Cremer, I; Marmey, B; Comperat, E; Viguie, F; Audouin, J; Rio, MC; Fridman, WH; Sautes-Fridman, C; Regnier, CH				Camilleri-Broet, S.; Cremer, I.; Marmey, B.; Comperat, E.; Viguie, F.; Audouin, J.; Rio, M-C; Fridman, W-H; Sautes-Fridman, C.; Regnier, C. H.			TRAF4 overexpression is a common characteristic of human carcinomas	ONCOGENE			English	Article						TRAF4; chromosome 17q11; ERBB2; amplification; lung	HUMAN BREAST-TUMORS; GENE-EXPRESSION; CDNA MICROARRAYS; COPY NUMBER; CANCER; ACTIVATION; RECEPTOR; FAMILY; IDENTIFICATION; CHROMOSOME-17	Tumor necrosis factor receptor (TNFR) associated factor 4 (TRAF4) was initially identified as a gene amplified and overexpressed in breast carcinomas. Our aim was to evaluate whether TRAF4 protein overexpression exists in other cancer types. Immunohistochemistry analysis of tumor samples from 623 patients with 20 different tumor types showed that TRAF4 was overexpressed in 268 tumors (43%), including 82 of 137 lung adenocarcinomas (60%). Interestingly, 32 primary tumors and their matching metastases exhibited mostly similar TRAF4 expression pattern. TRAF4 protein overexpression was limited to cancer cells and the subcellular localization was consistently cytoplasmic in a large majority of cases. To investigate changes in TRAF4 gene copy number, 125 cases from six different types of carcinomas were also analysed by fluorescence in situ hybridization. Out of the 28 cases (22%) showing an increased TRAF4 gene copy number, 23 (82%) were overexpressing the protein. Thus, TRAF4 gene amplification is one of the mechanisms responsible for TRAF4 protein overexpression in human cancers. Considering that TRAF4 is located at 17q11.2 in a region of amplification devoid of known oncogenes and is commonly overexpressed in cancer, our data support an oncogenic role for TRAF4.	Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, F-75006 Paris, France; Univ Paris Descartes, Fac Med, AP HP Hotel Dieu, Paris, France; Univ Paris 06, Fac Med, AP HA La Pitie Salpetriere, Paris, France; Univ Strasbourg 1, INSERM, U596,Dept Pathol Mol,IGBMC, CNRS,UPR 6520, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Regnier, CH (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	catherine.regnier@u255.bhdc.jussieu.fr	Cremer, Isabelle/D-4278-2017	Cremer, Isabelle/0000-0002-0963-1031; fridman, wolf herman/0000-0002-1332-0973; sautes-fridman, catherine/0000-0003-1735-8722; Regnier, Catherine/0000-0002-4386-1324				Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bieche I, 1996, CANCER RES, V56, P3886; Bowers AJ, 2004, GENE, V328, P135, DOI 10.1016/j.gene.2003.12.002; Chung JY, 2002, J CELL SCI, V115, P679; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Glauner H, 2002, EUR J BIOCHEM, V269, P4819, DOI 10.1046/j.1432-1033.2002.03180.x; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Krajewska M, 1998, AM J PATHOL, V152, P1549; Li JM, 2005, MOL CELL BIOL, V25, P2320, DOI 10.1128/MCB.25.6.2320-2330.2005; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takeshita F, 2005, EUR J IMMUNOL, V35, P2477, DOI 10.1002/eji.200526151; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	29	61	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					142	147		10.1038/sj.onc.1209762	http://dx.doi.org/10.1038/sj.onc.1209762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799635				2022-12-17	WOS:000243236500014
J	Ameri, K; Hammond, EM; Culmsee, C; Raida, M; Katschinski, DM; Wenger, RH; Wagner, E; Davis, RJ; Hai, T; Denko, N; Harris, AL				Ameri, K.; Hammond, E. M.; Culmsee, C.; Raida, M.; Katschinski, D. M.; Wenger, R. H.; Wagner, E.; Davis, R. J.; Hai, T.; Denko, N.; Harris, A. L.			Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway	ONCOGENE			English	Article						ATF3; hypoxia; anoxia; HIF; p53; MKK7/JNK	VASCULAR ENDOTHELIAL-CELLS; JUN NH2-TERMINAL KINASE; GENE-EXPRESSION; ATF3 GENE; C-JUN; INDUCIBLE FACTOR-1; STRESS RESPONSES; OVER-EXPRESSION; MESSENGER-RNA; BINDING	Solid tumors often have an inadequate blood supply, which results in large regions that are subjected to hypoxic or anoxic stress. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates much of the transcriptional response of cells to hypoxia. Activating transcription factor 3 (ATF3) is another transcription factor that responds to a variety of stresses and is often upregulated in cancer. We investigated the regulation of ATF3 by oxygen deprivation. ATF3 induction occurred most robustly under anoxia, is common, and it is not dependent on presence of HIF-1 or p53, but is sensitive to the inhibition of c-Jun NH2-terminal kinase activation and the antioxidant N-acetylcystein. ATF3 could also be induced by desferrioxamine but not by the mitochondrial poison cyanide or the nonspecific 2-oxoglutarate dioxygenase inhibitor dimethyloxalylglycine. We also show that anoxic ATF3 mRNA is more stable than normoxic mRNA providing a mechanism for this induction. Thus, this study demonstrates that the regulation of ATF3 under anoxia is independent of 2-oxoglutarate dioxygenase, HIF-1 and p53, presumably involving multiple regulatory pathways.	Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; Ctr Drug Res, Dept Pharm, Munich, Germany; Univ Leipzig, Dept Hematol Oncol, D-7010 Leipzig, Germany; Univ Gottingen, Ctr Physiol & Pathophysiol, Dept Heart & Circulatory Physiol, D-3400 Gottingen, Germany; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DU, England	Stanford University; University of Munich; Leipzig University; University of Gottingen; University of Zurich; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University System of Ohio; Ohio State University; Cancer Research UK; University of Oxford	Ameri, K (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, CCSR-S,269 Campus Dr, Stanford, CA 94305 USA.	kameri@stanford.edu	Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Culmsee, Carsten/ABC-3120-2021; Hai, Tsonwin/H-4480-2011; Harris, Adrian L/ABA-3343-2020; Hai, Tsonwin/E-3185-2011; Wenger, Roland H./B-7953-2009; denko, nicholas/F-8444-2010	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015; Hai, Tsonwin/0000-0003-4510-0315; Harris, Adrian L/0000-0003-1376-8409; Hai, Tsonwin/0000-0003-4510-0315; Wenger, Roland H./0000-0001-7592-4839; Davis, Roger/0000-0002-0130-1652; Hammond, Ester/0000-0002-2335-3146	NIDDK NIH HHS [DK59605] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bottone FG, 2005, J PHARMACOL EXP THER, V315, P668, DOI 10.1124/jpet.105.089607; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chilov D, 1999, J CELL SCI, V112, P1203; Culmsee C, 2003, J NEUROSCI, V23, P8586; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Inoue K, 2004, GENES CELLS, V9, P59, DOI 10.1111/j.1356-9597.2004.00707.x; Ishiguro T, 2000, ONCOL RES, V12, P181; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Ryan HE, 2000, CANCER RES, V60, P4010; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Vengellur A, 2005, PHYSIOL GENOMICS, V22, P308, DOI 10.1152/physiolgenomics.00045.2004; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	41	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					284	289		10.1038/sj.onc.1209781	http://dx.doi.org/10.1038/sj.onc.1209781			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847457	Green Accepted			2022-12-17	WOS:000243398300012
J	Komiya, T; Park, Y; Modi, S; Coxon, AB; Oh, H; Kaye, FJ				Komiya, T.; Park, Y.; Modi, S.; Coxon, A. B.; Oh, H.; Kaye, F. J.			Sustained expression of Mect1-Mam12 is essential for tumor cell growth in salivary gland cancers carrying the t(11 ; 19) translocation	ONCOGENE			English	Article						mucoepidermoid cancer; salivary gland cancer; chromosomal translocation; RNAi	MUCOEPIDERMOID CARCINOMA; GENE FUSION; IDENTIFICATION; FAMILY; COACTIVATORS; ACTIVATION; BENIGN	Mucoepidermoid (MEC) salivary gland tumors arise from a t(11; 19) rearrangement which generates a fusion oncogene, Mect1-Maml2, that functions to activate CREB-responsive target genes. To determine if sustained expression of Mect1-Maml2 is required for tumor cell growth, we first showed that ectopic expression of Mect1-Maml2 in rat epithelial RK3E cells is tumorigenic in vivo in nude mice and that excised xenografts continue to express the fusion oncogene. We then generated a hairpin RNAi vector that selectively suppressed the fusion peptide and showed that ectopic expression in either parotid or pulmonary MEC tumor cell lines containing the t(11; 19) rearrangement resulted in at least 90% colony growth inhibition. In contrast, single nucleotide changes within this RNAi sequence abolished the ability to suppress Mect1-Maml2 protein and abolished all growth inhibition of these MEC tumor lines. In addition, the RNAi-specific vector had no effect on colony growth of non-MEC tumors including a lung tumor or two other salivary gland cell lines that do not express Mect1-Maml2. We also generated a mutant Mect1-Maml2 expression plasmid that carried silent nucleotide changes within the RNAi target sequence and observed that co-transfection of this mutant, but not wild-type Mect1-Maml2, could partially rescue RNAi growth inhibition in the MEC tumor line. The recent detection of acquired fusion oncogenes in epithelial solid tumors has suggested new possibilities for the diagnosis and therapy of these cancers. Our data show that the 'gain-of-function' activity from aberrant Mect1-Maml2 expression is a candidate therapeutic target for this group of malignant salivary gland tumors.	NCI, Canc Res Ctr, Genat Branch, Bethesda, MD 20892 USA; Natl Naval Med Ctr, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center	Kaye, FJ (corresponding author), Bldg 8,Rm 5101, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007256, Z01SC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Cho-Chung YS, 2003, ANN NY ACAD SCI, V1002, P124, DOI 10.1196/annals.1281.011; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; ElNaggar AK, 1996, CANCER GENET CYTOGEN, V87, P29, DOI 10.1016/0165-4608(95)00266-9; Enlund F, 2004, EUR J ORAL SCI, V112, P545, DOI 10.1111/j.1600-0722.2004.00174.x; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Roberts Thomas G Jr, 2003, Clin Adv Hematol Oncol, V1, P486; Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x; Stenman G, 1998, VIRCHOWS ARCH, V433, P579, DOI 10.1007/s004280050293; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719	20	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6128	6132		10.1038/sj.onc.1209627	http://dx.doi.org/10.1038/sj.onc.1209627			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652146				2022-12-17	WOS:000241101200010
J	Galderisi, U; Cipollaro, M; Giordano, A				Galderisi, U.; Cipollaro, M.; Giordano, A.			The retinoblastoma gene is involved in multiple aspects of stem cell biology	ONCOGENE			English	Review						self-renewal; cell cycle; senescence; apoptosis differentiation	TARGETED DISRUPTION; CYCLE REGULATION; G(1) CONTROL; RB; PROTEIN; PRB; DIFFERENTIATION; FAMILY; P107; PHOSPHORYLATION	Genetic programs controlling self-renewal and multipotentiality of stem cells have overlapping pathways with cell cycle regulation. Components of cell cycle machinery can play a key role in regulating stem cell self-renewal, proliferation, differentiation and aging. Among the negative regulators of cell cycle progression, the RB family members play a prominent role in controlling several aspects of stem cell biology. Stem cells contribute to tissue homeostasis and must have molecular mechanisms that prevent senescence and hold 'stemness'. RB can induce senescence-associated changes in gene expression and its activity is downregulated in stem cells to preserve self-renewal. Several reports evidenced that RB could play a role in lineage specification of several types of stem cells. RB has a role in myogenesis as well as in cardiogenesis. These effects are not only related to its role in suppressing E2F-responsive genes but also to its ability to modulate the activity of tissue-specific transcription factors. RB is also involved in adipogenesis through a strict control of lineage commitment and differentiation of adipocytes as well in determining the switch between brown and white adipocytes. Also, hematopoietic progenitor cells utilize the RB pathway to modulate cell commitment and differentiation. In this review, we will also discuss the role of the other two RB family members: Rb2/p130 and p107 showing that they have both specific and overlapping functions with RB gene.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Naples 2, Excellence Res Ctr Cardiovasc Dis, Sect Biotechnol & Mol Biol, Dept Expt Med, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli	Galderisi, U (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA.	umberto.galderisi@unina2.it	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cipollaro, Marilena/0000-0003-4350-4324; GALDERISI, Umberto/0000-0003-0909-7403				Bergh G, 1999, BLOOD, V94, P1971; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cole KA, 2004, AM J PHYSIOL-CELL PH, V286, pC349, DOI 10.1152/ajpcell.00255.2003; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Galderisi U, 2006, CELL DEATH DIFFER, V13, P5, DOI 10.1038/sj.cdd.4401757; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jori FP, 2004, J CELL PHYSIOL, V200, P201, DOI 10.1002/jcp.20026; JORI FP, 2006, IN PRESS; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Papadimou E, 2005, EMBO J, V24, P1750, DOI 10.1038/sj.emboj.7600652; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Rosen ED, 2000, GENE DEV, V14, P1293; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seigel GM, 2005, MOL VIS, V11, P729; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SPARKS RL, 1986, CANCER RES, V46, P5312; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Stiegler P, 1998, J CELL BIOCHEM, P30; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; WANG H, 1993, CELL PROLIFERAT, V26, P55, DOI 10.1111/j.1365-2184.1993.tb00006.x; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; Zheng L, 2002, CANCER RES, V62, P2498; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	52	61	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5250	5256		10.1038/sj.onc.1209736	http://dx.doi.org/10.1038/sj.onc.1209736			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936744				2022-12-17	WOS:000240064100009
J	Moniaux, N; Nemos, C; Schmied, BM; Chauhan, SC; Deb, S; Morikane, K; Choudhury, A; VanLith, M; Sutherlin, M; Sikela, JM; Hollingsworth, MA; Batra, SK				Moniaux, N.; Nemos, C.; Schmied, B. M.; Chauhan, S. C.; Deb, S.; Morikane, K.; Choudhury, A.; VanLith, M.; Sutherlin, M.; Sikela, J. M.; Hollingsworth, M. A.; Batra, S. K.			The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis	ONCOGENE			English	Article						hPaf1; hPAF1 complex; amplicon; pancreatic cancer	COMPARATIVE GENOMIC HYBRIDIZATION; CELL-CYCLE REGULATION; PROTEIN-KINASE; AKT2 ONCOGENE; BREAST-CANCER; PANCREATIC ADENOCARCINOMA; MOLECULAR-CLONING; PAF1 COMPLEX; DNA GAINS; EXPRESSION	The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis. PD2 is the human homologue of the RNA polymerase II-associated factor 1 (hPaf1). In yeast, Paf1 is part of the transcription machinery, acting as a docking protein in between the complexes Rad6-Bre1, COMPASS-Dot1p, and the phosphorylated carboxyl terminal domain of the RNA polymerase II. As such, Paf1 is directly involved in transcription elongation via histone H2B ubiquitination and histone H3 methylation. The PD2 sequence is highly conserved from Drosophila to humans with up to 98% identity between rodent and human, suggesting the functional importance of PD2/hPaf1 to maintain cellular homeostasis. PD2 is a modular protein composed of RNA recognition motif, DEAD-boxes, an aspartic/serine (DS)-domain, a regulator of the chromosome condensation domain and myc-type helix-loop-helix domains. Our results further showed that PD2 is a nuclear 80kDa protein, which interacts with RNA polymerase II. In addition, we have demonstrated that the overexpression of PD2 in the NIH 3T3 cells result in enhanced growth rates in vitro and tumor formation in vivo. Altogether, this paper presents strong evidence that the overexpression of PD2/hPaf1 is involved in cancer development.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Schmied, Bruno/0000-0003-4552-7386; Morikane, Keita/0000-0002-4215-7829	NATIONAL CANCER INSTITUTE [R01CA078590, P50CA072712] Funding Source: NIH RePORTER; NCI NIH HHS [CA78590, CA72712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Arboleda MJ, 2003, CANCER RES, V63, P196; BATRA SK, 1991, CELL GROWTH DIFFER, V2, P385; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Bauer B, 2002, MOL IMMUNOL, V38, P1087, DOI 10.1016/S0161-5890(02)00011-1; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grande MA, 1997, J CELL SCI, V110, P1781; GRIFFIN CA, 1994, GENE CHROMOSOME CANC, V9, P93, DOI 10.1002/gcc.2870090204; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; LAN MS, 1990, J BIOL CHEM, V265, P15294; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIED T, 1994, CANCER RES, V54, P1801; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Werner CA, 1997, AM J PATHOL, V151, P335; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274	43	61	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3247	3257		10.1038/sj.onc.1209353	http://dx.doi.org/10.1038/sj.onc.1209353			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16491129				2022-12-17	WOS:000237951200003
J	Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP				Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP			BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						FOXA1; BRCA1; cell cycle regulation	TRANSCRIPTION FACTOR HNF3; GENE-EXPRESSION; FORK-HEAD; BREAST-CANCER; MAMMARY-GLAND; MOUSE EMBRYO; IN-VIVO; BINDING; HELIX; DNA	We have previously shown that the breast cancer susceptibility gene, BRCA1, can transcriptionally activate the p27(Kip1) promoter. The BRCA1-responsive element was defined as a 35 bp region from position -545 to -511. We next determined that within this region is also a potential binding site for the transcription factor Forkhead box (FOX)A1. RNA and protein analysis as well as immunohistochemistry showed that expression of FOXA1 correlated with the expression of the estrogen receptor in a panel of breast cancer cell lines and tissues. In transient transfection reporter assays, FOXA1 could activate the p27(Kip1) promoter. Cotransfection of BRCA1 and FOXA1 resulted in a synergistic activation of the p27(Kip1) promoter. Mutation of the FOXA1 DNA-binding site in the p27(Kip1) promoter-luciferase construct significantly diminished the activity of FOXA1 alone or in combination with BRCA1. Cotransfection of FOXA1 and BRCA1 resulted in a greater amount of each protein compared to transfection of each expression vector alone. The half-life of FOXA1 was increased when coexpressed with BRCA1. Electrophoretic mobility shift assay analysis demonstrated that FOXA1 could bind to a wild-type oligonucleotide containing the FOXA1 binding site in the p27(Kip1) promoter, but this binding was lost upon mutation of this FOXA1 binding site. The protein-DNA binding complex could be supershifted with an antibody directed against FOXA1. The activity of the p27(Kip1) promoter as well as FOXA1 expression was reduced in cells treated with BRCA1 siRNA, thus silencing the expression of BRCA1 protein. In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27(Kip1) promoter and showed that FOXA1 activated the promoter alone and in conjunction with BRCA1. Furthermore, we identified high expression of FOXA1 in breast cancer cell lines and tissues, discovered a role for BRCA1 in the regulation of p27(Kip1) transcription and a possible interaction with BRCA1.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med Hematol Oncol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Williamson, EA (corresponding author), Univ New Mexico, Canc Res Facil, 1UNM MSCO8 4630,Room 117, Albuquerque, NM 87131 USA.	ewilliamson@salud.unm.edu						Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; COSTA RH, 2001, CELL MOL PHYSL, V280, pL823; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Masciullo V, 1999, CANCER RES, V59, P3790; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Robyr D, 2000, J BIOL CHEM, V275, P28291; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	42	61	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2006	25	9					1391	1399		10.1038/sj.onc.1209170	http://dx.doi.org/10.1038/sj.onc.1209170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331276				2022-12-17	WOS:000235708200012
J	Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM				Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM			Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis	ONCOGENE			English	Article						selenium; TRAIL; apoptosis; prostate; cancer	NF-KAPPA-B; DEATH RECEPTOR; BAD PHOSPHORYLATION; SIGNALING COMPLEX; TNF RECEPTOR; LIGAND TRAIL; LINE LNCAP; VITAMIN-E; IN-VIVO; C-FLIP	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Unfortunately, some tumor cells remain resistant to TRAIL. Therefore, agents that sensitize malignant cells to TRAIL-mediated cell death might be of particular importance for the development of novel antitumor therapeutic regimens. Recent studies establish a critical role of selenium in prostate cancer prevention in vitro and in vivo. Here, we demonstrate that concomitant administration of TRAIL and methylseleninic acid (MSA) produces synergistic effects on the induction of apoptosis in androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells. MSA rapidly and specifically downregulates expression of the cellular FLICE inhibitory protein, a negative regulator of death receptor signaling. In addition, we demonstrate that the synergistic effects of MSA and TRAIL result from the activation of the mitochondrial pathway-mediated amplification loop. Addition of MSA effectively blocked TRAIL-mediated BAD phosphorylation at Ser112 and Ser136 in DU-145 cells and was accompanied by induction of the mitochondrial permeability transition and release of apoptogenic cytochrome c and Smac/DIABLO proteins from the mitochondria and into the cytosol. These results suggest that selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prostate cancer cells.	Fox Chase Canc Ctr, Dept Urol Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kolenko, VM (corresponding author), Fox Chase Canc Ctr, Dept Urol Oncol, 333 Cottman Ave,W329, Philadelphia, PA 19111 USA.	vm_kolenko@fccc.edu	Crispen, Paul/AGE-5677-2022; Uzzo, Robert G./U-5238-2019					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CHINNAIYAN AM, 1995, CELL, V81, P512; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Deeb D, 2004, MOL CANCER THER, V3, P803; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Dong Y, 2003, CANCER RES, V63, P52; Dong Y, 2002, CANCER RES, V62, P708; Dramsi S, 2002, J BIOL CHEM, V277, P6399, DOI 10.1074/jbc.M109990200; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gupta S, 2003, INT J ONCOL, V22, P15; He Q, 2002, CANCER BIOL THER, V1, P287, DOI 10.4161/cbt.83; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; IP C, 1991, CANCER RES, V51, P595; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang C, 2001, CANCER RES, V61, P3062; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim T, 2001, CARCINOGENESIS, V22, P559, DOI 10.1093/carcin/22.4.559; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Klein EA, 2003, UROL ONCOL-SEMIN ORI, V21, P59, DOI 10.1016/S1078-1439(02)00301-0; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Taghiyev AF, 2003, MOL CANCER RES, V1, P500; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Venkateswaran V, 2002, CANCER RES, V62, P2540; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wu GS, 1999, CANCER RES, V59, P2770; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003; Zu K, 2003, CANCER RES, V63, P6988	57	61	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5868	5877		10.1038/sj.onc.1208742	http://dx.doi.org/10.1038/sj.onc.1208742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897871				2022-12-17	WOS:000231590400009
J	Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV				Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV			Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta	ONCOGENE			English	Article						metastasis; TGF-beta; tropomyosin; Smad; DNA methylation	GROWTH-FACTOR-BETA; RAS-TRANSFORMED FIBROBLASTS; ACTIVATED PROTEIN-KINASE; ALPHA 2(I) COLLAGEN; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; MESENCHYMAL TRANSDIFFERENTIATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; CANCER-CELLS	Loss of actin stress fibers has been associated with cell transformation and metastasis. TGF-beta induction of stress fibers in epithelial cells requires high molecular weight tropomyosins encoded by TPM1 and TPM2 genes. Here, we investigated the mechanism underlying the failure of TGF-beta to induce stress fibers and inhibit cell migration in metastatic cells. RT-PCR analysis in carcinoma cell lines revealed a significant reduction in TPM1 transcripts in metastatic MDA-MB-231, MDA-MB-435 and SW620 cell lines. Treatment of these cells with demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) increased mRNA levels of TPM1 with no effect on TPM2. Importantly, 5-aza-dC treatment of MDA-MB-231 cells restored TGF-beta induction of TPM1 and formation of stress fibers. Forced expression of TPM1 by using Tet- Off system increased stress fibers in MDA-MB-231 cells and reduced cell migration. A potential CpG island spanning the TPM1 proximal promoter, exon 1, and the beginning of intron 1 was identified. Bisulfite sequencing showed significant cytosine methylation in metastatic cell lines that correlated with a reduced expression of TPM1. Together these results suggest that epigenetic suppression of TPM1 may alter TGF-beta tumor suppressor function and contribute to metastatic properties of tumor cells.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org	Quan, Lei/GXN-1280-2022	Bakin, Andrei/0000-0002-7728-1969; Quan, Lei/0000-0002-6572-0530	NCI NIH HHS [R01 CA95263] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakin AV, 2002, J CELL SCI, V115, P3193; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAGOS S, 1995, ANTICANCER RES, V15, P369; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249; Masuda A, 1996, ONCOGENE, V12, P2081; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Park IK, 2000, BBA-GENE STRUCT EXPR, V1490, P302, DOI 10.1016/S0167-4781(99)00246-8; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Piek E, 1999, J CELL SCI, V112, P4557; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Robbins J, 1998, CIRC RES, V82, P134; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Saito H, 2000, ANTICANCER RES, V20, P4489; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Temm-Grove CJ, 1998, CELL MOTIL CYTOSKEL, V40, P393, DOI 10.1002/(SICI)1097-0169(1998)40:4<393::AID-CM7>3.0.CO;2-C; Varga AE, 2004, NEOPLASIA, V6, P128, DOI 10.1593/neo.03337; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang FL, 1996, CANCER RES, V56, P3634; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	53	61	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5043	5052		10.1038/sj.onc.1208688	http://dx.doi.org/10.1038/sj.onc.1208688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897890				2022-12-17	WOS:000230816900004
J	Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X				Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X			Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis	ONCOGENE			English	Article						apoptosis; c-IAP2; upregulation; human papillomavirus; oral keratinocyte	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CELLULAR INHIBITOR; CANCER-CELLS; PROTEIN; DEGRADATION; ACTIVATION; IAPS; DIFFERENTIATION; KERATINOCYTES	Inhibition of apoptosis plays an important role in the cellular immortalization and transformation induced by E6 and E7 oncoproteins of human papillomavirus (HPV). Here, we report that the transcription of the inhibitor of apoptosis gene, cellular inhibitor of apoptosis protein 2, (c-IAP2), is significantly upregulated in HPV16 E6/ E7-immortalized human oral keratinocytes (HOK16E6E7). Overexpression of E6/ E7 from the high-risk HPV16 or 18, but not from the low-risk HPV6, activated c-IAP2 promoter. E6 from HPV16 and 18 played a major role in the activation. In addition, the induction of c- IAP2 transcription required nuclear factor-kappa B activity. Overexpression of c- IAP2 in normal human oral keratinocyte conferred resistance to tumor necrosis factor-alpha ( TNF-alpha)/ cycloheximide (CHX)- induced apoptosis, suggesting the increased c- IAP2 expression in HOK16E6E7 may protect the cells from TNF-alpha- mediated cell death. Moreover, depletion of endogenous c- IAP2 using RNA interference in HOK16E6E7 induced apoptosis, indicating that c- IAP2 is necessary for HPV16 E6/E7-induced resistance to apoptosis and cell survival. Of note, high levels of c- IAP2 transcription were found in several HPV16- or HPV18-positive cancer cells, and depletion of c- IAP2 caused cell death in HPV18- positive HeLa cells. Thus, upregulation of c- IAP2 by E6 and E7 may confer resistance to apoptosis that is necessary for sustained growth of some HPV16- and HPV18- positive cancer cells.	Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90059 USA; Charles R Drew Univ Med & Sci, Dept Otolaryngol, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, AIDS Inst, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Charles R. Drew University of Medicine & Science; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Liu, X (corresponding author), Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, 1621 E 120th St, Los Angeles, CA 90059 USA.	xuliu@cdrewu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K23DE000430] Funding Source: NIH RePORTER; NCRR NIH HHS [G12-RR03026-15] Funding Source: Medline; NIDCR NIH HHS [K23 DE00430] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		An DS, 2003, HUM GENE THER, V14, P1207, DOI 10.1089/104303403322168037; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duffy CL, 2003, VIROLOGY, V314, P196, DOI 10.1016/S0042-6822(03)00390-8; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Havard L, 2002, VIROLOGY, V298, P271, DOI 10.1006/viro.2002.1468; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hui EKW, 2004, J GEN VIROL, V85, P1877, DOI 10.1099/vir.0.79906-0; Jewett A, 2003, HUM IMMUNOL, V64, P505, DOI 10.1016/S0198-8859(03)00039-9; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Min BM, 1999, EXP CELL RES, V249, P377, DOI 10.1006/excr.1999.4489; Mota F, 1999, CLIN EXP IMMUNOL, V116, P33; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; NISHITANI J, 2002, CELL MOL BIOL, V48, P331; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200; Yuan HD, 2003, J VIROL, V77, P2063, DOI 10.1128/JVI.77.3.2063-2070.2003; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9	50	61	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5069	5078		10.1038/sj.onc.1208691	http://dx.doi.org/10.1038/sj.onc.1208691			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856013				2022-12-17	WOS:000230816900006
J	Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M				Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M			Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer	ONCOGENE			English	Article						K3326X; BRCA2; familial pancreatic cancer	GERMLINE MUTATIONS; GENE-MUTATIONS; RISK	Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%)(odds ratio, 4.84; 95% CI, 1.27-18.55, P<0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A>G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR:4.24, P<0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer -7/250 (OR:2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu						Bartsch DK, 2002, ANN SURG, V236, P730, DOI 10.1097/00000658-200212000-00005; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Claes K, 2003, GENE CHROMOSOME CANC, V37, P314, DOI 10.1002/gcc.10221; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Figer A, 2001, BRIT J CANCER, V84, P478, DOI 10.1054/bjoc.2000.1605; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Goggins M, 1996, CANCER RES, V56, P5360; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Haraldsson K, 1998, CANCER RES, V58, P1367; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Klein AP, 2001, CANCER J, V7, P266; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Lynch HT, 2000, GASTROENTEROLOGY, V119, P1756, DOI 10.1053/gast.2000.20335; Matsubayashi H, 2003, CANCER BIOL THER, V2, P652; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Morimatsu M, 1998, CANCER RES, V58, P3441; Murphy KM, 2002, CANCER RES, V62, P3789; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; Ozcelik H, 1997, NAT GENET, V16, P17, DOI 10.1038/ng0597-17; Petersen GM, 2003, JNCI-J NATL CANCER I, V95, P180, DOI 10.1093/jnci/95.3.180; Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609; van der Heijden MS, 2003, CANCER RES, V63, P2585; Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.3.CO;2-L; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamamoto H, 2001, CANCER RES, V61, P3139; Yeo CJ, 1998, ANN SURG, V227, P821, DOI 10.1097/00000658-199806000-00005	30	61	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3652	3656		10.1038/sj.onc.1208411	http://dx.doi.org/10.1038/sj.onc.1208411			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806175				2022-12-17	WOS:000229221800012
J	Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I				Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I			PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia	ONCOGENE			English	Article						T cells; Notch3; PKC theta; NF-kappa B; leukemia	NF-KAPPA-B; KINASE-C-THETA; PROTEIN-KINASE; TRANSGENIC MICE; ACTIVATION; RECEPTOR; EXPRESSION; LEUKEMIA/LYMPHOMA; COSTIMULATION; LYMPHOCYTES	Protein kinase (PK) Ctheta is a critical regulator of mature T-cell activation and proliferation, being implicated in TCR-triggered nuclear factor (NF)-kappaB activation and providing important survival signals to leukemic T cells. We previously showed that overexpression of pTalpha/pre-TCR and constitutive activation of NF-kappaB characterize the T-cell leukemia/lymphoma developing in Notch3-IC transgenic mice. We report here that PKCtheta is a downstream target of Notch3 signaling and that its activation and membrane translocation require a functional pre-TCR in order to trigger NF-kappaB activation in thymocytes and lymphoma cells of transgenic mice. Furthermore, deletion of PKCtheta in Notch3-IC transgenic mice reduces the incidence of leukemia, correlating with decreased NF-kappaB activation. This paper therefore suggests that PKCtheta mediates the activation of NF-kappaB by pre-TCR in immature thymocytes and contributes to the development of Notch3-dependent T-cell lymphoma.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Neuromed Inst, I-86077 Pozzilli, Italy; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome; University of L'Aquila; IRCCS Neuromed; Fondazione Cenci Bolognetti; Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Talora, Claduio/AIC-4932-2022; Frati, Luigi/ABI-7437-2020; Palermo, Rocco/I-5140-2016; Bellavia, Diana/AAO-6348-2021; Campese, Antonio/A-9783-2015	Talora, Claduio/0000-0002-6973-2184; Palermo, Rocco/0000-0003-0134-9370; FELLI, MARIA PIA/0000-0002-5765-2611; VACCA, Alessandra/0000-0002-0006-5379; CHECQUOLO, Saula/0000-0001-5109-8392; CAMPESE, Antonio Francesco/0000-0002-8535-6609				Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cipriani B, 2002, J IMMUNOL, V169, P5761, DOI 10.4049/jimmunol.169.10.5761; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Maroder M, 1996, J IMMUNOL, V157, P2864; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Szamel M, 1998, J IMMUNOL, V160, P2207; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, CURR CANCER DRUG TAR, V2, P125, DOI 10.2174/1568009023333908; Villunger A, 1999, EUR J IMMUNOL, V29, P3549, DOI 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433	30	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					992	1000		10.1038/sj.onc.1208302	http://dx.doi.org/10.1038/sj.onc.1208302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592506				2022-12-17	WOS:000226749200005
J	Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH				Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH			RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells	ONCOGENE			English	Article						colon cancer; oncogenic phenotype; receptor tyrosine kinase; RNA interference	MACROPHAGE-STIMULATING PROTEIN; SPLICING VARIANT; POINT MUTATIONS; INVASIVE GROWTH; TUMOR-FORMATION; BETA-CATENIN; C-MET; IDENTIFICATION; EXPRESSION; CANCER	Altered expression of receptor tyrosine kinases contributes to tumorigenic behaviors of epithelial cancers. In this study, the pathogenic roles of receptor tyrosine kinase RON (recepteur d'origine nantais) in regulating oncogenic phenotypes in colorectal epithelial cells were studied. Increased expression of RON and its variants resulted in colony formation and motile activities of colonic epithelial AA/C1 cells as evident in soft-agar and migration assays, respectively. These results suggest that overexpression of wild-type RON mediates the transformed phenotypes in immortalized colon epithelial cells. In colorectal cancer cells (HT-29, HCT116, and SW620) that naturally express RON, the RON gene expression was silenced by RNA interference. The introduction of RON-specific small interfering ( si) RNA significantly affected cancer cell proliferation, motility, and led to increased apoptotic cell death. Focus-forming activities and anchorage-independent growth of colon cancer cells were also dramatically reduced. Moreover, it was demonstrated in tumor growth assays that silencing RON gene expression significantly reduces tumorigenic activities of SW620 cells in vivo. By analysing signaling proteins involved in colon carcinogenesis, we found that the effect of RON-specific siRNA is associated with diminished expression of beta-catenin, a critical component in the Wnt signaling pathway. Taken together, our results demonstrate that altered expression of RON in colon cancer cells is required to maintain tumorigenic phenotypes. Thus, silencing RON gene expression could have potential to reverse malignant activities of colon tumors in vivo.	Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; Zhejiang Univ, Coll Med, Affiliated Hosp 1,Inst Infect Dis, Lab Cheung Kong Scholars Program Biomed Sci, Hangzhou 310027, Peoples R China	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Zhejiang University	Wang, MH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter Dr, Amarillo, TX 79106 USA.	minghai.wang@ttuhsc.edu			NCI NIH HHS [R01 CA91980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Crawford J., 1994, GASTROINTESTINAL TRA; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; Earp H Shelton 3rd, 2003, Trans Am Clin Climatol Assoc, V114, P315; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	45	61	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8464	8474		10.1038/sj.onc.1207907	http://dx.doi.org/10.1038/sj.onc.1207907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378025				2022-12-17	WOS:000224870700007
J	Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K				Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K			Cyclin-dependent kinase inhibitor indirubin-3 '-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies	ONCOGENE			English	Article						cancer; cell cycle; centrosome anomalies; chromosomal instability; human papillomavirus	RETINOBLASTOMA TUMOR-SUPPRESSOR; E7 ONCOPROTEIN; CELL-DIVISION; DNA-SYNTHESIS; DUPLICATION; CDK2; DEGRADATION; INDUCTION; PROTEIN; DIFFERENTIATION	Dysregulation of the centrosome duplication cycle has been implicated in tumorigenesis. Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rapidly induces aberrant centrosome and centriole duplication in normal human cells. We report here that HPVE7-induced abnormal centriole duplication is specifically abrogated by a small molecule CDK inhibitor, indirubin-3'-oxime (IO), but not a kinase-inactive derivative. Importantly, normal centriole duplication was not markedly affected by IO, and the inhibitory effects were observed at concentrations that did not affect the G1/S transition of the cell division cycle. Depletion of CDK2 by siRNA similarly abrogated HPV E7-induced abnormal centrosome duplication and ectopic expression of CDK2 in combination with cyclin E or cyclin A could rescue the inhibitory effect of IO. IO treatment also reduced the steady-state level of aneuploid cells in HPV-16 E7-expressing cell populations. Our results suggest that cyclin/CDK2 activity is critically involved in abnormal centrosome duplication induced by HPV-16 E7 oncoprotein expression, but may be dispensable for normal centrosome duplication and cell cycle progression.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece; CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, Bretagne, France	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; National & Kapodistrian University of Athens; Centre National de la Recherche Scientifique (CNRS)	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu; karl_munger@hms.harvard.edu	skaltsounis, alexios leandros/AAE-9617-2019; MEIJER, Laurent/ABE-7465-2021	Manuel, Edwin/0000-0002-4602-7060; , laurent/0000-0003-3511-4916; Duensing, Anette/0000-0002-0168-4067; Munger, Karl/0000-0003-3288-9935				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Boyer SN, 1996, CANCER RES, V56, P4620; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Klausner RD, 2002, CANCER CELL, V1, P3, DOI 10.1016/S1535-6108(02)00020-X; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Paoletti A, 1996, J CELL SCI, V109, P3089; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pihan GA, 1998, CANCER RES, V58, P3974; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	61	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8206	8215		10.1038/sj.onc.1208012	http://dx.doi.org/10.1038/sj.onc.1208012			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378001				2022-12-17	WOS:000224749500003
J	Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N				Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N			Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-x(L) and RIP	ONCOGENE			English	Article						apoptosis; TRAIL; caspase-8; neuroblastoma; chemotherapeutic drugs; cycloheximide	DEATH RECEPTORS 4; CYTOCHROME-C; LIGAND TRAIL; APO-2 LIGAND; TUMOR-CELLS; EXPRESSION; PROTEIN; CD95; AMPLIFICATION; RESISTANCE	Neuroblastorna (NB) is a childhood neoplasm which heterogeneous behavior can be explained by differential regulation of apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces rapid apoptosis in most tumor cells and thus represents a promising anticancer agent. We have reported silencing of caspase-8 expression in highly malignant NB cells as a possible mechanism of resistance to TRAIL-induced apoptosis. To explore the particular contribution of caspase-8 in such resistance, retroviral-mediated stable caspase-8 expression was induced in the IGR-N91 cells. As a result, sensitivity to TRAIL was fully restored in the caspase-8-complemented cells. TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner. Sensitization to TRAIL involved enhanced death receptor DR5 expression, activation of Bid and the complete caspases cascade. Interestingly, combined treatments also enhanced the cleavage-mediated inactivation of antiapoptotic molecules, XIAP, Bcl-x(L) and RIP. Our results show that restoration of active caspase-8 expression in a caspase-8-deficient NB cell line is necessary and sufficient to fully restore TRAIL sensitivity. Moreover, the synergistic effect of drugs and TRAIL results from activation of the caspase cascade via a mitochondrial pathway-mediated amplification loop and from the inactivation of apoptosis inhibitors.	CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Gross, N (corresponding author), CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland.	nicole.gross@chuv.hospvd.ch	, Mühlethaler-Mottet/H-2848-2019	, Mühlethaler-Mottet/0000-0001-8274-0907				Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Brambilla E, 1996, AM J PATHOL, V149, P1941; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Eggert A, 2001, CANCER RES, V61, P1314; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fulda S, 2000, CANCER RES, V60, P3947; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada K, 2002, CANCER RES, V62, P5897; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Johnson DE, 2000, CANCER RES, V60, P1818; Keane MM, 1999, CANCER RES, V59, P734; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2001, CANCER RES, V61, P1645; Lee SH, 1999, CANCER RES, V59, P5683; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; REED JC, 1991, CANCER RES, V51, P6529; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, CANCER RES, V58, P1593; Shin MS, 2001, CANCER RES, V61, P4942; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THORNE M, 1997, NATURE, V386, P517; Vassal G, 1997, EUR J CANCER, V33, P2011, DOI 10.1016/S0959-8049(97)00296-7; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang XH, 2003, CANCER LETT, V197, P137, DOI 10.1016/S0304-3835(03)00093-4; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	59	61	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5415	5425		10.1038/sj.onc.1207704	http://dx.doi.org/10.1038/sj.onc.1207704			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094781				2022-12-17	WOS:000222588400001
J	Cuadrado, A; Gonzalez, L; Suarez, Y; Martinez, T; Munoz, A				Cuadrado, A; Gonzalez, L; Suarez, Y; Martinez, T; Munoz, A			JNK activation is critical for Aplidin (TM)-induced apoptosis	ONCOGENE			English	Article						Aplidin (TM); apoptosis; JNK; c-Jun; AP-1 NF-kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; TYROSINE PHOSPHORYLATION; DEHYDRODIDEMNIN B; CANCER-CELLS; C-MYC; DEGRADATION; REQUIREMENT; APLIDINE	Aplidin(TM) is an antitumor drug that induces apoptosis and activates EGFR, Src, JNK and p38MAPK. Here, we show that Aplidin(TM) induces c-JUN, JUN B, JUN D, c-FOS, FRA-1 and FOS B genes of the activator-protein (AP)-1 family, and also p65/RELA, a major component of nuclear factor-kappaB (NF-kappaB). Concordantly, Aplidin(TM) increases AP-1 and NF-kappaB activity. c-FOS induction depends on EGFR, Src and JNK/p38MAPK. In contrast, induction of c-JUN does not require EGFR activity and p65/RELA induction is only partially dependent on these kinases. We used several genetically deficient cells to identify the critical target of Aplidin(TM). Mouse embryo fibroblasts (MEFs) deficient for src, yes and fyn, and those lacking all p38MAPK isoforms displayed normal Aplidin(TM) sensitivity (IC50 = 12 nM). In contrast, MEFs lacking jnk1 and jnk2, which do not express any JNK isoform, were much less sensitive (IC50 > 500 nM). Furthermore, cells lacking c-jun or expressing a c-Jun protein in which JNK targets Ser(63/73) were mutated (c-JunAA) showed intermediate sensitivity (IC50 = 60 nM). Additionally, Aplidin(T) has higher cytotoxic activity against proliferating than quiescent cells, which is reflected in higher JNK activation. We conclude that phosphorylation by JNK of c-Jun and additional substrate(s) is crucial for Aplidin(TM) activity.	Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, E-28029 Madrid, Spain; Pharma Mar SA, E-28770 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); PharmaMar	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Cuadrado, Ana/HGU-4777-2022; Munoz, Alberto/O-6393-2014; Cuadrado, Ana/AAA-9277-2019	Munoz, Alberto/0000-0003-3890-4251; Cuadrado, Ana/0000-0002-9752-5932; Suarez, Yajaira/0000-0003-4549-2953				Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788; Canty TG, 1999, CIRCULATION, V100, P361; Cuadrado A, 2003, J BIOL CHEM, V278, P241, DOI 10.1074/jbc.M201010200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Depenbrock H, 1998, BRIT J CANCER, V78, P739, DOI 10.1038/bjc.1998.570; Erba E, 2002, BRIT J CANCER, V86, P1510, DOI 10.1038/sj.bjc.6600265; Erba E., 1999, P AM ASSOC CANC RES, V40, P3; Faircloth G., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P103; Garcia-Fernandez LF, 2002, ONCOGENE, V21, P7533, DOI 10.1038/sj.onc.1205972; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GomezFabre PM, 1997, CANCER LETT, V113, P141, DOI 10.1016/S0304-3835(96)04591-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Lobo C, 1997, ANTICANCER RES, V17, P333; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; ONGIL SL, 1998, BRIT J PHARMACOL, V124, P447; Raymond E., 2001, European Journal of Cancer, V37, pS32, DOI 10.1016/S0959-8049(01)80599-2; Sakai R, 1996, J MED CHEM, V39, P2819, DOI 10.1021/jm960048g; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Urdiales JL, 1996, CANCER LETT, V102, P31, DOI 10.1016/0304-3835(96)04151-1; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yao L, 2003, IDRUGS, V6, P246	37	61	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4673	4680		10.1038/sj.onc.1207636	http://dx.doi.org/10.1038/sj.onc.1207636			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122339				2022-12-17	WOS:000221799200003
J	Mitra, J; Enders, GH				Mitra, J; Enders, GH			Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells	ONCOGENE			English	Article						cell cycle; Cdk1; Cdk2; Cdc25B; Cdc25C; G2	CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; MAMMALIAN-CELLS; PROTEIN-KINASE; HELA-CELLS; S-PHASE; MITOSIS; PHOSPHORYLATION; CHECKPOINT; EXTRACTS	Mitotic entry, a critical decision point for maintaining genetic stability, is governed by the cyclin B/Cyclin dependent kinase 1 (Cdc2) complex. In Xenopus oocytes and early embryos, accumulation of cyclin B activates Cdk1, which then phosphorylates and activates the positive regulator Cdc25 in an autocatalytic feedback loop. However, cyclin B levels do not increase as some human cells approach mitosis, and the key factors regulating Cdk1 activation in human cells are unknown. We report here that reducing cyclin A expression by RNA interference (RNAi) in primary human fibroblasts inhibited activation of Cdc25B and Cdc25C and dephosphorylation of Cdk1 on tyrosine (tyr) 15. These results were reproduced in U2-OS cells by inducing the expression of a dominant-negative (dn) mutant of Cdk2, the principal cyclin A binding partner. Cdk2-dn induction could inhibit Cdc25B activity and foster Cdk1 tyr phosphorylation within the S phase, temporally dissociating these events from Cdk1 activation at mitosis. In contrast, reducing Cdk1 expression delayed mitotic entry without markedly impairing Cdc25B or Cdc25C activity. These results suggest that cyclin A/Cdk2 complexes are key regulators of Cdc25 and Cdk1 activation in human cells. This pathway appears to be commonly deregulated in cancer.	Univ Penn, Dept Med, GI Div, CRB, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Mitra, J (corresponding author), Univ Penn, Dept Med, GI Div, CRB, Room 600,415 Curie Blvd, Philadelphia, PA 19104 USA.	jmitra@mail.med.upenn.edu; endersgh@mail.med.upenn.edu	Mitra, Joydeep/GQP-7505-2022		NIDDK NIH HHS [P30 DK050306, 1-K01-DK61280-01, K01 DK061280, P30 DK50306] Funding Source: Medline; NIGMS NIH HHS [R01 GM065514-02, R01 GM065514] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, K01DK061280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; NORBURY C, 1990, CIBA F SYMP, V150, P168; NOVAK B, 1993, J CELL SCI, V106, P1153; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	41	61	66	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3361	3367		10.1038/sj.onc.1207446	http://dx.doi.org/10.1038/sj.onc.1207446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14767478	Green Accepted			2022-12-17	WOS:000220975000010
J	Huang, DT; Walden, H; Duda, D; Schulman, BA				Huang, DT; Walden, H; Duda, D; Schulman, BA			Ubiquitin-like protein activation	ONCOGENE			English	Review						ubiquitin; E1; ubiquitin activating enzyme; SUMO; NEDD8; MoeB	CONJUGATING ENZYME COMPLEX; TUMOR-SUPPRESSOR P53; CYCLE MUTANT TS85; CRYSTAL-STRUCTURE; CELL-CYCLE; ESCHERICHIA-COLI; LUNG-CANCER; DNA-REPAIR; KAPPA-B; U-BOX	Post-translational covalent attachment of ubiquitin and ubiquitin-like proteins (ubls) has emerged as a predominant cellular regulatory mechanism, with important roles in controlling cell division, signal transduction, embryonic development, endocytic trafficking and the immune response. Ubls function by remodeling the surface of their target proteins, changing their target's half-life, enzymatic activity, protein - protein interactions, subcellular localization or other properties. At least 10 different ubiquitin-like modi. cations exist in mammals, and attachment of different ubls to a target leads to different biological consequences. Ubl-conjugation cascades are initiated by activating enzymes, which also coordinate the ubls with their downstream pathways. A number of biochemical and structural studies have provided insights into the mechanism of ubl-activating enzymes and their roles in ubl conjugation cascades.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schulman, BA (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, MS 311, Memphis, TN 38105 USA.	Brenda.schulman@stjude.org	Huang, Danny/AAM-3631-2021	Huang, Danny/0000-0002-6192-259X	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069530] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA21765] Funding Source: Medline; NIGMS NIH HHS [R01GM69530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1981, J BIOL CHEM, V256, P1525; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Jones D, 2000, DEV BIOL, V226, P152, DOI 10.1006/dbio.2000.9847; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacQuillan GC, 2003, J MED VIROL, V70, P219, DOI 10.1002/jmv.10381; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Nicholl MJ, 2000, J GEN VIROL, V81, P2215, DOI 10.1099/0022-1317-81-9-2215; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; Pitterle DM, 1998, IN VIVO, V12, P643; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Pringa E, 2001, J BIOL CHEM, V276, P19617, DOI 10.1074/jbc.M100192200; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramelot Theresa A., 2003, Journal of Structural and Functional Genomics, V4, P25, DOI 10.1023/A:1024674220425; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sheng WY, 2002, PROTEIN SCI, V11, P1482, DOI 10.1110/ps.0201602; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Sidow A, 1999, NAT GENET, V23, P104, DOI 10.1038/12709; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VanDemark AP, 2003, NAT STRUCT BIOL, V10, P244, DOI 10.1038/nsb0403-244; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WILKINSON KD, 1990, BIOCHEMISTRY-US, V29, P7373, DOI 10.1021/bi00484a004; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yewdell JW, 2001, CURR OPIN IMMUNOL, V13, P13, DOI 10.1016/S0952-7915(00)00175-8; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	168	61	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					1958	1971		10.1038/sj.onc.1207393	http://dx.doi.org/10.1038/sj.onc.1207393			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021884				2022-12-17	WOS:000220213400001
J	Kim, O; Jiang, TY; Xie, XQ; Guo, ZY; Chen, HG; Qiu, Y				Kim, O; Jiang, TY; Xie, XQ; Guo, ZY; Chen, HG; Qiu, Y			Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells	ONCOGENE			English	Article						protein kinase; prostate cancer; androgen independence; cytokine	PLECKSTRIN-HOMOLOGY DOMAIN; FOCAL ADHESION KINASE; TYROSINE KINASE; INTERLEUKIN-6 RECEPTOR; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; GENE-EXPRESSION; PIM-1 KINASE; SERUM LEVELS; PH-DOMAIN	IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NCI NIH HHS [CA85380, PC020169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Y, 1991, Rinsho Ketsueki, V32, P1458; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akimoto S, 1998, ENDOCR J, V45, P183, DOI 10.1507/endocrj.45.183; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chen TS, 2000, CANCER RES, V60, P2132; CUYPERS HT, 1984, CELL, V37, P141; DAYNES RA, 1993, J IMMUNOL, V150, P5219; Debes JD, 2002, CANCER RES, V62, P5632; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; Hobisch A, 1998, CANCER RES, V58, P4640; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1992, ONCOGENE, V7, P727; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; PLANTE M, 1994, CANCER, V73, P1882, DOI 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Smith PC, 2001, PROSTATE, V48, P47; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	38	61	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1838	1844		10.1038/sj.onc.1207304	http://dx.doi.org/10.1038/sj.onc.1207304			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981536				2022-12-17	WOS:000220129500005
J	Carloni, V; Mazzocca, A; Ravichandran, KS				Carloni, V; Mazzocca, A; Ravichandran, KS			Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells	ONCOGENE			English	Article						phosphatidylinositol-4 phosphate; phosphatidylinositol-4; kinase; cell growth	PHOSPHOTYROSINE-BINDING DOMAIN; SUPERFAMILY TM4SF PROTEINS; PLASMA-MEMBRANE; LIPID RAFTS; B-CELLS; COMPLEXES; ADHESION; TAPA-1; MIGRATION; FAMILY	Tetraspanins is a large family of membrane proteins that are implicated in cell proliferation, differentiation and tumor invasion. Specifically, the tetraspanin CD81 has been involved in cell proliferation but the mechanism is unknown. Here, we show that CD81 clustering stimulates ERK/MAPKinase activity and tyrosine phosphorylation of the adapter protein Shc in Huh7 cancer cells. In addition, overexpression of CD81 in HepG2 cells, NIH3T3 cells, and murine. broblasts GD25 lacking the beta1 family of integrins induces cell proliferation and ERK/MAPKinase activation. Linked with this event, we observed an increase in CD81-associated type II phosphatidylinositol 4-kinase activity. A mutant in the PTB domain of Shc failed to interact with phosphoinositides and localize to the plasma membrane thus blocking CD81-induced ERK/MAPKinase activation. Therefore, we conclude that CD81 stimulates synthesis of phosphoinositides with the recruitment of Shc to the plasma membrane via PTB domain, and this sequence of events induces activation of ERK/MAPKinase. These findings define a novel mechanism of ERK/MAPKinase activation and tumor cell proliferation.	Univ Florence, Dipartimento Med Interna, I-50134 Florence, Italy; Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA USA; Univ Virginia, Dept Microbiol, Charlottesville, VA USA	University of Florence; University of Virginia; University of Virginia	Carloni, V (corresponding author), Univ Florence, Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.	v.carloni@dfc.unifi.it		MAZZOCCA, Antonio/0000-0003-0940-7352				Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 2001, J CELL SCI, V114, P4143; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LEVY S, 1991, J BIOL CHEM, V266, P14597; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1998, P NATL ACAD SCI USA, V95, P2458, DOI 10.1073/pnas.95.5.2458; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mazzocca A, 2002, J HEPATOL, V37, P322, DOI 10.1016/S0168-8278(02)00175-7; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Owens DM, 2001, CANCER RES, V61, P5248; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; SCHICK MR, 1993, J IMMUNOL, V151, P4090; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	34	61	65	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2004	23	8					1566	1574		10.1038/sj.onc.1207287	http://dx.doi.org/10.1038/sj.onc.1207287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14676841				2022-12-17	WOS:000189219500010
J	Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S				Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S			Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process	ONCOGENE			English	Article						leukemia; apoptosis; adaphostin; ROS; ERK; Akt	ACTIVATED PROTEIN-KINASE; CHRONIC MYELOGENOUS LEUKEMIA; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; IN-VIVO; GROWTH-FACTOR; MAP KINASES; PATHWAY; JNK; PHOSPHORYLATION	Effects of the tyrphostin tyrosine kinase inhibitor adaphostin (NSC 680410) have been examined in human leukemia cells ( Jurkat, U937) in relation to mitochondrial events, apoptosis, and perturbations in signaling and cell cycle regulatory events. Exposure of cells to adaphostin concentrations greater than or equal to0.75 muM for intervals greater than or equal to6 h resulted in a pronounced release of cytochrome c and AIF, activation of caspase-9, -8, and -3, and apoptosis. These events were accompanied by the caspase-independent downregulation of Raf-1, inactivation of MEK1/2, ERK, Akt, p70S6K, dephosphorylation of GSK-3, and activation of c-Jun-N-terminal kinase (JNK) and p38 MAPK. Adaphostin also induced cleavage and dephosphorylation of pRb on CDK2- and CDK4-specific sites, as well as the caspase-dependent downregulation of cyclin D-1. Inducible expression of a constitutively active MEK1 construct markedly diminished adaphostin-induced cytochrome c and AIF release, JNK activation, and apoptosis in Jurkat cells. Ectopic expression of Raf-1 or constitutively activated ( myristolated) Akt also significantly attenuated adaphostin-induced apoptosis, but protection was less than that conferred by enforced activation of MEK. Lastly, antioxidants (e.g., L-N-acetylcysteine; L-NAC) opposed adaphostin-mediated mitochondrial dysfunction, Raf-1/ MEK/ERK downregulation, JNK activation, and apoptosis. However, in contrast to L-NAC, enforced activation of MEK failed to block adaphostin-mediated ROS generation. Together, these findings demonstrate that the tyrphostin adaphostin induces multiple perturbations in signal transduction pathways in human leukemia cells, particularly inactivation of the cytoprotective Raf-1/ MEK/ERK and Akt cascades, that culminate in mitochondrial injury, caspase activation, and apoptosis. They also suggest that adaphostin-related oxidative stress acts upstream of perturbations in these signaling pathways to trigger the cell death process.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93738, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arguello F, 1998, BLOOD, V91, P2482; Avramis IA, 2002, CANCER CHEMOTH PHARM, V50, P479, DOI 10.1007/s00280-002-0507-6; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Carlson B, 1999, CANCER RES, V59, P4634; CHANDRA J, 2003, BLOOD; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wolf C, 2001, FEBS LETT, V488, P154, DOI 10.1016/S0014-5793(00)02403-0; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2003, CANCER RES, V63, P1822; Yu CR, 2003, CANCER RES, V63, P2118; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143	45	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1364	1376		10.1038/sj.onc.1207248	http://dx.doi.org/10.1038/sj.onc.1207248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647418				2022-12-17	WOS:000189035800004
J	Manohar, CF; Bray, JA; Salwen, HR; Madafiglio, J; Cheng, A; Flemming, C; Marshall, GM; Norris, MD; Haber, M; Cohn, SL				Manohar, CF; Bray, JA; Salwen, HR; Madafiglio, J; Cheng, A; Flemming, C; Marshall, GM; Norris, MD; Haber, M; Cohn, SL			MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; MYCN; MRP1; gene regulation	RESISTANCE-ASSOCIATED PROTEIN; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; N-MYC; LUNG-CANCER; CELL-LINE; DNA-BINDING; P53; ONCOGENE; DIFFERENTIATION	In the childhood cancer neuroblastoma ( NB), the level of expression of the multidrug resistance-associated protein (MRP1) gene is strongly correlated with expression of the MYCN oncogene in primary NB tumors, suggesting that MRP1 may be a target for MYCN-mediated gene regulation. In this study, we show that MYCN induction in human NB cells results in increased MRP1 mRNA and protein levels, which in turn is accompanied by increased drug resistance and enhanced MRP1-mediated drug efflux. Furthermore, luciferase activity from MRP1 promoter/luciferase gene reporter constructs was significantly increased in NB cells with exogenous overexpression of MYCN, whereas activity was decreased in NB cells stably transfected with MYCN-antisense vectors. Decreased luciferase activity was observed with promoter constructs that lacked one or two E-box sequences or had E-box double point mutations, while a truncated MRP1 promoter lacking all three E-boxes exhibited only basal levels of activity. Specific electrophoretic mobility shifts of MRP1 E-box sequences were detected with nuclear extracts from NB cells with MYCN overexpression, and complex formation was inhibited with the addition of antibodies directed against MYCN or MYC. These findings indicate that by interacting with E-box elements within the promoter, MYCN can upregulate MRP1 expression and modulate drug resistance in NB.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Children's Cancer Institute; Children's Medical Research Institute - Australia; Northwestern University; Feinberg School of Medicine	Cohn, SL (corresponding author), Childrens Mem Hosp, Div Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA.	scohn@northwestern.edu	Cohn, Susan/AAB-6010-2021	Norris, Murray/0000-0002-0632-4589; Haber, Michelle/0000-0003-2036-8817; Cohn, Susan/0000-0001-5749-7650	NCI NIH HHS [5P30CA60553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bader P, 1999, ONCOL REP, V6, P1143; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BORDOW SB, 1994, CANCER RES, V54, P5036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 2001, PRINCIPLES PRACTICE, P895; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FAVROT M, 1991, BRIT J CANCER, V64, P233, DOI 10.1038/bjc.1991.282; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Haber M, 2000, NEUROBLASTOMA, P207; HABER M, 1989, J NATL CANCER I, V81, P1250, DOI 10.1093/jnci/81.16.1250; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Keshelava N, 2001, CANCER RES, V61, P6185; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Kurz EU, 2001, BIOCHEM BIOPH RES CO, V285, P981, DOI 10.1006/bbrc.2001.5262; Kuss BJ, 2002, INT J CANCER, V98, P128, DOI 10.1002/ijc.10159; Lutz W, 1996, ONCOGENE, V13, P803; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Matsunaga T, 1998, JPN J CANCER RES, V89, P1276, DOI 10.1111/j.1349-7006.1998.tb00524.x; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; Oshika Y, 1998, MODERN PATHOL, V11, P1059; Peaston AE, 2001, BRIT J CANCER, V85, P1564, DOI 10.1054/bjoc.2001.2144; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shohet JM, 2002, CANCER RES, V62, P1123; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; VOGAN K, 1993, CANCER RES, V53, P5269; Wang QJ, 1998, CANCER RES, V58, P5762; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; Young LC, 1999, CLIN CANCER RES, V5, P673; Zhu QC, 1996, DNA CELL BIOL, V15, P105, DOI 10.1089/dna.1996.15.105; ZHU QC, 1994, CANCER RES, V54, P4488	51	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					753	762		10.1038/sj.onc.1207151	http://dx.doi.org/10.1038/sj.onc.1207151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737110				2022-12-17	WOS:000188304900014
J	Cannon, ML; Cesarman, E				Cannon, ML; Cesarman, E			The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells	ONCOGENE			English	Article						Kaposi's sarcoma-associated virus (KSHV); G protein-coupled receptor (GPCR); primary effusion lymphoma (PEL); signaling	SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; SRC TYROSINE KINASE; KAPOSIS-SARCOMA; PHOSPHOLIPASE-C; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8 ENCODES; VASCULAR-PERMEABILITY; CONSTITUTIVE ACTIVITY	Kaposi#39;s sarcoma-associated virus (KSHV) is the causative agent of Kaposi#39;s sarcoma (KS) and primary effusion lymphoma (PEL). The KSHV G protein-couple receptor (vGPCR) is a homologue of the human IL-8 receptor that signals constitutively, activates mitogen- and stress-activated kinases, and induces transcription via multiple transcription factors including AP-1 and NF#954;B. Furthermore, vGPCR causes cellular transformation in vitro and leads to KS-like tumors in transgenic mouse models. vGPCR has therefore become an exciting potential therapeutic target for KSHV-mediated disease, but its signaling properties need to be better understood in the context of KSHV-infected hematopoietic cells. We recently described a PEL cell line that expresses vGPCR via an inducible promoter and have shown that vGPCR has broad capabilities of affecting cellular and viral transcription patterns in this highly relevant cell type. To elucidate the predominant signaling pathways used by vGPCR in PEL cells, we have used reporter gene assays to measure vGPCR activity in the presence of various pharmacologic enzyme inhibitors and plasmid constructs. We show that vGPCR-induced activation of AP-1 and CREB is mediated cooperatively by a Gq-ERK-1#47;2 and a Gi#8211;PI3K-Src axis. Furthermore, unlike in other cell types, NF#954;B activation by vGPCR seems not to be substantially mediated by Gi or PI3K#47;Akt in PEL cells.Oncogene (2004) 23, 514#8211;523. doi:10.1038/sj.onc.1207021	Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Cornell University; Cornell University	Cannon, ML (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, 1300 York Ave,Room A-421, New York, NY 10021 USA.	mlcannon@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA073531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI053971] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA73531] Funding Source: Medline; NIAID NIH HHS [K08-AI53971-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Aoki Y, 1999, BLOOD, V94, P4247, DOI 10.1182/blood.V94.12.4247; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Burger M, 1999, J IMMUNOL, V163, P2017; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; CIVATI G, 1988, TRANSPLANT P, V20, P924; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Franceschi S, 1995, TUMORI, V81, P308, DOI 10.1177/030089169508100502; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Jones KD, 1999, BLOOD, V94, P2871; Keller SA, 2000, BLOOD, V96, P2537; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1998, J Natl Cancer Inst Monogr, P79; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Pati S, 2003, J VIROL, V77, P5759, DOI 10.1128/JVI.77.10.5759-5773.2003; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Polson AG, 2002, CANCER RES, V62, P4525; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SHEPARD LW, 2001, J BIOL CHEM, V4, P4; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2000, CANCER RES, V60, P4873; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wakeling MN, 2001, J GEN VIROL, V82, P1187, DOI 10.1099/0022-1317-82-5-1187; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Ziegler JL, 1996, INT J CANCER, V65, P200, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;200::AID-IJC12&gt;3.0.CO;2-H; Zoeteweij JP, 2001, BLOOD, V97, P2374, DOI 10.1182/blood.V97.8.2374	77	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					514	523		10.1038/sj.onc.1207021	http://dx.doi.org/10.1038/sj.onc.1207021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724579				2022-12-17	WOS:000188098300022
J	Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A				Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A			Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma	ONCOGENE			English	Article						BRAF; KRAS2; barrett; neoplasia	B-RAF; CANCER; GENE; ACTIVATION; CARCINOMA; ESOPHAGUS; PROGRESSION; MELANOMA; PROTEINS; PATHWAY	Activation of the Raf/MEK/ERK (MAPK) signal transduction cascade by RAS mutations has been found in a variety of human cancers. Mutations of BRAF provide an alternative route for activation of this signalling pathway. To determine the role of mutations in BRAF and KRAS2 in the neoplastic progression of Barrett's adenocarcinoma, we analysed both genes for common mutations. After microdissection, DNA of 19 Barrett's adenocarcinomas, 56 Barrett's intraepithelial neoplasias (n=29 low-grade intraepithelial neoplasia (LGIN) and n=27 high-grade intraepithelial neoplasia (HGIN)), 30 Barrett's mucosa without neoplasia and normal squamous, as well as gastric epithelium, were analysed for BRAF and KRAS2 mutation. Activating BRAF mutations were identified in 2/19 Barrett's adenocarcinomas (11%) and in 1/27 HGIN (4%). KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%). In LGIN as well as in normal gastric or oesophageal mucosa, neither BRAF nor KRAS2 mutations were detected. All lesions with KRAS2 mutations had an intact BRAF gene. The status of mismatch-repair proteins was neither related to BRAF nor KRAS2 mutations. These data indicate that RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas. We conclude that the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; HSK Clin Wiesbaden, Clin Internal Med 2, D-65199 Wiesbaden, Germany; Klinikum Bayreuth, Inst Pathol, D-95445 Bayreuth, Germany; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany	Leipzig University; Otto von Guericke University; Klinikum Bayreuth; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn JR, 2003, ONCOGENE, V22, P4134, DOI 10.1038/sj.onc.1206466; Fitzgerald RC, 2003, GUT, V52, P16, DOI 10.1136/gut.52.1.16; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Kimura ET, 2003, CANCER RES, V63, P1454; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Morales CP, 2002, LANCET, V360, P1587, DOI 10.1016/S0140-6736(02)11569-8; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ruschoff J, 1998, PATHOLOGE, V19, P269, DOI 10.1007/s002920050283; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; Stahl J, 2000, ADV ANAT PATHOL, V7, P85, DOI 10.1097/00125480-200007020-00003; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Weber CK, 2001, CANCER RES, V61, P3595; Yuen ST, 2002, CANCER RES, V62, P6451	32	61	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					554	558		10.1038/sj.onc.1207189	http://dx.doi.org/10.1038/sj.onc.1207189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724583				2022-12-17	WOS:000188098300026
J	Bertrand, P; Lambert, S; Joubert, C; Lopez, BS				Bertrand, P; Lambert, S; Joubert, C; Lopez, BS			Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells	ONCOGENE			English	Article						Rad51; homologous recombination; tumorigenesis; centrosome; aneuploidy	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; DIRECTED REPAIR; DNA-REPAIR; P53; EXPRESSION; PROTEIN; MOUSE; BRCA1; GENE; CYCLE	Rad51 protein plays a pivotal role in homologous recombination (HR), which is involved in double-strand break repair and in genome maintenance. Despite interactions with tumor suppressor proteins, the role of mammalian Rad51 and more generally of HR in tumor prevention is not clearly established. Indeed, both high and low frequencies of HR as well as high and low levels of RAD51 expression have been reported in tumors and in precancerous conditions. To address the question of the impact of HR on tumorigenesis, we used Chinese hamster ovary (CHO) p53-defective cell lines overexpressing the mouse MmRAD51, which stimulates HR ( we name these lines: Hyper-rec lines). In parallel, we used CHO cell lines expressing a RAD51 dominant-negative form that specifically inhibits gene conversion without affecting cell viability (Hypo-rec lines). These different lines were injected into nude mice to measure their tumorigenicity. Hypo-rec lines generated a higher frequency of tumors, which also exhibited faster growth, compared to control and Hyper-rec lines. Consistent with tumorigenicity, Hypo-rec cells exhibit spontaneous centrosome duplication defects and aneuploidy. These results are the first direct evidence of involvement of RAD51 in tumor repression.	CEA, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 6-68 Av Gen Leclerc, F-92265 Fontenay Aux Roses, France.	lopez@dsvidf.cea.fr	Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X; lambert, sarah/0000-0002-1403-3204				Ausubel F., 1999, CURRENT PROTOCOLS MO; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Pihan GA, 1998, CANCER RES, V58, P3974; Raderschall E, 2002, CANCER RES, V62, P219; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sokal R. P., 1995, BIOMETRY PRINCIPLE P; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Wiese C, 2002, CANCER RES, V62, P1279; Wiesmuller L, 1996, J VIROL, V70, P737; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4	37	61	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7587	7592		10.1038/sj.onc.1206998	http://dx.doi.org/10.1038/sj.onc.1206998			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576820				2022-12-17	WOS:000186113000005
J	Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ				Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ			Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form	ONCOGENE			English	Article						rap1; nucleus; regulation; carcinoma	BINDING PROTEINS; HUMAN-PLATELETS; MYOGENIC DIFFERENTIATION; GOLGI-COMPLEX; GROWTH-FACTOR; MAP KINASE; ACTIVATION; TRANSFORMATION; ASSOCIATION; INHIBITION	We recently showed that rap1 regulates growth and proliferation in normal keratinocytes, which provoked us to investigate its expression and regulation in malignant cells. Rap1 is variably expressed in whole cell lysates of squamous cell carcinoma (SCC) cell lines. Immunoblot analysis of nuclear and cytosolic fractions and immunohistochemistry revealed that in addition to cytoplasmic expression, SCC cells also exhibit prominent punctate rap1 expression in the nucleus. This unexpected nuclear distribution was confirmed by the evaluation of human oral cancer specimens by immunohistochemistry, which showed both nuclear and cytoplasmic localization. Cytoplasmic rap1 expression was observed mostly in large differentiated cells, whereas nuclear localization was found in morphologically less differentiated cells. Quantitative reverse transcriptase polymerase chain reaction and Northern blot analysis showed that both rap1A and rap1B are expressed in SCC cell lines although rap1B signals are more prominent. Transfection with enhanced GFP-tagged constitutively active and inactive forms of rap1B demonstrated that the active GTP-bound form translocates to the nucleus whereas inactive rap1B(GDP) is retained in the cytoplasm, much of which is in a perinuclear distribution. Furthermore, growth factors induce nuclear translocation of rap1 in oral cancer cells. This novel discovery that active, GTP-bound rap1 translocates to the nucleus makes it only the second of over 100 small GTP-binding proteins to be identified in the nucleus, and the striking prominence of rap1 expression in the nucleus of SCC cells suggests that activated rap1 plays a role in the malignant process.	Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Otolaryngol, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA.		D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [1 P50 CA97248] Funding Source: Medline; NIDCR NIH HHS [DE00452-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carey TE, 1994, ATLAS HUMAN TUMOR CE, P79; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; D'Silva NJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1667, DOI 10.1152/ajpcell.1998.274.6.C1667; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; JORDAN, 1997, J CAN DENT ASS, V63, P517; Jordan RC, 1997, J CAN DENT ASSOC, V63, P521; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Pizon V, 1996, EUR J CELL BIOL, V69, P224; QIAO J, 2002, J BIOL CHEM, V8, P8; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WAGNER ACC, 1994, AM J PHYSIOL, V266, pG1, DOI 10.1152/ajpgi.1994.266.1.G1; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YA, 2002, MOL CELL NEUROSCI, V19, P430, DOI 10.1006/mcne.2001.1076; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	39	61	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6243	6256		10.1038/sj.onc.1206534	http://dx.doi.org/10.1038/sj.onc.1206534			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679863				2022-12-17	WOS:000185506200014
J	Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC				Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC			Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway	ONCOGENE			English	Article						IL-4; androgen receptor; PSA; prostate cancer	STIMULATORY FACTOR-I; JAK-3 JANUS KINASE; CANCER CELLS; GENE-EXPRESSION; IL-4 RECEPTOR; PROTEIN; PHOSPHORYLATION; INSULIN; IGE; ACQUISITION	Androgen receptor (AR) plays an important role in the development and progression of prostate cancer upon the action of androgen through the binding of the androgen-responsive elements (AREs) on the target genes. Abnormal activation of the AR by nonandrogen has been implicated in the progression of androgen-independent prostate cancer. The levels of interleukin-4 (IL-4) are significantly elevated in sera of patients with hormone refractory prostate cancer. The potential role of IL-4 on the activation of AR was investigated in prostate cancer cells. IL-4 enhances AR-mediated prostate-specific antigen (PSA) expression and ARE-containing gene activity through activation of the AR in the androgen ablation condition in human prostate cancer cells. The AR can also be sensitized by IL-4 and activated by significantly lower levels of androgen (10 pm of R1881) in prostate cancer cells. IL-4 enhances nuclear translocation of AR and increases binding of the AR to the ARE in LNCaP prostate cancer cells. Blocking of the Akt pathway by an Akt-specific inhibitor LY294002 abrogates IL-4-induced PSA expression and AR signaling. These results demonstrate that IL-4 enhances PSA expression through activation of the AR and Akt signaling pathways in LNCaP prostate cancer cells. Understanding IL-4-induced signaling leading to abnormal activation of AR will provide insights into the molecular mechanisms of androgen-independent progression of prostate cancer cells.	Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Roswell Park Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gao, AC (corresponding author), Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA90271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrack ER, 1996, MT SINAI J MED, V63, P403; Chen TS, 2000, CANCER RES, V60, P2132; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; ISAACS JT, 1994, VITAM HORM, V49, P433; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murata T, 1996, J IMMUNOL, V156, P2972; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pang S, 1997, CANCER RES, V57, P495; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; UEDA T, 2001, J BIOL CHEM, V19, P19; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Wen Y, 2000, CANCER RES, V60, P6841; Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	36	61	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7981	7988		10.1038/sj.onc.1206735	http://dx.doi.org/10.1038/sj.onc.1206735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970746				2022-12-17	WOS:000185388200013
J	Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P				Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P			Signal transduction by several KIT juxtamembrane domain mutations	ONCOGENE			English	Article						receptor; mutation; STI571; GIST	RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; PROTOONCOGENE C-KIT; CELL LUNG-CANCER; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; LIGAND-INDEPENDENT ACTIVATION; MAST-CELLS; CATALYTIC DOMAIN; POINT MUTATION	Mutations of KIT receptor tyrosine kinase are found in the majority of patients with mastocytosis and in most gastrointestinal stromal tumors. Oncogenic KIT mutations in GISTs are located in the KIT juxtamembrane domain (JMD), while codon 816 in the KIT kinase domain is mutated in systemic mastocytosis. We describe and characterize a mutation in the KIT-JMD named KDelta27. We show that KDelta27 mutant is constitutively dimerized and phosphorylated. KDelta27 ectopic expression renders both the Ba/F3 cell line and primary cultures of bone marrow mast cells independent of cytokines for proliferation and cell survival. The classical signaling pathways activated by wild-type KIT upon ligand stimulation are constitutively activated by KDelta27 and other JMD mutations. However, a side-to-side comparison revealed differences between the wild-type and JMD mutations. First, in vitro kinase assays reveal a change in peptide substrate specificity. Second, STAT proteins are preferentially phosphorylated by KIT mutants. Third, inhibitors of KIT kinase are more efficient on JMD mutations than on WT KIT. We conclude that KDelta27 is a new oncogenic KIT mutation showing constitutive activation of downstream signaling pathways, and suggest that specific pathways are activated by oncogenic KIT.	INSERM, U119, Mol & Funct Hematopoiesis Lab, F-13009 Marseille, France; Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; University Health Network Toronto	De Sepulveda, P (corresponding author), INSERM, U119, Mol & Funct Hematopoiesis Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; LETARD, Sebastien/0000-0002-6508-7376; Rottapel, Robert/0000-0002-6024-5558				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 1998, BLOOD CELL MOL DIS, V24, P262, DOI 10.1006/bcmd.1998.0191; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Casteran N, 1998, LEUKEMIA, V12, P1089, DOI 10.1038/sj.leu.2401057; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; DASTYCH J, 1994, J IMMUNOL, V152, P213; Frost MJ, 2002, MOL CANCER THER, V1, P1115; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; KINASHI T, 1994, BLOOD, V83, P1033; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1997, CANCER RES, V57, P2203; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; London CA, 1999, EXP HEMATOL, V27, P689, DOI 10.1016/S0301-472X(98)00075-7; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Ma YS, 1999, J INVEST DERMATOL, V112, P165, DOI 10.1046/j.1523-1747.1999.00488.x; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakao M, 1996, LEUKEMIA, V10, P1911; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sperr WR, 1998, BRIT J HAEMATOL, V103, P740; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; Tsujimura Tohru, 1997, Leukemia (Basingstoke), V11, P396; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	53	61	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4710	4722		10.1038/sj.onc.1206587	http://dx.doi.org/10.1038/sj.onc.1206587			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879016				2022-12-17	WOS:000184157000012
J	Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M				Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M			Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases	ONCOGENE			English	Article						FOXO3a; transcription; cleavage; caspase; Fas; apoptosis	SERUM RESPONSE FACTOR; RECEPTOR-INDUCED APOPTOSIS; INDUCED CELL-DEATH; SIGNALING COMPLEX; FACTOR FKHR-L1; FACTOR FKHRL1; FAS LIGAND; T-CELLS; PROTEIN; DOWNSTREAM	Forkhead family transcription factors are critical regulators of cell cycle progression and apoptosis in hematopoietic cells. Here, we show that FOXO3a (also known as FKHRL1) is a new substrate of caspase-3-like proteases during apoptosis in T lymphocytes. FOXO3a was cleaved in vivo by caspases in leukemic Jurkat cells following engagement of Fas (CD95) receptor, staurosporine, and etoposide treatment, but not following engagement of CD99, a caspase-independent cell death inducer. Caspase-mediated cleavage of FOXO3a was also observed in CD4 +. peripheral T cells subjected to activation-induced cell death. The expression of the death adapter FADD and caspase-8 was required for Fas-induced FOXO3a cleavage, but activation of survival pathways by overexpression of FLICE-inhibitory protein or phorbol myristate acetate treatment prevented it. FOXO3a was cleaved in vitro by caspase-3-like proteases at the consensus sequence DELD(304)A, releasing the N-terminal DNA-binding domain of FOXO3a from its C-terminal transactivating domain. Whereas full-length FOXO3a enhanced Forkhead response element-dependent transcription and apoptosis in Jurkat cells, both fragments were inactive to promote gene activation and cell death. In contrast, a caspase-resistant FOXO3a mutant exhibited enhanced transcriptional and proapoptotic activities. Together, these results indicate that the proteolytic cleavage of FOXO3a by caspases may represent a novel regulatory mechanism of FOXO3a activity during death receptors signaling.	Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France; Fac Med Nice, INSERM, U526, IFR50, F-06107 Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Deckert, M (corresponding author), Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France.		luciano, frederic/P-6264-2016; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/AAJ-4760-2021; Jacquel, Arnaud/O-1928-2017; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	luciano, frederic/0000-0001-9253-4998; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Deckert, Marcel/0000-0003-2094-559X				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Noraz N, 2000, J BIOL CHEM, V275, P15832, DOI 10.1074/jbc.M908568199; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ravi R, 1998, CANCER RES, V58, P882; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	41	61	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4557	4568		10.1038/sj.onc.1206778	http://dx.doi.org/10.1038/sj.onc.1206778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881712				2022-12-17	WOS:000184054700011
J	Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS				Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS			Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells	ONCOGENE			English	Article						TFPI-2; 5 '-CpG methylation; gliomas; methyl CpG-group binding protein; historic deacetylation; gene silencing; epigenetic mechanisms; proteinase inhibitor	HISTONE DEACETYLASE INHIBITION; IN-VITRO; TRANSCRIPTIONAL REPRESSOR; PROTEASE INHIBITOR; CANCER-CELLS; CDNA CLONING; GENE; DNA; MATRIX; EXPRESSION	We have shown previously that the tissue factor pathway inhibitor-2 (TFPI-2), a broad range proteinase inhibitor, is highly expressed in low-grade gliomas, but, minimally expressed or undetectable in glioblastomas, and that enforced expression of this gene reduces the invasive properties of brain tumor cells. Here, we examined the role of promoter methylation as a mechanism of TFPI-2 gene silencing. In SNB19 glioblastoma cells, which have no detectable TFPI-2 expression, 5-aza-2'-deoxycytidine (5aC), an inhibitor of DNA methyltransferase, induced TFPI-2 mRNA in a dose-dependent manner. Trichostatin A (TSA), the histone deacetylase (HDAC) inhibitor, by itself, was more efficient than 5aC in inducing TFPI-2 transcripts, and the 5aC + TSA combination resulted in highly synergistic reactivation of the gene, both at the transcript and protein levels. In Hs683 glioma cells, which express the TFPI-2 gene at high levels, transfection of the in vitro methylated TFPI-2 promoter constructs resulted in a drastic decrease of promoter activity compared to the unmethylated promoter. Further, the methylation-specific PCR in SNB19 and Hs683 cells showed that TFPI-2 gene repression was closely linked with methylation of the CpG islands in the promoter. Finally, the chromatin immunoprecipitation assays in SNB19 cells showed that the methylated and repressed TFPI-2 promoter was associated with the methyl-CpG binding protein 2 (MeCP2), and that gene reactivation resulted in the loss of MeCP2 from this site. These studies establish that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.ed						BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Esteller M, 2001, CANCER RES, V61, P3225; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; McQueen HA, 1998, GENOME RES, V8, P621, DOI 10.1101/gr.8.6.621; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; RAO JS, 1993, CANCER RES, V53, P2208; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Yang XW, 2001, CANCER RES, V61, P7025	31	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4509	4516		10.1038/sj.onc.1206695	http://dx.doi.org/10.1038/sj.onc.1206695			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881707				2022-12-17	WOS:000184054700006
J	Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L				Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L			The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines	ONCOGENE			English	Article						glioma; MARK4; neural progenitor; upregulation and overexpression; intrachromosomal amplification; Wnt pathway	HUMAN-MALIGNANT GLIOMAS; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR GENE; BRAIN-TUMORS; HUMAN ASTROCYTOMAS; FACTOR RECEPTOR; FRAGILE SITES; EXPRESSION; AMPLIFICATION	Alterations of 19q13 are frequently observed in glial neoplasms, suggesting that this region harbors at least one gene involved in gliomagenesis. Following our previous studies on structural 19q chromosome rearrangements in gliomas, we have undertaken a detailed FISH analysis of the breakpoints and identified a 19q13.2 intrachromosomal amplification of the MAP/microtubule affinity-regulating kinase 4 (MARK4) gene in three primary glioblastoma cell lines. Recent data suggest that this gene is involved in the Wnt-signating pathway. We observed that the expression of the alternatively spliced MARK4L isoform is upregulated in both fresh and cultured gliomas and overexpressed in all of the above three glioblastoma cell lines. Interestingly, we also found that MARK4L expression is restricted to undifferentiated neural progenitor cells or proliferating glial precursor cells, whereas its expression is downregulated during glial differentiation. Perturbation of expression using antisense oligonucleotides against MARK4 in glioblastoma cell tines, consistently induced a decreased proliferation of tumor cells. Taken together, these data show that MARK4, which is normally expressed in neural progenitors, is re-expressed in gliomas and may become a key target of intrachromosomal amplification upon 19q rearrangements.	Univ Milan, Dept Biol & Genet, I-20133 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Milan; IRCCS Istituto Neurologico Besta; Roswell Park Cancer Institute	Beghini, A (corresponding author), Univ Milan, Dept Biol & Genet, Via Viotti 3-5, I-20133 Milan, Italy.	alessandro.beghini@unimi.it	Beghini, Alessandro/F-7306-2012; Finocchiaro, Gaetano/AAG-6791-2020; Pollo, Bianca/K-5347-2018	Pollo, Bianca/0000-0002-5523-4256; Cowell, John/0000-0002-2079-5950; Finocchiaro, Gaetano/0000-0003-3583-4040; Beghini, Alessandro/0000-0002-8234-3474; Moroni, Ramona Frida/0000-0002-0461-3213	NCI NIH HHS [CA76457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1995, INT J CANCER, V64, P207; BIGNER SH, 1988, CANCER RES, V48, P405; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hartmann C, 2002, CANCER RES, V62, P4100; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; JEN J, 1994, CANCER RES, V54, P6353; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Lee JC, 2000, GLIA, V30, P105, DOI 10.1002/(SICI)1098-1136(200004)30:2<105::AID-GLIA1>3.0.CO;2-H; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Magnani I, 1999, CANCER GENET CYTOGEN, V110, P82, DOI 10.1016/S0165-4608(98)00190-3; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MARSDEN HB, 1983, INT J CANCER, V31, P439, DOI 10.1002/ijc.2910310408; Megason SG, 2002, DEVELOPMENT, V129, P2087; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NOBEL M, 1997, J NEUROONCOL, V35, P193; PEREGO P, 1994, J CANCER RES CLIN, V120, P585, DOI 10.1007/BF01212812; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sano T, 1999, CANCER RES, V59, P1820; Satoh J, 2000, NEUROPATHOLOGY, V20, P113, DOI 10.1046/j.1440-1789.2000.00293.x; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zurawel RH, 1998, CANCER RES, V58, P896	42	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2581	2591		10.1038/sj.onc.1206336	http://dx.doi.org/10.1038/sj.onc.1206336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12735302				2022-12-17	WOS:000182569000006
J	Oertle, T; Merkler, D; Schwab, ME				Oertle, T; Merkler, D; Schwab, ME			Do cancer cells die because of Nogo-B?	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmatic reticulum; SaOS-2	NSP-ENCODED RETICULONS; ENDOPLASMIC-RETICULUM; LUNG-CANCER; SUBCELLULAR-LOCALIZATION; NEUROENDOCRINE MARKERS; GENE FAMILY; PROTEIN; APOPTOSIS; BCL-2; SURVIVAL	Nogo-A is a potent neurite outgrowth inhibitory protein in vitro and is suggested to play a role in the lack of regeneration in the central nervous system of adult higher vertebrates. A shorter splice isoform, ASY/Nogo-B, has recently been reported to act as a proapoptotic protein, the loss of which would be typical for cancer cells. Here, we show that the osteosarcoma cell line SaOS-2 and the cell line CHO do express high levels of endogenous Nogo-B and that stable transfectants overexpressing high levels of Nogo-B do not differ significantly from the respective parental wild-type or control cell lines both in respect to cell proliferation and to spontaneous apoptosis or cell death induced by staurosporine and tunicamycin. The deletion of the second transmembrane domain of Nogo-B, which has been claimed to abolish its proapoptotic activity, leads to a shift of the protein from the ER to a cytoplasmic localization, suggesting that ER stress of highly overexpressed Nogo-B may lead to aversive cellular reactions under particular conditions. Our data do not support a function of Nogo-B as a physiological proapoptotic protein in certain types of cancer.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Oertle, T (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016; Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Bongarzone ER, 2001, J NEUROSCI RES, V65, P485, DOI 10.1002/jnr.1178; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huber AB, 2002, J NEUROSCI, V22, P3553; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; MICHEL A, 1999, ELECT J PATHOL HISTO, V5, P993; Morris NJ, 1999, BBA-MOL CELL RES, V1450, P68, DOI 10.1016/S0167-4889(99)00033-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Senden N, 1997, HISTOCHEM CELL BIOL, V108, P155, DOI 10.1007/s004180050157; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; SENDEN NHM, 1994, EUR J CELL BIOL, V65, P341; Senden NHM, 1997, J PATHOL, V182, P13; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VANDEVELDE HJK, 1994, CANCER RES, V54, P4769; Woynarowska BA, 2002, BBA-MOL BASIS DIS, V1587, P309, DOI 10.1016/S0925-4439(02)00094-7	29	61	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1390	1399		10.1038/sj.onc.1206278	http://dx.doi.org/10.1038/sj.onc.1206278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618765				2022-12-17	WOS:000181360900014
J	Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H				Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H			Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer	ONCOGENE			English	Article						oncogene; amplification; quantitative PCR; therapy	TRANSCRIPTION-PCR ASSAY; P53 GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; C-MYC; MULTIVARIATE-ANALYSIS; MONOCLONAL-ANTIBODY; CARCINOMAS; CHEMOTHERAPY; EXPRESSION	Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.	Hop St Louis, Serv Biochim B, F-75475 Paris 10, France; Hop St Louis, CNRS, UPR9051, F-75475 Paris 10, France; UPRES, Fac Sci Pharmaceut & Biol, Genet Mol Lab, JE 2195, F-75006 Paris, France; Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, F-92210 St Cloud, France; Hop St Louis, Serv Anat Pathol, F-75475 Paris 10, France; Hop St Louis, INSERM, ERM 0220, F-75475 Paris 10, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Hop St Louis, Serv Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr	Bièche, Ivan/O-7399-2017; Vidaud, Michel/O-7346-2017	Bièche, Ivan/0000-0002-2430-5429; 				BERTHEAU P, 2002, IN PRESS LANCET; Bieche I, 1999, CANCER RES, V59, P2759; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Bieche I, 1999, CLIN CHEM, V45, P1148; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang S, 1998, CANCER, V82, P2366; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COLES C, 1992, CANCER RES, V52, P5291; Cuny M, 2000, CANCER RES, V60, P1077; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Degeorges A, 1998, BREAST CANCER RES TR, V47, P47, DOI 10.1023/A:1005824216444; Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P5, DOI 10.1089/cbr.1999.14.5; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P303; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; GARCIA I, 1989, CANCER RES, V49, P6675; Gradishar WJ, 1996, SEMIN SURG ONCOL, V12, P352; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUERIN M, 1988, ONCOGENE RES, V3, P21; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kerangueven F, 1997, CANCER RES, V57, P5469; Nakopoulou LL, 1996, J PATHOL, V179, P31, DOI 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sainsbury JRC, 2000, BRIT MED J, V321, P745, DOI 10.1136/bmj.321.7263.745; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Sjostrom J, 1998, BRIT J CANCER, V78, P812, DOI 10.1038/bjc.1998.584; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Turpin E, 1999, ONCOGENE, V18, P7834, DOI 10.1038/sj.onc.1203196; *UICC, 1909, TNM CLASS MAL TUM, P123; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincent-Salomon A, 2000, EUR J CANCER, V36, P586, DOI 10.1016/S0959-8049(99)00339-1; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	43	61	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7593	7597		10.1038/sj.onc.1205932	http://dx.doi.org/10.1038/sj.onc.1205932			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386822				2022-12-17	WOS:000178618200015
J	Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH				Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH			ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation	ONCOGENE			English	Article						ETV6-NTRK3; IGF1 receptor; IRS-1	FACTOR-I RECEPTOR; CONGENITAL MESOBLASTIC NEPHROMA; DOMINANT-NEGATIVE MUTANT; MOUSE EMBRYO FIBROBLASTS; TYPE-1 IGF RECEPTOR; GENE FUSION; PLECKSTRIN HOMOLOGY; TUMOR PROGRESSION; BREAST-CANCER; INHIBITION	Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation. The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6.-NTRK3 (EN). EN transforms N1H3T3 fibroblasts through constitutive activation of both the Ras-mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'kinase (PI3K)-Akt pathway. However, the role of trisomy 11 in CFS and CMN remains unknown. In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors. Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation. EN only very weakly transformed so-called R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFR1), but transformation activity was fully restored in R cells engineered to re-express IGFRI (R + cells). We also observed that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunoprecipitated with EN in either R- or R+ cells expressing the EN oncoprotein. IRS-1 association with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, respectively, was enhanced in both cell types in the presence of EN. However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R- cells compared to EN-transformed R + cells. This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI. Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.	BC Res Inst Childrens & Womens Hlth, Dept Pathol, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; BC Res Inst Childrens & Womens Hlth, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Hop St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada	University of British Columbia; Universite de Montreal	Sorensen, PH (corresponding author), BC Res Inst Childrens & Womens Hlth, Dept Pathol, Room 3082-950,W 28Th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca						BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERNSTEIN R, 1994, CANCER GENET CYTOGEN, V78, P82, DOI 10.1016/0165-4608(94)90051-5; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Dal Cin P, 1998, CANCER GENET CYTOGEN, V103, P68, DOI 10.1016/S0165-4608(97)00350-6; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Downward J, 1996, CANCER SURV, V27, P87; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Fisher C, 1996, EUR J CANCER, V32A, P2094, DOI 10.1016/S0959-8049(96)00287-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; Hongo A, 1996, ONCOGENE, V12, P1231; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KANEKO Y, 1991, CANCER RES, V51, P5937; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Kriauciunas KM, 2000, MOL CELL BIOL, V20, P6849, DOI 10.1128/MCB.20.18.6849-6859.2000; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MASCARELLO JT, 1994, CANCER GENET CYTOGEN, V77, P50, DOI 10.1016/0165-4608(94)90148-1; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2001, J CELL PHYSIOL, V186, P35; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OMalley DP, 1996, ULTRASTRUCT PATHOL, V20, P417, DOI 10.3109/01913129609016344; Pahlman S, 1996, MOL MED TODAY, V2, P432, DOI 10.1016/1357-4310(96)84847-7; Pass HI, 1996, CANCER RES, V56, P4044; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLYCHRONAKOS C, 1995, DEV GENET, V17, P253, DOI 10.1002/dvg.1020170310; Ponten J, 1971, Virol Monogr, V8, P1; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHOFIELD DE, 1994, AM J SURG PATHOL, V18, P14, DOI 10.1097/00000478-199401000-00002; SCHOFIELD DE, 1993, AM J PATHOL, V143, P714; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHARIFAH NA, 1995, DIAGN MOL PATHOL, V4, P279, DOI 10.1097/00019606-199512000-00009; Steller MA, 1996, CANCER RES, V56, P5087; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tognon C, 2001, CANCER RES, V61, P8909; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang W, 1998, CANCER RES, V58, P4426; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Werner H, 1998, MOL CELL ENDOCRINOL, V141, P1, DOI 10.1016/S0303-7207(98)00099-9; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	70	61	63	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5684	5695		10.1038/sj.onc.1205669	http://dx.doi.org/10.1038/sj.onc.1205669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173038				2022-12-17	WOS:000177463400003
J	Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH				Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH			Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus	ONCOGENE			English	Article						mitochondrial DNA; D-Loop; mutation; Barrett's cancer; carcinogenesis	SOMATIC MUTATIONS; OXIDATIVE DAMAGE; GASTRIC TUMORS; NUCLEAR-DNA; CANCER; GENOME; P53; INSTABILITY; PROGRESSION; SEQUENCE	Mitochondrial DNA (mtDNA) is known for high mutation rates caused by lack of protective histones, inefficient DNA repair systems, and continuous exposure to mutagenic effects of oxygen radicals. We examined the frequency of mutations in the mtDNA D-Loop region in 20 patients with Barrett's carcinoma and associated Barrett's epithelium by automated DNA sequencing. Mutations were detected in eight of 20 (40%) patients in tumor and/or tumor-associated Barrett's epithelium. In six of eight positive cases, the mutations were detected only in the tumor, one of eight showed mutations in tumor and Barrett's epithelium, and one of eight only in Barrett's epithelium. The degree of dysplasia in Barrett's epithelium was classified low-grade in one and high grade in the two specimens. There was no association of mtDNA D-Loop mutations with histopathological stage of disease or tumor grading. We present the first study of frequent occurrence of mutations in the mtDNA D-Loop regions in adenocarcinomas in Barrett's esophagus. Furthermore, this study supports the hypothesis that oxidative damage might be a mechanism for the induction of adenocarcinoma in Barrett's esophagus. Since mutations were identified in tumor-associated dysplastic Barrett's epithelium, they also might become a marker for the malignant potential of Barrett's epithelium.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; Kagoshima Univ, Sch Med, Dept Surg 1, Kagoshima 8908520, Japan	University of Cologne; University of Cologne; Kagoshima University	Schneider, PM (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	Paul.Schneider@Medizin.Uni-Koeln.de		Warnecke-Eberz, Ute/0000-0002-2833-5633				Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Armstrong J, 2000, PEDIATR NEUROL, V23, P85, DOI 10.1016/S0887-8994(00)00158-2; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.3.CO;2-E; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; HEERDT BG, 1994, CANCER RES, V54, P3912; HERMANEK P, 1992, UICC TNM KLASSIFIKAT, P9; Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Miller KWP, 1996, INT J LEGAL MED, V109, P107, DOI 10.1007/BF01369668; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLYAEE M, 1995, GUT, V37, P168, DOI 10.1136/gut.37.2.168; Polkowski W, 1999, HISTOL HISTOPATHOL, V14, P927, DOI 10.14670/HH-14.927; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; Reid BJ, 1996, EUR J CANCER PREV, V5, P57, DOI 10.1097/00008469-199612002-00009; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REIDDEL RH, 1985, BARRETTS ESOPHAGUS, P224; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Schneider PM, 1996, J THORAC CARDIOV SUR, V111, P323, DOI 10.1016/S0022-5223(96)70441-5; Schneider PM, 2000, CLIN CANCER RES, V6, P3153; Schrump DS, 1999, DIS ESOPHAGUS, V12, P181; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Tamura G, 1999, EUR J CANCER, V35, P316, DOI 10.1016/S0959-8049(98)00360-8; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wetscher GJ, 1998, AM J SURG, V176, P569, DOI 10.1016/S0002-9610(98)00258-X; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; WILSON MR, 1995, BIOTECHNIQUES, V18, P662	36	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3780	3783		10.1038/sj.onc.1205532	http://dx.doi.org/10.1038/sj.onc.1205532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032845				2022-12-17	WOS:000175676000012
J	Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y				Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y			HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas	ONCOGENE			English	Article						CpG island; DNA methylation; HOX gene	DNA METHYLATION; EXPRESSION; COMPLEX	CpG island methylation results in the silencing of the associated gene and is an important step in tumorigenesis. Following a comprehensive isolation of CpG islands that were methylated in human lung adenocarcinoma, we found that in cancer cells de novo CpG island methylation generally occurred in a sporadic manner. However, some methylated CpG islands appeared to cluster in discrete chromosomal regions. In this study, we have investigated the methylation status of CpG islands located at such chromosomal loci. We have found that many CpG islands at the HOXA and HOXD loci were methylated in human lung adenocarcinoma. The de novo methylation of these CpG islands was also observed in patient's DNA from noncancerous portions of lung tissue. These results indicate the presence of specific chromosomal regions that are susceptible to de novo methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Golpon HA, 2001, AM J PATHOL, V158, P955, DOI 10.1016/S0002-9440(10)64042-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kappen C, 1996, AM J RESP CELL MOL, V15, P156, DOI 10.1165/ajrcmb.15.2.8703471; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 2002, IN PRESS ONCOGENE, V21; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426	19	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3659	3662		10.1038/sj.onc.1205453	http://dx.doi.org/10.1038/sj.onc.1205453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032868				2022-12-17	WOS:000175793700017
J	Li, D; Williams, JI; Pietras, RJ				Li, D; Williams, JI; Pietras, RJ			Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression	ONCOGENE			English	Article						VEGF; erb B2/neu; MAP kinase; carboplatin; vascular endothelial cells	HUMAN-BREAST; TUMOR XENOGRAFTS; FACTOR VEGF; IN-VIVO; RECEPTOR; EXPRESSION; KINASE; TRANSFORMATION; AMINOSTEROL; MECHANISMS	Angiogenesis is important for growth and progression of ovarian cancers. Squalamine is a natural antiangiogenic sterol, and its potential role in treatment of ovarian cancers with or without standard cisplatin chemotherapy was assessed. Since HER-2 gene overexpression is associated with cisplatin resistance in vitro and promotion of tumor angiogenesis in vivo, the response of ovarian cancer cells with or without HER-2 gene overexpression to squalamine and cisplatin was evaluated both in tumor xenograft models and in tissue culture. Ovarian cancer cells with or without HER-2 overexpression were grown as subcutaneous xenografts in nude mice. Animals were treated by intraperitoneal injection with control vehicle, cisplatin, squalamine or cisplatin combined with squalamine. At the end of the experiment, tumors were assessed for tumor growth inhibition and for changes in microvessel density and apoptosis. Additional in vitro studies evaluated effects of squalamine on tumor and endothelial cell growth and on signaling pathways in human endothetial cells. Profound growth inhibition was elicited by squalamine alone and by combined treatment with squalamine and cisplatin for both parental and HER-2-overexpressing ovarian tumor xenografts. Immunohistochemical evaluation of tumors revealed decreased microvessel density and increased apoptosis. Although HER-2-overexpressing tumors had more angiogenic and less apoptotic activity than parental cancers, growth of both tumor types was similarly suppressed by treatment with squalamine combined with cisplatin. In in vitro studies, we found that squalamine does not directly affect proliferation of ovarian cells. However, squalamine significantly blocked VEGF-induced activation of MAP kinase and cell proliferation in human vascular endothelial cells. The results suggest that squalamine is anti-angiogenic for ovarian cancer xenografts and appears to enhance cytotoxic effects of cisplatin chemotherapy independent of HER-2 tumor status.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Genaera Corp, Plymouth Meeting, PA 19462 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.	rpietras@ucla.edu		Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [R29CA60835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Akhter S, 1999, AM J PHYSIOL-CELL PH, V276, pC136, DOI 10.1152/ajpcell.1999.276.1.C136; Alvarez AA, 1999, CLIN CANCER RES, V5, P587; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen Q, 1999, CLIN CANCER RES, V5, p3768S; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; Eckhardt SG, 1999, HOSP PRACT, V34, P63, DOI 10.3810/hp.1999.01.124; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOLDMAN JM, 1993, STEM CELLS, V11, P4, DOI 10.1002/stem.5530110903; Hellstrom I, 2001, CANCER RES, V61, P2420; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolfschoten GM, 2000, GYNECOL ONCOL, V76, P362, DOI 10.1006/gyno.1999.5689; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Luna LG, 1968, MANUAL HISTOLOGIC ST; MOORE KS, 1993, P NATL ACAD SCI USA, V90, P1354, DOI 10.1073/pnas.90.4.1354; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozols RF, 1999, SEMIN ONCOL, V26, P84; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PATNAIK A, 1999, P AN M AM SOC CLIN, V622, P1999; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIETRAS RJ, 1981, J BIOL CHEM, V256, P8536; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Plumb JA, 2000, CANCER RES, V60, P6039; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schiller JH, 1999, CLIN CANCER RES, V5, P4287; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Teicher BA, 1998, ANTICANCER RES, V18, P2567; WONG YF, 1995, GYNECOL OBSTET INVES, V40, P209, DOI 10.1159/000292337; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0	43	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2805	2814		10.1038/sj.onc.1205410	http://dx.doi.org/10.1038/sj.onc.1205410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973639				2022-12-17	WOS:000175063700004
J	Singh, J; Murata, K; Itahana, Y; Desprez, PY				Singh, J; Murata, K; Itahana, Y; Desprez, PY			Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex	ONCOGENE			English	Article						helix-loop-helix protein; proliferation; invasion; metastasis; transcription	LOOP-HELIX PROTEINS; HISTONE DEACETYLASE; DNA-BINDING; GENE; DIFFERENTIATION; ID1; REGULATOR; CARCINOMA; ROLES	The helix-loop-helix protein Id-1 is a dominant negative regulator of basic helix -loop- helix transcription factors, and plays a key role in the control of breast epithelial cell growth, invasion and differentiation. Previous investigations in our laboratory have shown that Id-1 mRNA was constitutively expressed in highly aggressive and invasive human breast cancer cells in comparison to non-transformed or non-aggressive cancerous cells, and that this loss of regulation is mediated by a 2.2-kb region of the human Id-1 promoter. Here we show that a 31 bp sequence within this 2.2-kb promoter, located 200 bp upstream of the initiation of transcription, is responsible for the constitutive expression of Id-1 in metastatic human breast cancer cells. Using gel shift experiments, we identified a high molecular weight complex present only in non-aggressive breast cancer cells cultured in serum-free medium and which appear to be necessary for proper Id-1 repression. In contrast, nuclear extracts from highly aggressive and metastatic cell lines do not contain this large molecular weight complex. Using DNA affinity precipitation assays (DAPA), we show that this complex contains SP-1, NF-1, Rb and HDAC-1 proteins. On the basis of these findings, we propose a mechanism for the loss of regulation of Id-1 promoter in invasive and metastatic human breast cancer cells.	Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	California Pacific Medical Center	Desprez, PY (corresponding author), Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, 2330 Clay St,Stern Bldg, San Francisco, CA 94115 USA.	pdesprez@cooper.cpmc.org			NCI NIH HHS [R01 CA82548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; CHEN HC, 1994, ONCOGENE, V9, P2905; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hu YC, 2001, CLIN CANCER RES, V7, P2213; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kaluz S, 1999, BIOTECHNIQUES, V26, P446, DOI 10.2144/99263bm18; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Polsky D, 2001, CANCER RES, V61, P6008; Schindl M, 2001, CANCER RES, V61, P5703; Singh J, 2001, J BIOL CHEM, V276, P11852, DOI 10.1074/jbc.M006931200; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; TAMURA G, 1994, PATHOL INT, V44, P34, DOI 10.1111/j.1440-1827.1994.tb02583.x; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	45	61	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1812	1822		10.1038/sj.onc.1205252	http://dx.doi.org/10.1038/sj.onc.1205252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896613				2022-12-17	WOS:000174284500003
J	Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y				Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y			Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells	ONCOGENE			English	Article						RB1CC1 (RB1-inducible coiled-coil 1); RB1 (retinoblastoma 1); MDR (multidrug resistance); neoplasm	P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HUMAN OSTEOSARCOMA; EXPRESSION; CHILDHOOD; PROTEIN	Multidrug resistance to anti-cancer agents (MDR) is a major barrier to successful cancer treatment. Current knowledge about genes that contribute to MDR is limited, however, and its mechanisms remain unclear. To identify genes involved in MDR, we performed differential display analysis and isolated a novel human gene, RB1CC1 (RBI-inducible Coiled-Coil 1). The 6.6-kb RB1CC1 cDNA encodes a putative 1594-amino-acid protein that contains a nuclear localization signal, a leucine zipper motif and a coiled-coil structure. Western blot analysis and immunocytochemical staining with anti-RB1CC1 antibody showed that endogenously expressed RB1CC1 protein localized to the nucleus. In MDR variants of human osteosarcoma cells, RB1CC1 expression increased in response to doxorubicin-induced cytotoxic stress and remained elevated for the duration of drug treatment. RB1CC1 expression levels correlated closely with those of RB1 (retinoblastoma 1) in cancer cell lines as well as in various normal human tissues. Moreover, introduction of wild-type RB1CC1 significantly induced RB1 expression in human leukemic cells. These data suggest that RB1CC1 may be a key regulator of RB1 gene expression.	Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Clin Lab Med, Shiga 5202192, Japan; RIKEN, SNP Res Ctr, Lab Bone & Joint Dis, Tokyo 1088639, Japan; Rizzoli Inst, Lab Onc Res, I-40136 Bologna, Italy; Shiga Univ Med Sci, Dept Surg 2, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science; RIKEN; Shiga University of Medical Science	Chano, T (corresponding author), Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Tsukinowa Cho, Otsu, Shiga 5202192, Japan.		Baldini, Nicola/J-4806-2016; Chano, Tokuhiro/F-5816-2018; Ikegawa, Shiro/N-6895-2015	Baldini, Nicola/0000-0003-2228-3833; Chano, Tokuhiro/0000-0002-9959-1183; Ikegawa, Shiro/0000-0003-0316-2147				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chano T, 2000, OSTEOARTHR CARTILAGE, V8, P115, DOI 10.1053/joca.1999.0279; FERRACINI R, 1995, ONCOGENE, V10, P739; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Sauerbrey A, 1996, BRIT J HAEMATOL, V94, P99, DOI 10.1046/j.1365-2141.1996.d01-1753.x; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1997, TIBS, V21, P14; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	20	61	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1295	1298		10.1038/sj.onc.1205178	http://dx.doi.org/10.1038/sj.onc.1205178			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850849				2022-12-17	WOS:000173729400017
J	Silberstein, GB; Dressler, GR; Van Horn, K				Silberstein, GB; Dressler, GR; Van Horn, K			Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth	ONCOGENE			English	Article						breast cancer; mammary; PAX2; progesterone; Wilms' tumor	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; GLAND DEVELOPMENT; WT1; APOPTOSIS; RECEPTOR; KIDNEY; DIFFERENTIATION; REPRESSION; PRODUCT	In this study, we first describe expression of the paired domain transcription factor PAX2 in the normal and cancerous human breast, then demonstrate in a murine model a novel function for PAX2 in the regulation of progesterone stimulation of secondary ductal growth. In human mammary tissue, PAX2 expression was coincident with sub-populations of mammary ductal cells, some of which possessed an undifferentiated histiotype, and was also found in >50% of the human breast tumors surveyed (n=38). In the mouse, mammary parenchyma with a targeted deletion of PAX2 developed normal ductal systems when grafted into wild-type host mammary fat pads, but failed to undergo higher order side-branching and lobular development in response to progesterone. A previously unsuspected PAX2/WT1 (Wilms' tumor suppressor gene) regulatory axis in the mammary gland was also indicated. Using RT-PCR, a significant reduction in WT1 mRNA expression was detected in the PAX2 mutant glands compared to wildtype counterparts and double-antibody immunohistochemistry detected the co-localization of PAX2 and WT1 in the nuclei of normal and cancerous breast cells. These data indicate a role for PAX2 (and possibly WT1) in the regulation of the progesterone response of the mature mammary gland. The potential contribution of PAX2 to breast tumor pathogenesis is discussed.	Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of California System; University of California Santa Cruz; University of Michigan System; University of Michigan	Silberstein, GB (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.				NIDDK NIH HHS [DK-48883, DK-54740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054740, R01DK048883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Dehbi M, 1996, ONCOGENE, V13, P447; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRESSLER GR, 2002, MOUSE DEV PATTERNING, P395; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUBOIS M, 1984, DEV BIOL, V106, P70; GNARRA JR, 1995, CANCER RES, V55, P4092; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Loeb DM, 2001, CANCER RES, V61, P921; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SMITH GH, 1988, J CELL SCI, V89, P173; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TOKER C, 1967, J ULTRA MOL STRUCT R, V21, P9, DOI 10.1016/S0022-5320(67)80003-0; Torres MA, 1996, DEVELOPMENT, V122, P3381; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Zhang GJ, 1998, ONCOL REP, V5, P1211	34	61	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1009	1016		10.1038/sj.onc.1205172	http://dx.doi.org/10.1038/sj.onc.1205172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850818				2022-12-17	WOS:000173580100004
J	Wilhelmsen, K; Burkhalter, S; van der Geer, P				Wilhelmsen, K; Burkhalter, S; van der Geer, P			C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus	ONCOGENE			English	Article						phosphotyrosine; protein-tyrosine kinase; v-fms; ubiquitination	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FMS PROTO-ONCOGENE; MEDIATED NEGATIVE REGULATION; FACTOR-I RECEPTOR; V-FMS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE INSERT; RING FINGER	The colony-stimulating factor-1 (CSF-1) receptor is a protein-tyrosine kinase that regulates the proliferation and differentiation of monocyte and macrophage precursors. Binding of CSF-1 to its receptor results in activation of the kinase domain and autophosphorylation on a number of tyrosine residues. Phosphorylated tyrosine residues function as binding sites for SH2 domain-containing signaling proteins. It is known that activated receptors are internalized and degraded, but the mechanics of this process remain largely unknown. Recently, evidence has started to emerge that the ubiquitin-protein ligase c-Cbl is involved in CSF-1 receptor degradation. In addition, there is evidence that the CSF-1 receptor carboxy-terminus is involved in down regulation of the receptor. Here we show that the c-Cbl tyrosine kinase-binding (TKB) domain binds in vitro and in vivo to the CSF-1 receptor. Binding is dependent on the receptor's protein-kinase activity. Deletion of the carboxy-terminus or mutation of Tyr 973 blocks binding. We further provide evidence that the CSF-1 receptor's carboxy-terminus is a substrate for autophosphorylation. Our observations are consistent with a model in which receptor autophosphorylation at Tyr 973 creates a binding site for c-Cbl. Association of c-Cbl with the receptor leads to ubiquitination, followed by receptor degradation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NCI NIH HHS [5T32 CA 09523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Novak U, 1996, ONCOGENE, V13, P2607; Ota J, 2000, FEBS LETT, V466, P96, DOI 10.1016/S0014-5793(99)01767-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	61	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1079	1089		10.1038/sj.onc.1205166	http://dx.doi.org/10.1038/sj.onc.1205166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850825				2022-12-17	WOS:000173580100011
J	Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V				Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V			The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions	ONCOGENE			English	Article						hTERT; VNTR; polymorphism	REVERSE-TRANSCRIPTASE HTERT; EMBRYONIC STEM-CELLS; CATALYTIC SUBUNIT; AFFECTIVE-DISORDERS; VARIABLE NUMBER; C-MYC; PROMOTER; IDENTIFICATION; MINISATELLITE; CLONING	In this work, the full-length hTERT gene was isolated and the sequence of the previously unknown region in intron 6 as well as that of upstream and downstream hTERT regions was determined. We have shown that intron 6 includes a variable number of tandem repeats (VNTR) of a 38 bp sequence, (hTERT-VNTR 6-1). Eight alleles of hTERT-VNTR 6-1 were identified among 103 unrelated individuals, ranging front 27 to 47 repeats. hTERT-VNTR 2-2 is another new 61 bp minisatellite repeat found in intron 2 of hTERT. At least four alleles of hTERT-VNTR 2-2 can be distinguished. Previous studies have described polymorphisms for minisatellites hTERT-VNTR 2-1, a 42 bp repeat in intron 2, and hTERT-VNTR 6-2, a 36 bp repeat in intron 6. These, together with another minisatellite found in intron 12, add up to five such structures within the hTERT gene. The segregation of hTERT minisatellites was analysed in families, revealing that the VNTRs are transmitted through meiosis following a Mendelian inheritance. Minisatellites in hTERT were also analysed in matching normal and cancer tissues from patients with tumors; in one patient with a kidney tumor, the two VNTRs in intron 6 had undergone concomitant rearrangements. This observation suggests that chromosomal rearrangements implicating these VNTRs may be associated with the activation of telomerase expression in cancer cells.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; DongA Univ, Dept Biol, Pusan 604714, South Korea; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Larionov, V (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 49,Room 4A56, Bethesda, MD 20892 USA.		Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Avilion AA, 1996, CANCER RES, V56, P645; Bailly S, 1996, MOL IMMUNOL, V33, P999, DOI 10.1016/S0161-5890(96)00042-9; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Choi YM, 2000, J HUM GENET, V45, P218, DOI 10.1007/s100380070030; Chowdhury MR, 2000, HAEMOPHILIA, V6, P625, DOI 10.1046/j.1365-2516.2000.00442.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Desseyn JL, 1999, ELECTROPHORESIS, V20, P493, DOI 10.1002/(SICI)1522-2683(19990301)20:3<493::AID-ELPS493>3.0.CO;2-7; FAIK P, 1994, GENOMICS, V21, P122, DOI 10.1006/geno.1994.1233; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakamura Y, 1998, J HUM GENET, V43, P149, DOI 10.1007/s100380050059; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; Shay JW, 1999, SCIENCE, V286, P2284, DOI 10.1126/science.286.5448.2284; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TURRI MG, 1995, NUCLEIC ACIDS RES, V23, P1854, DOI 10.1093/nar/23.11.1854; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yang F, 2000, AM J MED GENET, V95, P385, DOI 10.1002/1096-8628(20001211)95:4<385::AID-AJMG16>3.0.CO;2-V; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	46	61	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					769	777		10.1038/sj.onc.1205122	http://dx.doi.org/10.1038/sj.onc.1205122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850805				2022-12-17	WOS:000173427000008
J	Komata, T; Kanzawa, T; Kondo, Y; Kondo, S				Komata, T; Kanzawa, T; Kondo, Y; Kondo, S			Telomerase as a therapeutic target for malignant gliomas	ONCOGENE			English	Article						telomerase; telomerase RNA; telomerase reverse transcriptase; apoptosis; glioma	CATALYTIC SUBUNIT HTERT; PEPTIDE NUCLEIC-ACIDS; HUMAN BRAIN-TUMORS; REVERSE-TRANSCRIPTASE; CANCER-CELLS; IN-VITRO; HAMMERHEAD RIBOZYME; RNA COMPONENT; MAMMALIAN TELOMERASE; INTRACRANIAL TUMORS	Telomerase, a ribonucleoprotein enzyme, is considered as a potential target of cancer therapy because of its preferential expression in tumors. In particular, malignant gliomas are one of the best candidates for telomerase-targeted therapy. It is because malignant gliomas are predominantly telomerase-positive, while normal brain tissues do not express telomerase. In theory, there are two telomerase-associated therapeutic approaches for telomerase-positive tumors. One approach is the anti-telomerase cancer therapy to directly inhibit telomerase activity, resulting in apoptotic cell death or growth arrest. Two major components of the telomerase holoenzyme complex, the RNA template (hTER) and catalytic subunit (reverse transcriptase, hTERT) are well considered as therapeutic targets. The other approach is the telomerase-specific cancer therapy by targeting telomerase-expressing tumor cells as a means to directly kill the cells. Strategies using the transfer of therapeutic gene under the hTERT promoter system as well as immunotherapy directed against telomerase-positive cells are generally included. These telomerase-associated therapies are very promising for the treatment of malignant gliomas.	Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA; Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA	Icahn School of Medicine at Mount Sinai; Cleveland Clinic Foundation	Kondo, S (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Neurosurg, 1 Gustave L Levy Pl,Box 1136, New York, NY 10029 USA.			KANZAWA, TAKAO/0000-0002-8165-5652	NATIONAL CANCER INSTITUTE [R01CA080233, R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA80233, CA88936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; Carroll T, 1999, J PATHOL, V188, P395; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Chong EYY, 1998, HUM PATHOL, V29, P599, DOI 10.1016/S0046-8177(98)80009-9; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; Falchetti ML, 1999, J CLIN PATHOL, V52, P234, DOI 10.1136/jcp.52.3.234; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1996, MOL CELL BIOL, V16, P66; Gu J, 2000, CANCER RES, V60, P5359; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harada K, 2000, J NEUROSURG, V93, P618, DOI 10.3171/jns.2000.93.4.0618; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Heiser A, 2001, CANCER RES, V61, P3388; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hiraga S, 1998, CANCER RES, V58, P2117; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Huang F, 1999, J NEURO-ONCOL, V43, P137, DOI 10.1023/A:1006258817785; Johnson OL, 1997, PHARM RES-DORDR, V14, P730, DOI 10.1023/A:1012142204132; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kleinschmidt-DeMasters BK, 1998, J CLIN PATHOL, V51, P284, DOI 10.1136/jcp.51.4.284; Kleinschmidt-Demasters BK, 2000, HUM PATHOL, V31, P905, DOI 10.1053/hupa.2000.9086; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Koga S, 2001, ANTICANCER RES, V21, P1937; Koga S, 2001, GENE THER, V8, P654, DOI 10.1038/sj.gt.3301449; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; Komata T, 2001, CANCER RES, V61, P5796; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kondo Y, 2001, INT J ONCOL, V18, P1287; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; Le SY, 1998, NEUROSURGERY, V42, P1120, DOI 10.1097/00006123-199805000-00099; Ludwig A, 2001, CANCER RES, V61, P3053; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Melana SM, 1998, CLIN CANCER RES, V4, P693; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Mukai S, 2000, CANCER RES, V60, P4461; Multani AS, 1998, INT J ONCOL, V13, P923; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Piepmeier JM, 1997, J NEURO-ONCOL, V34, P1, DOI 10.1023/A:1005798901779; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Ramakrishnan S, 1998, CANCER RES, V58, P622; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Sallinen P, 1997, AM J PATHOL, V150, P1159; Sano T, 1998, BRIT J CANCER, V77, P1633, DOI 10.1038/bjc.1998.267; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; Takakura M, 1999, CANCER RES, V59, P551; Tejera AM, 2001, BREAST CANCER RES TR, V65, P93, DOI 10.1023/A:1006477730934; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weil RJ, 1999, MODERN PATHOL, V12, P41; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wright WE, 1996, DEV GENET, V18, P173; Yokoyama Y, 1998, CANCER RES, V58, P5406; Yokoyama Y, 2000, BIOCHEM BIOPH RES CO, V273, P316, DOI 10.1006/bbrc.2000.2939; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu J, 1996, GENE THER, V3, P472	84	61	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					656	663		10.1038/sj.onc.1205072	http://dx.doi.org/10.1038/sj.onc.1205072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850793	Bronze			2022-12-17	WOS:000173390500020
J	Cuenco, GM; Ren, RB				Cuenco, GM; Ren, RB			Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia	ONCOGENE			English	Article						BCR - ABL; AML1/MDS1/EVI1; AML; differentiation	INTERNAL TANDEM DUPLICATION; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; MYELOPROLIFERATIVE DISEASE; FUSION GENE; FLT3 GENE; FETAL LIVER; MICE; HEMATOPOIESIS; PROTEIN; AML1	The development of acute myelogenous leukemia (AML), which is characterized by a block of myeloid differentiation, is a multi-step process that involves several genetic abnormalities, but the molecular mechanisms by which these genetic alterations cooperate in leukemogenesis are poorly understood. The human chronic myelogenous leukemia (CML) is a model for multi-step leukemogenesis. BCR-ABL, a constitutively active tyrosine kinase, is a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of CML patients. BCR-ABL efficiently induces a myeloproliferative disorder (MPD) in mice. but progression to CML blast phase requires additional mutations. The AML1/MDS1/EVI1 (AME) transcription factor fusion protein, is a product of the human t(3;21)(q26;q22) translocation found as a secondary mutation in some cases of CML during the blast phase. We have previously shown that AME can induce an AML in mice but with a greatly extended latency, suggesting a requirement for additional mutations. Here we demonstrate that AME alone does not block myeloid differentiation in vivo during the 4-month pre-leukemia stage, yet co-expression of BRC-ABL and AME in mice can block myeloid differentiation and rapidly induce an AML. Our results suggest that block of myeloid differentiation and induction of AML involves cooperation between mutations that dysregulate protein tyrosine kinase signaling and those that disrupt hematopoietic gene transcription.	Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, MS029, Waltham, MA 02454 USA.				NIGMS NIH HHS [GM07122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007122] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHUJA HG, 1990, BLOOD, V75, P1684; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FIALKOW PJ, 1991, BLOOD, V77, P1415; FREDERICKSON TN, 2000, ATLAS MOUSE HEMATOPA; Goldman J M, 1997, Curr Opin Hematol, V4, P277; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HEUTTNE CS, 2000, NAT GENET, V24, P57; HOFFMAN R, 2000, HEMATOLOGY BASIC PRI; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; JACOBS A, 1991, LEUKEMIA, V5, P277; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Nakao M, 1996, LEUKEMIA, V10, P1911; NEUBAUER A, 1994, BLOOD, V83, P1603; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	42	61	65	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8236	8248		10.1038/sj.onc.1205095	http://dx.doi.org/10.1038/sj.onc.1205095			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781838				2022-12-17	WOS:000172507800007
J	Schilling, D; Pittelkow, MR; Kumar, R				Schilling, D; Pittelkow, MR; Kumar, R			IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes	ONCOGENE			English	Article						IEX-1; immediate early gene; apoptosis; cellular growth; cell stress	EARLY-RESPONSE GENE; IDENTIFICATION; EXPRESSION; RADIATION; P22/PRG1	IEX-1, an immediate early gene, is widely expressed in epithelial and endothelial tissues, and is altered by a variety of growth regulatory factors. We have shown that expression of IEX-1 in keratinocytes increases the growth rate of these cells. The effects of IEX-1 on apoptosis, however, are unclear. To clarify the effects of IEX-1 on apoptosis, we investigated the effects of IEX-1 expression in keratinocytes (HaCaT cells) in the basal state and after the induction of cellular stress. Under normal, non-stressed conditions, both control (HaCaT) and 1EX-1-transfected (IEX-HaCaT) cell lines showed no significant differences in the activity of a key apoptotic enzyme, caspase 3 despite significantly higher levels of IEX-1 expression. IEX-HaCaT cells grew faster than HaCaT cells. When both cell lines were irradiated with ultraviolet B radiation, caspase 3 activity increased to a greater extent in the IEX-HaCaT cells than in HaCaT cells. Camptothecin increased caspase 3 activity twice as much in the IEX-HaCaT cells when compared to HaCaT cells. When histone-complex DNA fragments were measured in IEX-HaCaT or HaCaT cells following UVB irradiation or treatment with camptothecin, significantly higher amounts of nucleosomes were seen in the IEX-HaCaT transfected cells. Likewise, serum deprivation induced higher degrees of apoptosis in IEX-HaCaT cells than in HaCaT cells. We conclude that overexpression of IEX-1 in HaCaT keratinocytes increases the growth rate of cells under basal conditions; in the basal state the rate of apoptosis is unchanged. However, the rate of apoptosis increases in IEX-1 overexpressing HaCaT keratinocytes after cells are subjected to stress.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, 200 1st St SW,911A Guggenheim, Rochester, MN 55905 USA.			Kumar, Rajiv/0000-0003-3497-3057	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR027032, R01AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK025409] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-27032] Funding Source: Medline; NIDDK NIH HHS [DK 58546, DK 25409, R01 DK058546, R01 DK025409] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; CHARLES CH, 1993, ONCOGENE, V8, P797; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	13	61	63	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7992	7997		10.1038/sj.onc.1204965	http://dx.doi.org/10.1038/sj.onc.1204965			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753682				2022-12-17	WOS:000172288700008
J	Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA				Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA			A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31	ONCOGENE			English	Article						tumor suppressor; nuclear protein; 5qNCA; leukemia; zinc finger; jmjC domain	COMMONLY DELETED REGION; MOLECULAR DELINEATION; 1A LGMD1A; HAIRLESS; MYELODYSPLASIA; ABNORMALITIES; DIAGNOSIS; DELETIONS; SEQUENCE; INTERVAL	Interstitial deletion or loss of chromosome 5, del(5q) or -5, is a frequent finding in myeloid leukemias and myelodysplasias, suggesting the presence of a tumor suppressor gene within the deleted region. In our search for this gene, we identified a candidate, 5qNCA (LOC51780), which lies within a consistently-deleted segment of 5q31. 5qNCA expresses a 7.2-kb transcript with a 5286-bp open reading frame which is present at high levels in heart, skeletal muscle, kidney, placenta, and liver as well as CD34+ cells and AML cell lines. 5qNCA encodes a 191-kD nuclear protein which contains a highly-conserved C-terminus containing a zinc finger with the unique spacing Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys and a jmjC domain, which is often found in proteins that regulate chromatin remodeling. Expression of 5qNCA in a del(5q) cell line results in suppression of clonogenic growth. Preliminary sequence results in AML and MDS samples and cell lines has revealed a possible mutation in the KG-1 cell line resulting in a THR to ALA substitution that has not been found in over 100 normal alleles to date. We propose 5qNCA is a good candidate for the del(5q) tumor suppressor gene based on its predicted function and growth suppressive activities, and suggest that further mutational and functional study of this interesting gene is warranted.	Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; Avalon Pharmaceut, Gaithersburg, MD USA; Rush Canc Inst, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University	Westbrook, CA (corresponding author), Univ Illinois, Dept Med, Hematol Oncol Sect, M-C 734,900 S Ashland, Chicago, IL 60607 USA.	cwcw@uic.edu		Mar, Brenton/0000-0002-3857-9324	NATIONAL CANCER INSTITUTE [P01CA075606, R01CA072593] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-72593, P01-CA-75606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartoloni L, 1998, GENOMICS, V54, P250, DOI 10.1006/geno.1998.5579; Brandt JE, 1999, BLOOD, V94, P106, DOI 10.1182/blood.V94.1.106.413k01_106_113; Christiansen H, 1996, PLANT MOL BIOL, V32, P809, DOI 10.1007/BF00020479; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Fairman J, 1996, BLOOD, V88, P2259, DOI 10.1182/blood.V88.6.2259.bloodjournal8862259; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; FURLEY AJ, 1986, BLOOD, V68, P1101; GALLAGHER R, 1979, BLOOD, V54, P713; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Horrigan SK, 1999, GENOMICS, V57, P24, DOI 10.1006/geno.1999.5765; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Hu ZB, 2000, BLOOD, V95, P1047, DOI 10.1182/blood.V95.3.1047.003k43_1047_1055; Lai F, 2000, GENOMICS, V70, P123, DOI 10.1006/geno.2000.6345; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1993, CANC SURVEYS, V15, P143; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; ROWLEY JD, 1981, BLOOD, V58, P759; SAMUELS BL, 1988, LEUKEMIA, V2, P79; SCHIFFER CA, 1989, BLOOD, V73, P263; Steube KG, 1997, LEUKEMIA LYMPHOMA, V25, P345, DOI 10.3109/10428199709114174; Thompson CC, 1996, J NEUROSCI, V16, P7832; Westbrook CA, 2000, BRIT J HAEMATOL, V110, P847, DOI 10.1046/j.1365-2141.2000.02285.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xie H, 2000, LEUKEMIA, V14, P2128, DOI 10.1038/sj.leu.2401935; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	34	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6946	6954		10.1038/sj.onc.1204850	http://dx.doi.org/10.1038/sj.onc.1204850			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687974				2022-12-17	WOS:000171641000016
J	Tonin, PN; Hudson, TJ; Rodier, F; Bossolasco, M; Lee, PD; Novak, J; Manderson, EN; Provencher, D; Mes-Masson, AM				Tonin, PN; Hudson, TJ; Rodier, F; Bossolasco, M; Lee, PD; Novak, J; Manderson, EN; Provencher, D; Mes-Masson, AM			Microarray analysis of gene expression mirrors the biology of an ovarian cancer model	ONCOGENE			English	Article						epithelial ovarian cancer; cell model; high-density microarray analysis; RNA expression analysis; signature patterns	CARCINOMA CELL-LINE; MOLECULAR CLASSIFICATION; MESSENGER-RNA; ESTABLISHMENT; ADENOCARCINOMA; PATTERNS; EPITHELIUM; SURVIVAL; ASCITES; PROTEIN	We have previously described an ovarian cancer model based on four independent spontaneously immortalized epithelial ovarian cancer cell lines (TOV-21G, TOV-81D, TOV-112D and OV-90) from patients who were never exposed to chemotherapy or radiation therapy. These cell lines are particularly interesting since they retain characteristics of the original epithelial ovarian cancers (EOC) from which they were derived. Here we report the characterization of this model system using high-density DNA microarrays in order to assess gene expression. Expression profiles were generated from total RNAs extracted from the four EOC cell lines. For comparison, expression profiling is also provided for a primary culture of normal ovarian surface epithelium (NOV-31) and a fresh EOC sample (TOV-578G). Comparison of expression profiles revealed patterns of expression that distinguish NOV-31 from that of all tumor derived samples. The expression pattern of Tov-81D, an EOC cell line that was derived from a patient with indolent disease, most closely resembles NOV-31 while profiles of samples derived from patients with more aggressive disease (TOV-21G, OV-90, TOV-112D and TOV-578G) showed more divergent patterns of expression. The microarray analysis (http://genome.mcgill.ca) results confirm the usefulness of an ovarian cancer model based on the characterization of these EOC cell lines.	McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3G 1A4, Canada; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Univ Montreal, Ctr Hosp, Ctr Rech, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	McGill University; McGill University; McGill University; McGill University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, ICM, Ctr Rech, 1560 Rue Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	Anne-Marie.Mes-Masson@umontreal.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X; Rodier, Francis/0000-0003-2523-309X				Alama A, 1996, GYNECOL ONCOL, V62, P82, DOI 10.1006/gyno.1996.0194; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Asschert JGW, 1997, EUR J CANCER, V33, P2246, DOI 10.1016/S0959-8049(97)00240-2; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552; BUICK RN, 1985, CANCER RES, V45, P3668; BULLER RE, 1995, GYNECOL ONCOL, V56, P39, DOI 10.1006/gyno.1995.1007; Chambers SK, 1998, INT J CANCER, V79, P449; Courjal F, 1996, INT J CANCER, V69, P247; CRICKARD K, 1989, GYNECOL ONCOL, V32, P163, DOI 10.1016/S0090-8258(89)80028-9; DISAIA P J, 1975, Gynecologic Oncology, V3, P215, DOI 10.1016/S0090-8258(75)80006-0; Fogh J, 1975, NEW HUMAN TUMOR CELL; GOLOMBICK T, 1991, EUR J CELL BIOL, V56, P459; GOLOMBICK T, 1990, IN VITRO CELL DEV B, V26, P447; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRUNT TW, 1993, DIFFERENTIATION, V53, P45, DOI 10.1111/j.1432-0436.1993.tb00644.x; HAMILTON TC, 1983, CANCER RES, V43, P5379; HIRTE HW, 1994, CANCER, V74, P900, DOI 10.1002/1097-0142(19940801)74:3<900::AID-CNCR2820740317>3.0.CO;2-N; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Huleihel M, 1997, EUR CYTOKINE NETW, V8, P179; KRUK PA, 1990, LAB INVEST, V63, P132; LANGDON SP, 1988, CANCER RES, V48, P6166; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mok SC, 1996, ONCOGENE, V12, P1895; Neyns B, 1996, ONCOGENE, V12, P1247; Ono K, 2000, CANCER RES, V60, P5007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; PROVENCHER DM, 1993, GYNECOL ONCOL, V50, P78, DOI 10.1006/gyno.1993.1167; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SINNA GA, 1979, GYNECOL ONCOL, V7, P267, DOI 10.1016/0090-8258(79)90104-5; St Croix B, 2000, SCIENCE, V289, P1197; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanner B, 1998, INT J GYNECOL PATHOL, V17, P66, DOI 10.1097/00004347-199801000-00012; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WONG WSF, 1990, GYNECOL ONCOL, V38, P37, DOI 10.1016/0090-8258(90)90008-9; WOODS LK, 1979, CANCER RES, V39, P4449; WYSOCKI SJ, 1990, CANCER RES, V50, P1800; YAMADA T, 1991, GYNECOL ONCOL, V40, P118, DOI 10.1016/0090-8258(91)90102-B	47	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6617	6626		10.1038/sj.onc.1204804	http://dx.doi.org/10.1038/sj.onc.1204804			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641787				2022-12-17	WOS:000171404200015
J	Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y				Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y			Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSLC1 gene family encoding transmembrane proteins	ONCOGENE			English	Article						tumor suppressor gene; TSLC1; TSLL1; TSLL2; glioma; prostate cancer	BINDING INTERFACE; CHROMOSOME 19Q; GLYCOPHORIN-C; HYBRIDIZATION; NEUREXIN; DOMAIN	We have recently identified the TSLC1 gene as a novel tumor suppressor in human non-small cell lung cancers. TSLC1 encodes a membrane glycoprotein with an extracellular domain homologous to those of immunoglobulin superfamily proteins. Truncation of TSLC1 in the cytoplasmic domain in a primary human tumor suggests that this domain is important for tumor suppressor activity. Here, we report the isolation of two TSLC1-like genes, TSLL1 and TSLL2, based on their structural homology with the sequences corresponding to the cytoplasmic domain of TSLC1. Significant similarity was also observed in the extracellular domain as well as in the overall gene structure, indicating that these three genes form a unique subfamily (the TSLC1-gene family) in the immunoglobulin superfamily genes. In contrast to the ubiquitous expression of TSLC1, TSLL1 is expressed exclusively in adult and fetal human brain, while TSLL2 is expressed in several specific tissues including prostate, brain, kidney and some other organs. Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML Inc, R&D Ctr, Kawagoe, Saitama 3501101, Japan	National Cancer Center - Japan; BML, Inc.	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022	Nomura, Sachio/0000-0001-9214-4041				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; DebiecRychter M, 1995, CANCER GENET CYTOGEN, V85, P61, DOI 10.1016/0165-4608(95)00129-8; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Shimura M, 1999, CANCER RES, V59, P2259; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73	17	61	71	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5401	5407		10.1038/sj.onc.1204696	http://dx.doi.org/10.1038/sj.onc.1204696			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536053				2022-12-17	WOS:000170575500016
J	Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK				Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK			Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres	ONCOGENE			English	Article						telomerase; telomeres; senescence; cell division; cell cycle inhibitors	HUMAN-DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR; LIFE-SPAN; STOCHASTIC MECHANISM; EPITHELIAL-CELLS; CDK-INHIBITOR; P53 PROTEIN; IN-VIVO; EXPRESSION; ARREST	Ectopic expression of telomerase blocks both telomeric attrition and senescence, suggesting that telomeric attrition is a mitotic counting mechanism that culminates in replicative senescence, By holding human fibroblast cultures confluent for up to 12 weeks at a time, we confirmed previous observations and showed that telomeric attrition requires cell division and also, that senescence occurs at a constant average telomere length, not at a constant time point. However, on resuming cell division, these long-term confluent (LTC) cultures completed 15-25 fewer mean population doublings (MPDs) than the controls prior to senescence. These lost divisions were mainly accounted for by slow cell turnover of the LTC cultures and by permanent cell cycle exit of 94% of the LTC cells, which resulted in many cell divisions being unmeasured by the MPD method, In the LTC cultures, p27(KIPI) accumulated and pRb became under-phosphorylated and under-expressed. Also, coincident with permanent cell cycle exit and before 1 MPD was completed, the LTC cultures upregulated the cell cycle inhibitors p21(WAF) and p16(INK4A) but not p14(ARF) developed other markers of senescence. We then tested the relationship between cell cycle re-entry and the cell cycle-inhibitory proteins following subculture of the LTC cultures. Tn these cultures, the downregulation of p27(KIPI) and the phosphorylation of pRb preceded the complete resumption of normal proliferation rate, which was accompanied by the down-regulation of p16(INK4A). Our results show that most normal human fibroblasts can accumulate p16(INK4A), p21(WAF) and p27(KIPI) and senesce by cell division-independent mechanism(s). Furthermore, this form of senescence likely requires p16(INK4A) and perhaps p27(KIPI).	CRC, Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Parkinson, EK (corresponding author), CRC, Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Dietrich C, 1997, EXP CELL RES, V232, P72, DOI 10.1006/excr.1997.3507; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; GOLDSTEIN S, 1974, EXP CELL RES, V88, P359, DOI 10.1016/0014-4827(74)90252-3; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Kamijo T, 1999, CANCER RES, V59, P2464; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rubelj I, 1999, J THEOR BIOL, V197, P425, DOI 10.1006/jtbi.1998.0886; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SMITH JR, 1980, SCIENCE, V207, P82; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tresini M, 1998, CANCER RES, V58, P1; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	49	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3541	3552		10.1038/sj.onc.1204460	http://dx.doi.org/10.1038/sj.onc.1204460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429701				2022-12-17	WOS:000169478300010
J	Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK				Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK			Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells	ONCOGENE			English	Article						TRAIL; apoptosis; SNP; nitric oxide; mitochondria; caspase; cytochrome c; Bcl-2	CYTOCHROME-C RELEASE; OXIDE-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; DEATH DOMAIN; PERMEABILITY TRANSITION; CASPASE ACTIVATION; DECOY RECEPTORS; CANCER-CELLS; IN-VIVO	The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo-2L) is a recently characterized member of the family of programmed cell death-inducing ligands that includes TNF-alpha and CD95L (FasL), It is well known that TRAIL binds to the death signaling receptors, DR4 and DR5, and initiates the TRAIL death pathway, Activation of this pathway, mediated through a caspase cascade, causes apoptosis, In this study, we hypothesized that oxidative stress facilitates TRAIL-induced apoptosis by promoting caspase activity through cytochrome c release from mitochondria, Human colorectal carcinoma CX-1 cells were treated with various concentrations of TRAIL (12.5-200 ng/ml) and/or sodium nitroprusside (SNP; 0.03-1 mM) for 12 h, SNP, a nitric oxide donor, which had little toxic effect by itself, enhanced TRAIL-induced cytotoxicity, For example, TRAIL-induced apoptosis (200 ng/ml) was increased by a factor of 2.5-fold in the presence of 1 mM SNP. The combined treatment also caused an increase in cytochrome c release, caspase-3 activity, and PARR cleavage, Overexpression of Bcl-2 completely blocked the SNP-promoting effects, but only moderately inhibited TRAIL-induced apoptosis, Similar results were observed in the presence of hydrogen peroxide or peroxynitrite. Taken together, the present studies suggest that SNP enhances TRAIL-induced cytotoxicity by facilitating the mitochondria-mediated caspase signal transduction pathway.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, Pittsburgh, PA 15213 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wayne State University; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA64139] Funding Source: Medline; NIGMS NIH HHS [GM44100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bal-Price A, 1999, ANN NY ACAD SCI, V893, P376, DOI 10.1111/j.1749-6632.1999.tb07859.x; BIANCO FJ, 1995, AM J PATHOL, V146, P75; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; IRMIER M, 1997, NATURE, V388, P190; ITOH N, 1993, J IMMUNOL, V151, P621; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Nagane M, 2000, CANCER RES, V60, P847; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou YW, 1998, CELL IMMUNOL, V186, P103, DOI 10.1006/cimm.1998.1297; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	53	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1476	1485		10.1038/sj.onc.1204225	http://dx.doi.org/10.1038/sj.onc.1204225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313891				2022-12-17	WOS:000167595200008
J	Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D				Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D			A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process	ONCOGENE			English	Article						PSA; adhesion; metastasis; nude mice; carcinogenesis	CELL-ADHESION MOLECULE; N-CAM; NEUROECTODERMAL TUMORS; MONOCLONAL-ANTIBODY; NEURONAL MIGRATION; OLFACTORY-BULB; NCAM; EXPRESSION; PROGRESSION; MOUSE	PSA is an oncodevelopmental antigen usually expressed in human tumors with high metastatic potential. Here we set up a metastatic model in nude mice by using TE671 cells, which strongly express PSA-NCAM. We observed the formation of lung metastases when TE671 cells were injected intravenously, intramuscularly, and intraperitoneously, hut not subcutaneously. Intraperitoneous injections also induced peritoneal carcinosis, ascites, and liver metastases. To evaluate the putative role of PSA in the metastatic process we used a specific cleavage of PSA on NCAM by endoneuraminidase-N on intraperitoneous primary tumors. Mice with primary intramuscular tumors were taken as control. Repeated injections of endoneuraminidase-N led to a decrease in PSA expression in primary intraperitoneous nodules and ascites but not in intramuscular primary tumors. Endoneuraminidase-N also increased the delay in ascitic formation and decreased the number of lung or liver metastases in the case of intraperitoneous tumors but not in the case of intramuscular tumors. When metastases occurred in endoneuraminidase-N injected animals, they strongly expressed PSA-NCAM. Therefore, we established a relationship between PSA expression on the surface of primary tumor cells and the metastatic process.	Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, F-13385 Marseille 05, France; CNRS, Lab Genet & Physiol Dev, F-13288 Marseille 09, France; Immunotech SA, Dept Imagerie & Therapeut, F-13009 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Figarella-Branger, D (corresponding author), Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, JE2053,27 Bd Jean Moulin, F-13385 Marseille 05, France.		ROUGON, Genevieve/G-2578-2013; daniel, laurent/R-2826-2016	ROUGON, Genevieve/0000-0003-1316-8200; daniel, laurent/0000-0002-7539-0109				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Daniel L, 2000, CANCER RES, V60, P80; DUBOIS C, 1995, J IMMUNOL METHODS, V181, P125, DOI 10.1016/0022-1759(94)00336-U; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FIGARELLABRANGER D, 1992, J NEUROPATH EXP NEUR, V51, P12, DOI 10.1097/00005072-199201000-00003; FIGARELLABRANGER DF, 1990, CANCER RES, V50, P6364; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GAFFNEY EF, 1993, AM J SURG PATHOL, V17, P601, DOI 10.1097/00000478-199306000-00008; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Gluer S, 1998, PEDIATR RES, V43, P145, DOI 10.1203/00006450-199801000-00022; GOKAL R, 1992, OXFORD TXB CLIN NEPH, P1477; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; HUSMANN M, 1989, EUR J IMMUNOL, V19, P1761, DOI 10.1002/eji.1830190935; KUBOTA T, 1994, J CELL BIOCHEM, V56, P4, DOI 10.1002/jcb.240560103; LACKIE PM, 1990, DEVELOPMENT, V110, P933; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; MCALLISTER RM, 1977, INT J CANCER, V20, P206, DOI 10.1002/ijc.2910200207; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; OUSMENAR BN, 1995, EUR J NEUROSCI, V7, P480; PARISH RW, 1987, J CELL SCI, P181; Rapoport J, 1999, NEPHRON, V81, P375, DOI 10.1159/000045319; ROUGON G, 1986, J BIOL CHEM, V261, P3396; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUGON G, 1993, POLYSIALIC ACID MICR, P323; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SILOBRCIC V, 1990, INT J CANCER, V45, P325, DOI 10.1002/ijc.2910450220; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; STRATTON MR, 1989, NATURE, V337, P311, DOI 10.1038/337311c0; Theodosis DT, 1999, J NEUROSCI, V19, P10228; TOGO S, 1995, CANCER RES, V55, P681; WANG C, 1994, J NEUROSCI, V14, P4446; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	42	61	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					997	1004		10.1038/sj.onc.1204176	http://dx.doi.org/10.1038/sj.onc.1204176			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314035				2022-12-17	WOS:000167097000011
J	Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM				Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM			Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF	ONCOGENE			English	Article						nuclear body; PML; APL; non Hodgkin lymphoma	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA FUSION PROTEIN; GERMINAL-CENTER FORMATION; B-CELL LYMPHOMA; PML-RAR-ALPHA; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	Most acute promyelocytic leukemia (APL) cases are associated with recurrent translocations between the gene of retinoic receptor alpha and that of PML (t(15;17)) or PLZF (t(11;17)), PML localizes onto discrete intranuclear domains, the PML-nuclear bodies, and displays anti-oncogenic and pro-apoptotic properties. PLZF encodes a transcription factor belonging to the (PO) under barZ/domain and Kruppel zinc finger (POK) family which interacts directly with PML, PLZF is related to another POK protein, LAZ3(BCL6), which is structurally altered, and presumably misexpressed, in many non-Hodgkin lymphoma (NHL) cases. PLZF and LAZ3 share many functional properties: both inhibit cell growth, concentrate into punctated nuclear subdomains and are sequence-specific transcriptional repressors recruiting a histone deacetylase-repressing complex. Given these similarities, we tested whether both proteins could be targeted by each other, Here, LAZ3 and PLZF are shown to colocalize onto nuclear dots. Moreover, truncated derivatives of one protein, which display a diffuse nuclear localization, are recruited onto nuclear dots by the full-length other. The colocalization and the reciprocal 'rescue' is the result of a direct interaction between LAZ3 and PLZF, as indicated by yeast two hybrid assays, in vitro immunoprecipitations, and GST pull down experiments. In contrast to LAZ3 homomerization, LAZ3/PLZF heteromerization in yeast does not solely depend on POZ/POZ contacts but rather also relies on interactions between the two zinc finger regions and 'cross' contacts between the zinc finger region and the POZ domain of each partner, Likewise, LAZ3 shows some colocalization with the PLZF partner PML upon stable overexpression of both proteins in CHO cells and interacts with PML in yeast. Finally, endogenous LAZ3 and PLZF are co-induced and partially colocalized in myeloid MDS cells, These data indicate that a physical interaction between LAZ3 and PLZF underlies their simultaneous recruitment onto multiproteic nuclear complexes, presumably involved in transcriptional silencing and whose integrity (for APL) and/or function (for APL and NHL) may be altered in oncogenesis.	Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, F-75475 Paris 10, France; IRCL, INSERM U524, F-59045 Lille, France; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Hop St Louis, INSERM U462, F-75475 Paris 10, France; UPR 1983, F-94801 Villejuif, France; MNHN, Stn Biol Marine, F-29182 Concarneau, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN)	Koken, MHM (corresponding author), Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		koken, marcel/J-8154-2012; Zelent, Arthur/B-3532-2009; koken, marcel/N-1349-2019; Guidez, Fabien/B-3750-2009; Guidez, Fabien/P-4220-2019	koken, marcel/0000-0002-0839-0125; Guidez, Fabien/0000-0003-1380-4473; Zelent, Arthur/0000-0002-7968-9888				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1999, BLOOD, V94, p368A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; James P, 1996, GENETICS, V144, P1425; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MACLEY JP, 1998, TIBS, V23, P1; MIKI T, 1994, BLOOD, V83, P26; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Niu HF, 1999, BLOOD, V94, p693A; Numoto M, 1999, BIOCHEM BIOPH RES CO, V256, P573, DOI 10.1006/bbrc.1999.0375; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROSE MD, 1990, METHODS YEAST GENETI; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	62	61	62	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6240	6250		10.1038/sj.onc.1203976	http://dx.doi.org/10.1038/sj.onc.1203976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175338				2022-12-17	WOS:000166210500007
J	Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T				Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T			PKC eta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes	ONCOGENE			English	Article						PKC eta; cell cycle; keratinocytes; p21	PLECKSTRIN HOMOLOGY DOMAIN; CAPILLARY ENDOTHELIAL-CELLS; PROTEIN-KINASE; PHORBOL ESTER; C-DELTA; MOUSE KERATINOCYTES; ACTIVATING KINASE; BINDING PROTEIN; NPKC-ETA; DIFFERENTIATION	PKC is activated on the cell membrane by phospholipids, thereby transducing signals to intracellular pathways. We provide here another function of PKC, namely, regulating cell cycle by interaction with the cyclin E/cdk2/p21 complex. Among the 10 isoforms of PKC, PKC eta is predominantly expressed in squamous cell epithelia and induces terminal differentiation of keratinocytes, PKC eta that is endogenously expressed or overexpressed was found to associate with the cyclin E/cdk2/p21 complex in keratinocytes of mice and humans. Requirement of a possible adaptor protein to the binding was suggested by the reconstitution of PKC eta and the cyclin E/cdk2/p21 complex which were prepared from human keratinocytes or Sf9 insect cells. Colocalization of PKC eta with cdk2 and cyclin E was observed in the cytoplasm, particularly in the perinuclear region. p21 was phosphorylated in the complex in a PKC-activator dependent manner. Association of PKC eta with cdk2 resulted in marked inhibition of cdk2-kinase activity when measured by phosphorylation of Rb, Dominant negative PKC eta associated with the cyclin E/cdk2/p21 complex, but caused a little inhibition of cdk2 kinase activity. Among the known regulatory mechanisms of cdk2 activity, dephosphorylation of Thr160 was demonstrated.	Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; National Cancer Center - Japan	Kuroki, T (corresponding author), Showa Univ, Inst Mol Oncol, Shinagawa Ku, 1-5-8 Katanodai, Tokyo 1428555, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; Ishino K, 1998, JPN J CANCER RES, V89, P1126, DOI 10.1111/j.1349-7006.1998.tb00507.x; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jaumot M, 1997, BIOCHEM BIOPH RES CO, V241, P434, DOI 10.1006/bbrc.1997.7787; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Livneh E, 1996, ONCOGENE, V12, P1545; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mochly-Rosen D, 1998, FASEB J, V12, P35; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morrow TA, 1999, MOL CELL BIOL, V19, P5608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	51	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6334	6341		10.1038/sj.onc.1204028	http://dx.doi.org/10.1038/sj.onc.1204028			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175348				2022-12-17	WOS:000166210500017
J	Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW				Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW			Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion	ONCOGENE			English	Article						transcription; AP-1; invasion	ONCOGENE-INDUCED TRANSFORMATION; DOMINANT-NEGATIVE MUTANT; C-JUN; CELL-TRANSFORMATION; PROTO-ONCOGENE; TUMOR INVASION; DNA-BINDING; IN-VITRO; MORPHOLOGICAL TRANSFORMATION; NEOPLASTIC TRANSFORMATION	The transcription factor AP-1 (activator protein-1) is required for transformation by many oncogenes, which function upstream of it in the growth factor-ras signal transduction pathway. Previously, we proposed that one role of AP-1 in transformation is to regulate the expression of a multigenic invasion programme. As a test of this proposal we sought to identify AP-1 regulated genes based upon their differential expression in 208F rat fibroblasts transformed by FBR-v-fos (FBR), and to determine if they functioned in the invasion programme. Subtracted cDNA libraries specific for up- or down-regulated genes in FBRs compared to 208Fs were constructed and analysed. Northern analysis revealed that the cDNAs in both libraries represented differentially expressed genes. Nucleic acid sequence analysis of randomly selected cDNA clones from each library coupled with searches of nucleic acid and amino acid sequence databases determined that many of the cDNAs represented proteins that function in various aspects of the invasion process. Functional analysis of one the down-regulated genes, TSC-36/follistatin-related protein (TSC-36/Frp), which has not previously been associated with invasion, demonstrated that its expression in FBRs inhibited in vitro invasion. These results support the proposal that AP-1 in transformed cells regulates a multigenic invasion programme.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ozanne, BW (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Stapleton, Genevieve/0000-0002-7493-5277				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bardelli A, 1997, CIBA F SYMP, V212, P133; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guang RJ, 2000, CANCER RES, V60, P749; HAJNAL A, 1993, CANCER RES, V53, P4670; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOOSS KU, 1995, ONCOGENE, V10, P603; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim S, 1996, ONCOGENE, V12, P1043; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Liang P, 1997, Methods Mol Biol, V85, P3; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lutfiyya LL, 1998, GENETICS, V150, P1377; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RIGBY PWJ, 1984, PHILOS T ROY SOC B, V307, P347, DOI 10.1098/rstb.1984.0138; SAEZ E, 1995, CANCER RES, V55, P6196; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOH Y, 1994, J BIOL CHEM, V269, P22958; Treinies I, 1999, MOL CELL BIOL, V19, P321; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WERNERT N, 1994, CANCER RES, V54, P5683; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WICK M, 1992, ONCOGENE, V7, P859; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	95	61	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5348	5358		10.1038/sj.onc.1203927	http://dx.doi.org/10.1038/sj.onc.1203927			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103936				2022-12-17	WOS:000165302300006
J	Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15/IL-15R alpha intracellular trafficking in human melanoma cells and signal transduction through the IL-15R alpha	ONCOGENE			English	Article						IL-15; IL-15R alpha; secretion pattern; NF-kappa B; melanoma progression	NF-KAPPA-B; IL-15; RECEPTOR; EXPRESSION; CYTOKINE; PROTEINS; ISOFORMS; PEPTIDES; ALPHA; CHAIN	There are two IL-15 isoforms and eight isoforms for the IL-15R alpha chain whose biological role is poorly understood. Here, we have analysed the intracellular trafficking of IL-15 and IL-15R alpha and tried to shed some light on their function(s), In IL-15/GFP CHO transfectants both IL-15 isoforms show nuclear localization. Two melanoma cell lines (MELP and MELREO) spontaneously expressing the IL-15 isoforms, display different intracellular trafficking of the IL-15/IL-15R alpha complex, In MELP cells only IL-15R alpha is detected inside the nucleus, whereas IL-15 and IL-15R alpha assemble at the cell surface and are internalized, Moreover, the transducing molecule TRAF2 co-immunoprecipitates with IL-15R alpha and may be deflected to TNFRI using anti-IL-15 blocking mAbs and TNF-alpha, By contrast, MELREO cells display IL-15R alpha and IL-15 nuclear localization but only a partial co-localization of these molecules on the cell surface. In these cells, TRAF2 is strongly associated with IL-15R alpha and cannot be deflected by any treatment, Since TRAF2 activates the transcription factor NF-kappaB, IL-15 through IL-15R alpha, could have a role in the control of this pathway. Indeed, anti-IL-15 MaB inhibit the constitutive nuclear localization of NF kappaB and the phosphorylation of its inhibitor I kappa -B alpha, Thus, IL-15R alpha controls NF-KB activation, however differences in the intracellular trafficking of the IL-15 and/or IL-15R alpha suggest a different biological role for this complex in MELP versus MELREO cells.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Ist Nazl Ric Canc, I-16132 Genoa, Italy; DIMI, Fac Med, I-16132 Genoa, Italy; DOCS, Fac Med, F-94800 Villejuif, France; Lab Cytometrie, CNRS, UPS 47, F-94800 Villejuif, France; Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Indiveri, Francesco/AAE-9086-2020; Giron-Michel, Julien/Q-4503-2018; Azzarone, Bruno/AAH-9251-2019; Meazza, Raffaella/AAC-2425-2019	Giron-Michel, Julien/0000-0001-6613-6099; Azzarone, Bruno/0000-0002-5962-3849; Meazza, Raffaella/0000-0003-0242-3157; Ferrini, Silvano/0000-0001-7254-2616; Induveri, Francesco/0000-0002-9280-2232				Alleva DG, 1997, J IMMUNOL, V159, P2941; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Duffey DC, 1999, CANCER RES, V59, P3468; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Hallahan DE, 1998, CANCER RES, V58, P5484; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 1996, ONCOGENE, V12, P2187; Musso T, 1999, BLOOD, V93, P3531; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Shah MH, 1998, NAT MED, V4, P643, DOI 10.1038/nm0698-643a; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393	21	61	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5153	5162		10.1038/sj.onc.1203873	http://dx.doi.org/10.1038/sj.onc.1203873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064452				2022-12-17	WOS:000090124100004
J	Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A				Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A			MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression	ONCOGENE			English	Article						chemokine; MGSA/GRO; Ras; AP-I; melanocytes; transformation	GROWTH-STIMULATORY ACTIVITY; PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAY; TISSUE DISTRIBUTION; CANCER-CELLS; SKIN TUMORS; KAPPA-B; C-FOS; ALPHA; BETA	The MGSA/GRO protein is endogenously expressed in almost 70% of the melanoma cell lines and tumors, but not in normal melanocytes. We have previously demonstrated that over-expression of human MGSA/GRO alpha, beta or gamma in immortalized murine melanocytes (melan-a cells) enables these cells to form tumors in SCID and nude mice. To examine the possibility that the MGSA/GRO effect on melanocyte transformation requires expression of other genes, differential display was performed. One of the mRNA's identified in the screen as overexpressed in MGSA/GRO transformed melan-a clones was the newly described M-Ras or R-Ras3 gene, a member of the Ras gene superfamily, Over-expression of MGSA/GRO upregulates M-Ras expression at both the mRNA and protein levels, and this induction requires an intact glutamine-leucine-arginine (ELR)-motif in the MGSA/ GRO protein. Western blot examination of Ras expression revealed that K- and N-Ras proteins are also elevated in MGSA/GRO-expressing melan-a clones, leading to an overall increase in the amount of activated Ras, MGSA/GRO-expressing melan-a clones exhibited enhanced AP-1 activity. The effects of MGSA/GRO on AP-I activation could be mimicked by over-expression of wild-type M-Ras or a constitutively activated M-Ras mutant in control melan-a cells as monitored by an API-luciferase reporter, while expression of a dominant negative M-Ras blocked AP-1-luciferase activity in MGSA/GRO-transformed melan-a clones. In the in vitro transformation assay, over-expression of M-Ras mimicked the effects of MGSA/GRO by inducing cellular transformation in control melan-a cells, while over-expression of dominant negative M-Ras in MGSA/ GRO alpha-expressing melan-a-6 cells blocked transformation. These data suggest that MGSA/GRO-mediated transformation requires Ras activation in melanocytes.	Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA; VA Med Ctr, Nashville, TN 37232 USA; Chiba Univ, Dept Biol, Chiba, Japan	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Chiba University	Richmond, A (corresponding author), Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [R01 CA034590-19, CA56704, CA 68485, P30 CA068485, R01 CA034590, R01 CA034590-17, R01 CA056704-07, R01 CA034590-18, R01 CA056704-08] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FUJIMOTO J, 1995, J STEROID BIOCHEM, V55, P25, DOI 10.1016/0960-0760(95)00145-P; GEISER T, 1993, J BIOL CHEM, V268, P15419; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KURDOWSKA A, 1994, CYTOKINE, V6, P124, DOI 10.1016/1043-4666(94)90033-7; Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MANGUES R, 1992, ONCOGENE, V7, P2073; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rennekampff HO, 1997, ARCH DERMATOL RES, V289, P204, DOI 10.1007/s004030050181; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rutberg SE, 1997, MOL CARCINOGEN, V20, P88, DOI 10.1002/(SICI)1098-2744(199709)20:1<88::AID-MC10>3.0.CO;2-5; Sadhu C, 1998, J IMMUNOL, V160, P5622; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Shattuck-Brandt RL, 1997, DNA SEQUENCE, V7, P379, DOI 10.3109/10425179709034060; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	56	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4647	4659		10.1038/sj.onc.1203820	http://dx.doi.org/10.1038/sj.onc.1203820			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030154	Green Accepted			2022-12-17	WOS:000089438200011
J	Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S				Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S			The retinoblastoma protein is an essential mediator that links the interferon-inducible 204 gene to cell-cycle regulation	ONCOGENE			English	Article						Ifi 204; antiproliferative activity; cell cycle; retinoblastoma proteins	ANTIPROLIFERATIVE ACTIVITY; HIN-200 FAMILY; 3T3 CELLS; INHIBITION; P202; TRANSCRIPTION; PRB; EXPRESSION; INDUCTION; CLUSTER	We have previously demonstrated that overexpression of p204, a member of the Ifi 200 gene family, inhibits growth, delays G0/G1 progression into S phase, and impairs E2F-mediated transcriptional activity. In this study, we show that p204 directly binds the retinoblastoma protein (pRb) in vivo to exert its activity. Transient p204 overexpression in Rb+/+ mouse embryo fibroblasts (MEF) inhibits cell proliferation, but does not affect cell growth in MEF derived from Rb-/- mice. Two human cell lines, Saos2 and C33A, bearing an inactive pRb, but not primary human embryo fibroblasts, are resistant to the p204 antiproliferative activity. p204 contains two 200 amino acid motifs, designated as type a or b domains, each containing a canonical Rb binding motif (LXCXE). When dominant-negative mutants at the Rb binding motif were transfected in Rb+/+ MEF, p204 lost its ability to inhibit cell growth, delay cell transition from G1 to S phase, and impair DNA synthesis. Moreover p204 overexpression in Rb+/+ MEF led to a significant decrease of both DHFR and PCNA proteins, two S phase markers. BS contrast, this effect was not observed when Rb+/+ MEF were transfected with a p204 mutated at both Rb binding sites. Finally, overexpression of the LXCXE p204 mutant rendered Rb+/+ MEF resistant to the IFN-alpha antiproliferative activity, in comparison to the untransfected Rb+/+ MEF. As expected, Rb-/- cells were unsensitive to the IFN-alpha induced growth inhibition. Taken as a whole, these results suggest that (i) p204 contributes to the IFN-alpha antiproliferative activity and (ii) the primary target of p204 leading to efficient G1 arrest as web as to blockade of DNA replication from G1 phase is the pRb regulatory system.	CNR, Immunogenet & Expt Oncol Ctr, I-10126 Turin, Italy; Med Sch Novara, Dept Med Sci, Novara, Italy; Med Sch Torino, Dept Publ Hlth & Microbiol, Turin, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Eastern Piedmont Amedeo Avogadro	Landolfo, S (corresponding author), CNR, Immunogenet & Expt Oncol Ctr, Via Santan 9, I-10126 Turin, Italy.		Azzimonti, Barbara/K-3550-2016; Gribaudo, Giorgio/A-8872-2011; De Andrea, Marco/J-5253-2012	Azzimonti, Barbara/0000-0001-6364-6595; De Andrea, Marco/0000-0002-3188-5783; Gariglio, Marisa/0000-0002-5187-0140; Gribaudo, Giorgio/0000-0002-1583-9146				Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; BREJM A, 1999, BRIT J CANCER, V80, P38; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; Demaeyer E., 1988, INTERFERONS OTHER RE; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gariglio M, 1998, J LEUKOCYTE BIOL, V64, P608, DOI 10.1002/jlb.64.5.608; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; GARIGLIO M, 1994, EUR J BIOCHEM, V221, P731, DOI 10.1111/j.1432-1033.1994.tb18786.x; GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022-1759(95)00170-F; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Min W, 1996, MOL CELL BIOL, V16, P359; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	48	61	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3598	3608		10.1038/sj.onc.1203697	http://dx.doi.org/10.1038/sj.onc.1203697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951565				2022-12-17	WOS:000088568300005
J	Bernardi, R; Liebermann, DA; Hoffman, B				Bernardi, R; Liebermann, DA; Hoffman, B			Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation	ONCOGENE			English	Article						cdc25A; cell cycle; differentiation; myc; proteasome; protein degradation; ubiquitin	MYELOBLASTIC-LEUKEMIA CELLS; C-MYC; PROTEIN-DEGRADATION; G(1)/S TRANSITION; DEPENDENT KINASES; S-PHASE; PHOSPHATASE; PROTEOLYSIS; ACTIVATION; DEPHOSPHORYLATION	Members of the cdc25 family are protein phosphatases that play pivotal roles in cell cycle progression. Cdc25A has been shown to be a critical regulator of the G1/S transition of mammalian cells and to be a myc-target gene with oncongenic properties. We investigated the regulation of cdc25A during terminal differentiation using myeloblastic leukemia M1 cells, that can be induced to undergo differentiation into macrophages by interleukin-6 (IL-6) treatment. In this report it is shown that cdc25A protein is degraded by the ubiquitin-proteasome machinery in both terminally differentiating and cycling cells. Cdc25A was found to have two major peaks of accumulation during cell cycle progression, one in G1 and the other in S/G2, Evidence was obtained that degradation of cdc25A by the ubiquitin-proteasome machinery in terminally differentiating myeloid cells is accelerated compared to cycling cells, Moreover, deregulated expression of c-myc in M1 cells, which had been previously shown to block terminal differentiation, was also found to block IL-6 induced degradation of cdc25A.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336	NCI NIH HHS [1RO1CA51168, 1RO1CA4316] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dick LR, 1997, J BIOL CHEM, V272, P182; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Lammer C, 1998, J CELL SCI, V111, P2445; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vigo E, 1999, MOL CELL BIOL, V19, P6379	42	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2447	2454		10.1038/sj.onc.1203564	http://dx.doi.org/10.1038/sj.onc.1203564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828887				2022-12-17	WOS:000087018400010
J	Rokhlin, OW; Gudkov, AV; Kwek, S; Glover, RA; Gewies, AS; Cohen, MB				Rokhlin, OW; Gudkov, AV; Kwek, S; Glover, RA; Gewies, AS; Cohen, MB			p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP	ONCOGENE			English	Article						p53; prostatic neoplasms; TNF-alpha; apoptosis	ONCOGENE-DEPENDENT APOPTOSIS; FAS-MEDIATED APOPTOSIS; CANCER CELLS; DNA-DAMAGE; KAPPA-B; DEATH; RESISTANCE; CASPASES; CLEAVAGE; MITOCHONDRIA	The human prostatic carcinoma cell line LNCaP is sensitive to TNF-alpha treatment and expresses wild-type p53, To analyse the possible role of p53 in TNF-alpha-mediated apoptosis, we generated a derivative of LNCaP, LN-56, expressing a dominant-negative element of p53, GSE56, P53 inactivation in LN-56 was associated with an increased resistance to apoptosis induced by TNF-alpha, Surface expression of TNF-alpha receptors was unchanged in LN-56 compared to LNCaP, TNF-alpha treatment resulted in accumulation of p53 in LNCaP and upregulation of p21/WAF1, Activation of caspase-7 and PARP proteolysis were delayed in LN-56 under TNF-alpha treatment. TNF-alpha-induced apoptosis in LNCaP cells was accompanied by caspase-dependent proteolysis of p21/WAF1 and Rb, which was significantly attenuated in LN-56, Cytochrome c release was induced by TNF-alpha treatment in both cell lines, but caspase-9 was not activated. LNCaP and LN-56 were injected s.c. in nude mice and tumors were identified in all LN-56, but not LNCaP, bearing mice indicating that p53 plays an important role in growth control of prostatic neoplasms, Interestingly, accumulation of p53 in TNF-alpha-treated LNCaP cells was decreased in the presence of the caspase inhibitor Z-VAD-FMK, suggesting a new role of activated caspases in acceleration of p53 response, In summary, these results indicate that p53 is involved in TNF-alpha-mediated apoptosis in LNCaP.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 1175 ML, Iowa City, IA 52242 USA.			Gudkov, Andrei/0000-0003-2548-0154; Gewies, Andreas/0000-0002-7606-6482	NCI NIH HHS [CA 60730, CA 75179, CA 76673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179, R01CA076673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae I, 1996, CANCER RES, V56, P840; Bellamy COC, 1997, APOPTOSIS AND CANCER, P116; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brooks JD, 1996, CANCER RES, V56, P3814; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GOTLIEB WH, 1994, AM J OBSTET GYNECOL, V170, P1121, DOI 10.1016/S0002-9378(94)70106-7; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISAACS WB, 1991, CANCER RES, V51, P4716; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; LAZEBNIK YA, 1994, NATURE, V346, P371; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marcelli M, 1999, CANCER RES, V59, P382; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakajima Y, 1996, PROSTATE, V29, P296; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3042; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 1997, CANCER RES, V57, P3941; Rokhlin OW, 1997, CANCER RES, V57, P1758; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Srikanth S, 1998, CANCER RES, V58, P834; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THOMPSON TC, 1995, ONCOGENE, V10, P869; VANSTEENBRUGGE GJ, 1989, UROL RES, V17, P71, DOI 10.1007/BF00262024; Wong GHW, 1997, APOPTOSIS AND CANCER, P245; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; ZHAO X, 1992, UROL RES, V20, P193, DOI 10.1007/BF00299716	45	61	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1959	1968		10.1038/sj.onc.1203453	http://dx.doi.org/10.1038/sj.onc.1203453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773886				2022-12-17	WOS:000086424300012
J	North, S; El-Ghissassi, F; Pluquet, O; Verhaegh, G; Hainaut, P				North, S; El-Ghissassi, F; Pluquet, O; Verhaegh, G; Hainaut, P			The cytoprotective aminothiol WR1065 activates p21(waf-1) and down regulates cell cycle progression through a p53-dependent pathway	ONCOGENE			English	Article						WR1065; p53; redox control; cell cycle; radioprotection	DNA-BINDING ACTIVITY; P53 PROTEIN; RADIOPROTECTOR WR1065; AMIFOSTINE; WR-1065; MUTATIONS; EXPRESSION; PROTECTION; MODULATION; APOPTOSIS	The phosphoaminothiol WR1065, the active metabolite of the pro-drug amifostine (WR2721), protects cultured cells and tissues against cytotoxic exposure to radiation or chemotherapeutic agents. We show here that WR1065 and the pro-drug WR2721 activate the p53 tumor suppressor protein and induce the expression of the cyclin-dependent kinase inhibitor p21(waf-1) in the breast cancer cell line MCF-7, and in the mouse fibroblast cell line balb/c 3T3, Using two MCF-7 derived cell lines, MN1 and MDD2, we show that induction of p21(waf-1) is detectable in MN1 (expressing a functional p53) but not in MDD2 (p53 disabled). These effects are observed at concentrations of WR1065 (0.5 to 1 mM) identical to those required to protect against cytotoxicity by hydrogen peroxide. Induction of p53 is not prevented by addition of aminoguanidine, an inhibitor of Cu-dependent amine-oxidases which blocks the extra-cellular degradation of WR1065 into toxic metabolites. Moreover, spermidine, a natural polyamine structurally related to amifostine, does not activate p53. Induction of p53 by WR1065 results in a delay in the G1/S transition in MCF-7 and MN-1 cells, but not in the p53 disabled cells MDD2. These data indicate that WR1065, a polyamine analog with thiol anti-oxidant properties, activates a cell cycle check-point involving p53.	Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.		Hainaut, Pierre/B-6018-2012; Verhaegh, Gerald/L-4708-2015	Hainaut, Pierre/0000-0002-1303-1610; Verhaegh, Gerald/0000-0003-0227-2280				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bacus SS, 1996, ONCOGENE, V12, P2535; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; CALABROJONES PM, 1988, CANCER RES, V48, P3634; Capizzi RL, 1996, EUR J CANCER, V32A, pS5, DOI 10.1016/S0959-8049(96)00333-4; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clark LS, 1996, CARCINOGENESIS, V17, P2647, DOI 10.1093/carcin/17.12.2647; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; GRDINA DJ, 1985, CARCINOGENESIS, V6, P929, DOI 10.1093/carcin/6.6.929; GRDINA DJ, 1994, RADIAT RES, V138, P44, DOI 10.2307/3578845; GRDINA DJ, 1992, CELL PROLIFERAT, V25, P23, DOI 10.1111/j.1365-2184.1992.tb01434.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; KASTAN MB, 1991, CANCER RES, V51, P6304; Korst AEC, 1997, BRIT J CANCER, V75, P1439, DOI 10.1038/bjc.1997.247; Korst AEC, 1998, EUR J CANCER, V34, P412, DOI 10.1016/S0959-8049(97)10012-0; Kramer DL, 1999, CANCER RES, V59, P1278; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; List AF, 1998, LEUKEMIA, V12, P1596, DOI 10.1038/sj.leu.2401151; Liu SC, 1997, CARCINOGENESIS, V18, P2457, DOI 10.1093/carcin/18.12.2457; Loignon M, 1997, CANCER RES, V57, P3390; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Milligan JR, 1997, RADIAT RES, V148, P325, DOI 10.2307/3579517; Mitchell JLA, 1998, BIOCHEM J, V335, P329, DOI 10.1042/bj3350329; Murley JS, 1997, CELL PROLIFERAT, V30, P283, DOI 10.1046/j.1365-2184.1997.00092.x; Piette J, 1997, BIOL CHEM, V378, P1237; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Schiller JH, 1996, J CLIN ONCOL, V14, P1913, DOI 10.1200/JCO.1996.14.6.1913; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SMOLUK GD, 1988, CANCER RES, V48, P3641; TRESKES M, 1994, EUR J CANCER, V30A, P183, DOI 10.1016/0959-8049(94)90084-1; TRESKES M, 1992, CANCER RES, V52, P2257; VAUGHAN ATM, 1989, BRIT J CANCER, V60, P893, DOI 10.1038/bjc.1989.386; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; WOLOSCHAK GE, 1995, CANCER RES, V55, P4788; WYATT I, 1989, INT J RADIAT BIOL, V55, P463, DOI 10.1080/09553008914550491; YUHAS JM, 1980, CANCER RES, V40, P1519; ZHANG X, 1992, INT J RADIAT ONCOL, V42, P713	47	61	64	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1206	1214		10.1038/sj.onc.1203413	http://dx.doi.org/10.1038/sj.onc.1203413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713709				2022-12-17	WOS:000085567800011
J	Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG				Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG			Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins	ONCOGENE			English	Article						TFE3; PRCC; renal cell carcinoma; t(X;1) translocation	HELIX-LOOP-HELIX; HEAVY-CHAIN GENE; ACTIVATION DOMAINS; TRANSLOCATION X-1; PROLINE-RICH; DNA-BINDING; TRANSCRIPTION; ENHANCER; IDENTIFICATION; EXPRESSION	The papillary renal cell carcinoma-associated t(X;1)(p11;q21) leads to fusion of the transcription factor TFE3 gene on the X-chromosome to a novel gene, PRCC, on chromosome 1, As a result, two putative fusion proteins are formed: PRCCTFE3, which contains all known domains for DNA binding, dimerization, and transactivation of the TFE3 protein, and the reciprocal product TFE3PRCC, Upon transfection into COS cells, both wild type and fusion proteins were found to be located in the nucleus, When comparing the transactivating capacities of these (fusion) proteins, significant differences were noted. PRCCTFE3 acted as a threefold better transactivator than wild type TFE3 both in a TFE3-specific and in a general (Zebra) reporter assay. In addition, PRCC and the two fusion proteins were found to he potent transactivators in the Zebra reporter assay. We propose that, as a result of the (X;1) translocation, fusion of the N-terminal PRCC sequences to TFE3 alters the transactivation capacity of the transcription factor thus leading to aberrant gene regulation and, ultimately, tumor formation.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Askovic S, 1997, BIOTECHNIQUES, V22, P948, DOI 10.2144/97225rr02; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dijkhuizen T, 1998, CANCER GENET CYTOGEN, V104, P74; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rogaia D, 1997, CANCER RES, V57, P799; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444	30	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					69	74		10.1038/sj.onc.1203255	http://dx.doi.org/10.1038/sj.onc.1203255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644981				2022-12-17	WOS:000084844300008
J	Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T				Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T			Ku80 can translocate to the nucleus independent of the translocation of Ku70 using its own nuclear localization signal	ONCOGENE			English	Article						cell cycle; GFP; Ku; NLS; PTAC58/PTAC97	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; SV40-TRANSFORMED HUMAN KERATINOCYTES; SEVERE COMBINED IMMUNODEFICIENCY; PORE-TARGETING COMPLEX; DNA-BINDING PROTEINS; V(D)J RECOMBINATION; IN-VIVO; MONOCLONAL-ANTIBODIES; INTERACTION REGIONS	Ku antigen is a complex of Ku70 and Ku80 subunits and plays an important role in not only DNA double-strand breaks (DSB) repair and V(D)J recombination, but also in growth regulation, Ku is generally believed to always form and function as heterodimers on the basis of in vitro observations. Here we demonstrate that the localization of Ku80 does not completely coincide with that of Ku70, Ku70 and Ku80 were colocalized in the nucleus in the interphase but not in the late telophase/early G1 phase of the cell cycle, Since the in vivo function of Ku might be partially regulated by the control of its transport, we attempted to investigate the molecular mechanisms underlying the nuclear translocation of Ku. The nuclear translocation of Ku80 started during the late telophase/early G1 phase after the nuclear envelope was formed and this was preceded by the nuclear translocation of Ku70, Furthermore, we found that the Ku80 protein was transported to the nucleus without heterodimerization with Ku70, To understand in detail the mechanism of transport of Ku80, we attempted to identify the nuclear localization signal (NLS) of Ku80 and defined to a region spanning nine amino acid residues (positions 561-569), The Ku80 NLS was demonstrated to be mediated to the nuclear rim by two components of PTAC58 and PTAC97. All these findings support the idea that Ku80 can translocate to the nucleus using its own NLS independent of the translocation of Ku70.	Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, Chiba 2638555, Japan; Saitama Canc Ctr, Res Ctr, Ina, Saitama 3620806, Japan	National Institutes for Quantum Science & Technology	Koike, M (corresponding author), Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.		Koike, Manabu/AAP-3107-2021					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; DANZIEL RG, 1992, AUTOIMMUNITY, V13, P265; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fewell JW, 1996, J CELL SCI, V109, P1937; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koike M, 1998, BIOCHEM BIOPH RES CO, V252, P679, DOI 10.1006/bbrc.1998.9368; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; KOIKE M, 1995, ONCOGENE, V10, P117; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KOIKE M, 1993, MOL CARCINOGEN, V8, P105, DOI 10.1002/mc.2940080207; Koike M, 1996, GENOMICS, V38, P38, DOI 10.1006/geno.1996.0589; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; REEVES WH, 1994, RHEUM DIS CLIN N AM, V20, P1; Reeves WH, 1997, ANTIBODIES, P33; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	55	61	63	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7495	7505		10.1038/sj.onc.1203247	http://dx.doi.org/10.1038/sj.onc.1203247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602508				2022-12-17	WOS:000084119600010
J	Murphy, GA; Solski, PA; Jillian, SA; de la Ossa, PP; D'Eustachio, P; Der, CJ; Rush, MG				Murphy, GA; Solski, PA; Jillian, SA; de la Ossa, PP; D'Eustachio, P; Der, CJ; Rush, MG			Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth	ONCOGENE			English	Article						TC10; GTPases; actin cytoskeleton; transcription activation	SERUM RESPONSE FACTOR; MAP KINASE CASCADES; ACTIN CYTOSKELETON; KAPPA-B; RAS TRANSFORMATION; CYCLE PROGRESSION; GENE-EXPRESSION; BINDING PROTEIN; CDC42 GTPASES; ACTIVATION	The small Ras-related GTPase, TC10, has been classified on the basis of sequence homology to be a member of the Rho family. This family, which includes the Rho, Rac and CDC42 subfamilies, has been shown to regulate a variety of apparently diverse cellular processes such as actin cytoskeletal organization, mitogen-activated protein kinase (MAPK) cascades, cell cycle progression and transformation. In order to begin a study of TC10 biological function, we expressed wild type and various mutant forms of this protein in mammalian cells and investigated both the intracellular localization of the expressed proteins and their abilities to stimulate known Rho family-associated processes. Wild type TC10 was located predominantly in the cell membrane (apparently in the same regions as actin filaments), GTPase defective (75L) and GTP-binding defective (31N) mutants were located predominantly in cytoplasmic perinuclear regions, and a deletion mutant lacking the carboxyl terminal residues required for posttranslational prenylation was located predominantly in the nucleus. The GTPase defective (constitutively active) TC10 mutant: (1) stimulated the formation of long filopodia; (2) activated c-Jun amino terminal kinase (JNK); (3) activated serum response factor (SRF)-dependent transcription; (4) activated NF-kappa B-dependent transcription; and (5) synergized with an activated Raf-kinase (Raf-CAAX) to transform NIH3T3 cells. In addition, wild type TC10 function is required for full H-Ras transforming potential. We demonstrate that an intact effector domain and carboxyl terminal prenylation signal are required for proper TC10 function and that TC10 signals to at least two separable downstream target pathways. In addition, TC10 interacted with the actin-binding and filament-forming protein, profilin, in both a two-hybrid cDNA library screen, and an in vitro binding assay. Taken together, these data support a classification of TC10 as a member of the Rho family, and in particular, suggest that TC10 functions to regulate cellular signaling to the actin cytoskeleton and processes associated with cell growth.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	New York University; New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Rush, MG (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.			Repasky, Gretchen/0000-0001-6466-6467; D'Eustachio, Peter/0000-0002-5494-626X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA63071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Murphy GA, 1997, MOL BIOL CELL, V8, P2591, DOI 10.1091/mbc.8.12.2591; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN MD, 1995, MOL CELL BIOL, V15, P2117; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Rothkegel M, 1996, J CELL SCI, V109, P83; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	38	61	65	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3831	3845		10.1038/sj.onc.1202758	http://dx.doi.org/10.1038/sj.onc.1202758			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445846				2022-12-17	WOS:000081171700004
J	Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R				Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R			Immune responses to all ErbB family receptors detectable in serum of cancer patients	ONCOGENE			English	Article						ErbB receptors; cancer; serum antibody	EPIDERMAL GROWTH-FACTOR; NIH 3T3 CELLS; CARCINOMA PATIENTS; PROTO-ONCOGENE; OVARIAN-CANCER; BREAST-CANCER; SELF-PROTEIN; HER-2/NEU; ANTIBODY; TRANSFORMATION	Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4, Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4, Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3, Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates, Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in Light of immunotherapeutic approaches targeting these receptors.	Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy	G d'Annunzio University of Chieti-Pescara; IRCCS European Institute of Oncology (IEO); Sapienza University Rome	Muraro, R (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy.		Masuelli, Laura/AGW-4259-2022; Bei, Roberto/W-8023-2019	MASUELLI, Laura/0000-0001-8174-8034				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baulida J, 1996, J BIOL CHEM, V271, P5251; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; Clark MA, 1997, CLIN EXP IMMUNOL, V109, P166, DOI 10.1046/j.1365-2249.1997.4161316.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1991, ADV CELLULAR MOL BIO, P139; Disis ML, 1996, J IMMUNOL, V156, P3151; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; DISIS ML, 1994, CANCER RES, V54, P16; DISIS ML, 1994, CANCER RES, V54, P1071; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Glushkov AN, 1996, EXP ONCOL, V18, P81; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; MARIANICOSTANTINI R, 1991, CANCER-AM CANCER SOC, V67, P2880, DOI 10.1002/1097-0142(19910601)67:11<2880::AID-CNCR2820671129>3.0.CO;2-A; Nagata Y, 1997, J IMMUNOL, V159, P1336; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PUPA SM, 1993, CANCER RES, V53, P5864; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tuttle TM, 1996, CANCER IMMUNOL IMMUN, V43, P135, DOI 10.1007/s002620050314; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zafiropoulos A, 1997, J IMMUNOL METHODS, V200, P181, DOI 10.1016/S0022-1759(96)00207-4; Zhang K, 1996, J BIOL CHEM, V271, P3884	41	61	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1267	1275		10.1038/sj.onc.1202442	http://dx.doi.org/10.1038/sj.onc.1202442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022808				2022-12-17	WOS:000078510900002
J	Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R				Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R			The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice	ONCOGENE			English	Article						dHGF; hepatocellular carcinoma; liver; Met	FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; IN-VIVO; C-MET; HEPATOCELLULAR-CARCINOMA; STRUCTURAL ORGANIZATION; NEOPLASTIC DEVELOPMENT; LIVER-REGENERATION; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a polypeptide with mitogenic, motogenic, and morphogenic effects on different cell types including hepatocytes. HGF is expressed as two biologically active isotypes resulting from alternative RNA splicing, The roles of each HGF isoform in development, liver regeneration and tumorigenesis have not yet been well characterized. We report the generation and analysis of transgenic mice overexpressing the five amino acid-deleted variant of HGF (dHGF) in the liver by virtue of an albumin expression vector. These ALB-dHGF transgenic mice develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of hepatocellular carcinoma (HCC) beyond 17 months of age. Moreover, overexpression of dHGF dramatically accelerates diethyl-nitrosamine induced HCC tumorigenesis, These tumors arise faster, are significantly larger, more numerous and more invasive than those appearing in non-transgenic littermates. Approximately 90% of female dHGF-transgenic mice had multiple macroscopic HCCs 40 weeks after injection of DEN; whereas the non-transgenic counterparts had only microscopic nodules, Liver tumors and cultured tumor cell lines from dHGF transgenics showed high levels of HGF and c-Met mRNA and protein, Together, these results reveal that in vivo dHGF plays an active role in liver regeneration and HCC tumorigenesis.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA.				NIEHS NIH HHS [R01ES06109] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BLADT F, 1995, NATURE, V373, P702; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chan A, 1993, EXS, V65, P67; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; Chen QY, 1997, HEPATOLOGY, V26, P59; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOGAN B, 1986, MANIPULATING MOUSE E, P174; JOHNSON M, 1995, CANCER LETT, V96, P37, DOI 10.1016/0304-3835(95)03915-J; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1994, GENE, V144, P179, DOI 10.1016/0378-1119(94)90376-X; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKANUMA Y, 1993, LIVER, V13, P1; NALDINI L, 1991, ONCOGENE, V6, P501; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PUGH TD, 1983, CANCER RES, V43, P1261; RONG S, 1993, CANCER RES, V53, P5355; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; Shiota G, 1996, RES COMMUN MOL PATH, V91, P33; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TONJES RR, 1995, ONCOGENE, V10, P765; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WOLF H, 1991, AM J PATHOL, V138, P1305; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1989, CANCER RES, V49, P3314	50	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					887	895		10.1038/sj.onc.1202379	http://dx.doi.org/10.1038/sj.onc.1202379			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023664				2022-12-17	WOS:000078510600005
J	Wieser, RJ; Faust, D; Dietrich, C; Oesch, F				Wieser, RJ; Faust, D; Dietrich, C; Oesch, F			p16(INK4) mediates contact-inhibition of growth	ONCOGENE			English	Article						contact-inhibition; cdk4; p16(INK4)	PLASMA-MEMBRANE GLYCOPROTEINS; DENSITY-DEPENDENT REGULATION; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; HUMAN-FIBROBLASTS; KINASE; PHOSPHORYLATION; P27(KIP1); PROGRESSION; CANCER	Growth of non-transformed cells in vitro is regulated by density-dependent mechanisms via cell-cell contacts, leading to arrest in late G1-phase at confluency (contact-inhibition of growth). In the present study it is shown that this results from p16(INK4)-mediated dissociation of the complex cdk4-cyclin D1, which is responsible for the inactivation of the gate keeper of G1-S transition, the retinoblastoma protein pRb, As consequence of the inactivation of cdk4, downstream the activation of cdk2 and hyperphosphorylation and thus inactivation of pRb was impaired, Direct evidence for the central role of p16(INK4) in growth control comes from the observation that a competitive inhibitor of p16(INK4) repressed contact inhibition of growth, These findings provide an explanation for the high incidence of mutation or loss of INK4 in human tumours.	Inst Toxikol, D-55131 Mainz, Germany		Wieser, RJ (corresponding author), Inst Toxikol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.		Oesch, Franz/AAA-8746-2020					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Botz J, 1996, MOL CELL BIOL, V16, P3401; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higashi H, 1997, BIOCHEM BIOPH RES CO, V231, P743, DOI 10.1006/bbrc.1997.6181; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RINDERKNECHT SB, 1983, J IMMUNOL METHODS, V65, P293, DOI 10.1016/0022-1759(83)90124-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yasaka T, 1996, CELL STRUCT FUNCT, V21, P483, DOI 10.1247/csf.21.483	33	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					277	281		10.1038/sj.onc.1202270	http://dx.doi.org/10.1038/sj.onc.1202270			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926944				2022-12-17	WOS:000078166000031
J	Ghebranious, N; Donehower, LA				Ghebranious, N; Donehower, LA			Mouse models in tumor suppression	ONCOGENE			English	Review						tumor suppressors; knockout mice; cancer models; inherited cancer syndromes	WILD-TYPE P53; CELL-CYCLE CONTROL; RETINOBLASTOMA SUSCEPTIBILITY GENE; MULTIPLE INTESTINAL NEOPLASIA; OVARIAN-CANCER FAMILIES; ZINC FINGER GENE; BREAST-CANCER; POLYPOSIS-COLI; APC GENE; P53-DEFICIENT MICE	Genetic lesions found in tumors are often targeted to the negative growth regulatory tumor suppressor genes. Much of our understanding of tumor suppressor gene function is derived from experimental manipulations in cultured cells. Recently, however, the generation of mice with germ line tumor suppressor gene mutations through gene targeting in embryonic stem cells has provided another dimension by allowing experimental studies of tumor suppressor function in an organismal context. Novel insights into the role of tumor suppressors in development, differentiation, cell cycle control, and tumor suppression have been obtained from the studies on these 'knockout' mice, In addition, such mice may serve as disease models for humans with inherited cancer predisposition syndromes, Perhaps the greatest advantage of many of the mouse tumor suppressor models is that they facilitate study of the roles of tumor suppressor gene loss in tumor initiation and progression in vivo. Moreover, derivation of primary cells from tumor suppressor-deficient mice has provided an important resource for in vitro studies on the role of targeted genes in cell cycle regulation, DNA damage response, regulation of apoptotic pathways, and preservation of genomic stability. In this review, we discuss some of the mechanistic insights provided by tumor suppressor-deficient mice and their utility as models for human cancer syndromes.	Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Donehower, LA (corresponding author), Baylor Coll Med, Div Mol Virol, 1 Baylor Plaza, Houston, TX 77030 USA.							ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BADER JL, 1978, J PEDIATR-US, V92, P925, DOI 10.1016/S0022-3476(78)80362-X; BAIRD PN, 1992, ONCOGENE, V7, P2141; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; Bilger A, 1996, SEMIN CANCER BIOL, V7, P249, DOI 10.1006/scbi.1996.0033; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BULOW S, 1987, DAN MED BULL, V34, P1; Cairns P, 1997, CANCER RES, V57, P4997; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Cichowski K, 1996, SEMIN CANCER BIOL, V7, P291, DOI 10.1006/scbi.1996.0037; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; COUCH FJ, 1998, GENETIC BASIS HUMAN, P537; COWELL JK, 1991, ONCOGENE, V6, P595; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DIETRICH WF, 1995, P NATL ACAD SCI USA, V92, P10849, DOI 10.1073/pnas.92.24.10849; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DURO D, 1995, ONCOGENE, V11, P21; EASTON D, 1993, CANCER SURV, V18, P1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; ENG C, 1998, GENETIC BASIS HUMAN, P519; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Friedman LS, 1998, CANCER RES, V58, P1338; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRITH CH, 1981, J NATL CANCER I, V66, P703; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Goggins M, 1996, CANCER RES, V56, P5360; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GONDO Y, 1994, BIOCHEM BIOPH RES CO, V202, P830, DOI 10.1006/bbrc.1994.2005; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUTMANN DH, 1998, GENETIC BASIS HUMAN, P423; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1995, CANCER RES, V55, P1146; Hope D G, 1981, Adv Neurol, V29, P33; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; HUFF V, 1991, AM J HUM GENET, V48, P997; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; James C. David, 1996, Current Opinion in Oncology, V8, P188; JEN J, 1994, CANCER RES, V54, P6353; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johannsson O, 1996, AM J HUM GENET, V58, P441; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaelin WG, 1998, J INTERN MED, V243, P535; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1998, GENETIC BASIS HUMAN, P507; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KIRBY ML, 1993, DEV DYNAM, V198, P296, DOI 10.1002/aja.1001980407; KNUDSON A, 1991, CANCER RES, V51, P5435; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY DB, 1994, CANCER RES, V54, P5953; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LINEHAN WM, 1998, GENETIC BASIS HUMAN, P455; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; LIU L, 1995, ONCOGENE, V11, P405; LIVINGSTONE LR, 1992, CELL, V70, P605; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUONGO C, 1994, CANCER RES, V54, P5947; MACCOLLIN M, 1998, GENETIC BASIS HUMAN, P492; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAO L, 1995, CANCER RES, V55, P2995; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MCCLATCHEY AI, 1997, GENE DEV, V11, P1250; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; MORRIS JF, 1991, ONCOGENE, V6, P2339; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NEWSHAM I, 1998, GENETICS BASIS HUMAN, P392; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PURDIE CA, 1994, ONCOGENE, V9, P603; QUELLE DE, 1995, CELL, V83, P993; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Serova O, 1996, AM J HUM GENET, V58, P42; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Taverna D, 1998, CANCER RES, V58, P848; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; Varley JM, 1997, CANCER RES, V57, P3245; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 1998, MUTAT RES-FUND MOL M, V400, P391, DOI 10.1016/S0027-5107(98)00018-9; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZONANA J, 1976, J PEDIATR-US, V89, P600, DOI 10.1016/S0022-3476(76)80397-6	242	61	64	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3385	3400		10.1038/sj.onc.1202573	http://dx.doi.org/10.1038/sj.onc.1202573			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9917000				2022-12-17	WOS:000078048200019
J	Sementchenko, VI; Schweinfest, CW; Papas, TS; Watson, DK				Sementchenko, VI; Schweinfest, CW; Papas, TS; Watson, DK			ETS2 function is required to maintain the transformed state of human prostate cancer cells	ONCOGENE			English	Article						ETS; transcription factor; prostate cancer; oncogene; epithelial cancer	DNA-BINDING DOMAIN; TRANSCRIPTION FACTORS; EXPRESSION; GENES; PROTOONCOGENE; PROMOTER; ACTIVATION; METASTASIS; CARCINOMA; ELEMENTS	The contribution of the ETS2 transcription factor to the transformed state in prostate cancer cells has been assessed. Northern blot analysis easily detects ETS2 in DU145 and PC3, high grade human prostate cell lines, but ETS2 is not present in lower grade LNCaP cells. Stable transfection of PC3 and DU145 prostate cell lines with an antisense ETS2 vector or with a dominant negative ETS2 mutant significantly reduced the ability of DU145 and PC3 cells to form large colonies in soft agar. Thus, the presence of ETS2 is positively correlated with a more transformed phenotype and blockage of ETS2 function can reduce transformed properties of prostate cancer cells.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, 171 Ashley Ave, Charleston, SC 29425 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BOSTWICK DG, 1992, CANCER, V70, P291, DOI 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; CARTER HB, 1990, PROSTATE, V16, P39; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Gambarotta G, 1996, ONCOGENE, V13, P1911; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Isaacs JT, 1997, AM J PATHOL, V150, P1511; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; MOHLER JL, 1992, CANCER, V69, P511, DOI 10.1002/1097-0142(19920115)69:2<511::AID-CNCR2820690239>3.0.CO;2-3; MOSTOFI FK, 1992, CANCER, V70, P235, DOI 10.1002/1097-0142(19920701)70:1+<235::AID-CNCR2820701311>3.0.CO;2-G; NERLOV C, 1991, ONCOGENE, V6, P1583; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZHAU HYE, 1992, MOL CARCINOGEN, V5, P320, DOI 10.1002/mc.2940050413; Zhau HYE, 1996, PROSTATE, V28, P73	36	61	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2883	2888		10.1038/sj.onc.1202220	http://dx.doi.org/10.1038/sj.onc.1202220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879994				2022-12-17	WOS:000077286400008
J	Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G				Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G			Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor gene	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; ALLELIC LOSS; CARCINOMAS; ALLELOTYPE; DELETION	Many chromosomal regions undergo loss of heterozygosity (LOH) in ovarian adenocarcinomas but few of the target regions have been finely mapped. One of the chromosome arms likely to harbour one or more tumour suppressor genes inactivated in ovarian cancer is the short arm of chromosome 8 which is frequently deleted in many other solid tumours, We have examined a large panel of microsatellite markers on 8p for LOH in 53 ovarian adenocarcinomas. LOH was observed in 27 tumours (51%), with a significant trend towards a higher frequency of LOH in more advanced tumours, Detailed examination of nine tumours with partial deletions defined three regions of overlap, two in 8p23 and one in 8p22, which suggests that there might be as many as three tumour or metastasis suppressor genes on 8p which are inactivated during ovarian tumorigenesis. LOH on 8p was significantly associated with 9p LOH which suggests that inactivation of target genes on these chromosomes may be cooperative events.	Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Obstet & Gynaecol, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland	Chenevix-Trench, G (corresponding author), Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia.			Chenevix-Trench, Georgia/0000-0002-1878-2587				Becker SA, 1996, CANCER RES, V56, P5092; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CLIBY W, 1993, CANCER RES, V53, P2393; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IWABUCHI T, 1994, CANCER RES, V55, P6172; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Takle LA, 1996, ONCOGENE, V12, P1083; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Vocke CD, 1996, CANCER RES, V56, P2411; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	61	62	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1185	1188		10.1038/sj.onc.1202028	http://dx.doi.org/10.1038/sj.onc.1202028			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764830				2022-12-17	WOS:000075598400015
J	Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ				Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ			p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells	ONCOGENE			English	Article						p53; cell cycle; checkpoint; G2; Cdc2; phosphorylation	CYCLIN-DEPENDENT KINASES; P34CDC2 PROTEIN-KINASE; HUMAN CANCER-CELLS; TYROSINE PHOSPHORYLATION; DNA-DAMAGE; CHECKPOINT CONTROL; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; TYR15 PHOSPHORYLATION; G(2) DELAY	We have investigated the influence of p53 on radiation-induced G2 cell cycle arrest using human H1299 cells expressing temperature-sensitive p53. Gamma-irradiated cells lacking p53 arrested transiently in G2 with Cdc2 extensively phosphorylated at the inhibitory sites Thr14 and Tyr15, and with both Cdc2 and cyclin B1 restricted to the cytoplasm. Activation of p53 by temperature shift resulted in a more protracted G2 arrest that could not be overridden by checkpoint-abrogating drugs. Surprisingly, this enhancement of G2 arrest was associated with a marked lack of inhibitory phosphorylation of Cdc2 and with the nuclear localization of both Cdc2 and cyclin B1. While transient expression of an A14F15 mutant form of Cdc2 that is not subject to inhibitory phosphorylation induced mitotic catastrophe in cells lacking p53, the p53-expressing cells were relatively refractory to this effect. Enforced expression of p21(WAF1/CIP1) was sufficient to confer nuclear localization on Cdc2 in the p53 null cells, though immunodepletion experiments demonstrated that only a small proportion of Cdc2 was stably associated with p21(WAF1/CIP1) in the p53-expressing cells. We conclude that a p53-dependent pathway can operate after exposure of human cells to ionising radiation to promote G2 arrest accompanied by nuclear translocation rather than inhibitory phosphorylation of Cdc2.	Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England	University of Oxford	Norbury, CJ (corresponding author), Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020; Winters, Zoe Ellen/GYE-7947-2022	Harris, Adrian L/0000-0003-1376-8409; 				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CohenJonathan E, 1997, RADIAT RES, V147, P277, DOI 10.2307/3579333; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; McDonald E, 1996, CANCER RES, V56, P2250; Moore DD, 1995, GLOB MOB SURV; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Skladanowski A, 1997, CANCER RES, V57, P818; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMATO K, 1995, ONCOGENE, V11, P1; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	59	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					673	684		10.1038/sj.onc.1201991	http://dx.doi.org/10.1038/sj.onc.1201991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715268				2022-12-17	WOS:000075337200001
J	Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S				Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S			GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas	ONCOGENE			English	Article						glioma; amplification; overexpression; leucine-rich repeat; chromosome 1	MOUSE NERVOUS-SYSTEM; 2-DIMENSIONAL SEPARATIONS; ADHESION MOLECULE; GENOMIC DNA; GENE; SEQUENCE; PROTEIN; CDNA; CLONING; AMPLIFICATION	We have used two-dimensional electrophoresis of enzyme-digested genomic DNA to identify a novel gene GAC1, which maps at 1q32.1 and which is overexpressed in malignant gliomas in which it is amplified. GAC1 encodes a protein which belongs to the leucine-rich repeat superfamily. Amplification and overexpression of GAC1 was demonstrated in two of eight tumors where amplifications were previously evidenced by comparative genomic hybridization (one glioblastoma multiforme and one anaplastic astrocytoma), and in one of eight unselected glioblastomas multiforme. GAC1 exhibits sequence homology with other proteins which function as cell-adhesion molecules or as signal transduction receptor and is a likely candidate for the target gene in the 1q32.1 amplicon in malignant gliomas.	CNRS UMR 147, Inst Curie, F-75248 Paris 05, France; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Malfoy, B (corresponding author), CNRS UMR 147, Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.			Zhu, Charles/0000-0003-2922-0042				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALMEIDA A, 1994, GENE CHROMOSOME CANC, V11, P63, DOI 10.1002/gcc.2870110110; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BUCHANAN SGS, 1996, PROG BIOPHYS MOL BIO, V25, P1; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; Costello JF, 1997, CANCER RES, V57, P1250; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kim D, 1996, BBA-GENE STRUCT EXPR, V1309, P183, DOI 10.1016/S0167-4781(96)00158-3; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Kuick R, 1996, GENETICS, V144, P307; KUICK R, 1995, GENOMICS, V25, P345, DOI 10.1016/0888-7543(95)80032-H; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MULERIS M, 1994, ONCOGENE, V9, P2717; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; QIN H, 1993, HUM HERED, V43, P261, DOI 10.1159/000154142; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	36	61	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2997	3002		10.1038/sj.onc.1201828	http://dx.doi.org/10.1038/sj.onc.1201828			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662332				2022-12-17	WOS:000074125300006
J	Siddique, H; Zou, JP; Rao, VN; Reddy, ESP				Siddique, H; Zou, JP; Rao, VN; Reddy, ESP			The BRCA2 is a histone acetyltransferase	ONCOGENE			English	Article						BRCA2; histone acetyl transferase; protein-protein interaction; tumor suppressor	BREAST-CANCER SUSCEPTIBILITY; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; GENE BRCA1; FAMILIES; ACETYLATION; MUTATION; YEAST; CBP	Patients carrying mutations in BRCA1 or BRCA2 tumor suppressor genes have shown to have high risk in developing breast and ovarian cancers. Two potential functions of BRCA2 were proposed which includes role in the regulation of transcription and also in DNA repair. Forty-five-amino acid region encoded by exon 3 of BRCA2 was shown to have transcriptional activation function. Recent studies of the several enzymes involved in acetylation and deacetylation of histone residues have revealed a possible relationship between gene transcriptional activation and histone acetylation, Since BRCA2 appear to function as a transcriptional factor, we have tested for Histone acetyl transferase (HAT) activity of BRCA2, Here, we present evidence that BRCA2 has intrinsic HAT activity, which maps to the aminoterminal region of BRCA2, Our results demonstrate that BRCA2 proteins acetylate primarily H3 and H4 of free histones. These observations suggest that HAT activity of BRCA2 may play an important role in the regulation of transcription and tumor suppressor function.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA51083, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CUI J, 1998, IN PRESS ONCOL REP; EASTON DF, 1993, AM J HUM GENET, V52, P678; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Vaughn JP, 1996, CANCER RES, V56, P4590; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	35	61	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2283	2285		10.1038/sj.onc.1202003	http://dx.doi.org/10.1038/sj.onc.1202003			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619837	Bronze			2022-12-17	WOS:000073298000013
J	Hamilton, M; Wolfman, A				Hamilton, M; Wolfman, A			Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo	ONCOGENE			English	Article						Ras; Raf-1; MAPK; cell proliferation	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR; MAMMALIAN-CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; V-RAF; B-RAF; K-RAS	The Ras GTPases function as molecular switches, regulating a multiplicity of biological events, However the contribution, if any, of a specific c-Ras isoform (Ha-, N-, or Ki-ras A or B) in the regulation of a given biological or biochemical process, is unknown, Murine C3H10T1/2 fibroblasts transformed with activated (G12V)Ha-ras or (Q61K)N-ras proliferate in serum-free media and have constitutive MAPK activity, The growth factor antagonist, suramin, inhibited the serum-independent proliferation of Ha-ras transformed fibroblasts, but not the serum-independent proliferation of N-ras transformed cells. The inhibition of cell proliferation was concomitant with the abrogation of the constitutive MAPK activity in the Ha-ras transformed fibroblasts, Analysis of the Ras-signalling complexes in immunoprecipitates from Ha-ras transformed cells revealed that Raf-1 co-immunoprecipitated with endogenous c-N-ras but not (G12V)Ha-ras. Pretreatment with suramin resulted in the loss of Raf-1 from c-N-ras immunoprecipitates, A c-N-ras antisense oligonucleotide, which down-regulated c-N-ras protein levels, abrogated the constitutive MAPK activity and serum-independent proliferation of (G12V)Ha-ras transformed cells, The data suggest that Raf-1 has a higher affinity for N-ras then Ha-ras in vivo, and c-N-ras function is required for the serum-independent proliferation of Ha-ras transformed cells.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, M (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berkowitz EA, 1996, ONCOGENE, V12, P1991; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CARBONE A, 1991, ONCOGENE, V6, P731; CASTELLI C, 1994, CANCER RES, V54, P4785; COX AD, 1995, METHOD ENZYMOL, V255, P195; CREWS CM, 1993, CELL, V55, P915; DAWSON TP, 1995, CANCER RES, V55, P915; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.biochem.54.1.367; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KEHINDE EO, 1995, CANCER SURV, V23, P217; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1990, ONCOGENE, V5, P713; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAHER J, 1995, ONCOGENE, V11, P1639; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLDHAM SM, 1996, P NATL ACAD SCI USA, V93, P6294; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; RAK J, 1995, CANCER RES, V55, P4575; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	58	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1417	1428		10.1038/sj.onc.1201653	http://dx.doi.org/10.1038/sj.onc.1201653			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525741				2022-12-17	WOS:000072572400006
J	Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP				Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP			AATYK: A novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells	ONCOGENE			English	Article						AATYK; apoptosis; differentiation; SH3 binding motifs; tyrosine kinase; myeloid cells	GRANULOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; CONSERVED FEATURES; SIGNALING PROTEINS; LINE; EXPRESSION; DEATH; GENE; INTERLEUKIN-3	Apoptosis, or programmed cell death, is a process where developmental or environmental stimuli activate a genetic program to implement a series of events that culminate in cell death, To study the nature of genes that are induced during the apoptotic death of myeloid precursor cells. we utilized the 32Dc13 cell line, which is derived from normal mouse bone marrow, is non-tumorigenic and diploid, These cells are strictly dependent on IL-3 for growth and apoptose when deprived of IL-3, However, when these cells are transferred to medium containing G-CSF, the cell number increases 3-5-fold and after 12 days the entire population is differentiated into granulocytes followed by apoptotic death, In our search for genes that are induced during apoptosis and/or terminal differentiation of 32Dc13 cells, we identified a novel gene termed AATYK (Apoptosis Associated Tyrosine Kinase), whose expression is dramatically upregulated during IL-3 deprivation as well as G-CSF-induced terminal differentiation. In this report, we describe the sequence of the cDNA clone, derived from the mRNA transcript of this gene, These studies show that this gene encodes a protein with a tyrosine kinase domain at the N-terminal end and a proline-rich domain at the C-terminal end, We also report that the expression of this gene is blocked in v-abl or bcr-abl transformed myeloid cells which are unable to apoptose when grown in the absence of IL-3, However, AATYK expression is induced in 32D cells transformed by the v-abl gene when these cells are incubated in the presence of DMSO, which induces growth arrest and apoptotic death of the cells, On the other hand, DMSO fails to induce apoptosis or AATYK expression in 32D cells transformed by the bcr-abl oncogene, suggesting that AATYK expression may be a necessary pre-requisite for the induction of growth arrest and/or apoptosis of myeloid precursor cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER; NCI NIH HHS [CA68239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Ishino M, 1995, ONCOGENE, V11, P2331; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREIDER BL, 1990, MOL CELL BIOL, V131, P227; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lung CC, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90093-1; METTUS RV, 1994, ONCOGENE, V9, P3077; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1993, BLOOD, V81, P2844; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; RANE SG, 1994, ONCOGENE, V9, P2415; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROVERA G, 1987, ONCOGENE, V1, P29; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sieff C A, 1994, Curr Opin Hematol, V1, P310; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	41	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3127	3135		10.1038/sj.onc.1201575	http://dx.doi.org/10.1038/sj.onc.1201575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444961				2022-12-17	WOS:000070968000013
J	Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A				Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A			Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Ras; Ral; Rap; posttranslational modification	GUANINE-NUCLEOTIDE EXCHANGE; H-RAS; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; PROTEIN-KINASE; R-RAS; B-RAF; P21; TRANSFORMATION	Ral GDP dissociation stimulator (RalGDS), a putative effector protein of Ras, stimulated the GDP/GTP exchange reaction of the post-tanslationally lipid-modified but not the unmodified form of Ral in response to epidermal growth factor in COS cells, The RalGDS action on Ral was enhanced by an active form of Res but not a Ras mutant which was not post-translationally modified in the cells, The RalGDS activity was inhibited by acidic membrane phospholipids such as phosphatidylinositol and phosphatidylserine but not by phosphatidylcholine or phosphatidylethanolamines in vitro. The posttranslationally modified form but not unmodified form of Ras, Ral, and Rap were incorporated in liposomes consisting of these phospholipids. When Ral was incorporated alone in the liposomes, RalGDS did not stimulate the dissociation of GDP from Ral, When Rat was incorporated with the GTP-bound form of Ras in the liposomes, RalGDS stimulated the dissociation of GDP from Ral, while the GDP-bound form of Ras did not affect the RalGDS action, The Ras-dependent Ral activation through RalGDS required the Ras-binding domain of RalGDS, Rap, which shared the same effector loop as Ras, also stimulated the dissociation of GDP from Ral through RalGDS in the liposomes, although Rap did not enhance the RalGDS action in COS cells, Taken together with our previous observations that Ras recruits RalGDS to the membrane, these results indicate that the post-translational modifications of Ras and Ral are important for Ras-dependent Ral activation through RalGDS and that colocalization of Ras and Ral on the membrane is necessary for Ral activation in intact cells.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST INFECT DIS,DEPT VIROL 2,SHINJYUKU KU,TOKYO 162,JAPAN	Hiroshima University; National Institute of Infectious Diseases (NIID)				kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GORMAN CM, 1985, HIGH EFFICIENCY GENE; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; KAWAMURA S, 1991, JPN J CANCER RES, V82, P758, DOI 10.1111/j.1349-7006.1991.tb02699.x; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; Murai H, 1997, J BIOL CHEM, V272, P10483; Okada T, 1996, J BIOL CHEM, V271, P4671; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	43	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2899	2907		10.1038/sj.onc.1201473	http://dx.doi.org/10.1038/sj.onc.1201473			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416833				2022-12-17	WOS:A1997YK37700002
J	Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B				Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B			The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2B; Crk; Nck; paxillin	PHOSPHORYLATION-DEPENDENT MANNER; GROWTH-FACTOR RECEPTOR; COMPLEXES IN-VIVO; V-CRK; PROTO-ONCOGENE; HIGH-AFFINITY; MOLECULAR CHARACTERIZATION; TRANSFORMING ACTIVITY; ADAPTER PROTEINS; ENDOGENOUS CRK	The RET proto-oncogene encodes a Tyrosine Kinase Receptor (RTK) which plays an important function in the proliferation and/or differentiation of neuroectodermic cells, Germline mutation of a methionine to a threonine within the RET TK domain predisposes to the Multiple Endocrine Neoplasia type 2B (MEN 2B), It has been demonstrated that, unlike c-Ret, the MEN 2B mutated Ret displays constitutive TK activity, tyrosine autophosphorylation and transforms fibroblasts, However, this oncoprotein is more than a fully activated wildtype (WT) Ret TK since it also displays modified substrate specificity, Change in substrate specificity leads to the tyrosine autophosphorylation of MEN 2B Ret on new sites as well as the phosphorylation of several novel downstream targets, But, none of these substrates have been identified and the ability of MEN 2B Ret phosphoprotein to interact with Src Homology 2 (SH2) domain containing molecules has been poorly investigated, In this report, using a constitutively activated Ret TK form, Ret-ptc 2, we demonstrate that the MEN 2B as the activated WT Ret TK binds to several SH, signalling proteins such as Shc, Grb-2, Phospholipase C gamma, Crk and Nck, However, in contrast to the activated WT form, expression of the MEN 2B mutated Ret-ptc 2 results in the tyrosine phosphorylation of a panel of proteins which interestingly interact with Crk and Nck, We identified Paxillin, a cytoskeletal protein as one of the Crk associated proteins that is dramatically phosphorylated in MEN 2B but WT expressing cells, These data suggest that MEN 2B mutated Ret triggers distinct signalling pathways that might be related to its transforming power.	INSERM U364, FAC MED PASTEUR, NICE, FRANCE; IST GIANNINA GASLINI, GENET MOL LAB, I-16148 GENOA, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; HOP COCHIN, INSERM U363, INST COCHIN GENET MOL, F-75674 PARIS, FRANCE; INT AGCY RES CANC, F-69372 LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; World Health Organization; International Agency for Research on Cancer (IARC)			Pierotti, Marco Alessandro/AAC-4728-2022; Bocciardi, Renata/J-8577-2016; Mograbi, Baharia/N-5531-2018; Mograbi, Baharia/Q-7953-2019; Borrello, Maria Grazia/C-3161-2017; Pasini, Barbara/AHI-2004-2022	Pierotti, Marco Alessandro/0000-0002-7431-8332; Bocciardi, Renata/0000-0001-8415-3802; Borrello, Maria Grazia/0000-0002-6854-2848; Pasini, Barbara/0000-0002-4373-1212; Mograbi, Baharia/0000-0002-1025-3429; BOURGET, Isabelle/0000-0001-6369-8176				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Fugazzola L, 1996, ONCOGENE, V13, P1093; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROMANO A, 1994, ONCOGENE, V9, P2923; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2257	2265		10.1038/sj.onc.1201413	http://dx.doi.org/10.1038/sj.onc.1201413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393871				2022-12-17	WOS:A1997YE15700001
J	Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH			Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters	ONCOGENE			English	Article						c-Fos; Fra-2; mouse keratinocytes; differentiation; calcium; phorbol ester	PROTEIN-KINASE-C; HUMAN INVOLUCRIN GENE; HUMAN EPIDERMAL-KERATINOCYTES; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; RETINOIC ACID; CELL-ENVELOPE; EXPRESSION	The major differentiation products of maturing keratinocytes contain AP-I regulatory motifs, and AP-1 DNA binding activity increases in cultured keratinocytes induced to differentiate by calcium. Here, we have analysed AP-I transcriptional activity in mouse keratinocytes treated with calcium and 12-O-tetradecanoyl phorbol-13-acetate (TPA), two agents that induce terminal differentiation of keratinocytes with different phenotypic consequences. Reporter constructs representing multimers of AP-I sequences found in keratinocyte marker genes demonstrated that the calcium-induced AP-I DNA binding activity does not correlate with transcriptional activation. Moreover, expression from active subunits of the profilaggrin and spr 1 promoters increased in calcium-treated keratinocytes when the AP-1 sites were disrupted, indicating that AP-I may negatively regulate certain promoters in these cells. In contrast, AP-1 reporter activity was increased in keratinocytes treated with TPA. This induction was dependent upon the expression of c-Fos since AP-I transcriptional activity was not increased in TPA-treated keratinocytes derived from c-fos null mice. Analysis of AP-1 protein expression in calcium-and TPA-treated keratinocytes demonstrated that only TPA increased the expression of c-Jun, while Jun B and Jun D were induced by both of these agents. c-Fos was expressed only in TPA treated keratinocytes, Fra-2 was expressed only in calcium-treated cells, and Fra-1 was expressed in both. Exogenous expression of Fra-2 repressed AP-1 transcriptional activity in TPA-treated keratinocytes, while c-Fos expression activated the AP-I sequence in calcium-treated keratinocytes. These data indicate that Fra-2 and c-Fos play opposing roles in regulating AP-1 activity in keratinocytes and that multiple inducer-dependent regulatory pathways may exist for the expression of keratinocyte differentiation markers.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NIAMSD,SKIN BIOL LAB,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; Bernerd Francoise, 1993, Gene Expression, V3, P187; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LICHTI U, 1988, CANCER RES, V48, P74; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; REZZONICO R, 1995, ONCOGENE, V11, P1069; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SONOBE MH, 1995, ONCOGENE, V10, P689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TOFTGARD R, 1985, CANCER RES, V45, P5845; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIRTH PJ, 1987, CANCER RES, V47, P2831; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	64	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1337	1346		10.1038/sj.onc.1201293	http://dx.doi.org/10.1038/sj.onc.1201293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315102				2022-12-17	WOS:A1997XV84500012
J	Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P				Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P			The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p	ONCOGENE			English	Article						CYR61; immediate early gene; CCN family; mosaic protein	IDENTIFICATION; EXPRESSION; PROTEIN; CELLS; HYBRIDIZATION; DELETION; PRODUCT; FAMILY; BETA; NOV	Complementary DNA encoding the human CYR61 protein was isolated from human embryonic tissues and mapped to chromosome 1p22-p31. We show that CYR61 encodes a 381 amino acid protein rich in cysteine and proline residues that is strongly conserved with the mouse homologue. Sequence analysis reveals the presence of several distinct protein domains which confer a mosaic structure to this protein and makes human CYR61 a member of a recently described growth regulator family that includes several proto-oncogene products. From our results we hypothesize that this new immediate early gene may play a role in cell commitment during embryogenesis and more generally in the control of cell proliferation.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,INSERM U249,F-34033 MONTPELLIER,FRANCE; FAC MED MARSEILLE,INSERM U406,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Jay, Philippe/I-7116-2016; Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700				BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHEN ZY, 1993, GENOMICS, V16, P533, DOI 10.1006/geno.1993.1224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GEHRING M, 1995, CANCER RES, V55, P5366; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JAY P, 1996, IN PRESS GENOMICS; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SIMON D, 1991, ONCOGENE, V6, P765; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P121; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; ZABEL BU, 1985, P NATL ACAD SCI USA, V82, P469, DOI 10.1073/pnas.82.2.469	33	61	80	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1753	1757		10.1038/sj.onc.1200986	http://dx.doi.org/10.1038/sj.onc.1200986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135077				2022-12-17	WOS:A1997WR89300014
J	Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D				Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D			Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions	ONCOGENE			English	Article						ataxia telangiectasia; BRCA1; breast cancer; chromosome 10; chromosome 11; chromosome 17	SUSCEPTIBILITY GENE; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; CANCER; TUMORS; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; LOCUS	To appreciate the involvement of known or potential susceptibility genes in sporadic breast tumors, we have searched for chromosomal deletions by studying loss of heterozygosity (LOH) at 43 microsatellite (CA)(n) markers from human chromosomes 10, 11 and 17, in 115 unselected consecutive samples of breast carcinoma with particular emphasis on specific regions. No site of consistent LOH was identified on chromosome 10. Five regions of LOH were contained within bands q22-24 of chromosome 11 for which nearly 50% of the tumors had LOH at at least one marker. This region is thus a major site of deletion in breast cancer and several tumor suppressor genes seem to be involved. One of them may be the ataxia telangiectasia (ATM) gene which is located in one of the affected regions. Five regions of LOH, one of which is within the BRCA1 gene area, were recognized along chromosome 17. LOH at three of these regions were found in highly proliferative tumors, When combined with a previous study of chromosome 13 with emphasis on BRCA2 and Rb1 genes, this work allowed to distinguish a total of 12 regions of LOH, variably affected in breast tumors and correlated with prognostic parameters.	INST J PAOLI I CALMETTES,LAB BIOL TUMEURS,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT ONCOGENET,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; UNIV NIJMEGEN HOSP,NIJMEGEN,NETHERLANDS; IGGM,CNRS URA 9942,MONTPELLIER,FRANCE; INST J PAOLI I CALMETTES,DEPT PATHOL ANAT,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Radboud University Nijmegen; Universite de Montpellier; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm)			Padberg, G.W.A.M./H-8079-2014; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Eisinger, Francois/0000-0002-8794-0681; Eng, Charis/0000-0002-3693-5145				AGRESTI A, 1990, J AM STAT ASSOC, V85, P543; Baffa R, 1996, CANCER RES, V56, P268; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; CROPP CS, 1993, CANCER RES, V53, P5617; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eisinger F, 1996, CANCER RES, V56, P471; FERTIPASSANTONOPOULOU A, 1991, CANCER GENET CYTOGEN, V51, P183, DOI 10.1016/0165-4608(91)90130-M; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GRAY IC, 1995, CANCER RES, V55, P4800; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hollander M., 1973, NONPARAMETRIC STAT M, P115; HUI A, 1996, ONCOGENE, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Ittmann M, 1996, CANCER RES, V56, P2143; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kerangueven F, 1996, INT J ONCOL, V8, P1155; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P271; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LINDBLOM A, 1994, AM J HUM GENET, V54, P871; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NAGAI MA, 1995, ONCOLOGY, V52, P448; NEGRINI M, 1995, CANCER RES, V55, P3003; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SANCHEZ Y, 1996, CANCER RES, V93, P2551; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schultz DC, 1996, CANCER RES, V56, P1997; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; STARINK TM, 1986, CLIN GENET, V29, P222; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; THEILLET C, 1989, ONCOGENE, V4, P915; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660; ZHUANG ZP, 1995, CANCER RES, V55, P467	54	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					339	347		10.1038/sj.onc.1200818	http://dx.doi.org/10.1038/sj.onc.1200818			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018120	Green Published			2022-12-17	WOS:A1997WD51600010
J	Lohrum, M; Scheidtmann, KH				Lohrum, M; Scheidtmann, KH			Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes	ONCOGENE			English	Review						tumor suppressor; p53; okadaic acid; phosphorylation; transactivation	TUMOR-SUPPRESSOR PROTEIN; LARGE-T-ANTIGEN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; P53-MEDIATED TRANSACTIVATION; CELLULAR PROTEINS; EXCISION-REPAIR	The tumor suppressor protein p53 is phosphorylated at multiple sites in the amino-terminal transactivation domain and at several sites in the carboxy-terminal region. Phosphorylation appears to modulate its DNA binding activity. Here we demonstrate that phosphorylation of p53 also modulates its transcriptional activity. Okadaic acid treatment of cells resulted in enhanced phosphorylation of p53 and concomitantly in enhanced transactivation of an mdm2 promoter-linked luciferase reporter gene. This effect was cell type specific, however, since transactivation was enhanced in rat and mouse fibroblasts but reduced in the human Saos-2 cell line. Moreover, the effect was dependent on the promoter. In rat cells transcription from the mdm2, waf1 (cip1) and bar gene promoters, and the artificial PG13 promoter was enhanced by okadaic acid treatment whereas that from the cyclin G promoter was reduced. When various phosphorylation site mutants of p53 were tested for transactivation of these promoters, they behaved differently. Amino-terminal mutants exhibited reduced transcriptional activities on mdm2, waf1 and cyclin G promoters but enhanced activities with bar and PG13 promoters. On the other hand, a mutant at the cdk phosphorylation site, A313, showed reduced activity with mdm2 and waf1 promoters but enhanced activity with the cyclin G promoter, and finally, mutant A390 exhibited enhanced activity on waf1 and bar promoters, but reduced activity on the cyclin G promoter. These results suggest that phosphorylation of p53 may have different effects on its transcriptional activity, depending on the cellular environment and the particular response element. Moreover, both, amino- and carboxy-terminal phosphorylation sites seem to be involved in modulating the DNA-binding and the transactivation activities.	UNIV BONN,INST GENET,ABT MOL GENET,D-53117 BONN,GERMANY	University of Bonn								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; APPEL K, 1995, ONCOGENE, V11, P1971; APPEL K, 1994, INT J ONCOL, V5, P667; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUALBERTO A, 1995, J BIOL CHEM, V270, P16980; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARPER JW, 1993, CELL, V75, P805; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1992, BIOCHEM J, V287, P1; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller BF, 1996, ONCOGENE, V12, P1941; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PERREM K, 1995, ONCOGENE, V11, P1299; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHONTHAL A, 1991, ONCOGENE, V6, P423; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STRUZBECHER HW, 1996, EMBO J, V15, P1992; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WAGNER P, 1994, INT J ONCOL, V4, P987; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YATSUNAMI J, 1993, CANCER RES, V53, P239; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, CANCER RES, V54, P4448; ZHANG W, 1994, ONCOGENE, V9, P2513; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	121	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000127				2022-12-17	WOS:A1996VZ65400003
J	Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A				Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A			Biochemical and biological consequences of changing the specificity of p21(ras) from guanosine to xanthosine nucleotides	ONCOGENE			English	Article						Ras D119N mutant; interactions; change of specificity; xanthosine nucleotide	ELONGATION-FACTOR-TU; H-RAS P21; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; BINDING-PROTEINS; PC12 CELLS; GTP; IDENTIFICATION; HYDROLYSIS	The D119N mutation of p21(ras) was prepared by site-directed mutagenesis. Its nucleotide binding properties were investigated using fluorescently labelled guanosine and xanthosine nucleotides. Its affinity for guanosine nucleotides is severely reduced, with a concomitant increase in the affinity for xanthosine nucleotides, which leads to an almost complete reversal of base specificity. The protein is a GTPase as well as a XTPase and the hydrolysis reaction can be efficiently stimulated by GAP. Dissociation of XDP from the mutant is stimulated by the guanine nucleotide exchange factor Cdc25(Mm) in a similar manner to that of GDP from wildtype. The interaction of the mutant with the effector domain of c-Raf kinase or Ral-GEF is normal. In microinjection experiments in PC12 and NIH3T3 cells the protein behaves as an oncogenic mutant due to its high dissociation rate for GDP. However, when the protein is loaded with XDP before microinjection the onset of the oncogenic signal can be efficiently retarded. Thus, the protein behaves initially as wildtype and later as an oncogenic protein.	MAX PLANCK INST MOLEK PHYSIOL,ABT STRUKT BIOL,D-44139 DORTMUND,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	Max Planck Society; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Cool, Robbert/0000-0002-9845-2202				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; DER CJ, 1988, ONCOGENE, V3, P105; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GLAZEBROOK MA, 1990, J GEN MICROBIOL, V136, P581, DOI 10.1099/00221287-136-3-581; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GOODY RS, 1986, TETRAHEDRON LETT, V27, P3599, DOI 10.1016/S0040-4039(00)84859-5; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HERRMANN C, 1995, IN PRESS J BIOL CHEM; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; KANG C, 1994, J BIOL CHEM, V269, P24046; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO K, 1995, J BIOL CHEM, V270, P7816, DOI 10.1074/jbc.270.14.7816; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SCHWEINS T, 1994, CURR BIOL, V4, P547, DOI 10.1016/S0960-9822(00)00122-6; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3442; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	67	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					87	96						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552403				2022-12-17	WOS:A1996TQ01400011
J	YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E				YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E			Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53	ONCOGENE			English	Article						p53, apoptosis; transcriptional-activation	CELL-CYCLE CONTROL; DNA-BINDING; MONOCLONAL-ANTIBODIES; T-ANTIGEN; PROTEIN; MUTANT; TRANSFORMATION; IDENTIFICATION; INHIBITION; MUTATIONS	The p53 tumor suppressor gene has been implicated in the induction of apoptosis in several cell systems, We have recently reported that transiently-transfected wt p53 is capable of inducing apoptosis in certain transformed cell lines, We demonstrated by quantitative analysis using flow cytometry that apoptosis was restricted to the population expressing wt, but not mutant, p53, In the present study we use this model system to analyse the functional domains of p53 in the induction of apoptosis, Several constructs expressing mutations or deletions in the C-terminal oligomerization domain, the N-terminal transactivation domain or the central DNA-binding domain were introduced into HeLa cells, and the ability of the expressed proteins to induce apoptosis was evaluated, All the functional domains were found to be necessary for the induction of apoptosis, In addition, cycloheximide and actinomycin D inhibited wt p53-induced apoptosis, We therefore conclude that p53 acts in this cell system, at least in part, as a transcriptional activator in the induction of apoptosis.	INST RECH SCI CANC, CNRS, CYTOMETRIE LAB, F-94801 VILLEJUIF, FRANCE; MARIE CURIE RES INST, SURREY RH8 0TL, ENGLAND	Centre National de la Recherche Scientifique (CNRS)	YonishRouach, E (corresponding author), INST RECH SCI CANC, CNRS, ONCOL MOLEC LAB, 7 RUE GUY MOQUET, F-94801 VILLEJUIF, FRANCE.							ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HADLAR S, 1994, CANCER RES, V54, P2095; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEGROS Y, 1994, ONCOGENE, V9, P2071; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY E, 1991, ONCOGENE, V6, P1363; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG YS, 1993, ONCOGENE, V8, P3427; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1994, ONCOGENE, V9, P2513	61	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2197	2205						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570169				2022-12-17	WOS:A1995TK70200002
J	NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C				NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C			THE ANTIPROLIFERATIVE EFFECT OF VITAMIN-D-3 ANALOGS IS NOT MEDIATED BY INHIBITION OF THE AP-1 PATHWAY, BUT MAY BE RELATED TO PROMOTER SELECTIVITY	ONCOGENE			English	Article						REGULATION OF TRANSCRIPTION; CONTROL OF PROLIFERATION; MCF-7 BREAST CANCER CELLS; RETINOID-X-RECEPTOR VITAMIN-D-3 RECEPTOR HETERODIMERS; VITAMIN-D-3 RESPONSE ELEMENTS	CANCER CELL-PROLIFERATION; RETINOIC ACID RECEPTORS; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENTS; SIGNALING PATHWAYS; THYROID-HORMONE; C-JUN; DIFFERENTIATION; INVIVO	The hormone 1,25-dihydroxyvitamin D-3 (VD) is able to induce cellular differentiation and to inhibit cellular proliferation, which provides it with an interesting therapeutic potential in cancer. However, side effects of VD on homeostasis (eg hypercalcemia) had made the need for the development of VD analogues with low calcemic effect. On the human breast cancer cell line MCF-7 we obtained with the VD analogue EB1089 an about 100-fold higher anti-proliferative effect than with VD. We found that this difference in biological activity is neither related to increased functional affinity to the VD receptor nor to repression of AP-1 activity. The physiologically most prominent complex of the VD receptor is a heterodimer with the retinoid X receptor that binds VD response elements formed two hexameric core binding motifs being arranged either as direct repeats spaced by 3 nucleotides (DR3s) or as inverted palindromes spaced by 9 nucleotides (IP9s). We observed that EB1089 stimulates transcriptional activation from IP9-type elements at clearly lower concentrations than from DR3-type elements. It is possible that IP9-type response elements play an important role in or contribute to the control of cell proliferation, so that promoter-selectivity may explain the high anti-proliferative effect of EB1089.	HOP CANTONAL GENEVA,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; LEO PHARMACEUT PROD,BIOL RES & DEV,DK-2750 BALLERUP,DENMARK	University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BERG JP, 1994, J STEROID BIOCHEM, V50, P145, DOI 10.1016/0960-0760(94)90021-3; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BINDERUP L, 1992, BIOCHEM PHARMACOL, V43, P1885, DOI 10.1016/0006-2952(92)90630-2; BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357; CARLBERG C, 1994, J STEROID BIOCHEM, V51, P137, DOI 10.1016/0960-0760(94)90086-8; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; COLSTON KW, 1989, LANCET, V1, P188; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; JIANG HP, 1994, ONCOGENE, V9, P3397; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KISSMEYER AM, 1995, ENDOCRINE, V3, P263, DOI 10.1007/BF03021403; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MATHIASEN IS, 1993, J STEROID BIOCHEM, V46, P365, DOI 10.1016/0960-0760(93)90226-M; McElwain Mariann C., 1995, Molecular and Cellular Differentiation, V3, P31; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STERN PH, 1981, CALCIFIED TISSUE INT, V33, P1, DOI 10.1007/BF02409404; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	49	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1853	1858						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478614				2022-12-17	WOS:A1995TD09400021
J	RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O				RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O			ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS INVOLVED IN THE ACTIVATION OF THE SHC/GRB-2 PATHWAY BY THE ERBB-2 KINASE	ONCOGENE			English	Article						ERBB-2; SHC; GRBB-2; SIGNAL TRANSDUCTION	RECEPTOR TYROSINE KINASES; SH3 DOMAINS; SIGNAL TRANSDUCTION; EGF RECEPTOR; NEU ONCOGENE; RAS; GRB2; GENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION	In murine fibroblasts activation of the Shc/Grb-2 pathway by the ErbB-2 kinase involves tyrosine phosphorylation of She products and the formation of Shc/ErbB-2, Shc/Grb-2 and Grb-2/ErbB-2 complexes. Tyr 1139 of ErbB-2 bound to the Grb-2 SH2 domain in vitro as well as in intact cells. Tyr 1221 and 1248 are binding sites of gp185(ErbB-2) for Shc SH2 domain in vitro whereas Tyr 1196 and 1248 are major binding sites of ErbB-2 for She PTB domain. Inhibition of Shc/ErbB-2 complex formation in intact cells was obtained by simultaneous mutational inactivation of She SH2 and She PTB binding sites of gp185(Erb-2). Shc/ErbB-2 complexes are formed upon activation of the ErbB-2 kinase and tyrosine phosphorylation of She proteins; they are located in both cytosol and cellular membranes. ErbB-2 activation induces also translocation of Grb-2 from cytosol to membranes. This network of protein-protein interactions may reflect the ability of the Shc/Grb-2 pathway to act as a molecular snitch controlling different cellular functions regulated by RTK activation. In fact the Ras GDP exchanger mSOS was recruited in Grb-2/ErbB-2 complexes; furthermore besides mSOS, other polypeptides present in either cytosolic or membrane preparations were able to complex in vitro with Grb-2 SH3 domains.	REGINA ELENA INST CANC RES, IMMUNOL LAB, I-00156 ROME, ITALY; UNIV PERUGIA, IST CLIN MED, MOLEC BIOL LAB, I-06100 PERUGIA, ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Lanfrancone, Luisa/0000-0002-4523-3815; Segatto, Oreste/0000-0003-2561-1142; chiari, rita/0000-0002-7649-273X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V73, P611; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIESI G, 1992, HYBRIDOMA, V11, P519, DOI 10.1089/hyb.1992.11.519; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SEGATTO O, 1992, ONCOGENE, V7, P1339; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	60	61	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1519	1529						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478576				2022-12-17	WOS:A1995TC53500010
J	HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H				HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H			AUGMENTATION OF METALLOPROTEINASE (GELATINASE) ACTIVITY SECRETED FROM ROUS-SARCOMA VIRUS-INFECTED CELLS CORRELATES WITH TRANSFORMING ACTIVITY OF SRC	ONCOGENE			English	Article						SRC; TRANSFORMATION; ROUS SARCOMA VIRUS; METALLOPROTEINASE; GELATINASE	CHICKEN-EMBRYO FIBROBLASTS; BASEMENT-MEMBRANE COLLAGEN; PROTEIN-KINASE ACTIVITY; GENE-PRODUCT; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; TISSUE INHIBITOR; C-SRC; ASSOCIATION; MATRIX	To search for the biochemical properties of cells relevant to transformation by p60(v-src), we examined the activities and amounts of metalloproteinase (gelatinase) released from chicken embryonic fibroblasts infected with various mutants of Rous sarcoma virus by zymography and immunoblotting, While nontransforming Src proteins, including cellular p60(c-src) and its nonmyristylated form, had no stimulatory effect, wild-type p60(v-src) and the transforming mutant of cellular p60(c-src) stimulated the secretion and proteolytic activation of metalloproteinases, Moreover, the activation of metalloproteinase secretion strongly correlated with the invasiveness of cells assayed by the modified Boyden Chamber method, Chimeric mutants between v-src and c-src, which are transforming but produce less distinct morphological changes in infected cells, also stimulated the secretion of metalloproteinases as well as wild-type p60(v-src). Deletion mutants of v-Src in which varying portions of the NH2-terminal half of p60(v-src) are deleted stimulated secretion to a level similar to that of wild-type regardless of the degree of morphological change they induce, Together with Src protein, other oncogene products including Yes, Fps, ErbB and Crk were also found to stimulate the secretion of metalloproteinases, Thus, these results suggest that transformation of cells with src and other oncogenes is closely secretion of metalloproteinases associated with the enhanced that may play an important role in tumor invasion and metastasis.	AICHI CANC CTR,RES INST,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	Aichi Cancer Center; Rockefeller University	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT MOLEC PATHOGENESIS,SHOWA KU,TSURUMAI CHO 65,NAGOYA,AICHI 466,JAPAN.							ALBINI A, 1987, CANCER RES, V47, P3239; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CHEN JM, 1991, J BIOL CHEM, V266, P5113; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P1353; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0; YAMAGATA S, 1991, CANCER LETT, V59, P51, DOI 10.1016/0304-3835(91)90135-5	38	61	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1037	1043						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535415				2022-12-17	WOS:A1995QN35300002
J	ADAMSON, R; JONES, AS; FIELD, JK				ADAMSON, R; JONES, AS; FIELD, JK			LOSS OF HETEROZYGOSITY STUDIES ON CHROMOSOME-17 IN HEAD-AND-NECK-CANCER USING MICROSATELLITE MARKERS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; POLYMERASE CHAIN-REACTION; BREAST-CANCER; COLORECTAL-CANCER; ALLELE LOSS; P53 GENE; OVARIAN-CARCINOMA; FREQUENT LOSS; DELETION	In this study we have analysed 38 squamous cell carcinomas (SCC) two basal cell carcinomas (BCC), a malignant salivary gland carcinoma, a neurosarcoma and a Warthins carcinoma, all isolated from patients with head and neck cancers. These tumour types have been examined by PCR for loss of heterozygosity (LOH) on both arms of chromosome 17 using nine polymorphic microsatellite markers. LOH on 17p in SCCHN was found to be 50% (19/38), and often involved TP53 (42%) but more frequently involved the CHRNB1 locus (56%). Twelve tumours showed loss of heterozygosity on 17q (34%) and ten of these also had loss on 17p. Four SCCHN tumours lost an entire copy of chromosome 17. It was of particular note that 77% (10/13) of the SCCHN at the hypopharyngeal site had LOH at CHRNB1. We propose from our data that the 17p12-p11 region contains a novel predisposing gene for hypopharyngeal SCCHN that may function as a tumour suppressor gene.	UNIV LIVERPOOL,SCH DENT,DEPT CLIN DENT SCI,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT OTORHINOLARYNGOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CANN CI, 1985, OTOLARYNG CLIN N AM, V18, P367; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DELATTRE O, 1989, LANCET, V2, P353; ECCLES DM, 1990, ONCOGENE, V5, P1599; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, CELL, V61, P757; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FIELD JK, 1992, LANCET, V339, P502, DOI 10.1016/0140-6736(92)91122-O; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FIELD JK, 1994, INT J ONCOL, V4, P543; FIELD JK, 1994, IN PRESS CANCER DETE; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FULTS D, 1989, CANCER RES, V49, P6572; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JONES AS, 1993, CLIN OTOLARYNGOL, V17, P545; KELSELL DP, 1993, GENOMICS, V17, P522, DOI 10.1006/geno.1993.1362; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LATIF F, 1992, CANCER RES, V52, P1451; LEONE A, 1991, CANCER RES, V51, P2490; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MACKAY J, 1988, LANCET, V2, P1384; MAESTRO R, 1992, ONCOGENE, V7, P1159; MCKUSICK VA, 1993, J MED GENET, V10, P1; MELING GI, 1993, BRIT J CANCER, V67, P88, DOI 10.1038/bjc.1993.14; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; NAKSTAD B, 1992, TIDSSKR NOR LAEGEFOR, V113, P595; OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAKAI E, 1992, ONCOGENE, V7, P927; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STELL PM, 1989, EUR J SURG ONCOL, V15, P407; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VIANI L, 1991, J LARYNGOL OTOL, V105, P24, DOI 10.1017/S0022215100114732; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGATA T, 1993, CANCER RES, V53, P846; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YIN Y, 1993, EUR J CANCER ORAL ON, V29, P257; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	58	61	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2077	2082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208554				2022-12-17	WOS:A1994NR68500034
J	LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET				LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET			2 NOVEL HUMAN SERINE/THREONINE KINASES WITH HOMOLOGIES TO THE CELL-CYCLE REGULATING XENOPUS MO15, AND NIMA KINASES - CLONING AND CHARACTERIZATION OF THEIR EXPRESSION PATTERN	ONCOGENE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; COLORECTAL-CANCER; CATALYTIC SUBUNIT; FISSION YEAST; LUNG-CANCER; GENE; QUERCETIN; CDC2	Using polymerase chain reaction (PCR)-based methods, we have isolated cDNA clones of two new members of serine/threonine kinases, STK1 and STK2, from a cDNA library constructed from the BT-20 human breast cancer cell line. STK1 is transcribed as a 1.4 kilobase (kb) mRNA encoding for a protein of 346 amino acids. Based on amino acid sequence analysis, STK1 is 86% identical to the Xenopus p40(mol5), a cdc2-related serine/threonine kinase recently found to be the activating kinase for p34(cdc2) and p33(cdk2). Thus, STK1 is most likely the human homologue of MO15. An alternatively spliced STK1 message expressed variably in cell lines and in primary carcinomas generates a predicted 58 amino acid protein that lacks the kinase domain. STK2 is transcribed into a 4.0 kb mRNA encoding for an 841 residue protein which exhibits 50% identity in the kinase domain with the mouse nek1 gene product, the relative of the fungal G(2)-M regulator, nimA. STK1 and STK2 display a variable pattern of expression among a series of primary carcinomas as well as cancer cell lines. Both STK1 and STK2 were expressed at the highest levels in the heart but were also detected in all other organs tested. Tn embryonal tissues, lower levels of expression were noted. Using cell cycle inhibitors, we have shown that both STK1 and STK2 mRNA levels remain relatively invariant through the cell cycle. Chromosomal assignment has localized STK1 on chromosome 2pcen-2p15, a region implicated in hereditary non-polyposis colorectal carcinoma, and STK2 on chromosome 3p21.1, a region frequently showing chromosomal alterations in renal cells carcinomas.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA; UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Liu, Edison/C-4141-2008	Bowcock, Anne/0000-0001-8691-9090; Leach, Robin/0000-0002-3201-5579	NATIONAL CANCER INSTITUTE [R01CA027632, P50CA058223, K08CA001625] Funding Source: NIH RePORTER; NCI NIH HHS [CA27632, K08 CA01625, 1P50CA58223-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ANGLARD P, 1992, CANCER RES, V52, P348; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CANCE WG, 1993, INT J CANCEER, V54, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GRAZIANI Y, 1981, BIOCHIM BIOPHYS ACTA, V714, P415; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; LANG DR, 1974, BIOCHIM BIOPHYS ACTA, V333, P180, DOI 10.1016/0005-2728(74)90002-4; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MIURA I, 1992, CANCER RES, V52, P1322; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NANUS DM, 1991, ONCOGENE, V6, P2105; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RAPP UR, 1988, HDB ONCOGENES, P213; REED JC, 1992, CANCER RES, V52, P2802; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SETH A, 1988, ONCOGENE HDB, P195; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; SUNARA U, 1991, CELL, V65, P145; Swofford D., 1998, PAUP PHYLOGENETIC AN; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TODD SK, 1992, THESIS U TEXAS HLTH; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	62	61	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208544				2022-12-17	WOS:A1994NR68500022
J	MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J				MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J			ANALYSIS OF P53 IN HUMAN CUTANEOUS MELANOMA CELL-LINES	ONCOGENE			English	Note							MALIGNANT-MELANOMA; SV40-TRANSFORMED CELLS; MELANOCYTIC LESIONS; METASTATIC CAPACITY; DYSPLASTIC NEVUS; EXPRESSION; PROTEIN; MUTATIONS; GENE; SUPPRESSOR	Mutations in the p53 tumour suppressor gene have been detected in a variety of human malignancies. Mutations have been found predominantly in conserved regions two to five. Our aim was to analyse p53 at the protein and DNA level in seven melanoma cell lines of cutaneous origin (HMB-2, DX3, LT5.1, MJM, SK23, A375P and A375M), including two parental/metastatic derivatives (A375P and A375M; DX3 and LT5.1). By immunohistochemical staining with three mouse monoclonal antibodies and a rabbit polyclonal serum, it was possible to observe differential nuclear expression of p53. The quantitation of p53 protein levels by ELISA correlated with the nuclear staining pattern. Western blotting showed an intact p53 protein in all cell lines; p53 was polymorphic in three cell lines (MJM, A375P and A375M). DNA sequencing studies showed that all cell lines had wild type p53. These results suggest that p53 is unlikely to play a significant role in the genesis of cutaneous melanoma.	LONDON HOSP,COLL MED,DEPT EXPTL DERMATOL,LONDON E1 2BL,ENGLAND	University of London; Queen Mary University London	MONTANO, X (corresponding author), LONDON HOSP,COLL MED,IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,56 ASHFIELD ST,LONDON E1 2BL,ENGLAND.							ALBINO AP, 1991, J CUTAN PATHOL, V18, P273, DOI 10.1111/j.1600-0560.1991.tb01235.x; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEENKEN SW, 1991, NUCLEIC ACIDS RES, V19, P4747, DOI 10.1093/nar/19.17.4747; BERGMAN W, 1986, ANN HUM GENET, V50, P249, DOI 10.1111/j.1469-1809.1986.tb01046.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS PA, 1991, ONCOGENE, V6, P2363; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CARBONE D, 1991, ONCOGENE, V6, P1691; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOLES JP, 1993, ONCOGENE, V8, P583; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MUKAI S, 1986, CANCER GENET CYTOGEN, V22, P45, DOI 10.1016/0165-4608(86)90136-6; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; ORMEROD EJ, 1986, CANCER RES, V46, P884; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADDY P, 1992, CANCER RES, V52, P3804; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STRETCH JR, 1991, CANCER RES, V51, P5976; TOBAL K, 1992, BRIT J CANCER, V66, P900, DOI 10.1038/bjc.1992.382; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	46	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1455	1459						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152807				2022-12-17	WOS:A1994NH40100018
J	SUN, Y; HEGAMYER, G; COLBURN, NH				SUN, Y; HEGAMYER, G; COLBURN, NH			NASOPHARYNGEAL CARCINOMA SHOWS NO DETECTABLE RETINOBLASTOMA SUSCEPTIBILITY GENE ALTERATIONS	ONCOGENE			English	Note							EPSTEIN-BARR VIRUS; HUMAN PROSTATE CARCINOMA; CELL LINES HNE-1; LARGE T-ANTIGEN; HUMAN BLADDER; RB GENE; INACTIVATION; EXPRESSION; PROTEIN; MUTATIONS	Since multistage carcinogenesis is frequently associated with the loss of suppressor gene activity, and since in over 90% of cases of nasopharyngeal carcinoma (NPC) p53 alterations are not involved [Sun, Y., Hegamyer, G.H., Cheng, Y.-J., Hildesheim, A., Chen, J.-Y., Chen, I.-H., Cao, Y., Yao, K.-T. & Colburn, N.H. (1992). Proc. Natl. Acad. Sci. USA, 89, 6516-6520] we investigated the possible involvement of the inactivation of the retinoblastoma susceptibility gene (RB) in nasopharyngeal carcinogenesis. We analysed the expression, gross structure and possible point mutation of the RB gene in an NPC cell line as well as seven NPC biopsies obtained from seven patients. The NPC cell line expresses the RB gene with a normal size and abundance, as assayed by reverse transcriptase polymerase chain reaction (RT-PCR) and Northern hybridization. No point mutation was detected in two independent E1A/large T-binding regions, which are the common sites for mutations in the RB gene. NPC biopsies also showed no point mutations at four exon-intron boundaries at which point mutations have been reported in other human carcinomas. The biopsies and cell tine had no deletions in the promoter region of the gene and showed no gross deletions or rearrangements. Taken together, we conclude that, in contrast to multistage carcinogenesis leading to human retinoblastoma, osteogenic sarcomas and carcinomas of lung, breast, bladder and prostate, nasopharyngeal carcinogenesis appears unlikely to involve RB gene alterations.	NCI, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; NCI, FCRDC, DYNCORP, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYNTON RF, 1991, CANCER RES, V51, P5766; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG J, 1990, BLOOD, V75, P730; DETHE G, 1982, VIRAL INFECTIONS HUM, P126; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LERMAN MI, 1991, HUM GENET, V86, P567; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509; 1978, SCI SINICA, V21, P127	42	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					791	795						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437863				2022-12-17	WOS:A1993KN00800033
J	EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM				EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM			HYPERPLASIA OF MOUSE MAMMARY EPITHELIUM INDUCED BY EXPRESSION OF THE WNT-1 (INT-1) ONCOGENE IN RECONSTITUTED MAMMARY-GLAND	ONCOGENE			English	Article							CELL-LINE; TRANSGENIC MICE; RETROVIRAL VECTORS; GENE-TRANSFER; MYC ONCOGENE; TUMOR VIRUS; HA-RAS; PROTEIN; GROWTH; DIFFERENTIATION	We have expressed the Wnt-1 (formerly int-1) oncogene in Balb/c mouse mammary epithelium in vivo, using a tissue reconstitution method in which primary cultures of mammary epithelial cells are infected with a retrovirus vector and then transplanted into mouse mammary fat pads from which the natural epithelium has been removed. Transplants carrying the Wnt-1 gene grew in a hyperplastic pattern, the duct epithelium showing abundant fine side-branches, but without development of clusters of alveoli. The hyperplasias were similar, but not identical, to transplants of normal epithelium in a mid-pregnant host. Transplants of epithelium that expressed Wnt-1 into mammary fat pads of male or ovari-ectomized females grew to form a similar three-dimensional pattern, but the extent of growth, and so presumably the rate of growth, was slower than in intact females, and there were no terminal end buds at the edges of the outgrowths. Thus, although Wnt-1 may enhance growth of epithelium in the male or ovari-ectomized-female environment, it does not restore the major mode of growth in the intact female, the extension of major ducts from terminal end buds. Normal epithelium showed no change in morphology when in close proximity to hyperplasia induced by Wnt-1, confirming the limited range of diffusion of Wnt-1 protein in vivo. Our results are consistent with the hypothesis that Wnt-1 acts principally by mimicking the signal that causes ducts to develop side-branches in pregnancy.	INST CANC & DEV BIOL,PALO ALTO,CA 94304		EDWARDS, PAW (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV CELL & GENET PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				ADAMS LM, 1987, CANCER RES, V47, P4425; AGUILARCORDOVA E, 1991, ONCOGENE, V6, P1601; AIDELLS BD, 1974, J NATL CANCER I, V52, P1855, DOI 10.1093/jnci/52.6.1855; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BLASBAND A, 1992, ONCOGENE, V7, P153; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY A, 1990, CELL, V62, P1073; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1992, UNPUB DEV BIOL; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DANIEL CW, 1987, CANCER RES, V47, P6052; DEOME KB, 1959, CANCER RES, V19, P515; EDWARDS PAW, 1988, ONCOGENE, V2, P407; FAULKIN LJ, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1990, CANCER RES, V50, P6010; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICHARDS J, 1988, ENDOCRINOLOGY, V123, P1335, DOI 10.1210/endo-123-3-1335; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, P NATL ACAD SCI USA, V7, P487; SCULLY JL, 1991, INT J CANCER, V48, P128; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STRANGE R, 1989, ONCOGENE, V4, P309; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	52	61	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2041	2051						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408145				2022-12-17	WOS:A1992JP42400019
J	YU, Q; LENARDO, T; WEINBERG, RA				YU, Q; LENARDO, T; WEINBERG, RA			THE N-TERMINAL AND C-TERMINAL DOMAINS OF A RECEPTOR TYROSINE PHOSPHATASE ARE ASSOCIATED BY NONCOVALENT LINKAGE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN; DROSOPHILA; KINASES; FAMILY	We have cloned the rat homolog of the human leukocyte common antigen-related gene (LAR), which encodes a transmembrane receptor phosphotyrosine phosphatase, and raised antibodies against its protein product. We present evidence here for a processing event resulting in a two-chain structure of the mature receptor on the cell surface. The LAR protein is synthesized as a 190-kDa precursor which is subsequently cleaved into 145-kDa and 85-kDa fragments. The 145-kDa fragment, representing the amino terminus of the protein, is exclusively extracellular and is modified by N-linked glycosylation. The 85-kDa component, derived from the C-terminus of the protein, contains the transmembrane region and intracellular phosphotyrosine phosphatase domains. The two products, associated in a non-covalent manner, comprise the functional LAR cell-surface receptor.	MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute					NCI NIH HHS [CA-39852] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	16	61	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1051	1057						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317540				2022-12-17	WOS:A1992HU64200001
J	GRASSER, FA; LAMONTAGNE, K; WHITTAKER, L; STOHR, S; LIPSICK, JS				GRASSER, FA; LAMONTAGNE, K; WHITTAKER, L; STOHR, S; LIPSICK, JS			A HIGHLY CONSERVED CYSTEINE IN THE V-MYB DNA-BINDING DOMAIN IS ESSENTIAL FOR TRANSFORMATION AND TRANSCRIPTIONAL TRANSACTIVATION	ONCOGENE			English	Note							AVIAN-MYELOBLASTOSIS VIRUS; GENE-EXPRESSION; C-MYB; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT; PROTEINS; FOS; JUN	The v-Myb protein is nuclear, binds to DNA in a sequence-specific fashion, regulates the transcription of various reporter genes and transforms myelomonocytic cells. Cysteine is one of the most conserved residues during protein evolution and has been implicated in DNA binding, protein-protein interaction and redox regulation of various proteins. Therefore, we have now individually substituted each of the seven cysteines of v-Myb with a serine. All seven mutant proteins bound to DNA when they were expressed in E. coli. However, mutant C65S neither trans-activated transcription in vivo nor transformed myeloid cells, although it was transported into the nucleus. This cysteine is conserved in the Myb-related proteins of animals, plants, yeast and the cellular slime mold Dictyostelium discoideum. The C65S mutation and a nearby codon insertion mutation also abolished trans-activation by fusion proteins containing the v-Myb DNA-binding domain and the strong constitutive activation domain of herpes simplex virus (HSV) VP16. Because this domain of VP16 appears to activate transcription whenever it is bound upstream of an appropriate promoter, these results imply that C65 may be required for high-affinity DNA binding in vivo. In support of this hypothesis, we have also shown that, in contrast to wild-type v-Myb, mutant C65S is unable to block transcription from a reporter gene in which Myb binding sites overlap the initiation site.	SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV SAARLANDES KLINIKEN, INST MED MIKROBIOL & HYG, VIROL ABT, W-6650 HOMBURG, GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universitatsklinikum des Saarlandes					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA043592, K04CA001457] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-43592, P01-CA-28146, KO4-CA-01457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Fersht A., 1985, ENZYME STRUCTURE MEC; GARCIA A, 1991, ONCOGENE, V6, P265; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LOEBER G, 1991, IN PRESS J VIROL; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; STOBERGRASSER U, 1992, IN PRESS ONCOGENE; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	38	61	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1005	1009						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570148				2022-12-17	WOS:A1992HP64200022
J	THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB				THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB			IDENTIFICATION OF DISTINCT POPULATIONS OF PI-3 KINASE-ACTIVITY FOLLOWING T-CELL ACTIVATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; HUMAN PLATELETS; ANTIGEN RECEPTOR; CD4 RECEPTOR; PDGF RECEPTOR; RAT-LIVER; ASSOCIATION	Activation of mature CD4+ T lymphocytes by antigen-presenting cells involves engagement of the CD3/T-cell antigen receptor complex along with the CD4 surface glycoprotein and the phosphorylation of cellular proteins on tyrosine residues leading to stimulation of a variety of cellular second-messenger systems. Several recent studies have implicated non-receptor protein tyrosine kinases of the src family, especially p56lck and p59fyn, in mediating at least a portion of these tyrosine phosphorylation events. In the present study we have examined the involvement of one type of second-messenger system, phosphatidylinositol-3 kinase (PI-3 kinase), in signal transduction during antibody-induced activation of normal resting human CD4+ T cells. We demonstrate that PI-3 kinase activity is increased following co-approximation of CD4 with the T-cell receptor and that PI-3 kinase activity co-precipitates with the CD4-p56lck complex. We also show that following T-cell activation a complex containing PI-3 kinase activity can be demonstrated in CD3-epsilon-immunoprecipitates which is distinct from that which interacts with p56lck.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, NATURE, V312, P312; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HORAK ID, 1990, ONCOGENE, V5, P597; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	59	61	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373484				2022-12-17	WOS:A1992HQ68200014
J	BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP				BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP			CELLULAR-LOCALIZATION AND T-ANTIGEN BINDING OF THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article								Mutation of the retinoblastoma (Rb) gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary predisposition to retinoblastoma. The Rb protein is a nuclear phosphoprotein that is differentially phosphorylated during the cell cycle. Its precise function is unknown but it has been suggested that it may act as a transcriptional regulator or as a regulator of cellular DNA synthesis. The Rb protein forms specific complexes with the oncogenes of three different groups of DNA tumour viruses. We have prepared a new monoclonal antibody to the Rb protein and used it to establish sensitive immunoassays for Rb complexed to T antigen. In SV40-infected and transformed cells these assays showed that Rb enters a trimolecular complex containing p53. Rb and T. A large panel of human tumour cell lines was tested for expression, cellular localization and T-binding activity of Rb using the new antibody.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; MASARYK INST ONCOL, CS-65653 BRNO, CZECHOSLOVAKIA; UNIV BIRMINGHAM, DEPT CANC STUDIES, CANC RES CAMPAIGN LABS, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; Masaryk Memorial Cancer Institute; University of Birmingham			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014	Lane, David/0000-0003-0551-3545				AKIYAMA T, 1990, ONCOGENE, V5, P179; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1990, ONCOGENE, V5, P893; BENEDICT WF, 1987, ADV VIRAL ONCOL, P19; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAND RJA, 1989, ONCOGENE, V4, P1291; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; LANE DP, 1981, J IMMUNOL METHODS, V47, P303, DOI 10.1016/0022-1759(81)90286-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	57	61	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					101	108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741157				2022-12-17	WOS:A1992HC22700014
J	AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D				AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D			FLG-2, A NEW MEMBER OF THE FAMILY OF FIBROBLAST GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Note							CLONING; GENE	Two genes, flg and bek, have been recently shown to encode receptors for fibroblast growth factors (FGF). Here we report the molecular cloning and sequence of a new member of the FGF receptor family, denoted flg-2, which was isolated from a human keratinocyte cDNA library. The cDNA sequence predicts an extracellular region possessing three immunoglobulin-like domains, a single transmembrane region and a cytoplasmic portion containing the tyrosine kinase domain split by a short inter-kinase segment. The amino acid sequence of flg-2 shows 68% and 64% identity with bek and flg, respectively. The most variable domain among the three genes is the amino-terminal immunoglobulin-like domain. Comparison with the chicken FGF receptor genes suggests that flg-2 is homologous to cek-2, whereas flg and bek are homologous to cek-1 and cek-3, respectively. Analysis of mRNA from various tissues shows that flg-2 is expressed predominantly in skin, brain and lung.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	GIVOL, D (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012					BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; RAZ V, 1991, IN PRESS ONCOGENE; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	19	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1089	1092						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648703				2022-12-17	WOS:A1991GU62200029
J	QURESHI, SA; JOSEPH, CK; RIM, MH; MARONEY, A; FOSTER, DA				QURESHI, SA; JOSEPH, CK; RIM, MH; MARONEY, A; FOSTER, DA			V-SRC ACTIVATES BOTH PROTEIN-KINASE C-DEPENDENT AND INDEPENDENT SIGNALING PATHWAYS IN MURINE FIBROBLASTS	ONCOGENE			English	Article							3T3 CELLS; GROWTH-FACTORS; PHOSPHATIDYLINOSITOL KINASE; TRANSFORMED FIBROBLASTS; MAMMALIAN-CELLS; GENE; DNA; EXPRESSION; BINDING; PHOSPHORYLATION	Activating the protein-tyrosine kinase activity of v-Src rapidly induced expression of the two 'primary response' genes, TIS10 and Egr-1, in Balb/c 3T3 cells. Depleting cells of protein kinase C (PKC) by prolonged exposure to 12-O-tetradecanoylphorbol 13-acetate (TPA), blocked v-Src-induced TIS10 expression, but had no effect on v-Src-induced Egr-1 gene expression. in addition, the induction of TIS10 and Egr-1 by v-Src could be distinguished using protein kinase inhibitors. Thus, v-Src induced gene expression in murine fibroblasts via two distinguishable signaling pathways: one dependent upon PKC and another that is independent of PKC. Consistent with the use of PKC-mediated signaling pathway by v-Src in murine fibroblasts, we found that activating the kinase activity of v-Src led to increased phosphorylation of a major PKC substrate. Thus, data presented here suggest that v-Src-induced transformation involves the activation of multiple signalling pathways, one of which requires PKC.	CUNY HUNTER COLL,INST BIOMOLEC STRUCT,695 PK AVE,NEW YORK,NY 10021; CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; University of Pennsylvania	FOSTER, DA (corresponding author), CUNY HUNTER COLL,INST BIOMOLEC STRUCT,695 PK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA4667] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; Battey, 1986, BASIC METHODS MOL BI; BUTLERGRALLA E, 1981, J CELL PHYSIOL, V107, P59, DOI 10.1002/jcp.1041070108; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HALSEY DL, 1986, J BIOL CHEM, V261, P2234; HAN JW, 1990, ONCOGENE, V5, P467; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEN A, 1989, J BIOL CHEM, V264, P9118; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546	41	61	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					995	999						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067850				2022-12-17	WOS:A1991GU62200014
J	TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S				TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S			EXPRESSION OF THE CRE-BP1 TRANSCRIPTIONAL REGULATOR BINDING TO THE CYCLIC-AMP RESPONSE ELEMENT IN CENTRAL-NERVOUS-SYSTEM, REGENERATING LIVER, AND HUMAN TUMORS	ONCOGENE			English	Article							ADENYLATE-CYCLASE; PROTEIN-KINASE; GENE; FAMILY; BRAIN; YEAST; CDNA; FORM	CRE-BP1 is a transcriptional regulator binding to the cyclic AMP response element (CRE). To understand the role of CRE-BP1 in vivo, we studied the expression of the CRE-BP1 gene in monkey tissues including the central nervous system, in rat regenerating liver, and in human cancer tissues compared with normal tissues. The CRE-BP1 mRNA was detected in all tissues examined, and was fairly abundant in brain. The CRE-BP1 mRNA was expressed in monkey brain tissues with different region specificities. In the hippocampus, frontal lobe, and parietal lobe, the CRE-BP1 mRNA was abundant and two mRNA species 4.0 kb and 3.7 kb in length were expressed. In rat liver, the expression of the CRE-BP1 gene was increased up to 4- to 5-fold of the normal level within 12-24 h after partial hepatectomy. Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues. These results suggest that CRE-BP1 may be important for both the signal transduction in brain and cellular proliferation.	KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,DIV METAB & CLIN NUTR,KYOTO 606,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; KOBE UNIV,SCH MED,DEPT PHARMACOL,KOBE 650,JAPAN	Kyoto University; Kyoto University; RIKEN; University of Tokyo; Kobe University	ISHII, S (corresponding author), KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BLOOMFIELD CD, 1987, CYTOGENET CELL GENET, V46, P344, DOI 10.1159/000132485; BUCHANAN PD, 1983, AM J MED GENET, V15, P121, DOI 10.1002/ajmg.1320150116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Curran T, 1988, ONCOGENE HDB, P307; DALLAPICCOLA B, 1988, HUM GENET, V79, P92, DOI 10.1007/BF00291721; FRIEDMAN DL, 1984, HDB EXP PHARM, V58, P151; GONZALEZ GA, 1989, NATURE, V337, P794; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; ITO A, 1990, P NATL ACAD SCI USA, V87, P3195, DOI 10.1073/pnas.87.8.3195; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1990, IN PRESS ONCOGENE; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1983, CELL, V32, P417, DOI 10.1016/0092-8674(83)90461-0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; YAMADA Y, 1990, BIOCHEM BIOPH RES CO, V168, P1274, DOI 10.1016/0006-291X(90)91166-P; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	30	61	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1009	1014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829805				2022-12-17	WOS:A1991GU62200016
J	MCCORMICK, F				MCCORMICK, F			THE WORLD ACCORDING TO GAP	ONCOGENE			English	Review											MCCORMICK, F (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRENGEL U, 1990, IN PRESS CELL; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PAWSON T, 1988, ONCOGENE, V3, P491; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SCHLICHTING I, 1990, IN PRESS NATURE; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, IN PRESS CELL	34	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1281	1283						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699195				2022-12-17	WOS:A1990EC24100001
J	FAINSTEIN, E; EINAT, M; GOKKEL, E; MARCELLE, C; CROCE, CM; GALE, RP; CANAANI, E				FAINSTEIN, E; EINAT, M; GOKKEL, E; MARCELLE, C; CROCE, CM; GALE, RP; CANAANI, E			NUCLEOTIDE-SEQUENCE ANALYSIS OF HUMAN ABL AND BCR-ABL CDNAS	ONCOGENE			English	Article									TEMPLE UNIV,FELS INST,PHILADELPHIA,PA 19122; UNIV CALIF LOS ANGELES,MED CTR,DEPT MED,LOS ANGELES,CA 90024	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	FAINSTEIN, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Friedman-Einat, Miriam/0000-0002-9451-1025				CARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MESMASSON AM, 1987, P NATL ACAD SCI USA, V84, P207; MOAV B, 1986, GENE, V48, P297, DOI 10.1016/0378-1119(86)90089-2; NOWELL PC, 1960, SCIENCE, V132, P1497; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0	30	61	74	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1477	1481						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687768				2022-12-17	WOS:A1989CB65900009
J	MORRISON, LE; KABRUN, N; MUDRI, S; HAYMAN, MJ; ENRIETTO, PJ				MORRISON, LE; KABRUN, N; MUDRI, S; HAYMAN, MJ; ENRIETTO, PJ			VIRAL REL AND CELLULAR REL ASSOCIATE WITH CELLULAR PROTEINS IN TRANSFORMED AND NORMAL-CELLS	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [5P01CA28146-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN G, 1966, JNCI-J NATL CANCER I, V37, P747; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	30	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543940				2022-12-17	WOS:A1989AA66000002
J	VOGT, PK; TJIAN, R				VOGT, PK; TJIAN, R			JUN - A TRANSCRIPTIONAL REGULATOR TURNED ONCOGENIC	ONCOGENE			English	Review									UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT BIOCHEM,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	VOGT, PK (corresponding author), UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033, USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; FRANZA BR, 1987, ONCOGENE, V1, P213; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, IN PRESS SCIENCE; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316	21	61	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					3	7						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400001
J	KESHET, E; ROSENBERG, MP; MERCER, JA; PROPST, F; VANDEWOUDE, GF; JENKINS, NA; COPELAND, NG				KESHET, E; ROSENBERG, MP; MERCER, JA; PROPST, F; VANDEWOUDE, GF; JENKINS, NA; COPELAND, NG			DEVELOPMENTAL REGULATION OF OVARIAN-SPECIFIC MOS EXPRESSION	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Keshet, Eli/GQR-0445-2022	Mercer, John/0000-0003-0307-4438	NCI NIH HHS [N01-CO-23909] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO023909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BROWER PT, 1981, DEV BIOL, V86, P373, DOI 10.1016/0012-1606(81)90195-0; CASCIO SM, 1982, DEV BIOL, V89, P397, DOI 10.1016/0012-1606(82)90328-1; CLEGG KB, 1983, DEV BIOL, V95, P331, DOI 10.1016/0012-1606(83)90034-9; DEKEL N, 1979, BIOL REPROD, V20, P191, DOI 10.1095/biolreprod20.2.191; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; Eppig J J, 1985, Dev Biol (N Y 1985), V1, P313; EPPIG JJ, 1982, DEV BIOL, V89, P268, DOI 10.1016/0012-1606(82)90314-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HOGAN B, 1986, COLD SPRING HARBOUR; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; PEDERSEN T, 1969, ACTA ENDOCRINOL-COP, V62, P117, DOI 10.1530/acta.0.0620117; Pedersen T., 1972, Oogenesis., P361; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; WOOD TG, 1983, J VIROL, V46, P726, DOI 10.1128/JVI.46.3.726-736.1983	24	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					235	240						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3353114				2022-12-17	WOS:A1988M593100005
J	TOKSOZ, D; FARR, CJ; MARSHALL, CJ				TOKSOZ, D; FARR, CJ; MARSHALL, CJ			RAS-GENE ACTIVATION IN A MINOR PROPORTION OF THE BLAST POPULATION IN ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article											TOKSOZ, D (corresponding author), INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.			Farr, Christine/0000-0002-5357-5962				BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; COURTBROWN WM, 1955, LANCET, V1, P1283; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1979, NEW ENGL J MED, V301, P1, DOI 10.1056/NEJM197907053010101; FIALKOW PJ, 1981, BLOOD, V57, P1068; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; JACOBSON RJ, 1984, NEW ENGL J MED, V310, P1513, DOI 10.1056/NEJM198406073102307; MARUGG JE, 1983, TETRAHEDRON LETT, V24, P3989, DOI 10.1016/S0040-4039(00)88244-1; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VIGLIANI EC, 1964, NEW ENGL J MED, V271, P872, DOI 10.1056/NEJM196410222711703; VOUSDEN KH, 1984, EMBO J, V3, P913, DOI 10.1002/j.1460-2075.1984.tb01905.x; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304	26	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					409	413						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330783				2022-12-17	WOS:A1987K748300010
J	Li, XJ; Ding, JY; Wang, XY; Cheng, ZN; Zhu, QB				Li, Xiaojing; Ding, Junyao; Wang, Xueying; Cheng, Zeneng; Zhu, Qubo			NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULAR RNA; POLYADENYLATION; IDENTIFICATION	Circular RNAs (circRNAs) are a novel class of RNAs, which involve in many physiological processes and participate in many diseases, especially in cancer. Previous reports showed circRNAs were globally downregulated in hepatocellular carcinoma (HCC) and a lot of circRNAs involved in the tumorigenesis and metastasis of HCC. To understand the underlying mechanism of circRNAs' reduction, we explored the relationship between circRNA biogenesis and NUDT21, which was a RNA splice factor downregulated in HCC, and we found that NUDT21 elevated the formation of circRNA, and the UGUA sequences were critical for the cyclization of circRNA. Knockdown of NUDT21 disrupted the competitive endogenous RNA (ceRNA) pathway of circRNA-miRNA-mRNA, and overexpression of the downregulated circRNA could assist the NUDT21-mediated tumor suppression in HCC cells. In conclusion, the loss of NUDT21 prevented the cyclization of circRNA in HCC; without circRNA absorption, miRNAs were released to suppress the tumor-suppressor genes, leading to the uncontrolled cell proliferation.	[Li, Xiaojing; Ding, Junyao; Wang, Xueying; Cheng, Zeneng; Zhu, Qubo] Cent S Univ, Xiangya Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China	Central South University	Zhu, QB (corresponding author), Cent S Univ, Xiangya Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China.	qubozhu@csu.edu.cn	Zhu, Qubo/ACT-7180-2022		National Natural Science Foundation of China [C0709-31201056]; Hunan Provincial Natural Science Foundation of China [2018JJ2493]; Hunan Provincial Innovation Foundation for Postgraduate [CX20190244]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Hunan Provincial Innovation Foundation for Postgraduate	We thank the KangChen Bio-tech (Shanghai, China) for providing RNA sequencing and data analysis and the Molecular Medical Center in the Xiangya Hospital (Changsha, China) for the confocal microscopy. We thank Shifu Luo for data analysis. We also thank Dr Wang for kindly supplying the IRES-drived pCircGFP reporter. This research is supported by the National Natural Science Foundation of China (C0709-31201056), the Hunan Provincial Natural Science Foundation of China (2018JJ2493) and the Hunan Provincial Innovation Foundation for Postgraduate (CX20190244).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Ding JY, 2019, BIOL CHEM, V400, P247, DOI 10.1515/hsz-2018-0232; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Gao B, 2014, BIOMED PHARMACOTHER, V68, P143, DOI 10.1016/j.biopha.2013.09.005; Greene J, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00038; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Kelly S, 2015, J MOL BIOL, V427, P2414, DOI 10.1016/j.jmb.2015.02.018; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Kubo T, 2006, NUCLEIC ACIDS RES, V34, P6264, DOI 10.1093/nar/gkl794; Li P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0473-z; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Lin XM, 2018, MED SCI MONIT BASIC, V24, P70, DOI 10.12659/MSMBR.909737; Lin YF, 2012, NUCLEIC ACIDS RES, V40, P8460, DOI 10.1093/nar/gks637; Meng XW, 2017, BIOINFORMATICS, V33, P3314, DOI 10.1093/bioinformatics/btx446; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Song CL, 2019, J CELL PHYSIOL, V234, P2460, DOI 10.1002/jcp.26764; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tan S, 2018, ONCOGENE, V37, P4887, DOI 10.1038/s41388-018-0280-6; Verheijen BM, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00412; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Yao RZ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00332; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang H, 2015, CANCER LETT, V367, P49, DOI 10.1016/j.canlet.2015.07.010; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8	38	60	60	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					891	904		10.1038/s41388-019-1030-0	http://dx.doi.org/10.1038/s41388-019-1030-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570791				2022-12-17	WOS:000509197200011
J	Yao, N; Fu, Y; Chen, L; Liu, Z; He, J; Zhu, YC; Xia, TS; Wang, S				Yao, Na; Fu, Yue; Chen, Lie; Liu, Zhao; He, Jing; Zhu, Yichao; Xia, Tiansong; Wang, Shui			Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; CHEMORESISTANCE; METASTASIS; ACTIVATION; MIR-129-5P; CERNA; TWIST; PROLIFERATION	Drug resistance, including epirubicin-based therapeutic resistance, is one of the major reasons responsible for the unfavorable prognosis of patients diagnosed with breast cancer (BC). Acquired chemoresistance and metastatic properties have been identified to be closely associated with the process of epithelial-mesenchymal transition (EMT). Recently, dysregulation of long non-coding RNAs (lncRNAs) have been increasingly reported to perform promotive or suppressive functions in chemoresistance and EMT process in multiple cancers. However, relevant novel lncRNA participating in epirubicin resistance and EMT and its underlying molecular mechanisms remain unknown in BC. Herein, we established the epirubicin-resistant breast cancer cell subline (MCF-7/ADR), which presented mesenchymal phenotype and increased metastatic potential. A panel of differentially expressed lncRNAs, including 268 upregulated and 49 downregulated lncRNAs, were identified by high-flux microarray investigation in MCF-7 and MCF-7/ADR cells. The novel lncRNA NONHSAT101069 was significantly overexpressed in BC specimens, BC cell lines, and epirubicin-resistant cell sublines. The knockdown of NONHSAT101069 significantly repressed, whereas overexpression of NONHSAT101069 promoted the epirubicin resistance, migration, invasion and EMT process of BC cells both in vitro and in vivo. Further mechanism-related researches uncovered that NONHSAT101069 functioned as a ceRNA (competing endogenous RNA) via sponging miR-1295p. Twist1 was a direct downstream protein of NONHSAT101069/miR-129-5p axis in BC cells. To conclude, NONHSAT101069 was upregulated in BC tissues and promoted epirubicin resistance, migration and invasion of BC cells via regulation of NONHSAT101069/miR-129-5p/Twist1 axis, highlighting its potential as an oncogene and a therapeutic biomarker for BC.	[Yao, Na; Chen, Lie; Xia, Tiansong; Wang, Shui] Nanjing Med Univ, Breast Dis Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Yao, Na] Nanjing Univ TCM, Wuxi City Hosp TCM, Dept Thyroid & Breast Surg, Affiliated Hosp, Wuxi 214000, Jiangsu, Peoples R China; [Fu, Yue] Nanjing Med Univ, Dept Gen Surg, Affiliated Changzhou Peoples Hosp 2, Changzhou 213000, Jiangsu, Peoples R China; [Liu, Zhao] Xuzhou Med Univ, Dept Thyroid & Breast Surg, Affiliated Hosp, Xuzhou 222100, Jiangsu, Peoples R China; [He, Jing] Jiangnan Univ, Dept Surg Oncol, Affiliated Hosp, Wuxi 214000, Jiangsu, Peoples R China; [Zhu, Yichao] Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China; [Zhu, Yichao] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Xuzhou Medical University; Jiangnan University; Nanjing Medical University; Nanjing Medical University	Xia, TS; Wang, S (corresponding author), Nanjing Med Univ, Breast Dis Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, YC (corresponding author), Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China.; Zhu, YC (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.	zhuyichao@njmu.edu.cn; xiats@njmu.edu.cn; ws0801@hotmail.com	yao, na/HDL-8772-2022		National Natural Science Foundation of China [81572607, 81472703]; Natural Science Foundation of Jiangsu Province [BK20181367]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This work was supported by grants from the National Natural Science Foundation of China (81572607, 81472703) and the Natural Science Foundation of Jiangsu Province (BK20181367). The results shown here were partially based upon data obtained from public TCGA datasets. We thank Prof. Donglei Yang (Nanjing Agricultural University, Nanjing, China) and Dr. Macara (University of Virginia, VA) for providing the technical guidance to Northern blotting and the constructs of MS2-tagged RNA affinity purification assay, respectively.	Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Fang L, 2017, AM J PHYSIOL-GASTR L, V313, pG150, DOI 10.1152/ajpgi.00426.2016; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0807-2; Gao YR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.311; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Lee JW, 2018, CANCER SCI, V109, P1404, DOI 10.1111/cas.13588; Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591; Liang  Y., 2018, ADV MATER INTERFACES, V5, P1, DOI DOI 10.1017/S0266466617000317; Liang YR, 2018, CANCER BIOL THER, V19, P120, DOI 10.1080/15384047.2017.1394543; Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324; Lu W, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0685-9; Luan QX, 2016, EUR REV MED PHARMACO, V20, P4257; Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng QC, 2018, ONCOGENE, V37, P5843, DOI 10.1038/s41388-018-0392-z; Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shen CJ, 2017, J DRUG TARGET, V25, P637, DOI 10.1080/1061186X.2017.1307379; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Shi Y, 2015, INT J INF TECH DECIS, V14, P1, DOI 10.1142/S0219622015020022; Tang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.518; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tuck AC, 2013, CELL, V154, P996, DOI 10.1016/j.cell.2013.07.047; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang YF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0702-z; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932; Xu T, 2016, CANCER LETT, V377, P140, DOI 10.1016/j.canlet.2016.04.026; Xu Y, 2017, ONCOGENE, V36, P1157, DOI 10.1038/onc.2016.286; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yao N, 2019, MOL CARCINOGEN, V58, P1291, DOI 10.1002/mc.23011; Yu Y, 2015, ONCOTARGET, V6, P34423, DOI 10.18632/oncotarget.5406; Zhang DY, 2017, BIOMED PHARMACOTHER, V95, P1187, DOI 10.1016/j.biopha.2017.09.045; Zhang P, 2017, CELL PHYSIOL BIOCHEM, V42, P242, DOI 10.1159/000477323; Zhang YZ, 2016, ONCOL LETT, V12, P5163, DOI 10.3892/ol.2016.5372; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	50	60	62	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7216	7233		10.1038/s41388-019-0904-5	http://dx.doi.org/10.1038/s41388-019-0904-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31444414				2022-12-17	WOS:000497989400003
J	Bai, SS; Cao, SB; Jin, LJ; Kobelski, M; Schouest, B; Wang, XJ; Ungerleider, N; Baddoo, M; Zhang, WS; Corey, E; Vessella, RL; Dong, XS; Zhang, K; Yu, XH; Flemington, EK; Dong, Y				Bai, Shanshan; Cao, Subing; Jin, Lianjin; Kobelski, Margaret; Schouest, Blake; Wang, Xiaojie; Ungerleider, Nathan; Baddoo, Melody; Zhang, Wensheng; Corey, Eva; Vessella, Robert L.; Dong, Xuesen; Zhang, Kun; Yu, Xianghui; Flemington, Erik K.; Dong, Yan			A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer	ONCOGENE			English	Article							FULL-LENGTH; CELL-LINE; RADICAL PROSTATECTOMY; GENOMIC CLASSIFIER; INCREASED SURVIVAL; EXPRESSION; RESISTANCE; ENZALUTAMIDE; PROGRESSION; ABIRATERONE	Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants (AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of AR-FL and AR-V transcripts are often tightly correlated in individual CRPC samples, yet our understanding of how their expression is co-regulated is limited. Here, we report a role of c-Myc in accounting for coordinated AR-FL and AR-V expression. Analysis of gene-expression data from 159 metastatic CRPC samples and 2142 primary prostate tumors showed that the level of c-Myc is positively correlated with that of individual AR isoforms. A striking positive correlation also exists between the activity of the c-Myc pathway and the level of individual AR isoforms, between the level of c-Myc and the activity of the AR pathway, and between the activities of the two pathways. Moreover, the c-Myc signature is highly enriched in tumors expressing high levels of AR, as is the AR signature in c-Myc-high-expressing tumors. Using shRNA knockdown, we confirmed c-Myc regulation of expression and activity of AR-FL and AR-Vs in cell models and a patient-derived xenograft model. Mechanistically, c-Myc promotes the transcription of the AR gene and enhances the stability of the AR-FL and AR-V proteins without altering AR RNA splicing. Importantly, inhibiting c-Myc sensitizes enzalutamide-resistant cells to growth inhibition by enzalutamide. Overall, this study highlights a critical role of c-Myc in regulating the coordinated expression of AR-FL and AR-Vs that is commonly observed in CRPC and suggests the utility of targeting c-Myc as an adjuvant to AR-directed therapy.	[Bai, Shanshan; Wang, Xiaojie; Yu, Xianghui] Jilin Univ, Sch Life Sci, Changchun, Jilin, Peoples R China; [Bai, Shanshan; Cao, Subing; Jin, Lianjin; Kobelski, Margaret; Wang, Xiaojie; Dong, Yan] Tulane Univ, Dept Struct & Cellular Biol, Sch Med, Tulane Canc Ctr, New Orleans, LA 70118 USA; [Schouest, Blake; Ungerleider, Nathan; Baddoo, Melody; Flemington, Erik K.] Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70118 USA; [Zhang, Wensheng; Zhang, Kun] Xavier Univ Louisiana, Bioinformat Facil, Dept Comp Sci, Xavier RCMI Ctr Canc Res, New Orleans, LA USA; [Corey, Eva; Vessella, Robert L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada	Jilin University; Tulane University; Tulane University; Xavier University of Louisiana; University of Washington; University of Washington Seattle; University of British Columbia	Dong, Y (corresponding author), Tulane Univ, Dept Struct & Cellular Biol, Sch Med, Tulane Canc Ctr, New Orleans, LA 70118 USA.; Flemington, EK (corresponding author), Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70118 USA.	erik@tulane.edu; ydong@tulane.edu	Dong, Xuesen/AGF-9228-2022	Dong, Yan/0000-0003-1622-5354; Kobelski, Margaret/0000-0002-8829-4562	National Institutes of Health [R01CA188609, R01AI101046, R01AI106676, P01CA214091, RCMI 2G12MD007595, P20GM103518]; Department of Defense [W81XWH-15-1-0439, W81XWH-16-1-0317, W81XWH-16-1-0318, W81XWH-14-1-0485]; National Natural Science Foundation of China [81430087]; Richard M. Lucas Foundation; NATIONAL CANCER INSTITUTE [R21CA236549, R01CA243793, P01CA214091, R01CA188609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007595, G12MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Richard M. Lucas Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by the following grants: the National Institutes of Health grants R01CA188609, R01AI101046, R01AI106676, P01CA214091, RCMI 2G12MD007595, and P20GM103518; Department of Defense grants W81XWH-15-1-0439, W81XWH-16-1-0317, W81XWH-16-1-0318, and W81XWH-14-1-0485; National Natural Science Foundation of China Project 81430087. The Richard M. Lucas Foundation supported the development of the LuCaP 35CR model. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cao B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111201; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cao B, 2013, INT J CANCER, V132, P1277, DOI 10.1002/ijc.27754; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Carabet LA, 2018, EUR J MED CHEM, V160, P108, DOI 10.1016/j.ejmech.2018.09.023; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Dong Y, 2003, CANCER RES, V63, P52; Dong Y, 2005, MOL CANCER THER, V4, P1047, DOI 10.1158/1535-7163.MCT-05-0124; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Fan LL, 2018, P NATL ACAD SCI USA, V115, pE4584, DOI 10.1073/pnas.1802415115; Ferraldeschi R, 2016, CANCER RES, V76, P2731, DOI 10.1158/0008-5472.CAN-15-2186; Freedland SJ, 2016, EUR UROL, V70, P588, DOI 10.1016/j.eururo.2016.01.008; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Jung M, 2017, CANCER RES, V77, P971, DOI 10.1158/0008-5472.CAN-15-2906; Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017; Klein EA, 2015, EUR UROL, V67, P778, DOI 10.1016/j.eururo.2014.10.036; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kregel S, 2016, ONCOTARGET, V7, P26259, DOI 10.18632/oncotarget.8456; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2015, MOL CANCER THER, V14, P1884, DOI 10.1158/1535-7163.MCT-14-1057; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Pang S, 1997, CANCER RES, V57, P495; Piccolo SR, 2012, GENOMICS, V100, P337, DOI 10.1016/j.ygeno.2012.08.003; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ross AE, 2016, EUR UROL, V69, P157, DOI 10.1016/j.eururo.2015.05.042; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Shiota M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw005; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stockley J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13426; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Todenhofer T, 2017, J UROLOGY, V197, P135, DOI 10.1016/j.juro.2016.06.094; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tummala R, 2016, PROSTATE, V76, P445, DOI 10.1002/pros.23134; Ungerleider N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007206; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang ZQ, 2016, ONCOTARGET, V7, P15481, DOI 10.18632/oncotarget.7139; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751	83	60	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4977	4989		10.1038/s41388-019-0768-8	http://dx.doi.org/10.1038/s41388-019-0768-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30820039	Green Accepted			2022-12-17	WOS:000472145900007
J	Bao, DK; Zhao, J; Zhou, XC; Yang, Q; Chen, YB; Zhu, JJ; Yuan, P; Yang, J; Qin, T; Wan, SG; Xing, JL				Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Yang, Qi; Chen, Yibing; Zhu, Jianjun; Yuan, Peng; Yang, Jin; Qin, Tao; Wan, Shaogui; Xing, Jinliang			Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; DYNAMICS; DRP1; MICROENVIRONMENT; CONTRIBUTES; INHIBITION; EXPRESSION; SURVIVAL; RELEASE	Tumor-associated macrophages (TAMs) contribute to hepatocellular carcinoma (HCC) progression. However, the molecular mechanism underlying the infiltration of TAMs into HCC microenvironment is largely unclear. Recent studies have reported that alteration of mitochondrial nucleoid structures induces mitochondrial DNA (mtDNA) release into the cytosol, which is recognized as mtDNA stress, and consequently regulates innate immunity. Here we aimed to investigate whether mitochondrial fission induces mtDNA stress and then promotes TAM infiltration and HCC progression. Confocal microscopy and real-time PCR were used to detect cytosolic mtDNA content in HCC cells. The relationship between the expression of mitochondrial fission key regulator dynamin-related protein 1 (Drp1) and the percentage of CD163 (a marker of TAMs)-positive cells was investigated in HCC tissues using immunohistochemistry. Finally, the effect of Drp1 overexpression in HCC cells on recruitment and polarization of TAMs was investigated. Our data showed that increased Drp1 expression was positively correlated with the infiltration of TAMs into HCC tissues. Drp1-mediated mitochondrial fission induced the cytosolic mtDNA stress to enhance the CCL2 secretion from HCC cells by TLR9-mediated NF-kappa B signaling pathway, and thus promoted the TAM recruitment and polarization. Depleting cytosolic mtDNA using DNase I or blocking TLR9 pathway by TLR9 antagonist, siRNA for TLR9 or p65 in HCC cells with Drp1 overexpression significantly decreased the recruitment and polarization of TAMs. Blocking CCR2 by antagonist significantly reduced TAM infiltration and suppressed HCC progression in mouse model. In conclusion, our findings reveal a novel mechanism of TAM infiltration in HCC by mitochondrial fission-induced mtDNA stress.	[Bao, Dengke; Zhao, Jing; Yang, Qi; Wan, Shaogui] Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China; [Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Zhu, Jianjun; Yuan, Peng; Xing, Jinliang] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shanxi, Peoples R China; [Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Zhu, Jianjun; Yuan, Peng; Xing, Jinliang] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shanxi, Peoples R China; [Bao, Dengke; Qin, Tao] Henan Univ, Henan Prov Peoples Hosp, Dept Hepatobiliary Pancreat Surg, Zhengzhou 450002, Henan, Peoples R China; [Chen, Yibing] Zhengzhou Univ, Affiliated Hosp 1, Genet & Prenatal Diag Ctr, Dept Gynecol & Obstet, Zhengzhou 450052, Henan, Peoples R China; [Yang, Jin] Northwest Univ, Sch Life Sci, Institue Prevent Genom Med, Xian 710069, Shaanxi, Peoples R China	Gannan Medical University; Air Force Military Medical University; Air Force Military Medical University; Henan University; Zhengzhou University; Zhengzhou University; Northwest University Xi'an	Wan, SG (corresponding author), Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China.; Xing, JL (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shanxi, Peoples R China.; Xing, JL (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shanxi, Peoples R China.	wansg@gmu.edu.cn; xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81320108021, U1604167]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (grants No. 81320108021 and U1604167). We also thank Dr. Fanglin Zhang of Department of Microbiology, Fourth Military Medical University for providing the THP-1 cell line.	Bamboat ZM, 2010, HEPATOLOGY, V51, P621, DOI 10.1002/hep.23365; Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110; Bao DK, 2016, CANCER CHEMOTH PHARM, V78, P791, DOI 10.1007/s00280-016-3128-1; Capece D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/187204; Castanier C, 2010, EMBO REP, V11, P133, DOI 10.1038/embor.2009.258; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Ishihara T, 2015, MOL CELL BIOL, V35, P211, DOI 10.1128/MCB.01054-14; Kim H, 2011, MOL CELL, V44, P532, DOI 10.1016/j.molcel.2011.08.045; Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005; Lahiri A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013772; Lee JG, 2008, CELL SIGNAL, V20, P105, DOI 10.1016/j.cellsig.2007.09.003; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Montessuit S, 2010, CELL, V142, P889, DOI 10.1016/j.cell.2010.08.017; Nakahira K, 2015, ANTIOXID REDOX SIGN, V23, P1329, DOI 10.1089/ars.2015.6407; Park S, 2015, SCI REP-UK, V5, DOI 10.1038/srep15489; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Sahin H, 2010, NAT REV GASTRO HEPAT, V7, P682, DOI 10.1038/nrgastro.2010.168; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sun XC, 2018, LIVER INT, V38, P1263, DOI 10.1111/liv.13660; Tripathi C, 2014, ONCOTARGET, V5, P5350, DOI 10.18632/oncotarget.2110; Vilaysane A, 2009, SEMIN IMMUNOL, V21, P208, DOI 10.1016/j.smim.2009.05.006; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Wu WX, 2016, AUTOPHAGY, V12, P1675, DOI 10.1080/15548627.2016.1193656; Yasukawa K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000287; Ye LY, 2016, CANCER RES, V76, P818, DOI 10.1158/0008-5472.CAN-15-0977; Zhang JZ, 2014, INT J MOL MED, V33, P817, DOI 10.3892/ijmm.2014.1650; Zhang JY, 2018, HEPATOLOGY, V67, P1872, DOI 10.1002/hep.29681; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang Z, 2009, CANCER LETT, V286, P223, DOI 10.1016/j.canlet.2009.05.023; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494; Zhao YX, 2018, EXP CELL RES, V363, P171, DOI 10.1016/j.yexcr.2017.12.030; Zhou J, 2009, INT J CANCER, V125, P1640, DOI 10.1002/ijc.24556; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	44	60	62	5	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5007	5020		10.1038/s41388-019-0772-z	http://dx.doi.org/10.1038/s41388-019-0772-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30894684	hybrid, Green Published			2022-12-17	WOS:000472145900009
J	Baker, A; Wyatt, D; Bocchetta, M; Li, J; Filipovic, A; Green, A; Peiffer, DS; Fuqua, S; Miele, L; Albain, KS; Osipo, C				Baker, Andrew; Wyatt, Debra; Bocchetta, Maurizio; Li, Jun; Filipovic, Aleksandra; Green, Andrew; Peiffer, Daniel S.; Fuqua, Suzanne; Miele, Lucio; Albain, Kathy S.; Osipo, Clodia			Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+breast cancer cell proliferation and stem cell survival	ONCOGENE			English	Article							BREAST-CANCER; TRASTUZUMAB RESISTANCE; TENSIN HOMOLOG; CHROMOSOME-10 PTEN; GENE-EXPRESSION; PI3K PATHWAY; CYCLIN D1; NOTCH; ACTIVATION; RECEPTOR	Trastuzumab targets the HER2 receptor on breast cancer cells to attenuate HER2-driven tumor growth. However, resistance to trastuzumab-based therapy remains a major clinical problem for women with HER2+ breast cancer. Breast cancer stem cells (BCSCs) are suggested to be responsible for drug resistance and tumor recurrence. Notch signaling has been shown to promote BCSC survival and self-renewal. Trastuzumab-resistant cells have increased Notch-1 expression. Notch signaling drives cell proliferation in vitro and is required for tumor recurrence in vivo. We demonstrate herein a mechanism by which Notch-1 is required for trastuzumab resistance by repressing PTEN expression to contribute to activation of ERK1/2 signaling. Furthermore, Notch-1-mediated inhibition of PTEN is necessary for BCSC survival in vitro and in vivo. Inhibition of MEK1/2-ERK1/2 signaling in trastuzumab-resistant breast cancer cells mimics effects of Notch-1 knockdown on bulk cell proliferation and BCSC survival. These findings suggest that Notch-1 contributes to trastuzumab resistance by repressing PTEN and this may lead to hyperactivation of ERK1/2 signaling. Furthermore, high Notch-1 and low PTEN mRNA expression may predict poorer overall survival in women with breast cancer. Notch-1 protein expression predicts poorer survival in women with HER2+ breast cancer. These results support a potential future clinical trial combining anti-Notch-1 and anti-MEK/ERK therapy for trastuzumab-resistant breast cancer.	[Baker, Andrew; Peiffer, Daniel S.] Loyola Univ Chicago, Stritch Sch Med, Integrated Cell Biol Program, Maywood, IL 60153 USA; [Wyatt, Debra; Bocchetta, Maurizio; Osipo, Clodia] Loyola Univ Chicago, Stritch Sch Med, Oncol Res Inst, Maywood, IL 60153 USA; [Bocchetta, Maurizio] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA; [Li, Jun] Univ Notre Dame, Dept Appl & Computat Math & Stat, Notre Dame, IN 46556 USA; [Filipovic, Aleksandra] Imperial Coll London, London, England; [Green, Andrew] Univ Nottingham, Nottingham, England; [Peiffer, Daniel S.] Loyola Univ Chicago, Stritch Sch Med, MD PhD Program, Maywood, IL 60153 USA; [Fuqua, Suzanne] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Miele, Lucio] Louisiana State Univ, Dept Genet, New Orleans, LA 70112 USA; [Miele, Lucio] Louisiana State Univ, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL 60153 USA; [Osipo, Clodia] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; University of Notre Dame; Imperial College London; University of Nottingham; Loyola University Chicago; Baylor College of Medicine; Louisiana State University System; Louisiana State University System; Loyola University Chicago; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Oncol Res Inst, Maywood, IL 60153 USA.; Osipo, C (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.	cosipo@luc.edu	Li, Jun/C-3269-2015; Green, Andrew/AAF-1991-2020	Li, Jun/0000-0003-4353-5761; Green, Andrew/0000-0002-0488-5913; Miele, Lucio/0000-0002-5853-7287; Osipo, Clodia/0000-0003-1979-8465	American Cancer Society; Breast Cancer Research Foundation	American Cancer Society(American Cancer Society); Breast Cancer Research Foundation	This work was supported by the American Cancer Society (RSG-11-181-01-TBE) awarded to Dr. Clodia Osipo, the Arthur J. Schmitt Fellowship to Dr. Andrew Baker, and in part by the Breast Cancer Research Foundation to Drs. Kathy Albain and Clodia Osipo. We thank Ianina Bognini for assistance during animal studies.	Adachi R, 2011, BIOCHEM BIOPH RES CO, V411, P804, DOI 10.1016/j.bbrc.2011.07.033; Baker AT, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00360; Baldacchino S, 2014, EPMA J, V5, DOI 10.1186/1878-5085-5-3; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2; Chetram MA, 2012, J RECEPT SIG TRANSD, V32, P190, DOI 10.3109/10799893.2012.695798; Chu D, 2011, ANN ONCOL, V22, P2440, DOI 10.1093/annonc/mdq776; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Cohen B, 2010, BREAST CANCER RES TR, V123, P113, DOI 10.1007/s10549-009-0621-9; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Angelo RC, 2015, MOL CANCER THER, V14, P779, DOI 10.1158/1535-7163.MCT-14-0228; Das S, 2015, J BIOL CHEM, V290, P21705, DOI 10.1074/jbc.M115.655563; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Du C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-869; Ebbesen SH, 2016, P NATL ACAD SCI USA, V113, P3030, DOI 10.1073/pnas.1523693113; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Katoh M, 2007, INT J ONCOL, V31, P461; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Kopan R., 2012, COLD SPRING HARB PER, V4, P1; Loibl S, 2016, CLIN CANCER RES, V22, P2675, DOI 10.1158/1078-0432.CCR-15-0965; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218; Mao J, 2013, INT J BIOCHEM CELL B, V45, P1064, DOI 10.1016/j.biocel.2013.02.022; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Mittal S, 2014, MOL CANCER THER, V13, P3198, DOI 10.1158/1535-7163.MCT-14-0280; Mittal S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-128; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nunes J, 2016, ONCOTARGET, V7, P27599, DOI 10.18632/oncotarget.8504; O'Regan RM, 1998, JNCI-J NATL CANCER I, V90, P1552, DOI 10.1093/jnci/90.20.1552; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pandya K, 2011, BRIT J CANCER, V105, P796, DOI 10.1038/bjc.2011.321; Pandya K, 2016, CLIN CANCER RES, V22, P175, DOI 10.1158/1078-0432.CCR-15-0179; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Persson LM, 2010, J VIROL, V84, P1334, DOI 10.1128/JVI.01301-09; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stern HM, 2015, CLIN CANCER RES, V21, P2065, DOI 10.1158/1078-0432.CCR-14-2993; Thery JC, 2014, EUR J CANCER, V50, P892, DOI 10.1016/j.ejca.2014.01.003; Untch M, 2011, J CLIN ONCOL, V29, P3351, DOI 10.1200/JCO.2010.31.4930; Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475; WACHSMAN W, 1987, SCIENCE, V235, P674, DOI 10.1126/science.3027894; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Yakes FM, 2002, CANCER RES, V62, P4132; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yun J, 2015, J CELL PHYSIOL, V230, P3115, DOI 10.1002/jcp.25052	73	60	66	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4489	4504		10.1038/s41388-018-0251-y	http://dx.doi.org/10.1038/s41388-018-0251-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743588	Green Submitted, Green Accepted			2022-12-17	WOS:000441736700001
J	Fantini, D; Glaser, AP; Rimar, KJ; Wang, YD; Schipma, M; Varghese, N; Rademaker, A; Behdad, A; Yellapa, A; Yu, YN; Sze, CCL; Wang, L; Zhao, ZB; Crawford, SE; Hu, DQ; Licht, JD; Collings, CK; Bartom, E; Theodorescu, D; Shilatifard, A; Meeks, JJ				Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Schipma, Matthew; Varghese, Nobish; Rademaker, Alfred; Behdad, Amir; Yellapa, Aparna; Yu, Yanni; Sze, Christie Ching-Lin; Wang, Lu; Zhao, Zibo; Crawford, Susan E.; Hu, Deqing; Licht, Jonathan D.; Collings, Clayton K.; Bartom, Elizabeth; Theodorescu, Dan; Shilatifard, Ali; Meeks, Joshua J.			A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer	ONCOGENE			English	Article							SOMATIC ERCC2 MUTATIONS; ARISTOLOCHIC ACID; CELL-LINES; UROTHELIAL CANCER; CLONAL EVOLUTION; COPY NUMBER; GENOME; SIGNATURE; REPAIR; BASAL	The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model is an attractive model system of muscle-invasive bladder cancer (MIBC) as it recapitulates the histology of human tumors in a background with intact immune system. However, it was unknown whether this carcinogen-induced model also mimicked human MIBC at the molecular and mutational level. In our study, we analyzed gene expression and mutational landscape of the BBN model by next-generation sequencing followed by a bioinformatic comparison to human MIBC using data from The Cancer Genome Atlas and other repositories. BBN tumors showed overexpression of markers of basal cancer subtype, and had a high mutation burden with frequent Trp53 (80%), Kmt2d (70%), and Kmt2c (90%) mutations by exome sequencing, similar to human MIBC. Many variants corresponded to human cancer hotspot mutations, supporting their role as driver mutations. We extracted two novel mutational signatures from the BBN mouse genomes. The integrated analysis of mutation frequencies and signatures highlighted the contribution of aberrations to chromatin regulators and genetic instability in the BBN tumors. Together, our study revealed several similarities between human MIBC and the BBN mouse model, providing a strong rationale for its use in molecular and drug discovery studies.	[Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Yellapa, Aparna; Yu, Yanni; Meeks, Joshua J.] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Rademaker, Alfred; Shilatifard, Ali; Meeks, Joshua J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Schipma, Matthew; Varghese, Nobish; Sze, Christie Ching-Lin; Wang, Lu; Zhao, Zibo; Hu, Deqing; Collings, Clayton K.; Bartom, Elizabeth; Shilatifard, Ali] Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA; [Rademaker, Alfred] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Behdad, Amir] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Crawford, Susan E.] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; [Licht, Jonathan D.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA; [Theodorescu, Dan] Univ Colorado, Ctr Comprehens Canc, Dept Surg Urol & Pharmacol, Denver, CO 80202 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Saint Louis University; State University System of Florida; University of Florida; University of Colorado System; University of Colorado Denver	Meeks, JJ (corresponding author), Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA.; Meeks, JJ (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.	joshua.meeks@northwestern.edu	Licht, Jonathan/L-4239-2019; Zhao, Zibo/GWQ-3444-2022; Licht, Jonathan/AAL-9184-2020; Bartom, Elizabeth/S-4475-2017; Glaser, Alexander/D-5526-2015	Licht, Jonathan/0000-0002-3942-1369; Bartom, Elizabeth/0000-0002-5618-2582; Glaser, Alexander/0000-0003-1781-9023	John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University;  [BX003692];  [R01 CA180475];  [CA075115];  [R35CA197569]; NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115, F31CA228149, R35CA197569, T32CA009560, R01CA180475, R50CA221848] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003692] Funding Source: NIH RePORTER	John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Dr. Francesco Favero (Technical University of Denmark) for assistance with the use of the sequenza and copynumber R libraries, Dr. Vania Vidimar (Northwestern University) for insightful discussions and editorial assistance in writing the manuscript, and Dr. Andrea Piunti (Northwestern University) for help with RNA extraction and RNA-seq library preparation. JJM is supported by grant BX003692 and the John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, JDL is supported by R01 CA180475, DT is supported by CA075115. CKC, EB and AS are supported by R35CA197569 awarded to AS.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Calderwood SK, 2013, DISCOV MED, V15, P188; Chen CH, 2012, P NATL ACAD SCI USA, V109, P8241, DOI 10.1073/pnas.1119920109; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Glaser AP, 2017, NAT REV UROL, V14, P215, DOI 10.1038/nrurol.2017.11; Goodspeed A, 2016, MOL CANCER RES, V14, P3, DOI 10.1158/1541-7786.MCR-15-0189; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Horstmann M, 2008, GENDER MED, V5, P385, DOI 10.1016/j.genm.2008.11.002; Kardos J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85902; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Kobayashi T, 2015, NAT REV CANCER, V15, P42, DOI 10.1038/nrc3858; Kramer F, 2017, METHODS MOL BIOL, V1525, P123, DOI 10.1007/978-1-4939-6622-6_6; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li X, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3257-x; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Moriya M, 2011, INT J CANCER, V129, P1532, DOI 10.1002/ijc.26077; NAGAO M, 1977, CANCER RES, V37, P399; Nickerson ML, 2017, ONCOGENE, V36, P35, DOI 10.1038/onc.2016.172; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Peterson LA, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/284935; Pfister NT, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026054; Poon SL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0161-3; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Shin K, 2014, NAT CELL BIOL, V16, P469, DOI 10.1038/ncb2956; Sidorenko VS, 2012, NUCLEIC ACIDS RES, V40, P2494, DOI 10.1093/nar/gkr1095; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; SUMMERHAYES IC, 1979, J NATL CANCER I, V62, P1017; Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Vasconcelos-Nobrega C, 2012, IN VIVO, V26, P727; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Yao RS, 2004, NEOPLASIA, V6, P569, DOI 10.1593/neo.04223; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Zeegers MPA, 2000, CANCER-AM CANCER SOC, V89, P630, DOI 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q; Zhang YW, 2012, BJU INT, V109, P52, DOI 10.1111/j.1464-410X.2011.10283.x	60	60	60	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1911	1925		10.1038/s41388-017-0099-6	http://dx.doi.org/10.1038/s41388-017-0099-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367767	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000429303300008
J	Wan, W; Peng, K; Li, M; Qin, L; Tong, Z; Yan, J; Shen, B; Yu, C				Wan, W.; Peng, K.; Li, M.; Qin, L.; Tong, Z.; Yan, J.; Shen, B.; Yu, C.			Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1 alpha	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; GLUCOSE-METABOLISM; GENE-EXPRESSION; JHDM2A; TRANSCRIPTION; COMPLEX	High aerobic glycolysis not only provides energy to cancer cells, but also supports their anabolic growth. JMJD1A, a histone demethylase that specifically demethylates H3K9me1/2, is overexpressed in multiple cancers, including urinary bladder cancer (UBC). It is unclear whether JMJD1A could promote cancer cell growth through enhancing glycolysis. In this study, we found that downregulation of JMJD1A decreased UBC cell proliferation, colony formation and xenograft tumor growth. Knockdown of JMJD1A inhibited glycolysis by decreasing the expression of genes participated in glucose metabolism, including GLUT1, HK2, PGK1, PGM, LDHA and MCT4. Mechanistically, JMJD1A cooperated with hypoxia inducible factor 1 alpha (HIF1 alpha), an important transcription factor for glucose metabolism, to induce the glycolytic gene expression. JMJD1A was recruited to the promoter of glycolytic gene PGK1 to demethylate H3K9me2. However, the JMJD1A (H1120Y) mutant, which loses the demethylase activity, failed to cooperate with HIF1a to induce the glycolytic gene expression, and failed to demethylate H3K9me2 on PGK1 promoter, suggesting that the demethylase activity of JMJD1A is essential for its coactivation function for HIF1a. Inhibition of glycolysis through knocking down HIF1a or PGK1 decelerated JMJD1A-enhanced UBC cell growth. Consistent with these results, a positive correlation between JMJD1A and several key glycolytic genes in human UBC samples was established by analyzing a microarray-based gene expression profile. In conclusion, our study demonstrates that JMJD1A promotes UBC progression by enhancing glycolysis through coactivation of HIF1a, implicating that JMJD1A is a potential molecular target for UBC treatment.	[Wan, W.; Peng, K.; Li, M.; Qin, L.; Tong, Z.; Yu, C.] Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Peoples R China; [Li, M.] Xiamen Univ, Chenggong Hosp, Xiamen City Key Lab Biliary Tract Dis, Xiamen, Peoples R China; [Yan, J.] Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Yan, J.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Shen, B.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Shanghai, Peoples R China	Xiamen University; Xiamen University; Nanjing University; Nanjing University; Shanghai Jiao Tong University	Yu, C (corresponding author), Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Peoples R China.	cdyu@xmu.edu.cn	Tong, Zhangwei/V-2475-2019; Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952	National Basic Research Program of China (973 Program) [2015CB553800]; National Natural Science Foundation of China [81372176, U1405225, 81372168, 81470116]; Shanghai Natural Science Foundation [14ZR1433200]; Wu Jie Ping Medical Foundation [320.6750.16051]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Wu Jie Ping Medical Foundation	This study was supported by grants from National Basic Research Program of China (973 Program, No. 2015CB553800 to CY), the National Natural Science Foundation of China (No. 81372176 to CY, No. U1405225 to CY; No. 81372168 to JY; No. 81470116 to BS), Shanghai Natural Science Foundation (14ZR1433200 to BS) and Wu Jie Ping Medical Foundation (320.6750.16051 to BS).	Bayley JP, 2012, CURR OPIN ONCOL, V24, P62, DOI 10.1097/CCO.0b013e32834deb9e; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kobayashi T, 2015, NAT REV CANCER, V15, P42, DOI 10.1038/nrc3858; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Lee HY, 2013, CARCINOGENESIS, V34, P2706, DOI 10.1093/carcin/bgt256; Liu ZL, 2010, J BIOL CHEM, V285, P2758, DOI 10.1074/jbc.M109.066845; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Ma DK, 2008, STEM CELLS, V26, P2131, DOI 10.1634/stemcells.2008-0388; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Mo P, 2015, ONCOGENE, V34, P3935, DOI 10.1038/onc.2014.324; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Perez-Perri JI, 2016, CELL REP, V16, P37, DOI 10.1016/j.celrep.2016.05.082; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suikki HE, 2010, PROSTATE, V70, P889, DOI 10.1002/pros.21123; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thamotharan S, 2013, AM J PHYSIOL-ENDOC M, V304, pE583, DOI 10.1152/ajpendo.00513.2012; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wollenick K, 2012, NUCLEIC ACIDS RES, V40, P1928, DOI 10.1093/nar/gkr978; Xu Y, 2010, EURASIP J WIREL COMM, DOI 10.1155/2010/818964; Yamada D, 2012, ANN SURG ONCOL, V19, pS355, DOI 10.1245/s10434-011-1797-x; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang CS, 2015, CELL RES, V25, P1025, DOI 10.1038/cr.2015.90; Zhao W, 2014, J BIOL CHEM, V289, P11219, DOI 10.1074/jbc.M113.535989	36	60	64	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3868	3877		10.1038/onc.2017.13	http://dx.doi.org/10.1038/onc.2017.13			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263974				2022-12-17	WOS:000404848200007
J	Zandvakili, I; Lin, Y; Morris, JC; Zheng, Y				Zandvakili, I.; Lin, Y.; Morris, J. C.; Zheng, Y.			Rho GTPases: Anti- or pro-neoplastic targets?	ONCOGENE			English	Review							CANCER-CELL MOTILITY; DRIVER MUTATIONS; RATIONAL DESIGN; TUMOR-FORMATION; PROTEIN-KINASE; BREAST-CANCER; LUNG-CANCER; PERINEURAL INVASION; PROTEOMIC ANALYSIS; SIGNALING AXIS	Rho GTPases are critical signal transducers of multiple pathways. They have been proposed to be useful anti-neoplastic targets for over two decades, especially in Ras-driven cancers. Until recently, however, few in vivo studies had been carried out to test this premise. Several recent mouse model studies have verified that Rac1, RhoA, and some of their effector proteins such as PAK and ROCK, are likely anti-cancer targets for treating K-Ras-driven tumours. Other seemingly contradictory studies have suggested that at least in certain instances inhibition of individual Rho GTPases may paradoxically result in pro-neoplastic effects. Significantly, both RhoA GTPase gain-and loss-of-function mutations have been discovered in primary leukemia/lymphoma and gastric cancer by human cancer genome sequencing efforts, suggesting both pro-and anti-neoplastic roles. In this review we summarize and integrate these unexpected findings and discuss the mechanistic implications in the design and application of Rho GTPase targeting strategies in future cancer therapies.	[Zandvakili, I.; Lin, Y.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Mol & Dev Biol Grad Program, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Univ Cincinnati, Coll Med, Med Scientist Training Program, Cincinnati, OH USA; [Morris, J. C.] Univ Cincinnati, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@cchmc.org	Zandvakili, Inuk/P-7241-2019	Zandvakili, Inuk/0000-0003-3409-0019	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH [R01 CA193350, R01 DK104814, R01 HL134617]; NATIONAL CANCER INSTITUTE [R01CA193350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, R01DK104814] Funding Source: NIH RePORTER	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge support from the University of Cincinnati Medical Scientist Training Program and the Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center. The work in the Yi Zheng lab is partly supported by NIH grants R01 CA193350, R01 DK104814 and R01 HL134617.	Abiatari I, 2009, MOL CANCER THER, V8, P1494, DOI 10.1158/1535-7163.MCT-08-0755; Alan Jamie K, 2013, Small GTPases, V4, P159, DOI 10.4161/sgtp.26530; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker MS, 2016, ONCOTARGET, V7, P51908, DOI 10.18632/oncotarget.10188; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Biro M, 2014, BRIT J PHARMACOL, V171, P5491, DOI 10.1111/bph.12658; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Bosco EE, 2012, CHEM BIOL, V19, P228, DOI 10.1016/j.chembiol.2011.12.017; Boulter Etienne, 2010, Small GTPases, V1, P65; Bousquet E, 2009, CANCER RES, V69, P6092, DOI 10.1158/0008-5472.CAN-08-4147; Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Chew TW, 2014, ONCOGENE, V33, P2717, DOI 10.1038/onc.2013.240; Chiba Shigeru, 2015, Small GTPases, V6, P100, DOI 10.4161/21541248.2014.988088; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; Croise P, 2016, ENDOCR-RELAT CANCER, V23, P281, DOI 10.1530/ERC-15-0502; Cullis J, 2014, CANCER CELL, V25, P181, DOI 10.1016/j.ccr.2014.01.025; Deribe YL, 2016, P NATL ACAD SCI USA, V113, pE1296, DOI 10.1073/pnas.1513801113; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evelyn CR, 2009, J BIOMOL SCREEN, V14, P161, DOI 10.1177/1087057108328761; Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Forti FL, 2007, ENDOCR-RELAT CANCER, V14, P1117, DOI 10.1677/ERC-07-0154; Frances D, 2015, ONCOGENE, V34, P5505, DOI 10.1038/onc.2014.471; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fukumoto Y, 2007, J CARDIOVASC PHARM, V49, P117, DOI 10.1097/FJC.0b013e31802ef532; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gilbert-Ross M, 2015, GENES DIS, V2, P2, DOI 10.1016/j.gendis.2014.10.001; Grogg MW, 2010, RHO GTPASES IN CANCER, P93, DOI 10.1007/978-1-4419-1111-7_6; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heckman-Stoddard BM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2352; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holderfield M, 2014, BRIT J CANCER, V111, P640, DOI 10.1038/bjc.2014.139; Hu LD, 2007, ONCOL REP, V17, P1383; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ishikawa S, 2016, BLOOD, V127, P524, DOI 10.1182/blood-2015-12-683458; Jiang WG, 2003, CLIN CANCER RES, V9, P6432; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Koide N, 2006, CLIN CANCER RES, V12, P2419, DOI 10.1158/1078-0432.CCR-05-1852; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kumper S, 2016, ELIFE, V5, DOI 10.7554/eLife.12203; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kumar RD, 2016, NAT GENET, V48, P1288, DOI 10.1038/ng.3658; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2016, CANCER RES, V76, P3826, DOI 10.1158/0008-5472.CAN-15-2923; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin M, 2004, BREAST CANCER RES TR, V84, P49, DOI 10.1023/B:BREA.0000018424.43445.f3; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu N, 2007, J MOL MED-JMM, V85, P1149, DOI 10.1007/s00109-007-0217-y; Maeda M, 2016, GASTRIC CANCER, V19, P326, DOI 10.1007/s10120-015-0525-9; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Manso R, 2014, BLOOD, V123, P2893, DOI 10.1182/blood-2014-02-555946; Rojas AM, 2012, J CELL BIOL, V196, P189, DOI 10.1083/jcb.201103008; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; McHenry PR, 2010, CURR DRUG TARGETS, V11, P1043, DOI 10.2174/138945010792006852; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; Meyer N, 2014, J INVEST DERMATOL, V134, P203, DOI 10.1038/jid.2013.278; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Mizukawa B, 2011, BLOOD, V118, P5235, DOI 10.1182/blood-2011-04-351817; Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Huynh N, 2015, RES REP BIOCHEM, V5, P119, DOI 10.2147/RRBC.S57278; Nohata N, 2016, DEV BIOL, V411, P183, DOI 10.1016/j.ydbio.2016.02.005; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Orgaz Jose L, 2014, Small GTPases, V5, pe29019, DOI 10.4161/sgtp.29019; Pajic Marina, 2015, Small GTPases, V6, P123, DOI 10.4161/21541248.2014.973749; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Pranatharthi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5785786; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riou P, 2010, BIOESSAYS, V32, P986, DOI 10.1002/bies.201000060; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Rocken C, 2016, J CLIN PATHOL, V69, P70, DOI 10.1136/jclinpath-2015-202980; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sakamori R, 2014, CANCER RES, V74, P5480, DOI 10.1158/0008-5472.CAN-14-0267; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Samuel MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017143; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shang X, 2013, P NATL ACAD SCI USA, V110, P3155, DOI 10.1073/pnas.1212324110; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shimokawa H, 2002, J CARDIOVASC PHARM, V40, P749; Silva AL, 2013, EUR J ENDOCRINOL, V168, P795, DOI 10.1530/EJE-12-0960; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Skalnikova H, 2011, J PROTEOME RES, V10, P404, DOI 10.1021/pr100468w; Smithers CC, 2016, CELLS, P5; Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Hengel J, 2008, GASTROENTEROLOGY, V134, P781, DOI 10.1053/j.gastro.2008.01.002; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicari RM, 2005, J AM COLL CARDIOL, V46, P1803, DOI 10.1016/j.jacc.2005.07.047; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Vogel CJ, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12364; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Wang DS, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017453; Wang J., 2016, SHOCK VIB, V2016, P1, DOI DOI 10.1155/2016/9371563; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008-5472.CAN-14-1232-T; Wei L, 2016, ARCH IMMUNOL THER EX, V64, P259, DOI 10.1007/s00005-015-0382-6; Welch Heidi C E, 2015, Small GTPases, V6, P49, DOI 10.4161/21541248.2014.973770; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu CYC, 2014, GASTROENTEROLOGY, V147, P1405, DOI 10.1053/j.gastro.2014.08.032; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yang L, 2007, BLOOD, V110, P3853, DOI 10.1182/blood-2007-03-079582; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916; Zandvakili I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127923; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhang SY, 2009, MOL CANCER RES, V7, P570, DOI 10.1158/1541-7786.MCR-08-0248; Zhao L, 2008, J PROTEOME RES, V7, P3994, DOI 10.1021/pr800271b; Zhao LA, 2010, FEBS J, V277, P4195, DOI 10.1111/j.1742-4658.2010.07808.x; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99; Zhou J, 2014, CANCER CELL, V26, P9, DOI 10.1016/j.ccr.2014.06.022; Zhou W, 2014, J PATHOL, V234, P502, DOI 10.1002/path.4412; Zhou X, 2013, J BIOL CHEM, V288, P36179, DOI 10.1074/jbc.R113.515486	161	60	63	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3213	3222		10.1038/onc.2016.473	http://dx.doi.org/10.1038/onc.2016.473			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991930	Green Accepted			2022-12-17	WOS:000402869800001
J	Wang, S; Pan, Y; Zhang, R; Xu, T; Wu, W; Zhang, R; Wang, C; Huang, H; Calin, CA; Yang, H; Claret, FX				Wang, S.; Pan, Y.; Zhang, R.; Xu, T.; Wu, W.; Zhang, R.; Wang, C.; Huang, H.; Calin, C. A.; Yang, H.; Claret, F. X.			Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELL-GROWTH; DNA-DAMAGE; MICRORNAS; BINDING; REPAIR; TUMORIGENESIS; INVOLVEMENT; PROGRESSION; INHIBITION	Radiotherapy is the standard therapy for nasopharyngeal carcinoma (NPC); however, radioresistance can hinder successful treatment. Here we report that microRNA (miR)-24 acts as a tumor suppressor and radiosensitizer in NPC cells and xenografts by targeting Jab1/CSN5. Although accumulating evidence has shown that Jab1/CSN5 functions as an oncoprotein in human cancers, its regulation through miRs has not been described. In this study, we found that Jab1/CSN5 functioned in a manner opposite to that of miR-24 in NPC tumorigenesis and radioresistance. We demonstrated that miR-24 inhibits Jab1/CSN5 translation via direct binding to its 3'untranslated region (3'UTR) and 5'UTR, leading to tumor growth inhibition, and sensitizes NPC tumors to radiation in vivo. Furthermore, silencing Jab1/CSN5 phenocopied the function of miR-24 in NPC cells after ionizing radiation treatment, resulting in increased apoptosis. Finally, we analyzed 50 paired samples of primary and matched recurrent NPC tissues from 25 NPC patients and subjected them to high-throughput genomic quantitative nuclease protection assay for quantifying simultaneously miR and mRNA levels. Our results showed that miR-24 levels were significantly decreased in recurrent NPC and that levels of Jab1/CSN5, as its target, were higher than those in primary NPC. Together, our findings indicate that miR-24 inhibits NPC tumor growth and increases NPC radiosensitivity by directly regulating Jab1/CSN5 and that both miR-24 and Jab1/CSN5 can serve as prognostic markers for NPC recurrence; this, in turn, may provide a promising therapeutic strategy for reversing NPC radioresistance.	[Wang, S.; Wu, W.] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou 510370, Guangdong, Peoples R China; [Wang, S.; Xu, T.; Wang, C.; Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China; [Wang, S.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 6767 Bertner Ave, Houston, TX 77030 USA; [Pan, Y.] Jiangnan Univ, Wuxi Med Sch, Affiliated Hosp, Dept Pathol, Wuxi, Peoples R China; [Zhang, R.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Endoscopy, Guangzhou, Guangdong, Peoples R China; [Xu, T.] Sun Yat Sen Univ, Peoples Hosp Foshan 1, Dept Radiat Oncol, Foshan, Peoples R China; [Huang, H.] Shantou Cent Hosp, Ctr Canc, Dept Radiat, Oncol, Shantou, Peoples R China; [Calin, C. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, C. A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Claret, F. X.] Univ Texas Grad Sch Biomed Sci Houston, Expt Therapeut Acad Program & Canc Biol Program, Houston, TX USA	Guangzhou University of Chinese Medicine; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Jiangnan University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, S (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou 510370, Guangdong, Peoples R China.; Yang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China.; Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 6767 Bertner Ave, Houston, TX 77030 USA.	wangsumei198708@163.com; yanghl@mail.sysu.edu.cn; fxclaret@mdanderson.org	Claret, Francois X/R-2104-2016; Wang, Sumei/V-2800-2019	Claret, Francois X/0000-0003-4629-6495; Wang, Sumei/0000-0002-2011-4019; Pan, Yunbao/0000-0002-6311-2945	China Scholarship Council [201206380043]; National Natural Science Foundation of China [81071837, 81372410, 30670627]; Scientific and Technological Project of Guangdong, China [2008A030201009, 2010B050700016]; National Cancer Institute [R01-CA90853]; Sister Institution Network Fund (FXC); University of Texas MD Anderson Functional Proteomics Core Facility (NCI) [CA16672]; NATIONAL CANCER INSTITUTE [R01CA090853, R01CA182905, P30CA016672] Funding Source: NIH RePORTER	China Scholarship Council(China Scholarship Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific and Technological Project of Guangdong, China; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sister Institution Network Fund (FXC); University of Texas MD Anderson Functional Proteomics Core Facility (NCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michael Worley and the Department of Scientific Publications at MD Anderson Cancer Center for editing the manuscript. This study was supported by a fellowship from the China Scholarship Council (201206380043 to SW), the National Natural Science Foundation of China (81071837, 81372410 and 30670627 to HY) and the Scientific and Technological Project of Guangdong, China (2008A030201009 and 2010B050700016 to HY) and by grants from the National Cancer Institute (R01-CA90853 to FXC), the Sister Institution Network Fund (FXC) and The University of Texas MD Anderson Functional Proteomics Core Facility (NCI Cancer Center Support Grant CA16672).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Chan ATC, 2010, ANN ONCOL, V21, pv187, DOI 10.1093/annonc/mdq186; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Chhabra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-232; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Hsu MC, 2008, CLIN CANCER RES, V14, P4045, DOI 10.1158/1078-0432.CCR-07-5040; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126; Lim WT, 2011, CLIN CANCER RES, V17, P5481, DOI 10.1158/1078-0432.CCR-10-3409; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; MCCARTY KS, 1986, CANCER RES, V46, P4244; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Pan YB, 2012, CANCER LETT, V326, P155, DOI 10.1016/j.canlet.2012.07.033; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Pechhold S, 2009, NAT BIOTECHNOL, V27, P1038, DOI 10.1038/nbt.1579; Qu CJ, 2012, CELL CYCLE, V11, P785, DOI 10.4161/cc.11.4.19228; Qu YM, 2010, J CANCER RES CLIN, V136, P953, DOI 10.1007/s00432-009-0739-5; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; SHAM JST, 1990, LANCET, V335, P371, DOI 10.1016/0140-6736(90)90206-K; Sorrells S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002922; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709; Wang SM, 2014, MOL CANCER THER, V13, P3163, DOI 10.1158/1535-7163.MCT-14-0317; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Xie Y, 2013, ONCOGENE, V32, P2442, DOI 10.1038/onc.2012.258; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008	51	60	64	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6096	6108		10.1038/onc.2016.147	http://dx.doi.org/10.1038/onc.2016.147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157611	Green Accepted			2022-12-17	WOS:000388509800006
J	Kim, SJ; Lee, HW; Baek, JH; Cho, YH; Kang, HG; Jeong, JS; Song, J; Park, HS; Chun, KH				Kim, S-J; Lee, H-W; Baek, J-H; Cho, Y-H; Kang, H. G.; Jeong, J. S.; Song, J.; Park, H-S; Chun, K-H			Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; POSTTRANSLATIONAL REGULATION; GENE; UBIQUITINATION; APOPTOSIS	Mutation in PTEN has not yet been detected, but its function as a tumor suppressor is inactivated in many cancers. In this study we determined that, activated Notch signaling disables PTEN by phosphorylation and thereby contributes to gastric tumorigenesis. Notch inhibition by small interfering RNA or.-secretase inhibitor (GSI) induced mitotic arrest and apoptosis in gastric cancer cells. Notch inhibition induced dephosphorylation in the C-terminal domain of PTEN, which led to PTEN nuclear localization. Overexpression of activated Notch1-induced phosphorylation of PTEN and reversed GSI-induced mitotic arrest. Dephosphorylated nuclear PTEN caused prometaphase arrest by interaction with the cyclin B1-CDK1 complex, resulting in their accumulation in the nucleus and subsequent apoptosis. We found a correlation between high expression levels of Notch1 and low survival rates and, similarly, between reduced nuclear PTEN expression and increasing the TNM classification of malignant tumours stages in malignant tissues from gastric cancer patients. The growth of Notch1-depleted gastric tumors was significantly retarded in xenografted mice, and in addition, PTEN deletion restored growth similar to control tumors. We also demonstrated that combination treatment with GSI and chemotherapeutic agents significantly reduced the orthotopically transplanted gastric tumors in mice without noticeable toxicity. Overall, our findings suggest that inhibition of Notch signaling can be employed as a PTEN activator, making it a potential target for gastric cancer therapy.	[Kim, S-J; Lee, H-W; Baek, J-H; Cho, Y-H; Kang, H. G.; Chun, K-H] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea; [Kim, S-J; Baek, J-H; Cho, Y-H; Kang, H. G.; Chun, K-H] Severance Med Res Inst, Brain Korea PLUS Project Med Sci 21, Seoul, South Korea; [Lee, H-W; Song, J.] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul 120749, South Korea; [Jeong, J. S.] Dong A Univ, Sch Med, Dept Pathol, Busan, South Korea; [Park, H-S] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Gwangju, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Dong A University; Chonnam National University	Chun, KH (corresponding author), Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, 50 Yonsei Ro, Seoul 120752, South Korea.	khchun@yuhs.ac		Song, Jaewhan/0000-0001-8152-9210; Chun, Kyung-Hee/0000-0002-9867-7321	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [NRF-2014R1A2A1A11050600]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2014R1A1A2055009]	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	The authors are grateful to the FACS facility staff of the National Cancer Center (NCC) in Korea for their technical support. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2014R1A2A1A11050600), and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2014R1A1A2055009).	Ahn YH, 2012, CLIN EXP METASTAS, V29, P359, DOI 10.1007/s10585-012-9458-4; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691; Boosani CS, 2013, EXPERT OPIN THER PAT, V23, P569, DOI 10.1517/13543776.2013.768985; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; Cheong TC, 2010, CANCER SCI, V101, P94, DOI 10.1111/j.1349-7006.2009.01364.x; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Efferson CL, 2010, CANCER RES, V70, P2476, DOI 10.1158/0008-5472.CAN-09-3114; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Groth C, 2012, SEMIN CELL DEV BIOL, V23, P465, DOI 10.1016/j.semcdb.2012.01.016; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Kim JH, 2014, CELL DEATH DIFFER, V21, P594, DOI 10.1038/cdd.2013.181; Kim SJ, 2014, CELL DEATH DIFFER, V21, P1769, DOI 10.1038/cdd.2014.88; Kim SJ, 2013, ONCOTARGET, V4, P1461, DOI 10.18632/oncotarget.1219; Kim SJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3098; Kim SJ, 2011, CLIN EXP METASTAS, V28, P743, DOI 10.1007/s10585-011-9406-8; Kim SJ, 2011, J CONTROL RELEASE, V155, P427, DOI 10.1016/j.jconrel.2011.06.026; Kim SJ, 2010, GASTROENTEROLOGY, V138, P1035, DOI 10.1053/j.gastro.2009.09.061; Kim SK, 2011, AUTOMAT CONSTR, V20, P1, DOI 10.1016/j.autcon.2010.07.010; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kuhnert F, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-20; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069; Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Ohtsu A, 2008, J GASTROENTEROL, V43, P256, DOI 10.1007/s00535-008-2177-6; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vaisman N Ia, 2012, Izv Akad Nauk Ser Biol, P27; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Wang YG, 2012, EXP MOL MED, V44, P387, DOI 10.3858/emm.2012.44.6.044; Wen YG, 2010, ONCOL REP, V24, P89, DOI 10.3892/or_00000832; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang P, 2012, BIOMED PHARMACOTHER, V66, P485, DOI 10.1016/j.biopha.2012.04.004; Zhang Y, 2001, J CELL BIOCHEM, V82, P692, DOI 10.1002/jcb.1191	42	60	66	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					251	260		10.1038/onc.2015.80	http://dx.doi.org/10.1038/onc.2015.80			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823029				2022-12-17	WOS:000368193900011
J	Xing, F; Sharma, S; Liu, Y; Mo, YY; Wu, K; Zhang, YY; Pochampally, R; Martinez, LA; Lo, HW; Watabe, K				Xing, F.; Sharma, S.; Liu, Y.; Mo, Y-Y; Wu, K.; Zhang, Y-Y; Pochampally, R.; Martinez, L. A.; Lo, H-W; Watabe, K.			nmiR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-alpha	ONCOGENE			English	Article							BARRIER PERMEABILITY; PROSTATE-CANCER; MICRORNAS; EXPRESSION; LET-7; MICE	The median survival time of breast cancer patients with brain metastasis is less than 6 months, and even a small metastatic lesion often causes severe neurological disabilities. Because of the location of metastatic lesions, a surgical approach is limited and most chemotherapeutic drugs are ineffective owing to the blood brain barrier (BBB). Despite this clinical importance, the molecular basis of the brain metastasis is poorly understood. In this study, we have isolated RNA from samples obtained from primary breast tumors and also from brain metastatic lesions followed by microRNA profiling analysis. Our results revealed that the miR-509 is highly expressed in the primary tumors, whereas the expression of this microRNA is significantly decreased in the brain metastatic lesions. MicroRNA target prediction and the analysis of cytokine array for the cells ectopically expressed with miR-509 demonstrated that this microRNA was capable of modulating the two genes essential for brain invasion, RhoC and TNF-alpha that affect the invasion of cancer cells and permeability of BBB, respectively. Importantly, high levels of TNF-alpha and RhoC-induced MMP9 were significantly correlated with brain metastasis-free survival of breast cancer patients. Furthermore, the results of our in vivo experiments indicate that miR-509 significantly suppressed the ability of cancer cells to metastasize to the brain. These findings suggest that miR-509 has a critical role in brain metastasis of breast cancer by modulating the RhoC-TNF-alpha network and that this miR-509 axis may represent a potential therapeutic target or serve as a prognostic tool for brain metastasis.	[Xing, F.; Sharma, S.; Liu, Y.; Wu, K.; Lo, H-W; Watabe, K.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; [Xing, F.; Sharma, S.; Liu, Y.; Wu, K.; Lo, H-W; Watabe, K.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; [Mo, Y-Y; Zhang, Y-Y; Pochampally, R.; Martinez, L. A.] Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Mississippi; University of Mississippi Medical Center	Watabe, K (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Mo, Yin-Yuan/R-8255-2019	Pochampally, Radhika/0000-0002-4263-0364	National Institutes of Health [R01CA124650, R01CA129000, R01CA173499]; US Department of Defense [BC096982]; NATIONAL CANCER INSTITUTE [R01CA173499, R01CA129000, R01CA151851, R01CA124650, R01CA154989, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health (grants R01CA124650, R01CA129000 and R01CA173499 to K Watabe) and the US Department of Defense (BC096982 to K Watabe).	Arora S, 2011, INT J CANCER, V129, P2621, DOI 10.1002/ijc.25939; Arslan C, 2010, EXPERT OPIN PHARMACO, V11, P1089, DOI 10.1517/14656561003702412; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bindal AK, 1996, J NEUROSURG, V84, P748, DOI 10.3171/jns.1996.84.5.0748; BINDAL RK, 1993, J NEUROSURG, V79, P210, DOI 10.3171/jns.1993.79.2.0210; Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Eichler AF, 2008, CANCER, V112, P2359, DOI 10.1002/cncr.23468; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iiizumi M, 2008, CANCER RES, V68, P7613, DOI 10.1158/0008-5472.CAN-07-6700; Izraely S, 2012, INT J CANCER, V131, P1071, DOI 10.1002/ijc.27324; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Langley RR, 2003, CANCER RES, V63, P2971; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107; Nie WW, 2013, CANCER BIOTHER RADIO, V28, P71, DOI 10.1089/cbr.2012.1311; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Ramakrishna Rohan, 2013, Surg Neurol Int, V4, pS256, DOI 10.4103/2152-7806.111303; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Rosenthal DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040979; SAIJA A, 1995, LIFE SCI, V56, P775, DOI 10.1016/0024-3205(95)00008-T; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Tie J, 2011, HISTOL HISTOPATHOL, V26, P1353, DOI 10.14670/HH-26.1353; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; van Golen KL, 2000, CANCER RES, V60, P5832; Volinia S, 2013, P NATL ACAD SCI USA, V110, P7413, DOI 10.1073/pnas.1304977110; Wang W, 2011, EUR J GASTROEN HEPAT, V23, P552, DOI 10.1097/MEG.0b013e3283470212; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wilhelm I, 2013, INT J MOL SCI, V14, P1383, DOI 10.3390/ijms14011383; Yang GY, 1999, MOL BRAIN RES, V69, P135, DOI 10.1016/S0169-328X(99)00007-8; Yang YL, 2004, WORLD J GASTROENTERO, V10, P3161; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	40	60	64	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4890	4900		10.1038/onc.2014.412	http://dx.doi.org/10.1038/onc.2014.412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25659578	Green Accepted			2022-12-17	WOS:000361050000009
J	Prevete, N; Liotti, F; Visciano, C; Marone, G; Melillo, RM; de Paulis, A				Prevete, N.; Liotti, F.; Visciano, C.; Marone, G.; Melillo, R. M.; de Paulis, A.			The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FORMYLPEPTIDE RECEPTOR; ANNEXIN A1; PROTEIN; CELLS; ACTIVATION; EXPRESSION; GROWTH; FPR; CHEMOTAXIS	N-formyl peptide receptors (FPR1, FPR2 and FPR3) are involved in innate immunity, inflammation and cancer. FPR expression, initially described in immune cells, was later observed in non-hematopoietic cell populations and tissues. Several studies suggested a role for FPRs in the progression of various tumor histotypes, including gastric cancer (GC), for which a positive association with a specific FPR1 polymorphism has recently been described. We previously showed that FPRs are expressed on gastric epithelium and are required for wound repair and restitution of barrier integrity. Here we assess the role of FPRs in GC. We characterized the functions of FPRs in GC epithelial cells (MKN28, AGS and MKN45) cultured in vitro by assessing migration, proliferation, resistance to apoptosis and activation of the epithelial-to-mesenchymal transition. Activation of each FPR induced the epithelial-to-mesenchymal transition, proliferation, resistance to apoptosis and migration of GC cells in culture. Blocking compounds or RNA interference of each FPR reverted these effects. We also defined the in vivo tumorigenic potential of GC epithelial cells silenced for FPRs by xenograft experiments in immunocompromised mice. Interestingly, FPR1 silencing in GC cells (shFPR1) significantly enhanced xenograft growth with respect to shCTR, shFPR2 and shFPR3 xenografts, because of augmented vessel density and cell proliferation. Accordingly, HIF-1 alpha and VEGF mRNA levels were higher in shFPR1 xenografts than in controls. Moreover, the in vitro production of proangiogenic factors in response to FPR2/3 agonists (WKYMVm, LL-37, uPA, uPAR(84-95), AnxA1) or to other proinflammatory mediators (IL-1 alpha) was higher in shFPR1 GC cells than in shCTR, shFPR2 and shFPR3 cells, suggesting that FPR1 functions as an inhibitor of CG angiogenesis. Thus, we propose that FPR1 stimulation may represent a novel therapeutic approach to counteract tumor angiogenesis.	[Prevete, N.; Marone, G.; de Paulis, A.] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Prevete, N.; Marone, G.; de Paulis, A.] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, Naples, Italy; [Liotti, F.; Visciano, C.; Melillo, R. M.] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Liotti, F.; Visciano, C.; Melillo, R. M.] CNR, Inst Expt Oncol & Endocrinol IEOS, I-80125 Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Melillo, RM (corresponding author), Dept Mol Med & Med Biotechnol, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it; depaulis@unina.it	melillo, rosa marina/O-5255-2015; Liotti, Federica/AAC-1614-2019	Liotti, Federica/0000-0002-0145-988X; MELILLO, Rosa Marina/0000-0002-9233-5275; de Paulis, Amato/0000-0003-0347-2540	Ministero della Salute (Ricerca Finalizzata - IZSM RF); Regione Campania CISI-Lab Project; CREME Project; TIMING Project	Ministero della Salute (Ricerca Finalizzata - IZSM RF); Regione Campania CISI-Lab Project; CREME Project; TIMING Project	We are grateful to Jean Ann Gilder (Scientific Communication srl., Naples, Italy) for editing the text. This work was supported by grants from Ministero della Salute (Ricerca Finalizzata 2009 - IZSM RF 2009), Regione Campania CISI-Lab Project, CREME Project and TIMING Project.	Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; Babbin BA, 2007, J IMMUNOL, V179, P8112, DOI 10.4049/jimmunol.179.12.8112; Chen KD, 2013, J CLIN INVEST, V123, P1694, DOI 10.1172/JCI65569; Cheng TY, 2012, CANCER-AM CANCER SOC, V118, P5757, DOI 10.1002/cncr.27565; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; D'Acquisto F, 2008, BRIT J PHARMACOL, V155, P152, DOI 10.1038/bjp.2008.252; de Paulis A, 2004, J IMMUNOL, V173, P5739, DOI 10.4049/jimmunol.173.9.5739; de Paulis A, 2004, J IMMUNOL, V172, P7734, DOI 10.4049/jimmunol.172.12.7734; de Paulis A, 2009, J IMMUNOL, V183, P3761, DOI 10.4049/jimmunol.0900863; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Devosse T, 2011, J IMMUNOL, V187, P1475, DOI 10.4049/jimmunol.1003545; Gao JL, 2007, J IMMUNOL, V178, P1450, DOI 10.4049/jimmunol.178.3.1450; Huang J, 2010, BRIT J CANCER, V102, P1052, DOI 10.1038/sj.bjc.6605591; Jing YY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-98; Kalia S, 2008, J BIOCHEM MOL TOXIC, V22, P371, DOI 10.1002/jbt.20252; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831; Liu L, 2012, ASIAN PAC J CANCER P, V13, P3089, DOI 10.7314/APJCP.2012.13.7.3089; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Otani T, 2011, BIOCHEM BIOPH RES CO, V405, P356, DOI 10.1016/j.bbrc.2010.12.136; Pang MY, 2010, KIDNEY INT, V78, P257, DOI 10.1038/ki.2010.154; Paul SAM, 2004, J CELL PHYSIOL, V200, P20, DOI 10.1002/jcp.10479; Pott J, 2012, EMBO REP, V13, P684, DOI 10.1038/embor.2012.96; Prevete N, 2013, J BIOL REG HOMEOS AG, V27, P827; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Seifert R, 2001, J BIOL CHEM, V276, P42043, DOI 10.1074/jbc.M106621200; Shao GH, 2011, AM J RESP CELL MOL, V44, P264, DOI 10.1165/rcmb.2010-0246RC; Takahashi A, 2002, ONCOLOGY-BASEL, V62, P121, DOI 10.1159/000048257; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zhang XG, 2011, INVEST OPHTH VIS SCI, V52, P3160, DOI 10.1167/iovs.10-5156; Zhou Y, 2005, JNCI-J NATL CANCER I, V97, P823, DOI 10.1093/jnci/dji142	35	60	63	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3826	3838		10.1038/onc.2014.309	http://dx.doi.org/10.1038/onc.2014.309			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263443				2022-12-17	WOS:000358001600008
J	Ennen, M; Keime, C; Kobi, D; Mengus, G; Lipsker, D; Thibault-Carpentier, C; Davidson, I				Ennen, M.; Keime, C.; Kobi, D.; Mengus, G.; Lipsker, D.; Thibault-Carpentier, C.; Davidson, I.			Single-cell gene expression signatures reveal melanoma cell heterogeneity	ONCOGENE			English	Article							MITF TRANSCRIPTION FACTORS; MALIGNANT-MELANOMA; INITIATING CELLS; PHENOTYPE; RESISTANCE; IDENTIFICATION; MELANOGENESIS; PATHWAY; SWITCH; STATES	It is well established that tumours are not homogenous, but comprise cells with differing invasive, proliferative and tumourinitiating potential. A major challenge in cancer research is therefore to develop methods to characterize cell heterogeneity. In melanoma, proliferative and invasive cells are characterized by distinct gene expression profiles and accumulating evidence suggests that cells can alternate between these states through a process called phenotype switching. We have used microfluidic technology to isolate single melanoma cells grown in vitro as monolayers or melanospheres or in vivo as xenografted tumours and analyse the expression profiles of 114 genes that discriminate the proliferative and invasive states by quantitative PCR. Single-cell analysis accurately recapitulates the specific gene expression programmes of melanoma cell lines and defines subpopulations with distinct expression profiles. Cell heterogeneity is augmented when cells are grown as spheres and as xenografted tumours. Correlative analysis identifies gene-regulatory networks and changes in gene expression under different growth conditions. In tumours, subpopulations of cells that express specific invasion and drug resistance markers can be identified amongst which is the pluripotency factor POUF51 (OCT4) whose expression correlates with the tumorigenic potential. We therefore show that single-cell analysis can be used to define and quantify tumour heterogeneity based on detection of cells with specific gene expression profiles.	[Ennen, M.; Keime, C.; Kobi, D.; Mengus, G.; Lipsker, D.; Thibault-Carpentier, C.; Davidson, I.] CNRS INSERM UDS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Lipsker, D.] Hop Univ Strasbourg, Hop Civil, Fac Med, Strasbourg, France; [Lipsker, D.] Hop Univ Strasbourg, Hop Civil, Serv Dermatol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), CNRS INSERM UDS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	irwin@igbmc.fr		Lipsker, Dan/0000-0003-4675-0336; Davidson, Irwin/0000-0001-5533-1171; KEIME, Celine/0000-0001-7604-3814; MENGUS, Gabrielle/0000-0002-2844-1778; Thibault-Carpentier, Christelle/0000-0003-1562-1451	Centre National de la Recherche Scientifique; Institut National de Sante et de la Recherche Medicale; Universite de Strasbourg; Association pour la Recherche contre le Cancer; Ligue Nationale contre le Cancer; Institut National du Cancer PAIR-melanoma grant; French state fund through the Agence Nationale de la Recherche [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de Sante et de la Recherche Medicale; Universite de Strasbourg; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer PAIR-melanoma grant; French state fund through the Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank D Dembele for help with data analysis, all the staff of the IGBMC common facilities, as well as F Kardouz and the staff of the Strasbourg Hospital Dermatology Clinic, This work was supported by institutional grants from the Centre National de la Recherche Scientifique, the Institut National de Sante et de la Recherche Medicale, the Universite de Strasbourg, the Association pour la Recherche contre le Cancer, the Ligue Nationale contre le Cancer, the Institut National du Cancer PAIR-melanoma grant, the ANR-10-LABX-0030-INRT French state fund through the Agence Nationale de la Recherche under the frame programme Investissements d'Avenir labelled ANR-10-IDEX-0002-02. The IGBMC high throughput sequencing facility is a member of the 'France Genomique' consortium (ANR10-INBS-09-08). ID is an 'equipe labellisee' of the Ligue Nationale contre le Cancer. ME was supported by a fellowship from the Ligue Nationale contre le Cancer.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Castro FV, 2012, CANCER IMMUNOL IMMUN, V61, P1005, DOI 10.1007/s00262-011-1167-3; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Haass NK, 2014, PIGM CELL MELANOMA R, DOI [10.1111/pcmr.12274, DOI 10.1111/PCMR.12274)]; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu SH, 2008, PIGM CELL MELANOMA R, V21, P545, DOI 10.1111/j.1755-148X.2008.00484.x; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Perez-Lorenzo R, 2014, J INVEST DERMATOL, V134, P1359, DOI 10.1038/jid.2013.511; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Somasundaram R, 2012, ADV PHARMACOL, V65, P335, DOI 10.1016/B978-0-12-397927-8.00011-7; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Thurber AE, 2011, ONCOGENE, V30, P3036, DOI 10.1038/onc.2011.33; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x	31	60	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3251	3263		10.1038/onc.2014.262	http://dx.doi.org/10.1038/onc.2014.262			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132268				2022-12-17	WOS:000356592300004
J	Du, L; Zhao, Z; Ma, X; Hsiao, TH; Chen, Y; Young, E; Suraokar, M; Wistuba, I; Minna, JD; Pertsemlidis, A				Du, L.; Zhao, Z.; Ma, X.; Hsiao, T-H; Chen, Y.; Young, E.; Suraokar, M.; Wistuba, I.; Minna, J. D.; Pertsemlidis, A.			miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer	ONCOGENE			English	Article						DAB2; miRNA; miR-93; lung cancer	TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DISABLED-2 EXPRESSION; GASTRIC-CANCER; CELL-GROWTH; MICRORNAS; MIR-93; PROTEIN	The disabled homolog 2 (DAB2) gene was recently identified as a tumor suppressor gene with its expression downregulated in multiple cancer types. The role of DAB2 in lung tumorigenesis, however, is not fully characterized, and the mechanisms of DAB2 dysregulation in lung cancer are not defined. Here we show that low DAB2 levels in lung tumor specimens are significantly correlated with poor patient survival, and that DAB2 overexpression significantly inhibits cell growth in cultured lung cancer cells, indicating its potent tumor suppressor function. We next identify that microRNA miR-93 functions as a potent repressor of DAB2 expression by directly targeting the 3'UTR of the DAB2 mRNA. Using in vitro and in vivo approaches, we demonstrate that miR-93 overexpression has an important role in promoting lung cancer cell growth, and that its oncogenic function is primarily mediated by downregulating DAB2 expression. Our clinical investigations further indicate that high tumor levels of miR-93 are correlated with poor survival of lung cancer patients. The correlations of both low DAB2 and high miR-93 expression levels with poor patient survival strongly support the critical role of the miR-93/DAB2 pathway in determining lung cancer progression.	[Du, L.; Zhao, Z.; Ma, X.; Hsiao, T-H; Chen, Y.; Young, E.; Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Du, L.; Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Chen, Y.] UT Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Suraokar, M.; Wistuba, I.] UT MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA; [Wistuba, I.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA; [Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio	Du, L (corresponding author), UT Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC 7784, San Antonio, TX 78229 USA.	dul2@uthscsa.edu; pertsemlidis@uthscsa.edu	Pertsemlidis, Alexander/Q-7899-2017	Pertsemlidis, Alexander/0000-0003-1624-9372	Lung Cancer SPORE from NCI [P50 CA70907]; Department of Defense [W81XWH-07-1-0306]; Sun Microsystems [EDUD-7824-021007-US]; Cancer Center [P30 CA054174, P30 CA142543, P30 CA016672];  [R01 CA129632]; NATIONAL CANCER INSTITUTE [P30CA016672, P30CA054174, R01CA129632, P30CA142543, P50CA070907] Funding Source: NIH RePORTER	Lung Cancer SPORE from NCI; Department of Defense(United States Department of Defense); Sun Microsystems; Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Vivienne Rebel and Nicholas Dybdal-Hargreaves for critical reading of the manuscript. This work was supported in part by R01 CA129632 (A Pertsemlidis) and Lung Cancer SPORE P50 CA70907 (JD Minna and II Wistuba) from the NCI, W81XWH-07-1-0306 from the Department of Defense (II Wistuba), Academic Excellence grant EDUD-7824-021007-US (A Pertsemlidis) from Sun Microsystems and Cancer Center Support grants P30 CA054174, P30 CA142543 and P30 CA016672.	Anupam K, 2006, WORLD J GASTROENTERO, V12, P6041, DOI 10.3748/wjg.v12.i37.6041; Bagadi SAR, 2007, BREAST CANCER RES TR, V104, P277, DOI 10.1007/s10549-006-9422-6; Borchert GM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-347; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; CARNEY DN, 1985, SEMIN ONCOL, V12, P289; CARNEY DN, 1982, CLIN CHEST MED, V3, P389; Chao A, 2012, ONCOGENE, V31, P764, DOI 10.1038/onc.2011.269; Chuang TD, 2012, MOL ENDOCRINOL, V26, P1028, DOI 10.1210/me.2012-1075; Du LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039167; Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Karam JA, 2007, CLIN CANCER RES, V13, P4400, DOI 10.1158/1078-0432.CCR-07-0287; Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kluiver J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029275; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168; Mayorga ME, 2012, J CELL MOL MED, V16, P1106, DOI 10.1111/j.1582-4934.2011.01385.x; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Prudkin L, 2008, CLIN CANCER RES, V14, P41, DOI 10.1158/1078-0432.CCR-07-1252; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Wang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043268; Wang ZZ, 2010, INT J ONCOL, V37, P1315, DOI 10.3892/ijo_00000783; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Xu HT, 2013, APMIS, V121, P111, DOI 10.1111/j.1600-0463.2012.02946.x; Xu HT, 2011, HUM PATHOL, V42, P1491, DOI 10.1016/j.humpath.2011.01.004; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036; Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481	42	60	65	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4307	4315		10.1038/onc.2013.381	http://dx.doi.org/10.1038/onc.2013.381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24037530	Green Accepted, Bronze			2022-12-17	WOS:000341156900004
J	Ducker, GS; Atreya, CE; Simko, JP; Hom, YK; Matli, MR; Benes, CH; Hann, B; Nakakura, EK; Bergsland, EK; Donner, DB; Settleman, J; Shokat, KM; Warren, RS				Ducker, G. S.; Atreya, C. E.; Simko, J. P.; Hom, Y. K.; Matli, M. R.; Benes, C. H.; Hann, B.; Nakakura, E. K.; Bergsland, E. K.; Donner, D. B.; Settleman, J.; Shokat, K. M.; Warren, R. S.			Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors	ONCOGENE			English	Article						mTOR; colon cancer; PIK3CA; KRAS; xenograft; PP242	RENAL-CELL CARCINOMA; COLORECTAL-CANCER; KINASE INHIBITORS; BINDING PARTNER; PIK3CA MUTATION; GROWTH-CONTROL; COLON-CANCER; LUNG-CANCER; IN-VITRO; RAPAMYCIN	The mammalian target of rapamycin (mTOR) regulates cell growth by integrating nutrient and growth factor signaling and is strongly implicated in cancer. But mTOR is not an oncogene, and which tumors will be resistant or sensitive to new adenosine triphosphate (ATP) competitive mTOR inhibitors now in clinical trials remains unknown. We screened a panel of over 600 human cancer cell lines to identify markers of resistance and sensitivity to the mTOR inhibitor PP242. RAS and phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutations were the most significant genetic markers for resistance and sensitivity to PP242, respectively; colon origin was the most significant marker for resistance based on tissue type. Among colon cancer cell lines, those with KRAS mutations were most resistant to PP242, whereas those without KRAS mutations most sensitive. Surprisingly, cell lines with co-mutation of PIK3CA and KRAS had intermediate sensitivity. Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6). In a tumor growth inhibition trial of PP242 in patient-derived colon cancer xenografts, resistance to PP242-induced inhibition of 4E-BP1 phosphorylation and xenograft growth was again observed in KRAS mutant tumors without PIK3CA co-mutation, compared with KRAS wild-type controls. We show that, in the absence of PIK3CA co-mutation, KRAS mutations are associated with resistance to PP242 and that this is specifically linked to changes in the level of phosphorylation of 4E-BP1.	[Ducker, G. S.; Shokat, K. M.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Atreya, C. E.; Bergsland, E. K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Simko, J. P.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Hom, Y. K.; Hann, B.] Univ Calif San Francisco, Preclin Therapeut Core, San Francisco, CA 94143 USA; [Hom, Y. K.; Matli, M. R.; Hann, B.; Nakakura, E. K.; Donner, D. B.; Shokat, K. M.; Warren, R. S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Matli, M. R.; Nakakura, E. K.; Donner, D. B.; Warren, R. S.] Univ Calif San Francisco, Dept Surg, Sect Surg Oncol, San Francisco, CA 94115 USA; [Benes, C. H.; Settleman, J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; [Shokat, K. M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA; [Shokat, K. M.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 E 16th St,MC 2280, San Francisco, CA 94158 USA.	shokat@cmp.ucsf.edu; robert.warren@ucsfmedctr.org		Ducker, Gregory/0000-0002-8651-6846	American Cancer Society Postdoctoral Fellowship [11-183-TBG]; Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation; Littlefield Trust; Howard Hughes Medical Institute; Waxman Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001987] Funding Source: NIH RePORTER	American Cancer Society Postdoctoral Fellowship(American Cancer Society); Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation; Littlefield Trust; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Waxman Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Dan Moore for his critical assistance in the statistical analysis, Sandy Devries for FISH analysis, Katherine Pogue-Guile for permission to use the ColoCarta oligonucleotide primer design files and Morris Feldman, Jon Ostrem and Iana Serafimova for reagents. CEA is supported in part by American Cancer Society Postdoctoral Fellowship 11-183-TBG; she also acknowledges support Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation. RSW is supported in part by a charitable donation from the Littlefield 2000 Trust. KMS is supported by the Howard Hughes Medical Institute and the Waxman Foundation.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Atreya CE, 2012, INVEST NEW DRUG, V30, P2219, DOI 10.1007/s10637-012-9793-y; Barrett SD, 2008, BIOORG MED CHEM LETT, V18, P6501, DOI 10.1016/j.bmcl.2008.10.054; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Blaser B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-86; Bohanes P, 2011, SEMIN ONCOL, V38, P576, DOI 10.1053/j.seminoncol.2011.05.012; Brough R, 2011, CURR OPIN GENET DEV, V21, P34, DOI 10.1016/j.gde.2010.10.009; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fumagalli D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-101; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; House MG, 2010, J AM COLL SURGEONS, V210, P744, DOI 10.1016/j.jamcollsurg.2009.12.040; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Janku F, 2013, CANCER RES, V73, P276, DOI 10.1158/0008-5472.CAN-12-1726; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Le NT, 2012, CIRC RES, V110, P536, DOI 10.1161/CIRCRESAHA.111.254730; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pinheiro J., 2006, MIXED EFFECT MODELS; Rong L, 2008, RNA, V14, P1318, DOI 10.1261/rna.950608; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zunder ER, 2008, CANCER CELL, V14, P180, DOI 10.1016/j.ccr.2008.06.014	56	60	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1590	1600		10.1038/onc.2013.92	http://dx.doi.org/10.1038/onc.2013.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23542178	Green Accepted, Green Submitted			2022-12-17	WOS:000333244200012
J	Higgs, MR; Lerat, H; Pawlotsky, JM				Higgs, M. R.; Lerat, H.; Pawlotsky, J-M			Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events	ONCOGENE			English	Article						hepatitis C virus; hepatocellular carcinoma; c-Myc; oxidative stress; DNA damage; NS5A protein	HEPATOCELLULAR-CARCINOMA; DNA-DAMAGE; MITOCHONDRIAL BIOGENESIS; ROS PRODUCTION; TARGET GENES; PROTEIN; MICE; IDENTIFICATION; NS5A; P53	Chronic infection by hepatitis C virus (HCV) is a major risk factor for the onset and development of hepatocellular carcinoma (HCC), although the underlying mechanisms are unclear. The c-Myc oncogene contributes to the genesis of many types of cancers, including HCC, partly via the induction of genetic damage and the inhibition of the cellular response to genotoxic stress. Here, we show a previously undiscovered mechanistic link between HCV infection and enhanced c-Myc expression. c-Myc expression was augmented in non-tumoral liver tissues from HCV-infected individuals with or without HCC and in hepatocyte cell lines harboring an HCV replicon and the infectious HCV strain JFH1. Increased c-Myc expression was confirmed in vivo in a transgenic murine model expressing the entire HCV open reading frame, demonstrating a direct role for HCV protein expression in c-Myc induction. Mechanistically, activation of Akt by the HCV non-structural protein NS5A, and the subsequent stabilization of the transcription factor beta-catenin, was demonstrated to be responsible for activation of the c-Myc promoter, and for increased c-Myc transcription. beta-Catenin-dependent c-Myc expression in this context led to increased production of reactive oxygen species, mitochondrial perturbation, enhanced DNA damage and aberrant cell-cycle arrest. Together, these data provide a novel insight into the mechanisms involved in HCV-associated HCCs, strongly suggesting that c-Myc has a crucial contributory role in this process.	[Higgs, M. R.; Lerat, H.; Pawlotsky, J-M] Inst Mondor Rech Biomed, INSERM, U955, Creteil, France; [Pawlotsky, J-M] Univ Paris Est, Hop Henri Mondor, Dept Virol, Natl Reference Ctr Viral Hepatitis B C & Delta, Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Pawlotsky, JM (corresponding author), Hop Henri Mondor, Dept Virol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	jean-michel.pawlotsky@hmn.aphp.fr	Pawlotsky, Jean-Michel/R-8159-2018; Higgs, Martin/AAK-2108-2021; LERAT, Hervé/D-4331-2019	Higgs, Martin/0000-0002-8218-0089; LERAT, Hervé/0000-0002-8505-378X; Pawlotsky, Jean-Michel/0000-0003-0745-7559	Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS); ANRS	Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); ANRS(ANRSFrench National Research Agency (ANR))	This work was supported by a research grant from the Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS). MH was supported by a postdoctoral fellowship from the ANRS. We thank Aurore Gaudin and Olivier Gouin for technical assistance; Christine Perret and Thomas Decaens for manuscript comments; Czeslaw Wychowski, Bert Vogelstein and Xi He for JFH-1-infected cultures, pDEL1 and DKK1, respectively; Mark Harris for the NS5A antibody; Paulette Bioulac-Sage for patient biopsies; and Ralf Bartenschlager for the HCV genotype 1b subgenomic replicon, established in our laboratory by Abdelhakim Ahmed-Belkacem.	AbouElella A, 1996, MODERN PATHOL, V9, P95; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Cadoret A, 2001, CANCER RES, V61, P3245; Dang CV, 2005, CELL CYCLE, V4, P1465, DOI 10.4161/cc.4.11.2121; Disson O, 2004, GASTROENTEROLOGY, V126, P859, DOI 10.1053/j.gastro.2003.12.005; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Farinati F, 2007, J VIRAL HEPATITIS, V14, P821, DOI 10.1111/1365-2893.2007.00878.x; GAN FY, 1993, J HISTOCHEM CYTOCHEM, V41, P1185, DOI 10.1177/41.8.7687263; Garcia-Mediavilla MV, 2005, J HEPATOL, V43, P606, DOI 10.1016/j.jhep.2005.04.019; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Higgs MR, 2010, CANCER RES, V70, P4901, DOI 10.1158/0008-5472.CAN-09-4554; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kato J, 2001, CANCER RES, V61, P8697; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Keasler VV, 2006, VIROLOGY, V347, P466, DOI 10.1016/j.virol.2005.11.050; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 2011, EXPERT REV GASTROENT, V5, P341, DOI [10.1586/egh.11.14, 10.1586/EGH.11.14]; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li YC, 2007, FASEB J, V21, P2474, DOI 10.1096/fj.06-7345com; Machida K, 2006, J VIROL, V80, P7199, DOI 10.1128/JVI.00321-06; McGivern DR, 2011, ONCOGENE, V30, P1969, DOI 10.1038/onc.2010.594; McGivern DR, 2009, ANNU REV PATHOL-MECH, V4, P399, DOI 10.1146/annurev.pathol.4.110807.092202; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Meuleman P, 2008, ANTIVIR RES, V80, P231, DOI 10.1016/j.antiviral.2008.07.006; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Milward A, 2010, J GEN VIROL, V91, P373, DOI 10.1099/vir.0.015305-0; Mitchell C, 2009, AM J PATHOL, V175, P1929, DOI 10.2353/ajpath.2009.090332; Neiman PE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000132; Nishina S, 2008, GASTROENTEROLOGY, V134, P226, DOI 10.1053/j.gastro.2007.10.011; Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5; Park CY, 2009, J HEPATOL, V51, P853, DOI 10.1016/j.jhep.2009.06.026; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Rebouissou S, 2008, J HEPATOL, V48, P163, DOI [10.1016/j.jhep.2007.10.003, 10.1016/j.jhep.2008.02.001]; SAEGUSA M, 1993, J CANCER RES CLIN, V119, P737, DOI 10.1007/BF01195346; Sagun KC, 2006, MUTAT RES-FUND MOL M, V593, P64, DOI 10.1016/j.mrfmmm.2005.06.015; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Si YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019967; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; Simonin Y, 2009, HEPATOLOGY, V50, P1370, DOI 10.1002/hep.23169; Stewart B.W., 2003, WORLD CANC REPORT; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Yochum GS, 2007, P NATL ACAD SCI USA, V104, P3324, DOI 10.1073/pnas.0611576104; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874; Zhang Y, 2012, HEPATOLOGY IN PRESS	61	60	62	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4683	4693		10.1038/onc.2012.484	http://dx.doi.org/10.1038/onc.2012.484			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108410				2022-12-17	WOS:000325072200010
J	Nguyen, HB; Babcock, JT; Wells, CD; Quilliam, LA				Nguyen, H. B.; Babcock, J. T.; Wells, C. D.; Quilliam, L. A.			LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap	ONCOGENE			English	Article						LKB1; Yap; Hippo; polarity; growth	HIPPO SIGNALING PATHWAY; LUNG-CANCER; ORGAN SIZE; ACTIVATION; PROTEIN; TRANSCRIPTION; APOPTOSIS; POLARITY; ACTS; GENE	The liver kinase B1 (LKB1) tumor suppressor inhibits cell growth through its regulation of cellular metabolism and apical-basal polarity. The best understood mechanism whereby LKB1 limits cell growth is through activation of the AMP-activated-protein-kinase/mammalian-target-of-rapamycin (AMPK/mTOR) pathway to control metabolism. As LKB1 is also required for polarized epithelial cells to resist hyperplasia, it is anticipated to function through additional mechanisms. Recently, Yes-associated protein (Yap) has emerged as a transcriptional co-activator that modulates tissue homeostasis in response to cell-cell contact. Thus this study examined a possible connection between Yap and LKB1. Restoration of LKB1 expression in HeLa cells, which lack this tumor suppressor, or short-hairpin RNA knockdown of LKB1 in NTERT immortalized keratinocytes, demonstrated that LKB1 promotes Yap phosphorylation, nuclear exclusion and proteasomal degradation. The ability of phosphorylation-defective Yap mutants to rescue LKB1 phenotypes, such as reduced cell proliferation and cell size, suggest that Yap inhibition contributes to LKB1 tumor suppressor function(s). However, failure of Lats1/2 knockdown to suppress LKB1-mediated Yap regulation suggested that LKB1 signals to Yap via a non-canonical pathway. Additionally, LKB1 inhibited Yap independently of either AMPK or mTOR activation. These findings reveal a novel mechanism whereby LKB1 may restrict cancer cell growth via the inhibition of Yap.	[Nguyen, H. B.; Babcock, J. T.; Wells, C. D.; Quilliam, L. A.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Quilliam, LA (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, MS 4075,635 Barnhill Dr, Indianapolis, IN 46202 USA.	lquillia@iupui.edu			US Department of Defense [W81XWH1110355]; LAM Foundation; IUPUI; NATIONAL CANCER INSTITUTE [R01CA151765] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); LAM Foundation; IUPUI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dan Spandau for NTERT cells, Jacob Adler and Bill Ranahan for experimental advice. This work was supported by US Department of Defense award W81XWH1110355, the LAM Foundation and a research support funds grant from IUPUI to LAQ.	Asuri S, 2008, J CELL BIOCHEM, V105, P1027, DOI 10.1002/jcb.21902; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bao YJ, 2011, J BIOCHEM, V150, P199, DOI 10.1093/jb/mvr063; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Granot Z, 2009, CELL METAB, V10, P296, DOI 10.1016/j.cmet.2009.08.010; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Heller B, 2010, J BIOL CHEM, V285, P12308, DOI 10.1074/jbc.M109.096230; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Ranahan WP, 2011, CANCER RES, V71, P2203, DOI 10.1158/0008-5472.CAN-10-1995; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zong H, 2001, MOL CELL BIOL, V21, P5287, DOI 10.1128/MCB.21.16.5287-5298.2001	45	60	67	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4100	4109		10.1038/onc.2012.431	http://dx.doi.org/10.1038/onc.2012.431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027127	Green Accepted			2022-12-17	WOS:000323748500005
J	Yang, Y; Zhou, L; Lu, L; Wang, L; Li, X; Jiang, P; Chan, LKY; Zhang, T; Yu, J; Kwong, J; Cheung, T; Chung, T; Mak, K; Sun, H; Wang, H				Yang, Y.; Zhou, L.; Lu, L.; Wang, L.; Li, X.; Jiang, P.; Chan, L. K. Y.; Zhang, T.; Yu, J.; Kwong, J.; Cheung, T. H.; Chung, T.; Mak, K.; Sun, H.; Wang, H.			A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma	ONCOGENE			English	Article						YY1; EEC; APC; EZH2; H3K27me3; microRNA	YIN YANG 1; SKELETAL MYOGENESIS; TUMOR-SUPPRESSOR; CATENIN PATHWAY; DNA METHYLATION; CANCER; MICRORNAS; PATHOGENESIS; DISEASE; BIOLOGY	Aberrant expression and altered function of transcription factors (TFs) have vital roles in many aspects of tumor development and progression. In this study, we investigated the functional significance of a TF, Yin Yang1 (YY1) in tumorigenesis of endometrioid endometrial carcinoma (EEC). We demonstrated that YY1 is upregulated in EEC cell lines and primary tumors; and its expression is associated with tumor stages. Depletion of YY1 inhibits EEC cell proliferation and migration both in vitro and in vivo, whereas overexpression of YY1 promotes EEC cell growth. These results suggest that YY1 functions as an oncogenic factor in EEC. Transcriptome analysis revealed a significant effect of YY1 on critical aspects of EEC tumorigenesis through inhibition of APC expression. Further mechanistic investigation uncovered a new epigenetic silencing mode of APC by YY1 through recruitment of EZH2 and trimethylation of histone 3 lysine 27 on its promoter region. Moreover, YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay. Our results therefore establish a novel miR-193a-5p-YY1-APC axis, which contributes to EEC development, and may serve as future intervention target.	[Yang, Y.; Zhou, L.; Wang, L.; Chan, L. K. Y.; Zhang, T.; Kwong, J.; Cheung, T. H.; Chung, T.; Wang, H.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Yang, Y.; Zhou, L.; Lu, L.; Wang, L.; Li, X.; Jiang, P.; Chan, L. K. Y.; Zhang, T.; Yu, J.; Kwong, J.; Sun, H.; Wang, H.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Lu, L.; Jiang, P.; Sun, H.] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; [Li, X.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Li, X.; Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mak, K.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wang, H (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci 507A, Hong Kong, Hong Kong, Peoples R China.	huating.wang@cuhk.edu.hk	Wang, Huating/C-6719-2014; Yu, Jun/D-8569-2015; Zhou, Liang/P-4174-2015; Zhang, Tao/ADM-1606-2022; JIANG, Peiyong/AAZ-9898-2020; Sun, Hao/J-9964-2013; sun, hao/GRS-7732-2022; Kwong, Joseph/H-2368-2013; Sun, Hao/T-5576-2019; Li, Xiao-xing/B-9114-2008	Wang, Huating/0000-0001-5474-2905; Yu, Jun/0000-0001-5008-2153; Zhou, Liang/0000-0001-5973-7873; Zhang, Tao/0000-0002-8644-8468; Sun, Hao/0000-0002-5547-9501; Kwong, Joseph/0000-0002-3380-6882; Sun, Hao/0000-0002-5547-9501; Li, Xiao-xing/0000-0001-8791-7505; CHUNG, Tony/0000-0002-6362-8546; Jiang, Peiyong/0000-0003-4523-3476; Mak, Kingston King-Lun/0000-0002-4733-9146	Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China [CUHK476309, CUHK476310, CUHK473211]; CUHK direct grants [2041474, 2041492, 2041662]	Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK direct grants	The work described in this paper was substantially supported by three General Research Funds (GRFs) from Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China (CUHK476309 and CUHK476310 to HW, and CUHK473211 to HS), and three CUHK direct grants (2041474 to HS and 2041492 and 2041662 to HW).	Aguilera Oscar, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P13; Andl CD, 2010, J ONCOL, V2010, DOI 10.1155/2010/174715; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boren T, 2008, GYNECOL ONCOL, V110, P206, DOI 10.1016/j.ygyno.2008.03.023; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chung TKH, 2009, INT J CANCER, V124, P1358, DOI 10.1002/ijc.24071; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Knuutila S, 1998, AM J PATHOL, V152, P1107; Ko CY, 2008, J BIOL CHEM, V283, P30919, DOI 10.1074/jbc.M804029200; Lu LN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027596; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nebert DW, 2002, TOXICOLOGY, V181, P131, DOI 10.1016/S0300-483X(02)00269-X; Pan Q, 2008, SEMIN REPROD MED, V26, P479, DOI 10.1055/s-0028-1096128; RICHARDSON GS, 1984, GYNECOL ONCOL, V17, P213, DOI 10.1016/0090-8258(84)90080-5; SUI G, 2009, MOL CELL PHARM, V1, P157, DOI DOI 10.4255/MCPHARMACOL.09.20; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wang H, 2009, CELL CYCLE, V8, P1833, DOI 10.4161/cc.8.12.8851; Wang LJ, 2012, MOL THER, V20, P1222, DOI 10.1038/mt.2012.35; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zaravinos A, 2010, CELL CYCLE, V9, P512, DOI 10.4161/cc.9.3.10588; Zysman M, 2002, CANCER RES, V62, P3663	32	60	66	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3432	3442		10.1038/onc.2012.360	http://dx.doi.org/10.1038/onc.2012.360			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22907428				2022-12-17	WOS:000322014900004
J	Li, B; Wang, C; Zhang, Y; Zhao, XY; Huang, B; Wu, PF; Li, Q; Li, H; Liu, YS; Cao, LY; Dai, WM; Fang, WG; Shang, DS; Cao, L; Zhao, WD; Chen, YH				Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Huang, B.; Wu, P. F.; Li, Q.; Li, H.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Cao, L.; Zhao, W. D.; Chen, Y. H.			Elevated PLGF contributes to small-cell lung cancer brain metastasis	ONCOGENE			English	Article						blood-brain barrier; brain metastasis; PLGF; Rho kinase; small-cell lung cancer	ENDOTHELIAL GROWTH-FACTOR; TIGHT JUNCTION PROTEINS; BREAST-CANCER; VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY; KINASE; OCCLUDIN; BARRIER; PHOSPHORYLATION; ACTIVATION	Brain metastasis (BM) is a major cause of mortality in small-cell lung cancer (SCLC) patients; however, the molecular pathway of SCLC BM remains largely unknown because of a lack of investigation. Here we screen the levels of some candidate-soluble factors in the serum of SCLC patients and find that SCLC patients with high levels of placental growth factor (PLGF) are prone to BM. Using in vitro blood-brain barrier model, we show that PLGF derived from SCLC cells triggers vascular endothelial growth factor receptor1- Rho-extracellular regulated protein kinase 1/2 signaling axis activation, results in disassembly of tight junction in brain endothelial cells and promotes SCLC cell transendothelial migration. Furthermore, the downregulation of PLGF suppresses SCLC cell metastasis to the brain in an experimental BM model. These data suggest that PLGF is a potential signature of SCLC BM and a prospective therapeutic target for SCLC BM.	[Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Zhao, W. D.; Chen, Y. H.] China Med Univ, Dept Dev Biol, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110001, Peoples R China; [Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Cao, L.; Zhao, W. D.; Chen, Y. H.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Wang, C.] Liaoning Univ Tradit Chinese Med, Dept Cell Biol, Shenyang, Peoples R China; [Zhao, X. Y.] Shenyang Pharmaceut Univ, Dept Cell Biol, Shenyang, Peoples R China; [Huang, B.] Liaoning Canc Hosp & Inst, Dept Pathol, Shenyang, Peoples R China; [Wu, P. F.] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China; [Li, Q.] China Med Univ, Shengjing Hosp, Dept Med Examinat, Shenyang 110001, Peoples R China; [Li, H.] China Med Univ, Shengjing Hosp, Dept Geriatr Med, Shenyang 110001, Peoples R China; [Cao, L.] China Med Univ, Minist Educ, Minist Publ Hlth, Inst Translat Med,Key Lab Cell Biol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; Liaoning University of Traditional Chinese Medicine; Shenyang Pharmaceutical University; China Medical University; China Medical University; China Medical University; China Medical University	Chen, YH (corresponding author), China Med Univ, Dept Dev Biol, Minist Publ Hlth, Key Lab Cell Biol, 92 Bei Er Rd, Shenyang 110001, Peoples R China.	yhchen@mail.cmu.edu.cn	Liu, Yongshuo/GRX-6416-2022	Liu, Yongshuo/0000-0001-8190-0139	Trans-Century Training Program Foundation for Talents; Ministry of Education of China [JJH2002-48]; Innovation Team Program Foundation of Liaoning Province [2006T131, LT2011011]; National Natural Science Foundation of China [30600270]; Science and Technology Foundation of Liaoning Province [20102291]	Trans-Century Training Program Foundation for Talents; Ministry of Education of China(Ministry of Education, China); Innovation Team Program Foundation of Liaoning Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Liaoning Province	We are grateful to Drs Monique Stins and Kwang Sik Kim (Department of Pediatrics, John Hopkins University School of Medicine) for providing HBMEC and Dr Shuh Narumiya (Kyoto University Faculty of Medicine, Kyoto, Japan) for providing pCAGmyc, pCAG-myc-ROCK-WT and pCAG-myc-ROCK-KDIA. This work was supported by the Trans-Century Training Program Foundation for Talents, Ministry of Education of China (JJH2002-48), the Innovation Team Program Foundation of Liaoning Province (2006T131, LT2011011), the National Natural Science Foundation of China (30600270) and the Science and Technology Foundation of Liaoning Province (20102291).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Carbonell WS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005857; CARNEY DN, 1985, CANCER RES, V45, P2913; Casalou C, 2007, LEUKEMIA, V21, P1590, DOI 10.1038/sj.leu.2404668; Castrucci WA, 2008, CANCER J, V14, P138, DOI 10.1097/PPO.0b013e318172d6e1; Chen CN, 2004, CANCER LETT, V213, P73, DOI 10.1016/j.canlet.2004.05.020; Chen JF, 2008, J CELL BIOCHEM, V105, P313, DOI 10.1002/jcb.21831; Cipolla MJ, 2004, FRONT BIOSCI-LANDMRK, V9, P777, DOI 10.2741/1282; Clarke H, 2000, J CELL SCI, V113, P3187; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Dowell JE, 2010, AM J MED SCI, V339, P68, DOI 10.1097/MAJ.0b013e3181bccef5; Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001; FUJIMAKI T, 1993, INT J ONCOL, V3, P789; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Khan NA, 2009, INT J PARASITOL, V39, P1611, DOI 10.1016/j.ijpara.2009.06.004; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lee BC, 2004, MOL CANCER RES, V2, P327; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Li M, 2009, J IMMUNOL, V182, P5778, DOI 10.4049/jimmunol.0803013; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Meyer TN, 2003, AM J PHYSIOL-CELL PH, V285, pC1281, DOI 10.1152/ajpcell.00548.2002; Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Phelps RM, 1996, J CELL BIOCHEM, P32; Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4; Rottbauer W, 2005, GENE DEV, V19, P1624, DOI 10.1101/gad.1319405; Schreurs MPH, 2012, FASEB J, V26, P355, DOI 10.1096/fj.11-191916; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Taylor AP, 2010, BRIT J CANCER, V103, P82, DOI 10.1038/sj.bjc.6605746; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Vogel C, 2007, J CELL PHYSIOL, V212, P236, DOI 10.1002/jcp.21022; Wang X, 2011, BIOCHEM BIOPH RES CO, V410, P258, DOI 10.1016/j.bbrc.2011.05.128; Wei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831; Willis CL, 2010, J CEREBR BLOOD F MET, V30, P1847, DOI 10.1038/jcbfm.2010.119; Zhang CY, 2009, CANCER RES, V69, P828, DOI 10.1158/0008-5472.CAN-08-2588; Zhao WD, 2010, INFECT IMMUN, V78, P4809, DOI 10.1128/IAI.00377-10	47	60	66	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2952	2962		10.1038/onc.2012.313	http://dx.doi.org/10.1038/onc.2012.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797069				2022-12-17	WOS:000320369700005
J	Yin, G; Alvero, AB; Craveiro, V; Holmberg, JC; Fu, HH; Montagna, MK; Yang, Y; Chefetz-Menaker, I; Nuti, S; Rossi, M; Silasi, DA; Rutherford, T; Mor, G				Yin, G.; Alvero, A. B.; Craveiro, V.; Holmberg, J. C.; Fu, H-H; Montagna, M. K.; Yang, Y.; Chefetz-Menaker, I.; Nuti, S.; Rossi, M.; Silasi, D-A; Rutherford, T.; Mor, G.			Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential	ONCOGENE			English	Article						TWIST-1; ovarian cancer stem cells; ovarian cancer; metastasis; recurrence	TO-MESENCHYMAL TRANSITION; SIDE POPULATION; ACTIVATION; EXPRESSION; BREAST; IDENTIFICATION; PATHOGENESIS; MECHANISMS; APOPTOSIS; HYPOXIA	Epithelial-mesenchymal transition (EMT) is a critical process for embryogenesis but is abnormally activated during cancer metastasis and recurrence. This process enables epithelial cancer cells to acquire mobility and traits associated with stemness. It is unknown whether epithelial stem cells or epithelial cancer stem cells are able to undergo EMT, and what molecular mechanism regulates this process in these specific cell types. We found that epithelial-ovarian cancer stem cells (EOC stem cells) are the source of metastatic progenitor cells through a differentiation process involving EMT and mesenchymal-epithelial transition (MET). We demonstrate both in vivo and in vitro the differentiation of EOC stem cells into mesenchymal spheroid-forming cells (MSFCs) and their capacity to initiate an active carcinomatosis. Furthermore, we demonstrate that human EOC stem cells injected intraperitoneally in mice are able to form ovarian tumors, suggesting that the EOC stem cells have the ability to 'home' to the ovaries and establish tumors. Most interestingly, we found that TWIST-1 is constitutively degraded in EOC stem cells, and that the acquisition of TWIST-1 requires additional signals that will trigger the differentiation process. These findings are relevant for understanding the differentiation and metastasis process in EOC stem cells. Oncogene (2013) 32, 39-49; doi:10.1038/onc.2012.33; published online 20 February 2012	[Yin, G.; Alvero, A. B.; Craveiro, V.; Holmberg, J. C.; Fu, H-H; Montagna, M. K.; Yang, Y.; Chefetz-Menaker, I.; Nuti, S.; Rossi, M.; Silasi, D-A; Rutherford, T.; Mor, G.] Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA	Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu	Chefetz, Ilana/K-7589-2019; Yang-Hartwich, Yang/B-3489-2015	Alvero, Ayesha/0000-0002-6593-3595; Holmberg, Jennie/0000-0002-1106-4718	NCI/NIH [RO1CA127913, RO1CA118678]; Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; Brozman Foundation; NATIONAL CANCER INSTITUTE [R01CA112016, R01CA127913, R01CA118678, F32CA130472, R01CA111782] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; Brozman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros Memorial Foundation, The Sands Family Foundation and the Discovery To Cure Research Program. GY was supported by the Brozman Foundation. Special thanks to Dr Ernst-Martin Fuchtbauer for the plasmids, pEMSV, pEMSV-TWIST1 and pEMSV-E12; and to Dr Wange Lu for the plasmid pFUIGW.	Abrahams VM, 2003, CANCER RES, V63, P5573; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Alison MR, 2008, CELL TISSUE RES, V331, P109, DOI 10.1007/s00441-007-0510-7; Alix-Panabieres C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2326; Alvero AB, 2011, MOL CANCER THER, V10, P1385, DOI 10.1158/1535-7163.MCT-11-0023; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bechtel W, 2009, KIDNEY INT, V75, P1255, DOI 10.1038/ki.2009.102; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Carambula SF, 2002, ENDOCRINOLOGY, V143, P1495, DOI 10.1210/en.143.4.1495; Chaffer CL, 2007, DIFFERENTIATION, V75, P831, DOI 10.1111/j.1432-0436.2007.00210.x; CHAMBERS JT, 1986, GYNECOL ONCOL, V23, P346, DOI 10.1016/0090-8258(86)90136-8; Chefetz I, 2011, CELL CYCLE, V10, P2206, DOI 10.4161/cc.10.13.16348; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Curley MD, 2011, FRONT BIOSCI-LANDMRK, V16, P368, DOI 10.2741/3693; Curley MD, 2009, STEM CELLS, V27, P2875, DOI 10.1002/stem.236; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gao QL, 2009, ULTRASTRUCT PATHOL, V33, P175, DOI 10.1080/01913120903086072; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Green JM, 2009, CANCER BIOL THER, V8, P1747, DOI 10.4161/cbt.8.18.9285; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Horbinski C, 2010, AM J PATHOL, V177, P1044, DOI 10.2353/ajpath.2010.091270; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Koga K, 2009, AM J REPROD IMMUNOL, V61, P196, DOI 10.1111/j.1600-0897.2008.00682.x; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laursen KB, 2007, J BIOL CHEM, V282, P34623, DOI 10.1074/jbc.M707085200; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mor G, 2011, CANCER BIOL THER, V11, P708, DOI 10.4161/cbt.11.8.14967; Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341; Mutch DG, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31589; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Radisky Derek C, 2008, Proc Am Thorac Soc, V5, P316, DOI 10.1513/pats.200711-166DR; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Shih IM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.08.003; Shintani Y, 2008, AM J RESP CELL MOL, V38, P95, DOI 10.1165/rcmb.2007-0071OC; Steffensen KD, 2011, J ONCOL, V2011, DOI 10.1155/2011/620523; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Visintin I, 2008, CLIN CANCER RES, V14, P1065, DOI 10.1158/1078-0432.CCR-07-1569; Watanabe O, 2004, ANTICANCER RES, V24, P3851; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	64	60	64	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					39	49		10.1038/onc.2012.33	http://dx.doi.org/10.1038/onc.2012.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349827	Green Accepted			2022-12-17	WOS:000313029500004
J	Niemela, M; Kauko, O; Sihto, H; Mpindi, JP; Nicorici, D; Pernila, P; Kallioniemi, OP; Joensuu, H; Hautaniemi, S; Westermarck, J				Niemela, M.; Kauko, O.; Sihto, H.; Mpindi, J-P; Nicorici, D.; Pernila, P.; Kallioniemi, O-P; Joensuu, H.; Hautaniemi, S.; Westermarck, J.			CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes	ONCOGENE			English	Article						KIAA1524; breast cancer; gene expression profile; PLAUR; SERPINE2; PP2A B-subunit	C-MYC; EXPRESSION SIGNATURE; PP2A COMPLEXES; IDENTIFICATION; AMPLIFICATION; METAANALYSIS; CARCINOMA; APOPTOSIS; VARIANCE	Protein phosphatase 2A (PP2A) is a critical human tumor-suppressor complex. A recently characterized PP2A inhibitor protein, namely cancerous inhibitor of PP2A (CIP2A), has been found to be overexpressed at a high frequency in most of the human cancer types. However, our understanding of gene expression programs regulated by CIP2A is almost absent. Moreover, clinical relevance of the CIP2A-regulated transcriptome has not been addressed thus far. Here, we report a high-confidence transcriptional signature regulated by CIP2A. Bioinformatic pathway analysis of the CIP2A signature revealed that CIP2A regulates several MYC-dependent and MYC-independent gene programs. With regard to MYC-independent signaling, JNK2 expression and transwell migration were inhibited by CIP2A depletion, whereas MYC depletion did not affect either of these phenotypes. Instead, depletion of either CIP2A or MYC inhibited cancer cell colony growth with statistically indistinguishable efficiency. Moreover, CIP2A depletion was shown to regulate the expression of several established MYC target genes, out of which most were MYC-repressed genes. CIP2A small-interfering RNA-elicited inhibition of colony growth or activation of MYC-repressed genes was reversed at large by concomitant PP2A inhibition. Finally, the CIP2A signature was shown to cluster with basal-type and human epidermal growth factor receptor (HER) 2-positive (HER2+) breast cancer signatures. Accordingly, CIP2A protein expression was significantly associated with basal-like (P = 0.0014) and HER2+ (P<0.0001) breast cancers. CIP2A expression also associated with MYC gene amplification (P<0.001). Taken together, identification of CIP2A-driven transcriptional signature, and especially novel MYC-independent signaling programs regulated by CIP2A, provides important resource for understanding CIP2A's role as a clinically relevant human oncoprotein. With regard to MYC, these results both validate CIP2A's role in regulating MYC-mediated gene expression and provide a plausible novel explanation for the high MYC activity in basal-like and HER2+ breast cancers. Oncogene (2012) 31, 4266-4278; doi:10.1038/onc.2011.599; published online 16 January 2012	[Westermarck, J.] Univ Turku, Ctr Biotechnol, Dept Pathol, FIN-20520 Turku, Finland; [Niemela, M.; Kauko, O.; Westermarck, J.] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Niemela, M.; Kauko, O.; Westermarck, J.] Abo Akad Univ, Turku, Finland; [Niemela, M.; Kauko, O.] Turku Grad Sch Biomed Sci, Turku, Finland; [Niemela, M.] Univ Turku, Dept Med Biochem & Genet, FIN-20520 Turku, Finland; [Sihto, H.; Pernila, P.; Joensuu, H.] Univ Helsinki, Lab Mol Oncol, Biomedicum, Helsinki, Finland; [Mpindi, J-P; Nicorici, D.; Kallioniemi, O-P; Westermarck, J.] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Hautaniemi, S.] Univ Helsinki, Res Programs Unit, Helsinki, Finland; [Hautaniemi, S.] Univ Helsinki, Inst Biomed Biochem & Dev Biol, Helsinki, Finland	University of Turku; University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Westermarck, J (corresponding author), Univ Turku, Ctr Biotechnol, Dept Pathol, Tykistokatu 6A, FIN-20520 Turku, Finland.	jukwes@utu.fi	Hautaniemi, Sampsa/CAG-0362-2022; Westermarck, Jukka/AAL-6464-2020; Sihto, Harri J/B-3432-2015; Kallioniemi, Olli P/H-5111-2011; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Westermarck, Jukka/0000-0001-7478-3018; Sihto, Harri J/0000-0001-5265-5509; Kallioniemi, Olli P/0000-0002-3231-0332; Hautaniemi, Sampsa/0000-0002-7749-2694; Nicorici, Daniel/0000-0002-0278-8263; Joensuu, Heikki/0000-0003-0281-2507	Academy of Finland [125826, 1131449, 8217676]; Sigrid Juselius Foundation; Cancer Society of Finland; Helsinki University Central Hospital [TYH2009304]; Foundation of Finnish Cancer Institute; Cancer Foundation Finland sr [120139, 110071, 120084, 110134] Funding Source: researchfish	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Helsinki University Central Hospital; Foundation of Finnish Cancer Institute; Cancer Foundation Finland sr	We thank Taina Kalevo-Mattila for expert technical assistance. Melissa R Junttila is acknowledged for PP2A assay data and Minna-Maija Lintunen for performing the FISH hybridizations. Panu Jaakkola is acknowledged for B-subunit siRNAs. The Finnish DNA Microarray centre is acknowledged for the microarray and qRT-PCR analysis. This study was supported by grants from the Academy of Finland (grant no. 125826, 1131449 and 8217676), Sigrid Juselius Foundation, the Cancer Society of Finland, Helsinki University Central Hospital Research Funds (TYH2009304) and the Foundation of Finnish Cancer Institute.	Alles MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004710; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Ben-Israel H, 2008, J VIROL, V82, P9381, DOI 10.1128/JVI.00791-08; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Choi YA, 2011, FEBS LETT, V585, P755, DOI 10.1016/j.febslet.2011.01.018; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Ioannidis JPA, 2009, NAT GENET, V41, P149, DOI 10.1038/ng.295; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Joensuu H, 2003, CLIN CANCER RES, V9, P923; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Katz J, 2010, CANCER BIOL THER, V10, P694, DOI 10.4161/cbt.10.7.12895; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075; Mannava S, 2011, ONCOGENE, DOI [10.1038/onc.2011.339, DOI 10.1038/0NC.2011.339]; Mathiasen DP, 2011, ONCOGENE, DOI [10.1038/onc.2011.230, DOI 10.1038/0NC.2011.230]; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Qu W, 2010, MED ONCOL; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sihto H, 2008, CLIN CANCER RES, V14, P4103, DOI 10.1158/1078-0432.CCR-07-5003; Vaarala MH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-136; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	43	60	60	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4266	4278		10.1038/onc.2011.599	http://dx.doi.org/10.1038/onc.2011.599			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249265				2022-12-17	WOS:000309520200002
J	Jun, HJ; Acquaviva, J; Chi, D; Lessard, J; Zhu, H; Woolfenden, S; Bronson, RT; Pfannl, R; White, F; Housman, DE; Iyer, L; Whittaker, CA; Boskovitz, A; Raval, A; Charest, A				Jun, H. J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Bronson, R. T.; Pfannl, R.; White, F.; Housman, D. E.; Iyer, L.; Whittaker, C. A.; Boskovitz, A.; Raval, A.; Charest, A.			Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma; genetically engineered mouse model; EGFR; PTEN; c-MET	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; FACTOR-ALPHA CDNA; HUMAN GLIOMAS; KINASE INHIBITORS; TGF-ALPHA; IN-VIVO; NUCLEAR TRANSLOCATION; LENTIVIRAL VECTORS; MALIGNANT GLIOMAS	Glioblastoma multiforme (GBM) is an aggressive brain tumor for which there is no cure. Overexpression of wild-type epidermal growth factor receptor (EGFR) and loss of the tumor suppressor genes Ink4a/Arf and PTEN are salient features of this deadly cancer. Surprisingly, targeted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM to develop resistance. Efforts at modeling GBM in mice using wild-type EGFR have proven unsuccessful to date, hampering endeavors at understanding molecular mechanisms of therapeutic resistance. Here, we describe a unique genetically engineered mouse model of EGFR-driven gliomagenesis that uses a somatic conditional overexpression and chronic activation of wild-type EGFR in cooperation with deletions in the Ink4a/Arf and PTEN genes in adult brains. Using this model, we establish that chronic activation of wild-type EGFR with a ligand is necessary for generating tumors with histopathological and molecular characteristics of GBMs. We show that these GBMs are resistant to EGFR kinase inhibition and we define this resistance molecularly. Inhibition of EGFR kinase activity using tyrosine kinase inhibitors in GBM tumor cells generates a cytostatic response characterized by a cell cycle arrest, which is accompanied by a substantial change in global gene expression levels. We demonstrate that an important component of this pattern is the transcriptional activation of the MET receptor tyrosine kinase and that pharmacological inhibition of MET overcomes the resistance to EGFR inhibition in these cells. These findings provide important new insights into mechanisms of resistance to EGFR inhibition and suggest that inhibition of multiple targets will be necessary to provide therapeutic benefit for GBM patients. Oncogene (2012) 31, 3039-3050; doi: 10.1038/onc.2011.474; published online 24 October 2011	[Jun, H. J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Charest, A.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Bronson, R. T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Pfannl, R.; Boskovitz, A.; Raval, A.; Charest, A.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [White, F.; Housman, D. E.; Whittaker, C. A.; Charest, A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [White, F.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Housman, D. E.; Charest, A.] MIT, Dept Biol, Cambridge, MA USA; [Iyer, L.] Tufts Univ, Sch Med, Tufts Ctr Neurosci Res, Boston, MA 02111 USA	Tufts Medical Center; Harvard University; Harvard Medical School; Tufts University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Charest, A (corresponding author), Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St,Box 5609, Boston, MA 02111 USA.	alain.charest@tufts.edu		Whittaker, Charles/0000-0002-2400-0094; Iyer, Lakshmanan/0000-0001-9167-6396; White, Forest/0000-0002-1545-1651	NIH Grant [NCI U01 CA141556, U54 CA119349]; American Cancer Society Research Scholar Award [117409]; NINDS [P30 NS047243]; NCI [T32 CA009429]; NATIONAL CANCER INSTITUTE [T32CA009429, U54CA119349, U01CA141556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER	NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Research Scholar Award(American Cancer Society); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Bill Chiu and Ken Hung for helpful comments and Dr Robert R Langley (MD Anderson Cancer Center, Houston, TX, USA) for human TGF alpha cDNA. Dr Jason Coleman (MIT, Cambridge, MA, USA) for the pTyf vector and iCre cDNA. Dr John Alberta (DFCI, Boston, MA, USA) for the Olig2 antibody. This work was supported by NIH Grant NCI U01 CA141556 (AC and FW), American Cancer Society Research Scholar Award 117409 (AC), NIH Grant U54 CA119349 (DH and AC), NINDS P30 NS047243 (LI) and NCI T32 CA009429 (DC).	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cheng J, 2002, CANCER RES, V62, P4157; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, NAT IMMUN CELL GROW, V9, P209; DIMARCO E, 1989, ONCOGENE, V4, P831; Ding H, 2003, CANCER RES, V63, P1106; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Friedman HS, 2005, NEW ENGL J MED, V353, P1997, DOI 10.1056/NEJMp058186; Guillamo JS, 2009, CLIN CANCER RES, V15, P3697, DOI 10.1158/1078-0432.CCR-08-2042; Huang PH, 2007, CELL CYCLE, V6, P2750, DOI 10.4161/cc.6.22.4922; Huang TT, 2009, NEUROTHERAPEUTICS, V6, P500, DOI 10.1016/j.nurt.2009.04.008; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liang HY, 2004, INT J ONCOL, V24, P1057; Ling YH, 2007, MOL PHARMACOL, V72, P248, DOI 10.1124/mol.107.034827; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mellinghoff IK, 2007, CLIN CANCER RES, V13, P378, DOI 10.1158/1078-0432.CCR-06-1992; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Mueller KL, 2008, CANCER RES, V68, P3314, DOI 10.1158/0008-5472.CAN-08-0132; Mueller Kelly L, 2010, J Mol Signal, V5, P8, DOI 10.1186/1750-2187-5-8; Peng D, 1996, CANCER RES, V56, P3666; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAMUELS V, 1989, AM J PATHOL, V134, P895; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; SCHLEGEL U, 1990, ONCOGENE, V5, P1839; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Shimshek DR, 2002, GENESIS, V32, P19, DOI 10.1002/gene.10023; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; vanderValk P, 1997, ANN ONCOL, V8, P1023, DOI 10.1023/A:1008265905505; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; Woolfenden S, 2009, GENESIS, V47, P659, DOI 10.1002/dvg.20545; YUNG WKA, 1990, CANCER COMMUN, V2, P201, DOI 10.3727/095535490820874416; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zhu XC, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-98	55	60	62	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3039	3050		10.1038/onc.2011.474	http://dx.doi.org/10.1038/onc.2011.474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020333	Bronze, Green Submitted, Green Accepted			2022-12-17	WOS:000305705900003
J	Caldwell, ME; DeNicola, GM; Martins, CP; Jacobetz, MA; Maitra, A; Hruban, RH; Tuveson, DA				Caldwell, M. E.; DeNicola, G. M.; Martins, C. P.; Jacobetz, M. A.; Maitra, A.; Hruban, R. H.; Tuveson, D. A.			Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer	ONCOGENE			English	Article						senescence; Kras; PanIN; ADM; PDA; SA beta gal	ONCOGENE-INDUCED SENESCENCE; BARRIER; CELLS; MODEL; KRAS; PROGRESSION; MUTATIONS	During tumor initiation, oncogene-induced senescence (OIS) is proposed to limit the progression of preneoplasms to invasive carcinoma unless circumvented by the acquisition of certain tumor suppressor mutations. Using a variety of biomarkers, OIS has been previously reported in a wide range of human and murine precursor lesions, including the pancreas, lung, colon and skin. Here, we have characterized a panel of potential OIS biomarkers in human and murine pancreatic intraepithelial neoplasia (PanIN), and found that only senescence-associated beta-galactosidase (SA beta gal) activity is specifically enriched in these precursors, compared with pancreatic ductal adenocarcinoma (PDA). Indeed, many of the other proposed OIS biomarkers are detected in actively proliferating PanIN epithelium and in cells within the microenvironment. Surprisingly, acinar to ductal metaplasia (ADM), a distinct preneoplasm that is potentially a precursor for PanIN, also exhibits SA beta gal activity and contains a higher content of p21 and p53 than PanIN. Therefore, SA beta gal activity is the only biomarker that accurately identifies a small and heterogeneous population of non-proliferating premalignant cells in the pancreas, and the concomitant expression of p53 and p21 in ADM supports the possibility that PanIN and ADM each exhibit discrete senescence blocks. Oncogene (2012) 31, 1599-1608; doi:10.1038/onc.2011.350; published online 22 August 2011	[Caldwell, M. E.; DeNicola, G. M.; Martins, C. P.; Jacobetz, M. A.; Tuveson, D. A.] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 ORE, England; [Maitra, A.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA	Cancer Research UK; CRUK Cambridge Institute; Johns Hopkins University	Tuveson, DA (corresponding author), Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 ORE, England.	david.tuveson@cancer.org.uk		DeNicola, Gina/0000-0001-6611-6696	The Li Ka Shing Foundation; Hutchison Whampoa Limited; NIHR Cambridge Biomedical Research Centre; NIH [CA101973, CA111294, CA084291, CA105490]; University of Cambridge; Cancer Research UK; NATIONAL CANCER INSTITUTE [U01CA105490, R01CA101973, U01CA084291, U01CA111294] Funding Source: NIH RePORTER	The Li Ka Shing Foundation; Hutchison Whampoa Limited; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank P Krimpenfort, A Berns, R Taneja, F Alt, A Harris, M Malumbres C, Trejo, M McMahon, M Ferreira and F Watt for tissues and reagents. We thank Frances Connor and other members of the Tuveson lab for assistance and advice, the CRI animal care staff; S Vowler for statistical advice; Cancer Research UK Histopathology and In situ Hybridization Core, and the Microscopy and Imaging Core. This research was supported by the University of Cambridge and Cancer Research UK, The Li Ka Shing Foundation and Hutchison Whampoa Limited, the NIHR Cambridge Biomedical Research Centre and the NIH (grants CA101973, CA111294, CA084291 and CA105490) to DAT.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chien Y, 2008, CELL, V132, P339, DOI 10.1016/j.cell.2008.01.022; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Ivanova A, 2005, J MED GENET, V42, P565, DOI 10.1136/jmg.2004.029835; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Moskaluk CA, 1997, CANCER RES, V57, P2140; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhu LQ, 2007, AM J PATHOL, V171, P263, DOI 10.2353/ajpath.2007.061176	43	60	60	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1599	1608		10.1038/onc.2011.350	http://dx.doi.org/10.1038/onc.2011.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860420	Green Accepted			2022-12-17	WOS:000302132000012
J	Uemura, M; Zheng, Q; Koh, CM; Nelson, WG; Yegnasubramanian, S; De Marzo, AM				Uemura, M.; Zheng, Q.; Koh, C. M.; Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.			Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter hypomethylation	ONCOGENE			English	Article						epigenetics; rDNA; rRNA; DNA methylation; prostate cancer	POLYMERASE-I; C-MYC; TRANSCRIPTION; GENES; CELLS; NUCLEOLAR; DNA; HYPERMETHYLATION; METHYLATION; BIOLOGY	Alterations in nucleoli, including increased numbers, increased size, altered architecture and increased function are hallmarks of prostate cancer cells. The mechanisms that result in increased nucleolar size, number and function in prostate cancer have not been fully elucidated. The nucleolus is formed around repeats of a transcriptional unit encoding a 45S ribosomal RNA (rRNA) precursor that is then processed to yield the mature 18S, 5.8S and 28S RNA species. Although it has been generally accepted that tumor cells overexpress rRNA species, this has not been examined in clinical prostate cancer. We find that indeed levels of the 45S rRNA, 28S, 18S and 5.8S are overexpressed in the majority of human primary prostate cancer specimens as compared with matched benign tissues. One mechanism that can alter nucleolar function and structure in cancer cells is hypomethylation of CpG dinucleotides of the upstream rDNA promoter region. However, this mechanism has not been examined in prostate cancer. To determine whether rRNA overexpression could be explained by hypomethylation of these CpG sites, we also evaluated the DNA methylation status of the rDNA promoter in prostate cancer cell lines and the clinical specimens. Bisulfite sequencing of genomic DNA revealed two roughly equal populations of loci in cell lines consisting of those that contained densely methylated deoxycytidine residues within CpGs and those that were largely unmethylated. All clinical specimens also contained two populations with no marked changes in methylation of this region in cancer as compared with normal. We recently reported that MYC can regulate rRNA levels in human prostate cancer; here we show that MYC mRNA levels are correlated with 45S, 18S and 5.8S rRNA levels. Further, as a surrogate for nucleolar size and number, we examined the expression of fibrillarin, which did not correlate with rRNA levels. We conclude that rRNA levels are increased in human prostate cancer, but that hypomethylation of the rDNA promoter does not explain this increase, nor does hypomethylation explain alterations in nucleolar number and structure in prostate cancer cells. Rather, rRNA levels and nucleolar size and number relate more closely to MYC overexpression. Oncogene (2012) 31, 1254-1263; doi:10.1038/onc.2011.319; published online 8 August 2011	[Uemura, M.; Zheng, Q.; Koh, C. M.; Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA; [Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA; [Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA; [Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	De Marzo, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, CRB 2-144,1550 Orleans St, Baltimore, MD 21287 USA.	ademarz@jhmi.edu	uemura, motohide/G-6101-2011		Patrick C Walsh Prostate Cancer Fund; Prostate SPORE [P50CA58236]; NATIONAL CANCER INSTITUTE [P30CA006973, P50CA058236] Funding Source: NIH RePORTER	Patrick C Walsh Prostate Cancer Fund; Prostate SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Patrick C Walsh Prostate Cancer Fund of which AMD is the Peter J Sharp Scholar, and Prostate SPORE P50CA58236. We wish to thank Helen Fedor and the Brady Urological Institute Prostate Specimen Repository for fresh prostate tissues.	Bostwick DG, 1996, PROSTATE, V29, P117; Derenzini M, 1998, AM J PATHOL, V152, P1291; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; EPSTEIN JI, 2002, PROSTATE BIOPSY INTE; Espada J, 2007, NUCLEIC ACIDS RES, V35, P2191, DOI 10.1093/nar/gkm118; Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735; Gagnon-Kugler T, 2009, MOL CELL, V35, P414, DOI 10.1016/j.molcel.2009.07.008; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2010, FEBS J, V277, P4626, DOI 10.1111/j.1742-4658.2010.07892.x; Grummt I, 2010, CELL CYCLE, V9, P225, DOI 10.4161/cc.9.2.10614; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; Koh C, 2010, AM J PATHOL, V4, P1824; McGowan PO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002085; McMahon M, 2010, J BIOL CHEM, V285, P18309, DOI 10.1074/jbc.M110.108555; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Shiue CN, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.3.11376; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Williamson D, 2006, GENE CHROMOSOME CANC, V45, P839, DOI 10.1002/gcc.20347; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972	26	60	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1254	1263		10.1038/onc.2011.319	http://dx.doi.org/10.1038/onc.2011.319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822302	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000301344600005
J	Liu, RY; Dong, Z; Liu, J; Yin, JY; Zhou, L; Wu, X; Yang, Y; Mo, W; Huang, W; Khoo, SK; Chen, J; Petillo, D; Teh, BT; Qian, CN; Zhang, JT				Liu, R-Y; Dong, Z.; Liu, J.; Yin, J-Y; Zhou, L.; Wu, X.; Yang, Y.; Mo, W.; Huang, W.; Khoo, S. K.; Chen, J.; Petillo, D.; Teh, B. T.; Qian, C-N; Zhang, J-T			Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma	ONCOGENE			English	Article						cisplatin sensitivity; eIF3a; nasopharyngeal carcinoma; nucleotide excision repair; translational control	RIBONUCLEOTIDE REDUCTASE M2; INITIATION-FACTOR EIF3; BREAST-CANCER CELLS; DNA-DAMAGE; DRUG-RESISTANCE; OVEREXPRESSION; IDENTIFICATION; EXPRESSION; P150; CHEMORADIOTHERAPY	Translational control at the initiation step has been recognized as a major and important regulatory mechanism of gene expression. Eukaryotic initiation factor-3a (eIF3a), a putative subunit of the eIF3 complex, has recently been shown to have an important role in regulating the translation of a subset of mRNAs and is found to correlate with the prognosis of cancers. In this study, using nasopharyngeal carcinoma (NPC) cells as a model system, we tested the hypothesis that eIF3a negatively regulates the synthesis of nucleotide excision repair (NER) proteins, and, in turn, cellular response to treatments with DNA-damaging agents such as cisplatin (cis-dichlorodiammine platinum(II) (CDDP)). We found that a CDDP-sensitive sub-clone S16 isolated through limited dilution from an NPC cell line CNE-2 has increased eIF3a expression. Knocking down its expression in S16 cells increased cellular resistance to CDDP, NER activity and synthesis of the NER proteins XPA, XPC, RAD23B and RPA32. Altering eIF3a expression also changed the cellular response to CDDP and UV treatment in other NPC cell lines. Taken together, we conclude that eIF3a has an important role in the CDDP response and in NER activity of NPCs by suppressing the synthesis of NER proteins. Oncogene (2011) 30, 4814-4823; doi: 10.1038/onc.2011.189; published online 30 May 2011	[Zhang, J-T] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Liu, R-Y; Zhou, L.; Huang, W.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Khoo, S. K.] Van Andel Res Inst, Lab Microarray Technol, Grand Rapids, MI USA; [Chen, J.; Petillo, D.; Teh, B. T.] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI USA; [Petillo, D.; Teh, B. T.; Qian, C-N] Van Andel Res Inst, Lab Genome Biol, Grand Rapids, MI USA; [Teh, B. T.; Qian, C-N] Natl Canc Ctr Singapore, NCCS VARI Translat Res Lab, Singapore, Singapore; [Qian, C-N] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China	Indiana University System; Indiana University Bloomington; Sun Yat Sen University; Van Andel Institute; Van Andel Institute; Van Andel Institute; National Cancer Centre Singapore (NCCS); Sun Yat Sen University	Zhang, JT (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, IU Simon Canc Ctr, 980 W Walnut St,R3-510, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015; Yin, Ji-Ye/AAE-6794-2020; Liu, Ran-yi/L-1008-2019; mo, wei/N-5636-2014; huang, wen/GXW-0661-2022	Yin, Ji-Ye/0000-0002-1244-5045; Teh, Bin Tean/0000-0003-1514-1124	National Institutes of Health [CA94961]; Showalter Trust; National Natural Science Foundation of China [81071822]; NATIONAL CANCER INSTITUTE [R01CA094961] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Showalter Trust; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The CDDP-sensitive clone S16 was established and characterized at Van Andel Research Institute. The stable CNE-2 cells with eIF3a overexpression and the SUNE-1 cell line were studied at Sun Yat-sen University Cancer Center. All other studies were performed at the Indiana University School of Medicine. The VARI team dedicate this paper to the memory of a friend and co-worker, Dr Han-Mo Koo. This work was supported in part by the National Institutes of Health Grant CA94961 (JTZ), the Showalter Trust Fund (ZD) and the National Natural Science Foundation of China (no. 81071822) (RYL).	Afqir S, 2009, J CANCER RES THER, V5, P3, DOI 10.4103/0973-1482.48763; Agulnik M, 2005, BRIT J CANCER, V92, P799, DOI 10.1038/sj.bjc.6602449; Bachmann F, 1997, CANCER RES, V57, P988; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Chen GP, 2004, INT J CANCER, V112, P393, DOI 10.1002/ijc.20443; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2009, EXP CELL RES, V315, P1889, DOI 10.1016/j.yexcr.2009.03.009; Dong ZZ, 2005, NUCLEIC ACIDS RES, V33, P2715, DOI 10.1093/nar/gki569; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Furuta T, 2002, CANCER RES, V62, P4899; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Li Zhaomin, 2010, BMC Cancer, V10, P598, DOI 10.1186/1471-2407-10-598; Liu HL, 2008, MOL CANCER THER, V7, P263, DOI 10.1158/1535-7163.MCT-07-0445; Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Neher TM, 2010, ACS CHEM BIOL, V5, P953, DOI 10.1021/cb1000444; Neher TM, 2010, BIOCHEMISTRY-US, V49, P669, DOI 10.1021/bi901575h; Nouspikel T, 2009, CELL MOL LIFE SCI, V66, P994, DOI 10.1007/s00018-009-8737-y; OLDROYD NJ, 1995, ELECTROPHORESIS, V16, P334, DOI 10.1002/elps.1150160155; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Thephamongkhol K, 2004, J CLIN ONCOL, V22, p493S; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Xiao WW, 2009, INT J RADIAT ONCOL, V74, P1070, DOI 10.1016/j.ijrobp.2008.09.008; Xu JK, 2007, CANCER RES, V67, P4373, DOI 10.1158/0008-5472.CAN-06-3169; Yang YY, 2007, J BIOL CHEM, V282, P8821, DOI 10.1074/jbc.M700152200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Yin JY, 2011, CLIN CANC R IN PRESS; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	39	60	65	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4814	4823		10.1038/onc.2011.189	http://dx.doi.org/10.1038/onc.2011.189			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625209	Green Accepted			2022-12-17	WOS:000298134700005
J	Wang, Q; Li, DC; Li, ZF; Liu, CX; Xiao, YM; Zhang, B; Li, XD; Zhao, J; Chen, LP; Xing, XM; Tang, SF; Lin, YC; Lai, YD; Yang, P; Zeng, JL; Xiao, Q; Zeng, XW; Lin, ZN; Zhuang, ZX; Zhuang, SM; Chen, W				Wang, Q.; Li, D-C; Li, Z-F; Liu, C-X; Xiao, Y-M; Zhang, B.; Li, X-D; Zhao, J.; Chen, L-P; Xing, X-M; Tang, S-F; Lin, Y-C; Lai, Y-D; Yang, P.; Zeng, J-L; Xiao, Q.; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Zhuang, S-M; Chen, W.			Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen	ONCOGENE			English	Article						viral oncogene; SV40 small T antigen; miR-27a; protein phosphatase 2A; transformation; human cells	PROTEIN PHOSPHATASE 2A; SMALL TUMOR-ANTIGEN; HUMAN HEPATOCELLULAR-CARCINOMA; BREAST-CANCER CELLS; EARLY MESSENGER-RNA; SIMIAN VIRUS-40; CELLULAR-TRANSFORMATION; MICRORNA TARGETS; UBIQUITIN LIGASE; C-MYC	The introduction of the Simian virus 40 (SV40) early region, the telomerase catalytic subunit (hTERT) and an oncogenic allele of H-Ras directly transforms primary human cells. SV40 small T antigen (ST), which forms a complex with protein phosphatase 2A (PP2A) and inhibits PP2A activity, is believed to have a critical role in the malignant transformation of human cells. Recent evidence has shown that aberrant microRNA (miRNA) expression patterns are correlated with cancer development. Here, we identified miR-27a as a differentially expressed miRNA in SV40 ST-expressing cells. miR-27a is upregulated in SV40 ST-transformed human bronchial epithelial cells (HBERST). Suppression of miR-27a expression in HBERST cells or lung cancer cell lines (NCI-H226 and SK-MES-1) that exhibited high levels of miR-27a expression lead to cell growth arrested in the G(0)-G(1) phase. In addition, suppression of miR-27a in HBERST cells attenuated the capacity of such cells to grow in an anchorage-independent manner. We also found that suppression of the PP2A B56 gamma expression resulted in upregulation of miR-27a similar to that achieved by the introduction of ST, indicating that dysregulation of miR-27a expression in ST-expressing cells was mediated by the ST-PP2A interaction. Moreover, we discovered that Fbxw7 gene encoding F-box/WD repeat-containing protein 7 was a potential miR-27a target validated by dual-luciferase reporter system analysis. The inverse correlation between miR-27a expression levels and Fbxw7 protein expression was further confirmed in both cell models and human tumor samples. Fbxw7 regulates cell-cycle progression through the ubiquitin-dependent proteolysis of a set of substrates, including c-Myc, c-Jun, cyclin E1 and Notch 1. Thus, promotion of cell growth arising from the suppression of Fbxw7 by miR-27a overexpression might be responsible for the viral oncoprotein ST-induced malignant transformation. These observations demonstrate that miR-27a functions as an oncogene in human tumorigenesis. Oncogene (2011) 30, 3875-3886; doi:10.1038/onc.2011.103; published online 4 April 2011	[Chen, W.] Sun Yat Sen Univ, Sch Publ Hlth, Fac Prevent Med,Dept Toxicol, Guangdong Prov Key Lab Food Nutr & Hlth, Guangzhou 510080, Guangdong, Peoples R China; [Li, X-D] Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510080, Guangdong, Peoples R China; [Zhao, J.] Guangzhou Med Univ, Dept Thorac Surg, Affiliated Canc Hosp, Guangzhou, Guangdong, Peoples R China; [Zhuang, Z-X] Shenzhen Ctr Dis Control & Prevent, Dept Toxicol, Shenzhen, Peoples R China; [Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ,State Key Lab Biocontrol, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Shenzhen Center for Disease Control & Prevention (SZCDC); Sun Yat Sen University	Chen, W (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Fac Prevent Med,Dept Toxicol, Guangdong Prov Key Lab Food Nutr & Hlth, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	chenwen@mail.sysu.edu.cn	ZHANG, BO/K-4561-2013	ZHANG, BO/0000-0002-6352-1757; Zhuang, Shi-Mei/0000-0002-2512-3942	NSFC [30925029, 30925036, 30630055, 30800930, 30771832, 30901211]; National Key Basic Research and Development Program [2010CB912803]; National High Technology Research and Development Key Program of China [2008AA062504]; Ministry of Health of China [200902006]; Fundamental Research Funds for the Central Universities [10ykjc05, 10lgzd10]; Guangdong Province Universities; Colleges Pearl River Scholar Funded Scheme GDUPS	NSFC(National Natural Science Foundation of China (NSFC)); National Key Basic Research and Development Program(National Basic Research Program of China); National High Technology Research and Development Key Program of China(National High Technology Research and Development Program of China); Ministry of Health of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Province Universities; Colleges Pearl River Scholar Funded Scheme GDUPS	This work was supported by program of Distinguished Young Scholar of NSFC (30925029, 30925036), a Key NSFC Program (30630055) and NSFC (30800930, 30771832, 30901211), National Key Basic Research and Development Program (2010CB912803), National High Technology Research and Development Key Program of China (2008AA062504), Ministry of Health of China (200902006), the Fundamental Research Funds for the Central Universities (10ykjc05 and 10lgzd10), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme GDUPS (2010).	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096; CRAWFORD LV, 1978, P NATL ACAD SCI USA, V75, P117, DOI 10.1073/pnas.75.1.117; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; Godshalk SE, 2008, CELL CYCLE, V7, P3595, DOI 10.4161/cc.7.22.7120; Grochola LF, 2009, CLIN CANCER RES, V15, P6301, DOI 10.1158/1078-0432.CCR-09-0797; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Huang SL, 2008, INT J CANCER, V123, P972, DOI 10.1002/ijc.23580; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KHALILI K, 1987, CELL, V48, P639, DOI 10.1016/0092-8674(87)90242-X; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pang YQ, 2008, TOXICOL APPL PHARM, V232, P478, DOI 10.1016/j.taap.2008.08.009; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sablina AA, 2008, CANCER METAST REV, V27, P137, DOI 10.1007/s10555-008-9116-0; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sontag JM, 2006, CELL MOL LIFE SCI, V63, P2979, DOI 10.1007/s00018-006-6300-7; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; TOMITA M, 2009, INT J CANC IN PRESS; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	62	60	65	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3875	3886		10.1038/onc.2011.103	http://dx.doi.org/10.1038/onc.2011.103			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21460851				2022-12-17	WOS:000294687200005
J	Nogueira, L; Ruiz-Ontanon, P; Vazquez-Barquero, A; Lafarga, M; Berciano, MT; Aldaz, B; Grande, L; Casafont, I; Segura, V; Robles, EF; Suarez, D; Garcia, LF; Martinez-Climent, JA; Fernandez-Luna, JL				Nogueira, L.; Ruiz-Ontanon, P.; Vazquez-Barquero, A.; Lafarga, M.; Berciano, M. T.; Aldaz, B.; Grande, L.; Casafont, I.; Segura, V.; Robles, E. F.; Suarez, D.; Garcia, L. F.; Martinez-Climent, J. A.; Fernandez-Luna, J. L.			Blockade of the NF kappa B pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo	ONCOGENE			English	Article						NF kappa B; glioblastoma-initiating cells; senescence; differentiation	CANCER STEM-CELLS; BRAIN-TUMORS; ACTIVATION; PHENOTYPE; PROLIFERATION; EXPRESSION; SURVIVAL; THERAPY; GROWTH; MICE	Glioblastoma multiforme is one of the most devastating cancers and presents unique challenges to therapy because of its aggressive behavior. Cancer-initiating or progenitor cells have been described to be the only cell population with tumorigenic capacity in glioblastoma. Therefore, effective therapeutic strategies targeting these cells or the early precursors may be beneficial. We have established different cultures of glioblastoma-initiating cells (GICs) derived from surgical specimens and found that, after induction of differentiation, the NF kappa B transcriptional pathway was activated, as determined by analyzing key proteins such as p65 and I kappa B and the upregulation of a number of target genes. We also showed that blockade of nuclear factor (NF)kappa B signaling in differentiating GICs by different genetic strategies or treatment with small-molecule inhibitors, promoted replication arrest and senescence. This effect was partly mediated by reduced levels of the NF kappa B target gene cyclin D1, because its downregulation by RNA interference reproduced a similar phenotype. Furthermore, these results were confirmed in a xenograft model. Intravenous treatment of immunodeficient mice bearing human GIC-derived tumors with a novel small-molecule inhibitor of the NF kappa B pathway induced senescence of tumor cells but no ultrastructural alterations of the brain parenchyma were detected. These findings reveal that activation of NF kappa B may keep differentiating GICs from acquiring a mature postmitotic phenotype, thus allowing cell proliferation, and support the rationale for therapeutic strategies aimed to promote premature senescence of differentiating GICs by blocking key factors within the NF kappa B pathway. Oncogene (2011) 30, 3537-3548; doi:10.1038/onc.2011.74; published online 21 March 2011	[Nogueira, L.; Ruiz-Ontanon, P.; Grande, L.; Fernandez-Luna, J. L.] Hosp Valdecilla, Mol Genet Unit, Santander 39011, Spain; [Nogueira, L.; Ruiz-Ontanon, P.; Grande, L.; Fernandez-Luna, J. L.] Inst Formac & Invest Marques de Valdecilla IFIMAV, Santander, Spain; [Vazquez-Barquero, A.; Suarez, D.] Hosp Valdecilla, Neurosurg Serv, Santander 39011, Spain; [Lafarga, M.; Berciano, M. T.; Casafont, I.] Univ Cantabria IFIMAV, Dept Anat & Cell Biol, Santander, Spain; [Lafarga, M.; Berciano, M. T.; Casafont, I.] Univ Cantabria IFIMAV, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Santander, Spain; [Aldaz, B.; Robles, E. F.; Martinez-Climent, J. A.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, E-31080 Pamplona, Spain; [Segura, V.] Univ Navarra, Ctr Appl Med Res CIMA, Bioinformat Unit, E-31080 Pamplona, Spain; [Garcia, L. F.] PharmaMar, Madrid, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; CIBERNED; Universidad de Cantabria; University of Navarra; University of Navarra; PharmaMar	Fernandez-Luna, JL (corresponding author), Hosp Valdecilla, Mol Genet Unit, Edificio IFIMAV,Av Cardenal Herrera Oria S-N, Santander 39011, Spain.	fluna@humv.es	Segura, Victor/E-4531-2010; Lafarga, Miguel/K-3733-2014; Martinez-Climent, Jose A/I-9199-2012	Segura, Victor/0000-0002-7740-6290; Martinez-Climent, Jose A/0000-0002-7938-3950; CASAFONT, INIGO/0000-0001-5691-6841; Berciano, Maria T./0000-0002-8225-6995; Lafarga, Miguel/0000-0003-3402-1152	Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) [RD06/0020/0074, RD06/0020/0088]; Fundacion Marques de Valdecilla [API08/01];  [PI070196];  [PI081878]	Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation)(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Marques de Valdecilla(Instituto de Salud Carlos III); ; 	This work was supported by Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) grants RD06/0020/0074 (JLF-L) and RD06/0020/0088 (JAM-C) (Red Tematica de Investigacion Cooperativa en Cancer), PI070196, PI081878, and Accion Transversal del Cancer 2008, and grant API08/01 from Fundacion Marques de Valdecilla (JLF-L). We thank Francisco Moris (EntreChem, Spain) for providing the NF kappa B inhibitor 70124, and Ainara Sagardoy, Silvia Mora, Maria Collantes and Ivan Penuelas (University of Navarra, Spain) for support with intracraneal injections and microPET studies.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Berciano MT, 2004, HUM MOL GENET, V13, P829, DOI 10.1093/hmg/ddh101; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Chang BD, 1999, CANCER RES, V59, P3761; Cheng L, 2010, BIOCHEM PHARMACOL, V80, P654, DOI 10.1016/j.bcp.2010.04.035; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Kang HB, 2007, STEM CELLS DEV, V16, P615, DOI 10.1089/scd.2007.0014; Kawamata H, 2006, CURR PHARM DESIGN, V12, P379, DOI 10.2174/138161206775201947; Lam WA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-35; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee J, 2009, FASEB J, V23, P1739, DOI 10.1096/fj.08-121046; Li XL, 2006, P NATL ACAD SCI USA, V103, P17432, DOI 10.1073/pnas.0607939103; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miura T, 2004, AGING CELL, V3, P333, DOI 10.1111/j.1474-9728.2004.00134.x; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Ozes ON, 1999, NATURE, V401, P82; Pena E, 2001, J COMP NEUROL, V430, P250, DOI 10.1002/1096-9861(20010205)430:2<250::AID-CNE1029>3.0.CO;2-L; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Sabolek M, 2006, NEUROREPORT, V17, P1719, DOI 10.1097/01.wnr.0000236862.08834.50; Sanchez C, 2009, CHEM COMMUN, P4118, DOI 10.1039/b905068j; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Singh SK, 2003, CANCER RES, V63, P5821; Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392; Wehling N, 2009, ARTHRITIS RHEUM-US, V60, P801, DOI 10.1002/art.24352; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; Young KM, 2006, J NEUROSCI RES, V83, P39, DOI 10.1002/jnr.20702; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	42	60	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3537	3548		10.1038/onc.2011.74	http://dx.doi.org/10.1038/onc.2011.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423202				2022-12-17	WOS:000293782300006
J	Bordoli, MR; Stiehl, DP; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, RH; Camenisch, G				Bordoli, M. R.; Stiehl, D. P.; Borsig, L.; Kristiansen, G.; Hausladen, S.; Schraml, P.; Wenger, R. H.; Camenisch, G.			Prolyl-4-hydroxylase PHD2-and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis	ONCOGENE			English	Article						amphiregulin; hypoxia-inducible factors; mammary carcinoma; prolyl-4-hydroxylases; tumor vascularization	HYDROXYLASE DOMAIN PROTEIN-2; GROWTH-FACTOR-ALPHA; PROLYL HYDROXYLASE; GENE-EXPRESSION; CELL CARCINOMA; HUMAN CANCERS; OVEREXPRESSION; FACTOR-1-ALPHA; ANGIOGENESIS; INDUCTION	Hypoxia-elicited adaptations of tumor cells are essential for tumor growth and cancer progression. Although ample evidence exists for a positive correlation between hypoxia-inducible factors (HIFs) and tumor formation, metastasis and bad prognosis, the function of the HIF-alpha protein stability regulating prolyl-4-hydroxylase domain enzyme PHD2 in carcinogenesis is less well understood. In this study, we demonstrate that downregulation of PHD2 leads to increased tumor growth in a hormone-dependent mammary carcinoma mouse model. Tissue microarray analysis of PHD2 protein expression in 281 clinical samples of human breast cancer showed significantly shorter survival times of patients with low-level PHD2 tumors over a period of 10 years. An angiogenesis-related antibody array identified, amongst others, amphiregulin to be increased in the absence of PHD2 and normalized after PHD2 reconstitution. Cultivation of endothelial cells in conditioned media derived from PHD2-downregulated cells resulted in enhanced tube formation that was blocked by the addition of neutralizing anti-amphiregulin antibodies. Functionally, amphiregulin was regulated on the transcriptional level specifically by HIF-2 but not HIF-1. Our data suggest that PHD2/HIF-2/amphiregulin signaling has a critical role in the regulation of breast tumor progression and propose PHD2 as a potential tumor suppressor in breast cancer. Oncogene (2011) 30, 548-560; doi: 10.1038/onc.2010.433; published online 20 September 2010	[Wenger, R. H.] Univ Zurich, Cellular Oxygen Physiol Grp, Inst Physiol, CH-8057 Zurich, Switzerland; [Bordoli, M. R.; Stiehl, D. P.; Borsig, L.; Wenger, R. H.; Camenisch, G.] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Kristiansen, G.; Hausladen, S.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital	Wenger, RH (corresponding author), Univ Zurich, Cellular Oxygen Physiol Grp, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	roland.wenger@access.uzh.ch	Wenger, Roland H./B-7953-2009; Stiehl, Daniel/A-3622-2008	Wenger, Roland H./0000-0001-7592-4839; Borsig, Lubor/0000-0003-2263-9545; Stiehl, Daniel/0000-0002-0076-4874; Bordoli, Mattia/0000-0001-6917-8753	Swiss National Science Foundation; Krebsliga des Kantons Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga des Kantons Zurich	We thank P Spielmann for excellent technical assistance, K Wollenick, TF Luscher, PJ Ratcliffe (University of Oxford, Oxford, UK), SB Lee (National Institutes of Health, Bethesda, MD, USA), DA Chan (University of California, San Francisco, CA, USA) for gifts of antibodies, cells and plasmids and D Neri (Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland) for helpful discussions. This work was supported by the Swiss National Science Foundation and Krebsliga des Kantons Zurich (GC).	Aebersold DM, 2001, CANCER RES, V61, P2911; Balamurugan K, 2009, ONCOGENE, V28, P3274, DOI 10.1038/onc.2009.186; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Barth S, 2007, MOL CELL BIOL, V27, P3758, DOI 10.1128/MCB.01324-06; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chokki M, 2006, LIFE SCI, V78, P3051, DOI 10.1016/j.lfs.2005.12.023; Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258; ELSTON CW, 1993, J CLIN PATHOL, V46, P189; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2003, CANCER RES, V63, P8777; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Giusti C, 2003, INT J CANCER, V105, P769, DOI 10.1002/ijc.11158; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Kato H, 2006, INT J CANCER, V118, P1144, DOI 10.1002/ijc.21488; Lamber EP, 2010, CANCER RES, V70, P996, DOI 10.1158/0008-5472.CAN-09-2842; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Lee K, 2008, MOL CANCER RES, V6, P829, DOI 10.1158/1541-7786.MCR-07-2113; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McBryan J, 2008, J MAMMARY GLAND BIOL, V13, P159, DOI 10.1007/s10911-008-9075-7; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; O'Reilly SM, 2006, AM J PHYSIOL-CELL PH, V290, pC592, DOI 10.1152/ajpcell.00278.2005; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Takeda K, 2007, CIRCULATION, V116, P774, DOI 10.1161/CIRCULATIONAHA.107.701516; Theurillat JP, 2007, INT J CANCER, V120, P2411, DOI 10.1002/ijc.22376; Wagenaar GTA, 2004, FREE RADICAL BIO MED, V36, P782, DOI 10.1016/j.freeradbiomed.2003.12.007; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Willmarth NE, 2008, J MAMMARY GLAND BIOL, V13, P171, DOI 10.1007/s10911-008-9081-9; Wu SR, 2008, MOL THER, V16, P1227, DOI 10.1038/mt.2008.90; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029; Zhong H, 1999, CANCER RES, V59, P5830	52	60	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					548	560		10.1038/onc.2010.433	http://dx.doi.org/10.1038/onc.2010.433			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20856199	Green Published			2022-12-17	WOS:000286922300004
J	Borbone, E; Berlingieri, MT; De Bellis, F; Nebbioso, A; Chiappetta, G; Mai, A; Altucci, L; Fusco, A				Borbone, E.; Berlingieri, M. T.; De Bellis, F.; Nebbioso, A.; Chiappetta, G.; Mai, A.; Altucci, L.; Fusco, A.			Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation	ONCOGENE			English	Article						HDAC inhibitors; thyroid; carcinomas; apoptosis; TRAIL; proteasome	SUBEROYLANILIDE HYDROXAMIC ACID; REFRACTORY SOLID TUMORS; ACUTE MYELOID-LEUKEMIA; T-CELL LYMPHOMA; HDAC INHIBITORS; CLASS-II; ANTICANCER AGENT; PHASE-I; MALIGNANT PHENOTYPE; LIGAND TRAIL	Anaplastic thyroid carcinoma (ATC) is considered one of the most aggressive malignancies, having a poor prognosis and being refractory to conventional chemotherapy and radiotherapy. Alteration in histone deacetylase (HDAC) activity has been reported in cancer, thus encouraging the development of HDAC inhibitors, whose antitumor action has been shown in both solid and hematological malignancies. However, the molecular basis for their tumor selectivity is unknown. To find an innovative therapy for the treatment of ATCs, we studied the effects of deacetylase inhibitors on thyroid tumorigenesis models. We show that HDACs 1 and 2 are overexpressed in ATCs compared with normal cells or benign tumors and that HDAC inhibitors induce apoptosis selectively in the fully transformed thyroid cells. Our results indicate that these phenomena are mediated by a novel action of HDAC inhibitors that reduces tumor necrosis factor-related apoptosis-inducing ligand protein degradation by affecting the ubiquitin-dependent pathway. Indeed, the combined treatment with HDAC and proteasome inhibitors results in synergistic apoptosis. These results strongly encourage the preclinical application of the combination deacetylase-proteasome inhibitors for the treatment of ATC.	[Fusco, A.] IEOS, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Borbone, E.; Fusco, A.] NOGEC CEINGE, Naples, Italy; [De Bellis, F.; Nebbioso, A.; Altucci, L.] Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; [Chiappetta, G.] Natl Canc Inst G Pascale, Funct Genom Unit, Dept Expt Oncol, Naples, Italy; [Mai, A.] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; Fondazione Cenci Bolognetti; Sapienza University Rome	Fusco, A (corresponding author), IEOS, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	lucia.altucci@unina2.it; alfusco@unina.it	NEBBIOSO, ANGELA/GVS-1294-2022; Altucci, Lucia/S-8031-2019; Mai, Antonello/AAC-2144-2019; NEBBIOSO, Angela/C-3566-2016	Mai, Antonello/0000-0001-9176-2382; NEBBIOSO, Angela/0000-0001-5374-3527; altucci, lucia/0000-0002-7312-5387; Fusco, Alfredo/0000-0003-3332-5197	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU [LSHC-CT2005-518417, HEALTH-F2-2007200620, HEALTH-F4-2007-200767, HEALTH-F4-2009221952]; NOGEC-Naples Oncogenomic Center	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU; NOGEC-Naples Oncogenomic Center	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and from the Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU (LSHC-CT2005-518417; HEALTH-F2-2007200620; HEALTH-F4-2007-200767; HEALTH-F4-2009221952) and the NOGEC-Naples Oncogenomic Center. We thank Konstantina Vergadou for revising and editing the article, Mario Berardone for the artwork, and Pollice A for providing some plasmids.	Altucci L, 2005, INT J BIOCHEM CELL B, V37, P1752, DOI 10.1016/j.biocel.2005.04.019; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Altucci L, 2009, INT J BIOCHEM CELL B, V41, P2, DOI 10.1016/j.biocel.2008.09.010; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2; Bontempo P, 2007, INT J BIOCHEM CELL B, V39, P1902, DOI 10.1016/j.biocel.2007.05.010; Chiappetta G, 2008, EUR J CANCER, V44, P1015, DOI 10.1016/j.ejca.2008.02.039; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299; Duvic M, 2007, DRUG TODAY, V43, P585, DOI 10.1358/dot.2007.43.9.1112980; Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461; Hall MA, 2007, CANCER CELL, V12, P4, DOI 10.1016/j.ccr.2007.06.011; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Iervolino A, 2006, CANCER RES, V66, P6280, DOI 10.1158/0008-5472.CAN-06-0228; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Macher-Goeppinger S, 2009, CLIN CANCER RES, V15, P650, DOI 10.1158/1078-0432.CCR-08-0284; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a; Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Miller CP, 2009, BLOOD, V113, P4289, DOI 10.1182/blood-2008-08-174797; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2005, CLIN CANCER RES, V11, P3958, DOI 10.1158/1078-0432.CCR-03-0776; Nappi TC, 2009, CANCER RES, V69, P1916, DOI 10.1158/0008-5472.CAN-08-1693; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; PORTELLA G, 1989, ONCOGENE, V4, P181; Saltman B, 2006, SURGERY, V140, P899, DOI 10.1016/j.surg.2006.07.027; Scognamiglio A, 2008, BBA-MOL CELL RES, V1783, P2030, DOI 10.1016/j.bbamcr.2008.07.007; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu C, 2008, NEURO-ONCOLOGY, V10, P309, DOI 10.1215/15228517-2007-063	50	60	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					105	116		10.1038/onc.2009.306	http://dx.doi.org/10.1038/onc.2009.306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802013				2022-12-17	WOS:000273373500010
J	Mullenders, J; Bernards, R				Mullenders, J.; Bernards, R.			Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer	ONCOGENE			English	Review						RNAi screen; biomarkers of drug response; cancer therapy	WIDE RNAI SCREEN; PHASE-I; TUMOR SUPPRESSORS; TYROSINE KINASE; SIRNA SCREEN; IDENTIFICATION; INTERFERENCE; PACLITAXEL; CELLS; COMPONENTS	A major impediment to the effective treatment of cancer is the molecular heterogeneity of the disease, which is also reflected in an equally diverse pattern of clinical responses to therapy. Currently, only few drugs are available that can be used safely and effectively to treat cancer. To improve this situation, the development of novel and highly specific targets for therapy is of utmost importance. Possibly even more importantly, we need better tools to predict which patients will respond to specific therapies. Such drug response biomarkers will be instrumental to individualize the therapy of patients having seemingly similar cancers. In this study, we discuss how RNA interference-based genetic screens can be used to address these two pressing needs in the care for cancer patients. Oncogene (2009) 28, 4409-4420; doi:10.1038/onc.2009.295; published online 21 September 2009	[Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Mullenders, Jasper/J-2398-2015	Mullenders, Jasper/0000-0003-3737-6901; Bernards, Rene/0000-0001-8677-3423				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bjorklund M, 2006, NATURE, V439, P1009, DOI 10.1038/nature04469; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buchholz F, 2006, NAT METHODS, V3, P696, DOI 10.1038/NMETH912; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Cresta S, 2008, EUR J CANCER, V44, P1829, DOI 10.1016/j.ejca.2008.05.022; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Gobeil S, 2008, GENE DEV, V22, P2932, DOI 10.1101/gad.1714608; Goff SP, 2008, CELL, V135, P417, DOI 10.1016/j.cell.2008.10.007; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jatoi A, 2008, J THORAC ONCOL, V3, P516, DOI 10.1097/JTO.0b013e31816de276; Ji D, 2007, ONCOL REP, V18, P1499; Jones TR, 2009, P NATL ACAD SCI USA, V106, P1826, DOI 10.1073/pnas.0808843106; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Kittler R, 2007, NAT CELL BIOL, V9, P1401, DOI 10.1038/ncb1659; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Li LM, 2007, RNA, V13, P1765, DOI 10.1261/rna.599107; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma C, 2007, CANCER CHEMOTH PHARM, V59, P207, DOI 10.1007/s00280-006-0259-9; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Moffat J, 2006, NAT REV MOL CELL BIO, V7, P177, DOI 10.1038/nrm1860; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547; Mukherji M, 2006, P NATL ACAD SCI USA, V103, P14819, DOI 10.1073/pnas.0604320103; Neumann B, 2006, NAT METHODS, V3, P385, DOI 10.1038/NMETH876; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Oosterkamp HM, 2006, BRIT J DERMATOL, V155, P182, DOI 10.1111/j.1365-2133.2006.07224.x; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Pepperkok R, 2006, NAT REV MOL CELL BIO, V7, P690, DOI 10.1038/nrm1979; Rines DR, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r44; Rines DR, 2006, METHOD ENZYMOL, V414, P530, DOI 10.1016/S0076-6879(06)14028-8; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rottmann S, 2005, P NATL ACAD SCI USA, V102, P15195, DOI 10.1073/pnas.0505114102; Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560; Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946; Savage P, 2009, NAT CLIN PRACT ONCOL, V6, P43, DOI 10.1038/ncponc1260; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wheeler DB, 2005, NAT GENET, V37, pS25, DOI 10.1038/ng1560; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	89	60	62	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4409	4420		10.1038/onc.2009.295	http://dx.doi.org/10.1038/onc.2009.295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767776				2022-12-17	WOS:000272876500001
J	Shaw, A; Gipp, J; Bushman, W				Shaw, A.; Gipp, J.; Bushman, W.			The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts	ONCOGENE			English	Article						Hedgehog; prostate cancer; reactive stroma; myofibroblast; paracrine; tumor microenvironment	GLI TRANSCRIPTION FACTORS; REACTIVE STROMA; CANCER CELLS; ACTIVATION; PROLIFERATION; INHIBITION; NETWORKS; THERAPY	The Hedgehog (Hh) pathway contributes to prostate cancer growth and progression. The presence of robust Sonic Hedgehog (Shh) expression in both normal prostate and localized cancer challenged us to explain the unique growth-promoting effect in cancer. We show here that paracrine Hh signaling exerts a non-cell autonomous effect on xenograft tumor growth and that Hh pathway activation in myofibroblasts alone is sufficient to stimulate tumor growth. Nine genes regulated by Hh in the mesenchyme of the developing prostate were found to be regulated in the stroma of Hh overexpressing xenograft tumors. Correlation analysis of gene expression in matched specimens of benign and malignant human prostate tissue revealed a partial five-gene fingerprint of Hh-regulated expression in stroma of all cancers and the complete nine-gene fingerprint in the subset of tumors exhibiting a reactive stroma. No expression fingerprint was observed in benign tissues. We conclude that changes in the prostate stroma due to association with cancer result in an altered transcriptional response to Hh that mimics the growth-promoting actions of the fetal mesenchyme. Patients with an abundance of myofibroblasts in biopsy tissue may comprise a subgroup that will exhibit a particularly good response to anti-Hh therapy. Oncogene (2009) 28, 4480-4490; doi:10.1038/onc.2009.294; published online 28 September 2009	[Shaw, A.; Gipp, J.; Bushman, W.] Univ Wisconsin, Dept Surg, Div Urol, Madison, WI 53792 USA; [Shaw, A.; Bushman, W.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53792 USA; [Shaw, A.; Gipp, J.; Bushman, W.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bushman, W (corresponding author), Univ Wisconsin, Dept Surg, Div Urol, 600 Highland Ave, Madison, WI 53792 USA.	bushman@surgery.wisc.edu		Shaw, Aubie/0000-0002-5298-801X	Department of Defense [W81XWH-06-1-0060, W81XWH-04-1-0263]; NIDDK [DK056238-06]; Robert and Delores Schnoes Chair in Urologic Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Robert and Delores Schnoes Chair in Urologic Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Alejandro Munoz, PhD, and Glen Leverson, PhD, for assistance with statistical analysis. The Gli2-mutB expression construct was generously provided by Maximilian Muenke at NIH (Bethesda, MD, USA). This work was supported by the Department of Defense Prostate Cancer Program Graduate Training Award W81XWH-06-1-0060 (AS), Department of Defense Award W81XWH-04-1-0263 (WB), the NIDDK Award DK056238-06 (WB) and the Robert and Delores Schnoes Chair in Urologic Research.	Bai CB, 2002, DEVELOPMENT, V129, P4753; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bierhoff E, 1997, PROSTATE, V31, P234, DOI 10.1002/(SICI)1097-0045(19970601)31:4<234::AID-PROS4>3.0.CO;2-K; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Gustin MP, 2008, PHYSIOL GENOMICS, V34, P34, DOI 10.1152/physiolgenomics.00008.2008; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JANIK P, 1975, CANCER RES, V35, P3698; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kelleher FC, 2006, ACTA ONCOL, V45, P375, DOI 10.1080/02841860600602946; Lauth M, 2007, CURR OPIN INVEST DR, V8, P457; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Levitt RJ, 2007, CANCER LETT, V255, P300, DOI 10.1016/j.canlet.2007.05.006; Lipinski RJ, 2006, EXP CELL RES, V312, P1925, DOI 10.1016/j.yexcr.2006.02.019; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; McCarthy FRK, 2008, BIOCHEM BIOPH RES CO, V373, P109, DOI 10.1016/j.bbrc.2008.05.169; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; SCHIMMANG T, 1993, PROG CLIN BIOL RES, V383, P153; Schwarze SR, 2005, PROSTATE, V64, P67, DOI 10.1002/pros.20215; Shaw A, 2006, PROSTATE, V66, P1347, DOI 10.1002/pros.20357; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Yanagisawa N, 2008, HUM PATHOL, V39, P282, DOI 10.1016/j.humpath.2007.04.025; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yu M, 2009, J BIOL CHEM, V284, P5620, DOI 10.1074/jbc.M809172200; Zhang JX, 2007, J UROLOGY, V177, P1179, DOI 10.1016/j.juro.2006.10.032	33	60	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4480	4490		10.1038/onc.2009.294	http://dx.doi.org/10.1038/onc.2009.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19784071	Green Accepted			2022-12-17	WOS:000272876500007
J	Du, XL; Yang, H; Liu, SG; Luo, ML; Hao, JJ; Zhang, Y; Lin, DC; Xu, X; Cai, Y; Zhan, QM; Wang, MR				Du, X-L; Yang, H.; Liu, S-G; Luo, M-L; Hao, J-J; Zhang, Y.; Lin, D-C; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R			Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma	ONCOGENE			English	Article						Calreticulin; Cortactin; anoikis; motility; STAT3	2-DIMENSIONAL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM; PROTEOMIC ANALYSIS; INDUCED APOPTOSIS; DUCTAL CARCINOMA; CORTACTIN; EXPRESSION; GENE; OVEREXPRESSION; PROTEIN	We have shown earlier that overexpression of Calreticulin (CRT) contributed to a poor prognosis for patients with esophageal squamous cell carcinoma (ESCC). Here, we have shown an important role of CRT in tumorigenesis through enhancing cell motility and anoikis resistance. SiRNA-mediated knockdown of CRT caused impaired cell migration, invasion and resistance to anoikis. Notably, CRT downregulation decreased the expression of Cortactin (CTTN), which has been previously reported as a candidate oncogene associated with anoikis through the PI3K-Akt pathway. In addition, Akt phosphorylation was abolished after CRT downregulation and its activation can be refreshed by CRT upregulation, suggesting that CRT-enhanced cell resistance to anoikis through the CRT-CTTN-PI3K-Akt pathway. Moreover, the CTTN mRNA level was decreased in CRT-siRNA cells, coupled with the inactivation of STAT3. Expression of both CTTN and p-STAT3 was reduced in tumor cells following incubation with the JAK-specific inhibitor, AG490. Chromatin immunoprecipitation assay showed direct binding of p-STAT3 to the conservative STAT3-binding sequences in CTTN promoter. Furthermore, overexpression of CTTN in CRT-downregulated ESCC cells restored its motility and resistance to anoikis. This study not only reveals a role of CRT in motility promotion and anoikis resistance in ESCC cells, but also identifies CRT as an upstream regulator in the CRT-STAT3-CTTN Akt pathway. Oncogene (2009) 28, 3714-3722; doi: 10.1038/onc.2009.237; published online 17 August 2009	[Wang, M-R] Chinese Acad Med Sci, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Wang, MR (corresponding author), Chinese Acad Med Sci, Canc Inst Hosp, State Key Lab Mol Oncol, 17 Pan Jia Yuan, Beijing 100021, Peoples R China.	wangmr04@126.com	Luo, Man/GWQ-4789-2022; luo, man/HGC-7868-2022; LIN, DECHEN/K-9457-2014		National Basic Research Program of China [2004CB518705]; National High-tech R&D Program of China [2006AA02A403]; National Key Technologies R&D Program of China [2006BAI02A14]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20060023003]; National Natural Science Foundation [30872936, 30721001]	National Basic Research Program of China(National Basic Research Program of China); National High-tech R&D Program of China(National High Technology Research and Development Program of China); National Key Technologies R&D Program of China(National Key Technology R&D Program); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	We thank Professor Simon J Harris for the English revision of the article. This study was supported by National Basic Research Program of China (2004CB518705), National High-tech R&D Program of China (2006AA02A403), National Key Technologies R&D Program of China (2006BAI02A14), Specialized Research Fund for the Doctoral Program of Higher Education of China (20060023003) and National Natural Science Foundation (30872936, 30721001).	Alaiya A, 2000, ANAL CELL PATHOL, V21, P1, DOI 10.1155/2000/351963; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chahed K, 2005, INT J ONCOL, V27, P1425; Chen DQ, 2005, J BIOL CHEM, V280, P22425, DOI 10.1074/jbc.M413380200; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Clark ES, 2009, ONCOGENE, V28, P431, DOI 10.1038/onc.2008.389; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Du XL, 2007, J MOL MED, V85, P863, DOI 10.1007/s00109-007-0159-4; Eric A, 2009, PATHOL ONCOL RES, V15, P89, DOI 10.1007/s12253-008-9112-2; Gold LI, 2006, J INVEST DERM SYMP P, V11, P57, DOI 10.1038/sj.jidsymp.5650011; Hayashida Y, 2006, J BIOL CHEM, V281, P32469, DOI 10.1074/jbc.M607240200; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kim YM, 2004, MOL CELL BIOCHEM, V259, P23, DOI 10.1023/B:MCBI.0000021341.38630.52; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Li YS, 2001, CANCER RES, V61, P6906; Lim S, 2008, MOL CELLS, V25, P390; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Nishimori T, 2006, PROTEOMICS, V6, P1011, DOI 10.1002/pmic.200500262; Okunaga T, 2006, CANCER RES, V66, P8662, DOI 10.1158/0008-5472.CAN-05-4256; Pallero MA, 2008, FASEB J, V22, P3968, DOI 10.1096/fj.07-104802; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Vougas K, 2008, J BUON, V13, P101; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	37	60	69	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3714	3722		10.1038/onc.2009.237	http://dx.doi.org/10.1038/onc.2009.237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19684620				2022-12-17	WOS:000271023200004
J	Palamakumbura, AH; Vora, SR; Nugent, MA; Kirsch, KH; Sonenshein, GE; Trackman, PC				Palamakumbura, A. H.; Vora, S. R.; Nugent, M. A.; Kirsch, K. H.; Sonenshein, G. E.; Trackman, P. C.			Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling	ONCOGENE			English	Article						lysyl oxidase; tumor suppressor; prostate cancer; cell proliferation; fibroblast growth factor; Ras	HEPARAN-SULFATE PROTEOGLYCANS; TUMOR-SUPPRESSOR ACTIVITY; FACTOR RECEPTOR; MESSENGER-RNA; BREAST-CANCER; PHENOTYPIC REVERSION; MEDIATED MECHANISM; ANDROGEN RECEPTOR; IN-VITRO; H-RAS	Enhanced RAS signaling and decreased androgen dependence of prostate cancer cells accompany poor clinical outcomes. Elevated autocrine fibroblast growth factors 2 (FGF-2) signaling promotes prostate cancer cell growth and survival. Expression of lysyl oxidase (LOX) inhibits RAS transforming activity. LOX is secreted as 50 kDa pro-LOX protein and then undergoes extracellular proteolytic processing to form similar to 30 kDa LOX enzyme and similar to 18 kDa propeptide (LOX-PP). We have previously shown that LOX-PP inhibits breast cancer cell transformation and tumor formation, but mechanisms of action of LOX-PP have not been fully elucidated. Here we report that LOX expression is reduced in prostate cancer cell lines and that recombinant LOX-PP protein inhibits serum-stimulated DNA synthesis and MEK/ERK and PI3K/AKT pathways in DU 145 and PC-3 androgen-independent cell lines. In DU 145 cells, treatment with a pharmacologic FGF-receptor inhibitor or a neutralizing anti-FGFR1 antibody mimicked LOX-PP inhibition of serum-stimulated DNA synthesis. FGF-2-stimulated DNA synthesis, ERK1/2, AKT and FRS2 alpha activation were found all to be inhibited by LOX-PP in DU 145 cells. LOX-PP reduced specific binding of FGF-2 to DU 145 cells, suggesting that LOX-PP targets FGF signaling at the receptor. Interestingly, PC-3 cells did not respond to FGF-2, consistent with previous reports. We conclude that LOX-PP inhibits proliferation of DU 145 cells by interfering with FGFR(s) binding and signaling, and that LOX-PP has other mechanisms of action in PC-3 cells. Oncogene (2009) 28, 3390-3400; doi: 10.1038/onc.2009.203; published online 13 July 2009	[Palamakumbura, A. H.; Vora, S. R.; Trackman, P. C.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, Boston, MA 02118 USA; [Nugent, M. A.; Kirsch, K. H.; Sonenshein, G. E.; Trackman, P. C.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Trackman, PC (corresponding author), Boston Univ, Henry M Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, 700 Albany St,W-201, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Nugent, Matthew/0000-0002-8630-4712; Kirsch, Kathrin/0000-0003-1532-1715	NIH/NCI [CA082742]; DOD [W81XWH-08-1-0349]; NIH/NIDCR [DE14066]; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by NIH/NCI CA082742, DOD Award W81XWH-08-1-0349, NIH/NIDCR DE14066. We thank Danielle Stephens and Emilie Vu for expert preparation of rLOX-PP.	Bansal R, 2003, J NEUROSCI RES, V74, P486, DOI 10.1002/jnr.10773; Blanckaert VD, 2002, HYBRIDOMA HYBRIDOM, V21, P153, DOI 10.1089/153685902760173863; Bonaccorsi L, 2004, J CANCER RES CLIN, V130, P604, DOI 10.1007/s00432-004-0581-8; Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082; Chua CC, 2004, CIRC RES, V94, P316, DOI 10.1161/01.RES.0000112965.70691.AC; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Contente S, 2009, BBA-MOL CELL RES, V1793, P1272, DOI 10.1016/j.bbamcr.2009.04.013; Cronauer MV, 1997, PROSTATE, V31, P223; CULIG Z, 1994, CANCER RES, V54, P5474; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Forsten-Williams K, 2005, J THEOR BIOL, V233, P483, DOI 10.1016/j.jtbi.2004.10.020; Gioeli D, 2005, CLIN SCI, V108, P293, DOI 10.1042/CS20040329; Gioeli D, 1999, CANCER RES, V59, P279; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Giri D, 1999, CLIN CANCER RES, V5, P1063; Guo Y, 2007, AM J PHYSIOL-CELL PH, V292, pC2095, DOI 10.1152/ajpcell.00613.2006; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Hatziapostolou M, 2006, J BIOL CHEM, V281, P32217, DOI 10.1074/jbc.M607104200; He QM, 2003, J BIOL CHEM, V278, P21831, DOI 10.1074/jbc.M300880200; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Hurtado PA, 2008, BIOCHEM BIOPH RES CO, V366, P156, DOI 10.1016/j.bbrc.2007.11.116; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jones HE, 1997, INT J CANCER, V71, P1010, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1010::AID-IJC17>3.0.CO;2-H; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kominsky SL, 2000, CANCER RES, V60, P3904; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; McPherson RA, 2004, PROSTATE, V58, P325, DOI 10.1002/pros.10336; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NAKAMOTO T, 1992, CANCER RES, V52, P571; Natke B, 1999, Angiogenesis, V3, P249, DOI 10.1023/A:1009008824246; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Planz B, 2001, J UROLOGY, V166, P678, DOI 10.1016/S0022-5347(05)66042-9; Polnaszek N, 2003, CANCER RES, V63, P5754; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ren CZ, 1998, CANCER RES, V58, P1285; Richardson TP, 1999, J BIOL CHEM, V274, P13534, DOI 10.1074/jbc.274.19.13534; Ropiquet F, 2000, CANCER RES, V60, P4245; Ropiquet F, 1999, J UROLOGY, V162, P595, DOI 10.1016/S0022-5347(05)68632-6; SAMID D, 1993, J CLIN INVEST, V91, P2288, DOI 10.1172/JCI116457; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Shain SA, 2004, MOL CANCER RES, V2, P653; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426; Zhao YS, 2009, J BIOL CHEM, V284, P1385, DOI 10.1074/jbc.M802612200	70	60	63	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3390	3400		10.1038/onc.2009.203	http://dx.doi.org/10.1038/onc.2009.203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597471	Green Accepted			2022-12-17	WOS:000270103300006
J	Walker, M; Black, EJ; Oehler, V; Gillespie, DA; Scott, MT				Walker, M.; Black, E. J.; Oehler, V.; Gillespie, D. A.; Scott, M. T.			Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity	ONCOGENE			English	Article						Chk1; ATR; kinase activity	DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND BREAKS; IONIZING-RADIATION; GENOTOXIC STRESS; REQUIRES ATM; S-PHASE; KINASE; REPLICATION; RECRUITMENT; CHROMATIN	Chk1 is phosphorylated within its C-terminal regulatory domain by the upstream ATM/ATR kinases during checkpoint activation; however, how this modulates Chk1 function is poorly understood. Here, we show that Chk1 kinase activity is rapidly stimulated in a cell-cycle phase-specific manner in response to both DNA damage and replication arrest, and that the extent and duration of activation correlates closely with regulatory phosphorylation at serines (S) S317, S345 and S366. Despite their evident co-regulation, substitutions of individual Chk1 regulatory sites with alanine (A) residues have differential effects on checkpoint proficiency and kinase activation. Thus, whereas Chk1 S345 is essential for all functions tested, mutants lacking S317 or S366 retain partial proficiency for G2/M and S/M checkpoint arrests triggered by DNA damage or replication arrest. These phenotypes reflect defects in Chk1 kinase induction, as the mutants are either partially (317A and 366A) or completely (345A) resistant to kinase activation. Importantly, S345 phosphorylation is impaired in Chk1 S317A and S366A mutants, suggesting that modi. cation of adjacent SQ sites promotes this key regulatory event. Finally, we provide biochemical evidence that Chk1 catalytic activity is stimulated by a de-repression mechanism. Oncogene (2009) 28, 2314-2323; doi:10.1038/onc.2009.102; published online 4 May 2009	[Walker, M.; Black, E. J.; Oehler, V.; Gillespie, D. A.; Scott, M. T.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Gillespie, D. A.] Univ Glasgow, Fac Biomed & Life Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow	Scott, MT (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.scott@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Scott, Mary/0000-0002-7177-6960	Cancer Research UK [A3674] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bonilla CY, 2008, MOL CELL, V30, P267, DOI 10.1016/j.molcel.2008.03.023; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	36	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2314	2323		10.1038/onc.2009.102	http://dx.doi.org/10.1038/onc.2009.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421147	Green Accepted			2022-12-17	WOS:000267089100002
J	Kang, J; Perry, JK; Pandey, V; Fielder, GC; Mei, B; Qian, PX; Wu, ZS; Zhu, T; Liu, DX; Lobie, PE				Kang, J.; Perry, J. K.; Pandey, V.; Fielder, G. C.; Mei, B.; Qian, P. X.; Wu, Z. S.; Zhu, T.; Liu, D. X.; Lobie, P. E.			Artemin is oncogenic for human mammary carcinoma cells	ONCOGENE			English	Article						artemin; GDNF; mammary; carcinoma; oncogenicity	NEUROTROPHIC FACTOR GDNF; PANCREATIC-CANCER CELLS; HUMAN GROWTH-HORMONE; BREAST-CANCER; STROMAL FIBROBLASTS; NEURONAL CELLS; NUDE-MICE; FAMILY; EXPRESSION; RECEPTOR	We report that artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is oncogenic for human mammary carcinoma. Artemin is expressed in numerous human mammary carcinoma cell lines. Forced expression of artemin in mammary carcinoma cells results in increased anchorage-independent growth, increased colony formation in soft agar and in three-dimensional Matrigel, and also promotes a scattered cell phenotype with enhanced migration and invasion. Moreover, forced expression of artemin increases tumor size in xenograft models and leads to highly proliferative, poorly differentiated and invasive tumors. Expression data in Oncomine indicate that high artemin expression is significantly associated with residual disease after chemotherapy, metastasis, relapse and death. Artemin protein is detectable in 65% of mammary carcinoma and its expression correlates to decreased overall survival in the cohort of patients. Depletion of endogenous artemin with small interfering RNA, or antibody inhibition of artemin, decreases the oncogenicity and invasiveness of mammary carcinoma cells. Artemin is therefore oncogenic for human mammary carcinoma, and targeted therapeutic approaches to inhibit artemin function in mammary carcinoma warrant consideration. Oncogene (2009) 28, 2034-2045; doi:10.1038/onc.2009.66; published online 13 April 2009	[Kang, J.; Perry, J. K.; Pandey, V.; Fielder, G. C.; Liu, D. X.; Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1010, North Island, New Zealand; [Mei, B.; Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Mei, B.; Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Mei, B.] Anhui Med Univ, Inst Basic Med, Hefei, Anhui, Peoples R China; [Wu, Z. S.] Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China; [Lobie, P. E.] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1010, North Island, New Zealand	University of Auckland; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University; Anhui Medical University; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1010, North Island, New Zealand.	p.lobie@auckland.ac.nz	Pandey, Vijay/P-2767-2016; Qian, Pengxu/B-9376-2016	Kang, Jian/0000-0001-9998-4975; Perry, Jo/0000-0002-4418-947X; Qian, Pengxu/0000-0001-5636-6704	Breast Cancer Research Trust (NZ); Foundation for Research, Science and Technology of New Zealand; Hundred-Talent Scheme of Chinese Academy of Sciences; National Natural Science Foundation of China [2007CB914801, 2007CB914503]; National Basic Research Program of China [30571030]	Breast Cancer Research Trust (NZ); Foundation for Research, Science and Technology of New Zealand(New Zealand Foundation for Research, Science and Technology); Hundred-Talent Scheme of Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	We thank Alan Beedle for critical reading of the manuscript. This work was funded by the Breast Cancer Research Trust (NZ), the Foundation for Research, Science and Technology of New Zealand, the Hundred-Talent Scheme of Chinese Academy of Sciences, the National Natural Science Foundation of China (2007CB914801 & 2007CB914503) and the National Basic Research Program of China (30571030).	Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Bespalov MM, 2007, TRENDS PHARMACOL SCI, V28, P68, DOI 10.1016/j.tips.2006.12.005; BROUTYBOYE D, 1993, ANTICANCER RES, V13, P1087; Ceyhan GO, 2007, GUT, V56, P534, DOI 10.1136/gut.2006.105528; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; Duxbury MS, 2004, ANN SURG, V240, P667, DOI 10.1097/01.sla.0000140755.97224.9a; Enomoto H, 2004, NEURON, V44, P623, DOI 10.1016/j.neuron.2004.10.032; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Hutcheson IR, 2006, ENDOCR-RELAT CANCER, V13, pS89, DOI 10.1677/erc.1.01279; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Ito Y, 2005, SURGERY, V138, P788, DOI 10.1016/j.surg.2005.07.007; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu DX, 2007, CELL DEATH DIFFER, V14, P1893, DOI 10.1038/sj.cdd.4402209; Lubaroff D M, 1980, Prog Clin Biol Res, V37, P243; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Meng XJ, 2001, MOL CELL ENDOCRINOL, V184, P33, DOI 10.1016/S0303-7207(01)00649-9; Meng XJ, 2001, CANCER RES, V61, P3267; Okada Y, 1999, INT J CANCER, V81, P67, DOI 10.1002/(SICI)1097-0215(19990331)81:1<67::AID-IJC13>3.0.CO;2-V; Pandey V, 2008, ENDOCRINOLOGY, V149, P3909, DOI 10.1210/en.2008-0286; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Saarma M, 1999, MICROSC RES TECHNIQ, V45, P292, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Schueler-Furman O, 2006, TRENDS PHARMACOL SCI, V27, P72, DOI 10.1016/j.tips.2005.12.004; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Su G, 2007, J BIOL CHEM, V282, P14906, DOI 10.1074/jbc.M611739200; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Veit C, 2004, CANCER RES, V64, P5291, DOI 10.1158/0008-5472.CAN-04-1112; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje; Zhu T, 2005, CANCER RES, V65, P317; Zhu ZW, 2001, CLIN CANCER RES, V7, P105; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	43	60	70	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2034	2045		10.1038/onc.2009.66	http://dx.doi.org/10.1038/onc.2009.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363524				2022-12-17	WOS:000266023900004
J	McCabe, N; Cerone, MA; Ohishi, T; Seimiya, H; Lord, CJ; Ashworth, A				McCabe, N.; Cerone, M. A.; Ohishi, T.; Seimiya, H.; Lord, C. J.; Ashworth, A.			Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer	ONCOGENE			English	Article						BRCA1/2; Tankyrase 1; synthetic lethality; anticancer therapy	DNA-REPAIR DEFECT; POLY(ADP-RIBOSE) POLYMERASE; CENTROSOME AMPLIFICATION; HUMAN TELOMERES; MUTANT-CELLS; TRF1; PARP; INSTABILITY; PROGRESSION; SUBSTRATE	The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-of-function mutations in either BRCA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs. It has been demonstrated previously that inhibiting elements of the cellular DNA maintenance pathways represents a novel therapeutic approach to treating tumors in these individuals. Here, we show that inhibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA deficiency. We also demonstrate that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the centrosome amplification phenotype associated with BRCA deficiency. We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-associated cancers.	[McCabe, N.; Cerone, M. A.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [McCabe, N.; Ashworth, A.] Inst Canc Res, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England; [Ohishi, T.; Seimiya, H.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Biotherapy, Tokyo 170, Japan	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Japanese Foundation for Cancer Research	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Alan.Ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; Ohishi, Tomokazu/0000-0002-9039-4474; Seimiya, Hiroyuki/0000-0003-3314-9736	Breakthrough Breast Cancer; Cancer Research UK	Breakthrough Breast Cancer; Cancer Research UK(Cancer Research UK)	This work was funded by Breakthrough Breast Cancer and Cancer Research UK. We thank Jill Williamson and Dave Robertson for assistance with karyotyping and microscopy, respectively.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chang W, 2005, BIOCHEM J, V391, P177, DOI 10.1042/BJ20050885; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DelloRusso C, 2007, MOL CANCER RES, V5, P35, DOI 10.1158/1541-7786.MCR-06-0234; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kleine H, 2008, MOL CELL, V32, P57, DOI 10.1016/j.molcel.2008.08.009; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Seimiya H, 2006, BRIT J CANCER, V94, P341, DOI 10.1038/sj.bjc.6602951; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	26	60	66	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1465	1470		10.1038/onc.2008.483	http://dx.doi.org/10.1038/onc.2008.483			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19182824				2022-12-17	WOS:000264354400007
J	Kim, DJ; Angel, JM; Sano, S; DiGiovanni, J				Kim, D. J.; Angel, J. M.; Sano, S.; DiGiovanni, J.			Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis	ONCOGENE			English	Article						Stat3; skin carcinogenesis; UVB	SQUAMOUS-CELL CARCINOMAS; NUCLEOTIDE EXCISION-REPAIR; INDUCED CUTANEOUS DAMAGE; KINASE-C-EPSILON; EPITHELIAL CARCINOGENESIS; MEDIATED ACTIVATION; TUMOR-DEVELOPMENT; PROMOTION STAGES; HAIRLESS MOUSE; DNA-DAMAGE	In this study, the potential role of Stat3 in UVB-induced skin carcinogenesis was examined using skin-specific gain and loss of function transgenic mice, that is, K5.Stat3C and K5Cre.Stat3(fl/fl) mice, respectively. The epidermis of Stat3-deficient mice was highly sensitive to UVB-induced apoptosis, whereas the epidermis of K5.Stat3C mice was more resistant to UVB-induced apoptosis. In particular, the status of Stat3 influenced the survival of ultraviolet-photoproduct cells, including those located in the hair follicles. K5.Stat3C mice exhibited significantly increased epidermal proliferation and hyperplasia in response to UVB irradiation, whereas Stat3-deficient mice showed reduced epidermal proliferation and hyperplasia. Expression of target genes regulated by Stat3, such as cyclin D1 and Bcl-x(L), was increased in epidermis of both control and UVB-irradiated K5.Stat3C mice, and downregulated in epidermis of both control and UVB-irradiated K5Cre.Stat3(fl/fl) mice. Following UVB irradiation, the formation of skin tumors in K5.Stat3C mice was accelerated and both the incidence and multiplicity of skin tumors were significantly greater than wild-type controls. In contrast, Stat3-deficient mice were resistant to UVB skin carcinogenesis. These results show that Stat3 plays an important role in the development of UVB-induced skin tumors through its effects on both survival and proliferation of keratinocytes during carcinogenesis.	[Kim, D. J.; Angel, J. M.; DiGiovanni, J.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX USA; [Sano, S.] Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan	University of Texas System; UTMD Anderson Cancer Center; Osaka University	DiGiovanni, J (corresponding author), MD Anderson, Sci Pk,1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	jdigiova@mdanderson.org		KIM, DAE/0000-0002-7977-9955	NATIONAL CANCER INSTITUTE [R01CA076520, U01CA105345, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA105345, P30 CA016672, CA16672, R01 CA076520, CA105345, R01 CA076520-02, CA76520] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, P30 ES007784-12, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahsan H, 2005, BIOCHEM BIOPH RES CO, V333, P241, DOI 10.1016/j.bbrc.2005.05.106; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Aziz MH, 2007, CANCER RES, V67, P1385, DOI 10.1158/0008-5472.CAN-06-3350; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Frank David A, 2003, Cancer Treat Res, V115, P267; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Kataoka K, 2008, CARCINOGENESIS, V29, P1108, DOI 10.1093/carcin/bgn061; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kim AL, 2002, BIOCHEM BIOPH RES CO, V298, P377, DOI 10.1016/S0006-291X(02)02435-X; Kim DJ, 2007, MOL CARCINOGEN, V46, P725, DOI 10.1002/mc.20342; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Masuda M, 2002, CANCER RES, V62, P3351; Melnikova VO, 2005, MUTAT RES-FUND MOL M, V571, P91, DOI 10.1016/j.mrfmmm.2004.11.015; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Nijhof JGW, 2007, CARCINOGENESIS, V28, P792, DOI 10.1093/carcin/bgl213; Noonan FP, 2000, CANCER RES, V60, P3738; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sano S, 2005, CANCER RES, V65, P5720, DOI 10.1158/0008-5472.CAN-04-4359; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sano S, 2008, J DERMATOL SCI, V50, P1, DOI 10.1016/j.jdermsci.2007.05.016; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881	48	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					950	960		10.1038/onc.2008.453	http://dx.doi.org/10.1038/onc.2008.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19137019	Green Accepted			2022-12-17	WOS:000263457400002
J	Ohtani, Y; Harada, T; Funasaka, Y; Nakao, K; Takahara, C; Abdel-Daim, M; Sakai, N; Saito, N; Nishigori, C; Aiba, A				Ohtani, Y.; Harada, T.; Funasaka, Y.; Nakao, K.; Takahara, C.; Abdel-Daim, M.; Sakai, N.; Saito, N.; Nishigori, C.; Aiba, A.			Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma	ONCOGENE			English	Article						mGluR1; melanoma; transgenic; tetracycline	MGLUR1 MUTANT MICE; MALIGNANT-MELANOMA; GENE-EXPRESSION; CELLS; BRAF; MUTATIONS; GLUTAMATE-RECEPTOR-1; STIMULATION; ACTIVATION; PLASTICITY	Ectopic expression of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse melanocytes induces melanoma formation. Although requirement of mGluR1 for development of melanoma in the initial stage has been demonstrated, its role in melanoma growth in vivo remains unclear. In this study, we developed novel transgenic mice that conditionally express mGluR1 in melanocytes, using a tetracycline regulatory system. Pigmented lesions on the ears and tails of the transgenic mice began to appear 29 weeks after activation of the mGluR1 transgene, and the transgenic mice produced melanomas at a frequency of 100% 52 weeks after transgene activation. Subsequent inactivation of the mGluR1 transgene in melanoma-bearing mice inhibited melanoma growth with reduction of immunoreactivity to phosphorylated ERK1/2, whereas mice with persistent expression of mGluR1 developed larger melanoma burdens. mGluR1 expression is thus required not only for melanoma development but also for melanoma growth in vivo. These findings suggest that growth of melanoma can be inhibited in vivo by eliminating only one of the multiple genetic anomalies involved in tumorigenesis.	[Ohtani, Y.; Harada, T.; Takahara, C.; Aiba, A.] Kobe Univ, Div Mol Genet, Dept Physiol & Cell Biol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Funasaka, Y.; Abdel-Daim, M.; Nishigori, C.] Kobe Univ, Div Dermatol, Dept Clin Mol Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Nakao, K.] RIKEN, Lab Anim Resources & Genet Engn, Ctr Dev Biol, Kobe, Hyogo, Japan; [Sakai, N.] Hiroshima Univ, Dept Mol & Pharmacol Neurosci, Grad Sch Biomed Sci, Hiroshima, Japan; [Saito, N.] Kobe Univ, Mol Pharmacol Lab, Biosignal Res Ctr, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University; RIKEN; Hiroshima University; Kobe University	Aiba, A (corresponding author), Kobe Univ, Div Mol Genet, Dept Physiol & Cell Biol, Grad Sch Med,Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	aiba@med.kobe-u.ac.jp	Abdel-Daim, Mohamed M./B-2545-2013; Sakai, Norio/AAM-5822-2021	Abdel-Daim, Mohamed M./0000-0002-4341-2713; Sakai, Norio/0000-0002-6648-8761; zhong wei, he gui/0000-0002-3066-3564	Ministry of Education, Culture, Sports, Science and Technology of Japan; Naito Foundation; Takeda Science Foundation; Uehara Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Uehara Memorial Foundation(Uehara Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders	We thank Dr S Nakanishi for rat mGluR1a cDNA, Dr Y Ishida for beta-globin insulator and the members of Aiba lab for helpful discussion. This study supported in part by Grant-in-Aid for Scientific Research on Priority Areas Molecular Brain Science, a grant for the 21st Century COE Program 'Center for Excellence for Signal Transduction Disease: Diabetes Mellitus as Model' from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from the Naito Foundation, the Takeda Science Foundation, the Uehara Memorial Foundation and the Astellas Foundation for Research on Metabolic Disorders.	AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Handerson T, 2003, CANCER RES, V63, P5363; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Marin YE, 2005, NEUROPHARMACOLOGY, V49, P70, DOI 10.1016/j.neuropharm.2005.05.018; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nambiar S, 2005, ARCH DERMATOL, V141, P165, DOI 10.1001/archderm.141.2.165; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Thandi S, 2002, J NEUROCHEM, V83, P1139, DOI 10.1046/j.1471-4159.2002.01217.x; Thomas NE, 2006, MELANOMA RES, V16, P97, DOI 10.1097/01.cmr.0000215035.38436.87; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Wong CW, 2005, J CLIN PATHOL, V58, P640, DOI 10.1136/jcp.2004.022509	30	60	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7162	7170		10.1038/onc.2008.329	http://dx.doi.org/10.1038/onc.2008.329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18776920	Bronze			2022-12-17	WOS:000261384100003
J	Leikam, C; Hufnagel, A; Schartl, M; Meierjohann, S				Leikam, C.; Hufnagel, A.; Schartl, M.; Meierjohann, S.			Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence	ONCOGENE			English	Article						ROS; melanoma; senescence; oncogene; N-RAS; melanocyte	RECEPTOR TYROSINE KINASE; CELL-CYCLE ARREST; GROWTH-FACTOR; MALIGNANT-MELANOMA; RAS; EXPRESSION; PROTEIN; MUTATIONS; P53; PHOSPHORYLATION	Contrary to malignant melanoma, nevi are a benign form of melanocytic hyperproliferation. They are frequently observed as precursor lesions of melanoma, but they also feature biochemical markers of senescence. In particular, evidence for oncogene-induced melanocyte senescence as natural means to prevent tumorigenesis has been obtained in nevi with mutated B-Raf(V600E). Here, we demonstrate that strong oncogenic growth factor receptor signalling drives melanocytes into senescence, whereas weaker signals keep them in the proliferative state. Activation of oncogene-induced senescence also produces multinucleated giant cells, a long known histological feature of nevus cells. The protein levels of the senescence mediators, p53 and pRB, and their upstream activators do not correlate with senescence. However, strong oncogene signalling leads to pronounced reactive oxygen stress, and scavenging of reactive oxygen species (ROS) efficiently prevents the formation of multinucleated cells and senescence. Similarly, expression of oncogenic N-RAS results in ROS generation, DNA damage and the same multinuclear senescent phenotype. Hence, we identified oncogenic signalling-dependent ROS production as critical mediator of the melanocytic multinuclear phenotype and senescence, both of them being hallmarks of human nevus cells.	[Leikam, C.; Hufnagel, A.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany	University of Wurzburg	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de		Schartl, Manfred/0000-0001-9882-5948	Deutsche Forschungsgesellschaft; German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg	Deutsche Forschungsgesellschaft(German Research Foundation (DFG)); German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg	We thank Dr Thorsten Stiewe for kindly providing the PAB 122 hybridoma supernatant and Professor Jurgen Hoppe for his help with the time lapse experiment. In addition, we thank Johannes Haydn for generating the melan a pWHE459 cell lines and Toni Wagner for great technical support. This work was supported by the Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'). CL was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Chang DLF, 2007, ONCOGENE, V26, P4627, DOI 10.1038/sj.onc.1210254; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chen CR, 2005, CANCER RES, V65, P6017, DOI 10.1158/0008-5472.CAN-05-0677; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Geissinger E, 2002, CANCER RES, V62, P4820; Goding C R, 2000, Forum (Genova), V10, P176; Gorla GR, 2001, J CELL SCI, V114, P2943; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hayashi C, 2007, J CELL BIOCHEM, V101, P979, DOI 10.1002/jcb.21298; Hirose Y, 2005, CANCER RES, V65, P4861, DOI 10.1158/0008-5472.CAN-04-2633; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kopnin PB, 2007, CANCER RES, V67, P4671, DOI 10.1158/0008-5472.CAN-06-2466; Krueger C, 2006, J GENE MED, V8, P1037, DOI 10.1002/jgm.932; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lachat Y, 2004, ONCOGENE, V23, P6854, DOI 10.1038/sj.onc.1207872; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LEOPOLD JG, 1967, J PATHOL BACTERIOL, V94, P247, DOI 10.1002/path.1700940203; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2006, TRENDS GENET, V22, P654, DOI 10.1016/j.tig.2006.09.013; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Passos JF, 2006, FREE RADICAL RES, V40, P1277, DOI 10.1080/10715760600917151; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rangel J, 2008, CANCER-AM CANCER SOC, V112, P144, DOI 10.1002/cncr.23147; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Satyamoorthy K, 2003, CANCER RES, V63, P756; SAVCHENKO YY, 1988, TSITOL GENET+, V22, P20; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Spyridopoulos I, 2002, BASIC RES CARDIOL, V97, P117, DOI 10.1007/s003950200001; Straume O, 2000, CLIN CANCER RES, V6, P1845; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Vigneron A, 2005, CANCER RES, V65, P8927, DOI 10.1158/0008-5472.CAN-05-0461; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 2005, CURR BIOL, V15, P1629, DOI 10.1016/j.cub.2005.08.036; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	70	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	56					7070	7082		10.1038/onc.2008.323	http://dx.doi.org/10.1038/onc.2008.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18806824				2022-12-17	WOS:000261195900002
J	Calvo, A; Catena, R; Noble, MS; Carbott, D; Gil-Bazo, I; Gonzalez-Moreno, O; Huh, JI; Sharp, R; Qiu, TH; Anver, MR; Merlino, G; Dickson, RB; Johnson, MD; Green, JE				Calvo, A.; Catena, R.; Noble, M. S.; Carbott, D.; Gil-Bazo, I.; Gonzalez-Moreno, O.; Huh, J-I; Sharp, R.; Qiu, T-H; Anver, M. R.; Merlino, G.; Dickson, R. B.; Johnson, M. D.; Green, J. E.			Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis	ONCOGENE			English	Article						metastasis; vascular endothelial growth factor; transgenic mice; mammary cancer; tenascin-C	BREAST-CANCER METASTASIS; TRANSGENIC MICE; MOUSE MAMMARY; MYC; ANGIOGENESIS; EXPRESSION; PROGNOSIS; LAMININ-5; MIGRATION; INVASION	Metastasis is the primary cause of death in patients with breast cancer. Overexpression of c-myc in humans correlates with metastases, but transgenic mice only show low rates of micrometastases. We have generated transgenic mice that overexpress both c-myc and vascular endothelial growth factor (VEGF) (Myc/VEGF) in the mammary gland, which develop high rates of pulmonary macrometastases. Gene expression pro. ling revealed a set of deregulated genes in Myc/VEGF tumors compared to Myc tumors associated with the increased metastatic phenotype. Cross-comparisons between this set of genes with a human breast cancer lung metastasis gene signature identified five common targets: tenascin-C (TNC), matrix metalloprotease-2, collagen-6-A1, mannosidase-alpha-1A and HLA-DPA1. Signaling blockade or knockdown of TNC in MDA-MB-435 cells resulted in a significant impairment of cell migration and anchorage-independent cell proliferation. Mice injected with clonal MDA-MB-435 cells with reduced expression of TNC demonstrated a signifiant decrease (P < 0.05) in (1) primary tumor growth; (2) tumor relapse after surgical removal of the primary tumor and (3) incidence of lung metastasis. Our results demonstrate that VEGF induces complex alterations in tissue architecture and gene expression. The TNC signaling pathway plays an important role in mammary tumor growth and metastases, suggesting that TNC may be a relevant target for therapy against metastatic breast cancer.	[Calvo, A.; Huh, J-I; Sharp, R.; Qiu, T-H; Merlino, G.; Green, J. E.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Calvo, A.; Catena, R.; Gil-Bazo, I.; Gonzalez-Moreno, O.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, E-31080 Pamplona, Spain; [Calvo, A.; Catena, R.; Gil-Bazo, I.; Gonzalez-Moreno, O.] Univ Navarra, Dept Histol & Pathol, E-31080 Pamplona, Spain; [Noble, M. S.; Carbott, D.; Dickson, R. B.; Johnson, M. D.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Gil-Bazo, I.] Univ Navarra Clin, Dept Oncol, Pamplona, Spain; [Anver, M. R.] Frederick Canc Res & Dev Ctr, Pathol & Histol Lab, SAIC, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Navarra; University of Navarra; Georgetown University; University of Navarra; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Johnson, MD (corresponding author), NCI, Dr Lab Canc Biol & Genet, NIH, Bldg 37 Room 4054 37 Convent Dr, Bethesda, MD 20892 USA.	Johnsom@georgetown.edu; jegreen@nih.gov	Gil-Bazo, Ignacio/E-4581-2019; Calvo, Alfonso/V-7945-2017	Gil-Bazo, Ignacio/0000-0002-2626-5109; Calvo, Alfonso/0000-0003-4074-4242; , Janet/0000-0001-9020-6982	Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research; NIH [NO1-CO-12400, R01 CA72460, 2R01 CA104963, 2 R01 AG14963-06]; Susan G Komen Foundation; DOD Breast Cancer Program [DAMD17-01-1-0255]; ISCIII-RETIC [RD06/0020]; Fulbright-MEC fellowship; Spanish MEC fellowship; NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC010871, ZIABC011229] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); DOD Breast Cancer Program(United States Department of Defense); ISCIII-RETIC(Instituto de Salud Carlos III); Fulbright-MEC fellowship; Spanish MEC fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Ms Mercedes Calvo for manuscript preparation, Victor Segura and Elizabeth Guruceaga (CEIT and Tecnun, Pamplona, Spain) for their help in bioinformatic analysis, GlaxoSmithKline for the GW654652 compound, Dr Rene Bernards (The Netherlands Cancer Institute) for the pMSCV-Delta 3<SUP>1</SUP>LTR vector, Dr Linda Metheny-Barlow (at the LCCC) for helpful discussions, Edward C Rosfjord and Sandra L Deming and Gloria Chepko for contributions to the initial Myc/VEGF crossbreeding study. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, with funds from NIH(to GM) under Contract No. NO1-CO-12400, a grant from the Susan G Komen Foundation (to RBD), a grant from the DOD Breast Cancer Program DAMD17-01-1-0255 (to MDJ), NIH R01 CA72460 (to RBD), NIH 2R01 CA104963 (to RBD) ISCIII-RETIC (RD06/0020, to AC) and a Fulbright-MEC fellowship (AC); O G-M was supported by a Spanish MEC fellowship, and RBD by an NIH grant 2 R01 AG14963-06.	Adams J, 2000, CANCER RES, V60, P2898; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Calvo A, 2002, CANCER RES, V62, P5325; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; De Paola F, 2002, INT J CANCER, V98, P228, DOI 10.1002/ijc.10118; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huh JI, 2005, ONCOGENE, V24, P790, DOI 10.1038/sj.onc.1208221; Hundley JE, 1997, CANCER RES, V57, P600; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kalembeyi I, 2003, INT J CANCER, V105, P53, DOI 10.1002/ijc.11037; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Miyazaki K, 2006, CANCER SCI, V97, P91, DOI 10.1111/j.1349-7006.2006.00150.x; Noel A, 2004, J CLIN PATHOL, V57, P577, DOI 10.1136/jcp.2003.014472; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; PYKE C, 1994, AM J PATHOL, V145, P782; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schoeffner DJ, 2005, LAB INVEST, V85, P608, DOI 10.1038/labinvest.3700258; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Talts JF, 1999, J CELL SCI, V112, P1855; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Yamamoto H, 2001, CLIN CANCER RES, V7, P896; Zagzag D, 2002, CANCER RES, V62, P2660; Zagzag D, 2002, HISTOL HISTOPATHOL, V17, P301, DOI 10.14670/HH-17.301	35	60	66	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5373	5384		10.1038/onc.2008.155	http://dx.doi.org/10.1038/onc.2008.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18504437	Green Published, Green Accepted			2022-12-17	WOS:000259096100010
J	Lee, KY; Geng, H; Ng, KM; Yu, J; van Hasselt, A; Cao, Y; Zeng, YX; Wong, AHY; Wang, X; Ying, J; Srivastava, G; Lung, ML; Wang, LD; Kwok, TT; Levi, BZ; Chan, ATC; Sung, JJY; Tao, Q				Lee, K. Y.; Geng, H.; Ng, K. M.; Yu, J.; van Hasselt, A.; Cao, Y.; Zeng, Y-X; Wong, A. H. Y.; Wang, X.; Ying, J.; Srivastava, G.; Lung, M. L.; Wang, L-D; Kwok, T. T.; Levi, B-Z; Chan, A. T. C.; Sung, J. J. Y.; Tao, Q.			Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas	ONCOGENE			English	Article						IRF8; methylation; CpG island; tumor suppressor gene; carcinoma	BINDING-PROTEIN ICSBP; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; CELL CARCINOMA; MYELOID CELLS; GENE; CANCER; APOPTOSIS; EXPRESSION; ICSBP/IRF-8	16q24 is frequently deleted in multiple tumors including cancers of nasopharynx, esophagus, breast, prostate and liver. By array comparative genomic hybridization (aCGH), we refined a 16q24 hemizygous deletion in nasopharyngeal carcinoma (NPC) cell lines. Semi-quantitative RT-PCR analysis revealed interferon regulatory factor 8 (IRF8) as the only downregulated gene within this deletion. IRF8 belongs to a family of interferon (IFN) regulatory factors that modulate various important physiologic processes including host defense, cell growth and differentiation and immune regulation. In contrast to the broad expression of IRF8 in normal adult and fetal tissues, transcriptional silencing and promoter methylation of IRF8 were frequently detected in multiple carcinoma (except for hepatocellular) cell lines (100% in NPC, 88% in esophageal and 18-78% in other carcinoma cell lines) and in a large collection of primary carcinomas (78% in NPC, 36-71% in other carcinomas). Methylation of the IRF8 promoter led to the disruption of its response to IFN-gamma stimulation. Pharmacological and genetic demethylation could restore IRF8 expression, indicating a direct epigenetic mechanism. Ectopic expression of IRF8 in tumor cells lacking its expression strongly inhibited their clonogenicity, confirming its tumor suppressor function. Thus, IRF8 was identified as a functional tumor suppressor, which is frequently silenced by epigenetic mechanism in multiple carcinomas.	[Lee, K. Y.; Geng, H.; Ng, K. M.; Wong, A. H. Y.; Wang, X.; Ying, J.; Chan, A. T. C.; Tao, Q.] Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [van Hasselt, A.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Cao, Y.] Cent S Univ, Hunan Yale Xiang Ya Sch Med, Changsha 410083, Peoples R China; [Zeng, Y-X] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lung, M. L.] Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; [Wang, L-D] Zhengzhou Univ, Coll Med, Henan Key Lab Esophageal Canc, Zhengzhou, Henan, Peoples R China; [Kwok, T. T.] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Levi, B-Z] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Central South University; Sun Yat Sen University; University of Hong Kong; Hong Kong University of Science & Technology; Zhengzhou University; Chinese University of Hong Kong; Technion Israel Institute of Technology	Tao, Q (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; Kwok, Timothy/C-3725-2008; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Lung, Maria Li/C-4495-2009	Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; Kwok, Timothy/0000-0001-9253-3549; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Wang, Xian/0000-0003-0041-7589; Lung, Maria Li/0000-0003-2559-3626	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant [CA06/07.SC03]	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant(Hong Kong Research Grants Council)	This project was supported by a Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP) Grant to QT and a Hong Kong RGC Central Allocation Grant (CA06/07.SC03, QT). We thank Drs Bert Vogelstein, George Tsao (Dolly Huang), Sun Young Rha and Kaitai Yao for some cell lines, DSMZ (German Collection of Microorganisms and Cell Cultures) for the KYSE cell lines [Shimada et al., Cancer 69: 277-284 (1992)], Dr C Langford at the Wellcome Trust Sanger Institute, Cambridge, UK for aCGH slides, and Tzer- Jing Seng (Johns Hopkins Singapore) for her valuable help in aCGH analysis.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Egwuagu CE, 2006, ONCOGENE, V25, P3670, DOI 10.1038/sj.onc.1209402; Hashmueli S, 2003, INT IMMUNOL, V15, P807, DOI 10.1093/intimm/dxg077; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu GD, 2005, CANCER RES, V65, P7403, DOI 10.1158/0008-5472.CAN-05-0583; Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanno Y, 2005, J INTERF CYTOK RES, V25, P770, DOI 10.1089/jir.2005.25.770; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Paige AJW, 2000, CANCER RES, V60, P1690; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Watson GA, 2006, NEOPLASIA, V8, P31, DOI 10.1593/neo.05559; Wong ML, 2006, INT J ONCOL, V28, P767; Yang DF, 2007, J IMMUNOL, V179, P4775, DOI 10.4049/jimmunol.179.7.4775; Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	43	60	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5267	5276		10.1038/onc.2008.147	http://dx.doi.org/10.1038/onc.2008.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469857				2022-12-17	WOS:000258915100011
J	Chen, Z; Feng, J; Saldivar, JS; Gu, D; Bockholt, A; Sommer, SS				Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.			EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids	ONCOGENE			English	Article						EGFR; lung cancer; doublet; somatic mutation	GROWTH-FACTOR RECEPTOR; DRUG-RESISTANCE MUTATION; MULTIPLE MUTATIONS; GENE-MUTATIONS; GEFITINIB; AMPLIFICATION; SENSITIVITY; PATTERNS; MUTANTS; SUSCEPTIBILITY	Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a 'driver and passenger' mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.	[Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.] City Hope Natl Med Ctr, Dept Mol Genet, Duarte, CA 91010 USA	City of Hope	Sommer, SS (corresponding author), City Hope Natl Med Ctr, Dept Mol Genet, 1500 E Duarte Rd, Duarte, CA 91010 USA.	sommerlab@coh.org			NIA NIH HHS [R01-AG19784-02] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019784] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Buettner VL, 1999, ENVIRON MOL MUTAGEN, V33, P320, DOI 10.1002/(SICI)1098-2280(1999)33:4<320::AID-EM9>3.0.CO;2-S; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gu D, 2007, HUM MUTAT, V28, P760, DOI 10.1002/humu.20512; Hill KA, 2004, MUTAT RES-FUND MOL M, V554, P223, DOI 10.1016/j.mrfmmm.2004.05.005; Hill KA, 2003, MUTAT RES-GEN TOX EN, V534, P173, DOI 10.1016/S1383-5718(02)00277-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma ESK, 2007, INT J CANCER, V120, P1828, DOI 10.1002/ijc.22506; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shintani Satoru, 2003, Am J Clin Oncol, V26, pe150, DOI 10.1097/01.coc.0000091356.25759.69; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SOMMER SS, 1980, J MOL EVOL, V15, P37, DOI 10.1007/BF01732582; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Yokoyama T, 2006, CANCER SCI, V97, P753, DOI 10.1111/j.1349-7006.2006.00233.x; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017	30	60	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4336	4343		10.1038/onc.2008.71	http://dx.doi.org/10.1038/onc.2008.71			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372921				2022-12-17	WOS:000257691100008
J	Oxmann, D; Held-Feindt, J; Stark, AM; Hattermann, K; Yoneda, T; Mentlein, R				Oxmann, D.; Held-Feindt, J.; Stark, A. M.; Hattermann, K.; Yoneda, T.; Mentlein, R.			Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype	ONCOGENE			English	Article						breast cancer; metastasis; brain; tumor invasion; growth factor receptor	DIFFERENTIAL EXPRESSION; BRAIN-SEEKING; TGF-BETA; COMPLEX; CD105	Endoglin is a cell-surface adhesion protein as well as a coreceptor for transforming growth factor-beta (TGF-beta). It is located on endothelial and few other cells, but also found on certain tumor cells. Brain metastatic breast tumor cells derived from the MDA-MB-231 cell line heavily express endoglin in contrast to the corresponding parental ones. To clarify whether this determines their invasive phenotype, we compared their biological properties with endoglin-silenced brain-metastatic cells, low-expressing parental cells and these transfected with L- and S-endoglins, isoforms transducing or lacking TGF-beta signals. All L-endoglin-overexpressing cells were characterized by numerous invadopodia where endoglin was preferentially localized. Endoglin-expression resulted in elevated levels of the matrix metalloproteinases (MMP-1 and MMP-19) and downregulation of the plasminogen activator inhibitor-1. In Boyden-chamber and wound-healing assays, endoglin-overexpressing cells showed a considerably higher migration and chemotaxis to TGF-beta. In 3D spheroid confrontation assays between breast tumor cells and TGF-beta-secreting glioma cells, high L-endoglin-expressing cells invaded into the glioma-spheroids whereas low-endoglin-expressing cells dissociated in the culture; invasion was blocked by TGF-beta antibodies. In contrast to parental cells, endoglin-overexpressing cells invaded deeply into mouse brain slices. Thus, endoglin expression on tumor cells enhances their invasive character by formation of invadopodia, extracellular proteolysis, chemotaxis and migration.	[Oxmann, D.; Hattermann, K.; Mentlein, R.] Univ Kiel, Dept Anat, D-24098 Kiel, Germany; [Held-Feindt, J.; Stark, A. M.] Univ Klinikum Schleswig Holstein, Dept Neurosurg, Kiel, Germany; [Yoneda, T.] Univ Texas Hlth Sci Ctr San Antonio, Div Endocrinol & Metab, San Antonio, TX 78229 USA	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Texas System; University of Texas Health San Antonio	Mentlein, R (corresponding author), Univ Kiel, Dept Anat, Olshausenstr 40, D-24098 Kiel, Germany.	rment@anat.uni-kiel.de	Mentlein, Rolf/B-1613-2010; Hattermann, Kirsten/E-8043-2010; Held-Feindt, Janka/E-4690-2010	Mentlein, Rolf/0000-0002-6350-3911; 				Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Beck IM, 2007, J INVEST DERMATOL, V127, P1107, DOI 10.1038/sj.jid.5700674; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Djonov V, 2001, J PATHOL, V195, P147, DOI 10.1002/path.927; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Ludwig A, 2005, J NEUROCHEM, V93, P1293, DOI 10.1111/j.1471-4159.2005.03123.x; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mentlein R, 2004, J NEURO-ONCOL, V67, P9, DOI 10.1023/B:NEON.0000021737.89357.cc; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Postiglione L, 2005, INT J ONCOL, V26, P1193; Stark AM, 2005, NEUROSURG REV, V28, P115, DOI 10.1007/s10143-004-0364-3; Stark AM, 2007, J NEURO-ONCOL, V81, P39, DOI 10.1007/s11060-006-9207-0; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	26	60	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3567	3575		10.1038/sj.onc.1211025	http://dx.doi.org/10.1038/sj.onc.1211025			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223685				2022-12-17	WOS:000256468500008
J	Bermudez, O; Marchetti, S; Pages, G; Gimond, C				Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.			Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway	ONCOGENE			English	Article						ERK phosphatase DUSP6/MKP-3; mTOR; phosphorylation; degradation	ACTIVATED PROTEIN-KINASE; SPECIFICITY; MKP3; TRANSLATION; CANCER; MOTIF	MAP kinases phosphatases (MKPs) belong to the dual-specificity phosphatase family (DUSP) and dephosphorylate phosphothreonine and phosphotyrosine within MAP kinases. We had previously shown that DUSP6/MKP-3 was phosphorylated and degraded upon growth factor stimulation, in a MEK-dependent manner. Here we show that another pathway involved in growth factor signaling, the PI3K/mTOR signaling pathway, accounts for a part of the phosphorylation and degradation of DUSP6 induced by serum growth factors, as evidenced by experiments using pharmacological inhibitors of PI3 kinase and mammalian target of rapamycin (mTOR). Moreover, specific agonists of the mTOR pathway, such as amino acids or insulin/IGF-1, which do not activate extracellular signal regulated kinases (ERKs) in our cellular model, were also able to induce the phosphorylation and degradation of DUSP6. However, a basal activity of MEK was required for the mTOR pathway-mediated phosphorylation to occur. Mutagenesis studies identified serine 159 within DUSP6 as the target of the mTOR pathway. The ERK phosphatase DUSP6 may thus constitute a novel branch-point of the crosstalk between two major signaling pathways induced by growth factors, the MEK/ERK pathway and the PI3K/mTOR pathway.	[Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.] Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Gimond, C (corresponding author), Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.	gimond@unice.fr	Marchetti, Sandrine/P-6479-2016; Pages, Gilles/N-7135-2017	Marchetti, Sandrine/0000-0001-8326-5730; Gimond, Clotilde/0000-0003-1708-4629				Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Echevarria D, 2005, DEV BIOL, V277, P114, DOI 10.1016/j.ydbio.2004.09.011; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marchetti S, 2004, J CELL PHYSIOL, V199, P441, DOI 10.1002/jcp.10465; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Smith TG, 2006, FEBS LETT, V580, P4242, DOI 10.1016/j.febslet.2006.06.081	22	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3685	3691		10.1038/sj.onc.1211040	http://dx.doi.org/10.1038/sj.onc.1211040			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223677				2022-12-17	WOS:000256659300005
J	Yu, S; Wong, YC; Wang, XH; Ling, MT; Ng, CF; Chen, S; Chan, FL				Yu, S.; Wong, Y. C.; Wang, X. H.; Ling, M. T.; Ng, C. F.; Chen, S.; Chan, F. L.			Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer	ONCOGENE			English	Article						estrogen-related receptor; estrogen receptor-related; receptor; ERR beta; orphan nuclear receptor; tumor suppression; prostate cancer	PROLIFERATOR-ACTIVATED RECEPTOR; ANDROGEN RECEPTOR; GAMMA COACTIVATOR-1-ALPHA; TRANSCRIPTIONAL CONTROL; DNA-REPLICATION; MOUSE EMBRYOS; ERR-ALPHA; EXPRESSION; IDENTIFICATION; PGC-1-ALPHA	Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen receptor (ER) regulatory pathways and play roles in energy and lipid metabolism. Here, we analysed the functional role of ERR beta in prostate cancer cell growth regulation in an androgen-sensitive and androgen-insensitive prostate cancer cell lines. ERR beta was expressed in normal human prostates, but exhibited a reduced expression in prostate cancer lesions. Stable ERR beta expression suppressed significantly cell proliferation and tumorigenicity of LNCaP and DU145 cells, accompanied by an S-phase suppression and increased p21 expression. Reporter and chromatin immunoprecipitation assays showed that ERRb could directly transactivate p21 gene promoter, which could be further enhanced by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha. Truncation analysis showed that ERR beta-mediated p21 transactivation and prostate cancer cell growth inhibition required intact DNA-binding domain and AF2 domains in ERR beta. Interestingly, ERR beta displayed a cell cycle associated downregulated expression pattern in ERR beta-transduced and non-transduced cells. Finally, we showed that ERR beta-mediated growth inhibition could be potentiated by an ERRb/gamma agonist DY131. Knockdown of ERR beta by RNA interference could reduce the DY131-induced growth inhibition in prostate cancer cells. Taken together, our findings indicate that ERR beta performs a tumor suppressing function in prostate cancer cells, and targeting ERR beta could be a potential therapeutic strategy for prostate cancer.	[Yu, S.; Chan, F. L.] Chinese Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Wong, Y. C.; Wang, X. H.; Ling, M. T.] Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Ng, C. F.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Chen, S.] Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA USA	Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; City of Hope; Beckman Research Institute of City of Hope	Chan, FL (corresponding author), Chinese Univ Hong Kong, Dept Anat, Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	franky-chan@cuhk.edu.hk	Ng, Chi-Fai/E-5134-2011; Chi-fai, NG/AAV-8270-2021; Chan, Franky L./M-1043-2018	Ng, Chi-Fai/0000-0002-1723-9646; Chan, Franky L./0000-0003-0567-2052				Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005-0227; Chan PSF, 1999, PROSTATE, V41, P99; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Fujimoto J, 2005, J STEROID BIOCHEM, V94, P67, DOI 10.1016/j.jsbmb.2004.12.030; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Griffiths K, 2000, Prostate, V45, P87, DOI 10.1002/1097-0045(20001001)45:2<87::AID-PROS2>3.0.CO;2-G; Ho E, 2004, ARCH BIOCHEM BIOPHYS, V428, P109, DOI 10.1016/j.abb.2004.01.009; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Lu DS, 2001, CANCER RES, V61, P6755; Lui K, 2006, PROSTATE, V66, P1600, DOI 10.1002/pros.20429; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Mitsunaga K, 2004, MECH DEVELOP, V121, P237, DOI 10.1016/j.mod.2004.01.006; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Soriano FX, 2006, DIABETES, V55, P1783, DOI 10.2337/db05-0509; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vankoningsloo S, 2005, J LIPID RES, V46, P1133, DOI 10.1194/jlr.M400464-JLR200; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Yu DD, 2005, BIOORG MED CHEM LETT, V15, P1311, DOI 10.1016/j.bmcl.2005.01.025; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Zhang WH, 2002, MOL CELL ENDOCRINOL, V193, P1, DOI 10.1016/s0303-7207(02)00089-8; Zhou W, 2006, J CLIN ENDOCR METAB, V91, P569, DOI 10.1210/jc.2004-1957	45	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3313	3328		10.1038/sj.onc.1210986	http://dx.doi.org/10.1038/sj.onc.1210986			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071305				2022-12-17	WOS:000256111400010
J	Scian, MJ; Carchman, EH; Mohanraj, L; Stagliano, KER; Anderson, MAE; Deb, D; Crane, BM; Kiyono, T; Windle, B; Deb, SP; Deb, S				Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Kiyono, T.; Windle, B.; Deb, S. P.; Deb, S.			Wild-type p53 and p73 negatively regulate expression of proliferation related genes	ONCOGENE			English	Article						wild-type p53; transcriptional repression; cell cycle; DNA replication; microarray analysis	P53-MEDIATED TRANSCRIPTIONAL REPRESSION; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; DNA-DAMAGE; INDUCED APOPTOSIS; G(2)/M PROMOTERS; VIRAL PROMOTERS; PROTEIN; IDENTIFICATION; MODULATION	When normal cells come under stress, the wild-type (WT) p53 level increases resulting in the regulation of gene expression responsible for growth arrest or apoptosis. Here we show that elevated levels of WT p53 or its homologue, p73, inhibit expression of a number of cell cycle regulatory and growth promoting genes. Our analysis also identified a group of genes whose expression is differentially regulated by WT p53 and p73. We have infected p53-null H1299 human lung carcinoma cells with recombinant adenoviruses expressing WT p53, p73 or beta-galactosidase, and have undertaken microarray hybridization analyses to identify genes whose expression pro. le is altered by p53 or p73. Quantitative real-time PCR verified the repression of E2F5, centromere protein A and E, minichromosome maintenance proteins (MCM)-2, -3, -5, -6 and -7 and human CDC25B after p53 expression. 5-Fluorouracil treatment of col on carcinoma HCT116 cells expressing WT p53 results in a reduction of the cyclin B2 protein level suggesting that DNA damage may indeed cause repression of the se genes. Transient transcriptional assays verified that WT p53 repressed promoters of a number of these genes. Interestingly, a gain-of-function p53 mutant instead upregulated a number of the se promoters in transient transfection. Using promoter deletion mutants of MCM-7 we have found that WT p53-mediated repression needs a minimal promoter that contains a single E2F site and surrounding sequences. However, a single E2F site cannot be significantly repressed by WT p53. Many of the genes identified are also repressed by p21. Thus, our work shows that WT p53 and p73 repress a number of growth-related genes and that in many instances this repression may be through the induction of p21.	[Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Deb, S. P.; Deb, S.] Virginia Commonwealth Univ, Goodwin Res Lab, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Deb, S. P.; Deb, S.] Virginia Commonwealth Univ, Goodwin Res Lab, Massey Canc Ctr, Richmond, VA 23298 USA; [Kiyono, T.] Natl Canc Ctr, Res Inst, Div Virol, Tokyo 104, Japan; [Windle, B.] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Center - Japan; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Goodwin Res Lab, Dept Biochem & Mol Biol, 401 Coll St, Richmond, VA 23298 USA.	sdeb@vcu.edu	Kiyono, Tohru/H-5834-2011	Anderson, Michelle/0000-0003-1510-2942	NATIONAL CANCER INSTITUTE [R01CA074172, F31CA097520, R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712, CA74172, F31-CA97520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldaz CM, 2002, ONCOGENE, V21, P6366, DOI 10.1038/sj.onc.1205816; Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chae HD, 2005, EXP MOL MED, V37, P488, DOI 10.1038/emm.2005.60; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; Deb D, 2001, INT J ONCOL, V18, P401; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ichimiya S, 2001, MED PEDIATR ONCOL, V36, P42, DOI 10.1002/1096-911X(20010101)36:1<42::AID-MPO1011>3.0.CO;2-K; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Maeda Y, 2006, BIOCHEM J, V400, P303, DOI 10.1042/BJ20060614; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2003, MOL CANCER RES, V1, P1001; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prives C, 1999, J PATHOL, V187, P112; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Senoo M, 2001, BIOCHEM BIOPH RES CO, V286, P628, DOI 10.1006/bbrc.2001.5429; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; Stagliano Katherine E Roth, 2003, Methods Mol Biol, V234, P73; Stanelle J, 2003, CARDIOVASC RES, V59, P512, DOI 10.1016/S0008-6363(03)00392-4; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Thibault C, 2001, INT REV NEUROBIOL, V48, P219, DOI 10.1016/S0074-7742(01)48017-2; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Valerie E, 1999, UROLOGY, V54, P1082, DOI 10.1016/S0090-4295(99)00311-8; Van Bodegom D, 2006, J BIOL CHEM, V281, P31234, DOI 10.1074/jbc.M606510200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhang LL, 2000, CANCER RES, V60, P3655; Zhao R, 2000, COLD SPRING HARB SYM, V65, P475, DOI 10.1101/sqb.2000.65.475	69	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2583	2593		10.1038/sj.onc.1210898	http://dx.doi.org/10.1038/sj.onc.1210898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982488				2022-12-17	WOS:000255057000008
J	Molli, PR; Singh, RR; Lee, SW; Kumar, R				Molli, P. R.; Singh, R. R.; Lee, S. W.; Kumar, R.			MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene	ONCOGENE			English	Article						NURD complex; chromatin remodeling centrosome; aneuploidy	SPORADIC BREAST-CANCER; CENTROSOME AMPLIFICATION; CELL-CYCLE; ESTROGEN-RECEPTOR; DOWN-REGULATION; MTA1 GENE; PROTEIN; INSTABILITY; EXPRESSION; COMPLEX	Metastasis-associated tumor antigen 1 (MTA1), a component of the nucleosome remodeling and deacetylating (NuRD) complex is routinely upregulated in several cancers. In the present study, we investigated the potential role of MTA1 in BRCA1 transcriptional repression and subsequent chromosomal instability. MTA1-NuRD complex was found to negatively regulate BRCA1 transcription by physically associating with an atypical estrogen-responsive element (ERE) on the BRCA1 promoter. Moreover, MTA1 and HDAC complex recruited to the ERE of BRCA1 promoter in an ER a-dependent manner. Accordingly, BRCA1 protein levels were enhanced by silencing of either MTA1 expression or by treatment with the specific histone deacetylase inhibitor trichostatin A. MTA1's strong repressive effects on BRCA1 expression was supported by our observation that cells stably overexpressing MTA1 showed centrosome amplification which has been long implicated as a phenotype for BRCA1 repression. Accordingly, overexpression of BRCA1 in cells stably over expressing MTA1 resulted in restoration of normal centrosome numbers. Together, these findings strongly implicate MTA1 in the transcriptional repression of BRCA1 leading to abnormal centrosome number and chromosomal instability.	[Molli, P. R.; Singh, R. R.; Kumar, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Lee, S. W.] Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA USA; [Kumar, R.] Baylor Coll Med, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746, R01 CA065746, R01 CA098823-04, R01 CA065746-05, R01 CA098823, CA 098823, U01 CA065746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chen XW, 2006, EXPERT REV ANTICANC, V6, P187, DOI 10.1586/14737140.6.2.187; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Hamatsu T, 2003, ONCOL REP, V10, P599; Indraccolo S, 2006, EUR J CANCER, V42, P1475, DOI 10.1016/j.ejca.2006.01.057; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Ko MJ, 2006, ONCOGENE, V25, P298, DOI 10.1038/sj.onc.1209028; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Martin MD, 2006, BREAST CANCER RES TR, V95, P7, DOI 10.1007/s10549-005-9016-8; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; Ouchi T, 2006, CANCER BIOL THER, V5, P470, DOI 10.4161/cbt.5.5.2845; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Simbulan-Rosenthal CM, 2001, NUCLEIC ACIDS RES, V29, P841, DOI 10.1093/nar/29.3.841; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Talukder AH, 2003, J BIOL CHEM, V278, P11676, DOI 10.1074/jbc.M209570200; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yarden RI, 2006, MOL CANCER THER, V5, P1396, DOI 10.1158/1535-7163.MCT-05-0471	34	60	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1971	1980		10.1038/sj.onc.1210839	http://dx.doi.org/10.1038/sj.onc.1210839			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922032	Green Accepted			2022-12-17	WOS:000254359100002
J	Lin, DI; Lessie, M; Gladden, AB; Bassing, C; Wagner, K; Diehl, J				Lin, D. I.; Lessie, M. D.; Gladden, A. B.; Bassing, C. H.; Wagner, K. U.; Diehl, J. A.			Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis	ONCOGENE			English	Article						CDK4; cyclin D1; FBX4; mammary gland; PD0332991	GENOMIC INSTABILITY; DEPENDENT KINASE; BREAST-CANCER; TUMORIGENESIS; HYPERPLASIA; EXPRESSION; ONCOGENE; CELLS; MICE; MYC	Cyclin D1 levels are maintained at steady state by phosphorylation-dependent nuclear export and polyubiquitination by SCFFBX4-alpha B (crystallin). Inhibition of cyclin D1 proteolysis has been implicated as a causative factor leading to its overexpression in breast and esophageal carcinomas; however, the contribution of stable cyclin D1 to the genesis of such carcinomas has not been evaluated. We therefore generated transgenic mice wherein expression of either wild-type or a stable cyclin D1 allele ( D1T286A) is regulated by MMTV-LTR. MMTV-D1T286A mice developed mammary adenocarcinomas at an increased rate relative to MMTV-D1 mice. Similar to human cancers that overexpress cyclin D1, D1T286A tumors were estrogen receptor-positive and exhibited estrogen-dependent growth. Collectively, these results suggest that temporal control of cyclin D1 subcellular localization and proteolysis is critical for maintenance of homeostasis within the mammary epithelium.	[Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Lin, D. I.; Lessie, M. D.; Gladden, A. B.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bassing, C. H.] Univ Penn, Childrens Hosp, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wagner, K. U.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Pathol & Microbiol, Omaha, NE 68182 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Nebraska System; University of Nebraska Medical Center	Diehl, J (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 454 BRB 2 3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu		Wagner, Kay-Uwe/0000-0002-5081-0226; Lin, Douglas/0000-0003-0105-9760	NCI NIH HHS [CA11360, R01 CA111360, R01 CA125195-01A1, R01 CA111360-05, R01 CA125195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111360, R01CA125195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ip M. M., 2000, METHODS MAMMARY GLAN; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lu FM, 2003, CANCER RES, V63, P7056; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Rowse GJ, 1998, CANCER RES, V58, P2675; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Utsumi T, 2000, INT J CANCER, V89, P39, DOI 10.1002/(SICI)1097-0215(20000120)89:1<39::AID-IJC7>3.0.CO;2-T; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012	26	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1231	1242		10.1038/sj.onc.1210738	http://dx.doi.org/10.1038/sj.onc.1210738			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724472	Green Accepted			2022-12-17	WOS:000253407000005
J	Kurban, G; Duplan, E; Ramlal, N; Hudon, V; Sado, Y; Ninomiya, Y; Pause, A				Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Sado, Y.; Ninomiya, Y.; Pause, A.			Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2	ONCOGENE			English	Article						VHL; collagen IV; extracellular matrix; renal cell carcinoma	FIBRONECTIN MATRIX; REGULATE HIF; TUMORIGENESIS; ANGIOGENESIS; INHIBITION; THERAPY; DISEASE; COMPLEX; GENE; IV	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene predisposes to vascular tumor formation in several organs. VHL regulates two evolutionary conserved pathways: the targeting of hydroxylated hypoxia-inducible factor-alpha (HIF-alpha) for proteasomal degradation and the remodeling of extracellular matrix (ECM). The biochemical mechanisms of the ECM assembly pathway remain poorly defined. Here, we provide evidence supporting a biochemical role for VHL in ECM assembly. We show that VHL directly binds to the collagen IV alpha 2 (COL4A2) chain and that this interaction is necessary for its assembly into the ECM. The VHL-COL4A2 interaction is dependent on endoplasmic reticulum (ER)mediated COL4A2 hydroxylation and independent of cytosolic, hypoxia regulated HIF-alpha-modifying enzymes. We find that the N-terminal tail of COL4A2 protrudes from the ER lumen into the cytosol where it is bound by VHL. Failure of VHL to interact with COL4A2 correlates with loss of collagen IV network formation in vitro and collagen IV remodeling in vivo. Our data suggest a HIF-alpha-independent role for the VHL-COL4A2 interaction in suppression of angiogenic tumor formation through collagen IV network assembly.	[Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Pause, A.] McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Sado, Y.] Shigei Med Res Inst, Div Immunol, Okayama, Japan; [Ninomiya, Y.] Okayama Univ, Dept Mol Biol & Biochem, Grad Sch Med, Okayama, Japan	McGill University; Okayama University	Pause, A (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, McIntyre Bldg,3655 Sir William Osler Promenade,Ro, Montreal, PQ H3G 1Y6, Canada.	arnim.pause@mcgill.ca	Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507				Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soder S, 2004, BIOCHEM BIOPH RES CO, V325, P276, DOI 10.1016/j.bbrc.2004.10.034; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Zimmer M, 2004, MOL CANCER RES, V2, P89	21	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1004	1012		10.1038/sj.onc.1210709	http://dx.doi.org/10.1038/sj.onc.1210709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700531				2022-12-17	WOS:000252946300012
J	Le Bras, A; Lionneton, F; Mattot, V; Lelievre, E; Caetano, B; Spruyt, N; Soncin, F				Le Bras, A.; Lionneton, F.; Mattot, V.; Lelievre, E.; Caetano, B.; Spruyt, N.; Soncin, F.			HIF-2 alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites	ONCOGENE			English	Article						angiogenesis; endothelium; gene transcription	VASCULAR-ENDOTHELIAL-CADHERIN; PAS DOMAIN PROTEIN-1; INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR; EMBRYONIC-DEVELOPMENT; GENE-TRANSCRIPTION; TUMOR-GROWTH; HIF-ALPHA; EXPRESSION; FACTOR-1-ALPHA	The mechanisms that are responsible for the restricted pattern of express ion of the VE-cadherin gene in endothelial cells are not clearly understood. Regulation of express ion is under the control of an approximately 140 bp proximal promoter that provides basal, non-endothelial specific expression. A larger region contained within the 2.5 kb genomic DNA sequence located ahead of the transcription start is involved in the specific expression of the gene in endothelial cells. We show here that the VE-cadherin promoter contains several putative hypoxia response elements (HRE) which are able to bind endothelial nuclear factors under normoxia. The VE-cadherin gene is not responsive to hypoxia but hypoxia-inducible factor (HIF)-2 alpha specifically activates the promoter while HIF-1 alpha does not. The HRE, that are involved in this activity have been identified. Further, we show that HIF2 alpha cooperates with the Ets-1 transcription factor for activation of the VE-cadherin promoter and that this synergy is dependent on the binding of Ets-1 to DNA. This cooperative action of HIF-2 a with Ets-1 most probably participates to the transcriptional regulation of express ion of the gene in endothelial cells. This mechanism may also be involved in the expression of the VE-cadherin gene by tumor cells in the process of vascular mimicry.	CNRS, UMR 8161, Lille, France; Univ Lille 1, Lille, France; Univ Lille 2, Lille, France; Inst Pasteur, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Soncin, F (corresponding author), CNRS, Inst Biol Lille, UMR 8161, 1 Rue Calmette, BP 447, F-59021 Lille, France.	fabrice.soncin@ibl.fr	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Le Bras, Alexandra/0000-0001-7898-4618; Lelievre, Etienne/0000-0003-0452-1578				Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Hisatsune H, 2005, BLOOD, V105, P4657, DOI 10.1182/blood-2004-09-3554; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Iurlaro M, 2004, AM J PATHOL, V165, P181, DOI 10.1016/S0002-9440(10)63287-7; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lionneton F, 2003, ONCOGENE, V22, P9156, DOI 10.1038/sj.onc.1207241; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; May C, 2005, BLOOD, V105, P4337, DOI 10.1182/blood-2005-01-0010; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J, 1989, MOL CLONING LAB MANU; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHWEIKI D, 1992, NATURE, V359, P845; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Sowter HM, 2003, CANCER RES, V63, P6130; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	62	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7480	7489		10.1038/sj.onc.1210566	http://dx.doi.org/10.1038/sj.onc.1210566			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17563748				2022-12-17	WOS:000251282000009
J	Lim, SK; Gopalan, G				Lim, S. K.; Gopalan, G.			Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A	ONCOGENE			English	Article						degradation; antizyme; Aurora-A; ubiquitin-independent	ORNITHINE-DECARBOXYLASE-ANTIZYME; CELL-GROWTH; PROTEASOME PATHWAY; PROTEIN-KINASE; PROLIFERATION; POLYAMINES; EXPRESSION; MECHANISM; CANCER; OVEREXPRESSION	Overexpression of Aurora- A oncogene has been shown to induce genomic instability and tumorigenesis. Cellular levels of Aurora- A are regulated by multiple mechanisms including the proteasome- dependent degradation of Aurora-A protein. Cell- cycle- dependent turnover of Aurora- A protein is mediated by cdh1 through ubiquitin ( Ub)- and proteasome- dependent pathway. However, Aurora- A kinase interacting protein 1 ( AURKAIP1), a negative regulator of Aurora- A, also promotes proteasome- dependent Aurora- A degradation through an Ub- independent mechanism. In an attempt to understand how AURKAIP1 promotes Aurora- A degradation through Ub- independent pathway, we demonstrate here that antizyme1 ( Az1), a well- studied mediator of Ub- independent protein degradation pathway, regulates Aurora- A protein stability. We show that ectopic or polyamine- induced expression of Az1 can lower the steady- state levels of Aurora- A. The effect of Az1 on Aurora- A turnover was shown to be proteasome-dependent, but Ub- independent. Az1 interacts with Aurora-A in vivo and the interaction between Aurora- A and Az1 is essential for the Az1- mediated Aurora- A degradation. Furthermore, we observed that AURKAIP1 could not promote degradation of Aurora- A mutant, which is defective in Az1 interaction. Coexpression of the Az inhibitor ( AzI), which downregulates Az1 functions, also abrogated AURKAIP1- mediated degradation of Aurora- A. We further demonstrated that AURKAIP1, Az1 and Aurora- A could exist as a ternary complex and AURKAIP1 enhances the interaction between Az1 and Aurora-A. We propose that AURKAIP1 might function upstream of the Az1 by enhancing the binding affinity of Az1 to Aurora- A to promote recognition, targeting to proteasome and subsequent degradation.	Natl Canc Ctr, Div Mol & Cellular Res, Gene Struct & Express Lab, Singapore, Singapore	National Cancer Centre Singapore (NCCS)	Gopalan, G (corresponding author), 03-03 Singhlth Res Facil,Block A 7 Hosp Dr, Singapore 169611, Singapore.	cmrgop@nccs.com.sg						Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247; Cheng N, 2002, MOL CANCER RES, V1, P2; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gardini G, 2003, J HEPATOL, V39, P793, DOI 10.1016/S0168-8278(03)00386-6; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hoffman DW, 2005, BIOCHEMISTRY-US, V44, P11777, DOI 10.1021/bi051081k; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Koike C, 1999, CANCER RES, V59, P6109; Li DH, 2003, CLIN CANCER RES, V9, P991; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mangold U, 2006, CELL MOL LIFE SCI, V63, P2095, DOI 10.1007/s00018-005-5583-4; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka T, 1999, CANCER RES, V59, P2041; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	43	60	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6593	6603		10.1038/sj.onc.1210482	http://dx.doi.org/10.1038/sj.onc.1210482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17452972				2022-12-17	WOS:000250081500002
J	Jin, Z; Mori, Y; Yang, J; Sato, F; Ito, T; Cheng, Y; Paun, B; Hamilton, JP; Kan, T; Olaru, A; David, S; Agarwal, R; Abraham, JM; Beer, D; Montgomery, E; Meltzer, SJ				Jin, Z.; Mori, Y.; Yang, J.; Sato, F.; Ito, T.; Cheng, Y.; Paun, B.; Hamilton, J. P.; Kan, T.; Olaru, A.; David, S.; Agarwal, R.; Abraham, J. M.; Beer, D.; Montgomery, E.; Meltzer, S. J.			Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma	ONCOGENE			English	Article						hypermethylation; NELL1; EAC; ESCC; biomarker	SEGMENT BARRETTS-ESOPHAGUS; PROMOTER HYPERMETHYLATION; FOLLOW-UP; NEOPLASTIC PROGRESSION; CANCER; DYSPLASIA; NELL-1; CRANIOSYNOSTOSIS; INACTIVATION; METHYLATION	The nel-like1 ( NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma ( EAC). NELL1 promoter hypermethylation was examined by real-time methylation-specific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve pro. les, clearly distinguishing esophageal squamous cell carcinoma ( ESCC) and EAC from normal esophagus ( NE) ( P < 0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia ( BE), dysplastic Barrett's ( D) and EAC than in NE ( P < 0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significantly correlation between NELL1 hypermethylation and BE segment length. Three ( 11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P = 0.0264) but not in stages III-IV ( P = 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2'-deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter ( P 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21231 USA; Univ Michigan, Sch Med, Dept Surg, Div Gen Thorac Surg, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21231 USA.	smeltzer@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA001808, R21CA106763, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER; NCI NIH HHS [CA001808, CA085069, CA106763] Funding Source: Medline; NIDDK NIH HHS [T32 DK067872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender CM, 1999, MOL CELL BIOL, V19, P6690; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Fang MZ, 2005, INT J ONCOL, V26, P615; Gleeson CM, 1998, GENE CHROMOSOME CANC, V21, P49, DOI 10.1002/(SICI)1098-2264(199801)21:1<49::AID-GCC7>3.0.CO;2-8; Hage M, 2004, SCAND J GASTROENTERO, V39, P1175, DOI 10.1080/00365520410003524; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; International Union Against Cancer, 2002, TNM CLASS MAL TUM; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753; Lee EJ, 2006, EUR J CANCER, V42, P972, DOI 10.1016/j.ejca.2006.01.021; Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009; MATSUHASHI S, 1995, DEV DYNAM, V203, P212, DOI 10.1002/aja.1002030209; Matsuhashi S, 1996, DEV DYNAM, V207, P233; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Sharma P, 1997, AM J GASTROENTEROL, V92, P2012; Shibata DM, 2002, CANCER RES, V62, P5637; STEWART DM, 2003, WORLD CANC REPORT; WATANABE H, 2002, LANG COMPUT, V38, P273; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Zhang XL, 2006, LAB INVEST, V86, P633, DOI 10.1038/labinvest.3700430; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; Zhang XL, 2003, J BONE MINER RES, V18, P2126, DOI 10.1359/jbmr.2003.18.12.2126	33	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6332	6340		10.1038/sj.onc.1210461	http://dx.doi.org/10.1038/sj.onc.1210461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452981				2022-12-17	WOS:000249583300009
J	Brandes, JC; Carraway, H; Herman, JG				Brandes, J. C.; Carraway, H.; Herman, J. G.			Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter	ONCOGENE			English	Article						DNA methylation; ATM; breast cancer; lung cancer; methylation Specific PCR	NEAREST-NEIGHBOR THERMODYNAMICS; SQUAMOUS-CELL CARCINOMA; DOT-T MISMATCHES; LUNG-CANCER; DNA METHYLTRANSFERASE; ATAXIA-TELANGIECTASIA; BREAST-CANCER; GENE; HYPERMETHYLATION; INACTIVATION	Methylation-specific polymerase chain reaction (PCR) (MSP) is frequently used to study gene silencing by promoter hypermethylation. However, non-specific primer design can lead to false-positive detection of methylation. We present a novel, web-based algorithm for the design of primers for bisulfate-PCRs ( MSP, sequencing, COBRA and multiplex-MSP), allowing the determination of a specificity score, which is based on the thermodynamic characteristics of the primer 3'-end. PCR amplification with primers not reaching a high specificity score can result in false-positive findings. We used MSPprimer to design MSP primers for analysis of the ATM promoter. In 37 non-small cell lung cancer (NSCLC) samples and 43 breast cancer samples no promoter methylation was detected. Conversely, published MSP primers not reaching the required specificity score led to non-specific amplification of DNA not converted by bisul. te. The result was a false-positive incidence of ATM promoter methylation of 24% in NSCLC and 48% in breast cancers, similar to published studies. This highlights the critical need for specific primer design for MSP. MSPprimer is a convenient tool to achieve this goal, which is available free of charge to the scientific community.	Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Canc Biol Program, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Herman, JG (corresponding author), Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Bunting Blaustein Canc Res Bldg, 1650 Orleans Str Suite 543, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	Carraway, Hetty/AAR-4977-2020	Carraway, Hetty/0000-0001-5241-3614; Brandes, Johann/0000-0002-1815-8311				Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P9435, DOI 10.1021/bi9803729; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P2170, DOI 10.1021/bi9724873; Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P2694, DOI 10.1093/nar/26.11.2694; Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Bolt J, 2005, ORAL ONCOL, V41, P1013, DOI 10.1016/j.oraloncology.2005.06.003; Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058; Brandes JC, 2006, CANCER RES, V66, P6892, DOI 10.1158/0008-5472.CAN-06-0116; BRANES JC, 2006, CANCER RES, V66, P6893; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Gumy-Pause F, 2006, LEUKEMIA RES, V30, P335, DOI 10.1016/j.leukres.2005.07.012; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Luo LP, 1998, CANCER RES, V58, P2293; Miura F, 2005, BIOINFORMATICS, V21, P4363, DOI 10.1093/bioinformatics/bti716; Owczarzy R, 2004, BIOCHEMISTRY-US, V43, P3537, DOI 10.1021/bi034621r; Pellise M, 2004, CLIN CANCER RES, V10, P4444, DOI 10.1158/1078-0432.CCR-03-0600; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Tusnady GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012; Vallone PM, 2004, BIOTECHNIQUES, V37, P226, DOI 10.2144/04372ST03; Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	37	60	66	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6229	6237		10.1038/sj.onc.1210433	http://dx.doi.org/10.1038/sj.onc.1210433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17384671				2022-12-17	WOS:000249401300014
J	Kim, MM; Wiederschain, D; Kennedy, D; Hansen, E; Yuan, ZM				Kim, M. M.; Wiederschain, D.; Kennedy, D.; Hansen, E.; Yuan, Z-M			Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP)	ONCOGENE			English	Article						G3BP; p53; MDM2	FUNCTIONAL INACTIVATION; EXPRESSION; GROWTH; DOMAIN; IDENTIFICATION; RNA	Inactivation of the p53 tumor suppressor pathway is a critical step in human tumorigenesis. In addition to mutations, p53 can be functionally silenced through its increased degradation, inhibition of its transcriptional activity and/or its inappropriate subcellular localization. Using a proteomic approach, we have found that members of the Ras network of proteins, Ras-GTPase activating protein-SH3-domain-binding proteins 1 and 2 (G3BP1 and 2), bind to p53 in vitro and in vivo. Our data show that expression of G3BPs leads to the redistribution of p53 from the nucleus to the cytoplasm. The G3BP2 isoform additionally associated with murine double minute 2 (MDM2), a negative regulator of p53. G3BP2 expression resulted in significant reduction in MDM2-mediated p53 ubiquitylation and degradation. Interestingly, MDM2 was also stabilized in G3BP2-expressing cells and its ability to ubiquitylate itself was compromised. Accordingly, short hairpin RNA (shRNA)-mediated knockdown of G3BP2 caused a reduction in MDM2 protein levels. Furthermore, expression of shRNA targeting either G3BP1 or G3BP2 in human cancer cell lines resulted in marked upregulation of p53 levels and activity. Our results suggest that both G3BP isoforms may act as negative regulators of p53.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia	Harvard University; Harvard T.H. Chan School of Public Health; Griffith University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Kennedy, Hendrick/A-7635-2010	Kennedy, Hendrick/0000-0001-7937-3069	NCI NIH HHS [CA009078, R01CA85679-02] Funding Source: Medline; NIEHS NIH HHS [5P30ES00002, T32ES007155] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009078, R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155, P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; Barnes CJ, 2002, CANCER RES, V62, P1251; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Gu JJ, 2001, CANCER RES, V61, P6703; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Huang YP, 2005, ONCOGENE, V24, P3819, DOI 10.1038/sj.onc.1208527; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kennedy D, 2002, J CELL BIOCHEM, V84, P173, DOI 10.1002/jcb.1277; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Molinari AM, 2000, CANCER RES, V60, P2594; Pazman C, 2000, DEVELOPMENT, V127, P1715; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Zekri L, 2005, MOL CELL BIOL, V25, P8703, DOI 10.1128/MCB.25.19.8703-8716.2005	23	60	64	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4209	4215		10.1038/sj.onc.1210212	http://dx.doi.org/10.1038/sj.onc.1210212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297477				2022-12-17	WOS:000247619900003
J	Hawcroft, G; Ko, CWS; Hull, MA				Hawcroft, G.; Ko, C. W. S.; Hull, M. A.			Prostaglandin E-2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells	ONCOGENE			English	Article						colorectal cancer; cyclic AMP; EP receptor; prostaglandin E-2	GROWTH-FACTOR RECEPTOR; ELEMENT-BINDING PROTEIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTESTINAL EPITHELIAL-CELLS; EP4 PROSTANOID RECEPTORS; CARCINOMA CELLS; ADENOCARCINOMA CELLS; ADENOMA GROWTH; CYCLIC-AMP; E-2	The predominant product of cyclooxygenase ( COX) activity in the colon, prostaglandin ( PG) E-2 promotes intestinal tumorigenesis. Expression of the PGE(2) receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE(2)-EP4 receptor signalling in the protumorigenic activity of PGE2 by increasing EP4 receptor expression in HT-29 human colorectal cancer ( CRC) cells ( HT-29-EP4) by stable transfection. Elevated PGE(2)-induced EP4 receptor activity in HT-29 cells increased resistance to spontaneous apoptosis and promoted anchorage-independent growth, but had no effect on proliferation of HT-29-EP4 cells. EP4 receptor activation by PGE(2) in HT-29-EP4 cells also led to development of fluid-filled cysts, which was associated with increased tight junction protein ( occludin and zonula occludens-1) expression. Overexpression of the EP4 receptor in HT-29 cells led to basal EP4 receptor signalling in the absence of exogenous PGE(2), which was explained by autocrine activity of endogenous, COX-2-derived PGE(2) and constitutive, ligand-independent EP4 receptor activity. The predominant signalling pathway mediating antiapoptotic activity downstream of PGE(2)-EP4 receptor activation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate ( cAMP) levels, which was associated with phosphorylation of cAMP-response element binding protein. EP4 receptor activation led to a small increase in phosphorylated extracellular signal-regulated kinase ( ERK) 2 protein levels but inhibition of ERK phosphorylation did not abrogate the antiapoptotic activity of PGE(2). However, PGE(2)-EP4 receptor signalling did not lead to trans-activation of the epidermal growth factor receptor in HT-29 cells. Inhibition of protumorigenic PGE(2)-EP4 receptor signalling represents a potential strategy for anti-CRC therapy that may avoid the toxicity associated with systemic COX inhibition.	Univ Leeds, St James Univ Hosp, Inst Mol Med, Sect Mol Gastroenterol, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hawcroft, G (corresponding author), Univ Leeds, St James Univ Hosp, Inst Mol Med, Sect Mol Gastroenterol, Leeds LS9 7TF, W Yorkshire, England.	medgha@leeds.ac.uk			MRC [G116/146] Funding Source: UKRI; Medical Research Council [G116/146] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adamson RH, 1998, AM J PHYSIOL-HEART C, V274, pH1885, DOI 10.1152/ajpheart.1998.274.6.H1885; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Cahlin C, 2005, INT J ONCOL, V27, P913; Cassano G, 2000, CANCER LETT, V152, P217, DOI 10.1016/S0304-3835(00)00339-6; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chell SD, 2006, CANCER RES, V66, P3106, DOI 10.1158/0008-5472.CAN-05-3702; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fujino H, 2006, MOL PHARMACOL, V69, P13, DOI 10.1124/mol.105.017749; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hull MA, 2004, MOL CANCER THER, V3, P1031; Hull MA, 2005, EUR J CANCER, V41, P1854, DOI 10.1016/j.ejca.2005.04.013; Kato K, 2005, INT J APPL CERAM TEC, V2, P64, DOI 10.1111/j.1744-7402.2005.02006.x; Keese M, 2005, J BIOL CHEM, V280, P27826, DOI 10.1074/jbc.M504485200; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869; Krause W, 2000, PROSTAG OTH LIPID M, V61, P145, DOI 10.1016/S0090-6980(00)00069-1; Ma XR, 2006, CANCER RES, V66, P2923, DOI 10.1158/0008-5472.CAN-05-4348; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Misra UK, 2005, J BIOL CHEM, V280, P38276, DOI 10.1074/jbc.M507332200; Mutoh M, 2002, CANCER RES, V62, P28; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ophir I, 1995, TISSUE CELL, V27, P659, DOI 10.1016/S0040-8166(05)80021-7; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pavlovic S, 2006, J BIOL CHEM, V281, P3321, DOI 10.1074/jbc.M506846200; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shoji Y, 2004, GUT, V53, P1151, DOI 10.1136/gut.2003.028787; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251	51	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3006	3019		10.1038/sj.onc.1210113	http://dx.doi.org/10.1038/sj.onc.1210113			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130837				2022-12-17	WOS:000246395400006
J	Zafir-Lavie, I; Michaeli, Y; Reiter, Y				Zafir-Lavie, I.; Michaeli, Y.; Reiter, Y.			Novel antibodies as anticancer agents	ONCOGENE			English	Review						antibody; cancer immunotherapy; tumor antigens; anti tumor mechanisms; targeted therapy; antibody fusions	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; T-CELL-RECEPTOR; PHASE-I TRIAL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC BREAST-CANCER; RIBOSOME-INACTIVATING PROTEINS; HUMAN RECOMBINANT ANTIBODIES; CD19 BISPECIFIC ANTIBODIES; COLONY-STIMULATING FACTOR	In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.	Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Reiter, Y (corresponding author), Technion Israel Inst Technol, Fac Biol, Room 333, IL-32000 Haifa, Israel.	reiter@tx.technion.ac.il						ABASTADO JP, 1989, RES IMMUNOL, V140, P581, DOI 10.1016/0923-2494(89)90103-X; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Albanell J, 2003, ADV EXP MED BIOL, V532, P253; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; ANTMAN KH, 1980, CELL, V19, P627, DOI 10.1016/S0092-8674(80)80039-0; Archer GE, 1999, CLIN CANCER RES, V5, P2646; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGSHAWE KD, 1988, BRIT J CANCER, V58, P700, DOI 10.1038/bjc.1988.293; BAGSHAWE KD, 1987, BRIT J CANCER, V55, P299, DOI 10.1038/bjc.1987.58; Bagshawe KD, 1996, TRANSPLANT P, V28, P3156; Barbieri L, 2000, J DRUG TARGET, V8, P281, DOI 10.3109/10611860008997906; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Barzilay E, 2005, BIOCHEM BIOPH RES CO, V330, P561, DOI 10.1016/j.bbrc.2005.03.014; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BASELGA J, 2001, EJC SUPPL, V37, P16; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Beers R, 2000, CLIN CANCER RES, V6, P2835; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Birkle S, 2003, BIOCHIMIE, V85, P455, DOI 10.1016/S0300-9084(03)00006-3; BODMER WF, 1993, ANN NY ACAD SCI, V690, P42; Bolognesi A, 2002, J BIOL CHEM, V277, P13709, DOI 10.1074/jbc.M111514200; Brandl M, 1999, EXP HEMATOL, V27, P1264, DOI 10.1016/S0301-472X(99)00072-7; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cao YH, 2004, SEMIN CANCER BIOL, V14, P139, DOI 10.1016/j.semcancer.2003.09.018; Cardoso L.R., 2002, Planta daninha, V20, P1, DOI 10.1590/S0100-83582002000400001; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHARI RVJ, 1995, CANCER RES, V55, P4079; Chen X, 1998, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V20, P351; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; Cheng TL, 1999, BRIT J CANCER, V79, P1378, DOI 10.1038/sj.bjc.6690221; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cohen CJ, 2002, CANCER RES, V62, P5835; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Cohen CJ, 2003, J IMMUNOL, V170, P4349, DOI 10.4049/jimmunol.170.8.4349; Cohen Cyril J, 2003, Methods Mol Biol, V207, P269; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; Connor JP, 2004, J IMMUNOTHER, V27, P211, DOI 10.1097/00002371-200405000-00005; Csoka M, 1996, LEUKEMIA, V10, P1765; de Graaf M, 2002, BRIT J CANCER, V86, P811, DOI 10.1038/sj.bjc.6600143; Denkberg G, 2003, J IMMUNOL, V171, P2197, DOI 10.4049/jimmunol.171.5.2197; Denkberg G, 2002, J IMMUNOL, V169, P4399, DOI 10.4049/jimmunol.169.8.4399; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Denkberg G, 2006, AUTOIMMUN REV, V5, P252, DOI 10.1016/j.autrev.2005.07.004; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; DESHANE J, 1995, GYNECOL ONCOL, V59, P8, DOI 10.1006/gyno.1995.1260; DiJoseph JF, 2006, CLIN CANCER RES, V12, P242, DOI 10.1158/1078-0432.CCR-05-1905; Dreier T, 2003, J IMMUNOL, V170, P4397, DOI 10.4049/jimmunol.170.8.4397; Dreier T, 2002, INT J CANCER, V100, P690, DOI 10.1002/ijc.10557; DUC HT, 1993, INT IMMUNOL, V5, P427, DOI 10.1093/intimm/5.4.427; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Eichhorn ME, 2004, DRUG RESIST UPDATE, V7, P125, DOI 10.1016/j.drup.2004.03.001; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Endo Y, 1988, Cancer Treat Res, V37, P75; Engberg J, 1999, IMMUNOTECHNOLOGY, V4, P273; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FAVALORO EJ, 1987, DIS MARKERS, V5, P215; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; FitzGerald K, 1997, PROTEIN ENG, V10, P1221, DOI 10.1093/protein/10.10.1221; Fleischhauer K, 1996, J IMMUNOL, V157, P787; Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Fraser HM, 2005, J CLIN ENDOCR METAB, V90, P1114, DOI 10.1210/jc.2004-1572; FROSCHER BG, 1986, J EXP MED, V164, P196, DOI 10.1084/jem.164.1.196; Gargano N, 1997, FEBS LETT, V414, P537, DOI 10.1016/S0014-5793(97)01065-X; GATELY MK, 1993, CANCER INVEST, V11, P500, DOI 10.3109/07357909309018881; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Gillies SD, 2005, BLOOD, V105, P3972, DOI 10.1182/blood-2004-09-3533; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; GOLDMACHER VS, 1992, BIOCHEM BIOPH RES CO, V183, P758, DOI 10.1016/0006-291X(92)90548-Y; Graeven U, 2006, BRIT J CANCER, V94, P1293, DOI 10.1038/sj.bjc.6603083; Grana C, 2002, BRIT J CANCER, V86, P207, DOI 10.1038/sj.bjc.6600047; GRIFFIN JD, 1984, LEUKEMIA RES, V8, P521, DOI 10.1016/0145-2126(84)90001-8; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Haagen I A, 1994, Ther Immunol, V1, P279; Hakamori S, 1998, ACTA ANAT, V161, P79; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Harding J, 2005, DRUG TODAY, V41, P107, DOI 10.1358/dot.2005.41.2.882662; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Hassan R, 2002, CLIN CANCER RES, V8, P3520; Hassanizadeh SM, 2002, VADOSE ZONE J, V1, P38, DOI 10.2136/vzj2002.3800; Held G, 2004, EUR J IMMUNOL, V34, P2919, DOI 10.1002/eji.200425297; Hoffmann P, 2005, INT J CANCER, V115, P98, DOI 10.1002/ijc.20908; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holliger P, 1999, CANCER RES, V59, P2909; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Howard OMZ, 2000, BLOOD, V96, P840, DOI 10.1182/blood.V96.3.840.015k32_840_845; Huang SM, 1999, CANCER RES, V59, P1935; Hyland S, 2003, ONCOGENE, V22, P1557, DOI 10.1038/sj.onc.1206299; Irie RF, 2004, CANCER IMMUNOL IMMUN, V53, P110, DOI 10.1007/s00262-003-0436-1; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jhanwar YS, 2005, J NUCL MED, V46, p141S; Juweid ME, 1999, CANCER, V85, P1828, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Katayose Y, 1996, CANCER RES, V56, P4205; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kawakami Y, 2000, J IMMUNOTHER, V23, P17, DOI 10.1097/00002371-200001000-00004; KERR DE, 1995, CANCER RES, V55, P3558; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Kiewe P, 2006, CLIN CANCER RES, V12, P3085, DOI 10.1158/1078-0432.CCR-05-2436; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; King DM, 2004, J CLIN ONCOL, V22, P4463, DOI 10.1200/JCO.2004.11.035; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kipriyanov Sergey M, 2002, Methods Mol Biol, V178, P317; Kipriyanov SM, 1998, INT J CANCER, V77, P763, DOI 10.1002/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kollmannsberger C, 2006, ANN ONCOL, V17, P1007, DOI 10.1093/annonc/mdl042; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Kranz D M, 1995, J Hematother, V4, P403, DOI 10.1089/scd.1.1995.4.403; Kreitman RJ, 2005, J CLIN ONCOL, V23, P6719, DOI 10.1200/JCO.2005.11.437; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Lewis LD, 2002, CANCER CHEMOTH PHARM, V49, P375, DOI 10.1007/s00280-002-0424-8; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JL, 2003, J IMMUNOTHER, V26, P320, DOI 10.1097/00002371-200307000-00004; Loffler A, 2000, BLOOD, V95, P2098, DOI 10.1182/blood.V95.6.2098; Loffler A, 2003, LEUKEMIA, V17, P900, DOI 10.1038/sj.leu.2402890; Maletz K, 2001, INT J CANCER, V93, P409, DOI 10.1002/ijc.1348; Manzke O, 2001, INT J CANCER, V91, P508, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1068>3.0.CO;2-D; Manzke O, 2001, INT J CANCER, V91, P516, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1069>3.0.CO;2-A; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Matthey B, 2004, INT J CANCER, V111, P568, DOI 10.1002/ijc.20278; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; McNeel DG, 2005, CLIN CANCER RES, V11, P7851, DOI 10.1158/1078-0432.CCR-05-0262; Mehta K, 2004, MOL CANCER THER, V3, P345; MIESCHER S, 1986, J IMMUNOL, V136, P1899; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Modjtahedi H, 2003, INT J CANCER, V105, P273, DOI 10.1002/ijc.11055; MULE JJ, 1987, J IMMUNOL, V139, P285; Multani PS, 1998, CLIN CANCER RES, V4, P2599; NAGANE M, 2001, CANC LETT, V162, P17; Napier MP, 2000, CLIN CANCER RES, V6, P765; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Ogg GS, 2000, BRIT J CANCER, V82, P1058; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Omidfar K, 2004, TUMOR BIOL, V25, P179, DOI 10.1159/000081100; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Oved K, 2005, CANCER IMMUNOL IMMUN, V54, P867, DOI 10.1007/s00262-005-0666-5; PAGANELLI G, 1991, NUCL MED COMMUN, V12, P211, DOI 10.1097/00006231-199103000-00006; Paganelli G, 2001, CANCER BIOTHER RADIO, V16, P227, DOI 10.1089/10849780152389410; Pascolo S, 2001, CANCER RES, V61, P4072; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Plaksin D, 1997, J IMMUNOL, V158, P2218; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9; REIST CJ, 1995, CANCER RES, V55, P4375; Reiter Y, 1997, P NATL ACAD SCI USA, V94, P4631, DOI 10.1073/pnas.94.9.4631; Repp R, 2003, BRIT J CANCER, V89, P2234, DOI 10.1038/sj.bjc.6601367; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Riesenberg R, 2001, J HISTOCHEM CYTOCHEM, V49, P911, DOI 10.1177/002215540104900711; Robert B, 2000, EUR J IMMUNOL, V30, P3165, DOI 10.1002/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R; Robinson BWS, 1998, J IMMUNOTHER, V21, P211, DOI 10.1097/00002371-199805000-00007; Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rowinsky EK, 2004, J CLIN ONCOL, V22, P3003, DOI 10.1200/JCO.2004.11.061; Sacchi S, 2001, CRIT REV ONCOL HEMAT, V37, P13, DOI 10.1016/S1040-8428(00)00069-X; Saleh MN, 2000, J CLIN ONCOL, V18, P2282, DOI 10.1200/JCO.2000.18.11.2282; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Schaed SG, 2002, CLIN CANCER RES, V8, P967; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; Schlosser KL, 2006, SOC NATUR RESOUR, V19, P3, DOI 10.1080/08941920500323096; Schnirring L, 2002, PHYSICIAN SPORTSMED, V30, P4, DOI 10.3810/psm.2002.04.243; Schwaab T, 2001, J IMMUNOTHER, V24, P79, DOI 10.1097/00002371-200101000-00009; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sharkey RM, 2005, J NUCL MED, V46, P620; Sharkey RM, 2005, J NUCL MED, V46, p115S; SHAW DR, 1988, J BIOL RESP MODIF, V7, P204; Smith J, 2005, FASEB J, V19, P331, DOI 10.1096/fj.04-2863rev; Smith-Jones PM, 2004, METHOD ENZYMOL, V386, P262; SOIFFER RJ, 1993, BLOOD, V82, P2790, DOI 10.1182/blood.V82.9.2790.bloodjournal8292790; Sperr WR, 2005, LEUKEMIA LYMPHOMA, V46, P1115, DOI 10.1080/10428190500126075; STEVENSON GT, 1989, ANTI-CANCER DRUG DES, V3, P219; Stocks M, 2005, CURR OPIN CHEM BIOL, V9, P359, DOI 10.1016/j.cbpa.2005.06.003; Strube RW, 2002, J IMMUNOL METHODS, V263, P149, DOI 10.1016/S0022-1759(02)00035-2; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; TAMMINEN WL, 1987, EUR J IMMUNOL, V17, P999, DOI 10.1002/eji.1830170716; TIEBOUT RF, 1987, J IMMUNOL, V139, P3402; Tijink BM, 2006, J NUCL MED, V47, P1127; Tolcher AW, 1999, J CLIN ONCOL, V17, P478, DOI 10.1200/JCO.1999.17.2.478; Torres LA, 2005, NUCL MED COMMUN, V26, P1049, DOI 10.1097/00006231-200512000-00002; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Tur MK, 2003, CANCER RES, V63, P8414; Verheul HMW, 2004, J PATHOL, V202, P5, DOI 10.1002/path.1473; Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2002.5392; Visseren MJW, 1997, INT J CANCER, V73, P125, DOI 10.1002/(SICI)1097-0215(19970926)73:1<125::AID-IJC19>3.0.CO;2-F; Viti F, 1999, CANCER RES, V59, P347; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; WALLACE PM, 1994, CANCER RES, V54, P2719; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wimberger P, 2003, INT J CANCER, V105, P241, DOI 10.1002/ijc.11056; Witlox MA, 2002, J GENE MED, V4, P510, DOI 10.1002/jgm.308; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3; WOLFE F, 1994, J MUSCULOSKELET PAIN, V2, P24; Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; WYLIE DE, 1982, J EXP MED, V155, P403, DOI 10.1084/jem.155.2.403; Xiong DS, 2002, CANCER LETT, V177, P29, DOI 10.1016/S0304-3835(01)00758-3; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamano Y, 2004, J EXP MED, V199, P1367, DOI 10.1084/jem.20032042; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; Yang XD, 1999, CANCER RES, V59, P1236; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu Rui, 2005, Sheng Wu Gong Cheng Xue Bao, V21, P289; Zaki MH, 2002, J INVEST DERMATOL, V118, P366, DOI 10.1046/j.1523-1747.2002.01646.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521; ZHOU H, 1993, CANCER RES, V53, P3817; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192	240	60	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3714	3733		10.1038/sj.onc.1210372	http://dx.doi.org/10.1038/sj.onc.1210372			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530025				2022-12-17	WOS:000246816100014
J	Khatlani, TS; Wislez, M; Sun, M; Srinivas, H; Iwanaga, K; Ma, L; Hanna, AE; Liu, D; Girard, L; Kim, YH; Pollack, JR; Minna, JD; Wistuba, II; Kurie, JM				Khatlani, T. S.; Wislez, M.; Sun, M.; Srinivas, H.; Iwanaga, K.; Ma, L.; Hanna, A. E.; Liu, D.; Girard, L.; Kim, Y. H.; Pollack, J. R.; Minna, J. D.; Wistuba, I. I.; Kurie, J. M.			c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells	ONCOGENE			English	Article						c-Jun N-terminal kinase; lung cancer; cellular transformation	METASTASIS SUPPRESSOR GENE; NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; BREAST; GROWTH; JNK; MUTATIONS; MKK4; PROLIFERATION; EXPRESSION	c-Jun N-terminal kinase (JNK) has been reported to either potentiate or inhibit oncogenesis, depending upon the cellular context, but its role in lung neoplasia is unclear. Here we sought to de. ne the role of JNK in lung neoplasia by examining evidence of JNK phosphorylation in non-small-cell lung cancer (NSCLC) biopsy samples and by using genetic and pharmacologic approaches to modulate JNK expression and activity in cultured cells. Immunohistochemical staining for JNK phosphorylation was detected in 114 (45%) of 252 NSCLC biopsy samples and was predominantly nuclear, providing evidence of JNK activation in a subset of NSCLC cases. Introduction of a doxycycline-inducible, constitutively active, mutant mitogen-activated protein kinase kinase 4 (MKK4) into the human bronchial epithelial cell lines BEAS-2B and HB56B increased the cells' proliferation, migration, invasion and clonogenicity. Depletion of JNK in MKK4 mutant-transformed BEAS-2B cells by introduction of JNK1/2 short hairpin RNA reversed the transformed phenotype, indicating that JNK activation is oncogenic and MKK4 confers neoplastic properties in these cells. The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor. We conclude that JNK is activated in a subset of NSCLC biopsy samples and promotes oncogenesis in the bronchial epithelium, suggesting that strategies to inhibit the JNK pathway should be considered for the prevention and treatment of NSCLC.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Hop Tenon, AP HP, Dept Pulmonol, F-75970 Paris, France; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 0432,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkurie@mdanderson.org		wislez, marie/0000-0001-7518-7859	NCI NIH HHS [R01 CA105155, P50 CA070907, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R01CA105155] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmeier BE, 2005, THROMB HAEMOSTASIS, V93, P761, DOI 10.1160/TH04-09-0601; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cazillis M, 2004, ONCOGENE, V23, P4735, DOI 10.1038/sj.onc.1207619; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GEQIANG L, 2004, J BIOL CHEM, V279, P1123; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim HL, 2001, CANCER RES, V61, P2833; Kim MH, 2005, BIOCHEM BIOPH RES CO, V333, P874, DOI 10.1016/j.bbrc.2005.06.002; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee HY, 2002, CLIN CANCER RES, V8, P2970; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; REDDEL RR, 1991, INT J CANCER, V48, P764, DOI 10.1002/ijc.2910480522; REDDEL RR, 1988, CANCER RES, V48, P1904; Su GH, 1998, CANCER RES, V58, P2339; SUGIO K, 1992, CANCER RES, V52, P339; Teng DHF, 1997, CANCER RES, V57, P4177; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang YM, 2003, CLIN CANCER RES, V9, P391; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	45	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2658	2666		10.1038/sj.onc.1210050	http://dx.doi.org/10.1038/sj.onc.1210050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057737				2022-12-17	WOS:000245831200013
J	Wuerzberger-Davis, SM; Nakamura, Y; Seufzer, BJ; Miyamoto, S				Wuerzberger-Davis, S. M.; Nakamura, Y.; Seufzer, B. J.; Miyamoto, S.			NF-kappa B activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage	ONCOGENE			English	Article						NEMO; SUMOylation; ATM; H2O2	DOUBLE-STRAND BREAKS; FIELD GEL-ELECTROPHORESIS; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; TOPOISOMERASE-I; CLEAVABLE COMPLEXES; SIGNALING PATHWAY; GENOTOXIC STRESS	The inactive transcription factor NF-kappa B is localized in the cytoplasm and rapidly responds to a variety of extracellular factors and intracellular stress conditions to initiate multiple cellular responses. While the knowledge regarding NF-kappa B signaling pathways initiated by extracellular ligands is rapidly expanding, the mechanisms of activation by intracellular stress conditions are not well understood. We recently described a critical role for a small ubiquitin-like modifier (SUMO) modi. cation of NF-kappa B essential modulator (NEMO), the regulatory subunit of the I kappa B kinase, in response to certain genotoxic stress conditions. One important unanswered question is whether the role of this modi. cation is limited to the genotoxic agents or some other signaling pathways also employ SUMOylation of NEMO to regulate NF-kappa B activation. Here, we report that a variety of other stress conditions, including oxidative stress, ethanol exposure, heat shock and electric shock, also induce NEMO SUMOylation, thus demonstrating that DNA damage per se is not necessary for this NEMO modi. cation to occur. Moreover, combinations of certain SUMO stress and ATM (ataxia telangiectasia mutated) activation conditions lead to NF-kappa B activation without inducing DNA damage. Our study helps to conceptualize how individual or a combination of different stress conditions may funnel into this previously unappreciated signal transduction mechanism to regulate the activity of the ubiquitous NF-kappa B transcription factor.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Canc Biol Program, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Miyamoto, S (corresponding author), Univ Wisconsin, Dept Pharmacol, 3795 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	smiyamot@wisc.edu			NCI NIH HHS [R01-CA77474, R01-CA81065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081065, R01CA077474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGER DD, 1991, RADIAT RES, V128, P150, DOI 10.2307/3578132; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banath JP, 2003, CANCER RES, V63, P4347; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim SH, 2000, NUMER HEAT TR A-APPL, V38, P1, DOI 10.1080/10407780050134947; KINASHI Y, 1995, RADIAT RES, V141, P153, DOI 10.2307/3579042; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Leight ER, 2001, MOL CELL BIOL, V21, P4149, DOI 10.1128/MCB.21.13.4149-4161.2001; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Michalke M, 2000, FEBS LETT, V465, P64, DOI 10.1016/S0014-5793(99)01719-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connor S, 2004, MOL CELL BIOL, V24, P4895, DOI 10.1128/MCB.24.11.4895-4908.2004; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Szabo G, 2001, ALCOHOL CLIN EXP RES, V25, P1188; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Ward RJ, 1996, FEBS LETT, V389, P119, DOI 10.1016/0014-5793(96)00545-5; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wuerzberger-Davis SM, 2005, MOL CANCER RES, V3, P345, DOI 10.1158/1541-7786.MCR-05-0028; Yao Z, 2001, BONE, V28, P167, DOI 10.1016/S8756-3282(00)00425-7; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	67	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					641	651		10.1038/sj.onc.1209815	http://dx.doi.org/10.1038/sj.onc.1209815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862178				2022-12-17	WOS:000243902200002
J	Penserga, ETP; Skorski, T				Penserga, E. T. P.; Skorski, T.			Fusion tyrosine kinases: a result and cause of genomic instability	ONCOGENE			English	Review						fusion tyrosine kinase; genomic instability; ROS; DNA damage; DNA repair; imatinib mesylate	CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR-1; DOUBLE-STRAND BREAKS; CHROMOSOMAL TRANSLOCATION MECHANISMS; IMATINIB RESISTANCE MUTATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; NUCLEOTIDE EXCISION-REPAIR; HEMATOPOIETIC-CELL LINE; DNA-POLYMERASE-BETA	Reciprocal chromosomal translocations may arise as a result of unfaithful repair of spontaneous DNA double-strand breaks, most probably induced by oxidative stress, radiation, genotoxic chemicals and/or replication stress. Genes encoding tyrosine kinases are targeted by these mechanisms resulting in the generation of chimera genes encoding fusion tyrosine kinases (FTKs). FTKs display transforming activity owing to their constitutive kinase activity causing deregulated proliferation, apoptosis, differentiation and adhesion. Moreover, FTKs are able to facilitate DNA repair, prolong activation of G(2)/M and S cell cycle checkpoints, and elevate expression of antiapoptotic protein Bcl-X-L, making malignant cells less responsive to antitumor treatment. FTKs may also stimulate the generation of reactive oxygen species and enhance spontaneous DNA damage in tumor cells. Unfortunately, FTKs compromise the delity of DNA repair mechanisms, which contribute to the accumulation of additional genetic abnormalities leading to the resistance to inhibitors such as imatinib mesylate and malignant progression of the disease.	Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Skorski, T (corresponding author), Temple Univ, Dept Microbiol & Immunol, Sch Med, MRB 548A,3400 N Broad St, Philadelphia, PA 19140 USA.	tskorski@temple.edu			NIDDK NIH HHS [5R25DK059644-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R25DK059644] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; Akman SA, 2000, ANN NY ACAD SCI, V899, P88; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Aoki M, 2001, BRIT J DERMATOL, V145, P123, DOI 10.1046/j.1365-2133.2001.04295.x; Aplan PD, 2006, TRENDS GENET, V22, P46, DOI 10.1016/j.tig.2005.10.002; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; BARRETT A, 1992, BONE MARROW TRANSPL, V9, P305; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Baumann H, 2003, J BIOL CHEM, V278, P16198, DOI 10.1074/jbc.M300018200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BIERNAUX C, 1995, BLOOD, V86, P3118; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Bousquet M, 2005, ONCOGENE, V24, P7248, DOI 10.1038/sj.onc.1208850; Brady N, 2003, CANCER RES, V63, P1798; Brain JM, 2003, CANCER RES, V63, P4895; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 2003, BLOOD, V102, P2632, DOI 10.1182/blood-2002-10-3207; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHOU CL, 1993, J IMMUNOL, V150, P5350; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cross NCP, 2002, LEUKEMIA, V16, P1207, DOI 10.1038/sj.leu.2402556; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; De Keersmaecker K, 2006, LEUKEMIA, V20, P200, DOI 10.1038/sj.leu.2404064; Deininger MWN, 1998, CANCER RES, V58, P421; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Elliott B, 2005, MOL CELL, V17, P885, DOI 10.1016/j.molcel.2005.02.028; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gaymes TJ, 2002, CANCER RES, V62, P2791; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goldberg Z, 2004, CELL CYCLE, V3, P1188; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gorre ME, 2002, CURR OPIN HEMATOL, V9, P303, DOI 10.1097/00062752-200207000-00007; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hoser G, 2003, LEUKEMIA RES, V27, P267, DOI 10.1016/S0145-2126(02)00163-7; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; KELMAN Z, 1989, BLOOD, V74, P2318; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; KOPTYRA M, 2006, IN PRESS BLOOD, V9; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANEUVILLE P, 1992, BLOOD, V80, P1788; Laurent E, 2003, CLIN CANCER RES, V9, P3722; Lessen DS, 2005, CANCER GENET CYTOGEN, V160, P73, DOI 10.1016/j.cancergencyto.2004.11.013; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LILLICRAP DA, 1984, LANCET, V2, P699; Limoli CL, 2003, CANCER RES, V63, P3107; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Martinelli G, 2000, HAEMATOLOGICA, V85, P40; Maru Y, 2001, MUTAT RES-FUND MOL M, V483, P83, DOI 10.1016/S0027-5107(01)00229-9; Matsuda T, 2003, J BIOL CHEM, V278, P25947, DOI 10.1074/jbc.C300170200; McGill CB, 1998, GENETICS, V148, P1525; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Nieborowska-Skorska M, 2006, CELL CYCLE, V5, P994, DOI 10.4161/cc.5.9.2722; Nishii K, 1996, ONCOGENE, V13, P2225; NOWELL PC, 1960, SCIENCE, V132, P1497; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; O'Hare T, 2004, BLOOD, V104, P2532, DOI 10.1182/blood-2004-05-1851; Ott G, 1998, GENE CHROMOSOME CANC, V22, P114, DOI 10.1002/(SICI)1098-2264(199806)22:2<114::AID-GCC5>3.0.CO;2-#; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raderschall E, 2002, CANCER RES, V62, P219; Reddy EP, 2003, CANCER BIOL THER, V2, P115; Reed SH, 2005, DNA REPAIR, V4, P909, DOI 10.1016/j.dnarep.2005.04.009; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; ROWLEY JD, 1982, ADV CANCER RES, V36, P103, DOI 10.1016/S0065-230X(08)60423-6; Roy-Engel AM, 2002, J MOL BIOL, V316, P1033, DOI 10.1006/jmbi.2001.5380; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Sattler M, 1999, BLOOD, V93, P2928; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 2002, CANCER CELL, V1, P13, DOI 10.1016/S1535-6108(02)00022-3; Semenza GL, 2000, CIRC RES, V86, P117, DOI 10.1161/01.RES.86.2.117; Sercan HO, 2000, LEUKEMIA LYMPHOMA, V39, P385, DOI 10.3109/10428190009065838; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Shteper P, 2001, SEMIN CANCER BIOL, V11, P313, DOI 10.1006/scbi.2001.0387; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKINNER AM, 2005, SCI AGING KNOWLEDGE; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Stoklosa T, 2004, CELL CYCLE, V3, P1463, DOI 10.4161/cc.3.11.1229; Strick R, 2006, HUM GENET, V119, P479, DOI 10.1007/s00439-006-0146-9; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; TOKUHATA GK, 1968, BLOOD, V31, P216, DOI 10.1182/blood.V31.2.216.216; Tsao AS, 2002, BRIT J HAEMATOL, V119, P15, DOI 10.1046/j.1365-2141.2002.03899.x; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Varga T, 2005, DNA REPAIR, V4, P1038, DOI 10.1016/j.dnarep.2005.05.004; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Villamor N, 1999, ANN HEMATOL, V78, P478, DOI 10.1007/s002770050603; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Bubnoff N, 2005, BLOOD, V105, P1652, DOI 10.1182/blood-2004-06-2445; Weinstock DM, 2006, BLOOD, V107, P777, DOI 10.1182/blood-2005-06-2437; Weisberg E, 2001, DRUG RESIST UPDATE, V4, P22, DOI 10.1054/drup.2001.0180; Wlodarska I, 1998, BLOOD, V92, P2688, DOI 10.1182/blood.V92.8.2688.420a42_2688_2695; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yu TW, 1997, MUTAT RES-FUND MOL M, V379, P201, DOI 10.1016/S0027-5107(97)00141-3	161	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					11	20		10.1038/sj.onc.1209756	http://dx.doi.org/10.1038/sj.onc.1209756			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16785987				2022-12-17	WOS:000243236500002
J	Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV				Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV			Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas	ONCOGENE			English	Article						ING1; gene knockout; lymphoma; mouse; radiation sensitivity	CANDIDATE TUMOR-SUPPRESSOR; SQUAMOUS-CELL CARCINOMAS; PHD FINGER PROTEINS; GENE ING1; ALTERNATIVE TRANSCRIPTS; P53 EXPRESSION; MELANOMA-CELLS; MESSENGER-RNA; HUMAN HEAD; P33(ING1)	Ing1 belongs to the family of evolutionary conserved genes encoding nuclear PHD finger-containing proteins implicated in a variety of processes, including tumorigenesis, replicative senescence, excision repair and response to genotoxic stress. We have generated mice deficient in all the isoforms of Ing1 by targeted disruption of the exon that is common for all ing1 transcripts. Embryonic fibroblasts from ing1-knockout mice were similar to the wild-type cells in their growth characteristics, replicative lifespan in culture, p53 induction and sensitivity to various cytotoxic treatments with minor alterations in cell cycle distribution in response to genotoxic stress. ing1-deficient animals are characterized by reduced size with no obvious morphological, physiological or behavioral abnormalities, indicating that ing1 function is dispensable for the viability of mice under normal physiological conditions. Loss of ing1 was associated with earlier onset and higher incidence of lymphomas. Consistent with the possible involvement of Ing1 in DNA repair, ing1-deficient mice were more sensitive to total body gamma radiation. Our observations are well in line with the suggested role of ing1 as a candidate tumor suppressor gene involved in control of DNA damage response.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland BioLabs Inc, Cleveland, OH USA; Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; Cornell University	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	gudkov@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 60730, CA 17579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Campos EI, 2004, INT J ONCOL, V25, P73; Campos EI, 2002, BRIT J DERMATOL, V146, P574, DOI 10.1046/j.1365-2133.2002.04641.x; Chen LS, 2001, CANCER RES, V61, P4345; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gunduz M, 2000, CANCER RES, V60, P3143; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Helbing CC, 1997, CANCER RES, V57, P1255; Ito K, 2002, AM J HEMATOL, V69, P141, DOI 10.1002/ajh.10031; Kichina JV, 2003, ONCOGENE, V22, P4911, DOI 10.1038/sj.onc.1206741; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Maestro R, 1996, CANCER RES, V56, P1146; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Ohgi T, 2002, SCAND J GASTROENTERO, V37, P1440, DOI 10.1080/003655202762671332; Ohmori M, 1999, AM J HEMATOL, V62, P118; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sanchez-Cespedes M, 2000, GENE CHROMOSOME CANC, V27, P319, DOI 10.1002/(SICI)1098-2264(200003)27:3<319::AID-GCC13>3.0.CO;2-P; Sarela AI, 1999, EUR J CANCER, V35, P1264, DOI 10.1016/S0959-8049(99)00104-5; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P161; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zeremski M, 1997, SOMAT CELL MOLEC GEN, V23, P233, DOI 10.1007/BF02721376	48	60	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					857	866		10.1038/sj.onc.1209118	http://dx.doi.org/10.1038/sj.onc.1209118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170338				2022-12-17	WOS:000235212700005
J	Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M				Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M			Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors	ONCOGENE			English	Article						neuroblastoma; ganglioneuroma; methylation; methylator phenotype	RECEPTOR-BETA EXPRESSION; DNA METHYLATION; P73 GENE; PROMOTER METHYLATION; COLORECTAL-CANCER; BREAST-CANCER; HYPERMETHYLATION; DELTA-NP73; TUMORIGENESIS; PHENOTYPE	The hypermethylation of CpG islands within gene promoter regions is an epigenetic phenomenon that is often, but not always, associated with the transcriptional silencing of downstream genes and contributes to carcinogenesis. We have determined the pattern of methylation of several genes involved in distinct biological pathways, including cell proliferation and apoptosis, in neuroblastoma and in the nonmalignant ganglioneuroma. The purpose of this work was to search for epigenetic signatures that could be associated with defined clinical and biological parameters and that, in prospective, could identify specific risk categories among the patients. We have analysed 31 malignant neuroblastoma with or without MYCN amplification and 13 benign ganglioneuroma and we have observed dramatic differences in the methylation pattern of five genes (CASP8, 14.3.3 sigma, Delta N p73, RASSF1A and DCR2) between these tumors indicating that this phenomenon is not tissue-specific and can be considered as cancer-dependent. Furthermore, the methylation pattern of 14.3.3 sigma, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.	Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	massimo.romani@istge.it	Bonassi, Stefano/ABI-6281-2020; Banelli, Barbara/Y-1151-2019; Scaruffi, Paola/AAB-3999-2020	Bonassi, Stefano/0000-0003-3833-6717; Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X; scaruffi, paola/0000-0001-9799-1661				Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Corn PG, 1999, CANCER RES, V59, P3352; Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KALBFLEISCH JD, 1980, STAT ANAL FAILTURE T; Kawano S, 1999, BLOOD, V94, P1113; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TONINI GP, 1993, EUR J CANCER, V28, P1000; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van Noesel MM, 2002, CANCER RES, V62, P2157; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331	32	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5619	5628		10.1038/sj.onc.1208722	http://dx.doi.org/10.1038/sj.onc.1208722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16044164				2022-12-17	WOS:000231296100008
J	Tirado, OM; Mateo-Lozano, S; Notario, V				Tirado, OM; Mateo-Lozano, S; Notario, V			Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity	ONCOGENE			English	Article						apoptosis; DSRCT; EWS/WT1; proteasome; rapamycin	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TRANSLATION INITIATION; MAMMALIAN TARGET; WILMS-TUMOR; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; BINDING PROTEIN; SKELETAL-MUSCLE; T-LYMPHOCYTES	Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin ( mTOR). Rapamycin has been shown to induce G1-phase cell cycle arrest in diverse tumor cell types, and its derivatives RAD001 and CCI-779 are currently in phase I and phase II clinical trials, respectively, as anticancer agents. In this study, we show that rapamycin induced the apoptotic death of JN-DSRCT-1 cells, the only available in vitro model for Desmoplastic Small Round Cell Tumors (DSRCT), while having only minor effects on their cell cycle. Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level. Rapamycin also downregulated the levels of EWS/WT1, the fusion protein characteristic of DSRCT. Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity. Moreover, rapamycin treatment downregulated the mRNA and protein levels of the 26S p44.5 proteasome subunit, suggesting the involvement of the proteasome complex in the mechanisms of rapamycin-induced apoptosis. Treatment of JN-DSRCT-1 cells with MG-132, a proteasome specific inhibitor, also resulted in the induction of apoptosis through a similar increase in the Bax : Bcl-xL ratio specifically caused by inhibiting Bax degradation and turnover. These results suggested that rapamycin induces apoptosis by preventing the degradation of the Bax protein by the proteasome, and that this process is independent of mTOR inhibition. Furthermore, these results strongly support the introduction of the use of rapamycin as a cytotoxic agent for the treatment of DSRCT.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	/AFP-0764-2022; Tirado, Oscar Martínez/R-9604-2019; /AAB-6461-2022	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NATIONAL CANCER INSTITUTE [P30CA051008, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA51008, P01-CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranha O, 2003, INT J ONCOL, V22, P787; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Davis DL, 2000, BIOCHEM BIOPH RES CO, V277, P325, DOI 10.1006/bbrc.2000.3684; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Geoerger B, 2001, CANCER RES, V61, P1527; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Ito E, 2003, AM J PATHOL, V163, P2165, DOI 10.1016/S0002-9440(10)63573-0; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1994, CANCER RES, V54, P2837; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu FT, 2004, APOPTOSIS, V9, P377, DOI 10.1023/B:APPT.0000025815.78761.5c; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mateo-Lozano S, 2003, ONCOGENE, V22, P9282, DOI 10.1038/sj.onc.1207081; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Nishio J, 2002, LAB INVEST, V82, P1175, DOI 10.1097/01.LAB.0000028059.92642.03; OHNO T, 1994, ONCOGENE, V9, P3087; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Schimke JMC, 1999, GROWTH HORM IGF RES, V9, P179, DOI 10.1054/ghir.1999.0104; Schoffstall B, 2005, J PHARMACOL EXP THER, V312, P12, DOI 10.1124/jpet.104.073445; Sekulic A, 2000, CANCER RES, V60, P3504; SHEN WPV, 1992, CANCER GENET CYTOGEN, V64, P189; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang X, 1997, EUR J IMMUNOL, V27, P2781, DOI 10.1002/eji.1830271106; Zhou CX, 2003, MOL CANCER THER, V2, P789	56	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3348	3357		10.1038/sj.onc.1208471	http://dx.doi.org/10.1038/sj.onc.1208471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782132				2022-12-17	WOS:000228881800013
J	Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA				Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA			PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis	ONCOGENE			English	Article						PTPL1; phosphatase; EWS-FLI1; Ewing's sarcoma	PROTEIN-TYROSINE-PHOSPHATASE; FAS-ASSOCIATED PHOSPHATASE-1; KAPPA-B-ALPHA; PRIMITIVE NEUROECTODERMAL TUMOR; GTPASE-ACTIVATING PROTEIN; BREAST-CANCER CELLS; FACTOR-I RECEPTOR; GROWTH-FACTOR; MEDIATED APOPTOSIS; GENE-EXPRESSION	Ewing's Sarcoma family tumors (ESFT) are characterized by a translocation t(11: 22) forming an aberrant transcription factor EWS-FLI1. Protein tyrosine phosphatase L1 (PTPL1) was identified as a gene upregulated by EWS-FLI1 in transfected cells by microarray. Our results show that PTPL1 is a transcriptional target of EWS-FLI1 both by chromatin immunoprecipitation and promoter activation studies. We demonstrate that PTPL1 is highly expressed in ESFT cells and patient tumors compared with normal tissues, witha trend towards higher expression in metastatic versus primary tumors. Reduction of PTPL1 protein in ESFT cells correlated witha significant reduction in both monolayer and soft-agar cell growth. In addition, these PTPL1-reduced cells were more sensitive to etoposide-induced apoptosis than the controls. We therefore report a novel transcriptional activation of a phosphatase involved in the oncogenesis of ESFT. Increasing interest in specific phosphatase inhibitors would allow PTPL1 to be evaluated as a therapeutic target in ESFT.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University	Toretsky, JA (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Res Bldg,Room W311,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.	jat42@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA088004] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA088004, R01 CA88004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Irie S, 2001, DNA SEQUENCE, V11, P519, DOI 10.3109/10425170109041336; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Komada Y, 1997, BRIT J HAEMATOL, V99, P325, DOI 10.1046/j.1365-2141.1997.3903204.x; Kontny HU, 1998, CANCER RES, V58, P5842; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lee SH, 1999, J PATHOL, V188, P207; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Nakai Y, 2000, EUR J BIOCHEM, V267, P7170, DOI 10.1046/j.1432-1327.2000.01818.x; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Ungefroren H, 1998, CANCER RES, V58, P1741; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Uslu R, 1997, CLIN CANCER RES, V3, P963; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; XIAO S, 1994, J BIOL CHEM, V269, P21244; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	49	60	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2715	2722		10.1038/sj.onc.1208247	http://dx.doi.org/10.1038/sj.onc.1208247			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782144				2022-12-17	WOS:000228356700013
J	Xue, L; Firestone, GL; Bjeldanes, LF				Xue, L; Firestone, GL; Bjeldanes, LF			DIM stimulates IFN gamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways	ONCOGENE			English	Article						IFN gamma; JNK; p38; transcriptional regulation; breast cancer cells	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR INTERACTIONS; INTERFERON-GAMMA; BINDING-PROTEIN; TUMOR-CELLS; T-CELLS; 3,3'-DIINDOLYLMETHANE DIM; ESTROGEN-RECEPTOR; MESSENGER-RNA; IN-VITRO	3,3'-Diindolylmethane (DIM) is a promising anticancer agent derived from Brassica vegetables, but the mechanisms of DIM action are largely unknown. We have shown that DIM can upregulate the expression and stimulate the secretion of interferon-gamma (IFN gamma) in the human MCF-7 breast cancer cell line. This novel effect may provide important clues to explain the anticancer effects of DIM because it is well known that IFNy plays an important role in preventing the development of primary and transplanted tumors. Utilizing promoter deletions, we show here that the region between -108 and -36bp in the IFN gamma promoter, which contains two conserved and essential regulatory elements, is required for DIM-induced IFN gamma expression. DIM activates both JNK and p38 pathways, induces the phosphorylation of c-Jun and ATF-2, and increases the binding of the homodimer or heterodimer of c-Jun/ATF-2 to the proximal AP-1 (.) CREB-ATF-binding element. Moreover, studies with specific enzyme inhibitors showed that up-stream Ca2+-dependent kinase(s) is required for the inducing effects of DIM in MCF-7 cells. These results establish that DIM-induced IFN gamma expression in human breast tumor cells is mediated by activation of both JNK and p38 pathways, which is ultimately dependent on intracellular calcium signaling.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bjeldanes, LF (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall, Berkeley, CA 94720 USA.	lfb@nature.berkeley.edu			NCI NIH HHS [CA102360, CA69056, R01 CA102360-01A1, R01 CA102360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102360, R01CA069056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Auborn KJ, 2002, ANTIVIR THER, V7, P1; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; BENJAMIN D, 1986, AM J HEMATOL, V22, P169, DOI 10.1002/ajh.2830220207; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Cram EJ, 2001, J BIOL CHEM, V276, P22332, DOI 10.1074/jbc.M010539200; Csiszar A, 2000, CLIN EXP IMMUNOL, V122, P464, DOI 10.1046/j.1365-2249.2000.01369.x; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S; Garcia-Fernandez MO, 2003, BREAST CANCER RES TR, V77, P15, DOI 10.1023/A:1021196504944; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KASAHARA T, 1983, J IMMUNOL, V131, P2379; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Kiang JG, 1999, MOL CELL BIOCHEM, V199, P179, DOI 10.1023/A:1006946329581; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Mueller H, 1997, BIOL CHEM, V378, P1023, DOI 10.1515/bchm.1997.378.9.1023; Nachshon-Kedmi M, 2004, BRIT J CANCER, V91, P1358, DOI 10.1038/sj.bjc.6602145; Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANG YB, 1992, BLOOD, V80, P724; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; RADY PL, 1995, CYTOKINE, V7, P793, DOI 10.1006/cyto.1995.0095; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Rosfjord EC, 1999, EXP CELL RES, V248, P260, DOI 10.1006/excr.1998.4390; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sun SS, 2004, CELL STRESS CHAPERON, V9, P76; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wiatrak Brian J, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P433, DOI 10.1097/00020840-200312000-00005; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Young HA, 1997, PROG NUCLEIC ACID RE, V56, P109, DOI 10.1016/S0079-6603(08)61004-1	59	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2343	2353		10.1038/sj.onc.1208434	http://dx.doi.org/10.1038/sj.onc.1208434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735741				2022-12-17	WOS:000227877400007
J	Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A				Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A			Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells	ONCOGENE			English	Article						p53; p73; RanBPM; two-hybrid; ubiquitination	KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; BINDING-PROTEIN; P53-RELATED PROTEIN; INDUCE APOPTOSIS; NUCLEAR-PROTEIN; P53; DEGRADATION; NEUROBLASTOMA	Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73alpha by yeast-based two-hybrid screening, and also found that RanBPM has an ability to stabilize p73alpha. GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73alpha, whereas it failed to interact with p53. Co-expression of RanBPM with p73alpha resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73alpha, and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73alpha was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp						Agami R, 1999, NATURE, V399, P809; Bai D, 2003, BIOCHEM BIOPH RES CO, V309, P552, DOI 10.1016/j.bbrc.2003.08.033; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Gong JG, 1999, NATURE, V399, P806; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lutz W, 2003, BIOCHEM BIOPH RES CO, V303, P1186, DOI 10.1016/S0006-291X(03)00499-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Stiewe T, 2002, CANCER RES, V62, P3598; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang Y, 2002, BIOCHEM BIOPH RES CO, V297, P148, DOI 10.1016/S0006-291X(02)02020-X; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	33	60	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					938	944		10.1038/sj.onc.1208257	http://dx.doi.org/10.1038/sj.onc.1208257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558019				2022-12-17	WOS:000226577100019
J	Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M				Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M			Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta	ONCOGENE			English	Article						Smad4; TGF-beta; stable RNAi; cDNA microarray; pancreatic cancer	TUMOR-SUPPRESSOR GENE; MAMMALIAN-CELLS; MICROSATELLITE INSTABILITY; SIGNALING PATHWAY; RECEPTOR; TARGETS; DPC4; INHIBITION; PROMOTER; MUTATION	The transforming growth factor-beta (TGF-beta)-Smad signaling pathway inhibits the growth of human epithelial cells and plays a role in tumor suppression. The Smad4 gene is mutated or deleted in 50% of pancreatic cancers. In this study, we succeeded in establishing Smad4 knockdown (S4KD) pancreatic cancer cell lines using the stable RNA interference (RNAi) method. Smad4 protein expression was reduced dramatically and TGF-beta-Smad signaling was markedly inhibited in the S4KD cell lines. The S4KD and control cells were stimulated with TGF-beta and analysed using a cDNA microarray that contained 3756 genes, in order to screen for target molecules downstream of TGF-beta. The microarray analysis revealed that 187 S4KD genes and 155 genes in the control cells were regulated immediately upon TGF-beta stimulation. Quantitative RT-PCR analysis on several of these genes produced results that corroborated the outcome of the microarray analysis. Most of the genes in the S4KD and control cells identified by the array differed, which suggests signaling pathways that differ according to Smad4 status. Of the identified genes, 246 have not been reported previously as genes that lie downstream of TGF-beta. Genes that are involved in cell proliferation, adhesion, and motility were found to be regulated differentially with respect to S4KD and control cells. Cell migration induced by TGF-beta was inhibited in the S4KD cells, which might be associated with a different regulation of integrin beta7. The knock down of a specific gene using stable RNAi appears to be a promising tool for analysing endogenous gene function.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2600870, Japan; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo 1600023, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Ibaraki 3058562, Japan	University of Tokyo; University of Tokyo; Chiba University; Asahi Life Foundation; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Ijichi, Hideaki/AAE-6692-2022; IJICHI, Hideaki/AGZ-2874-2022; Miyagishi, Makoto/L-8174-2016; Ijichi, Hideaki/V-2720-2019	Ijichi, Hideaki/0000-0002-2379-7986; IJICHI, Hideaki/0000-0002-2379-7986; Miyagishi, Makoto/0000-0001-7654-3616; Tanaka, Yasuo/0000-0002-2917-3365				Akiyoshi S, 2001, JPN J CANCER RES, V92, P257, DOI 10.1111/j.1349-7006.2001.tb01090.x; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Lim SP, 1998, IMMUNOGENETICS, V48, P184, DOI 10.1007/s002510050422; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MORTON DM, 1995, CANCER RES, V55, P2596; Schutte M, 1996, CANCER RES, V56, P2527; Togo G, 1996, CANCER RES, V56, P5620; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang D, 2000, CANCER RES, V60, P4507; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	36	60	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					662	671		10.1038/sj.onc.1208102	http://dx.doi.org/10.1038/sj.onc.1208102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592526				2022-12-17	WOS:000226420400013
J	Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D				Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D			Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line	ONCOGENE			English	Article						Myc; serum; target genes; B-cells	GENE-EXPRESSION; GENOMIC TARGETS; GROWTH-FACTOR; LYMPHOCYTES; PROTEIN; FIBROBLASTS; CHROMATIN; CYCLE	Proliferation of higher eukaryotic cells is triggered by the proto-oncogene c-myc (myc), which is induced downstream of a large number of growth factor receptors. Myc, a basic helix-loop-helix leucine zipper transcription factor, transmits growth signals by up- and downregulation of target genes. The importance of Myc in growth control is well established. However, the number of growth control genes requiring Myc as an essential factor for regulation after mitogenic stimulation of cells is not yet clear. Here, we have studied the transcriptional programme of a human B-cell line, P493-6, in response to Myc and serum. P493-6 cells do not express the endogenous myc, nor is it induced by serum stimulation. Proliferation of the cells is dependent upon both the expression of a tetracycline-regulated myc gene and serum stimulation. Using DNA microarrays, expression pro. ling was performed following stimulation of cells with serum, with Myc, or with both. We observed serum regulation of > 1000 genes. A number of these genes were synergistically or antagonistically regulated by Myc. Moreover, we identified > 300 Myc-regulated genes that were almost unresponsive to serum. Gene ontology analysis revealed that a high proportion of Myc target genes are involved in ribosome biogenesis and tRNA metabolism. The data support our current notion that Myc is essential for the regulation of a large number of growth-related genes in B cells, and cannot be replaced by other serum-induced factors.	GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Max von Pettenkofer Inst, D-80336 Munich, Germany; Roche Diagnost GmbH, Roche Pharma Res Penzberg, Dept TR ON, D-82372 Penzberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Roche Holding	Eick, D (corresponding author), GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, Marchioninistr 25, D-81377 Munich, Germany.	eick@gsf.de	Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Newton JS, 1996, BIOCHEM SOC T, V24, pS7, DOI 10.1042/bst024007s; NORVELL A, 1995, J IMMUNOL, V154, P4404; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	25	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					520	524		10.1038/sj.onc.1208198	http://dx.doi.org/10.1038/sj.onc.1208198			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516975				2022-12-17	WOS:000226279700022
J	Das, D; Shah, RB; Imperiale, MJ				Das, D; Shah, RB; Imperiale, MJ			Detection and expression of human BK virus sequences in neoplastic prostate tissues	ONCOGENE			English	Review						polyomavirus BK; large T antigen; p53; postatrophic hyperplasia; proliferative inflammatory atrophy; in situ hybridization; immunohistochemistry; immunofluorescence; high-grade prostate intraepithelial neoplasia	LARGE-T-ANTIGEN; PROLIFERATIVE INFLAMMATORY ATROPHY; POLYMERASE-CHAIN-REACTION; P53 PROTEIN; HUMAN-PAPILLOMAVIRUS; HUMAN POLYOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; MONOCLONAL-ANTIBODIES; JC-VIRUS; CYTOPLASMIC SEQUESTRATION	BK virus (BKV) is ubiquitous in the human population and establishes a lifelong, subclinical persistent infection in the urinary tract. When the immune system is compromised, it can cause severe disease in the kidney and bladder. Detection of BKV sequences in urinary tract neoplasms has led to the postulate that this virus may induce human oncogenesis through the function of its large tumor antigen (TAg). In this study, examination of prostate tumor tissue sections using in situ hybridization shows the presence of BKV sequences in atrophic epithelium. Solution polymerase chain reaction on DNA extracted from the tissues and sequence analysis of the products reveal the presence of BKV regulatory and early region sequences. In addition, immunohistochemical analysis using monoclonal antibodies specific to TAg or p53 shows the expression of TAg in some of the samples and p53 staining that can be correlated to TAg expression. Although the normal cellular localization of TAg and p53 is nuclear, double immunofluorescence labeling with anti-p53 and TAg antibodies indicates colocalization of p53 and TAg to the cytoplasm in the glandular epithelial cells of the sections. Although BKV DNA was found in benign and atrophic lesions, TAg and p53 coexpression was observed only in atrophic lesions.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	imperial@umich.edu						Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BERGER CN, 1986, EMBO J, V5, P85, DOI 10.1002/j.1460-2075.1986.tb04181.x; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOSARI S, 1995, AM J PATHOL, V147, P790; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO;2-7; Brewster SF, 1999, J UROLOGY, V161, P1238, DOI 10.1016/S0022-5347(01)61646-X; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; CUZICK J, 1995, CANCER SURV, V23, P91; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Flaegstad T, 1999, CANCER RES, V59, P1160; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P617, DOI 10.1002/path.1700680234; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GARDNER SD, 1973, BMJ-BRIT MED J, V1, P77, DOI 10.1136/bmj.1.5845.77; GARDNER SD, 1971, LANCET, V1, P1253; GARDNER WA, 1987, J UROLOGY, V137, P53, DOI 10.1016/S0022-5347(17)43869-9; GARDNER WA, 1992, PATHOLOGY PATHOBIOLO, P129; Geetha D, 2002, TRANSPLANTATION, V73, P1933, DOI 10.1097/00007890-200206270-00015; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; HIRAOKA A, 1991, BONE MARROW TRANSPL, V7, P107; Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9; IBRAHIM GK, 1992, J UROLOGY, V148, P1822, DOI 10.1016/S0022-5347(17)37040-4; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Imperiale MJ, 2001, ONCOGENE, V20, P7917, DOI 10.1038/sj.onc.1204916; IWASAKA T, 1993, GYNECOL ONCOL, V48, P104, DOI 10.1006/gyno.1993.1016; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Jorgensen GEK, 2000, MED PEDIATR ONCOL, V35, P593, DOI 10.1002/1096-911X(20001201)35:6<593::AID-MPO22>3.0.CO;2-I; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; Knippschild U, 1996, ONCOGENE, V12, P1755; Kuefer R, 2002, AM J PATHOL, V161, P841, DOI 10.1016/S0002-9440(10)64244-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li RM, 2002, TRANSPLANTATION, V74, P1497, DOI 10.1097/00007890-200212150-00004; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P619, DOI 10.1097/00000478-198808000-00003; MCNICOL PJ, 1991, J UROLOGY, V145, P850, DOI 10.1016/S0022-5347(17)38476-8; Melamed J, 1997, CLIN CANCER RES, V3, P1867; MOENS U, 2001, HUMAN POLYOMAVIRUSES, P215; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NAKASHATRI H, 1988, J VIROL, V62, P4613; NEGRINI M, 1991, J VIROL, V65, P5092, DOI 10.1128/JVI.65.9.5092-5095.1991; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Noda T, 1998, UROL RES, V26, P165, DOI 10.1007/s002400050041; Nuovo G. J., 1996, PCR IN SITU HYBRIDIZ; Nupponen N, 1999, EUR UROL, V35, P351, DOI 10.1159/000019907; Osman I, 1999, CLIN CANCER RES, V5, P2082; PADGETT B, 1981, HUMAN PAPOVAVIRUSES, P339; Pappo O, 1996, MODERN PATHOL, V9, P105; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PORTOLANI M, 1975, J VIROL, V15, P420, DOI 10.1128/JVI.15.2.420-422.1975; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Randhawa PS, 1999, TRANSPLANTATION, V67, P103, DOI 10.1097/00007890-199901150-00018; Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813; ROTOLA A, 1992, INT J CANCER, V52, P359, DOI 10.1002/ijc.2910520306; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; RUBINSTEIN R, 1987, J VIROL, V61, P1747, DOI 10.1128/JVI.61.5.1747-1750.1987; Ruska KM, 1998, AM J SURG PATHOL, V22, P1073, DOI 10.1097/00000478-199809000-00005; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIF I, 1979, CELL, V18, P963, DOI 10.1016/0092-8674(79)90209-5; Shah KV, 1996, FIELDS VIROLOGY, P2027; Shah R, 2001, AM J PATHOL, V158, P1767, DOI 10.1016/S0002-9440(10)64132-6; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1995, ONCOGENIC MECH, P27; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; SUNDSFJORD A, 1990, J VIROL, V64, P3864, DOI 10.1128/JVI.64.8.3864-3871.1990; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vilchez RA, 2002, AIDS RES HUM RETROV, V18, P237, DOI 10.1089/088922202753472793; Vivaldi A, 2003, J CLIN ENDOCR METAB, V88, P892, DOI 10.1210/jc.2002-020436; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Volter C, 1997, VIROLOGY, V237, P389, DOI 10.1006/viro.1997.8772; WATANABE S, 1989, VIROLOGY, V169, P204, DOI 10.1016/0042-6822(89)90056-1; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Wiedorn KH, 1999, HISTOCHEM CELL BIOL, V111, P89, DOI 10.1007/s004180050338; YANG RCA, 1979, SCIENCE, V206, P456, DOI 10.1126/science.228391; Yang XMJ, 2002, AM J SURG PATHOL, V26, P921, DOI 10.1097/00000478-200207000-00011; Zambrano A, 2002, ONCOGENE, V21, P5725, DOI 10.1038/sj.onc.1205692; Zambrano A, 2002, PROSTATE, V53, P263, DOI 10.1002/pros.10157	113	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7031	7046		10.1038/sj.onc.1207920	http://dx.doi.org/10.1038/sj.onc.1207920			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258563				2022-12-17	WOS:000223885100004
J	Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R				Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R			Interaction of AF4 wild-type and AF4. MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?	ONCOGENE			English	Article						AF4; chromosomal MLL translocation t(4;11); SIAH1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOID PROGENITORS; PROTEASOME PATHWAY; AF4-RELATED GENE; UBIQUITIN LIGASE; NUCLEAR-PROTEIN; AF-4 GENE; CELL-LINE; HRX-ENL; EXPRESSION	The human AF4 (ALL-1 fused gene on chromosome 4) gene (4q11) is recurrently involved in reciprocal translocations to the MLL (mixed lineage leukemia) gene (11q23), correlated with high-risk acute lymphoblastic leukemia (ALL) in infants and early childhood. The t(4; 11) translocation is one of the most frequent MLL translocations known today. In general, MLL translocations are the result of an illegitimate recombination process leading to reciprocal fusions of unrelated translocation partner (TP) genes with the MLL gene. Owing to the constant presence of the derivative (11) product, it was hypothesised that only MLL. TP fusion genes are responsible for the leukemogenic process. This concept has been successfully tested for some known MLL fusions, while other MLL fusions failed. Here, we demonstrate growth-transforming potential of AF4 wild-type and the AF4. MLL fusion protein. The underlying oncogenic mechanism involves the two E3 ubiquitin ligases SIAH1 and SIAH2, the N-terminal portion of AF4 and the protection of the AF4. MLL fusion protein against proteosomal degradation.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44801 Bochum, Germany	Goethe University Frankfurt; Ruhr University Bochum	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHEN CS, 1993, BLOOD, V82, P1080; COHEN A, 1991, BLOOD, V78, P94; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; Frestedt JL, 1996, GENET ANAL-BIOMOL E, V12, P147, DOI 10.1016/1050-3862(95)00127-1; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Isaacs AM, 2003, J NEUROSCI, V23, P1631; Isnard P, 2000, BLOOD, V96, P705; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; von Bergh ARM, 2002, GENE CHROMOSOME CANC, V35, P92, DOI 10.1002/gcc.10091; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	61	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6237	6249		10.1038/sj.onc.1207837	http://dx.doi.org/10.1038/sj.onc.1207837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221006				2022-12-17	WOS:000223399000008
J	Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG				Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG			Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro	ONCOGENE			English	Article						cigarette smoke condensate; normal breast epithelial cells; anchorage-independent growth; transformation; Bcl-xL/Bax; neuropilin-1	PASSIVE SMOKING; ACTIVE SMOKING; GROWTH-FACTOR; TUMOR-CELLS; CANCER RISK; KAPPA-B; EXPRESSION; NEUROPILIN-1; GADD45; GENES	In the present study, we showed that a single-dose treatment of normal breast epithelial cell line, MCF10A, for 72h with cigarette smoke condensate (CSC) resulted in a transformed phenotype. The anchorage-dependent growth of these cells was decreased due to increased cell cycle arrest in S-G(2)/M phase; however, the surviving cells developed resistance due to an increased Bcl-xL to Bax ratio. Levels of PCNA and gadd45 proteins - involved in DNA repair in response to genomic damage - were increased, suggesting that the cells were responding to CSC-induced genomic damage. The transformation of MCF10A cells was determined by their colony-forming efficiency in soft-agar in an anchorage-independent manner. CSC-treated MCF10A cells efficiently formed colonies in soft-agar. We then re-established cell lines from the soft-agar colonies and further examined the persistence of their transforming characteristics. The re-established cell lines, when plated after 17 passages without CSC treatment, still formed colonies in the soft-agar. An increased staining of neuropilin-1 (NRP-1) further showed a transformation characteristic of MCF10A cells treated with CSC. In summary, our results suggest that CSC is capable of transforming the MCF10A cells in vitro, supporting the role cigarette smoking and increased risk for breast cancer.	Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Gainesville, FL 32610 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	State University System of Florida; University of Florida; Roswell Park Cancer Institute; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093				Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bachelder RE, 2001, CANCER RES, V61, P5736; Band PR, 2003, BIOMED PHARMACOTHER, V57, P110; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; HALL PA, 1995, ONCOGENE, V10, P2427; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lash TL, 1999, AM J EPIDEMIOL, V149, P5; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Millikan RC, 1998, CANCER EPIDEM BIOMAR, V7, P371; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Morabia A, 2002, EPIDEMIOLOGY, V13, P744, DOI 10.1097/00001648-200211000-00026; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Rodgman A, 2000, HUM EXP TOXICOL, V19, P573, DOI 10.1191/096032700701546514; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Russo I.H., 2001, J WOMENS CANC, V3, P29; Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SMITH SJ, 1994, BRIT J CANCER, V70, P112, DOI 10.1038/bjc.1994.258; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SOULE HD, 1990, CANCER RES, V50, P6075; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611; TAIT L, 1990, CANCER RES, V50, P6087; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Tomlinson IPM, 2001, BREAST CANCER RES, V3, P299, DOI 10.1186/bcr311; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; [No title captured]	57	60	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5880	5889		10.1038/sj.onc.1207792	http://dx.doi.org/10.1038/sj.onc.1207792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208684				2022-12-17	WOS:000222941100002
J	Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV				Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV			Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity	ONCOGENE			English	Article						breast cancer; IGF-IR; antisense strategies	ACTIVATED PROTEIN-KINASE; MOUSE MAMMARY ADENOCARCINOMAS; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; GLIOBLASTOMA CELLS; DOWN-REGULATION; GENE-TRANSFER; TUMOR-GROWTH; MCF-7 CELLS	The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S] ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous ( i. v.) injection of AS [S] ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S] ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs ( S[ S] ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[ S] ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[ S] ODNs treatment. Tumors from AS[ S] ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases ( MAPK) was abolished in tumors growing in AS[ S] ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[ S] ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S] ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S] ODNs.	Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, RA-1428 Buenos Aires, DF, Argentina; Sanatorio Mater Dei, Serv Pathol, Buenos Aires, DF, Argentina; Inst Invest Ingn Genet & Biol Mol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar		Elizalde, Patricia V./0000-0002-5923-9898				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chakravarti A, 2002, CANCER RES, V62, P200; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Dunn SE, 1998, CANCER RES, V58, P3353; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee CT, 1996, CANCER RES, V56, P3038; Lee CT, 2003, CANCER GENE THER, V10, P57, DOI 10.1038/sj.cgt.7700524; Li WQ, 2000, CANCER RES, V60, P3909; Liu XD, 1998, CANCER RES, V58, P5432; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Nakamura K, 2000, CANCER RES, V60, P760; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Oesterreich S, 2001, CANCER RES, V61, P5771; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	54	60	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5161	5174		10.1038/sj.onc.1207659	http://dx.doi.org/10.1038/sj.onc.1207659			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122317	Green Published			2022-12-17	WOS:000222382500006
J	Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R				Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R			Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells	ONCOGENE			English	Article						suppressive subtraction hybridization; signal transduction; ovarian cancer; gene regulation; mitogen-activated; protein kinase	JUNCTIONAL INTERCELLULAR COMMUNICATION; GENE-EXPRESSION PROFILES; K-RAS PROTOONCOGENE; GENOMIC INSTABILITY; DNA METHYLATION; PROTEIN-KINASES; DOWN-REGULATION; LUNG-CANCER; TUMOR-CELLS; E-CADHERIN	To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven by a mutated KRAS oncogene. We identified >200 genes whose expression was elevated or reduced following permanent KRAS expression. Deregulated KRAS-responsive genes encode transcriptional regulators, signaling effectors, proteases, extracellular matrix and adhesion proteins, transformation-suppressing proteins and negative growth regulators. Many of them have not been previously identified in cells expressing oncogenic RAS genes or in other well-studied models of oncogenic signaling. The number of critical genes related to the execution of anchorage-independent proliferation and epithelial-mesenchymal transition was narrowed down to 79 by selectively inhibiting the mitogen-activated protein kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3K) pathways. Blocking MAPK/ERK-signaling caused reversion to the normal epithelial phenotype in conjunction with the reversal of deregulated target transcription to pretransformation levels. In addition, silencing of the overexpressed transcriptional regulator Fra-1 by RNA interference resulted in growth reduction, suggesting that this factor partially contributes to, but is not sufficient for the proliferative capacity of KRAS-transformed epithelial cells.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Schäfer, Reinhold/AAB-5110-2021; Zuber, Johannes/E-7517-2011; Lund, Per/Q-6737-2017	Zuber, Johannes/0000-0001-8810-6835; Lund, Per/0000-0002-7457-4360; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOS JL, 1989, CANCER RES, V49, P4682; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVOUGE MW, 1992, ONCOGENE, V7, P109; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; DOWNWARD J, 1998, MOL B INT U, V3, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Evangelou A, 2000, CANCER RES, V60, P929; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Furuya M, 2000, GYNECOL ONCOL, V78, P106, DOI 10.1006/gyno.2000.5856; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; HOFMANN M, 1993, CANCER RES, V53, P1516; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; ICHIKAWA Y, 1994, CANCER RES, V54, P33; Imren S, 1996, CANCER RES, V56, P2891; IVER VR, 1999, SCIENCE, V283, P83; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; LUO XN, 1995, ONCOGENE, V11, P743; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Majidi M, 2000, J BIOL CHEM, V275, P6560, DOI 10.1074/jbc.275.9.6560; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mok SC, 1996, ONCOGENE, V12, P1895; MOK SCH, 1993, CANCER RES, V53, P1489; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Olski TM, 2001, J CELL SCI, V114, P525; OZAKI T, 1994, CANCER RES, V54, P646; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Patton SE, 1998, CANCER RES, V58, P2253; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schorge JO, 2000, GYNECOL ONCOL, V76, P369, DOI 10.1006/gyno.1999.5711; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sehgal A, 1997, J SURG ONCOL, V65, P249, DOI 10.1002/(SICI)1096-9098(199708)65:4<249::AID-JSO5>3.0.CO;2-5; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Umhauer S, 2000, AM J OBSTET GYNECOL, V182, P999, DOI 10.1016/S0002-9378(00)70135-9; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	90	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4536	4555		10.1038/sj.onc.1207585	http://dx.doi.org/10.1038/sj.onc.1207585			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064704				2022-12-17	WOS:000221799000004
J	Doan, DN; Veal, TM; Yan, ZJ; Wang, WD; Jones, SN; Imbalzano, AN				Doan, DN; Veal, TM; Yan, ZJ; Wang, WD; Jones, SN; Imbalzano, AN			Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes	ONCOGENE			English	Article						INI1; BRG1; SWI/SNF; tumor suppressor; gene regulation	CHROMATIN-REMODELING COMPLEX; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; MULTISUBUNIT COMPLEX; ORDERED RECRUITMENT; INTERFERON-GAMMA; BINDING PROTEIN	The INI1/hSNF5 tumor suppressor is an integral component of mammalian SWI/SNF chromatin remodeling enzymes that contain SNF2 family ATPases BRM (Brahma) or BRG1 (Brahma Related Gene 1) and that contribute to the regulation of many genes. Genetic studies of yeast SWI/SNF enzyme revealed similar phenotypes when single or multiple components of the enzyme were deleted, indicating a requirement for each subunit. To address the contribution of INI1 in the regulation of SWI/SNF-dependent genes in mammalian cells, we examined the expression of multiple BRG1-dependent, constitutively expressed genes in INI1-deficient cancer cell lines. At least one INI1-deficient line expressed each gene, and reintroduction of INI1 had negligible effects on expression levels. Lack of INI1 also did not prevent interferon gamma (IFNc)-mediated induction of CIITA, which is BRG1 dependent, and GBP-1, which is BRG1 enhanced, and reintroduction of INI1 had minimal effects. Chromatin immunoprecipitation experiments revealed that BRG1 inducibly binds to the CIITA promoter despite the absence of INI1. Unlike yeast deleted for the INI1 homologue, SWI/SNF enzymes in INI1-deficient cells were largely intact. Thus in human cells, SWI/SNF enzyme complex formation and the expression of many BRG1-dependent genes are independent of INI1.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	anthony.imbalzano@umassmed.edu	Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928	NATIONAL INSTITUTE ON AGING [Z01AG000650, ZIAAG000650] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; NEIGEBORN L, 1984, GENETICS, V108, P845; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Olave I, 2002, GENE DEV, V16, P2509, DOI 10.1101/gad.992102; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	73	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3462	3473		10.1038/sj.onc.1207472	http://dx.doi.org/10.1038/sj.onc.1207472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990991				2022-12-17	WOS:000220975000021
J	Wang, YL; Zhu, SJ; Cloughesy, TF; Liau, LM; Mischel, PS				Wang, YL; Zhu, SJ; Cloughesy, TF; Liau, LM; Mischel, PS			P53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition	ONCOGENE			English	Article						glioblastoma; p53; p16; senescence; apoptosis	KINASE C-ABL; APOPTOTIC RESPONSE; MOLECULAR SUBTYPES; CANCER; CAMPTOTHECIN; SENESCENCE; RECEPTOR; PATHWAY; CPT-11; ACTIVATION	A critical challenge in cancer research is to identify genetic lesions that sensitize patients to chemotherapy. p53, which is mutated in nearly one-third to half of glioblastomas, may be such a lesion. In this paper, we demonstrate that p53 disruption dramatically sensitizes glioblastoma cells to DNA topoisomerase I inhibitor-mediated apoptosis. Using 19 glioblastoma cell lines, including 15 low-passage ex vivo cell lines derived from patients, as well as isogenic glioblastoma cells varying in p53 status, we show that clinically relevant levels of SN-38 potently induce cell cycle arrest and temporary senescence in glioblastoma cells with wild-type p53 while causing massive apoptosis in p53-deficient cells (P<0.0002). We demonstrate that glioblastoma cells with wild-type p53 proliferate when recultured in drug-free medium, whereas p53-deficient cells do not. We also show that p16 protein expression is neither necessary nor sufficient for initiation and/or maintenance of SN-38-induced arrest/senescence. These results indicate that p53 disruption has a dramatic effect on how glioblastoma cells process topoisomerase I inhibitor-mediated DNA damage.	Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 13 317, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Henry E Singleton Brain Canc Res Program, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 13 317, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022	Liau, Linda/0000-0002-4053-0052	NCI NIH HHS [U01 CA88127] Funding Source: Medline; NINDS NIH HHS [K08NS43147-01, T32-NS07449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007449, K08NS043147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 1999, NATURE, V399, P809; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 1999, CANCER RES, V59, P3761; Choe G, 2003, CANCER RES, V63, P2742; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Coggins CA, 1998, CANCER CHEMOTH PHARM, V41, P485, DOI 10.1007/s002800050771; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Friedman HS, 1999, J CLIN ONCOL, V17, P1516, DOI 10.1200/JCO.1999.17.5.1516; GIANI C, 1994, CANCER RES, V54, P6338; Gong JG, 1999, NATURE, V399, P806; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hare CB, 1997, CANCER CHEMOTH PHARM, V39, P187; Ino Y, 2001, CLIN CANCER RES, V7, P839; JEN J, 1994, CANCER RES, V54, P6353; Keshelava N, 2001, CANCER RES, V61, P6185; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; LARSEN JK, 1994, METHOD CELL BIOL, V41, P377; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mischel PS, 2003, BRAIN PATHOL, V13, P52; MISHCEL PS, 2003, ONCOGENE, V22, P2361; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093/jnci/83.16.1164; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Roninson IB, 2003, CANCER RES, V63, P2705; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; te Poele RH, 2002, CANCER RES, V62, P1876; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weller M, 1998, INT J CANCER, V79, P640; Yang J, 2001, J BIOL CHEM, V276, P27129, DOI 10.1074/jbc.M100729200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	48	60	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1283	1290		10.1038/sj.onc.1207244	http://dx.doi.org/10.1038/sj.onc.1207244			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961077				2022-12-17	WOS:000188892200013
J	Ijichi, H; Otsuka, M; Tateishi, K; Ikenoue, T; Kawakami, T; Kanai, F; Arakawa, Y; Seki, N; Shimizu, K; Miyazono, K; Kawabe, T; Omata, M				Ijichi, H; Otsuka, M; Tateishi, K; Ikenoue, T; Kawakami, T; Kanai, F; Arakawa, Y; Seki, N; Shimizu, K; Miyazono, K; Kawabe, T; Omata, M			Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta	ONCOGENE			English	Article						p21/WAF1; TGF-beta; Smad4-independent signaling; Smad2/3-dependent signaling; pancreatic cancer	HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR GENE; SIGNALING PATHWAYS; SMAD PROTEINS; RECEPTOR; EXPRESSION; ACTIVATION; CELLS; DPC4; INACTIVATION	The transforming growth factor-beta (TGF-beta)-Smad signaling pathway inhibits the growth of human epithelial cells and plays a role in tumor suppression. The Smad4 gene is mutated or deleted in 50% of pancreatic cancers. In this study, the Smad4-null pancreatic cancer cell line BxPC-3 was transfected with either the Smad4 expression vector or the empty vector and incubated in the presence or absence of TGF-beta. The cells were analysed using a cDNA microarray, which included 2280 named genes to screen for target genes regulated by TGF-beta in either a Smad4-dependent or -independent manner. The microarray and subsequent quantitative RT-PCR analysis demonstrated that the Smad4-independent and -dependent signaling pathways driven by TGF-beta upregulated only one of the 2280 genes, respectively, suggesting that Smad4-independent signaling downstream of TGF-beta might be as widespread as Smad4-dependent signaling. In this study, we demonstrated that the cyclin-dependent kinase inhibitor p21/WAF1, which has been considered the major effector of the Smad-dependent growth inhibitory signal of TGF-beta, is upregulated in a Smad4-independent manner. The upregulation occurs through Smad2/3-dependent transcriptional activation of the p21/WAF1 promoter region. These results suggest a novel mechanism of gene regulation, that is, a novel signal mediator other than Smad4.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Helix Res Inst, Biol Technol Lab, Chiba 2920812, Japan; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo 1600023, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 1138655, Japan; Kirin Brewery Co Ltd, Div Pharmaceut, Takasaki, Gumma 3701295, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan	University of Tokyo; Asahi Life Foundation; University of Tokyo; Kirin Brewery Company Limited; University of Tokyo	Ijichi, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ijichi-2im@h.u-tokyo.ac.jp	Ijichi, Hideaki/V-2720-2019; IJICHI, Hideaki/AGZ-2874-2022; Otsuka, Motoyuki/H-9067-2019; Ijichi, Hideaki/AAE-6692-2022	IJICHI, Hideaki/0000-0002-2379-7986; Otsuka, Motoyuki/0000-0003-2869-2881; Ijichi, Hideaki/0000-0002-2379-7986				Akiyoshi S, 2001, JPN J CANCER RES, V92, P257, DOI 10.1111/j.1349-7006.2001.tb01090.x; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Otsuka M, 2001, BIOCHEM BIOPH RES CO, V289, P876, DOI 10.1006/bbrc.2001.6047; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Schutte M, 1996, CANCER RES, V56, P2527; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Togo G, 1996, CANCER RES, V56, P5620; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang D, 2000, CANCER RES, V60, P4507; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	39	60	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1043	1051		10.1038/sj.onc.1207222	http://dx.doi.org/10.1038/sj.onc.1207222			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762439				2022-12-17	WOS:000188749900003
J	Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T				Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T			FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells	ONCOGENE			English	Article						histone deacetylase inhibitor; osteosarcoma; apoptosis; Fas ligand; Fas	HISTONE DEACETYLASE INHIBITOR; CHROMOBACTERIUM-VIOLACEUM NO-968; ACUTE PROMYELOCYTIC LEUKEMIA; COLON-CANCER CELLS; MEDIATED APOPTOSIS; DEPSIPEPTIDE FR901228; IN-VITRO; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; OSTEOGENIC-SARCOMA	We investigated the antitumor effects of FR901228, a HDAC inhibitor, on human osteosarcoma cells, in vitro and in vivo to explore its possible utility in the treatment of pediatric bone cancers. FR901228 caused marked growth inhibition with a 50% inhibitory concentration of 1.2-7.3 nM and induction of apoptosis in all eight osteosarcoma cell lines tested. These effects of FR901228 were also observed in vivo xenograft models on BALB/c nude mice, and treatment with 5.6 mg/kg/day resulting in a >70% reduction in the mean final tumor volume compared with the mean initial tumor volume. TUNEL assays demonstrated extensive apoptosis in tumor sections of mice treated with FR901228. Induction of apoptosis was preceded by increased expression of Fas ligand ( FasL) mRNA, resulting in expression of membrane-bound FasL, which was followed by sequential activation of caspase-8 and -3. The level of apoptosis induction was reduced using a neutralizing anti-FasL antibody and overexpression of either the dominant-negative FADD or the viral FLICE inhibitory protein. Furthermore, treatment with a suboptimal dose of FR901228 greatly sensitized osteosarcoma cells to agonistic anti-Fas antibody-mediated apoptosis. These findings suggest that FR901228 is a highly promising antitumor agent against osteosarcoma, inducing apoptosis by the activation of the Fas/FasL system.	Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kyoto University	Adachi, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Nishikomori, Ryuta/AAM-5771-2020; Nishikomori, Ryuta/N-4039-2018	Nishikomori, Ryuta/0000-0002-9407-6158; Nishikomori, Ryuta/0000-0002-9407-6158; Yasumi, Takahiro/0000-0003-3257-5071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; BERON G, 1985, EUR PAEDIATR HAEMAT, V2, P77, DOI 10.3109/08880018509141211; Bonnotte B, 1998, CELL DEATH DIFFER, V5, P480, DOI 10.1038/sj.cdd.4400371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Debatin KM, 1999, DRUG RESIST UPDATE, V2, P85, DOI 10.1054/drup.1999.0073; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, INT J CANCER, V76, P105; Gastman BR, 1999, CANCER RES, V59, P5356; Glick RD, 1999, CANCER RES, V59, P4392; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamada T, 1999, INT J ONCOL, V15, P1125; Haruyama H, 2002, BIOL PHARM BULL, V25, P1537, DOI 10.1248/bpb.25.1537; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Himelstein Bruce P., 1998, Current Opinion in Oncology, V10, P326, DOI 10.1097/00001622-199807000-00009; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; ISHII S, 1982, INT ORTHOP, V6, P215; Jaboin J, 2002, CANCER RES, V62, P6108; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Lafleur EA, 2001, CANCER RES, V61, P4066; LINK MP, 1991, CLIN ORTHOP RELAT R, P8; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MARINA NM, 1992, CANCER-AM CANCER SOC, V70, P2722, DOI 10.1002/1097-0142(19921201)70:11<2722::AID-CNCR2820701125>3.0.CO;2-S; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; Mizutani Y, 1997, CANCER, V79, P1180, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W; Murakami H, 2002, CANCER LETT, V182, P203, DOI 10.1016/S0304-3835(02)00096-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OhYama T, 2000, MICROBIOL IMMUNOL, V44, P289, DOI 10.1111/j.1348-0421.2000.tb02498.x; Ozaki T, 2003, J CLIN ONCOL, V21, P334, DOI 10.1200/JCO.2003.01.142; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, J ANTIBIOT, V47, P315; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wu XX, 2000, CANCER RES, V60, P2912; Yonehara S, 2002, CYTOKINE GROWTH F R, V13, P393, DOI 10.1016/S1359-6101(02)00024-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	76	60	66	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9231	9242		10.1038/sj.onc.1207184	http://dx.doi.org/10.1038/sj.onc.1207184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14647441	Green Submitted			2022-12-17	WOS:000187400400005
J	Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J				Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J			Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions	ONCOGENE			English	Article						serpin; maspin; immunohistochemistry; lung cancer; preneoplastic	CELL CARCINOMA ANTIGEN; TUMOR-SUPPRESSOR; BREAST-CANCER; OVEREXPRESSION; INHIBITION; P53; METASTASIS; EPITHELIA; HEADPIN	Maspin, SCCA1/2 and hurpin were identified by cDNA microarray analyses as dramatically differentially expressed transcripts in primary non-small cell lung cancer (NSCLC). These sequences are located within a 10-gene serpin cluster on 18q21.3. Using comparative RT-PCR, we have investigated the expression of each of these serpins, including their flanking loci, in an independent NSCLC series. Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently over-represented sequence in both squamous cell carcinoma and adenocarcinoma. Using a well-characterized monoclonal antibody, we have shown strong maspin expression in tumour protein extracts, detected multiple isoforms of the 42 kDa protein and shown that maspin is localized specifically to the tumour cells within neoplastic lesions. In contrast, most cells in non-neoplastic lung tissue appear not to express the gene, with the exception of the multipotent basal epithelial cells that line the bronchial airway. These reserve cells generally show strong predominantly nuclear localization of maspin. Strong nuclear expression of maspin within primary tumour cells is correlated with increased survival (P = 0.05) and a longer remission duration (P = 0.02) in resectable-staged patients. However, within the airways of cancer patients and somewhat in contrast to this observation, such expression was more frequently detected in the superficial cells of preneoplastic over non-neoplastic epithelia (P < 0.0001), consistent with a role for the protein in early neoplasia.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool L3 9TA, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland	University of Liverpool; University of Bern	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool L3 9TA, Merseyside, England.	heighwayj@roycastle.liv.ac.uk	Betticher, Daniel C/G-5849-2013					Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Betticher DC, 1997, BRIT J CANCER, V75, P1761, DOI 10.1038/bjc.1997.300; Biliran H, 2001, CANCER RES, V61, P8676; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; Champelovier P, 2001, EUR UROL, V39, P343, DOI 10.1159/000052465; Duggan C, 1997, BRIT J CANCER, V76, P622, DOI 10.1038/bjc.1997.435; Fujita T, 1999, INT J ONCOL, V15, P927; HAMADA K, 2001, BIOCHIM BIOPHYS ACTA, V19, P124; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Heighway Jim, 2003, Methods Mol Med, V75, P291; Jayakumar A, 2003, ARCH BIOCHEM BIOPHYS, V409, P367, DOI 10.1016/S0003-9861(02)00635-5; Kato H., 1992, SEROLOGICAL CANC MAR, P437; Kishimoto H, 2001, INT J ONCOL, V18, P297; Maass N, 2001, J PATHOL, V195, P321; Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X; Miyata T, 2002, J CLIN INVEST, V109, P585, DOI 10.1172/JCI200214336; Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; Murakami A, 2000, TUMOR BIOL, V21, P224, DOI 10.1159/000030128; Nakashima T, 2000, BBA-GENE STRUCT EXPR, V1492, P441, DOI 10.1016/S0167-4781(00)00100-7; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Pierson CR, 2002, PROSTATE, V53, P255, DOI 10.1002/pros.10107; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ratschiller D, 2003, J CLIN ONCOL, V21, P2085, DOI 10.1200/JCO.2003.03.103; Reis JS, 2002, J PATHOL, V197, P272, DOI 10.1002/path.1104; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shi HY, 2001, CANCER RES, V61, P6945; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Stenman J, 2001, INT J CANCER, V95, P39, DOI 10.1002/1097-0215(20010120)95:1<39::AID-IJC1007>3.0.CO;2-N; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; Travis WD, 1999, HISTOLOGICAL TYPING; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	60	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8677	8687		10.1038/sj.onc.1207127	http://dx.doi.org/10.1038/sj.onc.1207127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647462				2022-12-17	WOS:000186844900005
J	Koshikawa, N; Iyozumi, A; Gassmann, M; Takenaga, K				Koshikawa, N; Iyozumi, A; Gassmann, M; Takenaga, K			Constitutive upregulation of hypoxia-inducible factor-1 alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure	ONCOGENE			English	Article						VEGF; HIF-1 alpha; hypoxia; angiogenesis; metastasis	C6 GLIOMA-CELLS; FACTOR 1-ALPHA; TUMOR-GROWTH; FACTOR GENE; UNFAVORABLE PROGNOSIS; FACTOR EXPRESSION; POOR-PROGNOSIS; HIF-ALPHA; FACTOR-I; ANGIOGENESIS	Neoangiogenesis is crucial for tumor growth and metastasis and is regulated by various angiogenic factors including vascular endothelial growth factor ( VEGF). However, little is known whether highly metastatic cells express higher level of VEGF in response to various stimuli, thereby increasing neoangiogenesis compared to low-metastatic cells. Here we report that hypoxia markedly induced the expression of VEGF mRNA in the cell lines with high-metastatic potential (A11 and D6 cells) compared to the cell lines with low-metastatic potential (P29 and P34 cells) established from Lewis lung carcinoma. A11 cells exhibited higher VEGF gene-promoter activity, produced a larger amount of VEGF and showed higher activity to induce neoangiogenesis than P29 cells. Although the degradation rate of VEGF mRNA under hypoxic conditions was similar in both cell lines, hypoxia-inducible factor-1alpha (HIF-1alpha) mRNA, but not HIF-1beta mRNA, was found to be constitutively upregulated in A11 cells compared to P29 cells. Accordingly, the level of HIF-1alpha protein in response to hypoxia was higher in A11 cells than in P29 cells. Upregulation of HIF-1alpha mRNA was also observed in D6 cells but not in P34 cells. Thus, the high-metastatic cells produced a larger amount of VEGF under hypoxic conditions through constitutive HIF-1alpha mRNA upregulation compared to the low-metastatic cells, thereby leading to extensive neoangiogenesis.	Chiba Canc Ctr, Res Inst, Div Chemotherapy, Chuoh Ku, Chiba 2608717, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba 2608717, Japan; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	Chiba Cancer Center; Chiba Cancer Center; University of Zurich	Takenaga, K (corresponding author), Chiba Canc Ctr, Res Inst, Div Chemotherapy, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.			Gassmann, Max/0000-0003-2750-8878				ASANO M, 1995, CANCER RES, V55, P5296; Birner P, 2000, CANCER RES, V60, P4693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Hofer T, 2002, PFLUG ARCH EUR J PHY, V443, P503, DOI 10.1007/s00424-001-0759-8; Hopfl G, 2002, CANCER RES, V62, P2962; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kaya M, 2000, CLIN CANCER RES, V6, P572; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kondo Y, 2000, CLIN CANCER RES, V6, P622; Koshikawa N, 2000, CANCER RES, V60, P2936; Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mori A, 1999, INT J CANCER, V80, P738, DOI 10.1002/(SICI)1097-0215(19990301)80:5<738::AID-IJC18>3.3.CO;2-Z; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Ravi R, 2000, GENE DEV, V14, P34; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saleh M, 1996, CANCER RES, V56, P393; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1997, BIOL CHEM, V378, P609; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213; Zhong H, 1999, CANCER RES, V59, P5830	39	60	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6717	6724		10.1038/sj.onc.1206765	http://dx.doi.org/10.1038/sj.onc.1206765			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555985				2022-12-17	WOS:000185799300007
J	Berretta, M; Cinelli, R; Martellotta, F; Spina, M; Vaccher, E; Tirelli, U				Berretta, M; Cinelli, R; Martellotta, F; Spina, M; Vaccher, E; Tirelli, U			Therapeutic approaches to AIDS-related malignancies	ONCOGENE			English	Review						AIDS; HIV infection; malignancies; treatment; HAART	HUMAN-IMMUNODEFICIENCY-VIRUS; NON-HODGKINS-LYMPHOMA; SQUAMOUS INTRAEPITHELIAL LESIONS; COLONY-STIMULATING FACTOR; STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; ITALIAN COOPERATIVE GROUP; PRIMARY EFFUSION LYMPHOMA	The introduction of highly active antiretroviral therapy ( HAART) has changed dramatically the landscape of HIV disease. Deaths from AIDS-related diseases have been reduced by 75% since protease inhibitor therapy and combination antiretroviral therapy came into use in late 1995. While KS is declining, the situation for non-Hodgkin's lymphoma is more complex with a reduced incidence of primary central nervous system lymphoma, but a relatively stability in the number of patients developing systemic NHL. AIDS related NHL appears not to be markedly decreased by the introduction of HAART and it is the greatest therapeutic challenge in the area of AIDS oncology. The emphasis has now shifted to cure while maintaining vigilance regarding the unique vulnerability of HIV-infected hosts. Furthermore, also for the prolongation of the survival expectancy of these patients, other non AIDS-defining tumors, such as Hodgkin's disease, anal and head and neck, lung and testicular cancer, and melanoma have been recently reported with increased frequency in patients with HIV infection.	Natl Canc Inst, Div Med Oncol A, Ctr Riferimento Oncol, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Tirelli, U (corresponding author), Natl Canc Inst, Div Med Oncol A, Ctr Riferimento Oncol, Via Pedemontana Occle 12, I-33081 Aviano, PN, Italy.	utirelli@cro.it	Berretta, Massimiliano/S-5853-2019; Spina, Michele/ABE-6014-2020; Martellotta, Ferdinando/ABE-2332-2020	Berretta, Massimiliano/0000-0002-9837-9148; Spina, Michele/0000-0001-6576-8182; Martellotta, Ferdinando/0000-0002-5646-0036				Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; ANDRIEU JM, 1993, ANN ONCOL, V4, P635, DOI 10.1093/oxfordjournals.annonc.a058617; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRON BA, 1971, CANCER, V27, P978, DOI 10.1002/1097-0142(197104)27:4<978::AID-CNCR2820270433>3.0.CO;2-2; BERNARDI D, 1995, J CLIN ONCOL, V13, P2705, DOI 10.1200/JCO.1995.13.11.2705; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; BOIOCCHI M, 1993, AM J PATHOL, V142, P33; CARBONE A, 1995, AM J CLIN PATHOL, V103, P561; Carbone A, 1997, BRIT J HAEMATOL, V97, P515, DOI 10.1046/j.1365-2141.1997.00064.x; CARTER PS, 1995, BRIT J SURG, V82, P473, DOI 10.1002/bjs.1800820414; CDC, 1993, MMWR-MORBID MORTAL W, V41, P1; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P83; *CDC, 1986, MMWR-MORBID MORTAL W, V35, P334; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CONANT M, 1999, 6 C RETR OPP INF CHI; Dal Maso L, 2003, LANCET ONCOL, V4, P110, DOI 10.1016/S1470-2045(03)00983-5; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DEASI J, 1999, CANCER, V86, P1840; Delecluse HJ, 1997, BLOOD, V89, P1413, DOI 10.1182/blood.V89.4.1413; EMILIE D, 1994, BLOOD, V84, P2472; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ERRANTE D, 1994, CANCER-AM CANCER SOC, V73, P437, DOI 10.1002/1097-0142(19940115)73:2<437::AID-CNCR2820730232>3.0.CO;2-2; Errante D, 1999, ANN ONCOL, V10, P189, DOI 10.1023/A:1008338915945; FICARRA G, 1998, ORAL SURG ORAL MED O, V66, P550; Franceschi S, 1999, INT J CANCER, V83, P481, DOI 10.1002/(SICI)1097-0215(19991112)83:4<481::AID-IJC8>3.3.CO;2-X; Franceschi S, 1998, BRIT J CANCER, V78, P966, DOI 10.1038/bjc.1998.610; FRAZER IH, 1986, LANCET, V2, P657; FRUCHTER RG, 1994, AM J OBSTET GYNECOL, V171, P531, DOI 10.1016/0002-9378(94)90294-1; Gabarre J, 1996, BONE MARROW TRANSPL, V18, P1195; Gabarre J, 2000, LANCET, V355, P1071, DOI 10.1016/S0140-6736(00)02041-9; Gaidano G, 1998, AM J PATHOL, V152, P623; Gates AE, 2002, ONCOLOGY-NY, V16, P441; GILL PS, 1989, AM J MED, V87, P57, DOI 10.1016/S0002-9343(89)80483-8; GILL PS, 1992, AIDS, V6, P1477, DOI 10.1097/00002030-199212000-00009; Gill PS, 1996, J CLIN ONCOL, V14, P2353, DOI 10.1200/JCO.1996.14.8.2353; GISSELBRECHT C, 1993, AM J MED, V95, P188, DOI 10.1016/0002-9343(93)90259-R; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Goldie SJ, 1999, JAMA-J AM MED ASSOC, V281, P1822, DOI 10.1001/jama.281.19.1822; HARRIS NL, 1994, BLOOD, V84, P1361; Hoffman R, 1999, INT J RADIAT ONCOL, V44, P127, DOI 10.1016/S0360-3016(98)00528-8; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; International Agency for Research and Cancer (IARC), 1996, HUM IMM VIR HUM T CE, V67; KAPLAN L, 1986, CANCER TREAT REP, V70, P1121; Kaplan LD, 1997, NEW ENGL J MED, V336, P1641, DOI 10.1056/NEJM199706053362304; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KAPLAN LD, 1998, P AN M AM SOC CLIN, V17, P185; KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404; Koblin BA, 1996, AM J EPIDEMIOL, V144, P916, DOI 10.1093/oxfordjournals.aje.a008861; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; Krishnan A, 2001, BLOOD, V98, P3857, DOI 10.1182/blood.V98.13.3857; Krown SE, 1997, J CLIN ONCOL, V15, P3085, DOI 10.1200/JCO.1997.15.9.3085; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Levine AM, 2000, J ACQ IMMUN DEF SYND, V24, P444; LEVINE AM, 1991, HEMATOL ONCOL CLIN N, V5, P331, DOI 10.1016/S0889-8588(18)30445-3; Levine AM, 2001, EUR J CANCER, V37, P1288, DOI 10.1016/S0959-8049(01)00109-5; LEVINE AM, 1993, JNCI-J NATL CANCER I, V85, P1382, DOI 10.1093/jnci/85.17.1382; Little RF, 2000, CURR OPIN ONCOL, V12, P438, DOI 10.1097/00001622-200009000-00009; LOBO DV, 1992, ARCH DERMATOL, V128, P623, DOI 10.1001/archderm.128.5.623; LYTER DW, 1998, INT ACQUIRED IMMUNE, V17, P13; MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MANDELBLATT JS, 1992, AIDS, V6, P173, DOI 10.1097/00002030-199202000-00005; MAZZA P, 1992, EUR J HAEMATOL, V49, P1; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Melbye M, 1996, INT J CANCER, V68, P559, DOI 10.1002/(SICI)1097-0215(19961127)68:5<559::AID-IJC1>3.0.CO;2-Y; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mitsuyasu Ronald T., 1993, Current Opinion in Oncology, V5, P835, DOI 10.1097/00001622-199309000-00011; Molina A, 2000, CANCER-AM CANCER SOC, V89, P680, DOI 10.1002/1097-0142(20000801)89:3<680::AID-CNCR25>3.3.CO;2-N; Nasti G, 2003, J CLIN ONCOL, V21, P2876, DOI 10.1200/JCO.2003.10.162; Northfelt DW, 1996, HEMATOL ONCOL CLIN N, V10, P1177, DOI 10.1016/S0889-8588(05)70392-0; Oksenhendler E, 1998, AM J HEMATOL, V57, P266, DOI 10.1002/(SICI)1096-8652(199803)57:3<266::AID-AJH25>3.0.CO;2-7; Palefsky J M, 1998, J Natl Cancer Inst Monogr, P15; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; PALEFSKY JM, 1995, CANCER EPIDEM BIOMAR, V4, P415; PALEFSKY JM, 1991, CANCER RES, V51, P1014; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Palefsky JM, 2000, SEMIN ONCOL, V27, P471; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; Peddada AV, 1997, INT J RADIAT ONCOL, V37, P1101, DOI 10.1016/S0360-3016(96)00596-2; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; RAPHAEL M, 1991, ARCH PATHOL LAB MED, V115, P15; Ratner L, 2001, J CLIN ONCOL, V19, P2171, DOI 10.1200/JCO.2001.19.8.2171; Re A, 2002, BLOOD, V100, p649A; REE HJ, 1991, CANCER-AM CANCER SOC, V67, P1614, DOI 10.1002/1097-0142(19910315)67:6<1614::AID-CNCR2820670624>3.0.CO;2-#; REMICK SC, 1993, J CLIN ONCOL, V11, P1691, DOI 10.1200/JCO.1993.11.9.1691; RUBIO R, 1994, CANCER-AM CANCER SOC, V73, P2400, DOI 10.1002/1097-0142(19940501)73:9<2400::AID-CNCR2820730925>3.0.CO;2-C; Said JW, 1997, SEMIN DIAGN PATHOL, V14, P48; SAVILLE MW, 1995, LANCET, V346, P26, DOI 10.1016/S0140-6736(95)92654-2; SERRAINO D, 1992, ANN ONCOL, V3, P595, DOI 10.1093/oxfordjournals.annonc.a058283; SPARANO J, 1999, 3 ANN AIDS MAL C BET; SPARANO J, 1998, 2 NAT AIDS MAL C BET; Sparano JA, 1996, J CLIN ONCOL, V14, P3026, DOI 10.1200/JCO.1996.14.11.3026; Spina M, 2003, AIDS, V17, P137, DOI 10.1097/00002030-200301030-00024; Spina M, 2002, BLOOD, V100, P1984, DOI 10.1182/blood-2002-03-0989; Spina M, 1999, ANN ONCOL, V10, P87; Spina M, 1999, ANN ONCOL, V10, P1271, DOI 10.1023/A:1008390028330; Spina Michele, 1999, Current Opinion in Oncology, V11, P522, DOI 10.1097/00001622-199911000-00015; STELZER KJ, 1993, INT J RADIAT ONCOL, V27, P1057, DOI 10.1016/0360-3016(93)90523-X; Straus David J., 1997, Current Opinion in Oncology, V9, P450, DOI 10.1097/00001622-199709050-00009; Straus DJ, 1998, J CLIN ONCOL, V16, P3601, DOI 10.1200/JCO.1998.16.11.3601; Tan Benjamin, 1997, Current Opinion in Oncology, V9, P455, DOI 10.1097/00001622-199709050-00010; Tavio M, 1996, CANCER-AM CANCER SOC, V77, P2117; Tirelli U, 1992, Ann Oncol, V3 Suppl 4, P69; Tirelli U, 1996, CANCER-AM CANCER SOC, V77, P2127, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2127::AID-CNCR25>3.0.CO;2-W; TIRELLI U, 1995, J CLIN ONCOL, V13, P373, DOI 10.1200/JCO.1995.13.2.373; Tirelli U, 2001, CANC TREAT, V104, P247; TIRELLI U, 1995, J CLIN ONCOL, V13, P1758, DOI 10.1200/JCO.1995.13.7.1758; Tirelli U, 2002, CRIT REV ONCOL HEMAT, V41, P299, DOI 10.1016/S1040-8428(01)00165-2; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Tirelli U, 2000, AIDS, V14, P1675, DOI 10.1097/00002030-200008180-00001; TIRELLI U, 1999, 3 ANN AIDS MAL C BET; Toschi E, 2002, ANTI-CANCER DRUG, V13, P977, DOI 10.1097/00001813-200211000-00001; Tulpule A, 1999, BLOOD REV, V13, P147, DOI 10.1054/blre.1999.0112; Turoglu HT, 1998, CLIN NUCL MED, V23, P446, DOI 10.1097/00003072-199807000-00010; Vaccher E, 1996, J CLIN ONCOL, V14, P2217, DOI 10.1200/JCO.1996.14.8.2217; Vaccher E, 2001, CANCER-AM CANCER SOC, V91, P155, DOI 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B; van Besien K, 1998, BLOOD, V91, P1178, DOI 10.1182/blood.V91.4.1178; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; VICIANA P, 1998, INT C AIDS, V12, P1150; WALSH C, 1993, J ACQ IMMUN DEF SYND, V6, P265; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591	124	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6646	6659		10.1038/sj.onc.1206771	http://dx.doi.org/10.1038/sj.onc.1206771			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528290				2022-12-17	WOS:000185700700022
J	Wang, SW; Yan-Neale, Y; Fischer, D; Zeremski, M; Cai, R; Zhu, J; Asselbergs, F; Hampton, G; Cohen, D				Wang, SW; Yan-Neale, Y; Fischer, D; Zeremski, M; Cai, R; Zhu, J; Asselbergs, F; Hampton, G; Cohen, D			Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line	ONCOGENE			English	Article						HDAC1; HDAC inhibitor; RhoB; expression profile; transcription regulation	GROWTH-FACTOR-BETA; BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; GERANYLGERANYLATED RHOB; DNA-DAMAGE; GENE RHOB; NF-Y; CANCER; TUMOR	The dynamic balance between histone acetylation and deacetylation plays a significant role in the regulation of gene transcription. Much of our current understanding of this transcriptional control comes from the use of HDAC inhibitors such as trapoxin A (TPX), which leads to hyperacetylated histone, alters local chromatin architecture and transcription and results in tumor cell death. In this study, we treated tumor cells with TPX and HDAC1 antisense oligonucleotides, and analysed the transcriptional consequences of HDAC inhibition. Among other genes, the small GTPase RhoB was found to be significantly upregulated by TPX and repressed by HDAC1. The induction of RhoB by HDAC inhibition was mediated by an inverted CCAAT box in the RhoB promoter. Interestingly, measurement of RhoB transcription in similar to130 tumor-derived cell lines revealed low expression in almost all of these samples, in contrast to RhoA and RhoC. Accumulating evidence indicates that the small GTPase Rho proteins are involved in a variety of important processes in cancer, including cell transformation, survival, invasion, metastasis and angiogenesis. This study for the first time demonstrates a link between HDAC inhibition and RhoB expression and provides an important insight into the mechanisms of HDAC-mediated transcriptional control and the potential therapeutic benefit of HDAC inhibition.	Novartis Pharmaceut Corp, Dept Funct Genom, Summit, NJ 07901 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis; Novartis	Cohen, D (corresponding author), Novartis Pharmaceut Corp, Dept Funct Genom, Summit, NJ 07901 USA.		Asselbergs, Folkert W./ABD-6752-2021	Asselbergs, Folkert W./0000-0002-1692-8669				Adnane J, 2002, CLIN CANCER RES, V8, P2225; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BUTLER LM, 2002, P NATL ACAD SCI USA, V20, P20; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Du W, 1999, CANCER RES, V59, P5492; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu L, 1999, MOL CELL BIOL, V19, P1202; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; van Golen KL, 2000, CANCER RES, V60, P5832; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Welsh JB, 2001, CANCER RES, V61, P5974; Yoshioka K, 1999, CANCER RES, V59, P2004; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	45	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6204	6213		10.1038/sj.onc.1206653	http://dx.doi.org/10.1038/sj.onc.1206653			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679859				2022-12-17	WOS:000185506200010
J	Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G				Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G			The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription	ONCOGENE			English	Article						BAG-1; breast cancer; oestrogen; receptor; hormone therapy; survival	HUMAN BREAST-CANCER; APOPTOTIC PROTEIN BAG-1; GENE BAG-1; CELL-LINES; RECEPTOR; EXPRESSION; SURVIVAL; HSC70; BINDS; OVEREXPRESSION	BAG-1 is a multifunctional protein that interacts with a wide range of cellular targets including heat-shock proteins and some nuclear hormone receptors. BAG-1 exists as three major isoforms, BAG-1L, BAG-1M and BAG-1S. BAG-1L contains a nuclear localization signal, which is not present in the other isoforms, and is predominantly localized in the cell nucleus. Here we have investigated the effects of BAG-1 on function of the oestrogen receptor (ER), a key growth control molecule and target for hormonal therapy in breast cancer. We demonstrate that BAG-1L, but not BAG-1S or BAG-1M increased oestrogen-dependent transcription in breast cancer cells. BAG-1L interacted with and stimulated the activity of both ER alpha and beta. Although BAG-1L and ERs colocalize to the nucleus, fusing BAG-1S to an heterologous nuclear localization sequence was not sufficient to stimulate transcription. Consistent with an important effect on receptor function, nuclear BAG-I expression in breast cancers was associated with expression of the progesterone receptor, a transcriptional target of ER(x, and was associated with improved survival in patients treated with hormonal therapy. These data suggest that BAG-1L is an important determinant of ER function in vitro and in human breast cancer.	Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Royal S Hants Hosp, Southampton Breast Unit, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Pathol, Southampton SO16 6YD, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Packham, G (corresponding author), Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Somers Canc Sci Bldg,Mail Point 824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018; Townsend, Paul/AAF-8234-2020	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Sharp, Adam/0000-0002-3740-1612; Packham, Graham/0000-0002-9232-5691; Sharp, Adam/0000-0002-3902-0135; Bateman, Adrian/0000-0003-2222-4104; Townsend, Paul/0000-0001-8956-9508	Breast Cancer Now [2001:180] Funding Source: Medline	Breast Cancer Now		*AJM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P2843; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Clarke M, 1998, LANCET, V351, P1451; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cutress RI, 2002, BRIT J CANCER, V87, P834, DOI 10.1038/sj.bjc.6600538; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Guzey M, 2000, J BIOL CHEM, V275, P40749, DOI 10.1074/jbc.M004977200; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Hohfeld J, 1998, BIOL CHEM, V379, P269; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; KINSEL LB, 1989, CANCER RES, V49, P1052; Knee DA, 2001, J BIOL CHEM, V276, P12718, DOI 10.1074/jbc.M010841200; Kudoh M, 2002, CANCER RES, V62, P1904; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Niyaz Y, 2001, J CELL SCI, V114, P1839; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Shindoh M, 2000, ORAL ONCOL, V36, P444, DOI 10.1016/S1368-8375(00)00025-7; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yamauchi H, 2001, CANCER LETT, V165, P103, DOI 10.1016/S0304-3835(01)00397-4; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1999, EXP CELL RES, V247, P200, DOI 10.1006/excr.1998.4349; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	52	60	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4973	4982		10.1038/sj.onc.1206688	http://dx.doi.org/10.1038/sj.onc.1206688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902980				2022-12-17	WOS:000184578900005
J	Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V				Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V			Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility	ONCOGENE			English	Article						c-Fos; Fra-1; Fra-2; cell locomotion	TRANSCRIPTION FACTOR AP-1; DNA-BINDING; TRANSFORMATION; ACTIVATION; MIGRATION; INTERACTS; INVASION; GENE; JUN; AP1	The AP-1 transcription factor is composed of members of the Fos, Jun and ATF families, and plays a key role in tumor progression. We investigated whether Fos proteins regulate cell motility, and if so, whether this capacity is related to their transactivation potential. Two cell tines with different expression profiles of AP-1 were employed focusing on the Fos-family members c-Fos, Fra-1 and Fra-2. Transactivation motifs are found in c-Fos, but not in Fra-1 or Fra-2. The adenocarcinoma CSML0 cells display a low motility and do not express Fra-1 or Fra-2, and only very little c-Fos. In contrast, the fibroblastoid L929 cells express both Fra-1 and Fra-2, but no c-Fos, and these cells display a high motility. Transfection with Fra-1 or c-Fos, but not with Fra-2, strongly enhanced the motility of CSML0 cells. The effect of Fra-1 required the presence of the N-terminal domain of this protein. Conversely, transfection with a Fos dominant-negative mutant or with anti-sense fra-1 or fra-2, strongly reduced the motility of L929 cells. Changes in cell motility correlated with the morphological appearance and the degree of contact with the substratum. We conclude that Fos proteins have distinct roles in the regulation of cell motility.	Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, DK-2200 Copenhagen N, Denmark; Danish Canc Soc, Dept Mol Cell Biol, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of Copenhagen; Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Berezin, V (corresponding author), Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, Blegdamsvej 3C,Bld 6-2, DK-2200 Copenhagen N, Denmark.	berezin@plab.ku.dk	Tulchinsky, Eugene/ABD-7070-2021		NATIONAL CANCER INSTITUTE [Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrektsen T, 2001, MOL PHARMACOL, V59, P567, DOI 10.1124/mol.59.3.567; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Dunn G A, 1983, Agents Actions Suppl, V12, P14; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P236; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lepekhin EA, 2001, METH MOL B, V161, P85; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; Walmod PS, 2001, METH MOL B, V161, P59; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	29	60	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5045	5054		10.1038/sj.onc.1206570	http://dx.doi.org/10.1038/sj.onc.1206570			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902987				2022-12-17	WOS:000184578900012
J	Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J				Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J			PPAR gamma controls cell proliferation and apoptosis in an RB-dependent manner	ONCOGENE			English	Article						cancer; cell cycle; colon; nuclear receptor; transcription	ACTIVATED RECEPTOR-GAMMA; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; INDUCE APOPTOSIS; DOWN-REGULATION; MOUSE LENS; DIFFERENTIATION; TRANSCRIPTION; INHIBITION; LIGANDS	The nuclear receptor PPARgamma is implicated in the control of cell proliferation and apoptosis. However, the molecular mechanisms by which it controls these processes remain largely elusive. We show here that PPARgamma activation in the presence of the retinoblastoma protein (RB) results in the arrest of cells at the G1 phase of the cell cycle, whereas in the absence of RB, cells accumulate in G2/M, endoreduplicate, and undergo apoptosis. Through the use of HDAC inhibitors and coimmunoprecipitations, we furthermore demonstrate that the effects of RB on PPARgamma-mediated control of the cell cycle and apoptosis depend on the recruitment of histone deacetylase 3 (HDAC3) to PPARgamma. In combination, these data hence demonstrate that the effects of PPARgamma on cell proliferation and apoptosis are dependent on the presence of an RB-HDAC3 complex.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.		Coll, Lluis Fajas/C-8567-2014	Fajas, Lluis/0000-0002-1283-9503; Auwerx, Johan/0000-0002-5065-5393; Lefebvre, Anne-Marie/0000-0001-5644-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 P01-DK59820-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Palakurthi SS, 2001, CANCER RES, V61, P6213; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2000, GENE DEV, V14, P1293; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805	31	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4186	4193		10.1038/sj.onc.1206530	http://dx.doi.org/10.1038/sj.onc.1206530			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833141				2022-12-17	WOS:000183979800005
J	Zhou, CY; Smith, JL; Liu, JS				Zhou, CY; Smith, JL; Liu, JS			Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1	ONCOGENE			English	Article						ovarian cancer; BRCA1; cell cycle; ionizing radiation; paclitaxel	TUMOR-SUPPRESSOR GENE; MUTATION; CYCLE; CARCINOMA; BREAST; P53; PHOSPHORYLATION; AMPLIFICATION; ASSOCIATION; INHIBITOR	BRCA1, the gene responsible for approximately half of all cases of hereditary breast cancer and almost all cases of combined hereditary breast and ovarian cancer, has been implicated in the maintenance of genomic stability through DNA repair. This function is mediated, at least in part, through two tandem BRCA1 C-terminal (BRCT) repeats. The role of BRCA1 in the develepment of ovarian cancer is poorly understood, partially owing to the lack of ovarian cancer cell lines with defective BRCA1 The purpose of this study was to further characterize an endometrioid ovarian cancer cell line, SNU-251, which was previously reported to carry a nonsense mutation (from G to A) at amino acid 1815 of BRCA1. In addition, we examined the role of BRCA1 in the cell cycle and in the responses to the chemotherapy drug paclitaxel and ionizing radiation. Loss of the C-terminal 49 amino acids due to this point mutation did not affect the expression of the truncated BRCA1 protein, but caused a loss of transcriptional activation of the endogenous p21(WAF1/CIP1) gene, and could not sustain arrest in the G(2)/M phase of the cell cycle. The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. This sensitivity was reversed by reintroduction of ectopic wild-type BRCA1 Our results suggest that the deletion of the C-terminal 49 amino acids of BRCA1 results in a loss of BRCA1 function in the SNU-251 cell line. BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Therefore, SNU-251 may be a useful model for studying the molecular mechanism of BRCA1 in the resistance of ovarian cancer to ionizing radiation and chemotherapy treatment and in the development of hereditary human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, Houston, TX 77030 USA; Dynagene, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, 1515 Holcomber Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org						Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK JG, 2002, J J CANC CHEMOTHE S1, V29, P89; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Sato N, 2000, CANCER RES, V60, P7052; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; To MD, 1998, AM J PATHOL, V153, P47, DOI 10.1016/S0002-9440(10)65544-7; Tomlinson GE, 1998, CANCER RES, V58, P3237; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yan T, 2001, CANCER RES, V61, P8290; Yuan Y, 1997, GYNECOL ONCOL, V66, P378, DOI 10.1006/gyno.1997.4785; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	34	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2396	2404		10.1038/sj.onc.1206319	http://dx.doi.org/10.1038/sj.onc.1206319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717416				2022-12-17	WOS:000182383500002
J	Marchetti, B; Ashrafi, GH; Tsirimonaki, E; O'Brien, PM; Campo, MS				Marchetti, B; Ashrafi, GH; Tsirimonaki, E; O'Brien, PM; Campo, MS			The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface	ONCOGENE			English	Article						papillomavirus; E5; MHC class I; immune evasion; Golgi apparatus	INTERCELLULAR COMMUNICATION; TRANSFORMING FUNCTIONS; DOWN-REGULATION; E8 PROTEIN; TYPE-4 E8; MONENSIN; DUCTIN; BINDS; MECHANISMS; EXPRESSION	During papillomavirus infection, the E5 protein localizes in the cell Golgi apparatus and other endomembrane compartments. Cells transformed by E5 do not express major histocompatibility class I complex (MHC 1) on the cell surface, while cells transformed by the other transforming proteins E6 and E7 do. In addition, the total amount of both MHC I protein and mRNA is reduced in E5-transformed cells. Here we show that expression of bovine papillomavirus E5 causes the retention of MHC I in the Golgi apparatus, thus preventing its transport to the cell surface. We ascribe this effect to a failure of acidification of the Golgi apparatus, as similar effects are observed in control cells treated with the ionophore monensin. Treatment of E5-transformed cells with either beta- or gamma-interferon increases the synthesis of MHC 1, showing that inhibition of MHC I expression by E5 is not irreversible. However, even after interferon treatment, MHC 1, although increased in quantity, is not transported to the cell surface. E5 therefore affects MHC I at several levels, but prevention of MHC I transport to the cell surface appears to be the dominant effect. Lack of surface MHC I would have profound consequences for presentation of viral peptides to the immune system.	Univ Glasgow, Sch Vet, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Campo, MS (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk		Ashrafi, G. Hossein/0000-0002-4516-5111				Agrawal S, 2000, J HEMATOTH STEM CELL, V9, P795, DOI 10.1089/152581600750062237; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; ASHRAFI GH, 1998, THESIS GLASGOW U UK; Bachert C, 2001, MOL BIOL CELL, V12, P3152, DOI 10.1091/mbc.12.10.3152; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BENSAID A, 1989, ANIM GENET, V20, P241; BOSS WF, 1984, EUR J CELL BIOL, V34, P1; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Chikuma T, 2002, NEUROSCI LETT, V326, P89, DOI 10.1016/S0304-3940(02)00329-4; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRAZER JH, 1996, PAPILLOMAVIRUS REV, P151; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Halaban R, 2002, J BIOL CHEM, V277, P14821, DOI 10.1074/jbc.M111497200; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Morgan IM, 2000, PAPILLOMAVIRUS REP, V11, P127; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; OBRIEN PM, 2002, VIRUS RES VIRUS ESCA; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schoonderwoert VTG, 2002, EUR J BIOCHEM, V269, P1844, DOI 10.1046/j.1432-1033.2002.02831.x; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Surti T, 1998, PROTEINS, V33, P601; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Yewdell JW, 1999, ANNU REV CELL DEV BI, V15, P579, DOI 10.1146/annurev.cellbio.15.1.579; ZHANG GF, 1993, J CELL SCI, V104, P819; Zhang GF, 1996, EUR J CELL BIOL, V71, P332	48	60	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7808	7816		10.1038/sj.onc.1205885	http://dx.doi.org/10.1038/sj.onc.1205885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420217				2022-12-17	WOS:000178946000005
J	Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY				Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY			Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers	ONCOGENE			English	Article						microsatellite instability; promoter methylation; mismatch repair gene mutation; colorectal cancer; HNPCC	MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; YOUNG-PATIENTS; COLON-CANCER; CELL-LINES; MUTATIONS; METHYLATION; EXPRESSION; TUMORS; GENE	High-frequency microsatellite instability (MSI-H) results from deficiency in nucleotide mismatch repair. It contributes significantly to carcinogenesis in the human colorectal mucosa. Here we study 41 colorectal and three other HNPCC-related cancers with MSI-H to provide comprehensive information on the mechanisms of inactivation of the two major proteins involved, hMLH1 and hMSH2. Seventeen of the patients had family histories meeting the criteria for Bethesda grades 1, 2 or 3. Of these familial cases, 14 (83%) had early-onset disease, defined on the basis of diagnosis prior to the age of 50, but in three the disease was of late onset (>50 years). A second subset of 20 patients had early onset disease without family history. The remaining seven patients were selected to allow comparisons with sporadic, late-onset disease, the molecular basis of which has been extensively reported elsewhere. We stratified the tumours initially on the basis of hMLH1 or hMSH2 protein deficiency, detected by immunohistochemistry, and then by analysis of germline and somatic mutation, mRNA transcription, loss of heterozygosity (LOH) at the hMLH1 and hMSH2 loci, and methylation status in two regions of the hMLH1 promoter. The functional significance of several of these changes in the MSI-H tumours was confirmed by comparisons with 16 tumours with low-frequency microsatellite instability and 56 tumours with stable microsatellites. As anticipated, patients with family histories usually showed germline mutation of hMSH2 or hMLH1. In many cases the residual normal allele was silenced in their tumours by loss of heterozygosity (LOH). The small subset of late-onset, sporadic cases confirmed the preponderance in this group of biallelic hMLH1 promoter methylation. In the early-onset, apparently sporadic subset there were 11 tumours with hMLH1 deficiency, five with hMSH2 deficiency and four with no detectable abnormality in expression of either protein. These showed a complex mixture of lesions, including germline and somatic mutations, promoter methylation, LOH, suppression of wild-type RNA by as yet undiscovered mechanisms, or no detectable abnormality in any of these parameters. Evidence is presented to indicate that methylation in proximal region of the hMLH1 promoter is a more reliable correlate of transcriptional silencing in colorectal cancers than methylation in upstream region. These observations have significant implications for management of patients with MSI-H tumours.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Cambridge	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.		Yuen, Siu/K-6311-2014; Leung, Suet Yi/C-4340-2009; Chung, Lap Ping/C-4258-2009; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.3.CO;2-T; Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376; Cunningham JM, 1998, CANCER RES, V58, P3455; Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shin KH, 2002, CANCER RES, V62, P38; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	22	60	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7585	7592		10.1038/sj.onc.1205968	http://dx.doi.org/10.1038/sj.onc.1205968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386821				2022-12-17	WOS:000178618200014
J	Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S				Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S			Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines	ONCOGENE			English	Article						gene expression profile; microarray; gastric cancer	PREDICTION; METAPLASIA; PATTERNS; DATABASE	Gastric adenocarcinoma is one of the major malignancies worldwide. Gastric cell lines have been widely used as the model to study the genetics, pharmacology and biochemistry of gastric cancers. Here we describe a comprehensive survey of the gene expression profiles of 12 gastric carcinoma cell lines, using cDNA microarray with 43000 clones. For comparison, we also explored the gene expression patterns of 15 cell lines derived from lymphoid, endothelial, stromal and other epithelial cancers. Expression levels of specific genes were validated through comparison to protein expression by immunohistochemistry using cell block arrays. We found sets of genes whose expression corresponds to the molecular signature of each cell type. In the gastric cancer cell lines, apart from genes that are highly expressed corresponding to their common epithelial origin from the gastrointestinal tract, we found marked heterogeneity among the gene expression patterns of these cell lines. Some of the heterogeneity may reflect their underlying molecular characteristics or specific differentiation program. Two putative gastric carcinoma cell lines were found to be B-cell lymphoma, and another one had no epithelial specific gene expression and hence was of doubtful epithelial origin. These cell lines should no longer be used in gastric carcinoma research. In conclusion, our gene expression database can serve as a powerful resource for the study of gastric cancer using these cell lines.	Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Surg, Beijing 100871, Peoples R China; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Pathol, Beijing 100871, Peoples R China; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Peking University; Stanford University; University of Hong Kong; Stanford University; University of Hong Kong; Peking University; Stanford University	So, S (corresponding author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr,Room H3680, Stanford, CA 94305 USA.		Chi, Jen-Tsan/AAI-4125-2020; Yuen, Siu/K-6311-2014; Chu, Kent/C-4251-2009; Leung, Suet Yi/C-4340-2009; Leung, Suet Yi/T-9620-2019	Chi, Jen-Tsan/0000-0003-3433-903X; JI, JIAFU/0000-0001-6878-5543; Leung, Suet Yi/0000-0001-8614-4619				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Debruyne P, 1999, ACTA GASTRO-ENT BELG, V62, P393; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Peddanna N, 1995, ANTICANCER RES, V15, P2055; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x	22	60	71	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6549	6556		10.1038/sj.onc.1205829	http://dx.doi.org/10.1038/sj.onc.1205829			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226758				2022-12-17	WOS:000177925300015
J	Liu, RT; Huang, CC; You, HL; Chou, FF; Hu, CCA; Chao, FP; Chen, CM; Cheng, JT				Liu, RT; Huang, CC; You, HL; Chou, FF; Hu, CCA; Chao, FP; Chen, CM; Cheng, JT			Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas	ONCOGENE			English	Article						TSG101; overexpression; immunohistochemistry; in situ hybridization; RT-PCR; human papillary thyroid carcinoma	ABERRANT TRANSCRIPTS; HUMAN-BREAST; PROTEIN; CHROMOSOME-11; CANCERS; ACCUMULATION; CELLS; HETEROZYGOSITY; SUPPRESSOR; FHIT	Functional inactivation of tumor susceptibility gene tsg101 leads to cellular transformation and tumorigenesis in mice. While human TSG101 is located in a region where frequent loss of heterozygosity can be detected in a variety of cancers, no genomic deletion in TSG101 gene has been reported, casting a doubt on the role of TSG101 as a classical tumor suppressor. Some studies have revealed that TSG101 is a frequent target of splicing defects, which correlate with cellular stress and p53 status. Furthermore, recent reports have identified TSG101 as a part of the MDM2/p53 regulatory circuitry, a well-recognized circuitry that upon deregulation results in tumorigenesis. Interestingly, overexpression of tsg101 from an adventitious promoter also leads to neoplastic transformation. On the basis of this information, we have analysed TSG101 gene expression in 20 human papillary thyroid carcinomas (PTCs) by immunohistochemistry and demonstrated that the overexpression of TSG101 protein is closely associated with human PTCs. Further sequence analysis reveals no mutation in cDNA region encoding steadiness box in these PTC specimens, indicating that the upregulation of TSG101 protein is not caused by the alteration of this region. In situ hybridization analysis confirms that overexpression of TSG101 also occurs at the transcriptional level. In addition, semi-quantitative RT-PCR and subsequent Southern hybridization verify that the amounts of TSG101 transcripts are indeed lower in three normal thyroid tissues than in PTC specimens. Here we report the upregulation of TSG101 expression in PTC cells, providing the first evidence of the association of TSG101 overexpression with human tumors and suggesting that upregulation of TSG101 steady-state level might play a role in mediating tumorigenesis of human PTC.	Natl Sun Yat Sen Univ, Dept Sci Biol, Kaohsiung 804, Taiwan; Chang Gung Mem Hosp, Div Metab, Kaohsiung 83305, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 83305, Taiwan; Chang Gung Mem Hosp, Dept Surg, Kaohsiung 833, Taiwan	National Sun Yat Sen University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Cheng, JT (corresponding author), Natl Sun Yat Sen Univ, Dept Sci Biol, Kaohsiung 804, Taiwan.			Hu, Chih-Chi/0000-0001-9024-2932				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Baffa R, 1996, CANCER RES, V56, P268; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chang JG, 1999, BRIT J CANCER, V79, P445, DOI 10.1038/sj.bjc.6690069; Feng GH, 2000, CANCER RES, V60, P1736; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hsu SF, 1998, HYBRIDOMA, V17, P251, DOI 10.1089/hyb.1998.17.251; Jennings T, 1995, EXP MOL PATHOL, V62, P199, DOI 10.1006/exmp.1995.1022; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin PM, 1998, BRIT J HAEMATOL, V102, P753, DOI 10.1046/j.1365-2141.1998.00815.x; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; McIver B, 2000, CLIN ENDOCRINOL, V52, P749, DOI 10.1046/j.1365-2265.2000.01009.x; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Ponting CP, 1997, J MOL MED-JMM, V75, P467; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Turpin E, 1999, ONCOGENE, V18, P7834, DOI 10.1038/sj.onc.1203196; Wang NM, 2000, INT J ONCOL, V16, P75; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; Willeke F, 1998, MOL CARCINOGEN, V23, P195; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699	36	60	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4830	4837		10.1038/sj.onc.1205612	http://dx.doi.org/10.1038/sj.onc.1205612			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101421				2022-12-17	WOS:000176716300012
J	Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS				Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS			Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis	ONCOGENE			English	Article						mitochondria; apoptosis; TRAIL; cytochrome c; Bax	FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C; TUMORICIDAL ACTIVITY; CRYSTAL-STRUCTURE; NECROSIS; LIGAND; RECEPTOR; EXPRESSION; TRANSLOCATION; SENSITIVITY	Mitochondrion is one of the master players in both apoptosis and necrosis. We studied the role of mitochondrial function in TRAIL-induced apoptosis. TRAIL killed SK-Hep1 cells with characteristic features of apoptosis such as DNA fragmentation, sub-G1 ploidy peak and cytochrome c translocation. In contrast, mitochondrial DNA-deficient SK-Hep1 rho(0) cells were resistant to TRAIL. Dissipation of mitochondrial potential or cytochrome e translocation did not occur in rho(0) cells after TRAIL treatment. TRAIL induced translocation of Bax subsequent to the cleavage of Bid in parental cells. However, Bax translocation was absent in rho(0) cells, accounting for the failure of cytochrome c release in rho(0) cells. Forced expression of Bax induced caspase-3 activity in rho(0) cells. Incubation of rho(0) cells with ADP+Pi to increase intracellular ATP restored sensitivity to TRAIL. Despite different sensitivity to TRAIL, parental cells and rho(0) cells did not show significant difference in susceptibility to agonistic anti-Fas antibody, TNF-alpha or staurosporine. Our results indicate that TRAIL-induced apoptosis is dependent on intact mitochondrial function and susceptibility of mitochondrial DNA-deficient cells to apoptosis depends on the type of apoptotic stimuli. Tumor cells with mitochondrial mutations or dysfunction might have the ability to evade tumor surveillance imposed by TRAIL in vivo.	Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, Seoul 135710, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Natl Inst Hlth, Div Metab Dis, Dept Biomed Sci, Eunpyung Ku, Seoul 122710, South Korea; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Pohang University of Science & Technology (POSTECH); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Juntendo University; Gwangju Institute of Science & Technology (GIST); Yonsei University	Lee, MS (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, 50 Irwon Dong, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Pak, Youngmi Kim/AAI-1091-2020; Oh, Byung-Ha/C-2061-2011; Lee, Myung Shik/C-9606-2011	Pak, Youngmi Kim/0000-0001-7424-3484; Lee, Myung-Shik/0000-0003-3292-1720				ALBERTS B, 1994, GARLAND PUB INC NEW, V3, P568; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kayagaki N, 1999, J IMMUNOL, V163, P1906; KERR JFR, 1995, METHOD CELL BIOL, V46, P1; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RUBIN BY, 1988, CANCER RES, V48, P6006; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, CANCER RES, V56, P2161; SKOWRONEK P, 1992, BIOCHEM BIOPH RES CO, V187, P991, DOI 10.1016/0006-291X(92)91295-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thomas WD, 1998, J IMMUNOL, V161, P2195; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wuchter C, 2001, LEUKEMIA, V15, P921, DOI 10.1038/sj.leu.2402131; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	57	60	65	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3139	3148		10.1038/sj.onc.1205406	http://dx.doi.org/10.1038/sj.onc.1205406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082629				2022-12-17	WOS:000175373600005
J	Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR				Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR			Differential function of STAT5 isoforms in head and neck cancer growth control	ONCOGENE			English	Article						STAT5; squamous cell carcinoma of the head and neck epidermal growth factor receptor	SQUAMOUS-CELL CARCINOMA; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; TGF-ALPHA; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCERS; GENE FAMILY; PROTEINS	Up-regulation of the epidermal growth factor receptor (EGFR) is critical for the loss of growth control in a variety of human cancers, including squamous cell carcinoma of the head and neck (SCCHN). Stimulation of EGFR results in activation of mitogenic signaling pathways including Signal Transducers and Activators of Transcription (STATs). Stat5 activation has been primarily demonstrated in hematopoietic malignancies. Gene disruption studies suggest potentially distinct functions of the Stat5 isoforms, Stat5a and Stat5b, which are encoded by two genes closely linked on human chromosome 17. To determine the function of Stat5 in SCCHN growth control, we studied the expression and constitutive activation of Stat5a and Stat5b in normal and transformed human squamous epithelial cells. Increased constitutive activation of Stat5 was detected in transformed compared with normal squamous cells. Blockade of TGF-alpha or EGFR, abrogated Stat5 activation. Targeting of Stat5b using antisense oligonucleotides inhibited SCCHN growth. In addition, SCCHN cells stably transfected with dominant negative mutant Stat5b failed to proliferate in vitro. In contrast, targeting of Stat5a using either antisense or dominant negative strategies had no effect on cell growth. These results suggest that TGF-alpha/EGFR-mediated autocrine growth of transformed epithelial cells is dependent on activation of Stat5b but not Stat5a.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NCI NIH HHS [CA77308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chai SK, 1997, J IMMUNOL, V159, P4720; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; HEO DS, 1989, CANCER RES, V49, P5167; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lango MN, 2001, CURR OPIN ONCOL, V13, P168, DOI 10.1097/00001622-200105000-00007; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; Okuda K, 1996, ONCOGENE, V13, P1147; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SACKS PG, 1988, CANCER RES, V48, P2858; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WeberNordt RM, 1996, BLOOD, V88, P809; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914	53	60	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2846	2853		10.1038/sj.onc.1205385	http://dx.doi.org/10.1038/sj.onc.1205385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973644				2022-12-17	WOS:000175063700009
J	Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM				Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM			Overexpression of B-type cyclins alters chromosomal segregation	ONCOGENE			English	Article						genetic instability; chromosomes; Clb5; cyclin B; yeast	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; KINETOCHORE PROTEIN; MESSENGER-RNA; MUTATIONS; ANAPHASE; GENE; TRANSFORMATION; INSTABILITY; PROMOTERS	To identify genes which overexpression results into chromosomal instability (CIN), we developed a biological approach based on a yeast indicator strain in which CIN can be detected by a sectoring phenotype. Screening in this strain of a yeast genomic Library cloned into a high copy vector led us to identify, among the clones generating 100% of sectoring colonies, Clb5, one of the six B-type cyclins present in yeast. Overexpression of cyclin B2 and cyclin B1, the two human homologs of Clb5, in the CIN indicator strain resulted also into a sectoring phenotype and induced, like overexpression of Clb5, an abnormal sensitivity to benomyl, indicating that overexpression of B-type cyclins alters the spindle checkpoint. In a series of 38 primary colorectal cancers, we detected in five tumors (13%) an accumulation of cyclin B1, which was neither related to mRNA overexpression nor to mutation within the coding region, and in five other tumors (13%) a 2-10-fold increase of cyclin B2 mRNA which was not related to gene amplification. These results suggest that overexpression of cyclins B, resulting from different mechanisms, could contribute, through an alteration of the spindle checkpoint, to the chromosomal instability observed in cancer.	IFRMP, INSERM, EMI 9906, Fac Med & Pharm, F-76183 Rouen, France; Ctr Hosp Univ, Serv Anat & Cytol Pathol, F-76031 Rouen, France; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; University of British Columbia	Frebourg, T (corresponding author), IFRMP, INSERM, EMI 9906, Fac Med & Pharm, 22 Blvd Gambetta, F-76183 Rouen, France.	Frebourg@chu-rouen.fr	Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018	Flaman, Jean-Michel/0000-0003-3544-0199				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Kotani T, 2001, MOL REPROD DEV, V59, P199, DOI 10.1002/mrd.1023; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; OHSUMI K, 1994, J CELL SCI, V107, P3005; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Segal M, 1998, J CELL BIOL, V143, P135, DOI 10.1083/jcb.143.1.135; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Soria JC, 2000, CANCER RES, V60, P4000; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Yin XY, 2001, CANCER RES, V61, P6487; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	32	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2051	2057		10.1038/sj.onc.1205257	http://dx.doi.org/10.1038/sj.onc.1205257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960377				2022-12-17	WOS:000174827000011
J	Chan, HM; Smith, L; La Thangue, NB				Chan, HM; Smith, L; La Thangue, NB			Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein	ONCOGENE			English	Article						pRb; E2F; HDAC; LXCXE; tumour suppressor	CELL-CYCLE ARREST; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; BINDING-SITE; E2F SITE; IN-VIVO; E GENE; RB; DOMAIN; CHROMATIN	Cell cycle control by pRb requires the integrity of the pocket domain, which is a region necessary for interactions with a variety of proteins, including E2F and LXCXE-motif containing proteins. Through knowledge of the crystal structure of pRb we have prepared a panel of pRb mutant derivatives in which a cluster of lysine residues that demark the LXCXE peptide binding domain were systematically mutated. One of the mutant derivatives, Rb6A, exhibits significantly reduced LXCXE-dependent interactions with HPV E7, cyclinD1 and HDAC2, but retained LXCXE-independent binding to E2F. Consistent with these results, Rb6A could down-regulate E2F-1-dependent activation of different E2F responsive promoters, but was compromised in Rb-dependent repression. Most importantly, Rb6A retained wild-type growth arrest activity, and colony forming activity similar to wild-type pRb. It is compatible with these results that directly targeting HDAC2 to E2F responsive promoters as an E2F/HDAC hybrid protein failed to effect cell cycle arrest. These results suggest that LXCXE-dependent interactions are not essential for pRb to exert growth arrest.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Blvd, Glasgow G12 8QQ, Lanark, Scotland.				MRC [G9400953] Funding Source: UKRI; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT L, 1999, MOL CELL BIOL, V19, P6632; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Goodman RH, 2000, GENE DEV, V14, P1553; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2000, CANCER RES, V60, P6068; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	44	60	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6152	6163		10.1038/sj.onc.1204793	http://dx.doi.org/10.1038/sj.onc.1204793			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593423				2022-12-17	WOS:000171206300006
J	Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY				Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY			Identification of a prostate-specific G-protein coupled receptor in prostate cancer	ONCOGENE			English	Article						G-protein coupled receptor; GPCRs; prostate cancer; Galpha12; PSGR	TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; CELL-GROWTH; P115 RHOGEF; G-ALPHA-12; KINASE; PATHWAY; EXPRESSION; ONCOGENES	Membrane receptors coupled to heterotrimeric G-proteins play an essential role in the transmission of signals from the extracellular environment to the cytoplasm of the cell. A wide variety of external stimuli, including neurotransmitters, hormones, phospholipids, photons, odorants, taste ligands, and growth factors, can activate specific members of the G-protein coupled receptors (GPCRs). Besides essential functions in fully differentiated cells and tissues, GPCRs are also involved in embryogenesis, tissue regeneration, cell growth stimulation, and cell proliferation. In this study, we identified a novel prostate-specific G-protein coupled receptor that interacts with G alpha (12) in our yeast two-hybrid assays. The expression of the receptor protein is highly restricted to human prostate tissues using multiple-tissue Northern blot analysis, and tissue expression array. Furthermore, the expression of prostate-specific receptor is increased significantly in prostate tumors in comparison with the matched normal prostate tissues using PCR and Southern blot analysis, suggesting a potential role of this tissue-specific G-protein coupled receptor in prostate cancer development.	Inst Biosci & Technol Houston, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Genetastix Corp, San Jose, CA 95131 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liu, MY (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu						ABE K, 1993, J BIOL CHEM, V268, P12033; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Xu LL, 2000, CANCER RES, V60, P6568; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	60	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5903	5907		10.1038/sj.onc.1204803	http://dx.doi.org/10.1038/sj.onc.1204803			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593396				2022-12-17	WOS:000171037200014
J	Borrmann, L; Wilkening, S; Bullerdiek, J				Borrmann, L; Wilkening, S; Bullerdiek, J			The expression of HMGA genes is regulated by their 3 ' UTR	ONCOGENE			English	Article						HMGA; high mobility group proteins; 3 ' UTR	BENIGN MESENCHYMAL TUMORS; GROUP PROTEIN I(Y); MESSENGER-RNA; 3'-UNTRANSLATED REGION; CHROMOSOMAL-PROTEINS; Y PROTEINS; REARRANGEMENTS; CELLS; IDENTIFICATION; SEQUENCE	Many benign mesenchymal tumors are characterized by chromosomal abnormalities of the regions 12q15 or 6p21.3 leading to aberrant expression of either HMGA2 (formerly HMGIC) or HMGA1 (formerly HMGIY). The proteins of both genes belong to the HMGA (formerly HMGI(Y)) family of architectural transcription factors. As a rule, aberrant HMGA transcripts found in a variety of benign tumors have intact coding regions at least for the DNA binding domains with a truncation of their 3' untranslated regions. Adding this to the finding that an altered HMGA protein level is not always correlated with an increased amount of corresponding mRNA indicates a posttranscriptional expression control mediated by regulatory elements within the 3'UTR. To check if HMGA expression is under control of such elements we performed luciferase assays with several HMGA2 and HMGA1 3'UTRs of different length. Experiments showed that an up to 12-fold increase in luciferase activity is obtained by the truncation of the 3'UTRs suggesting that the expression of HMGA2 and HMGA1 is controlled by negatively acting regulatory elements within their 3'UTR. Chromosomal aberrations affecting the HMGA genes may therefore influence their expression by an altered stability of the truncated transcripts as a result of the cytogenetic aberrations.	Univ Bremen, Ctr Human Genet, ZHG, D-28359 Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, ZHG, Leobenerstr, D-28359 Bremen, Germany.							Abe N, 2000, CANCER RES, V60, P3117; ASHAR HR, 1995, CELL, V82, P57; Ayoubi TAY, 1999, ONCOGENE, V18, P5076, DOI 10.1038/sj.onc.1202881; Battista S, 1999, CANCER RES, V59, P4793; Beaujean N, 2000, DEV BIOL, V221, P337, DOI 10.1006/dbio.2000.9668; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Chiappetta G, 1996, ONCOGENE, V13, P2439; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kazmierczak B, 1996, GENOMICS, V38, P223, DOI 10.1006/geno.1996.0619; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Klotzbucher M, 1999, AM J PATHOL, V155, P1535, DOI 10.1016/S0002-9440(10)65469-7; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Russell JE, 1997, PROG NUCLEIC ACID RE, V57, P249, DOI 10.1016/S0079-6603(08)60283-4; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; Tkachenko A, 1997, CANCER RES, V57, P2276; Xiao S, 1997, AM J PATHOL, V150, P901; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	34	60	62	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4537	4541		10.1038/sj.onc.1204577	http://dx.doi.org/10.1038/sj.onc.1204577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494149				2022-12-17	WOS:000170074900011
J	Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B				Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B			Defective caspase-3 relocalization in non-small cell lung carcinoma	ONCOGENE			English	Article						lung cancer; sensitivity; caspase; apoptosis	T-LYMPHOCYTE STIMULATION; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; DNA FRAGMENTATION; INDUCED APOPTOSIS; ANTICANCER DRUGS; FAMILY MEMBERS; DEATH; ACTIVATION	Many anticancer drugs exert their cytotoxicity through DNA damage and induction of apoptosis, Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) have different sensitivity to treatment,vith radiation and chemotherapeutic agents with SCLC being more sensitive than NSCLC both in vitro and in vivo, This difference might be related to the different susceptibility of small and non-small cell lung carcinoma to undergo apoptosis, The aim of this study was to investigate if deficiencies in the apoptotic pathways can explain the intrinsic resistance of NSCLC to anti-cancer treatment, Three different triggers were used to induce apoptosis, Etoposide and gamma -radiation, which are important parts of clinical lung cancer treatment, induce DNA-damage, whereas Fas ligation induces receptor-mediated apoptotic pathways. NSCLC cells were cross-resistant to all treatments, whereas SCLC cells, which do not express pro-caspase-8, were resistant to alpha Fas-, but not to DNA-damage-induced apoptosis. Cytochrome c release, activation of caspase-9 and the executioner caspase-3 were observed in both types of lung cancer cells, However, cleavage of known nuclear substrates for caspase-3, such as PARP and DFF45/ICAD, was documented only in the sensitive SCLC cells but not in the resistant NSCLC cells. Moreover, relocalization of active caspase-3 from the cytosol into the nucleus upon treatment was observed only in the SCLC cell line. These results indicate that the inhibition of apoptosis in NSCLC occurs downstream of mitochondrial changes and caspase activation, and upstream of nuclear events. Oncogene (2001) 20, 2877-2888.	Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Canc Ctr Karolinska R800, Unit Med Radiobiol, S-17176 Stockholm, Sweden; Fac Med Lille, Biol Cellulaire Lab, INSERM, U459, F-59045 Lille, France	Karolinska Institutet; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Dept Toxicol, Box 210, S-17177 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; MARCHETTI, Philippe/0000-0002-4663-6800; Joseph, Bertrand/0000-0001-5655-9979				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawara A, 1997, CANCER RES, V57, P4578; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; OWENS AH, 1985, MED ONCOL, P715; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL DEATH DIFFER, V6, P493, DOI 10.1038/sj.cdd.4400523; Watanabe Y, 1999, J CELL PHYSIOL, V179, P45, DOI 10.1002/(SICI)1097-4652(199904)179:1<45::AID-JCP6>3.0.CO;2-H; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	47	60	63	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2877	2888		10.1038/sj.onc.1204402	http://dx.doi.org/10.1038/sj.onc.1204402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420700				2022-12-17	WOS:000168901800003
J	Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR				Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR			Tumor suppression and potentiation by manipulation of pp32 expression	ONCOGENE			English	Article						pp32; oncogene; transformation	PROTEIN; PHOSPHATASE; GENE; IDENTIFICATION; INHIBITION; ACTIVATION	Alternative use of genes of the closely-related pp32 family is a common occurrence in human prostate cancer, pp32r1 and pp32r2, the oncogenic members of the pp32 family, are expressed in prostatic adenocarcinoma, while adjacent benign prostate continues to express pp32, This study focuses upon the role of pp32 in tumor suppression, We demonstrate that antisense inhibition of pp32 in NIH3T3 cells leads to a variety of phenotypic changes associated with transformation including reduced serum dependence and loss of contact inhibition. NIH3T3 cells with antisense-inhibited pp32 are not tumorigenic, but are markedly more susceptible to oncogenic stimuli such as vas, In contrast, constitutive expression of pp32 abolishes ras mediated transformation in vitro and tumorigenesis in vivo. These data demonstrate, from the functional aspect, that pp32 acts as a tumor suppressor. Furthermore, inactivation of pp32 function through alternative gene use may be a critical event in tumor evolution and progression.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Room 512 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA54404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; HAMILTON SR, 1988, J PATHOL, V154, P205, DOI 10.1002/path.1711540302; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; KADKOL SS, 1999, J MOL DIAGN, V1, P58; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Mills JC, 1998, J CELL SCI, V111, P625; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG RA, 1989, BIOCHEMISTRY-US, V28, P8263, DOI 10.1021/bi00447a001; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917	20	60	63	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2153	2160		10.1038/sj.onc.1204294	http://dx.doi.org/10.1038/sj.onc.1204294			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360199				2022-12-17	WOS:000168116700010
J	Lebrin, F; Chambaz, EM; Bianchini, L				Lebrin, F; Chambaz, EM; Bianchini, L			A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha	ONCOGENE			English	Article						proliferation; casein kinase 2; BrdU; dominant-negative	CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; BETA-SUBUNIT; MOLECULAR-CLONING; NA+/H+ ANTIPORTER; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; PHOSPHATASE 2A; GROWTH	Protein kinase CK2 is an ubiquitous and pleiotropic Ser/Thr protein kinase composed of two catalytic (alpha and/or alpha') and two regulatory (B) subunits generally combined to form alpha (2)beta (2), alpha alpha'beta (2), or alpha'(2)beta (2) heterotetramers, To gain more insight into the role of CK2 in the control of proliferation in mammalian cells, overexpression of isolated CK2 subunits alpha, alpha', or beta was carried out in two fibroblast cell lines: NIH3T3 and CCL39, To interfere with CK2 cellular functions, cells were also transfected with a kinase-inactive mutant of CK2 alpha catalytic subunit: CK2 alpha -K68A. In NIH3T3 cells, overexpression of either wild-type subunit (alpha, alpha' or beta) had no effect on cell proliferation, In contrast, overexpression of the CK2 alpha kinase-deficient mutant induced a marked inhibition of cell proliferation, This resulted from a defect in G1/S progression as demonstrated in transient transfection experiments in both NIH3T3 and CCL39 cells using BrdU incorporation measurements and in CCL39 clones stably overexpressing the CK2 alpha -K68A mutant by growth curve analysis. We demonstrated that the kinase-negative mutant has the capacity to integrate the endogenous CK2 subunit pool both as an isolated kinase-inactive alpha subunit and as associated to the beta subunit in a kinase-inactive tetramer. Finally we showed that expression of the kinase-inactive mutant interferes with phosphorylation of an endogenous CK2 substrate; we speculate that optimal phosphorylation of target proteins by CK2 is required to achieve optimal cell cycle progression.	CEA, BRCE, DBMS, INSERM U244, F-38054 Grenoble 9, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bianchini, L (corresponding author), Fac Sci, Ctr Biochim, UMR 6543 CNRS, Parc Valrose, F-06108 Nice 2, France.			lebrin, franck/0000-0002-1650-6757				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Cosmelli D, 1997, FEBS LETT, V410, P391, DOI 10.1016/S0014-5793(97)00625-X; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19	39	60	63	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2010	2022		10.1038/sj.onc.1204307	http://dx.doi.org/10.1038/sj.onc.1204307			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360185				2022-12-17	WOS:000168043800009
J	Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T				Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T			Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer	ONCOGENE			English	Article						paclitaxel; p53; tubulin; drug resistance; human cancer	ANTICANCER-DRUG; P53-EXPRESSING ADENOVIRUS; GENOMIC INSTABILITY; HUMAN-CELLS; GENE; TAXOL; SENSITIVITY; CHECKPOINT; EXPRESSION; APOPTOSIS	The efficacy of anticancer therapy is limited by the development of drug resistance. While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed. In this study me examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired P-tubulin mutations which impair paclitaxel's interaction with tubulin, In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive. Two of the resistant sublines expressed high levels of transcriptionally inactive p53 protein, each with a distinct point mutation in codons 236 and 239 of the DNA binding domain. The third subline presented a novel p53 pseudo-null phenotype as a result of markedly decreased wt p53 mRNA expression, Introduction of ectopic wt p53 had no effect on PTX sensitivity in both parental and resistant cells, while it induced p21(WAF1/CIP1), demonstrating an intact p53 pathway, While PTX resistance is primarily conferred by the tubulin mutations, the loss of functional p53 observed in all clones, suggests that this loss may facilitate the development of resistance potentially by providing a clonal advantage which promotes the isolation of paclitaxel resistant cells.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Giannakakou, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X				Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1998, J CLIN ENDOCR METAB, V83, P2516, DOI 10.1210/jc.83.7.2516; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Debernardis D, 1997, CANCER RES, V57, P870; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAVRE PA, 1995, CANCER RES, V55, P4420; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KASTAN MB, 1991, CANCER RES, V51, P6304; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIYASHITA T, 1995, CELL, V80, P293; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OConnor PM, 1997, CANCER RES, V57, P4285; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	33	60	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3078	3085		10.1038/sj.onc.1203642	http://dx.doi.org/10.1038/sj.onc.1203642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871860	Green Submitted			2022-12-17	WOS:000087903900005
J	Sadot, E; Simcha, I; Iwai, K; Ciechanover, A; Geiger, B; Ben-Ze'ev, A				Sadot, E; Simcha, I; Iwai, K; Ciechanover, A; Geiger, B; Ben-Ze'ev, A			Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system	ONCOGENE			English	Article						beta-catenin; plakoglobin; beta-TrCP; ubiquitination	GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; CELL-CELL ADHESION; XENOPUS EMBRYOS; AXIS FORMATION; E-CADHERIN; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; ALPHA-CATENIN	beta-Catenin and plakoglobin are closely related armadillo family proteins with shared and distinct properties; Both are associated with cadherins in actin-containing adherens junctions. Plakoglobin is also found in desmosomes where it anchors intermediate filaments to the desmosomal plaques. beta-Catenin, on the other hand, is a component of the Wnt signaling pathway, which is involved in embryonic morphogenesis and tumorigenesis. A key step in the regulation of this pathway involves modulation of beta-catenin stability. A multiprotein complex, regulated by Wnt, directs the phosphorylation of beta-catenin and its degradation by the ubiquitin-proteasome system. Plakoglobin can also associate with members of this complex, but inhibition of proteasomal degradation has little effect on its levels while dramatically increasing the levels of beta-catenin. beta-TrCP, an F-box protein of the SCF E3 ubiquitin ligase complex, was recently shown to play a role in the turnover of beta-catenin. To elucidate the basis for the apparent differences in the turnover of beta-catenin and plakoglobin we compared the handling of these two proteins by the ubiquitin-proteasome system. We show here that a deletion mutant of beta-TrCP, lacking the F-box, can stabilize the endogenous beta-catenin leading to its nuclear translocation and induction of beta-catenin/LEF-1-directed transcription, without affecting the levels of plakoglobin. However, when plakoglobin was overexpressed, it readily associated with beta-TrCP, efficiently competed with beta-catenin for binding to beta-TrCP and became polyubiquitinated. Fractionation studies revealed that about 85% of plakoglobin in 293 cells, is Triton X-100-insoluble compared to 50% of beta-catenin. These results suggest that while both plakoglobin and beta-catenin can comparably interact with beta-TrCP and the ubiquitination system, the sequestration of plakoglobin by the membrane-cytoskeleton system renders it inaccessible to the proteolytic machinery and stabilizes it.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Kyoto Univ, Dept Mol & Syst Biol, Sakyo Ku, Kyoto 6068501, Japan; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Weizmann Institute of Science; Kyoto University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		IWAI, KAZUHIRO/GSN-7385-2022; Ciechanover, Aaron J/C-9166-2017	ben-ze'ev, avri/0000-0001-6113-3921; Iwai, Kazuhiro/0000-0001-5620-5951				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KAM Z, 1993, BIOIMAGING, V1, P71; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kofron M, 1997, DEVELOPMENT, V124, P1553; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miyoshi Y, 1998, ONCOL RES, V10, P591; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAVARRO P, 1993, J CELL SCI, V105, P923; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palacios J, 1998, CANCER RES, V58, P1344; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PEIFER M, 1993, DEVELOPMENT, P163; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SOMMERS CL, 1994, CANCER RES, V54, P3544; Sparks AB, 1998, CANCER RES, V58, P1130; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zurawel RH, 1998, CANCER RES, V58, P896	88	60	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					1992	2001		10.1038/sj.onc.1203519	http://dx.doi.org/10.1038/sj.onc.1203519			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803460				2022-12-17	WOS:000086613200003
J	Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S				Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S			Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11)	ONCOGENE			English	Article						chondrosarcoma; gene fusion; translocation genetics; karyotyping	RNA-BINDING PROTEIN; EWINGS-SARCOMA TRANSLOCATION; ORPHAN NUCLEAR RECEPTOR; CHROMOSOME-TRANSLOCATION; EWS GENE; MYELOID-LEUKEMIA; FAMILY; TUMORS; CHOP; ERG	Although most extraskeletal myxoid chondrosarcomas (EMC) are cytogenetically characterized by the translocation t(9;22)(q22;q12), another subset has recently been identified carrying a t(9;17)(q22;q11). Whereas the t(9;22) is known to result in fusion of the CHN (TEC) gene from 9q22 with the EWS gene from 22q12, creating a chimeric EWS/CHN, the genes involved in the t(9;17) of EMC are unknown. We examined two EMC with t(9;17)(q22;q11) and found that the CHN gene was recombined with the RBP56 gene from 17q11 to generate a chimeric RBP56/CHN, RBP56 has not previously been shown to be involved in tumorigenesis but it encodes a putative RNA-binding protein similar to the EWS and FUS (TLS) proteins known to play a pathogenetic role in several sarcomas, The presence of the RBP56/CHN chimeric gene in EMC with t(9;17)(q22;q11) shows that the N-terminal parts of EWS and RBP56 have similar oncogenic potential making them pathogenetically equivalent in oncoproteins arising from fusions with certain transcription factors.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Inst Canc Res, N-0310 Oslo, Norway	Lund University; Skane University Hospital; University of Oslo; University of Oslo; University of Oslo	Panagopoulos, I (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.		Mencinger, Marina/AAC-9468-2022	Mencinger, Marina/0000-0002-4349-1511; Mertens, Fredrik/0000-0002-6278-5232; Panagopoulos, Ioannis/0000-0003-2159-5341				Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BJERKEHAGEN B, 1999, IN PRESS VIRCHOWS AR; Brody RI, 1997, AM J PATHOL, V150, P1049; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELIZALDE JM, 1993, TUMORI, V79, P283, DOI 10.1177/030089169307900413; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLIJANIENKO J, 1990, HISTOPATHOLOGY, V16, P196; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LIUSHINDO M, 1989, OTOLARYNG HEAD NECK, V101, P485, DOI 10.1177/019459988910100414; MITELMAN F, 1998, CATALOG CHROMOSOME A; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEFFEN CM, 1992, J SURG ONCOL, V50, P58, DOI 10.1002/jso.2930500116; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	30	60	62	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7594	7598		10.1038/sj.onc.1203155	http://dx.doi.org/10.1038/sj.onc.1203155			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602519				2022-12-17	WOS:000084119600021
J	Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M				Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M			Ras induces p21(Cip1/Waf1) cyclin kinase inhibitor transcriptionally through Sp1-binding sites	ONCOGENE			English	Article						Ras; p21(Cip1/Waf1); transcriptional activation	TUMOR-SUPPRESSOR GENE; CELL-CYCLE; P21(WAF1/CIP1) EXPRESSION; P53-INDEPENDENT PATHWAY; RETINOBLASTOMA PROTEIN; COOPERATING ONCOGENES; ECTOPIC EXPRESSION; LEUKEMIC-CELLS; PC12 CELLS; 3T3 CELLS	p21(Cip1/WafI) cyclin-dependent kinase inhibitor (p21) is inducible by Raf and mitogen-activated protein kinase kinase (MAPKK), but the level of regulation is unknown. We show here by conditional and transient Ras-expression models that Ras induces p21, Induction of p21 in conditionally Ras-expressing cells is posttranscriptional utilizing mitogen-activated protein kinase (MAPK) pathway. Transient, high-level Ras-expression induces transcriptional activation of p21 mediated by a GC-rich region in p21 promoter -83-54 bp relative to the transcription initiation site containing binding sites for Spl-family transcription factors. Mutation of either Sp1-binding site 2 or 4 in this region decreases the magnitude of induction of promoter activity by Ras, but only the simultaneous mutation of both sites abolishes fully the induction. Electrophoretic mobility shift assays using an oligonucleotide corresponding to Spl-binding site 2 indicate that both Spl and Sp3 transcription factors bind to this region. The results demonstrate that the central cytosolic growth regulator Ras is a potent transcriptional and posttranscriptional inducer of the nuclear growth inhibitor p21.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Helsinki; Duke University	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arber N, 1996, ONCOGENE, V12, P1903; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kivinen L, 1996, CELL GROWTH DIFFER, V7, P1705; KIVINEN L, 1993, ONCOGENE, V8, P2703; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LIU HS, 1992, CANCER RES, V52, P983; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557	65	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6252	6261		10.1038/sj.onc.1203000	http://dx.doi.org/10.1038/sj.onc.1203000			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597223				2022-12-17	WOS:000083934100008
J	Ruas, M; Brookes, S; McDonald, NQ; Peters, G				Ruas, M; Brookes, S; McDonald, NQ; Peters, G			Functional evaluation of tumour-specific variants of p16(INK4a)/CDKN2A: correlation with protein structure information	ONCOGENE			English	Article						cyclin-dependent kinase inhibitor; tumour suppressor; familial melanoma; ankyrin repeats; replicative senescence	CYCLIN-DEPENDENT KINASE-4; SQUAMOUS-CELL CARCINOMA; AUSTRALIAN MELANOMA KINDREDS; SUPPRESSOR GENE-PRODUCT; GERMLINE MUTATIONS; FAMILIAL MELANOMA; REPLICATIVE SENESCENCE; P16/CDKN2 GENE; INHIBITOR GENE; P16 GENE	Inherited mutations in the CDKN2A/INK4a/MTS1 tumour suppressor gene on chromosome 9p21 are associated with familial predisposition to melanoma and other tumour types. Nonsense and missense mutations are also found in a variety of sporadic cancers, and over 140 sequence variants have already been recorded in the literature. In assessing the relevance of these variants and for counselling members of affected families, it is important to distinguish inactivating mutations from harmless polymorphisms. Existing functional assays have frequently reached conflicting conclusions and no single test appears adequate. Here we evaluate a number of alternatives including a novel assay based on retroviral delivery of p16(INK4a) cDNAs into human diploid fibroblasts. Among the 17 sequence variants analysed, three distinct categories can be distinguished: those that abrogate the binding of p161(INK4a) to CDK4 and CDK6, those that alter the properties of the protein without preventing it from interacting with CDKs, and those that have no discernible effect on protein function. These distinctions can be rationalized by considering the impact of the amino acid changes on the three-dimensional structure of the protein.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), Imperial Canc Res Fund, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.			Ruas, Margarida/0000-0002-4872-7618				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; BATES S, 1994, ONCOGENE, V9, P71; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Boice JA, 1996, PROTEIN SCI, V5, P1776, DOI 10.1002/pro.5560050903; Borg A, 1996, CANCER RES, V56, P2497; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Castellano M, 1997, J INVEST DERMATOL, V109, P61, DOI 10.1111/1523-1747.ep12276538; Castellano M, 1997, CANCER RES, V57, P4868; DellaVecchia B, 1996, CONSTR APPROX, V12, P271, DOI 10.1007/s003659900013; Dracopoli NC, 1996, CANCER SURV, V26, P115; Enders GH, 1996, ONCOGENE, V12, P1239; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Fueyo J, 1996, ONCOGENE, V12, P103; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HALL M, 1995, ONCOGENE, V11, P1581; Hara E, 1996, MOL CELL BIOL, V16, P859; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOMIYA A, 1995, JPN J CANCER RES, V86, P622, DOI 10.1111/j.1349-7006.1995.tb02443.x; Konishi N, 1996, INT J ONCOL, V8, P549; Kyritsis AP, 1996, ONCOGENE, V12, P63; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIU Q, 1995, ONCOGENE, V10, P1061; Loughran O, 1996, ONCOGENE, V13, P561; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McDonald NQ, 1998, NAT STRUCT BIOL, V5, P85, DOI 10.1038/nsb0298-85; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORI T, 1994, CANCER RES, V54, P3396; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; POLLOCK PM, 1995, ONCOGENE, V11, P663; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; Reznikoff CA, 1996, CANCER RES, V56, P2886; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; Sun S, 1997, INT J CANCER, V73, P531, DOI 10.1002/(SICI)1097-0215(19971114)73:4<531::AID-IJC13>3.0.CO;2-C; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WICK ST, 1995, ONCOGENE, V11, P2013; YANG R, 1995, CANCER RES, V55, P2503; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; YOSHIDA S, 1995, CANCER RES, V55, P2756; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZHANG SY, 1994, CANCER RES, V54, P5050	86	60	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5423	5434		10.1038/sj.onc.1202918	http://dx.doi.org/10.1038/sj.onc.1202918			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498896				2022-12-17	WOS:000082718600007
J	Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA				Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA			MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia	ONCOGENE			English	Article						fibroblast growth factor; FGF8; fgf8; mammary tumorigenesis; oncogenesis; breast cancer	KERATINOCYTE GROWTH-FACTOR; BREAST-CANCER CELLS; GENE-EXPRESSION; TUMOR VIRUS; PROVIRAL INSERTION; CARCINOMA-CELLS; FACTOR FAMILY; RECEPTOR; FGF-8; ACTIVATION	Prior studies have identified Fibroblast Growth Factor-8 (Fgf8) as a possible proto-oncogene in mouse mammary tumorigenesis. We now report on the generation of two types of Fgf8 transgenic mice that each utilize the mouse mammary tumor virus (MMTV) promoter. The first transgene (MMTV-Fgf8b) results in the overexpression of the FGF8b isoform exclusively. Male and female MMTV-Fgf8b transgenic mice are viable and fertile. RNA for FGF8b is detected in mammary gland and salivary gland tissues of transgenic mice by Northern blot analysis. Nearly 85% of breeding transgenic female mice developed mammary lobular adenocarcinomas by 12 months of age, while no tumors developed in nontransgenic littermates. Salivary gland tumors occurred in some animals, always in association with mammary tumors. Several MMTV-Fgf8b transgenic mice had lung metastases at necropsy. The second transgene (MMTV-Fgf8) uses the entire Fgf8 gene and potentially encodes all FGF8 isoforms. Fgf8 is expressed by this transgene in several tissues in addition to those described above, notably the ovaries. The two MMTV-Fgf8 founders developed mammary ductal adenocarcinomas at five and eight months of age, and both displayed ovarian stromal hyperplasia. The founders expressing either transgene did not successfully nurse their pups. These results demonstrate that production of FGF8b, and possibly other FGF8 isoforms, in the mammary and salivary glands contributes to oncogenesis, and that ovarian expression results in stromal hyperplasia.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90027 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Children's Hospital Los Angeles; University of Southern California; University of Southern California; Washington University (WUSTL)	MacArthur, CA (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD053229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060673, R01CA070106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70106, R01 CA 60673] Funding Source: Medline; NICHD NIH HHS [N01-HD-53229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; HARAGUCHI S, 1992, INT J CANCER, V52, P928, DOI 10.1002/ijc.2910520617; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LeRicousse S, 1996, P NATL ACAD SCI USA, V93, P5072, DOI 10.1073/pnas.93.10.5072; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	46	60	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2711	2717		10.1038/sj.onc.1202212	http://dx.doi.org/10.1038/sj.onc.1202212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840935				2022-12-17	WOS:000077146700004
J	Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD				Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD			A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells	ONCOGENE			English	Article						MDM2; p53; oncogene; tumor suppressor; apoptosis; caspase; isoform	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; PROTEOLYTIC CLEAVAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; ONCOGENE; ONCOPROTEIN; EXPRESSION; GENE	The MDM2 oncogene product is a regulator of the p53 tumor suppressor. MDM2 is cleaved by Caspase 3 (CPP32) during apoptosis after aspartic acid-361, generating a 60 kd fragment. Here we report that human tumor cell lines often express high levels of a 60 kd MDM2 isoform (p60) in the absence of apoptosis. We demonstrate that p60 is a product of caspase cleavage of full length MDM2 after residue 361. The protease that cleaves MDM2 in non-apoptotic cells appears to be distinct from the apoptosis-specific Caspase 3, since Caspase 3 substrate poly(ADP-ribose) polymerase (PARP) is not cleaved in cells producing p60. The p60 form of MDM2 is a significant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. These observations suggest that MDM2 is regulated by caspase processing in non-apoptotic cells, and may account for the MDM2 proteins of similar mobility seen in tumors and other cell lines.	Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Stanley S Scott Canc Ctr, Dept Surg, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	Chen, JD (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol, 1901 Perdido St, New Orleans, LA 70112 USA.			Pochampally, Radhika/0000-0002-4263-0364	NCI NIH HHS [CA72915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Gorgoulis VG, 1996, J PATHOL, V180, P129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	41	60	60	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2629	2636		10.1038/sj.onc.1202206	http://dx.doi.org/10.1038/sj.onc.1202206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840926				2022-12-17	WOS:000077058900010
J	Mendoza, SM; Konishi, T; Miller, CW				Mendoza, SM; Konishi, T; Miller, CW			Integration of SV40 in human osteosarcoma DNA	ONCOGENE			English	Article						SV40; integration; osteosarcoma	LARGE-T-ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; PERIPHERAL-BLOOD CELLS; NORMAL HUMAN-TISSUES; LARGE-TUMOR-ANTIGEN; HUMAN BRAIN-TUMORS; SIMIAN-VIRUS 40; HEALTHY-INDIVIDUALS; HUMAN-FIBROBLASTS; CHOROID-PLEXUS	Simian virus 40 (SV40) has been demonstrated in several types of tumors, including osteosarcoma, by polymerase chain reaction (PCR), We detected SV40 sequences by PCR, followed by hybridization, in nine of 35 osteosarcoma tumors and one of 11 osteosarcoma explants, PCR can detect fewer than one virus per cell but gives little detail of the gross structure and abundance of the virus, Analysis by Southern blotting of total DNA from ten osteosarcomas, positive for SV40 by PCR, found viral integration in half of these. Analysis showed integration of one to four copies per cell of rearranged SV40. No SV40 was detectable on blots of the remaining five SV40(+) osteosarcomas, perhaps because of the lesser sensitivity of direct hybridization. Inactivation of the p53 and Rb tumor suppressors is a key activity of SV40 T-antigen, Unexpectedly, correlation of these findings with our prior studies indicated that five of ten osteosarcomas positive for SV40 DNA had mutations of p53, and two had deleted Rb, Apparently clonal integration with pre-existing alteration of a tumor suppressor gene, suggests that SV40 may play a role in the final conversion to malignant osteosarcoma.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mendoza, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Davis 5019, Los Angeles, CA 90048 USA.							BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fields BN, 1996, VIROLOGY; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; HUNTER DJ, 1994, J VIROL, V68, P787, DOI 10.1128/JVI.68.2.787-796.1994; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; Lednicky JA, 1997, INT J CANCER, V72, P791; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P299; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Martini F, 1996, CANCER RES, V56, P4820; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; ROWE WP, 1968, CANCER RES, V28, P1319; Sambrook J, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P569; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; Stewart AR, 1996, VIROLOGY, V221, P355, DOI 10.1006/viro.1996.0386; Strickler H, 1997, CANCER RES, V57, P3319; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292	37	60	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2457	2462		10.1038/sj.onc.1202179	http://dx.doi.org/10.1038/sj.onc.1202179			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824156				2022-12-17	WOS:000076927300005
J	Percesepe, A; Kristo, P; Aaltonen, LA; de Leon, MP; de la Chapelle, A; Peltomaki, P				Percesepe, A; Kristo, P; Aaltonen, LA; de Leon, MP; de la Chapelle, A; Peltomaki, P			Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability	ONCOGENE			English	Article						mismatch repair; microsatellite instability; colorectal cancer; mutation analysis; HNPCC	II RECEPTOR GENE; SACCHAROMYCES-CEREVISIAE; SOMATIC MUTATIONS; COLON-CANCER; DNA; CARCINOGENESIS; CELLS; MSH3; CARCINOMAS; POLYMERASE	Microsatellite instability occurs in 15% of colorectal carcinomas and may be due to replication errors (RER). The pattern of instability - 'severe' vs 'mild' - and the tumorigenic pathway, as reflected by the involvement of functionally important genes, may vary according to the underlying gene(s), We defined 'mild' RER as mono- or tetranucleotide repeat instability in the absence of widespread instability at dinucleotide repeats and studied 15 colorectal tumors with this phenotype for mutations in the DNA mismatch repair genes MSH2, MLH1, MSH3, and MSH6. No mutations were found, suggesting that these genes were not implicated. We then compared colorectal cancers with 'mild' RER (n = 15), and those with 'severe' RER without (n = 11) or with (n = 22) detectable mutations in MSH2 or MLH1 to assess the involvement of mononucleotide repeats contained in the coding regions of MSH3, MSH6, BAX, and TGF beta RII, The combined mutation rates of the above mentioned loci varied significantly between the three groups of tumors, being 0%, 25% and 52%, respectively. Furthermore, the individual genes showed specific patterns of involvement; for example, among tumors with 'severe' RER, TGF beta RII displayed uniformly high mutation rates while MSH3, MSH6, and BAX were more frequently altered in tumors that also showed MSH2 or MLH1 mutations. Our findings suggest that different subcategories exist among unstable tumors, defined by the RER pattern on the one hand and tumorigenic pathway on the other, and structural changes of MSH2 and MLH1 are likely to explain only a proportion of these cases.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Modena, Dept Internal Med, I-41100 Modena, Italy; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	University of Helsinki; Universita di Modena e Reggio Emilia; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Percesepe, A (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Aaltonen, Lauri/A-5375-2010; Percesepe, Antonio/A-6076-2012; de Leon, Maurizio Ponz/A-9356-2015	Aaltonen, Lauri/0000-0001-6839-4286; Percesepe, Antonio/0000-0002-3268-6786; de Leon, Maurizio Ponz/0000-0003-4465-1043; Peltomaki, Paivi/0000-0001-8819-2980	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Akiyama Y, 1997, CANCER RES, V57, P3920; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; Canzian F, 1996, CANCER RES, V56, P3331; Chadwick RB, 1996, BIOTECHNIQUES, V20, P676; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Kane MF, 1997, CANCER RES, V57, P808; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Nicolaides NC, 1996, GENOMICS, V31, P395, DOI 10.1006/geno.1996.0067; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WIJNEN J, 1994, HUM MOL GENET, V3, P2268, DOI 10.1093/hmg/3.12.2268-a; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	41	60	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					157	163		10.1038/sj.onc.1201944	http://dx.doi.org/10.1038/sj.onc.1201944			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674699				2022-12-17	WOS:000074706700003
J	Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR				Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR			Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis	ONCOGENE			English	Article						p53 mutants; c-ras(Ha); skin, chemical carcinogenesis; centrosome; genomic instability	GROWTH-FACTOR-ALPHA; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; SKIN-CANCER; CELL-CYCLE; MOUSE SKIN; V-FOS; MUTATIONS; RAS; PROGRESSION	To develop an in vivo model for studying the role of the p53 tumor suppressor in skin carcinogenesis, a murine p53(172H) mutant (equivalent to human p53(175H)) was expressed in the epidermis of transgenic mice, utilizing a targeting vector based on the human keratin 1 gene (HK1.p53(m)), HK1.p53(m) mice developed normally and did not exhibit an obvious epidermal phenotype or develop spontaneous tumors. However, these mice demonstrated an increased susceptibility to a two-stage chemical carcinogenesis protocol, with the rate of formation and number of papillomas being dramatically increased as compared to non-transgenic controls, The majority of papillomas in control mice regressed after termination of 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, whereas p53(m) papillomas progressed to carcinomas and metastases. In addition, more advanced malignancy, i.e., undifferentiated spindle cell carcinomas, were exclusively observed in p53(m) mice. Increased bromodeoxyuridine (BrdU) labeling, accompanied by decreased expression of p21, was observed in HK1.p53(m) papillomas. In situ examination of centrosomes in HK1.p53(m) papillomas also revealed marked abnormalities, with 75% of the cells containing greater than or equal to 3 centrosomes/cell, whereas centrosome numbers in papillomas from control animals remained normal. These data suggest that the accelerated tumorigenesis observed in chemically-treated p53(m) mice is most likely due to increased genomic instability resulting from an inhibition of G1 arrest and abnormal amplification of centrosomes.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA41424, CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607, R01CA041424, R37CA041424] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUFFLER SD, 1995, CANCER RES, V55, P3888; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; BURNS PA, 1991, ONCOGENE, V6, P2363; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Chung Su Y., 1994, Molecular and Cellular Differentiation, V2, P61; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DErrico M, 1997, CANCER RES, V57, P747; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenhalgh DA, 1996, CANCER RES, V56, P4413; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jacks T, 1996, J CANCER RES CLIN, V122, P319, DOI 10.1007/BF01220798; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE JM, 1994, ONCOGENE, V9, P3731; LI B, 1997, IN PRESS ONCOGENE; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OConnor PM, 1997, CANCER SURV, V29, P151; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHAEFER DI, 1993, CANCER RES, V53, P4946; Wahl GM, 1997, CANCER SURV, V29, P183; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZHANG W, 1993, ONCOGENE, V8, P2555; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	51	60	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					35	45		10.1038/sj.onc.1201890	http://dx.doi.org/10.1038/sj.onc.1201890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671312	Bronze			2022-12-17	WOS:000074677800005
J	Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D				Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D			Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins	ONCOGENE			English	Article						c-myc; AUF1 alternative exon; fetal liver; RNA stability	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGIONS; TRANSGENIC MICE; RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; STABILITY INVITRO; CODING REGION; HALF-LIFE; GENE; SEQUENCE	Several proteins that may regulate c-myc mRNA posttranscriptionally were previously isolated and characterized. Two of them, HuR and AUF1, bind specifically to the 3' untranslated region (UTR) of c-myc mRNA. Because c-myc is regulated post-transcriptionally in various mouse tissues, including quiescent tissues, fetal liver and regenerating liver, we investigated whether HuR and AUF1 expression was also regulated in these tissues. Concerning AUF1, we analysed the expression of various mRNA and protein isoforms, We discovered a new AUF1 mRNA variant with a long AU-rich 3' UTR. We show that AUF1 expression, regardless of the RNA isoform considered, and HuR mRNA expression parallel C-myc expression in quiescent tissues and during liver development; their expression is high in lymphoid tissues and fetal liver and low in adult liver. However, no upregulation of HuR or AUF1 accompanies the upregulation of c-myc mRNA following partial hepatectomy. We discuss our results in relation to the current hypothesis that HuR and AUF1 act as mRNA destabilizing factors.	Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, F-31062 Toulouse 04, France; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Wake Forest University; Wake Forest Baptist Medical Center	Morello, D (corresponding author), Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, 118 Rte Narbonne, F-31062 Toulouse 04, France.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; SOBCZAK J, 1989, ONCOGENE, V4, P1503; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WAGNER BJ, 1998, IN PRESS GENOMICS; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3413	3421		10.1038/sj.onc.1201895	http://dx.doi.org/10.1038/sj.onc.1201895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692549				2022-12-17	WOS:000074544100008
J	Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R				Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R			Allelic loss analysis of gamma-ray-induced mouse thymic lymphomas: two candidate tumor suppressor gene loci on chromosomes 12 and 16	ONCOGENE			English	Article						tumor suppressor gene; allelic loss (or LOH) analysis; thymic lymphoma; gamma-ray irradiation; p53	RADIATION-INDUCED APOPTOSIS; P53 MUTATIONS; P53-DEFICIENT MICE; FREQUENT LOSS; CANCER; IRRADIATION; HETEROZYGOSITY; DEFICIENCY; RESISTANCE; SUSCEPTIBILITY	A total of 429 gamma-ray-induced thymic lymphomas were obtained from F-1 and backcross mice between BALB/c and MSM strains, about a half of which carried a p53-deficient allele. A genome-wide allelic loss analysis has revealed two loci exhibiting frequent alleLic losses but no allelic preference, one is localized within a 2.9 cM region between D12Mit53 and D12Mit279 loci on chromosome 12, and the other is near the D16Mit122/D16Mit162 loci on chromosome 16, The frequency of allelic loss in the D12Mit279 region is 62% and does not differ in tumors between the presence and absence of the p53-deficient allele, In contrast, the loss frequency of D16Mit122 is raised by the existence of p53-deficient allele: 62% for p63(-/+) and 13% for p53(+/+), suggesting cooperative function of the two losses. The D12Mit279 and D16Mit122 regions probably harbor different types of tumor suppressor gene that play key roles in lymphoma development.	Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Radiat Med, Niigata 951, Japan; Univ Osaka Prefecture, Adv Sci & Technol Res Inst, Sakai, Osaka 593, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 60601, Japan; Kumamoto Univ, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 860, Japan	Niigata University; Niigata University; Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; Kyoto University; Kumamoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 951, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALEVY O, 1991, ONCOGENE, V6, P1593; Hamatani K, 1996, IMMUNOGENETICS, V45, P1, DOI 10.1007/s002510050159; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; Ohashi M, 1996, JPN J CANCER RES, V87, P696, DOI 10.1111/j.1349-7006.1996.tb00280.x; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; OOTSUYAMA A, 1994, MOL CARCINOGEN, V11, P236, DOI 10.1002/mc.2940110409; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; Santos J, 1996, ONCOGENE, V12, P669; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI T, 1989, CANCER RES, V49, P1095; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	40	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2747	2754		10.1038/sj.onc.1201810	http://dx.doi.org/10.1038/sj.onc.1201810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652741				2022-12-17	WOS:000073812200006
J	Carneiro, C; Alvarez, CV; Zalvide, J; Vidal, A; Dominguez, F				Carneiro, C; Alvarez, CV; Zalvide, J; Vidal, A; Dominguez, F			TGF-beta 1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth	ONCOGENE			English	Article						apoptosis; cell cycle; cyclin; thyroid; TGF-beta 1; p27	ALPHA MESSENGER-RNA; FACTOR-BETA; TGF-BETA; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; PROTHYMOSIN-ALPHA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; EXPRESSION	Little is known about the TGF-beta 1 mechanism that promotes thyroid cell growth arrest, We assessed TGF-beta 1 effects on Fisher rat thyroid cell line (FRTL-5), This allowed us to study TGF-beta 1 action on thyroid cells in various physiological situations such as actively proliferating cells, resting cells stimulated to proliferate by the action of various mitogens, and resting cells, TGF-beta 1 arrested proliferating FRTL-5 cells, increasing c-myc mRNA levels and reducing p27-free cyclin D1 protein levels, without affecting either the cellular content of p27 or the cyclin D1-p27 complexes, Moreover, TGF-beta 1 treatment reduced the activity of cyclin E-CDK2 complexes and, consequently, pRB was found to be hypophosphorylated. TGF-beta 1 prevented resting cells to enter in the cell cycle when stimulated with growing medium (newborn calf serum plus a mixture of five hormones) but not when TSH (thyroid stimulating hormone) plus IGF-1 (Insulin-like growth factor I) were used as mitogens, Both stimuli increased the levels of cyclins D1, D3 and E but TGF-beta 1 had a greater effect in decreasing these cyclin levels in growing-medium stimulated cells than in TSH + IGF-1. This suggests that for FRTL-5 cells, the content of these cyclins must exceed a threshold to progress through the cell cycle, TGF-beta 1 induced apoptosis in quiescent cells, accompanied by a reduction in p27 protein levels and an increase in c-myc expression, Interestingly, TGF-beta 1-induced variations in prothymosin alpha and c-myc mRNA levels were not correlated, TGF-beta 1 always promoted an increase of p15 mRNA levels, In summary, our results point to the fact that TGF-beta 1 could play a physiological role in the control of thyroid growth through the modification of cell cycle regulatory proteins.	Dept Fisiol, Lab Neurociencia Ramon Dominguez, Santiago De Compostela, Spain; Unidad Med Mol, Santiago De Compostela, Spain		Alvarez, CV (corresponding author), Dept Fisiol, Lab Neurociencia Ramon Dominguez, Santiago De Compostela, Spain.		Alvarez, Clara V/AAN-4173-2020; Vidal, Anxo/B-5010-2015; Zalvide, Juan/ABG-4050-2020	Vidal, Anxo/0000-0002-0866-4202; Alvarez, Clara V/0000-0003-1500-4058; Zalvide, Juan/0000-0001-7645-156X				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ALVAREZ CV, 1993, J MOL ENDOCRINOL, V11, P249, DOI 10.1677/jme.0.0110249; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BATES S, 1994, ONCOGENE, V9, P1633; BLAYDES JP, 1995, ONCOGENE, V10, P307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KHOSLA S, 1994, ENDOCRINOLOGY, V135, P1887, DOI 10.1210/en.135.5.1887; KO TC, 1995, ONCOGENE, V10, P177; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOGAN A, 1994, J ENDOCRINOL, V141, P45, DOI 10.1677/joe.0.1410045; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Packham G, 1996, ONCOGENE, V13, P461; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PANG XP, 1992, ENDOCRINOLOGY, V131, P45, DOI 10.1210/en.131.1.45; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK C, 1995, BIOCHIM BIOPHYS ACTA, V1242, P185; RAVITZ MJ, 1995, CANCER RES, V55, P1413; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TRAUTH BC, 1997, GUIDE CELL PROLIFERA; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; ZALVIDE JB, 1992, J BIOL CHEM, V267, P8692	43	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	1998	16	11					1455	1465		10.1038/sj.onc.1201662	http://dx.doi.org/10.1038/sj.onc.1201662			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525744				2022-12-17	WOS:000072572400009
J	Kangas, AL; Nicholson, DW; Holtta, E				Kangas, AL; Nicholson, DW; Holtta, E			Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; CPP32/Caspase-3; c-Myc; ODC	PROGRAMMED CELL-DEATH; WILD-TYPE P53; ORNITHINE DECARBOXYLASE ACTIVITY; CRMA-INHIBITABLE PROTEASE; TUMOR-SUPPRESSOR P53; POLY(ADP-RIBOSE) POLYMERASE; GRANZYME-B; CYCLE ARREST; CONVERTING-ENZYME; GENE-EXPRESSION	c-Myc is a transcriptional activator implicated in the control of cell proliferation, differentiation and transformation, but is also involved in the regulation of programmed cell death, apoptosis. Despite intensive research, the molecular mechanisms by which c-Myc triggers and executes cell death remain still elusive. Here, we made use of Rat 1A MycER cells expressing a conditionally active c-Myc protein and tested first the hypothesis that ornithine decarboxylase (ODC), which is a transcriptional target of c-Myc, were a mediator of c-Myc-induced apoptosis. However, our results show that the activity of ODC is not required for the c-Myc-mediated apoptosis to occur in these cells. We also found that the expression of p53, p21(waf1/cip1), Bcl-2, Bax, Bcl-x(L), Bad and cyclins D1, E, A and B did not show any significant changes following c-Myc induction. But, our studies revealed that the c-Myc induced apoptosis is associated with a specific cleavage of poly(ADPribose) polymerase (PARP), suggesting that a cysteine protease of the ICE/CED-3 family is involved. Moreover, we found that the cysteine protease CPP32/Caspase-3, which is known to cleave PARR, is processed from its inactive form to an active protease composed of 17 and 12 kDa subunits; whilst Ich-1/Caspase-2 belonging to another subset of this protease family was not processed/activated following c-Myc activation. The activation of CPP32 and apoptotic cell death were inhibited by addition of Z-VAD-fmk, a universal inhibitor of ICE-like proteases. Further, a selective inhibitor of CPP32-like proteases (Z-DEVD-fmk) partly inhibited apoptosis. These results provide evidence that the ICE/CED3-family proteases, CPP32 and likely others, play a critical role in the execution of a nuclear proto-oncogene, c-Myc-induced apoptosis.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Dorval, PQ H9R 4P8, Canada	University of Helsinki; Merck & Company	Holtta, E (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLIFFORD A, 1995, CANCER RES, V55, P1680; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDESALNEMR.F, 1996, P NATL ACAD SCI USA, V93, P7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEGOSH L, 1995, CANCER RES, V55, P4205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSHIER JA, 1993, CANCER RES, V53, P2618; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOBIAS KE, 1995, CELL GROWTH DIFFER, V6, P1279; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	89	60	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					387	398		10.1038/sj.onc.1201779	http://dx.doi.org/10.1038/sj.onc.1201779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467964				2022-12-17	WOS:000071582100011
J	Nguyen, H; Lin, RT; Hiscott, J				Nguyen, H; Lin, RT; Hiscott, J			Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; STAT1 (p91); apoptosis; transcription	TRANSCRIPTION FACTOR IRF-1; IFN-BETA; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; INTERFERON GENE; VIRUS INDUCTION; NUCLEAR FACTOR; FACTOR-I; KINASE; TRANSFORMATION	Interferon Regulatory Factor (IRF)-1 has been characterized as an important growth regulatory and immunomodulatory transcription factor. To further characterize the potential targets of IRF-1 antiproliferative activity, IRF-1 was expressed under the control of the tetracycline-inducible system in murine NIH3T3 cells. Due to their ability to mimic IRF-1 transactivator function, the regulatory potential of IRF-1/RelA and IRF-2/RelA fusion proteins consisting of the DNA binding domains of IRF-1 or IRF-2 fused to the transactivation domain of NF-kappa B RelA(p65) was also examined. Cells inducibly expressing IRF-1 or IRF/RelA in response to doxycycline treatment displayed significantly reduced growth rates compared to control cells, and inhibition of cell growth correlated directly with the level of transgene expression. Interestingly, IRF-1 and IRF/RelA expression also induced a low level of apoptosis, as detected by microscopic analyses. Furthermore, expression of the interferon inducible, double stranded RNA dependent kinase PKR was increased following IRF-1 or IRF/RelA induction. Most strikingly, induction of IRF-1 and IRF/RelA expression resulted in a significant increase in STAT1 (p91) protein and increased ISGF3 DNA binding activity, suggesting that IRF-1 tumor suppressor activity may involve a novel mechanism which activates the JAK-STAT pathway through STAT1. WAF1 levels were also constitutively elevated in IRF-1 and IRF-1/RelA cells. These studies demonstrate that inducible expression of the transactivation function of IRF-1 or IRF/RelA mediates tumor suppressor activity by inducing cell growth arrest, apoptosis and the differential activation of growth regulatory genes such as PKR, STAT1 and WAF1.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOL ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEHTONEN A, IN PRESS J IMMUNOL; LIN RT, 1994, J BIOL CHEM, V269, P17542; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; OZAWA H, 1996, NATURE, V382, P816; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	44	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1425	1435		10.1038/sj.onc.1201318	http://dx.doi.org/10.1038/sj.onc.1201318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333018				2022-12-17	WOS:A1997XW41100006
J	Lores, P; Morin, L; Luna, R; Gacon, G				Lores, P; Morin, L; Luna, R; Gacon, G			Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase	ONCOGENE			English	Article						Rac2GTPase; thymocyte; apoptosis; transgenic mice	GTP-BINDING-PROTEIN; THYMOCYTE DEVELOPMENT; HEMATOPOIETIC-CELLS; NADPH OXIDASE; LYMPHOCYTES; IDENTIFICATION; RAC	Rac proteins constitute a subgroup of the Rho family of small GTPases and include Rac1, which is expressed ubiquitously, and Rac2, a highly homologous protein only expressed in myelo-monocytic and lymphoid cell lineages. In fibroblasts, Rad plays a crucial role in control of actin cytoskeleton organisation, cell growth and Ras-induced transformation. In phagocyte, Rac1 and Rac2 regulate a specific enzymatic complex, NADPH oxidase. These multiple functions have been ascribed to Rac proteins only on the basis of cell culture and in vitro biochemical studies. To examine the role of Rac2 in vivo in a T cell lineage, we have expressed either wild-type or constitutively-activated forms of human Rac2 (Rac2V12 and Rac2L61) in transgenic mice under control of the thymus specific lck proximal promoter. We report here a striking atrophy of the thymus in mice expressing even low levels of either of the activated mutants of Rac2, while expression of Rac2wt has no effect. This phenotype is correlated with a marked decrease in the number of double positive (CD4 + CD8 +) and single positive (CD4 + CD8 - and CD8 + CD4 -) thymocytes, Cellular and molecular analyses demonstrate that this defect is due to an increase in apoptosis among thymocytes. As Rac2 is normally expressed in thymocytes and activated T cells, me propose that Rac2 dependent pathways could play an important role in control of growth and death of T cells.	INST COCHIN GENET MOL,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			LUNA, ROSA/F-3974-2016	LUNA, ROSA/0000-0002-6131-6610; Lores, Patrick/0000-0002-3191-9488				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHETTY M, 1995, BIOCHEM J, V306, P141, DOI 10.1042/bj3060141; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; QUI RG, 1995, NATURE, V374, P457; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	27	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					601	605		10.1038/sj.onc.1201378	http://dx.doi.org/10.1038/sj.onc.1201378			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247314				2022-12-17	WOS:A1997XN25500012
J	Yanai, A; Arama, E; Kilfin, G; Motro, B				Yanai, A; Arama, E; Kilfin, G; Motro, B			ayk1, a novel mammalian gene related to Drosophila aurora centrosome separation kinase, is specifically expressed during meiosis	ONCOGENE			English	Article						serine/threonine protein kinase; centrosome separation; meiosis	KINESIN-LIKE PROTEIN; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; MESSENGER-RNAS; MUTATIONS; SEQUENCES; IDENTIFICATION; CLASSIFICATION; MITOSIS; MEMBERS	A novel murine gene, designated ayk1, which encodes a putative serine/threonine kinase has been cloned and characterized, The predicted catalytic domain of the protein is highly similar to that of Drosophila aurora (62.9% identity), and to that of Saccharomyces Ipl1 (49.4% identity), All three proteins also have very basic calculated isoelectric points (higher than 10), aurora has been recently shown to be crucial for centrosome separation and chromosome segregation, while Ipl1 is essential for yeast viability and accurate chromosome segregation, The results of Northern analysis and in situ RNA localization support a similar role for ayk1. The gene is specifically expressed in meiotically active cells, and during spermatogenesis, ayk1 transcripts accumulate just before the first meiotic division, Much lower levels are found in mitotically active cells, We propose that Ayk1, aurora and Ipl1 belong to a distinct new subfamily of kinases, These results suggest that the pathways controlling chromosome segregation are evolutionary conserved, and that similar control mechanisms operate in mitosis and meiosis.	BAR ILAN UNIV, DEPT LIFE SCI, IL-52900 RAMAT GAN, ISRAEL	Bar Ilan University			Arama, Eli/GYJ-0491-2022; /ABF-8487-2022					[Anonymous], 1984, AM NAT; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASSOLD T, 1984, ANNU REV GENET, V6, P555; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MOTRO B, 1991, DEVELOPMENT, V113, P1207; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1988, MOL CLONIGN LAB MANU; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	34	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2943	2950		10.1038/sj.onc.1201144	http://dx.doi.org/10.1038/sj.onc.1201144			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205101				2022-12-17	WOS:A1997XF55500008
J	Reddy, TR; Tang, HL; Li, XQ; WongStaal, F				Reddy, TR; Tang, HL; Li, XQ; WongStaal, F			Functional interaction of the HTLV-1 transactivator Tax with activating transcription factor-4 (ATF4)	ONCOGENE			English	Article						human T-cell leukemia virus-1; Tax; ATF-4; transactivation	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; DNA-BINDING PROTEINS; RESPONSIVE ELEMENT; GENE; ENHANCER; IDENTIFICATION; TRANSFORMATION; LYMPHOCYTES	The Tax protein of the Human T-cell Leukemia Virus (HTLV) activates the expression of viral mRNA through a three 21 bp repeat enhancer located within the HTLV-1 LTR, Since Tax does not bind to the 21bp DNA repeats directly, it has been speculated that Tax interacts with cellular protein(s) which mediate binding to the enhancer, We employed the yeast two hybrid system to identify host proteins that are potentially relevant to Tax transactivation. We identified a Tax binding protein encoded from a cDNA expression library derived from peripheral blood lymphocytes. The corresponding cDNA has sequence identity with a known transcription factor, activating factor-4 (ATF-4). ATF-4 also binds to GST-Tax fusion protein in vitro. Tax mutants that did not transactivate the HTLV-1 LTR also failed to bind ATF-4. The critical domain for Tax binding resides in a 85 amino acid stretch in the C-terminus of ATF-4, which contains the basic domain and leucine zipper, We further demonstrated that both full length and N-terminal truncated ATF-4 were able to enhance Tax transactivation, Thus, ATF-4 may act as an adapter between Tax and the TRE (Tax responsive element), and play an important role in Tax-mediated transactivation.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Tang, Hengli/F-2085-2014		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI031378] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30-AI36214-03, R01 AI31378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P, 1991, NEW BIOL, V2, P1034; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REDDY TR, 1995, AIDS RES HUM RETROV, V11, P663, DOI 10.1089/aid.1995.11.663; SEEMES OJ, 1992, J VIROL, V66, P7183; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	37	60	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2785	2792		10.1038/sj.onc.1201119	http://dx.doi.org/10.1038/sj.onc.1201119			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190894				2022-12-17	WOS:A1997XD64300006
J	Guerra, B; Gotz, C; Wagner, P; Montenarh, M; Issinger, OG				Guerra, B; Gotz, C; Wagner, P; Montenarh, M; Issinger, OG			The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation	ONCOGENE			English	Article						p53; protein kinase CK2; MDM2; p21(WAF1/CIP1); phosphorylation	TUMOR-SUPPRESSOR PROTEIN; AUTOREGULATORY FEEDBACK LOOP; SOFT-TISSUE SARCOMAS; CASEIN KINASE-2; DNA-BINDING; CELLULAR-REGULATION; BETA-SUBUNIT; WILD-TYPE; DOMAIN; GENE	The oncogene product MDM2 can be phosphorylated by protein kinase CK2 in vitro 0.5-1 mol of phosphate were incorporated per mol MDM2 protein, The catalytic subunit of protein kinase CK2 (alpha-subunit) catalyzed the incorporation of twice as much phosphate into the MDM2 protein as it was obtained with the holoenzyme, Polylysine stimulated MDM2 phosphorylation by CK2 holoenzyme threefold in contrast to the alpha-subunit-catalyzed MDM2 phosphorylation which was reduced by about 66% when polylysine was added, Full length p53, but also a peptide representing a C-terminal fragment of the tumor suppressor gene product p53 (amino acids 264-393 which also harbors the CK2 beta interaction site at amino acids 287-340) mimicked the polylysine effect in all respects, ie, stimulation of phosphate incorporation by CK2 holoenzyme and inhibition in the presence of the catalytic CK2 alpha-subunit. Stimulation by p53(264-393) was on the average close to twofold and inhibition in the case of the alpha-subunit-catalyzed MDM2 phosphorylation was about 40%, Phosphorylation of MDM2 by CK2 holoenzyme in the presence of the p21(WAF1/CIP1), known to be a potent inhibitor of cyclin-dependent protein kinases, also led to a significant reduction of phosphate incorporation into MDM2 indicating that p21(WAF1/CIP1) does not exclusively inhibit cell cycle kinases, Furthermore, these data add new insight into the autoregulatory loop which include p21(WAF1/CIP1), MDM2 protein, CK2 and p53.	ODENSE UNIV,BIOKEMISK INST,DK-5230 ODENSE,DENMARK; UNIV SAARLAND,FR MED BIOCHEM,D-66424 HOMBURG,GERMANY	University of Southern Denmark; Saarland University			Montenarh, Mathias/AAB-6689-2020	Guerra, Barbara/0000-0003-1136-2413				ADDISON C, 1990, ONCOGENE, V5, P423; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BOLDYREFF B, 1995, 20 EUR S HORM CELL R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Filhol O, 1996, BIOCHEM J, V316, P331, DOI 10.1042/bj3160331; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gotz C, 1996, ONCOGENE, V13, P391; GOTZ C, 1995, REV PHYSL BIOCH PHAR, V127, P65; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HERRMANN CPE, 1991, ONCOGENE, V6, P877; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; ISSINGER OG, 1992, RECENT ADV CELLULAR, V4, P17; KRAISS S, 1990, ONCOGENE, V5, P845; LEACH FS, 1993, CANCER RES, V53, P2231; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MEED DW, 1990, J VIROL, V64, P1734; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Tuazon PT, 1990, ADV 2 MESSENGER PHOS, V23, P123; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WAGNER P, 1994, INT J ONCOL, V4, P491; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	59	60	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2683	2688		10.1038/sj.onc.1201112	http://dx.doi.org/10.1038/sj.onc.1201112			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178766				2022-12-17	WOS:A1997XB97800007
J	Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D				Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D			Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade	ONCOGENE			English	Article						urokinase receptor; extracellular signal regulated kinase; mitogen activated protein kinase; invasion	FIBROBLAST GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; MAP KINASE-KINASE; PROTEIN-KINASE; C-JUN; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; MATRIX INVASION; STROMAL CELLS; MUSCLE CELLS	The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix degradation in part by accelerating plasmin formation at the cell surface. We previously reported that u-PAR expression is elevated in colon cancer cell lines characterized by their in vitro invasive capacity. Since, u-PAR expression is increased by a variety of growth factors, which signal through the extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2), we determined if these mitogen-activated protein kinases (MAPKs) regulate u-PAR expression in two cultured colon cancer cell lines, An in-gel kinase assay showed that ERK1 activity was considerably higher in RKO cells, which display greater than or equal to 10(4) receptors/cell, than the GEO cells which have similar or equal to 10(4) urokinase receptors per cell. The expression of either an ERK-inactivating phosphatase (CL100), or a kinase-defective ERK1, decreased the activity of a u-PAR promoter-driven CAT reporter in RKO cells. Immune complex kinase assays indicated that the constitutive ERK1 activity in RKO cells was largely a result of an activated MEK1. Further, treatment of RKO cells with a specific inhibitor (PD 098059) of MEK1 activation, which diminished ERK1 activity, reduced the amount of urokinase specifically bound to the cell surface and this was associated with reduced laminin degradation. The expression of a dominant negative c-Raf-l also reduced u-PAR promoter activity suggesting that MEK1 activation involved an activator at, or upstream, of this serine-threonine kinase, Transfection of the u-PAR-deficient GEO cells with a constitutively activated MEK1 expression construct upregulated u-PAR promoter activity. Similarly treatment of GEO cells,vith a phosphatase inhibitor (sodium vanadate) caused a dose-dependent increase in ERK1 activity which paralleled increased cell surface binding of urokinase. Taken together, these data suggest that elevated u-PAR expression, in at least a sub-population of colon cancer, is partly a consequence of a constitutively activated ERK-1-dependent signaling cascade.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL HEAD & NECK SURG,HOUSTON,TX; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV MOL MED,MUCOSAL INFLAMMAT & CANC GRP,CANBERRA,ACT 2601,AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; Australian National University; John Curtin School of Medical Research			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOS JL, 1989, CANCER RES, V49, P4682; BOYD D, 1988, CANCER RES, V48, P3112; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CASEY JR, 1994, BLOOD, V84, P1151; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HOLLAS W, 1991, CANCER RES, V51, P3690; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JONES LG, 1994, J BIOL CHEM, V269, P23790; KARIKO K, 1993, CANCER RES, V53, P3109; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Muda M, 1996, J BIOL CHEM, V271, P4319; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; OHagan RC, 1996, ONCOGENE, V13, P1323; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; RAO VN, 1993, CANCER RES, V53, P3449; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, INT J CANCER, V57, P553, DOI 10.1002/ijc.2910570419; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHIRAKABE K, 1992, J BIOL CHEM, V207, P16685; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; STACEY DW, 1991, ONCOGENE, V6, P2297; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSAI PS, 1995, ENDOCRINOLOGY, V136, P3831, DOI 10.1210/en.136.9.3831; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI J, 1982, J CELL BIOL, V100, P86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	86	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2563	2573		10.1038/sj.onc.1201098	http://dx.doi.org/10.1038/sj.onc.1201098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191056				2022-12-17	WOS:A1997XA94900008
J	Voitenleitner, C; Fanning, E; Nasheuer, HP				Voitenleitner, C; Fanning, E; Nasheuer, HP			Phosphorylation of DNA polymerase alpha-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro	ONCOGENE			English	Article						DNA replication; cyclins; cyclin-dependent kinases; DNA polymerase alpha primase	P34CDC2 PROTEIN-KINASE; SV40 ORIGIN DNA; CELL-CYCLE; IN-VITRO; INVITRO; ANTIGEN; SUBUNIT	DNA polymerase alpha-primase is the only known eukaryotic enzyme that can start DNA replication de novo. In this study, we investigated the regulation of DNA replication by phosphorylation of DNA polymerase alpha-primase. The p180 and the p68 submits of DNA polymerase alpha-primase were phosphorylated using Cyclin A-, B- and E- dependent kinases. This phosphorylation did not influence its DNA polymerase activity on activated DNA, but slightly stimulated primase activity using poly(dT) single-stranded DNA (ssDNA) without changing the product length of primers. In contrast, site-specific initiation of replication on plasmid DNA containing the SV40 origin is affected: Cyclin A-Cdk2 and Cyclin A-Cdc2 inhibited initiation of SV40 DNA replication in vitro, Cyclin B-Cdc2 had no effect and Cyclin E-Cdk2 stimulated the initation reaction. DNA polymerase alpha-primase that was pre-phosphorylated by Cyclin A-Cdk2 was completely unable to initiate the SV40 DNA replication in vitro; Cyclin B-Cdc2-phosphorylated enzyme was moderately inhibited, while Cyclin E-Cdk2-treated DNA polymerase alpha-primase remained fully active in the initiation reaction.	UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY; VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; INST MOL BIOTECHNOL, BIOCHEM ABT, D-07745 JENA, GERMANY	University of Munich; Vanderbilt University			Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079				BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; FOIANI M, 1995, MOL CELL BIOL, V15, P883; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PODUST V, 1990, EUR J BIOCHEM, V193, P189, DOI 10.1111/j.1432-1033.1990.tb19322.x; PRUSSAK CE, 1989, BIOCHEM BIOPH RES CO, V159, P1397, DOI 10.1016/0006-291X(89)92265-1; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	30	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1611	1615		10.1038/sj.onc.1200975	http://dx.doi.org/10.1038/sj.onc.1200975			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129153				2022-12-17	WOS:A1997WQ54800013
J	Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H				Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H			Characterization of the kinase activity essential for tyrosine phosphorylation of p130(Cas) in fibroblasts	ONCOGENE			English	Article						p130(Cas); tyrosine phosphorylation; Src homology 2; signal transduction	PHOSPHOTYROSINE-CONTAINING PROTEINS; SRC HOMOLOGY REGION-2; CRK ONCOGENE PRODUCT; V-CRK; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; GROWTH-FACTOR; SH3 DOMAIN; CELLS	The cellular transformation by v-Src or v-Crk induces tyrosine phosphorylation of a common substrate molecule, p130(Cas) (Cas), which tightly binds these oncoproteins in vivo. From its structure, Cas is deduced to be an ideal substrate for Src family kinases and Abl kinase. The tyrosine kinase activity associated with Cas was analysed using mouse variant fibroblasts lacking at least one of tyrosine kinases. In normal fibroblasts, Cas is associated with a significant level of tyrosine kinase activity which efficiently phosphorylates Cas in vitro. The Cas-associated tyrosine kinase activity was remarkably elevated in Csk(-/-) cells, which resulted in hyperphosphorylation of cellular Cas. The associated kinase activity was slightly increased in Src(-/-) cells whereas not significantly changed in Abl(-/-) nor Fak(-/-) cells. On the contrary, the Cas-associated kinase activity was remarkably decreased in Fyn(-/-) cells. At the same time, association of Cas with Fyn kinase in vitro was most obviously detected in normal fibroblasts as well as Csk(-/-) cells. Transient expression of v-Crk induced elevation of the Cas-associated kinase activity in all of these cell lines except the primary culture of Fyn(-/-) fibroblasts. These results indicate that Fyn kinase plays an essential role in v-Crk-mediated phosphorylation of Cas.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOL BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KUMAMOTO UNIV, SCH MED, INST MOL EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	University of Tokyo; Jichi Medical University; Kumamoto University				Sakai, Ryuichi/0000-0001-6833-1103				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; DECUE JE, 1987, P NATL ACAD SCI USA, V84, P9064; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; ILLC D, 1995, NATURE, V377, P539; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NADA S, 1994, ONCOGENE, V9, P3571; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; ZAITSU H, 1988, BIOMED RES-TOKYO, V9, P181; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1419	1426		10.1038/sj.onc.1200954	http://dx.doi.org/10.1038/sj.onc.1200954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136985				2022-12-17	WOS:A1997WT58400004
J	Bies, J; Wolff, L				Bies, J; Wolff, L			Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway	ONCOGENE			English	Article						c-Myb; proteolytic stability; 26S proteasome; ubiquitin; PEST sequence	NEGATIVE REGULATORY DOMAIN; LEUKEMIA-CELL-LINE; V-MYB; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; PROTEIN-DEGRADATION; TRANS-ACTIVATION; MESSENGER-RNA; GENE; EXPRESSION	c-myb activation by insertional mutagenesis in murine myeloid leukemias can lead to amino (NH2)-terminal or carboxyl (COOH)-terminal truncation of its protein product, We observed that in these leukemias, the steady state level of the protein truncated at the COOH terminus was remarkably higher than that of the protein truncated at the NH2-terminus or full length wild-type protein, To examine the rate of proteolysis of different forms of Myb in a uniform cellular background, the proteins were constitutively expressed in the myeloblast cell line M1, using the retrovirus vector LXSN. In pulse chase experiments, using metabolically S-35-labeled proteins, it was determined that COOH-terminal truncation of c-Myb by 248 aa (CT-c-Myb) substantially increases protein stability, resulting in a t(1/2) of about 140 min, as compared to 50 min for full length c-Myb (FL-c-Myb). In an investigation of the mechanism involved in the in vivo degradation of this short lived transcription factor, inhibitors of the lysosomal (chloroquine), proteasomal (ALLM, ALLN, iactacystin) and calpains (EGTA, E-64d, BAPTA/AM) pathways were utilized, Results of this experiment identified the 26S proteasome as a major pathway responsible for rapid breakdown of the protein in hematopoietic cells, Further experiments carried out in vitro demonstrated that c-Myb cap be ubiquitinated, suggesting that this process may be involved in the targeting of wild-type c-Myb to degradation by the 26S proteasome. In addition, it was demonstrated that CT-c-Myb was less efficiently ubiquitinated than wild-type protein indicating that defects in modification account for its escape from rapid turnover, We speculate that the increased half-life of c-Myb resulting from truncation could contribute to its transforming potential.	NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; FERRAO P, 1995, ONCOGENE, V11, P1631; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PERRYMAN S, 1991, NUCLEIC ACIDS RES, V19, P6950; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	48	60	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					203	212		10.1038/sj.onc.1200828	http://dx.doi.org/10.1038/sj.onc.1200828			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010222				2022-12-17	WOS:A1997WC81800008
J	Lawe, DC; Hahn, C; Wong, AJ				Lawe, DC; Hahn, C; Wong, AJ			The Nck SH2/SH3 adaptor protein is present in the nucleus and associates with the nuclear protein SAM68	ONCOGENE			English	Article						Nck; SAM68; SH3 domains; signal transduction; tyrosine kinases	TYROSINE KINASE; SIGNAL-TRANSDUCTION; SH3 DOMAINS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-1; BINDING-PROTEIN; SRC; RECEPTOR	SH2/SH3 adaptor proteins are essential components of the signal transduction pathways initiated by tyrosine kinases. Nck is a ubiquitously expressed adaptor protein whose function has been enigmatic. We performed confocal microscopy to localize Nck in NIH3T3 and A431 cells. Surprisingly, Nck was identified in the nucleus as well as the cytoplasm with no visible change in localization due to PDGF or EGF stimulation. Western blot analysis of nuclear and cytosolic fractions confirmed that there was no translocation in response to growth factor and that tyrosine phosphorylation was specific to only cytosolic Nck. Far Western blot analysis with either Nck, the SH2 domain, or the SH3 domains revealed differential binding in nuclear and cytosolic lysates, indicating specific binding partners for each subcellular location. The major target of c-Src during mitosis is SAM68, a RNA-binding protein ordinarily localized to the nucleus. SAM68 was identified as a nuclear specific binding partner of Nck in both nonmitotic and mitotic cells. Several tyrosine kinases can be found in the nucleus but their signal transduction remains undefined. The discovery of an adaptor protein in the nucleus suggests there are signal transduction mechanisms within the nucleus that recapitulate those found in the cytoplasm.	KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; KIMMEL CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA053149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53149, T32-CA09678] Funding Source: Medline; NINDS NIH HHS [NS-31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FELLER SM, 1995, ONCOGENE, V10, P1465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU G, 1995, MOL CELL BIOL, V15, P1169; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NERI LM, 1994, CELL MOL BIOL, V40, P619; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAINE PL, 1983, J CELL BIOL, V97, P1240, DOI 10.1083/jcb.97.4.1240; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Romero F, 1996, MOL CELL BIOL, V16, P37; RON D, 1992, BIOTECHNIQUES, V13, P866; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	54	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					223	231		10.1038/sj.onc.1200821	http://dx.doi.org/10.1038/sj.onc.1200821			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010224	Bronze			2022-12-17	WOS:A1997WC81800010
J	vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB				vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB			Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: Dissection of the neurotrophic response from the anti-mitogenic response	ONCOGENE			English	Article						NGF; PC12; cyclin D1; p21(Cip1)/WAFI; cell cycle; differentiation	AFFINITY NGF RECEPTOR; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; KINASE; LINE; PHOSPHORYLATION; ENCODES; CDC2; RAS	PC12 cells treated with nerve growth factor (NGF) undergo a G1 block and differentiate. Expression of selected cell cycle regulatory proteins was studied under culture conditions which permit observation of differentiation response independently from a mitogenic or anti-mitogenic response. The expression of all cell cycle regulatory proteins studied is modulated by NGF addition to exponentially-growing cultures in the presence of serum. While levels of most of these proteins decrease, accumulation of cyclin D1 and the cyclin-dependent kinase inhibitor p21(Cip1/WAF1) is observed. Cyclin D1-associated kinase activity is inhibited, correlating with an increase in p21 protein. PC12 cells, synchronized by serum starvation, undergo morphological and functional differentiation in the presence of NGF. Neither cyclin D1 nor p21 are present in such cultures, nor is their expression upregulated by NGF, indicating that they are not required for this process. Removal of serum from differentiated PC12 cells results in loss of these proteins, but has no effect on differentiation or the nonproliferative state in presence of NGF, Together, the results indicate that cyclin D1 and p21 are not necessary for differentiation per se, nor are they required for maintenance of the differentiated state in the absence of serum.	ECOLE NORMALE SUPER LYON,DIFFERENTIAT & CELL CYCLE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,CNRS,UMR 49,VIRAL ONCOGENESIS & CELLULAR DIFFERENTIAT GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			SAVATIER, Pierre/J-4663-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ALLEN JM, 1984, NEUROSCI LETT, V46, P291, DOI 10.1016/0304-3940(84)90114-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P4554; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2006; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU BY, 1989, J BIOL CHEM, V264, P9000; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN G, 1992, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	64	60	60	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649837				2022-12-17	WOS:A1996UC06700020
J	Chen, SL; Maroulakou, IG; Green, JE; RomanoSpica, V; Modi, W; Lautenberger, J; Bhat, NK				Chen, SL; Maroulakou, IG; Green, JE; RomanoSpica, V; Modi, W; Lautenberger, J; Bhat, NK			Isolation and characterization of a novel gene expressed in multiple cancers	ONCOGENE			English	Article						differential display; lung cancer; epithelial cells; leucine zipper; gene expression	CHAIN; CDNA; CELLS	Using differential display method, we have isolated and characterized a novel gene, N8, encoding a similar to 24 kDa protein. It is located on human chromosome 8q13 region. N8 gene is expressed at high levels in tumor derived cell lines from multiple cancers. It is also expressed at higher levels in lung tumors than normal lung tissue, NS is also differentially expressed in fetal and adult tissues. In adult, N8 is expressed at high levels in brain, kidney, prostate, pancreas and intestine and at very low levels in lung, liver, hematopoietic cells and gonads. During murine embryonic development N8 is expressed in the epithelium of the intestine, stomach, olfactory epithelium, neuronal layers of retina, kidney and salivary gland. Taken together, these results suggest that N8 may play different roles during embryogenesis and in the adult animals.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,FREDERICK,MD 21702; CATHOLIC UNIV,INST HYG,ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Spica, Vincenzo Romano/V-5718-2019					AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BARRETT JC, 1994, ENVIRON HEALTH PERSP, V102, P19, DOI 10.2307/3432053; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BUCHHAGEN DL, 1991, BIOCHIM BIOPHYS ACTA, V1072, P159; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; BYRNE JA, 1995, CANCER RES, V55, P2896; ELLER M, 1989, FEBS LETT, V256, P21, DOI 10.1016/0014-5793(89)81710-7; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; GAZDAR AF, 1994, ANTICANCER RES, V13, P261; JAYE M, 1987, AM J HUM GENET, V41, P605; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MOLLO F, 1995, INT J CANCER, V60, P289; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; 1988, HLTH EFFECTS RADON O, P24	27	60	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					741	751						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632896				2022-12-17	WOS:A1996TW68600005
J	RICHARDSON, PM; ZON, LI				RICHARDSON, PM; ZON, LI			MOLECULAR-CLONING OF A CDNA WITH A NOVEL DOMAIN PRESENT IN THE TRE-2 ONCOGENE AND THE YEAST-CELL CYCLE REGULATORS BUB2 AND CDC16	ONCOGENE			English	Article						HEMATOPORESIS; MAST CELLS; CELL CYCLE; CDNA; GERM CELLS	BINDING TRANSCRIPTION FACTORS; MAST-CELLS; CARBOXYPEPTIDASE-A; PROTEIN CDNA; GENE; IDENTIFICATION; SEQUENCES; CYTOKINESIS; ENCODES; MITOSIS	Tn an effort to identify genes that are differentially regulated during mast cell development, subtracted cDNA prepared from wild-type murine P815 mastocytoma cells and a P815 subline that exhibits properties of mast cell differentiation was used to screen mast cell cDNA libraries. Several known mast cell-specific cDNAs were isolated including mast cell carboxypeptidase A (MC-CPA), murine mast cell protease-5 (MMCP-5), and gp49. A novel cDNA, designated Tbc1, was identified that showed differential expression in the two mast cell lines. The amino acid sequence predicted from the cDNA contains a 200 amino acid domain that is homologous to regions in the tre-2 oncogene and the yeast regulators of mitosis, BUB2 and cdc16. The N-terminal region contains a number of cysteine and histidine residues, potentially encoding a zinc finger domain. Tbc1 is a nuclear protein and is expressed in highest levels in hematopoietic cells, testis and kidney. Within these tissues, expression of Tbc1 is cell- and stage-specific. Based on sequence similarity, pattern of expression and subcellular localization, Tbc1 may play a role in the cell cycle and differentiation of various tissues.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute					NHLBI NIH HHS [P10 HL32262, R01 HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, R01HL046668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARM JP, 1991, J BIOL CHEM, V266, P15966; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; CHANG F, 1993, TRENDS GENET, V9, P333, DOI 10.1016/0168-9525(93)90022-A; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GURISH MF, 1991, J IMMUNOL, V146, P1527; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUANG RY, 1991, EUR J IMMUNOL, V21, P39; HUEBNER K, 1988, ONCOGENE, V3, P449; ITO E, 1993, NATURE, V3623, P466; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1990, DNA CELL BIOL, V9, P697, DOI 10.1089/dna.1990.9.697; ONNO M, 1993, DNA CELL BIOL, V12, P107, DOI 10.1089/dna.1993.12.107; ONNO M, 1992, ONCOGENE, V7, P2519; ORKIN SH, 1992, BLOOD, V80, P575; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PEVNY L, DEVELOPMENT, V121, P163; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, J CELL BIOL, V110, P1033; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; STEPHENSON DA, 1994, MAMM GENOME, V5, P342, DOI 10.1007/BF00356552; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TRANSY C, 1987, J EXP MED, V166, P341, DOI 10.1084/jem.166.2.341; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1991, J BIOL CHEM, V266, P22948	33	60	66	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1139	1148						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566974				2022-12-17	WOS:A1995RX18000017
J	YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N				YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N			A HUMAN TEMPERATURE-SENSITIVE P53 MUTANT P53(VAL-138) - MODULATION OF THE CELL-CYCLE, VIABILITY AND EXPRESSION OF P53-RESPONSIVE GENES	ONCOGENE			English	Article						HUMAN TS P53 MUTANT; G1 ARREST; G2 ARREST; APOPTOSIS	WILD-TYPE P53; MAMMALIAN-CELLS; BINDING-SITE; IN-VIVO; PROTEIN; DNA; INHIBITION; APOPTOSIS; SEQUENCE; POTENT	A human p53 mutant, p53(Val-138) (amino acid 138, Alanine-->Valine), generated by in vitro mutagenesis was introduced into Saos-2 human osteosarcoma and Jurkat acute T-lymphoblastic leukemia cell lines, both lacking p53 protein expression. p53(Val-138) caused growth arrest in Saos-2 cell line and apoptosis in Jurkat cell line at 32.5 degrees C while it allowed both cell lines to grow continuously at 37.5 degrees C. p53(Val-138) activated expression of p53-responsive genes including MDM2, GADD45 and WAF1/CIP1/SDI1 in Saos-2 cell line upon the temperature shift-down from 37.5 degrees C to 32.5 degrees C. Thus, p53(Val-138) acted as a temperature-sensitive p53 mutant. Taking advantage of these human cell systems, we demonstrated that p53-mediated cell cycle arrest occurred in G1 and G2/M phases of Saos-2 cell line but not in Jurkat cell line. The induced level of WAF1/CIP1/SDI1 mRNA by p53 was extremely lower in Jurkat cell line than that of Saos-2 cell line. However, MDM2 mRNA accumulated to the similar levels in these two cell lines. These results suggest that a factor(s) other than p53 may be involved in differential expression of WAF1/CIP1/SDI1 and MDM2 mRNA	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT PERIODONTOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P2939; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIRANO Y, ONCOGENE, V10, P1879; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWON HJ, 1992, CANCER RES, V52, P6926; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	57	60	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					1	6						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624116				2022-12-17	WOS:A1995RJ29500001
J	POLUHA, W; POLUHA, DK; ROSS, AH				POLUHA, W; POLUHA, DK; ROSS, AH			TRKA NEUROGENIC RECEPTOR REGULATES DIFFERENTIATION OF NEUROBLASTOMA-CELLS	ONCOGENE			English	Note						APHIDICOLIN; TERMINAL DIFFERENTIATION; TYROSINE KINASE; NERVE GROWTH FACTOR; NGF RECEPTOR; C-MYC	NERVE GROWTH-FACTOR; DEVELOPING SENSORY NEURONS; PROTOONCOGENE; EXPRESSION; BLASTOMA; LINES; PROTEIN; ENCODES; TUMORS	We examined events associated with neuronal differentiation of neuroblastoma cell line SH-SY5Y, Treatment with nerve growth factor (NGF) and aphidicolin, an inhibitor of DNA polymerases alpha and delta, induces terminal differentiation of SH-SY5Y cells, Following 3-4 days of treatment with NGF+aphidicolin, the cells irreversibly ceased proliferation and differentiated. There was a succession of events preceding differentiation, Downregulation of c-myc was an early event occurring after less than 1 day of treatment with NGF+aphidicolin. Upregulation of the trkA and low-affinity NGF receptors (LNGFR) occurred after 3 days of NGF+aphidicolin treatment and required treatment with both NGF and aphidicolin, To test the role of TrkA in neuroblastic differentiation, we transfected SH-SY5Y cells with a TrkA-expression plasmid, In response to NGF in the absence of aphidicolin, the TrkA-transformant line ceased proliferation and irreversibly differentiated. SH-SY5Y cells bearing a control plasmid displayed only modest, reversible differentiation and did not cease cell proliferation in response to NGF, Hence, expression of NGF receptors is upregulated during differentiation of SH-SY5Y cells, and overexpression of TrkA enhances NGF-induced differentiation.	WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research					NICHD NIH HHS [HD-07312] Funding Source: Medline; NINDS NIH HHS [NS-21716, NS-28760] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716, R01NS028760] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; DONOVAN MJ, 1993, AM J PATHOL, V143, P1560; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JENSEN LM, 1987, DEV BIOL, V120, P56, DOI 10.1016/0012-1606(87)90103-5; JENSEN LM, 1992, J BIOL CHEM, V267, P19325; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KOGNER P, 1993, CANCER RES, V53, P2044; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; ROSS AH, 1985, ARCH BIOCHEM BIOPHYS, V242, P540, DOI 10.1016/0003-9861(85)90241-3; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; WYATT S, 1993, DEVELOPMENT, V119, P635; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	26	60	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					185	189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824271				2022-12-17	WOS:A1995QA98000021
J	FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW				FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW			THE REGULATION OF ENDOTHELIAL-CELL MOTILITY BY P21 RAS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; METASTATIC PHENOTYPE; NIH/3T3 CELLS; ONCOGENE; PROTEIN; MICROINJECTION; PROLIFERATION; TRANSFORMATION; NIH-3T3-CELLS	Directed endothelial cell (EC) movement is required for the development and repair of blood vessels and plays a critical role in angiogenic processes obligatory for large tumor formation. We now report that vas proteins have a critical role in regulation of movement of normal mammalian cells. Bovine aortic EC microinjected with oncogenic Ha-ras enter further into an artificial wound than uninjected cells. Treatment with oncogenic Ha-ras also converts the cell paths from nearly linear in control cells to apparent 'random-walk' trajectories in treated cells, suggesting that oncogenic vas alters the normal control processes regulating cell motility. Botulinum toxin C blocks uas-stimulated motility indicating that a member of the p21 rho family is a downstream participant in the motile pathway. In related experiments we have observed that microinjection of the neutralizing, Pas-specific, Y13-259 monoclonal antibody completely blocks both basal and basic fibroblast growth factor-stimulated movement of aortic EC. Y13-259 blocks the initiation of EC movement, as well as the continued progress of cells already in motion, suggesting that uas activity is continuously required throughout the motile process. Together these data indicate that ras is an integral component of the signaling pathway regulating cell movement.	CLEVELAND CLIN,RES INST,DEPT BIOL MOLEC,CLEVELAND,OH 44195	Cleveland Clinic Foundation	FOX, PL (corresponding author), CLEVELAND CLIN,RES INST,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NCI NIH HHS [CA53496] Funding Source: Medline; NHLBI NIH HHS [HL41178, HL40352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040352, R01HL041178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; CHAMBERS AF, 1988, ANTICANCER RES, V8, P861; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KLEINSOYER C, 1992, BIOL CELL, V75, P155, DOI 10.1016/0248-4900(92)90136-O; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOHLER JL, 1993, CANCER METAST REV, V12, P53, DOI 10.1007/BF00689790; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURUGESAN G, 1994, CIRC RES, V74, P1149, DOI 10.1161/01.RES.74.6.1149; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; MYRDAL SE, 1985, EXP CELL RES, V159, P441, DOI 10.1016/S0014-4827(85)80017-3; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NICHOLSON GL, 1992, ONCOGENE, V7, P1127; OCHIENG J, 1991, INVAS METAST, V11, P38; PARTIN AW, 1988, CANCER RES, V48, P6050; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; REIF F, 1965, FUNDAMENTALS STATIST; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN EM, 1990, CANCER INVEST, V8, P647, DOI 10.3109/07357909009018936; SA G, 1994, J BIOL CHEM, V269, P3219; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VARANI J, 1986, INVAS METAST, V6, P335	42	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3519	3526						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970712				2022-12-17	WOS:A1994PT39200014
J	RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ				RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ			TRANSFORMATION BY RAF AND OTHER ONCOGENES RENDERS CELLS DIFFERENTIALLY SENSITIVE TO GROWTH-INHIBITION BY A DOMINANT-NEGATIVE C-JUN MUTANT	ONCOGENE			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; V-RAF; SIGNAL TRANSDUCTION; EMBRYO CELLS; MYC PROTEIN; TRANSCRIPTION; EXPRESSION; ACTIVATION; PHOSPHORYLATION	In NIH3T3 cells expressing active Raf-1 protein serine/threonine kinase (PSK) c-jun expression is constitutive while c-fos expression is attenuated. This alteration prompted us to determine whether oncogene transformation would render cells differentially sensitive to growth inhibition by a dominant negative mutant of c-jun, TAM 67. Growth inhibition was observed in three types of assays: (1) transfection of TAM 67 into cells stably transformed by a variety of oncogenes, (2) cotransfection of TAM 67 with oncogene expression plasmids into NIH3T3 cells and (3) titration of oncogene-expressing retroviruses on cells stably expressing TAM 67. The results clearly demonstrate that Raf-1 dependent oncogenes, which include receptor protein tyrosine kinases (PTKs)-, intracellular PTKs- and Ras-derived genes share the Raf phenotype of constitutive c-jun expression, attenuated c-fos induction, and high sensitivity to growth suppression by TAM 67. Additionally, the intracellular PSK oncogene, mos and the nuclear oncogenes c-myc, c-fos, and SV40 T antigen were TAM 67-sensitive for transformation This universal pattern of altered growth regulation in oncogene transformed fibroblast cell lines highlights the potential usefulness of c-jun based inhibitors for control of tumor cell growth.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; UNIV WURZBURG, INST STRAHLEN & ZELLFORSCH, WURZBURG, GERMANY; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Troppmair, Jakob/0000-0002-0611-3837				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRUGEL S, UNPUB; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MIYASHITA T, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1993, MOL BASIS HUMAN CANC, P173; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rapp U R, 1987, Haematol Blood Transfus, V31, P450; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, IN PRESS CELLULAR VI; RAPP UR, 1988, LUNG CANCER, V4, P162; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG HG, 1994, ONCOGENE, V9, P2751; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	52	60	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3493	3498						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970709				2022-12-17	WOS:A1994PT39200011
J	SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P				SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P			ACTIVATION OF THE E2F TRANSCRIPTION FACTOR BY CYCLIN D1 IS BLOCKED BY P16(INK4), THE PRODUCT OF THE PUTATIVE TUMOR-SUPPRESSOR GENE MTS1	ONCOGENE			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; FIBROBLASTS; G(1); SITE; IDENTIFICATION; OVEREXPRESSION; PROGRESSION; INHIBITION	The oncoprotein cyclin D1 binds to and activates cyclin-dependent kinase 4 (cdk4), whose activity is inhibited by p16(INK4), the product of the putative tumor suppressor gene MTS1. Cyclin D1 controls the timing of S phase onset in mammalian cells. We show that cyclin D1 acts as a positive regulator of the transcription factor E2F. In particular, cyclin D1 overexpression leads to the activation of the dihydrofolate reductase (DHFR) gene promoter. Activation depends on the E2F binding site in the DHFR promoter, known to mediate its activation at the G1/S transition in vivo. Cyclin D1 can also activate the adenovirus E2 promoter via E2F. Both promoters are repressed by p16(INK4) and this repression can be released by overexpression of cdk4. The data reported here support a direct role for cyclin D1 and its associated kinase in cell cycle regulation of E2F activity and S phase-specific gene expression. In addition, we show that both E2F sites bind complexes containing the retinoblastoma protein (pRB) and that in RB-deficient cell lines overexpression of cyclin D1 fails to activate E2F-dependent transcription, indicating that pRB may be involved in promoter activation.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCHUNGSSCHWERPUNKT ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Jansen-Dürr, Pidder/ABG-2466-2020; Schulze, Almut/AAX-8257-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Schulze, Almut/0000-0002-8199-6422				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BOEUF H, 1990, ONCOGENE, V5, P691; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARPER JW, 1993, CELL, V75, P805; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LOVEC H, 1994, ONCOGENE, V9, P323; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3475	3482						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970707				2022-12-17	WOS:A1994PT39200009
J	CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR				CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR			EXPRESSION OF LINEAGE RESTRICTED TRANSCRIPTION FACTORS PRECEDES LINEAGE-SPECIFIC DIFFERENTIATION IN A MULTIPOTENT HEMATOPOIETIC PROGENITOR-CELL LINE	ONCOGENE			English	Note							LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL LOCALIZATION; ERYTHROLEUKEMIA CELLS; STEM-CELLS; SCL GENE; GATA-1; ONCOGENE; CLONING; GROWTH	Lineage commitment and differentiation are likely to be coordinated by the combined effects of multiple transcription factors acting on numerous different target genes. The mechanisms by which lineage-restricted patterns of transcription factor expression are established are therefore of particular relevance to our understanding of the role of transcription factors both in normal development and in oncogenesis. Here, we report that the genes for the lineage-restricted transcription factors SCL, GATA-1 and GATA-2 are expressed in all multipotent, IL-3-dependent, haemopoietic progenitor cell lines tested. Moreover, a liquid differentiation assay has been used to demonstrate down regulation of SCL, GATA-1, GATA-2 and PU-1 during differentiation into non-expressing lineages. These data support the concept that multiple lineage-restricted transcription factors are expressed prior to lineage commitment.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge	CROSS, MA (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND.			Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218; Cross, Michael/0000-0002-8815-7621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HARRISON PR, 1978, EXP CELL RES, V115, P395, DOI 10.1016/0014-4827(78)90293-8; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEONARD M, 1993, BLOOD, V82, P1071; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3013	3016						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084606				2022-12-17	WOS:A1994PG82200029
J	KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ				KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ			PARTIAL INACTIVATION OF THE RB PRODUCT IN A FAMILY WITH INCOMPLETE PENETRANCE OF FAMILIAL RETINOBLASTOMA AND BENIGN RETINAL TUMORS	ONCOGENE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; MOLECULAR-CLONING; BINDING PROTEIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSCRIPTION	While familial retinoblastoma has served as the paradigm for the two-hit theory of tumorigenesis and for the concept of the tumor suppressor gene, the etiology of incomplete penetrance of familial retinoblastoma is poorly understood. To address the molecular basis for this phenotype we have studied the functional properties of a mutant Rb gene identified in a kindred with incomplete penetrance of familial retinoblastoma and evidence for regressed retinal lesions (retinomas). In contrast to all previously isolated RB mutant proteins, we demonstrated that the mutant product from this kindred retained the wildtype properties of nuclear localization, the ability to undergo hyperphosphorylation in vivo, and the capacity to suppress growth of RB((-)) cells. Protein binding ('pocket') activity, however, was defective defining a new class of RB mutant with partial inactivation. The presence of this unique RB mutant in the germline of obligate carriers with incomplete penetrance and regressed retinal lesions suggests a molecular basis for this phenotype and supports the hypothesis that a minimum 'RB threshold' level of protein binding activity is required to suppress tumorigenesis.	USN,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889; INST CHILD HLTH,IMPERIAL CANC RES FUND,LONDON WC1N 1EH,ENGLAND; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA; Cancer Research UK; University of London; University College London			kaye, frederic/E-2437-2011	Cowell, John/0000-0002-2079-5950				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHAR DH, 1974, AM J OPHTHALMOL, V78, P5, DOI 10.1016/0002-9394(74)90003-8; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YK, 1987, SCIENCE, V236, P218; Gallie B L, 1977, Prog Clin Biol Res, V16, P229; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; GALLIE BL, 1979, IMMUNOLOGY IMMUNOPAT; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HASHIMOTO T, 1991, ONCOGENE, V6, P463; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOGG A, 1992, ONCOGENE, V7, P1445; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAYOL X, 1993, ONCOGENE, V8, P2561; MEHRA KS, 1965, BRIT J OPHTHALMOL, V49, P381, DOI 10.1136/bjo.49.7.381; MUNCASTER MM, 1992, CANCER RES, V52, P654; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEWARD JK, 1956, BRIT J OPHTHALMOL, V40, P449; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WUSTENBERG W, 1950, Klin Monbl Augenheilkd Augenarztl Fortbild, V117, P423; YOKOTA J, 1988, ONCOGENE, V3, P471	60	60	62	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1321	1326						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152792				2022-12-17	WOS:A1994NH40100002
J	CHAPMAN, RM; CORCORAN, MM; GARDINER, A; HAWTHORN, LA; COWELL, JK; OSCIER, DG				CHAPMAN, RM; CORCORAN, MM; GARDINER, A; HAWTHORN, LA; COWELL, JK; OSCIER, DG			FREQUENT HOMOZYGOUS DELETIONS OF THE D13S25 LOCUS IN CHROMOSOME REGION 13Q14 DEFINES THE LOCATION OF A GENE CRITICAL IN LEUKEMOGENESIS IN CHRONIC B-CELL LYMPHOCYTIC-LEUKEMIA	ONCOGENE			English	Note							RETINOBLASTOMA GENE; LEUKEMIA; PROBES	Cytogenetic studies of B-cell chronic lymphocytic leukaemia show structural abnormalities involving the 13q14 chromosome region as the only karyotypic change in a significant proportion of tumours. This observation suggests the location of a gene important in leukaemogenesis. A series of 68 BCLL tumours have been analysed for allele loss using a series of probes from 13q14. Using intragenic polymorphic markers from the retinoblastoma predisposition gene LOH was observed in 25% of tumours including 3/6 showing cytogenetically obvious deletions of the 13q14 region and 3/6 showing translocations involving 13q14. However, three deletions with proximal breakpoints in 13q14 did not show allele loss, demonstrating that the breakpoint lay distal to RB1. Using the D13S25 locus, which lies 1.6 cM distal to RB1, allele loss was seen in 90% of tumours with structural rearrangements of 13q14 and 75% of tumours with an apparently normal karyotype. 50% of these tumours showed homozygous loss of D13S25, suggesting that a 'tumour suppressor gene' lies in this region. The more distal D13S31 locus, 1 cM distal to D13S25, was infrequently involved in allele loss demonstrating that the minimum region of overlap for homozygous deletions is aproximately 1 Mbp around the D13S25 locus.	ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,CASTLE LANE E,BOURNEMOUTH BH7 7DW,ENGLAND; INST CHILD HLTH,ICRF,ONCOL GRP,LONDON WC1N 1EH,ENGLAND	University of London; University College London				Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937				BOWCOCK AM, 1991, GENOMICS, V11, P517, DOI 10.1016/0888-7543(91)90058-M; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; EINHORN S, 1989, LEUKEMIA, V3, P871; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; KAY NE, 1993, BRIT J HAEMATOL, V84, P257, DOI 10.1111/j.1365-2141.1993.tb03061.x; LUI Y, 1992, GENE CHROMOSOME CANC, V4, P250; LUI Y, 1993, P NATL ACAD SCI USA, V90, P8697; MATUTES E, 1993, BRIT J HAEMATOL, V84, P13; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORRIS CM, 1991, GENE CHROMOSOME CANC, V3, P455, DOI 10.1002/gcc.2870030607; ONADIM Z, 1992, BRIT J CANCER, V65, P711, DOI 10.1038/bjc.1992.150; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; OSCIER D, 1990, BLOOD, V76, P241; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; STILGENBAUER S, 1993, BLOOD, V81, P2118; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305	20	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1289	1293						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134133				2022-12-17	WOS:A1994NC04800036
J	SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T				SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T			MOLECULAR-CLONING OF A NOVEL NONRECEPTOR TYROSINE KINASE, HYL (HEMATOPOIETIC CONSENSUS TYROSINE-LACKING KINASE)	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; MESSENGER-RNAS; FAMILY; GENE; SEQUENCE	We identified a novel non-receptor tyrosine kinase from a human megakaryoblastic cell line, UT-7, by means of a PCR-based cloning method. The HYL gene contained a SH2 and SH3 domain and a tyrosine kinase catalytic domain. The deduced amino acid sequence of the protein encoded by this gene was most homologous to CSK (c-src kinase). This gene and CSK shared some unique structural properties such as the absence of a myristylation signal and phosphorylation sites of tyrosine residues corresponding to tyrosines 416 and 527 of chicken p60c-src. Unlike CSK, the SH3 domain of HYL was unique since the ALYDY motif was absent. Northern blot analysis revealed a 2.2 kb transcript in various myeloid cell lines but not in adult tissues except for the brain and the lung, whereas CSK mRNA was ubiquitously expressed. The expression of HYL was upregulated when these myeloid cells were differentiated by induction with phorbol myristate acetate. We named this gene, hematopoietic consensus tyrosine-lacking kinase, HYL. The HYL gene was assigned to chromosome 19 at band p13. It is suggested that HYL plays a significant role in the signal transduction of hematopoietic cells.	KUMAMOTO UNIV, SCH MED,INST MOLEC EMBRYOL & GENET, DEPT DIFFERENTIAT,2-2-1 HONJO, KUMAMOTO 860, JAPAN; ASAHI CHEM IND CO LTD, FUNDAMENTAL RES LAB LIFE SCI, FUJI, SHIZUOKA 416, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG HEMATOL & ONCOL UNIT, KYOTO 602, JAPAN	Kumamoto University; Kyoto Prefectural University of Medicine			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KOMATSU N, 1991, CANCER RES, V51, P341; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Maniatis T., 1982, MOL CLONING; MATUDA M, 1992, MOL CELL BIOL, V12, P3482; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TABILIO A, 1983, CANCER RES, V43, P4569; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	44	60	67	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1155	1161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134117				2022-12-17	WOS:A1994NC04800018
J	LAI, C; LEMKE, G				LAI, C; LEMKE, G			STRUCTURE AND EXPRESSION OF THE TYRO-10 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; NEUROTROPHIC FACTOR; PROTEIN-KINASE; VISUAL CENTERS; FACTOR FAMILY; FACTOR-VIII; DOMAINS; SEQUENCE; MOLECULE	We have isolated cDNA clones encoding Tyro 10, a novel receptor protein-tyrosine kinase (PTK) whose catalytic domain exhibits significant similarity to the Trk family of neurotrophin receptors (Lai and Lemke, 1991). We find that the Tyro 10 gene is widely expressed, both within and outside the nervous system, and in both developing and mature neural tissue. The primary structure of Tyro 10, deduced from cDNA sequence, defines a new sub-family of receptor PTKs. Although the Tyro 10 kinase domain is more closely related to the equivalent domains of Trk, TrkB and TrkC than to the catalytic domains of other receptor PTKs, it is less closely related to these Trk domains than they are to each other. More significantly, the Tyro 10 extracellular (ligand binding) domain is not structurally related to the extracellular domains of the Trk receptors, but instead bears homology to cell surface mediators of protein-protein interactions, including blood coagulation Factors V and VIII, and the neuronal recognition protein A5. These appear to be structural features of a distinct receptor PTK sub-family, in that they are also found in the recently-described discoidin domain receptor (DDR).	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Salk Institute; Scripps Research Institute								BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERKEMEIER LR, 1992, SOMAT CELL MOLEC GEN, V18, P233, DOI 10.1007/BF01233860; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1990, N HORIZ TH, P119; HUNTER T, 1993, IN PRESS FRONTIERS B; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RODRIGUEZTEBAR A, 1991, PHILOS T ROY SOC B, V331, P255, DOI 10.1098/rstb.1991.0013; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					877	883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108131				2022-12-17	WOS:A1994MW55100024
J	GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R				GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R			INSERTIONAL ACTIVATION OF MEVALONATE KINASE BY HEPATITIS-B VIRUS-DNA IN A HUMAN HEPATOMA-CELL LINE	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; INBORN ERROR; ACIDURIA; GENE; BIOSYNTHESIS; CHOLESTEROL; INTEGRATION; P21RAS	Insertional mutagenesis of growth related genes by hepatitis B virus (HBV) DNA is presumed to play a role in hepatocarcinogenesis. Here, we report on insertional activation of the mevalonate kinase (MK) gene in the human hepatoma cell line PLC/PRF/5, Integration of HBV DNA dissociated the promoter and upstream regulatory elements of the gene from its coding sequences. This led to the over-expression of hybrid transcripts arising from an HBV promoter and the consequent over-production of functionally active mevalonate kinase. MK phosphorylates mevalonate, a major intermediate in the branched cholesterol/isoprenoid biosynthetic pathway. Isoprenylation is crucial to the functions of cellular proteins related to growth control, including the proto-oncogene ras. As the enzymes of these biosynthetic pathways are regulated at multiple points by negative feedback, both transcriptionally and at the protein level, the results discussed here support the idea that aberrant growth could result from deregulated overexpression of MK and, perhaps, other enzymes in the cholesterol pathway. These results invoke novel mechanisms by which cell transformation might occur.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,W-8000 MUNICH,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND	Imperial College London; Max Planck Society; University of Munich; University of Cambridge								BARBU V, 1990, ONCOGENE, V5, P1077; BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATTANEO R, 1984, EMBO J, V3, P2191, DOI 10.1002/j.1460-2075.1984.tb02113.x; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOCH S, 1984, NUCLEIC ACIDS RES, V12, P6871, DOI 10.1093/nar/12.17.6871; KOSHY R, 1992, REV MED VIROL, V2, P131, DOI 10.1002/rmv.1980020303; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZHANG XK, 1992, BIOCHEM BIOPH RES CO, V188, P344, DOI 10.1016/0006-291X(92)92391-A	24	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302606				2022-12-17	WOS:A1994MW24700010
J	KURATA, WE; LAU, AF				KURATA, WE; LAU, AF			P130(GAG-FPS) DISRUPTS GAP JUNCTIONAL COMMUNICATION AND INDUCES PHOSPHORYLATION OF CONNEXIN43 IN A MANNER SIMILAR TO THAT OF PP60(V-SRC)	ONCOGENE			English	Note							FUJINAMI SARCOMA-VIRUS; TYROSINE PROTEIN-KINASES; TO-CELL COMMUNICATION; SRC GENE-PRODUCT; PHORBOL ESTER; MAP KINASE; V-SRC; GROWTH; INHIBITION; PHOSPHOTYROSINE	The pp60v-src tyrosine kinase disrupts gap junctional communication in transformed fibroblasts and induces the phosphorylation of the gap junction protein, connexin43, on tyrosine. We report here that the p130(gag-fps) tyrosine kinase also profoundly disrupted gap junctional communication and markedly increased the phosphorylation of connexin43 which appeared to result from an accumulation of phosphotyrosine and phosphoserine. The disruption of gap junctional communication by pp60(v-src) and p130(gag-fps) did not appear to result from the gross alteration of gap junction plaques. Furthermore, two-dimensional phosphotryptic peptide mapping showed that the v-Src and V-Fps kinases stimulated the phosphorylation of multiple connexin43 peptides which contained phosphotyrosine and/or phosphoserine. Phosphotyrosine was detected in two connexin43 phosphotryptic peptides from v-src-transformed cells which suggested that more than one connexin43 tyrosine site may be recognized by pp60(v-src) in fibroblasts. The apparent higher levels of phosphoserine-containing connexin43 peptides in the oncogene-transformed cells pointed to the possibility that pp60(v-src) and p130(gag-fps) may also modulate connexin43 function through mechanism(s) involving the activation of signaling serine kinases. Taken together, these results suggested that connexin43 is a common target of the v-Src and v-Fps tyrosine kinase oncoproteins.	UNIV HAWAII, CANC RES CTR, MOLEC CARCINOGENESIS PROGRAM, HONOLULU, HI 96813 USA	Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA-52098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KUFFLER SW, 1976, NEURON BRAIN CELLULA, P154; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PAGE E, 1986, HEART CARDIOVASCULAR, P573; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7	41	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					329	335						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302599				2022-12-17	WOS:A1994MW24700042
J	ZERLIN, M; JULIUS, MA; GOLDFARB, M				ZERLIN, M; JULIUS, MA; GOLDFARB, M			NEP - A NOVEL RECEPTOR-LIKE TYROSINE KINASE EXPRESSED IN PROLIFERATING NEUROEPITHELIA	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; OLIGODENDROCYTE DEVELOPMENT; PHOSPHOTYROSINE ANTIBODY; BINDING-SITE; FAMILY; DIFFERENTIATION; DOMAINS; CELLS	We have isolated a murine cDNA, nep, which encodes a novel receptor-like protein tyrosine kinase. The kinase region of NEP protein bears 50% amino acid sequence identity to the neurotrophin receptors (TRKs). While the intracytoplasmic portion of NEP also contains a short kinase insert region and C-terminal tail reminiscent of the TRK proteins, the putative extracellular domain of NEP is unrelated to any known proteins. The nep gene is strongly expressed within proliferating neuroepithelia of mouse embryos, commencing at the early somite stage (embryonic day 8.0) and persisting in the proliferative ventricular zones of the brain and spinal cord, suggesting that one function of NEP kinase is to signal proliferation of neuroepithelial cells in response to an as yet unknown ligand. The nep gene is also expressed in embryonic sensory ganglia, striated muscle and epidermis, as well as in several adult tissues, including the ventricle linings and glia subpopulations tn the brain.	CTR MOLEC MED & IMMUNOL,NEWARK,NJ 07103; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University								BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1991, DEVELOPMENT, V112, P397; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	39	60	63	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2731	2739						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397369				2022-12-17	WOS:A1993LX34300014
J	QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B				QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B			P54(C-ETS-1) AND P68(C-ETS-1), THE 2 TRANSCRIPTION FACTORS ENCODED BY THE C-ETS-1 LOCUS, ARE DIFFERENTIALLY EXPRESSED DURING THE DEVELOPMENT OF THE CHICK-EMBRYO	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; ETS GENE FAMILY; V-ETS; C-ETS; DNA-BINDING; ERYTHROID-CELLS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; MYB	The chicken c-ets-1 proto-oncogene encodes two transcription factors, p54c-ets-1 and p68c-ets-1, which contain the same DNA-binding domain but differ in their transactivating activities. We have investigated the spatial and temporal distribution of the transcripts encoding p54c-ets-1 and p68c-ets-1 throughout the development of the chick embryo. We report that p68c-ets-1 as well as p54c-ets-1 is expressed in a wide variety of cells of mesodermal origin, including endothelial cells and mesenchymal cells interacting with epithelium. However, whereas p54c-ets-1 transcripts are detected in most cells, p68c-ets-1 transcripts are restricted to a subset of these cells, randomly distributed. In contrast, p54c-ets-1 is expressed in the absence of p68c-ets-1 in T and B lymphocytes. We show that, during erythropoiesis, both p68c-ets-1 and p54c-ets-1 are expressed in immature erythroid cells in extraembryonic blood islands. The pattern of expression of p54c-ets-1 and p68c-ets-1 during embryonic development suggests the involvement of these transcription factors in the regulation of morphogenetic processes. In addition, we provide the first clue that p68c-ets-1, the cellular progenitor of the v-ets oncogene, is expressed in erythroid cells. This result is very important with respect to the properties of the v-ets oncogene, which confers on the retrovirus E26 the ability to transform erythroid cells.	INST PASTEUR,CNRS,URA1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOUSSELUT R, 1990, EMBO J, V9, P3315; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARDICK I, 1978, TISSUE CELL, V10, P355, DOI 10.1016/0040-8166(78)90029-0; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Dieterlen-Lievre F., 1988, P257; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DIETERLENLIEVRE F, 1984, DEV COMP IMMUNOL S, V3, P75; DOMENGET C, 1992, ONCOGENE, V7, P2231; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P81; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JORCYK CL, 1991, ONCOGENE, V6, P523; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MINIE ME, 1992, DEVELOPMENT, V115, P1149; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YASSINE F, 1989, CELL DIFFER DEV, V27, P29, DOI 10.1016/0922-3371(89)90042-7	48	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2511	2520						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361762				2022-12-17	WOS:A1993LT36800023
J	SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP				SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP			CHARACTERIZATION OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION DOMAINS OF THE ERG PROTEIN	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS ONCOGENE; C-ETS-1 PROTOONCOGENE; C-ETS; V-ETS; GENE; SEQUENCE; CHROMOSOME-21	erg, an ets related gene encodes a sequence specific DNA binding transcriptional activator protein. We have identified four functional domains of erg protein that are responsible for DNA binding, transcriptional activation and negative regulation of transcriptional activation. Deletion analysis revealed that the 3'-ets domain of the erg protein is sufficient for DNA binding activity. Analysis of these deletion mutants also revealed the presence of two autonomous transcriptional activation domains, one at the amino and the other at the carboxy-terminal region. This aminoterminal transcriptional activator domain (5'-ets domain) is conserved in six of the ets genes suggesting that it (ETA, ets Transcriptional Activation domain) may contribute to a common function among these genes. The transcriptional activation function of the carboxy terminal transcriptional activation domain (CTA) was inhibited by the presence of a Negative Regulatory Transcriptional activation domain (NRT), which is located at the amino terminal region of erg DNA binding domain. These results may help in understanding the structure/function relationship of other erg/ets related proteins.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University					NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57157, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAO VN, 1993, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1993, IN PRESS ERG ELK 1 E; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	48	60	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1751	1755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510921				2022-12-17	WOS:A1993LG68200005
J	ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP				ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP			STRUCTURAL DETERMINANTS OUTSIDE OF THE LEUCINE ZIPPER INFLUENCE THE INTERACTIONS OF CREB AND ATF-2 - INTERACTION OF CREB WITH ATF-2 BLOCKS E1A ATF-2 COMPLEX-FORMATION	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN; T7 RNA-POLYMERASE; DNA-BINDING; RESPONSE ELEMENT; ENHANCER BINDING; TRANSCRIPTION; EXPRESSION; DOMAINS; ZINC; ADENOSINE-3',5'-MONOPHOSPHATE	Dimerization of leucine zipper-containing proteins has been associated characteristically with the formation of a coiled-coil structure between two compatible leucine zipper motifs. In the present study we demonstrate the association of the leucine zipper of cAMP response element-binding protein (CREB) with a zinc finger motif of ATF-2. The association of the CREB leucine zipper with the ATF-2 zinc finger is stabilized if the ATF-2 leucine zipper is intact, implying that the preferred interactive structure of ATF-2 juxtaposes the amino-terminal zinc finger motif of this protein with the carboxy-terminal leucine zipper of this same protein. Furthermore, we demonstrate that the association of the CREB leucine zipper with the ATF-2 zinc finger in vitro blocks the association of the adenoviral E1a protein with ATF-2. Similarly, overexpression of full-length CREB, or a truncated version of this protein corresponding to the carboxy-terminal 74 amino acids that make up the DNA-binding and dimerization domains, can block the ATF-2-mediated transcriptional stimulation by E1a in vivo. Mutation of the ATF-2 zinc finger motif stimulates DNA binding of this protein, and abolishes interactions with E1a and CREB proteins. These results demonstrate that the structural conformation of ATF-2 is critical for DNA binding and protein-protein interactions and, further, that leucine zippers can mediate protein-protein interactions with structural motifs other than leucine zippers.	UNIV COLORADO,SCH MED,CTR CANC,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,SCH PHARM,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV ENDOCRINOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen C Y, 1991, Protein Expr Purif, V2, P402, DOI 10.1016/1046-5928(91)90101-N; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT KJ, 1991, ONCOGENE, V6, P2019; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZU YL, 1991, J BIOL CHEM, V266, P24134	33	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1161	1174						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479741				2022-12-17	WOS:A1993KY32800007
J	SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F				SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F			ABROGATION OF P53-MEDIATED TRANSACTIVATION BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-ANTIGEN; P53 PROTEIN; DNA-REPLICATION; WILD-TYPE; TRANSFORMATION; CELLS; PROMOTERS; SEQUENCE; PRODUCT	p53 is known to bind specifically to the 44-bp human DNA sequence in an immunoprecipitation assay. We show here that the transcription of the reporter CAT gene linked with the herpesvirus thymidine kinase (tk) promoter containing the 44-base sequence is enhanced by mouse wild-type but not mutant-type p53 in F9 and p53-null Saos-2 cells. The p53-mediated transactivation was dramatically abrogated by introduction of SV40 large T antigen (SVLT) in Saos-2 cells in which p53 was clearly associated with SVLT. Furthermore, the p53-SVLT complex did not bind to the 44-base sequence at all. Thus, SVLT sequesters the transactivation function of the wild-type p53 by inhibiting the binding of p53 to the 44-base sequence. This is good evidence to show 'loss of functions' in the product of a tumor-suppressor oncogene by a dominant oncogene product at a molecular level.	INST PHYS & CHEM RES RIKEN,PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN	SEGAWA, K (corresponding author), KEIO UNIV,SCH MED,DEPT MICROBIOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVITCH K, 1989, CELL, V58, P1099; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGAWA K, 1986, VIROLOGY, V155, P334, DOI 10.1016/0042-6822(86)90197-2; SEGAWA K, 1987, MOL CELL BIOL, V7, P556, DOI 10.1128/MCB.7.1.556; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUGANO S, 1984, J VIROL, V52, P884, DOI 10.1128/JVI.52.3.884-891.1984; SUGASAWA K, 1992, P NATL ACAD SCI USA, V89, P1055, DOI 10.1073/pnas.89.3.1055; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	38	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382354				2022-12-17	WOS:A1993KN00800003
J	CHIARIOTTI, L; BERLINGIERI, MT; DEROSA, P; BATTAGLIA, C; BERGER, N; BRUNI, CB; FUSCO, A				CHIARIOTTI, L; BERLINGIERI, MT; DEROSA, P; BATTAGLIA, C; BERGER, N; BRUNI, CB; FUSCO, A			INCREASED EXPRESSION OF THE NEGATIVE GROWTH-FACTOR, GALACTOSIDE-BINDING PROTEIN, GENE IN TRANSFORMED THYROID-CELLS AND IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; EPITHELIAL-CELLS; MESSENGER-RNA; LECTIN GENE; RAT; SEQUENCE; PLASMIDS; CLONING; BLOCK; CDNA	Murine beta-galactoside-binding protein has been shown to be a cell growth regulatory molecule and a cytostatic factor. We analysed the beta-galactoside-binding protein gene expression in a thyroid cell system including two normal cell lines (FRTL-5 and PC Cl 3) and the same cells transfected by several oncogenes that induce different degrees of malignancy and differentiation. We show that beta-galactoside-binding protein mRNA levels correlate with the expression of the malignant phenotype. Run-on experiments suggest that a transcriptional effect accounts at least in part for such a difference. We also show that the beta-galactoside-binding protein gene expression is increased in most human papillary thyroid carcinomas compared with normal thyroid.	NAPLES UNIV,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CALIFANO,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; HOP ANTIQUAILLE,ANAT PATHOL LAB,F-69321 LYON,FRANCE	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; CHU Lyon			Chiariotti, Lorenzo/AAC-5262-2022	Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BERLINGIERI MT, 1989, EXP CELL RES, V183, P277, DOI 10.1016/0014-4827(89)90388-1; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; CARDING SR, 1985, BIOCHEM BIOPH RES CO, V127, P680, DOI 10.1016/S0006-291X(85)80215-1; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1989, ONCOGENES TUMOUR ANT, P17; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GREENBERG ME, 1984, NATURE, V311, P432; LEHARACH H, 1977, BIOCHEMISTRY-US, V16, P4743; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; RAZ A, 1987, INT J CANCER, V39, P353, DOI 10.1002/ijc.2910390314; RAZ A, 1988, CANCER RES, V48, P645; RAZ A, 1987, EXP CELL RES, V173, P109, DOI 10.1016/0014-4827(87)90336-3; RAZ A, 1986, CANCER RES, V46, P3667; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	31	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2507	2511						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461653				2022-12-17	WOS:A1992KA85600016
J	ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN				ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN			MALIGNANT TRANSFORMATION OF HUMAN MELANOCYTES - INDUCTION OF A COMPLETE MELANOMA PHENOTYPE AND GENOTYPE	ONCOGENE			English	Note							MOUSE MONOCLONAL-ANTIBODY; MURINE SARCOMA-VIRUS; SURFACE-ANTIGENS; CELL-LINES; TUMOR PROGRESSION; CYTOGENETIC ANALYSIS; METASTATIC MELANOMA; GROWTH-FACTOR; HUMAN HOMOLOG; RAS ONCOGENE	Human melanoma provides a model to study malignant transformation and tumor progression. Expression of ras oncogenes in cultured normal human diploid melanocytes has induced a subset of phenotypic traits that are characteristic of malignant melanoma cells, including altered morphology, anchorage independence, induction of class II MHC antigens, up-regulation of the ganglioside G(D3), and chromosomal abnormalities. However, other characteristics of melanoma, such as loss of expression of adenosine deaminase-binding protein and tumorigenicity, were not observed. We report here that melanocytes infected with a retrovirus containing the viral Ha-ras oncogene underwent complete transformation, acquiring all phenotypic characteristics of malignant melanomas observed in vivo. Transformation occurred in a sequential manner and was associated with spontaneous chromosomal instability. Cytogenetic analysis of transformed melanocytes indicated that the earliest structural chromosomal abnormalities were isochromosomes 6p and 9q followed by complete loss of chromosome 1p, all common karyotypic abnormalities described in human melanomas. The findings suggest that these chromosome regions which are deleted or relatively deficient may contain genes that are critical for the initiation and progression of the melanoma phenotype.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	ALBINO, AP (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.		sozzi, gabriella/G-8259-2011	sozzi, gabriella/0000-0001-9360-6914	NATIONAL CANCER INSTITUTE [R01CA037907, P01CA033049] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33049, CA-37907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ALBINO AP, 1991, J EXP MED, V51, P4815; ALBINO AP, 1988, PIGMENT CELL RES S, V1, P169; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; COWAN JM, 1986, CANCER GENET CYTOGEN, V20, P255, DOI 10.1016/0165-4608(86)90081-6; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; CUYPERS HT, 1986, HUM GENET, V72, P262, DOI 10.1007/BF00291892; DONIGER J, 1983, SCIENCE, V222, P1144, DOI 10.1126/science.6648529; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ELDER DE, 1989, CANCER RES, V49, P5091; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; GRIFFIN CA, 1988, CANCER GENET CYTOGEN, V32, P129, DOI 10.1016/0165-4608(88)90319-6; HALABAN R, 1988, ONCOGENE RES, V3, P177; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS; HERLYN M, 1988, ANNU REV IMMUNOL, V6, P283; HOLZMANN B, 1985, J EXP MED, V161, P366, DOI 10.1084/jem.161.2.366; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1987, J EXP MED, V164, P812; HUME CR, 1987, P NATL ACAD SCI USA, V84, P8603, DOI 10.1073/pnas.84.23.8603; ICHIKAWA T, 1990, CANCER RES, V50, P6349; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; JHANWAR SC, 1992, HEREDITARY COLON CAN; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; NAKAMURA Y, 1988, AM J HUM GENET, V16, P9369; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OHYASHIKI JH, 1986, CANCER GENET CYTOGEN, V23, P77, DOI 10.1016/0165-4608(86)90151-2; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PFEFFER LM, 1977, CELL, V10, P313, DOI 10.1016/0092-8674(77)90225-2; PRATT CI, 1992, CANCER RES, V52, P688; PRESTI JC, 1991, CANCER RES, V51, P1544; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REAL FX, 1985, CANCER RES, V45, P4401; REICHMANN A, 1984, CANCER GENET CYTOGEN, V13, P275, DOI 10.1016/0165-4608(84)90049-9; REY JA, 1985, CANCER GENET CYTOGEN, V16, P179, DOI 10.1016/0165-4608(85)90013-5; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RODRIGUEZ E, 1990, CANCER RES, V50, P6410; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; THOMSON TM, 1985, J INVEST DERMATOL, V85, P169, DOI 10.1111/1523-1747.ep12276608; TRAYLOR TD, 1980, J NEUROCHEM, V34, P126, DOI 10.1111/j.1471-4159.1980.tb04630.x; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	72	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437153				2022-12-17	WOS:A1992JW66500025
J	LITTLE, MH; DUNN, R; BYRNE, JA; SEAWRIGHT, A; SMITH, PJ; PRITCHARDJONES, K; VANHEYNINGEN, V; HASTIE, ND				LITTLE, MH; DUNN, R; BYRNE, JA; SEAWRIGHT, A; SMITH, PJ; PRITCHARDJONES, K; VANHEYNINGEN, V; HASTIE, ND			EQUIVALENT EXPRESSION OF PATERNALLY AND MATERNALLY INHERITED WT1 ALLELES IN NORMAL FETAL TISSUE AND WILMS-TUMORS	ONCOGENE			English	Article							GROWTH FACTOR-II; WIEDEMANN-BECKWITH SYNDROME; POLYMERASE CHAIN-REACTION; INTERSTITIAL DELETION; HUMAN CHROMOSOME-11; GENE; TUMORS; HETEROZYGOSITY; LOCUS; RETINOBLASTOMA	Observations of non-random maternal 11p allele loss in Wilms' tumour (WT) have implied the possible involvement of an imprinted 11p locus in WT aetiology. A proposed 11p13 Wilms' tumour gene, WT1, has recently been isolated and encodes a zinc finger DNA-binding protein, the 3' untranslated region of which contains a polymorphic dinucleotide repeat (CA repeat) motif. We have exploited this transcribed CA repeat to examine the allelic expression pattern of WT1 and thereby determine whether transcriptional imprinting of this gene occurs. DNA and reverse-transcribed RNA from tumours and normal tissue were subjected to the polymerase chain reaction (PCR) using radiolabelled primers flanking the CA repeat. The gene was seen to be expressed from both of the constitutive alleles in 9-week human fetal kidney, all informative Wilm's tumours and neonatal kidney tissue adjacent to the tumours. In one tumour, known to be heterozygous for a point mutation in zinc finger 2, direct sequencing confirmed that both mutant and wild-type transcripts were being expressed. These results demonstrate that this gene is not subject to transcriptional imprinting in tumours or normal fetal kidney.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV QUEENSLAND,SCH MED,DEPT PATHOL,BRISBANE 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,BRISBANE 4029,AUSTRALIA; ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Queensland; Royal Children's Hospital Brisbane			Pritchard-Jones, Kathy/F-4286-2014; van Heyningen, Veronica/B-8039-2008; Little, Melissa H/A-6170-2010; VAN HEYNINGEN, Veronica/GYE-0531-2022	Pritchard-Jones, Kathy/0000-0002-2384-9475; van Heyningen, Veronica/0000-0003-0359-0141; Little, Melissa H/0000-0003-0380-2263; Byrne, Jennifer Anne/0000-0002-8923-0587	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENEDICT WF, 1987, CANCER RES, V47, P4189; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL JK, 1991, ONCOGENE, V6, P595; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAAS OA, 1986, CANCER GENET CYTOGEN, V23, P95, DOI 10.1016/0165-4608(86)90409-7; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HUFF V, 1991, AM J HUM GENET, V48, P997; KANEKO Y, 1981, CANCER RES, V41, P4577; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; LITTLE MH, 1992, IN PRESS EUR J CANCE; LITTLE MH, 1992, IN PRESS P NATL ACAD; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WADEY RB, 1990, ONCOGENE, V5, P901; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILKINS RJ, 1988, LANCET, V1, P329; WILLIAMS JC, 1989, LANCET, V1, P283; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	43	60	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					635	641						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314367				2022-12-17	WOS:A1992HQ68200004
J	SU, HY; BOS, TJ; MONTECLARO, FS; VOGT, PK				SU, HY; BOS, TJ; MONTECLARO, FS; VOGT, PK			JUN INHIBITS MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							C-JUN; V-JUN; REGULATORY GENE; CELLS; ONCOGENES; MYOD1; EXPRESSION; TRANSFORMATION; TRANSCRIPTION; PROGRAM	Myoblasts from skeletal muscle of chicken or Japanese quail embryos were infected with avian sarcoma virus 17 (ASV-17), a retrovirus carrying the jun oncogene. At high multiplicities of infection ASV-17-induced morphologic transformation inhibited fusion of myoblasts into myotubes and stimulated extended replication. The expression of the muscle-specific proteins desmin, myosin and creatine phosphokinase was inhibited in ASV-17-infected cultures. Immunofluorescent staining detected strong expression of the ASV-17 Gag-Jun fusion protein in the nuclei of infected mononuclear myoblasts, but Gag-Jun was not detectable in multinucleated myotubes that occurred in clonal populations of ASV-17-infected quail myoblasts. This result suggests that the nuclear expression of viral jun and myogenic differentiation are mutually exclusive events. A mutant of ASV-17, ts jun-1, is partly temperature-sensitive in its ability to transform chicken embryo fibroblasts. At the non-permissive temperature of 41.5-degrees-C, multinucleated myotubes readily formed in ts jun-1-infected myoblast cultures and expressed muscle-specific proteins detectable by immunofluorescent staining. These myotubes also showed strong immunofluorescent staining for Gag-Jun in the cell nuclei. The nuclear expression of a Jun protein that is defective in its transforming function appears therefore to be compatible with myogenesis. Several retroviral constructs carrying various viral and cellular jun inserts, as well as jun deletion mutants and recombinants between c-jun and v-jun, were tested for their effect on myogenic differentiation. There was an approximate correlation between the ability of a construct to transform chicken embryo fibroblasts and its effectiveness in interfering with myogenic differentiation. We conclude that the expression of an oncogenic jun gene in myoblasts strongly inhibits myogenic differentiation, and that a highly transforming Jun protein cannot be expressed in the nuclei of differentiating myotubes, while the presence of transformation-defective variants of Jun is compatible with differentiation.	UNIV SO CALIF, SCH MED, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California	SU, HY (corresponding author), UNIV SO CALIF, SCH MED, DEPT MICROBIOL, 2011 ZONAL AVE, LOS ANGELES, CA 90033 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate C, 1990, Semin Cancer Biol, V1, P19; ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CAPLAN AI, 1976, J EMBRYOL EXP MORPH, V36, P175; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; CURRAN M, 1991, TRANSCRIPTIONAL REGU; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GROSSI M, 1991, ONCOGENE, V6, P1767; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LILLIE RD, 1969, BIOL STAINS, P74; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LOUGH J, 1977, DEV BIOL, V57, P330, DOI 10.1016/0012-1606(77)90219-6; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; TOYOSHIMA K, 1969, VIROLOGY, V39, P930, DOI 10.1016/0042-6822(69)90030-0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VOGT PK, 1969, FUNDAMENTAL TECHNIQU, P316; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Yaffe D, 1969, Curr Top Dev Biol, V4, P37, DOI 10.1016/S0070-2153(08)60480-9	32	60	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1759	1766						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656361				2022-12-17	WOS:A1991GX11800006
J	OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H				OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H			INHIBITION OF JUN TRANSFORMATION BY A MUTATED FOS GENE - DESIGN OF AN ANTIONCOGENE	ONCOGENE			English	Article							CHICKEN-EMBRYO FIBROBLASTS; GROWTH-STIMULATING ACTIVITY; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER PROTEINS; OSTEO-SARCOMA VIRUS; DNA-BINDING DOMAIN; PROTO-ONCOGENE; C-JUN; V-FOS; ANTISENSE RNA	The protein products of the fos and jun oncogenes (Fos and Jun) function as transcriptional regulators in the form of homo- or heterodimeric complexes that bind to DNA. Dimerization is mediated by a leucine zipper structure that serves to juxtapose-alpha-helical regions of each protein, rich in basic amino acids, that form a bipartite DNA-binding domain. Although Fos participates exclusively in heterodimeric complexes, Jun can function either as a homodimer that has a low apparent affinity for DNA or as a more stable heterodimer with Fos that has a higher apparent affinity for DNA. We have used these properties of Fos and Jun to design a mutated fos gene, lacking a functional DNA-binding domain (supfos1), that suppresses the transforming activity of jun in trans. Here we show that chicken embryo fibroblasts transformed by jun revert to a normal phenotype after infection by a retroviral vector encoding supFos1. Furthermore, infection of normal cells with the supfos1 vector renders them resistant to subsequent transformation by jun. Inhibition of jun transformation was associated with the appearance of supFos1-Jun heterodimers and a reduction in the AP-1 DNA-binding activity contributed by Jun homodimers. These findings demonstrate that the function of leucine zipper-containing transcription factors can be investigated by the procedure of intracellular immunization.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo; Roche Holding			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	51	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1491	1497						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923517				2022-12-17	WOS:A1991GX27400001
J	BOEHM, T; SPILLANTINI, MG; SOFRONIEW, MV; SURANI, MA; RABBITTS, TH				BOEHM, T; SPILLANTINI, MG; SOFRONIEW, MV; SURANI, MA; RABBITTS, TH			DEVELOPMENTALLY REGULATED AND TISSUE SPECIFIC EXPRESSION OF MESSENGER-RNAS ENCODING THE 2 ALTERNATIVE FORMS OF THE LIM DOMAIN ONCOGENE RHOMBOTIN - EVIDENCE FOR THYMUS EXPRESSION	ONCOGENE			English	Article							T-CELL ONCOGENE; ALPHA-LOCUS; V(D)J RECOMBINATION; EARLY THYMOCYTES; GENE; PROTEIN; REARRANGEMENTS; LYMPHOCYTES; HOMEODOMAIN; MOTIF	The T-cell oncogene rhombotin was first identified as a gene near a chromosomal translocation breakpoint in a human T-cell tumour and represents the first example of an oncogene carrying the duplicated cysteine-rich regions (CRR or LIM domains). Transgenic expression of a reporter gene under the control of one of the rhombotin gene promoters subsequently showed high levels of expression in the developing brain. These disparate sites of transcriptional activity suggested that the gene may have been activated de novo specifically in the T cell tumour via the translocation. Here, we assess this possibility by analysing rhombotin gene expression in mouse development by in situ hybridization of whole embryos, Northern filter hybridization, and a sensitive semi-quantitative PCR method. The results show that the central nervous system is the major site of rhombotin mRNA production. Low level expression does, however, occur in other tissues including thymus. Furthermore, both promoters are active and differentially regulated during mouse embryogenesis in both brain and thymus. In subregions of the adult brain, different levels of rhombotin activity can be observed, with evidence for regional variation in promoter usage. A detailed analysis of mouse and human T-cell differentiation suggests that fluctuating promoter activities are related to a general T-cell differentiation process rather than to the differentiation of functionally distinct subsets of T-cells. These data suggest that the transforming activity of rhombotin in the T-cell with the chromosomal translocation was not due to de novo transcriptional activation, but rather to a quantitative or qualitative change in expression levels of this CRR-containing oncogene after chromosomal translocation.	AFRC,INST ANIM PHYSIOL & GENET RES,DEPT MOLEC EMBRYOL,CAMBRIDGE CB2 4AT,ENGLAND; UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	BOEHM, T (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		; Rabbitts, Terence/D-6262-2016	Surani, Azim/0000-0002-8640-4318; Rabbitts, Terence/0000-0002-4982-2609				ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BAER R, 1988, EMBO J, V7, P1661, DOI 10.1002/j.1460-2075.1988.tb02993.x; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, IN PRESS P NATL ACAD, V88; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRENNER MB, 1987, NATURE, V325, P689, DOI 10.1038/325689a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LINDSTEN T, 1987, J EXP MED, V166, P761, DOI 10.1084/jem.166.3.761; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MINOWADA J, 1982, CURRENT CONCEPTS HUM, P74; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; RUGH R, 1968, MOUSE ITS REPRODUCTI; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	25	60	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					695	703						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052354				2022-12-17	WOS:A1991GT82500003
J	RAZ, V; KELMAN, Z; AVIVI, A; NEUFELD, G; GIVOL, D; YARDEN, Y				RAZ, V; KELMAN, Z; AVIVI, A; NEUFELD, G; GIVOL, D; YARDEN, Y			PCR-BASED IDENTIFICATION OF NEW RECEPTORS - MOLECULAR-CLONING OF A RECEPTOR FOR FIBROBLAST GROWTH-FACTORS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CDNA LIBRARIES; EXPRESSION; FAMILY; GENE; DNA; CELLS; HOMOLOGY; AMPLIFICATION; POLYMERASE	Transmembrane tyrosine kinases are involved in the control of cell growth and differentiation by extracellular signals. To enable identification of new receptor tyrosine kinases we developed a method that selectively amplifies segments of receptor genes. The method is based on a combination of polymerase chain reaction (PCR) and hybridization screening and it employs three oligonucleotide primers derived from conserved domains of receptor tyrosine' kinases. It yields amplification of receptors' genes and appears to ignore cytoplasmic tyrosine kinases. When applied to RNA from 12.5 days post coitum mouse placenta, this methodology resulted in the detection of several putative or established receptors. Molecular cloning of one of these genes, which is identical to the partially characterized bek gene, identified a transmembrane tyrosine kinase with three immunoglobulin-like domains in the extracellular portion, and a cytoplasmic tyrosine kinase sequence. The isolated cDNA shows remarkable homology to the murine flg gene that encodes a receptor for fibroblast growth factors. Indeed, an antibody directed to the carboxy terminus of the deduced bek protein specifically recognized a receptor for acidic and basic fibroblast growth factors in murine hepatoma cells. We therefore expect that the methodology we developed will enable the study of new receptors in hardly accessible biological systems such as early mammalian embryos or stem cells.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Weizmann Institute of Science; Technion Israel Institute of Technology	YARDEN, Y (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012; Neufeld, Gera/F-1524-2019					BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Hogan B., 1986, MANIPULATING MOUSE E; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHIBUYA M, 1990, ONCOGENE, V5, P519; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	43	60	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					753	760						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711190				2022-12-17	WOS:A1991GT82500010
J	FALCO, JP; TAYLOR, WG; DIFIORE, PP; WEISSMAN, BE; AARONSON, SA				FALCO, JP; TAYLOR, WG; DIFIORE, PP; WEISSMAN, BE; AARONSON, SA			INTERACTIONS OF GROWTH-FACTORS AND RETROVIRAL ONCOGENES WITH MITOGENIC SIGNAL TRANSDUCTION PATHWAYS OF BALB/MK KERATINOCYTES	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90027	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NCI NIH HHS [R01 CA36936, R01 CA39602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036936, R01CA039602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1970, VIROLOGY, V42, P9, DOI 10.1016/0042-6822(70)90233-3; AARONSON SA, 1978, J VIROL, V27, P366, DOI 10.1128/JVI.27.2.366-373.1978; AKIYAMA SK, 1987, ADV ENZYMOL RAMB, V59, P1; ANDERSEN PR, 1981, CELL, V26, P129, DOI 10.1016/0092-8674(81)90041-6; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BOTTENSTEIN JE, 1980, EXP CELL RES, V129, P361, DOI 10.1016/0014-4827(80)90504-2; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIFIORE PP, 1988, MOL CELL BIOL, V8, P557, DOI 10.1128/MCB.8.2.557; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; ETHIER SP, 1987, CANCER RES, V47, P5316; GAZIT A, 1986, J VIROL, V60, P19, DOI 10.1128/JVI.60.1.19-28.1986; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HILL DJ, 1985, PEDIATR RES, V19, P879, DOI 10.1203/00006450-198509000-00001; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; KOHN CR, 1985, ANNU REV MED, V36, P429; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCKEEHAN WL, 1976, J CELL BIOL, V71, P727, DOI 10.1083/jcb.71.3.727; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Pledger W. J., 1984, MAMMALIAN CELL CULTU, P1, DOI 10.1007/978-1-4615-9361-4_1; PORZIG KJ, 1979, VIROLOGY, V92, P91, DOI 10.1016/0042-6822(79)90217-4; RISS TL, 1987, CANCER RES, V47, P3776; ROVERA G, 1987, ONCOGENE, V1, P29; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SMITH HS, 1971, VIROLOGY, V44, P359, DOI 10.1016/0042-6822(71)90267-4; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TEMIN HOWARD M., 1967, WISTAR INST SYMP MONOGR, V7., P103; UHLRICH S, 1986, BIOCHEM BIOPH RES CO, V137, P1205, DOI 10.1016/0006-291X(86)90353-0; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V15, P59, DOI 10.1016/S0300-595X(86)80042-1; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	51	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					573	578						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290805				2022-12-17	WOS:A1988N841500007
J	Weeden, CE; Ah-Cann, C; Holik, AZ; Pasquet, J; Garnier, JM; Merino, D; Lessene, G; Asselin-Labat, ML				Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Pasquet, Julie; Garnier, Jean-Marc; Merino, Delphine; Lessene, Guillaume; Asselin-Labat, Marie-Liesse			Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition	ONCOGENE			English	Article							GENETIC ALTERATIONS; KINASE INHIBITOR; FAMILY PROTEINS; DOWN-REGULATION; CANCER; ABT-737; RESISTANCE; PREDICT; NVP-BGJ398; OVERCOME	Genetic alterations in the fibroblast growth factor receptors (FGFRs) have been described in multiple solid tumours including bladder cancer, head and neck and lung squamous cell carcinoma (SqCC). However, recent clinical trials showed limited efficacy of FGFR-targeted therapy in lung SqCC, suggesting combination therapy may be necessary to improve patient outcomes. Here we demonstrate that FGFR therapy primes SqCC for cell death by increasing the expression of the pro-apoptotic protein BIM. We therefore hypothesised that combining BH3-mimetics, potent inhibitors of pro-survival proteins, with FGFR-targeted therapy may enhance the killing of SqCC cells. Using patient-derived xenografts and specific inhibitors of BCL-2, BCL-XL, and MCL-1, we identified a greater reliance of lung SqCC cells on BCL-XL and MCL-1 compared to BCL-2 for survival. However, neither BCL-XL nor MCL-1 inhibitors alone provided a survival benefit in combination FGFR therapy in vivo. Only triple BCL-XL, MCL-1, and FGFR inhibition resulted in tumour volume regression and prolonged survival in vivo, demonstrating the ability of BCL-XL and MCL-1 proteins to compensate for each other in lung SqCC. Our work therefore provides a rationale for the inhibition of MCL-1, BCL-XL, and FGFR1 to maximize therapeutic response in FGFR1 -expressing lung SqCC.	[Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Pasquet, Julie; Asselin-Labat, Marie-Liesse] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic, Australia; [Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Garnier, Jean-Marc; Lessene, Guillaume; Asselin-Labat, Marie-Liesse] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Garnier, Jean-Marc; Lessene, Guillaume] Walter & Eliza Hall Inst Med Res, ACRF Chem Biol Div, Parkville, Vic, Australia; [Merino, Delphine] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Merino, Delphine] La Trobe Univ, Sch Canc Med, Melbourne, Vic, Australia; [Merino, Delphine] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Lessene, Guillaume] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne; Walter & Eliza Hall Institute; La Trobe University; Olivia Newton-John Cancer Research Institute; La Trobe University; Walter & Eliza Hall Institute; University of Melbourne	Asselin-Labat, ML (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic, Australia.; Asselin-Labat, ML (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.	labat@wehi.edu.au	Holik, Aliaksei/GYA-2218-2022; Holik, Aliaksei Z/H-5828-2015; Merino, Delphine/L-9159-2017	Holik, Aliaksei Z/0000-0002-3555-8587; Merino, Delphine/0000-0002-8075-6275; Weeden, Clare/0000-0002-1561-1416; Ah-Cann, Casey/0000-0001-9210-3776	Viertel Foundation Senior Medical Researcher Fellowship; Australian Postgraduate Award; Cancer Therapeutics CRC top-up scholarship; Deep Manchanda Lung Foundation Australia Early Career Fellowship; Lung Foundation Australia PhD Scholarship; NBCF Early Career Fellowship; NHMRC Project grant [1101378]; Servier; Cancer Therapeutics CRC; Harry Secomb Foundation; Ian Potter Foundation; Leukemia and Lymphoma Society; Australian Cancer Research Foundation; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC IRIISS; Victorian Cancer Agency	Viertel Foundation Senior Medical Researcher Fellowship; Australian Postgraduate Award(Australian Government); Cancer Therapeutics CRC top-up scholarship(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Deep Manchanda Lung Foundation Australia Early Career Fellowship; Lung Foundation Australia PhD Scholarship; NBCF Early Career Fellowship; NHMRC Project grant(National Health and Medical Research Council (NHMRC) of Australia); Servier(Servier); Cancer Therapeutics CRC(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Harry Secomb Foundation; Ian Potter Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Cancer Research Foundation; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency	M-LA-L is supported by a Viertel Foundation Senior Medical Researcher Fellowship. CEW is supported by an Australian Postgraduate Award, a Cancer Therapeutics CRC top-up scholarship, and a Deep Manchanda Lung Foundation Australia Early Career Fellowship. CA is supported by a Lung Foundation Australia PhD Scholarship. DM is supported by an NBCF Early Career Fellowship and NHMRC Project grant (1101378). This work was made possible through financial support from Servier, grants from the Victorian Cancer Agency, the Cancer Therapeutics CRC, the Harry Secomb Foundation, the Ian Potter Foundation, the Leukemia and Lymphoma Society, the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Fan WW, 2011, CANCER RES, V71, P4494, DOI 10.1158/0008-5472.CAN-10-2668; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Gardner EE, 2014, CANCER RES, V74, P2846, DOI 10.1158/0008-5472.CAN-13-3460; Gong JN, 2016, BLOOD, V128, P1834, DOI 10.1182/blood-2016-03-704908; Greenberg EF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.355; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lam LT, 2017, MOL CANCER THER, V16, P1511, DOI 10.1158/1535-7163.MCT-16-0459; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Merino D, 2009, APOPTOSIS, V14, P570, DOI 10.1007/s10495-008-0308-4; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; PRICHARD MN, 1991, ANTIMICROB AGENTS CH, V35, P1060, DOI 10.1128/AAC.35.6.1060; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thiagarajan PS, 2016, ONCOTARGET, V7, P82013, DOI 10.18632/oncotarget.13307; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Weeden CE, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.49; Weeden CE, 2017, MOL CANCER THER, V16, P1610, DOI 10.1158/1535-7163.MCT-17-0174; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wykosky J, 2015, CANCER RES, V75, P394, DOI 10.1158/0008-5472.CAN-14-2004; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Ye MX, 2017, CANCER RES, V77, P3527, DOI 10.1158/0008-5472.CAN-16-3470; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zeuner A, 2014, CELL DEATH DIFFER, V21, P1877, DOI 10.1038/cdd.2014.105	47	59	60	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4475	4488		10.1038/s41388-018-0268-2	http://dx.doi.org/10.1038/s41388-018-0268-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743589				2022-12-17	WOS:000441144300010
J	Wang, JX; Dong, MJ; Xu, Z; Song, XH; Zhang, SS; Qiao, Y; Che, L; Gordan, J; Hu, KW; Liu, Y; Calvisi, DF; Chen, X				Wang, Jingxiao; Dong, Mingjie; Xu, Zhong; Song, Xinhua; Zhang, Shanshan; Qiao, Yu; Che, Li; Gordan, John; Hu, Kaiwen; Liu, Yan; Calvisi, Diego F.; Chen, Xin			Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; INTRAHEPATIC CHOLANGIOCARCINOMA; MATURE HEPATOCYTES; ALAGILLE-SYNDROME; LIVER DEVELOPMENT; CELL; RECEPTORS; LIGAND; HEPATOBLASTOMA; PROLIFERATION	Liver cancer comprises a group of malignant tumors, among which hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common. ICC is especially pernicious and associated with poor clinical outcome. Studies have shown that a subset of human ICCs may originate from mature hepatocytes. However, the mechanisms driving the trans-differentiation of hepatocytes into malignant cholangiocytes remain poorly defined. We adopted lineage tracing techniques and an established murine hepatocyte-derived ICC model by hydrodynamic injection of activated forms of AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes. Wild-type, Notch1(flox/flox), and Notch2(flox/flox) mice were used to investigate the role of canonical Notch signaling and Notch receptors in AKT/Yap-driven ICC formation. Human ICC and HCC cell lines were transfected with siRNA against Notch2 to determine whether Notch2 regulates biliary marker expression in liver tumor cells. We found that AKT/Yap-induced ICC formation is hepatocyte derived and this process is strictly dependent on the canonical Notch signaling pathway in vivo. Deletion of Notch2 in AKT/Yap-induced tumors switched the phenotype from ICC to hepatocellular adenoma-like lesions, while inactivation of Notch] in hepatocytes did not result in significant histomorphological changes. Finally, in vitro studies revealed that Notch2 silencing in ICC and HCC cell lines down-regulates the expression of Sox9 and EpCAM biliary markers. Notch2 is the major determinant of hepatocyte-derived ICC formation in mice.	[Wang, Jingxiao; Dong, Mingjie; Xu, Zhong; Song, Xinhua; Zhang, Shanshan; Qiao, Yu; Che, Li; Gordan, John; Chen, Xin] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wang, Jingxiao; Hu, Kaiwen] Beijing Univ Chinese Med, Dongfang Hosp, Beijing, Peoples R China; [Dong, Mingjie; Liu, Yan] 307 Hosp Acad Mil Med Sci, Beijing, Peoples R China; [Xu, Zhong] Guizhou Prov Peoples Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China; [Song, Xinhua] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China; [Qiao, Yu] Beijing Hosp Natl Ctr Gerontol, Dept Oncol, Beijing, Peoples R China; [Calvisi, Diego F.] Univ Med Greifswald, Inst Pathol, Greifswald, Germany	University of California System; University of California San Francisco; Beijing University of Chinese Medicine; Fifth Medical Center of Chinese PLA General Hospital; China Agricultural University; Greifswald Medical School	Chen, X (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.; Liu, Y (corresponding author), 307 Hosp Acad Mil Med Sci, Beijing, Peoples R China.; Calvisi, DF (corresponding author), Univ Med Greifswald, Inst Pathol, Greifswald, Germany.	13911798288@163.com; diego.calvisi@uni-greifswald.de; xin.chen@ucsf.edu	Wang, Jingxiao/GWU-9986-2022; Xu, Zhong/AAA-8476-2022	Wang, Jingxiao/0000-0002-7799-781X; Xu, Zhong/0000-0001-7565-6053; che, li/0000-0001-7971-8725	NIH [R01CA190606, P30DK026743]; China Scholarship Council State Scholarship Fund [201606550015]; NATIONAL CANCER INSTITUTE [R01CA136606, R01CA190606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council State Scholarship Fund(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank Dr. Rong Wang at UCSF for providing Notch1<SUP>flox/flox</SUP> mice and Dr. Gregory J. Gores at Mayo Clinic for providing the HuCC-T1 cell line. This study is supported by NIH grants R01CA190606 to X.C., P30DK026743 for UCSF Liver Center; and China Scholarship Council State Scholarship Fund No. 201606550015 to J.W.	Avila JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052133; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Che L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.73; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chen YX, 2012, HEPATOLOGY, V55, P563, DOI 10.1002/hep.24712; Cigliano A, 2017, EXPERT OPIN THER TAR, V21, P471, DOI 10.1080/14728222.2017.1310842; Croquelois A, 2005, HEPATOLOGY, V41, P487, DOI 10.1002/hep.20571; D'Souza B, 2008, ONCOGENE, V27, P5148, DOI 10.1038/onc.2008.229; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Farshidfar F, 2017, CELL REP, V19, P2878, DOI 10.1016/j.celrep.2017.06.008; Geisler F, 2008, HEPATOLOGY, V48, P607, DOI 10.1002/hep.22381; Gil-Garcia B, 2016, BIOL CELL, V108, P29, DOI 10.1111/boc.201500029; Hu JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20484; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Jeliazkova P, 2013, HEPATOLOGY, V57, P2469, DOI 10.1002/hep.26254; Katsube KI, 2005, INT J DEV BIOL, V49, P369, DOI 10.1387/ijdb.041950kk; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kodama Y, 2004, GASTROENTEROLOGY, V127, P1775, DOI 10.1053/j.gastro.2004.09.004; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lim JS, 2017, NATURE, V545, P360, DOI 10.1038/nature22323; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Merrell AJ, 2016, NAT REV MOL CELL BIO, V17, P413, DOI 10.1038/nrm.2016.24; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Morell CM, 2013, CLIN RES HEPATOL GAS, V37, P447, DOI 10.1016/j.clinre.2013.05.008; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Qi RZ, 2003, CANCER RES, V63, P8323; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Storz P, 2017, NAT REV GASTRO HEPAT, V14, P296, DOI 10.1038/nrgastro.2017.12; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Wang CM, 2009, J BIOL CHEM, V284, P16183, DOI 10.1074/jbc.M109.002105; Wong CH, 2016, WORLD J GASTROENTERO, V22, P7046, DOI 10.3748/wjg.v22.i31.7046; Wu WR, 2014, INT J CLIN EXP PATHO, V7, P3272; Wu WR, 2014, ONCOL REP, V31, P2515, DOI 10.3892/or.2014.3123; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Yuan DT, 2017, CANCER CELL, V31, P771, DOI 10.1016/j.ccell.2017.05.006; Zender S, 2013, CANCER CELL, V23, P784, DOI 10.1016/j.ccr.2013.04.019; Zhang SS, 2017, J HEPATOL, V67, P1194, DOI 10.1016/j.jhep.2017.07.006; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140	47	59	61	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3229	3242		10.1038/s41388-018-0188-1	http://dx.doi.org/10.1038/s41388-018-0188-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29545603	Green Submitted, Green Accepted, hybrid, Green Published			2022-12-17	WOS:000435526600004
J	Liu, F; Dai, M; Xu, QY; Zhu, XL; Zhou, Y; Jiang, SH; Wang, YH; Ai, ZH; Ma, L; Zhang, YL; Hu, LP; Yang, Q; Li, J; Zhao, SJ; Zhang, ZG; Teng, YC				Liu, Fei; Dai, Miao; Xu, Qinyang; Zhu, Xiaolu; Zhou, Yang; Jiang, Shuheng; Wang, Yahui; Ai, Zhihong; Ma, Li; Zhang, Yanli; Hu, Lipeng; Yang, Qin; Li, Jun; Zhao, Shujie; Zhang, Zhigang; Teng, Yincheng			SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappa B-CD47 axis	ONCOGENE			English	Article							NF-KAPPA-B; GENE-EXPRESSION; INFLAMMATION; IDENTIFICATION; RESISTANCE; PATHWAY; EVENTS	High-risk human papillomavirus oncoproteins E6 and E7 are the major etiological factors of cervical cancer but are insufficient for malignant transformation of cervical cancer. Dysregulated alternative splicing, mainly ascribed to aberrant splicing factor levels and activities, contributes to most cancer hallmarks. However, do E6 and E7 regulate the expression of splicing factors? Does alternative splicing acts as an "accomplice" of E6E7 to promote cervical cancer progression? Here, we identified that the splicing factor SRSF10, which promotes tumorigenesis of cervix, was upregulated by E6E7 via E2F1 transcriptional activation. SRSF10 modulates the alternate terminator of interleukin-1 receptor accessory protein exon 13 to increase production of the membrane form of interleukin-1 receptor accessory protein. SRSF10-mediated mIL1RAP upregulates the expression of the "don't eat me" signal CD47 to inhibit macrophage phagocytosis by promoting nuclear factor-KB activation, which is pivotal in inflammatory, immune, and tumorigenesis processes. Altogether, these data reveal a close relationship among HPV infection, alternative splicing and tumor immune evasion, and also suggests that the SRSF10-mIL1RAP-CD47 axis could be an attractive therapeutic target for the treatment of cervical cancer.	[Liu, Fei; Dai, Miao; Xu, Qinyang; Zhu, Xiaolu; Zhou, Yang; Ai, Zhihong; Ma, Li; Teng, Yincheng] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gynecol & Obstet, Sch Med, Shanghai, Peoples R China; [Dai, Miao] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Xiangya Sch Med,Dept Gynecol Oncol, Changsha, Hunan, Peoples R China; [Jiang, Shuheng; Wang, Yahui; Zhang, Yanli; Hu, Lipeng; Yang, Qin; Li, Jun; Zhang, Zhigang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China; [Zhao, Shujie] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Jiangsu, Peoples R China	Shanghai Jiao Tong University; Central South University; Shanghai Jiao Tong University; Nanjing Medical University	Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.	zzhang@shsci.org; ycteng@sjtu.edu.cn	Jiang, Shuheng/M-6584-2019	Jiang, Shuheng/0000-0001-8516-6234	National Natural Science Foundation of China [81372794, 81672565, 81502382]; Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation [13JC404502]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation	We thank Dr. Xueli Zhang (State Key Laboratory for Oncogenes and Related Genes, Shanghai, China) for critical reading of manuscript; Experimental Animal Center of East China Normal University for animal feeding. This work was supported by grants from the National Natural Science Foundation of China (81372794; 81672565; 81502382), and the Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation (13JC404502).	Adamia S, 2013, CURR CANCER DRUG TAR, V13, P735, DOI 10.2174/15680096113139990083; Agerstam H, 2015, P NATL ACAD SCI USA, V112, P10786, DOI 10.1073/pnas.1422749112; Biewenga P, 2008, GYNECOL ONCOL, V108, P520, DOI 10.1016/j.ygyno.2007.11.024; Casey SC, 2015, SEMIN CANCER BIOL, V35, pS199, DOI 10.1016/j.semcancer.2015.02.007; Centers for Disease Control and Prevention, GLOB CANC STAT; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dai M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41404; Dunne Aisling, 2003, Sci STKE, V2003, pre3, DOI 10.1126/stke.2003.171.re3; Feng Y, 2008, NAT STRUCT MOL BIOL, V15, P1040, DOI 10.1038/nsmb.1485; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Da Costa RMG, 2016, ANTICANCER RES, V36, P2073; Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985; Iwata T, 2015, INT J CLIN ONCOL, V20, P126, DOI 10.1007/s10147-014-0680-8; Jabonowska- Fudziska D, 2014, PRZEGL LEK, V72, P103; Jensen LE, 2003, CELL SIGNAL, V15, P793, DOI 10.1016/S0898-6568(03)00039-1; Jensen LE, 2000, J IMMUNOL, V164, P5277, DOI 10.4049/jimmunol.164.10.5277; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Kozlovski I, 2017, HUM GENET, V136, P1113, DOI 10.1007/s00439-017-1803-x; Landberg N, 2016, LEUKEMIA, V30, P253, DOI 10.1038/leu.2015.135; Li H, 2014, MOL CELL BIOL, V34, P2198, DOI 10.1128/MCB.01674-13; Liu R, 2017, ONCOTARGET, V8, P39021, DOI 10.18632/oncotarget.16547; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Mehta AM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8913860; Munkley J, 2017, HUM GENET, V136, P1143, DOI 10.1007/s00439-017-1792-9; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Peng ZY, 2011, TUMOR BIOL, V32, P359, DOI 10.1007/s13277-010-0128-3; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Senapati R, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0107-4; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Tsai YS, 2015, ONCOTARGET, V6, P6825, DOI 10.18632/oncotarget.3145; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Waggoner SE, 2004, GYNAECOLOGIC CANC CO, P65; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; WHO World Health Organization, HUM PAP HPV CERV CAN; Zeng DD, 2016, ONCOTARGET, V7, P83040, DOI 10.18632/oncotarget.13349; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056; Zhang R, 2017, SCI REP-UK, V7, DOI 10.1038/srep44744; Zhang Wei, 2011, Zhejiang Da Xue Xue Bao Yi Xue Ban, V40, P540; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhou XX, 2014, NUCLEIC ACIDS RES, V42, P4019, DOI 10.1093/nar/gkt1387	55	59	63	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2394	2409		10.1038/s41388-017-0119-6	http://dx.doi.org/10.1038/s41388-017-0119-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429992	Green Published, hybrid			2022-12-17	WOS:000431386000004
J	Xiang, Z; Zhou, ZJ; Xia, GK; Zhang, XH; Wei, ZW; Zhu, JT; Yu, J; Chen, W; He, Y; Schwarz, RE; Brekken, RA; Awasthi, N; Zhang, CH				Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; He, Y.; Schwarz, R. E.; Brekken, R. A.; Awasthi, N.; Zhang, C-H			A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR 4 AXIS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CELL-MIGRATION; TUMOR HETEROGENEITY; COLORECTAL-CANCER; UP-REGULATION; EXPRESSION; INVASION	The molecular mechanism underlying gastric cancer (GC) invasion and metastasis is still poorly understood. In this study, we tried to investigate the roles of CXCR4 and CXCR2 signalings in gastric cancer metastasis. A highly invasive gastric cancer cell model was established. Chemokines receptors were profiled to search for the accountable ones. Then the underlying molecular mechanism was investigated using both in vitro and in vivo techniques, and the clinical relevance of CXCR4 and CXCR2 expression was studied in gastric cancer samples. CXCR4 and CXCR2 were highly expressed in a high invasive gastric cancer cell model and in gastric cancer tissues. Overexpression of CXCR4 and CXCR2 was associated with more advanced tumor stage and poorer survival for GC patients. CXCR4 and CXCR2 expression strongly correlated with each other in the way that CXCR2 expression changed accordingly with the activity of CXCR4 signaling and CXCR4 expression also changed in agreement with CXCR2 activity. Further studies demonstrated CXCR4 and CXCR2 can both activated NF-kappa B and STAT3 signaling, while NF-kappa Bp65 can then transcriptionally activate CXCR4 and STAT3 can activate CXCR2 expression. This crosstalk between CXCR4 and CXCR2 contributed to EMT, migration and invasion of gastric cancer. Finally, Co-inhibition of CXCR4 and CXCR2 is more effective in reducing gastric cancer metastasis. Our results demonstrated that CXCR4 and CXCR2 cross-activate each other to promote the metastasis of gastric cancer.	[Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; He, Y.; Zhang, C-H] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; Zhang, C-H] Sun Yat Sen Univ, Gastr Canc Ctr, Guangzhou, Guangdong, Peoples R China; [He, Y.] Sun Yat Sen Univ, Affiliated Hosp 1, Gastrointestinal Ctr, Guangzhou, Guangdong, Peoples R China; [Schwarz, R. E.; Awasthi, N.] Indiana Univ Sch Med, South Bend, IN USA; [Schwarz, R. E.; Awasthi, N.] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA; [Brekken, R. A.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA; [Brekken, R. A.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Indiana University System; Indiana University South Bend; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, CH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.; Zhang, CH (corresponding author), Sun Yat Sen Univ, Gastr Canc Ctr, Guangzhou, Guangdong, Peoples R China.	zhchangh@mail.sysu.edu.cn	Zhou, Zhijun/AAU-9428-2021	Zhou, Zhijun/0000-0003-2226-2223	National Natural Science Foundation of China [81272643, 81272637]; '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University	We acknowledge the use of NCBI GEO database, such as GSE29272, GSE15459 and GSE62254. This study was supported by the National Natural Science Foundation of China (No. 81272643 and No. 81272637) and '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; An HM, 2015, EUR J CANCER, V51, P1953, DOI 10.1016/j.ejca.2015.06.125; Becker P.S., 2014, BLOOD, V124, P386, DOI [10.1182, DOI 10.1182/blood.V124.21.386.386]; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Bertran E, 2009, CELL SIGNAL, V21, P1595, DOI 10.1016/j.cellsig.2009.06.006; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Borthakur G, 2014, BLOOD, V124, P950, DOI DOI 10.1182/blood.V124.21.950.950; Cambien B, 2009, BRIT J CANCER, V100, P1755, DOI 10.1038/sj.bjc.6605078; Chen G, 2012, J BIOL CHEM, V287, P12132, DOI 10.1074/jbc.M111.302299; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Feng YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136175; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FIDLER IJ, 1978, CANCER RES, V38, P2651; Fontanella R, 2016, CANCER LETT, V370, P100, DOI 10.1016/j.canlet.2015.10.018; Fujita T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130808; Galsky MD, 2014, CLIN CANCER RES, V20, P3581, DOI 10.1158/1078-0432.CCR-13-2686; Garcia-Irigoyen O, 2015, HEPATOLOGY, V62, P166, DOI 10.1002/hep.27798; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Heinrich EL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-68; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hu JJ, 2011, P NATL ACAD SCI USA, V108, P15984, DOI 10.1073/pnas.1113416108; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Kawada K, 2007, ONCOGENE, V26, P4679, DOI 10.1038/sj.onc.1210267; Ko YS, 2015, BRIT J CANCER, V113, P1186, DOI 10.1038/bjc.2015.273; Li Z, 2014, CYTOKINE, V69, P6, DOI 10.1016/j.cyto.2014.05.004; Liu H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9494; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Manu KA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-107; Maxwell PJ, 2007, ONCOGENE, V26, P7333, DOI 10.1038/sj.onc.1210536; Maxwell PJ, 2014, ONCOTARGET, V5, P4895, DOI 10.18632/oncotarget.2052; Mukherjee S, 2016, ONCOGENE, V35, P4937, DOI 10.1038/onc.2016.26; Murakami T, 2013, INT J CANCER, V132, P276, DOI 10.1002/ijc.27670; Naschberger E, 2008, INT J CANCER, V123, P2120, DOI 10.1002/ijc.23764; Nguyen-Jackson H, 2010, BLOOD, V115, P3354, DOI 10.1182/blood-2009-08-240317; Pozzobon T, 2016, IMMUNOL LETT, V177, P6, DOI 10.1016/j.imlet.2016.06.006; Pradelli E, 2009, INT J CANCER, V125, P2586, DOI 10.1002/ijc.24665; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Saintigny P, 2013, CANCER RES, V73, P571, DOI 10.1158/0008-5472.CAN-12-0263; Sarvaiya PJ, 2013, ONCOTARGET, V4, P2171, DOI 10.18632/oncotarget.1426; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002; Singh AK, 2013, CYTOKINE GROWTH F R, V24, P41, DOI 10.1016/j.cytogfr.2012.08.007; Sobolik T, 2014, MOL BIOL CELL, V25, P566, DOI 10.1091/mbc.E13-07-0360; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tsai TYC, 2008, SCIENCE, V321, P126, DOI 10.1126/science.1156951; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wang HY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0169-y; Wang SM, 2016, GUT, V65, P1427, DOI 10.1136/gutjnl-2014-308932; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei ZW, 2015, CANCER LETT, V359, P335, DOI 10.1016/j.canlet.2015.01.033; Xiang JY, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1114; Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483; Yang JM, 2004, MOL THER, V9, P846, DOI 10.1016/j.ymthe.2004.01.010; YANG K, 2015, MEDICINE, V94; Yao CJ, 2016, MOL NEUROBIOL, V53, P3948, DOI 10.1007/s12035-015-9340-x; Yasumoto K, 2006, CANCER RES, V66, P2181, DOI 10.1158/0008-5472.CAN-05-3393; Zhou SL, 2015, CANCER LETT, V358, P124, DOI 10.1016/j.canlet.2014.11.044	66	59	61	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5122	5133		10.1038/onc.2017.108	http://dx.doi.org/10.1038/onc.2017.108			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481874				2022-12-17	WOS:000409371100004
J	Kenny, TC; Hart, P; Ragazzi, M; Sersinghe, M; Chipuk, J; Sagar, MAK; Eliceiri, KW; LaFramboise, T; Grandhi, S; Santos, J; Riar, AK; Papa, L; D'Aurello, M; Manfredi, G; Bonini, MG; Germain, D				Kenny, T. C.; Hart, P.; Ragazzi, M.; Sersinghe, M.; Chipuk, J.; Sagar, M. A. K.; Eliceiri, K. W.; LaFramboise, T.; Grandhi, S.; Santos, J.; Riar, A. K.; Papa, L.; D'Aurello, M.; Manfredi, G.; Bonini, M. G.; Germain, D.			Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; BREAST-CANCER; OXIDATIVE-PHOSPHORYLATION; EXPRESSION; MUTATIONS; AMPK; TUMORIGENICITY; DEACETYLATION; ACCUMULATION; METABOLISM	By causing mitochondrial DNA (mtDNA) mutations and oxidation of mitochondrial proteins, reactive oxygen species (ROS) leads to perturbations in mitochondrial proteostasis. Several studies have linked mtDNA mutations to metastasis of cancer cells but the nature of the mtDNA species involved remains unclear. Our data suggests that no common mtDNA mutation identifies metastatic cells; rather the metastatic potential of several ROS-generating mutations is largely determined by their mtDNA genomic landscapes, which can act either as an enhancer or repressor of metastasis. However, mtDNA landscapes of all metastatic cells are characterized by activation of the SIRT/FOXO/SOD2 axis of the mitochondrial unfolded protein response (UPRmt). The UPRmt promotes a complex transcription program ultimately increasing mitochondrial integrity and fitness in response to oxidative proteotoxic stress. Using SOD2 as a surrogate marker of the UPRmt, we found that in primary breast cancers, SOD2 is significantly increased in metastatic lesions. We propose that the ability of selected mtDNA species to activate the UPRmt is a process that is exploited by cancer cells to maintain mitochondrial fitness and facilitate metastasis.	[Kenny, T. C.; Riar, A. K.; Papa, L.; Germain, D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl Box 1079, New York, NY 10029 USA; [Hart, P.; Bonini, M. G.] Univ Illinois, Dept Med, Chicago, IL USA; [Ragazzi, M.] Arcispedale Santa Maria Nuova IRCCS, Pathol Unit, Reggio Emilia, Italy; [Sersinghe, M.; Chipuk, J.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Sagar, M. A. K.; Eliceiri, K. W.] Univ Wisconsin, Dept Biomed Engn, Lab Opt & Computat Instrumentat, Madison, WI USA; [LaFramboise, T.; Grandhi, S.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Santos, J.] Natl Inst Environm Hlth Sci, Durham, NC USA; [D'Aurello, M.; Manfredi, G.] Brain & Mind Res Inst, Weill Cornell Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; IRCCS Arcispedale S. Maria Nuova; Icahn School of Medicine at Mount Sinai; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Cornell University	Germain, D (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl Box 1079, New York, NY 10029 USA.	doris.germain@mssm.edu	Ragazzi, Moira/J-5737-2018; Eliceiri, Kevin/ABD-4516-2020; Sagar, Abdul Kader/ABG-8019-2020	Ragazzi, Moira/0000-0002-8761-9265; Eliceiri, Kevin/0000-0001-8678-670X; Sagar, Abdul Kader/0000-0002-1564-0727; Riar, Amanjot Kaur/0000-0003-1357-3548; Kenny, Timothy Cole/0000-0001-8258-5716; Hart, Peter/0000-0003-1843-9102	NIH RO1 [CA1722046]; NATIONAL CANCER INSTITUTE [R01CA172046, R01CA206005, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NIH RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the electron microscopy facility at Mount Sinai and the sequencing core facility at Case Western. We thank Maria Gomez for her help in generating the Supplementary Tables, Elizabeth Slocum for her contribution to the analysis by electron microscopy and Yukie Takabatake for her contribution to the graphical illustration of the model in Figure 7. This work was funded by an NIH RO1 number CA1722046 to DG.	Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Conklin MW, 2009, CELL BIOCHEM BIOPHYS, V53, P145, DOI 10.1007/s12013-009-9046-7; Covarrubias D, 2008, J HUM GENET, V53, P924, DOI 10.1007/s10038-008-0331-x; Cruz-Bermudez A, 2015, ONCOTARGET, V6, P13628, DOI 10.18632/oncotarget.3698; D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326; Desmetz C, 2008, J PROTEOME RES, V7, P3830, DOI 10.1021/pr800130d; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Feeley KP, 2015, CANCER RES, V75, P4429, DOI 10.1158/0008-5472.CAN-15-0074; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Fiorese CJ, 2016, CURR BIOL, V26, P2037, DOI 10.1016/j.cub.2016.06.002; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Hashizume O, 2012, P NATL ACAD SCI USA, V109, P10528, DOI 10.1073/pnas.1202367109; Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Ishikawa K, 2012, J BIOENERG BIOMEMBR, V44, P639, DOI 10.1007/s10863-012-9468-6; Jandova J, 2012, EXP CELL RES, V318, P2215, DOI 10.1016/j.yexcr.2012.06.006; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; McMahon S, 2014, CARCINOGENESIS, V35, P1046, DOI 10.1093/carcin/bgu012; Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361; Mouchiroud L, 2013, CELL, V154, P430, DOI 10.1016/j.cell.2013.06.016; Munch C, 2016, NATURE, V534, P710, DOI 10.1038/nature18302; Nargund AM, 2015, MOL CELL, V58, P123, DOI 10.1016/j.molcel.2015.02.008; Nargund AM, 2012, SCIENCE, V337, P587, DOI 10.1126/science.1223560; Nunes JB, 2015, HUM MOL GENET, V24, P1977, DOI 10.1093/hmg/ddu612; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271; Ragazzi M, 2011, HUM PATHOL, V42, P166, DOI 10.1016/j.humpath.2010.07.014; Rappa F, 2016, CELL STRESS CHAPERON, V21, P927, DOI 10.1007/s12192-016-0721-5; Riggins RB, 2005, MOL CANCER THER, V4, P33; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Seo JH, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002507; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shi T, 2010, J DIGEST DIS, V11, P55, DOI 10.1111/j.1751-2980.2009.00416.x; Takibuchi G, 2013, MITOCHONDRION, V13, P881, DOI 10.1016/j.mito.2013.07.117; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tian Y, 2016, TRENDS CELL BIOL, V26, P563, DOI 10.1016/j.tcb.2016.06.006; van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Yang W, 2016, CELL, V167, P985, DOI 10.1016/j.cell.2016.10.016; Yuan Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1349-z; Yuzefovych LV, 2016, CANCER RES, V76, P30, DOI 10.1158/0008-5472.CAN-15-0692; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	54	59	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4393	4404		10.1038/onc.2017.52	http://dx.doi.org/10.1038/onc.2017.52			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368421	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000406806000002
J	Yu, PF; Huang, Y; Xu, CL; Lin, LY; Han, YY; Sun, WH; Hu, GH; Rabson, AB; Wang, Y; Shi, YF				Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Rabson, A. B.; Wang, Y.; Shi, Y. F.			Downregulation of CXCL12 in mesenchymal stromal cells by TGF beta promotes breast cancer metastasis	ONCOGENE			English	Article							STEM-CELLS; CHEMOKINE RECEPTOR; TUMOR-DEVELOPMENT; IN-VIVO; MIGRATION; GROWTH; RECRUITMENT; INTERLEUKIN-6; PROGRESSION; SECRETION	Mesenchymal stromal cells (MSCs) are one of major components of the tumour microenvironment. Recent studies have shown that MSC tumour residence and their close interactions with inflammatory factors are important factors that affect tumour progression. Among tumour-associated inflammatory factors, transforming growth factor beta (TGF beta) is regarded as a key determinant of malignancy. By employing a lung metastasis model of a murine breast cancer, we show here that the prometastatic effect of MSCs was dependent on their response to TGF beta. Interestingly, we found that MSC-produced CXCL12, an important chemokine in tumour metastasis, was markedly inhibited by TGF beta. Furthermore, silencing of CXCL12 in TGF beta-unresponsive MSCs restored their ability to promote tumour metastasis. We found that 4T1 breast cancer cells expressed high levels of CXCR7, but not of CXCR4, both of which are CXCL12 receptors. In presence of CXCL12, CXCR7 expression on tumour cells was decreased. Indeed, when CXCR7 was silenced in breast cancer cells, their metastatic ability was inhibited. Therefore, our data demonstrated that sustained expression of CXCL12 by MSCs in the primary tumour site inhibits metastasis through reduction of CXCR7, while, in the presence of TGF beta, this CXCL12 effect of MSCs on tumour cells is relieved. Importantly, elevated CXCR7 and depressed CXCL12 expression levels were prominent features of clinical breast cancer lesions and were related significantly with poor survival. Our findings reveal a novel mechanism of MSC effects on malignant cells through which crosstalk between MSCs and TGF beta regulates tumour metastasis.	[Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Wang, Y.; Shi, Y. F.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Yu, P. F.; Huang, Y.; Xu, C. L.; Lin, L. Y.; Han, Y. Y.; Sun, W. H.; Hu, G. H.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Shanghai, Peoples R China; [Rabson, A. B.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	HUANG, YIN/AAH-6871-2020; Yu, Pengfei/AHC-3497-2022; Shi, Yufang/AAE-4431-2020; Xu, Chunliang/R-7065-2018	HUANG, YIN/0000-0001-5602-9871; Yu, Pengfei/0000-0002-3894-5697; Shi, Yufang/0000-0001-8964-319X; wang, ying/0000-0002-2571-9367; Hu, Guohong/0000-0002-2980-5166; Sun, Weihong/0000-0002-6292-903X	Programs of National Natural Science of China [81330046, 81273316, 81571612, 81530043]; Scientific Innovation Project of the Chinese Academy of Science [XDA 01040100]; Ministry of Science and Technology of China [2015CB964400]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Rising-Star Program [14QA1404200]; Youth Innovation Promotion Association, Chinese Academy of Sciences	Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Rising-Star Program; Youth Innovation Promotion Association, Chinese Academy of Sciences	This study was supported by grants from the Programs of National Natural Science of China (81330046, 81273316, 81571612, 81530043), the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040100), the Ministry of Science and Technology of China (2015CB964400), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Rising-Star Program (14QA1404200) and the Youth Innovation Promotion Association, Chinese Academy of Sciences.	Arabanian LS, 2014, HAEMATOLOGICA, V99, P997, DOI 10.3324/haematol.2013.097675; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; De Luca A, 2012, J CELL BIOCHEM, V113, P3363, DOI 10.1002/jcb.24212; Duvall-Noelle N, 2016, ONCOGENE, V35, P1122, DOI 10.1038/onc.2015.166; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev-immunol-032712-095919; Ganju RK, 2012, SIGNALING PATHWAYS M, P221; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Meijer J, 2008, BRIT J CANCER, V99, P1493, DOI 10.1038/sj.bjc.6604727; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rattigan Y, 2010, EXP CELL RES, V316, P3417, DOI 10.1016/j.yexcr.2010.07.002; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Stacer AC, 2016, ONCOGENE, V35, P1716, DOI 10.1038/onc.2015.236; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Wright N, 2003, BLOOD, V102, P1978, DOI 10.1182/blood-2002-10-3190; Xu CL, 2014, J IMMUNOL, V192, P103, DOI 10.4049/jimmunol.1302164; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049	37	59	60	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					840	849		10.1038/onc.2016.252	http://dx.doi.org/10.1038/onc.2016.252			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27669436	hybrid, Green Published			2022-12-17	WOS:000394168200011
J	Nickerson, ML; Witte, N; Im, KM; Turan, S; Owens, C; Misner, K; Tsang, SX; Cai, Z; Wu, S; Dean, M; Costello, JC; Theodorescu, D				Nickerson, M. L.; Witte, N.; Im, K. M.; Turan, S.; Owens, C.; Misner, K.; Tsang, S. X.; Cai, Z.; Wu, S.; Dean, M.; Costello, J. C.; Theodorescu, D.			Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response	ONCOGENE			English	Article							INVASIVE BLADDER-CANCER; WHOLE-GENOME; IMPACT ANALYSIS; IDENTIFICATION; VISUALIZATION; ANNOTATION; RESOURCE; CHEMOSENSITIVITY; REGULARIZATION; COMBINATION	The utility of tumor-derived cell lines is dependent on their ability to recapitulate underlying genomic aberrations and primary tumor biology. Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA). We observed a mutation pattern associated with altered CpGs and APOBEC-family cytosine deaminases similar to mutation signatures derived from somatic alterations in muscle-invasive (Ml) primary tumors, highlighting a major mechanism(s) contributing to cancer associated alterations in the BCa cell line exomes. Non-silent sequence alterations were confirmed in 76 cancer-associated genes, including mutations that likely activate oncogenes TERT and PIK3CA, and alter chromatin-associated proteins (MLL3, ARID1A, CHD6 and KDM6A) and established BCa genes (TP53, RB1, CDKN2A and TSC1). We identified alterations in signaling pathways and proteins with related functions, including the PI3K/mTOR pathway, altered in 60% of lines; BRCA DNA repair, 44%; and SYNE1-SYNE2, 60%. Homozygous deletions of chromosome 9p21 are known to target the cell cycle regulators CDKN2A and CDKN2B. This loci was commonly lost in BCa cell lines and we show the deletions extended to the polyamine enzyme methylthioadenosine (MTA) phosphorylase (MTAP) in 36% of lines, transcription factor DMRTA1 (27%) and antiviral interferon epsilon (IFNE, 19%). Overall, the BCa cell line genomic aberrations were concordant with those found in BCa patient tumors. We used gene expression and copy number data to infer pathway activities for cell lines, then used the inferred pathway activities to build a predictive model of cisplatin response. When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response. Together, these data and analysis represent a valuable community resource to model basic tumor biology and to study the pharmacogenomics of BCa.	[Nickerson, M. L.; Turan, S.; Misner, K.; Dean, M.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Witte, N.; Costello, J. C.] Univ Colorado, Computat Biosci Program, Aurora, CO USA; [Im, K. M.] Data Sci Genom LLC, Ellicott City, MD USA; [Owens, C.; Theodorescu, D.] Univ Colorado, Dept Surg Urol, Aurora, CO USA; [Tsang, S. X.] BGI Shenzhen, Shenzhen, Peoples R China; [Cai, Z.; Wu, S.] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China; [Costello, J. C.; Theodorescu, D.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA; [Costello, J. C.; Theodorescu, D.] Univ Colorado, Ctr Comprehens Canc, Anschutz Med Campus,13001 E 17th Pl,F-434, Aurora, CO 80045 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Beijing Genomics Institute (BGI); Second People's Hospital of Shenzhen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Costello, JC (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA.; Theodorescu, D (corresponding author), Univ Colorado, Ctr Comprehens Canc, Anschutz Med Campus,13001 E 17th Pl,F-434, Aurora, CO 80045 USA.	james.costello@ucdenver.edu; dan.theodorescu@ucdenver.edu	Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631; Costello, James/0000-0003-3158-9682	NIH [CA143971, CA075115]; Intramural Research Program of the NIH; National Cancer Institute, Center for Cancer Research; National Library of Medicine T15 training grant [LM009451]; Shenzhen municipal science and technology project [CXZZ20140826163906370]; NATIONAL CANCER INSTITUTE [R01CA143971, R01CA075115, R29CA075115, P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM009451] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Library of Medicine T15 training grant; Shenzhen municipal science and technology project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We would like to thank Dr Neeraj Agarwal for providing the TERT experimental data. This work was in part supported by NIH grants CA143971 and CA075115 for DT; Intramural Research Program of the NIH, the National Cancer Institute, Center for Cancer Research for MLN and MD; National Library of Medicine T15 training grant LM009451 for NW; Shenzhen municipal science and technology project CXZZ20140826163906370 for SW.	1000 Genomes Project Consortium, 2012, Nature, V491, P56, DOI 10.1038/nature11632; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bertino JR, 2011, CANCER BIOL THER, V11, P627, DOI 10.4161/cbt.11.7.14948; Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200; Cao W, 2005, BIOCHEM BIOPH RES CO, V330, P1034, DOI 10.1016/j.bbrc.2005.02.188; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Earl J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1450-3; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fung KY, 2013, SCIENCE, V339, P1088, DOI 10.1126/science.1233321; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Goodspeed A, 2016, MOL CANCER RES, V14, P3, DOI 10.1158/1541-7786.MCR-15-0189; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497; Heidenblad M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-3; Hermant P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071320; Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim J, 2015, CLIN CANCER RES, V21, P4514, DOI 10.1158/1078-0432.CCR-14-1215; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li H, 2014, MOL CANCER RES, V12, P571, DOI 10.1158/1541-7786.MCR-13-0396; Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; Messing E, 2006, J UROLOGY, V176, P500, DOI 10.1016/j.juro.2006.03.061; Morrison CD, 2014, P NATL ACAD SCI USA, V111, pE672, DOI 10.1073/pnas.1313580111; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078-0432.CCR-14-0330; Plagnol V, 2012, BIOINFORMATICS, V28, P2747, DOI 10.1093/bioinformatics/bts526; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Seshan W, DNACOPY DNA COPY NUM; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith SC, 2011, LANCET ONCOL, V12, P137, DOI 10.1016/S1470-2045(10)70296-5; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; STADLER WM, 1994, CANCER RES, V54, P2060; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vuong H, 2015, BIOINFORMATICS, V31, P2748, DOI 10.1093/bioinformatics/btv200; Vuong H, 2014, BIOINFORMATICS, V30, P1013, DOI 10.1093/bioinformatics/btt655; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wijesundara DK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00412; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yap KL, 2014, CLIN CANCER RES, V20, P6605, DOI 10.1158/1078-0432.CCR-14-0257; Yu M, 2015, NATURE, V520, P307, DOI 10.1038/nature14397; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	56	59	60	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					35	46		10.1038/onc.2016.172	http://dx.doi.org/10.1038/onc.2016.172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270441	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000394069100004
J	Rajabi, H; Tagde, A; Alam, M; Bouillez, A; Pitroda, S; Suzuki, Y; Kufe, D				Rajabi, H.; Tagde, A.; Alam, M.; Bouillez, A.; Pitroda, S.; Suzuki, Y.; Kufe, D.			DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ZINC-FINGER PROTEINS; BREAST-CANCER CELLS; TRANSCRIPTIONAL REGULATION; MAINTENANCE METHYLATION; LUNG-CANCER; DE-NOVO; EXPRESSION; GENE; 3B	Aberrant expression of the DNA methyltransferases (DNMTs) and disruption of DNA methylation patterns are associated with carcinogenesis and cancer cell survival. The oncogenic MUC1-C protein is aberrantly overexpressed in diverse carcinomas; however, there is no known link between MUC1-C and DNA methylation. Our results demonstrate that MUC1-C induces the expression of DNMT1 and DNMT3b, but not DNMT3a, in breast and other carcinoma cell types. We show that MUC1-C occupies the DNMT1 and DNMT3b promoters in complexes with NF-kappa B p65 and drives DNMT1 and DNMT3b transcription. In this way, MUC1-C controls global DNA methylation as determined by analysis of LINE-1 repeat elements. The results further demonstrate that targeting MUC1-C downregulates DNA methylation of the CDH1 tumor suppressor gene in association with induction of E-cadherin expression. These findings provide compelling evidence that MUC1-C is of functional importance to induction of DNMT1 and DNMT3b and, in turn, changes in DNA methylation patterns in cancer cells.	[Rajabi, H.; Tagde, A.; Alam, M.; Bouillez, A.; Suzuki, Y.; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Pitroda, S.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Suzuki, Y.] Osaka Police Hosp, Dept Surg Gastroenterol, Osaka, Osaka 5430035, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Osaka Police Hospital	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this paper was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480, and by the Lung Cancer Research Foundation.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Berger N, 2007, EXP HEMATOL, V35, P1495, DOI 10.1016/j.exphem.2007.07.006; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Gnemmi V, 2014, CANCER LETT, V346, P225, DOI 10.1016/j.canlet.2013.12.029; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Ko YG, 2005, J BIOL CHEM, V280, P9627, DOI 10.1074/jbc.M413822200; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Lin RK, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-46; Lisanti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079044; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Qu Y, 2010, AM J CLIN PATHOL, V134, P826, DOI 10.1309/AJCPHGQ69FXDFWII; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Ratnam S, 2002, DEV BIOL, V245, P304, DOI 10.1006/dbio.2002.0628; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rodic N, 2014, AM J PATHOL, V184, P1280, DOI 10.1016/j.ajpath.2014.01.007; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen N, 2014, ONCOTARGET, V5, P5494, DOI 10.18632/oncotarget.2131; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tubio JMC, 2014, SCIENCE, V345, P531, DOI 10.1126/science.1251343; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Yamada N, 2008, CANCER RES, V68, P2708, DOI 10.1158/0008-5472.CAN-07-6844; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; ZRIHANLICHT S, 1995, INT J CANCER, V62, P245, DOI 10.1002/ijc.2910620303	41	59	62	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6439	6445		10.1038/onc.2016.180	http://dx.doi.org/10.1038/onc.2016.180			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27212035	Green Accepted, Green Submitted			2022-12-17	WOS:000390247600008
J	Venturutti, L; Russo, RIC; Rivas, MA; Mercogliano, MF; Izzo, F; Oakley, RH; Pereyra, MG; De Martino, M; Proietti, CJ; Yankilevich, P; Roa, JC; Guzman, P; Cortese, E; Allemand, DH; Huang, TH; Charreau, EH; Cidlowski, JA; Schillaci, R; Elizalde, PV				Venturutti, L.; Russo, R. I. Cordo; Rivas, M. A.; Mercogliano, M. F.; Izzo, F.; Oakley, R. H.; Pereyra, M. G.; De Martino, M.; Proietti, C. J.; Yankilevich, P.; Roa, J. C.; Guzman, P.; Cortese, E.; Allemand, D. H.; Huang, T. H.; Charreau, E. H.; Cidlowski, J. A.; Schillaci, R.; Elizalde, P. V.			MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN-1; GROWTH-HORMONE RECEPTOR; NF-KAPPA-B; CELL-PROLIFERATION; UP-REGULATION; RESISTANCE; EXPRESSION; MYC; MICRORNA; AMPLIFICATION	ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ-and lapatinib-resistant ErbB-2-positive BC and GC.	[Venturutti, L.; Russo, R. I. Cordo; Mercogliano, M. F.; Izzo, F.; Pereyra, M. G.; De Martino, M.; Proietti, C. J.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Mol Mech Carcinogenesis, Buenos Aires, DF, Argentina; [Rivas, M. A.] Weill Cornell Med, Dept Med, New York, NY USA; [Oakley, R. H.; Cidlowski, J. A.] NIEHS, US Dept HHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Pereyra, M. G.] Hosp Gen Agudos Juan A Fernandez, Serv Anat Patol, Buenos Aires, DF, Argentina; [Yankilevich, P.] Max Planck Gesell, Inst Invest Biomed Buenos Aires, CONICET, Partner Inst, Buenos Aires, DF, Argentina; [Roa, J. C.; Guzman, P.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Escuela Med, Dept Anat Patol, Santiago, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile; [Cortese, E.] Hosp Aeronaut Cent, Serv Ginecol, Buenos Aires, DF, Argentina; [Allemand, D. H.] Hosp Gen Agudos Juan A Fernandez, Unidad Patol Mamaria, Buenos Aires, DF, Argentina; [Huang, T. H.] Univ Texas San Antonio, Dept Mol Med, Inst Biotechnol Canc Therapy & Res Expt IBYME, San Antonio, TX USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; University of Buenos Aires; University of Texas System; University of Texas at San Antonio (UTSA)	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Russo, Rosalia Cordo/O-9149-2017; Roa, Juan C./K-4749-2014; Cidlowski, John A/G-2548-2019	Russo, Rosalia Cordo/0000-0002-5984-9717; Roa, Juan C./0000-0001-8313-8774; Cidlowski, John A/0000-0003-1420-0516; Mercogliano, Maria Florencia/0000-0003-1094-9247; Elizalde, Patricia V./0000-0002-5923-9898; Yankilevich, Patricio/0000-0002-9606-1072; De Martino, Mara/0000-0002-3049-6495; Schillaci, Roxana/0000-0002-7776-3378; Rivas, Martin/0000-0002-9603-6897	Susan G Komen for the Cure [KG090250]; National Institute of Cancer (INC, Argentina); National Agency of Scientific Promotion of Argentina (ANPCyT) [IDB/PICT 2012-668, PID 2012-066]; ANPCyT [IDB/PICT 2012-382, IDB/PICT 2008-189, 2012-1017]; Henry Moore Institute of Argentina [Oncomed-Reno CONICET 1819/03]; CONICET [PIP 59]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090057, ZICES102445, ZIAES090079] Funding Source: NIH RePORTER	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); National Institute of Cancer (INC, Argentina); National Agency of Scientific Promotion of Argentina (ANPCyT)(ANPCyT); ANPCyT(ANPCyT); Henry Moore Institute of Argentina; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank AA Molinolo (UCSD, San Diego, CA, USA) for his constant help. This work was supported by KG090250 investigator-initiated research grant from Susan G Komen for the Cure, Financial Assistance for National Research Projects from the National Institute of Cancer (INC, Argentina), IDB/PICT 2012-668 and PID 2012-066 from National Agency of Scientific Promotion of Argentina (ANPCyT), awarded to PVE; IDB/PICT 2012-382 from ANPCyT, awarded to RS; Oncomed-Reno CONICET 1819/03, from Henry Moore Institute of Argentina, awarded to PVE and RS; IDB/PICT 2008-189 and 2012-1017 from ANPCyT, PIP 59 from CONICET, awarded to CJP.	AGRA A, 2012, PLOS ONE, V0007; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bae CD, 2001, EXP MOL MED, V33, P15, DOI 10.1038/emm.2001.3; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bhat-Nakshatri P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02530; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Chamorro-Jorganes A, 2011, ARTERIOSCL THROM VAS, V31, P2595, DOI 10.1161/ATVBAHA.111.236521; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen L, 2013, FEBS LETT, V587, P1366, DOI 10.1016/j.febslet.2013.03.007; Chen L, 2015, CANCER RES, V75, P3832, DOI 10.1158/0008-5472.CAN-14-3690; Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192; Collins DC, 2015, ONCOGENE, V34, P525, DOI 10.1038/onc.2013.586; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Dai LX, 2012, CELL BIOL INT, V36, P765, DOI 10.1042/CBI20110404; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Elzein S, 2014, MOL ENDOCRINOL, V28, P1448, DOI 10.1210/me.2014-1183; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gayle SS, 2013, CURR MED CHEM, V20, P2486, DOI 10.2174/0929867311320190008; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Ichikawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031422; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Jiang QQ, 2013, ASIAN PAC J CANCER P, V14, P4127, DOI 10.7314/APJCP.2013.14.7.4127; Jiao LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032068; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kao SC, 2015, AM J RESP CRIT CARE, V191, P1467, DOI 10.1164/rccm.201503-0461LE; Kapeli K, 2011, J BIOL CHEM, V286, P38498, DOI 10.1074/jbc.M111.276675; Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3; Kim J, 2014, ANTICANCER RES, V34, P3807; Kim SY, 2008, INT J ONCOL, V32, P89; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Le XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041170; Lee YY, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.115; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Mei ZJ, 2015, RADIAT RES, V183, P196, DOI 10.1667/RR13784.1; Motoyama AB, 2002, CANCER RES, V62, P3151; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rivas MA, 2010, BREAST CANCER RES TR, V122, P111, DOI 10.1007/s10549-009-0546-3; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schneeweiss A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3690; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Stajduhar E, 2014, TUMOR BIOL, V35, P6425, DOI 10.1007/s13277-014-1827-y; Tagawa T, 2012, BIOCHEM J, V447, P449, DOI 10.1042/BJ20120434; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Venturutti L, 2015, ONCOGENE; von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261; Wang Shizhen Emily, 2013, Microrna, V2, P137; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Yang TQ, 2014, CANCER SCI, V105, P265, DOI 10.1111/cas.12351; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814; Yu XF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-29; Zhang FC, 2013, ONKOLOGIE, V36, P650, DOI 10.1159/000355659; Zhang J., 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1109/ICNP.2013.6733609; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	76	59	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6189	6202		10.1038/onc.2016.151	http://dx.doi.org/10.1038/onc.2016.151			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157613	Green Published, Green Accepted			2022-12-17	WOS:000388857700004
J	Najumudeen, AK; Jaiswal, A; Lectez, B; Oetken-Lindholm, C; Guzman, C; Siljamaki, E; Posada, IMD; Lacey, E; Aittokallio, T; Abankwa, D				Najumudeen, A. K.; Jaiswal, A.; Lectez, B.; Oetken-Lindholm, C.; Guzman, C.; Siljamaki, E.; Posada, I. M. D.; Lacey, E.; Aittokallio, T.; Abankwa, D.			Cancer stem cell drugs target K-ras signaling in a stemness context	ONCOGENE			English	Article							GENE-EXPRESSION; MEMBRANE ORIENTATION; PLASMA-MEMBRANE; SALINOMYCIN; CAVEOLIN-1; IDENTIFICATION; NANOCLUSTERS; RESISTANCE; CALMODULIN; PROTEINS	Cancer stem cells (CSCs) are considered to be responsible for treatment relapse and have therefore become a major target in cancer research. Salinomycin is the most established CSC inhibitor. However, its primary mechanistic target is still unclear, impeding the discovery of compounds with similar anti-CSC activity. Here, we show that salinomycin very specifically interferes with the activity of K-ras4B, but not H-ras, by disrupting its nanoscale membrane organization. We found that caveolae negatively regulate the sensitivity to this drug. On the basis of this novel mechanistic insight, we defined a K-ras-associated and stem cell-derived gene expression signature that predicts the drug response of cancer cells to salinomycin. Consistent with therapy resistance of CSC, 8% of tumor samples in the TCGA-database displayed our signature and were associated with a significantly higher mortality. Using our K-ras-specific screening platform, we identified several new candidate CSC drugs. Two of these, ophiobolin A and conglobatin A, possessed a similar or higher potency than salinomycin. Finally, we established that the most potent compound, ophiobolin A, exerts its K-ras4B-specific activity through inactivation of calmodulin. Our data suggest that specific interference with the K-ras4B/calmodulin interaction selectively inhibits CSC.	[Najumudeen, A. K.; Lectez, B.; Oetken-Lindholm, C.; Guzman, C.; Siljamaki, E.; Posada, I. M. D.; Abankwa, D.] Abo Akad Univ, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland; [Jaiswal, A.; Aittokallio, T.] Univ Helsinki, FIMM, Inst Mol Med Finland, Helsinki, Finland; [Lacey, E.] Microbial Screening Technol Pty Ltd, Bldg C, Smithfield, NSW, Australia	Abo Akademi University; University of Helsinki	Abankwa, D (corresponding author), Abo Akad Univ, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	daniel.abankwa@btk.fi	Aittokallio, Tero/B-6583-2009; Najumudeen, Arafath/AAH-2250-2020	Aittokallio, Tero/0000-0002-0886-9769; Najumudeen, Arafath/0000-0002-3764-5721; Jaiswal, Alok/0000-0002-1910-4681; Siljamaki, Elina/0000-0003-1709-8633; Abankwa, Daniel/0000-0003-2769-0745; Lectez, Benoit/0000-0001-9796-1606	Academy of Finland fellowship grant; Sigrid Juselius Foundation; Cancer Society of Finland; Marie-Curie Reintegration Grant; Jane and Aatos Erkko Foundation; Academy of Finland [272437, 269862, 279163]; ISB graduate school; Integrative Life Science Doctoral Program (ILS); Cancer Foundation Finland sr [150062] Funding Source: researchfish	Academy of Finland fellowship grant; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Marie-Curie Reintegration Grant(European Commission); Jane and Aatos Erkko Foundation; Academy of Finland(Academy of Finland); ISB graduate school; Integrative Life Science Doctoral Program (ILS); Cancer Foundation Finland sr	Plasmids encoding tagged LactC2 and MDCK cells stably expressing either mGFP-K- or H-rasG12V were kindly provided by Prof John Hancock. Plasmids encoding PTRF and Cav-1 were kindly provided by Prof Rob Parton. We thank Lingjia Kong for help with the ESTOOLS database. We thank Jasmin Varjonen for experimental support. This work was supported by the Academy of Finland fellowship grant, the Sigrid Juselius Foundation, the Cancer Society of Finland, the Marie-Curie Reintegration Grant and the Jane and Aatos Erkko Foundation grants to DA, as well as Academy of Finland (grants 272437, 269862, 279163) and the Cancer Society of Finland grants to TA. AKN was supported by the ISB graduate school and AJ by the Integrative Life Science Doctoral Program (ILS).	Abankwa D, 2007, SEMIN CELL DEV BIOL, V18, P599, DOI 10.1016/j.semcdb.2007.08.003; Abankwa D, 2008, EMBO J, V27, P727, DOI 10.1038/emboj.2008.10; Abankwa D, 2007, J CELL SCI, V120, P2953, DOI 10.1242/jcs.001404; Abankwa D, 2010, P NATL ACAD SCI USA, V107, P1130, DOI 10.1073/pnas.0903907107; Ansieau S, 2013, CANCER LETT, V338, P63, DOI 10.1016/j.canlet.2012.05.014; Ariotti N, 2014, J CELL BIOL, V204, P777, DOI 10.1083/jcb.201307055; Au TK, 1998, PLANT PHYSIOL, V118, P965, DOI 10.1104/pp.118.3.965; Baker N, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt276; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Blair K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002019; Boehmerle W, 2014, J MOL MED, V92, P889, DOI 10.1007/s00109-014-1155-0; Buganim Y, 2013, NAT REV GENET, V14, P427, DOI 10.1038/nrg3473; Cho KJ, 2012, J BIOL CHEM, V287, P43573, DOI 10.1074/jbc.M112.424457; Collins BM, 2012, DEV CELL, V23, P11, DOI 10.1016/j.devcel.2012.06.012; Coxon FP, 2014, EUR J MED CHEM, V84, P77, DOI 10.1016/j.ejmech.2014.06.062; Crouthamel M, 2010, MOL PHARMACOL, V78, P767, DOI 10.1124/mol.110.066340; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Fairn GD, 2011, J CELL BIOL, V194, P257, DOI 10.1083/jcb.201012028; Fuchs D, 2009, BIOCHEM BIOPH RES CO, V390, P743, DOI 10.1016/j.bbrc.2009.10.042; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Guzman C, 2016, JALA-J LAB AUTOM, V21, P238, DOI 10.1177/2211068215606048; Guzman C, 2014, J BIOL CHEM, V289, P9519, DOI 10.1074/jbc.M113.537001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Huczynski A, 2012, BIOORG MED CHEM LETT, V22, P7002, DOI 10.1016/j.bmcl.2012.09.046; Kirkham M, 2008, J CELL SCI, V121, P2075, DOI 10.1242/jcs.024588; Kohnke M, 2012, CHEM BIOL, V19, P866, DOI 10.1016/j.chembiol.2012.05.019; Kong LJ, 2013, NAT METHODS, V10, P814, DOI 10.1038/nmeth.2576; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Meissner P, 2001, BIOTECHNOL BIOENG, V75, P197, DOI 10.1002/bit.1179; Najumudeen AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066425; Najurnudeen AK, 2015, BIOCHEMISTRY-US, V54, P7212, DOI 10.1021/acs.biochem.5b00724; Nassar ZD, 2013, NAT REV UROL, V10, P529, DOI 10.1038/nrurol.2013.168; Naujokat C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/950658; Nussinov R, 2016, CANCER RES, V76, P18, DOI 10.1158/0008-5472.CAN-15-1536; Nussinov R, 2015, MOL CANCER RES, V13, P1265, DOI 10.1158/1541-7786.MCR-15-0165; Quinlan MP, 2008, MOL CELL BIOL, V28, P2659, DOI 10.1128/MCB.01661-07; Riccioni R, 2010, BLOOD CELL MOL DIS, V45, P86, DOI 10.1016/j.bcmd.2010.03.008; Rotblat B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011991; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031; Solman M, 2015, ELIFE, V4, DOI 10.7554/eLife.08905; Sotgia F, 2005, CELL CYCLE, V4, P1808, DOI 10.4161/cc.4.12.2198; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Sykes AM, 2012, J BIOL CHEM, V287, P43810, DOI 10.1074/jbc.M112.382903; Tian TH, 2007, NAT CELL BIOL, V9, P905, DOI 10.1038/ncb1615; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Wang MT, 2015, CELL, V163, P1237, DOI 10.1016/j.cell.2015.10.041; Witkiewicz AK, 2009, AM J PATHOL, V174, P2023, DOI 10.2353/ajpath.2009.080873; Zhou S, 2013, CURR MED CHEM, V20, P4095; Zhou Y, 2015, BBA-MOL CELL RES, V1853, P841, DOI 10.1016/j.bbamcr.2014.09.008; Zhou Y, 2014, MOL CELL BIOL, V34, P862, DOI 10.1128/MCB.01227-13; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	68	59	60	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5248	5262		10.1038/onc.2016.59	http://dx.doi.org/10.1038/onc.2016.59			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973241	Green Published, hybrid			2022-12-17	WOS:000386053000004
J	Lodillinsky, C; Infante, E; Guichard, A; Chaligne, R; Fuhrmann, L; Cyrta, J; Irondelle, M; Lagoutte, E; Vacher, S; Bonsang-Kitzis, H; Glukhova, M; Reyal, F; Bieche, I; Vincent-Salomon, A; Chavrier, P				Lodillinsky, C.; Infante, E.; Guichard, A.; Chaligne, R.; Fuhrmann, L.; Cyrta, J.; Irondelle, M.; Lagoutte, E.; Vacher, S.; Bonsang-Kitzis, H.; Glukhova, M.; Reyal, F.; Bieche, I.; Vincent-Salomon, A.; Chavrier, P.			p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer	ONCOGENE			English	Article							STEM-CELL ACTIVITY; MATRIX-METALLOPROTEINASE; TISSUE LOCALIZATION; TUMOR-CELLS; EXPRESSION; P63; MT1-MMP; IDENTIFICATION; PROGRESSION; METASTASIS	The transition of ductal carcinoma in situ (DCIS) to invasive breast carcinoma requires tumor cells to cross the basement membrane (BM). However, mechanisms underlying BM transmigration are poorly understood. Here, we report that expression of membranetype 1 (MT1)-matrix metalloproteinase (MMP), a key component of the BM invasion program, increases during breast cancer progression at the in situ to invasive breast carcinoma transition. In the intraductal xenograft model, MT1-MMP is required for BM transmigration of MCF10DCIS. com breast adenocarcinoma cells and is overexpressed in cell clusters overlying focal BM disruptions and at the invasive tumor front. Mirrored upregulation of p63 and MT1-MMP is observed at the edge of MCF10DCIS. com xenograft tumors and p63 is required for induction of MT1-MMP-dependent invasive program in response to microenvironmental signals. Immunohistochemistry and analysis of public database reveal that p63 and MT1-MMP are upregulated in human basal-like breast tumors suggesting that p63/MT1-MMP axis contributes to progression of basal-like breast cancers with elevated p63 and MT1-MMP levels.	[Lodillinsky, C.; Infante, E.; Guichard, A.; Fuhrmann, L.; Cyrta, J.; Irondelle, M.; Lagoutte, E.; Chavrier, P.] CNRS, Membrane & Cytoskeleton Dynam Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, 26 Rue Ulm, F-75248 Paris, France; [Chaligne, R.; Vincent-Salomon, A.] Inst Curie, Genet & Dev Biol Unit, Mammalian Dev Epigenet Grp, Paris, France; [Vacher, S.; Bieche, I.] Inst Curie, Dept Genet, Paris, France; [Bonsang-Kitzis, H.; Reyal, F.] Inst Curie, Team RT2Lab, Translat Res Dept, Paris, France; [Glukhova, M.] CNRS, Mol Mech Mammary Gland Dev Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, Paris, France; [Vincent-Salomon, A.] Inst Curie, Pathol Dept, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lodillinsky, C; Chavrier, P (corresponding author), CNRS, Membrane & Cytoskeleton Dynam Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, 26 Rue Ulm, F-75248 Paris, France.	catalina.lodillinsky@curie.fr; philippe.chavrier@curie.fr	CHAVRIER, Philippe/B-4707-2010; CHAVRIER, Philippe/AAG-2645-2020; Bièche, Ivan/O-7399-2017	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Bièche, Ivan/0000-0002-2430-5429; Guichard, Alan/0000-0001-8623-9570; VACHER, Sophie/0000-0002-0042-6023; Infante, Elvira/0000-0002-9883-8391	Agence Nationale pour la Recherche; Fondation Pierre-Gilles de Gennes pour la Recherche; Region Ile-de-France; Appel a Projet 'Biologie des Systemes' du Plan cancer (INVADE project); Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie; ARC [SL220100601356, SLR20130607099]; Ligue Nationale contre le Cancer (Comite de Paris); Agence Nationale pour la Recherche [ANR-08-BLAN-0111]; Institut National du Cancer [2012-1-PL BIO-02-IC-1]; Institut Curie; Centre National pour la Recherche Scientifique (CNRS)	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Fondation Pierre-Gilles de Gennes pour la Recherche; Region Ile-de-France(Region Ile-de-France); Appel a Projet 'Biologie des Systemes' du Plan cancer (INVADE project); Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie; ARC(Australian Research Council); Ligue Nationale contre le Cancer (Comite de Paris); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France); Institut Curie; Centre National pour la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	We acknowledge the Breast Cancer Study Group and patients of Institut Curie for the breast tumor samples, Dr G Scita for critical reading of the manuscript, the Nikon Imaging Centre @ Institut Curie-CNRS and Cell and Tissue Imaging Facility of Institut Curie for help with image acquisition, V Dangles-Marie and MA Deugnier for help with the intraductal xenograft model, K Lehti, GP Dotto, C Albiges-Rizo and O Destaing for providing reagents, D Gentien for the gift of breast tumor cell line mRNA samples and M Sefta for correlation analysis of MT1-MMP and p63 expression in breast tumor cell lines. CL was supported by grants from Agence Nationale pour la Recherche and Fondation Pierre-Gilles de Gennes pour la Recherche, EI by a grant from Region Ile-de-France, AG by a grant from Appel a Projet 'Biologie des Systemes' 2012 du Plan cancer 2009-2013 (INVADE project) and LF and MI by the Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie. Funding for this work was provided by grants from ARC (SL220100601356 and SLR20130607099), Ligue Nationale contre le Cancer (Comite de Paris), Agence Nationale pour la Recherche (ANR-08-BLAN-0111) and Institut National du Cancer (2012-1-PL BIO-02-IC-1) to PC and by core funding from Institut Curie and Centre National pour la Recherche Scientifique (CNRS).	Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127; Awadelkarim KD, 2012, INT J CANCER, V131, P2852, DOI 10.1002/ijc.27600; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bisson C, 2003, INT J CANCER, V105, P7, DOI 10.1002/ijc.11012; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Martynova E, 2012, ONCOTARGET, V3, P132; Matos I, 2005, VIRCHOWS ARCH, V447, P688, DOI 10.1007/s00428-005-0010-7; McDade SS, 2012, NUCLEIC ACIDS RES, V40, P7190, DOI 10.1093/nar/gks389; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Olsen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062547; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Polyak K, 2005, J MAMMARY GLAND BIOL, V10, P231, DOI 10.1007/s10911-005-9584-6; Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sakakibara M, 1999, CANCER, V85, P231, DOI 10.1002/(SICI)1097-0142(19990101)85:1<231::AID-CNCR31>3.0.CO;2-3; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shekhar MPV, 2013, ONCOTARGET, V4, P231, DOI 10.18632/oncotarget.818; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Tetu B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1503; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Ueno H, 1997, CANCER RES, V57, P2055; Vincent-Salomon A, 2007, BRIT J CANCER, V96, P654, DOI 10.1038/sj.bjc.6603584; Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu K, 2004, CANCER RES, V64, P2962, DOI 10.1158/0008-5472.CAN-03-2430; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231	59	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					344	357		10.1038/onc.2015.87	http://dx.doi.org/10.1038/onc.2015.87			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893299				2022-12-17	WOS:000369055300008
J	Mitra, AK; Chiang, CY; Tiwari, P; Tomar, S; Watters, KM; Peter, ME; Lengyel, E				Mitra, A. K.; Chiang, C. Y.; Tiwari, P.; Tomar, S.; Watters, K. M.; Peter, M. E.; Lengyel, E.			Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis	ONCOGENE			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; MESOTHELIAL CELLS; DNA METHYLATION; TUMOR INVASION; EXPRESSION; MICRORNA; PROGRESSION; SYSTEM; FIBROBLASTS; INHIBITOR	The cross-talk between ovarian cancer (OvCa) cells and the metastatic microenvironment is an essential determinant of successful colonization. MicroRNAs (miRNAs) have several critical roles during metastasis; however, the role of microenvironmental cues in the regulation of miRNAs in metastasizing cancer cells has not been studied. Using a three-dimensional culture model that mimics the human omentum, one of the principal sites of OvCa metastasis, we identified and characterized the microenvironment-induced downregulation of a tumor suppressor miRNA, miR-193b, in metastasizing OvCa cells. The direct interaction of the OvCa cells with mesothelial cells, which cover the surface of the omentum, caused a DNA methyltransferase 1-mediated decrease in the expression of miR-193b in the cancer cells. The reduction in miR-193b enabled the metastasizing cancer cells to invade and proliferate into human omental pieces ex vivo and into the omentum of a mouse xenograft model of OvCa metastasis. The functional effects of miR-193b were mediated, in large part, by the concomitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-associated protease. These findings link paracrine signals from the microenvironment to the regulation of a key miRNA in cancer cells. Targeting miR-193b, which is essential for metastatic colonization of cancer cells could prove effective in the treatment of OvCa metastasis.	[Mitra, A. K.; Chiang, C. Y.; Tiwari, P.; Watters, K. M.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, Chicago, IL 60637 USA; [Mitra, A. K.; Tomar, S.] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA; [Peter, M. E.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	University of Chicago; Indiana University System; Indiana University Bloomington; Northwestern University; Feinberg School of Medicine	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, MC 2050,5841 South Maryland Ave, Chicago, IL 60637 USA.	anmitra@indiana.edu; elengyel@uchicago.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Tomar, Sunil/0000-0002-9258-399X; Tiwari, Payal/0000-0002-7822-6857; Peter, Marcus Ernst/0000-0003-3216-036X	Marsha Rivkin Pilot Award; National Cancer Institute [R01 CA111882, RO1 CA169604]; Ovarian Cancer Research Fund Program Project Development Grant; NATIONAL CANCER INSTITUTE [R01CA169604, R01CA111882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS075702] Funding Source: NIH RePORTER	Marsha Rivkin Pilot Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund Program Project Development Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We want to thank Dr AF Haney for collecting omental biopsies, Dr Abir Mukherjee for helpful discussions and G Isenberg for carefully editing the manuscript (all at the University of Chicago, Department of Obstetrics and Gynecology). We are indebted to all the patients, resident and attending physicians in the Department of Obstetrics and Gynecology at the University of Chicago for their participation in tissue collection for these experiments. This research was supported by a Marsha Rivkin Pilot Award (AKM) and by National Cancer Institute R01 CA111882 and RO1 CA169604 grants (EL) and an Ovarian Cancer Research Fund Program Project Development Grant (EL, MEP).	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Konecny G, 2001, CLIN CANCER RES, V7, P1743; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061658; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Samudio-Ruiz SL, 2012, EPIGENETICS-US, V7, P216, DOI 10.4161/epi.7.3.19273; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Tang CH, 2008, J CELL SCI, V121, P3747, DOI 10.1242/jcs.029769; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang L, 2009, GYNECOL ONCOL, V114, P265, DOI 10.1016/j.ygyno.2009.04.031; White EA, 2014, ADV DRUG DELIVER REV, V79-80, P184, DOI 10.1016/j.addr.2014.07.003; Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang W, 2013, ONCOL REP, V29, P637, DOI 10.3892/or.2012.2148; Zhang YL, 2013, MOL CANCER THER, V12, P2628, DOI 10.1158/1535-7163.MCT-13-0204	45	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5923	5932		10.1038/onc.2015.43	http://dx.doi.org/10.1038/onc.2015.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25798837	Green Accepted, Green Submitted			2022-12-17	WOS:000365434000007
J	Zeng, L; Morinibu, A; Kobayashi, M; Zhu, Y; Wang, X; Goto, Y; Yeom, CJ; Zhao, T; Hirota, K; Shinomiya, K; Itasaka, S; Yoshimura, M; Guo, G; Hammond, EM; Hiraoka, M; Harada, H				Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Yeom, C. J.; Zhao, T.; Hirota, K.; Shinomiya, K.; Itasaka, S.; Yoshimura, M.; Guo, G.; Hammond, E. M.; Hiraoka, M.; Harada, H.			Aberrant IDH3 alpha expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis	ONCOGENE			English	Article							BREAST-CANCER PATIENTS; TRANSCRIPTIONAL ACTIVITY; RADIATION-THERAPY; GENE-EXPRESSION; HIF-1 ACTIVITY; FACTOR-I; HYPOXIA; CELLS; FACTOR-1; TRANSFORMATION	Cancer cells gain a growth advantage through the so-called Warburg effect by shifting glucose metabolism from oxidative phosphorylation to aerobic glycolysis. Hypoxia-inducible factor 1 (HIF-1) has been suggested to function in metabolic reprogramming; however, the underlying mechanism has not been fully elucidated. We found that the aberrant expression of wild-type isocitrate dehydrogenase 3 alpha (IDH3 alpha), a subunit of the IDH3 heterotetramer, decreased alpha-ketoglutarate levels and increased the stability and transactivation activity of HIF-1 alpha in cancer cells. The silencing of IDH3 alpha significantly delayed tumor growth by suppressing the HIF-1-mediated Warburg effect and angiogenesis. IDH3 alpha expression was associated with the poor postoperative overall survival of lung and breast cancer patients. These results justify the exploitation of IDH3 as a novel target for the diagnosis and treatment of cancers.	[Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Zhao, T.; Shinomiya, K.; Itasaka, S.; Yoshimura, M.; Hiraoka, M.; Harada, H.] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan; [Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Yeom, C. J.; Zhao, T.; Shinomiya, K.; Harada, H.] Kyoto Univ, Career Path Promot Unit Young Life Scientists, Grp Radiat & Tumor Biol, Kyoto 6068507, Japan; [Zeng, L.; Wang, X.; Zhao, T.; Guo, G.] Fourth Mil Med Univ, Dept Radiat Med, Xian, Shaanxi, Peoples R China; [Zhu, Y.] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Hirota, K.] Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan; [Hammond, E. M.] Univ Oxford, Oxford Inst Radiat Oncol, Dept Oncol, Oxford, England; [Harada, H.] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama, Japan	Kyoto University; Kyoto University; Air Force Military Medical University; Chongqing Medical University; Kyoto University; University of Oxford; Japan Science & Technology Agency (JST)	Harada, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hharada@kuhp.kyoto-u.ac.jp	; Hirota, Kiichi/E-9181-2010	Hammond, Ester/0000-0002-2335-3146; Kobayshi, Minoru/0000-0003-3843-3584; Hirota, Kiichi/0000-0003-1110-0827	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) Japan Society for the Promotion of Science (JSPS), Japan [LS071]; program for Precursory Research for Embryonic Science and Technology (PRESTO) Japan Science and Technology Agency (JST); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT, Japan [26293276, 26461886, 26670558, 26670555, 25861088, 24791293, 24659563]; Sagawa Foundation; Kobayashi Foundation; Takeda Science Foundation; Mochida Memorial Foundation; International Science and Technology Cooperation Project of China and Japan [2010DFA31900]; Cancer Research UK [19276] Funding Source: researchfish; Grants-in-Aid for Scientific Research [26670693] Funding Source: KAKEN	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) Japan Society for the Promotion of Science (JSPS), Japan; program for Precursory Research for Embryonic Science and Technology (PRESTO) Japan Science and Technology Agency (JST); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sagawa Foundation; Kobayashi Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Foundation; International Science and Technology Cooperation Project of China and Japan; Cancer Research UK(Cancer Research UK); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr M Suematsu, Dr YA Minamishima, and Dr N Hayakawa for critical discussion. This study was supported by the Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan to HH (No. LS071), by the program for Precursory Research for Embryonic Science and Technology (PRESTO) from Japan Science and Technology Agency (JST) to HH, by the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to HH, and by Grants-in-Aids for Scientific Research (B) to HH (No. 26293276), for Scientific Research (C) to AM (No. 26461886), for challenging Exploratory Research to HH (No. 26670558) and to MH (No. 26670555), and for Young Scientists (B) to MK (No. 25861088), MY (No. 24791293) and SI (No. 24659563) from MEXT, Japan, by the Sagawa Foundation for the Promotion of Cancer Research to HH, by the Kobayashi Foundation for Cancer Research to HH, by the Takeda Science Foundation to HH, by the Mochida Memorial Foundation for Medical and Pharmaceutical Research to HH, and by the International Science and Technology Cooperation Project of China and Japan to ZL and HH (No. 2010DFA31900).	Adler E, 1939, BIOCHEM J, V33, P1028, DOI 10.1042/bj0331028; Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019; Bao Y, 2013, MOL CANCER RES, V11, P973, DOI 10.1158/1541-7786.MCR-12-0669-T; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Harada H, 2007, ONCOGENE, V26, P7508, DOI 10.1038/sj.onc.1210556; Harada H, 2009, BRIT J CANCER, V100, P747, DOI 10.1038/sj.bjc.6604939; Harada H, 2007, BIOCHEM BIOPH RES CO, V360, P791, DOI 10.1016/j.bbrc.2007.06.149; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1786; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCarthy N, 2012, NAT REV CANCER, V12, P229, DOI 10.1038/nrc3248; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Wakamatsu T, 2009, EUR J PHARMACOL, V617, P17, DOI 10.1016/j.ejphar.2009.06.060; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Zeng LH, 2008, CANCER SCI, V99, P2327, DOI 10.1111/j.1349-7006.2008.00943.x	30	59	61	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4758	4766		10.1038/onc.2014.411	http://dx.doi.org/10.1038/onc.2014.411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531325				2022-12-17	WOS:000360931500009
J	Karanika, S; Karantanos, T; Li, L; Corn, PG; Thompson, TC				Karanika, S.; Karantanos, T.; Li, L.; Corn, P. G.; Thompson, T. C.			DNA damage response and prostate cancer: defects, regulation and therapeutic implications	ONCOGENE			English	Review							CELL-CYCLE CHECKPOINTS; BRCA MUTATION CARRIERS; DOUBLE-STRAND BREAK; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; SUPPRESSES TUMORIGENESIS; ATAXIA-TELANGIECTASIA; GENETIC INSTABILITY; SYNTHETIC LETHALITY; ANDROGEN RECEPTOR	DNA damage response (DDR) includes the activation of numerous cellular activities that prevent duplication of DNA lesions and maintain genomic integrity, which is critical for the survival of normal and cancer cells. Specific genes involved in the DDR such as BRCA1/2 and P53 are mutated during prostate cancer progression, while various oncogenic signaling such as Akt and c-Myc are activated, enhancing the replication stress and increasing the genomic instability of cancer cells. These events may render prostate cancer cells particularly sensitive to inhibition of specific DDR pathways, such as PARP in homologous recombination DNA repair and Chk1 in cell cycle checkpoint and DNA repair, creating opportunities for synthetic lethality or synergistic cytotoxicity. Recent reports highlight the critical role of androgen receptor (AR) as a regulator of DDR genes, providing a rationale for combining DNA-damaging agents or targeted DDR inhibitors with hormonal manipulation or AR inhibition as treatment for aggressive disease. The aims of this review are to discuss specific DDR defects in prostate cancer that occur during disease progression, to summarize recent advances in understanding the regulation of DDR in prostate cancer, and to present potential therapeutic opportunities through combinational targeting of the intact components of DDR signaling pathways.	[Karanika, S.; Karantanos, T.; Li, L.; Corn, P. G.; Thompson, T. C.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Thompson, TC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, 1515 Holcombe Blvd, Houston, TX 77030 USA.	timthomp@mdanderson.org	Karanika, Styliani/ABH-7576-2020; KARANTANOS, THEODOROS/ABH-7600-2020	Karanika, Styliani/0000-0003-2387-6075; KARANTANOS, THEODOROS/0000-0002-6792-8298	National Institutes of Health through MD Anderson's Cancer Center Support Grant [5 P30 CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathryn L Hale, MS, MLIS, for her expert editorial assistance. This research is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, 5 P30 CA016672.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Al-Ubaidi FLT, 2013, CLIN CANCER RES, V19, P1547, DOI 10.1158/1078-0432.CCR-12-2795; Albisinni S, 2012, UROLOGY, V80, P162, DOI 10.1016/j.urology.2012.01.068; Angele S, 2004, BRIT J CANCER, V91, P783, DOI 10.1038/sj.bjc.6602007; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; Balistreri CR, 2014, CANCER GENE THER, V21, P2, DOI 10.1038/cgt.2013.77; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beer TM, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.lba1; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cai BW, 2013, CELL REP, V4, P516, DOI 10.1016/j.celrep.2013.06.039; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Chatterjee P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060408; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, MOL CARCINOGEN, V53, P85, DOI 10.1002/mc.21948; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Do K, 2013, CELL CYCLE, V12, P3159, DOI 10.4161/cc.26062; Dombernowsky SL, 2008, J CLIN ONCOL, V26, P3057, DOI 10.1200/JCO.2007.14.6613; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Eastham JA, 1995, CLIN CANCER RES, V1, P1111; Elkahwaji JE, 2013, RES REP UROL, V5, P1, DOI 10.2147/RRU.S23386; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gabrielli B, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00009; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guerra L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008924; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Heaphy CM, 2013, CANCER DISCOV, V3, P1130, DOI 10.1158/2159-8290.CD-13-0135; Hoglund A, 2011, CLIN CANCER RES, V17, P7067, DOI 10.1158/1078-0432.CCR-11-1198; Ide H, 2012, PROSTATE, V72, P1407, DOI 10.1002/pros.22492; Iglehart JD, 2009, NEW ENGL J MED, V361, P189, DOI 10.1056/NEJMe0903044; Imamoto T, 2008, INT J UROL, V15, P472, DOI 10.1111/j.1442-2042.2008.02074.x; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; KASTAN MB, 1991, CANCER RES, V51, P6304; Khandrika L, 2009, CANCER LETT, V282, P125, DOI 10.1016/j.canlet.2008.12.011; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535-7163.MCT-11-0949; Lavin MF, 2007, RADIOTHER ONCOL, V83, P231, DOI 10.1016/j.radonc.2007.04.032; Leongamornlert D, 2012, BRIT J CANCER, V106, P1697, DOI 10.1038/bjc.2012.146; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Lieber MR, 2010, NAT STRUCT MOL BIOL, V17, P393, DOI 10.1038/nsmb0410-393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Malins DC, 2003, P NATL ACAD SCI USA, V100, P5401, DOI 10.1073/pnas.0931396100; Malins DC, 2001, CANCER RES, V61, P6025; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martin Y, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-21; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Pedram A, 2009, MOL BIOL CELL, V20, P3374, DOI 10.1091/mbc.E09-01-0085; Plo I, 2009, ONCOGENE, V28, P2231, DOI 10.1038/onc.2009.85; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sandhu SK, 2013, ANN ONCOL, V24, P1416, DOI 10.1093/annonc/mdt074; Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7; Schatzl G, 2001, PROSTATE, V47, P52; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schlomm T, 2008, MODERN PATHOL, V21, P1371, DOI 10.1038/modpathol.2008.104; Sciarra A, 2007, EUR UROL, V52, P964, DOI 10.1016/j.eururo.2007.06.038; Smith TB, 2010, J CLIN PSYCHOL, V67, P1, DOI DOI 10.1080/14681360903556749; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; van Asperen CJ, 2005, J MED GENET, V42, P711, DOI 10.1136/jmg.2004.028829; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wang XB, 2012, ONCOL REP, V28, P2247, DOI 10.3892/or.2012.2068; Zhou JY, 2013, AGING-US, V5, P3, DOI 10.18632/aging.100524	106	59	62	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2815	2822		10.1038/onc.2014.238	http://dx.doi.org/10.1038/onc.2014.238			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25132269	Green Accepted			2022-12-17	WOS:000355324300001
J	Kim, HP; Cho, GA; Han, SW; Shin, JY; Jeong, EG; Song, SH; Lee, WC; Lee, KH; Bang, D; Seo, JS; Kim, JI; Kim, TY				Kim, H-P; Cho, G-A; Han, S-W; Shin, J-Y; Jeong, E-G; Song, S-H; Lee, W-C; Lee, K-H; Bang, D.; Seo, J-S; Kim, J-Il; Kim, T-Y			Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis	ONCOGENE			English	Article						gene fusion; fusion transcript; gastric cancer; transcriptome sequencing; next-generation sequencing	PROSTATE-CANCER; GENE FUSIONS; KINASE; MET; IDENTIFICATION; REARRANGEMENTS; INHIBITORS; DISCOVERY; RNAS	Gene fusion is involved in the development of various types of malignancies. Recent advances in sequencing technology have facilitated identification of gene fusions and have stimulated the research of this field in cancer. In the present study, we performed next-generation transcriptome sequencing in order to discover novel gene fusions in gastric cancer. A total of 282 fusion transcript candidates were detected from 12 gastric cancer cell lines by bioinformatic filtering. Among the candidates, we have validated 19 fusion transcripts, which are 7 inter-chromosomal and 12 intra-chromosomal fusions. A novel DUS4L-BCAP29 fusion transcript was found in 2 out of 12 cell lines and 10 out of 13 gastric cancer tissues. Knockdown of DUS4L-BCAP29 transcript using siRNA inhibited cell proliferation. Soft agar assay further confirmed that this novel fusion transcript has tumorigenic potential. We also identified that microRNA-coding gene PVT1, which is amplified in double minute chromosomes in SNU-16 cells, is recurrently involved in gene fusion. PVT1 produced six different fusion transcripts involving four different genes as fusion partners. Our findings provide better insight into transcriptional and genetic alterations of gastric cancer: namely, the tumorigenic effects of transcriptional read-through and a candidate region for genetic instability.	[Kim, H-P; Cho, G-A; Han, S-W; Jeong, E-G; Song, S-H; Lee, K-H; Kim, T-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; [Han, S-W; Lee, K-H; Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Shin, J-Y; Lee, W-C; Seo, J-S; Kim, J-Il] Seoul Natl Univ, Genom Med Inst, Med Res Ctr, Seoul 110744, South Korea; [Shin, J-Y; Seo, J-S; Kim, J-Il] Psoma Therapeut Inc, Seoul, South Korea; [Lee, W-C; Seo, J-S; Kim, J-Il] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul 110744, South Korea; [Bang, D.] Yonsei Univ, Coll Sci, Dept Chem, Seoul 120749, South Korea; [Seo, J-S; Kim, J-Il] Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110744, South Korea; [Seo, J-S] Macrogen Inc, Seoul, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Seoul National University (SNU); Macrogen, Inc.; Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 110744, South Korea.	kimty@snu.ac.kr	Lee, Won-Chul/D-5789-2012; KIM, JONG-IL/D-1019-2011; Seo, Jeong-Sun/J-2763-2012	Lee, Won-Chul/0000-0001-8052-2420; KIM, JONG-IL/0000-0002-7240-3744; 	Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A091081]; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology, Republic of Korea [2009-0093820]	Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology, Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea)	This study was partially funded by the Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Grant No. A091081), and by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology, Republic of Korea (2009-0093820).	Berger MF, 2010, GENOME RES, V20, P413, DOI 10.1101/gr.103697.109; Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6; Forment JV, 2012, NAT REV CANCER, V12, P663, DOI 10.1038/nrc3352; FUSHIDA S, 1993, INT J ONCOL, V3, P1067; Gozgit JM, 2012, MOL CANCER THER, V11, P690, DOI 10.1158/1535-7163.MCT-11-0450; Huppi K, 2008, MOL CANCER RES, V6, P212, DOI 10.1158/1541-7786.MCR-07-0105; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Jung KW, 2013, CANCER RES TREAT, V45, P15, DOI 10.4143/crt.2013.45.1.15; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Kawamata N, 2009, LEUKEMIA RES, V33, P569, DOI 10.1016/j.leukres.2008.07.030; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Letunic I, 2011, NUCLEIC ACIDS RES, V39, pW475, DOI [10.1093/nar/gkr201, 10.1093/nar/gkr931]; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; Li H, 2009, CELL CYCLE, V8, P218, DOI 10.4161/cc.8.2.7358; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Sboner A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r104; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Sigrist CJA, 2013, NUCLEIC ACIDS RES, V41, pE344, DOI 10.1093/nar/gks1067; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tao J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001423; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749; Zhang YM, 2012, CANCER DISCOV, V2, P598, DOI 10.1158/2159-8290.CD-12-0042	35	59	66	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5434	5441		10.1038/onc.2013.490	http://dx.doi.org/10.1038/onc.2013.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240688				2022-12-17	WOS:000345120700005
J	Beltran, AS; Graves, LM; Blancafort, P				Beltran, A. S.; Graves, L. M.; Blancafort, P.			Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function	ONCOGENE			English	Article						Engrailed 1; inflammatory breast cancer; triple-negative breast cancer; dopaminergic neuron; reprogramming; interference peptides	TRANSFER-RNA SYNTHETASE; TUMOR-INITIATING CELLS; DOPAMINERGIC-NEURONS; MUTATIONAL PROCESSES; MOLECULAR PORTRAITS; GENE-EXPRESSION; OVARIAN-CANCER; TARGETING HOX; PBX; SUBTYPES	Basal-like breast tumors are aggressive cancers associated with high proliferation and metastasis. Chemotherapy is currently the only treatment option; however, resistance often occurs resulting in recurrence and patient death. Some extremely aggressive cancers are also associated with hypoxia, inflammation and high leukocyte infiltration. Herein, we discovered that the neural-specific transcription factor, Engrailed 1 (EN1), is exclusively overexpressed in these tumors. Short hairpin RNA (shRNA)-mediated knockdown of EN1 triggered potent and selective cell death. In contrast, ectopic overexpression of EN1 in normal cells activated survival pathways and conferred resistance to chemotherapeutic agents. Exogenous expression of EN1 cDNA reprogrammed the breast epithelial cells toward a long-lived, neural-like phenotype displaying dopaminergic markers. Gene expression microarrays demonstrated that the EN1 cDNA altered transcription of a high number of inflammatory molecules, notably chemokines and chemokine receptors, which could mediate prosurvival pathways. To block EN1 function, we engineered synthetic interference peptides (iPeps) comprising the EN1-specific sequences that mediate essential protein-protein interactions necessary for EN1 function and an N-terminal cell-penetrating peptide/nuclear localization sequence. These EN1-iPeps rapidly mediated a strong apoptotic response in tumor cells overexpressing EN1, with no toxicity to normal or non EN1-expressing cells. Delivery of EN1-iPeps into basal-like cancer cells significantly decreased the fifty percent inhibitory concentrations (IC50) of chemotherapeutic drugs routinely used to treat breast cancer. Lastly, matrix-assisted laser desorption/ionization-time of flight mass spectrometry and immunoprecipitation assays demonstrated that EN1-iPeps captured targets involved in transcriptional and post-transcriptional regulation. Importantly, the EN1-iPeps bound the glutamyl-prolyl tRNA synthetase (EPRS) target, which has been associated with the transcript-specific translational control of inflammatory proteins and activation of amino-acid stress pathways. This work unveils EN1 as an activator of intrinsic inflammatory pathways associated with prosurvival in basal-like breast cancer. We further build upon these results and describe the engineering of iPeps targeting EN1 (EN1-iPeps) as a novel and selective therapeutic strategy to combat these lethal forms of breast cancer.	[Beltran, A. S.; Graves, L. M.; Blancafort, P.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [Blancafort, P.] Univ Western Australia, Sch Anat Physiol & Human Biol, Canc Epigenet Grp, Crawley, WA 6009, Australia	University of North Carolina; University of North Carolina Chapel Hill; University of Western Australia	Blancafort, P (corresponding author), Univ Western Australia, Sch Anat Physiol & Human Biol, Canc Epigenet Grp, 35 Stirling Highway, Crawley, WA 6009, Australia.	pilar.blancafort@uwa.edu.au	Peptide Synthesis and Array Facility, High-Throughput/AFI-7866-2022; , Proteomics Core UNC/AFQ-7201-2022; Graves, Lee/AAG-5470-2021; , Proteomics Core UNC/AAH-3777-2022	Blancafort, Pilar/0000-0002-3881-7396	NIH-NCI [CA016086, 1R01CA125273, 3R01CA125273-03S1]; DOD [W81XWH-10-1-0265]; NATIONAL CANCER INSTITUTE [R01CA125273, R01CA170370, P30CA016086] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is based in part upon work conducted using the UNC Michael Hooker Proteomics Center, which is supported in part by the NIH-NCI Grant No. CA016086 to the Lineberger Comprehensive Cancer Center and by NHI-NCI Grants 1R01CA125273, 3R01CA125273-03S1 and DOD W81XWH-10-1-0265 to PB. We thank Drs DC Connolly, L Vartikovski and JE Green for providing the murine cell lines from genetically engineered mouse models.	Alberi L, 2004, DEVELOPMENT, V131, P3229, DOI 10.1242/dev.01128; Alvarez-Fischer D, 2011, NAT NEUROSCI, V14, P1260, DOI 10.1038/nn.2916; Arif A, 2012, MOL CELL BIOL, V32, P5046, DOI 10.1128/MCB.01168-12; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bell D, 2012, CANCER-AM CANCER SOC, V118, P1288, DOI 10.1002/cncr.26412; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Beltran AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024595; Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Craig DW, 2012, MOL CANCER THER, V2, P104; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; dos Santos MTMA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-23; Eiro N, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24010; Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3; Gray J, 2012, NATURE, V486, P328, DOI 10.1038/486328a; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang X, 2013, MOL CELL ENDOCRINOL; Keller TL, 2012, NAT CHEM BIOL, V8, P311, DOI [10.1038/nchembio.790, 10.1038/NCHEMBIO.790]; Kim J., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.5607/EN.2013.22.1.38; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108; LaRonde-LeBlanc NA, 2003, GENE DEV, V17, P2060, DOI 10.1101/gad.1103303; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Morrison BE, 2012, J IMMUNOL, V189, P5498, DOI 10.4049/jimmunol.1102150; Mukhopadhyay R, 2009, TRENDS BIOCHEM SCI, V34, P324, DOI 10.1016/j.tibs.2009.03.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ninkovic J, 2010, NEURON, V68, P682, DOI 10.1016/j.neuron.2010.09.030; Nokes BT, 2013, J CANCER, V4, P104, DOI 10.7150/jca.5002; Nolan YM, 2013, TRENDS MOL MED, V19, P187, DOI 10.1016/j.molmed.2012.12.003; Pandha H, 2012, BJU INT, V110, pE287, DOI 10.1111/j.1464-410X.2012.11208.x; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Perou CM, 2010, LANCET ONCOL, V11, P718, DOI 10.1016/S1470-2045(10)70176-5; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rachidi SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057911; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Sasaki Y, 2009, BREAST CANCER-TOKYO, V16, P254, DOI 10.1007/s12282-009-0153-5; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shears L, 2008, J UROLOGY, V180, P2196, DOI 10.1016/j.juro.2008.07.018; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Varticovski L, 2007, CLIN CANCER RES, V13, P2168, DOI 10.1158/1078-0432.CCR-06-0918; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Yao P, 2012, CELL CYCLE, V11, P1868, DOI 10.4161/cc.20417; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	55	59	61	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4767	4777		10.1038/onc.2013.422	http://dx.doi.org/10.1038/onc.2013.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141779	Green Published, hybrid			2022-12-17	WOS:000343239500007
J	Lin, A; Yao, J; Zhuang, L; Wang, D; Han, J; Lam, EWF; Gan, B				Lin, A.; Yao, J.; Zhuang, L.; Wang, D.; Han, J.; Lam, E. W-F; Gan, B.		TCGA Res Network	The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress	ONCOGENE			English	Article						FoxO; mTORC1; energy stress; BNIP3	TSC1-TSC2 COMPLEX; TUMOR SUPPRESSORS; MAMMALIAN TARGET; GROWTH-CONTROL; AMPK; LKB1; AUTOPHAGY; KINASE; FOXOS; PHOSPHORYLATION	Normal cells possess adaptive mechanisms to couple energy availability with cell growth (cell size increase) and survival, and imbalances are associated with major diseases such as cancer. Inactivation of critical regulators involved in energy stress response, including adenosine monophosphate-activated protein kinase (AMPK), liver kinase B1 (LKB1), tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis complex 2 (TSC2), leads to uncontrolled cell growth yet increased apoptosis under energy stress. These energy stress regulators are also important in tumor suppression and metabolism. Here, we show that forkhead box O (FoxO) transcription factor, a central regulator of tumor suppression and metabolism, plays a unique role in energy stress response. Fox Os inhibit the mammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell growth, under energy stress, and inactivation of Fox Os alleviates energy stress-mediated mTORC1 repression. Surprisingly, unlike AMPK-, Lkb1- or Tsc1/2-deficient cells, FoxO-deficient cells exhibit decreased apoptosis under energy stress. FoxOs operate to inhibit mTORC1 signaling and cell survival independent of AMPK and TSC. Integrated transcriptomic and functional analyses identified BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)-a negative regulator of both Rheb and Bcl2 prosurvival family members-as a key downstream target of FoxOs to inhibit mTORC1 function and promote apoptosis in response to energy stress. We show that p38 beta, but not AMPK, is likely to function upstream of FoxO-BNIP3 to mediate energy stress response. Finally, we reveal that low expression of FoxO or BNIP3 correlates with poor clinical outcomes in renal cancer patients. Together, our study uncovers a novel signaling circuit functioning to mediate cellular energy responses to control cell growth and survival. These findings also have important implications to human cancers.	[Lin, A.; Zhuang, L.; Wang, D.; Gan, B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Yao, J.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Han, J.] Xiamen Univ, Key Lab, Minist Educ Cell Biol & Tumor Cell Engn, Sch Life Sci, Xiamen, Peoples R China; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England; [TCGA Res Network] Univ Texas Hlth Sci Ctr Houston, Univ Texas MD Anderson Canc Ctr, TCGA Genome Data Anal Ctr, Houston, TX 77030 USA; [Gan, B.] Univ Texas Houston, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Xiamen University; Imperial College London; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Gan, B (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bgan@mdanderson.org	Han, J/G-4671-2010; Gan, Boyi/HDM-4206-2022; Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	MD Anderson Cancer Center, US Department of Defense [TS093049, PC100356]; LAM Foundation [LAM092P01-12]; Concern Foundation; Sidney Kimmel Foundation; TCGA grant from NCI/NIH [U24CA143883]; Cancer Research UK [12011] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U24CA143883, P30CA016672, R01CA181196] Funding Source: NIH RePORTER	MD Anderson Cancer Center, US Department of Defense(United States Department of Defense); LAM Foundation; Concern Foundation; Sidney Kimmel Foundation; TCGA grant from NCI/NIH; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Junjie Chen and Hui-Kuan Lin for critical reading of the paper. We also thank Dr Benoit Viollet for providing AMPK WT and KO MEFs and Dr Hsiao-Sheng Liu for providing BNIP3 expression plasmid. BG would also like to thank Ron DePinho for his encouragement and suggestions on this study. This study has been supported by grants from MD Anderson Cancer Center, US Department of Defense (TS093049 and PC100356), LAM Foundation (LAM092P01-12), Concern Foundation and Sidney Kimmel Foundation (to BG) and the TCGA grant U24CA143883 from NCI/NIH (to JY). BG is a Kimmel Scholar and a member of the MD Anderson Cancer Center (CA016672).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Chinnadurai G, 2008, ONCOGENE, V27, pS114, DOI 10.1038/onc.2009.49; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Davila D, 2012, CELL DEATH DIFFER, V19, P1677, DOI 10.1038/cdd.2012.49; Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gan BY, 2010, CANCER CELL, V18, P472, DOI 10.1016/j.ccr.2010.10.019; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871; Kim SG, 2013, MOL CELL, V49, P172, DOI 10.1016/j.molcel.2012.10.003; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zheng M, 2011, NAT CELL BIOL, V13, P263, DOI 10.1038/ncb2168	46	59	61	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3183	3194		10.1038/onc.2013.273	http://dx.doi.org/10.1038/onc.2013.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851496	Green Accepted			2022-12-17	WOS:000338410000011
J	Turner-Ivey, B; Manevich, Y; Schulte, J; Kistner-Griffin, E; Jezierska-Drutel, A; Liu, Y; Neumann, CA				Turner-Ivey, B.; Manevich, Y.; Schulte, J.; Kistner-Griffin, E.; Jezierska-Drutel, A.; Liu, Y.; Neumann, C. A.			Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer	ONCOGENE			English	Article						redox signaling; peroxiredoxin; senescence; oxidative stress; protein tyrosine phosphatases; p38MAPK	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; MAP KINASE; CATALYTIC ACTIVATION; PREMATURE SENESCENCE; P38; CELLS; PHOSPHATASE-1; PEROXIREDOXIN; STRESS	Recent studies suggest that Peroxiredoxin 1 (Prdx1), in addition to its known H2O2-scavenging function, mediates cell signaling through redox-specific protein-protein interactions. Our data illustrate how Prdx1 specifically coordinates p38MAPK-induced signaling through regulating p38MAPK alpha phosphatases in an H2O2 dose-dependent manner. MAPK phosphatases (MKP-1 and/or MKP-5), which are known to dephosphorylate and deactivate the senescence-inducing MAPK p38 alpha, belong to a group of redox-sensitive phosphatases (protein tyrosine phosphatases) characterized by a low pKa cysteine in their active sites. We found that Prdx1 bound to both MKP-1 and MKP-5, but dissociated from MKP-1 when the Prdx1 peroxidatic cysteine Cys52 was over-oxidized to sulfonic acid, which in turn resulted in MKP-1 oxidation-induced oligomerization and inactivity toward p38MAPK alpha. Conversely, over-oxidation of Prdx1-Cys52 was enhancing in the Prdx1:MKP-5 complex with increasing amounts of H2O2 concentrations and correlated with a protection from oxidation-induced oligomerization and inactivation of MKP-5 so that activation toward p38MAPK was maintained. Further examination of this Prdx1-specific mechanism in a model of reactive oxygen species-induced senescence of human breast epithelial cells revealed the specific activation of MKP-5, resulting in decreased p38MAPK alpha activity. Taken together, our data suggest that Prdx1 orchestrates redox signaling in an H2O2 dose-dependent manner through the oxidation status of its peroxidatic cysteine Cys52.	[Turner-Ivey, B.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; [Manevich, Y.; Schulte, J.; Jezierska-Drutel, A.; Neumann, C. A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut Med, Charleston, SC 29425 USA; [Kistner-Griffin, E.] Med Univ S Carolina, Dept Biostat & Epidemiol, Charleston, SC 29425 USA; [Liu, Y.] Nationwide Childrens Hosp, Res Inst, Dept Pediat, Columbus, OH USA; [Neumann, C. A.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA; [Neumann, C. A.] UPCI, Magee Womens Res Inst, Pittsburgh, PA 15213 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Neumann, CA (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, E1340 Thomas E Starzl Biomed Sci Tower 200 Lothro, Pittsburgh, PA 15261 USA.	neumannc@upmc.edu	Liu, Yusen/E-3527-2011	Neumann, Carola/0000-0003-2801-9531	 [K22 ES012985-01];  [W81XWH-07-1-0691];  [R01 CA131350];  [CCSG P30 CA138313];  [5T32CA119945-05]; NATIONAL CANCER INSTITUTE [P30CA138313, T32CA119945, R01CA131350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES012985] Funding Source: NIH RePORTER	; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We would like to thank Dr Eisuke Nishida for providing the MKP-5 cDNA; Dr Yusen Liu for providing MKP-1 WT and MKP-1 C258S cDNA; and Dr Steve Rosenzweig and Dr Scott Eblen for fruitful discussions. This work has been funded by K22 ES012985-01 (CAN), W81XWH-07-1-0691 (CAN), R01 CA131350, CCSG P30 CA138313 (HCC) and 5T32CA119945-05 (BT).	Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Bowers RR, 2012, BIOCHEMISTRY-US, V51, P7740, DOI 10.1021/bi301006w; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Coppe JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188; Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005; Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819; Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236; Dasgupta J, 2010, J CELL PHYSIOL, V225, P52, DOI 10.1002/jcp.22193; Day AM, 2012, MOL CELL, V45, P398, DOI 10.1016/j.molcel.2011.11.027; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Han YH, 2005, FEBS LETT, V579, P4897, DOI 10.1016/j.febslet.2005.07.049; Hou N, 2008, ENDOCRINOLOGY, V149, P1654, DOI 10.1210/en.2007-0988; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jeong DG, 2006, J MOL BIOL, V360, P946, DOI 10.1016/j.jmb.2006.05.059; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee JJ, 2010, ONCOGENE, V29, P561, DOI 10.1038/onc.2009.355; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Neumann CA, 1998, BLOOD, V92, p215A; Neumann CA, 2009, CELL CYCLE, V8, P4072, DOI 10.4161/cc.8.24.10242; Neumann CA, 2007, CURR OPIN PHARMACOL, V7, P375, DOI 10.1016/j.coph.2007.04.007; Nonn L, 2006, CANCER RES, V66, P4516, DOI 10.1158/0008-5472.CAN-05-3796; Nonn L, 2007, CARCINOGENESIS, V28, P1188, DOI 10.1093/carcin/bgl241; Parra E, 2010, ONCOL REP, V24, P1339, DOI 10.3892/or_00000991; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Schilder YDC, 2009, FREE RADICAL BIO MED, V46, P1598, DOI 10.1016/j.freeradbiomed.2009.03.013; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Staples CJ, 2010, J BIOL CHEM, V285, P25928, DOI 10.1074/jbc.M110.117911; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tephly LA, 2007, AM J RESP CELL MOL, V37, P366, DOI 10.1165/rcmb.2006-0268OC; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Trost TM, 2005, CANCER RES, V65, P840; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang ZQ, 2008, J BIOL CHEM, V283, P21011, DOI 10.1074/jbc.M802229200; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Zhou JY, 2006, CANCER RES, V66, P4888, DOI 10.1158/0008-5472.CAN-05-4229	50	59	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5302	5314		10.1038/onc.2012.624	http://dx.doi.org/10.1038/onc.2012.624			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23334324	hybrid, Green Accepted			2022-12-17	WOS:000326922100006
J	Eberlein, C; Kendrew, J; McDaid, K; Alfred, A; Kang, JS; Jacobs, VN; Ross, SJ; Rooney, C; Smith, NR; Rinkenberger, J; Cao, A; Churchman, A; Marshall, JF; Weir, HM; Bedian, V; Blakey, DC; Foltz, IN; Barry, ST				Eberlein, C.; Kendrew, J.; McDaid, K.; Alfred, A.; Kang, J. S.; Jacobs, V. N.; Ross, S. J.; Rooney, C.; Smith, N. R.; Rinkenberger, J.; Cao, A.; Churchman, A.; Marshall, J. F.; Weir, H. M.; Bedian, V.; Blakey, D. C.; Foltz, I. N.; Barry, S. T.			A human monoclonal antibody 264RAD targeting alpha v beta 6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo	ONCOGENE			English	Article						integrin; alpha v beta 6; alpha v beta 8; beta-6; beta-8; TGF-beta	SQUAMOUS CARCINOMA-CELLS; EPITHELIAL OVARIAN-CANCER; MOUTH-DISEASE VIRUS; FACTOR-BETA; BREAST-CANCER; UP-REGULATION; ACTIVATION; EXPRESSION; FIBROSIS; INVASION	alpha v beta 6 integrin expression is upregulated on a wide range of epithelial tumours, and is thought to play a role in modulating tumour growth. Here we describe a human therapeutic antibody 264RAD, which binds and inhibits alpha v beta 6 integrin function. 264RAD cross-reacts with human, mouse and cynomolgus monkey alpha v beta 6, and inhibits binding to all ligands including the latency-associated peptide of TGF-beta. Screening across a range of integrins revealed that 264RAD also binds and inhibits the related integrin alpha v beta 8, but not the integrins alpha 5 beta 1, alpha v beta 3, alpha v beta 5 and alpha 4 beta 1. In vitro 264RAD inhibited invasion of VB6 and Detroit 562 cells in a Matrigel invasion assay and alpha v beta 6 mediated production of matrix metalloproteinase-9 in Calu-3 cells. It inhibited TGF-beta-mediated activation of dermal skin fibroblasts by preventing local activation of TGF-beta by NCI-H358 tumour cells in a tumour cell - fibroblast co-culture assay. In vivo 264RAD showed dose-dependent inhibition of Detroit 562 tumour growth, regressing established tumours when dosed at 20 mg/kg once weekly. The reduction in growth associated with 264RAD was related to a dose-dependent inhibition of Ki67 and phospho-ERK and a reduction of alpha v beta 6 expression in the tumour cells, coupled to a reduction in fibronectin and alpha smooth muscle actin expression in stromal fibroblasts. 264RAD also reduced the growth and metastasis of orthotopic 4T1 tumours. At 20 mg/kg growth of both the primary tumour and the number of metastatic deposits in lung were reduced. The data support the conclusion that 264RAD is a potent inhibitor of alpha v beta 6 integrin, with some activity against alpha v beta 8 integrin, that reduces both tumour growth and metastasis.	[Eberlein, C.; Kendrew, J.; McDaid, K.; Jacobs, V. N.; Ross, S. J.; Rooney, C.; Smith, N. R.; Weir, H. M.; Blakey, D. C.; Barry, S. T.] AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England; [Alfred, A.; Kang, J. S.; Rinkenberger, J.; Foltz, I. N.] Amgen Inc, Burnaby, BC, Canada; [Cao, A.; Bedian, V.] AstraZeneca R&D Boston, Oncol iMED, Waltham, MA USA; [Churchman, A.; Marshall, J. F.] Queen Mary Univ London, Barts Canc Inst, London, England	AstraZeneca; AstraZeneca; University of London; Queen Mary University London	Barry, ST (corresponding author), AstraZeneca, Oncol iMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	Simon.T.Barry@astrazeneca.com		Marshall, John/0000-0002-0494-2295	MRC; MRC [G0800825] Funding Source: UKRI; Medical Research Council [G0800825] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Adrian Churchman was funded by a MRC Pilot Award.	Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Ahmed N, 2002, J HISTOCHEM CYTOCHEM, V50, P1371, DOI 10.1177/002215540205001010; Ahmed N, 2002, CARCINOGENESIS, V23, P237, DOI 10.1093/carcin/23.2.237; Al-Hazmi N, 2007, EUR J ORAL SCI, V115, P454, DOI 10.1111/j.1600-0722.2007.00481.x; Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; BUSK M, 1992, J BIOL CHEM, V267, P5790; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cambier S, 2000, CANCER RES, V60, P7084; Culhane AC, 2009, CANCER RES, V69, P7480, DOI 10.1158/0008-5472.CAN-08-3350; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; DiCara D, 2007, J BIOL CHEM, V282, P9657, DOI 10.1074/jbc.M610461200; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Hahm K, 2007, AM J PATHOL, V170, P110, DOI 10.2353/ajpath.2007.060158; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183; Kogelberg H, 2008, J MOL BIOL, V382, P385, DOI 10.1016/j.jmb.2008.07.013; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; Ma LJ, 2003, AM J PATHOL, V163, P1261, DOI 10.1016/S0002-9440(10)63486-4; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Morgan MR, 2011, ONCOGENE, V30, P1422, DOI 10.1038/onc.2010.535; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Popov Y, 2008, J HEPATOL, V48, P453, DOI 10.1016/j.jhep.2007.11.021; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Ryer EJ, 2006, ARTERIOSCL THROM VAS, V26, P780, DOI 10.1161/01.ATV.0000209517.00220.cd; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; Sipos B, 2004, HISTOPATHOLOGY, V45, P226, DOI 10.1111/j.1365-2559.2004.01919.x; Su H, 2010, AM J PATHOL, V176, P1018, DOI 10.2353/ajpath.2010.090453; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Van Aarsen LAK, 2008, CANCER RES, V68, P561, DOI 10.1158/0008-5472.CAN-07-2307; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; Zhong ZJ, 2010, CLIN CANCER RES, V16, P1191, DOI 10.1158/1078-0432.CCR-09-1634	49	59	64	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4406	4416		10.1038/onc.2012.460	http://dx.doi.org/10.1038/onc.2012.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23108397				2022-12-17	WOS:000324404200009
J	Nicol, SM; Bray, SE; Black, HD; Lorimore, SA; Wright, EG; Lane, DP; Meek, DW; Coates, PJ; Fuller-Pace, FV				Nicol, S. M.; Bray, S. E.; Black, H. Derek; Lorimore, S. A.; Wright, E. G.; Lane, D. P.; Meek, D. W.; Coates, P. J.; Fuller-Pace, F. V.			The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage	ONCOGENE			English	Article						p68 (DDX5) RNA helicase; p53; DNA damage; cell-cycle arrest; apoptosis	HEMATOPOIETIC STEM-CELLS; ESTROGEN-RECEPTOR-ALPHA; IN-VIVO; TRANSCRIPTIONAL COACTIVATOR; IONIZING-RADIATION; CANCER DEVELOPMENT; TUMOR-SUPPRESSOR; P53; PROTEINS; STRESS	The RNA helicase p68 (DDX5) is an established co-activator of the p53 tumour suppressor that itself has a pivotal role in orchestrating the cellular response to DNA damage. Although several factors influence the biological outcome of p53 activation, the mechanisms governing the choice between cell-cycle arrest and apoptosis remain to be elucidated. In the present study, we show that, while p68 is critical for p53-mediated transactivation of the cell-cycle arrest gene p21(WAF1/CIP1), it is dispensable for induction of several pro-apoptotic genes in response to DNA damage. Moreover, p68 depletion results in a striking inhibition of recruitment of p53 and RNA Pol II to the p21 promoter but not to the Bax or PUMA promoters, providing an explanation for the selective effect on p21 induction. Importantly, these findings are mirrored in a novel inducible p68 knockout mouse model in which p68 depletion results in a selective inhibition of p21 induction in several tissues. Moreover, in the bone marrow, p68 depletion results in an increased sensitivity to g-irradiation, consistent with an increased level of apoptosis. These data highlight a novel function of p68 as a modulator of the decision between p53-mediated growth arrest and apoptosis in vitro and in vivo.	[Nicol, S. M.; Lorimore, S. A.; Wright, E. G.; Meek, D. W.; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Dundee DD1 9SY, Scotland; [Bray, S. E.; Coates, P. J.] Univ Dundee, Ninewells Hosp & Med Sch, Tayside Tissue Bank, Dundee DD1 9SY, Scotland; [Black, H. Derek] Univ Dundee, Ninewells Hosp & Med Sch, Med Sch Resource Unit, Dundee DD1 9SY, Scotland; [Lane, D. P.] ASTAR, Immunos, Lab P53, Singapore, Singapore	University of Dundee; University of Dundee; University of Dundee; Agency for Science Technology & Research (A*STAR)	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Dundee DD1 9SY, Scotland.	f.v.fullerpace@dundee.ac.uk	Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306; Lane, David/0000-0003-0551-3545	Cancer Research UK [C8745/A11216]; Association for International Cancer Research [06-613]	Cancer Research UK(Cancer Research UK); Association for International Cancer Research	We thank Colin Henderson for helpful discussions. This work was supported by grants from Cancer Research UK (C8745/A11216) and the Association for International Cancer Research (06-613).	Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Coates PJ, 2003, J PATHOL, V201, P377, DOI 10.1002/path.1456; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fei PW, 2002, CANCER RES, V62, P7316; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; HOY CA, 1993, MUTAT RES, V290, P217, DOI 10.1016/0027-5107(93)90162-9; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; LORIMORE SA, 1995, CELL DEATH DIFFER, V2, P233; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lu X, 1996, ONCOGENE, V13, P413; MacCallum DE, 1996, ONCOGENE, V13, P2575; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022	34	59	63	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3461	3469		10.1038/onc.2012.426	http://dx.doi.org/10.1038/onc.2012.426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22986526	Green Accepted			2022-12-17	WOS:000322014900007
J	Luo, Y; Tsuchiya, KD; Park, DI; Fausel, R; Kanngurn, S; Welcsh, P; Dzieciatkowski, S; Wang, J; Grady, WM				Luo, Y.; Tsuchiya, K. D.; Park, D. Il; Fausel, R.; Kanngurn, S.; Welcsh, P.; Dzieciatkowski, S.; Wang, J.; Grady, W. M.			RET is a potential tumor suppressor gene in colorectal cancer	ONCOGENE			English	Article						colon neoplasia; methylation; RET	ISLAND METHYLATOR PHENOTYPE; RECEPTOR TYROSINE KINASE; HUMAN-COLON ADENOMAS; TGF-BETA; DNA METHYLATION; CELL LINE; HIRSCHSPRUNG-DISEASE; THYROID-CANCER; MICE LACKING; GDNF FAMILY	Cancer arises as the consequence of mutations and epigenetic alterations that activate oncogenes and inactivate tumor suppressor genes. Through a genome-wide screen for methylated genes in colon neoplasms, we identified aberrantly methylated RET in colorectal cancer. RET, a transmembrane receptor tyrosine kinase and a receptor for the glial cell-derived neurotrophic factor family ligands, was one of the first oncogenes to be identified, and has been shown to be an oncogene in thyroid cancer and pheochromocytoma. However, unexpectedly, we found RET is methylated in 27% of colon adenomas and in 63% of colorectal cancers, and now provide evidence that RET has tumor suppressor activity in colon cancer. The aberrant methylation of RET correlates with decreased RET expression, whereas the restoration of RET in colorectal cancer cell lines results in apoptosis. Furthermore, in support of a tumor suppressor function of RET, mutant RET has also been found in primary colorectal cancer. We now show that these mutations inactivate RET, which is consistent with RET being a tumor suppressor gene in the colon. These findings suggest that the aberrant methylation of RET and the mutational inactivation of RET promote colorectal cancer formation, and that RET can serve as a tumor suppressor gene in the colon. Moreover, the increased frequency of methylated RET in colon cancers compared with adenomas suggests RET inactivation is involved in the progression of colon adenomas to cancer. Oncogene (2013) 32, 2037-2047; doi:10.1038/onc.2012.225; published online 2 July 2012	[Luo, Y.; Wang, J.] Sun Yat Sen Univ, Dept Colorectal Surg, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China; [Luo, Y.; Tsuchiya, K. D.; Park, D. Il; Fausel, R.; Kanngurn, S.; Dzieciatkowski, S.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Tsuchiya, K. D.] Seattle Childrens Hosp, Dept Lab Med & Pathol, Seattle, WA USA; [Tsuchiya, K. D.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; [Park, D. Il] Sungkyunkwak Univ, Kangbuk Samsung Hosp, Dept Gastroenterol, Seoul, South Korea; [Fausel, R.; Grady, W. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA; [Kanngurn, S.] Prince Songkla Univ, Tumor Biol Res Unit, Hat Yai, Thailand; [Kanngurn, S.] Prince Songkla Univ, Dept Pathol, Hat Yai, Thailand; [Welcsh, P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	Sun Yat Sen University; Fred Hutchinson Cancer Center; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Washington; University of Washington Seattle; Prince of Songkla University; Prince of Songkla University; University of Washington; University of Washington Seattle	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,D4-100,POB 19024, Seattle, WA 98109 USA.	wgrady@fhcrc.org			NIH [RO1CA115513, P30CA15704, U54CA143862, UO1CA152756]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist; NATIONAL CANCER INSTITUTE [U54CA143862, P30CA015704, R01CA115513, P01CA077852, U01CA152756] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Translational Research Award for Clinician Scientist; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for these studies was provided by the NIH (RO1CA115513, P30CA15704, U54CA143862, UO1CA152756, WMG), and a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG).	Ahuja N, 1998, CANCER RES, V58, P5489; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alhopuro P, 2012, INT J CANCER, V130, P1558, DOI 10.1002/ijc.26167; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Arslan-Kirchner M, 2011, EUR J HUM GENET, V19, DOI 10.1038/ejhg.2011.68; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bogen O, 2008, EUR J NEUROSCI, V28, P12, DOI 10.1111/j.1460-9568.2008.06308.x; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Diaz-Rodriguez E, 2012, ONCOGENE, V31, P2824, DOI 10.1038/onc.2011.458; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Eskiocak U, 2011, CANCER RES, V71, P4359, DOI 10.1158/0008-5472.CAN-11-0794; Estecio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Gan FF, 2011, APOPTOSIS, V16, P856, DOI 10.1007/s10495-011-0611-3; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; Grady WM, 1998, CANCER RES, V58, P3101; HERMAN JG, 1995, CANCER RES, V55, P4525; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jain S, 2010, J CLIN INVEST, V120, P778, DOI 10.1172/JCI41619; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; PARASKEVA C, 1989, CANCER RES, V49, P1282; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Rojas A, 2008, INT J CANCER, V123, P14, DOI 10.1002/ijc.23608; Rojas A, 2009, BBA-MOL CELL RES, V1793, P1165, DOI 10.1016/j.bbamcr.2009.02.001; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181; Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074; Sipos JA, THER ADV MED ONCOL, V2, P3; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tang JZ, 2010, MOL CANCER THER, V9, P1697, DOI 10.1158/1535-7163.MCT-09-1077; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wartiovaara K, 1998, J PEDIATR SURG, V33, P1501, DOI 10.1016/S0022-3468(98)90485-7; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLSON JKV, 1987, CANCER RES, V47, P2704	58	59	69	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2037	2047		10.1038/onc.2012.225	http://dx.doi.org/10.1038/onc.2012.225			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22751117	Green Accepted			2022-12-17	WOS:000317919900005
J	Xue, X; Gao, W; Sun, B; Xu, Y; Han, B; Wang, F; Zhang, Y; Sun, J; Wei, J; Lu, Z; Zhu, Y; Sato, Y; Sekido, Y; Miao, Y; Kondo, Y				Xue, X.; Gao, W.; Sun, B.; Xu, Y.; Han, B.; Wang, F.; Zhang, Y.; Sun, J.; Wei, J.; Lu, Z.; Zhu, Y.; Sato, Y.; Sekido, Y.; Miao, Y.; Kondo, Y.			Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma	ONCOGENE			English	Article						angiogenesis; vasohibin 2; hepatocellular carcinoma; histone modification	NEGATIVE FEEDBACK REGULATOR; ANTI-VEGF THERAPY; BREAST-CARCINOMA; COLON-CANCER; HISTONE H3; EXPRESSION; CELLS	Hepatocellular carcinoma (HCC) typically relies on angiogenesis for its malignant behavior, including growth and metastasis. Vasohibin 2 (VASH2) was previously identified as an angiogenic factor, but its role in tumorigenesis is unknown. Using quantitative PCR and western blot analyses, we found that VASH2 is overexpressed in HCC cells and tissues. Using chromatin immunoprecipitation, we detected histone modifications at the putative VASH2 promoter, with increased H3K4 trimethylation and H3 acetylation and decreased H3K27 trimethylation, suggesting that epigenetic mechanisms are responsible for the deregulated VASH2 transcription in HCC. Knockdown of VASH2 via siRNA inhibited the proliferation of the hepatoma cell lines by delaying cell cycle progression and increasing apoptosis. Importantly, we found VASH2 secreted in the culture supernatant, and co-expression of its secretory chaperone small vasohibin-binding protein (SVBP) further enhanced VASH2 secretion. The supernatant from HepG2 cells expressing VASH2 enhanced the proliferation, migration and tube formation of human umbilical vein endothelial cells, and knockdown of VASH2 significantly inhibited these effects. In an in vivo study using a nude mouse model, we found that exogenous VASH2 significantly contributed to tumor growth, microvessel density and hemoglobin concentration in the tumors. Further analyses showed that the VASH2-mediated increase in the transcription of fibroblast growth factor-2, vascular endothelial growth factor and vasohibin 1 may be the mechanism underlying these effects. Taken together, these data indicate that VASH2 is abnormally expressed in HCC cells as a result of histone modifications and that VASH2 contributes to the angiogenesis in HCC via an SVBP-mediated paracrine mechanism. These results indicate a novel and important role for VASH2 in HCC angiogenesis and malignant transformation. Oncogene (2013) 32, 1724-1734; doi:10.1038/onc.2012.177; published online 21 May 2012	[Xue, X.; Gao, W.; Sun, B.; Xu, Y.; Wang, F.; Zhang, Y.; Sun, J.; Wei, J.; Lu, Z.; Zhu, Y.; Miao, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Han, B.] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Endocrinol, Nanjing 210029, Jiangsu, Peoples R China; [Sato, Y.] Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 980, Japan; [Sekido, Y.; Kondo, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nanjing Medical University; Nanjing Medical University; Tohoku University; Aichi Cancer Center	Miao, Y (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 300 GuangZhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	gao11@hotmail.com; miaoyi@njmu.edu.cn; ykondo@aichi-cc.jp	Lu, Zipeng/AAY-4893-2021; Sato, Yasufumi/AAF-3367-2019; Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	National Nature Science Foundation of China [81172267, 30901627]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are very grateful to Professor Yujie Sun from Nanjing Medical University for continuous technical support. This work was supported by grants from the National Nature Science Foundation of China (no. 81172267 and 30901627).	Cha HJ, 2011, HEPATO-GASTROENTEROL, V58, P790; Doger FK, 2006, EUR SURG RES, V38, P540, DOI 10.1159/000096774; Eccles Suzanne A., 2009, V467, P159, DOI 10.1007/978-1-59745-241-0_9; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2009, BLOOD, V113, P4810, DOI 10.1182/blood-2008-07-170316; Liu LZ, 2005, MOL PHARMACOL, V68, P635, DOI 10.1124/mol.105.011254; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mi J, 2007, BIOCHEM BIOPH RES CO, V359, P475, DOI 10.1016/j.bbrc.2007.05.125; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Shibuya T, 2006, ARTERIOSCL THROM VAS, V26, P1051, DOI 10.1161/01.ATV.0000216747.66660.26; Sitohy B, 2011, CANCER RES, V71, P7021, DOI 10.1158/0008-5472.CAN-11-1693; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suzuki Y, 2010, J CELL SCI, V123, P3094, DOI 10.1242/jcs.067538; Tamaki K, 2009, CANCER SCI, V100, P88, DOI 10.1111/j.1349-7006.2008.01015.x; Tammali R, 2011, ANGIOGENESIS, V14, P209, DOI 10.1007/s10456-011-9206-4; Wang F, 2010, BRIT J CANCER, V103, P567, DOI 10.1038/sj.bjc.6605724; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Yang ZF, 2008, ANAT REC, V291, P721, DOI 10.1002/ar.20668; Yoshinaga K, 2011, CANCER SCI, V102, P446, DOI 10.1111/j.1349-7006.2010.01812.x; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30	29	59	63	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1724	1734		10.1038/onc.2012.177	http://dx.doi.org/10.1038/onc.2012.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614011				2022-12-17	WOS:000316855800012
J	Copeland, RA; Moyer, MP; Richon, VM				Copeland, R. A.; Moyer, M. P.; Richon, V. M.			Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics	ONCOGENE			English	Review						epigenetics; protein methyltransferases; personalized therapeutics; drug discovery; enzyme inhibitors	HISTONE METHYLTRANSFERASE; SOMATIC MUTATIONS; MULTIPLE-MYELOMA; CONFORMATIONAL ADAPTATION; ELONGATION COMPLEX; H3K79 METHYLATION; LYSINE 27; EZH2; LEUKEMIA; INHIBITORS	The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human cancers, and in several cases these alterations have been demonstrated to confer a unique dependence of the cancer cells on PMT enzymatic activity for the tumorigenic phenotype. Examples of such driver alterations in PMTs will be presented together with a review of current efforts towards the discovery and development of small-molecule inhibitors of these enzymes as personalized cancer therapeutics. Oncogene (2013) 32, 939-946; doi:10.1038/onc.2012.552; published online 19 November 2012	[Copeland, R. A.; Moyer, M. P.; Richon, V. M.] R&D Epizyme Inc, Cambridge, MA 02139 USA		Copeland, RA (corresponding author), R&D Epizyme Inc, 325 Vassar St, Cambridge, MA 02139 USA.	RCopeland@Epizyme.com						Allan M, 2009, BIOORG MED CHEM LETT, V19, P1218, DOI 10.1016/j.bmcl.2008.12.075; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Basavapathruni A, 2012, CHEM BIOL DRUG DES, V80, P971, DOI 10.1111/cbdd.12050; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Burgess J. L., 2012, Patent No. [WO2012005805, 2012005805]; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; Copeland R.A., 2000, ENZYMES PRACTICAL IN, Vsecond; Copeland R. A., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012034132, 2012034132]; Copeland RA, 2012, DRUG DISCOV TODAY TH, V9, pe83, DOI DOI 10.1016/J.DDSTR.2011.08.001; Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082; Copeland RA, 2011, FUTURE MED CHEM, V3, P1491, DOI [10.4155/FMC.11.112, 10.4155/fmc.11.112]; Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Duquenne C., 2011, Indazoles, Patent No. 2011140325; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferguson A. D., 2011, STRUCTURE; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; He NH, 2011, P NATL ACAD SCI USA, V108, pE636, DOI 10.1073/pnas.1107107108; Hess JL, 2004, P NATL ACAD SCI USA, V101, P16985, DOI 10.1073/pnas.0407898101; Huynh T, 2009, BIOORG MED CHEM LETT, V19, P2924, DOI 10.1016/j.bmcl.2009.04.075; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Knight S. D., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012075080, 2012075080]; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; LaFrance L, 2011, Patent No. [WO2011140324, 2011140324]; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Li B, 2009, J BIOL CHEM, V284, P7970, DOI 10.1074/jbc.M808220200; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu F, 2009, J MED CHEM, V52, P7950, DOI 10.1021/jm901543m; Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Mochizuki-Kashio M, 2011, BLOOD, V118, P6553, DOI 10.1182/blood-2011-03-340554; Mori S, 2010, BIOORGAN MED CHEM, V18, P8158, DOI 10.1016/j.bmc.2010.10.022; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Purandare AV, 2008, BIOORG MED CHEM LETT, V18, P4438, DOI 10.1016/j.bmcl.2008.06.026; Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Spannhoff A, 2007, BIOORG MED CHEM LETT, V17, P4150, DOI 10.1016/j.bmcl.2007.05.088; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Webb KJ, 2010, BIOCHEMISTRY-US, V49, P5225, DOI 10.1021/bi100428x; Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	73	59	59	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					939	946		10.1038/onc.2012.552	http://dx.doi.org/10.1038/onc.2012.552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	23160372	Green Published, hybrid			2022-12-17	WOS:000316523200001
J	Nairismagi, ML; Vislovukh, A; Meng, Q; Kratassiouk, G; Beldiman, C; Petretich, M; Groisman, R; Fuchtbauer, EM; Harel-Bellan, A; Groisman, I				Nairismagi, M-L; Vislovukh, A.; Meng, Q.; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Fuchtbauer, E-M; Harel-Bellan, A.; Groisman, I.			Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression	ONCOGENE			English	Article						breast cancer; CPEB; microRNA; translational regulation; TWIST1	CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; TRANSCRIPTION FACTORS; PROTEIN; CPEB; METASTASIS; PROMOTES; MORPHOGENESIS; ONCOGENE; MCF10AT	TWIST1 is a highly conserved basic helix-loop-helix transcription factor that promotes epithelial-mesenchymal transition (EMT). Its misregulation has been observed in various types of tumors. Using the MCF-10A-series of cell lines that recapitulate the early stages of breast cancer formation and EMT, we found TWIST1 to be upregulated during EMT and downregulated early in carcinogenesis. The TWIST1 3'UTR contains putative regulatory elements, including miRNA target sites and two cytoplasmic polyadenylation elements (CPE). We found that miR-580, CPEB1, and CPEB2 act as negative regulators of TWIST1 expression in a sequence-specific and additive/cooperative manner.	[Nairismagi, M-L; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Harel-Bellan, A.; Groisman, I.] CEA Saclay, CNRS FRE 3377, F-91191 Gif Sur Yvette, France; [Meng, Q.] Harbin Med Univ, Affiliated Hosp 3, Breast Dept, Harbin, Peoples R China; [Vislovukh, A.] Natl Acad Sci Ukraine, Inst Mol Biol & Genet, Dept Translat Mechanisms, Kiev, Ukraine; [Nairismagi, M-L; Fuchtbauer, E-M] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark	CEA; UDICE-French Research Universities; Universite Paris Saclay; Harbin Medical University; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Aarhus University	Groisman, I (corresponding author), CEA Saclay, CNRS FRE 3377, F-91191 Gif Sur Yvette, France.	irina.groisman@gmail.com	Harel-Bellan, Annick/M-9795-2015	Kratassiouk, Gueorgui/0000-0003-1174-004X; Groisman, Regina/0000-0003-3990-7622; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Sonia/0000-0003-1153-3841	European Commission [LSHG-CT-2006-037900]; Danish Cancer Society [DP08036]	European Commission(European CommissionEuropean Commission Joint Research Centre); Danish Cancer Society(Danish Cancer Society)	We thank Valentina Evdokimova for providing us with the MCF-10ANeoT-MSCV and MCF-10ANeoT-YB-1 cell lines, Linda Louise Pritchard for editorial and scientific advice, and Leslie-Ann Largitte for technical assistance. This work was supported in part by grant no LSHG-CT-2006-037900 from the European Commission Sixth Framework Programme to AHB and by grant no DP08036 from The Danish Cancer Society to EMF.	BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Dawson PJ, 1996, AM J PATHOL, V148, P313; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Germanguz I, 2007, DEV DYNAM, V236, P2615, DOI 10.1002/dvdy.21267; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; Hagele S, 2009, BIOCHEM J, V417, P235, DOI 10.1042/BJ20081353; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; SOULE HD, 1990, CANCER RES, V50, P6075; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	27	59	65	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4960	4966		10.1038/onc.2011.650	http://dx.doi.org/10.1038/onc.2011.650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266852				2022-12-17	WOS:000311430200007
J	Rothschild, SI; Tschan, MP; Federzoni, EA; Jaggi, R; Fey, MF; Gugger, M; Gautschi, O				Rothschild, S. I.; Tschan, M. P.; Federzoni, E. A.; Jaggi, R.; Fey, M. F.; Gugger, M.; Gautschi, O.			MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma	ONCOGENE			English	Article						miR-29b; inhibitor of differentiation protein 1; ID1; Src; c-Myc; lung cancer	CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN BREAST-CANCER; TUMOR-GROWTH; EXPRESSION; SRC; GENES; CELLS; ID1; SIGNATURE; CARCINOMA	The c-Src kinase regulates cancer cell invasion through inhibitor of DNA binding/differentiation 1 (ID1). Src and ID1 are frequently overexpressed in human lung adenocarcinoma. The current study aimed at identifying microRNAs (miRNAs) involved in the Src-ID1 signaling in lung cancer. Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3'-untranslated region (UTR). Luciferase reporter assays confirmed direct binding of miR-29b to the ID1 3'-UTR. Expression of miR-29b suppressed ID1 levels and significantly reduced migration and invasion. Expression of antisense-miR-29b (anti-miR-29b), on the other hand, enhanced ID1 mRNA and protein levels, and significantly increased lung cancer cell migration and invasion, a hallmark of the Src-ID1 pathway. The ectopic expression of ID1 in miR-29b-overexpressing cells was able to rescue the migratory potential of these cells. Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion. Saracatinib and dasatinib decreased c-Myc transcriptional repression on miR-29b and led to increased ID1 protein levels, whereas forced expression of c-Myc repressed miR-29b and induced ID1. In agreement, we showed direct recruitment of c-Myc to the miR-29b promoter. miR-29b was significantly downregulated in primary lung adenocarcinoma samples compared with matched alveolar lung tissue, and miR-29b expression was a significant prognostic factor for patient outcome. These results suggest that miR-29b is involved in the Src-ID1 signaling pathway, is dysregulated in lung adenocarcinoma and is a potential predictive marker for Src kinase inhibitors. Oncogene (2012) 31, 4221-4232; doi:10.1038/onc.2011.578; published online 16 January 2012	[Rothschild, S. I.; Tschan, M. P.; Federzoni, E. A.; Jaggi, R.; Gautschi, O.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Rothschild, S. I.] Univ Basel Hosp, Dept Med Oncol, CH-4031 Basel, Switzerland; [Tschan, M. P.; Fey, M. F.] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland; [Gugger, M.] Univ Bern, Inst Pathol, Bern, Switzerland; [Gautschi, O.] Luzerner Kantonsspital, Klin Onkol, Luzern, Switzerland	University of Bern; University of Basel; University of Bern; University Hospital of Bern; University of Bern; Lucerne Cantonal Hospital	Gautschi, O (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.	oliver.gautschi@onkologie.ch	Rothschild, Sacha/AAV-4003-2020	Rothschild, Sacha/0000-0003-1304-9340; Tschan, Mario P./0000-0001-5897-3647	Swiss Cancer League [KLS 02164-02-2008]; Bernese Cancer League; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bernese Foundation of Cancer Research; Marlies-Schwegler Foundation; Ursula-Hecht-Foundation for Leukemia Research	Swiss Cancer League; Bernese Cancer League; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bernese Foundation of Cancer Research; Marlies-Schwegler Foundation; Ursula-Hecht-Foundation for Leukemia Research	Deborah Shan is gratefully acknowledged for excellent technical support. We acknowledge Dr John Minna (UT Southwestern, Medical Center, Dallas, TX, USA) and Dr Yitzhak Zimmer for providing us with cell lines. We thank Wieslawa Blank for support with Western blotting and Dr Daniel Betticher for providing us with primary tumors from the tumor tissue bank. We also thank Dr Jasmin Batliner for support with luciferase assays. We thank AstraZeneca (Manchester, UK) for providing saracatinib. This study was supported by Swiss Cancer League (Grant KLS 02164-02-2008 to OG and MG), the Bernese Cancer League (to MG, OG and MPT), the Werner and Hedy Berger-Janser Foundation of Cancer Research (to MFF and MPT), the Bernese Foundation of Cancer Research, the Marlies-Schwegler Foundation and the Ursula-Hecht-Foundation for Leukemia Research (to MFF).	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Bishop JA, 2010, CLIN CANCER RES, V16, P610, DOI 10.1158/1078-0432.CCR-09-2638; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fong S, 2004, TRENDS MOL MED, V10, P387, DOI 10.1016/j.molmed.2004.06.008; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Muniyappa MK, 2009, EUR J CANCER, V45, P3104, DOI 10.1016/j.ejca.2009.09.014; Oberli A, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-9; Patnaik SK, 2010, CANCER RES, V70, P36, DOI 10.1158/0008-5472.CAN-09-3153; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Rothschild SI, 2011, LUNG CANCER, V71, P306, DOI 10.1016/j.lungcan.2010.06.018; Rothschild SI, 2010, CLIN LUNG CANCER, V11, P238, DOI 10.3816/CLC.2010.n.030; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Sun XL, 2009, CARCINOGENESIS, V30, P2109, DOI 10.1093/carcin/bgp251; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Voortman J, 2010, CANCER RES, V70, P8288, DOI 10.1158/0008-5472.CAN-10-1348; Wu X, 2009, J THORAC ONCOL, V4, P1028, DOI 10.1097/JTO.0b013e3181a99c77; Xu H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008	50	59	66	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4221	4232		10.1038/onc.2011.578	http://dx.doi.org/10.1038/onc.2011.578			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22249264				2022-12-17	WOS:000308975800005
J	Chen, BB; Glasser, JR; Coon, TA; Mallampalli, RK				Chen, B. B.; Glasser, J. R.; Coon, T. A.; Mallampalli, R. K.			F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest	ONCOGENE			English	Article						ubiquitin; camodulin; lung	CALCIUM-CONCENTRATION; REGULATORY ENZYME; D1 DEGRADATION; CALMODULIN; CANCER; PHOSPHORYLATION; EXPRESSION; KINASE; IDENTIFICATION; ALPHA	Dysregulated behavior of cell cycle proteins and their control by ubiquitin E3 ligases is an emerging theme in human lung cancer. Here, we identified and characterized the activity of a novel F-box protein, termed FBXL2, belonging to the SCF (Skip-Cullin1-F-box protein) E3 ligase family. Ectopically expressed FBXL2 triggered G2/M-phase arrest, induced chromosomal anomalies and increased apoptosis of transformed lung epithelia by mediating polyubiquitination and degradation of the mitotic regulator, cyclin D3. Unlike other F-box proteins that target phosphodegrons within substrates, FBXL2 uniquely recognizes a canonical calmodulin (CaM)-binding motif within cyclin D3 to facilitate its polyubiquitination. CaM bound and protected cyclin D3 from FBXL2 by direct intermolecular competition with the F-box protein for access within this motif. The chemotherapeutic agent vinorelbine increased apoptosis of human lung carcinoma cells by inducing FBXL2 expression and cyclin D3 degradation, an effect accentuated by CaM knockdown. Depletion of endogenous FBXL2 stabilized cyclin D3 levels, accelerated cancer cell growth and increased cell viability after vinorelbine treatment. Last, ectopic expression of FBXL2 significantly inhibited the growth and migration of tumorogenic cells and tumor formation in athymic nude mice. These observations implicate SCFFBXL2 as an indispensible regulator of mitosis that serves as a tumor suppressor. Oncogene (2012) 31, 2566-2579; doi:10.1038/onc.2011.432; published online 24 October 2011	[Mallampalli, R. K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA; [Mallampalli, R. K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Mallampalli, RK (corresponding author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, NW 628, Pittsburgh, PA 15213 USA.	mallampallirk@upmc.edu			US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096376, R01HL097376, R01HL098174] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002200] Funding Source: NIH RePORTER	US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development(US Department of Veterans Affairs); US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	We thank AF Stewart for critical review of the manuscript and helpful suggestions. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to RKM). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government.	Agassandian M, 2010, FASEB J, V24, P1271, DOI 10.1096/fj.09-136044; Brown E M, 1984, Prog Clin Biol Res, V168, P139; Butler PL, 2010, J BIOL CHEM, V285, P6246, DOI 10.1074/jbc.M109.017350; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen BB, 2011, MOL CELL BIOL, V22, P22; Chen BB, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706472200; Chen BB, 2009, MOL CELL BIOL, V29, P3062, DOI 10.1128/MCB.01824-08; Choi J, 2006, CELL CYCLE, V5, P2183, DOI 10.4161/cc.5.19.3265; Choi J, 2006, CIRC RES, V98, P1273, DOI 10.1161/01.RES.0000223059.19250.91; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Duan YN, 2010, INFLAMMATION, V33, P189, DOI 10.1007/s10753-009-9173-8; Fang MZ, 2002, J VET MED SCI, V64, P201, DOI 10.1292/jvms.64.201; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; Ilyin GP, 1999, FEBS LETT, V459, P75, DOI 10.1016/S0014-5793(99)01211-9; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Korkotian E, 1996, J PHYSIOL-LONDON, V496, P39, DOI 10.1113/jphysiol.1996.sp021663; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; Malard V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-147; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Papay J, 2007, APPL IMMUNOHISTO M M, V15, P19, DOI 10.1097/01.pai.0000213143.32030.f5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Pszczolkowski MA, 1999, MOL CELL ENDOCRINOL, V158, P163, DOI 10.1016/S0303-7207(99)00167-7; Ray NB, 2010, NAT MED, V16, P1120, DOI 10.1038/nm.2213; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Skaar JR, 2009, CELL, V137, DOI 10.1016/j.cell.2009.05.039; Sterlacci W, 2010, J THORAC ONCOL, V5, P1325, DOI 10.1097/JTO.0b013e3181e77efc; Tanaka Y, 2008, MOL CELL BIOL, V28, P4805, DOI 10.1128/MCB.01784-07; Tanguay DA, 2001, J IMMUNOL, V166, P4273, DOI 10.4049/jimmunol.166.7.4273; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tsang WY, 2006, MOL BIOL CELL, V17, P3423, DOI 10.1091/mbc.E06-04-0371; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Weiderpass Elisabete, 2010, J Prev Med Public Health, V43, P459, DOI 10.3961/jpmph.2010.43.6.459; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	56	59	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2566	2579		10.1038/onc.2011.432	http://dx.doi.org/10.1038/onc.2011.432			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	22020328	Green Accepted			2022-12-17	WOS:000304191800007
J	Taketani, K; Kawauchi, J; Tanaka-Okamoto, M; Ishizaki, H; Tanaka, Y; Sakai, T; Miyoshi, J; Maehara, Y; Kitajima, S				Taketani, K.; Kawauchi, J.; Tanaka-Okamoto, M.; Ishizaki, H.; Tanaka, Y.; Sakai, T.; Miyoshi, J.; Maehara, Y.; Kitajima, S.			Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells	ONCOGENE			English	Article						DR5; ATF3; p53; CPT; TRAIL	ACTIVATING TRANSCRIPTION FACTOR-3; NECROSIS-FACTOR-ALPHA; APOPTOSIS-INDUCING LIGAND; RESPONSE GENE ATF3; ENDOTHELIAL-CELLS; P53 TRANSCRIPTION; STRESS RESPONSES; GENOTOXIC STRESS; KILLER/DR5 GENE; DEATH LIGAND	Stress response gene ATF3 is one of the p53 target genes and has a tumor suppressor role in cancer. However, the biological role of p53-ATF3 pathway is not well understood. Death receptor 5 (DR5) is a death domain-containing transmembrane receptor that triggers cell death upon binding to its ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), and a combination of TRAIL and agents that increase the expression of DR5 is expected as a novel anticancer therapy. In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells. In the absence of ATF3, induction of DR5 messenger RNA and protein is remarkably abrogated, and this is associated with reduced cell death by TRAIL and CPT. By contrast, exogenous expression of ATF3 causes more rapid and elevated expression of DR5, resulting in enhanced sensitivity to apoptotic cell death by TRAIL/CPT. Reporter assay and DNA affinity precipitation assay demonstrate that at least three ATF/CRE motifs at the proximal promoter of the human DR5 gene are involved in the activation of DNA damage-induced DR5 gene transcription. Furthermore, ATF3 is shown to interact with p53 to form a complex on the DR5 gene by Re-chromatin immunoprecipitation assay. Taken together, our results provide a novel insight into the role of ATF3 as an essential co-transcription factor for p53 upon DNA damage, and this may represent a useful biomarker for TRAIL-based anticancer therapy. Oncogene (2012) 31, 2210-2221; doi:10.1038/onc.2011.397; published online 19 September 2011	[Kitajima, S.] Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; [Taketani, K.; Maehara, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; [Tanaka-Okamoto, M.; Ishizaki, H.; Miyoshi, J.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Mol Biol, Osaka, Japan; [Sakai, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan	Tokyo Medical & Dental University (TMDU); Kyushu University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto Prefectural University of Medicine	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp		Tanaka-Okamoto, Miki/0000-0002-6429-7662	Ministry of Education, Culture, Sports, Science, and Technology of Japan [18012015, 18055008, 21590302, 22300330]; Grants-in-Aid for Scientific Research [22700878] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr WS El-Deiry for a kind gift of valuable plasmid pGL2-Full. This work was supported in part by a grant-in-aid for Research on Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [18012015, 18055008, 21590302] to SK and [22300330] to JM.	Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Farczadi E, 1999, NEOPLASMA, V46, P219; Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016/j.ctrv.2006.07.001; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Legarza K, 2006, ANTICANCER RES, V26, P3301; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naka T, 2002, CANCER RES, V62, P5800; Nesterov A, 2004, CANCER RES, V64, P3922, DOI 10.1158/0008-5472.CAN-03-2219; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; PAN JL, 1993, J BIOL CHEM, V268, P22600; Pelzer AE, 2006, J UROLOGY, V175, P1517, DOI 10.1016/S0022-5347(05)00651-8; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sheikh MS, 1998, CANCER RES, V58, P1593; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sussman RT, 2007, CANCER BIOL THER, V6, P1490, DOI 10.4161/cbt.6.9.4905; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Turchi L, 2008, CELL DEATH DIFFER, V15, P1472, DOI 10.1038/cdd.2008.74; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wei MC, 2000, GENE DEV, V14, P2060; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yoon K, 2011, CARCINOGENESIS, V32, P836, DOI 10.1093/carcin/bgr040; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang C, 2002, BIOCHEM BIOPH RES CO, V297, P1302, DOI 10.1016/S0006-291X(02)02382-3	55	59	59	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2210	2221		10.1038/onc.2011.397	http://dx.doi.org/10.1038/onc.2011.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927023	Bronze			2022-12-17	WOS:000303415900009
J	Oneyama, C; Morii, E; Okuzaki, D; Takahashi, Y; Ikeda, J; Wakabayashi, N; Akamatsu, H; Tsujimoto, M; Nishida, T; Aozasa, K; Okada, M				Oneyama, C.; Morii, E.; Okuzaki, D.; Takahashi, Y.; Ikeda, J.; Wakabayashi, N.; Akamatsu, H.; Tsujimoto, M.; Nishida, T.; Aozasa, K.; Okada, M.			MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression	ONCOGENE			English	Article						c-Src; miRNA; ILK; tumor progression	CANCER-CELLS; C-SRC; THERAPEUTIC TARGET; DOWN-REGULATION; FAMILY KINASES; PROTEIN-KINASE; BREAST-CANCER; ILK; GROWTH; EXPRESSION	The tyrosine kinase c-Src is upregulated in various human cancers; however, the molecular mechanisms underlying c-Src-mediated tumor progression remain unclear. Here we show that downregulation of microRNA (miR)-542-3p is tightly associated with tumor progression via c-Src-related oncogenic pathways. In c-Src-transformed fibroblasts and human cancer cells that overexpress c-Src, miR-542-3p is substantially downregulated, and the ectopic expression of miR-542-3p suppresses tumor growth. We identified the integrin-linked kinase (ILK) as a conserved target of miR-542-3p. ILK upregulation promotes cell adhesion and invasion by activating the integrin-focal adhesion kinase (FAK)/c-Src pathway, and can also contribute to tumor growth via the AKT and glycogen synthase kinase 3 beta pathways. MiR-542-3p expression is downregulated by the activation of c-Src-related signaling molecules, including epidermal growth factor receptor, K-Ras and Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase. In human colon cancer tissues, downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. Oncogene (2012) 31, 1623-1635; doi:10.1038/onc.2011.367; published online 22 August 2011	[Oneyama, C.; Takahashi, Y.; Wakabayashi, N.; Okada, M.] Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 5650871, Japan; [Morii, E.; Ikeda, J.; Aozasa, K.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Okuzaki, D.] Osaka Univ, Microbial Dis Res Inst, DNA Chip Dev Ctr Infect Dis, Suita, Osaka 5650871, Japan; [Akamatsu, H.; Tsujimoto, M.; Nishida, T.] Osaka Police Hosp, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka Police Hospital	Oneyama, C (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp	Okuzaki, Daisuke/AAN-5641-2020	Okuzaki, Daisuke/0000-0002-4552-783X	Ministry of Education, Culture, Sports, Science and Technology of Japan; Osaka University; Grants-in-Aid for Scientific Research [22689009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Osaka University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs A Imamoto, T Akagi and M Yutsudo for their generous gifts of reagents. This work was supported by a Grant-in-aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan and The Exciting Leading-Edge Research Project at Osaka University.	Abboud ER, 2007, INT J ONCOL, V30, P113; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142; Kim YB, 2008, J BIOL CHEM, V283, P10089, DOI 10.1074/jbc.M708300200; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oneyama C, 2011, ONCOGENE, V30, P3489, DOI 10.1038/onc.2011.63; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Toloubeydokhti T, 2008, REPROD SCI, V15, P993, DOI 10.1177/1933719108324132; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Yang L, 2010, ONCOGENE, V29, P516, DOI 10.1038/onc.2009.370; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025	43	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1623	1635		10.1038/onc.2011.367	http://dx.doi.org/10.1038/onc.2011.367			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860426				2022-12-17	WOS:000302231400002
J	Jin, HO; Seo, SK; Kim, YS; Woo, SH; Lee, KH; Yi, JY; Lee, SJ; Choe, TB; Lee, JH; An, S; Hong, SI; Park, IC				Jin, H-O; Seo, S-K; Kim, Y-S; Woo, S-H; Lee, K-H; Yi, J-Y; Lee, S-J; Choe, T-B; Lee, J-H; An, S.; Hong, S-I; Park, I-C			TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1	ONCOGENE			English	Article						ATF4; mTOR; Redd1; TXNIP; 2-deoxyglucose	THIOREDOXIN-INTERACTING PROTEIN; CELL-GROWTH; OXIDATIVE STRESS; MAMMALIAN TARGET; ENERGY STRESS; EXPRESSION; KINASE; RAPAMYCIN; HYPOXIA; CANCER	The mammalian target of rapamycin (mTOR) is a highly conserved serine-threonine kinase activated in response to growth factors and nutrients. Because of frequent dysregulation of the mTOR signaling pathway in diverse human cancers, this kinase is a key therapeutic target. Redd1 is a negative regulator of mTOR, mediating dissociation of 14-3-3 from tuberous sclerosis complex (TSC)2, which allows formation of a TSC-TSC2 complex. In the present study, we identify TXNIP that inhibits mTOR activity by binding to and stabilizing Redd1 protein. Redd1 and TXNIP expression was induced by a synthetic glucose analog, 2-deoxyglucose (2-DG). Moreover, Redd1 expression in response to 2-DG was regulated by activating transcription factor 4 (ATF4). Overexpression of TXNIP was associated with reduced mTOR activity mediated by an increase in Redd1 level, whereas knockdown of TXNIP using small interfering RNA resulted in recovery of mTOR activity via downregulation of Redd1 during treatment with 2-DG. Interestingly, Redd1 was additionally stabilized via interactions with N-terminal-truncated TXNIP, leading to suppression of mTOR activity. Our results collectively demonstrate that TXNIP stabilizes Redd1 protein induced by ATF4 in response to 2-DG, resulting in potentiation of mTOR suppression. To the best of our knowledge, this is the first study to identify TXNIP as a novel member of the mTOR upstream that acts as a negative regulator in response to stress signals. Oncogene (2011) 30, 3792-3801; doi:10.1038/onc.2011.102; published online 4 April 2011	[Jin, H-O; Seo, S-K; Kim, Y-S; Woo, S-H; Lee, K-H; Hong, S-I; Park, I-C] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Yi, J-Y] Korea Inst Radiol & Med Sci, Lab Modulat Radiobiol Responses, Seoul 139706, South Korea; [Lee, S-J] Hanyang Univ, Dept Chem, Lab Mol Biochem, Seoul 133791, South Korea; [Choe, T-B; Lee, J-H; An, S.] Konkuk Univ, Dept Microbiol Engn, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Hanyang University; Konkuk University	Jin, HO (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 215-4 Gongneung Dong, Seoul 139706, South Korea.	hyeonok@kirams.re.kr; parkic@kirams.re.kr			National Nuclear RD Program; Basic Science Research Program; Ministry of Education, Science and Technology in Republic of Korea [2010-0009503]	National Nuclear RD Program; Basic Science Research Program; Ministry of Education, Science and Technology in Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Nuclear R&D Program and the Basic Science Research Program and the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0009503) in Republic of Korea.	Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chung JW, 2006, J DERMATOL, V33, P662, DOI 10.1111/j.1346-8138.2006.00156.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fidler IJ, 1996, J NATL CANCER I, V88, P1700, DOI 10.1093/jnci/88.23.1700; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jin HO, 2009, IUBMB LIFE, V61, P1153, DOI 10.1002/iub.271; Jin HO, 2009, FREE RADICAL BIO MED, V46, P1158, DOI 10.1016/j.freeradbiomed.2009.01.015; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001; Katiyar S, 2009, EMBO REP, V10, P866, DOI 10.1038/embor.2009.93; Kim KY, 2004, BIOCHEM BIOPH RES CO, V315, P369, DOI 10.1016/j.bbrc.2004.01.047; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Nakamura H, 2006, SEMIN CANCER BIOL, V16, P444, DOI 10.1016/j.semcancer.2006.09.001; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Oka S, 2006, FASEB J, V20, pA45, DOI 10.1096/fj.05-4439fje; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Saxena G, 2010, J BIOL CHEM, V285, P3997, DOI 10.1074/jbc.M109.034421; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586; Schulze PC, 2004, J BIOL CHEM, V279, P30369, DOI 10.1074/jbc.M400549200; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Stoltzman CA, 2008, P NATL ACAD SCI USA, V105, P6912, DOI 10.1073/pnas.0712199105; Sudarsanam S, 2010, CURR OPIN DRUG DISC, V13, P31; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200; Wang Z, 2006, ONCOGENE, V25, P1903, DOI 10.1038/sj.onc.1209218; Whitney ML, 2009, BIOCHEM BIOPH RES CO, V379, P451, DOI 10.1016/j.bbrc.2008.12.079	40	59	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3792	3801		10.1038/onc.2011.102	http://dx.doi.org/10.1038/onc.2011.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460850				2022-12-17	WOS:000294481400006
J	Booth, BW; Boulanger, CA; Anderson, LH; Smith, GH				Booth, B. W.; Boulanger, C. A.; Anderson, L. H.; Smith, G. H.			The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells	ONCOGENE			English	Article						erbB2/HER2; mammary; microenvironment; regeneration; suppression of tumorigenesis	ESTROGEN-RECEPTOR-ALPHA; HUMAN-BREAST-CANCER; TRANSGENIC MICE; GLAND DEVELOPMENT; TERATOCARCINOMA CELLS; METASTATIC-DISEASE; EPITHELIAL-CELLS; STEM-CELLS; IN-VIVO; ONCOGENE	The microenvironment of the mammary gland has been shown to exert a deterministic control over cells from different normal organs during murine mammary gland regeneration in transplantation studies. When mouse mammary tumor virus (MMTV)-neu-induced tumor cells were mixed with normal mammary epithelial cells (MECs) in a dilution series and inoculated into epithelium-free mammary fat pads, they were redirected to noncarcinogenic cell fates by interaction with untransformed MECs during regenerative growth. In the presence of non-transformed MECs (50:1), tumor cells interacted with MECs to generate functional chimeric outgrowths. When injected alone, tumor cells invariably produced tumors. Here, the normal microenvironment redirects MMTV-neu-transformed tumorigenic cells to participate in the regeneration of a normal, functional mammary gland. In addition, the redirected tumor cells show the capacity to differentiate into normal mammary cell types, including luminal, myoepithelial and secretory. The results indicate that signals emanating from a normal mammary microenvironment, comprised of stromal, epithelial and host-mediated signals, combine to suppress the cancer phenotype during glandular regeneration. Clarification of these signals offers improved therapeutic possibilities for the control of mammary cancer growth. Oncogene (2011) 30, 679-689; doi:10.1038/onc.2010.439; published online 4 October 2010	[Booth, B. W.; Boulanger, C. A.; Anderson, L. H.; Smith, G. H.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bldg 10,Room 5B56,9000 Rockville Pike, Bethesda, MD 20892 USA.	gs4d@nih.gov			Center for Cancer Research, NCI; NIH; Institute for Biological Interfaces of Engineering of Clemson University; NATIONAL CANCER INSTITUTE [ZIABC010021] Funding Source: NIH RePORTER	Center for Cancer Research, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institute for Biological Interfaces of Engineering of Clemson University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank KU Wagner for the gift of the triple transgenic WAP-Cre/Rosa26/MMTV-neu cell lines and for providing paraffin blocks from WAP-Cre/Rosa26R/MMTV-neu mouse mammary tissues. BK Vonderhaar, DS Salomon, R Callahan and GW Robinson for critical evaluation of the manuscript. The intramural research program of the Center for Cancer Research, NCI, NIH and the Institute for Biological Interfaces of Engineering of Clemson University contributed support to this work.	Bissell MJ, 2008, P NATL ACAD SCI USA, V105, P15637, DOI 10.1073/pnas.0808457105; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Booth BW, 2008, P NATL ACAD SCI USA, V105, P14891, DOI 10.1073/pnas.0803214105; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Choong LY, 2007, MOL CANCER THER, V6, P2828, DOI 10.1158/1535-7163.MCT-06-0809; DEOME KB, 1959, CANCER RES, V19, P515; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; McCullough KD, 1998, P NATL ACAD SCI USA, V95, P15333, DOI 10.1073/pnas.95.26.15333; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323	32	59	59	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					679	689		10.1038/onc.2010.439	http://dx.doi.org/10.1038/onc.2010.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890308	Green Accepted			2022-12-17	WOS:000287192000005
J	Hornle, M; Peters, N; Thayaparasingham, B; Vorsmann, H; Kashkar, H; Kulms, D				Hoernle, M.; Peters, N.; Thayaparasingham, B.; Voersmann, H.; Kashkar, H.; Kulms, D.			Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						caspase-3; XIAP; melanoma; apoptosis	X-LINKED INHIBITOR; NF-KAPPA-B; PROTEIN LIGASE ACTIVITY; DOWN-REGULATION; PROTEASOMAL DEGRADATION; UBIQUITIN LIGASE; RESISTANCE; IAPS; SURVIVAL; SMAC	Successful treatment of melanoma is still challenging, because metastasis remain chemoresistant and radioresistant. Accordingly, combinational treatments involving death ligands are mandatory. In a recent study from our lab, the majority out of 18 melanoma cell lines remained resistant against treatment with the death ligand TRAIL (tumor necrosis factor related apoptosis inducing ligand). Resistance was shown to be mainly due to incomplete processing of caspase-3 into catalytically inactive p21 by binding of the anti-apoptotic protein X-linked inhibitor of apoptosis protein (XIAP). Co-irradiation with sub-lethal ultraviolet (UV) B caused depletion of XIAP resulting in synergistic sensitization of all but two melanoma cell lines to TRAIL. We show here the XIAP depletion to essentially require initial caspasemediated cleavage, which promotes proteasomal degradation of XIAP. Utilizing specific caspase inhibitors and small interfering RNA-mediated knockdown, we further identified caspase-3 to be responsible for performing the initial cleavage of XIAP after UVB treatment. Additional evidence suggests an accelerated mitochondrial outer membrane permeabilization in response to co-treatment with TRAIL and UVB, which directs the release of XIAP antagonizing factors including Smac. Distraction of XIAP consequently liberates caspase-3 to autocatalytically process into active p17. Activated caspase-3 cleaves XIAP and further enhances its activation in a positive regulatory feedback loop. The molecular mechanism discovered here appears to have broader implications, because cleavage of XIAP was also shown to accompany cisplatin-induced sensitization of melanoma cells to TRAIL. Oncogene (2011) 30, 575-587; doi: 10.1038/onc.2010.434; published online 20 September 2010	[Hoernle, M.; Peters, N.; Thayaparasingham, B.; Voersmann, H.; Kulms, D.] Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Baden Wurttembe, Germany; [Kashkar, H.] Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med Cologne, Cologne, Germany	University of Stuttgart; University of Cologne	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Baden Wurttembe, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014		Deutsche Krebshilfe [108717]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank the Deutsche Krebshilfe/108717 for funding this project.	Blankenship JW, 2009, BIOCHEM J, V417, P149, DOI 10.1042/BJ20081885; Chen L, 2003, MOL PHARMACOL, V64, P334, DOI 10.1124/mol.64.2.334; Cheung HH, 2008, MOL BIOL CELL, V19, P2729, DOI 10.1091/mbc.E08-01-0107; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Denault JB, 2007, BIOCHEM J, V405, P11, DOI 10.1042/BJ20070288; Desplanques G, 2009, HAEMATOL-HEMATOL J, V94, P87, DOI 10.3324/haematol.13483; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Edmondson SR, 1999, J CLIN ENDOCR METAB, V84, P1638, DOI 10.1210/jc.84.5.1638; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Hougardy BMT, 2006, INT J CANCER, V118, P1892, DOI 10.1002/ijc.21580; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Hussain AR, 2009, LEUKEMIA LYMPHOMA, V50, P1204, DOI 10.1080/10428190902951799; Inoue T, 2006, ANTI-CANCER DRUG, V17, P261, DOI 10.1097/00001813-200603000-00004; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Kashkar H, 2006, BLOOD, V108, P3434, DOI 10.1182/blood-2006-05-021675; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Lasithiotakis KG, 2006, CANCER-AM CANCER SOC, V107, P1331, DOI 10.1002/cncr.22126; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Liou JY, 2007, J CELL PHYSIOL, V212, P840, DOI 10.1002/jcp.21082; Liu L, 2010, BIOCHEM PHARMACOL, V79, P137, DOI 10.1016/j.bcp.2009.08.015; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Maas C, 2010, CELL DEATH DIFFER, V17, P1613, DOI 10.1038/cdd.2010.39; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; McStay GP, 2008, CELL DEATH DIFFER, V15, P322, DOI 10.1038/sj.cdd.4402260; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Rehm M, 2006, EMBO J, V25, P4338, DOI 10.1038/sj.emboj.7601295; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Shi RX, 2005, CANCER RES, V65, P7815, DOI 10.1158/0008-5472.CAN-04-3875; Silke J, 2005, P NATL ACAD SCI USA, V102, P16182, DOI 10.1073/pnas.0502828102; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Sun HY, 2008, J MED CHEM, V51, P7169, DOI 10.1021/jm8006849; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thayaparasingham B, 2009, ONCOGENE, V28, P345, DOI 10.1038/onc.2008.397; Twiddy Davina, 2007, Biochem J, V405, pe1; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zeise E, 2004, J INVEST DERMATOL, V123, P746, DOI 10.1111/j.0022-202X.2004.23420.x; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084	51	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					575	587		10.1038/onc.2010.434	http://dx.doi.org/10.1038/onc.2010.434			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20856198				2022-12-17	WOS:000286922300006
J	Steer, HJ; Lake, RA; Nowak, AK; Robinson, BWS				Steer, H. J.; Lake, R. A.; Nowak, A. K.; Robinson, B. W. S.			Harnessing the immune response to treat cancer	ONCOGENE			English	Review						tumour immunity; T lymphocytes; cancer chemotherapy; immune escape; immunotherapy	T-CELL RESPONSES; ANTIGEN CROSS-PRESENTATION; GROWTH-FACTOR-BETA; CLASS-I EXPRESSION; DENDRITIC CELLS; TUMOR-CELLS; ANTICANCER CHEMOTHERAPY; HUMAN-MELANOMA; CUTTING EDGE; MEMORY	It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer. Oncogene (2010) 29, 6301-6313; doi:10.1038/onc.2010.437; published online 20 September 2010	[Steer, H. J.] Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia; [Steer, H. J.; Lake, R. A.; Nowak, A. K.; Robinson, B. W. S.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Nowak, A. K.] Dept Med Oncol, Perth, WA, Australia; [Steer, H. J.; Robinson, B. W. S.] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Steer, HJ (corresponding author), Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, 4th Floor G Block, Perth, WA 6009, Australia.	hsteer@meddent.uwa.edu.au	Robinson, Bruce/N-1900-2014; Nowak, Anna K/B-2487-2013	Nowak, Anna K/0000-0002-9317-9526				Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Antonia SJ, 2006, CLIN CANCER RES, V12, P878, DOI 10.1158/1078-0432.CCR-05-2013; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bannard O, 2009, SCIENCE, V323, P505, DOI 10.1126/science.1166831; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Beyer M, 2009, CANCER RES, V69, P4346, DOI 10.1158/0008-5472.CAN-08-3796; Bioley G, 2009, CLIN CANCER RES, V15, P4467, DOI 10.1158/1078-0432.CCR-09-0582; Bioley G, 2009, CLIN CANCER RES, V15, P299, DOI 10.1158/1078-0432.CCR-08-1747; Bioley G, 2009, J IMMUNOTHER, V32, P161, DOI 10.1097/CJI.0b013e31819302f6; Blank C, 2004, CANCER RES, V64, P1140, DOI 10.1158/0008-5472.CAN-03-3259; Broomfield S, 2005, CANCER RES, V65, P7580, DOI 10.1158/0008-5472.CAN-05-0328; Broomfield SA, 2009, J IMMUNOL, V182, P5217, DOI 10.4049/jimmunol.0803826; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Bundell CS, 2006, CANCER IMMUNOL IMMUN, V55, P933, DOI 10.1007/s00262-005-0086-6; Burgdorf S, 2008, CURR OPIN IMMUNOL, V20, P89, DOI 10.1016/j.coi.2007.12.002; Burgdorf S, 2008, NAT IMMUNOL, V9, P558, DOI 10.1038/ni.1601; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chaput N, 2007, J MOL MED, V85, P1069, DOI 10.1007/s00109-007-0214-1; Chen X, 2004, J IMMUNOL, V173, P2985, DOI 10.4049/jimmunol.173.5.2985; Cloosen S, 2007, CANCER RES, V67, P3919, DOI 10.1158/0008-5472.CAN-06-2112; Costantino CM, 2008, EUR J IMMUNOL, V38, P921, DOI 10.1002/eji.200738104; Currie AJ, 2008, J IMMUNOL, V180, P1535, DOI 10.4049/jimmunol.180.3.1535; Darrasse-Jeze G, 2009, J CLIN INVEST, V119, P2648, DOI 10.1172/JCI36628; Deeths MJ, 1999, J IMMUNOL, V163, P102; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dummer W, 2002, J CLIN INVEST, V110, P185, DOI 10.1172/JCI200215175; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Feau S, 2009, SCIENCE, V323, P466, DOI [10.1126/SCIENCE.1169409, 10.1126/science.1169409]; Feng HP, 2002, BLOOD, V100, P4108, DOI 10.1182/blood-2002-05-1389; Fife BT, 2006, J EXP MED, V203, P2737, DOI 10.1084/jem.20061577; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Frey DM, 2010, INT J CANCER, V126, P2635, DOI 10.1002/ijc.24989; Gajewski TF, 2006, J IMMUNOTHER, V29, P233, DOI 10.1097/01.cji.0000199193.29048.56; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilboa E, 2001, NAT IMMUNOL, V2, P789, DOI 10.1038/ni0901-789; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hamilton DH, 2008, CANCER IMMUNOL IMMUN, V57, P1125, DOI 10.1007/s00262-007-0442-9; Hipp MM, 2008, BLOOD, V111, P5610, DOI 10.1182/blood-2007-02-075945; Hodi FS, 2007, CLIN CANCER RES, V13, P5238, DOI 10.1158/1078-0432.CCR-07-0813; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hu HM, 2002, CANCER RES, V62, P3914; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Hwang ML, 2007, J IMMUNOL, V179, P5829, DOI 10.4049/jimmunol.179.9.5829; Jackaman C, 2003, J IMMUNOL, V171, P5051, DOI 10.4049/jimmunol.171.10.5051; Jackaman C, 2008, INT IMMUNOL, V20, P1467, DOI 10.1093/intimm/dxn104; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Javid B, 2007, J IMMUNOL, V179, P2035, DOI 10.4049/jimmunol.179.4.2035; Kaminski JM, 2005, CANCER TREAT REV, V31, P159, DOI 10.1016/j.ctrv.2005.03.004; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Kennedy R, 2006, J IMMUNOL, V177, P2862, DOI 10.4049/jimmunol.177.5.2862; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kim S, 2008, CANCER RES, V68, P10247, DOI 10.1158/0008-5472.CAN-08-1494; Kim SJ, 2004, IMMUNITY, V21, P643, DOI 10.1016/j.immuni.2004.09.009; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Larmonier N, 2008, J IMMUNOL, V181, P6955, DOI 10.4049/jimmunol.181.10.6955; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080; Li M, 2001, J IMMUNOL, V166, P6099, DOI 10.4049/jimmunol.166.10.6099; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Lob S, 2009, NAT REV CANCER, V9, P445, DOI 10.1038/nrc2639; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Marzo AL, 1997, CANCER RES, V57, P3200; Marzo AL, 1999, J IMMUNOL, V162, P5838; Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047; Mattarollo SR, 2006, INT J CANCER, V119, P1630, DOI 10.1002/ijc.22019; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mescher MF, 2007, SEMIN CANCER BIOL, V17, P299, DOI 10.1016/j.semcancer.2007.06.008; Nelson D, 2000, J IMMUNOL, V165, P6123, DOI 10.4049/jimmunol.165.11.6123; Nelson DJ, 2001, J IMMUNOL, V166, P5557, DOI 10.4049/jimmunol.166.9.5557; Nishikawa H, 2003, P NATL ACAD SCI USA, V100, P10902, DOI 10.1073/pnas.1834479100; Nishimura T, 2000, CANCER CHEMOTH PHARM, V46, pS52, DOI 10.1007/PL00014051; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Nowak AK, 2003, CANCER RES, V63, P4490; Nowak AK, 2006, ADV DRUG DELIVER REV, V58, P975, DOI 10.1016/j.addr.2006.04.002; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Onizuka S, 1999, CANCER RES, V59, P3128; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Poitrasson-Riviere M, 2008, J IMMUNOL, V180, P7294, DOI 10.4049/jimmunol.180.11.7294; Rad AN, 2003, CANCER RES, V63, P5143; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Robinson BWS, 1999, IMMUNOL CELL BIOL, V77, P552, DOI 10.1046/j.1440-1711.1999.00876.x; Robinson BWS, 2001, CLIN CANCER RES, V7, p811S; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Rovere P, 1999, J LEUKOCYTE BIOL, V66, P345, DOI 10.1002/jlb.66.2.345; Rudge G, 2007, J IMMUNOL, V178, P4089, DOI 10.4049/jimmunol.178.7.4089; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sarween N, 2004, J IMMUNOL, V173, P2942, DOI 10.4049/jimmunol.173.5.2942; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; Schietinger A, 2008, SEMIN IMMUNOL, V20, P276, DOI 10.1016/j.smim.2008.07.001; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sinai P, 2007, J IMMUNOL, V178, P2028, DOI 10.4049/jimmunol.178.4.2028; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Srivastava N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006094; Stumbles PA, 2004, J IMMUNOL, V173, P5923, DOI 10.4049/jimmunol.173.10.5923; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tomlinson I, 2002, AM J PATHOL, V160, P755, DOI 10.1016/S0002-9440(10)64896-1; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; van der Most RG, 2006, CANCER RES, V66, P601, DOI 10.1158/0008-5472.CAN-05-2967; van der Most RG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006982; van der Most RG, 2009, CANCER IMMUNOL IMMUN, V58, P1219, DOI 10.1007/s00262-008-0628-9; VANDERBRUGGEN P, 2009, T CELL DEFINED TUMOU; Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Watson NFS, 2006, INT J CANCER, V118, P6, DOI 10.1002/ijc.21303; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Welters MJP, 2010, P NATL ACAD SCI USA, V107, P11895, DOI 10.1073/pnas.1006500107; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Wolchok JD, 2008, ONCOLOGIST, V13, P2, DOI 10.1634/theoncologist.13-S4-2; WORTZEL RD, 1983, J IMMUNOL, V130, P2461; Xiao T, 2009, IMMUNOL RES, V43, P98, DOI 10.1007/s12026-008-8053-x; Yuan JD, 2008, P NATL ACAD SCI USA, V105, P20410, DOI 10.1073/pnas.0810114105; Zheng XF, 2006, J IMMUNOL, V177, P5639, DOI 10.4049/jimmunol.177.8.5639; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	140	59	61	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6301	6313		10.1038/onc.2010.437	http://dx.doi.org/10.1038/onc.2010.437			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20856204				2022-12-17	WOS:000284874700001
J	Behrens, ME; Grandgenett, PM; Bailey, JM; Singh, PK; Yi, CH; Yu, F; Hollingsworth, MA				Behrens, M. E.; Grandgenett, P. M.; Bailey, J. M.; Singh, P. K.; Yi, C-H; Yu, F.; Hollingsworth, M. A.			The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF	ONCOGENE			English	Article						MUC1; CTGF; signal transduction; transcriptional activation; pancreatic cancer	TISSUE-GROWTH-FACTOR; CARCINOMA-ASSOCIATED ANTIGEN; CYTOPLASMIC TAIL; IN-VITRO; C-SRC; CANCER; BETA; EXPRESSION; CELLS; P53	The MUC1 cytoplasmic tail (MUC1.CT) conducts signals from spatial and extracellular cues (growth factor and cytokine stimulation) to evoke a reprogramming of the cellular transcriptional profile. Specific phosphorylated forms of the MUC1.CT achieve this function by differentially associating with transcription factors and redirecting their transcriptional regulatory capabilities at specific gene regulatory elements. The specificity of interaction between MUC1.CT and several transcription factors is dictated by the phosphorylation pattern of the 18 potential phosphorylation motifs within the MUC1.CT. To better appreciate the scope of differential gene expression triggered by MUC1.CT activation, we performed microarray gene expression analysis and chromatin immunoprecipitation (ChIP)-chip promoter analysis and identified the genome-wide transcriptional targets of MUC1.CT signaling in pancreatic cancer. On a global scale, MUC1.CT preferentially targets genes related to invasion, angiogenesis and metastasis, suggesting that MUC1.CT signaling contributes to establishing a reactive tumor microenvironment during tumor progression to metastatic disease. We examined in detail the molecular mechanisms of MUC1.CT signaling that induces the expression of connective tissue growth factor (CTGF/CCN2), a potent mediator of ECM remodeling and angiogenesis. We demonstrate a robust induction of CTGF synthesis and secretion in response to serum factors that is enabled only when MUC1 is highly expressed. We demonstrate the requirement of phosphorylation at distinct tyrosine motifs within the MUC1.CT for MUC1-induced CTGF expression and demonstrate a phosphorylation-specific localization of MUC1.CT to the CTGF promoter. We found that MUC1 reorganizes transcription factor occupancy of genomic regions upstream of the CTGF gene, directing beta-catenin and mutant p53 to CTGF gene regulatory elements to promote CTGF expression and destabilizing the interaction at these regions of the transcriptional repressor, c-Jun. With this example we illustrate the capacity of MUC1.CT to mediate transcription factor activity in a context-dependent manner to achieve wide spread and robust changes in gene expression and facilitate creation of the reactive tumor microenvironment. Oncogene (2010) 29, 5667-5677; doi:10.1038/onc.2010.327; published online 9 August 2010	[Behrens, M. E.; Grandgenett, P. M.; Bailey, J. M.; Singh, P. K.; Yi, C-H; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Behrens, M. E.; Singh, P. K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Yu, F.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Hollingsworth, MA (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	mahollin@unmc.edu	Yu, Fang/B-9874-2013	Bailey-Lundberg, Jennifer/0000-0002-4750-106X	NATIONAL CANCER INSTITUTE [U01CA111294, R01CA057362, P50CA127297] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057362, P50 CA127297, U01 CA111294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Aikawa T, 2006, MOL CANCER THER, V5, P1108, DOI 10.1158/1535-7163.MCT-05-0516; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Gao JC, 2009, INT J ONCOL, V35, P337, DOI 10.3892/ijo_00000345; Gatto M, 2008, LAB INVEST, V88, P986, DOI 10.1038/labinvest.2008.63; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; Kohlgraf KG, 2003, CANCER RES, V63, P5011; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Masaki Y, 1999, HEPATO-GASTROENTEROL, V46, P2240; Masuko Kayo, 2010, BMC Res Notes, V3, P5, DOI 10.1186/1756-0500-3-5; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Pemberton LF, 1996, J BIOL CHEM, V271, P2332, DOI 10.1074/jbc.271.4.2332; Qu CF, 2004, BRIT J CANCER, V91, P2086, DOI 10.1038/sj.bjc.6602232; Raina D, 2008, CANCER BIOL THER, V7, P1959, DOI 10.4161/cbt.7.12.6956; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tsutsumida H, 2006, CLIN CANCER RES, V12, P2976, DOI 10.1158/1078-0432.CCR-05-1197; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Yang DH, 1998, J CLIN ENDOCR METAB, V83, P2593, DOI 10.1210/jc.83.7.2593; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478; Yuan ZL, 2009, J SURG RES, V157, pE39, DOI 10.1016/j.jss.2008.09.005; Zarrinkalam KH, 2003, KIDNEY INT, V64, P331, DOI 10.1046/j.1523-1755.2003.00069.x	39	59	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5667	5677		10.1038/onc.2010.327	http://dx.doi.org/10.1038/onc.2010.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697347	Green Accepted			2022-12-17	WOS:000283262500003
J	Cheung, LWT; Leung, PCK; Wong, AST				Cheung, L. W. T.; Leung, P. C. K.; Wong, A. S. T.			Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; GnRH; cadherin; p120(ctn); motility	RHO-FAMILY GTPASES; BREAST-CANCER; N-CADHERIN; P-CADHERIN; EXPRESSION; RECEPTOR; ADHESION; GROWTH; PROGRESSION; PATHWAY	Gonadotropin-releasing hormone (GnRH) receptor expression is often elevated in ovarian cancer, but its potential role in ovarian cancer metastasis has just begun to be revealed. Cadherin switching is a crucial step during tumorigenesis, particularly in metastasis. Here, we showed that GnRH is an inducer of E-to P-cadherin switching, which is reminiscent of that seen during ovarian tumor progression. Overexpression of P-cadherin significantly enhanced, whereas knockdown of P-cadherin reduced migration and invasion regardless of E-cadherin expression, suggesting that inappropriate expression of P-cadherin contributes to the invasive phenotype. These effects of P-cadherin were mediated by activation of the Rho GTPases, Rac1, and Cdc42, through accumulation of p120 catenin (p120(ctn)) in the cytoplasm. The use of p120(ctn) small interfering RNA or chimeric cadherin construct to inhibit p120(ctn) expression and cytoplasmic localization, respectively, resulted in significant inhibition of cell migration and invasion, with a concomitant reduction in Rac1 and Cdc42 activation, confirming that the effect was p120(ctn) specific. Similarly, the migratory/invasive phenotype could be reversed by expression of dominant-negative Rac1 and Cdc42. These results identify for the first time cadherin switching and p120(ctn) signaling as important targets of GnRH function and as novel mediators of invasiveness and tumor progression in ovarian cancer. Oncogene (2010) 29, 2427-2440; doi:10.1038/onc.2009.523; published online 1 February 2010	[Cheung, L. W. T.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Cheung, Lydia Wai Ting/0000-0003-1137-3200; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health; Hong Kong Research Grant Council [778108]; HKU	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Hong Kong Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Drs N Auersperg, A Hall, and C Gottardi for cell lines and plasmids. This work was supported by Canadian Institutes of Health Research grant (PCK Leung), and by Hong Kong Research Grant Council Grant 778108 and HKU Outstanding Young Researcher Award (AST Wong).	Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chen CL, 2007, ENDOCRINE, V31, P311, DOI 10.1007/s12020-007-0041-8; Chen GTC, 2002, MOL REPROD DEV, V62, P289, DOI 10.1002/mrd.10121; Cheng CK, 2005, ENDOCR REV, V26, P283, DOI 10.1210/er.2003-0039; Cheung LWT, 2008, FEBS J, V275, P5479, DOI 10.1111/j.1742-4658.2008.06677.x; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; EMONS G, 1989, EUR J CANCER CLIN ON, V25, P215, DOI 10.1016/0277-5379(89)90011-4; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Feltes CM, 2002, CANCER RES, V62, P6688; IRMER G, 1995, CANCER RES, V55, P817; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang SK, 2000, ENDOCRINE, V13, P297, DOI 10.1385/ENDO:13:3:297; Kim KY, 2006, ENDOCR-RELAT CANCER, V13, P211, DOI 10.1677/erc.1.01033; LI SL, 1994, ENDOCRINOLOGY, V135, P45, DOI 10.1210/en.135.1.45; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774; Patel IS, 2003, INT J CANCER, V106, P172, DOI 10.1002/ijc.11086; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; SOMMERS CL, 1994, CANCER RES, V54, P3544; Soubry A, 2005, CANCER RES, V65, P2224, DOI 10.1158/0008-5472.CAN-04-2020; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wong AST, 1999, INT J CANCER, V81, P180	35	59	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2427	2440		10.1038/onc.2009.523	http://dx.doi.org/10.1038/onc.2009.523			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118984				2022-12-17	WOS:000276951500011
J	Monsel, G; Ortonne, N; Bagot, M; Bensussan, A; Dumaz, N				Monsel, G.; Ortonne, N.; Bagot, M.; Bensussan, A.; Dumaz, N.			c-Kit mutants require hypoxia-inducible factor 1 alpha to transform melanocytes	ONCOGENE			English	Article						c-Kit; imatinib; MAPK pathway; melanoma; PI3K/Akt pathway	TYROSINE KINASE; FACTOR-RECEPTOR; MELANOMA-CELLS; INHIBITION; ACTIVATION; IMATINIB; MUTATION; EXPRESSION; ONCOGENE; SURVIVAL	Many studies have highlighted the critical role of c-Kit in normal melanocyte development but its role in melanoma development remains unclear. Although c-Kit expression is often lost during melanoma progression, a subset of melanoma has been found to overexpress c-Kit and mutations activating c-Kit have recently been identified in some acral and mucosal melanoma. To address the role of these c-Kit mutants in the transformation of melanocytes, we characterized the physiological responses of melanocytes expressing the most frequent c-Kit mutants found in melanoma (K642E and L576P) and a novel mutant we identified in an acral melanoma. We analysed signaling pathways activated downstream of c-Kit and showed that all three mutants led to a strong activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway but only weak activation of the Ras/Raf/Mek/Erk pathway, which was not sufficient to promote uncontrolled melanocyte proliferation and transformation. However, in hypoxic conditions or coexpressed with a constitutively active form of hypoxia-inducible factor 1 alpha (HIF-1 alpha), c-Kit mutants activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes. Proliferation of melanocytes transformed by these mutants was specifically inhibited by imatinib. These results show for the first time that melanocytes require a specific epigenetic environment to be transformed by c-Kit mutants and highlight a distinct molecular mechanism of melanocyte transformation. Oncogene (2010) 29, 227-236; doi:10.1038/onc.2009.320; published online 5 October 2009	[Monsel, G.; Ortonne, N.; Bagot, M.; Bensussan, A.; Dumaz, N.] Hop St Louis, INSERM, U976, F-75475 Paris 10, France; [Ortonne, N.] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France; [Bagot, M.; Bensussan, A.] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Dermatol, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Dumaz, N (corresponding author), Hop St Louis, INSERM, U976, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	nicolas.dumaz@inserm.fr	Dumaz, Nicolas/B-5907-2008; Bensussan, Armand/E-5434-2017	Dumaz, Nicolas/0000-0003-3511-2160; Bensussan, Armand/0000-0002-0409-2497	INSERM; Universite Paris XII, Societe Francaise de Dermatologie; Ligue Contre le Cancer (Comite du Val de Marne); Institut National du Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris XII, Societe Francaise de Dermatologie; Ligue Contre le Cancer (Comite du Val de Marne); Institut National du Cancer(Institut National du Cancer (INCA) France)	We thank Professor Richard Marais for 501mel cells and pMCEF vector, Dr Lars Ronnstrand for a wild-type c-Kit expression vector and Dr Frank Bunn for the vector expressing HIF-1 alpha (401 Delta 603). This work was funded by INSERM, Universite Paris XII, Societe Francaise de Dermatologie, Ligue Contre le Cancer (Comite du Val de Marne) and Institut National du Cancer.	Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; LASSAM N, 1992, ONCOGENE, V7, P51; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Muchemwa FC, 2008, BRIT J DERMATOL, V158, P411, DOI 10.1111/j.1365-2133.2007.08292.x; NATALI PG, 1992, CANCER RES, V52, P6139; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200	25	59	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					227	236		10.1038/onc.2009.320	http://dx.doi.org/10.1038/onc.2009.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802003				2022-12-17	WOS:000273650000006
J	Keenen, B; Qi, H; Saladi, SV; Yeung, M; de la Serna, IL				Keenen, B.; Qi, H.; Saladi, S. V.; Yeung, M.; de la Serna, I. L.			Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma	ONCOGENE			English	Article						SWI/SNF; BRG1; MITF; melanoma; chromatin; differentiation	CELL-CYCLE ARREST; LINEAGE-SURVIVAL; RETINOBLASTOMA PROTEIN; MALIGNANT-MELANOMA; MASTER REGULATOR; LUNG-CANCER; IN-VITRO; DIFFERENTIATION; MITF; BRG1	The microphthalmia-associated transcription factor (MITF) promotes melanocyte differentiation and cell-cycle arrest. Paradoxically, MITF also promotes melanoma survival and proliferation, acting like a lineage survival oncogene. Thus, it is critically important to understand the mechanisms that regulate MITF activity in melanoma cells. SWI/SNF chromatin remodeling enzymes are multiprotein complexes composed of one of two related ATPases, BRG1 or BRM, and 9-12-associated factors (BAFs). We previously determined that BRG1 interacts with MITF to promote melanocyte differentiation. However, it was unclear whether SWI/SNF enzymes regulate the expression of different classes of MITF target genes in melanoma. In this study, we characterized SWI/SNF subunit expression in melanoma cells and observed downregulation of BRG1 or BRM, but not concomitant loss of both ATPases. Re-introduction of BRG1 in BRG1-deficient SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to cisplatin. Downregulation of the single ATPase, BRM, in SK-MEL5 cells inhibited expression of both differentiation-specific and pro-proliferative MITF target genes and inhibited tumorigenicity in vitro. Our data suggest that heterogeneous SWI/SNF complexes composed of either the BRG1 or BRM subunit promote expression of distinct and overlapping MITF target genes and that at least one ATPase is required for melanoma tumorigenicity.	[Keenen, B.; Qi, H.; Saladi, S. V.; Yeung, M.; de la Serna, I. L.] Univ Toledo, Dept Biochem & Canc Biol, Coll Med, Toledo, OH 43614 USA	University System of Ohio; University of Toledo	de la Serna, IL (corresponding author), Univ Toledo, Dept Biochem & Canc Biol, Coll Med, 3035 Arlington Ave, Toledo, OH 43614 USA.	ivana.delaserna@utoledo.edu	Saladi, SrinivasVinod/AAM-3146-2020	Saladi, SrinivasVinod/0000-0001-8147-4379	National Institute of Environmental Health Sciences; Ohio Cancer Research Associates, American Cancer Society, Ohio Division [5K22ES12981]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES012981] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Ohio Cancer Research Associates, American Cancer Society, Ohio Division(American Cancer Society); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr David Fisher (Dana Farber) for the MITF antibody, Ruth Halaban (Yale Tissue Culture Facility) for melanocytes and melanoma cells, and Stephen Smale (Howard Hughes Medical Institute, UCLA) for shRNA constructs. ILD was supported by the National Institute of Environmental Health Sciences; Grant number: 5K22ES12981, Ohio Cancer Research Associates, American Cancer Society, Ohio Division.	Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x; Becker TM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-4; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622; Eberle J, 1995, PIGM CELL RES, V8, P307, DOI 10.1111/j.1600-0749.1995.tb00679.x; Flowers S, 2009, J BIOL CHEM, V284, P10067, DOI 10.1074/jbc.M808782200; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gong F, 2008, CELL CYCLE, V7, P1067, DOI 10.4161/cc.7.8.5647; Gong F, 2006, NAT STRUCT MOL BIOL, V13, P902, DOI 10.1038/nsmb1152; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Link KA, 2008, CANCER RES, V68, P4551, DOI 10.1158/0008-5472.CAN-07-6392; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; POLLACK MS, 1981, J NATL CANCER I, V66, P1003, DOI 10.1093/jnci/66.6.1003; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Reisman DN, 2003, CANCER RES, V63, P560; Rosson GB, 2005, J CELL PHYSIOL, V205, P286, DOI 10.1002/jcp.20397; Shen LL, 2007, CANCER RES, V67, P11335, DOI 10.1158/0008-5472.CAN-07-1502; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; Svensson SPS, 2003, PIGM CELL RES, V16, P351, DOI 10.1034/j.1600-0749.2003.00030.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VINK J, 1993, LAB INVEST, V68, P192; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601	54	59	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					81	92		10.1038/onc.2009.304	http://dx.doi.org/10.1038/onc.2009.304			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784067	Green Accepted			2022-12-17	WOS:000273373500008
J	Orgaz, JL; Ladhani, O; Hoek, KS; Fernandez-Barral, A; Mihic, D; Aguilera, O; Seftor, EA; Bernad, A; Rodriguez-Peralto, JL; Hendrix, MJC; Volpert, OV; Jimenez, B				Orgaz, J. L.; Ladhani, O.; Hoek, K. S.; Fernandez-Barral, A.; Mihic, D.; Aguilera, O.; Seftor, E. A.; Bernad, A.; Rodriguez-Peralto, J. L.; Hendrix, M. J. C.; Volpert, O. V.; Jimenez, B.			'Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'	ONCOGENE			English	Article						PEDF; melanoma progression; vasculogenic mimicry; anti-angiogenic factors	CEREBELLAR GRANULE NEURONS; DOWN-REGULATION; FACTOR PEDF; NEUROTROPHIC ACTIVITY; RETINOBLASTOMA CELLS; ENDOTHELIAL-CELLS; MOTOR-NEURONS; ANGIOGENESIS; EXPRESSION; IDENTIFICATION	Pigment epithelium-derived factor (PEDF) is a multifunctional secreted glycoprotein that displays broad antitumor activity based on dual targeting of the tumor microenvironment (anti-angiogenic action) and the tumor cells (direct anti-tumor action). Here, we show that PEDF expression is high in melanocytes, but it is lost during malignant progression of human melanoma. Using a high-throughput analysis of the data from microarray studies of molecular profiling of human melanoma, we found that PEDF expression is lost in highly invasive melanomas. In paired cell lines established from the same lesion but representing the high and low extremes of malignant potential, abundant PEDF expression was restricted to the poorly aggressive counterparts. We used RNA interference to directly address the functional consequences of PEDF silencing. PEDF knockdown in poorly aggressive melanoma cell lines augmented migration, invasion and vasculogenic mimicry, which translated into an increased in vivo metastatic potential. PEDF interference also significantly enhanced the migratory and invasive capability of normal melanocytes and moderately increased their proliferative potential. Our results show that loss of PEDF enables melanoma cells to acquire an invasive phenotype and, therefore, modulation of this multifunctional factor could be critical for the malignant progression of human melanoma. Oncogene (2009) 28, 4147-4161; doi: 10.1038/onc.2009.284; published online 21 September 2009	[Orgaz, J. L.; Fernandez-Barral, A.; Aguilera, O.; Jimenez, B.] Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed, CSIC, Madrid 28029, Spain; [Ladhani, O.; Volpert, O. V.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Hoek, K. S.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Mihic, D.] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; [Seftor, E. A.; Hendrix, M. J. C.] Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Bernad, A.] Ctr Nacl Invest Cardiovasc, Dept Regenerat Cardiol, Madrid, Spain; [Rodriguez-Peralto, J. L.] Hosp Univ 12 Octubre Madrid, Dept Pathol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Hospital Universitario 12 de Octubre	Jimenez, B (corresponding author), Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed, CSIC, Arturo Duperier 4, Madrid 28029, Spain.	bjimenez@iib.uam.es	Fernández-Barral, Asunión/O-8133-2015; Orgaz, Jose L./ABH-1835-2020; Cuenca, Benilde Jimenez/K-9959-2014	Fernández-Barral, Asunión/0000-0002-1278-4645; Orgaz, Jose L./0000-0002-9776-7544; Bernad, Antonio/0000-0003-0620-9668; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Rodriguez-Peralto, Jose Luis/0000-0002-6578-7153	Ministerio de Educacion y Ciencia [SAF2007-62292]; Comunidad de Madrid [SAL-0311-2006]; NIH [RO1 HL68033, CA59702]; NIH/NCI [T32CA009560]; Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship; NATIONAL CANCER INSTITUTE [T32CA009560, R01CA059702, R37CA059702] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068033, R01HL077471] Funding Source: NIH RePORTER	Ministerio de Educacion y Ciencia(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We acknowledge with gratitude all researchers that contributed with cell lines: M Herlyn, PF Penas, F Vidal-Vanaclocha, GN Van Muijen, AM Valverde, M Garcia and M del Rio. We also thank P Fernandez for her technical assistance in lentivirus production. Supported by grants: Ministerio de Educacion y Ciencia grant SAF2007-62292 (BJ), Comunidad de Madrid SAL-0311-2006 (BJ), NIH grant RO1 HL68033 (OV), NIH merit grant CA59702 (MJCH). JL Orgaz has been supported by a Ministerio de Educacion y Ciencia fellowship, O Ladhani by an NIH/NCI training grant T32CA009560 and A Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship.	Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104; Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bilak MM, 2002, J NEUROSCI, V22, P9378; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Ek ETH, 2006, TRENDS MOL MED, V12, P497, DOI 10.1016/j.molmed.2006.08.009; Ek ETH, 2006, MOL CANCER THER, V5, P1641, DOI 10.1158/1535-7163.MCT-06-0107; Fernandez-Garcia NI, 2007, J MOL MED-JMM, V85, P15, DOI 10.1007/s00109-006-0111; Fernandez-Garcia NI, 2005, ONCOGENE, V24, P6533, DOI 10.1038/sj.onc.1208801; Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guan M, 2003, J CLIN PATHOL, V56, P277, DOI 10.1136/jcp.56.4.277; Halin S, 2004, CANCER RES, V64, P5664, DOI 10.1158/0008-5472.CAN-04-0835; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489; Notari L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200; Punzon I, 2004, BLOOD, V103, P580, DOI 10.1182/blood-2003-07-2298; Quan GMY, 2005, CALCIFIED TISSUE INT, V76, P146, DOI 10.1007/s00223-004-0068-2; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sato S, 2001, PIGM CELL RES, V14, P428, DOI 10.1034/j.1600-0749.2001.140602.x; Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041; Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497; SEIGEL GM, 1994, GROWTH FACTORS, V10, P289, DOI 10.3109/08977199409010995; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176; Uehara H, 2004, CANCER RES, V64, P3533, DOI 10.1158/0008-5472.CAN-03-3725; van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474	48	59	61	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4147	4161		10.1038/onc.2009.284	http://dx.doi.org/10.1038/onc.2009.284			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19767774	Green Accepted			2022-12-17	WOS:000272876100002
J	Astanehe, A; Finkbeiner, MR; Hojabrpour, P; To, K; Fotovati, A; Shadeo, A; Stratford, AL; Lam, WL; Berquin, IM; Duronio, V; Dunn, SE				Astanehe, A.; Finkbeiner, M. R.; Hojabrpour, P.; To, K.; Fotovati, A.; Shadeo, A.; Stratford, A. L.; Lam, W. L.; Berquin, I. M.; Duronio, V.; Dunn, S. E.			The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1	ONCOGENE			English	Article						breast cancer; invasion; PI3K; PIK3CA; uPA; YB-1	RIBOSOMAL S6 KINASE; BREAST-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMINOGEN-ACTIVATOR; HEMATOPOIETIC-CELLS; OVARIAN-CANCER; HIGH-FREQUENCY; COPY NUMBER	PIK3CA, which codes for the p110 alpha catalytic subunit of phosphatidylinositol-3-kinase (PI3K), is implicated as an oncogene. Despite importance of PIK3CA in cancer, little is known about what drives up its expression in tumor cells. We recently characterized the PIK3CA promoter and reported that it is transcriptionally silenced by the tumor suppressor protein p53. In the present study, we demonstrate that PIK3CA can be induced by the oncogenic transcription factor Y-box binding protein-1(YB-1). Three YB-1-responsive elements were identified on the PIK3CA promoter using chromatin immunoprecipitation and electrophoretic mobility shift assays. Interestingly, silencing YB-1 with siRNA in models of basal-like breast cancer decreased p110 alpha protein levels regardless of whether PIK3CA was wild type, amplified or mutated. This decrease in p110 alpha led to a reduction in PI3K activity and the downstream signaling primarily through p90 ribosomal S6 kinase and S6 ribosomal protein. Disruption in PIK3CA-dependent signaling suppressed cellular invasion correlative with loss of urokinase plasminogen activator (uPA). Similarly, silencing YB-1 suppressed invasion and uPA production however this was reversible through the introduction of constitutively active PIK3CA. In conclusion, YB-1 is the first reported oncogene to induce the expression of PIK3CA through transcriptional control of its promoter. Oncogene (2009) 28, 2406-2418; doi:10.1038/onc.2009.81; published online 11 May 2009	[Astanehe, A.; Finkbeiner, M. R.; To, K.; Fotovati, A.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Lab Oncogen Res, Dept Pediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Astanehe, A.; Finkbeiner, M. R.; To, K.; Fotovati, A.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Hojabrpour, P.; Duronio, V.] Univ British Columbia, Dept Med, Jack Bell Res Ctr, Vancouver, BC V5Z 4H4, Canada; [Shadeo, A.; Lam, W. L.] Univ British Columbia, Dept Canc Genet & Dev Biol, British Columbia Canc Res Ctr, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27109 USA	Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; Wake Forest University	Dunn, SE (corresponding author), Univ British Columbia, Lab Oncogen Res, Dept Pediat, Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca		Shadeo, Ashleen/0000-0002-0866-0519	National Cancer Institute of Canada (SED) [RO1 CA114017-01A1]; Canadian Institute of Health Research; Canadian Breast Cancer Research Alliance IDEA; Canadian Institute of Health Research MD/PhD; Michael Smith Foundation for Health Research Studentships.; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	National Cancer Institute of Canada (SED); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance IDEA; Canadian Institute of Health Research MD/PhD(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research Studentships.(Michael Smith Foundation for Health Research); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute of Canada (SED), RO1 CA114017-01A1 (SED and IB), Canadian Institute of Health Research (VD), Canadian Breast Cancer Research Alliance IDEA (WL). AA was supported by the Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research Studentships.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Clark DE, 2005, CANCER RES, V65, P3108; Deleeuw RJ, 2007, GASTROENTEROLOGY, V132, P1902, DOI 10.1053/j.gastro.2007.03.036; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dunn SE, 2001, CANCER RES, V61, P1367; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Smith JA, 2005, CANCER RES, V65, P1027; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Wu GJ, 2005, BREAST CANCER RES, V7, pR609, DOI 10.1186/bcr1262; Wu Joyce, 2007, Transl Oncogenomics, V2, P49; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	44	59	59	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2406	2418		10.1038/onc.2009.81	http://dx.doi.org/10.1038/onc.2009.81			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430491				2022-12-17	WOS:000267342400005
J	Menigatti, M; Truninger, K; Gebbers, JO; Marbet, U; Marra, G; Schar, P				Menigatti, M.; Truninger, K.; Gebbers, J-O; Marbet, U.; Marra, G.; Schaer, P.			Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the hMLH1 and MGMT promoters	ONCOGENE			English	Article						hMLH1; MGMT; promoter methylation; colorectal mucosa; colorectal cancer	NORMAL COLONIC-MUCOSA; CPG ISLAND METHYLATION; ABERRANT CRYPT FOCI; MICROSATELLITE INSTABILITY; GENE-EXPRESSION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROXIMAL COLON; MLH1 PROMOTER; K-RAS; CANCER	Silencing of gene expression by aberrant cytosine methylation is a prominent feature of human tumors, including colorectal cancers. Epigenetic changes of this type play undisputed roles in cell transformation when they involve genes that safeguard genome stability, and they can also be detected in precancerous lesions and seemingly normal peritumoral tissues. We explored physiological conditions associated with aberrant promoter methylation involving two DNA-repair genes in normal colorectal mucosa. Samples of cecal, transverse colon, sigmoid and rectal mucosa collected from 100 healthy individuals undergoing screening colonoscopy were analysed for hMLH1 and MGMT promoter methylation with a quantitative PCR assay. Positivity in at least one colon segment was common in both sexes, with methylation involving 0.1-18.8% of the alleles (median = 0.49%). Samples from males showed no consistent patterns for either promoter, but there were striking age- and colon segment-specific differences in the female subgroup. Here, the prevalence of hMLH1 and MGMT methylation increased significantly with age, particularly in the right colon, where there was also an age- related increase in the percentage of alleles showing hMLH1 methylation. Concomitant methylation of both promoters was also significantly more common in the right colon of women. These findings paralleled immunohistochemical patterns of hMLH1 and MGMT protein loss in an independent series of 231 colorectal cancers and were consistent with current epigenetic profiles of colorectal cancer subsets. They suggest the intriguing possibility that the epigenetic signatures of cancers may have early-stage, normal-tissue counterparts that reflect potentially important aspects of the initial carcinogenetic process.	[Marra, G.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Menigatti, M.; Schaer, P.] Univ Basel, Dept Biomed, Basel, Switzerland; [Truninger, K.] SRO Hosp Langenthal, Langenthal, Switzerland; [Gebbers, J-O] Cantonal Hosp Lucerne, Dept Pathol, Luzern, Switzerland; [Marbet, U.] Cantonal Hosp Altdorf, Clin Internal Med, Altdorf, Switzerland	University of Zurich; University of Basel; Lucerne Cantonal Hospital	Marra, G (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	marra@imcr.uzh.ch	Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147	Swiss National Science Foundation; Krebsliga Zentralschweiz; Krebsliga Beider Basel; Julius-Muller Stiftung, Zurich; Hanne-Liebermann Stiftung, Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga Zentralschweiz; Krebsliga Beider Basel; Julius-Muller Stiftung, Zurich; Hanne-Liebermann Stiftung, Zurich	We thank Josef Jiricny at the Institute of Molecular Cancer Research of the University of Zurich and our colleagues at the Department of Biomedicine of the University of Basel for helpful discussions and support throughout the project. We are also grateful to Patric Urfer and Christophe Kunz for critical reading of the manuscript, Ritva Haider for technical assistance, and Marian E Kent for editorial assistance. The study was supported by the Swiss National Science Foundation (to GM), the Krebsliga Zentralschweiz (to GM), the Krebsliga Beider Basel (to PS), Julius-Muller Stiftung, Zurich (to KT) and the Hanne-Liebermann Stiftung, Zurich (to KT).	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1998, CANCER RES, V58, P5489; Al-Ghnaniem R, 2007, AM J CLIN NUTR, V86, P1064, DOI 10.1093/ajcn/86.4.1064; Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502; Capel E, 2007, ONCOGENE, V26, P7596, DOI 10.1038/sj.onc.1210581; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Deng GR, 1999, CANCER RES, V59, P2029; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fox EJ, 2006, J MOL DIAGN, V8, P68, DOI 10.2353/jmoldx.2006.050084; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Greenspan EJ, 2007, CARCINOGENESIS, V28, P769, DOI 10.1093/carcin/bgl209; Hiraoka S, 2006, GASTROENTEROLOGY, V131, P379, DOI 10.1053/j.gastro.2006.04.027; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Kane MF, 1997, CANCER RES, V57, P808; Kawakami K, 2006, BRIT J CANCER, V94, P593, DOI 10.1038/sj.bjc.6602940; Kim SH, 2003, MOL CARCINOGEN, V37, P32, DOI 10.1002/mc.10116; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Lindblom A, 2001, CURR OPIN ONCOL, V13, P63, DOI 10.1097/00001622-200101000-00013; Malkhosyan SR, 2000, GASTROENTEROLOGY, V119, P598, DOI 10.1053/gast.2000.16154; Menigatti M, 2001, GENE CHROMOSOME CANC, V31, P357, DOI 10.1002/gcc.1154; Menigatti M, 2007, ONCOL REP, V17, P1421; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nakagawa H, 2001, CANCER RES, V61, P6991; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ogino S, 2007, GUT, V56, P1564, DOI 10.1136/gut.2007.119750; Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Slattery ML, 2001, CANCER RES, V61, P126; Soetikno RM, 2008, JAMA-J AM MED ASSOC, V299, P1027, DOI 10.1001/jama.299.9.1027; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Whitehall VLJ, 2001, CANCER RES, V61, P827; Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799; Ye CZ, 2006, ONCOL REP, V16, P429	49	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					899	909		10.1038/onc.2008.444	http://dx.doi.org/10.1038/onc.2008.444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060925				2022-12-17	WOS:000263320000012
J	Ischenko, I; Camaj, P; Seeliger, H; Kleespies, A; Guba, M; De Toni, EN; Schwarz, B; Graeb, C; Eichhorn, ME; Jauch, KW; Bruns, CJ				Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; De Toni, E. N.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.			Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling	ONCOGENE			English	Article						5-fluorouracil; acquired resistance; thymidylate synthase; Src kinase inhibition; mouse xenograft pancreatic tumor model; epidermal growth factor receptor	THYMIDYLATE SYNTHASE INHIBITORS; COLORECTAL-CANCER CELLS; DIHYDROPYRIMIDINE DEHYDROGENASE; FAMILY KINASES; TUMOR-CELLS; STEM-CELLS; EXPRESSION; RESISTANCE; PROTEIN; DNA	Resistance to chemotherapy is believed to be a major cause of treatment failure in pancreatic cancer. Thus, it is necessary to explore alternative therapeutic modalities to overcome drug resistance in pancreatic cancer treatment. We tested the hypothesis that Src tyrosine kinase inhibition could augment the chemosensitivity of 5-fluorouracil (5-FU)-resistant human pancreatic cancer cells to 5-FU. As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU_Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells. Furthermore, when small-interfering RNA approach to silence Src gene expression was applied, the degree of 5-FU-induced apoptosis was increased in all cell lines independently of the chemoresistance status. Western blotting and RT-PCR analysis revealed that the expression of thymidylate synthase (TS) was higher in 5-FU-resistant cells, however, decreased significantly after pretreatment with PP2. Furthermore, the combination of 5-FU_PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Finally, PP2 in combination with 5-FU substantially decreased the in vivo tumor growth and inhibited distant metastases. Taken together, 5-FU chemoresistance can be reversed through indirect TS regulation by inhibiting Src tyrosine kinase. A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation.	[Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.] Univ Munich, Dept Surg, D-81377 Munich, Germany; [De Toni, E. N.] Univ Munich, Dept Gastroenterol, D-81377 Munich, Germany	University of Munich; University of Munich	Ischenko, I (corresponding author), Univ Munich, Dept Surg, Grosshadern Campus,Marchioninistr 15, D-81377 Munich, Germany.	Ivan.Ischenko@med.uni-muenchen.de	Eichhorn, Martin/AAU-7204-2020; Eichhorn, Martin/GRE-9126-2022; Guba, Markus/M-4309-2019; De Toni, Enrico N/C-6496-2008; Ischenko, Ivan/A-4591-2011	Eichhorn, Martin/0000-0002-0362-0374; 	Deutsche Forschungsgemeinschaft (DFG) [KFO 128/1-3]; Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm [GU 489/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm(German Research Foundation (DFG))	We thank AstraZeneca for providing with AZM475271. This research was supported by the grant of the clinical research group KFO 128/1-3 of the Deutsche Forschungsgemeinschaft (DFG) and the research grant GU 489/3-1 of the Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm 'The tumor-vessel interface'. This report includes data that were generated during the doctoral thesis of Bettina Schwarz at the Medical School of the Ludwig-Maximilians-University, Munich.	BECK A, 1994, EUR J CANCER, V30A, P1517, DOI 10.1016/0959-8049(94)00216-R; Blaszkowsky Lawrence, 1998, Frontiers in Bioscience, V3, pE214; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; DECAPRIO JA, 1991, J CLIN ONCOL, V9, P2128, DOI 10.1200/JCO.1991.9.12.2128; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hamaji Masayasu, 2002, Gan To Kagaku Ryoho, V29, P889; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kleespies A, 2006, DRUG RESIST UPDATE, V9, P1, DOI 10.1016/j.drup.2006.02.002; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; KOLLMANNSBERGER C, 1996, CANCER, V78, P654; LONN U, 1984, CANCER RES, V44, P3414; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAJOR PP, 1982, CANCER RES, V42, P3005; Masumoto N, 1997, Gan To Kagaku Ryoho, V24, P424; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nam JS, 2002, CLIN CANCER RES, V8, P2430; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Paul Manash K, 2004, Int J Med Sci, V1, P101; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Schaeybroeck S, 2005, CLIN CANCER RES, V11, P7480, DOI 10.1158/1078-0432.CCR-05-0328; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753; Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972; Wang WG, 2001, CANCER RES, V61, P5505; Wu YP, 1998, INT J ONCOL, V13, P1241; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621; Zhao YP, 2006, J SURG RES, V136, P325, DOI 10.1016/j.jss.2006.06.031	47	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7212	7222		10.1038/onc.2008.326	http://dx.doi.org/10.1038/onc.2008.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794807				2022-12-17	WOS:000261384100008
J	Karam, R; Carvalho, J; Bruno, I; Graziadio, C; Senz, J; Huntsman, D; Carneiro, F; Seruca, R; Wilkinson, MF; Oliveira, C				Karam, R.; Carvalho, J.; Bruno, I.; Graziadio, C.; Senz, J.; Huntsman, D.; Carneiro, F.; Seruca, R.; Wilkinson, M. F.; Oliveira, C.			The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers	ONCOGENE			English	Article						NMD; E-cadherin; CDH1; gastric cancer; HDGC; KATO-III	NONSENSE-MEDIATED DECAY; GENE; MECHANISM; FAMILIES	Germline mutations in the gene encoding the tumour suppressor E-cadherin (CDH1) are the underlying genetic defect responsible for hereditary diffuse gastric cancer (HDGC). A remarkably high percentage (similar to 80%) of CDH1 mutations in HDGC patients and carriers generate premature termination codons (PTCs). Here, we examined whether CDH1 transcripts harbouring PTCs are downregulated by nonsense-mediated decay (NMD), an RNA surveillance pathway that degrades PTC-bearing transcripts. Using an allele-specific expression (ASE) assay to differentiate between mutated and wild-type CDH1 alleles, we found that PTC-bearing CDH1 mRNAs are strongly downregulated in normal gastric tissue from several CDH1 mutation carriers. We show that NMD is responsible for this robust downregulation, as CDH1 transcripts harbouring PTCs in the KATO-III gastric tumour cell line were upregulated in response to protein synthesis inhibitors or depletion of the NMD factors UPF1 and eIF4AIII. Analysis of HDGC patients harbouring CDH1 alleles with PTCs at a wide variety of different positions indicates an association of their predicted ability to induce NMD and an earlier age of onset of gastric cancer. This suggests that NMD may be detrimental for HDGC patients and therefore NMD is a potentially useful therapeutic target for CDH1 mutation carriers.	[Karam, R.; Bruno, I.; Wilkinson, M. F.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA; [Karam, R.; Carvalho, J.; Carneiro, F.; Seruca, R.; Oliveira, C.] Univ Porto, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal; [Karam, R.; Carneiro, F.; Seruca, R.; Oliveira, C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Graziadio, C.] FFFCMPA, Dept Genet, Porto Alegre, RS, Brazil; [Senz, J.; Huntsman, D.] British Columbia Canc Agcy, Hereditary Canc Program, Vancouver, BC V5Z 4E6, Canada	University of Texas System; UTMD Anderson Cancer Center; Universidade do Porto; Universidade do Porto; British Columbia Cancer Agency	Wilkinson, MF (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org; carlaol@ipatimup.pt	Carneiro, Fatima/J-6432-2013; Carneiro, Fatima/AAV-8677-2021; Graziadio, Carla/G-5566-2015; seruca, raquel/F-8187-2011; Huntsman, David/ABE-6082-2020; Carvalho, Joana/J-9476-2013; Oliveira, Carla/F-8188-2011	Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Carvalho, Joana/0000-0001-9743-438X; Oliveira, Carla/0000-0001-8340-2264; Graziadio, Carla/0000-0001-6569-5278; Seruca, Raquel/0000-0002-8851-4166	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-RO1GM058595-08, R01 GM111838] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Dussaulx-Garin L, 2001, EUR J GASTROEN HEPAT, V13, P711, DOI 10.1097/00042737-200106000-00016; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Frebourg T, 2006, J MED GENET, V43, P138, DOI 10.1136/jmg.2005.031385; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Kaurah P, 2007, JAMA-J AM MED ASSOC, V297, P2360, DOI 10.1001/jama.297.21.2360; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oliveira C, 2006, INT J SURG PATHOL, V14, P21, DOI 10.1177/106689690601400105; Oliveira C, 2004, ONCOGENE, V23, P2236, DOI 10.1038/sj.onc.1207335; Sasaki CY, 2000, CANCER RES, V60, P7057; Suriano G, 2003, HUM MOL GENET, V12, P3007, DOI 10.1093/hmg/ddg316; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007	16	59	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4255	4260		10.1038/onc.2008.62	http://dx.doi.org/10.1038/onc.2008.62			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18427545				2022-12-17	WOS:000257496800013
J	Torng, PL; Lee, YCG; Huang, CYF; Ye, JH; Lin, YS; Chu, YW; Huang, SC; Cohen, P; Wu, CW; Lin, CT				Torng, P-L; Lee, Y-CG; Huang, C-YF; Ye, J-H; Lin, Y-S; Chu, Y-W; Huang, S-C; Cohen, P.; Wu, C-W; Lin, C-T			Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma	ONCOGENE			English	Article						ovarian endometrioid carcinoma; invasion; suppressor; insulin-like growth factor binding protein-3	CANCER; STAGE; GENE; ADENOCARCINOMA; EXPRESSION	Metastasis and invasion occur in the majority of epithelial ovarian carcinoma at diagnosis. To delineate the molecular signature in ovarian cancer invasion, we established and characterized a human ovarian endometrioid carcinoma (EC) cell line OVTW59-P0 and its invasion-related sublines (P1-P4, in the order of increasing invasive activity). P4 showed faster migration and larger xenograft formation with metastasis than P0. By microarray analysis of different gene expression among P0-P4 sublines, one group of gene was found negatively correlated with cancer invasion. Among these genes, IGFBP-3 was identified as one of the most remarkably suppressed gene that showed lower gene expression in P4 than P0. Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation. In 35 patients with EC tumors, low IGFBP-3 expression correlated clinically with higher tumor grade, advanced stage and poor survival. Our results provide evidence and indicate that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.	[Lin, C-T] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10020, Taiwan; [Torng, P-L; Ye, J-H; Huang, S-C; Lin, C-T] Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei 10020, Taiwan; [Cohen, P.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA 90024 USA; [Huang, C-YF; Lin, Y-S; Chu, Y-W; Wu, C-W] Natl Hlth Res Inst, Natl Hlth Canc Res, Taipei, Taiwan; [Lee, Y-CG] Taipei Med Univ, Grad Inst Med Informat, Taipei, Taiwan; [Torng, P-L; Huang, S-C] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; University of California System; University of California Los Angeles; National Health Research Institutes - Taiwan; Taipei Medical University; National Taiwan University; National Taiwan University Hospital	Lin, CT (corresponding author), Natl Taiwan Univ Hosp, Dept Pathol, 7 Chung Shan S Rd, Taipei 10020, Taiwan.	ctl@ha.mc.ntu.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; TORNG, PAO-LING/0000-0002-6834-8295				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Bell KA, 2000, AM J SURG PATHOL, V24, P1465, DOI 10.1097/00000478-200011000-00002; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Goodman MT, 2003, CANCER, V97, P2648, DOI 10.1002/cncr.11347; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Jiang XX, 1998, CANCER RES, V58, P1707; Juan HF, 2002, ELECTROPHORESIS, V23, P2490, DOI 10.1002/1522-2683(200208)23:15<2490::AID-ELPS2490>3.0.CO;2-3; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katsaros D, 2001, EUR J CANCER, V37, P478, DOI 10.1016/S0959-8049(00)00423-8; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; LIN CT, 1993, LAB INVEST, V68, P716; Lu LG, 2006, CLIN CANCER RES, V12, P1208, DOI 10.1158/1078-0432.CCR-05-1801; McCluggage WG, 2002, HISTOPATHOLOGY, V40, P309, DOI 10.1046/j.1365-2559.2002.01384.x; McGuire WP, 1996, SEMIN ONCOL, V23, P40; Mishra S, 2004, MOL CELL BIOCHEM, V267, P83, DOI 10.1023/B:MCBI.0000049368.40558.0a; Oh SH, 2006, MOL CANCER THER, V5, P2685, DOI 10.1158/1535-7163.MCT-06-0142; Oh SH, 2006, CLIN CANCER RES, V12, P653, DOI 10.1158/1078-0432.CCR-05-1725; Ohwada M, 2001, CANCER CYTOPATHOL, V93, P376, DOI 10.1002/cncr.10137; Sayer RA, 2005, GYNECOL ONCOL, V96, P355, DOI 10.1016/j.ygyno.2004.10.012; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Simpson JL, 2002, ANN NY ACAD SCI, V955, P239, DOI 10.1111/j.1749-6632.2002.tb02785.x; Torng PL, 2004, GYNECOL ONCOL, V92, P559, DOI 10.1016/j.ygyno.2003.11.011; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x	25	59	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2137	2147		10.1038/sj.onc.1210864	http://dx.doi.org/10.1038/sj.onc.1210864			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952116	Green Published			2022-12-17	WOS:000254621300004
J	Wang, P; Lushnikova, T; Odvody, J; Greiner, TC; Jones, SN; Eischen, CM				Wang, P.; Lushnikova, T.; Odvody, J.; Greiner, T. C.; Jones, S. N.; Eischen, C. M.			Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells	ONCOGENE			English	Article						Mdm2; Myc; p53; ARF; lymphoma chromosome	MYC-INDUCED LYMPHOMAGENESIS; BURKITTS-LYMPHOMA; DNA-DAMAGE; C-MYC; P53; ONCOGENE; OVEREXPRESSION; APOPTOSIS; PATHWAY; ARF	Mdm2, a regulator of the p53 tumor suppressor, is frequently overexpressed in lymphomas, including lymphomas that have inactivated p53. However, the biological consequences of Mdm2 overexpression in lymphocytes are not fully resolved. Here, we report that increased expression of Mdm2 in B cells augmented proliferation and reduced susceptibility to p53-dependent apoptosis, which was due to inhibition of p53 and suppression of p21 expression. Notably, developing and mature B cells from Mdm2 transgenic mice had an increased frequency of chromosomal/chromatid breaks and/or aneuploidy. This Mdm2-mediated genome instability occurred at a similar frequency as that in B cells overexpressing the oncogene c-Myc, but the chromosomal instability was not further enhanced when Mdm2 and c-Myc were overexpressed together. Elevated Mdm2 expression alone increased the occurrence of B-cell transformation in vivo and cooperated with c-Myc overexpression, resulting in an acceleration of B-cell lymphomagenesis. In addition, the frequency of p53 mutations was reduced, but not eliminated, in lymphomas arising in Mdm2/E mu-myc double transgenic mice. Therefore, increased Mdm2 expression facilitated B-cell lymphomagenesis, in part, through regulation of p53 by altering B-cell proliferation and susceptibility to apoptosis, and by inducing chromosomal instability.	[Wang, P.; Lushnikova, T.; Odvody, J.; Eischen, C. M.] Vanderbilt Univ, Ctr Med, Dept Pathol, Sch Med, Nashville, TN 37232 USA; [Greiner, T. C.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68182 USA; [Jones, S. N.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Eischen, CM (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pathol, Sch Med, MCN C3321,1161 21st Ave S, Nashville, TN 37232 USA.	eischen@vanderbilt.edu			NCI NIH HHS [CA098139, CA117935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139, R01CA117935] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Ghobrial IM, 2005, BLOOD, V105, P3722, DOI 10.1182/blood-2004-10-3999; Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; STRASSER A, 1993, ONCOGENE, V8, P1; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wilda M, 2004, LEUKEMIA, V18, P584, DOI 10.1038/sj.leu.2403254; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	29	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1590	1598		10.1038/sj.onc.1210788	http://dx.doi.org/10.1038/sj.onc.1210788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828300				2022-12-17	WOS:000253815800011
J	Nuytten, M; Beke, L; Van Eynde, A; Ceulemans, H; Beullens, M; Van Hummelen, P; Fuks, F; Bollen, M				Nuytten, M.; Beke, L.; Van Eynde, A.; Ceulemans, H.; Beullens, M.; Van Hummelen, P.; Fuks, F.; Bollen, M.			The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing	ONCOGENE			English	Article						EZH2; gene silencing; NIPP1; polycomb group proteins; PRC2; transcriptional repression	POLYCOMB GROUP PROTEIN; PHOSPHATASE-1 REGULATOR NIPP1; BREAST EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; HISTONE H3; DEVELOPMENTAL REGULATORS; PROSTATE-CANCER; GROUP-COMPLEXES; TARGET GENES; KINASE MELK	EZH2 is a Polycomb group (PcG) protein that promotes the late-stage development of cancer by silencing a specific set of genes, at least in part through trimethylation of associated histone H3 on Lys 27 (H3K27). Nuclear inhibitor of protein phosphatase-1 (NIPP1) is a ubiquitously expressed transcriptional repressor that has binding sites for the EZH2 interactor EED. Here, we examine the contribution of NIPP1 to EZH2-mediated gene silencing. Studies on NIPP1-deficient cells disclose a widespread and essential role of NIPP1 in the trimethylation of H3K27 by EZH2, not only in the onset of this trimethylation during embryonic development, but also in the maintenance of this repressive mark in proliferating cells. Consistent with this notion, EZH2 and NIPP1 silence a common set of genes, as revealed by gene-expression pro. ling, and NIPP1 is associated with established Polycomb target genes and with genomic regions that are enriched in Polycomb targets. Furthermore, most NIPP1 target genes are trimethylated on H3K27 and the knockdown of either NIPP1 or EZH2 is often associated with a loss of this modi. cation. Our data reveal that NIPP1 is required for the global trimethylation of H3K27 and is implicated in gene silencing by EZH2.	[Nuytten, M.; Beke, L.; Van Eynde, A.; Ceulemans, H.; Beullens, M.; Bollen, M.] Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, B-3000 Louvain, Belgium; [Van Hummelen, P.] VIB, Microarray Facil, Louvain, Belgium; [Fuks, F.] Free Univ Brussels, Fac Med, Lab Canc Epigenet, Louvain, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB)	Van Eynde, A (corresponding author), Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Campus Gasthuisberg,O&N1,Herestr 49, B-3000 Louvain, Belgium.	aleyde.vaneynde@med.kuleuven.be		Ceulemans, Hugo/0000-0002-7059-4399				Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; FAUST C, 1995, DEVELOPMENT, V121, P273; Gray D, 2005, CANCER RES, V65, P9751, DOI 10.1158/0008-5472.CAN-04-4531; Isono K, 2005, GENE DEV, V19, P536, DOI 10.1101/gad.1284605; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; Jagiello I, 2000, J CELL SCI, V113, P3761; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Kirmizis A, 2004, EXP BIOL MED, V229, P705, DOI 10.1177/153537020422900803; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Ringrose L, 2007, CURR OPIN CELL BIOL, V19, P290, DOI 10.1016/j.ceb.2007.04.010; ROY N, 2007, BIOCH BIOPHYS ACTA; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Eynde A, 2004, MOL CELL BIOL, V24, P5863, DOI 10.1128/MCB.24.13.5863-5874.2004; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472	47	59	61	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1449	1460		10.1038/sj.onc.1210774	http://dx.doi.org/10.1038/sj.onc.1210774			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724462				2022-12-17	WOS:000253548200012
J	Li, QF; Huang, WR; Duan, HF; Wang, H; Wu, CT; Wang, LS				Li, Q-F; Huang, W-R; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S			Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells	ONCOGENE			English	Article						BCR/ABL; sphingosine kinase-1; Mcl-1; CML	ABL TYROSINE KINASE; BCR-ABL; HEMATOPOIETIC-CELLS; ACTIVATION; APOPTOSIS; SURVIVAL; GROWTH; TRANSFORMATION; PROGRESSION; PATHWAY	The signaling mechanisms responsible for BCR/ABL-induced regulation of Mcl-1 expression in chronic myelogenous leukemia (CML) cells remain unclear. In this study, we show that BCR/ABL could upregulate sphingosine kinase-1 (SPK1) expression via multiple signal pathways, including mitogen-activated protein kinase ( MAPK), phosphoinositide 3-kinase (PI3K) and Janus kinase 2 (JAK2), leading to increase cellular SPK1 activity in CML cells. Retrovirus-mediated overexpression of bcr-abl gene in NIH-3T3, Ba/F3 and HL-60 cells results in upregulation and increased cellular activity of SPK1, whereas treatment of CML cells with specific inhibitors of the BCR/ABL, PI3K, MAPK and JAK2 pathways decreases BCR/ABLinduced SPK1 expression and cellular activity. BCR/ABL also induces upregulation of Mcl-1 expression in CML cells. Inhibition of SPK1 by adenovirus-mediated transfer of small interfering RNA or N,N-dimethylsphingosine reduced expression of Mcl-1 in CML cells. Our data indicated that BCR/ABL induces SPK1 expression and increases its cellular activity, leading to upregulation of Mcl-1 in CML cells. SPK1 silencing enhances the STI571-induced apoptosis of CML cell lines. It is suggested that SPK1 may be a potential therapeutic target in CML.	[Li, Q-F; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S] Beijing Inst Radiat Med, Dept Expt Hematol, Beijing 100850, Peoples R China; [Huang, W-R] Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Chinese People's Liberation Army General Hospital	Wang, LS (corresponding author), Beijing Inst Radiat Med, Dept Expt Hematol, 27 Taiping Rd, Beijing 100850, Peoples R China.	wangls@nic.bmi.ac.cn						Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Cortez D, 1996, ONCOGENE, V13, P2589; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Duan HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Le Scolan E, 2005, BLOOD, V106, P1808, DOI 10.1182/blood-2004-12-4832; Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood-2004-02-0452; Lu ZZ, 2006, EXP HEMATOL, V34, P1171, DOI 10.1016/j.exphem.2006.05.005; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	22	59	72	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7904	7908		10.1038/sj.onc.1210587	http://dx.doi.org/10.1038/sj.onc.1210587			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599053				2022-12-17	WOS:000252163500008
J	Markey, MP; Bergseid, J; Bosco, EE; Stengel, K; Xu, H; Mayhew, C; Schwemberger, SJ; Braden, WA; Jiang, Y; Babcock, G; Jegga, AG; Aronow, BJ; Reed, MF; Wang, JYJ; Knudsen, ES				Markey, M. P.; Bergseid, J.; Bosco, E. E.; Stengel, K.; Xu, H.; Mayhew, Cn; Schwemberger, S. J.; Braden, W. A.; Jiang, Y.; Babcock, Gf; Jegga, A. G.; Aronow, B. J.; Reed, M. F.; Wang, J. Y. J.; Knudsen, E. S.			Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function	ONCOGENE			English	Article						RB; E2F; transcriptional repression; inflammation; cell cycle	ELEMENT CLUSTERS; GAMMA-INDUCTION; RB; PROTEIN; E2F; EXPRESSION; IDENTIFICATION; REPLICATION; ACTIVATION; TRANSITION	Functional inactivation of the retinoblastoma tumor suppressor gene product (RB) is a common event in human cancers. Classically, RB functions to constrain cellular proliferation, and loss of RB is proposed to facilitate the hyperplastic proliferation associated with tumorigenesis. To understand the repertoire of regulatory processes governed by RB, two models of RB loss were utilized to perform microarray analysis. In murine embryonic fibroblasts harboring germline loss of RB, there was a striking deregulation of gene expression, wherein distinct biological pathways were altered. Specifically, genes involved in cell cycle control and classically associated with E2F-dependent gene regulation were upregulated via RB loss. In contrast, a program of gene expression associated with immune function and response to pathogens was significantly downregulated with the loss of RB. To determine the specific influence of RB loss during a defined period and without the possibility of developmental compensation as occurs in embryonic fibroblasts, a second system was employed wherein Rb was acutely knocked out in adult fibroblasts. This model confirmed the distinct regulation of cell cycle and immune modulatory genes through RB loss. Analyses of cis-elements supported the hypothesis that the majority of those genes upregulated with RB loss are regulated via the E2F family of transcription factors. In contrast, those genes whose expression was reduced with the loss of RB harbored different promoter elements. Consistent with these analyses, we found that disruption of E2F-binding function of RB was associated with the upregulation of gene expression. In contrast, cells harboring an RB mutant protein ( RB-750F) that retains E2F-binding activity, but is specifically deficient in the association with LXCXE-containing proteins, failed to upregulate these same target genes. However, downregulation of genes involved in immune function was readily observed with disruption of the LXCXE-binding function of RB. Thus, these studies demonstrate that RB plays a significant role in both the positive and negative regulations of transcriptional programs and indicate that loss of RB has distinct biological effects related to both cell cycle control and immune function.	Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Aronow, Bruce J/F-8438-2012; Mayhew, Christopher N/AGB-4929-2022; Jegga, Anil/H-6140-2011	Jegga, Anil/0000-0002-4881-7752; Stengel, Kristy/0000-0002-8330-5744; Markey, Michael/0000-0002-8593-2290; Reed, Michael/0000-0001-8478-8605	NATIONAL CANCER INSTITUTE [R01CA058320, T32CA117846] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, T32 CA117846, F32 CA174162] Funding Source: Medline; NIGMS NIH HHS [R35 GM147213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arany I, 1996, SEX TRANSM DIS, V23, P475, DOI 10.1097/00007435-199611000-00007; Batsche E, 2005, J BIOL CHEM, V280, P16088, DOI 10.1074/jbc.M413427200; Black EP, 2003, CANCER RES, V63, P3716; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Eason DD, 2001, CANCER LETT, V171, P209, DOI 10.1016/S0304-3835(01)00603-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jegga AG, 2005, NUCLEIC ACIDS RES, V33, pW408, DOI 10.1093/nar/gki486; Jegga AG, 2002, GENOME RES, V12, P1408, DOI 10.1101/gr.255002; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Le Buanec H, 1999, BIOMED PHARMACOTHER, V53, P424, DOI 10.1016/S0753-3322(99)80122-X; LU YM, 1994, ONCOGENE, V9, P1015; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Osborne AR, 2004, J BIOL CHEM, V279, P28911, DOI 10.1074/jbc.M403118200; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Xin H, 2003, ONCOGENE, V22, P4775, DOI 10.1038/sj.onc.1206780; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	40	59	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6307	6318		10.1038/sj.onc.1210450	http://dx.doi.org/10.1038/sj.onc.1210450			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452985				2022-12-17	WOS:000249583300007
J	Suzuki, E; Umezawa, K; Bonavida, B				Suzuki, E.; Umezawa, K.; Bonavida, B.			Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis	ONCOGENE			English	Article						rituximab; Akt pathway; chemosensitization; apoptosis	NON-HODGKINS-LYMPHOMA; THERAPEUTIC INTERVENTION; 3-KINASE-AKT PATHWAY; SIGNALING PATHWAY; PROSTATE-CANCER; DOWN-REGULATION; BCL-XL; EXPRESSION; PTEN; KINASE	Rituximab ( chimeric anti-CD20 monoclonal antibody) is currently being used, alone or in combination with chemotherapy, in the treatment of B-non-Hodgkin's lymphoma (B-NHL). We have reported that rituximab treatment of B-NHL cell lines sensitizes the drug-resistant tumor cells to apoptosis by various chemotherapeutic drugs and chemosensitization was, in large part, owing to the selective inhibition of the anti-apoptotic Bcl-XL gene product. The constitutive activation of the Akt pathway in B-NHL results in overexpression and functional activation of Bcl-xL. Hence, we hypothesized that rituximab- induced inhibition of Bcl-xL expression and chemosensitization may result, in part, from its inhibitory activity of the Akt pathway. This hypothesis was tested using the drug-resistant Ramos and Daudi B-NHL cell lines. Time kinetic analysis revealed that treatment with rituximab inhibited phosphorylation of Akt, but not unphosphorylated Akt, and the inhibition was first detected at 6 h post-rituximab treatment. Similar time kinetics revealed rituximab- induced inhibition of p-PDK1, p-Bad, p-IKK alpha/beta and p- I kappa beta alpha and no inhibition of unphosphorylated proteins. In addition, rituximab treatment resulted in significant increase of Bcl-(xL)-Bad heterodimeric complexes as compared to untreated cells. The role of the Akt pathway in the regulation of resistance was corroborated by the use of the Akt inhibitor, LY294002, and by transfection with siRNA Akt. Treatment of tumor cells with LY294002 or with Akt siRNA, but not control siRNA, resulted in inhibition of Bcl-xL expression and sensitization to drug-induced apoptosis. Although rituximab did not inhibit the Akt pathway nor sensitized the rituximab- resistant Ramos RR1 clone, treatment with LY294002 or Akt siRNA sensitized the clone to drug-induced apoptosis. The present. findings demonstrate for the first time that rituximab inhibits the constitutively activated Akt pathway in B-NHL cell lines, and this inhibition contributes to sensitization of drug-resistant cells to apoptosis by chemotherapeutic drugs. The findings also identify the Akt pathway as target for therapeutic intervention in the reversal of rituximab and drug-resistant B-NHL.	Calif State Univ Los Angeles, Jonsson Comprehensive Canc Ctr, David Geffen Medicine, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; Keio Univ, Dept Appl Chem, Yokohama, Kanagawa, Japan	California State University System; California State University Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Keio University	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Le Conte Ave, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu						Alas S, 2001, CANCER RES, V61, P5137; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Goswami A, 2006, CANCER RES, V66, P2889, DOI 10.1158/0008-5472.CAN-05-4458; Haiman CA, 2006, CANCER EPIDEM BIOMAR, V15, P1021, DOI 10.1158/1055-9965.EPI-05-0896; Hayakawa J, 2000, CANCER RES, V60, P5988; Jazirehi AR, 2007, CANCER RES, V67, P1270, DOI 10.1158/0008-5472.CAN-06-2184; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2005, CANCER RES, V65, P264; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Poh TW, 2005, CANCER RES, V65, P6264, DOI 10.1158/0008-5472.CAN-05-0152; Rennie PS, 1998, CANCER METAST REV, V17, P401, DOI 10.1023/A:1006121219097; Rogers Barbara Barnes, 2006, Semin Oncol Nurs, V22, P67, DOI 10.1016/j.soncn.2006.01.002; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Sugimori K, 2005, J BONE MINER METAB, V23, P411, DOI 10.1007/s00774-005-0622-7; Tachiiri S, 2000, JPN J CANCER RES, V91, P1314, DOI 10.1111/j.1349-7006.2000.tb00919.x; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weintraub SJ, 2004, CANCER CELL, V5, P3, DOI 10.1016/S1535-6108(03)00338-6; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yin DL, 2006, J NEUROIMMUNOL, V174, P101, DOI 10.1016/j.jneuroim.2006.02.001; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901	33	59	65	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6184	6193		10.1038/sj.onc.1210448	http://dx.doi.org/10.1038/sj.onc.1210448			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420722				2022-12-17	WOS:000249401300009
J	Murayama, K; Kimura, T; Tarutani, M; Tomooka, M; Hayashi, R; Okabe, M; Nishida, K; Itami, S; Katayama, I; Nakano, T				Murayama, K.; Kimura, T.; Tarutani, M.; Tomooka, M.; Hayashi, R.; Okabe, M.; Nishida, K.; Itami, S.; Katayama, I.; Nakano, T.			Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors	ONCOGENE			English	Article						Akt; epidermis; hair follicle; stem cells; proliferation	HAIR FOLLICLE MORPHOGENESIS; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; TRANSIENT ACTIVATION; PTEN; MOUSE; MICE; SKIN; POPULATIONS; SUFFICIENT	Various common signaling pathways maintain tissue stem cells, including Notch and Wnt/beta-catenin signals. Phosphoinositide3 kinase (PI3K)/Akt signaling regulates the 'stemness' of several stem cells in culture, specifically in maintaining embryonic stem and neural stem cells, and in deriving embryonic germ cells from primordial germ cells. We examined the effect of Akt signaling in epidermal cells in transgenic mice expressing an Akt-Mer fusion protein whose kinase activity was conditionally activated by treatment with 4-hydroxytamoxifen (4OHT). The topical application of 4OHT to adult skin of the transgenic mice induced new hair growth in resting phase follicles. In addition, the mice showed hyperplasia in interfollicular epidermis (IFE) and hair follicles, which was presumably caused by the extensive proliferation of keratinocytes in basal layer of IFE and outer root sheath of hair follicles, respectively. The progenitor cell population increased consistently in 4OHT-treated transgenic mice. Our results show that PI3K/Akt signaling induces epidermal hyperplasia and proliferation of epidermal progenitors.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Med, Dept Dermatol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Pathol Div, Suita, Osaka 565, Japan; Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Aoba Ku, Sendai, Miyagi 980, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Expt Genome Res, Genome Informat Res Ctr, Suita, Osaka 565, Japan; Grad Sch Med, Dept Regenerat Dermatol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; Tohoku University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamada Oka, Suita, Osaka 565, Japan.	tkimura@patho.med.osaka-u.ac.jp	Hayashi, Ryuhei/AAW-4737-2020; Okabe, Masaru/B-6917-2015	Kimura, Tohru/0000-0001-9227-0996; Nishida, Kohji/0000-0001-9069-3610; Hayashi, Ryuhei/0000-0002-4699-8617; Okabe, Masaru/0000-0002-0803-9044				Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; MORRIS RJ, 1987, CANCER LETT, V34, P297, DOI 10.1016/0304-3835(87)90180-7; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Suzuki A, 2003, CANCER RES, V63, P674; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	59	61	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4882	4888		10.1038/sj.onc.1210274	http://dx.doi.org/10.1038/sj.onc.1210274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297448				2022-12-17	WOS:000248170400014
J	Vecchi, M; Nuciforo, P; Romagnoli, S; Confalonieri, S; Pellegrini, C; Serio, G; Quarto, M; Capra, M; Roviaro, GC; Contessini Avesani, E; Corsi, C; Coggi, G; Di Fiore, PP; Bosari, S				Vecchi, M.; Nuciforo, P.; Romagnoli, S.; Confalonieri, S.; Pellegrini, C.; Serio, G.; Quarto, M.; Capra, M.; Roviaro, G. C.; Contessini Avesani, E.; Corsi, C.; Coggi, G.; Di Fiore, P. P.; Bosari, S.			Gene expression analysis of early and advanced gastric cancers	ONCOGENE			English	Article						gastric cancer; early gastric cancer; advanced gastric cancer; gene expression profiling; tissue microarrays	LONG-TERM; MUCOSA; CARCINOGENESIS; METASTASIS; PROFILES; INVASION; CLAUDINS	Gastric carcinoma is one of the major causes of cancer mortality worldwide. Early detection results in excellent prognosis for patients with early cancer (EGC), whereas the prognosis of advanced cancer (AGC) patients remains poor. It is not clear whether EGC and AGC are molecularly distinct, and whether they represent progressive stages of the same tumor or different entities ab initio. Gene expression profiles of EGC and AGC were determined by Affymetrix technology and quantitative polymerase chain reaction. Representative regulated genes were further analysed by in situ hybridization (ISH) on tissue microarrays. Expression analysis allowed the identification of a signature that differentiates AGC from EGC. In addition, comparison with normal gastric mucosa indicated that the majority of alterations associated with EGC are retained in AGC, and that further expression changes mark the transition from EGC to AGC. Finally, ISH analysis showed that representative genes, differentially expressed in the invasive areas of EGC and AGC, are not differentially expressed in the non-invasive areas of the same tumors. Our data are more directly compatible with a progression model of gastric carcinogenesis, whereby EGC and AGC may represent different molecular stages of the same tumor. Finally, the identification of an AGC-specific signature might help devising novel therapeutic strategies for advanced gastric cancer.	Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy; IFOM Fdn, Ist FIRC Oncol Mol, Milan, Italy; Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Dipartimento Sci Chirurg, Milan, Italy; AO San Paolo, Dipartimento Chirurg & Special Chirurg, Milan, Italy; Ist Europeo Oncol, Dipartimento Oncol Sperimentale, Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	University of Milan; IFOM - FIRC Institute of Molecular Oncology; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS European Institute of Oncology (IEO); University of Milan	Bosari, S (corresponding author), Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy.	pierpaolo.difiore@ifom-ieocampus.it; silvano.bosari@unimi.it	Nuciforo, Paolo/Q-2885-2019; Serio, Gabriella/AAU-4967-2020; Vecchi, Manuela/L-3502-2017; Confalonieri, Stefano/AAQ-6786-2020; Di Fiore, Pier Paolo/K-2130-2012; Bosari, Silvano/K-7744-2016	Serio, Gabriella/0000-0001-9021-4560; Vecchi, Manuela/0000-0002-2750-9160; Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bosari, Silvano/0000-0002-9744-6951; Nuciforo, Paolo/0000-0003-1380-0990				Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Boussioutas A, 2003, CANCER RES, V63, P2569; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Dicken BJ, 2005, ANN SURG, V241, P27, DOI 10.1097/01.sla.0000149300.28588.23; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI200212529; Hasegawa S, 2002, CANCER RES, V62, P7012; HENDERSON BE, 1990, J NATL CANCER I, V82, P1186, DOI 10.1093/jnci/82.14.1186; Hippo Y, 2001, CANCER RES, V61, P889; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886; KAJITANI T, 1981, JPN J SURG, V11, P127; Katoh M, 2003, INT J MOL MED, V11, P683; Kim B, 2003, CANCER RES, V63, P8248; Kirikoshi H, 2002, INT J ONCOL, V21, P655; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LAWRENCE M, 1991, ANN SURG, V213, P327, DOI 10.1097/00000658-199104000-00007; Lee Jong Hoon, 2003, Korean J Gastroenterol, V42, P484; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Meireles SI, 2004, CANCER RES, V64, P1255, DOI 10.1158/0008-5472.CAN-03-1850; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; MULLIN JM, 2004, SCI STKE; Norsett KG, 2004, CANCER LETT, V210, P227, DOI 10.1016/j.canlet.2004.01.022; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Parkin DM, 2004, ONCOGENE, V23, P6329, DOI 10.1038/sj.onc.1207726; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rugge M, 2003, GUT, V52, P1111, DOI 10.1136/gut.52.8.1111; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang CS, 1997, J AM COLL SURGEONS, V185, P476, DOI 10.1016/S1072-7515(97)00076-8; Wang TC, 1998, GASTROENTEROLOGY, V115, P780, DOI 10.1016/S0016-5085(98)70159-3; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu CD, 2005, WORLD J GASTROENTERO, V11, P2390, DOI 10.3748/wjg.v11.i16.2390	37	59	62	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4284	4294		10.1038/sj.onc.1210208	http://dx.doi.org/10.1038/sj.onc.1210208			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297478				2022-12-17	WOS:000247619900011
J	Schwartz, B; Melnikova, VO; Tellez, C; Mourad-Zeidan, A; Blehm, K; Zhao, YJ; McCarty, M; Adam, L; Bar-Eli, M				Schwartz, B.; Melnikova, V. O.; Tellez, C.; Mourad-Zeidan, A.; Blehm, K.; Zhao, Y-J; McCarty, M.; Adam, L.; Bar-Eli, M.			Loss of AP-2 alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo	ONCOGENE			English	Review						AP-2 alpha; colon cancer; MMP-9; E-cadherin; transcriptional regulation	TRANSCRIPTION FACTOR AP-2; GENE-EXPRESSION; HUMAN-MELANOMA; COLORECTAL-CARCINOMA; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION; TUMOR-GROWTH; METASTASIS; CLONING	Activator protein-2 (AP-2) is a transcription factor that regulates proliferation and differentiation in mammalian cells and has been implicated in the acquisition of the metastatic phenotype in several types of cancer. Herein, we examine the role of AP-2 alpha in colon cancer progression. We provide evidence for the lack of AP-2 alpha expression in the late stages of colon cancer cells. Re-expression of the AP-2 alpha gene in the AP-2 alpha-negative SW480 colon cancer cells suppressed their tumorigenicity following orthotopic injection into the cecal wall of nude mice. The inhibition of tumor growth could be attributed to the increased expression of E-cadherin and decreased expression and activity of matrix-metalloproteinase-9 (MMP-9) in the transfected cells, as well as a substantial loss of their in vitro invasive properties. Conversely, targeting constitutive expression of AP-2 alpha in AP-2-positive KM12C colon cancer cells with small interfering RNA resulted in an increase in their invasive potential, downregulation of E-cadherin and increased expression of MMP-9. In SW480 cells, re-expression of AP-2 alpha resulted in a fourfold increase in the activity of E-cadherin promoter, and a 5-14-fold decrease in the activity of MMP-9 promoter, indicating transcriptional regulation of these genes by AP-2 alpha. Chromatin immunoprecipitation assay showed that re-expressed AP-2 alpha directly binds to the promoter of E-cadherin, where it has been previously reported to act as a transcriptional activator. Furthermore, chromatin immunoprecipitation assay revealed AP-2 alpha binding to the MMP-9 promoter, which ensued by decreased binding of transcription factor Sp-1 and changes in the recruitment of transcription factors to a distal AP-1 element, thus, contributing to the overall downregulation of MMP-9 promoter activity. Collectively, our data provide evidence that AP-2 alpha acts as a tumor suppressor gene in colon cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA-76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Boedefeld WM, 2003, ANN SURG ONCOL, V10, P839, DOI 10.1245/ASO.2003.02.021; Bosher JM, 1996, ONCOGENE, V13, P1701; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang WH, 2002, J MOL MODEL, V8, P8, DOI 10.1007/s00894-001-0060-y; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORIKAWA K, 1988, CANCER RES, V48, P6863; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rozen P, 2004, EUR J CANCER PREV, V13, P71, DOI 10.1097/00008469-200402000-00011; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SATO H, 1993, ONCOGENE, V8, P395; Sumigama S, 2004, ONCOGENE, V23, P5496, DOI 10.1038/sj.onc.1207723; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vainio H, 2003, ACTA ONCOL, V42, P809, DOI 10.1080/02841860310010673; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	35	59	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4049	4058		10.1038/sj.onc.1210193	http://dx.doi.org/10.1038/sj.onc.1210193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224907				2022-12-17	WOS:000247252700001
J	Kohonen-Corish, MRJ; Sigglekow, ND; Susanto, J; Chapuis, PH; Bokey, EL; Dent, OF; Chan, C; Lin, BPC; Seng, TJ; Laird, PW; Young, J; Leggett, BA; Jass, JR; Sutherland, RL				Kohonen-Corish, M. R. J.; Sigglekow, N. D.; Susanto, J.; Chapuis, P. H.; bokey, E. L.; Dent, O. F.; Chan, C.; Lin, B. P. C.; Seng, T. J.; Laird, P. W.; Young, J.; Leggett, B. A.; Jass, J. R.; Sutherland, R. L.			Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer	ONCOGENE			English	Article						mutated in colorectal cancer (MCC); promoter hypermethylation; serrated polyps; clinico-pathologic correlations	NF-KAPPA-B; MICROSATELLITE INSTABILITY; SERRATED POLYPS; DNA METHYLATION; BRAF MUTATION; COLON-CANCER; K-RAS; PHENOTYPE; MCC; HYPERMETHYLATION	The mutated in colorectal cancer (MCC) gene is in close linkage with the adenomatous polyposis coli (APC) gene on chromosome 5, in a region of frequent loss of heterozygosity in colorectal cancer. The role of MCC in carcinogenesis, however, has not been extensively analysed, and functional studies are emerging, which implicate it as a candidate tumor suppressor gene. The aim of this study was to examine loss of MCC expression due to promoter hypermethylation and its clinicopathologic signifi. cance in colorectal cancer. Correspondence of MCC methylation with gene silencing was demonstrated using bisulfi. te sequencing, reverse transcription-polymerase chain reaction and Western blotting. MCC methylation was detected in 45-52% of 187 primary colorectal cancers. There was a striking association with CDKN2A methylation (P < 0.0001), the CpG island methylator phenotype ( P < 0.0001) and the BRAF V600E mutation (P < 0.0001). MCC methylation was also more common (P = 0.0084) in serrated polyps than in adenomas. In contrast, there was no association with APC methylation or KRAS mutations. This study demonstrates for the. first time that MCC methylation is a frequent change during colorectal carcinogenesis. Furthermore, MCC methylation is significantly associated with a distinct spectrum of precursor lesions, which are suggested to give rise to cancers via the serrated neoplasia pathway.	Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia; Concord Hosp, Dept Colorectal Surg, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW, Australia; Concord Hosp, Dept Anat Pathol, Sydney, NSW, Australia; USC Norris Comprehens Canc Ctr, Los Angeles, CA USA; Queensland Inst Med Res, Mol Canc Epidemiol Lab, Herston, Qld, Australia; Royal Brisbane & Womens Hosp Fdn, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Garvan Institute of Medical Research; University of New South Wales Sydney; Concord Repatriation General Hospital; University of Sydney; Concord Repatriation General Hospital; University of Southern California; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute; McGill University	Kohonen-Corish, MRJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	m.corish@garvan.org.au	Leggett, Barbara A/D-3579-2011; Sutherland, Robert L/A-8378-2008; Kohonen-Corish, Maija/Q-9763-2019; Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Laird, Peter W/G-8683-2012	Kohonen-Corish, Maija/0000-0002-4073-1479; Laird, Peter W/0000-0001-9117-3641; Leggett, Barbara/0000-0003-2062-7380	NATIONAL CANCER INSTITUTE [R01CA075090, R01CA118699] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA118699, R01 CA075090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esteller M, 2000, CANCER RES, V60, P2368; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ikenoue T, 2003, CANCER RES, V63, P8132; Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kohonen-Corish MRJ, 2005, J CLIN ONCOL, V23, P2318, DOI 10.1200/JCO.2005.00.109; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001; Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Senda T, 1999, J HISTOCHEM CYTOCHEM, V47, P1149, DOI 10.1177/002215549904700907; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841	28	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4435	4441		10.1038/sj.onc.1210210	http://dx.doi.org/10.1038/sj.onc.1210210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260021				2022-12-17	WOS:000247620000011
J	Carie, AE; Sebti, SM				Carie, A. E.; Sebti, S. M.			A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway	ONCOGENE			English	Article						cAMP; Raf-1; Erk1/2; beta 2 adrenergic receptor; Pirbuterol; cancer therapy	ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; GERANYLGERANYLTRANSFERASE-I INHIBITOR; MAP KINASE; SIGNAL-TRANSDUCTION; CYCLIC-AMP; H-RAS; K-RAS; B-RAF	A chemical biology approach identifies a beta 2 adrenergic receptor (beta 2AR) agonist ARA-211 (Pirbuterol), which causes apoptosis and human tumor regression in animal models. b2AR stimulation of cAMP formation and protein kinase A (PKA) activation leads to Raf-1 (but not B-Raf) kinase inactivation, inhibition of Mek-1 kinase and decreased phospho-extracellular signal-regulated kinase (Erk)1/2 levels. ARA-211 inhibition of the Raf/Mek/Erk1/2 pathway is mediated by PKA and not exchange protein activated by cAMP (EPAC). ARA-211 is selective and suppresses P-Erk1/2 but not P-JNK, P-p38, P-Akt or P-STAT3 levels. b2AR stimulation results in inhibition of anchorage-dependent and -independent growth, induction of apoptosis in vitro and tumor regression in vivo. b2AR antagonists and constitutively active Mek-1 rescue from the effects of ARA-211, demonstrating that b2AR stimulation and Mek kinase inhibition are required for ARA-211 antitumor activity. Furthermore, suppression of growth occurs only in human tumors where ARA-211 induces cAMP formation and decreases P-Erk1/2 levels. Thus, b2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu		Carie, Adam/0000-0001-7804-0465				Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Blaskovich MA, 2003, CANCER RES, V63, P1270; BOS JL, 1989, CANCER RES, V49, P4682; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; DIMARCO E, 1989, ONCOGENE, V4, P831; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FLEMING TP, 1992, EXP GERONTOL, V27, P523, DOI 10.1016/0531-5565(92)90007-M; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; GRASSI V, 1986, INT J CLIN PHARM RES, V6, P93; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Jiang Z, 2004, HISTOPATHOLOGY, V45, P218, DOI 10.1111/j.1365-2559.2004.01930.x; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson JR, 2005, CLIN CANCER RES, V11, P6414, DOI 10.1158/1078-0432.CCR-05-0790; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MOORE PF, 1978, J PHARMACOL EXP THER, V207, P410; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slotkin TA, 2000, BREAST CANCER RES TR, V60, P153, DOI 10.1023/A:1006338232150; Slotkin TA, 2000, BREAST CANCER RES TR, V64, P259, DOI 10.1023/A:1026508605951; STEEN SN, 1974, CURR THER RES CLIN E, V16, P1077; Steinberg SF, 2000, CIRC RES, V87, P1079, DOI 10.1161/01.RES.87.12.1079; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Sun JZ, 2005, ONCOGENE, V24, P4701, DOI 10.1038/sj.onc.1208391; Sun JZ, 2003, CANCER RES, V63, P8922; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEBER N, 1994, EUR J CANCER, V30A, P1352, DOI 10.1016/0959-8049(94)90186-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yu M, 1998, CLIN EXP METASTAS, V16, P185	52	59	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3777	3788		10.1038/sj.onc.1210172	http://dx.doi.org/10.1038/sj.onc.1210172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17260025				2022-12-17	WOS:000247026400002
J	Waldmann, TA				Waldmann, T. A.			Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma	ONCOGENE			English	Review						IL-2 receptor; adult T-cell leukemia; anti-Tac; monoclonal antibody	T-CELL LEUKEMIA; ANTI-CD25 MONOCLONAL-ANTIBODY; IN-VIVO BLOCKADE; INTERLEUKIN-2 RECEPTOR; MURINE MODEL; TRANSPLANT RECIPIENTS; MULTIPLE-SCLEROSIS; HUMANIZED ANTIBODY; ACUTE REJECTION; GROWTH-FACTOR	Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with Y-90 has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Waldmann, TA (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Room 4N115,10 Ctr Dr 1374, Bethesda, MD 20892 USA.	tawald@helix.nih.gov	Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC004002, Z01SC004002] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beniaminovitz A, 2000, NEW ENGL J MED, V342, P613, DOI 10.1056/NEJM200003023420902; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bielekova B, 2004, P NATL ACAD SCI USA, V101, P8705, DOI 10.1073/pnas.0402653101; DEPPER JM, 1984, J IMMUNOL, V133, P3054; Eckhoff DE, 2000, TRANSPLANTATION, V69, P1867, DOI 10.1097/00007890-200005150-00022; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JUNGHANS RP, 1990, CANCER RES, V50, P1495; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; Lehky TJ, 1998, ANN NEUROL, V44, P942, DOI 10.1002/ana.410440613; LEONARD WJ, 1985, J BIOL CHEM, V260, P1872; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Maciejewski JP, 2003, BLOOD, V102, P3584, DOI 10.1182/blood-2003-04-1032; Morris JC, 2000, ANN RHEUM DIS, V59, P109, DOI 10.1136/ard.59.suppl_1.i109; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; Nussenblatt RB, 1999, P NATL ACAD SCI USA, V96, P7462, DOI 10.1073/pnas.96.13.7462; OMAHONEY D, 2006, J NUCL MED, V47, pP98; Phillips KE, 2000, CANCER RES, V60, P6977; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; Sloand EM, 2006, ANN INTERN MED, V144, P181, DOI 10.7326/0003-4819-144-3-200602070-00006; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Tan C, 2002, CANCER RES, V62, P1083; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; Waldmann TA, 2003, ANNU REV IMMUNOL, V21, P1, DOI 10.1146/annurev.immunol.21.120601.140933; WALDMANN TA, 1988, BLOOD, V72, P1805; Wiseman LR, 1999, DRUGS, V58, P1029, DOI 10.2165/00003495-199958060-00006; Zhang ML, 2006, CANCER RES, V66, P8227, DOI 10.1158/0008-5472.CAN-06-1189; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182/blood-2004-05-1709; Zhang ML, 2004, CANCER RES, V64, P5825, DOI 10.1158/0008-5472.CAN-04-1088	42	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3699	3703		10.1038/sj.onc.1210368	http://dx.doi.org/10.1038/sj.onc.1210368			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530023				2022-12-17	WOS:000246816100012
J	Frost, P; Shi, Y; Hoang, B; Lichtenstein, A				Frost, P.; Shi, Y.; Hoang, B.; Lichtenstein, A.			AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; angiogenesis; internal ribosome entry sites; cap-independent translation; drug resistance; xenograft	ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW ANGIOGENESIS; MESSENGER-RNA CONTAINS; RIBOSOME ENTRY SITE; MAMMALIAN TARGET; PROGNOSTIC VALUE; CYCLIN D1; IN-VIVO; TRANSLATION; ACTIVATION	We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in immunodeficient mice. This antitumor effect was associated with prevention of cell proliferation, induction of apoptosis and inhibition of angiogenesis. Interestingly, myeloma tumors with heightened AKT activation were particularly sensitive to a CCI-779-induced antitumor response. To investigate whether part of the differential sensitivity was due to an AKT-regulated effect on angiogenesis, we compared the effects of mTOR inhibitors against isogenic MM cell lines that only differ by their degree of AKT activity. In this model, heightened AKT activity significantly sensitized MM cells to the following inhibitory effects of mTOR inhibition: angiogenesis in vivo, vascular endothelial growth factor (VEGF) expression in vitro and in vivo and VEGF translation (but not transcription). Assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines suggesting that an adverse effect on VEGF cap-dependent translation would be comparable. Internal ribosome entry site (IRES)-mediated cap-independent translation is a salvage pathway for protein expression when mTOR is inhibited, so we analyzed a possible regulatory role of AKT on VEGF IRES activity. We found that elevated AKT activity inhibited VEGF IRES function. These results support a mechanism whereby AKT prevents VEGF IRES activity in myeloma cells during mTOR inhibition resulting in a more complete abrogation of VEGF translation, and ultimately, angiogenesis.	VA W Los Angeles Hosp, Dept Hematol Oncol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Frost, P (corresponding author), VA W Los Angeles Hosp, Dept Hematol Oncol, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	pfrost@ucla.edu		Frost, Patrick/0000-0003-3348-5983	NATIONAL CANCER INSTITUTE [K01CA111623, R01CA096920, R01CA111448] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA111623, R01CA96920, R01CA111448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellamy WT, 1999, CANCER RES, V59, P728; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kumar S, 2004, LEUKEMIA, V18, P624, DOI 10.1038/sj.leu.2403285; Kumar S, 2003, BLOOD, V101, P1715, DOI 10.1182/blood-2002-08-2441; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LeBlanc R, 2002, CANCER RES, V62, P4996; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Sugawara M, 2002, HUM PATHOL, V33, P524, DOI 10.1053/hupa.2002.124783; Tu YP, 2000, CANCER RES, V60, P6763; Yan HJ, 2006, CANCER RES, V66, P2305, DOI 10.1158/0008-5472.CAN-05-2447; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	33	59	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2255	2262		10.1038/sj.onc.1210019	http://dx.doi.org/10.1038/sj.onc.1210019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016437				2022-12-17	WOS:000245466000001
J	Choi, SH; Mendrola, JM; Lemmon, MA				Choi, S. H.; Mendrola, J. M.; Lemmon, M. A.			EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer	ONCOGENE			English	Article						EGFR; ErbB; somatic mutations; constitutive activation; internalization; autoinhibition	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; KINASE DOMAIN; TYROSINE KINASE; TRANSFORMATION; INHIBITOR; ONCOGENE; MUTANTS; PROGRESSION; EXPRESSION	Several somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to getfitnib. To test the hypothesis that these mutations cause constitutive EGF receptor signaling, and to investigate its mechanistic basis, we expressed representative examples in a null background and analysed their biochemical properties. Each mutation caused significant EGF-independent tyrosine phosphorylation of EGFR, and allowed the receptor to promote Ba/F3 cell mitogenesis in the absence of EGF, arguing that these are oncogenic mutations. Active mutated receptors are present at the cell surface and are fully competent to bind EGF. Recent structural studies show that the inactive EGFR tyrosine kinase domain is autoinhibited by intramolecular interactions between its activation loop and alpha C helix. We find that mutations predicted to disrupt this autoinhibitory interaction (including several that have not been described in NSCLC) elevate EGF-independent tyrosine kinase activity, thus providing new insight into how somatic mutations activate EGFR and other ErbB family members.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 809C Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu		Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA096768] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096768, R01-CA096768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Dent R, 2006, CANCER TREAT REV, V32, P144, DOI 10.1016/j.ctrv.2006.01.005; DI FP, 1987, CELL, V51, P1063; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ozcan F, 2006, P NATL ACAD SCI USA, V103, P5735, DOI 10.1073/pnas.0601469103; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Sakai K, 2006, FASEB J, V20, P311, DOI 10.1096/fj.05-4034fje; SCHECHTER Y, 1979, NATURE, V278, P835, DOI 10.1038/278835a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	41	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1567	1576		10.1038/sj.onc.1209957	http://dx.doi.org/10.1038/sj.onc.1209957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953218				2022-12-17	WOS:000244782500006
J	Saigusa, K; Imoto, I; Tanikawa, C; Aoyagi, M; Ohno, K; Nakamura, Y; Inazawa, J				Saigusa, K.; Imoto, I.; Tanikawa, C.; Aoyagi, M.; Ohno, K.; Nakamura, Y.; Inazawa, J.			RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest	ONCOGENE			English	Article						RGC32; p53; Plk1; glioma; array-CGH	COMPARATIVE GENOMIC HYBRIDIZATION; POLO-LIKE KINASES; MULTIPLE-MYELOMA; CHROMOSOME 13Q; CANCER-CELLS; TUMOR; PLK1; P53; AMPLIFICATION; GLIOBLASTOMAS	To identify target genes for the hemizygous deletions of chromosome 13 that are recurrently observed in malignant gliomas, we performed genome-wide DNA copy-number analysis using array-based comparative genomic hybridization and gene expression analysis using an oligonucleotide-array. The response gene to complement 32 (RGC32) at 13q14.11 was identified as a deletion target, and its expression was frequently silenced in glioma cell lines compared with normal brain. Levels of RGC32 mRNA tended to decrease toward higher grades of primary astrocytomas, especially in tumors with mutations of p53. Expression of RGC32 mRNA was dramatically increased by exogenous p53 in a p53-mutant glioma cell line, and also by endogenous p53 in response to DNA damage in p53(+/+) colon-cancer cells, but not in isogenic p53(-/-) cells. Chromatin immunoprecipitation and reporter assays demonstrated binding of endogenous p53 protein to the promoter region of the RGC32 gene, implying p53-dependent transcriptional activity. Transiently and stably overexpressed RGC32 suppressed the growth of glioma cells, probably owing to induction of G2/M arrest. Immunocytochemical analysis revealed a concentration of RGC32 protein at the centrosome during mitosis. RGC32 formed a protein complex with polo-like kinase 1 and was phosphorylated in vitro. These observations implied a novel mechanism by which p53 might negatively regulate cell-cycle progression by way of this newly identified transcriptional target. Our results provide the first evidence that RGC32 might be a possible tumor-suppressor for glioma, that it is directly induced by p53, and that it mediates the arrest of mitotic progression.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Neurosurg, Tokyo 1138510, Japan; Japan Sci & Technol Corp, JST, CREST, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan; Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); University of Tokyo; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012	Tanikawa, Chizu/0000-0003-4759-4793				Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inda MD, 2003, MOL CARCINOGEN, V36, P6, DOI 10.1002/mc.10085; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Jongsma APM, 2002, J CLIN PATHOL-MOL PA, V55, P305, DOI 10.1136/mp.55.5.305; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kunwar S, 2001, CANCER RES, V61, P7683; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu W, 2006, PROSTATE, V66, P405, DOI 10.1002/pros.20363; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; MIYASHITA T, 1995, CELL, V80, P293; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okamoto Y, 2004, ACTA NEUROPATHOL, V108, P49, DOI 10.1007/s00401-004-0861-z; Pan HJ, 2005, CANCER RES, V65, P1664, DOI 10.1158/0008-5472.CAN-04-3297; Saigusa K, 2005, CANCER SCI, V96, P676, DOI 10.1111/j.1349-7006.2005.00099.x; SATO T, 1991, CANCER RES, V51, P5794; Shaughnessy J, 2000, BLOOD, V96, P1505, DOI 10.1182/blood.V96.4.1505.h8001505_1505_1511; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	41	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1110	1121		10.1038/sj.onc.1210148	http://dx.doi.org/10.1038/sj.onc.1210148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	17146433				2022-12-17	WOS:000244406400002
J	Bhatt, KV; Hu, R; Spofford, LS; Aplin, AE				Bhatt, K. V.; Hu, R.; Spofford, L. S.; Aplin, A. E.			Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells	ONCOGENE			English	Article						adhesion; cell cycle; melanocyte; proteasome	CDK INHIBITOR P27; UBIQUITIN LIGASE; S-PHASE; DEPENDENT DEGRADATION; MALIGNANT-MELANOMA; NUCLEAR EXPORT; BRAF MUTATIONS; SKP2; EXPRESSION; PROGRESSION	Levels of cyclins and cyclin-dependent kinase (Cdk) inhibitors are tightly controlled during normal cell proliferation and are frequently dysregulated in cancerous cells. In melanoma, cyclin D1 is highly expressed and downregulation of the Cdk inhibitor, p27(Kip1), is associated with a poor prognosis. Mutant B-RAF is frequently expressed in melanoma and overrides growth factor and matrix adhesion control of cyclin D1 and p27(Kip1) levels in human melanocytes. Here, we demonstrate that p27(Kip1) expression is regulated by multiple mechanisms in melanoma cells. B-RAF regulates p27(Kip1) mRNA abundance independently of cyclin D1. Additionally, B-RAF and cyclin D1 control the levels of S-phase kinase-associated protein 2 (Skp2) that directs ubiquitin-mediated proteolysis of p27(Kip1). The cofactor for Skp2, Cdc kinase subunit 1 (Cks1) controls levels of Skp2 in melanoma cells and acts jointly with Skp2 to regulate p27(Kip1) levels. Importantly, expression of Cks1 is regulated by B-RAF and cyclin D1 at the mRNA level. Reduced Cks1 or Skp2 expression and enhanced p27(Kip1) levels inhibit melanoma cell growth. In summary, p27(Kip1) expression in melanoma is regulated by B-RAF at the mRNA level, and via B-RAF and cyclin D1 control of Cks1/Skp2- mediated proteolysis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Bond M, 2004, J BIOL CHEM, V279, P37304, DOI 10.1074/jbc.M404307200; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hingorani SR, 2003, CANCER RES, V63, P5198; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.jdermsci.2005.12.016; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 2002, CANCER RES, V62, P3200; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Woenckhaus C, 2005, HISTOL HISTOPATHOL, V20, P501, DOI 10.14670/HH-20.501; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	68	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1056	1066		10.1038/sj.onc.1209861	http://dx.doi.org/10.1038/sj.onc.1209861			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16924241				2022-12-17	WOS:000244245400012
J	Vegran, F; Boidot, R; Oudin, C; Defrain, C; Rebucci, M; Lizard-Nacol, S				Vegran, F.; Boidot, R.; Oudin, C.; Defrain, C.; Rebucci, M.; Lizard-Nacol, S.			Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer	ONCOGENE			English	Article						survivin expression; alternative splicing; p53 status; breast cancer	ANTI-APOPTOSIS GENE; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; SURVIVIN-DELTA-EX3; INDUCTION; CELLS; INHIBITOR; MUTATIONS	Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-Delta Ex3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-Delta Ex3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2 alpha) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.	Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, F-21034 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Georges-Francois Leclerc	Lizard-Nacol, S (corresponding author), Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, 1 Rue Prof Marion, F-21034 Dijon, France.	slizard@dijon.fnclcc.fr	VEGRAN, Frédérique/H-4792-2017; VEGRAN, Frederique/O-9986-2018	VEGRAN, Frederique/0000-0002-4377-1441				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Caldas H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-11; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Franco N, 2003, ARCH SURG-CHICAGO, V138, P291, DOI 10.1001/archsurg.138.3.291; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahotka C, 1999, CANCER RES, V59, P6097; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NASU S, 2002, ANTICANCER RES, V22, P2613; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Punga T, 2003, FEBS LETT, V552, P214, DOI 10.1016/S0014-5793(03)00927-X; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsuji N, 2004, BREAST CANCER RES TR, V87, P23, DOI 10.1023/B:BREA.0000041575.73262.aa; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vegran F, 2005, INT J ONCOL, V27, P1151; Xu H, 2003, ONCOL RES, V13, P429; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhou XL, 1999, CANCER RES, V59, P843; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	33	59	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					290	297		10.1038/sj.onc.1209784	http://dx.doi.org/10.1038/sj.onc.1209784			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847456	Bronze			2022-12-17	WOS:000243398300013
J	Reed-Inderbitzin, E; Moreno-Miralles, I; Vanden-Eynden, SK; Xie, J; Lutterbach, B; Durst-Goodwin, KL; Luce, KS; Irvin, BJ; Cleary, ML; Brandt, SJ; Hiebert, SW				Reed-Inderbitzin, E.; Moreno-Miralles, I.; Vanden-Eynden, S. K.; Xie, J.; Lutterbach, B.; Durst-Goodwin, K. L.; Luce, K. S.; Irvin, B. J.; Cleary, M. L.; Brandt, S. J.; Hiebert, S. W.			RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription	ONCOGENE			English	Article						Suv39h1; RUNX1; AML1; histone; deacetylase	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; SYNERGISTICALLY ACTIVATE; DEPENDENT ACTIVATION; AUTO-INHIBITION; NUCLEAR-MATRIX; FUSION PROTEIN; N-COR; GENE; T(8-21)	RUNX1 (AML1) is a gene that is frequently disrupted by chromosomal translocations in acute leukemia. Like its Drosophila homolog Runt, RUNX1 both activates and represses transcription. Both Runt and RUNX1 are required for gene silencing during development and a central domain of RUNX1, termed repression domain 2 (RD2), was defined as being required for transcriptional repression and for the silencing of CD4 during T-cell maturation in thymic organ cultures. Although transcriptional co-repressors are known to contact other repression domains in RUNX1, the factors that bind to RD2 had not been defined. Therefore, we tested whether RD2 contacts histone-modifying enzymes that may mediate both repression and gene silencing. We found that RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous Suv39h1 associates with a Runx1-regulated repression element in murine erythroleukemia cells. In addition, one of these SUV39H1-binding motifs is also sufficient for binding to histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-mediated transcriptional repression. The association between RUNX1, histone deacetylases and SUV39H1 provides a molecular mechanism for repression and possibly gene silencing mediated by RUNX1.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Tennessee Valley VA Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Preston Res Bldg,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA077274, P30CA068485, R01CA064140] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01-CA64140, R01-CA77274] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; PHS HHS [R01-87549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ERICKSON PF, 1994, CANCER RES, V54, P1782; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guidez F, 2000, BLOOD, V96, P2557; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Javed A, 2000, J CELL SCI, V113, P2221; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nishimura M, 2004, BLOOD, V103, P562, DOI 10.1182/blood-2003-06-2109; NUCIFORA G, 1995, P NATL ACAD SCI USA, V92, P4917; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; RAYNAUD S, 1995, GENE, V159, P245; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	46	59	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5777	5786		10.1038/sj.onc.1209591	http://dx.doi.org/10.1038/sj.onc.1209591			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652147				2022-12-17	WOS:000240765800008
J	Cheng, WC; Berman, SB; Ivanovska, I; Jonas, EA; Lee, SJ; Chen, Y; Kaczmarek, LK; Pineda, F; Hardwick, JM				Cheng, W. -C; Berman, S. B.; Ivanovska, I.; Jonas, E. A.; Lee, S. J.; Chen, Y.; Kaczmarek, L. K.; Pineda, F.; Hardwick, J. M.			Mitochondrial factors with dual roles in death and survival	ONCOGENE			English	Review						apoptosis; Fis1; CED-9; yeast; aging; virus	PROGRAMMED CELL-DEATH; DYNAMIN-RELATED GTPASE; CYTOCHROME-C RELEASE; WD REPEAT PROTEIN; PERMEABILITY TRANSITION; BH3-ONLY PROTEINS; REGULATES APOPTOSIS; CASPASE ACTIVATION; VITAL FUNCTIONS; BCL-2 HOMOLOGS	At least in mammals, we have some understanding of how caspases facilitate mitochondria-mediated cell death, but the biochemical mechanisms by which other factors promote or inhibit programmed cell death are not understood. Moreover, most of these factors are only studied after treating cells with a death stimulus. A growing body of new evidence suggests that cell death regulators also have 'day jobs' in healthy cells. Even caspases, mitochondrial fission proteins and pro-death Bcl-2 family proteins appear to have normal cellular functions that promote cell survival. Here, we review some of the supporting evidence and stretch beyond the evidence to seek an understanding of the remaining questions.	Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Yale Univ, Dept Endocrinol, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hardwick, JM (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Rm E5140 BSPH,615 N Wolfe St, Baltimore, MD 21205 USA.	hardwick@jhu.edu	Berman, Sarah/I-2792-2014; Cheng, Wen-Chih/B-4088-2009	Berman, Sarah/0000-0002-5096-4962; 	NCI NIH HHS [R01 CA073581] Funding Source: Medline; NINDS NIH HHS [R01 NS037402, R01 NS034175, R01 NS045876] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037402, R01NS034175, R01NS045876] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Blackstone NW, 1999, BIOESSAYS, V21, P84, DOI 10.1002/(SICI)1521-1878(199901)21:1<84::AID-BIES11>3.0.CO;2-0; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Borrello ME, 2005, ENDEAVOUR, V29, P43, DOI 10.1016/j.endeavour.2004.11.003; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Colon-Ramos DA, 2003, MOL BIOL CELL, V14, P4162, DOI 10.1091/mbc.E03-03-0139; Dohm JA, 2004, PROTEINS, V54, P153, DOI 10.1002/prot.10524; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Engelberg-Kulka H, 2003, SCIENCE, V301, P467, DOI 10.1126/science.1088051; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Goldstein JC, 2005, CELL DEATH DIFFER, V12, P453, DOI 10.1038/sj.cdd.4401596; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Ivanovska I, 2005, J CELL BIOL, V170, P391, DOI 10.1083/jcb.200503069; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Jonas EA, 2005, ANTIOXID REDOX SIGN, V7, P1092, DOI 10.1089/ars.2005.7.1092; Jonas EA, 2005, J BIOL CHEM, V280, P4491, DOI 10.1074/jbc.M410661200; Jonas EA, 2004, P NATL ACAD SCI USA, V101, P13590, DOI 10.1073/pnas.0401372101; Jonas EA, 2003, J NEUROSCI, V23, P8423; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; LLERMEIER CD, 2006, CELL, V124, P549; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NICHOLLS DG, 2002, BIOENERGETICS, V3; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reiter J, 2005, J CELL BIOL, V168, P353, DOI 10.1083/jcb.200408071; Rine J, 2005, SCIENCE, V310, P1124, DOI 10.1126/science.1121310; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Strasser A, 2003, IMMUNOL REV, V193, P82, DOI 10.1034/j.1600-065X.2003.00036.x; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yu XC, 2005, STRUCTURE, V13, P1725, DOI 10.1016/j.str.2005.09.006; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	129	59	63	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4697	4705		10.1038/sj.onc.1209596	http://dx.doi.org/10.1038/sj.onc.1209596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892083				2022-12-17	WOS:000239687000007
J	Sun, C; Shi, Y; Xu, LL; Nageswararao, C; Davis, LD; Segawa, T; Dobi, A; McLeod, DG; Srivastava, S				Sun, C.; Shi, Y.; Xu, L. L.; Nageswararao, C.; Davis, L. D.; Segawa, T.; Dobi, A.; McLeod, D. G.; Srivastava, S.			Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival	ONCOGENE			English	Article						prostate cancer; androgen receptor; mutation; p53; cell proliferation; cell apoptosis	WILD-TYPE P53; DOWN-REGULATION; BINDING DOMAIN; EXPRESSION; GENE; APOPTOSIS; PROGRESSION; CARCINOMA; LEADS	Alteration of the AR functions due to amplication, overexpression and somatic mutation of the AR itself or altered interaction of AR with other cell growth regulatory proteins, may contribute to a significant subset of advanced prostate cancer (CaP). Very little is known about the pathways impacted by AR dysfunctions, although CaP associated AR alterations suggest the biological role of the AR dysfunction in disease progression. Comparative evaluations of wild type (wt) AR and mutant (mt) ARs in appropriate experimental models should provide a better understanding of the functional impact of AR alterations in CaP. Here, we provide direct evidence showing cell growth/cell survival promoting effects of the widely studied CaP associated AR mutation (T877A). In contrast to Ad-wtAR or Ad-control infected LNCaP or LAPC4 cells, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells continued to grow in the androgen-deprived medium and exhibited an androgen independent AR-transcription factor activity. Further, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells exhibited enhanced cell growth in the presence of lower concentrations of the synthetic androgen, R1881. Of note, Ad-mtAR (T877A) infected LNCaP cells showed striking resistance to cell growth inhibition/apoptosis mediated by the wt p53. Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression. These observations have important implications for developing biology-based prognostic biomarkers and therapeutic strategies for CaP showing such AR dysfunctions.	Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org						Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huggins C, 1941, CANCER RES, V1, P293; Ioffe ML, 2004, PROSTATE, V61, P243, DOI 10.1002/pros.20108; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; SCHUURMANS ALG, 1990, J STEROID BIOCHEM, V37, P849, DOI 10.1016/0960-0760(90)90431-J; Segawa T, 1998, CANCER RES, V58, P2282; Shi XB, 2002, CANCER RES, V62, P1496; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Tsui KH, 2004, J UROLOGY, V172, P2035, DOI 10.1097/01.ju.0000138053.78518.b2; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Wen Y, 2000, CANCER RES, V60, P6841; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; YANG CL, 1995, CANCER RES, V55, P4210; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	35	59	59	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3905	3913		10.1038/sj.onc.1209424	http://dx.doi.org/10.1038/sj.onc.1209424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16636679				2022-12-17	WOS:000238668800003
J	Rashi-Elkeles, S; Elkon, R; Weizman, N; Linhart, C; Amariglio, N; Sternberg, G; Rechavi, G; Barzilai, A; Shamir, R; Shiloh, Y				Rashi-Elkeles, S; Elkon, R; Weizman, N; Linhart, C; Amariglio, N; Sternberg, G; Rechavi, G; Barzilai, A; Shamir, R; Shiloh, Y			Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue	ONCOGENE			English	Article						ATM; NF-kappa B; p53; IR response; microarrays	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; P53; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The ATM protein kinase, functionally missing in patients with the human genetic disorder ataxia-telangiectasia, is a master regulator of the cellular network induced by DNA double-strand breaks. The ATM gene is also frequently mutated in sporadic cancers of lymphoid origin. Here, we applied a functional genomics approach that combined gene expression pro. ling and computational promoter analysis to obtain global dissection of the transcriptional response to ionizing radiation in murine lymphoid tissue. Cluster analysis revealed a prominent pattern characterizing dozens of genes whose response to irradiation was Atm-dependent. Computational analysis identified significant enrichment of the binding site signatures of NF-kappa B and p53 among promoters of these genes, pointing to the major role of these two transcription factors in mediating the Atm-dependent transcriptional response in the irradiated lymphoid tissue. Examination of the response showed that pro- and antiapoptotic signals were simultaneously induced, with the proapoptotic pathway mediated by p53 targets, and the prosurvival pathway by NF-kappa B targets. These findings further elucidate the molecular network induced by IR, point to novel putative NF-kappa B targets, and suggest a mechanistic model for cellular balancing between pro- and antiapoptotic signals induced by IR in lymphoid tissues, which has implications for cancer management. The emerging model suggests that restoring the p53-mediated apoptotic arm while blocking the NF-kappa B-mediated prosurvival arm could effectively increase the radiosensitivity of lymphoid tumors.	Sackler Sch Med, David Inez Myers Lab Genet Res, Dept Human Genet, IL-66978 Tel Aviv, Israel; George S Wise Fac Life Sci, Dept Neurobiochem, Tel Aviv, Israel; Sch Comp Sci, Tel Aviv, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Shiloh, Y (corresponding author), Sackler Sch Med, David Inez Myers Lab Genet Res, Dept Human Genet, IL-66978 Tel Aviv, Israel.	yossih@post.tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Clamp M, 2003, NUCLEIC ACIDS RES, V31, P38, DOI 10.1093/nar/gkg083; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ding GR, 2003, RADIAT RES, V160, P232, DOI 10.1667/RR3018; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; MIYASHITA T, 1995, CELL, V80, P293; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Qin ZH, 1999, J NEUROSCI, V19, P4023; Robles AI, 2001, CANCER RES, V61, P6660; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Sharan R, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P307; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Stankovic T, 2002, LEUKEMIA LYMPHOMA, V43, P1563, DOI 10.1080/1042819021000002884; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weston VJ, 2004, BLOOD, V104, P1465, DOI 10.1182/blood-2003-11-4039; WU HY, 1994, J BIOL CHEM, V269, P20067	41	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1584	1592		10.1038/sj.onc.1209189	http://dx.doi.org/10.1038/sj.onc.1209189			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16314843				2022-12-17	WOS:000235890400015
J	Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC				Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC			Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis	ONCOGENE			English	Article						C/EBP; apoptosis; carcinogenesis	CCAAT/ENHANCER-BINDING-PROTEINS; GENE-EXPRESSION; CARCINOMA-CELLS; ONCOGENIC RAS; DIFFERENTIATION; INACTIVATION; APOPTOSIS; ARREST	The CCAAT/enhancer binding protein beta(C/EBP beta) is implicated in the regulation of many different molecular and physiological processes. Mice with a germline deletion of C/EBP beta (C/EBP beta(-/-)) display phenotypes in a multitude of cell types and organ systems, including skin where C/EBP beta(-/-) mice exhibit increased apoptosis in epidermal keratinocytes in response to carcinogen treatment and are completely resistant to carcinogen-induced skin tumorigenesis. To determine the contribution of systemic versus cell autonomous functions of C/EBP beta to specific phenotypes, mice with a conditional 'floxed' C/EBP beta null allele were generated. Epidermal-specific deletion of C/EBP beta was achieved by Cre recombinase expression from a keratin 5 (K5) promoter. Similar to C/EBP beta(-/-) mice, K5-Cre; C/EBP beta(fl)/(fl) mice were completely refractory to 7,12 dimethylbenz[a] anthracene (DMBA)-induced skin tumorigenesis and these mice displayed increased DMBA-induced apoptosis in epidermal keratinocytes compared to wild-type mice. In contrast, mice lacking the related gene, C/ EBP delta, were not resistant to DMBA-induced skin tumorigenesis, indicating a unique role of C/EBP beta in skin tumor development. Our findings demonstrate that C/EBP beta exerts an essential, keratinocyte-intrinsic role in cell survival in response to carcinogen treatment and the elimination of C/EBP beta in keratinocytes is sufficient to confer complete resistance of the skin to chemical carcinogenesis.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA; NCI, Mol Mech Dev Grp, Lab Prot Dynam & Signaling, Frederick, MD USA; CIEMAT, Repair & Tissue Engn Program, Madrid, Spain	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; Sterneck, Esta/0000-0001-7716-8766; Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [Z01BC010307, R01CA046637, R29CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637, R01 CA046637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUTWELL RK, 1983, CANCER RES, V43, P2465; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Klatt P, 2003, CARCINOGENESIS, V24, P817, DOI 10.1093/carcin/bgg057; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Ma WB, 2003, CANCER RES, V63, P5320; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Porter KL, 2002, TOXICOL SCI, V69, P42, DOI 10.1093/toxsci/69.1.42; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tessarollo L, 2000, METH MOL B, V158, P47; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	31	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1272	1276		10.1038/sj.onc.1209144	http://dx.doi.org/10.1038/sj.onc.1209144			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205634	Green Accepted			2022-12-17	WOS:000235537500014
J	Speidel, D; Helmbold, H; Deppert, W				Speidel, D; Helmbold, H; Deppert, W			Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress	ONCOGENE			English	Article						p53; Bax; non-transcriptional apoptosis; transcription; senescence; fibroblasts	TUMOR-SUPPRESSOR P53; DNA-BINDING; IN-VIVO; APOPTOSIS; CELLS; PROTEIN; BAX; TRANSACTIVATION; MITOCHONDRIA; ACTIVATION	Following genotoxic stress, p53 either rescues a damaged cell or promotes its elimination. The parameters determining a specific outcome of the p53 response are largely unknown. In mouse. broblasts treated with different irradiation schemes, we monitored transcriptional and non-transcriptional p53 activities and identifi. ed determinants that initiate an anti- or a pro-apoptotic p53 response within the context of p53-independent stress signaling. The primary, transcription-mediated p53 response in these cells is anti-apoptotic, while induction of p53-dependent apoptosis requires an additional, transcription-independent p53 activity, provided by high intracellular levels of activated p53. High intracellular levels of p53 were selectively generated after apoptosis-inducing high-dose UV-irradiation, and correlated with a strongly delayed upregulation of Mdm2. Following high-dose UV-irradiation, p53 accumulated in the cytoplasm and led to activation of the pro-apoptotic protein Bax. As p53-dependent Bax-activation is transcription-independent, we postulated that certain transcription-deficient mutant p53 proteins might also exert this activity. Indeed we found an endogenous, transcription-inactive mutant p53 that upon genotoxic stress induced Bax-activation in vivo. Our results demonstrate the impact and in vivo relevance of non-transcriptional mechanisms for wild- type and mutant p53-mediated apoptosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de	Speidel, Daniel/I-4244-2012					Chen X, 2002, CELL RES, V12, P229, DOI 10.1038/sj.cr.7290129; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERMEKING H, 2003, NAT REV CANCER, V2, P594; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Roninson IB, 2003, CANCER RES, V63, P2705; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZIEGLER C, 1998, THESIS U HAMBURG HAM	33	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					940	953		10.1038/sj.onc.1209126	http://dx.doi.org/10.1038/sj.onc.1209126			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247471				2022-12-17	WOS:000235212700013
J	Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C				Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C			P38 alpha MAPK is required for contact inhibition	ONCOGENE			English	Article						contact inhibition; p38 MAPK; fibroblasts	CELL-CYCLE ARREST; PLASMA-MEMBRANE GLYCOPROTEINS; DEPENDENT INHIBITION; PROTEIN-KINASE; HUMAN-FIBROBLASTS; GROWTH; ACTIVATION; PATHWAY; SIGNAL; D1	Proliferation of nontransformed cells is regulated by cell cell contacts, which are referred to as contact-inhibition. Despite its generally accepted importance for cell cycle control, knowledge about the intracellular signalling pathways involved in contact inhibition is scarce. In the present work we show that p38 alpha mitogen-activated protein kinase (MAPK) is involved in the growth-inhibitory signalling cascade of contact inhibition in fibroblasts. p38 alpha activity is increased in confluent cultures of human fibroblasts compared to proliferating cultures. Time course studies show a sustained activation of p38 alpha in response to cell-cell contacts in contrast to a transient activation after serum stimulation. The induction of contact inhibition by addition of glutaraldehyde-fixed cells is impaired by pharmacological inhibition of p38 as well as in p38 alpha-/- fibroblasts. Further evidence for a central role of p38a in contact inhibition comes from the observation that p38 alpha-/- fibroblasts show a higher saturation density compared to wild-type (wt) fibroblasts, which is reversed by reconstituted expression of p38 alpha. In agreement with a defect in contact inhibition, p27(Kip1) accumulation is impaired in p38 alpha-/- fibroblasts compared to wt fibroblasts. Hence, our work shows a new role for p38 alpha in contact inhibition and provides a mechanistic basis for the recently proposed tumour suppressive function of this MAPK pathway.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain	Johannes Gutenberg University of Mainz; Centro Nacional de Investigaciones Oncologicas (CNIO)	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	cdietric@uni-mainz.de	Weiss, Carsten/I-1811-2013; Nebreda, Angel Rodriguez/R-9594-2019; Cuadrado, Ana/AAA-9277-2019; Cuadrado, Ana/HGU-4777-2022; Oesch, Franz/AAA-8746-2020	Weiss, Carsten/0000-0002-5380-3208; Cuadrado, Ana/0000-0002-9752-5932; 				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Haq R, 2002, CANCER RES, V62, P5076; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nakatsuji Y, 1998, GLIA, V22, P379, DOI 10.1002/(SICI)1098-1136(199804)22:4<379::AID-GLIA7>3.0.CO;2-Z; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1995, GLYCOCONJUGATE J, V12, P672, DOI 10.1007/BF00731264	33	59	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7941	7945		10.1038/sj.onc.1208948	http://dx.doi.org/10.1038/sj.onc.1208948			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027723	Bronze			2022-12-17	WOS:000233463000013
J	Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG				Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG			FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model	ONCOGENE			English	Article						FLT3 tyrosine kinase; transgenic; mouse; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; HEMATOPOIETIC-CELLS; CONSTITUTIVE ACTIVATION; EXPRESSION; GENE; TRANSFORMATION; COMPARTMENT; PKC412; LIGAND	Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been identified in similar to 30% of patients with acute myelogenous leukemia (AML), and recently in a smaller subset of patients with acute lymphoblastic leukemia (ALL). To explore the in vivo consequences of an activating FLT3 internal tandem duplication mutation (FLT3-ITD), we created a transgenic mouse model in which FLT3-ITD was expressed under the control of the vav hematopoietic promoter. Five independent lines of vavFLT3-ITD transgenic mice developed a myeloproliferative disease with high penetrance and a disease latency of 6-12 months. The phenotype was characterized by splenomegaly, megakaryocytic hyperplasia, and marked thrombocythemia, but without leukocytosis, polycythemia, or marrow fibrosis, displaying features reminiscent of the human disease essential thrombocythemia (ET). Clonal immature B- or T-lymphoid disease was observed in two additional founder mice, respectively, that could be secondarily transplanted to recipient mice that rapidly developed lymphoid disease. Treatment of these mice with the FLT3 tyrosine kinase inhibitor, PKC412, resulted in suppression of disease and a statistically significant prolongation of survival. These results demonstrate that FLT3-ITD is capable of inducing myeloproliferative as well as lymphoid disease, and indicate that small-molecule tyrosine kinase inhibitors may be an effective treatment for lymphoid malignancies in humans that are associated with activating mutations in FLT3.	Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Novartis Pharma AG, Basel, Switzerland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Emory University; Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Dept Med, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NCI NIH HHS [CA66996] Funding Source: Medline; NHLBI NIH HHS [5T32HL 07627-16] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P1076, DOI 10.1046/j.1365-2141.2001.02821.x; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BRASEL K, 1995, LEUKEMIA, V9, P1212; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; DASILVA N, 1994, LEUKEMIA, V8, P885; DELAPEYRIERE O, 1995, DIFFERENTIATION, V58, P351, DOI 10.1007/s002580050094; Drexler HG, 1996, LEUKEMIA, V10, P588; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Griffin JD, 2001, BLOOD, V97, P2193; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Ishii E, 1999, PEDIATR HEMAT ONCOL, V16, P437, DOI 10.1080/088800199276994; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MAROC N, 1993, ONCOGENE, V8, P909; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; Rosnet O, 1996, LEUKEMIA, V10, P238; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Turner AM, 1996, BLOOD, V88, P3383, DOI 10.1182/blood.V88.9.3383.bloodjournal8893383; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	33	59	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7882	7892		10.1038/sj.onc.1208933	http://dx.doi.org/10.1038/sj.onc.1208933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116483				2022-12-17	WOS:000233463000007
J	Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM				Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM			Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases	ONCOGENE			English	Article						PDGF-B; proprotein convertases; prosegments; secretion; processing	GROWTH-FACTOR-A; PROTEASE-ACTIVATED LIGAND; CONNECTIVE-TISSUE; HUMAN-PLATELETS; ALPHA-RECEPTOR; BETA-RECEPTOR; FURIN; CELL; CHAIN; EXPRESSION	Platelet-derived growth factor-B (PDGF-B) is important for normal tissue growth and maintenance and its overexpression has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Here, we show that synthesized as a precursor, proPDGF-B is converted to a mature form by proteolytic cleavage at two sites and its N-terminal cleavage is a prerequisite for processing at its C-terminus. The first cleavage occurs at residues RGRR(81)down arrow, and the second cleavage close to residues ARPVT(190), just before the C-terminal amino-acid sequence crucial for PDGF-B retention to cell surface. Cotransfection of a Furin-deficient cell line LoVo-C5 with proPDGF-B and different PC members revealed that Furin, PACE4, PC5, and PC7 are candidate proPDGF-B convertases. This finding is consistent with the in vitro digestions of a synthetic peptide mimicking the cleavage site of proPDGF-B. The processing of proPDGF-B is blocked by site-directed mutagenesis of the RGRR(81)down arrow sequence and by various PC inhibitors. Mutation of the PDGF-A and/or PDGF-B convertase sites, revealed that processing of both A and B chains is required for the formation of mature PDGF-B dimers and that the processing of the B chain controls the level of secreted and matrix-bound PDGF-BB forms. Our findings emphasize the importance of the convertase-directed processing of proPDGF-B at the RGRR(81)down arrow sequence for PDGF-B maturation and secretion.	INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, F-75010 Paris, France; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Ottawa Hlth Res Inst, Dis Ageing Unit, Reg Prot Chem Ctr, Ottawa, ON K1Y 4E9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Khatib, AM (corresponding author), INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.	majid.khatib@stlouis.inserm.fr	KHATIB, Abdel-Majid/A-9948-2015; Siegfried, Géraldine/N-6017-2018; Seidah, Nabil/I-3596-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; Seidah, Nabil/0000-0001-6503-9342; calvo, fabien/0000-0002-0298-7633; siegfried, geraldine/0000-0002-6346-5206				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; Eming SA, 1999, AM J PATHOL, V154, P281, DOI 10.1016/S0002-9440(10)65274-1; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Sundberg C, 1997, AM J PATHOL, V151, P479; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	42	59	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6925	6935		10.1038/sj.onc.1208838	http://dx.doi.org/10.1038/sj.onc.1208838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007151				2022-12-17	WOS:000232701700007
J	Letterio, JJ				Letterio, JJ			TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia	ONCOGENE			English	Review						transforming growth factor beta ( TGF-beta); lymphocyte; neoplasia; leukemia; inflammation; Smad3	TRANSFORMING-GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; SMAD3 MUTANT MICE; DOWN-REGULATION; IN-VIVO; TUMOR-SUPPRESSOR; THYMOCYTE PROLIFERATION; LYMPHOBLASTIC-LEUKEMIA; INFLAMMATORY RESPONSE; IL-12 RESPONSIVENESS	Transforming growth factor-beta (TGF-beta) plays an essential role in regulating the homeostasis of cells in the lymphoid lineage. TGF-beta signaling is not required for normal thymopoiesis, but is essential for regulating the expansion, activation, and effector function of the mature CD4(+) and CD8(+) T cells in the peripheral lymphoid organs and target tissues. Recent studies in both mice and humans have elucidated an important and complex role for TGF-beta in regulatory T-cell biology. Disruption of TGF-beta signaling in T cells impairs the maintenance of regulatory T cells, results in the expansion of activated effector T cells, and is associated with the production of cytokines that have major effects on cells in their environment. While autoimmunity and inflammation are the principal phenotypes associated with the abrogation of TGF-beta signaling in T cells in mice, emerging evidence now also directly links Smad-dependent TGF-beta signaling in T cells to the suppression of epithelial neoplasia. The TGF-beta receptor-activated Smad3 plays a critical role in mediating many of the inhibitory effects of TGF-beta signaling in T cells, and has now been established as an important suppressor of leukemogenesis. These studies are increasing our awareness of the many complex mechanisms through which TGF-beta signaling controls the pathogenesis of cancer.	NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Letterio, JJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bldg 41,Room C629,41 Lib Dr, Bethesda, MD 20892 USA.	letterij@mail.nih.gov						Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Baroni T, 2003, J PERIODONTOL, V74, P1447, DOI 10.1902/jop.2003.74.10.1447; Beck C, 2001, MICROSC RES TECHNIQ, V52, P387, DOI 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker C, 2005, CELL CYCLE, V4, P217; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; Bright JJ, 1998, J IMMUNOL, V161, P1772; Brown KA, 2004, BREAST CANCER RES, V6, pR130, DOI 10.1186/bcr762; Campbell JDM, 2001, J IMMUNOL, V167, P553, DOI 10.4049/jimmunol.167.1.553; CHANTRY D, 1989, EUR J IMMUNOL, V19, P783, DOI 10.1002/eji.1830190433; Chen CH, 2003, J EXP MED, V197, P1689, DOI 10.1084/jem.20021170; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; CHRIST M, 1994, J IMMUNOL, V153, P1936; Chrobak Pavel, 2003, Acta Medica (Hradec Kralove), V46, P131; Coste A, 1998, ARCH OTOLARYNGOL, V124, P1361, DOI 10.1001/archotol.124.12.1361; DANGEAC AD, 1991, J CELL PHYSIOL, V147, P460, DOI 10.1002/jcp.1041470312; DANGEAC AD, 1993, J CELL PHYSIOL, V154, P44, DOI 10.1002/jcp.1041540107; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Downing JR, 2004, NEW ENGL J MED, V351, P528, DOI 10.1056/NEJMp048121; Ebert EC, 1999, CLIN EXP IMMUNOL, V115, P415; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Fox SW, 2003, J IMMUNOL, V170, P3679, DOI 10.4049/jimmunol.170.7.3679; Fu TH, 2000, INT J CANCER, V87, P680, DOI 10.1002/1097-0215(20000901)87:5<680::AID-IJC10>3.0.CO;2-P; Fuchs O, 2005, Cas Lek Cesk, V144, P90; Garba ML, 2002, J IMMUNOL, V168, P2247, DOI 10.4049/jimmunol.168.5.2247; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Gorham JD, 1998, J IMMUNOL, V161, P1664; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Herrmann S, 1996, ANN NY ACAD SCI, V795, P168, DOI 10.1111/j.1749-6632.1996.tb52665.x; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; INGE TH, 1992, CANCER RES, V52, P1386; Iwamoto T, 2002, HISTOL HISTOPATHOL, V17, P887, DOI 10.14670/HH-17.887; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Kaklamani Virginia G, 2004, Expert Rev Anticancer Ther, V4, P649, DOI 10.1586/14737140.4.4.649; Kao JY, 2003, J IMMUNOL, V170, P3806, DOI 10.4049/jimmunol.170.7.3806; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kulkarni Ashok B., 2002, Current Molecular Medicine (Hilversum), V2, P303; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Letterio JJ, 1996, J CLIN INVEST, V98, P2109, DOI 10.1172/JCI119017; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin JT, 2005, J IMMUNOL, V174, P5950, DOI 10.4049/jimmunol.174.10.5950; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lucas PJ, 2004, CANCER RES, V64, P6524, DOI 10.1158/0008-5472.CAN-04-0896; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Lyakh LA, 2005, J IMMUNOL, V174, P2061, DOI 10.4049/jimmunol.174.4.2061; Mamura M, 2004, BLOOD, V103, P4594, DOI 10.1182/blood-2003-08-2897; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; McKarns SC, 2000, IMMUNOPHARMACOLOGY, V48, P101, DOI 10.1016/S0162-3109(00)00183-1; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Monteleone G, 2004, GASTROENTEROLOGY, V126, P674, DOI 10.1053/j.gastro.2003.11.048; MOSSALAYI MD, 1995, BLOOD, V85, P3594, DOI 10.1182/blood.V85.12.3594.bloodjournal85123594; Moustakas A, 2003, GENE DEV, V17, P2855, DOI 10.1101/gad.1161403; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Mukamoto M, 2000, VET IMMUNOL IMMUNOP, V77, P121, DOI 10.1016/S0165-2427(00)00223-3; MULE JJ, 1988, CANCER IMMUNOL IMMUN, V26, P95; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ohta K, 2000, INVEST OPHTH VIS SCI, V41, P2591; Pardoux C, 1999, BLOOD, V93, P1448, DOI 10.1182/blood.V93.5.1448.403k36_1448_1455; Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; PLUM J, 1995, J IMMUNOL, V154, P5789; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Rosendahl A, 2003, INT IMMUNOL, V15, P1401, DOI 10.1093/intimm/dxg139; RUSCETTI F W, 1991, Progress in Growth Factor Research, V3, P159, DOI 10.1016/S0955-2235(05)80006-7; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sitnicka E, 1996, BLOOD, V88, P82; Smeltz RB, 2005, IMMUNOLOGY, V114, P484, DOI 10.1111/j.1365-2567.2005.02115.x; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sudarshan C, 1999, J IMMUNOL, V162, P2974; TADA T, 1991, J IMMUNOL, V146, P1077; TAKAHAMA Y, 1994, J EXP MED, V179, P1495, DOI 10.1084/jem.179.5.1495; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang JH, 1997, J IMMUNOL, V159, P117; Terabe M, 2003, J EXP MED, V198, P1741, DOI 10.1084/jem.20022227; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Touw IP, 2000, MOL CELL ENDOCRINOL, V160, P1, DOI 10.1016/S0303-7207(99)00206-3; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; WEISKIRCH LM, 1994, CANCER IMMUNOL IMMUN, V38, P215, DOI 10.1007/BF01533512; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; Williamson E A, 1995, Curr Opin Hematol, V2, P29; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang L, 2004, J BIOL CHEM, V279, P28315, DOI 10.1074/jbc.C400115200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	127	59	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5701	5712		10.1038/sj.onc.1208922	http://dx.doi.org/10.1038/sj.onc.1208922			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123803				2022-12-17	WOS:000231452800005
J	Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL				Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL			Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						ErbB receptors; neuregulin-1; neurofibromatosis; malignant peripheral nerve sheath tumor; neurofibroma	GROWTH-FACTOR RECEPTOR; POINT MUTATION; NEUROFIBROMATOSIS TYPE-1; SUPPRESSOR MUTATIONS; NEU ONCOGENE; TRANSFORMATION; PATHOGENESIS; EXPRESSION; DELETIONS; GENE	Patients with neurofibromatosis type 1 develop aggressive Schwann cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs). Although tumor suppressor gene mutations play an important role in MPNST pathogenesis, it is likely that dysregulated signaling by as yet unidentified growth factors also contributes to the formation of these sarcomas. To test the hypothesis that neuregulin-1 (NRG-1) growth factors promote mitogenesis in MPNSTs, we examined the expression and action of NRG-1 in human MPNSTs and neurofibromas, the benign precursor lesions from which MPNSTs arise. Multiple alpha and beta transmembrane precursors from the class II and III NRG-1 subfamilies are present in both tumor types. Neoplastic Schwann cells within these neoplasms variably express the erbB kinases mediating NRG-1 responses (erbB2, erbB3 and/or erbB4). Human MPNST cell lines (Mash-1, YST-1, NMS-2 and NMS-2PC cells) similarly coexpress multiple NRG-1 isoforms and erbB receptors. These MPNST lines are NRG-1 responsive and demonstrate constitutive erbB phosphorylation. Treatment with PD168393 and PD158780, two structurally and mechanistically distinct erbB inhibitors, abolishes erbB phosphorylation and reduces DNA synthesis in these lines. These findings suggest that autocrine and/or paracrine NRG-1/erbB signaling promotes neoplastic Schwann cell proliferation and may be an important therapeutic target in neurofibromas and MPNSTs.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Carroll, SL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, 1720 7th Ave S,SC843, Birmingham, AL 35294 USA.	carroll@path.uab.edu		Carroll, Steven/0000-0001-6714-4373	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048353] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS048353] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carroll SL, 2005, J NEUROPATH EXP NEUR, V64, P1; Carroll SL, 2004, J NEUROPATH EXP NEUR, V63, P1115, DOI 10.1093/jnen/63.11.1115; Carroll SL, 1997, J NEUROSCI, V17, P1642; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; Endo H, 2002, BRIT J DERMATOL, V147, P821, DOI 10.1046/j.1365-2133.2002.49279.x; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Ferner RE, 2002, CURR OPIN NEUROL, V15, P679, DOI 10.1097/00019052-200212000-00004; Ferner RE, 2002, CANCER RES, V62, P1573; Frohnert PW, 2003, J NEUROPATH EXP NEUR, V62, P520, DOI 10.1093/jnen/62.5.520; Frohnert PW, 2003, GLIA, V43, P104, DOI 10.1002/glia.10232; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Kourea HP, 1999, AM J PATHOL, V155, P1885, DOI 10.1016/S0002-9440(10)65508-3; Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO;2-N; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Li HZ, 2002, CANCER RES, V62, P4507; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; METHENY LJ, 1995, J NEUROPATH EXP NEUR, V54, P753, DOI 10.1097/00005072-199511000-00001; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NAGASHIMA Y, 1990, VIRCHOWS ARCH B, V59, P321, DOI 10.1007/BF02899420; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Parada LF, 2000, BBA-REV CANCER, V1471, pM13, DOI 10.1016/S0304-419X(00)00014-7; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Perry A, 2001, AM J PATHOL, V159, P57, DOI 10.1016/S0002-9440(10)61673-2; Rahmatullah M, 1998, MOL CELL BIOL, V18, P6245, DOI 10.1128/MCB.18.11.6245; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Tucker T, 2002, CLIN GENET, V62, P345, DOI 10.1034/j.1399-0004.2002.620501.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	62	59	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5589	5605		10.1038/sj.onc.1208730	http://dx.doi.org/10.1038/sj.onc.1208730			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897877				2022-12-17	WOS:000231296100006
J	Sundararajan, R; Chen, GH; Mukherjee, C; White, E				Sundararajan, R; Chen, GH; Mukherjee, C; White, E			Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling	ONCOGENE			English	Article						apoptosis; TNF-alpha; mitochondria; DBC-1; caspase; proapoptotic	SCAFFOLD ATTACHMENT FACTOR; CYTOCHROME-C; CHROMOSOME 8P; HEPATOCELLULAR-CARCINOMA; MITOCHONDRIAL FUSION; SUPPRESSOR GENES; CELL-DEATH; TNF-ALPHA; KAPPA-B; SAF-A	Deleted in breast cancer-1 (DBC-1) was initially cloned from a homozygously deleted region in breast and other cancers on human chromosome 8p21, although no function is known for the protein product it encodes. We identified the generation of amino-terminally truncated versions of DBC-1 during tumor necrosis factor (TNF)-alpha-mediated apoptosis. Full-length 150 kDa DBC-1 underwent caspase-dependent processing during TNF-alpha-mediated death signaling, to produce p120 DBC-1 and p66 DBC-1 carboxy-terminal fragments. Endogenous DBC-1 localized to the nucleus in healthy cells, but localized to the cytoplasm during TNF-alpha-mediated apoptosis, consistent with the loss of the amino-terminus containing the nuclear localization signal. Overexpression of an amino-terminal truncated DBC-1, resembling p120 DBC-1, caused mitochondrial clustering, mitochondrial matrix condensation, and sensitized cells to TNF-alpha-mediated apoptosis. The carboxy-terminal coiled-coil domain of DBC-1 was responsible for the cytoplasmic and mitochondrial localization, and for the death-promoting activity of DBC-1. Thus, caspase-dependent processing of DBC-1 may act as a feed-forward mechanism to promote apoptosis and possibly also tumor suppression. DBC-1, like its homolog cell cycle and apoptosis regulatory protein-1 (CARP-1), may function in the regulation of apoptosis.	Rutgers State Univ, CABM, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	White, E (corresponding author), Rutgers State Univ, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053370, R37CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kim KW, 2002, J CELL BIOCHEM, V85, P334, DOI 10.1002/jcb.10139; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kurimoto F, 2001, INT J MOL MED, V8, P89; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Nachmias B, 2003, CANCER RES, V63, P6340; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Rojo M, 2002, J CELL SCI, V115, P1663; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Santel A, 2001, J CELL SCI, V114, P867; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Swalwell JI, 2002, GENE CHROMOSOME CANC, V33, P201, DOI 10.1002/gcc.10015; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Xu ZH, 2003, BIOCHEM BIOPH RES CO, V311, P1057, DOI 10.1016/j.bbrc.2003.10.109; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	57	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4908	4920		10.1038/sj.onc.1208681	http://dx.doi.org/10.1038/sj.onc.1208681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824730				2022-12-17	WOS:000230646500004
J	Johansson, FK; Goransson, H; Westermark, B				Johansson, FK; Goransson, H; Westermark, B			Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice	ONCOGENE			English	Article						glioma; PDGF; Sox10; tumor progression; retroviral insertional mutagenesis	PDGF ALPHA-RECEPTOR; GROWTH-FACTOR; HUMAN GLIOMAS; AUTOCRINE STIMULATION; MALIGNANT PROGRESSION; MESSENGER-RNA; IN-VIVO; MICROARRAY; IDENTIFICATION; INVASION	Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice. In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors. Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendrogliomia (OD) and had 2.3 insertions per tumor. Several known and novel genes of tumor progression or cell markers were differentially expressed between OD- and GBM-like tumors. Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfr alpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain. The retrovirally tagged genes Plekhb1, Prex1, Prkg2, Sox10 and 1200004M23Rik were upregulated in the tumors but had a different expression profile than Pdgfr alpha whereas Rap1gap, GO, Neurl and Camk2b were downregulated in the tumors. The present study accentuates the proposed role of the retrovirally tagged genes in PDGF-driven gliomagenesis and indicates that insertional mutagenesis can promote glioma progression.	Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Westermark, B (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	bengt.westermark@genpat.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Westermark, Bengt/0000-0001-7153-5545				Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; FUJIMOTO M, 1988, NEUROLOGY, V38, P289, DOI 10.1212/WNL.38.2.289; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HERMANSON M, 1992, CANCER RES, V52, P3213; Hesselager G, 2003, CANCER RES, V63, P4305; Huang HT, 2000, CANCER RES, V60, P6868; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lafuente JV, 2000, NEUROPATHOLOGY, V20, P176, DOI 10.1046/j.1440-1789.2000.00329.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonnstedt I, 2002, STAT SINICA, V12, P31; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; NISTER M, 1988, CANCER RES, V48, P3910; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Popko B, 2002, J NEUROPATH EXP NEUR, V61, P329, DOI 10.1093/jnen/61.4.329; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; Rajaraman R, 1978, Ann N Y Acad Sci, V312, P444, DOI 10.1111/j.1749-6632.1978.tb16832.x; Rickman DS, 2001, CANCER RES, V61, P6885; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Saal LH, 2002, GENOME BIOL, V3; Sallinen SL, 2000, CANCER RES, V60, P6617; Schultz C, 2002, CANCER RES, V62, P6270; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Uhrbom L, 1998, CANCER RES, V58, P5275; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	59	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3896	3905		10.1038/sj.onc.1208553	http://dx.doi.org/10.1038/sj.onc.1208553			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750623				2022-12-17	WOS:000229435300005
J	Munoz-Fontela, C; Garcia, MA; Garcia-Cao, I; Collado, M; Arroyo, J; Esteban, M; Serrano, M; Rivas, C				Munoz-Fontela, C; Garcia, MA; Garcia-Cao, I; Collado, M; Arroyo, J; Esteban, M; Serrano, M; Rivas, C			Resistance to viral infection of super p53 mice	ONCOGENE			English	Article						p53; vesicular stomatitis virus; vaccinia virus; tumor suppressor; antiviral activity; `super p53' mice	VESICULAR STOMATITIS-VIRUS; SV40-TRANSFORMED CELLS; ONCOLYTIC VIRUS; APOPTOSIS; ANTIGEN; INDUCTION; REPLICATION; ACTIVATION; CARCINOMA; PROTEINS	Induction of expression of the tumor suppressor p53 after interferon treatment has been recently demonstrated (Takaoka et al., 2003), suggesting an antiviral activity of the protein. In addition, a direct correlation between p53 levels and tumor resistance has been addressed by generating mice with an extra copy of p53 ('super p53' mice) (Garcia-Cao et al., 2002). Here, we show that vesicular stomatitis virus replication in mouse embryo fibroblasts derived from 'super p53' mice is impaired as a result of apoptosis induction via p53 activation. These findings unequivocally demonstrate an antiviral activity of p53, a process that may contribute to inhibit the spread of the virus in vivo.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Madrid, Spain; CNIO, Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Centro Nacional de Investigaciones Oncologicas (CNIO)	Rivas, C (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Plaza Ramon & Cajal SN, E-28040 Madrid, Spain.	mdcrivas@farm.ucm.es	Rivas, Carmen/L-3162-2017; Rivas, Carmen/AAB-6278-2019; Arroyo, Javier/E-9308-2016; Serrano, Manuel/H-2634-2015; Collado, Manuel/K-8140-2014; Garcia, Maria Angel MA/I-5116-2016	Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199; Arroyo, Javier/0000-0002-1971-1721; Serrano, Manuel/0000-0001-7177-9312; Collado, Manuel/0000-0002-0330-0880; Garcia, Maria Angel MA/0000-0003-2003-3769; ESTEBAN, MARIANO/0000-0003-0846-2827; Munoz-Fontela, Cesar/0000-0002-7725-2586				Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Clemens MJ, 2003, J INTERF CYTOK RES, V23, P277, DOI 10.1089/107999003766628124; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Gadaleta P, 2002, VIRUS RES, V86, P87, DOI 10.1016/S0168-1702(02)00049-7; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Giedlin MA, 2003, CANCER CELL, V4, P241, DOI 10.1016/S1535-6108(03)00251-4; GONZALO JA, 1994, EUR J IMMUNOL, V24, P48, DOI 10.1002/eji.1830240108; Humlova Z, 2002, J GEN VIROL, V83, P2821, DOI 10.1099/0022-1317-83-11-2821; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sur JH, 2003, VET PATHOL, V40, P512, DOI 10.1354/vp.40-5-512; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; WAGNER RR, 1996, FIELDS VIROLOGY	28	59	64	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3059	3062		10.1038/sj.onc.1208477	http://dx.doi.org/10.1038/sj.onc.1208477			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	17726827	Bronze			2022-12-17	WOS:000228649500016
J	Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H				Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H			EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin	ONCOGENE			English	Article						chromatin immunoprecipitation; Ewing's sarcoma; EWS-FLI1; MAP kinase phosphatase; RNA interference	FUSION PROTEINS; UP-REGULATION; TRANSCRIPTIONAL ACTIVATION; PROGNOSTIC IMPACT; DNA-BINDING; CELL-LINES; EWS/FLI-1; DIFFERENTIATION; ONCOPROTEINS; EXPRESSION	In all, 85% of Ewing's sarcoma family tumors (ESFT), a neoplasm of unknown histogenesis, express EWS-FLI1 transcription factor gene fusions. To characterize direct target genes avoiding artificial model systems, we cloned genomic DNA from ESFT chromatin precipitating with EWS-FLI1. We now present a comprehensive list of 99 putative transcription factor targets identified, for the first time, by a hypothesis-free approach based on physical interaction. Gene-derived chromatin fragments co-precipitating with EWS-FLI1 were nonrandomly distributed over the human genome and localized predominantly to the upstream region and the first two introns of the genes. At least 20% of putative direct EWS-FLI1 targets were neural genes. One-third of genes recovered showed a significant ESFT-specific expression pattern and were found to be altered upon RNAi-mediated knockdown of EWS-FLI1. Among them, MK-STYX, encoding a MAP kinase phosphatase-like protein, was consistently expressed in ESFT. EWS-FLI1 was found to drive MK-STYX expression by binding to a single ETS binding motif within the first gene intron. MK-STYX serves as precedence for successful recovery of direct EWS-FLI1 targets from the authentic ESFT cellular context, the most relevant system to study oncogenic mechanisms for the discovery of new therapeutic targets in this disease.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany	Saint Anna Children's Hospital; Heinrich Heine University Dusseldorf	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.univie.ac.at		Kovar, Heinrich/0000-0001-6873-9109				Arvand A, 2001, CANCER RES, V61, P5311; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chansky HA, 2001, CANCER RES, V61, P3586; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078-0432.CCR-03-0038; Fuchs B, 2003, FEBS LETT, V553, P104, DOI 10.1016/S0014-5793(03)00984-0; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Im YH, 2000, CANCER RES, V60, P1536; Kovar H, 2001, CANCER RES, V61, P5992; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Matsui Y, 2003, J BIOL CHEM, V278, P11369, DOI 10.1074/jbc.M300164200; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; OHNO T, 1993, CANCER RES, V53, P5859; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Spahn L, 2002, CANCER RES, V62, P4583; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Takahashi A, 2003, CANCER RES, V63, P8338; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1996, ONCOGENE, V13, P2649; Torchia EC, 2003, CANCER RES, V63, P3464; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Wishart MJ, 2002, P NATL ACAD SCI USA, V99, P2112, DOI 10.1073/pnas.251686198; Zwerner JP, 2003, EXP CELL RES, V290, P414, DOI 10.1016/S0014-4827(03)00371-9	47	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2512	2524		10.1038/sj.onc.1208455	http://dx.doi.org/10.1038/sj.onc.1208455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735734				2022-12-17	WOS:000228180600009
J	Hu, JT; Bianchi, F; Ferguson, M; Cesario, A; Margaritora, S; Granone, P; Goldstraw, P; Tetlow, M; Ratcliffe, C; Nicholson, AG; Harris, A; Gatter, K; Pezzella, F				Hu, JT; Bianchi, F; Ferguson, M; Cesario, A; Margaritora, S; Granone, P; Goldstraw, P; Tetlow, M; Ratcliffe, C; Nicholson, AG; Harris, A; Gatter, K; Pezzella, F			Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer	ONCOGENE			English	Article						lung cancer; angiogenesis; gene expression	LON PROTEASE; TUMOR-GROWTH; THROMBOSPONDIN-1; TRANSLATION; RELEVANCE; VEGF	Angiogenesis is regarded as essential for tumour growth. However, we have demonstrated that some other aggressive non-small-cell lung carcinomas (n-SCLC) do not have angiogenesis. In this study, using cDNA microarray analysis, we demonstrate that angiogenic and nonangiogenic tumour types can be distinguished by their gene expression profiles. Tissue samples from 42 n-SCLC patients were obtained with consent. In all, 12 tumours were nonangiogenic and 30 angiogenic. The two groups were matched by age, sex, smoking and tumour stage. Total RNAs were extracted followed by microarray hybridization and image scan procedure. Data were analysed using GeneSpring 5.1 software. A total of 62 genes were found to be able to separate angiogenic from nonangiogenic tumours. Nonangiogenic tumours have higher levels of genes concerned with mitochondrial metabolism, mRNA transcription, protein synthesis and the cell cycle. Angiogenic tumours have higher levels of genes coding for membrane vesicles, integrins, remodelling, angiogenesis and apoptosis. These results further support our first finding that nonangiogenic lung tumours are fast-growing tumours filling the alveoli in the absence of vascular remodelling. We raise the hypothesis that in nonangiogenic tumours, hypoxia leads to a higher activation of the mitochondrial respiratory chain, which allows tumour growth without triggering angiogenesis.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Canc Res UK,Tumour Pathol Grp, Oxford OX3 9DU, England; IFOM FIRC, Inst Mol Oncol, I-20139 Milan, Italy; Catholic Univ Rome, Dept Surg Sci, Div Thorac Surg, I-00168 Rome, Italy; Royal Brompton Hosp, Dept Thorac Surg, London SW3 6NP, England; Radcliffe Infirm, NTRAC Coordinating Ctr, Oxford OX2 6HE, England; Royal Brompton Hosp, Dept Histopathol, London SW3 6NP, England; Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England	Cancer Research UK; University of Oxford; IFOM - FIRC Institute of Molecular Oncology; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Royal Brompton Hospital; Radcliffe Infirmary; Royal Brompton Hospital; Cancer Research UK; University of Oxford	Pezzella, F (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Canc Res UK,Tumour Pathol Grp, Oxford OX3 9DU, England.	francesco.pezzella@cancer.org.uk	Bianchi, Fabrizio/W-7037-2019; Bianchi, Fabrizio/B-5995-2017; CESARIO, Alfredo/O-4215-2015; Harris, Adrian L/ABA-3343-2020	Bianchi, Fabrizio/0000-0001-7412-8638; Bianchi, Fabrizio/0000-0001-7412-8638; CESARIO, Alfredo/0000-0003-4687-0709; Harris, Adrian L/0000-0003-1376-8409				Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; GIL SG, 1994, J INVEST DERMATOL, V103, P31; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Miller LD, 2002, CANCER CELL, V2, P353, DOI 10.1016/S1535-6108(02)00181-2; Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Pezzella F, 1996, EUR J CANCER, V32A, P2494, DOI 10.1016/S0959-8049(96)00377-2; Pezzella F, 2000, LANCET, V355, P1787; Pezzella F, 1997, AM J PATHOL, V151, P1417; Smeitink J, 1998, HUM GENET, V103, P245, DOI 10.1007/s004390050813; Su JD, 2003, CANCER RES, V63, P3585; Van Coillie E, 2001, AM J PATHOL, V159, P1405, DOI 10.1016/S0002-9440(10)62527-8; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349	20	59	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1212	1219		10.1038/sj.onc.1208242	http://dx.doi.org/10.1038/sj.onc.1208242			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592519				2022-12-17	WOS:000226898700008
J	Schulte, JH; Schramm, A; Klein-Hitpass, L; Klenk, M; Wessels, H; Hauffa, BP; Eils, JR; Eils, R; Brodeur, GM; Schweigerer, L; Havers, W; Eggert, A				Schulte, JH; Schramm, A; Klein-Hitpass, L; Klenk, M; Wessels, H; Hauffa, BP; Eils, JR; Eils, R; Brodeur, GM; Schweigerer, L; Havers, W; Eggert, A			Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas	ONCOGENE			English	Article						neuroblastoma; expression profiling; Trk receptors; microarrays	FACTOR BINDING-PROTEINS; GROWTH-FACTOR-II; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; CYTOTOXIC DRUGS; NERVOUS-SYSTEM; CELLS; RECEPTORS; SURVIVAL; ACTIVATION	Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.	Univ Childrens Hosp Essen, Div Oncol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Inst Cell Biol, Essen, Germany; DKFZ Heidelberg, Div Intelligent Bioinformat Syst, Heidelberg, Germany; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Childrens Hosp Gottingen, Gottingen, Germany	University of Duisburg Essen; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Gottingen	Eggert, A (corresponding author), Univ Childrens Hosp Essen, Div Oncol, Hufelandstr 55, D-45122 Essen, Germany.	angelika.eggert@uni-essen.de	Schulte, Johannes H/G-3981-2010; Schulte, Johannes H./V-2474-2018; Eggert, Angelika/AAE-6907-2022; Schramm, Alexander/G-5688-2010; Eils, Roland/B-6121-2009	Eggert, Angelika/0000-0003-3476-8184; Schramm, Alexander/0000-0001-7670-7529; Eils, Roland/0000-0002-0034-4036; Schulte, Johannes Hubertus/0000-0003-0671-1201	NATIONAL CANCER INSTITUTE [R01CA094194] Funding Source: NIH RePORTER; NCI NIH HHS [CA-94194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDLER JL, 1973, CANCER RES, V33, P2643; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Ferrone S, 2001, RECENT RESULTS CANC, V158, P231; Ferry RJ, 1999, HORM RES, V51, P53; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; FUJIWARA Y, 1990, JPN J CANCER RES, V81, P527, DOI 10.1111/j.1349-7006.1990.tb02602.x; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Ho R, 2002, CANCER RES, V62, P6462; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jaboin J, 2002, CANCER RES, V62, P6756; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MATSUMOTO K, 1995, CANCER RES, V55, P1798; McGregor LM, 1999, P NATL ACAD SCI USA, V96, P4540, DOI 10.1073/pnas.96.8.4540; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Middlemas DS, 1999, J BIOL CHEM, V274, P16451, DOI 10.1074/jbc.274.23.16451; Middlemas DS, 1999, J NEURO-ONCOL, V45, P27, DOI 10.1023/A:1006342423175; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Orike N, 2001, J NEUROBIOL, V47, P295, DOI 10.1002/neu.1036; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Scala S, 1996, CANCER RES, V56, P3737; Singleton JR, 1996, CANCER RES, V56, P4522; Smith AJ, 2000, J BIOL CHEM, V275, P23530, DOI 10.1074/jbc.M909002199; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teitler Milt, 2002, Current Topics in Medicinal Chemistry, V2, P529, DOI 10.2174/1568026023393859; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552	46	59	69	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					165	177		10.1038/sj.onc.1208000	http://dx.doi.org/10.1038/sj.onc.1208000			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637590				2022-12-17	WOS:000226125800019
J	Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT				Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT			Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling	ONCOGENE			English	Article						medulloblastoma; suppressor of fused; SUFU; brain tumor; WNT signaling; cerebellum	ADENOMATOUS POLYPOSIS-COLI; RUBINSTEIN-TAYBI SYNDROME; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; CUBITUS INTERRUPTUS; GENE-EXPRESSION; SONIC HEDGEHOG; SPORADIC MEDULLOBLASTOMAS; PATHWAY COMPONENTS; NEGATIVE REGULATOR	Germline mutations of APC in patients with Turcot syndrome (colon cancer and medulloblastoma), was well as somatic mutations of APC, beta-catenin, and Axin in sporadic medulloblastomas (MBs) have shown the importance of WNT signaling in the pathogenesis of MB. A subset of children with MB have germline mutations of SUFU, a known inhibitor of Hedgehog signal transduction. A recent report suggested that murine Sufu can bind beta-catenin, export it from the nucleus, and thereby repress beta-catenin/T-cell factor (Tcf)-mediated transcription. We show that an MB-derived mutant of SUFU has lost the ability to decrease nuclear levels of beta-catenin, and cannot inhibit beta-catenin/Tcf-mediated transcription as compared to wild type SUFU. Our results suggest that loss of function of SUFU results in overactivity of both the Sonic Hedgehog, and the WNT signaling pathways, leading to excessive proliferation and failure to differentiate resulting in MB.	Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Div Med & Mol Genet, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Queensland, Ritchie Res Labs, St Lucia, Qld 4072, Australia	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Queensland	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Suite 1504,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999; Taylor, Michael/0000-0001-7009-3466; Wainwright, Brandon/0000-0003-0406-2092				Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; Dahmen RP, 2001, CANCER RES, V61, P7039; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; EVANS G, 1993, MED PEDIATR ONCOL, V21, P433, DOI 10.1002/mpo.2950210608; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Iwao K, 1998, CANCER RES, V58, P1021; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kitas G, 2001, CLIN MED, V1, P18, DOI 10.7861/clinmedicine.1-1-18; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee CS, 2000, DEVELOPMENT, V127, P109; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Mainprize T G, 2000, Clin Neurosurg, V47, P259; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Meng XW, 2001, J BIOL CHEM, V276, P40113, DOI 10.1074/jbc.M105317200; Methot N, 2000, DEVELOPMENT, V127, P4001; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Nakagawa H, 1999, JPN J CANCER RES, V90, P982, DOI 10.1111/j.1349-7006.1999.tb00845.x; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skousen GJ, 1996, AM J MED GENET, V66, P367, DOI 10.1002/(SICI)1096-8628(19961218)66:3<367::AID-AJMG27>3.3.CO;2-8; Steigerwald K, 2001, J MED GENET, V38, P257, DOI 10.1136/jmg.38.4.257; Stone DM, 1999, J CELL SCI, V112, P4437; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Taylor MD, 2001, PEDIATR NEUROSURG, V35, P235, DOI 10.1159/000050428; Taylor MD, 1999, J NEUROSURG, V90, P946, DOI 10.3171/jns.1999.90.5.0946; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vortmeyer AO, 1999, CANCER, V85, P2662, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2662::AID-CNCR24>3.0.CO;2-0; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wechsler-Reya RJ, 2003, RECENT PROG HORM RES, V58, P227, DOI 10.1210/rp.58.1.227; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; YONG WH, 1995, NEW ENGL J MED, V333, P524; Zurawel RH, 1998, CANCER RES, V58, P896	53	59	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4577	4583		10.1038/sj.onc.1207605	http://dx.doi.org/10.1038/sj.onc.1207605			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077159				2022-12-17	WOS:000221799000007
J	D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL				D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL			Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint	ONCOGENE			English	Article						centrioles; cyclin; genomic instability; p53; retinoblastoma	GENOMIC INSTABILITY; S-PHASE; MUTANT P53; DNA-PLOIDY; EXPRESSION; KINASE; REPLICATION; DUPLICATION; INDUCTION; STABILITY	Centrosome amplification plays a key role in the origin of chromosomal instability during cancer development and progression. In this study, breast cancer cell lines with different p53 backgrounds were used to investigate the relationship between genotoxic stress, G(1)/S cell cycle checkpoint integrity, and the development of centrosome amplification. Introduction of DNA damage in the MCF-7 cell line by treatment with hydroxyurea (HU) or daunorubicin (DR) resulted in the arrest of both G(1)/S cell cycle progression and centriole duplication. In these cells, which carry functional p53, HU treatment also led to nuclear accumulation of p53 and p21(WAF1), retinoblastoma hypophosphorylation, and downregulation of cyclin A. MCF-7 cells carrying a recombinant dominant-negative p53 mutant (vMCF-7(DNp53)) exhibited a shortened G(1) phase of the cell cycle and retained a normal centrosome phenotype. However, these cells developed amplified centrosomes following HU treatment. The MDA-MB 231 cell line, which carries mutant p53 at both alleles, showed amplified centrosomes at the outset, and developed a hyperamplified centrosome phenotype following HU treatment. In cells carrying defective p53, the development of centrosome amplification also occurred following treatment with another DNA damaging agent, DR. Taken together, these findings demonstrate that loss of p53 function alone is not sufficient to drive centrosome amplification, but plays a critical role in this process following DNA damage through abrogation of the G(1)/S cell cycle checkpoint. Furthermore, these studies have important clinical implications because they suggest that breast cancers with compromised p53 function may develop centrosome amplification and consequent chromosomal instability following treatment with genotoxic anticancer drugs.	Mayo Clin Coll Med, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin Coll Med, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER; NCI NIH HHS [CA72836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANBAZHAGAN R, 1991, ANN ONCOL, V2, P47, DOI 10.1093/oxfordjournals.annonc.a057824; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Duensing S, 2003, CRIT REV EUKAR GENE, V13, P9, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.20; Duensing S, 2002, CANCER RES, V62, P7075; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gartel AL, 2003, ONCOL RES, V13, P405; Goepfert TM, 2002, CANCER RES, V62, P4115; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jin SK, 2001, J CELL SCI, V114, P4139; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kronenwett U, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-8; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loeb LA, 2001, CANCER RES, V61, P3230; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palazzo RE, 2003, CELL MOTIL CYTOSKEL, V54, P148, DOI 10.1002/cm.10103; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pinto AE, 2003, INT J BIOL MARKER, V18, P7, DOI 10.1177/172460080301800102; Riley RR, 2003, CANCER RES, V63, P4862; RUBIN EH, 2003, CANC MED, V6, P781; Sakano K, 2001, JPN J CANCER RES, V92, P1166, DOI 10.1111/j.1349-7006.2001.tb02136.x; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351	51	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4068	4075		10.1038/sj.onc.1207568	http://dx.doi.org/10.1038/sj.onc.1207568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064746				2022-12-17	WOS:000221520200004
J	Zhang, JM; Liu, LM; Pfeifer, GP				Zhang, JM; Liu, LM; Pfeifer, GP			Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene	ONCOGENE			English	Article						TIG1; retinoic acid receptor beta; estrogen receptor; RASSF1A; DNA methylation; prostate cancer	TUMOR-SUPPRESSOR GENE; CPG ISLAND; SHORT ARM; ESTROGEN-RECEPTOR; DNA METHYLATION; LUNG-CANCER; SMALL-CELL; HYPERMETHYLATION; EXPRESSION; PROMOTER	Methylation of CpG islands and associated gene silencing may lead to malignant progression, but the mechanisms of CpG island methylation in cancer are unknown. The tazarotene- induced gene 1 ( TIG1), also known as retinoid acid ( RA) receptor- responsive 1 gene was first identified as an RA- responsive gene and was shown to be downregulated in prostate cancer. Here, we show that this downregulation is caused by the methylation of the promoter and CpG island of TIG1. TIG1 was methylated in 26 of 50 ( 52%) primary prostate cancers, but was not methylated in normal tissues or benign hyperplasias. Three of four tumors that metastasized, five of six that were poorly differentiated and all that were assigned a Gleason score higher than 8 ( 7/ 7) were methylated in the promoter of TIG1. The samples with peripheral invasion were more frequently methylated ( 21/ 32, 66%) than tissues without peripheral invasion ( 5/ 18, 28%). In addition, Gleason 7 - 10 cancers ( 21/ 30, 70%) were significantly more frequently methylated compared with Gleason 4 - 6 cancers ( 4/ 18, 22%) ( P < 0.01). The retinoic acid receptor beta ( RAR- beta) gene was frequently methylated as well ( 42/ 50, 84%). When TIG1 showed methylation, RAR- beta was also methylated ( 25/ 26 samples). In almost all samples where RAR- beta was not methylated, TIG1 was also in an unmethylated state ( 14/ 15 samples). The methylation of TIG1 and RAR- beta was positively correlated ( r = 0.35; P = 0.017). It is possible that the methylation of the retinoid response gene TIG1 occurred in response to the methylation and inactivation of RAR- beta. These observations may contribute to our understanding of mechanistic events leading to CpG island methylation in cancer.	City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org			NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DE LUCA LM, 1991, FASEB J, V5, P2924; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2002, CANCER RES, V62, P5902; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; HOWELL JM, 1967, BRIT J NUTR, V21, P373, DOI 10.1079/BJN19670038; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Lau KM, 2000, CANCER RES, V60, P3175; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li LC, 2000, CANCER RES, V60, P702; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lotan R, 2002, J NATL CANCER I, V94, P469; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nelson JB, 1997, CANCER RES, V57, P35; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Ozen M, 2000, ANTICANCER RES, V20, P1905; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; PIENTA KJ, 1993, CANCER RES, V53, P224; POLLARD M, 1991, CANCER RES, V51, P3610; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; STEARNS ME, 1993, CANCER RES, V53, P3073; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; Wei MH, 1996, CANCER RES, V56, P1487; WOLBACH SB, 1978, NUTR REV, V36, P16	50	59	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2241	2249		10.1038/sj.onc.1207328	http://dx.doi.org/10.1038/sj.onc.1207328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14691453				2022-12-17	WOS:000220280900015
J	McMullen, M; Keller, R; Sussman, M; Pumiglia, K				McMullen, M; Keller, R; Sussman, M; Pumiglia, K			Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2	ONCOGENE			English	Article						p38; VEGF; migration; RAFTK/Pyk2; Src	FOCAL ADHESION KINASE; PROTEIN-KINASE; TYROSINE KINASE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; CELL-MIGRATION; NITRIC-OXIDE; VEGF; ANGIOGENESIS; CALCIUM	Vascular endothelial growth factor ( VEGF) induces activation of p38 mitogen-activated protein kinase ( MAPK) in primary endothelial cells and may be critical for VEGF-induced angiogenesis. We investigated the molecular basis for p38 activation in response to VEGF. The expression of a C-terminal splice variant of FAK, FRNK, had no affect on VEGF-induced activation of p38; however, expression of a dominant-negative RAFTK/ Pyk2 mutant led to a decrease in the activation of p38, but had no affect on extracellular signal-regulated kinase (ERK). Since calcium regulates RAFTK/ Pyk2, we investigated its role in p38 activity. Preincubation with EGTA suppressed p38 activation, while calcium ionophore induced p38 activity. Inhibition of phospholipase C ( PLC) resulted in complete inhibition of ERK, while having no affect on p38 activity. These data suggested a bifurcation in the regulation of MAPKs that occurs at the level of PLC and RAFTK/ Pyk2 activation. Src family kinases interact with RAFTK/ Pyk2. Inhibition of Src by either pharmacological or genetic means decreased p38 activity. Finally, we found that both Src and RAFTK/ Pyk2 were essential for endothelial cell migration. These data identified a novel regulatory network involving extracellular calcium, RAFTK/ Pyk2, Src and p38. This signaling network appears to be critical for VEGF-induced endothelial cell migration.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Cincinnati Childrens Hosp, Div Cardiol, Cincinnati, OH USA	Albany Medical College; Albany Medical College; Cincinnati Children's Hospital Medical Center	Pumiglia, K (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu	; Sussman, Mark/H-2284-2014	Pumiglia, Kevin/0000-0003-4655-0334; Sussman, Mark/0000-0002-0104-4799	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blanquet PR, 2003, NEUROSCIENCE, V118, P477, DOI 10.1016/S0306-4522(02)00963-6; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Faehling M, 2002, FASEB J, V16, P1805, DOI 10.1096/fj.01-0938fje; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garnier-Raveaud S, 2001, GROWTH FACTORS, V19, P35, DOI 10.3109/08977190109001074; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Huser J, 1997, AM J PHYSIOL-CELL PH, V273, pC1775, DOI 10.1152/ajpcell.1997.273.5.C1775; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ishii Y, 2001, LEUKEMIA RES, V25, P813, DOI 10.1016/S0145-2126(01)00026-1; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lian JP, 1999, J IMMUNOL, V163, P4527; Lin Q, 1998, DEVELOPMENT, V125, P4565; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; McShan GD, 2002, INT J ONCOL, V21, P197; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Pocock TM, 2000, AM J PHYSIOL-HEART C, V279, pH1625, DOI 10.1152/ajpheart.2000.279.4.H1625; Pocock TM, 2001, J PHYSIOL-LONDON, V534, P479, DOI 10.1111/j.1469-7793.2001.00479.x; Rikitake Y, 2001, AM J PHYSIOL-HEART C, V281, pH266, DOI 10.1152/ajpheart.2001.281.1.H266; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sarkar S, 2002, LEUKEMIA LYMPHOMA, V43, P1663, DOI 10.1080/1042819021000003009; Seymour LW, 1996, LAB INVEST, V75, P427; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Suarez S, 2001, J CELL SCI, V114, P1229; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Zahalka MA, 2003, FASEB J, V17, P955, DOI 10.1096/fj.02-0960fje; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	59	59	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1275	1282		10.1038/sj.onc.1207243	http://dx.doi.org/10.1038/sj.onc.1207243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676843				2022-12-17	WOS:000188892200012
J	Jiang, K; Delarue, FL; Sebti, SM				Jiang, K; Delarue, FL; Sebti, SM			EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation	ONCOGENE			English	Article						RhoB; Ras; EGFR; ErbB2; transformation; apoptosis	EPIDERMAL-GROWTH-FACTOR; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; CELL-GROWTH; GTPASES; FAMILY; KINASE; ONCOPROTEIN; PHENOTYPE	While some low molecular weight GTPases such as Ras and RhoA contribute to malignant transformation, a closely related family member, RhoB, has tumor-suppressive activity, but little is known about its regulation by oncogenes. In this study, we show that H-Ras, N-Ras, K-Ras, EGFR and ErbB2 but not v-Src suppress RhoB promoter transcriptional activity in NIH3T3 cells and human cancer cell lines derived from lung (A-549), pancreatic (Panc-1) and cervical (C33A) tumors. The EGFR and ErbB2 suppression of RhoB promoter activity is mediated by Ras. Furthermore, Ras suppresses basal as well as 5-fluorouracil (5-FU)-induced RhoB promoter activity and RhoB protein levels. Ectopic expression of RhoB, but not the closely related family member RhoA, antagonizes the ability of EGFR, ErbB2, H-Ras, N-Ras and K-Ras but not v-Src to transform NIH3T3 cells. Furthermore, RhoB, but not RhoA, inhibits colony formation and proliferation and induces anoikis in A-549 cells and Ras-transformed NIH3T3 cells. Finally, Ras-mediated resistance to 5-FU-induced apoptosis is reversed by RhoB. These results demonstrate that RhoB expression is negatively regulated by oncogenes that are prevalent in human cancers, and that ectopic expression of RhoB antagonizes the ability of these oncogenes to induce transformation. Taken together the data suggest that certain oncogenes suppress RhoB as one of the critical steps leading to malignant transformation.	Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Sebti@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, MOL CELL BIOL, V19, P1831; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VAN AL, 1997, GENE DEV, V11, P2295; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	25	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1136	1145		10.1038/sj.onc.1207236	http://dx.doi.org/10.1038/sj.onc.1207236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647415				2022-12-17	WOS:000188749900012
J	Gan, DD; Khalili, K				Gan, DD; Khalili, K			Interaction between JCV large T-antigen and beta-catenin	ONCOGENE			English	Article						human polyomavirus; T-antigen; Wnt pathway; beta-catenin; medulloblastoma	BRAIN-TUMORS; VIRUS; IDENTIFICATION; MUTATION; PROTEIN; TARGET; GENE	Expression of the JCV early protein T-antigen in transgenic mice leads to the development of cerebellar primitive neuroectodermal tumors (PNETs). In light of earlier reports on the association of JCV with PNETs in humans and the involvement of the Wnt signaling pathway in the development of cerebellar tumors, we investigated the interplay between T-antigen and beta-catenin, the key protein of the Wnt pathway. Our results demonstrate the physical interaction of T-antigen with beta-catenin through the central domain of T-antigen spanning residues 82-628, and the C-terminus of beta-catenin located between amino acids 695 and 781. The association of T-antigen with beta-catenin elevates the level of beta-catenin in the cells due to increased in the stability of the protein. In the presence of T-antigen, beta-catenin was found in the nuclei of cells, suggesting that the interaction of beta-catenin with T-antigen facilitates its nuclear import. In cells expressing mutant T-antigen with no nuclear localization domain, beta-catenin was found in the cytoplasm. Coexpression of T-antigen with beta-catenin increased the transcription of the c-myc promoter, a known downstream target of beta-catenin, and artificial promoter whose activity is beta-catenin dependent. These observations ascribe a new oncogenic pathway for T-antigen, and offer an alternative mechanism for the deregulation of the Wnt pathway through stabilization of beta-catenin upon its association with the viral oncoprotein.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu						AGOSTINI HT, 2001, HUMAN POLYOMAVIRUSES, P491; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Berger JR, 1999, SEMIN NEUROL, V19, P193, DOI 10.1055/s-2008-1040837; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; RAJ GV, 1995, INT J ONCOL, V7, P801; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Walker D L, 1983, Prog Clin Biol Res, V105, P99; Weiner HL, 2002, CANCER RES, V62, P6385; Xu LF, 2000, GENE DEV, V14, P585	27	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					483	490		10.1038/sj.onc.1207018	http://dx.doi.org/10.1038/sj.onc.1207018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724577				2022-12-17	WOS:000188098300019
J	Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI				Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI			Characterization of the common fragile site FRA9E and its potential role in ovarian cancer	ONCOGENE			English	Article						common fragile sites; FRA9E; chromosomal deletions; ovarian cancer; PAPPA	PLASMA PROTEIN-A; MOLECULAR CHARACTERIZATION; REPEAT EXPANSION; INTEGRATION SITE; BREAST-CANCER; BROAD REGION; X-SYNDROME; PREGNANCY; CELLS; GENE	Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial cultures and ovarian cancer cell tines identified pregnancy-associated plasma protein-A (PAPPA) because of its frequent loss of expression (LOE) in ovarian cancer cell lines. PAPPA is localized to human chromosome 9q32-33.1, a region associated with significant loss of heterozygosity (LOH) in ovarian tumors (> 50%) and in close proximity to the FRA9E CFS. FISH analysis determined that PAPPA was contained within the distal end of FRA9E. Characterization of FRA9E determined that aphidicolin-induced instability extended over 9 Mb, identifying FRA9E as the largest CFS characterized to date. Comprehensive LOH analysis revealed several distinct peaks of LOH within FRA9E. Semiquantitative RT-PCR analysis of 16 genes contained within FRA9E indicated that genes showing LOE in ovarian tumors coincided with regions of high LOH. PAPPA displayed the most significant loss (72%). This study provides evidence to suggest that instability within FRA9E may play an important role in the development of ovarian cancer and lends further support for the hypothesis that CFSs may be causally related to cancer.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.		Seal, Sudipta/A-7698-2012; Lomberk, Gwen/AAL-8490-2020	Lomberk, Gwen/0000-0001-5463-789X	NATIONAL CANCER INSTITUTE [T32CA075926, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA 75926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BECKER NA, 2002, IN PRESS ONCOGENE; Bednarek AK, 2000, CANCER RES, V60, P2140; Chen BK, 2002, ENDOCRINOLOGY, V143, P1199, DOI 10.1210/en.143.4.1199; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Denison SR, 2002, GENE CHROMOSOME CANC, V34, P406, DOI 10.1002/gcc.10084; DURHAM SK, 1995, ENDOCRINOLOGY, V136, P1374, DOI 10.1210/en.136.4.1374; GABRA H, 1997, BIOL FEMALE CANC, P93; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HAMILTON TC, 1984, SEMIN ONCOL, V11, P285; Hewett DR, 1998, MOL CELL, V1, P773, DOI 10.1016/S1097-2765(00)80077-5; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KRUK PA, 1990, LAB INVEST, V63, P132; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SILAHTAROGLU AN, 1993, CYTOGENET CELL GENET, V62, P214, DOI 10.1159/000133479; Smith DI, 1998, INT J ONCOL, V12, P187; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Stabile I, 1988, Obstet Gynecol Surv, V43, P73; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Verma R.S., 1989, HUMAN CHROMOSOMES MA, P240; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	46	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					590	601		10.1038/sj.onc.1206171	http://dx.doi.org/10.1038/sj.onc.1206171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555072				2022-12-17	WOS:000180538200012
J	Ego, T; Ariumi, Y; Shimotohno, K				Ego, T; Ariumi, Y; Shimotohno, K			The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression	ONCOGENE			English	Article						HTLV-1; Tax; HDAC; HAT; CBP	NF-KAPPA-B; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; DNA METHYLATION; PROTEIN; CREB; ACETYLATION; REPRESSOR; COMPLEX; FAMILY	Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to interact with several transcription factors and regulate their transcriptional activities. The human T-cell leukemia virus type I (HTLV1) Tax oncoprotein activates transcription from its long terminal repeat (LTR) through interaction with cellular factors such as CREB and a transcriptional coactivator CBP/p300. However, little is known about the interaction between Tax and transcriptional repressors. Here, we demonstrate the physical and functional interaction between Tax and HDAC1. We found that HDAC1 represses the trans-activation function of Tax in 293T and MT4 cells. However, this repression was restored by treatment with an HDAC inhibitor, Trichostatin A. We also observed physical interaction between Tax and HDAC1 both in vitro and in vivo. The N-terminal region of HDAC I (amino acid residues 28-97) was required for this binding. Moreover, HDAC1 inhibited the synergistic trans-activation of Tax observed on ectopic expression of CBP. However, this repression was relieved by overexpression of CBP. Thus, HDAC1 is likely to compete with CBP in binding with Tax and functions as a negative regulator for the transcriptional activation by Tax.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SAGGIORO D, 1991, VIROLOGY, V182, P68, DOI 10.1016/0042-6822(91)90649-V; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	30	59	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7241	7246		10.1038/sj.onc.1205701	http://dx.doi.org/10.1038/sj.onc.1205701			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370815				2022-12-17	WOS:000178504600013
J	Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G				Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G			Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells	ONCOGENE			English	Article						HER2/neu; ATRA; Grb2; Akt	GROWTH-FACTOR RECEPTOR; TUMOR NECROSIS FACTOR; GRB2 DOWN-REGULATION; PROTEIN-KINASE-B; MCF-7 CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ALPHA GENE; RAR-ALPHA; INHIBITION	We observed that all-trans retinoic acid (ATRA) inhibited the growth of MCF-7 breast cancer cells, but not those transfected with HER2/NEU or its transactivating ligand HEREGULIN. This suggests that Her2/neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. To confirm this observation, MDA-MB-453 and BT-474 cells, which have high levels of Her2/neu and are resistant to ATRA, were incubated with the trastuzumab (Herceptin(TM)) antibody so that we could determine whether inhibition of the expression and function of Her2/neu would resensitize these cells to ATRA. Indeed, we found that MDA-MB-453 and BT-474 cells treated with trastuzumab were growth inhibitory by ATRA. We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Liposome-incorporated Grb2 antisense oligonucleotides (L-Grb2) and a dominant negative (DN) AKT mutant were used to down-regulate Grb2 expression and inhibit Akt activity, respectively. When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. ATRA sensitivity was also correlated with RARalpha protein levels since higher RARalpha protein levels were observed in cells in which the Her2/neu pathway was inhibited.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, 1515 Holcombe Blvd,Box 422, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Esteva, Francisco J./0000-0003-2437-3920	NCI NIH HHS [K23-CA82119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K23CA082119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baselga J, 1998, CANCER RES, V58, P2825; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carter CA, 2000, EXP MOL PATHOL, V68, P170, DOI 10.1006/exmp.2000.2301; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; De Luca LM, 1997, J CELL PHYSIOL, V173, P297, DOI 10.1002/(SICI)1097-4652(199711)173:2<297::AID-JCP39>3.0.CO;2-A; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FRAKER LD, 1984, CANCER RES, V44, P5757; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; Lenferink AEG, 2001, CANCER RES, V61, P6583; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; LOTAN R, 1979, CANCER RES, V39, P1014; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Mangelsdorf David J., 1994, P319; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; Muller A, 1997, CANCER LETT, V113, P95, DOI 10.1016/S0304-3835(97)04601-6; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rishi AK, 1996, CANCER RES, V56, P5246; ROULIER S, 1994, MOL CELL ENDOCRINOL, V105, P165, DOI 10.1016/0303-7207(94)90166-X; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; SANG H, 1995, J NEUROSURG, V82, P841; Schneider SM, 2000, CANCER RES, V60, P5479; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tang CK, 1996, CANCER RES, V56, P3350; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang LM, 1997, CANCER RES, V57, P4652; YU DH, 1992, ONCOGENE, V7, P2263; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LF, 2002, LAB INVEST, V82, P71, DOI 10.1038/labinvest.3780396; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	59	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5224	5232		10.1038/sj.onc.1205660	http://dx.doi.org/10.1038/sj.onc.1205660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149644				2022-12-17	WOS:000177193900004
J	Alcalay, M; Orleth, A; Sebastiani, C; Meani, N; Chiaradonna, F; Casciari, C; Sciurpi, MT; Gelmetti, V; Riganelli, D; Minucci, S; Fagioli, M; Pelicci, PG				Alcalay, M; Orleth, A; Sebastiani, C; Meani, N; Chiaradonna, F; Casciari, C; Sciurpi, MT; Gelmetti, V; Riganelli, D; Minucci, S; Fagioli, M; Pelicci, PG			Common themes in the pathogenesis of acute myeloid leukemia	ONCOGENE			English	Review						acute myeloid leukemia; fusion proteins; transcription factors; differentiation; cell survival	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PLZF-RAR-ALPHA; ZINC-FINGER PROTEIN; MYOSIN HEAVY-CHAIN; CBF-BETA-SMMHC; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; HISTONE DEACETYLASE COMPLEX; FETAL LIVER HEMATOPOIESIS; INHIBITS CELL-GROWTH	The pathogenesis of acute myeloid leukemia is associated with the appearance of oncogenic fusion proteins generated as a consequence of specific chromosome translocations. Of the two components of each fusion protein, one is generally a transcription factor, whereas the other partner is mo re variable in function, but often involved in the control of cell survival and apoptosis. As a consequence, AML-associated fusion proteins function as aberrant transcriptional regulators that interfere with the process of myeloid differentiation, determine a stage-specific arrest of maturation and enhance cell survival in a cell-type specific manner. The abnormal regulation of transcriptional networks occurs through common mechanisms that include recruitment of aberrant corepressor complexes, alterations in chromatin remodeling, and disruption of specific subnuclear compartments. The identification and analysis of common and specific target genes regulated by AML fusion proteins will be of fundamental importance for the full understanding of acute myeloid leukemogenesis and for the implementation of disease-specific drug design.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, I-06100 Perugia, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia	Alcalay, M (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Sebastiani, Carla/AAB-9817-2022; Alcalay, Myriam/B-3182-2016; CHIARADONNA, Ferdinando/K-4959-2016; Alcalay, Myriam/AAB-4300-2019; Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Sebastiani, Carla/0000-0003-3927-3279; Alcalay, Myriam/0000-0002-5558-4272; CHIARADONNA, Ferdinando/0000-0001-8529-2732; Alcalay, Myriam/0000-0002-5558-4272; CASCIARI, CRISTINA/0000-0002-9170-370X				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Akao Y, 1998, CANCER RES, V58, P3773; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Bradbury DA, 1997, LEUKEMIA LYMPHOMA, V24, P221, DOI 10.3109/10428199709039010; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CALIGIURI MA, 1994, CANCER RES, V54, P370; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; CHOMIENNE C, 1990, BLOOD, V76, P1710; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEGOS L, 1992, BIOMED PHARMACOTHER, V46, P201, DOI 10.1016/0753-3322(92)90083-J; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERA T, 1995, LEUKEMIA, V9, pS26; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Ferhat L, 1998, J NEUROCYTOL, V27, P887, DOI 10.1023/A:1006949006728; Ferrara FF, 2001, CANCER RES, V61, P2; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Funakoshi M, 1997, GENES CELLS, V2, P329, DOI 10.1046/j.1365-2443.1997.1230320.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Golling G, 1996, MOL CELL BIOL, V16, P932; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERVI C, 2001, CANCER RES, V61, P1247; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Johnstone RW, 2001, MOL CELL BIOL, V21, P1672, DOI 10.1128/MCB.21.5.1672-1681.2001; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kanda Y, 1998, J BIOL CHEM, V273, P5248, DOI 10.1074/jbc.273.9.5248; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; Kieslinger M, 2000, GENE DEV, V14, P232; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsushita H, 1999, BRIT J CANCER, V79, P1325, DOI 10.1038/sj.bjc.6690214; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.0.CO;2-B; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; MITELMAN F, 1994, CATALOGUE CHROMOSOME; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Puig-Kroger A, 2000, J BIOL CHEM, V275, P28507, DOI 10.1074/jbc.M004323200; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Rhoades KL, 2000, BLOOD, V96, P2108; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Rogaia D, 1997, CANCER RES, V57, P799; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; RUBNITZ JE, 1994, BLOOD, V84, P1747; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Stein GS, 2000, J CELL SCI, V113, P2527; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; YonedaKato N, 1996, ONCOGENE, V12, P265; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang HT, 2000, CHEM J CHINESE U, V21, P156; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	180	59	60	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5680	5694		10.1038/sj.onc.1204642	http://dx.doi.org/10.1038/sj.onc.1204642			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607818				2022-12-17	WOS:000170887500009
J	Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M				Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M			Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells	ONCOGENE			English	Article						liver cancer; p73; retinoblastoma; P16(INK4a); p14(ARF); cyclin E	P53 HOMOLOG P73; KINASE C-ABL; APOPTOTIC RESPONSE; DNA-DAMAGE; FAMILY; GENE; RETINOBLASTOMA; LINES; PROTEINS; MUTATION	p53 and p73 proteins activate similar target genes and induce apoptosis and cell cycle arrest. However, p53, but not p73 is considered a tumour-suppressor gene. Unlike p53, p73 deficiency in mice does not lead to a cancer-prone phenotype, and p73 gene is not mutated in human cancers, including hepatocellular carcinoma. Here we report that normal liver cells express only DeltaN-p73 transcript forms giving rise to the synthesis of N-terminally truncated, transcriptionally inactive and dominant negative p73 proteins. In contrast, most hepatocellular carcinoma cells express TA-p73 transcript forms encoding full-length and transcriptionally active p73 proteins, in addition to DeltaN-p73. We also show that together with the acquired expression of TA-p73, the 'retinoblastoma pathway' is inactivated, and E2F1-target genes including cyclin E and p14(ARF) are activated in hepatocellular carcinoma. However, there was no full correlation between 'retinoblastoma pathway' inactivation and TA-p73 expression. Most TA-p73-expressing hepatocellular carcinoma cells have also lost p53 function either by lack of expression or missense mutations. The p73 gene, encoding only DeltaN-p73 protein, may function as a tumour promoter rather than a tumour suppressor in liver tissue. This may be one reason why p73 is not a mutation target in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey	Ihsan Dogramaci Bilkent University	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021; Findikli, Necati/I-4924-2018; SAYAN, A. EMRE/H-7330-2012	OZTURK, MEHMET/0000-0002-6092-9706; Findikli, Necati/0000-0001-9362-5912; SAYAN, A. EMRE/0000-0002-5291-1485				Agami R, 1999, NATURE, V399, P809; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; BOUZAHZAH B, 1995, J CELL PHYSIOL, V165, P459, DOI 10.1002/jcp.1041650303; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; Morel AP, 2000, J HEPATOL, V33, P254, DOI 10.1016/S0168-8278(00)80366-9; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 1999, BRIT J CANCER, V80, P1069, DOI 10.1038/sj.bjc.6690465; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yolcu E, 2001, ONCOGENE, V20, P1398, DOI 10.1038/sj.onc.1204240; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257	33	59	60	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5111	5117		10.1038/sj.onc.1204669	http://dx.doi.org/10.1038/sj.onc.1204669			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526499	Green Submitted, Green Published			2022-12-17	WOS:000170464000004
J	Lu, Y; Jamieson, L; Brasier, AR; Fields, AP				Lu, Y; Jamieson, L; Brasier, AR; Fields, AP			NF-kappa B/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival	ONCOGENE			English	Article						protein kinase C iota; apoptosis; taxol; nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; MYELOGENOUS LEUKEMIA-CELLS; DRUG-INDUCED APOPTOSIS; ABL TYROSINE KINASE; FACTOR-ALPHA; TRANSCRIPTION FACTOR; B ACTIVATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INTERLEUKIN-8 GENE	In chronic myelogenous leukemia (CML), the oncogene bcr-abl encodes a dysregulated tyrosine kinase that inhibits apoptosis. We showed previously that human erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through the atypical protein kinase C iota isozyme (PKC iota), a kinase downstream of Bcr-Abl. The mechanism(s) by which PKC iota mediates cell survival to taxol is unknown. Here we demonstrate that PKC iota requires the transcription factor nuclear factor-kappaB (NF-kappaB) to confer cell survival. At apoptosis-inducing concentrations, taxol weakly induces I kappaB alpha proteolysis and NF-kappaB translocation in K562 cells, but potently induces its transcriptional activity. Inhibition of NF-kappaB activity (by blocking l kappaB alpha degradation) significantly sensitizes cells to taxol-induced apoptosis. Likewise, K562 cells expressing antisense PKC iota mRNA or kinase dead PKC iota (PKC iota -KD) are sensitized to taxol; these cells are rescued from apoptosis by NF-kappaB overexpression. Expression of constitutively active PKC iota (PKC iota -CA) upregulates NF-kappaB transactivation and rescues cells from apoptosis in the absence of Bcr-Abl tyrosine kinase activity. Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription. This activation was further upregulated by expression of PKC iota -CA and inhibited by expression of PKC iota -KD. Our results indicate that RelA transactivation is an important downstream target of the PKC iota -mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.			Brasier, Allan/0000-0002-5012-4090	NCI NIH HHS [CA56869] Funding Source: Medline; NIAID NIH HHS [AI40218] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ANAFI M, 1993, BLOOD, V82, P3524; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blobe GC, 1996, CANCER SURV, V27, P213; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Granville DJ, 1998, LAB INVEST, V78, P893; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kaur G, 1996, ANTI-CANCER DRUG, V7, P815, DOI 10.1097/00001813-199611000-00001; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Samali A, 1997, Adv Pharmacol, V41, P533, DOI 10.1016/S1054-3589(08)61071-6; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WANG D, 2000, J BIOL CHEM; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	61	59	66	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4777	4792		10.1038/sj.onc.1204607	http://dx.doi.org/10.1038/sj.onc.1204607			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521190				2022-12-17	WOS:000170271800003
J	Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ				Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ			HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutL alpha and hMLH1-hEXO1 complexes	ONCOGENE			English	Article						hEXO1; hMLH1; hPMS2; DNA mismatch repair; HNPCC	NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; MEIOTIC CROSSING-OVER; HUMAN MUTL HOMOLOGS; MITOTIC RECOMBINATION; MLH1 MUTATIONS; EXONUCLEASE-I; TUMOR-CELLS; IDENTIFICATION; HETERODIMER	Hereditary nonpolyposis colorectal cancer (HNPCC) is common inherited form of neoplasia caused by germline mutations in DNA mismatch repair (MMR) genes, MMR proteins have been reported to associate with several proteins, including the human exonuclease 1 (hEXO1). We report here novel HNPCC-hMLH1 mutant proteins (T117M, Q426X and 1813insA) in Danish HNPCC patients, We demonstrate that these mutant HNPCC-hMLH1 proteins are unable to form complexes with hEXO1 and hPMS2 in vivo. The results indicate that mutations found in HNPCC gene carriers disrupt hMLH1 - hEXO1 complex formation and hMutL alpha heterodimer assembly essential for MMR activity.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Roskilde University; Rigshospitalet; University of Copenhagen; Johns Hopkins University; Johns Hopkins Medicine	Rasmussen, LJ (corresponding author), Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.		Nielsen, Finn Cilius/AAA-4926-2020	Nielsen, Finn Cilius/0000-0002-9829-1031; Rasmussen, Lene Juel/0000-0001-6864-963X	PHS HHS [R01 09714-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Nicholson A, 2000, GENETICS, V154, P133; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Risinger JI, 1998, CANCER RES, V58, P2978; Saparbaev M, 1996, GENETICS, V142, P727; Schmutte C, 1998, CANCER RES, V58, P4537; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762	30	59	63	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3590	3595		10.1038/sj.onc.1204467	http://dx.doi.org/10.1038/sj.onc.1204467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429708				2022-12-17	WOS:000169478300017
J	Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R				Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R			Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27	ONCOGENE			English	Article						ovarian carcinoma; senescence; chromosome 6q27; Class II tumor suppressor gene; ribonuclease	NON-HODGKIN-LYMPHOMA; 2 DISTINCT REGIONS; CANCER CELL-LINES; SELF-INCOMPATIBILITY; NICOTIANA-ALATA; LONG ARM; BREAST CARCINOMAS; ALLELIC IMBALANCE; EPITHELIAL-CELLS; FREQUENT LOSS	Cytogenetic, molecular and functional analysis has shown that chromosome region 6q27 harbors a senescence inducing gene and a tumor suppressor gene involved in several solid and hematologic malignancies. We have cloned at 6q27 and characterized the RNASE6PL gene which belongs to a family of cytoplasmic RNases highly conserved from plants, to man. Analysis of 55 primary ovarian tumors and several ovarian tumor cell lines indicated that the RNASE6PL gene is not mutated in tumor tissues, but its expression is significantly reduced in 30% of primary ovarian tumors and: in 75% of ovarian tumor cell lines. The promoter region of the gene was unaffected in tumors cell lines. Transfection of RNASE6PL cDNA into HEY4 and SG10G ovarian tumor cell lines suppressed tumorigenicity in nude mice. When tumors were induced by RNASE6PL-transfected cells, they completely lacked expression of RNASE6PL cDNA. Tumorigenicity was suppressed also in RNASE6PL-transfected pRPcT1/ H6c12T cells, derived from a human/mouse monochromosomic hybrid carrying a human chromosome 6 deleted at 6q27. Moreover, 63.6% of HEY4 clones and 42.8% of the clones of XP12ROSV, a Xeroderma pigmentosum SV40-immortalized cell line, transfected with RNASE6PL cDNA, developed a marked senescence process during in vitro growth. We therefore propose that RNASE6PL may be a candidate for the 6q27 senescence inducing and class II tumor suppressor gene in ovarian cancer.	Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Ancona, Ist Sci Biomed, I-60131 Ancona, Italy; Osped Circolo, Lab Anat Patol, Varese, Italy; Ist Nazl Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	University of Insubria; University of Ferrara; University of Genoa; IRCCS AOU San Martino IST; Marche Polytechnic University; Ospedale Circolo & Fondazione Macchi; Fondazione IRCCS Istituto Nazionale Tumori Milan; Mayo Clinic	Taramelli, R (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy.		Negrini, Massimo/J-2377-2016; smith, jeremy c/B-7287-2012; Varesco, Liliana/AAF-6521-2019; Daidone, Maria Grazia/E-9232-2017	Negrini, Massimo/0000-0002-0007-1920; smith, jeremy c/0000-0002-2978-3227; Varesco, Liliana/0000-0003-4871-6668; Daidone, Maria Grazia/0000-0002-4786-1321; Gismondi, Viviana/0000-0002-1115-0325				Abdollahi A, 1997, CANCER RES, V57, P2029; ACQUATI F, 2000, IN PRESS METH MOL BI; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; ARDELT W, 1991, J BIOL CHEM, V266, P245; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bruening W, 1999, CANCER RES, V59, P4973; BUICK RN, 1985, CANCER RES, V45, P3668; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COOKE I, 1996, GENE CHROMOSOME CANC, V15, P13; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVELLE P, 1991, ONCOGENE, V6, P1705; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Garzetti G. G., 1992, European Journal of Gynaecological Oncology, V13, P514; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HAYASHI Y, 1990, BLOOD, V76, P1626; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; Honchel R, 1996, CANCER RES, V56, P145; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lin HC, 1999, CANCER RES, V59, P807; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MEADOR J, 1990, GENE, V95, P1, DOI 10.1016/0378-1119(90)90406-H; MILLIKIN D, 1991, CANCER RES, V51, P5449; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; MORITA R, 1991, CANCER RES, V51, P5817; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; SIMON L, 1981, CARCINOGENESIS, V2, P567, DOI 10.1093/carcin/2.6.567; Smith MR, 1999, EXP CELL RES, V247, P220, DOI 10.1006/excr.1998.4317; Tahara H, 1996, CANCER RES, V56, P599; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214	55	59	65	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					980	988		10.1038/sj.onc.1204178	http://dx.doi.org/10.1038/sj.onc.1204178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314033				2022-12-17	WOS:000167097000009
J	Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T				Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T			Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer	ONCOGENE			English	Article						bladder cancer; methylation; DBCCR1; chromosome 9q	DNA METHYLATION; HOMOZYGOUS DELETION; CELL CARCINOMA; CPG ISLANDS; GENE; INACTIVATION; LOCUS	Transcriptional silencing by CpG island hypermethylation of gene regulatory regions is one mechanism for inactivation of tumour suppressor genes. Chromosome 9q deletion is frequently found in transitional cell carcinoma (TCC) of the bladder and upper urinary tract and one of the putative tumour suppressor loci has been mapped to 9q32-33, A gene designated as DBCCR1 was identified in the candidate region and its mRNA expression is thought to be suppressed by hypermethylation, To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. Aberrant hypermethylation levels mere found in 36 (52%) of 69 tumours without any association with tumour grade or stage. Methylation was weakly detected in the normal urothelium in association with ageing. Although recurrent tumours tended to have higher methylation levels than the initial tumours, the methylation pattern was mostly maintained between multifocal TCCs in individual patients. The results suggest that hypermethylation of the DBCCR1 region is one of the earliest alterations in the development of TCCs and there may be an age-related hypermethylation-based field defect in normal urothelium. Methylator or methylation-resistant phenotype seems to be maintained during multifocal development or recurrence of most TCCs.	Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan; St Jamess Univ Hosp, ICRF, Canc Med Unit, Leeds, W Yorkshire, England	Akita University; Kyoto University; Saint James's University Hospital; University of Leeds	Kato, T (corresponding author), Akita Univ, Sch Med, Dept Urol, 1-1-1 Hondo, Akita 0108543, Japan.		Tsuchiya, Norihiko/H-6538-2019; Wang, Lizhong/J-4268-2019	Wang, Lizhong/0000-0003-1980-4730; Knowles, Margaret/0000-0002-9363-8657				Ahuja N, 1998, CANCER RES, V58, P5489; CEDER H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1; Choi EK, 1996, MUTAT RES-FUND MOL M, V354, P123, DOI 10.1016/0027-5107(96)00056-5; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermanek P, 1992, TNM CLASSIFICATION M; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; KNOWLES MA, 1994, CANCER RES, V54, P531; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Maesawa C, 1996, CANCER RES, V56, P3875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSING EM, 1998, CAMPBELLS UROLOGY, P2327; Mostofi FK, 1973, HISTOLOGICAL TYPING; Muto S, 2000, CANCER RES, V60, P4021; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; SAKAI T, 1991, AM J HUM GENET, V48, P880; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Takahashi T, 1998, CANCER RES, V58, P5835; Toyota M, 1999, CANCER RES, V59, P5438; van Tilborg AAG, 1999, BRIT J CANCER, V80, P489, DOI 10.1038/sj.bjc.6690383	34	59	64	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					531	537		10.1038/sj.onc.1204122	http://dx.doi.org/10.1038/sj.onc.1204122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313984				2022-12-17	WOS:000166562500013
J	Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L				Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L			Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6	ONCOGENE			English	Article						papillomavirus E6 protein; protein kinase A; Dlg; PDZ-domain; ubiquitin; cervical cancer	PROTEASOME-MEDIATED DEGRADATION; CALCIUM-INDUCED DIFFERENTIATION; LARGE TUMOR-SUPPRESSOR; CELL-CYCLE REGULATION; P70 S6 KINASE; IN-VIVO; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; HPV-18 E6; P53	The protein Kinase A (PKA) pathway was found to selectively regulate the function of oncogenic but not non-oncogenic E6 proteins, High risk E6 proteins are phosphorylated at their D1g/PDZ binding motif at the C-terminus by a PKA like activity. This PKA and PDZ binding module is found only for human PV, is strictly conserved in all the transforming HPVs and is absent in all the low risk HPV types. We present evidence of a conditional regulation of E6 induced degradation of Dig, HPV18E6 positive but not HPV negative keratinocytes exhibit increased Dig steady state levels under conditions of high PKA activity, with a concomitant increase in the presence of Dig at tight junctions, vitro binding experiments show that E6 phosphorylation by PKA reduces its binding to Dig and molecular modelling can explain this observation in a structural context, E6 dependent degradation of Dig in cells with high PKA levels is inhibited and this is dependent on phosphorylation of the PDZ binding site in E6, In contrast, the degradation of p53 induced by E6 is not affected by PKA, We propose a differential regulation of E6 for the ubiquitin mediated degradation of specific E6 target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8010 Graz, Austria	International Center for Genetic Engineering & Biotechnology (ICGEB); Austrian Academy of Sciences	Kuhne, C (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Amenitsch, Heinz/0000-0002-0788-1336				Balda MS, 1998, J CELL SCI, V111, P541; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; deVilliers EM, 1997, INT J CANCER, V73, P356, DOI 10.1002/(SICI)1097-0215(19971104)73:3<356::AID-IJC9>3.3.CO;2-S; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fernandez A, 1995, Prog Cell Cycle Res, V1, P241; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Maki CG, 1996, CANCER RES, V56, P2649; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIM D, 1994, ONCOGENE, V9, P1869; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	59	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5884	5891		10.1038/sj.onc.1203988	http://dx.doi.org/10.1038/sj.onc.1203988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127819				2022-12-17	WOS:000165563100007
J	Sun, SY; Yue, P; Lotan, R				Sun, SY; Yue, P; Lotan, R			Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells	ONCOGENE			English	Article						retinoids; CD437; apoptosis; oncogenes; death receptors; prostate cancer	CANCER CELLS; GROWTH ARREST; IN-VIVO; ACID RECEPTORS; MELANOMA-CELLS; LEUKEMIA-CELLS; CDK INHIBITOR; P53; INDUCTION; P21(CIP1/WAF1)	The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces apoptosis in several types of cancer cell. CD437 inhibited the growth of both androgen-dependent and -independent human prostate carcinoma (HPC) cells in a concentration-dependent manner by rapid induction of apoptosis, CD437 was more effective in killing androgen-independent HPC cells such as DU145 and PC-3 than the androgen-dependent LNCaP cells. The caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK blocked apoptosis induced by CD437 in DU145 and LNCaP cells, in which increased caspase-3 activity and PARP cleavage were observed, but not in PC-3 cells, in which CD437 did not induce caspase-3 activation and PARP cleavage. Thus, CD437 can induce either caspase-dependent or caspase-independent apoptosis in HPC cells. CD437 increased the expression of c-Myc, c-Jun, c-Fos, and death receptors DR4, DR5 and Fas. CD437's potency in apoptosis induction in the different cell lines was correlated with its effects on the expression of oncogenes and death receptors, thus implicating these genes in CD437-induced apoptosis in HPC cells. However, the importance and contribution of each of these genes in different HPC cell Lines may vary. Because CD437 induced the expression of DR4, DR5 and Fas, we examined the effects of combining CD437 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas ligand, respectively, in HPC cells. We found synergistic induction of apoptosis, highlighting the importance of the modulation of these death receptors in CD437-induced apoptosis in HPC cells. This result also suggests a potential strategy of using CD437 with TRAIL for treatment of HPC.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 80, Houston, TX 77030 USA.							Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fontana JA, 2000, INT J CANCER, V86, P474, DOI 10.1002/(SICI)1097-0215(20000515)86:4<474::AID-IJC5>3.0.CO;2-Z; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HARRISS DR, 1995, BRIT J UROL, V75, P27; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; ISAACS JT, 1994, SEMIN CANCER BIOL, V5, P391; ISAACS WB, 1991, CANCER RES, V51, P4716; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu XP, 1999, INT J CANCER, V80, P272, DOI 10.1002/(SICI)1097-0215(19990118)80:2<272::AID-IJC17>3.3.CO;2-O; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Preston GA, 1996, MOL CELL BIOL, V16, P211; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Sun SY, 1999, MOL PHARMACOL, V55, P403; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1997, CANCER RES, V57, P4931; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	55	59	62	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4513	4522		10.1038/sj.onc.1203810	http://dx.doi.org/10.1038/sj.onc.1203810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002424				2022-12-17	WOS:000089236800008
J	Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A				Meroni, G; Cairo, S; Merla, G; Messali, S; Brent, R; Ballabio, A; Reymond, A			Mlx, a new Max-Like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?	ONCOGENE			English	Article						bHLHZip; Myc; Max; Rox; cell proliferation	HELIX-ZIPPER PROTEIN; C-MYC; DNA-BINDING; HISTONE DEACETYLASE; GROWTH-FACTOR; CELL-PROLIFERATION; E-BOX; RAS COTRANSFORMATION; OPPOSITE REGULATION; MAMMALIAN-CELLS	The Myc proto-oncogene family members have been identified as the cellular homologs of the transforming oncogene of avian retro viruses. They encode central regulators of mammalian cell proliferation and apoptosis, and they associate with the bHLHZip protein Max to hind specific DNA sequences and regulate the expression of genes important for cell cycle progression. The other family members, Mad1, Mxi1, Mad3, Mad4 and Rox (Mnt) antagonize their activities. The Mads and Ros compete with Myc in heterodimerizing with Max and in binding to the same specific target sequences, These Mads:Max and Rox:Max dimers repress transcription through binding to the mSIN3 corepressor protein and by tethering histone deacetylase-containing complexes to the DNA. In a screen for Rox interactors we isolated Mlx, a bHLHZip protein previously identified in a screen for Mad1 interactors. In the present work we extend the known dimerization partners of Mlx by demonstrating its ability to interact with Rox. Moreover, we show that contrary to previous reports Mlx is able to homodimerize and to bind E-box sequences at low concentration Levels. The possible role of Mlx in an emerging regulatory pathway and acting parallel to the Max driven network is discussed.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Inst Mol Sci, Berkeley, CA 94704 USA; Univ Vita & Salute, Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); The Molecular Sciences Institute; Vita-Salute San Raffaele University	Reymond, A (corresponding author), Telethon Inst Genet & Med, SAn Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020; Cairo, Stefano/O-2831-2016	merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; Cairo, Stefano/0000-0002-4725-5970; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM00S01, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Bjerknes M, 1996, GENE, V181, P7, DOI 10.1016/S0378-1119(96)00376-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Eilers M, 1999, MOL CELLS, V9, P1; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HESKETH R, 1997, ONCOGENE TUMOUR SUPP, P1; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li XJ, 1999, JPN J CANCER RES, V90, P740, DOI 10.1111/j.1349-7006.1999.tb00809.x; Lo Nigro C, 1998, GENOMICS, V49, P275; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; REYMOND A, 1995, ONCOGENE, V11, P1173; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Tangir J, 1996, ONCOGENE, V12, P735; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VASTRIK I, 1993, ONCOGENE, V8, P503; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WALKER CW, 1992, ONCOGENE, V7, P2007; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; Zhao Z, 1996, MAMM GENOME, V7, P686, DOI 10.1007/s003359900206	86	59	63	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3266	3277		10.1038/sj.onc.1203634	http://dx.doi.org/10.1038/sj.onc.1203634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918583				2022-12-17	WOS:000088019300005
J	Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z				Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z			Differential modulation of paclitaxel-mediated apoptosis by p21(Waf1) and p27(Kip1)	ONCOGENE			English	Article						paclitaxel; chemoresistance; cell cycle; p21(Waf1); p27(Kip1)	TAXOL-INDUCED APOPTOSIS; CELL-CYCLE ARREST; P34(CDC2) KINASE; DNA-REPLICATION; CARCINOMA-CELLS; PROTEIN-KINASE; G(2)-M ARREST; CANCER CELLS; M-PHASE; PHOSPHORYLATION	The impact of the cyclin dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) on paclitaxel-mediated cytotoxicity was investigated in RKO human colon adenocarcinoma cells with the ecdysone-inducible expression of p21(Waf1) or p27(Kip1). Ectopic expression of p27(Kip1) arrested cells at G1 phase, whereas p21(Waf1) expression arrested cells at G1 and G2, Expression of p21(Waf1) after paclitaxel treatment produced much greater resistance to paclitaxel than did expression of p27(Kip1). We attributed this difference to the additional block at G2 induced by p21(Waf1), which prevented cells from entering M phase and becoming paclitaxel susceptible. Expression of p21(Waf1) inhibited p34cdc2 activity and markedly reduced paclitaxel-mediated mitotic arrest, from 87.5 to 23%, In contrast, p27(Kip1) expression also inhibited p34cdc2 but reduced mitotic arrest only slightly, from 87.4 to 74.5%, We concluded that the G2 block produced by p21(Waf1), but not by p27(Kip1), contributed to their unequal modulation of sensitivity to paclitaxel-mediated apoptosis in RKO cells, and there is no causal relationship between paclitaxel-mediated cytotoxicity and elevation of p34cdc2 activity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA16672, CA68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amato SF, 1998, CANCER RES, V58, P241; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Frankel A, 1997, CANCER RES, V57, P2388; Haldar S, 1996, CANCER RES, V56, P1253; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Ibrado AM, 1997, CANCER RES, V57, P1109; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rakovitch E, 1999, INT J RADIAT ONCOL, V44, P1119, DOI 10.1016/S0360-3016(99)00109-1; ROWINSKY EK, 1997, SEMIN ONCOL S19, V24, P1; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; van Bree C, 1999, J CANCER RES CLIN, V125, P549, DOI 10.1007/s004320050315; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wu XP, 1996, ONCOGENE, V12, P1397; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	33	59	62	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2423	2429		10.1038/sj.onc.1203546	http://dx.doi.org/10.1038/sj.onc.1203546			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828884				2022-12-17	WOS:000087018400007
J	Santos, SCR; Dumon, S; Mayeux, P; Gisselbrecht, S; Gouilleux, F				Santos, SCR; Dumon, S; Mayeux, P; Gisselbrecht, S; Gouilleux, F			Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; STAT5; PI3-kinase; Bad; Bcl-x	COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; HEMATOPOIETIC-CELLS; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ERYTHROPOIETIN RECEPTOR; INDUCED PROLIFERATION; TYROSINE RESIDUES; GROWTH-HORMONE	Cytokine-dependent activation of distinct signaling pathways is a common scheme thought to be required for the subsequent programmation into cell proliferation and survival. The PI 3-kinase/Akt, Ras/MAP kinase, Ras/NFIL3 and JAK/STAT pathways have been shown to participate in cytokine mediated suppression of apoptosis in various cell types. However the relative importance of these signaling pathways seems to depend on the cellular context. In several cases, individual inhibition of each pathway is not sufficient to completely abrogate cytokine mediated cell survival suggesting that cooperation en these pathways is required. Here we showed individual inhibition of STAT5, PI 3-kinase or MEK activities did not or weakly affected the IL-3 dependent survival of the bone marrow derived Ba/F3 cell line. However, the simultaneous inhibition of STAT5 and PI 3-kinase activities but not that of STAT5 and MEK reduced the IL-3 dependent survival of Ba/F3, Analysis of the expression of the Bcl-2 members indicated that phosphorylation of Bad and Bcl-x expression which are respectively regulated by the PI 3-kinase/Akt pathway and STAT5 probably explain this cooperation. Furthermore, me showed by co-immunoprecipitation studies and pull down experiments with fusion proteins encoding the GST-SH2 domains of p85 that STAT5 in its phosphorylated form interacts with the p85 subunit of the PI 3-kinase, These results indicate that the activations of STAT5 and the PI 3-kinase by IL-3 in Ba/F3 cells are tightly connected and cooperate to mediate IL-3-dependent suppression of apoptosis by modulating Bad phosphorylation and Bcl-x expression.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gouilleux, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Santos, Susana/AAM-8902-2021	Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lotem J, 1996, LEUKEMIA, V10, P925; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miike S, 1999, J LEUKOCYTE BIOL, V65, P700, DOI 10.1002/jlb.65.5.700; MIURA O, 1994, J BIOL CHEM, V269, P614; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Onishi M, 1998, Int Rev Immunol, V16, P617, DOI 10.3109/08830189809043011; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ozaki K, 1998, BLOOD, V92, P4652; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Park J R, 1996, Curr Opin Hematol, V3, P191; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	56	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1164	1172		10.1038/sj.onc.1203418	http://dx.doi.org/10.1038/sj.onc.1203418			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713704	Green Published			2022-12-17	WOS:000085567800006
J	Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J				Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J			Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK); A novel nuclear target of Akt	ONCOGENE			English	Article						human; S6 kinase; Akt; nucleus	ACTIVATION; PHOSPHORYLATION; GENE; TRANSLOCATION; EXPRESSION; P70(S6K); PDK1	Akt is stimulated by several growth factors, and mediates their cell survival signals. Recent studies have shown that Akt may play an intermediate role between phosphatidylinositol 3-kinase (PI3K) and p70 S6 kinase (p70S6K), Here we show that a novel nuclear p70S6K-related kinase (SRK) exists and that its in vivo function is also augmented by over-expression of Akt, Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K, However, the Nand C-terminal domains of SRK were quite different from those of p70S6K. In immunolocalization analyses, we demonstrated a constitutive nuclear localization of SRK and the presence of a nuclear localization signal in its C-terminus, In vitro S6 phosphotransferase activities of SRK were stimulated with a slower kinetics by a variety of agonists to p70S6K, Interestingly, overexpression of the proto-oncogene Akt resulted in EGF-independent activation of SRK, while over-expression of kinase-dead Akt actually had an inhibitory effect, This relationship between Akt and SRK suggests that SRK may be a novel target of Akt and perhaps an important downstream component in the nuclear function of Akt.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Chonnam National University; Pai Chai University	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649	18	59	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5115	5119		10.1038/sj.onc.1202895	http://dx.doi.org/10.1038/sj.onc.1202895			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490848				2022-12-17	WOS:000082497100011
J	Rebollo, A; Perez-Sala, D; Martinez, C				Rebollo, A; Perez-Sala, D; Martinez, C			Bcl-2 differentially targets K-, N-, and H-Ras to mitochondria in IL-2 supplemented or deprived cells: Implications in prevention of apoptosis	ONCOGENE			English	Article						Ras; Bcl-2; apoptosis; mitochondria; IL-2; receptor	FARNESYL-PROTEIN TRANSFERASE; INTERLEUKIN-2 RECEPTOR; HIGH-AFFINITY; IN-VITRO; ASSOCIATION; PRENYLATION; EXPRESSION; ACTIVATION; KINASE; FARNESYLTRANSFERASE	IL-2 deprivation triggers apoptosis in the murine T cell line TS1 alpha beta, a process that can be blocked by overexpression of Bcl-2, Here we show that Bcl-2 and Ras proteins interact in mitochondria from TS1 alpha beta cells in the presence or absence of IL-2, as evidenced by coimmunoprecipitation, All three Ras proteins, K-, N- and H-Ras, interact with Bcl-2; however, their mitochondrial localization is differentially regulated in IL-2-supplemented or -deprived cells, K-Ras is found in mitochondria only in IL-2-supplemented cells, whereas H-Ras is observed in mitochondria only after IL-2 withdrawal. N-Ras is detected in mitochondria under both experimental conditions. Bcl-2 transfection partially restored K- and N-Ras association with mitochondria in IL-2-deprived cells and rendered H-Ras association independent of IL-2 withdrawal. Inhibitors of Ras posttranslational processing did not alter the IL-2-induced differential pattern of mitochondrial localization, The processed forms of K- and N-Ras associated with mitochondria, although unprocessed H-Ras was also detected in mitochondria from mevastatin-treated cells, These results evidence a distinct behavior among the three Ras proteins in TS1 alpha beta cells, depending on IL-2 supply, and suggest homologue-specific roles for Ras proteins in IL-2-dependent events.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Perez-Sala, Dolores/L-5969-2014; Rebollo, Angelita/P-2118-2017	Perez-Sala, Dolores/0000-0003-0600-665X; Rebollo, Angelita/0000-0002-1293-9686				BROOME HE, 1995, IMMUNOLOGY, V84, P375; BROOME HE, 1995, J IMMUNOL, V155, P2311; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; DEJONG D, 1994, CANCER RES, V54, P256; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Gomez J, 1996, J IMMUNOL, V157, P2272; GOMEZ J, 1998, IN PRESS ONCOGENE, V16; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Okada T, 1996, J BIOL CHEM, V271, P4671; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang FL, 1997, J BIOL CHEM, V272, P10232	43	59	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4930	4939		10.1038/sj.onc.1202875	http://dx.doi.org/10.1038/sj.onc.1202875			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490827				2022-12-17	WOS:000082321700005
J	Oki, E; Oda, S; Maehara, Y; Sugimachi, K				Oki, E; Oda, S; Maehara, Y; Sugimachi, K			Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair	ONCOGENE			English	Article						hMSH2; hMSH6 (GTBP); hMLH1; microsatellite instability; RER	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; HMSH2 MUTATIONS; TUMOR-CELLS; HOMOLOG; MSH2; DEFECTS; HMLH1; ASSOCIATION	Mutations in DNA mismatch repair (MMR) genes in hereditary non-polyposis colon cancer (HNPCC) patients revealed the importance of MMR deficiency as a risk for carcinogenesis. Since diverse mutations occur in several MMR genes, the instability of repeat sequences dispersed in the genome, which are also governed by the MMR system, is a well used marker. However, the relationship between repeat sequence instability and MMR gene mutation in human cells has not been well defined mainly because precise systems to analyse repeat sequences have not been available. Using our newly developed system, we analysed alteration of dinucleotide repeats in human cell lines which harbour mutations in MMR genes. Among 24 subclones of DLD-1 cells (hMSH6(-)) only one had a dinucleotide repeat alteration in only one microsatellite locus, while LoVo cells (hMSH2(-)/hMSH6(-)) exhibited marked dinucleotide repeat instability (DRI). HCT116 cells, a hMLH1-mutant, showed an ultimate DRI phenotype. Interestingly, SW48 cells lacking hMLH1 expression also demonstrated DRI, albeit the extent of diversity being significantly lower than HCT116. These data suggest that the DRI phenotype in human cells is highly dependent on mutated MMR genes and on forms of mutation. The results of DRI analyses used to detect MMR-deficiency should be interpreted with caution.	Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Oda, S (corresponding author), Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Ahuja N, 1997, CANCER RES, V57, P3370; Akiyama Y, 1997, CANCER RES, V57, P3920; Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oda S, 1997, NUCLEIC ACIDS RES, V25, P3415, DOI 10.1093/nar/25.17.3415; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Schug MD, 1997, NAT GENET, V15, P99, DOI 10.1038/ng0197-99; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Weber TK, 1997, CANCER RES, V57, P3798; Wu MS, 1997, CANCER LETT, V112, P161, DOI 10.1016/S0304-3835(96)04565-X; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	32	59	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2143	2147		10.1038/sj.onc.1202583	http://dx.doi.org/10.1038/sj.onc.1202583			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321739				2022-12-17	WOS:000079346200012
J	Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C				Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C			Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis	ONCOGENE			English	Article						Met-mediated metastasis; met signaling; PI 3-kinase; Grb2; Ras	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; DOCKING PROTEIN; TPR-MET; TRANSFORMATION; ONCOGENE; MOTILITY	The Met tyrosine kinase - the HGF receptor - induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase, We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met(2xGrb2)) is permissive for motility, increases transformation, but - surprisingly - is impaired in causing invasion and metastasis. In this work, we used Met mutants optimized for binding either p85 alone (Met(2xPI3K)) Or p85 and Grb2 (Met(P13/Grb2)) to evaluate the relative importance of Pas and PI 3-kinase as downstream effecters of Met. Met(2xPI3K) was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, Met(PI3K/Grb2) induced motility, transformation, invasion and metastasis as efficiently as wild type Met. Furthermore, the expression of constitutively active PI 3-kinase in cells transformed by the Met(2xGrb2) mutant, fully rescued their ability to invade and metastasize. These data point to a central role for PI 3-kinase in Met-mediated invasiveness, and indicate that simultaneous activation of Ras and PI 3-kinase is required to unleash the Met metastatic potential.	Univ Turin, Sch Med, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10126 Turin, Italy; Imperial Canc Res Fund, London WC2A 3PX, England; Ist Nazl Tumori, I-20133 Milan, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ponzetto, C (corresponding author), Univ Turin, Sch Med, Dept Biomed Sci & Oncol, Cso Massimo dAzeglio 52, I-10126 Turin, Italy.		Giordano, Silvia/J-9858-2018; menard, sylvie mm/C-7940-2011; BARDELLI, Alberto/J-9721-2018	Giordano, Silvia/0000-0003-1854-1086; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Audero, Enrica/0000-0002-6138-244X				Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DERMAN MP, 1996, AM J PHYSIOL, V268, pF1211; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHAW LM, 1972, CELL, V9194, P97; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Sporken R, 1997, MRS INTERNET J N S R, V2, part. no.; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	44	59	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1139	1146		10.1038/sj.onc.1202607	http://dx.doi.org/10.1038/sj.onc.1202607			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022119				2022-12-17	WOS:000078510700002
J	Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ			Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation	ONCOGENE			English	Article						cell cycle; cyclins; CDK; epidermis; terminal differentiation; keratinocytes	RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; IN-VITRO; G1 PHASE; EXPRESSION; GENE; P21; INHIBITOR; GROWTH; PROGRESSION	Differentiation of cells is typically marked by a cessation of proliferation with a concurrent entrance into a distinct metabolic state marked by tissue specific gene expression, The mechanism by which the cell exits the cell cycle in this process is poorly understood. To determine the potential roles of the cell cycle machinery in the regulation of the terminal differentiation process of epidermal cells, we selected a well characterized in vitro model in which primary mouse keratinocytes are induced to differentiate in response to a raised calcium ion concentration in the medium. The withdrawal from the cell cycle correlates very well with a number of changes in the cell cycle machinery. Changes in the phosphorylation status of the Rb family of proteins occurs coordinately with an increased association of p21, p27 and p57 with cdk2, Furthermore, we find that inhibition of cdk2 activity is not sufficient to elicit changes that occur during keratinocyte differentiation. Finally, the previously described v-Ha-ras block of keratinocyte differentiation correlates with altered regulation of both cyclin D1 and cdk2 suggesting that these genes may play a role in the Ha-ras transformation of a keratinocyte.	Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.				NCI NIH HHS [CA 57596, CA 42157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Gotz C, 1996, ONCOGENE, V13, P391; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG WC, 1995, ONCOGENE, V10, P2271; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	48	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					397	406		10.1038/sj.onc.1202300	http://dx.doi.org/10.1038/sj.onc.1202300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927196				2022-12-17	WOS:000078166500012
J	Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM				Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM			Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma	ONCOGENE			English	Article						gene amplification; neuroblastoma; N-myc amplicon	HUMAN NEURO-BLASTOMA; DEAD BOX GENE; DNA-SEQUENCES; CELL-LINES; ORNITHINE DECARBOXYLASE; SINGLE-COPY; EXPRESSION; COAMPLIFICATION; CHROMOSOMES; FRAGMENTS	Substantial evidence implicates amplification of the N-myc gene with aggressive tumor growth and poor outcome in neuroblastoma. However some evidence suggests that this gene alone is not the sole determinant of outcome in N-myc amplified tumors. We have searched for genes that co-amplify with N-myc in neuroblastoma by means of two-dimensional analysis of genomic restriction digests. Using this approach, we have identified and cloned a novel genomic fragment which is co-amplified with N-myc in neuroblastomas, This fragment was mapped in close vicinity to N-myc on chromosome arm 2p24, It was amplified in 5/8 N-myc amplified neuroblastoma cell lines and in 9/13 N-myc amplified tumors. Using a PCR-based approach we isolated a 4.5 kb c-DNA sequence that is partly contained in the genomic fragment, The open reading frame of the cDNA encodes a predicted protein of 1353 amino acids (aa), The homology of the predicted protein, which we designated NAG (neuroblastoma amplified gene), to a C, elegans protein of as yet unknown function, and its ubiquious expression suggest that NAG may serve an essential function, By Northern blot analysis we showed that amplification of the cloned gene correlates with over-expression in neuroblastoma cell lines. Amplification and consequent over-expression of NAG may, therefore, contribute to the phenotype of a subset of neuroblastomas.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	University of Michigan System; University of Michigan; Saint Anna Children's Hospital	Wimmer, K (corresponding author), Univ Vienna, Dept Med Biol, Wahringerstr 10, A-1090 Vienna, Austria.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Zhu, Charles/0000-0003-2922-0042; Kovar, Heinrich/0000-0001-6873-9109	NCI NIH HHS [CA-26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AKIYAMA K, 1994, NUCLEIC ACIDS RES, V25, P157; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambros IM, 1997, EUR J CANCER, V33, P2043, DOI 10.1016/S0959-8049(97)00204-9; AMLER LC, 1995, ONCOGENE, V10, P1095; AMLER LC, 1992, ONCOGENE, V7, P807; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHN SL, 1995, CANCER RES, V55, P721; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; George RE, 1996, ONCOGENE, V12, P1583; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; KANDA N, 1983, P NATL ACAD SCI-BIOL, V80, P4069, DOI 10.1073/pnas.80.13.4069; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuick R, 1996, GENETICS, V144, P307; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lutz W, 1997, ONCOGENE, V15, P303, DOI 10.1038/sj.onc.1201195; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Pandita A, 1997, GENE CHROMOSOME CANC, V20, P243, DOI 10.1002/(SICI)1098-2264(199711)20:3<243::AID-GCC4>3.0.CO;2-2; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Schweizer D, 1994, Methods Mol Biol, V29, P97; SHILOH Y, 1986, CANCER RES, V46, P5297; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; SLAVC I, 1990, CANCER RES, V50, P1459; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Thoraval D, 1996, P NATL ACAD SCI USA, V93, P4442, DOI 10.1073/pnas.93.9.4442; TONIN PN, 1989, ONCOGENE, V4, P1117; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	40	59	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					233	238		10.1038/sj.onc.1202287	http://dx.doi.org/10.1038/sj.onc.1202287			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926938				2022-12-17	WOS:000078166000025
J	Kawahara, A; Kobayashi, T; Nagata, S				Kawahara, A; Kobayashi, T; Nagata, S			Inhibition of Fas-induced apoptosis by Bcl-2	ONCOGENE			English	Article						apoptosis; Bcl-2; caspase; Fas	SIGNALING COMPLEX DISC; MEDIATED CELL-DEATH; PROTEASE ACTIVATION; T-CELLS; FAMILY; LIGAND; FLICE; REGULATORS; RESISTANCE; EXPRESSION	Jurkat cells express Fas, and rapidly undergo apoptosis in response to Fas ligand or an agonistic anti-Fas antibody. This apoptotic pathway is mediated by a cascade of caspases, In this report, we show that Fas activation induced the processing of caspase 8 in Jurkat cells with a time frame similar to the activation of caspase 3 and the proteolysis of nuclear proteins. Jurkat cell transformants that overexpress Bcl-2 were partially but not completely resistant to the Fas-induced apoptosis. Little processing of caspase 8 was observed upon Fas activation in these transformants. Furthermore, although caspase 8 was recruited to Fas upon Fas activation in the parental Jurkat cells, the recruitment of caspase 8 to Fas was inhibited in the transformants overexpressing Bcl-2, These results suggest that Bcl-2 inhibits Fas-induced apoptosis by preventing the formation of the death-inducing signaling complex that is composed of Fas, FADD/MORT1, and caspase 8.	Osaka Biosci Inst, Osaka 5650874, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; MBL Co Ltd, Ina Labs, Nagano 3960002, Japan	Osaka University	Nagata, S (corresponding author), NICHHD, Mol Genet Lab, NIH, Bldg 6B,Room 420, Bethesda, MD 20892 USA.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	59	67	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2549	2554		10.1038/sj.onc.1202192	http://dx.doi.org/10.1038/sj.onc.1202192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840917				2022-12-17	WOS:000077058900001
J	Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA				Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA			Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers	ONCOGENE			English	Article						microsatellite instability; p53; BAX; colorectal cancer	WILD-TYPE P53; MICROSATELLITE MUTATOR PHENOTYPE; II RECEPTOR GENE; DNA-DAMAGE; GASTROINTESTINAL TUMORS; GENOMIC INSTABILITY; SOMATIC MUTATIONS; GASTRIC-CANCER; CELL-LINES; EXPRESSION	Though most colorectal cancers show allelic losses, a subset of colorectal cancers (microsatellite instability or MSI-positive cancers) develop numerous small insertion and deletion mutations in repetitive DNA, Some of these sequences occur in coding regions of cancer related genes which, when targeted by frameshift mutations, produce truncations in their protein product, Such a gene is the proapoptotic tumor suppressor, BAX, mutated by frameshifts within a polyG sequence in approximately 50% of MSI-positive colorectal cancers. BAX is directly transactivated by p53, a gene commonly mutated in colorectal cancers but not often in MSI-positive lesions. Here we sought to characterize the relationship between BAX and p53 by simultaneously analysing a selected series of 65 colorectal tumors for mutations in the entire coding regions of both genes. The tumors comprised 19 MSI-high, 12 MSI-low and 34 MSI-null cancers. Eight of 19 MSI-high sporadic colorectal cancers (42%) contained insertions and deletions at the polyG tract in the BAX gene, In addition, three somatic BAX missense mutations were identified in two tumors. A single missense mutation was detected in an MSI-high tumor that also contained a frameshift microdeletion, and two missense mutations were identified in an MSI-null tumor wild-type for p53, p53 mutations were detected in 5/12 MSI-low tumors (42%) and 12/34 MSI-null tumors (35%), Of significance, no p53 mutations were detected in MSI-high tumors. This study demonstrates that a reciprocal relationship exists between p53 and BAX in sporadic colorectal cancers, and further supports the hypothesis that MSI-low tumors are biologically similar to MSI-null tumors.	Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Gastroenterol, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Herston, Qld 4006, Australia; Univ Maryland, Sch Med, Dept Pathol & Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Simms, LA (corresponding author), Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia.		Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Cummings, Margaret/B-5747-2011; Radford-Smith, Graham/H-2792-2013; Leggett, Barbara A/D-3579-2011; Radford-Smith, Graham L/G-5749-2017	Cummings, Margaret/0000-0002-7657-0240; Radford-Smith, Graham/0000-0002-2047-6239; Radford-Smith, Graham L/0000-0002-2047-6239; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA067497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA77057, CA67497] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chou D, 1996, CANCER GENET CYTOGEN, V88, P136, DOI 10.1016/0165-4608(95)00341-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gallagher WM, 1997, ONCOGENE, V14, P185; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hanski C, 1996, CANCER LETT, V103, P163, DOI 10.1016/0304-3835(96)04208-5; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTHE RA, 1993, CANCER RES, V53, P5849; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; PARSONS R, 1995, CANCER RES, V55, P5548; Perego P, 1996, CANCER RES, V56, P556; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; RHYU MG, 1994, ONCOGENE, V9, P29; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SMITH ML, 1995, ONCOGENE, V10, P1053; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Souza RF, 1997, CANCER RES, V57, P2350; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Watatani M, 1996, CANCER, V77, P1688, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1688::AID-CNCR16>3.0.CO;2-U; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; ZHAN QM, 1994, ONCOGENE, V9, P3743	57	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2003	2008		10.1038/sj.onc.1202109	http://dx.doi.org/10.1038/sj.onc.1202109			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788444				2022-12-17	WOS:000076423500014
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	LUNG-CANCER CELLS; IN-VIVO; GENE; ADENOVIRUS; INDUCTION	Because 2-methoxyestradiol (2-MeOE2) induces and stabilizes wild-type p53 protein (wt p53) in human lung cancer cell lines posttranscriptionally, we sought to study its effects on Ad5p53-transduced lung cancer cell lines at a low multiplicity of infection (1 MOI). Treating these cells with 2-MeOE2 resulted in superinduction of wt p53 protein expression followed by apoptosis, as shown by terminal deoxynucleotidyl transferase (TdT) staining, and upregulation of wt p53 expression, as shown by Western blot analysis. When transduced with Ad5p53 alone at 1 MOI, the cell lines grew rapidly. Moreover, adenoviral-vector-mediated p53 gene transfer followed by 2-MeOE2 treatment caused 80% growth inhibition in the cell lines regardless of their p53 status, Thus, p53 superinduction and apoptosis after 2-MeOE2 treatment in Ad5p53-transduced cells appears to be a unique strategy with significant implications for cancer gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attalla H, 1996, BIOCHEM BIOPH RES CO, V228, P467, DOI 10.1006/bbrc.1996.1683; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; FOTIS T, 1994, NATURE, V368, P237; FUJIWARA T, 1994, CANCER RES, V54, P2287; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	20	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					241	246		10.1038/sj.onc.1201909	http://dx.doi.org/10.1038/sj.onc.1201909			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674709				2022-12-17	WOS:000074706700013
J	Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG				Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG			Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival	ONCOGENE			English	Article						PML; Ring; B-boxes; coiled-coil; apoptotic cell death	ACUTE PROMYELOCYTIC LEUKEMIA; GREEN FLUORESCENT PROTEIN; RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR MATRIX; ZINC FINGER; GENE; FUSION; EXPRESSION; BINDING	PML/RAR alpha is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation, Both the PML and RAR alpha components are required for the PML/RAR alpha biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML; localizes to the cytoplasm and within specific nuclear bodies (NBs), In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RAR alpha protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region, We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring + B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring + B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML, These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring+B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RAR alpha on survival derive from the activation of the incorporated PML sequence.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Mitochrondial Physiol, I-35121 Padua, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/AAB-4300-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Alcalay, Myriam/B-3182-2016; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Ferrucci, Pier Francesco/0000-0001-6255-5851				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1998, IN PRESS MOL CELL BI; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Boddy MN, 1996, ONCOGENE, V13, P971; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GANDINI D, 1994, BLOOD, V84, pA439; Gorczyca W., 1993, CANCER RES, V53, P945; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Stadler M, 1995, ONCOGENE, V11, P2565; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TKAHASHI M, 1988, MOL CELL BIOL, V8, P1853; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	51	59	60	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2905	2913		10.1038/sj.onc.1201811	http://dx.doi.org/10.1038/sj.onc.1201811			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671411				2022-12-17	WOS:000073988200009
J	Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M				Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M			A role of the tuberous sclerosis gene-2 product during neuronal differentiation	ONCOGENE			English	Article						neuronal differentiation; tuberin; tuberous sclerosis; TSC2	DOMINANTLY INHERITED CANCER; TUBEROUS-SCLEROSIS-2 TSC2 GENE; NEUROBLASTOMA CELL-LINES; EKER RAT MODEL; RETINOIC ACID; RENAL-CARCINOMA; DNA-SYNTHESIS; EXPRESSION; HETEROZYGOSITY; BLASTOMA	Tuberous sclerosis is an autosomal dominant disorder, Besides the development of benign growths (hamartomas) in different tissues, one hallmark of this disease is the presence of highly epileptogenic dysplastic lesions in the cerebral cortex (tubers) composed of abnormal shaped neurones. Patients often show evidence of severe mental retardation. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16, The TSC2 gene on chromosome 16 encodes a 1784-amino acid putative tumour suppressor protein, tuberin, that functions as a GTPase-activating protein. Here me show that tuberin expression is upregulated upon induction of neuronal differentiation in the neuroblastoma cell lines SK-N-SH and LAN-1. This upregulation occurs at post-transcriptional level and is independent of the proliferation status. TSC2 expression is unaffected during differentiation of C2C12 myoblasts into myotubes and of F9 embryonal carcinoma cells into cells resembling parietal endoderm, Antisense inhibition of tuberin expression in SK-N-SH or LAN-1 cells inhibits neuronal differentiation, but does not affect the differentiation of F9 cells, Ectopic overexpression of TSC2 not only reverts the antisense-associated phenotype but furthermore accelerates the neuronal differentiation process. Our data show for the first time that tuberin plays a critical role in neuronal differentiation. Such role is consistent with the phenotype of tuberous sclerosis patients, who inherit one defective TSC2 allele, and frequently lose the remaining normal allele in many of the tubers/hamartomas which develop in the central nervous system of these patients.	Univ Vienna, Dept Prenatal Diag & Therapy, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diag & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HUTTENLOCHER PR, 1991, ANN NY ACAD SCI, V615, P140; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kerfoot C, 1996, BRAIN PATHOL, V6, P367, DOI 10.1111/j.1750-3639.1996.tb00866.x; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Menchine M, 1996, MODERN PATHOL, V9, P1071; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NELLIST M, 1993, CELL, V75, P1305; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; SAMPSON JR, 1994, HUM MOL GENET, V3, P1477, DOI 10.1093/hmg/3.suppl_1.1477; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL, P317; SEEGER RC, 1977, CANCER RES, V37, P1364; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; SOUCEK T, 1997, J BIOL CHEM, V272, P29031; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAHIRA T, 1991, ONCOGENE, V6, P2333; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	47	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2197	2204		10.1038/sj.onc.1201743	http://dx.doi.org/10.1038/sj.onc.1201743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619828				2022-12-17	WOS:000073298000004
J	Xie, GF; Habbersett, RC; Jia, YW; Peterson, SR; Lehnert, BE; Bradbury, EM; D'Anna, JA				Xie, GF; Habbersett, RC; Jia, YW; Peterson, SR; Lehnert, BE; Bradbury, EM; D'Anna, JA			Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints	ONCOGENE			English	Article						gamma radiation; DNA replication; flow cytometry; cyclin-dependent kinases; p53(-/-) mouse fibroblasts; ataxia telangiectasia	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; ATAXIA-TELANGIECTASIA; DNA-SYNTHESIS; RADIATION; FIBROBLASTS; ARREST; GROWTH; MICE; INHIBITION	We investigated the requirements for protein p53 and the ATM gene product in radiation-induced inhibition of DNA synthesis and regulation of the cyclin E/ and cyclin A/cyclin dependent kinases (Cdks), Wild mouse lung fibroblasts (MLFs), p53(-/-) knock-out, normal human skin fibroblasts (HSF-55), and human AT skin fibroblasts (GM02052) were used in the investigations, The absence of p53 had no significant effect on the inhibition or recovery of DNA synthesis throughout the S phase, as determined from BrdU labeling and flow cytometry, or the rapid inhibition of cyclin A/Cdks., gamma: radiation (8 Gy) inhibited DNA synthesis and progression into G2 during the first 3 h after irradiation, and the recovery of these processes occurred at similar rates in both WT and p53(-/-) MLFs., The cyclin A/Cdks were inhibited 55-70% at Ih after irradiation in both cell types, but 921(WAF1/Clp1) levels or p21 interaction with Cdk2 did not increase in the irradiated p53(-/-) MLFs., Although p53(-/-) MLFs do not exhibit prolonged arrest at a G1 checkpoint, radiation did induce a rapid 20% reduction and small super-recovery of cyclin E/Cdk2 within 1-2 h after irradiation, Similar inhibition and recovery of cyclin E/Cdk2 previously had been associated with regulation of transient G1 delay and the inhibition of initiation at an apparent G1/S checkpoint in Chinese hamster cells, In contrast, loss of the ATM gene product abrogated transient cyclin E/Cdk2 inhibition, most inhibition of DNA synthesis and all, but a 10-15% inhibition, of the cyclin A/Cdks, The results indicate that neither p53 nor p21 is required for transient inhibition of cyclin E/Cdk2 associated with the G1/S checkpoint or for inhibition of DNA synthesis at 'checkpoints' within the S phase, Conversely, the ATM gene product appears to be essential for regulation of the G1/S checkpoint and for inhibition of DNA replication the inhibition of cyclin A/Cdk2., of DNA synthesis inhibition among cell types are presented and discussed in the context of S phase checkpoints,.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	D'Anna, JA (corresponding author), Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA.		Jia, Yanwei/AAX-1317-2021	Jia, Yanwei/0000-0001-5795-7450	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01315] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; CRISSMAN HA, 1993, EUR J HISTOCHEM, V37, P129; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; GRAY JW, 1981, J CELL PHYSIOL, V108, P135, DOI 10.1002/jcp.1041080204; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HARVEY M, 1993, ONCOGENE, V8, P2457; HENNEQUIN C, 1994, CANCER RES, V54, P1720; Higashikubo R, 1996, CELL PROLIFERAT, V29, P43, DOI 10.1111/j.1365-2184.1996.tb00093.x; KHANNA KK, 1995, ONCOGENE, V11, P609; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEHNERT BE, 1994, AM J RESP CELL MOL, V11, P375, DOI 10.1165/ajrcmb.11.4.7917306; MICHIELI P, 1994, CANCER RES, V54, P3391; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; Petrocelli T, 1996, ONCOGENE, V12, P1387; POVIRK LF, 1982, BIOCHEMISTRY-US, V21, P5857, DOI 10.1021/bi00266a020; SACHEZ Y, 1997, SCIENCE, V277, P1497; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALTERS RA, 1970, BIOPHYS J, V10, P556, DOI 10.1016/S0006-3495(70)86319-6; WALTERS RA, 1975, BIOCHEM BIOPH RES CO, V65, P265, DOI 10.1016/S0006-291X(75)80088-X; Wang Y, 1997, CANCER RES, V57, P1654; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; Wyllie FS, 1996, ONCOGENE, V12, P1077; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	40	59	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					721	736		10.1038/sj.onc.1201793	http://dx.doi.org/10.1038/sj.onc.1201793			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488036				2022-12-17	WOS:000071931800004
J	Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R				Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R			Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts	ONCOGENE			English	Article						cyclin-dependent kinase regulation; contact-inhibition; serum-deprivation	CYCLIN-DEPENDENT KINASES; PLASMA-MEMBRANE GLYCOPROTEINS; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; G1 PHASE; RETINOBLASTOMA PROTEIN; P27(KIP1); ARREST; PHOSPHORYLATION; EXPRESSION	In the present work we studied mechanisms of growth control in contact-inhibited and serum-deprived human diploid fibroblasts. The observation that the effects on [H-3]thymidine incorporation and reduction of retinoblastoma gene product-phosphorylation were additive when contact-inhibition and serum-deprivation were combined led us to the conclusion that the underlying mechanisms might be different. Both contact-inhibition and serum-deprivation led to a strong decrease of cdk4-kinase-activity and cdk2-phosphorylation at Thr 160, while the total amounts of cdk4 and cdk2 remained constant. In contact-inhibited cells, we revealed a strong protein accumulation of the cdk2-inhibitor p27 and a slight, but significant increase of the cdk4-inhibitor p16. In serum-deprived cells, the protein levels in p27 and p16 remained low. In contrast, we detected a rapid decrease of cyclin D1 and cyclin D3 which did not occur in contact-inhibited cells. These results indicate that serum-deprivation and contact-inhibition have different mechanisms although they affect the same pathway cyclin D-cdk4, pRB, cyclin E-cdk2.	UNIV MAINZ,INST TOXICOL,D-55131 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Oesch, Franz/AAA-8746-2020					APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; MORETON K, 1995, BIOCHEM SOC T, V23, pS446, DOI 10.1042/bst023446s; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	37	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2743	2747		10.1038/sj.onc.1201439	http://dx.doi.org/10.1038/sj.onc.1201439			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401001				2022-12-17	WOS:A1997YH46800012
J	Reinke, V; Lozano, G				Reinke, V; Lozano, G			The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo	ONCOGENE			English	Article						apoptosis; p53; targets; ionizing radiation; mice	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; GROWTH-CHARACTERISTICS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DNA-REPLICATION; CELL-GROWTH; BAX GENE	The tumor suppressor p53 can exert its anti-oncogenic activity in part by inducing apoptosis in cells that have sustained damage to their DNA. It is likely that p53 activates the transcription of target genes that mediate this response. Known p53 targets with potential roles in cell cycle control and apoptosis induction include: p21(WAF1/CIP1), mdm2, cyclin G, bax and Fas. We examined the p53 pathway in the thymus of the mouse after irradiation, FACS analysis demonstrated that the thymocytes of mice with wild-type p53, but not those lacking p53, underwent apoptosis after irradiation. Expression analysis of the target genes revealed that all tested genes underwent p53-dependent induction, although the extent and timing varied. The target genes implicated in cell cycle (p21, mdm2 and cyclin G) were induced 2 h after irradiation, in contrast to targets with a possible role in apoptosis (bax and Fas), which were induced at 4 h. This analysis is the first demonstration that Fas is a p53-responsive gene in vivo. Since p21 and bax expression are not required for p53-dependent apoptosis, we tested whether other target genes affected apoptosis in vivo. We discovered that mdm2 has no role in preventing apoptosis independently of p53 inactivation, and that Fas, like p21 and bax, is not necessary for p53-mediated induction of apoptosis. Therefore, no p53 target identified and tested to date is singly responsible for p53-dependent apoptosis in response to DNA damage in vivo.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAMURA T, 1995, ONCOGENE, V11, P1939; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	49	59	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1527	1534		10.1038/sj.onc.1201316	http://dx.doi.org/10.1038/sj.onc.1201316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380404				2022-12-17	WOS:A1997XX36900003
J	Janson, W; Brandner, G; Siegel, J				Janson, W; Brandner, G; Siegel, J			Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis	ONCOGENE			English	Article						p53; butyrate; DNA damage; differentiation; apoptosis	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; LARGE-T-ANTIGEN; SODIUM-BUTYRATE; IN-VIVO; MONOCLONAL-ANTIBODIES; P53-DEPENDENT APOPTOSIS; P53-DEFICIENT MICE	Butyrate, a physiologically occurring agent, has been reported to decrease constitutively high expressed p53 levels in transformed cells. To elucidate,whether butyrate also inhibits DNA-damage-induced p53 response we investigated the effects of butyrate and the anticancer drug mitomycin C in normal C3H10T1/2 cells harbouring wild-type p53. In comparison with p53-deficient fibroblasts we examined p53 protein level, cell cycle arrest, differentiation, and apoptosis. Butyrate induced G1 phase arrest, differentiation, and p53-independent increase in p21(waf1/cip1) protein. Moreover, butyrate induced p53-independent apoptosis, which was, as well as p53-mediated apoptosis, associated with a dose-dependent increase in Bax and c-Myc protein. Pretreatment with butyrate repressed dose-dependently mitomycin-C-induced p53 accumulation and interfered with p53-dependent cell cycle arrest. Butyrate further partially inhibited p53-mediated apoptosis, but low doses of butyrate were more effective than higher concentrations. This was reflected in an enhanced decrease in c-Myc and Bax protein in response to mitomycin C with low concentrations of butyrate. Our data indicate that the differentiation stimulus of butyrate, in association with p21(waf1/cip1) induction, and apoptosis, may explain antineoplastic effects of butyrate. Co-carcinogenic features of butyrate may result from inhibition of p53-mediated DNA damage response.	UNIV FREIBURG,INST MED MICROBIOL & HYG,DEPT VIROL,D-79104 FREIBURG,GERMANY	University of Freiburg								ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BERRY RD, 1988, CARCINOGENESIS, V9, P447, DOI 10.1093/carcin/9.3.447; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHEN YQ, 1995, CANCER RES, V55, P4536; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG GERM; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAZITT Y, 1994, CANCER RES, V54, P950; GOETZ C, 1995, INT J ONCOL, V6, P1129; GOLDBERG YP, 1992, J CELL BIOCHEM, V49, P74, DOI 10.1002/jcb.240490113; GOPE R, 1993, CELL MOL BIOL, V39, P589; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HALDAR S, 1994, CANCER RES, V54, P2095; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HOJO ETS, 1994, MUTAT RES-FUND MOL M, V309, P165, DOI 10.1016/0027-5107(94)90089-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; JANSON W, 1996, THESIS FREIBURG GERM; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KITAMURA N, 1993, P ELECTROCHEM SOC, V12, P187; KRUH J, 1982, MOL CELL BIOCHEM, V42, P5; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLTAVI ZN, 1993, CELL, V74, P609; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SAITO Y, 1995, ONCOGENE, V11, P1013; SANKARANARAYANA.K, 1984, GENET RES, V56, P267; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAO ZM, 1995, ONCOGENE, V11, P493; SIEGEL J, 1995, ONCOGENE, V11, P1363; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBALLE PW, 1994, MELANOMA RES, V4, P213, DOI 10.1097/00008390-199408000-00003; SOLARY E, 1993, BLOOD, V81, P1359; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEINMEYER JE, 1988, ONCOGENE, V5, P1691; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEWART N, 1995, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TOSCANI A, 1988, ONCOGENE RES, V3, P223; UTESCH D, 1993, CARCINOGENESIS, V14, P457, DOI 10.1093/carcin/14.3.457; WAGA S, 1994, NATURE, V369, P578; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WARELL RP, 1993, NEW ENGL J MED, V329, P177; WINTERSBERGER E, 1984, FEBS LETT, V166, P326, DOI 10.1016/0014-5793(84)80105-2; WINTERSBERGER E, 1983, J CELL BIOCHEM, V21, P239, DOI 10.1002/jcb.240210306; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	89	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1395	1406		10.1038/sj.onc.1201304	http://dx.doi.org/10.1038/sj.onc.1201304			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333015				2022-12-17	WOS:A1997XW41100003
J	Lavender, P; Vandel, L; Bannister, AJ; Kouzarides, T				Lavender, P; Vandel, L; Bannister, AJ; Kouzarides, T			The HMG-box transcription factor HBP1 is targeted by the pocket proteins and E1A	ONCOGENE			English	Article						HMG-box; retinoblastoma; E1A	RETINOBLASTOMA PROTEIN; FUNCTIONAL INTERACTION; ACTIVATION DOMAIN; CELL-CYCLE; RB; BINDING; FOS; E2F; REPRESSION; EXPRESSION	A yeast two-hybrid screen has identified HBP1 as a transcription factor capable of interacting with the pocket protein family. We show that HBP1 can interact with one of these, RE, both in vitro and in mammalian cells. Two distinct RE binding sites are present within HBP1 - a high affinity binding site, mediated by an LXCXE motif and a separate low affinity binding site present within an activation domain. GAL4-fusion experiments indicate that HBP1 contains a masked activation domain. Deletion of two independent N- and C-terminal inhibitor domains unmasks an activation domain which is 100-fold more active than the full length protein. The released activation capacity is repressed by RE, p130 and p107. In addition, E1A can repress the activity of HBP1 via conserved region 1 sequences in a manner independent of the CBP coactivator. We show by stable expression in NIH3T3 cells that HBP1 has the capacity to induce morphological transformation of cells in culture.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge				Kouzarides, Tony/0000-0002-8918-4162; Lavender, Paul/0000-0001-8710-0263; Vandel, Laurence/0000-0002-3692-2942; Bannister, Andrew/0000-0002-6312-4436	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P228; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NEVINS JR, 1992, SCIENCE, V258, P424; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	34	59	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2721	2728		10.1038/sj.onc.1201243	http://dx.doi.org/10.1038/sj.onc.1201243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178770				2022-12-17	WOS:A1997XB97800011
J	Lomax, ME; Barnes, DM; Gilchrist, R; Picksley, SM; Varley, JM; Camplejohn, RS				Lomax, ME; Barnes, DM; Gilchrist, R; Picksley, SM; Varley, JM; Camplejohn, RS			Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	ONCOGENE			English	Article						p53; Li-Fraumeni syndrome; oligomerisation domain; functional assays	SV40-TRANSFORMED CELLS; CANCER; APOPTOSIS; CARCINOMA; PROTEIN; ANTIGEN; BLOOD	Previous investigations of a Li-Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene, In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient, The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene, A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was confirmed by sequencing of genomic DNA, This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain, This mutation results in a protein which still retains partial transactivational activity in the FASAY, The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.	ST THOMAS HOSP,UMDS,RICHARD DIMBLEBY DEPT CANC RES,LONDON SE1 7EH,ENGLAND; GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; PATERSON INST CANC RES,CRC,DEPT CANC GENET,MANCHESTER M20 9BX,LANCS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Dundee; Paterson Institute for Cancer Research								BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BIRCH JM, 1994, CANCER RES, V54, P1298; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Eeles RA, 1995, CANCER SURV, V25, P101; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HAINAUT P, 1994, ONCOGENE, V9, P299; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182	21	59	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1869	1874		10.1038/sj.onc.1201133	http://dx.doi.org/10.1038/sj.onc.1201133			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150393				2022-12-17	WOS:A1997WW16600013
J	Xu, YQ; Grundy, P; Polychronakos, C				Xu, YQ; Grundy, P; Polychronakos, C			Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor	ONCOGENE			English	Article						imprinting; Wilms' tumor; insulin-like growth factor II; receptor; gene dosage	MATERNAL-SPECIFIC METHYLATION; IGF2R LOCUS; EXPRESSION; MOUSE; HETEROZYGOSITY; RELAXATION; CANCER; SIGNAL; WT1	Wilms' tumor (WT) is an embryonal renal malignancy, which overexpresses insulin-like growth factor II (IGF-II a fetal mitogen. Relaxation of parental imprinting of IGF2, the gene encoding IGF-II, is found in Wilms' tumors, suggesting an important role for IGF2 dosage in tumorigenesis. The IGF2R gene encodes a nonmitogenic receptor which targets IGF-II to the lysosomes for degradation and, therefore, inhibits the mitogenic function of IGF-II. The human IGF2R is imprinted in a proportion of normal individuals. To test the hypothesis that IGF2R imprinting predisposes to Wilms' tumor through the effect of decreased IGF2R dosage on IGF-II inactivation, we examined IGF2R imprinting in Wilms' tumors. Two transcribed CA repeat polymorphisms were used to distinguish the two alleles in the RT-PCR product. We observed that in 7/16 of Wilms' tumor patients, the paternal IGF2R was markedly but not completely repressed in both tumor and normal kidney. In one additional case, IGF2R was likewise imprinted in the tumor but not in the normal kidney. A similar imprinting was observed in fetal tissues and placenta prior to 20 weeks fetal age but not in term placenta or postnatal blood cells, indicating abnormal persistence of a fetal pattern in the kidneys of Wilms' patients, Genetic analysis showed association of the imprinting with a cis-acting locus. The high frequency of aberrant persistence of IGF2R imprinting in the kidneys of Wilms' tumor patients, which may be an embryonic feature, suggests that it is a predisposing factor in tumorigenesis. This is in accordance with evidence that IGF2R is a tumour suppressor in other types of malignancies.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT PEDIAT,DIV ENDOCRINOL,MONTREAL,PQ H3H 1P3,CANADA; CROSS CANC INST,EDMONTON,AB T6G 1Z2,CANADA	McGill University; University of Alberta			Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635				ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARLOW DP, 1991, NATURE, V349, P8487; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Ellis MJC, 1996, MOL ENDOCRINOL, V10, P286, DOI 10.1210/me.10.3.286; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOTO J, 1992, NUCLEIC ACIDS RES, V20, P923, DOI 10.1093/nar/20.4.923; HAIG D, 1991, CELL, V64, P1045; Hankins GR, 1996, ONCOGENE, V12, P2003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KIESS W, 1987, J BIOL CHEM, V262, P12745; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OKA Y, 1985, J BIOL CHEM, V260, P9435; POLYCHRONAKOS C, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P369; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIS A, 1994, AM J HUM GENET, V54, P741; Riesewijk AM, 1996, GENOMICS, V31, P158, DOI 10.1006/geno.1996.0027; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542	34	59	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1041	1046		10.1038/sj.onc.1200926	http://dx.doi.org/10.1038/sj.onc.1200926			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070652				2022-12-17	WOS:A1997WM07000005
J	Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H				Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H			Involvement of the Tp1-2/cot oncogene in MMTV tumorigenesis	ONCOGENE			English	Article						MMTV; Tp1-2/cot; mammary tumor	MAMMARY-TUMOR VIRUS; T-CELL LYMPHOMAS; PROTEIN-KINASE; COT PROTOONCOGENE; TRANSFORMING GENE; SERINE KINASE; EXPRESSION; TPL-2; IDENTIFICATION; ACTIVATION	We report for the first time a relationship between the Tpl-2/cot oncogene and Mouse Mammary Tumor Virus (MMTV) associated transformation of mammary gland cells, A sub-genomic library generated from a primary mammary gland tumor yielded a novel MMTV integration site which disrupted the Tpl-2/cot proto-oncogene between exons 7 and 8, Comparison of a cell line derived from normal mammary gland (comma-D) and a cell line established from an MMTV induced mammary tumor (GR) demonstrated similar rearrangements within Tpl-2/cot for the GR cells but not in the comma-D cells, These rearrangements in the cell line were accompanied by an increase in the level of Tpl-2/cot specific mRNA, This data suggests that Tpl-2/cot expression may be important in epithelial cell transformation or tumor progression.	CHU VAUDOIS, INST MICROBIOL, CH-1011 LAUSANNE, SWITZERLAND; SWISS INST CANC RES, ISREC, EPALINGES, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research				Erny-Albrecht, Katrina/0000-0003-3538-1475				AOKI M, 1993, J BIOL CHEM, V268, P22723; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1993, ONCOGENE, V8, P1329; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LAMBERT JF, 1993, MOL IMMUNOL, V30, P1399, DOI 10.1016/0161-5890(93)90101-G; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; OHARA R, 1995, J CELL SCI, V108, P97; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; PADMA R, 1991, CANCER RES, V51, P2486; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RINGOLD G, 1975, VIROLOGY, V65, P135, DOI 10.1016/0042-6822(75)90014-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Varmus H E, 1983, Prog Clin Biol Res, V119, P23; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	25	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2015	2020						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934549				2022-12-17	WOS:A1996VR79500022
J	Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A				Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A			A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines	ONCOGENE			English	Article						antisense RNA; hybrid RNA; synthetic oligonucleotides; apoptosis; bcl-2 regulation	MESSENGER-RNA DEGRADATION; FIBROBLAST GROWTH-FACTOR; 3' UNTRANSLATED REGION; AU-RICH SEQUENCES; C-MYC GENE; BURKITTS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION; IN-VITRO; B-CELLS; GM-CSF	The 14;18 chromosome translocation, characteristic of most human follicular B-cell lymphomas, juxtaposes the bcl-2 gene with the IgH locus, creating a bcl-2/IgH hybrid gene, By mechanisms that are still under investigation, this event increases the cellular levels of the bcl-2 mRNA and thereby induces an overproduction of the antiapoptotic BCL-2 protein which is likely responsible for neoplastic transformation, In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHHZ and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion, This antisense transcript is a hybrid bcl-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and spans at least the complete 3' UTR region of the bcl-2 mRNA, To achieve some insight into its biological function, we treated the t(14;18) DOHH2 cell line with oligonucleotides (ODNs) by specifically targeting the bcl-2/IgH antisense strand, These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis, We would like to propose the hypothesis that the bcl-2/IgH antisense transcript may contribute, by an unknown mechanism, to upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.	SCH MED, DEPT PHARMACOL, I-20129 MILAN, ITALY; UNIV FLORENCE, INST GEN PATHOL, I-50134 FLORENCE, ITALY	University of Florence			Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Quattrone, Alessandro/0000-0003-3333-7630; Schiavone, Nicola/0000-0002-1592-4244				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; APEL TW, 1992, ONCOGENE, V7, P1267; ASSONBATRES MA, 1994, ANN NY ACAD SCI, V712, P34, DOI 10.1111/j.1749-6632.1994.tb33560.x; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARBONARI M, 1994, BLOOD, V83, P1268; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORNELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P7203, DOI 10.1093/nar/17.18.7203; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COTTER FE, 1994, ONCOGENE, V9, P3049; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; GESSANI S, 1993, VIROLOGY, V193, P507, DOI 10.1006/viro.1993.1154; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GREENBERG ME, 1990, ENZYME, V44, P181, DOI 10.1159/000468756; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOB CO, 1993, NUCLEIC ACIDS RES, V21, P2761, DOI 10.1093/nar/21.11.2761; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JOCHUM C, 1990, J VIROL, V64, P1956, DOI 10.1128/JVI.64.5.1956-1963.1990; KHOCHBIN S, 1992, ANN NY ACAD SCI, V660, P77, DOI 10.1111/j.1749-6632.1992.tb21060.x; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kitada S, 1993, Antisense Res Dev, V3, P157; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNEBA M, 1991, CANCER RES, V51, P3243; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LERNER A, 1993, J IMMUNOL, V151, P3152; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUNIR MI, 1992, ANTISENSE RNA PRODUC; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PETERSON JA, 1993, NUCLEIC ACIDS RES, V21, P5500, DOI 10.1093/nar/21.23.5500; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; QUATTRONE A, 1995, CANCER RES, V55, P90; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RAYMOND V, 1989, ONCOGENE RES, V5, P1; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1990, CANCER RES, V50, P6565; RIVKIN M, 1993, MOL REPROD DEV, V35, P394, DOI 10.1002/mrd.1080350413; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROY N, 1992, NUCLEIC ACIDS RES, V20, P5753, DOI 10.1093/nar/20.21.5753; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIANG R, 1993, AM J HUM GENET, V53, P836; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; TAYLOR ER, 1991, J MOL ENDOCRINOL, V7, P145, DOI 10.1677/jme.0.0070145; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHOU BS, 1992, CANCER RES, V52, P4280; ZUNIGA A, 1993, DEV BIOL, V157, P110, DOI 10.1006/dbio.1993.1116	80	59	64	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					105	115						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700536				2022-12-17	WOS:A1996UX31900012
J	Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H				Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H			Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies	ONCOGENE			English	Article						AML1; transformation; fibroblasts; DNA-binding; transactivational potencies	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; FUSION TRANSCRIPT; POLYOMAVIRUS ENHANCER; HEMATOPOIETIC-CELLS; ONCOGENIC ACTIVITY; NUCLEAR FACTOR; RUNT; EXPRESSION; RECEPTOR	The AML1 gene encodes DNA-binding proteins that contain the runt homology domain and is found at the breakpoints of t(8;21) and t(3;21) translocations associated with myelogenous leukemias. From the AML1 gene, two representative forms of proteins, AML1a and AML1b, are generated by alternative splicing. Both forms have the runt homology domain that possesses the DNA-binding ability but, unlike AML1b, AML1a lacks a putative transcriptional activation domain downstream of the runt homology domain. By using retroviral infection, we demonstrated that AML1b causes neoplastic transformation of NIH3T3 cells, AML1b-expressing cells form macroscopic colonies in soft agar and induce tumors in nude mice, indicating that AML1 can be a transforming gene when overexpressed in fibroblasts. Both the runt homology domain and the transactivational domain were required to transform NIH3T3 cells. By analysis of deletion mutants, it was shown that an element determining the transactivational potency exists between amino acids 288 and 396 within the region downstream of the runt homology domain. Furthermore, we demonstrated that this region was also required for fibroblast transformation, indicating that the transforming activity of AML1 is correlated with the transactivational potencies. These results suggest a role of AML1 in the regulation of cellular proliferation, as well as myeloid cell differentiation.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P2090; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOZU T, 1993, BLOOD, V82, P1270; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	54	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					883	892						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632911				2022-12-17	WOS:A1996TW68600020
J	DHANWADA, KR; DICKENS, M; NEADES, R; DAVIS, R; PELLING, JC				DHANWADA, KR; DICKENS, M; NEADES, R; DAVIS, R; PELLING, JC			DIFFERENTIAL-EFFECTS OF UV-B AND UV-C COMPONENTS OF SOLAR-RADIATION ON MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS IN EPIDERMAL-KERATINOCYTES	ONCOGENE			English	Article						UV-B/C RADIATION; MAP KINASE; KERATINOCYTES; JUN NH2-TERMINAL KINASE (JNK); ERK KINASE	HUMAN-SKIN; ACTIVATION DOMAIN; PROTEIN-KINASE; PHORBOL ESTER; JUN ACTIVITY; PHOSPHORYLATION; RAS; CANCER; GENE; CARCINOGENESIS	Exposure to solar ultraviolet (UV) light is a major cause of skin cancer, the most common human neoplasm. The earth's upper atmosphere absorbs the high energy UV-C wavelengths (100-280 mm), while allowing transmission of UV-B (280-320 nm) and UV-A (320-400 nm). It is therefore UV-B and to some extent UV-A, that contributes to most human skin malignancies. We report that the exposure of cultured keratinocytes or skin to UV-C radiation causes activation of MAP kinases (ERK and JNK). In contrast, the solar radiation associated with skin cancer (UV-B) was an ineffective activator of the ERK and JNK signal transduction pathways. Therefore, while exposure of epidermal cells to UV-C radiation under laboratory conditions causes marked activation of MAP kinase signal transduction pathways, only a low level of MAP kinase signaling is involved in the response of skin to biologically relevant solar radiation.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA	University of Nebraska System; University of Nebraska Medical Center; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA58396, CA65861, CA40847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396, R01CA040847, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, IN PRESS CELL GROWTH; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BETZ NA, 1995, MOL CARCINOGEN, V12, P66, DOI 10.1002/mc.2940120203; BETZ NA, 1992, MOL CARCINOGEN, V6, P10, DOI 10.1002/mc.2940060104; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1985, CANCER RES, V45, P6254; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BUSCHER M, 1988, ONCOGENE, V3, P301; BUZZELL RA, 1993, OTOLARYNG CLIN N AM, V26, P1; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COWLEY S, 1994, CELL, V11, P841; DARR DJ, 1988, CUTANEOUS AGING, P415; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HALL PA, 1993, ONCOGENE, V8, P203; HERRLICH P, 1984, ADV ENZYME REGUL, V25, P485; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMBERT WC, 1995, SKIN CANC MECH HUMAN, P39; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6940; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STRICKLAND JE, 1988, CANCER RES, V48, P165; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAN MH, 1994, NATURE, V372, P798; YUSPA SH, 1991, PHYSL BIOCH MOL BIOL, P1365	58	59	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1947	1953						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478512				2022-12-17	WOS:A1995TF29700003
J	FORD, HL; SALIM, MM; CHAKRAVARTY, R; ALUIDDIN, V; ZAIN, SB				FORD, HL; SALIM, MM; CHAKRAVARTY, R; ALUIDDIN, V; ZAIN, SB			EXPRESSION OF MTS1, A METASTASIS-ASSOCIATED GENE, INCREASES MOTILITY BUT NOT INVASION OF A NONMETASTATIC MOUSE MAMMARY ADENOCARCINOMA CELL-LINE	ONCOGENE			English	Article						MTS1; METASTASIS; MOTILITY; BREAST CANCER MODEL	CALCIUM-BINDING PROTEIN; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; CARCINOMA CELLS; STRONG HOMOLOGY; TUMOR INVASION; MELANOMA-CELLS; MESSENGER-RNA; SEQUENCE; FAMILY	The mts1 gene codes for a 101 amino acid protein belonging to the S100 subfamily of Ca2+-binding proteins. Mts1 is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, and although mts1 is known to be involved in the metastatic phenotype (Davies et al., 1993; Grigorian et al., 1993), the role mts1 plays in this process is not clearly understood. In order to determine what role mts1 plays in the process of metastasis, we have transfection studies on nonmetastatic and mouse mammary adenocarcinoma cell lines, CSML0 and CSML100, respectively (Senin et al., 1983, 1984). The metastatic variant, CSML100, expresses high levels of mts1, whereas the nonmetastatic variant, CSML0, expresses almost no mts1. CSML0 cells transfected with mts1 were assessed in in vitro motility and invasion assays, as web as in vivo metastasis assays to determine the role of mts1 in these processes, Cell lines expressing mts1 display an altered morphology as, well as increased motility in modified Boyden chemotaxis chambers, However, no significant increase in in vitro invasion or in in vivo metastasis was observed. Therefore, the presence of mts1 may be important for metastasis by increasing motility, but may not be sufficient for invasion in vitro or metastasis in vivo. Very low levels of type IV collagenase activities were observed in CSML0 cells and the transfectants, as opposed to the highly metastatic CSML100 cells, where high levels of type IV collagenase activities were observed. It is possible that the presence of these proteases in addition to mts1 may be responsible for the high metastatic potential of the CSML100 in vivo.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NCI NIH HHS [P30CA11198, R01CA62376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R01CA062376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAHLER DW, 1985, J IMMUNOL, V134, P2790; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PD, 1990, CANCER RES, V550, P6184; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; Carson FL, 1990, HISTOTECHNOLOGY SELF; DAVIES BR, 1993, ONCOGENE, V8, P999; DELEON M, 1991, J NEUROSCI RES, V29, P155; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORD HL, 1995, ONCOGENE, V10, P1597; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KORCZAK B, 1991, CELL GROWTH DIFFER, V2, P335; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, CANCER RES, V46, P1; MAEMURA M, 1994, BREAST CANCER RES TR, V32, P239, DOI 10.1007/BF00666002; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RAY JM, 1994, EUR RESPIR J, V7, P2062; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SENIN VM, 1983, EXP ONCOL USSR, V5, P35038; SILBERMAN S, 1990, EXP CELL RES, V189, P64, DOI 10.1016/0014-4827(90)90257-B; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	48	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2067	2075						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478526				2022-12-17	WOS:A1995TF29700017
J	MAZZARELLI, JM; ATKINS, GB; GEISBERG, JV; RICCIARDI, RP				MAZZARELLI, JM; ATKINS, GB; GEISBERG, JV; RICCIARDI, RP			THE VIRAL ONCOPROTEINS AD5 E1A, HPV16 E7 AND SV40 TAG BIND A COMMON REGION OF THE TBP-ASSOCIATED FACTOR-110	ONCOGENE			English	Article						DTAF(II)110; HPV16 E7; SV40 TAG; AD5 E1A	TRANSCRIPTION FACTOR; ADENOVIRUS-E1A PROTEIN; DOMAIN BINDS; ACTIVATION; GENES	A function shared by the adenovirus E1A, papillomavirus E7 and SV40 TAg oncoproteins is their ability to interfere with normal cell growth by interacting with members of the retinoblastoma protein family, In this study, are show that each of these oncoproteins can also bind to the 921 amino acid TBP-associated factor-110 (TAF-110), The significance of the binding is underscored by the observation that each oncoprotein binds to the same 77 amino acid carboxyl region of TAF-110, In the case of E1A and TAg, this finding is consistent with their abilities to stimulate transcription initiation, in part, through their known interactions with TBP, While it is not clear whether E7 can also activate promoters through protein:protein interactions with components of the transcription initiation complex, our demonstration that E7 can bind to TAF-110, as well as TBP, suggests that E7 may modulate the expression of specific promoters which could contribute to the pathogenesis of human papillomavirus.	UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, GRAD GRP BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, MD PHD PROGRAM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA29797] Funding Source: Medline; NIAID NIH HHS [AI07324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broker T.R., 1986, CANCER CELL, V4, P17; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; GALLOWAY DA, 1989, ADV VIRUS RES, V37, P125; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; Ricciardi R, 1995, DNA TUMOR VIRUSES ON, P195; RICCIARDI RP, 1981, P NATL ACAD SCI-BIOL, V78, P6121, DOI 10.1073/pnas.78.10.6121; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; ZUE J, 1991, J VIROL, V65, P2778	25	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1859	1864						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478615				2022-12-17	WOS:A1995TD09400022
J	ORMONDROYD, E; DELALUNA, S; LATHANGUE, NB				ORMONDROYD, E; DELALUNA, S; LATHANGUE, NB			A NEW MEMBER OF THE DP FAMILY, DP-3, WITH DISTINCT PROTEIN PRODUCTS SUGGESTS A REGULATORY ROLE FOR ALTERNATIVE SPLICING IN THE CELL-CYCLE TRANSCRIPTION FACTOR DRTF1/E2F	ONCOGENE			English	Article						E2F; DP; TRANSCRIPTION FACTOR; CELL CYCLE; SPLICING	RETINOBLASTOMA GENE-PRODUCT; COMPLEX-FORMATION; BINDING PROTEIN; MESSENGER-RNA; FACTOR E2F; CLONING; P107; TRANSACTIVATION; PROLIFERATION; TRANSLATION	Integrating cell cycle progression with transcription provides an important level of control during proliferation, The cellular transcription factor DRTF1/E2F is implicated in this integration process by virtue of its physical interaction and control by key regulators of proliferation, such as retinoblastoma protein, cyclins and cyclin-dependent kinases and regulation of target genes required for cell cycle progression, Generic DRTF1/E2F DNA binding activity arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers, Here, we report the isolation and characterisation of a new member of the murine DP family, called DP-3 (also referred to as human DP-2), In contrast to previously characterised members of the DP and E2F families, processing of DP-3 RNA provides an important level of control by generating at least four distinct DP-3 proteins, of which three have been isolated, called alpha, beta and gamma, Processing events, which we show are both tissue- and cell-restricted, can occur either in the 5' region of DP-3 RNA and determine whether translation begins at one or two potential intiating codons, or within the coding sequence, producing variations in internal domains of the DP-3 proteins, The DP-3 proteins studied can co-operate with E2F-1 in DNA binding activity and trans activation of E2F site-dependent transcription, This analysis of DP-3, which has uncovered a hitherto unexpected and surprising level of complexity, documents a new member of the DP family and novel levels of control which may influence the activity DRTF1/E2F and hence cell cycle progression.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			de la Luna, Susana/E-9553-2015	de la Luna, Susana/0000-0001-7765-916X; Ormondroyd, Elizabeth/0000-0002-9116-4064				ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCK V, 1995, ONCOGENE, V11, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HEIBERT SW, 1992, GENE DEV, V6, P177; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILL JR, 1993, J BIOL CHEM, V268, P726; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7032; NEVINS JR, 1992, SCIENCE, V258, P424; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	59	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1437	1446						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478568				2022-12-17	WOS:A1995TC53500002
J	CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V				CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V			FARNESYLTRANSFERASE INHIBITORS ARE INHIBITORS OF RAS BUT NOT R-RAS2/TC21, TRANSFORMATION	ONCOGENE			English	Article						R-RAS2/TC21; P21 RAS; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE I; BISUBSTRATE ANALOGS; FARNESYLATION	GTP-BINDING PROTEINS; GERANYLGERANYL TRANSFERASE; PRENYLATION; ISOPRENYLATION; GROWTH; CELLS; FARNESYLATION; REQUIREMENT; SPECIFICITY; SEQUENCE	Recent results from several laboratories including ours strongly suggest that farnesyltransferase (FT) inhibitors belonging to distinct chemical classes block growth of oncogenic Ras transformed cells at concentrations that do not affect the growth and viability of normal cells, This is despite blocking the farnesylation and thus the membrane association of Ras in both cell types. This is a paradox given the requirement for Ras function in normal cell growth. Recent evidence that R-Ras2/TC21 utilizes components of Ras signal transduction pathways to trigger cellular transformation (Graham et al., MCB 14, 4108-4115, 1994) prompted us to consider the possibility that R-Ras2/TC21 is involved in some aspects of the growth regulation of normal cells. If so, R-Ras2/TC21 may be compensating for Ras function in untransformed cells treated with FT inhibitors. In this study, we demonstrated that a cell active bisubstrate analog FT inhibitor, BMS-186511, completely blocked the function of oncogenic Ras, but did not affect the function of oncogenic R-Ras2/TC21, as determined by several criteria including inhibition of anchorage dependent and independent growth, reversal of transformed morphology and restoration of actin cytoskeleton. While it is known that TC21 protein becomes prenylated, it is not known whether it is farnesylated or geranylgeranylated. Our in vitro prenylation experiments indicate that R-Ras2/TC21 protein serves as a good substrate for FT as well as geranylgeranyltransferase I (GGTI) and thus provide the apparent molecular basis for these differences. Overall, these results, coupled with the ubiquitous expression of R-Ras2/TC21 in many cells including untransformed NIH3T3 cells, are consistent with the possibility that R-Ras2/TC21 may be one of the factors that render normal cells insensitive to the growth inhibitory action of FT inhibitors.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; manne, veeraswamy/B-1954-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COX AD, 1993, J BIOL CHEM, V268, P11548; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOBERTY G, 1993, FEBS LETT, V330, P323, DOI 10.1016/0014-5793(93)80897-4; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1995, IN PRESS ONCOGENE; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SELF AJ, 1993, ONCOGENE, V8, P655; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	54	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1905	1913						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761092				2022-12-17	WOS:A1995QZ92600004
J	HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR				HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR			EFFECTS OF HETEROZYGOSITY FOR THE RB-1(T19NEO) ALLELE IN THE MOUSE	ONCOGENE			English	Article						RB-1; TRANSGENIC; MOUSE; PITUITARY; TUMORIGENESIS; NESIDIOBLASTOSIS	RETINOBLASTOMA GENE-PRODUCT; HUMAN-BREAST-CARCINOMA; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; PROTEIN; PHOSPHORYLATION; MUTATION; BINDING	We describe the pathology of a cohort of 80 mice heterozygous for an inactive allele of the Rb-1 tumour suppressor gene. The majority of these mice developed locally invasive tumours, arising from the pituitary gland. The time of onset of overt signs of disease in mice known to have inherited their mutant allele paternally shows a small but statistically significant shift to the lower end of the spectrum, suggesting that tumorigenesis is influenced by gametic imprinting. In situ hybridisation analysis demonstrates the presence in the tumours of proopiomelanocortin mRNA, which is normally found both in corticotroph and melanotroph cells. Mice within this cohort also develop systemic defects. Most notably, there is increased siderosis in the spleen indicating the possibility of an abnormality in red blood cell turnover, This is consistent with the abnormalities of erythropoiesis described previously in homozygous R6-1-deficient mice. In addition, a proportion of mice developed liver steatosis, probably representing the end organ effects of hormonal imbalance as a direct consequence of tumour presence. A significant proportion showed C cell hyperplasia in the thyroid. The spectrum of pathology in mice differs from that in the human but does provide a useful model of site-specific tumour predisposition.			HARRISON, DJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Armstrong, Jane/0000-0002-0524-0260				BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOWMAKER JK, 1991, VISION VISUAL DYSFUN, V2, P63; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANEE WK, 1983, NATURE, V305, P779; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V362, P849; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARQUHARSON MA, 1992, J CLIN PATHOL, V45, P999, DOI 10.1136/jcp.45.11.999; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOOPER ML, 1995, IN PRESS J CELL SC S, V18; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JACKS T, 1992, NATURE, V359, P285; KATO J, 1993, GENE DEV, V7, P331; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAINS RE, 1979, J BIOL CHEM, V254, P7885; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER RG, 1981, SURVIVAL ANAL, pCH4; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PURDIE CA, 1994, ONCOGENE, V9, P603; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; ROBERTS JL, 1980, BIOCHEM, V17, P3609; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1993, ONCOGENE, V8, P279; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	44	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1615	1620						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731716				2022-12-17	WOS:A1995QU68100018
J	CIOSSEK, T; MILLAUER, B; ULLRICH, A				CIOSSEK, T; MILLAUER, B; ULLRICH, A			IDENTIFICATION OF ALTERNATIVELY SPLICED MESSENGER-RNAS ENCODING VARIANTS OF MDK1, A NOVEL RECEPTOR TYROSINE KINASE EXPRESSED IN THE MURINE NERVOUS	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; NEURAL DEVELOPMENT	GROWTH-FACTOR RECEPTOR; PROTO-ONCOGENE; W-LOCUS; GENE; MOUSE; FAMILY; MEMBERS; CLONING; CHICKEN; DNA	A novel member of the eck/eph family of receptor tyrosine kinases (RTKs), termed mouse developmental kinase 1 (MDK1), was identified and shown to be closely related to the Eek, Ehk1/Cek7, Ehk2, Cek4/Mek4/hek and Sek/Cek8 subfamily. Northern blot analysis revealed MDK1 mRNA transcripts of 6.8, 5.7, 4.0, 3.2 and 2.6 kb that encode apparent splice variants. Sequence analyses of MDK1 cDNA clones from adult mouse brain predict the existence of at least five isoforms, including two truncated receptor variants lacking the kinase domain. Northern blot and in situ hybridization analysis indicate that in the adult mouse MDK1 RNA expression is restricted to brain, testes and spleen. The distinct patterns of MDK1 gene expression during mouse development suggest an important role in the formation of neuronal structures and possibly other morphogenic processes.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Max Planck Society								BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Ito M, 1984, CEREBELLUM NEURAL CO; Jensen D, 1980, HUMAN NERVOUS SYSTEM; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROHEN JW, 1985, FUNKTIONELLE ANATOMI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1992, J BIOL CHEM, V267, P1470; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					97	108						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824284				2022-12-17	WOS:A1995QA98000012
J	SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP				SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP			IN-VITRO PHOSPHORYLATION OF CAVEOLIN-RICH MEMBRANE DOMAINS - IDENTIFICATION OF AN ASSOCIATED SERINE KINASE-ACTIVITY AS A CASEIN KINASE II-LIKE ENZYME	ONCOGENE			English	Article							TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; GROWTH-FACTOR; CELL-SURFACE; 3T3-L1 CELLS; INSULIN; PROTEIN; BINDING; DIFFERENTIATION	Caveolae are flask-shaped micro-invaginations associated with the plasma membrane of a wide variety of cell types. Caveolin, an integral membrane component of caveolae, was first identified as the major phosphoprotein whose phosphorylation was elevated in v-Src transformed cells. As both v-Src transformation and elevated caveolin phosphorylation were dependent on membrane attachment of v-Src, it has been suggested that caveolin is a critical target in v-Src transformation. Although an increase in tyrosine phosphorylation of caveolin was evident, the increase in caveolin phosphorylation was predominantly on serine residues. In accordance with these in vivo observations, isolated caveolin-rich membrane domains undergo phosphorylation in vitro predominantly on serine and contain an unidentified serine kinase activity. Here, we have identified this serine kinase activity as a casein kinase II-like enzyme, since the phosphorylation of caveolin-rich membrane domains is stimulated and inhibited by known effecters of casein kinase II (poly-L-lysine, endogenous polyamines, and a casein kinase II inhibitor peptide), but is unaffected by modulators of other known kinases. In support of these observations, caveolin contains a consensus sequence for casein kinase II phosphorylation in its cytoplasmic N-terminal domain (Ser-88). A peptide containing this sequence inhibits the in vitro phosphorylation of caveolin-rich membrane domains, while many other peptides derived from the N-terminal domain of caveolin do not affect phosphorylation. Caveolin-rich membrane domains were also a substrate for exogenously added purified casein kinase II, but not casein kinase I. Finally, immunoblotting of these domains with an antibody directed against the alpha and alpha' subunits of casein kinase II reveals two bands with apparent molecular weights consistent with the known molecular weights of the alpha and alpha' subunits of casein kinase II. As casein kinase II appears to play a role in mitogenic signalling events and casein kinase II activators (endogenous polyamines) are required for v-Src transformation, our results may have implications for understanding the mechanism of v-Src oncogenesis.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,DEPT PEDIAT GASTROENTEROL,DIV MUCOSAL IMMUNOL,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047618, R37DK047618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47618] Funding Source: Medline; NIGMS NIH HHS [GM-50443, GM-49516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1993, J CELL BIOL, V124, P307; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TELLEZ R, 1992, FEBS LETT, V308, P113, DOI 10.1016/0014-5793(92)81255-K; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S	36	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2589	2595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058322				2022-12-17	WOS:A1994PC05400018
J	LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G				LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G			EVIDENCE FOR RETINOBLASTOMA PROTEIN (RB) DEPENDENT AND INDEPENDENT IFN-GAMMA RESPONSES - RB COORDINATELY RESCUES IFN-GAMMA INDUCTION OF MHC CLASS-II GENE-TRANSCRIPTION IN NONINDUCIBLE BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; MALIGNANT PHENOTYPE; DERMAL FIBROBLASTS; SURFACE EXPRESSION; MESSENGER-RNAS; TUMOR-CELLS; CHAIN GENE; HLA-DR; C-FOS; ANTIGENS	The class II major histocompatibility (MHC) genes encode cell surface heterodimers that present processed antigen to CD4 positive T-cells. The class II genes are expressed constitutively on B-cells and can be induced by IFN-gamma on a variety of other cell types. Because the class II genes are aberrantly expressed on many mesenchymal tumors, which are frequently defective for the retinoblastoMa tumor suppressor protein (RB), we investigated the role of RB in the regulation of HLA-DR and -DP. The RB defective breast carcinomas cell line, MDA-468-S4 (S4), as well as S4 subclones reconstituted with RB coding sequences under the control of a zinc inducible promoter, were treated with IFN-gamma and examined for DR and DP expression. Surface DR is not inducible in S4 cells, but inducibility is rescued by RB. DP is only slightly inducible in S4, but inducible to a much higher level in the RB positive subclones of S4. IFN-gamma induction of DR and DP mRNAs are correspondingly dependent on RB. IFN-gamma receptors are present on S4 cells, and the guanylate binding protein and ICAM-1 genes respond to IFN-gamma, ruling out the possibility that all IFN-gamma signal transduction pathways are defective in S4 cells. These data indicate RB regulates the coordinate response of class II genes to IFN-gamma. Possible roles for RB in this process are discussed, as well as the role of the class II-noninducible phenotype in tumor rejection.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV TORONTO,DEPT MOLEC GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO M5G 1X8,ONTARIO,CANADA	State University System of Florida; University of South Florida; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Blanck, George/A-5365-2012	Gallie, Brenda/0000-0002-9697-9211				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BASTA PV, 1987, J IMMUNOL, V138, P1275; BERNARD DJ, 1992, BRIT J CANCER, V66, P88, DOI 10.1038/bjc.1992.222; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BLANCK G, 1992, J FLORIDA MED ASS, V79, P97; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENTS VK, 1992, J IMMUNOL, V149, P2391; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DETRICK B, 1988, CANCER RES, V48, P1633; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; HAMMEL PA, 1992, MOL CELL BIOL, V12, P3431; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIOU HC, 1990, SCIENCE, V24, P1581; MAUER DH, 1987, TISSUE ANTIGENS, V31, P174; MOLLER P, 1989, AM J PATHOL, V135, P73; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCOTLANDI K, 1992, ANTICANCER RES, V12, P767; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SRIKUMAR P, 1991, CELL, V65, P1053; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	48	59	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1015	1019						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134104				2022-12-17	WOS:A1994NC04800002
J	HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T			ABERRANT UP-REGULATION OF A NOVEL INTEGRIN ALPHA-SUBUNIT GENE AT 3P21.3 IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							ADHESION RECEPTOR; SHORT ARM; EXPRESSION; VLA-4; FIBRONECTIN; CARCINOMA; DISTINCT; DELETION; FAMILY; ABNORMALITIES	Our recent identification of homozygous deletions at 3p21.3 in lung cancer has provided further support for the presence of a tumor suppressor gene in this chromosomal region. As a part of our efforts for positional cloning of a tumor suppressor gene at 3p21.3, we have characterized a transcriptional unit within this region using genomic fragments with interspecies conservation. The identified gene was found to encode a novel integrin alpha subunit, termed alpha(RLC), which is closely related to alpha(4) in structure but clearly different from alpha(4) in its expression pattern in the physiological and pathological setting of the lung. This finding and the exact localization of the gene suggest that it is a good candidate for a tumor suppressor gene in lung cancer, but our extensive search covering one third of the gene did not reveal any somatic mutations within the coding region. Interestingly, however, alpha(RLC) was abundantly expressed in fetal lung and lung cancers, particularly small cell lung cancers (SCLC). Its aberrant upregulation in the SCLC samples, both cell lines and primary tumors, which might have been caused by a yet unidentified mutations or by deletions of other gene, and its homology to alpha which is thought to play a role in metastasis, suggest that altered alpha(RLC) expression may contribute to the acquisition of malignant phenotypes of this type of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; CANC INST,DEPT BIOCHEM,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Japanese Foundation for Cancer Research			Yamakawa, Kazuhiro/N-5050-2015; Takahashi, Takashi/I-7262-2014; Tamari, Mayumi/N-5378-2015	Yamakawa, Kazuhiro/0000-0002-1478-4390; Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORETZ K, 1991, AM J PATHOL, V138, P741; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; MATTILA P, 1992, INT J CANCER, V52, P918, DOI 10.1002/ijc.2910520615; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAKAKURA T, 1983, UNDERSTANDING BREAST, P261; SUZUKI H, 1992, CANCER RES, V52, P734; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOYAMA S, 1992, CANCER RES, V52, P873; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	37	59	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					611	619						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290272				2022-12-17	WOS:A1994MW24800029
J	GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR				GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR			HYPERPLASIA, HYPERKERATOSIS AND BENIGN-TUMOR PRODUCTION IN TRANSGENIC MICE BY A TARGETED V-FOS ONCOGENE SUGGEST A ROLE FOR FOS IN EPIDERMAL DIFFERENTIATION AND NEOPLASIA	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; MOUSE SKIN CARCINOGENESIS; TRANSCRIPTION FACTOR AP-1; KERATIN GENE-EXPRESSION; C-FOS; CHEMICAL CARCINOGENESIS; CELL-LINES; PROTEIN; JUN; ACTIVATION	A vector, derived from the human K1 keratin gene, has been employed to target v-fos expression exclusively in the epidermis of transgenic mice. Adult transgenic mice expressors (3-4 months) displayed hyperplasia and hyperkeratosis, initially in wounded (tagged) ears, which later became bilateral. This phenotype appeared at other epidermal sites, most notably in the axilla and inguinal areas. This indicates that a second promoting event, such as wounding or friction, is required to elicit these pathological changes. Highly keratotic benign ear lesions and benign squamous papillomas appeared after long latency at sites of phenotypic epidermis. These data suggest that v-fos may be interfering with c-fos function in normal keratinocyte differentiation, but by itself is insufficient to elicit overt benign lesions.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; UPJOHN CO,KALAMAZOO,MI 49001	Baylor College of Medicine; Pfizer			Rothnagel, Joe/A-4874-2010	Rothnagel, Joe/0000-0002-6710-3165	NCI NIH HHS [CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALDAZ CM, 1988, CANCER RES, V48, P3253; ARGYRIS TS, 1982, CARCINOGENESIS COCAR, P43; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER PA, 1983, METHOD ENZYMOL, V96, P589; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; GREENHALGH DA, 1989, MOL CARCINOG, V3, P154; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hogan B., 1986, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS RJ, 1986, CANCER RES, V46, P3061; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V95, pS59, DOI 10.1111/1523-1747.ep12505805; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYNECK RP, 1991, ONCOGENE, V6, P533; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STRICKLAND JE, 1988, CANCER RES, V48, P165; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	63	59	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2145	2157						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687760				2022-12-17	WOS:A1993LP17100015
J	CHENG, JT; HSU, HL; HWANG, LY; BAER, R				CHENG, JT; HSU, HL; HWANG, LY; BAER, R			PRODUCTS OF THE TAL1-ONCOGENE - BASIC HELIX LOOP HELIX PROTEINS PHOSPHORYLATED AT SERINE RESIDUES	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ENHANCER-BINDING; TAL-1 GENE; SCL GENE; C-MYC; EXPRESSION; LOCUS	TAL1 gene rearrangement is observed in nearly 30% of patients with T-cell acute lymphoblastic leukemia (T-ALL), and thus it represents the most common genetic lesion associated with this disease. Nevertheless, the presence of TAL1 gene products in normal or leukemic cells has not been reported. Therefore, immunoprecipitation with anti-TAL1 antisera was used to demonstrate the presence of TAL1 phosphoproteins, pp42TAL1 and pp22TAL1, in both T-ALL and erythroleukemia cell lines. The pp42TAL1 and pp22TAL1 proteins appear to be phosphorylated forms of full-length and truncated TAL1 gene products respectively. Phosphoamino acid analysis revealed that pp42TAL1 contains phosphoserine residues. The TAL1 phosphoproteins were detected in all of the T-ALL cell lines that harbor obvious TAL1 gene rearrangements. Interestingly, pp42TAL1 and pp22TAL1 were also present in some, but not all, of the T-ALL lines without detectable TAL1 gene alterations. Therefore, TAL1 activation may promote leukemogenesis in a far greater proportion of T-ALL patients than the 30% that bear gross TAL1 gene rearrangements.	UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [CA46593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DUCLOS B, 1991, METHOD ENZYMOL B, V201, P10; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FITZGERALD TJ, 1991, BLOOD, V78, P2686; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GREEN AR, 1991, ONCOGENE, V6, P475; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MINOWADA J, 1988, Cancer Reviews, V10, P1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RG, 1981, J IMMUNOL, V126, P596; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	35	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437851				2022-12-17	WOS:A1993KN00800019
J	LAMMIE, GA; SMITH, R; SILVER, J; BROOKES, S; DICKSON, C; PETERS, G				LAMMIE, GA; SMITH, R; SILVER, J; BROOKES, S; DICKSON, C; PETERS, G			PROVIRAL INSERTIONS NEAR CYCLIN D1 IN MOUSE LYMPHOMAS - A PARALLEL FOR BCL1 TRANSLOCATIONS IN HUMAN B-CELL NEOPLASMS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; T(11-14) CHROMOSOME-TRANSLOCATION; MAMMARY-TUMOR VIRUS; C-MYC ONCOGENE; T-CELL; CANDIDATE ONCOGENE; MOLECULAR-CLONING; PUTATIVE ONCOGENE; VIRAL INTEGRATION; ACTIVATION	By isolating genomic DNA clones that encompass the mouse Cyl-1 (cyclin D1) locus, we have identified a putative CpG island close to the 5' end of the gene. Pulsed-field gel electrophoresis with probes derived from either the 5' or 3' side of the CpG island established physical linkage to two independent markers on mouse chomosome 7, in a region that is syntenic with human chromosome 11q13. On the 3' side, Cyl-1 is approximately 75 kb from Hst-1 and Int-2, although there is an additional CpG island in the intervening DNA, while on the 5' side, Cyl-1 is less than 300 kb from Fis-1, an integration site for Friend murine leukaemia virus. As there is no intervening CpG island, proviral insertions at Fis-1 could influence the expression of Cyl-1 and we describe two virally induced tumours in which this appears to be the case. The data suggest that proviral insertions near Cyl-1 in mouse lymphomas are functionally equivalent to the BCL1 translocations that activate cyclin D1 expression in human B-cell malignancies.	IMPERIAL CANC RES FUND, MOLEC ONCOL LABS, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, VIRAL CARCINOGENESIS LABS, LONDON WC2A 3PX, ENGLAND; NIH, BETHESDA, MD 20982 USA	Cancer Research UK; Cancer Research UK; National Institutes of Health (NIH) - USA								ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIOUSSIS D, 1987, EMBO J, V6, P355, DOI 10.1002/j.1460-2075.1987.tb04762.x; KOEHNE CF, 1989, J VIROL, V63, P2366, DOI 10.1128/JVI.63.5.2366-2369.1989; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; NUSSE R, 1991, CURR TOP MICROBIOL, V171, P44; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SILVER J, 1986, J VIROL, V60, P1156, DOI 10.1128/JVI.60.3.1156-1158.1986; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; TSICHLIS PN, 1990, J VIROL, V64, P2236, DOI 10.1128/JVI.64.5.2236-2244.1990; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VILLENEUVE L, 1986, MOL CELL BIOL, V6, P1834, DOI 10.1128/MCB.6.5.1834; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	41	59	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2381	2387						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461646				2022-12-17	WOS:A1992KA85600002
J	GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW				GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW			CATALYTIC PROPERTIES, TISSUE AND INTRACELLULAR-DISTRIBUTION OF NEUROFIBROMIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYPE-1 GENE-PRODUCT; RAS GTPASE; IDENTIFICATION; SEQUENCE; DOMAIN; LIPIDS; GAP; MUTANTS; LOCUS	The neurofibromatosis type 1 (NF1) gene encodes a protein, neurofibromin, that shows homology with members of the GTPase-activating protein (GAP) family. To study neurofibromin, rabbit polyclonal antisera were raised against two synthetic peptides. These antisera immunoprecipitated a specific protein of about 240 kDa in lysates of adult murine and rat tissues both in the soluble (S100) and to a lesser degree in the particulate (P100) fractions. The neurofibromin immunoprecipitated from the lysates of several murine organs stimulated the intrinsic GTPase activity of p21 c-Ha-ras protein. Based on immunoblotting, immunoprecipitation and GTPase assays, neurofibromin appears to be at least 10-fold more abundant in the brain than in the other murine organs. The GTPase-stimulatory activity of full-length neurofibromin, like the catalytic GAP-related domain, is inhibited by arachidonic acid and the detergent dodecyl maltoside, while phosphatidic acid, containing arachidonic and stearic acid, is non-inhibitory. Immunofluorescence analysis with anti-neurofibromin sera in NIH3T3 cells suggests that at least some of the cellular protein associates with cytoplasmic structures that are distinct from actin or tubulin filaments.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	GOLUBIC, M (corresponding author), CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,NC1 150,CLEVELAND,OH 44195, USA.			Roudebush, Margaret/0000-0001-9005-3672	NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER; NCI NIH HHS [CA48662, CA53436] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HATTORI S, 1992, ONCOGENE, V7, P481; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANREGENMORTEL MHV, 1988, SYNTHETIC POLYPEPTID, P104; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	33	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2151	2159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437143				2022-12-17	WOS:A1992JW66500007
J	COOPER, CS				COOPER, CS			THE MET ONCOGENE - FROM DETECTION BY TRANSFECTION TO TRANSMEMBRANE RECEPTOR FOR HEPATOCYTE GROWTH-FACTOR	ONCOGENE			English	Review							PROTEIN TYROSINE KINASE; CYSTIC-FIBROSIS LOCUS; HUMAN CELL-LINE; MOLECULAR-CLONING; SCATTER FACTOR; MNNG-HOS; ACTIVATION; GENE; REARRANGEMENT; EXPRESSION				COOPER, CS (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KING HWS, 1988, ONCOGENE, V2, P617; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; RHIM JS, 1975, J NATL CANCER I, V55, P1291, DOI 10.1093/jnci/55.6.1291; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAWYER RH, 1983, EPITHELIAL MESENCHYM; SCAMBLER PJ, 1990, HUM GENET, V84, P274; SCAMBLER PJ, 1986, NUCLEIC ACIDS RES, V14, P7159, DOI 10.1093/nar/14.18.7159; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TEMPEST PR, 1988, BRIT J CANCER, V58, P1; TESTA JR, 1990, ONCOGENE, V5, P1565; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0	47	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					3	7						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1531516				2022-12-17	WOS:A1992HC22700001
J	VANDAM, H; OFFRINGA, R; SMITS, AMM; BOS, JL; JONES, NC; VANDEREB, AJ				VANDAM, H; OFFRINGA, R; SMITS, AMM; BOS, JL; JONES, NC; VANDEREB, AJ			THE REPRESSION OF THE GROWTH FACTOR-INDUCIBLE GENES JE, C-MYC AND STROMELYSIN BY ADENOVIRUS E1A IS MEDIATED BY CONSERVED REGION-1	ONCOGENE			English	Article									LEIDEN STATE UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2312 AV LEIDEN,NETHERLANDS; IMPERIAL CANC RES FUND,GENE REGULAT LAB,LONDON WC2A 3PX,ENGLAND	Leiden University; Leiden University - Excl LUMC; Cancer Research UK				van Dam, Hans/0000-0002-8307-4325				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOS JL, 1983, VIROLOGY, V129, P393, DOI 10.1016/0042-6822(83)90178-2; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FLINT SJ, 1980, MOL BIOL TUMOR VIRUS, V2, P547; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; JOCHEMSEN AG, 1987, THESIS LEIDEN; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PEAR WS, 1986, P NATL ACAD SCI USA, V83, P7376, DOI 10.1073/pnas.83.19.7376; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANDEREB AJ, 1984, CANCER CELL, V2, P501; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	39	59	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1207	1212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2529466				2022-12-17	WOS:A1989AU50800007
J	HAMMERLING, U; BJELFMAN, C; PAHLMAN, S				HAMMERLING, U; BJELFMAN, C; PAHLMAN, S			DIFFERENT REGULATION OF N-MYC AND C-MYC EXPRESSION DURING PHORBOL ESTER-INDUCED MATURATION OF HUMAN SH-SY5Y NEURO-BLASTOMA CELLS	ONCOGENE			English	Article									UNIV UPPSALA, DEPT PATHOL, S-75105 UPPSALA, SWEDEN	Uppsala University								ADEM A, 1987, DEV BRAIN RES, V33, P235, DOI 10.1016/0165-3806(87)90156-8; AKERMAN KEO, 1984, NEUROCHEM INT, V6, P77, DOI 10.1016/0197-0186(84)90029-9; AMATRUDA TT, 1985, BIOCHEM BIOPH RES CO, V126, P1189, DOI 10.1016/0006-291X(85)90311-0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1984, CELL, V36, P259; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; GRADY EF, 1987, CANCER RES, V47, P2931; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUBITZ RM, 1987, J NEUROCHEM, V48, P144; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; MANIATIS T, 1982, MOL CLONING LABORATO, P93; MATTSSON MEK, 1984, EXP CELL RES, V155, P105, DOI 10.1016/0014-4827(84)90771-7; MATTSSON MEK, 1986, J CELL BIOL, V102, P1949, DOI 10.1083/jcb.102.5.1949; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PAHLMAN S, 1983, CELL DIFFER DEV, V12, P165, DOI 10.1016/0045-6039(83)90006-4; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBSON JA, 1985, NEUROSCIENCE, V14, P1149, DOI 10.1016/0306-4522(85)90284-2; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; SIDELL N, 1982, J NATL CANCER I, V68, P589; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	49	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	2	1					73	77						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3325885				2022-12-17	WOS:A1987L481300011
J	Guo, P; Ma, X; Zhao, W; Huai, W; Li, T; Qiu, Y; Zhang, Y; Han, L				Guo, P.; Ma, X.; Zhao, W.; Huai, W.; Li, T.; Qiu, Y.; Zhang, Y.; Han, L.			TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; NLRP3 INFLAMMASOME; DOWN-REGULATION; LIVER-CANCER; PROTEIN; LIGASE; CELLS; TSC1; DEGRADATION; CONTRIBUTES	Tripartite motif (TRIM) 31 is a member of the tripartite motif-containing protein family, and TRIM family proteins are involved in a broad range of biological and pathological processes. However, the role of TRIM31 in hepatocellular carcinoma (HCC) progression is not known. Here we demonstrated that TRIM31 expression was significantly upregulated in liver cancer tissues compared with paired distal non-cancerous liver tissues from HCC patients, and its overexpression was significantly correlated with advanced disease status. Both gain and loss of function assay verified that TRIM31 promoted the malignant behaviors of HCC cells through overactivation of mammalian target of rapamycin complex1 (mTORC1) pathway. We further demonstrated that TRIM31 exerted its oncogenic effect by directly interacting with the tuberous sclerosis complex (TSC) 1 and TSC2 complex, the upstream suppressor of mTORC1 pathway, and promoting the E3 ligase-mediated K48-linked ubiquitination and degradation of this complex. In conclusion, this study demonstrated TRIM31 could promote HCC progression by targeting TSC1-TSC2 complex for degradation and further overactivating mTORC1 pathway. Thus, it revealed a novel molecular mechanism of HCC progression and indicated a potential therapeutic strategy against HCC by targeting TRIM31.	[Guo, P.; Ma, X.; Zhao, W.; Huai, W.; Qiu, Y.; Zhang, Y.; Han, L.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, T.] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250021, Shandong, Peoples R China	Shandong University; Shandong University	Han, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	hanlihui@sdu.edu.cn		Han, Lihui/0000-0003-1030-2232; Zhao, Wei/0000-0001-8440-2274	National Natural Science Foundation of China [81472269, 81672391]; Science and Technology Development Project of Shandong Province [2015GSF118047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Project of Shandong Province	We thank Dr Brendan D Manning (Harvard University) and Dr Cheryl Lyn Walker (Texas A&M University) for providing the TSC1 and TSC2 plasmids. This study was supported by the National Natural Science Foundation of China (No. 81472269 and No. 81672391) and the Science and Technology Development Project of Shandong Province (No. 2015GSF118047).	Argyriou P, 2011, ANN HEMATOL, V90, P315, DOI 10.1007/s00277-010-1070-6; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Chano T, 2006, INT J MOL MED, V18, P425; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Ding QS, 2015, TUMOR BIOL, V36, P8761, DOI 10.1007/s13277-015-3572-2; Dodd KM, 2015, ONCOGENE, V34, P2239, DOI 10.1038/onc.2014.164; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Feng M, 2013, PROTEIN CELL, V4, P142, DOI 10.1007/s13238-012-2088-4; Han S, 2008, CELL SIGNAL, V20, P1084, DOI 10.1016/j.cellsig.2008.01.020; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hu J, 2008, GENE DEV, V22, P866, DOI 10.1101/gad.1624008; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huynh H, 2015, MOL CANCER THER, V14, P1224, DOI 10.1158/1535-7163.MCT-14-0768; Iwai K, 2010, SUBCELL BIOCHEM, V54, P100, DOI 10.1007/978-1-4419-6676-6_8; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kim YH, 2016, BRIT J NEUROSURG, V2016, P1, DOI DOI 10.1155/2016/1489692; Kozakova L, 2015, CELL CYCLE, V14, P920, DOI 10.1080/15384101.2014.1000112; Li H, 2014, TUMOR BIOL, V35, P5747, DOI 10.1007/s13277-014-1763-x; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388; Ra EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11726; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shen WC, 2015, AUTOPHAGY, V11, P685, DOI 10.4161/auto.36098; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Sugiura T, 2011, CELL BIOL INT, V35, P657, DOI 10.1042/CBI20100772; Sugiura T, 2008, J CELL BIOCHEM, V105, P1081, DOI 10.1002/jcb.21908; Sun XF, 2013, HEPATOLOGY, V57, P205, DOI 10.1002/hep.25989; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wang Y, 2015, BIOCHEM BIOPH RES CO, V463, P458, DOI 10.1016/j.bbrc.2015.05.117; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Wei Q, 2015, LAB INVEST, V95, P804, DOI 10.1038/labinvest.2015.63; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Wei Q, 2013, PURINERG SIGNAL, V9, P585, DOI 10.1007/s11302-013-9369-0; Yamada D, 2014, J BIOCHEM, V155, P227, DOI 10.1093/jb/mvt112; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Zhang L, 2014, INT J CLIN EXP PATHO, V7, P3887; Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248; Zhao X, 2014, CANCER RES, V74, P2455, DOI 10.1158/0008-5472.CAN-13-3009	40	58	62	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					478	488		10.1038/onc.2017.349	http://dx.doi.org/10.1038/onc.2017.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967907				2022-12-17	WOS:000423331600006
J	Yang, N; Wang, C; Wang, Z; Zona, S; Lin, SX; Wang, X; Yan, M; Zheng, FM; Li, SS; Xu, B; Bella, L; Yong, JS; Lam, EWF; Liu, Q				Yang, N.; Wang, C.; Wang, Z.; Zona, S.; Lin, S-X; Wang, X.; Yan, M.; Zheng, F-M; Li, S-S; Xu, B.; Bella, L.; Yong, J-S; Lam, E. W-F; Liu, Q.			FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; SELECTIVE AURORA; EXPRESSION; INHIBITOR; FOXO3A; CARCINOMA; PROTEINS; MLN8237	Substantial evidence suggests that breast cancer initiation, recurrence and drug resistance is supported by breast cancer stem cells (BCSCs). Recently, we reported a novel role of Aurora kinase A (AURKA) in BCSCs, as a transactivating co-factor in the induction of the c-Myc oncoprotein. However, the mode of action and transcriptional network of nuclear AURKA in BCSCs remain unknown. Here, we report that nuclear AURKA can be recruited by Forkhead box subclass M1 (FOXM1) as a co-factor to transactivate FOXM1 target genes in a kinase-independent manner. In addition, we show that AURKA and FOXM1 participate in a tightly coupled positive feedback loop to enhance BCSC phenotype. Indeed, kinase-dead AURKA can effectively transactivate the FOXM1 promoter through a Forkhead response element, whereas FOXM1 can activate AURKA expression at the transcriptional level in a similar manner. Consistently, breast cancer patient samples portrayed a strong and significant correlation between the expression levels of FOXM1 and AURKA. Moreover, both FOXM1 and AURKA were essential for maintaining the BCSC population. Finally, we demonstrated that the AURKA inhibitor AKI603 and FOXM1 inhibitor thiostrepton acted synergistically to inhibit cytoplasmic AURKA activity and disrupt the nuclear AURKA/FOXM1-positive feedback loop, respectively, resulting in a more effective inhibition of the tumorigenicity and self-renewal ability of BCSCs. Collectively, our study uncovers a previously unknown tightly coupled positive feedback signalling loop between AURKA and FOXM1, crucial for BCSC self-renewal. Remarkably, our data reveal a novel potential therapeutic strategy for targeting both the cytoplasmic and nuclear AURKA function to effectively eliminate BCSCs, so as to overcome both breast cancer and drug resistance.	[Yang, N.; Wang, C.; Wang, Z.; Lin, S-X; Wang, X.; Yan, M.; Li, S-S; Liu, Q.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, N.; Wang, C.; Wang, Z.; Lin, S-X; Wang, X.; Yan, M.; Li, S-S; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Yang, N.; Xu, B.] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Lab Med, Guangzhou, Guangdong, Peoples R China; [Zona, S.; Bella, L.; Yong, J-S; Lam, E. W-F] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England; [Zheng, F-M] Sun Yat Sen Univ, Eastern Hosp, Affiliated Hosp 1, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Guangzhou Medical University; Imperial College London; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, 651 Dongfeng Rd East, Guangzhou, Guangdong, Peoples R China.; Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.; Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China.	eric.lam@imperial.ac.uk; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	National Basic Research Program of China (973 Program) [2012CB967000]; National Natural Science Foundation of China [81630005, 81130040, 81573025, 81301734, 81602434]; Program for Innovative Research Team in University [IRT13049]; Liaoning [NSF2014029102]; Natural Science Foundation of Guangdong [2016A030311038]; Cancer Now [2012MayPR070, 2012NovPhD016]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Imperial College London; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; MRC [MR/N012097/1] Funding Source: UKRI	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team in University; Liaoning; Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Cancer Now; CRUK(Cancer Research UK); Breast Cancer Now; Imperial College London(General Electric); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Quentin Liu's lab members for their critical commends and technical support. This work is supported by the National Basic Research Program of China (973 Program; no. 2012CB967000 to Q Liu), National Natural Science Foundation of China (no. 81630005, 81130040 and 81573025 to Q Liu; no. 81301734 to Z Wang; no. 81602434 to N Yang), Program for Innovative Research Team in University (IRT13049 to Q Liu), Liaoning (NSF2014029102 to Q Liu) and Natural Science Foundation of Guangdong (2016A030311038 to Q.L.). Eric W-F Lam's work is supported by Cancer Now (2012MayPR070 and 2012NovPhD016) and CRUK (A12011) and Breast. Stefania Zona and Laura Bella are supported by Breast Cancer Now (2012MayPR070 and 2012NovPhD016, respectively). Jay-Sze Yong is supported by an Imperial College London studentship.	Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; Burum-Auensen E, 2007, J HISTOCHEM CYTOCHEM, V55, P477, DOI 10.1369/jhc.6A7077.2007; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cervantes A, 2012, CLIN CANCER RES, V18, P4764, DOI 10.1158/1078-0432.CCR-12-0571; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Cheng C, 2012, MOL PHARMACEUT, V9, P1971, DOI 10.1021/mp2006714; Cheung CH, 2014, EXPERT OPIN THER PAT, V24, P1021; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Consolaro F, 2015, INT J ONCOL, V47, P1230, DOI 10.3892/ijo.2015.3139; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Friedberg JW, 2014, J CLIN ONCOL, V32, P44, DOI 10.1200/JCO.2012.46.8793; Gomes AR, 2013, CHIN J CANCER, V32, P365, DOI 10.5732/cjc.012.10277; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hay AE, 2015, LEUKEMIA LYMPHOMA, V2015, P1; Huang XF, 2008, BLOOD, V111, P2854, DOI 10.1182/blood-2007-07-099325; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kristeleit R, 2009, J CLIN ONCOL, P27; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Mosse YP, 2012, CLIN CANCER RES, V18, P6058, DOI 10.1158/1078-0432.CCR-11-3251; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Piazzolla D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5226; Qu Hongzhu, 2013, Genomics Proteomics Bioinformatics, V11, P135, DOI 10.1016/j.gpb.2013.05.001; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tamotsu K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1329-3; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tanaka T, 1999, CANCER RES, V59, P2041; Velasco-Velazquez MA, 2012, INT J BIOCHEM CELL B, V44, P573, DOI 10.1016/j.biocel.2011.12.020; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Wu KL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091910, 10.1371/journal.pone.0087348, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0087588, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0095536, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0093049, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0099366]; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	48	58	58	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3428	3440		10.1038/onc.2016.490	http://dx.doi.org/10.1038/onc.2016.490			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114286	Green Published, hybrid			2022-12-17	WOS:000403340700007
J	Prange, KHM; Mandoli, A; Kuznetsova, T; Wang, SY; Sotoca, AM; Marneth, AE; van der Reijden, BA; Stunnenberg, HG; Martens, JHA				Prange, K. H. M.; Mandoli, A.; Kuznetsova, T.; Wang, S-Y; Sotoca, A. M.; Marneth, A. E.; van der Reijden, B. A.; Stunnenberg, H. G.; Martens, J. H. A.			MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia	ONCOGENE			English	Article							MLL FUSION PROTEINS; H3K79 METHYLATION; TRANSCRIPTION FACTORS; HOX GENES; INHIBITION; CHROMATIN; BET; EXPRESSION; COMPLEX; MEIS1	In 11q23 leukemias, the N-terminal part of the mixed lineage leukemia (MLL) gene is fused to 460 different partner genes. In order to define a core set of MLL rearranged targets, we investigated the genome-wide binding of the MLL-AF9 and MLL-AF4 fusion proteins and associated epigenetic signatures in acute myeloid leukemia (AML) cell lines THP-1 and MV4-11. We uncovered both common as well as specific MLL-AF9 and MLL-AF4 target genes, which were all marked by H3K79me2, H3K27ac and H3K4me3. Apart from promoter binding, we also identified MLL-AF9 and MLL-AF4 binding at specific subsets of non-overlapping active distal regulatory elements. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, which represents part of the RUNX1 gene program and constitutes of CD34(+) and monocyte-specific genes. Comparing these data sets identified several zinc finger transcription factors (TFs) as potential MLL-AF9 co-regulators. Together, these results suggest that MLL fusions collaborate with specific subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs. Oncogene (2017)	[Prange, K. H. M.; Mandoli, A.; Kuznetsova, T.; Wang, S-Y; Sotoca, A. M.; Stunnenberg, H. G.; Martens, J. H. A.] Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl 26, NL-6500 HB Nijmegen, Netherlands; [Marneth, A. E.; van der Reijden, B. A.] Radboud Univ Nijmegen, Dept Lab Med, Lab Hematol, Med Ctr, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Martens, JHA (corresponding author), Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl 26, NL-6500 HB Nijmegen, Netherlands.	j.martens@ncmls.ru.nl	Martens, Joost/D-4966-2012; Stunnenberg, Hendrik G./D-6875-2012; van der Reijden, Bert A/A-3543-2014; Marneth, Anna/G-6236-2016	Martens, Joost/0000-0003-2008-6537; Stunnenberg, Hendrik G./0000-0002-0066-1576; Wang, Shuang-Yin/0000-0001-9683-4103; Prange, Koen/0000-0002-9835-1735; Kuznetsova, Tatyana/0000-0001-7533-3334; Marneth, Anna/0000-0001-9065-0581	Dutch Cancer Foundation [KWF KUN 2009-4527, KUN 2011-4937]; Netherlands Organization for Scientific Research (NWO-VIDI)	Dutch Cancer Foundation(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO))	We thank A Singh, A Brinkman, G Georgiou, S van Heeringen and K Francoijs for bioinformatic support. This work was supported by the Dutch Cancer Foundation (KWF KUN 2009-4527 and KUN 2011-4937) and Netherlands Organization for Scientific Research (NWO-VIDI to JHAM).	Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Benito JM, 2015, CELL REP, V13, P2715, DOI 10.1016/j.celrep.2015.12.003; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Bousquet M, 2013, MOL CANCER RES, V11, P912, DOI 10.1158/1541-7786.MCR-13-0002-T; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Erben P, 2010, HAEMATOL-HEMATOL J, V95, P738, DOI 10.3324/haematol.2009.016345; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Geng HM, 2012, CANCER DISCOV, V2, P1004, DOI 10.1158/2159-8290.CD-12-0208; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Kuntimaddi A, 2015, CELL REP, V11, P808, DOI 10.1016/j.celrep.2015.04.004; LANGE B, 1987, BLOOD, V70, P192; Leach BI, 2013, STRUCTURE, V21, P176, DOI 10.1016/j.str.2012.11.011; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Mandoli A, 2014, GENOM DATA, V2, P170, DOI 10.1016/j.gdata.2014.06.014; Mandoli A, 2014, LEUKEMIA, V28, P770, DOI 10.1038/leu.2013.257; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; Merkenschlager M, 2013, CELL, V152, P1285, DOI 10.1016/j.cell.2013.02.029; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Okuda H, 2014, NUCLEIC ACIDS RES, V42, P4241, DOI 10.1093/nar/gkt1394; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Patel B, 2014, LEUKEMIA, V28, P349, DOI 10.1038/leu.2013.158; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Pession A, 2003, ONCOGENE, V22, P8671, DOI 10.1038/sj.onc.1207125; Phillips-Cremins JE, 2013, MOL CELL, V50, P461, DOI 10.1016/j.molcel.2013.04.018; Pospisil V, 2011, EMBO J, V30, P4450, DOI 10.1038/emboj.2011.317; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Quentmeier H, 2004, LEUKEMIA LYMPHOMA, V45, P567, DOI 10.1080/10428190310001609942; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Rousseau M, 2013, NUCLEIC ACIDS RES, V42; Rousseau M, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r60; Sotoca AM, 2016, ONCOGENE, V35, P1965, DOI 10.1038/onc.2015.261; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; van Heeringen SJ, 2011, BIOINFORMATICS, V27, P270, DOI 10.1093/bioinformatics/btq636; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Zhao XiuHai, 2014, Forest Ecosystems, V1, P8, DOI 10.1186/2197-5620-1-8	65	58	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3346	3356		10.1038/onc.2016.488	http://dx.doi.org/10.1038/onc.2016.488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28114278	Green Published, hybrid			2022-12-17	WOS:000402869800013
J	Anadon, C; Guil, S; Simo-Riudalbas, L; Moutinho, C; Setien, F; Martinez-Cardus, A; Moran, S; Villanueva, A; Calaf, M; Vidal, A; Lazo, PA; Zondervan, I; Savola, S; Kohno, T; Yokota, J; de Pouplana, LR; Esteller, M				Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Villanueva, A.; Calaf, M.; Vidal, A.; Lazo, P. A.; Zondervan, I.; Savola, S.; Kohno, T.; Yokota, J.; Ribas de Pouplana, L.; Esteller, M.			Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CANCER; TRANSCRIPTOME; SITES; CELLS	The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-to-inosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis.	[Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Villanueva, A.; Calaf, M.] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Catalonia, Spain; [Vidal, A.] Bellvitge Unvivers Hosp, Dept Pathol Anat, Barcelona, Catalonia, Spain; [Lazo, P. A.] Univ Salamanca, Expt Therapeut & Translat Oncol Program, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain; [Lazo, P. A.] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Zondervan, I.; Savola, S.] MRC Holland, Amsterdam, Netherlands; [Kohno, T.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Genome Biol, Tokyo, Japan; [Yokota, J.] Inst Predict & Personalized Med Canc IMPPC, Genom & Epigen Canc Predict Program, Badalona, Catalonia, Spain; [Ribas de Pouplana, L.; Esteller, M.] IRB, C Baldiri Reixac 10, Barcelona 08028, Catalonia, Spain; [Ribas de Pouplana, L.] ICREA, Barcelona, Catalonia, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); National Cancer Center - Japan; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Barcelona	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Spain.	mesteller@idibell.cat	Vidal, August/N-4662-2016; Esteller, Manel/L-5956-2014; Lazo, Pedro A./M-6435-2014; Martinez, Anna/AAA-4939-2020; Guil, Sonia/M-8036-2015; Moran, Sebastian/G-5293-2013	Vidal, August/0000-0001-5727-2099; Esteller, Manel/0000-0003-4490-6093; Lazo, Pedro A./0000-0001-8997-3025; Guil, Sonia/0000-0002-2257-3331; Moran, Sebastian/0000-0003-4192-8983; Anadon Galindo, Carmen Maria/0000-0002-8851-4545; Savola, Suvi/0000-0002-6221-8617	European Research Council under the European Community's Seventh Framework Programme (FP7)/ERC [268626-EPINORC, HEALTH-F2-2010-258677-CURELUNG]; Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2011-22803, PI13-01339, SAF2014-55000-R]; Institute of Health Carlos III (ISCIII) [PI10/02992]; Ministerio de Educacion, Ciencia e Innovacion [SAF2010-14935]; Cellex Foundation; National Cancer Center Research and Development Fund (NCC Biobank) [23 A-1]; Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR [2009SGR1315, 2014SGR633]; ICREA Funding Source: Custom	European Research Council under the European Community's Seventh Framework Programme (FP7)/ERC(European Research Council (ERC)); Spanish Ministry of Economy and Competitiveness (MINECO); Institute of Health Carlos III (ISCIII); Ministerio de Educacion, Ciencia e Innovacion; Cellex Foundation(Foundation CELLEX); National Cancer Center Research and Development Fund (NCC Biobank); Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR; ICREA(ICREA)	This work was supported by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268626-EPINORC project, the Grant agreement number HEALTH-F2-2010-258677-CURELUNG project, the Spanish Ministry of Economy and Competitiveness (MINECO Projects no. SAF2011-22803, PI13-01339 and SAF2014-55000-R), the Institute of Health Carlos III (ISCIII)-PI10/02992, Ministerio de Educacion, Ciencia e Innovacion Grant SAF2010-14935, the Cellex Foundation, the National Cancer Center Research and Development Fund (NCC Biobank: 23 A-1) and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR-project no. 2009SGR1315 and 2014SGR633. We thank the staff of the Animal Core Facility of IDIBELL for mouse care and maintenance. LRdP and ME are ICREA Research Professors.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Avesson L, 2014, BBA-REV CANCER, V1845, P308, DOI 10.1016/j.bbcan.2014.03.001; Bazak L, 2014, GENOME RES, V24, P365, DOI 10.1101/gr.164749.113; Buettner R, 2013, J CLIN ONCOL, V31, P1858, DOI 10.1200/JCO.2012.45.9867; Chan THM, 2014, GUT, V63, P832, DOI 10.1136/gutjnl-2012-304037; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Daniel C, 2012, NUCLEIC ACIDS RES, V40, P9876, DOI 10.1093/nar/gks691; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Jiang QF, 2013, P NATL ACAD SCI USA, V110, P1041, DOI 10.1073/pnas.1213021110; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Liu MM, 2013, MUTAT RES-FUND MOL M, V743, P4, DOI 10.1016/j.mrfmmm.2012.12.003; Peng ZY, 2012, NAT BIOTECHNOL, V30, P253, DOI 10.1038/nbt.2122; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Rommel PC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069208; Sakurai M, 2014, GENOME RES, V24, P522, DOI 10.1101/gr.162537.113; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Shoshan E, 2015, NAT CELL BIOL, V17, P311, DOI 10.1038/ncb3110; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Skalsky RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024248; Wang ZY, 2015, ONCOTARGET, V6, P3147, DOI 10.18632/oncotarget.3061; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Yeo JC, 2010, P NATL ACAD SCI USA, V107, P20715, DOI 10.1073/pnas.1009231107	23	58	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4407	4413		10.1038/onc.2015.469	http://dx.doi.org/10.1038/onc.2015.469			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26640150	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000382152100012
J	Bajpai, R; Matulis, SM; Wei, C; Nooka, AK; Von Hollen, HE; Lonial, S; Boise, LH; Shanmugam, M				Bajpai, R.; Matulis, S. M.; Wei, C.; Nooka, A. K.; Von Hollen, H. E.; Lonial, S.; Boise, L. H.; Shanmugam, M.			Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax	ONCOGENE			English	Article							ANTITUMOR-ACTIVITY; CELL-SURVIVAL; MCL-1; INHIBITOR; APOPTOSIS; EXPRESSION; DEPENDENCE; RITONAVIR; ABT-199; POTENT	Multiple myeloma (MM) is a plasma cell malignancy that is largely incurable due to development of resistance to therapy-elicited cell death. Nutrients are intricately connected to maintenance of cellular viability in part by inhibition of apoptosis. We were interested to determine if examination of metabolic regulation of BCL-2 proteins may provide insight on alternative routes to engage apoptosis. MM cells are reliant on glucose and glutamine and withdrawal of either nutrient is associated with varying levels of apoptosis. We and others have demonstrated that glucose maintains levels of key resistance-promoting BCL-2 family member, myeloid cell leukemic factor 1 (MCL-1). Cells continuing to survive in the absence of glucose or glutamine were found to maintain expression of MCL-1 but importantly induce pro-apoptotic BIM expression. One potential mechanism for continued survival despite induction of BIM could be due to binding and sequestration of BIM to alternate pro-survival BCL-2 members. Our investigation revealed that cells surviving glutamine withdrawal in particular, enhance expression and binding of BIM to BCL-2, consequently sensitizing these cells to the BH3 mimetic venetoclax. Glutamine deprivation-driven sensitization to venetoclax can be reversed by metabolic supplementation with TCA cycle intermediate alpha-ketoglutarate. Inhibition of glucose metabolism with the GLUT4 inhibitor ritonavir elicits variable cytotoxicity in MM that is marginally enhanced with venetoclax treatment, however, targeting glutamine metabolism with 6-diazo-5-oxo-L-norleucine uniformly sensitized MM cell lines and relapse/refractory patient samples to venetoclax. Our studies reveal a potent therapeutic strategy of metabolically driven synthetic lethality involving targeting glutamine metabolism for sensitization to venetoclax in MM.	[Bajpai, R.; Matulis, S. M.; Wei, C.; Nooka, A. K.; Von Hollen, H. E.; Lonial, S.; Boise, L. H.; Shanmugam, M.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University	Shanmugam, M (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.	mala.shan@emory.edu	Shanmugam, Mala/M-6491-2019; Boise, Lawrence/AAD-2314-2019; Bajpai, Richa/H-6404-2019	Shanmugam, Mala/0000-0002-4415-8083; Boise, Lawrence/0000-0001-9436-8815	American Cancer Society Research scholar grant [RSG-11-254-01-CSM]; TJ Martell Foundation;  [P30CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER	American Cancer Society Research scholar grant(American Cancer Society); TJ Martell Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the American Cancer Society Research scholar grant (RSG-11-254-01-CSM) to MS. LHB is a Georgia Research Alliance distinguished cancer scientist and also received support from the TJ Martell Foundation and P30CA138292.	Accardi F, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.2067.2067; Barlogie B, 2014, BLOOD, V124, P3043, DOI 10.1182/blood-2014-07-552059; Bartel TB, 2009, BLOOD, V114, P2068, DOI 10.1182/blood-2009-03-213280; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Brown G, 2008, BIOCHEMISTRY-US, V47, P5724, DOI 10.1021/bi800097h; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Coloff JL, 2011, J BIOL CHEM, V286, P5921, DOI 10.1074/jbc.M110.179101; Dalva-Aydemir S, 2015, CLIN CANCER RES, V21, P1161, DOI 10.1158/1078-0432.CCR-14-1088; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Eguchi T, 2009, MOL CANCER THER, V8, P1460, DOI 10.1158/1535-7163.MCT-08-1159; Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood-2014-03-557298; McBrayer SK, 2012, BLOOD, V119, P4686, DOI 10.1182/blood-2011-09-377846; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mishra RK, 2015, J BIOL CHEM, V290, P14441, DOI 10.1074/jbc.M114.628826; Morales AA, 2011, BLOOD, V118, P1329, DOI 10.1182/blood-2011-01-327197; Nakajima W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.6; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Olsen RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116998; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Podar K, 2008, ONCOGENE, V27, P721, DOI 10.1038/sj.onc.1210679; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Prideaux Steven M, 2014, Adv Hematol, V2014, P864058, DOI 10.1155/2014/864058; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; ROBERTS RS, 1976, J CELL SCI, V21, P609; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Shanmugam M, 2009, J BIOL CHEM, V284, P26816, DOI 10.1074/jbc.M109.000646; SHAPIRO RA, 1979, J BIOL CHEM, V254, P2835; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Vo TT, 2012, CELL, V151, P344, DOI 10.1016/j.cell.2012.08.038; Thomas RL, 2013, GENE DEV, V27, P1365, DOI 10.1101/gad.215871.113; Touzeau C, 2014, LEUKEMIA, V28, P210, DOI 10.1038/leu.2013.216; Tuffy LP, 2010, MOL CELL BIOL, V30, P5484, DOI 10.1128/MCB.00575-10; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vyas AK, 2010, J BIOL CHEM, V285, P36395, DOI 10.1074/jbc.M110.176321; Wensveen FM, 2010, IMMUNITY, V32, P754, DOI 10.1016/j.immuni.2010.06.005; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	49	58	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3955	3964		10.1038/onc.2015.464	http://dx.doi.org/10.1038/onc.2015.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26640142	Green Accepted			2022-12-17	WOS:000381013100007
J	Yonesaka, K; Hirotani, K; Kawakami, H; Takeda, M; Kaneda, H; Sakai, K; Okamoto, I; Nishio, K; Janne, PA; Nakagawa, K				Yonesaka, K.; Hirotani, K.; Kawakami, H.; Takeda, M.; Kaneda, H.; Sakai, K.; Okamoto, I.; Nishio, K.; Jaenne, P. A.; Nakagawa, K.			Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; KINASE DOMAIN; INACTIVE HER3; EGFR; GEFITINIB; AMPLIFICATION; RESISTANCE; THERAPY; ERBB3; ACTIVATION	Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for the drug has yet to be identified. In the present study, we examined whether heregulin, a HER3 ligand that is also overexpressed in a subset of NSCLC, can be used as a biomarker to predict the antitumorigenic efficacy of patritumab and whether the drug can overcome the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance induced by heregulin. Patritumab sensitivity was associated with heregulin expression, which, when abolished, resulted in the loss of HER3 and AKT activation and growth arrest. Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. Sustained HER3-AKT activation was blocked by combining erlotinib with either anti-HER2 or anti-HER3 antibody. Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. These results indicate that patritumab can overcome heregulin-dependent EGFR inhibitor resistance in NSCLC in vitro and in vivo and suggest that it can be used in combination with EGFR TKIs to treat a subset of heregulin-overexpressing NSCLC patients.	[Yonesaka, K.; Kawakami, H.; Takeda, M.; Kaneda, H.; Nakagawa, K.] Kinki Univ, Sch Med, Dept Med Oncol, 377-2 Ohnohigashi Osaka Sayamashi, Osaka 5898511, Japan; [Kawakami, H.] Daiichi Sankyo Pharmaceut Dev, Tokyo, Japan; [Sakai, K.; Nishio, K.] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan; [Okamoto, I.] Kyushu Univ, Ctr Clin & Translat Res, Fukuoka 812, Japan; [Jaenne, P. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Jaenne, P. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Jaenne, P. A.] Harvard Univ, Sch Med, Brigham Womens Hosp, Dept Med, Boston, MA 02115 USA	Kindai University (Kinki University); Daiichi Sankyo Company Limited; Kindai University (Kinki University); Kyushu University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Yonesaka, K (corresponding author), Kinki Univ, Sch Med, Dept Med Oncol, 377-2 Ohnohigashi Osaka Sayamashi, Osaka 5898511, Japan.; Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,HIM223, Boston, MA 02215 USA.	yonesaka@sakai.med.kindai.ac.jp; pjanne@partners.org	Kawakami, Hisato/L-6845-2019	Kawakami, Hisato/0000-0002-3280-4850	Daiichi-Sankyo Pharmaceutical Development	Daiichi-Sankyo Pharmaceutical Development	We thank Haruka Yamaguchi, Yume Shinkai, Michiko Kitano and Mami Kitano for technical support. This work was financially funded in part by Daiichi-Sankyo Pharmaceutical Development.	Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Cappuzzo F, 2005, BRIT J CANCER, V93, P1334, DOI 10.1038/sj.bjc.6602865; Cho BC, 2007, J CLIN ONCOL, V25, P2528, DOI 10.1200/JCO.2006.10.4166; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Guerra-Vladusic FK, 2001, ONCOL REP, V8, P1203; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; LoRusso P, 2013, CLIN CANCER RES, V19, P3078, DOI 10.1158/1078-0432.CCR-12-3051; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Murakami H, 2013, ANN ONCOL S9, V24; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Ohsaki Y, 2000, ONCOL REP, V7, P603; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Von Pawel J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8045; Wakui H, 2014, CANCER CHEMOTH PHARM, V73, P511, DOI 10.1007/s00280-014-2375-2; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Yi ES, 1997, MODERN PATHOL, V10, P142; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhang Q, 2012, P NATL ACAD SCI USA, V109, P13237, DOI 10.1073/pnas.1200105109; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	37	58	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					878	886		10.1038/onc.2015.142	http://dx.doi.org/10.1038/onc.2015.142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961915				2022-12-17	WOS:000370332200008
J	Marcel, V; Catez, F; Diaz, JJ				Marcel, V.; Catez, F.; Diaz, J-J			p53, a translational regulator: contribution to its tumour-suppressor activity	ONCOGENE			English	Review							RNA-BINDING PROTEINS; EXTENDS LIFE-SPAN; GENE-EXPRESSION; NONCODING RNA; POLYMERASE I; P53-RNA INTERACTIONS; TERMINAL DOMAIN; MICE DEFICIENT; TARGET; CANCER	A growing body of evidences indicate that deregulation of translation contributes to tumourigenesis. In tumours, alterations of translational control of specific mRNAs encoding oncogenes or tumour suppressors have been extensively reported. Moreover, restricting the rate of protein synthesis has been shown to delays tumourigenesis in C-Myc overexpressing or PTEN deleted mice models. Finally, the specific inhibition of RNA polymerase I (RNA pol I) has been shown to kill cancer cells without affecting normal cells. It thus emerges that a tight coordination between the rate of global protein synthesis and a defined translational program is required to prevent tumour development. In this review, we expose the evidences supporting that p53 acts as a translational regulator. In addition, this review discusses the notion that the ability to maintain both a selective translational program and a low level of protein synthesis could directly contribute to the p53 tumour-suppressor activity.	[Marcel, V.; Catez, F.; Diaz, J-J] Ctr Leon Berard, UMR INSERM CNRS 5286 1052, Canc Cell Plast Dept, Ctr Rech Cancerol Lyon, F-69373 Lyon, France; [Marcel, V.; Catez, F.; Diaz, J-J] Univ Lyon 1, ISPB, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Marcel, V (corresponding author), Canc Res Ctr Lyon, Canc Cell Plast, 28 Rue Laennec, F-69622 Rhone, France.	virginie.marcel@lyon.unicancer.fr	DIAZ, Jean-Jacques/H-3018-2014; MARCEL, Virginie/ABF-1904-2020; CATEZ, Frédéric/AAM-4854-2020; DIAZ, Jean-Jacques/AAT-3846-2021; Marcel, Virginie/H-3037-2011; CATEZ, Frédéric/GQP-7328-2022	DIAZ, Jean-Jacques/0000-0002-7914-4319; MARCEL, Virginie/0000-0002-9557-8221; CATEZ, Frédéric/0000-0001-8255-9091; DIAZ, Jean-Jacques/0000-0002-7914-4319; Marcel, Virginie/0000-0002-9557-8221; 	CNRS; INSERM; Universite Claude Bernard Lyon 1; Centre Leon Berard; Fondation ARC pour la Recherche sur le Cancer [SFI20121205802]; Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire [13-763C]; ANR [13-BSV8-0012-01 Ribometh]; PAIR Sein [ARC_INCa_LNCC_7625]	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Claude Bernard Lyon 1; Centre Leon Berard; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire; ANR(French National Research Agency (ANR)); PAIR Sein	We apologize to those works that have not been cited in this article because of lack of space. This article was supported by CNRS, INSERM, Universite Claude Bernard Lyon 1, Centre Leon Berard, Fondation ARC pour la Recherche sur le Cancer (no SFI20121205802), Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire (no13-763C), ANR (13-BSV8-0012-01 Ribometh) and PAIR Sein (noARC_INCa_LNCC_7625). VM was a recipient of a postdoctoral fellowship from Centre Leon Berard. VM and J-JD are members of INSERM. FC is member of CNRS.	Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Anger AM, 2013, NATURE, V497, P80, DOI 10.1038/nature12104; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bellodi C, 2013, CELL REP, V3, P1493, DOI 10.1016/j.celrep.2013.04.030; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bisio A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-552; Boldrup L, 2012, EUR J CANCER, V48, P1401, DOI 10.1016/j.ejca.2011.06.032; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555-010-9257-9; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Candi E, 2015, CELL DEATH DIFFER, V22, P12, DOI 10.1038/cdd.2014.113; Castello A, 2013, TRENDS GENET, V29, P318, DOI 10.1016/j.tig.2013.01.004; Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Comas M, 2012, AGING-US, V4, P715, DOI 10.18632/aging.100496; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; Crawford L V, 1984, Mol Biol Med, V2, P261; Delloye-Bourgeois C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002456; Deng GR, 2013, INT J MOL SCI, V14, P18319, DOI 10.3390/ijms140918319; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2012, AGING-US, V4, P660, DOI 10.18632/aging.100494; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Freeman JA, 2013, BRIEF FUNCT GENOMICS, V12, P46, DOI 10.1093/bfgp/els058; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Griseri P, 2014, WORLD J CLIN ONCOL, V5, P323, DOI 10.5306/wjco.v5.i3.323; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Henras AK, 2008, CELL MOL LIFE SCI, V65, P2334, DOI 10.1007/s00018-008-8027-0; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jenner L, 2012, CURR OPIN STRUC BIOL, V22, P759, DOI 10.1016/j.sbi.2012.07.013; Komarova EA, 2012, AGING-US, V4, P709, DOI 10.18632/aging.100498; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Krastev DB, 2011, NAT CELL BIOL, V13, P809, DOI 10.1038/ncb2264; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin SC, 2013, AGING CELL, V12, P863, DOI 10.1111/acel.12108; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Marcel V, 2013, ONCOTARGET, V4, P1554, DOI 10.18632/oncotarget.1511; Marcel V, 2013, CANCER CELL, V24, P318, DOI 10.1016/j.ccr.2013.08.013; Martinez-Salas E, 2013, INT J MOL SCI, V14, P21705, DOI 10.3390/ijms141121705; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meijer HA, 2013, SCIENCE, V340, P82, DOI 10.1126/science.1231197; Melnikov S, 2012, NAT STRUCT MOL BIOL, V19, P560, DOI 10.1038/nsmb.2313; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Muller-McNicoll M, 2013, NAT REV GENET, V14, P275, DOI 10.1038/nrg3434; Nathan CAO, 2000, CANCER RES, V60, P3599; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pederson T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000521; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Petersson J, 2012, BIOL CELL, V104, P462, DOI 10.1111/boc.201100099; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Riley KJL, 2007, RNA, V13, P1825, DOI 10.1261/rna.673407; Riley KJL, 2007, BIOCHEM BIOPH RES CO, V363, P381, DOI 10.1016/j.bbrc.2007.08.181; Riley KJL, 2006, RNA, V12, P620, DOI 10.1261/rna.2286706; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2013, COLD SPRING HARB PER, V5; Sharathchandra A, 2014, WIRES RNA, V5, P131, DOI 10.1002/wrna.1202; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Teng T, 2013, CURR OPIN GENET DEV, V23, P63, DOI 10.1016/j.gde.2013.02.001; Tessarz P, 2014, NATURE, V505, P564, DOI 10.1038/nature12819; Tilleray V, 2006, FEBS LETT, V580, P1766, DOI 10.1016/j.febslet.2006.02.030; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Trere D, 2004, J HISTOCHEM CYTOCHEM, V52, P1601, DOI 10.1369/jhc.4A6454.2004; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vilborg A, 2010, J MOL MED, V88, P645, DOI 10.1007/s00109-010-0609-2; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Wurth L, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/178525; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zaccara S, 2014, CELL DEATH DIFFER, V21, P1522, DOI 10.1038/cdd.2014.79; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang Q, 2014, SCIENCE, V343, P298, DOI 10.1126/science.1246384; Zhu NX, 2005, BIOCHEM BIOPH RES CO, V335, P1272, DOI 10.1016/j.bbrc.2005.08.026	118	58	61	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5513	5523		10.1038/onc.2015.25	http://dx.doi.org/10.1038/onc.2015.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25728674				2022-12-17	WOS:000364594000001
J	Starenki, D; Hong, SK; Lloyd, RV; Park, JI				Starenki, D.; Hong, S-K; Lloyd, R. V.; Park, J-I			Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells	ONCOGENE			English	Article							INHIBITORY FACTOR/JAK/STAT PATHWAY; BREAST-CANCER; HSP70 FAMILY; MITOCHONDRIA; STRESS; RET; 2-DEOXYGLUCOSE; MUTATIONS; PROTEINS; KINASE	Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. For therapy of advanced MTC, the Food and Drug Administration recently approved vandetanib and cabozantinib, the tyrosine kinase inhibitors targeting RET, vascular endothelial growth factor receptor, epidermal growth factor receptor and/or c-MET. Nevertheless, not all patients respond to these drugs, demanding additional therapeutic strategies. We found that mortalin (HSPA9/GRP75), a member of HSP70 family, is upregulated in human MTC tissues and that its depletion robustly induces cell death and growth arrest in MTC cell lines in culture and in mouse xenografts. These effects were accompanied by substantial downregulation of RET, induction of the tumor-suppressor TP53 and altered expression of cell cycle regulatory machinery and apoptosis markers, including E2F-1, p21(CIP1), p27(KIP1) and Bcl-2 family proteins. Our investigation of the molecular mechanisms underlying these effects revealed that mortalin depletion induces transient MEK/ERK (extracellular signal-regulated kinase) activation and altered mitochondrial bioenergetics in MTC cells, as indicated by depolarized mitochondrial membrane, decreased oxygen consumption and extracellular acidification and increased oxidative stress. Intriguingly, mortalin depletion induced growth arrest partly via the MEK/ERK pathway, whereas it induced cell death by causing mitochondrial dysfunction in a Bcl-2-dependent manner. However, TP53 was not necessary for these effects except for p21CIP1 induction. Moreover, mortalin depletion downregulated RET expression independently of MEK/ERK and TP53. These data demonstrate that mortalin is a key regulator of multiple signaling and metabolic pathways pivotal to MTC cell survival and proliferation, proposing mortalin as a novel therapeutic target for MTC.	[Starenki, D.; Hong, S-K; Park, J-I] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Lloyd, R. V.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Park, JI (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jipark@mcw.edu	Starenki, Dmytro/D-9241-2014	Park, Jong-In/0000-0001-7248-4735	American Cancer Society [RSGM-10-189-01-TBE]; National Cancer Institute [R01CA138441]; NATIONAL CANCER INSTITUTE [R01CA138441] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Sergey Tarima at the Division of Biostatistics, Medical College of Wisconsin (MCW) for statistical analysis; Dr Alexandra F Lerch-Gaggl (Pediatric BioBank and Analytical Tissue Core, MCW) for imaging immunohistochemistry data; and the MCW Cancer Center Bioenergetics shared resource and Advancing Healthier Wisconsin for Seahorse analysis. This work was supported by the American Cancer Society (RSGM-10-189-01-TBE) and the National Cancer Institute (R01CA138441) to J-IP.	Agrawal N, 2013, J CLIN ENDOCR METAB, V98, pE364, DOI 10.1210/jc.2012-2703; Arthan D, 2010, CANCER LETT, V297, P31, DOI 10.1016/j.canlet.2010.04.021; Boichard A, 2012, J CLIN ENDOCR METAB, V97, pE2031, DOI 10.1210/jc.2012-2092; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheng G, 2012, CANCER RES, V72, P2634, DOI 10.1158/0008-5472.CAN-11-3928; Ciampi R, 2013, THYROID, V1, P1, DOI DOI 10.1089/THY.2013.2301.OB; Degrauwe N., 2012, CLIN MED INSIGHTS ON, V6, P243; Deocaris CC, 2007, ANN NY ACAD SCI, V1119, P165, DOI 10.1196/annals.1404.007; Dundas SR, 2005, J PATHOL, V205, P74, DOI 10.1002/path.1672; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Iosefson O, 2010, FEBS LETT, V584, P1080, DOI 10.1016/j.febslet.2010.02.019; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kaul SC, 2005, J BIOL CHEM, V280, P39373, DOI 10.1074/jbc.M500022200; Kaul SC, 2007, EXP GERONTOL, V42, P263, DOI 10.1016/j.exger.2006.10.020; Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; Lu WJ, 2011, CELL DEATH DIFFER, V18, P1046, DOI 10.1038/cdd.2010.177; Lu WJ, 2011, INT J CANCER, V129, P1806, DOI 10.1002/ijc.25857; Merrick BA, 1997, CANCER LETT, V119, P185, DOI 10.1016/S0304-3835(97)00270-X; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nagilla M, 2012, ADV THER, V29, P925, DOI 10.1007/s12325-012-0060-6; Park JI, 2005, CYTOKINE, V29, P125, DOI 10.1016/j.cyto.2004.10.005; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Park Jong-In, 2014, Front Biol (Beijing), V9, P95; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49; Sarosiek KA, 2013, TRENDS CELL BIOL, V23, P612, DOI 10.1016/j.tcb.2013.08.003; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sosonkina N., 2011, Experimental Oncology, V33, P42; Sosonkina N, 2014, CANCERS, V6, P526, DOI 10.3390/cancers6010526; Starenki D, 2013, CANCER LETT, V339, P144, DOI 10.1016/j.canlet.2013.07.006; Starenki D, 2013, J CLIN ENDOCR METAB, V98, P1529, DOI 10.1210/jc.2012-3671; Tuttle RM, 2010, J NATL COMPR CANC NE, V8, P512, DOI 10.6004/jnccn.2010.0040; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2003, BIOCHEM BIOPH RES CO, V302, P735, DOI 10.1016/S0006-291X(03)00226-2; Wadhwa R, 2006, INT J CANCER, V118, P2973, DOI 10.1002/ijc.21773; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13	40	58	61	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4624	4634		10.1038/onc.2014.392	http://dx.doi.org/10.1038/onc.2014.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435367	Green Accepted			2022-12-17	WOS:000360189300008
J	Bai, XL; Zhang, Q; Ye, LY; Liang, F; Sun, X; Chen, Y; Hu, QD; Fu, QH; Su, W; Chen, Z; Zhuang, ZP; Liang, TB				Bai, X. L.; Zhang, Q.; Ye, L. Y.; Liang, F.; Sun, X.; Chen, Y.; Hu, Q. D.; Fu, Q. H.; Su, W.; Chen, Z.; Zhuang, Z. P.; Liang, T. B.			Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling	ONCOGENE			English	Article							BREAST-CANCER CELLS; MESENCHYMAL TRANSITION; VASCULOGENIC MIMICRY; BETA-CATENIN; TUMOR-CELL; TRANSCRIPTION; MEF2C; EXPRESSION; PROGRESSION; MUTATIONS	Hepatocellular carcinoma (HCC) is one of the leading malignancies worldwide. Myocyte enhancer factor 2C (MEF2C) was traditionally regarded as a development-associated factor and was recently reported to be an oncogene candidate. We have previously reported overexpression of MEF2C in HCC; however, the roles of MEF2C in HCC remain to be clarified. In this study, HCC cell lines and a xenograft mouse model were used to determine the functions of MEF2C in vitro and in vivo, respectively. Specific plasmids and small interfering RNA were used to upregulate and downregulate MEF2C expression, respectively. Functional assays were performed to assess the influence of MEF2C on cell proliferation, and VEGF-induced vasculogenic mimicry, migration/invasion as well as angiogenesis. Co-immunoprecipitation was conducted to identify the interaction of MEF2C and beta-catenin. Human HCC tissue microarrays were used to investigate correlations among MEF2C, beta-catenin and involved biomarkers. MEF2C was found to mediate VEGF-induced vasculogenic mimicry, angiogenesis and migration/invasion, with involvement of the p38 MAPK and PKC signaling pathways. However, MEF2C itself inhibited tumor growth in vitro and in vivo. MEF2C was upregulated by and directly interacted with beta-catenin. The nuclear translocation of beta-catenin blocked by MEF2C was responsible for MEF2C-mediated growth inhibition. The nuclear translocation of MEF2C was associated with intracellular calcium signaling induced by beta-catenin. HCC microarrays showed correlations of nuclear MEF2C with the angiogenesis-associated biomarker, CD31, and cytosolic MEF2C with the proliferation-associated biomarker, Ki-67. MEF2C showed double-edged activities in HCC, namely mediating VEGF-induced malignancy enhancement while inhibiting cancer proliferation via blockade of Wnt/beta-catenin signaling. The overall effect of MEF2C in HCC progression regulation was dictated by its subcellular distribution. This should be determined prior to any MEF2C-associated intervention in HCC.	[Bai, X. L.; Zhang, Q.; Ye, L. Y.; Sun, X.; Hu, Q. D.; Fu, Q. H.; Su, W.; Liang, T. B.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Bai, X. L.; Zhang, Q.; Ye, L. Y.; Liang, T. B.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent, Hangzhou 310009, Zhejiang, Peoples R China; [Liang, F.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China; [Chen, Y.] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Gen Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Chen, Z.] Zhejiang Chinese Med Univ, Zhejiang Hosp Tradit Chinese Med, Zhejiang Key Lab Gastrointestinal Pathophysiol, Hangzhou, Zhejiang, Peoples R China; [Zhuang, Z. P.] NINDS, NIH, Bethesda, MD 20892 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang Chinese Medical University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Liang, TB (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn	Hu, Qi-Da/B-4558-2009	Hu, Qi-Da/0000-0002-9092-7808	National Natural Science Foundation of China [81171884]; National Key Basic Research Program of China [2014CB542101]; Ministry-Province Co-supportive Project of China; Innovation and High-Level Talent Training Program of Department of Health of Zhejiang	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program of China(National Basic Research Program of China); Ministry-Province Co-supportive Project of China; Innovation and High-Level Talent Training Program of Department of Health of Zhejiang	We thank Professor Xu Qiang (State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, China) for the generous gift of MEF2C overexpression plasmid. We appreciate Mr Xie Shangzhi, Mr Hu Liqiang, and Miss Chen Conglin (The Second Affiliated Hospital, Zhejiang University School of Medicine, China) for their great help in certain experiments. This study was financially supported by the National Natural Science Foundation of China (No. 81171884), the National Key Basic Research Program of China (No. 2014CB542101), the Ministry-Province Co-supportive Project of China, and Innovation and High-Level Talent Training Program of Department of Health of Zhejiang.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bai X, 2008, J CANCER RES CLIN, V134, P83, DOI 10.1007/s00432-007-0252-7; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Bienvenu T, 2013, NEUROGENETICS, V14, P71, DOI 10.1007/s10048-012-0344-7; Borghi S, 2001, J CELL SCI, V114, P4477; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Jen KY, 2012, BLOOD, V119, P805, DOI 10.1182/blood-2011-01-327619; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Li BQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033393; Lin Q, 1998, DEVELOPMENT, V125, P4565; Liu YQ, 2013, J BIOL CHEM, V288, P11572, DOI 10.1074/jbc.M112.434951; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Maiti D, 2008, INVEST OPHTH VIS SCI, V49, P3640, DOI 10.1167/iovs.08-1760; Mcgee SL, 2008, DIABETES, V57, P860, DOI 10.2337/db07-0843; Novara F, 2013, EUR J MED GENET, V56, P260, DOI 10.1016/j.ejmg.2013.01.011; Oka M, 2008, Patent Number, Patent No. [CN100398663(C), 100398663]; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Riazi AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005698; Ribeiro MSJ, 2009, NUCLEIC ACIDS RES, V37, P6691, DOI 10.1093/nar/gkp724; Seftor REB, 2012, AM J PATHOL, V181, P1115, DOI 10.1016/j.ajpath.2012.07.013; Shang YL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001527; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Xu JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027165; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhao JX, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199372; Zhou L, 2012, ONCOL REP, V28, P874, DOI 10.3892/or.2012.1880	38	58	60	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4089	4097		10.1038/onc.2014.337	http://dx.doi.org/10.1038/onc.2014.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328135				2022-12-17	WOS:000358780500007
J	Xue, G; Yan, HL; Zhang, Y; Hao, LQ; Zhu, XT; Mei, Q; Sun, SH				Xue, G.; Yan, H-L; Zhang, Y.; Hao, L-Q; Zhu, X-T; Mei, Q.; Sun, S-H			c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2 alpha and promotes tumor angiogenesis and metastasis by upregulating FGF2	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BREAST-CANCER; METABOLISM; CELLS; HIF-1; TUMORIGENESIS; BIOGENESIS; APOPTOSIS; PATHWAYS	Previous studies have established the link between aberrant microRNA (miRNA) expression and hypoxia in various neoplasms. However, how these hypoxia-related miRNAs modulate tumor progression is still unclear. Therefore, the patterns of miRNA in colorectal carcinoma cell lines in response to hypoxia or not were first screened and the hypoxia-induced repression of the miR-15-16 cluster was confirmed. Then, this repression was found to be associated with high tumor stage and poor prognosis in colorectal carcinoma and is shown to promote tumor angiogenesis and metastasis by the loss of restriction of its target gene, fibroblast growth factor-2 (FGF2). Moreover, the general and alterative promoters of the miR-15-16 host (deleted in lymphocytic leukemia 2, DLEU2) were mapped, and three c-Myc/Max binding sites in response to the hypoxia-induced repression of miR-15-16 were further identified. Finally, an enhanced stability of c-Myc/Max heterodimer promoted by increased hypoxia-inducible factor-2 alpha (HIF-2 alpha) was validated, and we also verified that the enhancement contributed to the hypoxia-induced repression of miR-15-16. In brief, the c-Myc-mediated transcriptional repression of miR-15-16 in hypoxia is induced by increased HIF-2 alpha and promoted tumor angiogenesis and hematogenous metastasis by the further loss of post-transcriptional inhibition of FGF2. Our study provides a better understanding of the coping mechanisms in response to tumor hypoxia and may be helpful in developing an effective prognostic marker or treatment target against solid tumors.	[Xue, G.; Yan, H-L; Zhang, Y.; Zhu, X-T; Mei, Q.; Sun, S-H] Second Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Shanghai 200433, Peoples R China; [Hao, L-Q] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai 200433, Peoples R China	Naval Medical University; Naval Medical University	Sun, SH (corresponding author), Second Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Xiang Yin Rd 800, Shanghai 200433, Peoples R China.	shsun@vip.sina.com			National Natural Science Foundation of China [31100920, 30972877]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank the National Natural Science Foundation of China for the financial support (Nos. 31100920 and 30972877).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Banning A, 2008, CANCER RES, V68, P9746, DOI 10.1158/0008-5472.CAN-08-1321; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Buendia MA, 2012, GASTROENTEROLOGY, V142, P214, DOI 10.1053/j.gastro.2011.12.023; Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chaudary N, 2007, CLIN CANCER RES, V13, P1947, DOI 10.1158/1078-0432.CCR-06-2971; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; FROMOWITZ FB, 1987, HUM PATHOL, V18, P1268, DOI 10.1016/S0046-8177(87)80412-4; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Hackl C, 2013, GUT, V62, P259, DOI 10.1136/gutjnl-2011-301585; Horan AD, 2001, RADIAT RES, V156, P388, DOI 10.1667/0033-7587(2001)156[0388:TKMFRO]2.0.CO;2; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x; Kaluz S, 2009, BBA-REV CANCER, V1795, P162, DOI 10.1016/j.bbcan.2009.01.001; Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Lerner M, 2009, EXP CELL RES, V315, P2941, DOI 10.1016/j.yexcr.2009.07.001; Marinescu VD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-79; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Voss MJ, 2010, CURR MOL MED, V10, P381, DOI 10.2174/156652410791317020; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	40	58	61	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1393	1406		10.1038/onc.2014.82	http://dx.doi.org/10.1038/onc.2014.82			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704828				2022-12-17	WOS:000350806500006
J	Pierobon, M; Wulfkuhle, J; Liotta, L; Petricoin, E				Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.			Application of molecular technologies for phosphoproteomic analysis of clinical samples	ONCOGENE			English	Review							PHASE PROTEIN MICROARRAYS; HUMAN BREAST-CANCER; LASER CAPTURE MICRODISSECTION; FLOW-CYTOMETRY; TISSUE; TRIAL; PHOSPHORYLATION; PROTEOMICS; INHIBITOR; PATHWAY	The integration of small kinase inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treating cancer patients. As proteins are the direct targets of the new generations of targeted therapeutics, many of which are kinase/enzymatic inhibitors, there is an increasing interest in developing technologies capable of monitoring post-translational changes of the human proteome for the identification of new predictive, prognostic and therapeutic biomarkers. It is well known that the vast majority of the activation/deactivation of these drug targets is driven by phosphorylation. This review provides a description of the main proteomic platforms (planar and bead array, reverse phase protein microarray, phosphoflow, AQUA and mass spectrometry) that have successfully been used for measuring changes in phosphorylation level of drug targets and downstream substrates using clinical specimens. Major emphasis was given to the strengths and weaknesses of the different platforms and to the major barriers that are associated with the analysis of the phosphoproteome. Finally, a number of examples of application of the above-mentioned technologies in the clinical setting are reported.	[Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA 20110 USA	George Mason University	Petricoin, E (corresponding author), George Mason Univ, Ctr Appl Prote & Mol Med, 10900 Univ Blvd,Bull Run Hall,Room 324, Manassas, VA 20110 USA.	epetrico@gmu.edu	Pierobon, Mariaelena/GXA-0544-2022					Angevin E, 2013, CLIN CANCER RES, V19, P1257, DOI 10.1158/1078-0432.CCR-12-2885; Arends JW, 2000, J PATHOL, V190, P412; Balboni I, 2006, ANNU REV IMMUNOL, V24, P391, DOI 10.1146/annurev.immunol.24.021605.090709; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Baselga J, 2010, CLIN CANCER RES, V16, P4876, DOI 10.1158/1078-0432.CCR-10-0748; Braeckmans K, 2002, NAT REV DRUG DISCOV, V1, P447, DOI 10.1038/nrd817; Breen EC, 2011, CLIN VACCINE IMMUNOL, V18, P1229, DOI 10.1128/CVI.05032-11; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; Carbone M, 2004, SEMIN CANCER BIOL, V14, P399, DOI 10.1016/j.semcancer.2004.06.002; Chen L, 2011, ELECTROPHORESIS, V32, P1984, DOI 10.1002/elps.201100101; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Dabitao D, 2011, J IMMUNOL METHODS, V372, P71, DOI 10.1016/j.jim.2011.06.033; Dahut WL, 2008, CLIN CANCER RES, V14, P209, DOI 10.1158/1078-0432.CCR-07-1355; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Drobin Kimi, 2013, Methods Mol Biol, V1023, P137, DOI 10.1007/978-1-4614-7209-4_8; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Espina V, 2008, MOL CELL PROTEOMICS, V7, P1998, DOI 10.1074/mcp.M700596-MCP200; Espina V, 2011, METHODS MOL BIOL, V785, P23, DOI 10.1007/978-1-61779-286-1_3; Espina V, 2009, CLIN LAB MED, V29, P1, DOI 10.1016/j.cll.2009.03.001; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Faratian D, 2011, EUR J CANCER, V47, P1420, DOI 10.1016/j.ejca.2011.01.014; Fu Q, 2010, CLIN CHEM, V56, P314, DOI 10.1373/clinchem.2009.135087; Gamez-Pozo A, 2011, MOL BIOSYST, V7, P2368, DOI 10.1039/c1mb05113j; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Institute of Cancer Research (United Kingdom), 2000, AN PHARM CHANG AUY92; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Irwin ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070608; Jameson GS, 2012, J CLIN ONCOL, V30; Kornblau SM, 2010, CLIN CANCER RES, V16, P3721, DOI 10.1158/1078-0432.CCR-10-0093; Krutzik Peter O, 2011, Curr Protoc Cytom, VChapter 6, DOI 10.1002/0471142956.cy0631s55; Krutzik PO, 2011, METHODS MOL BIOL, V699, P179, DOI 10.1007/978-1-61737-950-5_9; Kummar S, 2011, EUR J CANCER, V47, P997, DOI 10.1016/j.ejca.2010.12.016; Leng SX, 2008, J GERONTOL A-BIOL, V63, P879, DOI 10.1093/gerona/63.8.879; Lineberger Comprehensive Cancer Center, 2000, DEF TRIPL NEG BREAST; Liu Angen, 2010, J Biomol Tech, V21, P120; Mascaux C, 2011, CLIN CANCER RES, V17, P7796, DOI 10.1158/1078-0432.CCR-11-0209; Mueller C, 2010, MOL ONCOL, V4, P461, DOI 10.1016/j.molonc.2010.09.003; Narumi R, 2012, J PROTEOME RES, V11, P5311, DOI 10.1021/pr3005474; Oberprieler NG, 2011, CELL SIGNAL, V23, P14, DOI 10.1016/j.cellsig.2010.07.009; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pectasides E, 2011, CLIN CANCER RES, V17, P2947, DOI 10.1158/1078-0432.CCR-10-2040; Perkins G, 2010, INT J CANCER, V127, P1321, DOI 10.1002/ijc.25152; Perl AE, 2012, CLIN CANCER RES, V18, P1716, DOI 10.1158/1078-0432.CCR-11-2346; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Pierobon M, 2012, METHODS MOL BIOL, V823, P215, DOI 10.1007/978-1-60327-216-2_14; Pierobon M, 2011, METHODS MOL BIOL, V785, P3, DOI 10.1007/978-1-61779-286-1_1; Rimm D, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-S5-4; Rimm DL, 2011, J CLIN ONCOL, V29, P2282, DOI 10.1200/JCO.2010.33.2023; Roth BJ, 2013, J CLIN ONCOL, V31, P131, DOI 10.1200/JCO.2012.47.1938; Sato T, 2011, AM J CANCER RES, V1, P347; Schwenk JM, 2011, METHODS MOL BIOL, V723, P29, DOI 10.1007/978-1-61779-043-0_3; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Shi TJ, 2012, P NATL ACAD SCI USA, V109, P15395, DOI 10.1073/pnas.1204366109; Silvestri A, 2010, LAB INVEST, V90, P787, DOI 10.1038/labinvest.2010.47; Sourial S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/187426; Speer R, 2006, P AM ASS CANC RES, V47; Sprung RW, 2012, J PROTEOME RES, V11, P3498, DOI 10.1021/pr300130t; Stasyk T, 2012, TRENDS MOL MED, V18, P43, DOI 10.1016/j.molmed.2011.11.001; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tong FK, 2006, CYTOM PART B-CLIN CY, V70B, P107, DOI 10.1002/cyto.b.20092; University of Michigan University Hospital, 2000, CET BEV TREAT PAT RE; VanMeter A, 2007, EXPERT REV MOL DIAGN, V7, P625, DOI 10.1586/14737159.7.5.625; VanMeter AJ, 2008, MOL CELL PROTEOMICS, V7, P1902, DOI 10.1074/mcp.M800204-MCP200; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wulfkuhle JD, 2008, J PROTEOME RES, V7, P1508, DOI 10.1021/pr7008127; Wulfkuhle JD, 2012, CLIN CANCER RES, V18, P6426, DOI 10.1158/1078-0432.CCR-12-0452; Xu BJ, 2010, PROTEOM CLIN APPL, V4, P116, DOI 10.1002/prca.200900138; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263	75	58	58	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					805	814		10.1038/onc.2014.16	http://dx.doi.org/10.1038/onc.2014.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608425				2022-12-17	WOS:000349472000001
J	Zhang, C; Zhang, S; Zhang, Z; He, J; Xu, Y; Liu, S				Zhang, C.; Zhang, S.; Zhang, Z.; He, J.; Xu, Y.; Liu, S.			ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc	ONCOGENE			English	Article						ROCK; c-Myc; prostate cancer cells; proliferation; protein stability	B-CELL LYMPHOMAS; PROTEIN STABILITY; GENE-EXPRESSION; BREAST-CANCER; KINASE; PHOSPHORYLATION; TRANSFORMATION; DEGRADATION; CYCLE; FBW7	Rho-associated kinase (ROCK) has an essential role in governing cell morphology and motility, and increased ROCK activity contributes to cancer cell invasion and metastasis. Burgeoning data suggest that ROCK is also involved in the growth regulation of tumor cells. However, thus far, the molecular mechanisms responsible for ROCK-governed tumor cell growth have not been clearly elucidated. Here we showed that inhibition of ROCK kinase activity, either by a selective ROCK inhibitor Y27632 or by specific ROCK small interfering RNA (siRNA) molecules, attenuated not only motility but also the proliferation of PC3 prostate cancer cells in vitro and in vivo. Importantly, mechanistic investigation revealed that ROCK endowed cancer cells with tumorigenic capability, mainly by targeting c-Myc. ROCK could increase the transcriptional activity of c-Myc by promoting c-Myc protein stability, and ROCK inhibition reduced c-Myc-mediated expression of mRNA targets (such as HSPC111) and microRNA targets (such as miR-17-92 cluster). We provided evidence demonstrating that ROCK1 directly interacted with and phosphorylated c-Myc, resulting in stabilization of the protein and activation of its transcriptional activity. Suppression of ROCK-c-Myc downstream molecules, such as c-Myc-regulated miR-17, also impaired tumor cell growth in vitro and in vivo. In addition, c-Myc was shown to exert a positive feedback regulation on ROCK by increasing RhoA mRNA expression. Therefore, inhibition of ROCK and its stimulated signaling might prove to be a promising strategy for restraining tumor progression in prostate cancer.	[Zhang, C.; Zhang, S.; Liu, S.] Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China; [Zhang, C.; Zhang, Z.; Xu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China; [He, J.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Tianjin Medical University; Tufts University	Liu, S (corresponding author), Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China.	xuyong8816@sina.com; sjliu@rcees.ac.cn			National Natural Science Foundation of China [21377159, 81172451]; national '973' program [2014CB932000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); national '973' program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grant numbers: 21377159, 81172451) and from the national '973' program (grant number: 2014CB932000). We thank lab members for their invaluable assistance with experiments and reagents, and Michael Rosenblatt, MD, of Merck & Co. Inc. for his review of the manuscript and helpful suggestions.	Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Boku S, 2013, BRAIN RES, V1492, P7, DOI 10.1016/j.brainres.2012.11.034; Bu Qiang, 2011, Zhonghua Zhong Liu Za Zhi, V33, P202; Butt AJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1985; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gualco G, 2009, AM J SURG PATHOL, V33, P1815, DOI 10.1097/PAS.0b013e3181bb9a18; Hahmann C, 2010, CELL MOL LIFE SCI, V67, P171, DOI 10.1007/s00018-009-0189-x; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hesan Luo JZ, 2012, BIOCHEM J, V442, P311; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; James K, 2007, J CARDIOVASC PHARM, V50, P17; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Lin SL, 2007, CARCINOGENESIS, V28, P310, DOI 10.1093/carcin/bgl134; Liu SJ, 2007, J CLIN INVEST, V117, P3296, DOI 10.1172/JCI32084; Liu SJ, 2011, MOL BIOL REP, V38, P1363, DOI 10.1007/s11033-010-0238-4; Liu SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011272; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Riento K, 2005, EMBO J, V24, P1170, DOI 10.1038/sj.emboj.7600612; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang Y, 2009, J CELL SCI, V122, P2197, DOI 10.1242/jcs.040659	43	58	60	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5582	5591		10.1038/onc.2013.505	http://dx.doi.org/10.1038/onc.2013.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24317511				2022-12-17	WOS:000346088700002
J	Cappellari, M; Bielli, P; Paronetto, MP; Ciccosanti, F; Fimia, GM; Saarikettu, J; Silvennoinen, O; Sette, C				Cappellari, M.; Bielli, P.; Paronetto, M. P.; Ciccosanti, F.; Fimia, G. M.; Saarikettu, J.; Silvennoinen, O.; Sette, C.			The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells	ONCOGENE			English	Article						alternative splicing; SND1; SAM68; CD44; prostate cancer	BINDING PROTEIN SAM68; RNA-POLYMERASE-II; MALE GERM-CELLS; ANDROGEN RECEPTOR; MESSENGER-RNAS; IN-VIVO; ELONGATION; CD44; P100; SPERMATOGENESIS	Splicing abnormalities have profound impact in human cancer. Several splicing factors, including SAM68, have pro-oncogenic functions, and their increased expression often correlates with human cancer development and progression. Herein, we have identified using mass spectrometry proteins that interact with endogenous SAM68 in prostate cancer (PCa) cells. Among other interesting proteins, we have characterized the interaction of SAM68 with SND1, a transcriptional co-activator that binds spliceosome components, thus coupling transcription and splicing. We found that both SAM68 and SND1 are upregulated in PCa cells with respect to benign prostate cells. Upregulation of SND1 exerts a synergic effect with SAM68 on exon v5 inclusion in the CD44 mRNA. The effect of SND1 on CD44 splicing required SAM68, as it was compromised after knockdown of this protein or mutation of the SAM68-binding sites in the CD44 pre-mRNA. More generally, we found that SND1 promotes the inclusion of CD44 variable exons by recruiting SAM68 and spliceosomal components on CD44 pre-mRNA. Inclusion of the variable exons in CD44 correlates with increased proliferation, motility and invasiveness of cancer cells. Strikingly, we found that knockdown of SND1, or SAM68, reduced proliferation and migration of PCa cells. Thus, our findings strongly suggest that SND1 is a novel regulator of alternative splicing that promotes PCa cell growth and survival.	[Cappellari, M.; Bielli, P.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Cappellari, M.; Bielli, P.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Paronetto, M. P.] Fdn Santa Lucia, Lab Cellular & Mol Neurobiol, Rome, Italy; [Paronetto, M. P.] Univ Rome Foro Italico, Dept Hlth Sci, Rome, Italy; [Ciccosanti, F.; Fimia, G. M.] Natl Inst Infect Dis Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, Rome, Italy; [Saarikettu, J.; Silvennoinen, O.] Tampere Univ, Fac Med, Lab Mol Immunol, FIN-33101 Tampere, Finland; [Silvennoinen, O.] Tampere Univ, Inst Biomed Technol Biomeditech, Tampere, Finland; [Silvennoinen, O.] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland	University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Santa Lucia; Foro Italico University of Rome; IRCCS Lazzaro Spallanzani; Tampere University; Tampere University; Tampere University; Tampere University Hospital	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.	claudio.sette@uniroma2.it	Fimia, Gian Maria/K-3232-2016; Sette, Claudio/S-4307-2019; Ciccosanti, Fabiola/B-5284-2017; Bielli, Pamela/K-1208-2018; Paronetto, Maria Paola/A-9578-2012	Fimia, Gian Maria/0000-0003-4438-3325; Sette, Claudio/0000-0003-2864-8266; Ciccosanti, Fabiola/0000-0003-0481-6878; Bielli, Pamela/0000-0003-3347-8345; Paronetto, Maria Paola/0000-0001-5324-0903	Association for International Cancer Research (AICR) [12-0150]; Associazione Italiana Ricerca sul Cancro (AIRC) [10348]; Associazione Italiana Ricerca sul Cancro (MFAG) [11658]; Worldwide Cancer Research [12-0150] Funding Source: researchfish	Association for International Cancer Research (AICR); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (MFAG)(Fondazione AIRC per la ricerca sul cancro); Worldwide Cancer Research	We wish to thank Dr Roberta Busa for suggestions with chromatin immunoprecipitation experiments and Dr Maria Loiarro for assistance with luciferase reporter assays. This work was supported by the Association for International Cancer Research (AICR grant no. 12-0150 to CS) and the Associazione Italiana Ricerca sul Cancro (AIRC grant no. 10348 to CS and MFAG no. 11658 to MPP).	Babic I, 2006, ONCOGENE, V25, P4955, DOI 10.1038/sj.onc.1209504; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Blanco MA, 2011, J BIOL CHEM, V286, P19982, DOI 10.1074/jbc.M111.240077; Busa R, 2007, ONCOGENE, V26, P4372, DOI 10.1038/sj.onc.1210224; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Chawla G, 2009, MOL CELL BIOL, V29, P201, DOI 10.1128/MCB.01349-08; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Elliott DJ, 2010, J PATHOL, V222, P223, DOI 10.1002/path.2753; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gao XJ, 2012, J BIOL CHEM, V287, P18130, DOI 10.1074/jbc.M111.311852; Germann S, 2012, J NUCLEIC ACIDS, V2012, DOI 10.1155/2012/269570; Grange J, 2009, J NEUROSCI RES, V87, P12, DOI 10.1002/jnr.21824; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368; Hong W, 2002, MOL CANCER RES, V1, P48; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Huot ME, 2009, J BIOL CHEM, V284, P31903, DOI 10.1074/jbc.M109.018465; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kuruma H, 2009, AM J PATHOL, V174, P2044, DOI 10.2353/ajpath.2009.080776; Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Messina V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039729; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Oesterreich FC, 2011, TRENDS CELL BIOL, V21, P328, DOI 10.1016/j.tcb.2011.03.002; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Paronetto MP, 2011, NUCLEIC ACIDS RES, V39, P4961, DOI 10.1093/nar/gkr085; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Paronetto MP, 2009, J CELL BIOL, V185, P235, DOI 10.1083/jcb.200811138; Paronetto MP, 2006, MOL BIOL CELL, V17, P14, DOI 10.1091/mbc.e05-06-0548; Pedrotti S, 2010, EMBO J, V29, P1235, DOI 10.1038/emboj.2010.19; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Santhekadur PK, 2012, J BIOL CHEM, V287, P13952, DOI 10.1074/jbc.M111.321646; Sergeant KA, 2007, J CELL SCI, V120, P309, DOI 10.1242/jcs.03344; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 2010, ADV EXP MED BIOL, V693, P54; Shukla S, 2012, BBA-GENE REGUL MECH, V1819, P673, DOI 10.1016/j.bbagrm.2012.01.014; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666; Song LB, 2010, J PATHOL, V222, P227, DOI 10.1002/path.2751; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Tisserant A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001418; Valineva T, 2005, J BIOL CHEM, V280, P14989, DOI 10.1074/jbc.M410465200; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang J, 2002, EMBO J, V21, P4950, DOI 10.1093/emboj/cdf463; Yang J, 2007, NUCLEIC ACIDS RES, V35, P4485, DOI 10.1093/nar/gkm470; Yoo BK, 2011, HEPATOLOGY, V53, P1538, DOI 10.1002/hep.24216; Zhou HL, 2011, P NATL ACAD SCI USA, V108, pE627, DOI 10.1073/pnas.1103344108; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	60	58	60	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3794	3802		10.1038/onc.2013.360	http://dx.doi.org/10.1038/onc.2013.360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995791	Green Published			2022-12-17	WOS:000339394100005
J	Burks, J; Reed, RE; Desai, SD				Burks, J.; Reed, R. E.; Desai, S. D.			ISGylation governs the oncogenic function of Ki-Ras in breast cancer	ONCOGENE			English	Article						ISG15; Ki-Ras; UbcH8; ISGylation; breast cancer; oncogenic transformation	UBIQUITIN-LIKE PROTEIN; ISG15 MODIFICATION; DOWN-REGULATION; TUMOR-CELLS; GENE; EXPRESSION; PATHWAY; SYSTEM; ENDOCYTOSIS; TRANSITION	Aberrant expression of the oncogenic Kirsten-Ras (Ki-Ras) and interferon-stimulated gene 15 (ISG15) pathways is common in breast and other cancers. However, whether these dysregulated pathways cooperate to promote malignancy is not known. This study links Ki-Ras and ISG15 in a previously unidentified regulatory loop that may underlie malignant transformation of mammary cells. We show that oncogenic Ki-Ras regulates the expression of the ISG15 pathway (free ISG15 and ISG15 conjugates), and ISG15, in turn, stabilizes Ki-Ras protein by inhibiting its targeted degradation via lysosomes in breast cancer cells. Disruption of this loop by silencing either Ki-Ras or the ISG15 pathway restored the disrupted cellular architecture, a hallmark feature of most cancer cells. We also demonstrate that ISG15 and UbcH8 (ISG15-specific conjugating enzyme) shRNAs reversed Ki-Ras mutation-associated phenotypes of cancer cells, such as increased cell proliferation, colony formation, anchorage-independent growth in soft agar, cell migration, and epithelial-mesenchymal transition. As UbcH8-silenced breast cancer cells are devoid of ISG15 conjugates but have free ISG15, our results using UbcH8-silenced cells suggest that ISG15 conjugates, and not free ISG15, contributes to oncogenic Ki-Ras transformation. We have thus identified the conjugated form of ISG15 as a critical downstream mediator of oncogenic Ki-Ras, providing a potential mechanistic link between ISG15 and Ki-Ras-mediated breast tumorigenesis. Our findings, which show that inhibition of the ISGylation reverses the malignant phenotypes of breast cancer cells expressing oncogenic Ki-Ras, support the development of ISG15 conjugation inhibitors for treating breast and also other cancers expressing oncogenic Ki-Ras.	[Burks, J.; Reed, R. E.; Desai, S. D.] LSU Hlth Sci Center, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA		Desai, SD (corresponding author), LSU Hlth Sci Center, Sch Med, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	sdesai@lsuhsc.edu			LSU-Health Science Center School of Medicine	LSU-Health Science Center School of Medicine	This work was supported by start-up funds from the LSU-Health Science Center School of Medicine to SD.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Begum R, 2004, EXP MOL MED, V36, P358, DOI 10.1038/emm.2004.47; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1167, DOI 10.1038/sj.cdd.4401691; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Farassati F, 2008, AM J PATHOL, V173, P1861, DOI 10.2353/ajpath.2008.080376; FRIEDMAN E, 1984, CANCER RES, V44, P3040; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Guo YL, 2012, MOL CANCER THER, V11, P1968, DOI 10.1158/1535-7163.MCT-12-0248; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Harty RN, 2009, J INNATE IMMUN, V1, P397, DOI 10.1159/000226245; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; Kiessling A, 2009, ONCOGENE, V28, P2606, DOI 10.1038/onc.2009.115; Kim SE, 2009, J CELL SCI, V122, P842, DOI 10.1242/jcs.040493; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Kuang ZZ, 2011, J VIROL, V85, P7153, DOI 10.1128/JVI.02610-10; Lauwers E, 2009, J CELL BIOL, V185, P493, DOI 10.1083/jcb.200810114; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009; NIELSCH U, 1992, J VIROL, V66, P1884, DOI 10.1128/JVI.66.4.1884-1890.1992; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Pincetic A, 2010, J VIROL, V84, P4725, DOI 10.1128/JVI.02478-09; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; SCOTT N, 1993, GUT, V34, P621, DOI 10.1136/gut.34.5.621; Shim JH, 2006, J CELL BIOL, V172, P1045, DOI 10.1083/jcb.200509041; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Takeuchi T, 2005, BIOCHEM BIOPH RES CO, V336, P9, DOI 10.1016/j.bbrc.2005.08.034; Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V328, P43, DOI 10.1016/j.bbrc.2004.12.142; Tsai YC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024291; Ward DMV, 2005, J BIOL CHEM, V280, P10548, DOI 10.1074/jbc.M413734200; Wood LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016422; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yin XY, 2009, LUNG CANCER, V63, P194, DOI 10.1016/j.lungcan.2008.05.009; Zou WG, 2007, BIOCHEM BIOPH RES CO, V354, P321, DOI 10.1016/j.bbrc.2006.12.210; Zou WG, 2005, BIOCHEM BIOPH RES CO, V336, P61, DOI 10.1016/j.bbrc.2005.08.038	53	58	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					794	803		10.1038/onc.2012.633	http://dx.doi.org/10.1038/onc.2012.633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23318454				2022-12-17	WOS:000331129200013
J	Teoh-Fitzgerald, ML; Fitzgerald, MP; Zhong, W; Askeland, RW; Domann, FE				Teoh-Fitzgerald, M. L.; Fitzgerald, M. P.; Zhong, W.; Askeland, R. W.; Domann, F. E.			Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis	ONCOGENE			English	Article						three-dimensional culture; DNA methylation; experimental lung metastasis; spontaneous metastasis; acinar morphogenesis; laminin-enriched extracellular matrix	EXTRACELLULAR-SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; MATRIX COMPONENTS; DNA METHYLATION; BINDING-SITE; CANCER; GROWTH; INACTIVATION; OVEREXPRESSION; IDENTIFICATION	Expression of the antioxidant enzyme EcSOD in normal human mammary epithelial cells was not recognized until recently. Although expression of EcSOD was not detectable in non-malignant human mammary epithelial cells (HMEC) cultured in conventional two-dimensional (2D) culture conditions, EcSOD protein expression was observed in normal human breast tissues, suggesting that the 2D-cultured condition induces a repressive status of EcSOD gene expression in HMEC. With the use of laminin-enriched extracellular matrix (IrECM), we were able to detect expression of EcSOD when HMEC formed polarized acinar structures in a 3D-culture condition. Repression of the EcSOD-gene expression was again seen when the HMEC acini were sub-cultured as a monolayer, implying that IrECM-induced acinar morphogenesis is essential in EcSOD-gene activation. We have further shown the involvement of DNA methylation in regulating EcSOD expression in HMEC under these cell culture conditions. EcSOD mRNA expression was strongly induced in the 2D-cultured HMEC after treatment with a DNA methyltransferase inhibitor. In addition, epigenetic analyses showed a decrease in the degree of CpG methylation in the EcSOD promoter in the 3D versus 2D-cultured HMEC. More importantly, > 80% of clinical mammary adenocarcinoma samples showed significantly decreased EcSOD mRNA and protein expression levels compared with normal mammary tissues and there is an inverse correlation between the expression levels of EcSOD and the clinical stages of breast cancer. Combined bisulfite restriction analysis analysis of some of the tumors also revealed an association of DNA methylation with the loss of EcSOD expression in vivo. Furthermore, overexpression of EcSOD inhibited breast cancer metastasis in both the experimental lung metastasis model and the syngeneic mouse model. This study suggests that epigenetic silencing of EcSOD may contribute to mammary tumorigenesis and that restoring the extracellular superoxide scavenging activity could be an effective strategy for breast cancer treatment.	[Teoh-Fitzgerald, M. L.; Fitzgerald, M. P.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Zhong, W.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; [Askeland, R. W.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of Iowa	Teoh-Fitzgerald, ML (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	m.teohfitzgerald@unmc.edu; frederick-domann@uiowa.edu		Domann, Frederick/0000-0002-0489-2179	NIH [R01 CA073612, R01 CA115438]; Susan G Komen for the Cure [KG080437]; SFRBM Research Mini-Fellowship; Oberley Seed Grant; Carver Research Program of Excellence in Redox Biology and Medicine; Holden Comprehensive Cancer Center Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA086862, R01CA115438, R01CA073612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); SFRBM Research Mini-Fellowship; Oberley Seed Grant; Carver Research Program of Excellence in Redox Biology and Medicine; Holden Comprehensive Cancer Center Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr James Crapo (National Jewish Medical and Research Center, Denver, CO, USA) for providing antibodies to EcSOD and Dr Michael Henry (Department of Molecular Physiology and Biophysics, University of Iowa, IA, USA) for providing the 4T1 luc cells. We also thank Justin Fishbaugh from the Flow Cytometry Core Facility for assisting with the DCFH assays as well as the Central Microscopy Research Facility. This study was supported by NIH grant R01 CA073612 and R01 CA115438 (FE Domann), Susan G Komen for the Cure grant KG080437 (M Teoh-Fitzgerald), SFRBM Research Mini-Fellowship (M Teoh-Fitzgerald), Oberley Seed Grant (M Teoh-Fitzgerald), and Carver Research Program of Excellence in Redox Biology and Medicine, and by the Holden Comprehensive Cancer Center Breast Cancer Research Fund.	ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; Case AJ, 2011, FREE RADICAL BIO MED, V50, P448, DOI 10.1016/j.freeradbiomed.2010.11.025; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Henrotin Y, 2009, ADV CLIN CHEM, V49, P31, DOI 10.1016/S0065-2423(09)49002-4; Hewetson A, 2002, MOL ENDOCRINOL, V16, P2101, DOI 10.1210/me.2002-0064; HICKS CL, 1979, J DAIRY SCI, V62, P529, DOI 10.3168/jds.S0022-0302(79)83285-3; HICKS CL, 1980, J DAIRY SCI, V63, P1199, DOI 10.3168/jds.S0022-0302(80)83065-7; Jolivet G, 2005, J CELL BIOCHEM, V95, P313, DOI 10.1002/jcb.20397; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Raats CJI, 1997, J BIOL CHEM, V272, P26734, DOI 10.1074/jbc.272.42.26734; Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025; Shan WH, 2010, FREE RADICAL BIO MED, V49, P2078, DOI 10.1016/j.freeradbiomed.2010.10.691; Svensson RU, 2007, CANCER RES, V67, P10445, DOI 10.1158/0008-5472.CAN-07-1955; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang XY, 2011, J BIOL CHEM, V286, P13244, DOI 10.1074/jbc.M110.206615; Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005; Teoh ML, 2007, CLIN CANCER RES, V13, P7441, DOI 10.1158/1078-0432.CCR-07-0851; Teoh MLT, 2009, CANCER RES, V69, P6355, DOI 10.1158/0008-5472.CAN-09-1195; Teoh-Fitzgerald MLT, 2012, MOL CANCER RES, V10, P40, DOI 10.1158/1541-7786.MCR-11-0501; Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200	41	58	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					358	368		10.1038/onc.2012.582	http://dx.doi.org/10.1038/onc.2012.582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318435	Green Accepted			2022-12-17	WOS:000330214000010
J	Pandey, PR; Xing, F; Sharma, S; Watabe, M; Pai, SK; Iiizumi-Gairani, M; Fukuda, K; Hirota, S; Mo, YY; Watabe, K				Pandey, P. R.; Xing, F.; Sharma, S.; Watabe, M.; Pai, S. K.; Iiizumi-Gairani, M.; Fukuda, K.; Hirota, S.; Mo, Y-Y; Watabe, K.			Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer	ONCOGENE			English	Article						lipogenesis; ductal carcinoma in situ; breast cancer; stem-like cells; apoptosis; resveratrol	FATTY-ACID SYNTHASE; ACTIVATION; EXPRESSION; RAS; PROGRESSION; APOPTOSIS; RECEPTOR; PATHWAY; GENE; GROWTH	Upregulation of lipogenesis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by apoptosis. However, the exact role of lipogenesis in tumor initiation is as yet poorly understood. We examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma in situ (DCIS) of breast cancer and found that these genes were significantly upregulated in DCIS. We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population. Furthermore, the CSCs showed significantly higher level of expression of all lipogenic genes than the counterpart population from non-tumorigenic breast cancer cell line, MCF10A. Importantly, ectopic expression of SREBP1, the master regulator of lipogenic genes, in MCF10A significantly enhanced lipogenesis in stem-like cells and promoted cell growth as well as mammosphere formation. Moreover, SREBP1 expression significantly increased the ability of cell survival of CSCs from MCF10AT, another cell line that is capable of generating DCIS, in mouse and in cell culture. These results indicate that upregulation of lipogenesis is a pre-requisite for DCIS formation by endowing the ability of cell survival. We have also shown that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly suppressed their ability to generate DCIS in animals, which provides us with a strong rationale to use this agent for chemoprevention against DCIS.	[Pandey, P. R.; Xing, F.; Sharma, S.; Watabe, M.; Pai, S. K.; Iiizumi-Gairani, M.; Fukuda, K.; Watabe, K.] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL USA; [Hirota, S.] Iwate Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Morioka, Iwate 020, Japan; [Xing, F.; Mo, Y-Y; Watabe, K.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA	Southern Illinois University System; Southern Illinois University; Iwate Medical University; University of Mississippi; University of Mississippi Medical Center	Watabe, K (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Arthur Guyton Res Bldg G654, Jackson, MS 39216 USA.	kwatabe@umc.edu	Mo, Yin-Yuan/R-8255-2019; Xia, Bo/P-9380-2016		National Institutes of Health [R01CA124650, R01CA129000, R01CA124650-04S1]; US Department of Defense [BC096982]; McElroy Foundation; NATIONAL CANCER INSTITUTE [R01CA124650, R01CA129000] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); McElroy Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (Grants R01CA124650, R01CA129000 and R01CA124650-04S1 to KW), the US Department of Defense (BC096982 to KW) and McElroy Foundation (to KW).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Allan Alison L, 2006, Breast Dis, V26, P87; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Barnes NLP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e797; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Caron RW, 2005, CELL CYCLE, V4, P456, DOI 10.4161/cc.4.3.1249; Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Damonte P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2104; Dawson PJ, 1996, AM J PATHOL, V148, P313; Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505; Esslimani-Sahla M, 2007, INT J CANCER, V120, P224, DOI 10.1002/ijc.22202; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Guillet-Deniau I, 2004, J CELL SCI, V117, P1937, DOI 10.1242/jcs.01069; Heppner Gloria H., 1999, Breast J, V5, P122, DOI 10.1046/j.1524-4741.1999.00136.x; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206; JANES PW, 1994, ONCOGENE, V9, P3601; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Lee CM, 2005, GYNECOL ONCOL, V99, P415, DOI 10.1016/j.ygyno.2005.05.045; Liu W, 2011, BREAST CANCER RES TR, V128, P57, DOI 10.1007/s10549-010-1076-8; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Pandey PR, 2012, RECENT PAT ANTI-CANC, V7, P185; Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1998, CANCER RES, V58, P4611; Porter DA, 2001, CANCER RES, V61, P5697; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; Rashid A, 1997, AM J PATHOL, V150, P201; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Uttarwar L, 2012, AM J PHYSIOL-RENAL, V302, pF329, DOI 10.1152/ajprenal.00136.2011; Valverde AM, 1998, EXP CELL RES, V243, P274, DOI 10.1006/excr.1998.4154; Vazquez-Martin A, 2008, CELL PROLIFERAT, V41, P59, DOI 10.1111/j.1365-2184.2007.00498.x; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Yamashita T, 2009, J HEPATOL, V50, P100, DOI 10.1016/j.jhep.2008.07.036	46	58	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5111	5122		10.1038/onc.2012.519	http://dx.doi.org/10.1038/onc.2012.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208501				2022-12-17	WOS:000325937900012
J	Li, Q; Yang, XH; Xu, F; Sharma, C; Wang, HX; Knoblich, K; Rabinovitz, I; Granter, SR; Hemler, ME				Li, Q.; Yang, X. H.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Rabinovitz, I.; Granter, S. R.; Hemler, M. E.			Tetraspanin CD151 plays a key role in skin squamous cell carcinoma	ONCOGENE			English	Article						tetraspanin CD151; skin squamous cell carcinoma; chemical carcinogenesis; integrin alpha 6 beta 4; STAT3; PKC alpha	TRANSMEMBRANE 4 SUPERFAMILY; KERATINOCYTE STEM-CELLS; ALPHA-6-BETA-4 INTEGRIN; BETA-4 INTEGRIN; MICE LACKING; MALIGNANT PROGRESSION; PROSTATE-CANCER; IN-VIVO; KINASE; STAT3	Here we provide the first evidence that tetraspanin CD151 can support de novo carcinogenesis. During two-stage mouse skin chemical carcinogenesis, CD151 reduces tumor lag time and increases incidence, multiplicity, size and progression to malignant squamous cell carcinoma (SCC), while supporting both cell survival during tumor initiation and cell proliferation during the promotion phase. In human skin SCC, CD151 expression is selectively elevated compared with other skin cancer types. CD151 support of keratinocyte survival and proliferation may depend on activation of transcription factor STAT3 (signal transducers and activators of transcription), a regulator of cell proliferation and apoptosis. CD151 also supports protein kinase C (PKC)alpha-alpha 6 beta 4 integrin association and PKC-dependent beta 4 S1424 phosphorylation, while regulating alpha 6 beta 4 distribution. CD151-PKC alpha effects on integrin beta 4 phosphorylation and subcellular localization are consistent with epithelial disruption to a less polarized, more invasive state. CD151 ablation, while minimally affecting normal cell and normal mouse functions, markedly sensitized mouse skin and epidermoid cells to chemicals/drugs including 7,12-dimethylbenz[alpha]anthracene (mutagen) and camptothecin (topoisomerase inhibitor), as well as to agents targeting epidermal growth factor receptor, PKC, Jak2/Tyk2 and STAT3. Hence, CD151 'co-targeting' may be therapeutically beneficial. These findings not only support CD151 as a potential tumor target, but also should apply to other cancers utilizing CD151/laminin-binding integrin complexes. Oncogene (2013) 32, 1772-1783; doi: 10.1038/onc.2012.205; published online 23 July 2012	[Li, Q.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Hemler, M. E.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Li, Q.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Rabinovitz, I.; Hemler, M. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Yang, X. H.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Rabinovitz, I.] Beth Israel Deaconess Med Ctr, Div Canc Biol & Angiogenesis, Dept Pathol, Boston, MA 02215 USA; [Granter, S. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Room D1430,44 Binney St, Boston, MA 02115 USA.	martin_hemler@dfci.harvard.edu	Knoblich, Konstantin/B-5980-2009; Li, Qinglin/K-2570-2015	Knoblich, Konstantin/0000-0002-5646-837X; Li, Qinglin/0000-0002-4125-1944	NIH [CA42368]; SG Komen Career Catalyst Award; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SG Komen Career Catalyst Award(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr R Bronson for assistance with mouse histopathology, Dr Julie Aldridge for assistance with statistical analyses, and Drs David Frank, Sarah Walker and coworkers for nifuroxazide, ST3-01, assistance with STAT3 functional assay and helpful discussions. This work was supported by NIH grant CA42368 (to MEH), and a SG Komen Career Catalyst Award (to XHY).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Cowin AJ, 2006, J INVEST DERMATOL, V126, P680, DOI 10.1038/sj.jid.5700142; Crew VK, 2004, BLOOD, V104, P2217, DOI 10.1182/blood-2004-04-1512; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; de Wit J, 2011, BLOOD, V118, P6107, DOI 10.1182/blood-2011-05-352682; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dudley Andrew C, 2004, Cell Commun Signal, V2, P8, DOI 10.1186/1478-811X-2-8; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; Franco M, 2010, J BIOL CHEM, V285, P38756, DOI 10.1074/jbc.M110.145417; Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017; Frijns E, 2010, J BIOL CHEM, V285, P37650, DOI 10.1074/jbc.M110.138818; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hara T, 2005, CANCER RES, V65, P7356, DOI 10.1158/0008-5472.CAN-04-4241; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kangsamaksin T, 2007, MOL CARCINOGEN, V46, P579, DOI 10.1002/mc.20355; Kashyap T, 2011, LAB INVEST, V91, P1414, DOI 10.1038/labinvest.2011.104; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Kim DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010290; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Madoux F., 2010, MODULATORS STAT TRAN; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718; Owens DM, 2001, CANCER RES, V61, P5248; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Raymond K, 2007, MOL BIOL CELL, V18, P4210, DOI 10.1091/mbc.E06-08-0720; Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sattler M, 2003, CANCER RES, V63, P5462; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sheng KC, 2009, EUR J IMMUNOL, V39, P50, DOI 10.1002/eji.200838798; Sincock PM, 1999, J CELL SCI, V112, P833; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Sterk LMT, 2002, J CELL SCI, V115, P1161; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Syed ZA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-180; Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970; Takeda Y, 2011, BLOOD, V118, P464, DOI 10.1182/blood-2010-08-302240; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Tokura Yoshiki, 2010, Journal of UOEH, V32, P317; Torrero MN, 2006, CLIN CANCER RES, V12, P257, DOI 10.1158/1078-0432.CCR-05-1514; Tran M, 2008, CANCER RES, V68, P2885, DOI 10.1158/0008-5472.CAN-07-6160; Voss MA, 2011, BRIT J CANCER, V104, P1611, DOI 10.1038/bjc.2011.80; Weinberg AS, 2007, DERMATOL SURG, V33, P885, DOI 10.1111/j.1524-4725.2007.33190.x; Wilhelmsen K, 2007, MOL BIOL CELL, V18, P3512, DOI 10.1091/mbc.E07-04-0306; Winterwood NE, 2006, MOL BIOL CELL, V17, P2707, DOI 10.1091/mbc.E05-11-1042; Wright MD, 2004, MOL CELL BIOL, V24, P5978, DOI 10.1128/MCB.24.13.5978-5988.2004; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yang XWH, 2012, J CELL SCI, V125, P1478, DOI 10.1242/jcs.093963; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	77	58	62	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1772	1783		10.1038/onc.2012.205	http://dx.doi.org/10.1038/onc.2012.205			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22824799	Green Accepted, Green Submitted			2022-12-17	WOS:000317043900004
